Generalized	B-T047
Epilepsy	I-T047
and	O
Myoclonic	B-T047
Seizures	I-T047
in	O
22q11.2	B-T047
Deletion	I-T047
Syndrome	I-T047
Prompted	O
by	O
the	O
observations	O
of	O
juvenile	B-T047
myoclonic	I-T047
epilepsy	I-T047
(	O
JME	B-T047
)	O
in	O
22q11.2	B-T047
deletion	I-T047
syndrome	I-T047
(	O
22q11DS	B-T047
)	O
and	O
recurrent	O
copy	O
number	O
variants	O
in	O
genetic	O
generalized	B-T047
epilepsy	I-T047
(	O
GGE	B-T047
)	O
,	O
we	O
searched	O
for	O
further	O
evidence	O
supporting	O
a	O
possible	O
correlation	O
of	O
22q11DS	B-T047
with	O
GGE	B-T047
and	O
with	O
myoclonic	B-T047
seizures	I-T047
.	O
Through	O
routine	B-T060
diagnostics	I-T060
,	O
we	O
identified	O
3	O
novel	O
individuals	O
with	O
the	O
seemingly	O
uncommon	O
combination	O
of	O
22q11DS	B-T047
and	O
JME	B-T047
.	O
We	O
subsequently	O
screened	B-T058
the	O
literature	O
for	O
reports	O
focussing	O
on	O
the	O
epilepsy	O
phenotype	O
in	O
22q11DS	B-T047
.	O
We	O
additionally	O
screened	B-T058
a	O
database	O
of	O
173	O
22q11DS	B-T047
patients	O
and	O
identified	O
a	O
fourth	O
individual	O
with	O
JME	B-T047
as	O
well	O
as	O
2	O
additional	O
cases	O
with	O
GGE	B-T047
.	O
We	O
describe	O
6	O
novel	O
and	O
22	O
published	O
cases	O
with	O
co	B-T033
-	I-T033
occurrence	I-T033
of	O
22q11DS	B-T047
and	O
GGE	B-T047
.	O
In	O
many	O
patients	O
,	O
GGE	B-T047
was	O
associated	O
with	O
myoclonic	B-T047
seizures	I-T047
allowing	O
for	O
a	O
diagnosis	B-T033
of	O
JME	B-T047
in	O
at	O
least	O
6	O
individuals	O
.	O
Seventeen	O
of	O
the	O
173	O
22q11DS	B-T047
cases	O
(	O
10	O
%	O
)	O
had	O
a	O
diagnosis	B-T033
of	O
either	O
focal	B-T047
or	O
generalized	B-T047
epilepsy	I-T047
.	O
In	O
these	O
cases	O
,	O
focal	B-T047
epilepsy	I-T047
could	O
often	O
be	O
attributed	O
to	O
syndrome	B-T047
-	I-T047
associated	I-T047
hypocalcaemia	I-T047
,	O
cerebral	B-T033
bleeds	I-T033
,	O
or	O
structural	B-T033
brain	I-T033
anomalies	I-T033
.	O
However	O
,	O
the	O
cause	O
of	O
GGE	B-T047
remained	O
unclear	O
.	O
In	O
this	O
study	O
,	O
we	O
describe	O
and	O
review	O
28	O
individuals	O
with	O
22q11DS	B-T047
and	O
GGE	B-T047
(	O
especially	O
JME	B-T047
)	O
,	O
showing	O
that	O
both	O
disorders	B-T047
frequently	B-T033
co	I-T033
-	I-T033
occur	I-T033
.	O
Compared	O
to	O
the	O
reported	O
prevalence	O
of	O
15	O
-	O
21	O
%	O
,	O
in	O
our	O
case	O
series	O
only	O
10	O
%	O
of	O
22q11DS	B-T047
individuals	O
were	O
found	O
to	O
have	O
epilepsy	B-T047
,	O
often	O
GGE	B-T047
.	O
Since	O
22q11.2	O
does	O
not	O
contain	O
convincing	O
GGE	B-T047
candidate	O
genes	O
,	O
we	O
discuss	O
the	O
possibility	O
of	O
an	O
aetiological	O
correlation	O
through	O
a	O
possibly	O
disturbed	O
interaction	O
with	O
the	O
GABAB	O
receptor	O
.	O
      
The	O
Histone	O
Acetyltransferase	O
Gcn5	O
Positively	O
Regulates	O
T	O
Cell	O
Activation	O
Histone	O
acetyltransferases	O
(	O
HATs	O
)	O
regulate	O
inducible	O
transcription	O
in	O
multiple	O
cellular	O
processes	O
and	O
during	O
inflammatory	O
and	O
immune	O
response	O
.	O
However	O
,	O
the	O
functions	O
of	O
general	O
control	O
nonrepressed	O
-	O
protein	O
5	O
(	O
Gcn5	O
)	O
,	O
an	O
evolutionarily	O
conserved	O
HAT	O
from	O
yeast	O
to	O
human	O
,	O
in	O
immune	O
regulation	O
remain	O
unappreciated	O
.	O
In	O
this	O
study	O
,	O
we	O
conditionally	O
deleted	O
Gcn5	O
(	O
encoded	O
by	O
the	O
Kat2a	O
gene	O
)	O
specifically	O
in	O
T	O
lymphocytes	O
by	O
crossing	O
floxed	O
Gcn5	O
and	O
Lck	O
-	O
Cre	O
mice	O
,	O
and	O
demonstrated	O
that	O
Gcn5	O
plays	O
important	O
roles	O
in	O
multiple	O
stages	O
of	O
T	O
cell	O
functions	O
including	O
development	O
,	O
clonal	O
expansion	O
,	O
and	O
differentiation	O
.	O
Loss	B-T033
of	I-T033
Gcn5	O
functions	O
impaired	O
T	O
cell	O
proliferation	O
,	O
IL-2	O
production	O
,	O
and	O
Th1	O
/	O
Th17	O
,	O
but	O
not	O
Th2	O
and	O
regulatory	O
T	O
cell	O
differentiation	O
.	O
Gcn5	O
is	O
recruited	O
onto	O
the	O
il-2	O
promoter	O
by	O
interacting	O
with	O
the	O
NFAT	O
in	O
T	O
cells	O
upon	O
TCR	O
stimulation	O
.	O
Interestingly	O
,	O
instead	O
of	O
directly	O
acetylating	O
NFAT	O
,	O
Gcn5	O
catalyzes	O
histone	O
H3	O
lysine	O
H9	O
acetylation	O
to	O
promote	O
IL-2	O
production	O
.	O
T	O
cell	O
-specific	O
suppression	O
of	O
Gcn5	O
partially	O
protected	O
mice	O
from	O
myelin	O
oligodendrocyte	O
glycoprotein	O
-	O
induced	O
experimental	B-T050
autoimmune	I-T050
encephalomyelitis	I-T050
,	O
an	O
experimental	O
model	O
for	O
human	O
multiple	B-T047
sclerosis	I-T047
.	O
Our	O
study	O
reveals	O
previously	O
unknown	O
physiological	O
functions	O
for	O
Gcn5	O
and	O
a	O
molecular	O
mechanism	O
underlying	O
these	O
functions	O
in	O
regulating	O
T	O
cell	O
immunity	O
.	O
Hence	O
Gcn5	O
may	O
be	O
an	O
important	O
new	O
target	O
for	O
autoimmune	B-T047
disease	I-T047
therapy	B-T061
.	O
      
Effects	O
of	O
soybean	O
isoflavone	O
on	O
intestinal	B-T023
antioxidant	O
capacity	O
and	O
cytokines	O
in	O
young	O
piglets	O
fed	O
oxidized	O
fish	B-T121
oil	I-T121
To	O
investigate	O
the	O
effect	O
of	O
glycitein	O
,	O
a	O
synthetic	O
soybean	O
isoflavone	O
(	O
ISF	O
)	O
,	O
on	O
the	O
intestinal	B-T023
antioxidant	O
capacity	O
,	O
morphology	O
,	O
and	O
cytokine	O
content	O
in	O
young	O
piglets	O
fed	O
oxidized	O
fish	B-T121
oil	I-T121
,	O
72	O
4	O
-	O
d	O
-	O
old	O
male	O
piglets	O
were	O
assigned	O
to	O
three	O
treatments	B-T061
.	O
The	O
control	O
group	O
was	O
fed	O
a	O
basal	O
diet	O
containing	O
fresh	O
fish	B-T121
oil	I-T121
,	O
and	O
the	O
other	O
two	O
groups	O
received	O
the	O
same	O
diet	O
except	O
for	O
the	O
substitution	O
with	O
the	O
same	O
dosage	O
of	O
oxidized	O
fish	B-T121
oil	I-T121
alone	O
or	O
with	O
ISF	O
(	O
oxidized	O
fish	B-T121
oil	I-T121
plus	O
ISF	O
)	O
.	O
After	O
21	O
d	O
of	O
feeding	O
,	O
supplementation	B-T061
of	O
oxidized	O
fish	B-T121
oil	I-T121
increased	O
the	O
levels	O
of	O
malondialdehyde	O
(	O
MDA	O
)	O
,	O
oxidized	B-T121
glutathione	I-T121
(	O
GSSG	B-T121
)	O
,	O
interleukin-1β	O
(	O
IL-1β	O
)	O
,	O
tumor	O
necrosis	O
factor	O
-	O
α	O
(	O
TNF	O
-	O
α	O
)	O
,	O
interleukin-2	O
(	O
IL-2	O
)	O
,	O
nuclear	O
factor	O
κ	O
B	O
(	O
NF	O
-	O
κB	O
)	O
,	O
inducible	O
nitric	O
oxide	O
synthase	O
(	O
iNOS	O
)	O
,	O
NO	B-T121
,	O
and	O
Caspase-3	O
in	O
jejunal	B-T023
mucosa	I-T023
,	O
and	O
decreased	O
the	O
villous	B-T023
height	O
in	O
duodenum	B-T023
and	O
the	O
levels	O
of	O
secretory	O
immunoglobulin	O
A	O
(	O
sIgA	O
)	O
and	O
IL-4	O
in	O
the	O
jejunal	B-T023
mucosa	I-T023
compared	O
with	O
supplementation	B-T061
with	O
fresh	O
oil	B-T121
.	O
The	O
addition	O
of	O
oxidized	O
fish	B-T121
oil	I-T121
plus	O
ISF	O
partially	O
alleviated	O
this	O
negative	O
effect	O
.	O
The	O
addition	O
of	O
oxidized	O
fish	B-T121
oil	I-T121
plus	O
ISF	O
increased	O
the	O
villous	B-T023
height	O
and	O
levels	O
of	O
sIgA	O
and	O
IL-4	O
in	O
jejunal	B-T023
mucosa	I-T023
,	O
but	O
decreased	O
the	O
levels	O
of	O
IL-1β	O
and	O
IL-2	O
in	O
jejunal	B-T023
mucosa	I-T023
(	O
P<0.05	O
)	O
compared	O
with	O
oxidized	O
fish	B-T121
oil	I-T121
.	O
Collectively	O
,	O
these	O
results	O
show	O
that	O
dietary	B-T061
supplementation	I-T061
of	O
ISF	O
could	O
partly	O
alleviate	O
the	O
negative	O
effect	O
of	O
oxidized	O
fish	B-T121
oil	I-T121
by	O
improving	O
the	O
intestinal	B-T023
morphology	I-T023
as	O
well	O
as	O
the	O
antioxidant	O
capacity	O
and	O
immune	O
function	O
in	O
young	O
piglets	O
.	O
      
Preclinical	O
fibrinolysis	O
in	O
patients	O
with	O
ST	B-T047
-	I-T047
segment	I-T047
elevation	I-T047
myocardial	I-T047
infarction	I-T047
in	O
a	O
rural	O
region	O
In	O
the	O
current	O
guidelines	O
for	O
the	O
treatment	B-T061
of	O
patients	O
with	O
ST	B-T047
-	I-T047
segment	I-T047
elevation	I-T047
myocardial	I-T047
infarction	I-T047
(	O
STEMI	B-T047
)	O
,	O
the	O
European	O
Society	O
of	O
Cardiology	O
(	O
ESC	O
)	O
recommends	O
preclinical	O
fibrinolysis	O
as	O
a	O
reperfusion	B-T061
therapy	I-T061
if	O
,	O
due	O
to	O
long	O
transportation	O
times	O
,	O
no	O
cardiac	B-T058
catheterisation	I-T058
is	O
available	O
within	O
90	O
-	O
120	O
min	O
.	O
However	O
,	O
there	O
is	O
little	O
remaining	O
in	O
-	O
depth	O
expertise	O
in	O
this	O
method	O
because	O
fibrinolysis	O
is	O
presently	O
only	O
rarely	O
indicated	B-T033
.	O
In	O
a	O
rural	O
area	O
in	O
southwestern	O
Germany	O
,	O
where	O
an	O
emergency	B-T061
primary	I-T061
percutaneous	I-T061
coronary	I-T061
intervention	I-T061
was	O
not	O
routinely	O
available	O
within	O
90	O
-	O
120	O
min	O
,	O
156	O
STEMI	B-T047
patients	O
underwent	O
fibrinolysis	O
with	O
the	O
plasminogen	B-T121
activator	I-T121
reteplase	I-T121
,	O
performed	O
by	O
trained	O
emergency	O
physicians	O
.	O
The	O
practicality	O
of	O
the	O
treatment	B-T061
,	O
as	O
well	O
as	O
complications	O
and	O
the	O
mortality	O
of	O
the	O
patients	O
in	O
the	O
preclinical	O
phase	O
until	O
arrival	O
at	O
the	O
hospital	O
,	O
were	O
retrospectively	O
studied	O
.	O
The	O
mean	O
time	O
from	O
onset	O
of	O
the	O
symptoms	B-T184
to	O
first	O
medical	B-T058
contact	I-T058
was	O
114	O
±	O
116	O
min	O
.	O
The	O
mean	O
interval	O
to	O
the	O
start	O
of	O
fibrinolysis	O
of	O
13.5	O
±	O
6.4	O
min	O
was	O
within	O
the	O
30	O
min	O
mandated	O
by	O
the	O
ESC	O
.	O
Patients	O
with	O
inferior	B-T047
STEMI	I-T047
represented	O
the	O
largest	O
subgroup	O
.	O
Occurring	O
in	O
39	O
cases	O
(	O
25	O
%	O
)	O
,	O
complications	O
due	O
to	O
infarction	O
were	O
relatively	O
common	O
during	O
the	O
prehospital	B-T058
phase	O
,	O
including	O
15	O
cases	O
(	O
9.6	O
%	O
)	O
of	O
cardiogenic	O
shock	O
,	O
but	O
in	O
all	O
cases	O
the	O
complications	O
were	O
manageable	B-T033
.	O
No	O
patient	O
died	B-T033
before	O
arrival	O
at	O
the	O
hospital	O
.	O
As	O
lysis	O
-	O
associated	O
adverse	O
effects	O
,	O
merely	O
two	O
uncomplicated	O
mucosal	B-T184
haemorrhages	I-T184
and	O
one	O
case	O
of	O
mild	B-T047
allergic	I-T047
skin	I-T047
reactions	I-T047
were	O
seen	O
.	O
In	O
emergency	O
situations	O
with	O
long	O
transportation	O
times	O
to	O
the	O
nearest	O
suitable	O
cardiac	B-T058
catheterisation	I-T058
laboratory	O
,	O
preclinical	O
fibrinolysis	O
in	O
STEMI	B-T047
still	O
represents	O
a	O
workable	O
method	O
.	O
Success	O
of	O
this	O
strategy	O
requires	O
particularly	O
strong	O
training	O
of	O
the	O
emergency	O
physicians	O
in	O
ECG	B-T060
and	O
lysis	O
therapy	B-T061
,	O
and	O
co	O
-	O
operation	O
with	O
nearby	O
cardiac	O
centres	O
.	O
      
How	O
should	O
proxies	O
of	O
cognitive	O
reserve	O
be	O
evaluated	B-T058
in	O
a	O
population	O
of	O
healthy	O
older	O
adults	O
?	O
While	O
some	O
tools	O
have	O
been	O
developed	O
to	O
estimate	O
an	O
individual	O
's	O
cognitive	O
reserve	O
(	O
CR	O
)	O
,	O
no	O
study	O
has	O
assessed	O
the	O
adequacy	O
of	O
the	O
method	O
used	O
for	O
assessing	O
these	O
CR	O
proxy	O
indicators	O
.	O
Therefore	O
,	O
we	O
aimed	O
to	O
determine	O
the	O
most	O
appropriate	O
method	O
to	O
estimate	O
CR	O
by	O
comparing	O
two	O
approaches	O
:	O
(	O
1	O
)	O
the	O
common	O
assessment	B-T058
of	O
CR	O
proxies	O
in	O
the	O
literature	O
(	O
e.g.	O
years	O
of	O
education	O
)	O
and	O
(	O
2	O
)	O
the	O
calculation	O
of	O
a	O
comprehensive	O
index	O
based	O
on	O
most	O
significant	O
parameters	B-T033
used	O
in	O
the	O
estimation	O
of	O
CR	O
.	O
Data	O
on	O
CR	O
proxies	O
(	O
i.e.	O
education	O
,	O
occupation	O
,	O
and	O
leisure	O
activities	O
)	O
were	O
obtained	O
in	O
a	O
sample	O
of	O
204	O
older	O
adults	O
.	O
Regression	O
analyses	O
were	O
used	O
to	O
develop	O
the	O
two	O
indices	O
of	O
CR	O
(	O
i.e.	O
ICR	O
-	O
standard	O
and	O
ICR	O
-	O
detailed	O
)	O
and	O
to	O
determine	O
which	O
index	O
best	O
represented	O
the	O
level	O
of	O
one	O
's	O
CR	O
.	O
The	O
ICR	O
-	O
standard	O
was	O
calculated	O
using	O
a	O
combination	O
of	O
the	O
three	O
most	O
common	O
measures	O
of	O
reserve	O
in	O
the	O
literature	O
:	O
number	O
of	O
schooling	O
years	O
,	O
complexity	O
of	O
the	O
primary	O
occupation	O
,	O
and	O
amount	O
of	O
current	O
participation	O
in	O
stimulating	O
activities	O
.	O
The	O
ICR	O
-	O
detailed	O
was	O
calculated	O
using	O
the	O
most	O
significant	O
parameters	B-T033
(	O
established	O
in	O
initial	O
analyses	O
)	O
of	O
CR	O
:	O
highest	B-T033
level	I-T033
of	I-T033
education	I-T033
combined	O
with	O
the	O
number	O
of	O
training	O
courses	O
,	O
last	O
occupation	O
,	O
and	O
amount	O
of	O
current	O
participation	O
in	O
social	O
and	O
intellectual	O
activities	O
.	O
The	O
comparison	O
of	O
both	O
indices	O
showed	O
that	O
higher	O
levels	O
of	O
ICR	O
-	O
standard	O
and	O
ICR	O
-	O
detailed	O
were	O
associated	O
with	O
a	O
greater	O
minimization	O
of	O
the	O
effects	O
of	O
age	O
on	O
cognition	O
.	O
However	O
,	O
the	O
ICR	O
-	O
detailed	O
was	O
more	O
strongly	O
associated	O
to	O
this	O
minimization	O
than	O
the	O
ICR	O
-	O
standard	O
,	O
suggesting	O
that	O
the	O
ICR	O
-	O
detailed	O
best	O
reflect	O
one	O
's	O
CR	O
.	O
This	O
study	O
is	O
the	O
first	O
to	O
show	O
that	O
it	O
is	O
of	O
great	O
importance	O
to	O
question	O
methods	O
measuring	O
CR	O
proxies	O
in	O
order	O
to	O
develop	O
a	O
clinical	O
tool	O
allowing	O
a	O
comprehensive	O
and	O
accurate	O
estimation	O
of	O
CR	O
.	O
      
Identification	O
of	O
potential	O
predictive	O
markers	O
of	O
dexamethasone	B-T121
resistance	O
in	O
childhood	O
acute	B-T191
lymphoblastic	I-T191
leukemia	I-T191
Response	O
to	O
dexamethasone	B-T121
(	O
DEXA	B-T121
)	O
,	O
as	O
a	O
hallmark	B-T121
drug	I-T121
in	O
the	O
treatment	O
of	O
childhood	O
acute	B-T191
lymphoblastic	I-T191
leukemia	I-T191
(	O
ALL	B-T191
)	O
,	O
is	O
one	O
of	O
the	O
pivotal	O
prognostic	O
factors	O
in	O
the	O
prediction	B-T058
of	I-T058
outcome	I-T058
in	O
ALL	B-T191
.	O
Identification	O
of	O
predictive	O
markers	O
of	O
chemoresistance	O
is	O
beneficial	O
to	O
selecting	O
of	O
the	O
best	O
therapeutic	B-T061
protocol	I-T061
with	O
the	O
lowest	O
effect	O
adverse	O
.	O
Hence	O
,	O
we	O
aimed	O
to	O
find	O
drug	O
targets	O
using	O
the	O
2DE	B-T059
/	O
MS	B-T059
proteomics	B-T059
study	I-T059
of	O
a	O
DEXA	B-T121
-	O
resistant	O
cell	O
line	O
(	O
REH	O
)	O
as	O
a	O
model	O
for	O
poor	O
DEXA	B-T121
responding	O
patients	O
before	O
and	O
after	O
drug	B-T061
treatment	I-T061
.	O
Using	O
the	O
proteomic	B-T059
methods	I-T059
,	O
three	O
differentially	O
expressed	O
proteins	O
were	O
detected	B-T033
,	O
including	O
voltage	O
dependent	O
anion	O
channel	O
1	O
(	O
VDAC1	O
)	O
,	O
sorting	O
Nexin	O
3	O
(	O
SNX3	O
)	O
,	O
and	O
prefoldin	O
subunit	O
6	O
(	O
PFDN6	O
)	O
.	O
We	O
observed	O
low	O
expression	O
of	O
three	O
proteins	O
after	O
DEXA	B-T121
treatment	O
in	O
REH	O
cells	O
.	O
We	O
subsequently	O
verified	O
low	O
expression	O
of	O
resulted	O
proteins	O
at	O
the	O
mRNA	O
level	O
using	O
the	O
quantitative	B-T059
PCR	I-T059
method	I-T059
.	O
These	O
proteins	O
are	O
promising	O
proteins	O
because	O
of	O
their	O
important	O
roles	O
in	O
drug	O
resistance	O
and	O
regulation	O
of	O
apoptosis	O
(	O
VDAC1	O
)	O
,	O
protein	O
trafficking	O
(	O
SNX3	O
)	O
,	O
and	O
protein	O
folding	O
(	O
PFDN6	O
)	O
.	O
Additionally	O
,	O
mRNA	O
expression	O
level	O
of	O
these	O
proteins	O
was	O
assessed	O
in	O
17	O
bone	O
marrow	O
samples	O
from	O
children	O
with	O
newly	O
diagnosed	O
ALL	B-T191
and	O
7	O
non	O
-	O
cancerous	O
samples	O
as	O
controls	O
.	O
The	O
results	O
indicated	O
that	O
independent	O
of	O
the	O
molecular	O
subtypes	O
of	O
leukemia	B-T191
,	O
mRNA	O
expression	O
of	O
VDAC1	O
,	O
SNX3	O
,	O
and	O
PFDN6	O
decreased	O
in	O
ALL	B-T191
samples	O
compared	O
with	O
non	O
-	O
cancerous	O
samples	O
particularly	O
in	O
VDAC1	O
(	O
p	O
<	O
0.001	O
)	O
.	O
Additionally	O
,	O
mRNA	O
expression	O
of	O
three	O
proteins	O
was	O
also	O
declined	O
in	O
high	B-T033
-	I-T033
risk	I-T033
samples	O
compared	O
with	O
standard	O
risk	O
cases	O
.	O
These	O
results	O
demonstrated	O
diagnostic	O
and	O
prognostic	O
value	O
of	O
these	O
proteins	O
in	O
childhood	O
ALL	B-T191
.	O
Furthermore	O
,	O
investigation	B-T058
of	O
protein	O
-	O
protein	O
interaction	O
using	O
STRING	O
database	O
indicated	O
that	O
these	O
proteins	O
involved	O
in	O
the	O
signaling	O
pathway	O
of	O
NR3C1	O
as	O
dexamethasone	B-T121
target	B-T033
.	O
In	O
conclusion	O
,	O
our	O
proteomic	B-T059
study	I-T059
in	O
DEXA	B-T121
resistant	O
leukemic	O
cells	O
revealed	O
VDAC1	O
,	O
SNX3	O
,	O
and	O
PFDN6	O
are	O
promising	O
proteins	O
that	O
might	O
serve	O
as	O
potential	O
biomarkers	O
of	O
prognosis	B-T058
and	O
chemotherapy	B-T061
in	O
childhood	O
ALL	B-T191
.	O
      
Beneficial	O
effects	O
of	O
voglibose	B-T121
administration	B-T061
on	O
body	O
weight	O
and	O
lipid	O
metabolism	O
via	O
gastrointestinal	O
bile	O
acid	O
modification	O
This	O
study	O
was	O
designed	O
with	O
the	O
goal	O
of	O
examining	O
the	O
effects	O
of	O
voglibose	B-T121
administration	B-T061
on	O
body	O
weight	O
and	O
lipid	O
metabolism	O
and	O
underlying	O
mechanism	O
high	B-T061
fat	I-T061
diet	I-T061
-induced	O
obese	O
mice	O
.	O
Male	O
C57BL/6	O
mice	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
four	O
groups	O
:	O
a	O
control	O
diet	O
(	O
CTL	O
)	O
,	O
high	O
-	O
fat	O
diet	O
(	O
HF	O
)	O
,	O
high	O
-	O
fat	O
diet	O
supplemented	O
with	O
voglibose	O
(	O
VO	O
)	O
,	O
and	O
high	O
fat	O
diet	O
pair	O
-	O
fed	O
group	O
(	O
PF	O
)	O
.	O
After	O
12	O
weeks	O
,	O
the	O
following	O
characteristics	O
were	O
investigated	O
:	O
serum	B-T059
lipid	I-T059
and	O
glucose	O
levels	O
,	O
serum	O
polar	O
metabolite	O
profiles	O
,	O
and	O
expression	O
levels	O
of	O
genes	O
involved	O
in	O
lipid	O
and	O
bile	O
acid	O
metabolism	O
.	O
In	O
addition	O
,	O
pyrosequencing	B-T059
was	O
used	O
to	O
analyze	O
the	O
composition	O
of	O
gut	B-T001
microbiota	I-T001
found	O
in	O
feces	O
.	O
Total	B-T033
body	I-T033
weight	I-T033
gain	I-T033
was	O
significantly	O
lower	O
in	O
the	O
VO	O
group	O
than	O
in	O
the	O
CTL	O
,	O
HF	O
,	O
and	O
PF	O
groups	O
.	O
The	O
VO	O
group	O
exhibited	O
improved	O
metabolic	O
profiles	O
including	O
those	O
of	O
blood	B-T059
glucose	I-T059
,	O
triglyceride	O
,	O
and	O
total	O
cholesterol	O
levels	O
.	O
The	O
12-	O
week	O
voglibose	B-T121
administration	B-T061
decreased	O
the	O
ratio	O
of	O
Firmicutes	B-T007
to	O
Bacteroidetes	B-T007
found	O
in	O
feces	O
.	O
Circulating	O
levels	O
of	O
taurocholic	B-T121
and	O
cholic	B-T121
acid	I-T121
were	O
significantly	O
higher	O
in	O
the	O
VO	O
group	O
than	O
in	O
the	O
HF	O
and	O
CTL	O
groups	O
.	O
Deoxycholic	B-T121
acid	I-T121
levels	O
tended	O
to	O
be	O
higher	O
in	O
the	O
VO	O
group	O
than	O
in	O
the	O
HF	O
group	O
.	O
Voglibose	B-T121
administration	B-T061
downregulated	O
expression	O
levels	O
of	O
CYP8B1	O
and	O
HNF4α	O
genes	O
and	O
upregulated	O
those	O
of	O
PGC1α	O
,	O
whereas	O
FXRα	O
was	O
not	O
affected	O
.	O
Voglibose	B-T121
administration	B-T061
elicits	O
changes	O
in	O
the	O
composition	O
of	O
the	O
intestinal	B-T001
microbiota	I-T001
and	O
circulating	O
metabolites	O
,	O
which	O
ultimately	O
has	O
systemic	O
effects	O
on	O
body	O
weight	O
and	O
lipid	O
metabolism	O
in	O
mice	O
.	O
      
Smooth	O
versus	O
Textured	O
Surfaces	O
:	O
Feature	O
-Based	O
Category	O
Selectivity	O
in	O
Human	O
Visual	B-T023
Cortex	I-T023
In	O
fMRI	B-T060
studies	I-T060
,	O
human	O
lateral	B-T023
occipital	I-T023
(	I-T023
LO	I-T023
)	I-T023
cortex	I-T023
is	O
thought	O
to	O
respond	O
selectively	O
to	O
images	O
of	O
objects	O
,	O
compared	O
with	O
nonobjects	O
.	O
However	O
,	O
it	O
remains	O
unresolved	O
whether	O
all	O
objects	O
evoke	O
equivalent	O
levels	O
of	O
activity	O
in	O
LO	B-T023
,	O
and	O
,	O
if	O
not	O
,	O
which	O
image	O
features	O
produce	O
stronger	O
activation	O
.	O
Here	O
,	O
we	O
used	O
an	O
unbiased	O
parametric	O
texture	O
model	O
to	O
predict	O
preferred	O
versus	O
nonpreferred	O
stimuli	O
in	O
LO	B-T023
.	O
Observation	O
and	O
psychophysical	O
results	O
showed	O
that	O
predicted	O
preferred	O
stimuli	O
(	O
both	O
objects	O
and	O
nonobjects	O
)	O
had	O
smooth	O
(	O
rather	O
than	O
textured	O
)	O
surfaces	O
.	O
These	O
predictions	O
were	O
confirmed	O
using	O
fMRI	B-T060
,	O
for	O
objects	O
and	O
nonobjects	O
.	O
Similar	O
preferences	O
were	O
also	O
found	O
in	O
the	O
fusiform	O
face	O
area	O
(	O
FFA	O
)	O
.	O
Consistent	O
with	O
this	O
:	O
(	O
1	O
)	O
FFA	O
and	O
LO	B-T023
responded	O
more	O
strongly	O
to	O
nonfreckled	O
(	O
smooth	O
)	O
faces	O
,	O
compared	O
with	O
otherwise	O
identical	O
freckled	B-T033
(	O
textured	O
)	O
faces	O
;	O
and	O
(	O
2	O
)	O
strong	O
functional	O
connections	O
were	O
found	O
between	O
LO	B-T023
and	O
FFA	O
.	O
Thus	O
,	O
LO	B-T023
and	O
FFA	O
may	O
be	O
part	O
of	O
an	O
information	O
-	O
processing	O
stream	O
distinguished	O
by	O
feature	O
-based	O
category	O
selectivity	O
(	O
smooth	O
>	O
textured	O
)	O
.	O
      
In	O
situ	O
stabilization	O
of	O
heavy	O
metals	O
in	O
multiple-	O
metal	O
contaminated	O
paddy	O
soil	O
using	O
different	O
steel	O
slag	O
-based	O
silicon	O
fertilizer	O
Steel	O
slag	O
has	O
been	O
widely	O
used	O
as	O
amendment	O
and	O
silicon	O
fertilizer	O
to	O
alleviate	O
the	O
mobility	B-T033
and	O
bioavailability	O
of	O
heavy	O
metals	O
in	O
soil	O
.	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	B-T058
the	O
influence	O
of	O
particle	O
size	O
,	O
composition	O
,	O
and	O
application	O
rate	O
of	O
slag	O
on	O
metal	O
immobilization	O
in	O
acidic	O
soil	O
,	O
metals	O
uptake	O
by	O
rice	O
and	O
rice	O
growth	O
.	O
The	O
results	O
indicated	O
that	O
application	O
of	O
slag	O
increased	O
soil	O
pH	O
,	O
plant	O
-available	O
silicon	O
concentrations	O
in	O
soil	O
,	O
and	O
decreased	O
the	O
bioavailability	O
of	O
metals	O
compared	O
with	O
control	O
treatment	O
,	O
whereas	O
pulverous	O
slag	O
(	O
S1	O
)	O
was	O
more	O
effective	O
than	O
granular	O
slag	O
(	O
S2	O
and	O
S3	O
)	O
.	O
The	O
acid	O
-	O
extractable	O
fraction	O
of	O
Cd	O
in	O
the	O
spiked	O
soil	O
was	O
significantly	O
decreased	O
with	O
application	O
of	O
S1	O
at	O
rates	O
of	O
1	O
and	O
3	O
%	O
,	O
acid	O
-	O
extractable	O
fractions	O
of	O
Cu	B-T121
and	O
Zn	B-T121
were	O
decreased	O
when	O
treated	O
at	O
3	O
%	O
.	O
Use	O
of	O
S1	O
at	O
both	O
rates	O
resulted	O
in	O
significantly	O
lower	O
Cd	O
,	O
Cu	B-T121
,	O
and	O
Zn	B-T121
concentrations	O
in	O
rice	O
tissues	O
than	O
in	O
controls	O
by	O
82.6	O
-	O
92.9	O
,	O
88.4	O
-	O
95.6	O
,	O
and	O
67.4	O
-	O
81.4	O
%	O
,	O
respectively	O
.	O
However	O
,	O
use	O
of	O
pulverous	O
slag	O
at	O
1	O
%	O
significantly	O
promotes	O
rice	O
growth	O
,	O
restricted	O
rice	O
growth	O
when	O
treated	O
at	O
3	O
%	O
.	O
Thus	O
,	O
the	O
results	O
explained	O
that	O
reduced	O
particle	O
size	O
and	O
suitable	O
application	O
rate	O
of	O
slag	O
could	O
be	O
beneficial	O
to	O
rice	O
growth	O
and	O
metals	O
stabilization	O
.	O
      
Genetic	O
Diversity	O
in	O
Various	O
Accessions	O
of	O
Pineapple	O
[	O
Ananas	O
comosus	O
(	O
L.	O
)	O
Merr	O
.	O
]	O
Using	O
ISSR	O
and	O
SSR	O
Markers	O
Inter	O
simple	O
sequence	O
repeat	O
(	O
ISSR	O
)	O
and	O
simple	O
sequence	O
repeat	O
(	O
SSR	O
)	O
markers	O
were	O
used	O
to	O
assess	O
the	O
genetic	O
diversity	O
of	O
36	O
pineapple	O
accessions	O
that	O
were	O
introduced	O
from	O
10	O
countries	O
/	O
regions	O
.	O
Thirteen	O
ISSR	O
primers	O
amplified	B-T059
96	O
bands	O
,	O
of	O
which	O
91	O
(	O
93.65	O
%	O
)	O
were	O
polymorphic	O
,	O
whereas	O
20	O
SSR	O
primers	O
amplified	B-T059
73	O
bands	O
,	O
of	O
which	O
70	O
(	O
96.50	O
%	O
)	O
were	O
polymorphic	O
.	O
Nei	O
's	O
gene	O
diversity	O
(	O
h	O
=	O
0.28	O
)	O
,	O
Shannon	O
's	O
information	O
index	O
(	O
I	O
=	O
0.43	O
)	O
,	O
and	O
polymorphism	O
information	O
content	O
(	O
PIC	O
=	O
0.29	O
)	O
generated	O
using	O
the	O
SSR	O
primers	O
were	O
higher	O
than	O
that	O
with	O
ISSR	O
primers	O
(	O
h	O
=	O
0.23	O
,	O
I	O
=	O
0.37	O
,	O
PIC	O
=	O
0.24	O
)	O
,	O
thereby	O
suggesting	O
that	O
the	O
SSR	O
system	O
is	O
more	O
efficient	O
than	O
the	O
ISSR	O
system	O
in	O
assessing	O
genetic	O
diversity	O
in	O
various	O
pineapple	O
accessions	O
.	O
Mean	O
genetic	O
similarities	O
were	O
0.74	O
,	O
0.61	O
,	O
and	O
0.69	O
,	O
as	O
determined	O
using	O
ISSR	O
,	O
SSR	O
,	O
and	O
combined	O
ISSR	O
/	O
SSR	O
,	O
respectively	O
.	O
These	O
results	O
suggest	O
that	O
the	O
genetic	O
diversity	O
among	O
pineapple	O
accessions	O
is	O
very	O
high	O
.	O
We	O
clustered	O
the	O
36	O
pineapple	O
accessions	O
into	O
three	O
or	O
five	O
groups	O
on	O
the	O
basis	O
of	O
the	O
phylogenetic	O
trees	O
constructed	O
based	O
on	O
the	O
results	O
of	O
ISSR	O
,	O
SSR	O
,	O
and	O
combined	O
ISSR	O
/	O
SSR	O
analyses	O
using	O
the	O
unweighted	O
pair	O
-	O
group	O
with	O
arithmetic	O
averaging	O
(	O
UPGMA	O
)	O
method	O
.	O
The	O
results	O
of	O
principal	O
components	O
analysis	O
(	O
PCA	O
)	O
also	O
supported	O
the	O
UPGMA	O
clustering	O
.	O
These	O
results	O
will	O
be	O
useful	O
not	O
only	O
for	O
the	O
scientific	O
conservation	O
and	O
management	O
of	O
pineapple	O
germplasm	O
but	O
also	O
for	O
the	O
improvement	O
of	O
the	O
current	O
pineapple	O
breeding	O
strategies	O
.	O
      
An	O
evaluation	B-T058
of	O
neuroendocrine	O
dysfunction	O
following	O
acute	O
aneurysmal	O
subarachnoid	O
hemorrhage	O
:	O
A	O
prospective	O
study	O
The	O
aim	O
was	O
to	O
investigate	O
the	O
incidence	O
and	O
pattern	O
of	O
neuroendocrine	O
changes	O
in	O
cases	O
of	O
acute	O
aneurysmal	O
subarachnoid	O
hemorrhage	O
(	O
SAH	O
)	O
.	O
Endocrine	O
assessment	B-T058
was	O
performed	O
in	O
100	O
consecutive	O
cases	O
of	O
acute	O
aneurysmal	O
SAH	O
presenting	O
within	O
7	O
days	O
of	O
ictus	B-T047
.	O
The	O
gonadotropic	B-T121
,	O
somatotrophic	B-T121
,	O
thyrotropic	B-T121
,	O
and	O
corticotrophic	B-T121
axes	O
were	O
evaluated	B-T058
for	O
their	O
possible	O
dysfunction	O
.	O
A	O
total	O
of	O
100	O
cases	O
(	O
38	O
males	O
,	O
62	O
females	O
;	O
age	O
range	O
-	O
17	O
-	O
76	O
years	O
;	O
mean	O
age	O
-	O
43.6	O
years	O
)	O
of	O
acute	O
SAH	O
were	O
studied	O
.	O
The	O
aneurysms	B-T047
were	O
located	O
in	O
the	O
anterior	O
circulation	O
(	O
n	O
=	O
95	O
)	O
and	O
posterior	O
circulation	O
(	O
n	O
=	O
5	O
)	O
.	O
The	O
most	O
common	O
hormone	B-T047
deficiency	I-T047
was	O
of	O
growth	B-T121
hormone	I-T121
(	O
n	O
=	O
67	O
)	O
,	O
followed	O
by	O
gonadotrophin	B-T121
(	O
n	O
=	O
50	O
)	O
,	O
corticotrophin	B-T121
(	O
n	O
=	O
49	O
)	O
and	O
thyrotrophin	B-T121
(	O
n	O
=	O
35	O
)	O
.	O
Hyperprolactinemia	B-T047
was	O
noted	O
in	O
10	O
cases	O
.	O
One	B-T033
-	I-T033
pituitary	I-T033
hormone	I-T033
axis	I-T033
deficiency	I-T033
was	O
noted	O
in	O
26	O
cases	O
while	O
67	O
cases	O
had	O
two	O
or	O
more	O
pituitary	O
hormone	O
axes	O
dysfunction	O
.	O
A	O
total	O
of	O
93	O
cases	O
had	O
hormonal	O
dysfunction	O
in	O
one	O
or	O
more	O
pituitary	O
hormone	O
axes	O
,	O
and	O
seven	O
cases	O
had	O
no	O
hormonal	O
dysfunction	O
.	O
Endocrine	B-T047
dysfunction	I-T047
occurs	O
in	O
93	O
%	O
cases	O
of	O
acute	O
SAH	O
and	O
multiple	O
pituitary	O
hormone	O
axes	O
dysfunction	O
occurs	O
in	O
67	O
%	O
cases	O
.	O
It	O
is	O
suggested	O
that	O
hormonal	O
evaluation	B-T058
should	O
be	O
considered	O
as	O
part	O
of	O
management	O
of	O
acute	O
SAH	O
.	O
      
Determining	O
putative	O
vectors	O
of	O
the	O
Bogia	B-T047
Coconut	I-T047
Syndrome	I-T047
phytoplasma	B-T007
using	O
loop	B-T059
-	I-T059
mediated	I-T059
isothermal	I-T059
amplification	I-T059
of	O
single	O
-	O
insect	O
feeding	O
media	O
Phytoplasmas	B-T007
are	O
insect	B-T007
vectored	I-T007
mollicutes	I-T007
responsible	O
for	O
disease	B-T047
in	O
many	O
economically	O
important	O
crops	O
.	O
Determining	O
which	O
insect	O
species	O
are	O
vectors	O
of	O
a	O
given	O
phytoplasma	B-T007
is	O
important	O
for	O
managing	O
disease	B-T047
but	O
is	O
methodologically	O
challenging	O
because	O
disease	O
-	O
free	O
plants	O
need	O
to	O
be	O
exposed	O
to	O
large	O
numbers	O
of	O
insects	O
,	O
often	O
over	O
many	O
months	O
.	O
A	O
relatively	O
new	O
method	O
to	O
detect	O
likely	O
transmission	O
involves	O
molecular	B-T059
testing	I-T059
for	O
phytoplasma	B-T007
DNA	O
in	O
sucrose	O
solution	O
that	O
insects	O
have	O
fed	O
upon	O
.	O
In	O
this	O
study	O
we	O
combined	O
this	O
feeding	B-T059
medium	I-T059
method	I-T059
with	O
a	O
loop	B-T059
-	I-T059
mediated	I-T059
isothermal	I-T059
amplification	I-T059
(	I-T059
LAMP	I-T059
)	I-T059
assay	I-T059
to	O
study	O
627	O
insect	O
specimens	O
of	O
11	O
Hemiptera	O
taxa	O
sampled	O
from	O
sites	O
in	O
Papua	O
New	O
Guinea	O
affected	O
by	O
Bogia	B-T047
coconut	I-T047
syndrome	I-T047
(	O
BCS	B-T047
)	O
.	O
The	O
LAMP	B-T059
assay	I-T059
detected	O
phytoplasma	B-T007
DNA	O
from	O
the	O
feeding	O
solution	O
and	O
head	O
tissue	O
of	O
insects	O
from	O
six	O
taxa	O
belonging	O
to	O
four	O
families	O
:	O
Derbidae	O
,	O
Lophopidae	O
,	O
Flatidae	O
and	O
Ricaniidae	O
.	O
Two	O
other	O
taxa	O
yielded	O
positives	O
only	O
from	O
the	O
heads	O
and	O
the	O
remainder	O
tested	O
negative	O
.	O
These	O
results	O
demonstrate	O
the	O
utility	O
of	O
combining	O
single	B-T059
-	I-T059
insect	I-T059
feeding	I-T059
medium	I-T059
tests	I-T059
with	O
LAMP	B-T059
assays	I-T059
to	O
identify	O
putative	O
vectors	O
that	O
can	O
be	O
the	O
subject	O
of	O
transmission	O
tests	O
and	O
to	O
better	O
understand	O
phytoplasma	B-T007
pathosystems	O
.	O
      
A	O
Case	O
Presenting	O
with	O
Splenic	B-T047
Infarct	I-T047
Diagnosed	B-T033
as	O
Primary	O
Bone	O
Marrow	O
CD5	O
Positive	O
DLBCL	B-T191
:	O
A	O
Clinicopathological	O
Correlation	O
De	O
novo	O
CD5	O
+	O
Diffuse	B-T033
large	I-T033
B	I-T033
cell	I-T033
lymphoma	I-T033
(	O
DLBCL	B-T191
)	O
is	O
a	O
rare	O
and	O
aggressive	B-T033
subtype	I-T033
of	O
DLBCL	B-T191
.	O
It	O
is	O
a	O
distinct	O
clinicopathologic	B-T033
entity	O
with	O
complex	O
molecular	O
profile	O
and	O
poor	B-T033
prognosis	I-T033
.	O
A	O
59	O
year	O
old	O
female	O
presented	B-T033
with	I-T033
pyrexia	B-T184
of	I-T184
unknown	I-T184
origin	I-T184
since	O
1	O
month	O
.	O
On	O
examination	B-T058
,	O
there	O
was	O
severe	B-T033
pallor	I-T033
,	O
hepatosplenomegaly	B-T184
and	O
no	O
palpable	O
lymphadenopathy	B-T047
.	O
Complete	B-T059
blood	I-T059
count	I-T059
revealed	O
bicytopenia	O
with	O
normal	B-T033
total	I-T033
leucocyte	I-T033
count	I-T033
.	O
Liver	B-T059
and	O
renal	B-T059
function	I-T059
tests	I-T059
were	O
normal	O
.	O
Ultrasonography	B-T060
abdomen	I-T060
revealed	O
splenic	B-T033
enlargement	I-T033
with	O
two	B-T033
focal	I-T033
lesions	I-T033
attributed	O
to	O
either	O
splenic	B-T047
abscess	I-T047
or	O
infarcts	B-T047
.	O
Patient	O
was	O
being	O
managed	O
as	O
splenic	B-T047
infarct	I-T047
but	O
continued	O
to	O
have	O
bicytopenia	O
.	O
Further	O
investigation	B-T058
showed	O
elevated	B-T033
serum	I-T033
ferritin	I-T033
,	O
triglycerides	B-T033
and	O
LDH	O
.	O
With	O
a	O
clinical	O
suspicion	O
of	O
infection	O
and	O
haemophagocytic	B-T047
lymphohistiocytosis	I-T047
bone	B-T060
marrow	I-T060
aspiration	I-T060
bone	B-T060
marrow	I-T060
aspiration	I-T060
(	I-T060
BMA	I-T060
)	I-T060
and	I-T060
biopsy	I-T060
(	I-T060
BMBx	I-T060
)	I-T060
BMA	B-T060
biopsy	B-T060
was	O
done	O
.	O
BMA	O
showed	O
extensive	O
haemophagocytosis	B-T047
and	O
~7.4	O
%	O
large	B-T191
lymphoma	I-T191
-	I-T191
like	I-T191
cells	I-T191
.	O
On	O
this	O
basis	O
PET	B-T060
-	I-T060
CT	I-T060
was	O
suggested	O
which	O
showed	O
enlarged	B-T033
spleen	I-T033
with	O
diffuse	B-T033
uptake	I-T033
.	O
BMBx	B-T060
showed	O
nodular	B-T020
and	O
intrasinusoidal	O
collection	O
of	O
abnormal	O
lymphoid	O
cells	O
.	O
On	O
immunohistochemistry	B-T060
,	O
these	O
cells	O
were	O
positive	O
for	O
CD20	O
,	O
CD5	O
,	O
MUM1	O
,	O
BCL-2	O
,	O
BCL-6	O
and	O
negative	B-T033
for	O
CD3	O
,	O
CD10	O
and	O
CD23	O
.	O
CD34	O
highlighted	O
focal	O
intrasinusoidal	O
pattern	O
.	O
The	O
complete	O
clinicopathological	B-T058
profile	I-T058
suggested	O
the	O
diagnosis	B-T033
of	O
de	O
novo	O
CD5	O
+	O
DLBCL	B-T191
,	O
with	O
primary	B-T047
hepatosplenic	I-T047
pattern	O
of	O
involvement	O
.	O
CD5	O
+	O
DLBCL	B-T191
presenting	O
as	O
splenic	B-T047
infarct	I-T047
is	O
very	B-T033
rare	I-T033
.	O
This	O
case	O
was	O
unusual	O
as	O
the	O
diagnosis	B-T033
of	O
a	O
primary	B-T191
aggressive	I-T191
lymphoma	I-T191
with	O
haemophagocytosis	B-T047
was	O
established	O
in	O
a	O
patient	O
who	O
presented	O
with	O
fever	B-T184
and	O
splenic	B-T047
infarct	I-T047
without	O
lymphadenopathy	B-T047
.	O
This	O
indicates	O
the	O
importance	O
of	O
good	O
morphological	O
assessment	O
of	O
a	O
bone	O
marrow	O
aspirate	O
and	O
biopsy	B-T060
to	O
make	O
a	O
correct	B-T033
diagnosis	I-T033
.	O
      
Opioid	B-T121
Use	O
in	O
Chronic	B-T184
Pain	I-T184
Patients	O
with	O
Chronic	B-T047
Kidney	I-T047
Disease	I-T047
:	O
A	O
Systematic	O
Review	O
To	O
investigate	O
the	O
prevalence	O
of	O
chronic	B-T184
pain	I-T184
and	O
opioid	B-T121
management	B-T058
among	O
patients	O
with	O
chronic	B-T047
kidney	I-T047
disease	I-T047
(	O
CKD	B-T047
)	O
.	O
Systematic	O
review	O
.	O
A	O
systematic	O
search	O
was	O
performed	O
,	O
including	O
citations	O
from	O
1960	O
to	O
May	O
2015	O
.	O
The	O
review	O
highlights	O
methodological	O
quality	O
assessment	O
of	O
the	O
selected	O
studies	O
;	O
prevalence	O
of	O
pain	B-T184
;	O
type	O
,	O
dose	O
,	O
and	O
reason	O
for	O
opioid	B-T121
use	O
;	O
effectiveness	O
of	O
pain	B-T061
control	I-T061
and	O
associated	O
adverse	O
effects	O
of	O
opioids	B-T121
in	O
CKD	B-T047
patients	O
.	O
Twelve	O
of	O
131	O
articles	O
met	O
inclusion	O
criteria	O
.	O
There	O
were	O
no	O
randomized	O
controlled	O
trials	O
(	O
RCT	O
)	O
evaluable	O
,	O
and	O
12	O
were	O
observational	O
studies	O
.	O
Out	O
of	O
12	O
studies	O
,	O
four	O
were	O
of	O
high	O
quality	O
,	O
six	O
were	O
of	O
moderate	O
quality	O
,	O
and	O
the	O
remaining	O
two	O
were	O
low	O
-	O
quality	O
studies	O
.	O
The	O
studies	O
were	O
from	O
different	O
countries	O
with	O
sample	O
size	O
ranging	O
from	O
10	O
to	O
12,782	O
.	O
Several	O
studies	O
showed	O
a	O
high	O
prevalence	O
of	O
chronic	O
uncontrolled	B-T184
pain	I-T184
.	O
The	O
effectiveness	O
of	O
different	O
categories	O
of	O
opioids	B-T121
,	O
dose	O
,	O
duration	O
,	O
and	O
commonly	O
prescribed	B-T058
opioids	B-T121
varied	O
across	O
studies	O
.	O
Based	O
on	O
a	O
systematic	O
review	O
of	O
the	O
current	O
literature	O
,	O
there	O
is	O
fair	O
evidence	O
for	O
the	O
high	O
prevalence	O
of	O
chronic	B-T184
pain	I-T184
among	O
patients	O
with	O
CKD	B-T047
,	O
which	O
is	O
not	O
being	O
effectively	O
managed	O
,	O
probably	O
due	O
to	O
underprescription	O
of	O
analgesics	B-T121
or	O
opioids	B-T121
in	O
the	O
CKD	B-T047
population	O
.	O
Clinicians	O
are	O
in	O
need	O
of	O
additional	O
and	O
well	O
-	O
designed	O
randomized	O
control	O
trials	O
that	O
focus	O
on	O
the	O
indications	O
for	O
opioid	B-T121
therapy	B-T061
,	O
appropriate	O
opioid	B-T121
doses	O
and	O
dosing	O
intervals	O
,	O
outcomes	O
with	O
adequacy	O
of	O
symptom	B-T061
control	I-T061
,	O
and	O
reporting	O
on	O
the	O
incidence	O
of	O
adverse	O
side	O
effects	O
.	O
      
Genome	B-T059
-	I-T059
Wide	I-T059
SNP	I-T059
Linkage	I-T059
Mapping	I-T059
and	O
QTL	O
Analysis	B-T059
for	O
Fiber	O
Quality	O
and	O
Yield	O
Traits	O
in	O
the	O
Upland	O
Cotton	O
Recombinant	O
Inbred	O
Lines	O
Population	O
It	O
is	O
of	O
significance	O
to	O
discover	O
genes	O
related	O
to	O
fiber	O
quality	O
and	O
yield	O
traits	O
and	O
tightly	O
linked	O
markers	O
for	O
marker	O
-	O
assisted	O
selection	O
(	O
MAS	O
)	O
in	O
cotton	O
breeding	O
.	O
In	O
this	O
study	O
,	O
188	O
F8	O
recombinant	O
inbred	O
lines	O
(	O
RILs	O
)	O
,	O
derived	O
from	O
a	O
intraspecific	O
cross	O
between	O
HS46	O
and	O
MARCABUCAG8US-1	O
-	O
88	O
were	O
genotyped	O
by	O
the	O
cotton	O
63	O
K	O
single	B-T059
nucleotide	I-T059
polymorphism	I-T059
(	I-T059
SNP	I-T059
)	I-T059
assay	I-T059
.	O
Field	O
trials	O
were	O
conducted	O
in	O
Sanya	O
,	O
Hainan	O
Province	O
,	O
during	O
the	O
2014	O
-	O
2015	O
cropping	O
seasons	O
under	O
standard	O
conditions	O
.	O
Results	O
revealed	O
significant	O
differences	O
(	O
P	O
<	O
0.05	O
)	O
among	O
RILs	O
,	O
environments	O
and	O
replications	O
for	O
fiber	O
quality	O
and	O
yield	O
traits	O
.	O
Broad	O
-	O
sense	O
heritabilities	O
of	O
all	O
traits	O
including	O
fiber	O
length	O
,	O
fiber	O
uniformity	O
,	O
micronaire	O
,	O
fiber	O
elongation	O
,	O
fiber	O
strength	O
,	O
boll	O
weight	O
,	O
and	O
lint	O
percentage	O
ranged	O
from	O
0.26	O
to	O
0.66	O
.	O
A	O
1784.28	O
cM	O
(	O
centimorgans	O
)	O
linkage	B-T059
map	I-T059
,	O
harboring	O
2618	O
polymorphic	O
SNP	O
markers	O
,	O
was	O
constructed	O
,	O
which	O
had	O
0.68	O
cM	O
per	O
marker	O
density	O
.	O
Seventy	O
-	O
one	O
quantitative	O
trait	O
locus	O
(	O
QTLs	O
)	O
for	O
fiber	O
quality	O
and	O
yield	O
traits	O
were	O
detected	O
on	O
21	O
chromosomes	O
,	O
explaining	O
4.70~32.28	O
%	O
phenotypic	O
variance	O
,	O
in	O
which	O
16	O
were	O
identified	O
as	O
stable	O
QTLs	O
across	O
two	O
environments	O
.	O
Meanwhile	O
,	O
12	O
certain	O
regions	O
were	O
investigated	O
to	O
be	O
involved	O
in	O
the	O
control	O
of	O
one	O
(	O
hotspot	O
)	O
or	O
more	O
(	O
cluster	O
)	O
traits	O
,	O
mainly	O
focused	O
on	O
Chr05	O
,	O
Chr09	O
,	O
Chr10	O
,	O
Chr14	O
,	O
Chr19	O
,	O
and	O
Chr20	O
.	O
Nineteen	O
pairs	O
of	O
epistatic	O
QTLs	O
(	O
e	O
-	O
QTLs	O
)	O
were	O
identified	O
,	O
of	O
which	O
two	O
pairs	O
involved	O
in	O
two	O
additive	O
QTLs	O
.	O
These	O
additive	O
QTLs	O
,	O
e	O
-	O
QTLs	O
,	O
and	O
QTL	O
clusters	O
were	O
tightly	O
linked	O
to	O
SNP	O
markers	O
,	O
which	O
may	O
serve	O
as	O
target	O
regions	O
for	O
map	B-T059
-	I-T059
based	I-T059
cloning	I-T059
,	O
gene	O
discovery	O
,	O
and	O
MAS	O
in	O
cotton	O
breeding	O
.	O
      
Safety	O
and	O
immunogenecity	O
of	O
a	O
live	O
attenuated	B-T121
Rift	B-T121
Valley	I-T121
fever	I-T121
vaccine	I-T121
(	O
CL13	B-T121
T	I-T121
)	O
in	O
camels	O
Rift	B-T047
Valley	I-T047
fever	I-T047
is	O
an	O
emerging	O
zoonotic	B-T001
viral	B-T047
disease	I-T047
,	O
enzootic	B-T047
and	O
endemic	B-T047
in	O
Africa	O
and	O
the	O
Arabian	O
Peninsula	O
,	O
which	O
poses	O
a	O
significant	O
threat	O
to	O
both	O
human	O
and	O
animal	O
health	B-T047
.	O
The	O
disease	B-T047
is	O
most	O
severe	O
in	O
ruminants	O
causing	O
abortions	O
in	O
pregnant	O
animals	O
,	O
especially	O
sheep	O
animals	O
and	O
high	O
mortality	O
in	O
young	O
populations	O
.	O
High	O
mortality	O
rates	O
and	O
severe	O
clinical	O
manifestation	O
have	O
also	O
been	O
reported	O
among	O
camel	O
populations	O
in	O
Africa	O
,	O
to	O
attend	O
however	O
none	O
of	O
the	O
currently	O
available	O
live	B-T121
vaccines	I-T121
against	O
RVF	B-T047
have	O
been	O
tested	O
for	O
safety	O
and	O
efficacy	O
in	O
this	O
species	O
.	O
In	O
this	O
study	O
,	O
the	O
safety	O
and	O
efficacy	O
(	O
through	O
a	O
neutralizing	O
antibody	O
response	O
)	O
of	O
the	O
thermostable	B-T121
live	I-T121
attenuated	I-T121
RVF	B-T121
CL13	I-T121
T	I-T121
vaccine	I-T121
were	O
evaluated	B-T058
in	O
camels	O
in	O
two	O
different	O
preliminary	O
experiments	O
involving	O
16	O
camels	O
,	O
(	O
that	O
12	O
camels	O
and	O
4	O
pregnant	O
camels	O
)	O
.	O
The	O
study	O
revealed	O
that	O
the	O
CL13	B-T121
T	I-T121
vaccine	I-T121
was	O
safe	O
to	O
use	O
in	O
camels	O
and	O
no	O
abortions	O
or	O
teratogenic	O
effects	O
were	O
observed	O
.	O
The	O
single	O
dose	O
of	O
the	O
vaccine	B-T121
stimulated	O
a	O
strong	O
and	O
long	O
-	O
lasting	O
neutralizing	O
antibody	O
response	O
for	O
up	O
to	O
12	O
months	O
.	O
The	O
presence	B-T033
of	O
neutralization	O
antibodies	O
is	O
likely	O
to	O
correlate	O
with	O
protection	B-T033
;	O
however	O
protection	B-T033
would	O
need	O
to	O
be	O
confirmed	O
by	O
challenge	O
experiments	O
using	O
the	O
virulent	O
RVF	B-T005
virus	I-T005
.	O
      
Adverse	O
events	O
risk	O
associated	O
with	O
angiogenesis	B-T121
inhibitors	I-T121
addition	O
to	O
therapy	B-T061
in	O
ovarian	B-T191
cancer	I-T191
:	O
a	O
meta	O
-	O
analysis	O
of	O
randomized	O
controlled	O
trials	O
Inhibition	O
of	O
angiogenesis	O
has	O
been	O
regarded	O
as	O
an	O
attractive	O
treatment	B-T061
strategy	I-T061
for	O
advanced	B-T191
or	O
recurrent	B-T191
ovarian	I-T191
cancer	I-T191
.	O
We	O
conduct	O
this	O
meta	O
-	O
analysis	O
to	O
investigate	O
the	O
risk	O
of	O
adverse	O
events	O
of	O
special	O
interest	O
related	O
to	O
angiogenesis	B-T121
inhibitors	I-T121
(	O
AIs	B-T121
)	O
in	O
ovarian	B-T191
cancer	I-T191
.	O
Databases	O
from	O
PubMed	O
,	O
Web	O
of	O
Science	O
and	O
Cochrane	O
library	O
up	O
to	O
December	O
2015	O
were	O
searched	O
to	O
identify	O
relevant	O
studies	O
.	O
Eligible	O
studies	O
included	O
prospective	O
randomized	O
controlled	O
phase	O
II	O
/	O
III	O
clinical	O
trials	O
evaluating	B-T058
therapy	B-T061
with	O
or	O
without	O
AIs	B-T121
for	O
ovarian	B-T191
cancer	I-T191
.	O
Summary	O
relative	O
risk	O
(	O
RR	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
CIs	O
)	O
were	O
calculated	O
using	O
random	O
-	O
effects	O
or	O
fixed	O
-	O
effects	O
according	O
to	O
the	O
heterogeneity	O
among	O
included	O
trials	O
.	O
A	O
total	O
of	O
7,761	O
patients	O
from	O
ten	O
clinical	O
trials	O
were	O
included	O
in	O
the	O
meta	O
-	O
analysis	O
.	O
Pooled	O
RR	O
showed	O
that	O
the	O
use	O
of	O
AIs	B-T121
was	O
associated	O
with	O
a	O
statistically	O
increased	O
risk	O
in	O
four	O
of	O
the	O
adverse	O
outcomes	O
studied	O
:	O
arterial	O
thromboembolic	O
events	O
(	O
RR	O
=	O
2.0	O
)	O
,	O
gastrointestinal	B-T047
(	I-T047
GI	I-T047
)	I-T047
perforation	I-T047
(	O
RR	O
=	O
3.86	O
)	O
,	O
proteinuria	B-T033
(	O
RR	O
=	O
2.44	O
)	O
,	O
and	O
hypertension	B-T047
(	O
RR	O
=	O
5.39	O
)	O
.	O
No	B-T033
statistically	I-T033
significant	I-T033
differences	O
were	O
found	O
for	O
hemorrhagic	O
events	O
(	O
p	O
=	O
0.07	O
)	O
,	O
venous	B-T047
thromboembolic	I-T047
events	O
(	O
p	O
=	O
0.13	O
)	O
,	O
or	O
fatal	O
adverse	O
events	O
(	O
p	O
=	O
0.26	O
)	O
.	O
The	O
addition	O
of	O
AIs	B-T121
to	O
therapy	B-T061
in	O
ovarian	B-T191
cancer	I-T191
did	O
significantly	O
increase	O
the	O
risk	O
of	O
arterial	O
thromboembolic	O
events	O
,	O
GI	B-T047
perforation	I-T047
,	O
proteinuria	B-T033
and	O
hypertension	B-T047
,	O
but	O
not	O
for	O
venous	B-T047
thromboembolic	I-T047
events	O
,	O
hemorrhagic	O
events	O
,	O
or	O
fatal	O
adverse	O
events	O
.	O
      
The	O
Aortic	O
Root	O
:	O
Natural	O
History	O
After	O
Root	B-T061
-	I-T061
Sparing	I-T061
Ascending	I-T061
Replacement	I-T061
in	O
Nonsyndromic	B-T033
Aneurysmal	O
Patients	O
Leaving	O
native	O
aortic	O
tissue	O
in	O
situ	O
in	O
root	B-T061
-	I-T061
sparing	I-T061
ascending	I-T061
aortic	I-T061
replacement	I-T061
raises	O
concern	O
regarding	O
potential	O
later	O
need	O
for	O
root	O
reoperation	B-T061
or	O
for	O
the	O
potential	O
occurrence	O
of	O
localized	O
dissections	B-T047
or	O
rupture	O
in	O
the	O
residual	O
root	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	B-T058
the	O
natural	O
growth	O
of	O
the	O
aortic	O
root	O
after	O
root	B-T061
-	I-T061
sparing	I-T061
aortic	I-T061
replacement	I-T061
.	O
In	O
all	O
,	O
102	O
consecutive	O
patients	O
(	O
mean	O
age	O
61.8	O
±	O
12.5	O
years	O
;	O
60	O
%	O
male	O
)	O
who	O
had	O
undergone	O
root	B-T061
-	I-T061
sparing	I-T061
aortic	I-T061
replacement	I-T061
had	O
sufficient	O
retrievable	O
information	O
regarding	O
their	O
aortic	O
root	O
diameter	O
at	O
postoperative	O
baseline	O
and	O
follow	B-T058
-	I-T058
up	I-T058
imaging	B-T060
by	O
computed	B-T060
tomography	I-T060
or	O
echocardiography	B-T060
.	O
The	O
annual	O
growth	O
rate	O
was	O
evaluated	O
and	O
also	O
compared	O
according	O
to	O
the	O
influence	O
of	O
valve	O
morphology	O
and	O
concomitant	O
aortic	B-T061
valve	I-T061
replacement	I-T061
.	O
Furthermore	O
,	O
the	O
years	O
of	O
natural	O
history	O
that	O
would	O
require	O
for	O
root	O
enlargement	B-T190
to	O
meet	O
a	O
50	O
mm	O
threshold	O
of	O
the	O
root	O
diameter	O
were	O
calculated	O
.	O
The	O
estimated	O
growth	O
rate	O
of	O
the	O
aortic	O
root	O
after	O
root	B-T061
-	I-T061
sparing	I-T061
aortic	I-T061
replacement	I-T061
is	O
between	O
0.27	O
and	O
0.51	O
mm	O
per	O
year	O
(	O
mean	O
0.41	O
mm	O
,	O
varying	O
according	O
to	O
the	O
underlying	O
diameter	O
)	O
and	O
therefore	O
fivefold	O
less	O
than	O
other	O
aortic	O
regions	O
.	O
Accordingly	O
,	O
a	O
root	B-T047
aneurysm	I-T047
indicating	O
reoperation	B-T061
would	O
not	O
be	O
expected	O
for	O
29.1	O
years	O
on	O
average	O
.	O
Only	O
patients	O
with	O
a	O
diameter	O
of	O
45	O
mm	O
or	O
more	O
are	O
at	O
risk	O
for	O
reoperation	B-T061
,	O
and	O
not	O
until	O
at	O
least	O
after	O
10.4	O
years	O
have	B-T033
passed	I-T033
.	O
Neither	O
the	O
valve	O
morphology	O
(	O
p	O
=	O
0.62	O
)	O
nor	O
concomitant	O
aortic	B-T061
valve	I-T061
replacement	I-T061
(	O
p	O
=	O
0.86	O
)	O
influenced	O
rate	O
of	O
root	B-T047
dilation	I-T047
.	O
In	O
nonsyndromic	B-T033
patients	O
,	O
the	O
aortic	O
root	O
is	O
the	O
slowest	O
growing	O
portion	O
of	O
the	O
thoracic	B-T023
aorta	I-T023
.	O
Leaving	O
the	O
native	O
root	O
,	O
as	O
in	O
root	B-T061
-	I-T061
sparing	I-T061
ascending	I-T061
aortic	I-T061
replacement	I-T061
,	O
is	O
a	O
safe	O
approach	O
regarding	O
secondary	O
root	O
intervention	B-T061
for	O
aortic	O
root	O
diameters	O
of	O
45	O
mm	O
or	O
less	O
.	O
      
Acute	O
clinical	O
adverse	O
radiation	O
effects	O
after	O
Gamma	B-T061
Knife	I-T061
surgery	I-T061
for	O
vestibular	B-T191
schwannomas	I-T191
OBJECTIVE	O
Vestibular	B-T191
schwannomas	I-T191
(	O
VSs	B-T191
)	O
represent	O
a	O
common	O
indication	O
of	O
Gamma	B-T061
Knife	I-T061
surgery	I-T061
(	O
GKS	B-T061
)	O
.	O
While	O
most	O
studies	O
focus	O
on	O
the	O
long	O
-	O
term	O
morbidity	O
and	O
adverse	O
radiation	O
effects	O
(	O
AREs	O
)	O
,	O
none	O
describe	O
the	O
acute	O
clinical	O
AREs	O
that	O
might	O
appear	O
on	O
a	O
short	O
-	O
term	O
basis	O
.	O
These	O
types	O
of	O
events	O
are	O
investigated	O
,	O
and	O
their	O
incidence	O
,	O
type	O
,	O
and	O
outcomes	O
are	O
reported	O
in	O
the	O
present	O
paper	O
.	O
METHODS	O
The	O
included	O
patients	O
were	O
treated	O
between	O
July	O
2010	O
and	O
March	O
2016	O
,	O
underwent	O
at	O
least	O
6	O
months	O
of	O
follow	B-T058
-	I-T058
up	I-T058
,	O
and	O
presented	O
with	O
a	O
disabling	B-T047
symptom	B-T184
during	O
the	O
first	O
6	O
months	O
after	O
GKS	B-T061
that	O
affected	O
their	O
quality	O
of	O
life	O
.	O
The	O
timing	O
of	O
appearance	O
,	O
as	O
well	O
as	O
the	O
type	O
of	O
main	O
symptom	B-T184
and	O
outcome	O
,	O
were	O
noted	O
.	O
The	O
prescribed	B-T058
dose	O
was	O
12	O
Gy	O
at	O
the	O
margin	O
.	O
RESULTS	O
Thirty	O
-	O
five	O
(	O
22	O
%	O
)	O
of	O
159	O
patients	O
who	O
fulfilled	O
the	O
inclusion	O
criteria	O
had	O
acute	O
clinical	O
AREs	O
.	O
The	O
mean	O
followup	B-T058
period	O
was	O
30	O
months	O
(	O
range	O
6	O
-	O
49.2	O
months	O
)	O
.	O
The	O
mean	O
time	O
of	O
appearance	O
was	O
37.9	O
days	O
(	O
median	O
31	O
days	O
;	O
range	O
3	O
-	O
110	O
days	O
)	O
.	O
In	O
patients	O
with	O
de	O
novo	O
symptoms	B-T184
,	O
the	O
more	O
frequent	O
symptoms	B-T184
were	O
vertigo	B-T184
(	O
n	O
=	O
4	O
;	O
11.4	O
%	O
)	O
and	O
gait	B-T033
disturbance	I-T033
(	O
n	O
=	O
3	O
;	O
8.6	O
%	O
)	O
.	O
The	O
exacerbation	B-T033
of	O
a	O
preexisting	O
symptom	B-T184
was	O
more	O
frequently	O
related	O
to	O
hearing	B-T033
loss	I-T033
(	O
n	O
=	O
10	O
;	O
28.6	O
%	O
)	O
,	O
followed	O
by	O
gait	B-T033
disturbance	I-T033
(	O
n	O
=	O
7	O
;	O
20	O
%	O
)	O
and	O
vertigo	B-T184
(	O
n	O
=	O
3	O
,	O
8.6	O
%	O
)	O
.	O
In	O
the	O
univariate	O
logistic	O
regression	O
analysis	O
,	O
the	O
following	O
factors	O
were	O
statistically	O
significant	O
:	O
age	O
(	O
p	O
=	O
0.002	O
;	O
odds	O
ratio	O
[	O
OR	O
]	O
0.96	O
)	O
,	O
hearing	O
at	O
baseline	O
by	O
Gardner	O
-	O
Robertson	O
(	O
GR	O
)	O
class	O
(	O
p	O
=	O
0.006	O
;	O
OR	O
0.21	O
)	O
,	O
pure	O
tone	O
average	O
at	O
baseline	O
(	O
p	O
=	O
0.006	O
;	O
OR	O
0.97	O
)	O
,	O
and	O
Koos	O
grade	O
at	O
baseline	O
(	O
with	O
Koos	O
Grade	O
I	O
used	O
as	O
a	O
reference	O
)	O
(	O
for	O
Koos	O
Grade	O
II	O
,	O
OR	O
0.17	O
and	O
p	O
=	O
0.002	O
;	O
for	O
Koos	O
Grade	O
III	O
,	O
OR	O
0.42	O
and	O
p	O
=	O
0.05	O
)	O
.	O
The	O
following	O
were	O
not	O
statistically	O
significant	O
but	O
showed	O
a	O
tendency	O
toward	O
significance	O
:	O
the	O
number	O
of	O
isocenters	O
(	O
p	O
=	O
0.06	O
;	O
OR	O
0.94	O
)	O
and	O
the	O
maximal	O
dose	O
received	O
by	O
the	O
cochlea	B-T047
(	O
p	O
=	O
0.07	O
;	O
OR	O
0.74	O
)	O
.	O
Fractional	O
polynomial	O
regression	O
analysis	O
showed	O
a	O
nonlinear	O
relationship	O
between	O
the	O
outcome	O
and	O
the	O
radiation	O
dose	O
rate	O
(	O
minimum	O
reached	O
at	O
a	O
cutoff	O
of	O
2.5	O
Gy	O
/	O
minute	O
)	O
and	O
the	O
maximal	O
vestibular	O
dose	O
(	O
maximum	O
reached	O
at	O
a	O
cutoff	O
of	O
8	O
Gy	O
)	O
,	O
but	O
the	O
small	O
sample	O
size	O
precludes	O
a	O
detailed	O
analysis	O
of	O
the	O
former	O
.	O
The	O
clinical	O
acute	O
AREs	O
disappeared	O
in	O
32	O
(	O
91.4	O
%	O
)	O
patients	O
during	O
the	O
first	O
6	O
months	O
after	O
appearance	O
.	O
Permanent	O
and	O
somewhat	O
disabling	B-T047
morbidity	O
was	O
found	O
in	O
3	O
cases	O
(	O
1.9	O
%	O
from	O
the	O
whole	O
series	O
):	O
1	O
each	O
with	O
complete	B-T033
hearing	I-T033
loss	I-T033
(	O
GR	O
Class	O
I	O
before	O
and	O
V	O
after	O
)	O
,	O
hemifacial	B-T033
spasm	I-T033
(	O
persistent	O
but	O
alleviated	O
)	O
,	O
and	O
dysgeusia	B-T033
.	O
CONCLUSIONS	O
Acute	O
effects	O
after	O
radiosurgery	B-T061
for	O
VS	B-T191
are	O
not	O
rare	O
.	O
They	O
concern	O
predominantly	O
de	O
novo	O
vertigo	B-T184
and	O
gait	B-T033
disturbance	I-T033
and	O
the	O
exacerbation	B-T033
of	O
preexistent	O
hearing	B-T033
loss	I-T033
.	O
In	O
de	O
novo	O
vestibular	O
symptom	B-T184
s	O
,	O
a	O
vestibular	O
dose	O
of	O
more	O
than	O
8	O
Gy	O
is	O
thought	O
to	O
play	O
a	O
role	O
.	O
In	O
most	O
cases	O
,	O
none	O
of	O
these	O
effects	O
are	O
permanent	O
,	O
and	O
they	O
will	O
ultimately	O
improve	O
or	O
disappear	O
with	O
steroid	B-T061
therapy	I-T061
.	O
Permanent	O
AREs	O
remain	O
very	O
rare	O
.	O
      
Adenosine	B-T121
and	O
the	O
adenosine	B-T121
A2A	I-T121
receptor	I-T121
agonist	I-T121
,	O
CGS21680	B-T121
,	O
upregulate	O
CD39	O
and	O
CD73	O
expression	O
through	O
E2F-1	O
and	O
CREB	O
in	O
regulatory	O
T	O
cells	O
isolated	O
from	O
septic	O
mice	O
The	O
number	O
of	O
regulatory	O
T	O
cells	O
(	O
Treg	O
cells	O
)	O
and	O
the	O
expression	O
of	O
ectonucleoside	O
triphosphate	O
diphosphohydrolase	O
1	O
(	O
ENTPD1	O
;	O
also	O
known	O
as	O
CD39	O
)	O
and	O
5'-ectonucleotidase	O
(	O
NT5E	O
;	O
also	O
known	O
as	O
CD73	O
)	O
on	O
the	O
Treg	O
cell	O
surface	O
are	O
increased	O
during	O
sepsis	B-T047
.	O
In	O
this	O
study	O
,	O
to	O
determine	O
the	O
factors	O
leading	O
to	O
the	O
high	O
expression	O
of	O
CD39	O
and	O
CD73	O
,	O
and	O
the	O
regulation	O
of	O
the	O
CD39	O
/	O
CD73	O
/	O
adenosine	B-T121
pathway	O
in	O
Treg	O
cells	O
under	O
septic	O
conditions	O
,	O
we	O
constructed	O
a	O
mouse	B-T050
model	I-T050
of	O
sepsis	B-T047
and	O
separated	O
the	O
Treg	O
cells	O
using	O
a	O
flow	O
cytometer	O
.	O
The	O
Treg	O
cells	O
isolated	O
from	O
the	O
peritoneal	B-T058
lavage	I-T058
and	O
splenocytes	O
of	O
the	O
mice	O
were	O
treated	B-T061
with	I-T061
adenosine	B-T121
or	O
the	O
specific	O
adenosine	B-T121
A2A	I-T121
receptor	I-T121
agonist	I-T121
,	O
CGS21680	B-T121
,	O
and	O
were	O
transfected	O
with	O
specific	O
siRNA	O
targeting	O
E2F	O
transcription	O
factor	O
1	O
(	O
E2F-1	O
)	O
or	O
cyclic	O
adenosine	O
monophosphate	O
(	O
cAMP	O
)	O
response	O
element	O
-	O
binding	O
protein	O
(	O
CREB	O
)	O
,	O
which	O
are	O
predicted	O
transcription	O
regulatory	O
factors	O
of	O
CD39	O
or	O
CD73	O
.	O
The	O
regulatory	O
relationships	O
among	O
these	O
factors	O
were	O
then	O
determined	O
by	O
western	B-T059
blot	I-T059
analysis	I-T059
and	O
dual	B-T059
-	I-T059
luciferase	I-T059
reporter	I-T059
assay	I-T059
.	O
In	O
addition	O
,	O
changes	O
in	O
adenosine	O
metabolism	O
were	O
measured	O
in	O
the	O
treated	O
cells	O
.	O
The	O
results	O
revealed	O
that	O
adenosine	B-T121
and	O
CGS21680	B-T121
significantly	O
upregulated	O
CD39	O
and	O
CD73	O
expression	O
(	O
P<0.01	O
)	O
.	O
E2F-1	O
and	O
CREB	O
induced	O
CD39	O
and	O
CD73	O
expression	O
,	O
and	O
were	O
upregulated	O
by	O
adenosine	B-T121
and	O
CGS21680	B-T121
.	O
Adenosine	O
triphosphate	O
(	O
ATP	O
)	O
hydrolysis	O
and	O
adenosine	B-T121
generation	O
were	O
inhibited	O
by	O
the	O
knockdown	O
of	O
E2F-1	O
or	O
CREB	O
,	O
and	O
were	O
accelerated	O
in	O
the	O
presence	O
of	O
CGS21680	B-T121
.	O
Based	O
on	O
these	O
results	O
,	O
it	O
can	O
be	O
inferred	O
that	O
adenosine	B-T121
,	O
the	O
adenosine	B-T121
A2A	I-T121
receptor	I-T121
agonist	I-T121
,	O
E2F-1	O
and	O
CREB	O
are	O
the	O
possible	O
factors	O
contributing	O
to	O
the	O
high	O
expression	O
of	O
CD39	O
and	O
CD73	O
on	O
the	O
Treg	O
cell	O
surface	O
during	O
sepsis	B-T047
.	O
Adenosine	B-T121
and	O
its	O
A2A	B-T121
receptor	I-T121
agonist	I-T121
served	O
as	O
the	O
signal	O
transducer	O
factors	O
of	O
the	O
CD39	O
/	O
CD73	O
/	O
adenosine	B-T121
pathway	O
,	O
accelerating	O
adenosine	B-T121
generation	O
.	O
Our	O
study	O
may	O
benefit	O
further	O
research	O
on	O
adenosine	O
metabolism	O
for	O
the	O
treatment	B-T061
of	O
sepsis	B-T047
.	O
      
Variation	O
in	O
the	O
age	O
of	O
first	O
reproduction	O
:	O
different	O
strategies	O
or	O
individual	O
quality	O
?	O
Although	O
age	O
at	O
first	O
reproduction	O
is	O
a	O
key	O
demographic	O
parameter	O
that	O
is	O
probably	O
under	O
high	B-T033
selective	I-T033
pressure	I-T033
,	O
it	O
is	O
highly	O
variable	O
and	O
the	O
cause	O
of	O
this	O
variability	O
is	O
not	O
well	O
understood	O
.	O
Two	O
non	O
-	O
exclusive	O
hypotheses	O
may	O
explain	O
such	O
variability	O
.	O
It	O
could	O
be	O
the	O
expression	O
of	O
different	O
individual	O
strategies	O
,	O
i.e.	O
,	O
different	O
allocation	O
strategies	O
in	O
fitness	O
components	O
,	O
or	O
the	O
consequences	O
of	O
individual	O
difference	O
in	O
intrinsic	O
quality	O
,	O
i.e.	O
,	O
some	O
individuals	O
always	O
doing	O
better	O
than	O
others	O
in	O
all	O
fitness	O
components	O
.	O
We	O
tested	O
these	O
hypotheses	O
in	O
the	O
Wandering	O
Albatross	O
investigating	O
relationships	O
between	O
the	O
age	O
at	O
first	O
reproduction	O
and	O
subsequent	O
adult	O
demographic	O
traits	O
.	O
Using	O
finite	O
mixture	O
capture	O
recapture	O
modeling	O
,	O
we	O
demonstrate	O
that	O
the	O
age	O
at	O
first	O
reproduction	O
is	O
negatively	B-T033
related	O
to	O
both	O
reproductive	O
performances	O
and	O
adult	O
survival	O
,	O
suggesting	O
that	O
individual	O
quality	O
was	O
an	O
important	O
factor	O
explaining	O
variation	O
in	O
the	O
age	O
at	O
first	O
reproduction	O
.	O
Our	O
results	O
suggest	O
that	O
age	O
at	O
first	O
breeding	O
is	O
a	O
good	O
predictor	O
of	O
quality	O
in	O
this	O
long	O
-	O
lived	O
seabird	O
species	O
.	O
      
Methodology	O
development	O
on	O
aquatic	O
environmental	O
assessment	B-T058
The	O
Water	O
Framework	O
Directive	O
aims	O
at	O
reaching	O
the	O
good	O
ecological	O
status	O
of	O
the	O
surface	O
and	O
ground	O
water	O
bodies	O
(	O
László	O
et	O
al	O
.	O
Microchem	O
J	O
85(1):65	O
-	O
71	O
,	O
2007	O
)	O
.	O
The	O
paper	O
deals	O
with	O
quality	O
evaluation	B-T058
of	O
waters	B-T121
with	O
special	O
focus	O
on	O
the	O
water	B-T121
chemistry	O
parameters	O
as	O
defined	O
in	O
the	O
Water	O
Framework	O
Directive	O
and	O
pertaining	O
legal	O
regulations	O
.	O
The	O
purpose	O
of	O
this	O
paper	O
is	O
to	O
devise	O
a	O
quantitative	O
type	O
of	O
water	B-T121
quality	O
assessment	B-T058
method	O
which	O
could	O
provide	O
rapid	O
,	O
accurate	O
,	O
and	O
reliable	O
information	O
on	O
the	O
quality	O
of	O
the	O
surface	O
waters	B-T121
by	O
using	O
water	B-T121
chemistry	O
parameters	O
.	O
Quality	O
classes	O
have	O
been	O
defined	O
for	O
every	O
water	B-T121
chemistry	O
parameter	O
in	O
light	O
of	O
the	O
legal	O
limit	O
values	O
of	O
the	O
water	B-T121
parameters	O
.	O
In	O
addition	O
to	O
this	O
,	O
weight	O
indices	O
were	O
calculated	B-T059
on	O
the	O
basis	O
of	O
the	O
outcome	O
of	O
the	O
paired	O
comparison	O
of	O
water	B-T121
chemistry	O
parameters	O
and	O
normalized	O
matrix	O
.	O
This	O
was	O
followed	O
by	O
the	O
parametric	O
level	O
analysis	O
of	O
the	O
water	B-T121
chemistry	O
parameters	O
,	O
and	O
finally	O
,	O
the	O
aquatic	O
environment	O
index	O
(	O
AEI	O
)	O
was	O
calculated	B-T059
,	O
which	O
provided	O
general	O
information	O
on	O
the	O
quality	O
of	O
water	B-T121
regarding	O
the	O
water	B-T121
chemistry	O
parameters	O
.	O
The	O
method	O
was	O
illustrated	O
on	O
Lake	O
Balaton	O
,	O
Hungary	O
in	O
which	O
case	O
water	B-T121
samples	O
taken	O
from	O
Balatonfüred	O
City	O
lake	O
area	O
were	O
analyzed	O
and	O
evaluated	B-T058
with	O
the	O
method	O
devised	O
.	O
      
Nutrients	O
influence	O
the	O
thermal	O
ecophysiology	O
of	O
an	O
intertidal	O
macroalga	O
:	O
multiple	O
stressors	O
or	O
multiple	O
drivers	O
?	O
Urbanization	O
of	O
coastlines	O
is	O
leading	O
to	O
increased	O
introduction	O
of	O
nutrients	O
from	O
the	O
terrestrial	O
environment	O
to	O
nearshore	O
habitats	O
.	O
While	O
such	O
nutrient	O
influxes	O
can	O
be	O
detrimental	O
to	O
coastal	O
marine	B-T001
organisms	I-T001
due	O
to	O
increased	O
eutrophication	O
and	O
subsequent	O
reduced	O
oxygen	B-T121
,	O
they	O
could	O
also	O
have	O
positive	O
effects	O
(	O
i.e.	O
,	O
increased	O
food	O
availability	O
)	O
on	O
species	O
that	O
are	O
nitrogen	O
-	O
limited	O
such	O
as	O
macroalgae	O
.	O
Nutrient	O
enrichment	O
in	O
this	O
environment	O
thus	O
has	O
the	O
potential	O
to	O
counteract	O
some	O
of	O
the	O
negative	O
impacts	O
of	O
increasing	O
temperatures	O
,	O
at	O
least	O
for	O
some	O
species	O
.	O
Characterizing	O
the	O
physiological	O
response	O
of	O
organisms	B-T001
to	O
simultaneous	O
changes	O
in	O
multiple	O
drivers	O
such	O
as	O
these	O
is	O
an	O
important	O
first	O
step	O
in	O
predicting	O
how	O
global	O
climate	O
change	O
may	O
lead	O
to	O
ecological	O
responses	O
at	O
more	O
local	O
levels	O
.	O
We	O
evaluated	O
how	O
nutrient	O
enrichment	O
(	O
i.e.	O
,	O
nitrogen	O
availability	O
)	O
affected	O
the	O
growth	O
of	O
Fucus	O
vesiculosus	O
,	O
a	O
foundational	O
macroalgal	O
species	O
in	O
the	O
North	O
Atlantic	O
rocky	O
intertidal	O
zone	O
,	O
and	O
found	O
that	O
nutrient	O
-enriched	O
algal	O
blades	O
showed	O
a	O
significant	O
increase	O
in	O
tissue	O
growth	O
compared	O
to	O
individuals	O
grown	O
under	O
ambient	O
conditions	O
.	O
We	O
further	O
quantified	O
net	O
photosynthesis	O
by	O
ambient	O
and	O
nutrient	O
-enriched	O
tissues	O
at	O
saturating	O
irradiance	O
over	O
a	O
range	O
of	O
temperature	O
conditions	O
(	O
6	O
-	O
30	O
°	O
C	O
)	O
.	O
Respiration	O
was	O
unaffected	O
by	O
nutrient	O
treatment	O
;	O
however	O
,	O
there	O
was	O
a	O
significant	O
increase	O
in	O
photosynthetic	O
oxygen	B-T121
production	O
for	O
nutrient	O
-enriched	O
tissue	O
compared	O
to	O
ambient	O
,	O
but	O
only	O
at	O
elevated	O
(	O
≥18	O
°	O
C	O
)	O
temperatures	O
.	O
This	O
study	O
contributes	O
to	O
a	O
growing	O
body	O
of	O
literature	O
showing	O
the	O
complexity	O
of	O
responses	O
to	O
changes	O
in	O
multiple	O
drivers	O
,	O
and	O
highlights	O
the	O
importance	O
of	O
studying	O
the	O
impacts	O
of	O
global	O
climate	O
change	O
within	O
the	O
context	O
of	O
more	O
local	O
environmental	O
conditions	O
.	O
      
Gga	O
-	O
miR-21	O
inhibits	O
chicken	O
pre	O
-	O
adipocyte	O
proliferation	O
in	O
part	O
by	O
down	O
-	O
regulating	O
Kruppel	O
-	O
like	O
factor	O
5	O
Gga	O
-	O
miR-21	O
is	O
abundantly	O
expressed	O
in	O
chicken	O
pre	O
-	O
adipocytes	O
,	O
but	O
its	O
role	O
is	O
unclear	O
.	O
The	O
present	O
study	O
investigated	O
the	O
role	O
of	O
gga	O
-	O
miR-21	O
in	O
chicken	O
pre	O
-	O
adipocyte	O
proliferation	O
.	O
Cell	O
proliferation	O
assay	O
and	O
gene	O
expression	O
analysis	O
of	O
proliferating	O
cell	O
nuclear	O
antigen	O
(	O
PCNA	O
)	O
showed	O
that	O
the	O
gga	O
-	O
miR-21	O
mimic	O
inhibited	O
pre	O
-	O
adipocyte	O
proliferation	O
.	O
In	O
contrast	O
,	O
the	O
gga	O
-	O
miR-21	O
inhibitor	O
enhanced	O
pre	O
-	O
adipocyte	O
proliferation	O
.	O
The	O
subsequent	O
investigation	O
identified	O
Kruppel	O
-	O
like	O
factor	O
5	O
(	O
KLF5	O
)	O
mRNA	O
as	O
a	O
target	O
of	O
gga	O
-	O
miR-21	O
.	O
The	O
gga	O
-	O
miR-21	O
mimic	O
inhibited	O
KLF5	O
3(')UTR	O
reporter	O
activity	O
and	O
decreased	O
endogenous	O
KLF5	O
expression	O
in	O
primary	O
pre	O
-	O
adipocytes	O
.	O
KLF5	O
knockdown	O
using	O
RNAi	O
had	O
a	O
similar	O
effect	O
to	O
that	O
of	O
the	O
gga	O
-	O
miR-21	O
mimic	O
on	O
cell	O
proliferation	O
.	O
The	O
promoting	O
effect	O
of	O
the	O
gga	O
-	O
miR-21	O
inhibitor	O
on	O
pre	O
-	O
adipocyte	O
proliferation	O
was	O
partially	O
attenuated	O
by	O
KLF5	O
knockdown	O
.	O
Taken	O
together	O
,	O
our	O
results	O
demonstrated	O
that	O
miR-21	O
inhibits	O
chicken	O
pre	O
-	O
adipocyte	O
proliferation	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
targeting	O
KLF5	O
.	O
      
Distal	O
posterior	B-T023
cerebral	I-T023
artery	I-T023
revascularization	B-T061
for	O
a	O
fusiform	O
PCA	B-T023
aneurysm	B-T047
:	O
A	O
lesson	O
learned	O
The	O
need	O
for	O
revascularization	B-T061
with	O
proximal	O
posterior	B-T023
cerebral	I-T023
artery	I-T023
occlusion	B-T020
in	O
the	O
treatment	O
of	O
giant	B-T047
and	O
fusiform	B-T190
aneurysms	I-T190
is	O
unclear	O
.	O
While	O
early	O
series	O
demonstrated	O
only	O
about	O
a	O
10	O
%	O
chance	O
of	O
infarction	O
following	O
posterior	B-T023
cerebral	I-T023
artery	I-T023
occlusion	B-T020
,	O
recently	O
several	O
authors	O
have	O
advocated	O
a	O
bypass	B-T061
prior	O
to	O
parent	O
vessel	B-T023
sacrifice	O
in	O
all	O
cases	O
.	O
We	O
present	O
the	O
case	O
of	O
an	O
adult	O
man	O
with	O
a	O
fusiform	B-T190
aneurysm	I-T190
of	O
the	O
right	O
posterior	B-T023
cerebral	I-T023
artery	I-T023
at	O
the	O
P2	O
-	O
P3	O
junction	O
.	O
He	O
clinically	B-T033
failed	I-T033
a	O
balloon	B-T058
test	I-T058
occlusion	I-T058
preoperatively	O
and	O
therefore	O
underwent	O
an	O
occipital	B-T023
artery	I-T023
to	O
distal	O
posterior	B-T023
cerebral	I-T023
artery	I-T023
bypass	B-T061
with	O
subsequent	O
endovascular	B-T061
occlusion	I-T061
of	I-T061
the	I-T061
parent	I-T061
vessel	I-T061
and	O
aneurysm	B-T047
.	O
Despite	O
the	O
fact	O
that	O
the	O
immediate	O
and	O
6	O
month	O
follow	B-T058
up	I-T058
cerebral	B-T060
angiography	I-T060
confirmed	O
a	O
patent	O
bypass	B-T061
,	O
the	O
patient	O
still	O
developed	O
a	O
posterior	B-T023
cerebral	I-T023
artery	I-T023
territory	B-T047
stroke	I-T047
.	O
We	O
believe	O
this	O
case	O
demonstrates	O
that	O
successful	O
distal	O
revascularization	B-T061
in	O
the	O
setting	O
of	O
proximal	O
posterior	B-T023
cerebral	I-T023
artery	I-T023
occlusion	B-T020
does	O
not	O
guarantee	O
against	O
cerebral	B-T047
ischemia	I-T047
and	O
infarction	O
even	O
in	O
those	O
patients	O
that	O
fail	O
a	O
test	B-T058
occlusion	I-T058
.	O
      
Transcriptome	B-T059
sequencing	I-T059
and	O
de	O
novo	O
characterization	O
of	O
Korean	O
endemic	O
land	O
snail	O
,	O
Koreanohadra	O
kurodana	O
for	O
functional	O
transcripts	O
and	O
SSR	O
markers	O
The	O
Korean	O
endemic	O
land	O
snail	O
Koreanohadra	O
kurodana	O
(	O
Gastropoda	O
:	O
Bradybaenidae	O
)	O
found	O
in	O
humid	O
areas	O
of	O
broadleaf	O
forests	O
and	O
shrubs	O
have	O
been	O
considered	O
vulnerable	O
as	O
the	O
number	O
of	O
individuals	O
are	O
declining	O
in	O
recent	O
years	O
.	O
The	O
species	O
is	O
poorly	O
characterized	O
at	O
the	O
genomic	O
level	O
that	O
limits	O
the	O
understanding	O
of	O
functions	O
at	O
the	O
molecular	O
and	O
genetics	O
level	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
performed	O
de	O
novo	O
transcriptome	B-T059
sequencing	I-T059
to	O
produce	O
a	O
comprehensive	O
transcript	O
dataset	O
of	O
visceral	O
mass	O
tissue	O
of	O
K.	O
kurodana	O
by	O
the	O
Illumina	O
paired	O
-	O
end	O
sequencing	O
technology	O
.	O
Over	O
234	O
million	O
quality	O
reads	O
were	O
assembled	O
to	O
a	O
total	O
of	O
315,924	O
contigs	O
and	O
191,071	O
unigenes	O
,	O
with	O
an	O
average	O
and	O
N50	O
length	O
of	O
585.6	O
and	O
715	O
bp	O
and	O
678	O
and	O
927	O
bp	O
,	O
respectively	O
.	O
Overall	O
,	O
36.32	O
%	O
of	O
the	O
unigenes	O
found	O
matches	O
to	O
known	O
protein	O
/	O
nucleotide	O
sequences	O
in	O
the	O
public	O
databases	O
.	O
The	O
direction	O
of	O
the	O
unigenes	O
to	O
functional	O
categories	O
was	O
determined	O
using	O
COG	O
,	O
GO	O
,	O
KEGG	O
,	O
and	O
InterProScan	O
protein	O
domain	O
search	O
.	O
The	O
GO	O
analysis	O
search	O
resulted	O
in	O
22,967	O
unigenes	O
(	O
12.02	O
%	O
)	O
being	O
categorized	O
into	O
40	O
functional	O
groups	O
.	O
The	O
KEGG	O
annotation	O
revealed	O
that	O
metabolism	O
pathway	O
genes	O
were	O
enriched	O
.	O
The	O
most	O
prominent	O
protein	O
motifs	O
include	O
the	O
zinc	O
finger	O
,	O
ribonuclease	O
H	O
,	O
reverse	O
transcriptase	O
,	O
and	O
ankyrin	O
repeat	O
domains	O
.	O
The	O
simple	O
sequence	O
repeats	O
(	O
SSRs	O
)	O
identified	O
from	O
>	O
1	O
kb	O
length	O
of	O
unigenes	O
show	O
a	O
dominancy	O
of	O
dinucleotide	O
repeat	O
motifs	O
followed	O
with	O
tri-	O
and	O
tetranucleotide	O
motifs	O
.	O
A	O
number	O
of	O
unigenes	O
were	O
putatively	O
assessed	O
to	O
belong	O
to	O
adaptation	O
and	O
defense	O
mechanisms	O
including	O
heat	O
shock	O
proteins	O
70	O
,	O
Toll	O
-	O
like	O
receptor	O
4	O
,	O
AMP	O
-	O
activated	O
protein	O
kinase	O
,	O
aquaporin-2	O
,	O
etc	O
.	O
Our	O
data	O
provide	O
a	O
rich	O
source	O
for	O
the	O
identification	O
and	O
functional	O
characterization	O
of	O
new	O
genes	O
and	O
candidate	O
polymorphic	O
SSR	O
markers	O
in	O
K.	O
kurodana	O
.	O
The	O
availability	O
of	O
transcriptome	O
information	O
(	O
http://bioinfo.sch.ac.kr/submission/	O
)	O
would	O
promote	O
the	O
utilization	O
of	O
the	O
resources	O
for	O
phylogenetics	O
study	O
and	O
genetic	O
diversity	O
assessment	O
.	O
      
The	O
cancer	B-T191
Warburg	O
effect	O
may	O
be	O
a	O
testable	O
example	O
of	O
the	O
minimum	O
entropy	O
production	O
rate	O
principle	O
Cancer	O
cells	O
consume	O
more	O
glucose	B-T121
by	O
glycolytic	O
fermentation	O
to	O
lactate	B-T121
than	O
by	O
respiration	O
,	O
a	O
characteristic	O
known	O
as	O
the	O
Warburg	O
effect	O
.	O
In	O
contrast	O
with	O
the	O
34	O
moles	O
of	O
ATP	B-T121
produced	O
by	O
respiration	O
,	O
fermentation	O
produces	O
two	O
moles	O
of	O
ATP	B-T121
per	O
mole	O
of	O
glucose	B-T121
consumed	O
,	O
which	O
poses	O
a	O
puzzle	O
on	O
the	O
function	O
of	O
the	O
Warburg	O
effect	O
.	O
Productions	O
of	O
free	O
energy	O
(	O
ΔG	O
)	O
,	O
enthalpy	O
(	O
ΔH	O
)	O
and	O
entropy	O
(	O
ΔS	O
)	O
per	O
mole	O
linearly	O
vary	O
with	O
the	O
fraction	O
(	O
x	O
)	O
of	O
glucose	B-T121
consumed	O
by	O
fermentation	O
that	O
is	O
frequently	O
estimated	O
around	O
0.9	O
.	O
Hence	O
,	O
calculation	O
shows	O
that	O
,	O
in	O
respect	O
to	O
pure	O
respiration	O
,	O
the	O
predominant	O
fermentative	O
metabolism	O
decreases	O
around	O
10	O
%	O
the	O
production	O
of	O
entropy	O
per	O
mole	O
of	O
glucose	B-T121
consumed	O
in	O
cancer	O
cells	O
.	O
We	O
hypothesize	O
that	O
increased	O
fermentation	O
could	O
allow	O
cancer	O
cells	O
to	O
accomplish	O
the	O
Prigogine	O
theorem	O
of	O
the	O
trend	O
to	O
minimize	O
the	O
rate	O
of	O
production	O
of	O
entropy	O
.	O
According	O
the	O
theorem	O
,	O
open	O
cellular	O
systems	O
near	O
the	O
steady	O
state	O
could	O
evolve	O
to	O
minimize	O
the	O
rates	O
of	O
entropy	O
production	O
that	O
may	O
be	O
reached	O
by	O
modified	B-T033
replicating	O
cells	O
producing	O
entropy	O
at	O
low	O
rate	O
.	O
Remarkably	O
,	O
at	O
CO2	O
concentrations	O
above	O
930	O
ppm	O
,	O
glucose	B-T121
respiration	O
produces	O
less	O
entropy	O
than	O
fermentation	O
,	O
which	O
suggests	O
experimental	O
tests	B-T059
to	O
validate	O
the	O
hypothesis	O
of	O
minimization	O
of	O
the	O
rate	O
of	O
entropy	O
production	O
through	O
the	O
Warburg	O
effect	O
.	O
      
Birth	B-T058
Preparedness	I-T058
and	I-T058
Complication	I-T058
Readiness	I-T058
Practice	I-T058
and	O
Associated	O
Factors	O
among	O
Pregnant	O
Women	O
,	O
Northwest	O
Ethiopia	O
Background	O
.	O
Little	O
is	O
known	O
about	O
birth	B-T058
preparedness	I-T058
and	I-T058
complication	I-T058
readiness	I-T058
(	O
BPCR	B-T058
)	O
plan	O
in	O
resource	O
limited	O
settings	O
to	O
decrease	O
maternal	O
mortality	O
.	O
Therefore	O
,	O
this	O
study	O
was	O
done	O
to	O
assess	B-T058
the	O
status	O
of	O
BPCR	B-T058
and	O
associated	O
factors	O
among	O
pregnant	O
women	O
in	O
South	O
Wollo	O
,	O
Northwest	O
Ethiopia	O
,	O
by	O
involving	O
819	O
pregnant	O
women	O
from	O
March	O
to	O
April	O
,	O
2014	O
.	O
Data	O
were	O
collected	O
by	O
using	O
pretested	O
interviewer	O
administered	O
questionnaire	O
and	O
analyzed	O
using	O
a	O
computer	O
program	O
of	O
SPSS	O
version	O
20.00	O
.	O
Results	O
.	O
Pregnant	O
women	O
who	O
were	O
prepared	B-T033
for	O
at	O
least	O
three	O
elements	O
of	O
BPCR	B-T058
were	O
24.1	O
%	O
.	O
Pregnant	O
women	O
knowing	O
at	O
least	O
three	O
key	O
danger	B-T184
signs	I-T184
during	O
pregnancy	O
,	O
delivery	O
,	O
and	O
postnatal	O
period	O
were	O
23.2	O
%	O
,	O
22.6	O
%	O
,	O
and	O
9.6	O
%	O
,	O
respectively	O
.	O
Women	O
having	O
secondary	O
education	O
and	O
higher	O
were	O
6.20	O
(	O
95	O
%	O
CI	O
=	O
[	O
1.36	O
,	O
28.120	O
]	O
)	O
times	O
more	O
likely	O
to	O
be	O
prepared	B-T033
than	O
illiterates	B-T033
.	O
Women	O
having	O
a	O
lifetime	O
history	O
of	O
stillbirth	B-T033
[	O
5.80	O
(	O
1.13	O
,	O
29.63	O
)	O
]	O
,	O
attending	O
ANC	B-T058
for	O
last	O
child	O
pregnancy	O
[	O
5.44	O
(	O
2.07	O
,	O
14.27	O
)	O
]	O
,	O
participating	O
in	O
community	O
BPCR	B-T058
group	O
discussion	O
[	O
4.36	O
(	O
1.17	O
,	O
16.26	O
)	O
]	O
,	O
and	O
having	O
their	O
male	O
partner	O
involved	O
in	O
BPCR	B-T058
counseling	B-T058
during	O
ANC	B-T058
follow	B-T058
-	I-T058
up	I-T058
[	O
4.45	O
(	O
1.95	O
,	O
10.16	O
)	O
]	O
were	O
more	O
likely	O
to	O
be	O
prepared	B-T033
.	O
Conclusions	O
.	O
BPCR	B-T058
was	O
very	O
low	O
and	O
should	O
be	O
strengthened	O
through	O
health	B-T058
communication	I-T058
by	O
involving	O
partner	O
in	O
BPCR	B-T058
counseling	B-T058
.	O
      
A	O
child	O
with	O
phenylketonuria	B-T047
and	O
focal	B-T047
segmental	I-T047
glomerulosclerosis	I-T047
,	O
the	O
bright	O
side	O
of	O
proteinuria	B-T033
Phenylketonuria	B-T047
(	O
PKU	B-T047
)	O
is	O
the	O
most	O
common	O
inborn	B-T047
error	I-T047
of	I-T047
amino	I-T047
acid	I-T047
metabolism	I-T047
.	O
Phenylalanine	O
hydroxylase	O
is	O
the	O
underlying	O
deficient	O
enzyme	O
.	O
If	O
left	O
untreated	B-T033
,	O
growth	B-T047
failure	I-T047
,	O
microcephaly	B-T019
,	O
global	B-T048
developmental	I-T048
delay	I-T048
,	O
seizures	B-T184
and	O
severe	B-T048
intellectual	I-T048
impairment	I-T048
would	O
characterize	O
the	O
clinical	O
picture	O
of	O
PKU	B-T047
.	O
On	O
the	O
other	O
side	O
of	O
protein	O
homeostasis	O
lies	O
nephrotic	B-T047
syndrome	I-T047
.	O
It	O
is	O
a	O
well	O
-	O
known	O
quantitative	O
defect	O
due	O
to	O
significant	O
proteinuria	B-T033
.	O
Focal	B-T047
segmental	I-T047
glomerulosclerosis	I-T047
(	O
FSGS	B-T047
)	O
is	O
a	O
special	O
congenital	O
variant	O
affecting	O
children	O
and	O
adults	O
.	O
Hereby	O
,	O
we	O
describe	O
a	O
three-	O
year	O
old	O
male	O
child	O
who	O
presented	B-T033
with	O
generalized	B-T033
edema	I-T033
and	O
global	B-T048
developmental	I-T048
delay	I-T048
.	O
Investigations	B-T058
revealed	O
PKU	B-T047
along	O
with	O
FSGS	B-T047
.	O
We	O
assume	O
that	O
congenital	B-T047
nephrosis	I-T047
ameliorated	B-T033
the	O
picture	O
of	O
PKU	B-T047
,	O
and	O
had	O
a	O
salutary	O
effect	O
on	O
the	O
growth	O
and	O
development	O
.	O
Such	O
coexistence	O
between	O
PKU	B-T047
and	O
FSGS	B-T047
has	O
n't	O
been	O
described	O
before	O
.	O
      
Targeting	O
the	O
Nrf2	O
/	O
Amyloid	O
-	O
Beta	O
Liaison	O
in	O
Alzheimer	B-T047
's	I-T047
Disease	I-T047
:	O
A	O
Rational	O
Approach	O
Amyloid	O
is	O
a	O
prominent	O
feature	O
of	O
Alzheimer	B-T047
's	I-T047
disease	I-T047
(	O
AD	B-T047
)	O
.	O
Yet	O
,	O
a	O
linear	O
linkage	O
between	O
amyloid	O
-	O
β	O
peptide	O
(	O
Aβ	O
)	O
and	O
the	O
disease	O
onset	O
and	O
progression	O
has	O
recently	O
been	O
questioned	O
.	O
In	O
this	O
context	O
,	O
the	O
crucial	O
partnership	O
between	O
Aβ	O
and	O
Nrf2	O
pathways	O
is	O
acquiring	O
paramount	O
importance	O
,	O
offering	O
prospects	O
for	O
deciphering	O
the	O
Aβ	O
-centered	O
disease	B-T047
network	O
.	O
Here	O
,	O
we	O
report	O
on	O
a	O
new	O
class	O
of	O
antiaggregating	B-T121
agents	I-T121
rationally	O
designed	O
to	O
simultaneously	O
activate	O
transcription	O
-based	O
antioxidant	B-T121
responses	O
,	O
whose	O
lead	B-T121
1	I-T121
showed	O
interesting	O
properties	O
in	O
a	O
preliminary	O
investigation	O
.	O
Relying	O
on	O
the	O
requirements	B-T033
of	O
Aβ	O
recognition	O
,	O
we	O
identified	O
the	O
catechol	B-T121
derivative	I-T121
12	I-T121
.	O
In	O
SH	O
-	O
SY5Y	O
neuroblastoma	O
cells	O
,	O
12	B-T121
combined	O
remarkable	O
free	O
radical	O
scavenger	O
properties	O
to	O
the	O
ability	O
to	O
trigger	O
the	O
Nrf2	O
pathway	O
and	O
induce	O
the	O
Nrf2	O
-	O
dependent	O
defensive	B-T033
gene	O
NQO1	O
by	O
means	O
of	O
electrophilic	O
activation	O
of	O
the	O
transcriptional	O
response	O
.	O
Moreover	O
,	O
12	O
prevented	O
the	O
formation	O
of	O
cytotoxic	O
stable	O
oligomeric	B-T121
intermediates	I-T121
,	O
being	O
significantly	O
more	O
effective	O
,	O
and	O
per	O
se	O
less	O
toxic	O
,	O
than	O
prototype	B-T121
1	I-T121
.	O
More	O
importantly	O
,	O
as	O
different	O
chemical	O
features	O
were	O
exploited	O
to	O
regulate	O
Nrf2	O
and	O
Aβ	O
activities	O
,	O
the	O
two	O
pathways	O
could	O
be	O
tuned	O
independently	O
.	O
These	O
findings	O
point	O
to	O
compound	B-T121
12	I-T121
and	O
its	O
derivatives	B-T121
as	O
promising	O
tools	O
for	O
investigating	O
the	O
therapeutic	O
potential	O
of	O
the	O
Nrf2	O
/	O
Aβ	O
cellular	O
network	O
,	O
laying	O
foundation	O
for	O
generating	O
new	O
drug	B-T121
leads	I-T121
to	O
confront	O
AD	B-T047
.	O
      
Pediatric	O
Hypovitaminosis	B-T047
D	I-T047
:	O
Molecular	O
Perspectives	O
and	O
Clinical	O
Implications	O
Vitamin	B-T121
D	I-T121
,	O
a	O
secosteroid	O
,	O
is	O
essential	O
for	O
the	O
development	O
and	O
maintenance	O
of	O
healthy	O
bone	B-T023
in	O
both	O
the	O
adult	O
and	O
pediatric	O
populations	O
.	O
Low	O
level	O
of	O
25	B-T121
-	I-T121
hydroxy	I-T121
vitamin	I-T121
D	I-T121
(	O
25-(OH)-D	B-T121
)	O
is	O
highly	O
prevalent	O
in	O
children	O
worldwide	O
and	O
has	O
been	O
linked	O
to	O
various	O
adverse	O
health	O
outcomes	O
including	O
rickets	B-T047
,	O
osteomalacia	B-T047
,	O
osteomalacic	B-T047
myopathy	I-T047
,	O
sarcopenia	B-T047
,	O
and	O
weakness	B-T184
,	O
growth	O
retardation	O
,	O
hypocalcemia	B-T047
,	O
seizure	B-T184
and	O
tetany	B-T047
,	O
autism	B-T048
,	O
cardiovascular	B-T047
diseases	I-T047
,	O
diabetes	B-T047
mellitus	I-T047
,	O
cancers	B-T191
(	O
prostate	B-T191
,	O
colon	B-T191
,	O
breast	B-T191
)	O
,	O
infectious	B-T047
diseases	I-T047
(	O
viral	B-T047
,	O
tuberculosis	B-T047
)	O
,	O
and	O
autoimmune	B-T047
diseases	I-T047
,	I-T047
such	O
as	O
multiple	B-T047
sclerosis	I-T047
and	O
Hashimoto	B-T047
's	I-T047
thyroiditis	I-T047
.	O
Risk	B-T033
factors	I-T033
for	O
hypovitaminosis	B-T047
D	I-T047
are	O
people	O
with	O
darker	O
skin	O
pigmentation	O
,	O
use	O
of	O
sunscreen	O
,	O
insufficient	O
ultraviolet	O
B	O
exposure	O
,	O
prematurity	B-T047
,	O
living	O
in	O
northern	O
latitudes	O
,	O
malnutrition	B-T047
,	O
obesity	B-T047
,	O
exclusive	O
breastfeeding	O
,	O
low	B-T033
maternal	I-T033
vitamin	I-T033
D	I-T033
level	I-T033
,	O
certain	O
medications	B-T121
,	O
drinking	O
unfortified	O
cow	O
's	O
milk	O
,	O
liver	B-T047
failure	I-T047
,	O
chronic	B-T047
renal	I-T047
insufficiency	I-T047
,	O
cystic	B-T047
fibrosis	I-T047
,	O
asthma	B-T047
,	O
and	O
sickle	B-T047
cell	I-T047
hemoglobinopathy	I-T047
.	O
This	O
review	O
highlights	O
and	O
summarizes	O
the	O
molecular	O
perspectives	O
of	O
vitamin	B-T047
D	I-T047
deficiency	I-T047
and	O
its	O
potential	O
adverse	O
health	O
outcomes	O
in	O
pediatric	O
age	O
groups	O
.	O
The	O
recommended	B-T033
treatment	I-T033
regimen	I-T033
is	O
beyond	O
the	O
scope	O
of	O
this	O
review	O
.	O
      
A	O
new	O
light	O
on	O
Alkaptonuria	B-T047
:	O
A	O
Fourier	B-T059
-	I-T059
transform	I-T059
infrared	I-T059
microscopy	I-T059
(	O
FTIRM	B-T059
)	O
and	O
low	B-T059
energy	I-T059
X	I-T059
-	I-T059
ray	I-T059
fluorescence	I-T059
microscopy	I-T059
(	O
LEXRF	B-T059
)	O
correlative	O
study	O
on	O
a	O
rare	B-T047
disease	I-T047
Alkaptonuria	B-T047
(	O
AKU	B-T047
)	O
is	O
an	O
ultra	B-T047
-	I-T047
rare	I-T047
disease	I-T047
associated	O
to	O
the	O
lack	O
of	O
an	O
enzyme	O
involved	O
in	O
tyrosine	O
catabolism	O
.	O
This	O
deficiency	O
results	O
in	O
the	O
accumulation	B-T033
of	O
homogentisic	O
acid	O
(	O
HGA	O
)	O
in	O
the	O
form	O
of	O
ochronotic	O
pigment	O
in	O
joint	O
cartilage	O
,	O
leading	O
to	O
a	O
severe	O
arthropathy	B-T047
.	O
Secondary	B-T047
amyloidosis	I-T047
has	O
been	O
also	O
unequivocally	O
assessed	O
as	O
a	O
comorbidity	O
of	O
AKU	B-T047
arthropathy	B-T047
.	O
Composition	O
of	O
ochronotic	O
pigment	O
and	O
how	O
it	O
is	O
structurally	O
related	O
to	O
amyloid	O
is	O
still	O
unknown	O
.	O
We	O
exploited	O
Synchrotron	O
Radiation	O
Infrared	B-T059
and	O
X	B-T059
-	I-T059
Ray	I-T059
Fluorescence	I-T059
microscopies	I-T059
in	O
combination	O
with	O
conventional	O
bio	B-T059
-	I-T059
assays	I-T059
and	O
analytical	O
tools	O
to	O
characterize	O
chemical	O
composition	O
and	O
morphology	O
of	O
AKU	B-T047
cartilage	O
.	O
We	O
evinced	O
that	O
AKU	B-T047
cartilage	O
is	O
characterized	O
by	O
proteoglycans	O
depletion	O
,	O
increased	B-T033
Sodium	I-T033
levels	I-T033
,	O
accumulation	B-T033
of	O
lipids	O
in	O
the	O
peri	O
-	O
lacunar	O
regions	O
and	O
amyloid	O
formation	O
.	O
We	O
also	O
highlighted	O
an	O
increase	O
of	O
aromatic	O
compounds	O
and	O
oxygen	O
-	O
containing	O
species	O
,	O
depletion	O
in	O
overall	O
Magnesium	O
content	O
(	O
although	O
localized	O
in	O
the	O
peri	O
-	O
lacunar	O
region	O
)	O
and	O
the	O
presence	B-T033
of	O
calcium	B-T121
carbonate	I-T121
fragments	O
in	O
proximity	O
of	O
cartilage	O
lacunae	O
.	O
We	O
highlighted	O
common	O
features	O
between	O
AKU	B-T047
and	O
arthropathy	B-T047
,	O
but	O
also	O
specific	O
signatures	O
of	O
the	O
disease	B-T047
,	O
like	O
presence	B-T033
of	O
amyloids	O
and	O
peculiar	B-T033
calcifications	O
.	O
Our	O
analyses	O
provide	O
a	O
unified	O
picture	O
of	O
AKU	B-T047
cartilage	O
,	O
shedding	O
a	O
new	O
light	O
on	O
the	O
disease	B-T047
and	O
opening	O
new	O
perspectives	O
.	O
Ochronotic	O
pigment	O
is	O
a	O
hallmark	O
of	O
AKU	B-T047
and	O
responsible	O
of	O
tissue	O
degeneration	O
.	O
Conventional	O
bio	B-T059
-	I-T059
assays	I-T059
have	O
not	O
yet	O
clarified	O
its	O
composition	O
and	O
its	O
structural	O
relationship	O
with	O
amyloids	O
.	O
The	O
present	O
work	O
proposes	O
new	O
strategies	O
for	O
filling	O
the	O
aforementioned	O
gap	O
that	O
encompass	O
the	O
integration	O
of	O
new	O
analytical	O
approaches	O
with	O
standardized	O
analyses	O
.	O
      
Production	O
of	O
bioactive	O
conjugated	B-T121
linoleic	I-T121
acid	I-T121
by	O
the	O
multifunctional	O
enolase	O
from	O
Lactobacillus	B-T007
plantarum	I-T007
Lactobacillus	B-T007
plantarum	I-T007
α	O
-	O
enolase	O
,	O
a	O
multifunctional	O
-anchorless-	O
surface	O
protein	O
belonging	O
to	O
the	O
conserved	O
family	O
of	O
enolases	O
with	O
a	O
central	O
role	O
in	O
glycolytic	O
metabolism	O
,	O
was	O
characterized	O
to	O
have	O
a	O
side	O
role	O
in	O
the	O
intricate	O
metabolism	O
of	O
biohydrogenation	O
of	O
linoleic	B-T121
acid	I-T121
,	O
catalyzing	O
the	O
formation	O
of	O
bioactive	O
9	O
-	O
cis-11	O
-	O
trans	O
-	O
CLA	O
through	O
dehydration	O
and	O
isomerization	O
of	O
10	O
-	O
hydroxy-12	O
-	O
cis	O
-	O
octadecenoic	O
acid	O
.	O
The	O
identity	O
of	O
the	O
enolase	O
was	O
confirmed	O
through	O
mass	B-T059
spectrometric	I-T059
analysis	I-T059
that	O
showed	O
the	O
characteristic	O
442	O
amino	O
acid	O
sequence	O
with	O
a	O
molecular	O
mass	O
of	O
48.03	O
kDa	O
.	O
The	O
enolase	O
was	O
not	O
capable	O
of	O
using	O
linoleic	B-T121
acid	I-T121
directly	O
as	O
a	O
substrate	O
but	O
instead	O
uses	O
its	O
hydroxyl	O
derivative	O
10	O
-	O
hydroxi-12	O
-	O
cis	O
-	O
octadecenoic	O
acid	O
to	O
finally	O
form	O
bioactive	O
conjugated	O
linoleic	O
acid	O
.	O
Biochemical	O
optimization	O
studies	O
were	O
carried	O
out	O
to	O
elucidate	O
the	O
conditions	O
for	O
maximum	O
production	O
of	O
9	O
-	O
cis-11	O
-	O
trans	O
-	O
CLA	O
and	O
maximum	O
stability	O
of	O
α	O
-	O
enolase	O
when	O
catalyzing	O
this	O
reaction	O
.	O
Furthermore	O
,	O
through	O
structural	B-T061
analysis	I-T061
of	O
the	O
protein	O
,	O
we	O
propose	O
the	O
binding	O
sites	O
of	O
substrate	O
and	O
product	O
molecules	O
that	O
were	O
characterized	O
as	O
two	O
hydrophobic	O
superficial	O
pockets	O
located	O
at	O
opposite	O
ends	O
of	O
the	O
enolase	O
connected	O
through	O
a	O
channel	O
where	O
the	O
catalysis	O
of	O
dehydration	O
and	O
isomerization	O
might	O
occur	O
.	O
These	O
results	O
prove	O
that	O
multifunctional	O
α	O
-	O
enolase	O
also	O
plays	O
a	O
role	O
in	O
cell	O
detoxification	O
from	O
polyunsaturated	O
fatty	O
acids	O
such	O
as	O
linoleic	B-T121
acid	I-T121
,	O
along	O
with	O
the	O
linoleate	O
isomerase	O
complex	O
.	O
      
Museum	O
specimen	O
data	O
reveal	O
emergence	O
of	O
a	O
plant	B-T047
disease	I-T047
may	O
be	O
linked	O
to	O
increases	O
in	O
the	O
insect	O
vector	O
population	O
The	O
emergence	O
rate	O
of	O
new	O
plant	B-T047
diseases	I-T047
is	O
increasing	O
due	O
to	O
novel	O
introductions	O
,	O
climate	O
change	O
,	O
and	O
changes	O
in	O
vector	O
populations	O
,	O
posing	O
risks	O
to	O
agricultural	O
sustainability	O
.	O
Assessing	O
and	O
managing	O
future	O
disease	B-T047
risks	O
depends	O
on	O
understanding	O
the	O
causes	O
of	O
contemporary	O
and	O
historical	O
emergence	O
events	O
.	O
Since	O
the	O
mid-1990s	O
,	O
potato	O
growers	O
in	O
the	O
western	O
United	O
States	O
,	O
Mexico	O
,	O
and	O
Central	O
America	O
have	O
experienced	O
severe	O
yield	O
loss	O
from	O
Zebra	B-T047
Chip	I-T047
disease	I-T047
and	O
have	O
responded	O
by	O
increasing	O
insecticide	O
use	O
to	O
suppress	O
populations	O
of	O
the	O
insect	O
vector	O
,	O
the	O
potato	O
psyllid	O
,	O
Bactericera	O
cockerelli	O
(	O
Hemiptera	O
:	O
Triozidae	O
)	O
.	O
Despite	O
the	O
severe	O
nature	O
of	O
Zebra	B-T047
Chip	I-T047
outbreaks	O
,	O
the	O
causes	O
of	O
emergence	O
remain	O
unknown	O
.	O
We	O
tested	O
the	O
hypotheses	O
that	O
1	O
)	O
B.	O
cockerelli	O
occupancy	O
has	O
increased	O
over	O
the	O
last	O
century	B-T121
in	O
California	O
and	O
2	O
)	O
such	O
increases	O
are	O
related	O
to	O
climate	O
change	O
,	O
specifically	O
warmer	O
winters	O
.	O
We	O
compiled	O
a	O
dataset	O
of	O
87,000	O
museum	O
specimen	O
occurrence	O
records	O
across	O
the	O
order	O
Hemiptera	O
collected	O
between	O
1900	O
and	O
2014	O
.	O
We	O
then	O
analyzed	O
changes	O
in	O
B.	O
cockerelli	O
distribution	O
using	O
a	O
hierarchical	O
occupancy	O
model	O
using	O
changes	O
in	O
background	O
species	O
lists	O
to	O
correct	O
for	O
collecting	O
effort	O
.	O
We	O
found	O
evidence	O
that	O
B.	O
cockerelli	O
occupancy	O
has	O
increased	O
over	O
the	O
last	O
century	B-T121
.	O
However	O
,	O
these	O
changes	O
appear	O
to	O
be	O
unrelated	O
to	O
climate	O
changes	O
,	O
at	O
least	O
at	O
the	O
scale	O
of	O
our	O
analysis	O
.	O
To	O
the	O
extent	O
that	O
species	O
occupancy	O
is	O
related	O
to	O
abundance	O
,	O
our	O
analysis	O
provides	O
the	O
first	O
quantitative	O
support	O
for	O
the	O
hypothesis	O
that	O
B.	O
cockerelli	O
population	O
abundance	O
has	O
increased	O
,	O
but	O
further	O
work	O
is	O
needed	O
to	O
link	O
B.	O
cockerelli	O
population	O
dynamics	O
to	O
Zebra	B-T047
Chip	I-T047
Zebra	B-T047
Chip	I-T047
epidemics	I-T047
.	O
Finally	O
,	O
we	O
demonstrate	O
how	O
this	O
historical	O
macro	O
-	O
ecological	O
approach	O
provides	O
a	O
general	O
framework	O
for	O
comparative	B-T058
risk	I-T058
assessment	I-T058
of	O
future	O
pest	O
and	O
insect	O
vector	O
outbreaks	O
.	O
This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O
All	O
rights	O
reserved	O
.	O
      
Elective	B-T061
Nephron	B-T061
Sparing	I-T061
Surgery	I-T061
Decreases	O
Other	B-T033
Cause	I-T033
Mortality	I-T033
Relative	O
to	O
Radical	B-T061
Nephrectomy	I-T061
Only	O
in	O
Specific	O
Subgroups	O
of	O
Patients	O
with	O
Renal	B-T191
Cell	I-T191
Carcinoma	I-T191
There	O
is	O
no	O
consensus	O
regarding	O
a	O
protective	B-T033
effect	I-T033
on	O
mortality	O
due	O
to	O
a	O
cause	O
other	O
than	O
cancer	B-T191
in	O
patients	O
treated	B-T061
with	I-T061
elective	B-T061
nephron	B-T061
sparing	I-T061
surgery	I-T061
relative	O
to	O
their	O
radical	B-T061
nephrectomy	I-T061
counterparts	O
.	O
We	O
test	O
whether	O
the	O
protective	B-T033
effect	I-T033
of	O
nephron	B-T061
sparing	I-T061
surgery	I-T061
relative	O
to	O
radical	B-T061
nephrectomy	I-T061
is	O
universal	O
or	O
present	O
in	O
specific	O
subgroups	O
of	O
patients	O
.	O
A	O
collaborative	O
database	O
of	O
5	O
institutions	O
was	O
queried	O
to	O
evaluate	B-T058
1,783	O
patients	O
without	O
chronic	B-T047
kidney	I-T047
disease	I-T047
diagnosed	B-T033
with	O
a	O
clinical	O
T1	B-T191
renal	I-T191
mass	I-T191
that	O
was	O
treated	B-T061
with	I-T061
nephron	B-T061
sparing	I-T061
surgery	I-T061
or	O
radical	B-T061
nephrectomy	I-T061
.	O
Multivariable	O
Cox	O
regression	O
analysis	O
was	O
done	O
to	O
assess	B-T058
the	O
impact	O
of	O
surgery	B-T061
type	O
(	O
nephron	B-T061
sparing	I-T061
surgery	I-T061
vs	O
radical	B-T061
nephrectomy	I-T061
)	O
on	O
other	B-T033
cause	I-T033
mortality	I-T033
after	O
adjustment	O
for	O
patient	O
and	O
cancer	B-T191
characteristics	O
.	O
Interaction	O
terms	O
were	O
used	O
to	O
test	O
the	O
hypothesis	O
that	O
the	O
impact	O
of	O
surgery	B-T061
type	O
varies	O
according	O
to	O
specific	O
subcohorts	O
of	O
patients	O
.	O
Ten	O
-	O
year	O
other	B-T033
cause	I-T033
mortality	I-T033
-free	O
survival	O
rates	O
were	O
90	O
%	O
and	O
88	O
%	O
after	O
nephron	B-T061
sparing	I-T061
surgery	I-T061
and	O
radical	B-T061
nephrectomy	I-T061
,	O
respectively	O
.	O
In	O
the	O
overall	O
population	O
radical	B-T061
nephrectomy	I-T061
was	O
not	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
other	B-T033
cause	I-T033
mortality	I-T033
on	O
multivariable	O
analysis	O
compared	O
to	O
nephron	B-T061
sparing	I-T061
surgery	I-T061
(	O
HR	O
0.91	O
,	O
95	O
%	O
CI	O
0.6	O
-	O
1.38	O
,	O
p	O
=	O
0.6	O
)	O
.	O
However	O
,	O
radical	B-T061
nephrectomy	I-T061
increased	O
the	O
risk	O
of	O
other	B-T033
cause	I-T033
mortality	I-T033
according	O
to	O
the	O
increasing	O
baseline	O
Charlson	O
comorbidity	O
index	O
(	O
interaction	O
test	O
p	O
=	O
0.0008	O
)	O
.	O
For	O
example	O
,	O
in	O
a	O
patient	O
with	O
a	O
Charlson	O
comorbidity	O
index	O
of	O
4	O
the	O
probability	O
of	O
10	O
-	O
year	O
other	B-T033
cause	I-T033
mortality	I-T033
-free	O
survival	O
was	O
86	O
%	O
after	O
nephron	B-T061
sparing	I-T061
surgery	I-T061
and	O
60	O
%	O
after	O
radical	B-T061
nephrectomy	I-T061
.	O
Elective	B-T061
nephron	B-T061
sparing	I-T061
surgery	I-T061
does	O
not	O
improve	B-T033
other	O
cause	O
survival	O
relative	O
to	O
radical	B-T061
nephrectomy	I-T061
consistently	O
in	O
all	O
patients	O
with	O
kidney	B-T191
cancer	I-T191
.	O
Patients	O
who	O
are	O
more	O
ill	B-T184
with	O
relevant	O
comorbidities	O
are	O
those	O
who	O
benefit	O
the	O
most	O
from	O
nephron	B-T061
sparing	I-T061
surgery	I-T061
in	O
terms	O
of	O
other	B-T033
cause	I-T033
mortality	I-T033
.	O
      
Morphological	O
characteristics	O
regulating	O
phallic	B-T023
glans	I-T023
engorgement	B-T047
in	O
the	O
American	O
alligator	O
The	O
distal	O
part	O
of	O
the	O
crocodilian	O
phallus	B-T023
consists	O
of	O
a	O
bulbous	B-T023
glans	I-T023
containing	O
well	O
-	O
developed	O
vascular	O
tissues	O
that	O
can	O
inflate	O
before	O
or	O
during	O
sexual	O
activity	O
,	O
enlarging	O
and	O
elaborating	O
the	O
glans	B-T023
into	O
a	O
complex	O
,	O
though	O
still	O
functionally	O
undefined	O
,	O
copulatory	O
structure	O
.	O
An	O
enlarged	O
glans	B-T023
putatively	O
interacts	O
with	O
the	O
female	O
cloaca	B-T023
and	O
may	O
change	O
the	O
shape	O
of	O
her	O
reproductive	O
tract	O
to	O
facilitate	O
insemination	O
and	O
increase	O
the	O
probability	O
of	O
fertilization	O
.	O
Here	O
,	O
we	O
investigated	O
the	O
cellular	O
-	O
level	O
properties	O
of	O
the	O
glans	B-T023
and	O
other	O
inflatable	O
phallic	O
tissues	O
associated	O
with	O
the	O
sperm	O
-conducting	O
sulcus	O
spermaticus	B-T023
in	O
the	O
American	O
alligator	O
(	O
Alligator	O
mississippiensis	O
)	O
.	O
Using	O
histochemical	B-T059
staining	I-T059
,	O
we	O
visualized	O
and	O
defined	O
collagen	O
and	O
elastin	O
fiber	O
densities	O
and	O
orientations	O
in	O
these	O
tissues	O
.	O
Extracellular	O
matrix	O
architectures	O
provided	O
insights	O
about	O
phallic	B-T023
glans	I-T023
material	O
properties	O
and	O
how	O
they	O
may	O
affect	O
tissue	O
strength	O
and	O
flexibility	O
during	O
inflation	O
and	O
in	O
response	O
to	O
copulatory	O
forces	O
.	O
We	O
also	O
investigated	O
the	O
potential	O
sources	O
of	O
fluids	O
that	O
induce	O
inflation	O
in	O
alligator	O
phalli	B-T023
.	O
Combining	O
serial	B-T059
sectioning	I-T059
and	O
three	B-T059
-	I-T059
dimensional	I-T059
reconstruction	I-T059
,	O
we	O
identified	O
a	O
pair	O
of	O
supracrucal	B-T023
plexus	I-T023
vascular	I-T023
bodies	O
at	O
the	O
proximal	O
end	O
of	O
the	O
alligator	O
phallus	B-T023
that	O
extend	O
distally	O
adjacent	O
to	O
ventro	O
-	O
medial	O
sulcus	O
tissues	O
.	O
Together	O
,	O
our	O
gross	O
and	O
histological	B-T033
examination	I-T033
of	O
the	O
American	O
alligator	O
phallic	B-T023
glans	I-T023
suggests	O
that	O
its	O
tissues	O
are	O
arranged	O
in	O
a	O
manner	O
that	O
would	O
allow	O
vascular	B-T023
inflation	O
to	O
expand	O
the	O
glans	B-T023
to	O
a	O
specific	O
and	O
repeatable	O
shape	O
,	O
and	O
potentially	O
release	O
secretory	O
products	O
into	O
the	O
female	O
reproductive	O
tract	O
.	O
Both	O
elements	O
could	O
play	O
roles	O
in	O
postcopulatory	O
sexual	O
selection	O
,	O
by	O
mechanically	O
and/or	O
chemically	O
affecting	O
female	O
reproductive	O
physiology	O
.	O
      
Gut	B-T001
microbiota	I-T001
after	O
Roux	B-T061
-	I-T061
en	I-T061
-	I-T061
Y	I-T061
gastric	I-T061
bypass	I-T061
and	O
sleeve	B-T061
gastrectomy	I-T061
in	O
a	O
diabetic	B-T047
rat	O
model	B-T050
:	O
Increased	O
diversity	O
and	O
associations	O
of	O
discriminant	O
genera	O
with	O
metabolic	O
changes	O
Recent	O
work	O
with	O
gut	B-T001
microbiota	I-T001
after	O
bariatric	B-T061
surgery	I-T061
is	O
limited	O
,	O
and	O
the	O
results	O
have	O
not	O
been	O
in	O
agreement	O
.	O
Given	O
the	O
role	O
of	O
the	O
gut	B-T001
microbiota	I-T001
in	O
regulating	O
host	B-T001
metabolism	O
,	O
we	O
explored	O
the	O
effect	O
of	O
Roux	B-T061
-	I-T061
en	I-T061
-	I-T061
Y	I-T061
gastric	I-T061
bypass	I-T061
(	O
RYGB	B-T061
)	O
and	O
sleeve	B-T061
gastrectomy	I-T061
(	O
SG	B-T061
)	O
on	O
the	O
modifications	O
of	O
gut	B-T001
microbiota	I-T001
with	O
regard	O
to	O
the	O
potential	O
influence	O
of	O
food	O
intake	O
and/or	O
weight	O
loss	O
and	O
examined	O
their	O
links	O
with	O
host	B-T001
metabolism	O
.	O
Zucker	O
diabetic	B-T047
fatty	O
rats	O
were	O
divided	O
into	O
the	O
following	O
groups	O
:	O
RYGB	B-T061
;	O
sham	B-T061
-	I-T061
operated	I-T061
with	O
pair	O
-	O
fed	O
as	O
RYGB	B-T061
;	O
sham	B-T061
-	I-T061
operated	I-T061
fed	O
ad	O
libitum	O
;	O
and	O
SG	B-T061
.	O
The	O
metabolic	O
effects	O
and	O
gut	B-T001
microbiota	I-T001
profile	O
were	O
analyzed	O
10	O
weeks	O
postoperatively	O
.	O
Associations	O
between	O
discriminating	O
genera	O
and	O
metabolic	O
markers	O
after	O
RYGB	B-T061
were	O
explored	O
.	O
The	O
2	O
procedures	B-T061
induced	O
similar	O
glucose	B-T121
improvement	O
and	O
increased	O
flora	B-T001
diversity	O
after	O
10	O
weeks	O
compared	O
with	O
sham	B-T061
-	I-T061
operated	I-T061
groups	O
.	O
RYGB	B-T061
induced	O
a	O
marked	O
higher	O
relative	O
abundance	O
of	O
Proteobacteria	B-T007
/	O
Gammaproteobacteria	B-T007
and	O
Betaproteobacteria	B-T007
and	O
increased	O
emergence	O
of	O
Fusobacteria	B-T007
and	O
Clostridium	B-T007
,	O
whereas	O
SG	B-T061
resulted	O
in	O
more	O
abundant	O
Actinobacteria	B-T007
compared	O
with	O
other	O
groups	O
.	O
Most	O
of	O
the	O
12	O
discriminant	O
genera	O
correlated	O
with	O
changes	O
in	O
metabolic	O
phenotype	O
,	O
but	O
only	O
28.6	O
%	O
of	O
these	O
correlations	O
were	O
independent	O
of	O
weight	O
,	O
and	O
4	O
discriminant	O
genera	O
still	O
negatively	O
correlated	O
with	O
serum	O
insulin	O
level	O
independent	O
of	O
food	O
intake	O
and	O
weight	O
loss	O
after	O
RYGB	B-T061
.	O
These	O
data	O
demonstrate	O
that	O
RYGB	B-T061
and	O
SG	B-T061
surgery	O
produced	O
similar	O
diversity	O
but	O
different	O
microbiota	B-T001
compositions	O
changes	O
in	O
Zucker	O
diabetic	B-T047
fatty	O
rats	O
.	O
These	O
findings	O
stimulate	O
deeper	O
explorations	O
of	O
functions	O
of	O
the	O
discriminate	O
microbiota	B-T001
and	O
the	O
mechanisms	O
linking	O
postsurgical	O
modulation	O
of	O
gut	B-T001
microbiota	I-T001
and	O
improvements	O
in	O
insulin	O
resistance	O
.	O
      
Malignancy	B-T191
is	O
associated	O
with	O
microcalcification	O
and	O
higher	O
AP	O
/	O
T	O
ratio	O
in	O
ultrasonography	B-T060
,	O
but	O
not	O
with	O
Hashimoto	B-T047
's	I-T047
thyroiditis	I-T047
in	O
histopathology	B-T059
in	O
patients	O
with	O
thyroid	B-T191
nodules	I-T191
evaluated	O
as	O
Bethesda	B-T191
Category	I-T191
III	I-T191
(	O
AUS	O
/	O
FLUS	B-T033
)	O
in	O
cytology	B-T059
The	O
predictors	O
of	O
malignancy	B-T191
are	O
important	O
for	O
the	O
decision	O
of	O
appropriate	O
management	B-T058
in	O
nodules	B-T191
with	O
atypia	O
of	O
undetermined	O
significance	O
/	O
follicular	B-T033
lesion	I-T033
of	I-T033
undetermined	I-T033
significance	I-T033
(	O
AUS	O
/	O
FLUS	B-T033
)	O
.	O
Our	O
aim	O
was	O
to	O
determine	O
the	O
ultrasonographical	O
,	O
clinical	O
,	O
and	O
biochemical	O
predictors	O
of	O
malignancy	B-T191
in	O
these	O
patients	O
.	O
A	O
total	O
of	O
427	O
patients	O
with	O
cytologically	B-T191
Bethesda	I-T191
Category	I-T191
III	I-T191
(	O
AUS	O
/	O
FLUS	B-T033
)	O
thyroid	B-T191
nodules	I-T191
were	O
included	O
in	O
this	O
retrospective	O
study	O
.	O
We	O
divided	O
the	O
nodules	B-T191
into	O
two	O
subgroups	O
according	O
to	O
the	O
histopathology	B-T059
as	O
benign	O
and	O
malignant	O
,	O
and	O
compared	O
the	O
preoperative	O
ultrasonographical	O
,	O
clinical	O
,	O
and	O
biochemical	B-T033
findings	I-T033
.	O
In	O
overall	O
,	O
427	O
patients	O
with	O
449	O
AUS	O
/	O
FLUS	B-T033
nodules	B-T191
who	O
had	O
undergone	O
surgery	B-T061
,	O
the	O
rate	O
of	O
malignancy	B-T191
was	O
23.4	O
%	O
(	O
105/449	O
)	O
.	O
When	O
evaluated	O
separately	O
,	O
the	O
rate	O
of	O
malignancy	B-T191
was	O
25.8	O
%	O
in	O
nodules	B-T191
with	O
AUS	O
(	O
82/318	O
)	O
and	O
17.6	O
%	O
in	O
nodules	B-T191
with	O
FLUS	B-T033
(	O
23/131	O
)	O
(	O
p	O
=	O
0.061	O
)	O
.	O
The	O
vast	O
majority	O
of	O
malignant	O
specimens	O
in	O
histopathology	B-T059
consisted	O
of	O
papillary	B-T191
thyroid	I-T191
carcinoma	I-T191
(	O
PTC	B-T191
)	O
(	O
n	O
=	O
91	O
,	O
86.7	O
%	O
)	O
.	O
Preoperative	O
ultrasonographic	O
features	O
of	O
105	O
malignant	B-T191
nodules	I-T191
in	O
histopathology	B-T059
were	O
compared	O
with	O
the	O
344	O
benign	B-T191
nodules	I-T191
in	O
histopathology	B-T059
.	O
Anteroposterior	O
/	O
Transverse	O
(	O
AP	O
/	O
T	O
)	O
ratio	O
was	O
significantly	O
higher	O
in	O
malignant	O
group	O
compared	O
to	O
benign	O
group	O
(	O
p	O
=	O
0.013	O
)	O
.	O
In	O
multiple	O
logistic	O
analysis	O
,	O
we	O
found	O
that	O
higher	O
AP	O
/	O
T	O
ratio	O
and	O
microcalcification	O
were	O
independently	O
associated	O
with	O
malignancy	B-T191
(	O
p	O
<	O
0.05	O
)	O
.	O
The	O
malignancy	B-T191
-associated	O
cut	O
-	O
off	O
value	O
of	O
AP	O
/	O
T	O
ratio	O
at	O
maximum	O
sensitivity	O
and	O
specificity	O
was	O
≥0.81	O
.	O
We	O
did	O
not	O
find	O
any	O
correlation	O
between	O
malignancy	B-T191
and	O
Hashimoto	B-T047
's	I-T047
thyroiditis	I-T047
in	O
histopathology	B-T059
in	O
multivariate	O
analysis	O
(	O
p	O
>	O
0.05	O
)	O
.	O
In	O
Bethesda	B-T191
Category	I-T191
III	I-T191
nodules	I-T191
with	O
higher	O
AP	O
/	O
T	O
ratio	O
and	O
microcalcification	O
,	O
surgery	B-T061
might	O
be	O
considered	O
as	O
a	O
first	O
therapeutic	O
option	O
instead	O
of	O
repeat	O
fine	B-T060
-	I-T060
needle	I-T060
aspiration	I-T060
biopsy	I-T060
or	O
observation	O
.	O
      
Differential	O
control	O
and	O
function	O
of	O
Arabidopsis	O
ProDH1	O
and	O
ProDH2	O
genes	O
on	O
infection	O
with	O
biotrophic	B-T033
and	O
necrotrophic	B-T033
pathogens	B-T001
Arabidopsis	O
contains	O
two	O
proline	O
dehydrogenase	O
(	O
ProDH	O
)	O
genes	O
,	O
ProDH1	O
and	O
ProDH2	O
,	O
encoding	O
for	O
homologous	O
and	O
functional	O
isoenzymes	O
.	O
Although	O
ProDH1	O
has	O
been	O
studied	O
extensively	O
,	O
especially	O
under	O
abiotic	O
stress	O
,	O
ProDH2	O
has	O
only	O
started	O
to	O
be	O
analysed	O
in	O
recent	O
years	O
.	O
These	O
genes	O
display	O
distinctive	O
expression	O
patterns	O
and	O
show	O
weak	O
transcriptional	O
co	O
-	O
regulation	O
,	O
but	O
are	O
both	O
activated	O
in	O
pathogen	B-T001
-	O
infected	B-T033
tissues	O
.	O
We	O
have	O
demonstrated	O
previously	O
that	O
Arabidopsis	O
plants	O
with	O
silenced	O
ProDH1	O
/	O
2	O
expression	O
fail	O
to	O
trigger	O
defences	O
against	O
the	O
hemibiotrophic	B-T033
bacterial	B-T007
pathogen	B-T001
Pseudomonas	B-T007
syringae	I-T007
pv	I-T007
.	I-T007
tomato	I-T007
AvrRpm1	I-T007
(	O
Pst	B-T007
-	I-T007
AvrRpm1	I-T007
)	O
,	O
and	O
that	O
ProDH1	O
and	O
ProDH2	O
are	O
differentially	O
regulated	O
by	O
salicylic	B-T121
acid	I-T121
(	O
SA	B-T121
)	O
.	O
In	O
the	O
current	O
work	O
,	O
we	O
used	O
prodh1	O
and	O
prodh2	O
single-	O
mutant	O
plants	O
to	O
assess	O
the	O
particular	O
contribution	O
of	O
each	O
gene	O
to	O
resistance	O
against	O
Pst	B-T007
-	I-T007
AvrRpm1	I-T007
and	O
the	O
necrotrophic	B-T033
fungal	O
pathogen	O
Botrytis	O
cinerea	O
.	O
In	O
addition	O
,	O
we	O
studied	O
the	O
sensitivity	O
of	O
ProDH1	O
and	O
ProDH2	O
to	O
the	O
jasmonic	O
acid	O
(	O
JA	O
)	O
defence	O
pathway	O
.	O
We	O
found	O
that	O
ProDH1	O
and	O
ProDH2	O
are	O
both	O
necessary	O
to	O
achieve	O
maximum	O
resistance	O
against	O
Pst	B-T007
-	I-T007
AvrRpm1	I-T007
and	O
B.	O
cinerea	O
.	O
However	O
,	O
ProDH2	O
has	O
a	O
major	O
effect	O
on	O
early	O
restriction	O
of	O
B.	O
cinerea	O
growth	O
.	O
Interestingly	O
,	O
ProDH1	O
is	O
up	O
-	O
regulated	O
by	O
SA	B-T121
and	O
JA	O
,	O
whereas	O
ProDH2	O
is	O
only	O
activated	O
by	O
JA	O
,	O
and	O
both	O
genes	O
display	O
transcriptional	O
inter	O
-	O
regulation	O
at	O
basal	O
and	O
infection	O
conditions	O
.	O
These	O
studies	O
provide	O
the	O
first	O
evidence	O
of	O
the	O
contribution	O
of	O
ProDH2	O
to	O
disease	O
resistance	O
,	O
and	O
describe	O
the	O
differential	O
regulation	O
and	O
non	O
-	O
redundant	O
but	O
complementary	O
function	O
of	O
both	O
enzyme	O
isoforms	O
in	O
infected	B-T033
tissues	O
,	O
providing	O
support	O
for	O
a	O
fundamental	O
role	O
of	O
ProDH	O
in	O
the	O
control	O
of	O
biotrophic	B-T033
and	O
necrotrophic	B-T033
pathogens	B-T001
.	O
      
Quantification	O
of	O
intact	O
plasma	O
AGT	O
consisting	O
of	O
oxidized	O
and	O
reduced	O
conformations	O
using	O
a	O
modified	O
ELISA	B-T059
The	O
pleiotropic	O
actions	O
of	O
the	O
renin	O
-	O
angiotensin	O
system	O
(	O
RAS	O
)	O
depend	O
on	O
the	O
availability	O
of	O
angiotensinogen	O
(	O
AGT	O
)	O
which	O
generates	O
angiotensin	O
I	O
(	O
ANG	O
I	O
)	O
when	O
cleaved	O
by	O
renin	O
.	O
Thus	O
,	O
quantification	O
of	O
the	O
intact	O
AGT	O
(	O
iAGT	O
)	O
concentrations	O
is	O
important	O
to	O
evaluate	O
the	O
actual	O
renin	O
substrate	O
available	O
.	O
The	O
iAGT	O
conformation	O
exists	O
as	O
oxidized	O
AGT	O
(	O
oxi	O
-	O
AGT	O
)	O
and	O
reduced	O
AGT	O
(	O
red	O
-	O
AGT	O
)	O
in	O
a	O
disulfide	O
bond	O
,	O
and	O
oxi	O
-	O
AGT	O
has	O
a	O
higher	O
affinity	O
for	O
renin	O
,	O
which	O
may	O
exacerbate	O
RAS	O
-	O
associated	O
diseases	O
.	O
Accordingly	O
,	O
we	O
determined	O
iAGT	O
,	O
oxi	O
-	O
AGT	O
,	O
and	O
red	O
-	O
AGT	O
levels	O
in	O
plasma	O
from	O
rats	O
and	O
mice	O
.	O
Blood	O
samples	O
were	O
obtained	O
by	O
cardiac	B-T059
puncture	I-T059
and	O
then	O
immediately	O
mixed	O
with	O
an	O
inhibitor	O
solution	O
containing	O
a	O
renin	B-T121
inhibitor	I-T121
.	O
Total	O
AGT	O
(	O
tAGT	O
)	O
levels	O
were	O
measured	O
by	O
tAGT	O
ELISA	B-T059
which	O
detects	B-T033
both	O
cleaved	O
and	O
iAGT	O
.	O
iAGT	O
levels	O
were	O
determined	O
by	O
iAGT	O
ELISA	B-T059
which	O
was	O
found	O
to	O
only	O
detect	B-T033
red	O
-	O
AGT	O
.	O
Thus	O
,	O
it	O
was	O
necessary	O
to	O
treat	O
samples	O
with	O
dithiothreitol	B-T121
,	O
a	O
reducing	O
agent	O
,	O
to	O
quantify	O
total	O
iAGT	O
concentration	O
.	O
tAGT	O
levels	O
in	O
rat	O
and	O
mouse	O
plasma	O
were	O
1,839	O
±	O
139	O
and	O
1,082	O
±	O
77	O
ng	O
/	O
ml	O
,	O
respectively	O
.	O
iAGT	O
levels	O
were	O
53	O
%	O
of	O
tAGT	O
in	O
rat	O
plasma	O
but	O
only	O
22	O
%	O
in	O
mouse	O
plasma	O
,	O
probably	O
reflecting	O
the	O
greater	O
plasma	O
renin	O
activity	O
in	O
mice	O
.	O
The	O
ratios	O
of	O
oxi	O
-	O
AGT	O
and	O
red	O
-	O
AGT	O
were	O
∼4:1	O
(	O
rat	O
)	O
and	O
16:1	O
(	O
mouse	O
)	O
.	O
Plasma	O
iAGT	O
consists	O
of	O
oxi	O
-	O
AGT	O
and	O
red	O
-	O
AGT	O
,	O
suggesting	O
that	O
oxidative	O
stress	O
can	O
influence	O
ANG	O
I	O
generation	O
by	O
the	O
AGT	O
conformation	O
switch	O
.	O
Furthermore	O
,	O
the	O
lower	O
availability	O
of	O
plasma	O
iAGT	O
in	O
mice	O
suggests	O
that	O
it	O
may	O
serve	O
as	O
a	O
limiting	O
factor	O
in	O
ANG	O
I	O
formation	O
in	O
this	O
species	O
.	O
      
Neutrophil	O
and	O
Monocyte	O
Function	O
in	O
Patients	O
with	O
Chronic	B-T047
Hepatitis	I-T047
C	I-T047
Undergoing	O
Antiviral	B-T061
Therapy	I-T061
with	O
Regimens	B-T061
Containing	O
Protease	B-T121
Inhibitors	I-T121
with	O
and	O
without	O
Interferon	B-T121
Real	O
-	O
life	O
data	O
showed	O
an	O
increased	O
incidence	O
of	O
bacterial	B-T047
infections	I-T047
in	O
patients	O
with	O
advanced	O
liver	B-T047
disease	I-T047
receiving	O
a	O
protease	B-T121
inhibitor	I-T121
PI	B-T121
(	O
PI)-containing	O
antiviral	B-T061
regimen	I-T061
against	O
hepatitis	B-T005
C	I-T005
(	O
HCV	B-T005
)	O
.	O
However	O
,	O
the	O
causes	O
of	O
this	O
event	O
are	O
unknown	O
.	O
We	O
hypothesized	O
that	O
PIs	B-T121
might	O
impair	O
innate	O
immune	O
responses	O
through	O
the	O
inhibition	O
of	O
proteases	O
participating	O
in	O
the	O
anti	O
-	O
bacterial	O
functions	O
of	O
neutrophils	O
and	O
monocytes	O
.	O
The	O
aims	O
of	O
the	O
study	O
were	O
to	O
assess	B-T058
phagocytic	O
and	O
oxidative	O
burst	O
capacity	O
in	O
neutrophils	O
and	O
monocytes	O
obtained	O
from	O
patients	O
receiving	O
a	O
PI	B-T121
containing-	O
antiviral	B-T061
regimen	I-T061
,	O
and	O
to	O
determine	O
cytokine	O
secretion	O
after	O
neutrophil	O
stimulation	O
with	O
flagellin	O
.	O
Forty	O
patients	O
with	O
chronic	B-T047
HCV	I-T047
(	O
80	O
%	O
with	O
cirrhosis	B-T047
)	O
were	O
enrolled	O
in	O
the	O
study	O
,	O
28	O
received	O
triple	B-T061
therapy	I-T061
(	O
Group	O
A	O
)	O
with	O
pegylated	B-T121
-	I-T121
interferon	I-T121
and	O
ribavirin	B-T121
for	O
4	O
weeks	O
followed	O
by	O
the	O
addition	O
of	O
a	O
PI	B-T121
(	O
telaprevir	B-T121
,	O
boceprevir	B-T121
or	O
simeprevir	B-T121
)	O
,	O
and	O
12	O
patients	O
received	O
an	O
interferon	B-T121
interferon	B-T061
-free	I-T061
regimen	I-T061
(	O
Group	O
B	O
)	O
with	O
simeprevir	B-T121
and	O
sofosbuvir	B-T121
.	O
Phagocytosis	O
and	O
oxidative	O
burst	O
capacity	O
were	O
analyzed	O
by	O
flow	B-T059
cytometry	I-T059
at	O
baseline	O
,	O
week	O
4	O
,	O
and	O
week	O
8	O
of	O
therapy	B-T061
.	O
In	O
neutrophils	O
from	O
Group	O
A	O
patients	O
,	O
oxidative	O
burst	O
rate	O
and	O
oxidative	O
enzymatic	O
activity	O
per	O
cell	O
significantly	O
decreased	O
throughout	O
the	O
study	O
period	O
(	O
p	O
=	O
0.014	O
and	O
p	O
=	O
0.010	O
,	O
respectively	O
)	O
.	O
Pairwise	O
comparisons	O
showed	O
a	O
decrease	O
between	O
baseline	O
and	O
week	O
4	O
and	O
8	O
of	O
therapy	B-T061
.	O
No	O
differences	O
were	O
observed	O
after	O
the	O
introduction	B-T061
of	O
the	O
PI	B-T121
.	O
The	O
oxidative	O
enzymatic	O
activity	O
per	O
cell	O
in	O
monocytes	O
significantly	O
decrease	O
during	O
the	O
study	O
period	O
(	O
p	O
=	O
0.042	O
)	O
due	O
to	O
a	O
decrease	O
from	O
baseline	O
to	O
week	O
8	O
of	O
therapy	B-T061
(	O
p	O
=	O
0.037	O
)	O
in	O
patients	O
from	O
Group	O
A.	O
None	O
of	O
these	O
findings	O
were	O
observed	O
in	O
Group	O
B	O
patients	O
.	O
Cytokine	O
secretion	O
did	O
not	O
significantly	O
change	O
during	O
the	O
study	O
in	O
both	O
groups	O
.	O
In	O
conclusion	O
,	O
our	O
data	O
suggest	O
that	O
the	O
use	O
interferon	B-T121
(	O
rather	O
than	O
the	O
PI	B-T121
)	O
has	O
a	O
deleterious	O
effect	O
on	O
neutrophil	O
and	O
monocyte	O
phagocytic	O
and	O
oxidative	O
burst	O
capacity	O
in	O
this	O
cohort	O
of	O
patients	O
with	O
HCV	B-T005
-related	O
advanced	B-T047
liver	I-T047
fibrosis	I-T047
.	O
      
Studying	O
neuroprotective	O
effect	O
of	O
Atorvastatin	B-T121
as	O
a	O
small	O
molecule	O
drug	B-T121
on	O
high	B-T033
glucose	I-T033
-	O
induced	O
neurotoxicity	O
in	O
undifferentiated	O
PC12	O
cells	O
:	O
role	O
of	O
NADPH	O
oxidase	O
Overproduction	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
by	O
NADPH	O
oxidase	O
(	O
NOX	O
)	O
activation	O
has	O
been	O
considered	O
the	O
essential	O
mechanism	O
induced	O
by	O
hyperglycemia	B-T047
in	O
various	O
tissues	O
.	O
However	O
,	O
there	O
is	O
no	O
comprehensive	O
study	O
on	O
the	O
role	O
of	O
NOXs	O
in	O
high	B-T033
glucose	I-T033
HG	B-T033
(	O
HG)-	O
induced	O
toxic	O
effect	O
in	O
neural	O
tissues	O
.	O
Recently	O
,	O
a	O
therapeutic	O
strategy	O
in	O
oxidative	O
related	O
pathologies	O
has	O
been	O
introduced	O
by	O
blocking	O
the	O
undesirable	O
actions	O
of	O
NOX	O
enzymes	O
by	O
small	O
molecules	O
.	O
The	O
protective	B-T033
roles	O
of	O
Statins	B-T121
in	O
ameliorating	O
oxidative	O
stress	O
by	O
NOX	O
inhibition	O
have	O
been	O
shown	O
in	O
some	O
tissues	O
except	O
neural	O
.	O
We	O
hypothesized	O
then	O
,	O
that	O
different	O
NOXs	O
may	O
have	O
role	O
in	O
HG	B-T033
-	O
induced	O
neural	O
cell	O
injury	O
.	O
Furthermore	O
,	O
we	O
postulate	O
that	O
Atorvastatin	B-T121
as	O
a	O
small	O
molecule	O
may	O
modulate	O
this	O
NOXs	O
activity	O
to	O
protect	B-T033
neural	O
cells	O
.	O
Undifferentiated	O
PC12	O
cells	O
were	O
treated	B-T061
with	I-T061
HG	B-T033
(	O
140	O
mM/	O
24	O
h	O
)	O
in	O
the	O
presence	B-T033
and	O
absence	O
of	O
Atorvastatin	B-T121
(	O
1	O
μM/	O
96	O
h	O
)	O
.	O
The	O
cell	O
viability	O
was	O
measured	O
by	O
MTT	O
assay	O
and	O
the	O
gene	O
and	O
protein	O
expressions	O
profile	O
of	O
NOX	O
(	O
1	O
-	O
4	O
)	O
were	O
determined	O
by	O
RT	O
-	O
PCR	O
and	O
western	B-T059
blotting	I-T059
,	O
respectively	O
.	O
Levels	O
of	O
ROS	O
and	O
malondialdehyde	O
(	O
MDA	O
)	O
were	O
also	O
evaluated	O
.	O
Gene	O
and	O
protein	O
expression	O
levels	O
of	O
NOX	O
(	O
1	O
-	O
4	O
)	O
and	O
consequently	B-T033
ROS	O
and	O
MDA	O
levels	O
were	O
elevated	O
in	O
HG	B-T033
-	O
treated	O
PC12	O
cells	O
.	O
Atorvastatin	B-T121
could	O
significantly	O
decrease	O
HG	B-T033
-	O
induced	O
NOXs	O
,	O
ROS	O
and	O
MDA	O
elevation	O
and	O
improve	B-T033
impaired	O
cell	O
viability	O
.	O
It	O
can	O
be	O
concluded	O
that	O
HG	B-T033
could	O
elevate	O
NOXs	O
activity	O
,	O
ROS	O
and	O
MDA	O
levels	O
in	O
neural	O
tissues	O
and	O
Atorvastatin	B-T121
as	O
a	O
small	O
molecule	O
NOX	B-T121
inhibitor	I-T121
drug	I-T121
may	O
prevent	O
and	O
delay	O
diabetic	B-T047
complications	I-T047
,	O
particularly	O
neuropathy	B-T047
.	O
      
Characterization	O
of	O
novel	O
DeoR	O
-	O
family	O
member	O
from	O
the	O
Streptomyces	B-T007
ahygroscopicus	I-T007
strain	B-T001
CK-15	I-T001
that	O
acts	O
as	O
a	O
repressor	O
of	O
morphological	O
development	O
Wuyiencin	O
is	O
produced	O
by	O
Streptomyces	B-T007
ahygroscopicus	I-T007
var	I-T007
.	I-T007
wuyiensis	I-T007
,	O
which	O
has	O
been	O
widely	O
used	O
in	O
China	O
as	O
an	O
industrially	O
produced	O
biopesticide	O
to	O
control	O
various	O
fungal	B-T047
diseases	I-T047
.	O
Although	O
its	O
mechanism	O
of	O
action	O
,	O
breeding	O
,	O
and	O
fermentation	O
had	O
been	O
extensively	O
characterized	O
,	O
less	O
is	O
known	O
about	O
the	O
regulatory	O
functions	O
that	O
affect	O
its	O
biosynthesis	O
or	O
morphological	O
development	O
.	O
The	O
wysR3	O
gene	O
of	O
S.	B-T007
ahygroscopicus	I-T007
strain	B-T001
CK-15	I-T001
,	O
a	O
novel	O
member	O
of	O
the	O
DeoR	O
family	O
of	O
regulatory	O
genes	O
,	O
was	O
assessed	O
to	O
determine	O
its	O
function	O
by	O
gene	O
knockdown	O
.	O
Herein	O
,	O
we	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
DeoR	O
family	O
proteins	O
derived	O
from	O
the	O
same	O
source	B-T033
are	O
likely	O
to	O
be	O
a	O
single	O
branch	O
in	O
a	O
phylogenetic	O
tree	O
and	O
show	O
that	O
wysR3	O
acts	O
as	O
a	O
repressor	O
for	O
its	O
morphological	O
development	O
without	O
effecting	O
wuyiencin	O
production	O
.	O
We	O
found	O
that	O
the	O
ΔwysR3	O
strain	B-T001
can	O
grow	O
quickly	O
to	O
reach	O
a	O
plateau	O
stage	O
of	O
maximum	O
biomass	O
at	O
60	O
h	O
,	O
which	O
is	O
~12	O
h	O
faster	O
than	O
the	O
wild	O
-	O
type	O
strain	B-T001
.	O
In	O
the	O
industrial	O
fermentation	O
production	O
process	O
,	O
the	O
ΔwysR3	O
strain	B-T001
can	O
reduce	O
consumption	O
and	O
save	O
both	O
time	O
and	O
money	O
.	O
      
Role	O
of	O
cysteine	O
residues	O
in	O
regulation	O
of	O
peptidyl	O
-	O
prolyl	O
cis	O
-	O
trans	O
isomerase	O
activity	O
of	O
wheat	O
cyclophilin	O
TaCYPA-1	O
Oxidative	O
conditions	O
result	O
in	O
inhibition	O
of	O
peptidyl	O
-	O
prolyl	O
cis	O
-	O
trans	O
isomerase	O
(	O
PPIase	O
)	O
activity	O
of	O
several	O
cyclophilins	O
.	O
Thiol	O
groups	O
have	O
been	O
implicated	O
in	O
redox	O
regulation	O
of	O
these	O
proteins	O
.	O
In	O
our	O
previous	O
study	O
,	O
we	O
proposed	O
that	O
activity	O
of	O
wheat	O
cyclophilin	O
,	O
TaCYPA-1	O
,	O
may	O
be	O
modulated	O
through	O
a	O
novel	O
dual	O
mechanism	O
of	O
redox	O
regulation	O
.	O
To	O
further	O
understand	O
the	O
regulation	O
of	O
PPIase	O
activity	O
of	O
TaCYPA-1	O
,	O
we	O
generated	O
mutants	O
of	O
TaCYPA-1	O
by	O
substituting	O
cysteine	O
residues	O
at	O
positions	O
-40	O
and	O
-122	O
with	O
serine	B-T121
,	O
and	O
at	O
-126	O
with	O
proline	O
.	O
Comparative	O
analysis	O
of	O
their	O
PPIase	O
activity	O
revealed	O
that	O
catalytic	O
efficiencies	O
(	O
Kcat	O
/	O
Km	O
)	O
of	O
TaCYPA-1C40S	O
(	O
0.37	O
X	O
106	O
M-1	O
s-1	O
)	O
and	O
TaCYPA-1C122S	O
(	O
0.31	O
X	O
106	O
M-1	O
s-1	O
)	O
were	O
significantly	O
lower	O
as	O
compared	O
to	O
the	O
native	O
TaCYPA-1	O
(	O
1.33	O
X	O
106	O
M-1	O
s-1	O
)	O
,	O
whereas	O
Kcat	O
/	O
Km	O
of	O
the	O
double	O
mutant	O
TaCYPA-1C40S	O
/	O
C122S	O
was	O
significantly	O
higher	O
(	O
2.36	O
X	O
106	O
M-1	O
s-1	O
)	O
.	O
Compared	O
to	O
wild	O
-	O
type	O
TaCYPA-1	O
,	O
the	O
different	O
mutants	O
also	O
showed	O
differential	O
sensitivity	O
to	O
Cu2	B-T121
+	I-T121
.	O
Furthermore	O
,	O
the	O
results	O
of	O
this	O
study	O
also	O
revealed	O
that	O
despite	O
lacking	O
PPIase	O
activity	O
,	O
the	O
mutant	O
TaCYPA-1C126P	O
was	O
able	O
to	O
confer	O
partial	O
protection	B-T033
against	O
heat	O
stress	O
.	O
These	O
observations	O
suggest	O
that	O
the	O
mechanism	O
of	O
TaCYPA-1	O
-induced	O
thermotolerance	O
may	O
also	O
involve	O
other	O
activities	O
besides	O
cis	O
to	O
trans	O
isomerisation	O
,	O
which	O
needs	O
to	O
be	O
identified	O
further	O
.	O
      
Manipulation	O
of	O
an	O
existing	O
crystal	O
form	O
unexpectedly	B-T033
results	I-T033
in	O
interwoven	O
packing	O
networks	O
with	O
pseudo	O
-	O
translational	O
symmetry	O
Nonribosomal	O
peptide	O
synthetases	O
(	O
NRPSs	O
)	O
are	O
multimodular	O
enzymes	O
that	O
synthesize	O
a	O
myriad	O
of	O
diverse	O
molecules	O
.	O
Tailoring	O
domains	O
have	O
been	O
co	O
-	O
opted	O
into	O
NRPSs	O
to	O
introduce	O
further	O
variety	O
into	O
nonribosomal	O
peptide	O
products	O
.	O
Linear	B-T195
gramicidin	I-T195
synthetase	I-T195
contains	O
a	O
unique	O
formylation	O
-	O
tailoring	O
domain	O
in	O
its	O
initiation	O
module	O
(	O
F	O
-	O
A	O
-	O
PCP	O
)	O
.	O
The	O
structure	O
of	O
the	O
F	O
-	O
A	O
di	O
-	O
domain	O
has	O
previously	O
been	O
determined	O
in	O
a	O
crystal	O
form	O
which	O
had	O
large	O
solvent	O
channels	O
and	O
no	O
density	O
for	O
the	O
minor	O
Asub	O
subdomain	O
.	O
An	O
attempt	O
was	O
made	O
to	O
take	O
advantage	O
of	O
this	O
packing	O
by	O
removing	O
the	O
Asub	O
subdomain	O
from	O
the	O
construct	O
(	O
F	O
-	O
A	O
Δ	O
sub	O
)	O
in	O
order	O
to	O
produce	O
a	O
crystal	O
that	O
could	O
accommodate	O
the	O
PCP	O
domain	O
.	O
In	O
the	O
resulting	O
crystal	O
the	O
original	O
packing	O
network	O
was	O
still	O
present	O
,	O
but	O
a	O
second	O
network	O
with	O
the	O
same	O
packing	O
and	O
almost	O
no	O
contact	O
with	O
the	O
original	O
network	O
took	O
the	O
place	O
of	O
the	O
solvent	O
channels	O
and	O
changed	O
the	O
space	O
group	O
of	O
the	O
crystal	O
.	O
      
Metatranscriptomics	B-T059
Reveals	O
the	O
Active	O
Bacterial	B-T007
and	O
Eukaryotic	B-T007
Fibrolytic	I-T007
Communities	I-T007
in	O
the	O
Rumen	B-T023
of	O
Dairy	O
Cow	O
Fed	O
a	O
Mixed	O
Diet	O
Ruminants	O
have	O
a	O
unique	O
ability	O
to	O
derive	O
energy	O
from	O
the	O
degradation	O
of	O
plant	O
polysaccharides	B-T121
through	O
the	O
activity	O
of	O
the	O
rumen	B-T023
microbiota	O
.	O
Although	O
this	O
process	O
is	O
well	O
studied	O
in	O
vitro	O
,	O
knowledge	O
gaps	O
remain	O
regarding	O
the	O
relative	O
contribution	O
of	O
the	O
microbiota	O
members	O
and	O
enzymes	O
in	O
vivo	O
.	O
The	O
present	O
study	O
used	O
RNA	B-T059
-	I-T059
sequencing	I-T059
to	O
reveal	O
both	O
the	O
expression	O
of	O
genes	O
encoding	O
carbohydrate	O
-	O
active	O
enzymes	O
(	O
CAZymes	O
)	O
by	O
the	O
rumen	B-T023
microbiota	O
of	O
a	O
lactating	O
dairy	O
cow	O
and	O
the	O
microorganisms	B-T001
forming	O
the	O
fiber	O
-degrading	O
community	O
.	O
Functional	O
analysis	O
identified	O
12,237	O
CAZymes	O
,	O
accounting	O
for	O
1	O
%	O
of	O
the	O
transcripts	O
.	O
The	O
CAZyme	O
profile	O
was	O
dominated	O
by	O
families	O
GH94	O
(	O
cellobiose	O
-	O
phosphorylase	O
)	O
,	O
GH13	B-T121
(	O
amylase	B-T121
)	O
,	O
GH43	B-T121
and	O
GH10	B-T121
(	O
hemicellulases	B-T121
)	O
,	O
GH9	O
and	O
GH48	O
(	O
cellulases	O
)	O
,	O
PL11	O
(	O
pectinase	O
)	O
as	O
well	O
as	O
GH2	O
and	O
GH3	O
(	O
oligosaccharidases	O
)	O
.	O
Our	O
data	O
support	O
the	O
pivotal	O
role	O
of	O
the	O
most	O
characterized	O
fibrolytic	B-T007
bacteria	I-T007
(	O
Prevotella	B-T007
,	O
Ruminocccus	B-T007
and	O
Fibrobacter	B-T007
)	O
,	O
and	O
highlight	O
a	O
substantial	O
,	O
although	O
most	O
probably	O
underestimated	O
,	O
contribution	O
of	O
fungi	O
and	O
ciliate	O
protozoa	O
to	O
polysaccharide	B-T121
degradation	O
.	O
Particularly	O
these	O
results	O
may	O
motivate	O
further	O
exploration	O
of	O
the	O
role	O
and	O
the	O
functions	O
of	O
protozoa	O
in	O
the	O
rumen	B-T023
.	O
Moreover	O
,	O
an	O
important	O
part	O
of	O
the	O
fibrolytic	B-T007
bacterial	I-T007
community	I-T007
remains	O
to	O
be	O
characterized	O
since	O
one	O
third	O
of	O
the	O
CAZyme	O
transcripts	O
originated	O
from	O
distantly	O
related	O
strains	B-T007
.	O
These	O
findings	O
are	O
used	O
to	O
highlight	O
limitations	O
of	O
current	O
metatranscriptomics	B-T059
approaches	O
to	O
understand	O
the	O
functional	O
rumen	B-T023
microbial	B-T001
community	I-T001
and	O
opportunities	O
to	O
circumvent	O
them	O
.	O
      
Draft	O
Genome	O
Sequence	O
of	O
Providencia	B-T007
stuartii	I-T007
PS71	I-T007
,	O
a	O
Multidrug	O
-	O
Resistant	O
Strain	B-T001
Associated	O
with	O
Nosocomial	B-T047
Infections	I-T047
in	O
Greece	O
Providencia	B-T007
stuartii	I-T007
is	O
frequently	O
associated	O
with	O
nosocomial	B-T047
outbreaks	I-T047
and	O
displays	O
intrinsic	O
resistance	O
to	O
many	O
commonly	O
used	O
antimicrobials	B-T121
.	O
We	O
report	O
here	O
the	O
draft	O
genome	O
sequence	O
of	O
a	O
P.	B-T007
stuartii	I-T007
strain	I-T007
carrying	O
acquired	O
resistance	O
genes	O
conferring	O
panresistance	O
to	O
cephalosporins	B-T195
(	O
blaSHV-5	O
and	O
blaVEB-1	O
)	O
,	O
carbapenems	B-T195
(	O
blaVIM-1	O
)	O
,	O
and	O
aminoglycosides	B-T121
(	O
rmtB	O
)	O
involved	O
in	O
an	O
outbreak	O
in	O
Greek	O
hospitals	O
.	O
      
Interventions	B-T058
to	O
Improve	B-T033
Grandparent	O
Caregivers	O
'	O
Mental	O
and	O
Physical	B-T033
Health	I-T033
:	O
An	O
Integrative	O
Review	O
The	O
aim	O
of	O
this	O
integrative	O
review	O
is	O
to	O
appraise	O
grandparent	O
caregiver	O
interventions	B-T058
that	O
are	O
designed	O
to	O
improve	B-T033
their	O
physical	B-T033
and	O
mental	O
health	O
.	O
A	O
database	O
search	O
was	O
performed	O
to	O
identify	O
relevant	O
studies	O
published	O
between	O
January	O
1	O
,	O
1980	O
,	O
and	O
December	O
31	O
,	O
2014	O
.	O
Thirteen	O
publications	O
,	O
including	O
11	O
studies	O
,	O
met	O
all	O
inclusion	O
and	O
exclusion	O
criteria	O
.	O
All	O
studies	O
included	O
grandparent	O
mental	O
health	O
outcomes	O
with	O
fewer	O
focusing	O
on	O
physical	B-T033
health	I-T033
and	O
social	O
relations	O
.	O
Improvements	O
were	O
found	O
in	O
all	O
three	O
areas	O
with	O
fewer	O
improvements	O
seen	O
in	O
physical	B-T033
health	I-T033
.	O
However	O
,	O
small	O
effect	O
sizes	O
were	O
seen	O
with	O
most	O
measures	O
of	O
these	O
outcomes	O
.	O
Although	O
the	O
interventions	B-T058
led	O
to	O
positive	O
grandparent	O
caregiver	O
outcomes	O
,	O
the	O
studies	O
were	O
limited	O
by	O
their	O
design	O
,	O
only	O
one	O
of	O
which	O
was	O
a	O
randomized	O
controlled	O
trial	O
.	O
Also	O
,	O
interventions	B-T058
did	O
not	O
consider	O
variations	O
in	O
the	O
grandchild	O
's	O
or	O
parent	O
's	O
ages	O
or	O
if	O
the	O
grandparent	O
provided	O
primary	O
or	O
shared	O
care	O
.	O
These	O
gaps	O
should	O
be	O
addressed	O
in	O
future	O
research	O
.	O
      
Perspectives	O
on	O
cardiovascular	O
effects	O
of	O
incretin	B-T121
-based	O
drugs	B-T121
:	O
From	O
bedside	O
to	O
bench	O
,	O
return	O
trip	O
Recently	O
,	O
cardiovascular	O
outcome	O
trials	O
with	O
glucose	B-T121
-lowering	O
drugs	B-T121
used	O
in	O
type	B-T047
2	I-T047
diabetes	I-T047
mellitus	I-T047
,	O
namely	O
glucagon	O
-	O
like	O
peptide-1	O
receptor	O
agonists	B-T121
(	O
GLP-1RA	B-T121
)	O
,	O
liraglutide	B-T121
and	O
semaglutide	O
,	O
showed	O
a	O
reduction	O
in	O
cardiovascular	B-T033
events	I-T033
,	O
which	O
had	O
not	O
been	O
observed	O
in	O
trials	O
with	O
other	O
incretin	B-T121
-based	O
drugs	B-T121
,	O
such	O
as	O
lixisenatide	B-T121
or	O
with	O
dipeptidyl	B-T121
peptidase-4	I-T121
inhibitors	I-T121
(	O
DPP4i	B-T121
)	O
.	O
Mechanisms	O
underlying	O
the	O
observed	O
cardiovascular	O
differences	O
between	O
DPP4i	B-T121
and	O
GLP1	B-T121
-	I-T121
RA	I-T121
,	O
and	O
across	O
individual	O
GLP1	B-T121
-	I-T121
RA	I-T121
are	O
poorly	O
understood	O
.	O
This	O
review	O
is	O
aimed	O
at	O
collecting	O
and	O
summarizing	O
available	O
evidence	O
from	O
experimental	O
and	O
mechanistic	O
studies	O
on	O
the	O
action	O
of	O
GLP1	B-T121
-	I-T121
RA	I-T121
and	O
DPP4i	B-T121
on	O
the	O
cardiovascular	O
system	O
,	O
both	O
deriving	O
from	O
clinical	O
and	O
pre	O
-	O
clinical	O
sources	O
.	O
The	O
results	O
of	O
cardiovascular	O
outcome	O
trials	O
are	O
interpreted	O
on	O
the	O
basis	O
of	O
the	O
experimental	O
preclinical	O
data	O
available	O
,	O
paying	O
particular	O
attention	O
to	O
the	O
heart	B-T047
failure	I-T047
results	O
,	O
and	O
suggesting	O
some	O
novel	O
intriguing	O
hypotheses	O
to	O
explain	O
some	O
of	O
the	O
unexpected	O
findings	O
of	O
cardioprotection	O
of	O
incretin	B-T121
-based	O
drugs	B-T121
.	O
In	O
particular	O
,	O
we	O
discuss	O
the	O
possible	O
contribution	O
to	O
the	O
incretin	B-T121
cardiovascular	O
effects	O
of	O
a	O
direct	O
cardiac	B-T023
action	O
of	O
GLP-1	O
metabolites	O
through	O
GLP-1	O
receptor	O
-independent	O
pathways	O
,	O
and	O
of	O
DPP4	O
substrates	O
other	O
than	O
GLP-1	O
.	O
      
Physical	O
Exercise	O
for	O
Late	O
-	O
Life	O
Depression	B-T048
:	O
Effects	O
on	O
Heart	O
Rate	O
Variability	O
Late	O
-	O
life	O
major	B-T048
depression	I-T048
is	O
associated	O
with	O
increased	O
cardiovascular	B-T033
risk	I-T033
and	O
impaired	B-T047
autonomic	I-T047
control	I-T047
of	I-T047
the	I-T047
heart	I-T047
,	O
as	O
evident	O
from	O
reduced	O
heart	O
rate	O
variability	O
(	O
HRV	O
)	O
.	O
Moreover	O
,	O
antidepressant	B-T121
drug	I-T121
therapy	B-T061
also	O
might	O
be	O
associated	O
with	O
further	O
reductions	O
of	O
HRV	O
.	O
In	O
the	O
SEEDS	O
study	O
,	O
we	O
investigated	O
whether	O
sertraline	B-T121
associated	O
with	O
physical	O
exercise	O
protocols	O
led	O
to	O
improvements	O
of	O
HRV	O
,	O
compared	O
with	O
antidepressant	B-T121
drug	I-T121
therapy	B-T061
alone	O
.	O
Single	O
-	O
blind	O
randomized	O
controlled	O
trial	O
.	O
Psychiatric	O
consultation	O
-liaison	O
program	O
for	O
primary	B-T058
care	I-T058
.	O
Patients	O
aged	O
65	O
-	O
85	O
years	O
with	O
major	B-T048
depression	I-T048
,	O
recruited	O
from	O
primary	B-T058
care	I-T058
.	O
Sertraline	B-T121
plus	O
structured	O
,	O
tailored	O
group	O
physical	O
exercise	O
(	O
S	O
+	O
EX	O
)	O
versus	O
sertraline	B-T121
alone	O
(	O
S	O
)	O
for	O
24	O
weeks	O
.	O
HRV	O
indices	O
(	O
RR	O
,	O
percentage	O
of	O
NN	O
intervals	O
greater	O
than	O
50	O
msec	O
[	O
pNN50	O
]	O
,	O
square	O
root	O
of	O
the	O
mean	O
squared	O
differences	O
of	O
successive	O
NN	O
intervals	O
[	O
RMSSD	O
]	O
,	O
standard	O
deviation	O
of	O
heart	O
rate	O
[	O
SDHR	O
]	O
,	O
standard	O
deviation	O
of	O
the	O
NN	O
interval	O
[	O
SDNN	O
]	O
,	O
high	O
-	O
frequency	O
band	O
[	O
HF	O
]	O
,	O
low	O
-	O
frequency	O
band	O
[	O
LF	O
]	O
,	O
and	O
their	O
ratio	O
[	O
LF	O
/	O
HF	O
]	O
)	O
were	O
measured	O
at	O
baseline	O
,	O
week	O
12	O
,	O
and	O
week	O
24	O
.	O
Psychiatric	B-T060
and	O
medical	B-T058
assessments	I-T058
.	O
Participants	O
displayed	O
significant	O
improvements	O
of	O
most	O
HRV	O
indices	O
over	O
time	O
,	O
irrespective	O
of	O
the	O
group	O
assignment	O
(	O
pNN50	O
,	O
RMSSD	O
,	O
SDHR	O
,	O
SDNN	O
,	O
HF	O
,	O
LF	O
,	O
and	O
LF	O
/	O
HF	O
)	O
.	O
Moreover	O
,	O
patients	O
in	O
the	O
S	O
+	O
EX	O
group	O
displayed	O
greater	O
increases	O
of	O
different	O
HRV	O
indices	O
(	O
RR	O
,	O
pNN50	O
,	O
RMSSD	O
,	O
SDHR	O
,	O
SDNN	O
,	O
HF	O
,	O
and	O
LF	O
)	O
compared	O
with	O
those	O
in	O
the	O
S	O
group	O
.	O
The	O
combination	O
of	O
structured	O
physical	O
exercise	O
and	O
sertraline	B-T121
might	O
exert	O
positive	B-T033
effects	O
on	O
the	O
autonomic	O
control	O
of	O
the	O
heart	O
among	O
older	O
patients	O
with	O
major	B-T048
depression	I-T048
.	O
      
Effect	O
of	O
type	B-T047
2	I-T047
diabetes	I-T047
mellitus	I-T047
on	O
the	O
pharmacokinetics	O
and	O
transplacental	O
transfer	O
of	O
nifedipine	B-T121
in	O
hypertensive	B-T047
pregnant	O
women	O
Diabetes	B-T047
mellitus	I-T047
can	O
inhibit	O
cytochrome	O
P450	O
3A4	O
,	O
an	O
enzyme	O
responsible	O
for	O
the	O
metabolism	O
of	O
nifedipine	B-T121
,	O
used	O
for	O
the	O
treatment	B-T061
of	O
hypertension	B-T047
in	O
pregnant	O
women	O
.	O
We	O
aimed	O
to	O
assess	B-T058
the	O
effect	O
of	O
type	B-T047
2	I-T047
diabetes	I-T047
mellitus	I-T047
(	O
T2DM	B-T047
)	O
on	O
the	O
pharmacokinetics	O
,	O
placental	O
transfer	O
and	O
distribution	O
of	O
nifedipine	B-T121
in	O
amniotic	O
fluid	O
in	O
hypertensive	B-T047
pregnant	O
women	O
.	O
The	O
study	O
was	O
conducted	O
in	O
12	O
hypertensive	B-T047
pregnant	O
women	O
[	O
control	O
group	O
(	O
CG	O
)	O
]	O
and	O
10	O
hypertensive	B-T047
pregnant	O
women	O
with	O
T2DM	B-T047
taking	O
slow	O
-	O
release	O
nifedipine	B-T121
(	O
20	O
mg	O
,	O
12/12	O
h	O
)	O
.	O
On	O
the	O
34th	O
week	O
of	O
gestation	O
,	O
serial	O
blood	O
samples	O
were	O
collected	O
(	O
0	O
-	O
12	O
h	O
)	O
after	O
administration	B-T061
of	O
the	O
medication	B-T121
.	O
At	O
delivery	O
,	O
samples	O
of	O
maternal	O
and	O
fetal	O
blood	O
and	O
amniotic	O
fluid	O
were	O
collected	O
for	O
determination	B-T059
of	O
nifedipine	B-T121
distribution	O
in	O
these	O
compartments	O
.	O
The	O
median	O
pharmacokinetic	O
parameters	O
of	O
CG	O
were	O
:	O
peak	O
plasma	O
concentration	O
(	O
Cmax	O
)	O
26.41	O
ng	O
ml(-1	O
)	O
,	O
time	O
to	O
reach	O
Cmax	O
(	O
tmax	O
)	O
1.79	O
h	O
,	O
area	O
under	O
the	O
plasma	O
concentration	O
vs.	O
time	O
curve	O
from	O
0	O
-	O
12	O
h	O
(	O
AUC	O
0	O
-	O
12	O
)	O
235.99	O
ng.h	O
ml(-1	O
)	O
,	O
half	O
-	O
life	O
(	O
t½	O
)	O
4.34	O
h	O
,	O
volume	O
of	O
distribution	O
divided	O
by	O
bioavailability	O
(	O
Vd	O
/	O
F	O
)	O
560.96	O
l	O
,	O
and	O
ClT	O
/	O
F	O
84.77	O
l	O
h(-1	O
)	O
.	O
The	O
parameters	O
for	O
T2DM	B-T047
group	O
were	O
:	O
Cmax	O
23.52	O
ng	O
ml(-1	O
)	O
,	O
tmax	O
1.48	O
h	O
,	O
AUC	O
0	O
-	O
12	O
202.23	O
ng.h	O
ml(-1	O
)	O
,	O
t½	O
5.00	O
h	O
,	O
Vd	O
/	O
F	O
609.40	O
l	O
,	O
and	O
apparent	O
total	O
clearance	O
(	O
ClT	O
/	O
F	O
)	O
98.94	O
l	O
h(-1	O
)	O
.	O
The	O
ratios	O
of	O
plasma	O
concentrations	O
of	O
nifedipine	B-T121
in	O
the	O
umbilical	B-T018
vein	I-T018
,	O
intervillous	O
space	O
and	O
amniotic	O
fluid	O
to	O
those	O
in	O
the	O
maternal	O
vein	O
for	O
CG	O
and	O
T2DM	B-T047
were	O
0.53	O
and	O
0.44	O
,	O
0.78	O
and	O
0.87	O
,	O
respectively	O
,	O
with	O
an	O
amniotic	O
fluid	O
/	O
maternal	O
plasma	O
ratio	O
of	O
0.05	O
for	O
both	O
groups	O
.	O
The	O
ratios	O
of	O
plasma	O
concentrations	O
in	O
the	O
umbilical	B-T018
artery	I-T018
to	O
those	O
in	O
the	O
umbilical	B-T018
vein	I-T018
were	O
0.82	O
for	O
CG	O
and	O
0.88	O
for	O
T2DM	B-T047
.	O
There	O
was	O
no	O
influence	O
of	O
T2DM	B-T047
on	O
the	O
pharmacokinetics	O
or	O
placental	O
transfer	O
of	O
nifedipine	B-T121
in	O
hypertensive	B-T047
women	O
with	O
controlled	B-T033
diabetes	B-T047
.	O
      
A	O
Delayed	O
Diagnosis	B-T033
of	O
Chronic	B-T047
Mesenteric	I-T047
Ischaemia	I-T047
:	O
The	O
Role	O
of	O
Clinicians	O
'	O
Cognitive	O
Errors	O
Chronic	O
diarrhoeal	B-T047
illnesses	I-T047
with	O
nausea	B-T184
and	O
weight	B-T033
loss	I-T033
are	O
a	O
common	O
indication	O
for	O
gastroenterology	O
review	O
.	O
While	O
many	O
such	O
cases	O
have	O
intra	O
-	O
luminal	O
aetiologies	O
,	O
such	O
as	O
inflammatory	B-T047
bowel	I-T047
disease	I-T047
,	O
coeliac	B-T047
disease	I-T047
or	O
other	O
malabsorptive	B-T033
conditions	I-T033
,	O
with	O
many	O
other	O
cases	O
due	O
to	O
functional	O
gut	B-T023
disorders	B-T047
or	O
systemic	O
malignancy	B-T191
,	O
clinicians	O
must	O
also	O
keep	O
vascular	B-T047
disorders	I-T047
in	O
mind	O
.	O
Here	O
we	O
report	O
a	O
patient	O
with	O
a	O
delayed	O
diagnosis	B-T033
of	O
chronic	B-T047
mesenteric	I-T047
ischaemia	I-T047
after	O
6	O
months	O
of	O
gastrointestinal	B-T184
symptoms	I-T184
strongly	O
mimicking	O
an	O
alternative	O
diagnosis	B-T033
such	O
as	O
inflammatory	B-T047
bowel	I-T047
disease	I-T047
due	O
an	O
atypical	O
predominance	O
of	O
nausea	B-T184
and	O
diarrhoea	B-T184
rather	O
than	O
pain	B-T184
.	O
We	O
briefly	O
review	O
the	O
literature	O
on	O
treatment	O
of	O
this	O
condition	B-T047
but	O
also	O
discuss	O
with	O
particular	O
attention	O
the	O
sequence	O
of	O
cognitive	O
errors	O
made	O
by	O
clinicians	O
that	O
led	O
to	O
a	O
diagnostic	B-T033
delay	O
,	O
inviting	O
readers	O
to	O
thus	O
reflect	O
on	O
how	O
such	O
errors	O
can	O
be	O
minimised	O
in	O
their	O
practice	O
.	O
      
Erlotinib	B-T121
plus	O
gemcitabine	B-T121
versus	O
gemcitabine	B-T121
for	O
pancreatic	B-T191
cancer	I-T191
:	O
real	O
-	O
world	O
analysis	O
of	O
Korean	O
national	O
database	O
A	O
randomized	O
clinical	O
trial	O
has	O
found	O
that	O
the	O
addition	O
of	O
erlotinib	B-T121
to	O
gemcitabine	B-T121
(	O
GEM	B-T121
-	O
E	B-T121
)	O
for	O
pancreatic	B-T191
cancer	I-T191
led	O
to	O
a	O
modest	O
increase	O
in	O
survival	O
.	O
The	O
aim	O
of	O
this	O
national	O
population	O
-	O
based	O
retrospective	O
study	O
was	O
to	O
compare	O
the	O
effectiveness	O
of	O
GEM	B-T121
-	O
E	B-T121
to	O
GEM	B-T121
alone	O
for	O
pancreatic	B-T191
cancer	I-T191
patients	O
in	O
real	O
clinical	O
practice	O
.	O
Patients	O
with	O
pancreatic	B-T191
cancer	I-T191
(	O
ICD-10	O
:	O
C25	O
)	O
with	O
prescription	O
claims	O
of	O
gemcitabine	B-T121
or	O
erlotinib	B-T121
between	O
Jan	O
1	O
,	O
2007	O
and	O
Dec	O
31	O
,	O
2012	O
were	O
retrospectively	O
identified	O
from	O
the	O
Korean	O
Health	B-T058
Insurance	I-T058
claims	O
database	O
.	O
To	O
be	O
included	O
in	O
the	O
study	O
population	O
,	O
patients	O
were	O
required	O
to	O
have	O
had	O
a	O
histological	O
or	O
cytological	B-T033
diagnosis	I-T033
within	O
one	O
year	O
before	O
chemotherapy	B-T061
.	O
Patients	O
treated	B-T033
with	I-T033
prior	O
radiotherapy	B-T061
,	O
surgery	B-T058
,	O
or	O
chemotherapy	B-T061
were	O
excluded	O
to	O
reduce	B-T061
heterogeneity	O
.	O
Overall	O
survival	O
from	O
the	O
initiation	O
of	O
therapy	B-T061
and	O
the	O
medical	O
costs	O
of	O
GEM	B-T121
-	O
E	B-T121
and	O
GEM	B-T121
were	O
compared	O
.	O
A	O
total	O
of	O
4,267	O
patients	O
were	O
included	O
in	O
the	O
analysis	O
.	O
Overall	O
survival	O
was	O
not	O
significantly	O
longer	O
in	O
patients	O
treated	B-T033
with	O
GEM	B-T121
-	O
E	B-T121
(	O
median	O
6.77	O
months	O
for	O
GEM	B-T121
-	O
E	B-T121
vs.	O
6.68	O
months	O
for	O
GEM	B-T121
,	O
p	O
=	O
0.0977	O
)	O
.	O
There	O
was	O
also	O
no	B-T033
significant	I-T033
difference	O
in	O
the	O
respective	O
one	O
-	O
year	O
survival	O
rates	O
(	O
27.0	O
%	O
vs.	O
27.3	O
%	O
;	O
p	O
=	O
0.5988	O
)	O
.	O
Multivariate	O
analysis	O
using	O
age	O
,	O
gender	O
,	O
and	O
comorbidities	O
as	O
covariates	O
did	O
not	O
reveal	O
any	O
significant	O
differences	O
in	O
survival	O
.	O
Based	O
on	O
this	O
relative	O
effectiveness	O
,	O
the	O
incremental	O
cost	O
per	O
life	O
year	O
gained	O
over	O
GEM	B-T121
was	O
estimated	O
at	O
USD	O
70,843.64	O
for	O
GEM	B-T121
E	B-T121
-	O
E.	O
GEM	B-T121
-	O
E	B-T121
for	O
pancreatic	B-T191
cancer	I-T191
is	O
not	O
more	O
effective	O
than	O
GEM	B-T121
in	O
a	O
real	O
-	O
world	O
setting	O
,	O
and	O
it	O
does	O
not	O
provide	O
reasonable	B-T033
cost	O
-	O
effectiveness	O
over	O
GEM	B-T121
.	O
      
Eosinophilic	B-T047
Gastroenteritis	I-T047
as	O
a	O
Rare	O
Cause	O
of	O
Recurrent	O
Epigastric	O
Pain	O
Eosinophilic	B-T047
gastroenteritis	I-T047
(	O
EGE	B-T047
)	O
is	O
a	O
rare	O
inflammatory	B-T047
disorder	I-T047
of	O
gastrointestinal	O
tract	O
characterized	O
by	O
eosinophilic	O
infiltration	O
of	O
the	O
bowel	B-T023
wall	I-T023
.	O
It	O
can	O
mimic	O
many	O
gastrointestinal	B-T047
disorders	I-T047
due	O
to	O
its	O
wide	B-T033
spectrum	I-T033
of	I-T033
presentations	I-T033
.	O
Diagnose	B-T033
is	O
mostly	O
based	O
on	O
excluding	O
other	O
disorders	B-T047
and	O
a	O
high	O
suspicion	O
.	O
Here	O
we	O
report	O
a	O
case	O
of	O
26	O
year	O
old	O
man	O
with	O
a	O
history	B-T033
of	O
sever	B-T184
epigastric	I-T184
pain	I-T184
followed	O
by	O
nausea	B-T184
,	O
vomiting	B-T184
since	O
a	O
few	O
days	O
before	O
admission	B-T058
with	O
final	O
diagnosis	B-T033
of	O
EGE	B-T047
.	O
      
Peer	O
Exclusion	O
During	O
the	O
Pubertal	B-T033
Transition	O
:	O
The	O
Role	O
of	O
Social	O
Competence	O
For	O
some	O
youth	O
,	O
early	B-T047
puberty	I-T047
is	O
accompanied	O
by	O
peer	O
exclusion	O
.	O
Yet	O
early	O
developers	O
may	O
experience	O
less	O
peer	O
exclusion	O
if	O
they	O
have	O
social	O
competence	O
,	O
which	O
would	O
bolster	O
their	O
ability	O
to	O
develop	O
and	O
maintain	O
positive	B-T033
relationships	O
with	O
their	O
peers	O
.	O
Accordingly	O
,	O
the	O
present	B-T033
study	O
tests	O
whether	O
pubertal	B-T033
timing	O
and	O
tempo	O
predicts	O
decrements	O
in	O
children	O
's	O
social	O
competence	O
and	O
whether	O
decrements	O
in	O
social	O
competence	O
account	O
for	O
associations	O
between	O
puberty	O
(	O
timing	O
and	O
tempo	O
)	O
and	O
peer	O
exclusion	O
over	O
time	O
.	O
Longitudinal	O
data	O
were	O
drawn	O
from	O
1364	O
families	O
(	O
48	O
%	O
female	O
;	O
76	O
%	O
White	O
;	O
M	O
=	O
9.32	O
years	O
,	O
SD	O
=	O
.48	O
,	O
at	O
Wave	O
3	O
)	O
who	O
participated	O
in	O
Waves	O
3	O
-	O
5	O
(	O
i.e.	O
,	O
grades	O
4	O
-	O
6	O
)	O
of	O
Phase	O
III	O
of	O
the	O
NICHD	O
-	O
SECCYD	O
.	O
The	O
results	O
from	O
latent	O
growth	O
curve	O
models	O
indicated	O
that	O
earlier	O
pubertal	B-T033
timing	O
and	O
more	O
rapid	O
pubertal	B-T033
tempo	O
among	O
girls	O
were	O
associated	O
with	O
high	O
initial	O
levels	O
of	O
peer	O
exclusion	O
.	O
Moreover	O
,	O
mediation	O
analyses	O
revealed	O
that	O
early	O
developers	O
'	O
susceptibility	O
to	O
peer	O
exclusion	O
was	O
associated	O
with	O
their	O
initial	O
level	O
of	O
social	O
competence	O
.	O
In	O
boys	O
,	O
pubertal	B-T033
timing	O
and	O
tempo	O
were	O
not	O
directly	O
associated	O
with	O
peer	O
exclusion	O
;	O
instead	O
,	O
indirect	O
effects	O
of	O
pubertal	B-T033
timing	O
on	O
peer	O
exclusion	O
(	O
intercept	O
,	O
slope	O
)	O
occurred	O
through	O
initial	O
levels	O
of	O
social	O
competence	O
.	O
On	O
average	O
,	O
early	O
developers	O
'	O
who	O
had	O
low	O
levels	O
of	O
social	O
competence	O
also	O
had	O
high	O
initial	O
levels	O
of	O
peer	O
exclusion	O
but	O
experienced	O
decrements	O
in	O
peer	O
exclusion	O
over	O
time	O
.	O
The	O
association	O
between	O
the	O
intercepts	O
for	O
puberty	O
and	O
peer	O
exclusion	O
and	O
the	O
slopes	O
for	O
social	O
competence	O
and	O
peer	O
exclusion	O
were	O
stronger	O
for	O
boys	O
than	O
girls	O
.	O
Overall	O
,	O
our	O
findings	B-T033
suggest	O
that	O
early	O
developers	O
'	O
susceptibility	O
to	O
and	O
experiences	O
of	O
peer	O
exclusion	O
are	O
associated	O
with	O
their	O
development	O
of	O
social	O
competence	O
.	O
      
Differential	O
Roles	O
of	O
AXIN1	O
and	O
AXIN2	O
in	O
Tankyrase	O
Inhibitor	B-T121
-	I-T121
Induced	I-T121
Formation	O
of	O
Degradasomes	O
and	O
β	O
-	O
Catenin	O
Degradation	O
Inhibition	O
of	O
the	O
tankyrase	O
enzymes	O
(	O
TNKS1	O
and	O
TNKS2	O
)	O
has	O
recently	O
been	O
shown	O
to	O
induce	O
highly	O
dynamic	O
assemblies	O
of	O
β	O
-	O
catenin	O
destruction	O
complex	O
components	O
known	O
as	O
degradasomes	O
,	O
which	O
promote	O
degradation	O
of	O
β	O
-	O
catenin	O
and	O
reduced	O
Wnt	O
signaling	O
activity	O
in	O
colorectal	B-T191
cancer	I-T191
cells	O
.	O
AXIN1	O
and	O
AXIN2	O
/	O
Conductin	O
,	O
the	O
rate	O
-	O
limiting	O
factors	O
for	O
the	O
stability	O
and	O
function	O
of	O
endogenous	O
destruction	O
complexes	O
,	O
are	O
stabilized	B-T033
upon	O
TNKS	O
inhibition	O
due	O
to	O
abrogated	O
degradation	O
of	O
AXIN	O
by	O
the	O
proteasome	O
.	O
Since	O
the	O
role	O
of	O
AXIN1	O
versus	O
AXIN2	O
as	O
scaffolding	O
proteins	O
in	O
the	O
Wnt	O
signaling	O
pathway	O
still	O
remains	O
incompletely	O
understood	O
,	O
we	O
sought	O
to	O
elucidate	O
their	O
relative	O
contribution	O
in	O
the	O
formation	O
of	O
degradasomes	O
,	O
as	O
these	O
protein	O
assemblies	O
most	O
likely	O
represent	O
the	O
morphological	O
and	O
functional	O
correlates	O
of	O
endogenous	O
β	O
-	O
catenin	O
destruction	O
complexes	O
.	O
In	O
SW480	O
colorectal	B-T191
cancer	I-T191
cells	O
treated	O
with	O
the	O
tankyrase	B-T121
inhibitor	I-T121
(	O
TNKSi	B-T121
)	O
G007	B-T121
-	I-T121
LK	I-T121
we	O
found	B-T033
that	O
AXIN1	O
was	O
not	O
required	O
for	O
degradasome	O
formation	O
.	O
In	O
contrast	O
,	O
the	O
formation	O
of	O
degradasomes	O
as	O
well	O
as	O
their	O
capacity	O
to	O
degrade	O
β	O
-	O
catenin	O
were	O
considerably	O
impaired	O
in	O
G007	B-T121
-	I-T121
LK	I-T121
-	I-T121
treated	I-T121
cells	O
depleted	O
of	O
AXIN2	O
.	O
These	O
findings	B-T033
give	O
novel	O
insights	O
into	O
differential	O
functional	O
roles	O
of	O
AXIN1	O
versus	O
AXIN2	O
in	O
the	O
β	O
-	O
catenin	O
destruction	O
complex	O
.	O
      
A	O
case	O
of	O
retrograde	B-T020
intussusception	I-T020
at	O
Roux	B-T061
-	I-T061
en	I-T061
-	I-T061
Y	I-T061
anastomosis	I-T061
10	O
years	O
after	O
total	B-T061
gastrectomy	I-T061
:	O
review	O
of	O
the	O
literature	O
A	O
63	O
-	O
year-	O
old	O
man	O
,	O
who	O
had	O
undergone	O
total	B-T061
gastrectomy	I-T061
and	O
Roux	B-T061
-	I-T061
en	I-T061
-	I-T061
Y	I-T061
reconstruction	I-T061
for	O
gastric	B-T191
cancer	I-T191
10	O
years	O
previously	O
,	O
was	O
admitted	B-T058
to	O
our	O
hospital	O
with	O
complaints	B-T184
of	O
abdominal	B-T184
pain	I-T184
,	O
palpable	O
abdominal	B-T191
tumor	I-T191
,	O
and	O
hematemesis	B-T033
.	O
On	B-T058
admission	I-T058
,	O
the	O
abdominal	B-T184
tenderness	I-T184
was	O
improving	O
and	O
no	O
abdominal	B-T191
tumor	I-T191
was	O
palpable	O
.	O
Mild	O
inflammatory	O
changes	O
and	O
anemia	B-T047
were	O
noted	O
on	O
blood	B-T059
examination	I-T059
.	O
Abdominal	O
computed	B-T060
tomography	I-T060
revealed	O
a	O
tumor	B-T191
with	O
a	O
layered	O
structure	O
in	O
the	O
left	O
abdomen	O
.	O
The	O
patient	O
was	O
diagnosed	B-T033
with	O
intestinal	B-T047
obstruction	I-T047
secondary	O
to	O
intussusception	B-T047
,	O
and	O
surgery	B-T061
was	O
performed	O
.	O
Retrograde	B-T020
intussusception	I-T020
was	O
found	O
at	O
the	O
site	O
of	O
the	O
Y	B-T061
anastomosis	I-T061
.	O
We	O
conducted	O
manual	B-T061
reduction	I-T061
using	O
the	O
Hutchinson	B-T061
procedure	I-T061
.	O
The	O
intestinal	B-T023
color	O
after	O
the	O
reduction	B-T061
was	O
good	O
,	O
and	O
no	O
intestinal	B-T061
resection	I-T061
was	O
required	O
.	O
Postoperative	B-T033
recovery	I-T033
was	O
uneventful	O
,	O
and	O
the	O
patient	O
was	O
discharged	B-T058
12	O
days	O
after	O
surgery	B-T061
.	O
Reports	O
of	O
jejunal	B-T023
intussusception	B-T047
after	O
total	B-T061
gastrectomy	I-T061
with	O
Roux	B-T061
-	I-T061
en	I-T061
-	I-T061
Y	I-T061
reconstruction	I-T061
are	O
relatively	O
rare	O
.	O
Here	O
,	O
we	O
report	O
a	O
case	O
of	O
jejunal	B-T023
intussusception	B-T047
after	O
total	B-T061
gastrectomy	I-T061
with	O
Roux	B-T061
-	I-T061
en	I-T061
-	I-T061
Y	I-T061
reconstruction	I-T061
.	O
      
Dataset	O
of	O
the	O
molecular	O
dynamics	O
simulations	O
of	O
bilayers	O
consisting	O
of	O
short	O
amyloidogenic	O
peptide	O
VDSWNVLVAG	O
from	O
Bgl2p	O
-	O
glucantransferase	O
of	O
S.	O
cerevisiae	O
cell	O
wall	O
The	O
amyloidogenic	O
peptide	O
VDSWNVLVAG	O
from	O
Bgl2p	O
-	O
glucantransferase	O
of	O
Saccharomyces	O
cerevisiae	O
cell	O
wall	O
and	O
its	O
modifying	O
analog	O
VESWNVLVAG	O
were	O
taken	O
for	O
the	O
construction	O
of	O
four	O
types	O
of	O
bilayers	O
which	O
differ	O
by	O
orientation	O
of	O
the	O
peptides	O
in	O
the	O
layers	O
and	O
of	O
the	O
layers	O
relative	O
to	O
each	O
other	O
.	O
These	O
bilayers	O
were	O
used	O
as	O
starting	O
models	O
for	O
the	O
molecular	O
dynamics	O
(	O
MD	O
)	O
at	O
three	O
charge	O
states	O
(	O
neutral	O
,	O
pH3	O
,	O
and	O
pH5	O
)	O
.	O
The	O
changes	O
of	O
the	O
fraction	O
of	O
secondary	O
structure	O
during	O
1	O
ns	O
simulations	O
were	O
received	O
for	O
96	O
MD	O
trajectories	O
.	O
The	O
data	O
article	O
contains	O
the	O
necessary	O
information	O
for	O
the	O
construction	O
of	O
models	O
of	O
β	O
-	O
strands	O
organization	O
in	O
the	O
oligomer	O
structure	O
.	O
These	O
results	O
were	O
used	O
in	O
the	O
associated	O
research	O
article	O
"	O
Structural	O
model	O
of	O
amyloid	O
fibrils	O
for	O
amyloidogenic	O
peptide	O
from	O
Bgl2p	O
-	O
glucantransferase	O
of	O
S.	O
cerevisiae	O
cell	O
wall	O
and	O
its	O
modifying	O
analog	O
.	O
New	O
morphology	O
of	O
amyloid	O
fibrils	O
"	O
(	O
Selivanova	O
et	O
al	O
.	O
,	O
2016	O
)	O
[	O
1	O
]	O
.	O
      
Prevalence	O
of	O
Physical	O
Activity	O
and	O
Sitting	O
Time	O
Among	O
South	O
Korean	O
Adolescents	O
:	O
Results	B-T033
From	O
the	O
Korean	O
National	O
Health	O
and	O
Nutrition	O
Examination	O
Survey	O
,	O
2013	O
This	O
study	O
aimed	O
to	O
describe	O
physical	O
activity	O
(	O
PA	O
)	O
and	O
sitting	O
time	O
,	O
and	O
to	O
examine	O
associations	O
between	O
sociodemographic	O
factors	O
,	O
weight	O
status	O
,	O
PA	O
,	O
and	O
sitting	O
time	O
among	O
South	O
Korean	O
adolescents	O
(	O
12	O
-	O
18	O
years	O
)	O
.	O
Findings	O
are	O
based	O
on	O
self	O
-	O
report	O
data	O
from	O
638	O
participants	O
in	O
the	O
2013	O
Korea	O
National	O
Health	O
and	O
Nutrition	O
Examination	O
Survey	O
.	O
Only	O
4.9	O
%	O
of	O
adolescents	O
accumulated	O
60	O
minutes	O
of	O
moderate	O
-	O
to	O
-	O
vigorous	O
PA	O
daily	O
.	O
Adolescents	O
spent	O
532.4	O
±	O
9.3	O
mins	O
/	O
d	O
sitting	O
.	O
After	O
controlling	O
for	O
age	O
and	O
sex	O
,	O
individuals	O
in	O
higher	O
income	O
groups	O
compared	O
with	O
the	O
lowest	O
income	O
group	O
,	O
living	O
in	O
nonmetro	O
Seoul	O
compared	O
with	O
metro	O
Seoul	O
,	O
and	O
who	O
were	O
overweight	B-T184
compared	O
with	O
nonoverweight	O
were	O
more	O
likely	O
to	O
meet	O
PA	O
guidelines	O
.	O
Participants	O
in	O
the	O
highest	O
income	O
group	O
compared	O
with	O
lowest	O
income	O
group	O
,	O
and	O
residing	O
in	O
nonmetro	O
Seoul	O
compared	O
with	O
metro	O
Seoul	O
were	O
more	O
likely	O
to	O
be	O
in	O
the	O
high	O
sitting	O
time	O
group	O
(	O
>	O
720	O
min	O
/	O
d	O
)	O
(	O
P	O
<	O
.05	O
)	O
.	O
Increasing	O
PA	O
and	O
reducing	O
sitting	O
should	O
be	O
a	O
public	O
health	O
priority	O
in	O
South	O
Korea	O
.	O
      
Masitinib	B-T121
for	O
treatment	B-T061
of	O
severely	O
symptomatic	O
indolent	B-T047
systemic	I-T047
mastocytosis	I-T047
:	O
a	O
randomised	O
,	O
placebo	O
-	O
controlled	O
,	O
phase	O
3	O
study	O
Indolent	B-T047
systemic	I-T047
mastocytosis	I-T047
,	O
including	O
the	O
subvariant	O
of	O
smouldering	B-T191
systemic	I-T191
mastocytosis	I-T191
,	O
is	O
a	O
lifelong	O
condition	O
associated	O
with	O
reduced	B-T033
quality	I-T033
of	I-T033
life	I-T033
.	O
Masitinib	B-T121
inhibits	O
KIT	O
and	O
LYN	O
kinases	O
that	O
are	O
involved	O
in	O
indolent	B-T047
systemic	I-T047
mastocytosis	I-T047
pathogenesis	O
.	O
We	O
aimed	O
to	O
assess	O
safety	O
and	O
efficacy	O
of	O
masitinib	B-T121
versus	O
placebo	O
in	O
severely	B-T033
symptomatic	I-T033
patients	O
who	O
were	O
unresponsive	O
to	O
optimal	O
symptomatic	O
treatments	B-T061
.	O
In	O
this	O
randomised	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
phase	O
3	O
study	O
,	O
we	O
enrolled	O
adults	O
(	O
aged	O
18	O
-	O
75	O
years	O
)	O
with	O
indolent	B-T047
or	O
smouldering	B-T191
systemic	I-T191
mastocytosis	I-T191
,	O
according	O
to	O
WHO	O
classification	O
or	O
documented	O
mastocytosis	B-T047
based	O
on	O
histological	O
criteria	O
,	O
at	O
50	O
centres	O
in	O
15	O
countries	O
.	O
We	O
excluded	O
patients	O
with	O
cutaneous	O
or	O
non	O
-	O
severe	O
systemic	B-T047
mastocytosis	I-T047
after	O
a	O
protocol	O
amendment	O
.	O
Patients	O
were	O
centrally	O
randomised	O
(	O
1:1	O
)	O
to	O
receive	O
either	O
oral	O
masitinib	B-T121
(	O
6	O
mg	O
/	O
kg	O
per	O
day	O
over	O
24	O
weeks	O
with	O
possible	O
extension	O
)	O
or	O
matched	O
placebo	O
with	O
minimisation	O
according	O
to	O
severe	B-T033
symptoms	I-T033
.	O
The	O
primary	O
endpoint	O
was	O
cumulative	O
response	O
(	O
≥75	O
%	O
improvement	O
from	O
baseline	O
within	O
weeks	O
8	O
-	O
24	O
)	O
in	O
at	O
least	O
one	O
severe	B-T033
baseline	I-T033
symptom	I-T033
from	O
the	O
following	O
:	O
pruritus	B-T184
score	O
of	O
9	O
or	O
more	O
,	O
eight	O
or	O
more	O
flushes	O
per	O
week	O
,	O
Hamilton	O
Rating	O
Scale	O
for	O
Depression	O
of	O
19	O
or	O
more	O
,	O
or	O
Fatigue	O
Impact	O
Scale	O
of	O
75	O
or	O
more	O
.	O
We	O
assessed	O
treatment	O
effect	O
using	O
repeated	O
measures	O
methodology	O
for	O
rare	B-T047
diseases	I-T047
via	O
the	O
generalised	O
estimating	O
equation	O
model	O
in	O
a	O
modified	O
intention	O
-	O
to	O
-	O
treat	O
population	O
,	O
including	O
all	O
participants	O
assigned	O
to	O
treatment	B-T061
minus	O
those	O
who	O
withdrew	O
due	O
to	O
a	O
non	B-T033
-	I-T033
treatment	I-T033
-	I-T033
related	I-T033
cause	I-T033
.	O
We	O
assessed	O
safety	O
in	O
all	O
patients	O
who	O
received	O
at	O
least	O
one	O
dose	O
of	O
study	O
drug	O
.	O
This	O
trial	O
is	O
registered	O
with	O
ClinicalTrials.gov	O
,	O
number	O
NCT00814073	O
.	O
Between	O
Feb	O
19	O
,	O
2009	O
,	O
and	O
July	O
15	O
,	O
2015	O
,	O
135	O
patients	O
were	O
randomly	O
assigned	O
to	O
masitinib	B-T121
(	O
n=71	O
)	O
or	O
placebo	O
(	O
n=64	O
)	O
.	O
By	O
24	O
weeks	O
,	O
masitinib	B-T121
was	O
associated	O
with	O
a	O
cumulative	O
response	O
of	O
18·7	O
%	O
in	O
the	O
primary	O
endpoint	O
(	O
122·6	O
responses	O
of	O
656·5	O
possible	O
responses	O
[	O
weighted	O
generalised	O
estimating	O
equation	O
]	O
)	O
compared	O
with	O
7·4	O
%	O
for	O
placebo	O
(	O
48·9	O
of	O
656·5	O
;	O
difference	O
11·3	O
%	O
;	O
odds	O
ratio	O
3·6	O
;	O
95	O
%	O
CI	O
1·2	O
-	O
10·8	O
;	O
p=0·0076	O
)	O
.	O
Frequent	O
severe	B-T033
adverse	I-T033
events	I-T033
(	O
>	O
4	O
%	O
difference	O
from	O
placebo	O
)	O
were	O
diarrhoea	B-T184
(	O
eight	O
[	O
11	O
%	O
]	O
of	O
70	O
in	O
the	O
masitinib	B-T121
group	O
vs	O
one	O
[	O
2	O
%	O
]	O
of	O
63	O
in	O
the	O
placebo	O
group	O
)	O
,	O
rash	O
(	O
four	O
[	O
6	O
%	O
]	O
vs	O
none	O
)	O
,	O
and	O
asthenia	B-T184
(	O
four	O
[	O
6	O
%	O
]	O
vs	O
one	O
[	O
2	O
%	O
]	O
)	O
.	O
The	O
most	O
frequent	O
serious	B-T033
adverse	I-T033
events	I-T033
were	O
diarrhoea	B-T184
(	O
three	O
patients	O
[	O
4	O
%	O
]	O
vs	O
one	O
[	O
2	O
%	O
]	O
)	O
and	O
urticaria	B-T047
(	O
two	O
[	O
3	O
%	O
]	O
vs	O
none	O
)	O
,	O
and	O
no	O
life	B-T033
-	I-T033
threatening	I-T033
toxicities	O
occurred	O
.	O
One	O
patient	O
in	O
the	O
placebo	O
group	O
died	B-T033
(	O
unrelated	O
to	O
study	O
treatment	O
)	O
.	O
These	O
study	B-T033
findings	I-T033
indicate	O
that	O
masitinib	B-T121
is	O
an	O
effective	O
and	O
well	O
tolerated	B-T121
agent	I-T121
for	O
the	O
treatment	B-T061
of	O
severely	B-T033
symptomatic	I-T033
indolent	B-T047
or	O
smouldering	B-T191
systemic	I-T191
mastocytosis	I-T191
.	O
AB	O
Science	O
(	O
Paris	O
,	O
France	O
)	O
.	O
      
Collaborating	O
for	O
Systems	O
Change	O
:	O
A	O
Social	O
Science	O
Framework	O
for	O
Academic	O
Roles	O
in	O
Community	O
Partnerships	O
Environmental	O
health	O
researchers	O
,	O
government	O
agencies	O
,	O
and	O
community	O
groups	O
have	O
endorsed	O
long	O
-	O
term	O
community	O
-	O
academic	O
partnerships	O
as	O
an	O
effective	O
strategy	O
to	O
support	O
science	O
-based	O
improvements	O
in	O
environmental	O
health	O
.	O
Social	O
sciences	O
concepts	O
,	O
approaches	O
,	O
and	O
methods	O
are	O
fundamental	O
to	O
these	O
translational	O
partnerships	O
.	O
However	O
,	O
appropriate	O
roles	O
for	O
academic	O
partners	O
vary	O
throughout	O
the	O
process	O
of	O
changing	O
systems	O
(	O
policies	O
,	O
practices	O
,	O
programs	O
,	O
etc	O
.	O
)	O
.	O
This	O
can	O
complicate	O
planning	O
,	O
evaluating	O
,	O
and	O
sustaining	O
such	O
partnerships	O
.	O
We	O
set	O
forth	O
a	O
conceptual	O
framework	O
for	O
academic	O
partners	O
'	O
roles	O
at	O
different	O
stages	O
of	O
systems	O
change	O
.	O
We	O
apply	O
this	O
framework	O
to	O
three	O
longstanding	O
academic	O
-	O
community	O
partnerships	O
involving	O
National	O
Institute	O
of	O
Environmental	O
Health	O
Sciences	O
Community	O
Outreach	O
and	O
Engagement	O
Cores	O
.	O
We	O
conclude	O
by	O
discussing	O
how	O
the	O
framework	O
can	O
help	O
academic	O
partners	O
tap	O
appropriate	O
expertise	O
,	O
redefine	O
their	O
roles	O
,	O
and	O
evaluate	O
their	O
contributions	O
to	O
community	O
efforts	O
to	O
improve	B-T033
environmental	O
health	O
.	O
      
Bioavailability	O
and	O
health	B-T061
risk	I-T061
assessment	I-T061
of	O
potentially	O
toxic	O
elements	O
in	O
Thriasio	O
Plain	O
,	O
near	O
Athens	O
,	O
Greece	O
Elevated	O
concentrations	O
of	O
potentially	O
toxic	O
elements	O
(	O
PTEs	O
)	O
are	O
usually	O
found	O
in	O
areas	B-T033
of	I-T033
intense	I-T033
industrial	I-T033
activity	I-T033
.	O
Thriasio	O
Plain	O
is	O
a	O
plain	O
near	O
Athens	O
,	O
Greece	O
,	O
where	O
most	O
of	O
the	O
heavy	O
industry	O
of	O
the	O
country	O
has	O
been	O
situated	O
for	O
decades	O
,	O
but	O
it	O
also	O
is	O
a	O
residential	O
and	O
horticultural	O
area	O
.	O
We	O
aimed	O
at	O
measuring	O
the	O
levels	O
of	O
PTEs	O
in	O
soils	O
and	O
indigenous	O
plant	O
species	O
and	O
assessing	B-T061
the	I-T061
health	I-T061
risk	I-T061
associated	O
with	O
direct	O
soil	O
ingestion	O
.	O
Samples	O
of	O
soils	O
at	O
roadsides	O
and	O
growing	O
plants	O
were	O
collected	O
from	O
31	O
sites	O
of	O
that	O
area	O
.	O
Concentrations	O
of	O
Al	O
,	O
As	B-T121
,	O
Cd	O
,	O
Co	O
,	O
Cr	O
,	O
Cu	B-T121
,	O
Fe	B-T121
,	O
Mn	O
,	O
Mo	O
,	O
Ni	O
,	O
Pb	O
,	O
V	O
and	O
Zn	B-T121
were	O
measured	O
in	O
both	O
soils	O
(	O
as	O
pseudo	O
-	O
total	O
)	O
and	O
aerial	O
plant	O
tissues	O
.	O
We	O
found	O
that	O
As	B-T121
,	O
Cd	O
,	O
Cr	O
,	O
Cu	B-T121
,	O
Ni	O
,	O
Pb	O
and	O
Zn	B-T121
were	O
higher	O
than	O
maximum	O
regulatory	O
limits	O
.	O
Element	O
concentrations	O
in	O
plants	O
were	O
rather	O
lower	O
than	O
expected	O
,	O
probably	O
because	O
indigenous	O
plants	O
have	O
developed	O
excluder	O
behaviour	O
over	O
time	O
.	O
Copper	B-T121
and	O
Zn	B-T121
soil	O
-to-	O
plant	O
coefficients	O
were	O
highest	O
among	O
the	O
other	O
elements	O
;	O
for	O
Cu	B-T121
this	O
was	O
unexpected	O
,	O
and	O
probably	O
associated	O
with	O
recent	O
Cu	B-T121
-	O
releasing	O
industrial	O
activity	O
.	O
Risk	B-T058
assessment	I-T058
analysis	I-T058
indicated	O
that	O
As	B-T121
was	O
the	O
element	O
contributing	O
more	O
than	O
50	O
%	O
of	O
the	O
health	O
risk	O
related	O
to	O
direct	O
soil	O
ingestion	O
,	O
followed	O
by	O
Cr	O
,	O
Pb	O
,	O
and	O
,	O
surprisingly	O
,	O
Mn	O
.	O
We	O
concluded	O
that	O
in	O
a	O
multi	O
-	O
element	O
contamination	O
situation	O
,	O
elevated	O
risk	O
of	O
PTEs	O
(	O
such	O
as	O
As	B-T121
,	O
Cr	O
and	O
Pb	O
)	O
may	O
reduce	O
the	O
tolerance	O
limits	O
of	O
exposure	O
to	O
less-	O
toxic	O
elements	O
(	O
here	O
,	O
Mn	O
)	O
.	O
      
New	O
Breast	B-T184
Pain	I-T184
Chart	O
for	O
Objective	O
Record	O
of	O
Mastalgia	B-T184
Mastalgia	B-T184
is	O
the	O
commonest	O
affliction	O
of	O
mammary	B-T023
gland	I-T023
among	O
ladies	O
of	O
the	O
reproductive	O
age	O
group	O
.	O
Since	O
etiopathogenesis	O
and	O
therapy	B-T061
are	O
different	O
for	O
cyclical	B-T184
and	O
noncyclical	B-T184
pain	I-T184
,	O
it	O
is	O
imperative	O
to	O
ascertain	O
the	O
exact	O
type	O
correctly	O
.	O
This	O
is	O
usually	O
done	O
in	O
the	O
breast	O
clinics	O
by	O
advising	O
the	O
patient	O
to	O
fill	O
a	O
pain	O
diary	O
over	O
a	O
period	O
of	O
2	O
months	O
over	O
two	O
menstrual	O
cycles	O
.	O
The	O
Cardiff	O
pain	O
chart	O
records	O
the	O
severity	O
of	O
pain	B-T184
in	O
the	O
form	O
of	O
a	O
triangle	O
for	O
mild	O
to	O
moderate	B-T184
pain	I-T184
and	O
a	O
square	O
for	O
severe	B-T033
pain	I-T033
.	O
Moreover	O
,	O
Cardiff	O
pain	O
chart	O
does	O
not	O
allow	O
a	O
patient	O
to	O
record	O
the	O
severity	O
of	O
pain	B-T184
on	O
days	O
of	O
menses	O
,	O
as	O
she	O
has	O
to	O
put	O
the	O
letter	O
"	O
P	O
"	O
in	O
the	O
box	O
.	O
These	O
problems	B-T033
have	O
been	O
resolved	O
in	O
the	O
new	O
breast	B-T184
pain	I-T184
chart	O
.	O
In	O
the	O
new	O
pain	O
chart	O
,	O
the	O
lady	O
records	O
pain	B-T184
severity	O
in	O
the	O
form	O
of	O
visual	O
linear	O
analogue	O
scale	O
score	O
on	O
every	O
day	O
of	O
menstrual	O
cycle	O
.	O
She	O
enters	O
her	O
menstrual	O
experience	O
on	O
a	O
separate	O
part	O
of	O
chart	O
,	O
which	O
allows	O
us	O
to	O
visualize	O
the	O
full	O
month	O
's	O
pain	B-T184
severity	O
in	O
an	O
uncluttered	O
way	O
.	O
      
Effects	O
of	O
Static	B-T059
Cold	I-T059
Storage	I-T059
and	O
Hypothermic	B-T061
Machine	I-T061
Perfusion	I-T061
on	O
Oxidative	B-T059
Stress	I-T059
Factors	I-T059
,	O
Adhesion	O
Molecules	O
,	O
and	O
Zinc	O
Finger	O
Transcription	O
Factor	O
Proteins	O
Before	O
and	O
After	O
Liver	B-T061
Transplantation	I-T061
BACKGROUND	O
This	O
study	O
aimed	O
to	O
investigate	O
the	O
effects	O
of	O
static	B-T059
cold	I-T059
storage	I-T059
(	O
SCS	B-T059
)	O
and	O
hypothermic	B-T061
machine	I-T061
perfusion	I-T061
(	O
HMP	B-T061
)	O
on	O
the	O
oxidative	B-T059
stress	I-T059
factors	I-T059
(	O
OSF	B-T059
)	O
,	O
adhesion	O
molecules	O
(	O
AM	O
)	O
,	O
and	O
zinc	O
finger	O
transcription	O
factor	O
(	O
Snail	O
)	O
before	O
and	O
after	O
liver	B-T061
transplantation	I-T061
.	O
MATERIAL	O
AND	O
METHODS	O
Experimental	O
dogs	O
were	O
randomly	O
divided	O
into	O
donor	B-T058
(	O
group	O
A	O
)	O
,	O
SCS	B-T059
(	O
group	O
B	O
)	O
,	O
and	O
HMP	B-T061
(	O
group	O
C	O
)	O
(	O
n=30	O
)	O
groups	O
.	O
Livers	B-T061
retrieved	I-T061
from	O
group	O
A	O
were	O
transplanted	B-T061
into	O
group	O
B	O
after	O
SCS	B-T059
,	O
and	O
the	O
livers	B-T023
sampled	O
from	O
group	O
B	O
were	O
transplanted	B-T061
into	O
group	O
C	O
after	O
HMP	B-T061
.	O
The	O
dogs	O
in	O
group	O
A	O
were	O
euthanized	B-T058
and	O
discarded	O
,	O
and	O
the	O
livers	B-T023
sampled	O
from	O
group	O
C	O
were	O
used	O
for	O
other	O
experiments	O
.	O
Twenty	O
dogs	O
with	O
successful	O
liver	B-T061
transplants	I-T061
were	O
randomly	O
selected	O
from	O
groups	O
B	O
and	O
C	O
for	O
analysis	O
.	O
RESULTS	O
During	O
the	O
liver	B-T023
sampling	O
process	O
,	O
the	O
levels	O
of	O
OSF	B-T059
,	O
AM	O
,	O
and	O
Snail	O
between	O
the	O
2	O
groups	O
showed	O
no	B-T033
significant	I-T033
differences	I-T033
(	O
P>0.05	O
)	O
;	O
before	O
the	O
transplantation	B-T061
,	O
the	O
levels	O
of	O
chemokine	O
CXCL14	O
and	O
Snail	O
between	O
the	O
2	O
groups	O
showed	O
no	B-T033
significant	I-T033
differences	I-T033
(	O
P>0.05	O
)	O
,	O
and	O
compared	O
with	O
group	O
B	O
,	O
HIF-1α	O
and	O
P	O
-	O
selectin	O
in	O
group	O
C	O
were	O
lower	O
(	O
P<0.01	O
)	O
;	O
60	O
min	O
after	O
the	O
transplantation	B-T061
,	O
HIF-1α	O
,	O
chemokine	O
CXCL14	O
,	O
P	O
-	O
selectin	O
,	O
and	O
Snail	O
in	O
group	O
C	O
were	O
lower	O
than	O
that	O
in	O
group	O
B	O
(	O
P<0.01	O
)	O
.	O
CONCLUSIONS	O
HMP	B-T061
can	O
significantly	O
reduce	O
the	O
levels	O
of	O
OSF	B-T059
and	O
inflammatory	O
factors	O
,	O
which	O
is	O
conducive	B-T033
for	O
liver	B-T061
transplantation	I-T061
.	O
      
Impact	O
of	O
Chemotherapy	B-T061
on	O
Diet	O
and	O
Nutritional	B-T033
Status	I-T033
of	O
Women	O
with	O
Breast	B-T191
Cancer	I-T191
:	O
A	O
Prospective	O
Study	O
Certain	O
food	O
groups	O
are	O
often	O
rejected	O
during	O
chemotherapy	B-T061
(	O
CT	B-T061
)	O
due	O
to	O
the	O
side	O
effects	O
of	O
treatment	O
,	O
which	O
may	O
interfere	O
with	O
adequate	O
diet	O
and	O
nutritional	B-T033
status	I-T033
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	B-T058
the	O
treatment	O
impact	O
on	O
the	O
diet	O
and	O
nutritional	B-T033
status	I-T033
of	O
women	O
with	O
breast	B-T191
cancer	I-T191
(	O
BC	B-T191
)	O
.	O
In	O
this	O
prospective	O
longitudinal	O
study	O
,	O
conducted	O
in	O
2014	O
-	O
2015	O
,	O
55	O
women	O
diagnosed	O
with	O
BC	B-T191
,	O
with	O
a	O
mean	O
age	O
51.5±10.1	O
years	O
,	O
were	O
followed	O
and	O
data	O
were	O
collected	O
at	O
three	O
different	O
times	O
.	O
Anthropometric	O
and	O
dietary	B-T060
assessments	I-T060
were	O
performed	O
,	O
the	O
latter	O
by	O
applying	O
nine	O
24h	O
dietary	B-T061
recall	I-T061
s	O
,	O
by	O
using	O
the	O
Brazilian	O
Healthy	O
Eating	O
Index	O
Revised	O
(	O
BHEI	O
-	O
R	O
)	O
,	O
and	O
calculating	O
the	O
prevalence	O
of	O
inadequacy	O
by	O
the	O
EAR	O
cut	O
-	O
off	O
point	O
method	O
.	O
Regarding	O
the	O
BHEI	O
-	O
R	O
analysis	O
,	O
the	O
majority	O
of	O
women	O
had	O
a	O
"	O
diet	O
requires	O
modification	B-T033
'	O
,	O
both	O
at	O
the	O
beginning	O
(	O
T0	O
,	O
58.2	O
%	O
,	O
n	O
=	O
32	O
)	O
and	O
during	O
treatment	O
(	O
T1	O
,	O
54.5	O
%	O
,	O
n	O
=	O
30	O
)	O
.	O
However	O
,	O
after	O
the	O
end	O
of	O
the	O
CT	B-T061
,	O
the	O
greater	O
percentage	O
of	O
patients	O
(	O
T2	O
,	O
49.1	O
%	O
,	O
n	O
=	O
27	O
)	O
were	O
classified	O
as	O
having	O
an	O
"	O
inadequate	B-T033
diet	I-T033
"	O
,	O
since	O
the	O
Total	O
Fruit	O
consumption	O
as	O
well	O
as	O
the	O
Dark	O
Green	O
and	O
Orange	O
Vegetable	O
and	O
Legume	O
consumption	O
decreased	O
significantly	O
during	O
treatment	O
(	O
p	O
=	O
0.043	O
and	O
p	O
=	O
0.026	O
,	O
respectively	O
)	O
.	O
There	O
was	O
a	O
significant	O
reduction	O
in	O
the	O
intake	O
of	O
macro	O
and	O
micronutrients	O
,	O
with	O
a	O
high	O
prevalence	O
of	O
inadequacy	O
,	O
of	O
up	O
to	O
100	O
%	O
,	O
for	O
calcium	O
,	O
iron	O
,	O
phosphorus	O
,	O
magnesium	O
,	O
niacin	B-T121
,	O
riboflavin	B-T121
,	O
thiamin	O
,	O
vitamin	B-T121
B6	I-T121
,	O
vitamin	B-T121
C	I-T121
and	O
zinc	O
.	O
Assessment	B-T060
of	O
the	O
nutritional	B-T033
status	I-T033
indicated	O
that	O
56	O
%	O
(	O
n	O
=	O
31	O
)	O
of	O
patients	O
were	O
overweight	B-T184
at	O
these	O
three	O
different	O
times	O
.	O
Weight	O
,	O
BMI	O
and	O
Waist	O
Circumference	O
increased	O
significantly	O
,	O
indicating	O
a	O
worse	B-T033
nutritional	B-T033
status	I-T033
,	O
and	O
there	O
was	O
a	O
correlation	O
between	O
poor	O
diet	O
quality	O
and	O
higher	O
values	O
for	O
BMI	O
,	O
Waist	O
-	O
Hip	O
Ratio	O
and	O
Waist	B-T033
-	I-T033
to	I-T033
-	I-T033
Height	I-T033
Ratio	I-T033
.	O
Chemotherapy	B-T061
interferes	O
in	O
the	O
patients	O
'	O
diet	O
generating	O
a	O
negative	O
impact	O
on	O
the	O
quality	O
and	O
intake	O
of	O
micro	O
and	O
macronutrients	O
,	O
as	O
well	O
as	O
an	O
impact	O
on	O
their	O
nutritional	B-T033
status	I-T033
,	O
with	O
an	O
increase	O
in	O
anthropometric	O
measurements	O
.	O
      
Women	O
's	O
perspectives	O
on	O
human	B-T005
papillomavirus	I-T005
self	B-T060
-	I-T060
sampling	I-T060
in	O
the	O
context	O
of	O
the	O
UK	O
cervical	B-T023
screening	B-T058
programme	I-T058
Testing	O
for	O
human	B-T005
papillomavirus	I-T005
(	O
HPV	B-T005
)	O
is	O
being	O
incorporated	O
into	O
the	O
cervical	B-T023
screening	B-T058
programme	I-T058
,	O
with	O
the	O
probable	O
future	O
introduction	O
of	O
HPV	B-T005
as	O
a	O
primary	O
test	O
and	O
a	O
possibility	O
of	O
HPV	B-T005
self	B-T060
-	I-T060
sampling	I-T060
.	O
In	O
anticipation	O
of	O
this	O
development	O
,	O
we	O
sought	O
to	O
inform	O
future	O
policy	O
and	O
practice	O
by	O
identifying	O
potential	O
barriers	B-T033
to	O
HPV	B-T005
self	B-T060
-	I-T060
sampling	I-T060
.	O
A	O
cross	O
-	O
sectional	O
survey	O
of	O
194	O
women	O
aged	O
20	O
-	O
64	O
years	O
was	O
conducted	O
.	O
Logistic	O
regression	O
analysis	O
was	O
used	O
to	O
identify	O
determinants	O
of	O
self	B-T060
-	I-T060
sampling	I-T060
intentions	O
.	O
A	O
purposive	O
subsample	O
of	O
19	O
women	O
who	O
reported	O
low	O
self	B-T060
-	I-T060
sampling	I-T060
intentions	O
were	O
interviewed	O
.	O
Interviews	O
were	O
framework	O
-	O
analysed	O
.	O
Most	O
survey	O
participants	O
(	O
N=133	O
,	O
69.3	O
%	O
)	O
intended	O
to	O
HPV	B-T005
self	O
-	O
sample	O
.	O
Lower	O
intention	O
was	O
associated	O
with	O
lower	O
self	O
-	O
efficacy	O
(	O
OR=24.96	O
,	O
P≤.001	O
)	O
,	O
lower	O
education	O
(	O
OR=6.06	O
,	O
P≤.05	O
)	O
and	O
lower	O
perceived	O
importance	O
of	O
HPV	B-T005
as	O
a	O
cause	O
of	O
cervical	B-T191
cancer	I-T191
(	O
OR=2.33	O
,	O
P≤.05	O
)	O
.	O
Interviews	O
revealed	O
personal	O
and	O
system	O
-	O
related	O
barriers	B-T033
.	O
Personal	O
barriers	B-T033
included	O
a	O
lack	O
of	O
knowledge	O
about	O
HPV	B-T005
self	B-T060
-	I-T060
sampling	I-T060
,	O
women	O
's	O
low	B-T033
confidence	I-T033
in	O
their	O
ability	O
to	O
self	O
-	O
sample	O
correctly	O
and	O
low	B-T033
confidence	I-T033
in	O
the	O
subsequent	O
results	O
.	O
System	O
-	O
related	O
factors	O
included	O
a	O
lack	B-T033
of	I-T033
confidence	I-T033
in	O
the	O
rationale	O
for	O
modifying	O
the	O
current	O
cervical	B-T023
screening	B-T058
programme	I-T058
,	O
and	O
concerns	O
about	O
sample	O
contamination	O
and	O
identity	O
theft	O
.	O
Insights	O
gained	O
from	O
this	O
research	O
can	O
be	O
used	O
to	O
guide	O
further	O
enquiry	O
into	O
the	O
possibility	O
of	O
HPV	B-T005
self	B-T060
-	I-T060
sampling	I-T060
and	O
to	O
help	O
inform	O
future	O
policy	O
and	O
practice	O
.	O
Personal	O
and	O
system	B-T033
-	I-T033
related	I-T033
barriers	I-T033
including	O
low	B-T033
confidence	I-T033
in	O
the	O
reasons	O
for	O
changing	O
current	O
cervical	B-T023
screening	B-T058
provision	O
need	O
to	O
be	O
addressed	O
,	O
should	O
HPV	B-T005
self	B-T060
-	I-T060
sampling	I-T060
be	O
incorporated	O
into	O
the	O
cervical	B-T023
screening	B-T058
programme	I-T058
.	O
      
Difference	O
-	O
in	O
-	O
Differences	O
Method	O
in	O
Comparative	O
Effectiveness	O
Research	O
:	O
Utility	O
with	O
Unbalanced	O
Groups	O
Comparative	O
effectiveness	O
research	O
(	O
CER	O
)	O
often	O
includes	O
observational	O
studies	O
utilizing	O
administrative	B-T033
data	I-T033
.	O
Multiple	O
conditioning	O
methods	O
can	O
be	O
used	O
for	O
CER	O
to	O
adjust	O
for	O
group	O
differences	O
,	O
including	O
difference	O
-	O
in	O
-	O
differences	O
(	O
DiD	O
)	O
estimation	O
.	O
This	O
study	O
presents	O
DiD	O
and	O
demonstrates	O
how	O
to	O
apply	O
this	O
conditioning	O
method	O
to	O
estimate	O
treatment	O
outcomes	O
in	O
the	O
CER	O
setting	O
by	O
utilizing	O
the	O
MarketScan	O
®	O
Databases	O
for	O
multiple	B-T047
sclerosis	I-T047
(	O
MS	B-T047
)	O
patients	O
receiving	O
different	O
therapies	B-T061
.	O
The	O
sample	O
included	O
6762	O
patients	O
,	O
with	O
363	O
in	O
the	O
Test	O
Cohort	O
[	O
glatiramer	B-T121
acetate	I-T121
(	O
GA	B-T121
)	O
switched	B-T058
to	O
fingolimod	B-T121
(	O
FTY	B-T121
)	O
]	O
and	O
6399	O
in	O
the	O
Control	O
Cohort	O
(	O
GA	B-T121
only	O
,	O
no	B-T033
switch	I-T033
)	O
from	O
a	O
US	O
administrative	O
claims	O
database	O
.	O
A	O
trend	O
analysis	O
was	O
conducted	O
to	O
rule	O
out	O
concerns	O
regarding	O
regression	O
to	O
the	O
mean	O
and	O
to	O
compare	O
relapse	O
rates	O
among	O
treatment	O
cohorts	O
.	O
DiD	O
analysis	O
was	O
used	O
to	O
enable	O
comparisons	O
among	O
the	O
Test	O
and	O
Control	O
Cohorts	O
.	O
Logistic	O
regression	O
was	O
used	O
to	O
estimate	O
the	O
probability	O
of	O
relapse	O
after	O
switching	B-T058
from	O
GA	B-T121
to	O
FTY	B-T121
,	O
and	O
to	O
compare	O
group	O
differences	O
in	O
the	O
pre	O
-	O
and	O
post	O
-	O
index	O
periods	O
.	O
Crude	O
DiD	O
analysis	O
showed	O
that	O
in	O
the	O
pre	O
-	O
index	O
period	O
more	O
patients	O
in	O
the	O
Test	O
Cohort	O
experienced	O
an	O
MS	B-T047
relapse	O
and	O
had	O
a	O
higher	O
mean	O
number	O
of	O
relapses	O
than	O
in	O
the	O
Control	O
Cohort	O
.	O
During	O
the	O
pre	O
-	O
index	O
period	O
,	O
numeric	O
and	O
relative	O
data	O
for	O
MS	B-T047
relapses	O
in	O
patients	O
in	O
the	O
Test	O
Cohort	O
were	O
significantly	O
higher	O
than	O
in	O
the	O
Control	O
Cohort	O
,	O
while	O
no	B-T033
significant	I-T033
between-	O
group	O
differences	O
emerged	O
during	O
the	O
post	O
-	O
index	O
period	O
.	O
Generalized	O
linear	O
modeling	O
with	O
DiD	O
regression	O
estimation	O
showed	O
that	O
the	O
mean	O
number	O
of	O
MS	B-T047
relapses	O
decreased	O
significantly	O
in	O
the	O
post	O
-	O
index	O
period	O
among	O
patients	O
in	O
the	O
Test	O
Cohort	O
compared	O
with	O
patients	O
in	O
the	O
Control	O
Cohort	O
.	O
In	O
this	O
study	O
,	O
an	O
MS	B-T047
population	O
was	O
utilized	O
to	O
demonstrate	O
how	O
DiD	O
can	O
be	O
applied	O
to	O
estimate	O
treatment	B-T033
effects	I-T033
in	O
a	O
heterogeneous	O
population	O
,	O
where	O
the	O
Test	O
and	O
Control	O
Cohorts	O
varied	O
greatly	O
.	O
The	O
results	O
show	O
that	O
DiD	O
offers	O
a	O
robust	O
method	O
for	O
comparing	O
diverse	O
cohorts	O
when	O
other	O
risk	O
-	O
adjustment	O
methods	O
may	O
not	O
be	O
adequate	O
.	O
      
A	O
Comparative	O
Study	O
of	O
the	O
Efficacy	O
of	O
IV	O
Dexketoprofen	B-T121
,	O
Lornoxicam	B-T121
,	O
and	O
Diclophenac	B-T121
Sodium	I-T121
on	O
Postoperative	B-T061
Analgesia	I-T061
and	O
Tramadol	B-T121
Consumption	O
in	O
Patients	O
Receiving	O
Patient	B-T061
-	I-T061
Controlled	I-T061
Tramadol	B-T121
This	O
study	O
was	O
designed	O
to	O
compare	O
the	O
effects	O
of	O
dexketoprofen	B-T121
,	O
lornoxicam	B-T121
,	O
and	O
diclophenac	B-T121
sodium	I-T121
on	O
postoperative	B-T061
analgesia	I-T061
and	O
tramadol	B-T121
consumption	O
in	O
patients	O
receiving	O
postoperative	O
patient	B-T061
-	I-T061
controlled	I-T061
tramadol	B-T121
after	O
a	O
major	O
abdominal	B-T061
surgery	I-T061
.	O
Eighty	O
patients	O
were	O
randomized	B-T033
to	O
receive	O
one	O
of	O
the	O
four	O
study	O
drugs	B-T121
.	O
Patients	O
in	O
group	O
dexketoprofen	B-T121
(	O
DT	B-T121
)	O
received	O
IV	O
50	O
mg	O
dexketoprofen	B-T121
,	O
group	O
lornoxicam	B-T121
(	O
LR	B-T121
)	O
received	O
IV	O
8	O
mg	O
lornoxicam	B-T121
,	O
group	O
diclophenac	B-T121
sodium	I-T121
(	O
DS	B-T121
)	O
received	O
75	O
mg	O
IV	O
diclophenac	B-T121
sodium	I-T121
and	O
group	O
saline	O
(	O
S	O
)	O
received	O
0.9	O
%	O
saline	O
in	O
2	O
mL	O
syringes	O
,	O
20	O
min	O
before	O
the	O
end	O
of	O
anaesthesia	B-T061
.	O
A	O
standardized	O
(	O
1	O
mg	O
kg(-1	O
)	O
)	O
dose	O
of	O
tramadol	B-T121
was	O
routinely	O
administered	O
to	O
all	O
patients	O
as	O
the	O
loading	O
dose	O
at	O
the	O
end	O
of	O
surgery	B-T061
.	O
Postoperatively	O
,	O
whenever	O
patients	O
requested	O
,	O
they	O
were	O
allowed	O
to	O
use	O
a	O
tramadol	B-T121
patient	B-T033
-	I-T033
controlled	I-T033
analgesia	I-T033
device	I-T033
giving	O
a	O
bolus	B-T061
dose	I-T061
(	O
0.2	O
mg	O
kg(-1	O
)	O
)	O
of	O
tramadol	B-T121
.	O
Pain	B-T184
,	O
discomfort	B-T184
,	O
and	O
sedation	B-T033
scores	O
,	O
cumulative	O
tramadol	B-T121
consumption	O
,	O
supplemental	O
meperidine	B-T121
requirement	O
,	O
and	O
side	O
effects	O
were	O
recorded	O
.	O
Visual	O
rating	O
scale	O
and	O
patient	O
discomfort	B-T184
scores	O
were	O
significantly	O
lower	O
in	O
DT	B-T121
,	O
LR	B-T121
and	O
DS	B-T121
groups	O
compared	O
to	O
those	O
in	O
in	O
group	O
S	O
(	O
p<0.001	O
)	O
.	O
Cumulative	O
tramadol	B-T121
consumption	O
was	O
significantly	O
lower	O
in	O
non	B-T121
-	I-T121
steroidal	I-T121
anti	I-T121
-	I-T121
inflammatory	I-T121
drug	I-T121
NSAID	B-T121
(	O
NSAID)-	O
treated	O
groups	O
at	O
each	O
study	O
period	O
after	O
the	O
second	O
postoperative	O
hour	O
than	O
in	O
group	O
S	O
(	O
p<0.001	O
)	O
.	O
Supplemental	O
meperidine	B-T121
requirement	O
was	O
significantly	O
higher	O
in	O
group	O
S	O
at	O
each	O
study	O
period	O
after	O
postoperative	O
30	O
min	O
than	O
in	O
NSAID	B-T121
-	O
treated	O
groups	O
(	O
p<0.01	O
)	O
.	O
After	O
major	O
abdominal	B-T061
surgery	I-T061
,	O
adding	O
IV	O
diclophenac	B-T121
,	O
lornoxicam	B-T121
or	O
dexketoprofen	B-T121
to	O
patient	B-T061
-	I-T061
controlled	I-T061
tramadol	B-T121
resulted	O
in	O
lower	O
pain	B-T184
scores	O
,	O
smaller	O
tramadol	B-T121
consumption	O
,	O
less	O
rescue	O
supplemental	O
analgesic	B-T121
requirement	O
,	O
and	O
fewer	O
side	O
effects	O
compared	O
with	O
the	O
tramadol	B-T121
alone	O
group	O
.	O
      
Non	B-T061
-	I-T061
intubated	I-T061
subxiphoid	O
uniportal	B-T061
video	I-T061
-	I-T061
assisted	I-T061
thoracoscopic	I-T061
thymectomy	I-T061
thymectomy	B-T061
using	O
glasses	B-T033
-	I-T033
free	I-T033
3D	O
vision	O
Trans	B-T061
-	I-T061
sternal	I-T061
thymectomy	I-T061
has	O
long	O
been	O
accepted	O
as	O
the	O
standard	O
surgical	B-T061
procedure	I-T061
for	O
thymic	B-T023
masses	I-T023
.	O
Recently	O
,	O
minimally	O
invasive	O
methods	O
,	O
such	O
as	O
video	B-T061
-	I-T061
assisted	I-T061
thoracoscopic	I-T061
surgery	I-T061
(	B-T061
VATS	I-T061
)	I-T061
and	O
,	O
even	O
more	O
recently	O
,	O
non	B-T061
-	I-T061
intubated	I-T061
anesthesia	B-T061
,	O
have	O
emerged	O
.	O
These	O
methods	O
provide	O
advantages	O
including	O
reductions	O
in	O
surgical	B-T033
trauma	I-T033
,	O
postoperative	B-T184
associated	I-T184
pain	I-T184
,	O
and	O
in	O
regards	O
to	O
VATS	B-T061
,	O
provide	O
certain	O
cosmetic	B-T061
benefits	O
.	O
Considering	O
these	O
advantages	O
,	O
we	O
herein	O
present	O
a	O
case	O
of	O
subxiphoid	O
uniportal	B-T061
VATS	I-T061
for	O
thymic	O
mass	O
using	O
a	O
glasses	B-T033
-	I-T033
free	I-T033
3D	O
thoracoscopic	O
display	O
system	O
.	O
      
Pirfenidone	B-T121
normalizes	O
the	O
tumor	O
microenvironment	O
to	O
improve	O
chemotherapy	B-T061
Normalization	B-T061
of	O
the	O
tumor	O
microenvironment	O
by	O
selectively	O
targeting	O
components	O
of	O
the	O
tumor	B-T191
extracellular	O
matrix	O
has	O
been	O
recently	O
proposed	O
to	O
have	O
the	O
potential	O
to	O
decompress	O
tumor	B-T191
blood	B-T023
vessels	I-T023
,	O
increase	O
vessel	B-T023
perfusion	O
and	O
thus	O
,	O
improve	O
drug	B-T061
delivery	I-T061
and	O
the	O
efficacy	O
of	O
cancer	B-T061
therapy	I-T061
.	O
Therefore	O
,	O
we	O
now	O
need	O
to	O
identify	O
safe	O
and	O
well	O
tolerated	B-T033
pharmaceutical	B-T121
agents	I-T121
that	O
are	O
able	O
to	O
remodel	O
the	O
microenvironment	O
of	O
solid	B-T191
tumors	I-T191
and	O
enhance	O
chemotherapy	B-T061
.	O
In	O
this	O
study	O
,	O
we	O
repurposed	O
Pirfenidone	B-T121
,	O
a	O
clinically	O
approved	O
anti	B-T121
-	I-T121
fibrotic	I-T121
drug	I-T121
for	O
the	O
treatment	B-T061
of	O
idiopathic	B-T047
pulmonary	I-T047
fibrosis	I-T047
,	O
to	O
investigate	O
its	O
possible	O
role	O
on	O
tumor	O
microenvironment	O
normalization	B-T061
.	O
Using	O
two	O
orthotopic	O
mammary	B-T023
tumor	O
models	O
we	O
demonstrate	O
that	O
Pirfenidone	B-T121
reduces	O
collagen	O
and	O
hyaluronan	B-T121
levels	O
and	O
,	O
as	O
a	O
result	O
,	O
significantly	O
increases	O
blood	B-T023
vessel	I-T023
functionality	O
and	O
perfusion	O
and	O
improves	O
the	O
anti	O
-	O
tumor	O
efficacy	O
of	O
doxorubicin	B-T195
.	O
Reduction	O
of	O
extracellular	O
matrix	O
components	O
were	O
mediated	O
via	O
TGFβ	O
signaling	O
pathway	O
inhibition	O
due	O
to	O
downregulation	O
of	O
TGFβ1	O
,	O
COL1A1	O
,	O
COL3A1	O
,	O
HAS2	O
,	O
HAS3	O
expression	O
levels	O
.	O
Our	O
findings	B-T033
provide	O
evidence	O
that	O
repurposing	O
Pirfenidone	B-T121
could	O
be	O
used	O
as	O
a	O
promising	O
strategy	O
to	O
enhance	O
drug	B-T061
delivery	I-T061
to	O
solid	B-T191
tumors	I-T191
by	O
normalizing	B-T061
the	O
tumor	O
microenvironment	O
.	O
      
Contextual	O
Factors	O
for	O
Stunting	O
Among	O
Children	O
of	O
Age	O
6	O
to	O
24	O
Months	O
in	O
an	O
Under	O
-	O
Privileged	O
Community	O
of	O
Dhaka	O
,	O
Bangladesh	O
To	O
determine	O
factors	O
associated	O
with	O
stunting	O
among	O
children	O
aged	O
6	O
to	O
24	O
months	O
in	O
a	O
slum	O
of	O
Dhaka	O
,	O
Bangladesh	O
.	O
We	O
conducted	O
this	O
case	O
control	O
study	O
during	O
November	O
2009	O
to	O
December	O
2012	O
.	O
Children	O
were	O
classified	O
as	O
case	O
if	O
length	O
-	O
for	O
-	O
age	O
Z	O
-	O
score	O
(	O
LAZ	O
)	O
was	O
<	O
-2	O
and	O
as	O
control	O
if	O
LAZ	O
was	O
>	O
-1	O
SD	O
.	O
The	O
logistic	O
regression	O
model	O
was	O
used	O
to	O
find	O
the	O
factors	O
associated	O
with	O
stunting	O
.	O
The	O
significant	O
risk	B-T033
factors	I-T033
for	O
stunting	O
were	O
:	O
child	O
's	O
age	O
>	O
12	O
months	O
,	O
maternal	O
undernutrition	B-T047
,	O
mother	B-T033
's	I-T033
education	I-T033
<	O
5	O
years	O
,	O
consumption	O
of	O
untreated	O
drinking	O
water	O
and	O
monthly	O
family	O
income	O
<	O
100	O
USD	O
.	O
The	O
findings	B-T033
of	O
this	O
study	O
reiterated	O
the	O
role	O
of	O
maternal	O
undernutrition	B-T047
and	O
less	B-T033
education	I-T033
,	O
consumption	O
of	O
untreated	O
drinking	O
water	O
and	O
poor	O
family	O
income	O
as	O
important	O
associated	O
factors	O
of	O
childhood	O
stunting	O
in	O
resource	O
-	O
poor	O
setting	O
.	O
      
Quality	O
of	O
nursing	O
intensity	O
data	O
:	O
inter	O
-	O
rater	O
reliability	O
of	O
the	O
patient	O
classification	O
after	O
two	O
decades	O
in	O
clinical	O
use	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
measure	O
the	O
inter	O
-	O
rater	O
reliability	O
of	O
the	O
Oulu	O
Patient	O
Classification	O
and	O
to	O
discuss	O
existing	O
methods	O
of	O
reliability	O
testing	O
.	O
The	O
Oulu	O
Patient	O
Classification	O
,	O
part	O
of	O
the	O
RAFAELA	O
(	O
®	O
)	O
System	O
,	O
has	O
been	O
developed	O
to	O
assist	O
nursing	O
managers	O
with	O
the	O
proper	O
allocation	O
of	O
nursing	B-T058
resources	O
.	O
Due	O
to	O
the	O
increased	O
intensity	O
of	O
inpatient	B-T058
care	I-T058
during	O
recent	O
years	O
,	O
there	O
is	O
a	O
need	O
for	O
the	O
reliability	O
testing	O
of	O
the	O
classification	O
,	O
which	O
has	O
been	O
in	O
clinical	O
use	O
for	O
20	O
years	O
.	O
Retrospective	O
statistical	O
study	O
.	O
To	O
test	O
inter	O
-	O
rater	O
reliability	O
,	O
a	O
pair	O
of	O
nurses	O
classified	O
the	O
same	O
patients	O
,	O
without	O
knowledge	O
of	O
each	O
other	O
's	O
ratings	O
,	O
as	O
a	O
part	O
of	O
annually	O
conducted	O
standardization	O
.	O
Data	O
on	O
the	O
parallel	O
classifications	O
(	O
n	O
=	O
19,997	O
)	O
was	O
obtained	O
from	O
inpatient	O
units	O
(	O
n	O
=	O
32	O
)	O
with	O
different	O
specialties	O
at	O
a	O
university	O
hospital	O
in	O
Finland	O
during	O
2010	O
-	O
2015	O
.	O
Parallel	O
classification	O
practices	O
were	O
also	O
analysed	O
.	O
The	O
reliability	O
of	O
the	O
overall	O
classification	O
and	O
its	O
subareas	O
were	O
calculated	O
using	O
suitable	O
statistical	O
coefficients	O
.	O
Inter	O
-	O
rater	O
reliability	O
coefficients	O
were	O
a	O
reliable	O
or	O
almost	O
perfect	O
means	O
of	O
considering	O
the	O
nursing	B-T058
intensity	O
category	O
and	O
various	O
practices	O
,	O
but	O
there	O
were	O
detectable	B-T033
differences	O
between	O
subareas	O
.	O
The	O
lowest	O
agreement	O
levels	O
occurred	O
in	O
the	O
subareas	O
'	O
Planning	B-T058
and	I-T058
Coordination	I-T058
of	I-T058
Nursing	I-T058
Care	I-T058
'	O
and	O
'	O
Guiding	B-T058
of	I-T058
Care	I-T058
/	O
Continued	B-T058
Care	I-T058
and	O
Emotional	B-T058
Support	I-T058
'	O
.	O
There	O
is	O
a	O
need	O
to	O
develop	O
the	O
descriptions	O
of	O
subareas	O
and	O
to	O
clarify	O
the	O
related	O
concepts	O
.	O
Precise	O
nursing	B-T058
documentation	I-T058
can	O
promote	O
a	O
high	O
level	O
of	O
agreement	O
and	O
reliable	O
results	O
.	O
The	O
traditional	O
overall	O
proportion	O
of	O
agreement	O
does	O
not	O
provide	O
an	O
adequate	O
picture	O
of	O
reliability	O
-	O
weighted	O
kappa	O
coefficients	O
should	O
be	O
used	O
instead	O
.	O
      
Identification	O
of	O
Predictive	O
DNA	O
Methylation	O
Biomarkers	O
for	O
Chemotherapy	B-T061
Response	O
in	O
Colorectal	B-T191
Cancer	I-T191
Resistance	O
to	O
5	B-T121
-	I-T121
Fluorouracil	I-T121
(	O
5	B-T121
-	I-T121
FU	I-T121
)	O
is	O
a	O
major	O
obstacle	O
to	O
the	O
successful	O
treatment	O
of	O
colorectal	B-T191
cancer	I-T191
(	O
CRC	B-T191
)	O
and	O
posed	O
an	O
increased	O
risk	O
of	O
recurrence	O
.	O
DNA	O
methylation	O
has	O
been	O
suggested	O
as	O
one	O
of	O
the	O
underlying	O
mechanisms	O
for	O
recurrent	B-T047
disease	I-T047
and	O
its	O
contribution	O
to	O
the	O
development	O
of	O
drug	O
resistance	O
remains	O
to	O
be	O
clarified	O
.	O
This	O
study	O
aimed	O
to	O
determine	O
the	O
methylation	O
phenotype	O
in	O
CRC	B-T191
for	O
identification	O
of	O
predictive	O
markers	O
for	O
chemotherapy	B-T061
response	O
.	O
We	O
performed	O
DNA	O
methylation	O
profiling	O
on	O
43	O
non	O
-	O
recurrent	O
and	O
five	O
recurrent	O
CRC	B-T191
patients	O
using	O
the	O
Illumina	O
Infinium	O
HumanMethylation450	O
Beadchip	O
assay	O
.	O
In	O
addition	O
,	O
CRC	B-T191
cells	O
with	O
different	O
genetic	O
backgrounds	O
,	O
response	O
to	O
5	B-T121
-	I-T121
FU	I-T121
and	O
global	O
methylation	O
levels	O
(	O
HT29	O
and	O
SW48	O
)	O
were	O
treated	O
with	O
5	B-T121
-	I-T121
FU	I-T121
and	O
DNA	O
methylation	O
inhibitor	O
5	B-T121
-	I-T121
aza-2'-deoxycytidine	I-T121
(	O
5	B-T121
-	I-T121
azadC	I-T121
)	O
.	O
The	O
singular	O
and	O
combined	O
effects	O
of	O
these	O
two	O
drug	B-T121
classes	O
on	O
cell	O
viability	O
and	O
global	O
methylation	O
profiles	B-T059
were	O
investigated	O
.	O
Our	O
genome	O
-	O
wide	O
methylation	O
study	O
on	O
the	O
clinical	O
specimens	O
showed	O
that	O
recurrent	O
CRCs	B-T191
exhibited	O
higher	O
methylation	O
levels	O
compared	O
to	O
non	O
-	O
recurrent	O
CRCs	B-T191
.	O
We	O
identified	O
4787	O
significantly	O
differentially	O
methylated	O
genes	O
(	O
P	O
<	O
0.05	O
)	O
;	O
3112	O
genes	O
were	O
hyper	B-T033
-	O
while	O
1675	O
genes	O
were	O
hypomethylated	B-T033
in	O
the	O
recurrent	O
group	O
compared	O
to	O
the	O
non	O
-	O
recurrent	O
.	O
Fifty	O
eight	O
and	O
47	O
of	O
the	O
significantly	O
hypermethylated	O
and	O
hypomethylated	O
genes	O
have	O
an	O
absolute	O
recurrent	O
/	O
non	O
-	O
recurrent	O
methylation	O
difference	O
of	O
≥20	O
%	O
.	O
Most	O
of	O
the	O
hypermethylated	O
genes	O
were	O
involved	O
in	O
the	O
MAPK	O
signaling	O
pathway	O
which	O
is	O
a	O
key	O
regulator	O
for	O
apoptosis	O
while	O
the	O
hypomethylated	O
genes	O
were	O
involved	O
in	O
the	O
PI3K	O
-	O
AKT	O
signaling	O
pathway	O
and	O
proliferation	O
process	O
.	O
We	O
also	O
demonstrate	O
that	O
5	B-T121
-	I-T121
azadC	I-T121
treatment	O
enhanced	O
response	O
to	O
5	B-T121
-	I-T121
FU	I-T121
which	O
resulted	O
in	O
significant	O
growth	O
inhibition	O
compared	O
to	O
5	B-T121
-	I-T121
FU	I-T121
alone	O
in	O
hypermethylated	O
cell	O
lines	O
SW48	O
.	O
In	O
conclusion	O
,	O
we	O
found	O
the	O
evidence	O
of	O
five	O
potentially	O
biologically	O
important	O
genes	O
in	O
recurrent	O
CRCs	B-T191
that	O
could	O
possibly	O
serve	O
as	O
a	O
new	O
potential	O
therapeutic	B-T061
targets	O
for	O
patients	O
with	O
chemoresistance	O
.	O
We	O
postulate	O
that	O
aberrant	O
methylation	O
of	O
CCNEI	O
,	O
CCNDBP1	O
,	O
PON3	O
,	O
DDX43	O
,	O
and	O
CHL1	O
in	O
CRC	B-T191
might	O
be	O
associated	O
with	O
the	O
recurrence	O
of	O
CRC	B-T191
and	O
5	B-T121
-	I-T121
azadC	I-T121
-mediated	O
restoration	O
of	O
5	B-T121
-	I-T121
FU	I-T121
sensitivity	O
is	O
mediated	O
at	O
least	O
in	O
part	O
by	O
MAPK	O
signaling	O
pathway	O
.	O
      
3Mo	O
:	O
A	O
Model	O
for	O
Music	O
-	O
Based	O
Biofeedback	B-T061
In	O
the	O
domain	O
of	O
sports	O
and	O
motor	O
rehabilitation	O
,	O
it	O
is	O
of	O
major	O
importance	O
to	O
regulate	O
and	O
control	O
physiological	O
processes	O
and	O
physical	O
motion	O
in	O
most	O
optimal	O
ways	O
.	O
For	O
that	O
purpose	O
,	O
real	O
-	O
time	O
auditory	O
feedback	O
of	O
physiological	O
and	O
physical	O
information	O
based	O
on	O
sound	O
signals	O
,	O
often	O
termed	O
"	O
sonification	O
,	O
"	O
has	O
been	O
proven	O
particularly	O
useful	O
.	O
However	O
,	O
the	O
use	O
of	O
music	O
in	O
biofeedback	B-T061
systems	O
has	O
been	O
much	O
less	O
explored	B-T061
.	O
In	O
the	O
current	O
article	O
,	O
we	O
assert	O
that	O
the	O
use	O
of	O
music	O
,	O
and	O
musical	O
principles	O
,	O
can	O
have	O
a	O
major	O
added	O
value	O
,	O
on	O
top	O
of	O
mere	O
sound	O
signals	O
,	O
to	O
the	O
benefit	O
of	O
psychological	O
and	O
physical	O
optimization	O
of	O
sports	O
and	O
motor	O
rehabilitation	O
tasks	O
.	O
In	O
this	O
article	O
,	O
we	O
present	O
the	O
3Mo	O
model	O
to	O
describe	O
three	O
main	O
functions	O
of	O
music	O
that	O
contribute	O
to	O
these	O
benefits	O
.	O
These	O
functions	O
relate	O
the	O
power	O
of	O
music	O
to	O
Motivate	O
,	O
and	O
to	O
Monitor	B-T058
and	O
Modify	O
physiological	O
and	O
physical	O
processes	O
.	O
The	O
model	O
brings	O
together	O
concepts	O
and	O
theories	O
related	O
to	O
human	O
sensorimotor	O
interaction	O
with	O
music	O
,	O
and	O
specifies	O
the	O
underlying	O
psychological	O
and	O
physiological	O
principles	O
.	O
This	O
3Mo	O
model	O
is	O
intended	O
to	O
provide	O
a	O
conceptual	O
framework	O
that	O
guides	O
future	O
research	O
on	O
musical	O
biofeedback	B-T061
systems	O
in	O
the	O
domain	O
of	O
sports	O
and	O
motor	O
rehabilitation	O
.	O
Journal	O
      
Professional	O
reinventions	O
:	O
Swedish	O
psychologists	O
,	O
1990	O
-	O
2010	O
Since	O
the	O
early	O
20th	O
century	O
,	O
the	O
Swedish	O
psychology	O
profession	O
has	O
undergone	O
several	O
changes	O
in	O
its	O
essential	O
tasks	O
,	O
epistemological	O
foundations	O
,	O
and	O
social	O
roles	O
.	O
These	O
changes	O
occurred	O
through	O
an	O
ongoing	O
"	O
tuning	O
"	O
with	O
Swedish	O
society	O
,	O
in	O
which	O
the	O
profession	O
strove	O
to	O
appear	O
relevant	O
to	O
society	O
's	O
concerns	O
and	O
problems	B-T033
as	O
well	O
as	O
enroll	O
others	O
to	O
share	O
the	O
profession	O
's	O
goals	O
and	O
aims	O
.	O
Studying	O
the	O
history	O
of	O
the	O
profession	O
can	O
thus	O
shed	O
light	O
on	O
the	O
changing	O
definitions	O
and	O
contours	O
of	O
the	O
psychology	O
profession	O
itself	O
as	O
well	O
as	O
on	O
the	O
organization	O
of	O
the	O
society	O
in	O
which	O
it	O
acts	O
.	O
This	O
article	O
examines	O
the	O
history	O
of	O
the	O
Swedish	O
psychology	O
profession	O
from	O
1990	O
to	O
2010	O
,	O
through	O
an	O
analysis	O
of	O
the	O
discussions	O
and	O
debates	O
taking	O
place	O
in	O
the	O
Swedish	O
Psychological	O
Association	O
's	O
journal	O
.	O
The	O
analytical	O
framework	O
used	O
draws	O
on	O
work	O
done	O
within	O
actor	O
-	O
network	O
theory	O
and	O
science	O
studies	O
.	O
We	O
argue	O
that	O
the	O
profession	O
's	O
institutional	O
connections	O
,	O
defining	O
tasks	O
,	O
epistemological	O
underpinnings	O
,	O
and	O
social	O
position	O
have	O
changed	O
in	O
major	O
ways	O
during	O
these	O
2	O
decades	O
.	O
Overall	O
,	O
as	O
a	O
result	O
of	O
an	O
increasingly	O
felt	O
insecurity	O
,	O
the	O
profession	O
has	O
turned	O
outward	O
and	O
tried	O
to	O
find	O
new	O
ways	O
to	O
legitimize	O
itself	O
to	O
politicians	O
,	O
the	O
media	O
,	O
patients	O
,	O
and	O
customers	O
through	O
means	O
such	O
as	O
a	O
more	O
economized	O
vocabulary	O
and	O
novel	O
forms	O
of	O
empirical	O
research	O
.	O
These	O
changes	O
have	O
led	O
to	O
a	O
more	O
socialized	O
profession	O
,	O
now	O
more	O
closely	O
tuned	O
to	O
other	O
actors	O
in	O
Swedish	O
society	O
,	O
leading	O
to	O
conflicts	O
within	O
the	O
profession	O
over	O
whether	O
this	O
is	O
an	O
opportunity	O
to	O
better	O
control	O
their	O
own	O
destiny	O
or	O
if	O
it	O
will	O
lead	O
to	O
a	O
loss	B-T033
of	I-T033
autonomy	I-T033
.	O
(	O
PsycINFO	O
Database	O
Record	O
      
Albumin	O
-Bioinspired	O
Gd	O
:	O
CuS	O
Nanotheranostic	O
Agent	O
for	O
In	O
Vivo	O
Photoacoustic	B-T060
Photoacoustic	B-T061
/	I-T061
Magnetic	I-T061
Resonance	I-T061
Imaging	I-T061
-Guided	I-T061
Tumor	I-T061
-Targeted	I-T061
Photothermal	I-T061
Therapy	I-T061
Magnetic	B-T060
Resonance	I-T060
Imaging	I-T060
Tumor	B-T191
Photothermal	B-T061
therapy	I-T061
(	O
PTT	B-T061
)	O
is	O
attracting	O
increasing	O
interest	O
and	O
becoming	O
more	O
widely	O
used	O
for	O
skin	B-T061
cancer	I-T061
therapy	I-T061
in	O
the	O
clinic	O
,	O
as	O
a	O
result	O
of	O
its	O
noninvasiveness	O
and	O
low	O
systemic	O
adverse	O
effects	O
.	O
However	O
,	O
there	O
is	O
an	O
urgent	O
need	O
to	O
develop	O
biocompatible	O
PTT	O
agents	O
,	O
which	O
enable	O
accurate	O
imaging	B-T060
,	O
monitoring	B-T058
,	O
and	O
diagnosis	B-T033
.	O
Herein	O
,	O
a	O
biocompatible	O
Gd	O
-integrated	O
CuS	O
nanotheranostic	O
agent	O
(	O
Gd	O
:	O
CuS	O
@	O
BSA	O
)	O
was	O
synthesized	O
via	O
a	O
facile	O
and	O
environmentally	O
friendly	O
biomimetic	O
strategy	O
,	O
using	O
bovine	O
serum	O
albumin	O
(	O
BSA	O
)	O
as	O
a	O
biotemplate	O
at	O
physiological	O
temperature	O
.	O
The	O
as	O
-	O
prepared	O
Gd	O
:	O
CuS	O
@	O
BSA	O
nanoparticles	O
(	O
NPs	O
)	O
with	O
ultrasmall	B-T033
sizes	I-T033
(	O
ca	O
.	O
9	O
nm	O
)	O
exhibited	O
high	O
photothermal	B-T033
conversion	I-T033
efficiency	I-T033
and	O
good	O
photostability	B-T033
under	O
near	O
-	O
infrared	O
(	O
NIR	O
)	O
laser	O
irradiation	O
.	O
With	O
doped	O
Gd	O
species	O
and	O
strong	O
tunable	O
NIR	O
absorbance	O
,	O
Gd	O
:	O
CuS	O
@	O
BSA	O
NPs	O
demonstrate	O
prominent	O
tumor	B-T060
-	I-T060
contrasted	I-T060
imaging	I-T060
performance	O
both	O
on	O
the	O
photoacoustic	B-T060
and	O
magnetic	B-T060
resonance	I-T060
imaging	I-T060
modalities	O
.	O
The	O
subsequent	O
Gd	B-T061
:	I-T061
CuS	I-T061
@	I-T061
BSA	I-T061
-mediated	I-T061
PTT	I-T061
result	O
shows	O
high	O
therapy	B-T033
efficacy	I-T033
as	O
a	O
result	O
of	O
their	O
potent	O
NIR	B-T033
absorption	I-T033
and	O
high	O
photothermal	B-T033
conversion	I-T033
efficiency	I-T033
.	O
The	O
immune	O
response	O
triggered	O
by	O
Gd	B-T061
:	I-T061
CuS	I-T061
@	I-T061
BSA	I-T061
-mediated	I-T061
PTT	I-T061
is	O
preliminarily	O
explored	O
.	O
In	O
addition	O
,	O
toxicity	B-T060
studies	I-T060
in	O
vitro	O
and	O
in	O
vivo	O
verify	O
that	O
Gd	O
:	O
CuS	O
@	O
BSA	O
NPs	O
qualify	O
as	O
biocompatible	O
agents	O
.	O
A	O
biodistribution	O
study	O
demonstrated	O
that	O
the	O
NPs	O
can	O
undergo	O
hepatic	O
clearance	O
from	O
the	O
body	O
.	O
This	O
study	O
highlights	O
the	O
practicality	O
and	O
versatility	O
of	O
albumin	O
-mediated	O
biomimetic	O
mineralization	O
of	O
a	O
nanotheranostic	O
agent	O
and	O
also	O
suggests	O
that	O
bioinspired	O
Gd	O
:	O
CuS	O
@	O
BSA	O
NPs	O
possess	O
promising	O
imaging	B-T061
guidance	I-T061
and	O
effective	O
tumor	B-T061
ablation	I-T061
properties	I-T061
,	O
with	O
high	O
spatial	O
resolution	O
and	O
deep	O
tissue	O
penetration	O
.	O
      
Causes	O
of	O
ecological	O
gradients	O
in	O
leaf	O
margin	O
entirety	O
:	O
Evaluating	O
the	O
roles	O
of	O
biomechanics	O
,	O
hydraulics	O
,	O
vein	O
geometry	O
,	O
and	O
bud	O
packing	O
A	O
recent	O
commentary	O
by	O
Edwards	O
et	O
al	O
.	O
(	O
Am	O
.	O
J.	O
Bot	O
.	O
103	O
:	O
975	O
-	O
978	O
)	O
proposed	O
that	O
constraints	O
imposed	O
by	O
the	O
packing	O
of	O
young	O
leaves	O
in	O
buds	O
could	O
explain	O
the	O
positive	B-T033
association	O
between	O
non	O
-	O
entire	O
leaf	O
margins	O
and	O
latitude	O
but	O
did	O
not	O
thoroughly	O
consider	O
alternative	O
explanations	O
.	O
We	O
review	O
the	O
logic	O
and	O
evidence	O
underlying	O
six	O
major	O
hypotheses	O
for	O
the	O
functional	O
significance	O
of	O
marginal	O
teeth	O
,	O
involving	O
putative	O
effects	O
on	O
(	O
1	O
)	O
leaf	O
cooling	O
,	O
(	O
2	O
)	O
optimal	O
support	O
and	O
supply	O
of	O
the	O
areas	O
served	O
by	O
major	O
veins	B-T023
,	O
(	O
3	O
)	O
enhanced	O
leaf	O
-	O
margin	O
photosynthesis	O
,	O
(	O
4	O
)	O
hydathodal	O
function	O
,	O
(	O
5	O
)	O
defense	O
against	O
herbivores	O
,	O
and	O
(	O
6	O
)	O
bud	O
packing	O
.	O
Theoretical	O
and	O
empirical	O
problems	B-T033
undermine	O
all	O
hypotheses	O
except	O
the	O
support	O
-	O
supply	O
hypothesis	O
,	O
which	O
implies	O
that	O
thinner	O
leaves	O
should	O
have	O
non	O
-	O
entire	O
margins	O
.	O
Phylogenetically	O
structured	O
analyses	O
across	O
angiosperms	O
,	O
the	O
El	O
Yunque	O
flora	B-T033
,	O
and	O
the	O
genus	O
Viburnum	O
all	O
demonstrate	O
that	O
non	O
-	O
entire	O
margins	O
are	O
indeed	O
more	O
common	O
in	O
thinner	O
leaves	O
.	O
Across	O
angiosperms	O
,	O
the	O
association	O
of	O
leaf	O
thickness	O
with	O
non	O
-	O
entire	O
leaf	O
margins	O
is	O
stronger	O
than	O
that	O
of	O
latitude	O
.	O
We	O
outline	O
a	O
synthetic	O
model	O
showing	O
how	O
biomechanics	O
,	O
hydraulics	O
,	O
vein	B-T023
geometry	O
,	O
rates	O
of	O
leaf	O
expansion	O
,	O
and	O
length	O
of	O
development	O
within	O
resting	B-T033
buds	O
,	O
all	O
tied	O
to	O
leaf	O
thickness	O
,	O
drive	B-T033
patterns	O
in	O
the	O
distribution	O
of	O
entire	O
vs.	O
non	O
-	O
entire	O
leaf	O
margins	O
.	O
Our	O
model	O
accounts	O
for	O
dominance	O
of	O
entire	O
margins	O
in	O
the	O
tropics	O
,	O
Mediterranean	O
scrub	O
,	O
and	O
tundra	O
,	O
non	O
-	O
entire	O
margins	O
in	O
cold	O
temperate	O
deciduous	O
forests	O
and	O
tropical	O
vines	O
and	O
early	O
-	O
successional	O
trees	O
,	O
and	O
entire	O
leaf	O
margins	O
in	O
monocots	O
.	O
Spinose	O
-	O
toothed	O
leaves	O
should	O
be	O
favored	O
in	O
short	B-T033
-	I-T033
statured	I-T033
evergreen	O
trees	O
and	O
shrubs	O
,	O
primarily	O
in	O
Mediterranean	O
scrub	O
and	O
related	O
semiarid	O
habitats	O
.	O
      
Diffuse	O
traumatic	O
brain	O
injury	O
affects	O
chronic	O
corticosterone	B-T121
function	O
in	O
the	O
rat	O
As	O
many	O
as	O
20	O
-	O
55	O
%	O
of	O
patients	O
with	O
a	O
history	B-T033
of	O
traumatic	O
brain	O
injury	O
(	O
TBI	O
)	O
experience	O
chronic	O
endocrine	B-T047
dysfunction	I-T047
,	O
leading	O
to	O
impaired	O
quality	O
of	O
life	O
,	O
impaired	O
rehabilitation	O
efforts	O
and	O
lowered	B-T033
life	I-T033
expectancy	I-T033
.	O
Endocrine	B-T047
dysfunction	I-T047
after	O
TBI	O
is	O
thought	O
to	O
result	O
from	O
acceleration	O
-	O
deceleration	O
forces	O
to	O
the	O
brain	B-T023
within	O
the	O
skull	B-T023
,	O
creating	O
enduring	O
hypothalamic	B-T023
and	O
pituitary	B-T023
neuropathology	O
,	O
and	O
subsequent	O
hypothalamic	B-T023
-pituitary	O
endocrine	O
(	O
HPE	O
)	O
dysfunction	O
.	O
These	O
experiments	O
were	O
designed	O
to	O
test	O
the	O
hypothesis	O
that	O
a	O
single	O
diffuse	O
TBI	O
results	O
in	O
chronic	O
dysfunction	O
of	O
corticosterone	B-T121
(	O
CORT	B-T121
)	O
,	O
a	O
glucocorticoid	O
released	O
in	O
response	O
to	O
stress	O
and	O
testosterone	B-T121
.	O
We	O
used	O
a	O
rodent	B-T050
model	I-T050
of	O
diffuse	O
TBI	O
induced	O
by	O
midline	O
fluid	O
percussion	O
injury	O
(	O
mFPI	O
)	O
.	O
At	O
2	O
months	O
postinjury	O
compared	O
with	O
uninjured	O
control	O
animals	O
,	O
circulating	O
levels	O
of	O
CORT	B-T121
were	O
evaluated	O
at	O
rest	O
,	O
under	O
restraint	O
stress	O
and	O
in	O
response	O
to	O
dexamethasone	B-T121
,	O
a	O
synthetic	B-T121
glucocorticoid	I-T121
commonly	O
used	O
to	O
test	O
HPE	O
axis	O
regulation	O
.	O
Testosterone	B-T121
was	O
evaluated	O
at	O
rest	O
.	O
Further	O
,	O
we	O
assessed	O
changes	O
in	O
injury	O
-	O
induced	O
neuron	O
morphology	O
(	O
Golgi	B-T059
stain	I-T059
)	O
,	O
neuropathology	O
(	O
silver	B-T059
stain	I-T059
)	O
and	O
activated	O
astrocytes	O
(	O
GFAP	B-T059
)	O
in	O
the	O
paraventricular	B-T023
nucleus	I-T023
(	O
PVN	B-T023
)	O
of	O
the	O
hypothalamus	B-T023
.	O
Resting	O
plasma	O
CORT	B-T121
levels	O
were	O
decreased	O
at	O
2	O
months	O
postinjury	O
and	O
there	O
was	O
a	O
blunted	O
CORT	B-T121
increase	O
in	O
response	O
to	O
restraint	O
induced	O
stress	O
.	O
No	B-T033
changes	I-T033
in	O
testosterone	B-T121
were	O
measured	O
.	O
These	O
changes	O
in	O
CORT	B-T121
were	O
observed	O
concomitantly	O
with	O
altered	O
complexity	O
of	O
neuron	O
processes	O
in	O
the	O
PVN	B-T023
over	O
time	O
,	O
devoid	O
of	O
neuropathology	O
or	O
astrocytosis	O
.	O
Results	O
provide	O
evidence	O
that	O
a	O
single	O
moderate	O
diffuse	O
TBI	O
leads	O
to	O
changes	O
in	O
CORT	B-T121
function	O
,	O
which	O
can	O
contribute	O
to	O
the	O
persistence	B-T033
of	I-T033
symptoms	I-T033
related	O
to	O
endocrine	B-T047
dysfunction	I-T047
.	O
Future	O
experiments	O
aim	O
to	O
evaluate	O
additional	O
HP	O
-	O
related	O
hormones	O
and	O
endocrine	O
circuit	O
pathology	O
following	O
diffuse	O
TBI	O
.	O
      
High	O
-	O
Throughput	O
Genotyping	B-T059
with	O
TaqMan	B-T059
Allelic	I-T059
Discrimination	I-T059
and	O
Allele	B-T059
-	I-T059
Specific	I-T059
Genotyping	I-T059
Assays	I-T059
Real	O
-	O
time	O
PCR	O
-based	O
genotyping	B-T059
methods	I-T059
,	O
such	O
as	O
TaqMan	B-T059
allelic	I-T059
discrimination	I-T059
assays	I-T059
and	O
allele	B-T059
-	I-T059
specific	I-T059
genotyping	I-T059
,	O
are	O
particularly	O
useful	O
when	O
screening	B-T060
a	O
handful	O
of	O
single	O
nucleotide	O
polymorphisms	O
in	O
hundreds	O
of	O
samples	O
;	O
either	O
derived	O
from	O
different	O
individuals	O
,	O
tissues	O
,	O
or	O
pre	O
-	O
amplified	O
DNA	O
.	O
Although	O
real	O
-	O
time	O
PCR	O
-	O
based	O
methods	O
such	O
as	O
TaqMan	B-T059
are	O
well	O
-	O
established	O
,	O
alternative	O
methods	O
,	O
like	O
allele	B-T059
-	I-T059
specific	I-T059
genotyping	I-T059
,	O
are	O
powerful	O
alternatives	O
,	O
especially	O
for	O
genotyping	B-T059
short	O
tandem	O
repeat	O
(	O
STR	O
)	O
length	O
polymorphisms	O
.	O
Here	O
,	O
we	O
describe	O
all	O
relevant	O
aspects	O
when	O
developing	O
an	O
assay	B-T059
for	O
a	O
new	O
SNP	O
or	O
STR	O
using	O
either	O
TaqMan	B-T059
or	O
allele	B-T059
-	I-T059
specific	I-T059
genotyping	I-T059
,	O
respectively	O
,	O
such	O
as	O
primer	O
and	O
probe	O
design	O
,	O
optimization	O
of	O
reaction	O
conditions	O
,	O
the	O
experimental	B-T059
procedure	I-T059
for	I-T059
typing	I-T059
hundreds	O
of	O
samples	O
,	O
and	O
finally	O
the	O
data	O
evaluation	B-T058
.	O
Our	O
goal	O
is	O
to	O
provide	O
a	O
guideline	O
for	O
developing	O
genotyping	B-T059
assays	I-T059
using	O
these	O
two	O
approaches	O
that	O
render	O
reliable	O
and	O
reproducible	O
genotype	B-T059
calls	I-T059
involving	O
minimal	O
optimization	O
.	O
      
Effect	O
of	O
New	B-T033
-	I-T033
Onset	I-T033
Left	B-T047
Bundle	I-T047
Branch	I-T047
Block	I-T047
After	O
Transcatheter	B-T061
Aortic	I-T061
Valve	I-T061
Implantation	I-T061
(	O
CoreValve	O
)	O
on	O
Mortality	O
,	O
Frequency	O
of	O
Re	B-T058
-	I-T058
Hospitalization	I-T058
,	O
and	O
Need	O
for	O
Pacemaker	O
New	B-T033
-	I-T033
onset	I-T033
conduction	O
disturbances	O
are	O
common	O
after	O
transcatheter	B-T061
aortic	I-T061
valve	I-T061
implantation	I-T061
(	O
TAVI	B-T061
)	O
.	O
The	O
most	O
common	O
complication	O
is	O
left	B-T047
bundle	I-T047
branch	I-T047
block	I-T047
(	O
LBBB	B-T047
)	O
.	O
The	O
clinical	O
impact	O
of	O
new	B-T033
-	I-T033
onset	I-T033
LBBB	B-T047
after	O
TAVI	B-T061
remains	O
controversial	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
analyze	O
the	O
clinical	O
impact	O
of	O
new	B-T033
-	I-T033
onset	I-T033
LBBB	B-T047
in	O
terms	O
of	O
mortality	O
and	O
morbidity	O
(	O
need	O
for	O
pacemakers	O
and	O
admissions	B-T058
for	O
heart	B-T047
failure	I-T047
)	O
at	O
long	B-T058
-	I-T058
term	I-T058
follow	I-T058
-	I-T058
up	I-T058
.	O
From	O
April	O
2008	O
to	O
December	O
2014	O
,	O
220	O
patients	O
who	O
had	O
severe	O
aortic	B-T047
stenosis	I-T047
were	O
treated	B-T061
with	I-T061
the	O
implantation	B-T061
of	O
a	O
CoreValve	O
prosthesis	O
.	O
Sixty	O
-	O
seven	O
of	O
these	O
patients	O
were	O
excluded	O
from	O
the	O
analysis	O
,	O
including	O
22	O
patients	O
with	O
pre	O
-	O
existing	O
LBBB	B-T047
and	O
45	O
with	O
a	O
permanent	O
pacemaker	O
,	O
implanted	O
previously	O
or	O
within	O
72	O
hours	O
of	O
implantation	B-T061
.	O
The	O
remaining	O
153	O
patients	O
were	O
divided	O
into	O
2	O
groups	O
:	O
group	O
1	O
(	O
n	O
=	O
80	O
)	O
,	O
those	O
with	O
persistent	O
new	B-T033
-	I-T033
onset	I-T033
LBBB	B-T047
,	O
and	O
group	O
2	O
(	O
n	O
=	O
73	O
)	O
,	O
those	O
without	O
conduction	O
disturbances	O
after	O
treatment	B-T061
.	O
Both	O
groups	O
were	O
followed	B-T058
up	I-T058
at	O
1	O
month	O
,	O
6	O
months	O
,	O
12	O
months	O
,	O
and	O
yearly	O
thereafter	O
.	O
Persistent	O
new	B-T033
-	I-T033
onset	I-T033
LBBB	B-T047
occurred	O
in	O
80	O
patients	O
(	O
36	O
%	O
)	O
immediately	O
after	O
TAVI	B-T061
;	O
73	O
patients	O
(	O
33	O
%	O
)	O
did	O
not	O
develop	O
conduction	O
disturbances	O
.	O
The	O
mean	O
follow	B-T058
-	I-T058
up	I-T058
time	O
of	O
both	O
groups	O
was	O
32	O
±	O
22	O
months	O
(	O
range	O
3	O
to	O
82	O
months	O
)	O
,	O
and	O
there	O
were	O
no	O
differences	O
in	O
time	O
between	O
the	O
groups	O
.	O
There	O
were	O
no	O
differences	O
in	O
mortality	O
between	O
the	O
groups	O
(	O
39	O
%	O
vs	O
48	O
%	O
,	O
p	O
=	O
0.58	O
)	O
.	O
No	O
differences	O
were	O
observed	O
between	O
the	O
groups	O
in	O
re	B-T058
-	I-T058
hospitalizations	I-T058
for	O
heart	B-T047
failure	I-T047
(	O
11	O
%	O
vs	O
16	O
%	O
,	O
p	O
=	O
0.55	O
)	O
.	O
Group	O
1	O
did	O
not	O
require	O
pacemaker	B-T061
implantation	I-T061
more	O
often	O
at	O
follow	B-T058
-	I-T058
up	I-T058
(	O
10	O
%	O
vs	O
13	O
%	O
,	O
p	O
=	O
0.38	O
)	O
than	O
group	O
2	O
.	O
In	O
conclusion	O
,	O
new	B-T033
-	I-T033
onset	I-T033
LBBB	B-T047
was	O
not	O
associated	O
with	O
a	O
higher	O
incidence	O
of	O
late	O
need	O
for	O
a	O
permanent	O
pacemaker	O
after	O
CoreValve	O
implantation	B-T061
.	O
In	O
addition	O
,	O
it	O
was	O
not	O
associated	O
with	O
a	O
higher	O
risk	O
of	O
late	O
mortality	O
or	O
re	B-T058
-	I-T058
hospitalization	I-T058
.	O
      
The	O
sensitivity	O
and	O
specifity	O
of	O
DR-70	O
immunoassay	B-T059
as	O
a	O
tumor	O
marker	O
for	O
non	B-T191
-	I-T191
small	I-T191
cell	I-T191
lung	I-T191
cancer	I-T191
Lung	B-T191
cancer	I-T191
is	O
the	O
most	O
important	O
causes	O
of	O
the	O
cancer	O
related	O
mortality	O
.	O
Patients	O
with	O
lung	B-T191
cancer	I-T191
are	O
usually	O
diagnosed	B-T060
at	O
advanced	O
or	O
locally	O
advanced	O
stage	O
,	O
for	O
this	O
reason	O
early	B-T060
diagnosis	I-T060
of	O
lung	B-T191
cancer	I-T191
is	O
very	O
important	O
.	O
For	O
early	B-T060
detection	I-T060
of	O
lung	B-T191
cancer	I-T191
some	O
methods	O
are	O
emphasized	O
such	O
as	O
low	B-T060
-	I-T060
dose	I-T060
computed	I-T060
tomography	I-T060
or	O
tumor	O
biomarkers	O
.	O
In	O
this	O
study	O
we	O
aimed	O
to	O
evaluate	B-T058
DR-70	O
sensitivity	O
and	O
specificity	O
as	O
a	O
tumor	O
marker	O
in	O
detection	B-T061
of	O
non	B-T191
-	I-T191
small	I-T191
cell	I-T191
lung	I-T191
cancers	I-T191
.	O
Between	O
May	O
2013	O
and	O
April	O
2014	O
,	O
the	O
serum	O
samples	O
from	O
88	O
non	B-T191
lung	I-T191
cancer	I-T191
patients	O
,	O
86	O
patients	O
with	O
chronic	B-T047
obstructive	I-T047
pulmonary	I-T047
disesase	I-T047
were	O
obtained	O
.	O
Blood	O
samples	O
from	O
each	O
participant	O
were	O
analyzed	O
for	O
DR-70	O
level	O
.	O
Totally	O
174	O
patients	O
were	O
enrolled	O
to	O
the	O
study	O
(	O
152	O
male	O
,	O
22	O
female	O
)	O
.	O
Histopathologically	O
47(53.4	O
%	O
)	O
patients	O
were	O
diagnosed	B-T060
with	O
squamous	B-T191
cell	I-T191
lung	I-T191
cancer	I-T191
,	O
34	O
(	O
38.6	O
%	O
)	O
with	O
adenocarcinoma	B-T191
,	O
and	O
7	O
(	O
8	O
%	O
)	O
with	O
non	B-T191
-	I-T191
small	I-T191
cell	I-T191
lung	I-T191
cancer	I-T191
.	O
The	O
mean	O
serum	O
DR-70	O
levels	O
in	O
lung	B-T191
cancer	I-T191
patients	O
(	O
2.43	O
±	O
1.82	O
µg	O
/	O
mL	O
)	O
was	O
significantly	B-T033
higher	I-T033
compared	O
to	O
the	O
86	O
non	B-T033
-	I-T033
cancerous	I-T033
subjects	O
(	O
1.15	O
±	O
0.70	O
µg	O
/	O
mL	O
)	O
(	O
p	O
<	O
0.01	O
)	O
.	O
DR-70	O
exhibited	O
clinical	O
sensitivity	O
and	O
specificity	O
of	O
54.5	O
and	O
83.7	O
%	O
,	O
respectively	O
,	O
at	O
an	O
optimal	O
cut	O
off	O
at	O
1.98	O
µg	O
/	O
mL.	O
It	O
could	O
be	O
said	O
that	O
the	O
risk	O
of	O
the	O
presence	O
of	O
the	O
disease	B-T047
is	O
6.171	O
times	O
higher	O
in	O
the	O
cases	O
where	O
DR-70	O
level	O
is	O
1.98	O
µg	O
/	O
mL	O
and	O
higher	O
.	O
DR-70	O
,	O
a	O
marker	O
used	O
to	O
measure	O
fibrin	O
degradation	O
products	O
,	O
generated	O
by	O
all	O
major	O
cancers	B-T191
,	O
may	O
helps	O
to	O
find	O
high	B-T033
risk	I-T033
lung	B-T191
cancer	I-T191
patients	O
.	O
      
Patient	B-T061
Mobility	I-T061
for	O
Elective	O
Secondary	B-T058
Health	I-T058
Care	I-T058
Services	I-T058
in	O
Response	O
to	O
Patient	O
Choice	O
Policies	O
:	O
A	O
Systematic	O
Review	O
Our	O
review	O
establishes	O
the	O
empirical	O
evidence	O
for	O
patient	B-T061
mobility	I-T061
for	O
elective	B-T058
secondary	I-T058
care	I-T058
services	I-T058
in	O
countries	O
that	O
allow	O
patients	O
to	O
choose	O
their	O
health	O
care	O
provider	O
.	O
PubMed	O
and	O
Embase	O
were	O
searched	O
for	O
relevant	O
articles	O
between	O
1990	O
and	O
2015	O
.	O
Of	O
5,994	O
titles	O
/	O
abstracts	O
reviewed	O
,	O
26	O
studies	O
were	O
included	O
.	O
The	O
studies	O
used	O
three	O
main	O
methodological	O
models	O
to	O
establish	O
mobility	B-T033
.	O
Variation	O
in	O
the	O
extent	O
of	O
patient	B-T061
mobility	I-T061
was	O
observed	O
across	O
the	O
studies	O
.	O
Mobility	B-T033
was	O
positively	O
associated	O
with	O
lower	O
waiting	O
times	O
,	O
indicators	O
of	O
better	B-T058
service	I-T058
quality	I-T058
,	O
and	O
access	O
to	O
advanced	O
technology	O
.	O
It	O
was	O
negatively	O
associated	O
with	O
advanced	O
age	O
or	O
lower	O
socioeconomic	O
backgrounds	O
.	O
From	O
a	O
policy	O
perspective	O
we	O
demonstrate	O
that	O
a	O
significant	O
proportion	O
of	O
patients	O
are	O
prepared	O
to	O
travel	O
beyond	O
their	O
nearest	O
provider	O
for	O
elective	O
services	O
.	O
As	O
a	O
consequence	O
,	O
some	O
providers	O
are	O
likely	O
to	O
be	O
"	O
winners	B-T058
"	O
and	O
others	O
"	O
losers	B-T033
,	O
"	O
which	O
could	O
result	O
in	O
overall	O
decreased	O
provider	O
capacity	O
or	O
inefficient	O
utilization	O
of	O
existing	O
services	B-T058
.	O
Equity	O
also	O
remains	O
a	O
key	O
concern	O
.	O
      
Comprehensive	O
functional	O
analysis	O
of	O
large	O
lists	O
of	O
genes	O
and	O
proteins	O
The	O
interpretation	O
of	O
high	O
dimensional	O
datasets	O
resulting	O
from	O
genomic	O
and	O
proteomic	O
experiments	O
in	O
a	O
timely	O
and	O
efficient	O
manner	O
is	O
challenging	O
.	O
ClueGO	O
software	O
is	O
a	O
Cytoscape	O
App	O
that	O
extracts	O
representative	O
functional	O
biological	O
information	O
for	O
large	O
lists	O
of	O
genes	O
or	O
proteins	O
.	O
The	O
functional	O
enrichment	O
analysis	O
is	O
based	O
on	O
the	O
latest	O
publicly	O
available	O
data	O
from	O
multiple	O
annotation	O
and	O
ontology	O
resources	O
that	O
can	O
be	O
automatically	O
accessed	O
through	O
ClueGO	O
.	O
Predefined	O
settings	O
for	O
the	O
selection	O
of	O
the	O
terms	O
are	O
provided	O
to	O
facilitate	O
the	O
analysis	O
.	O
Results	O
are	O
visualized	O
as	O
networks	O
in	O
which	O
Gene	O
Ontology	O
(	O
GO	O
)	O
terms	O
and	O
pathways	O
are	O
grouped	O
based	O
on	O
their	O
biological	O
role	O
.	O
Many	O
species	O
are	O
now	O
supported	O
by	O
ClueGO	O
and	O
additional	O
organisms	B-T001
are	O
added	O
on	O
demand	O
.	O
ClueGO	O
can	O
be	O
used	O
together	O
with	O
the	O
CluePedia	O
App	O
to	O
enable	O
the	O
visualization	O
of	O
protein	O
-	O
protein	O
interactions	O
within	O
or	O
between	O
pathways	O
.	O
      
The	O
relationship	O
between	O
histological	O
prostatitis	B-T047
and	O
lower	B-T184
urinary	I-T184
tract	I-T184
symptoms	I-T184
and	O
sexual	O
function	O
This	O
prospective	O
analysis	O
assessed	O
the	O
effect	O
of	O
histological	O
prostatitis	B-T047
on	O
lower	O
urinary	O
tract	O
functions	O
and	O
sexual	O
function	O
.	O
The	O
patients	O
were	O
separated	O
into	O
two	O
groups	O
as	O
histologically	O
observed	O
prostatitis	B-T047
(	O
Group	O
A	O
)	O
and	O
no	B-T033
prostatitis	I-T033
(	O
Group	O
B	O
)	O
according	O
to	O
the	O
biopsy	B-T060
outcomes	O
.	O
International	O
prostate	O
symptom	O
score	O
,	O
international	O
index	O
of	O
erectile	O
function-5	O
scores	O
,	O
maximal	B-T033
and	O
average	B-T033
flow	I-T033
rate	I-T033
,	O
and	O
residual	B-T033
urine	I-T033
volumes	I-T033
were	O
compared	O
statistically	O
between	O
groups	O
.	O
There	O
was	O
no	O
significant	O
difference	O
(	O
P>0.05	O
)	O
in	O
baseline	O
age	O
(	O
t=0.64	O
)	O
,	O
body	O
mass	O
index	O
value	O
(	O
t=0.51	O
)	O
,	O
prostate	O
volume	O
(	O
t=0.87	O
)	O
,	O
prostate	B-T059
-	I-T059
specific	I-T059
antigen	I-T059
levels	I-T059
(	O
t=0.43	O
)	O
,	O
maximal	B-T033
(	O
t=0.84	O
)	O
and	O
average	B-T033
flow	I-T033
rate	I-T033
(	O
t=0.59	O
)	O
,	O
and	O
post	O
-	O
void	O
residual	B-T033
urine	I-T033
volume	I-T033
(	O
t=0.71	O
)	O
.	O
Mean	O
international	O
prostate	O
symptom	O
score	O
in	O
patients	O
with	O
prostatitis	B-T047
was	O
numerically	O
but	O
not	O
significantly	O
higher	O
than	O
that	O
in	O
those	O
without	O
prostatitis	B-T047
(	O
t=0.794	O
,	O
P=0.066	O
)	O
.	O
Mean	O
international	O
index	O
of	O
erectile	O
function-5	O
score	O
in	O
the	O
prostatitis	B-T047
group	O
was	O
significantly	O
lower	O
than	O
that	O
in	O
those	O
without	O
prostatitis	B-T047
(	O
t=1.854	O
,	O
P=0.013	O
)	O
.	O
Histological	O
prostatitis	B-T047
notably	O
affected	O
sexual	O
function	O
of	O
patients	O
and	O
may	O
serve	O
as	O
a	O
major	O
risk	B-T033
factor	I-T033
for	O
sexual	B-T047
dysfunction	I-T047
while	O
having	O
little	O
effect	O
on	O
lower	B-T184
urinary	I-T184
tract	I-T184
symptoms	I-T184
.	O
      
Clinical	B-T184
Features	I-T184
and	O
Complications	O
of	O
the	O
HLA	O
-	O
B27	O
-associated	O
Acute	B-T047
Anterior	I-T047
Uveitis	I-T047
:	O
A	O
Metanalysis	O
In	O
this	O
article	O
,	O
we	O
report	O
a	O
literature	O
-	O
based	O
metanalysis	O
we	O
have	O
conducted	O
to	O
outline	O
the	O
clinical	B-T184
features	I-T184
of	O
the	O
HLA	O
-	O
B27	O
Acute	B-T047
Anterior	I-T047
Uveitis	I-T047
(	O
AAU	B-T047
)	O
.	O
The	O
examined	B-T033
material	O
was	O
based	O
on	O
observational	O
studies	O
in	O
which	O
participants	O
were	O
affected	O
by	O
Acute	B-T047
Anterior	I-T047
Uveitis	I-T047
and	O
divided	O
into	O
HLA	O
B27	O
+	O
and	O
HLA	O
B27-	O
.	O
We	O
performed	O
a	O
search	O
on	O
articles	O
with	O
the	O
words	O
"	O
HLA	B-T047
B27	I-T047
uveitis	I-T047
"	O
dated	O
before	O
May	O
2014	O
.	O
Among	O
these	O
,	O
29	O
articles	O
were	O
selected	O
for	O
a	O
second	O
review	O
.	O
After	O
a	O
further	O
evaluation	O
,	O
22	O
articles	O
were	O
analyzed	O
.	O
The	O
clinical	O
characteristics	O
studied	O
in	O
the	O
metanalysis	O
were	O
:	O
(	O
1	O
)	O
systemic	B-T047
disease	I-T047
;	O
(	O
2	O
)	O
sex	O
distribution	O
;	O
(	O
3	O
)	O
laterality	O
;	O
(	O
4	O
)	O
visual	O
acuity	O
;	O
(	O
5	O
)	O
hypopion	B-T047
;	O
(	O
6	O
)	O
anterior	B-T121
chamber	I-T121
's	I-T121
fibrin	I-T121
;	O
(	O
7	O
)	O
elevated	B-T033
intraocular	I-T033
pressure	I-T033
(	O
IOP	O
)	O
during	O
inflammation	O
;	O
(	O
8)	O
glaucoma	B-T047
;	O
(	O
9	O
)	O
posterior	B-T047
synechiae	I-T047
;	O
(	O
10	O
)	O
cataract	B-T020
;	O
(	O
11	O
)	O
cystoid	B-T047
macular	I-T047
edema	I-T047
;	O
(	O
12	O
)	O
papillitis	B-T047
.	O
We	O
have	O
calculated	O
a	O
relative	O
risk	O
(	O
RR	O
)	O
for	O
each	O
outcome	O
measured	O
.	O
The	O
results	O
obtained	O
remark	O
some	O
of	O
the	O
peculiar	O
features	O
linked	O
to	O
the	O
HLA	O
B27	O
Acute	B-T047
Anterior	I-T047
Uveitis	I-T047
,	O
such	O
as	O
strong	O
association	O
with	O
ankylosing	B-T047
spondylitis	I-T047
(	O
RR	O
=	O
6.80	O
)	O
and	O
systemic	B-T047
diseases	I-T047
(	O
RR	O
=	O
9.9	O
)	O
,	O
male	O
prevalence	O
(	O
RR	O
=	O
1.2	O
)	O
,	O
unilateral	O
(	O
RR	O
=	O
1.1	O
)	O
or	O
alternating	O
bilateral	O
(	O
RR	O
=	O
2.2	O
)	O
involvement	O
,	O
hypopion	B-T047
(	O
RR	O
=	O
5.5	O
)	O
,	O
fibrinous	O
reaction	O
and	O
even	O
papillitis	B-T047
(	O
R	O
=	O
7.7	O
)	O
.	O
Simultaneous	O
bilateral	O
(	O
RR	O
=	O
0.3	O
)	O
AAU	B-T047
is	O
more	O
frequent	O
in	O
HLA	O
-	O
B27	O
negative	B-T033
form	O
.	O
We	O
report	O
higher	O
risk	O
of	O
elevated	B-T033
IOP	I-T033
and	O
glaucoma	B-T047
(	O
RR	O
=	O
0.6	O
)	O
in	O
B27-	B-T047
Acute	I-T047
Anterior	I-T047
Uveitis	I-T047
.	O
No	O
significant	O
difference	O
between	O
HLA	B-T033
B	I-T033
27	I-T033
positive	I-T033
and	O
negative	B-T033
AAU	B-T047
was	O
observed	O
according	O
to	O
final	O
visual	O
acuity	O
and	O
complications	O
such	O
as	O
posterior	B-T047
synechiae	I-T047
,	O
cataract	B-T020
,	O
and	O
maculare	B-T047
edema	I-T047
.	O
We	O
trust	O
that	O
this	O
will	O
inform	O
on	O
the	O
clinical	B-T058
evaluation	I-T058
and	O
therapeutic	O
decision	O
in	O
addressing	O
a	O
still	O
ill	O
-	O
defined	O
ophthalmologic	O
condition	O
.	O
      
Influence	O
of	O
ozone	O
and	O
paracetic	O
acid	O
disinfection	B-T061
on	O
adhesion	O
of	O
resilient	O
liners	O
to	O
acrylic	O
resin	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effect	O
of	O
paracetic	O
acid	O
(	O
PAA	O
)	O
and	O
ozone	O
disinfection	B-T061
on	O
the	O
tensile	O
bond	O
strength	O
(	O
TBS	O
)	O
of	O
silicone	O
-	O
based	O
resilient	O
liners	O
to	O
acrylic	O
resins	O
.	O
One	O
hundred	O
and	O
twenty	O
dumbbell	O
shaped	O
heat	O
-	O
polymerized	O
acrylic	O
resins	O
were	O
prepared	O
.	O
From	O
the	O
mid	O
segment	O
of	O
the	O
specimens	O
,	O
3	O
mm	O
of	O
acrylic	O
were	O
grinded	O
off	O
and	O
separated	O
parts	O
were	O
reattached	O
by	O
resilient	O
liners	O
.	O
The	O
specimens	O
were	O
divided	O
into	O
2	O
control	O
(	O
control1	O
,	O
control7	O
)	O
and	O
4	O
test	O
groups	O
of	O
PAA	O
and	O
ozone	O
disinfection	B-T061
(	O
PAA1	O
,	O
PAA7	O
,	O
ozone1	O
and	O
ozone7	O
;	O
n=10	O
)	O
.	O
While	O
control	O
groups	O
were	O
immersed	O
in	O
distilled	B-T121
water	I-T121
for	O
10	O
min	O
(	O
control1	O
)	O
and	O
7	O
days	O
(	O
control7	O
)	O
,	O
test	O
groups	O
were	O
subjected	O
to	O
PAA	O
(	O
16	O
g	O
/	O
L	O
)	O
or	O
ozone	O
rich	O
water	B-T121
(	O
4	O
mg	O
/	O
L	O
)	O
for	O
1	O
cycle	O
(	O
10	O
min	O
for	O
PAA	O
and	O
60	O
min	O
for	O
ozone	O
)	O
per	O
day	O
for	O
7	O
days	O
prior	O
to	O
tensile	O
tests	B-T059
.	O
Measurements	O
of	O
the	O
TBS	O
were	O
analyzed	O
using	O
3	O
-	O
way	O
ANOVA	O
and	O
Tukey	B-T059
's	I-T059
HSD	I-T059
test	I-T059
.	O
Adhesive	O
strength	O
of	O
Mollosil	O
decreased	O
significantly	O
by	O
application	O
of	O
ozone	O
disinfection	B-T061
.	O
PAA	O
disinfection	B-T061
had	O
no	O
negative	O
effect	O
on	O
the	O
TBS	O
values	O
of	O
Mollosil	O
and	O
Molloplast	O
B	O
to	O
acrylic	O
resin	O
.	O
Single	O
application	O
of	O
ozone	O
disinfection	B-T061
did	O
not	O
have	O
any	O
negative	O
effect	O
on	O
TBS	O
values	O
of	O
Molloplast	O
B	O
,	O
but	O
prolonged	O
exposure	B-T033
to	I-T033
ozone	I-T033
decreased	O
its	O
adhesive	O
strength	O
.	O
The	O
adhesion	O
of	O
resilient	O
liners	O
to	O
acrylic	O
was	O
not	O
adversely	O
affected	O
by	O
PAA	O
disinfection	B-T061
.	O
Immersion	O
in	O
ozonated	O
water	B-T121
significantly	O
decreased	O
TBS	O
of	O
Mollosil	O
.	O
Prolonged	O
exposure	O
to	O
ozone	O
negatively	O
affects	O
adhesion	O
of	O
Molloplast	O
B	O
to	O
denture	O
base	O
materials	O
.	O
      
Modeling	O
nurse	O
-	O
patient	O
assignments	O
considering	O
patient	O
acuity	O
and	O
travel	O
distance	O
metrics	O
Balancing	O
workload	O
among	O
nurses	O
on	O
a	O
hospital	O
unit	O
is	O
important	O
for	O
the	O
satisfaction	O
and	O
safety	O
of	O
nurses	O
and	O
patients	O
.	O
To	O
balance	O
nurse	O
workloads	O
,	O
direct	O
patient	B-T058
care	I-T058
activities	I-T058
,	O
indirect	O
patient	B-T058
care	I-T058
activities	I-T058
,	O
and	O
non	B-T058
-	I-T058
patient	I-T058
care	I-T058
activities	I-T058
that	O
occur	O
throughout	O
a	O
shift	O
must	O
be	O
considered	O
.	O
The	O
layout	O
of	O
a	O
hospital	O
unit	O
and	O
the	O
location	O
of	O
a	O
nurse	O
's	O
assigned	O
patients	O
relative	O
to	O
other	O
resources	O
on	O
the	O
unit	O
are	O
also	O
important	O
factors	O
in	O
achieving	B-T033
workload	O
balance	O
.	O
In	O
most	O
hospitals	O
,	O
a	O
unit	O
charge	O
nurse	O
is	O
responsible	B-T033
for	O
the	O
shift	O
assignment	O
of	O
patients	O
to	O
nurses	O
based	O
on	O
experience	O
and	O
past	O
practices	O
.	O
The	O
nurse	O
-	O
patient	O
assignment	O
process	O
is	O
also	O
often	O
a	O
manual	O
process	O
in	O
which	O
the	O
charge	O
nurse	O
must	O
sort	O
through	O
multiple	O
decision	O
criteria	O
in	O
a	O
limited	O
amount	O
of	O
time	O
.	O
In	O
this	O
paper	O
,	O
a	O
methodology	O
for	O
the	O
construction	O
of	O
balanced	O
nurse	O
-	O
patient	O
workload	O
assignments	O
is	O
proposed	O
.	O
Through	O
the	O
illustration	O
of	O
this	O
methodology	O
new	O
scoring	O
metrics	O
are	O
developed	O
using	O
measures	O
currently	O
available	O
on	O
,	O
or	O
from	O
,	O
the	O
hospital	O
unit	O
.	O
It	O
was	O
demonstrated	O
that	O
the	O
complex	O
scheduling	O
problem	B-T033
can	O
be	O
captured	O
.	O
While	O
the	O
methodology	O
was	O
illustrated	O
for	O
a	O
scheduling	O
problem	B-T033
commonly	O
encountered	O
on	O
a	O
hospital	O
unit	O
,	O
the	O
approach	O
can	O
be	O
adapted	O
to	O
other	O
workforce	O
scheduling	O
problems	B-T033
in	O
which	O
measures	O
of	O
workload	O
are	O
required	O
and	O
composed	O
of	O
elements	O
imposed	O
by	O
the	O
work	O
environment	O
,	O
variability	O
within	O
the	O
required	O
tasks	O
,	O
and	O
a	O
measurable	O
perception	O
of	O
the	O
relative	O
intensity	O
of	O
the	O
work	O
elements	O
.	O
      
Interaction	O
of	O
multiple	O
gene	O
variants	O
and	O
their	O
effects	O
on	O
schizophrenia	B-T048
phenotypes	O
Schizophrenia	B-T048
is	O
a	O
clinically	O
heterogeneous	B-T033
disorder	I-T033
and	O
may	O
be	O
explained	O
by	O
its	O
complex	O
genetic	O
architecture	O
.	O
Many	O
schizophrenia	B-T048
susceptibility	O
genes	O
were	O
identified	O
but	O
the	O
picture	O
remains	O
unclear	O
due	O
to	O
inconsistent	O
or	O
contradictory	O
genetic	O
association	O
studies	O
.	O
This	O
confusion	O
may	O
,	O
in	O
part	O
,	O
be	O
because	O
symptoms	B-T184
result	O
from	O
the	O
combined	O
interaction	O
of	O
many	O
genes	O
and	O
these	O
interacting	O
genes	O
are	O
associated	O
with	O
specific	O
sub	O
-	O
phenotypes	O
of	O
schizophrenia	B-T048
rather	O
than	O
schizophrenia	B-T048
as	O
a	O
whole	O
.	O
This	O
study	O
investigates	O
the	O
relationship	O
between	O
schizophrenia	B-T048
susceptibility	O
genes	O
and	O
schizophrenia	B-T048
sub	O
-	O
phenotypes	O
by	O
identifying	O
multiple	O
gene	O
variant	O
interactions	O
.	O
Fifty	O
SNPs	O
from	O
21	O
genes	O
were	O
genotyped	B-T059
in	O
235	O
Australian	O
participants	O
with	O
schizophrenia	B-T048
screened	B-T058
for	O
various	O
phenotypes	O
.	O
Schizophrenia	B-T048
participants	O
were	O
grouped	O
into	O
relevant	O
phenotype	O
clusters	O
using	O
cluster	O
analysis	O
and	O
normalized	O
phenotype	O
cluster	O
scores	O
were	O
calculated	O
for	O
each	O
patient	O
.	O
The	O
relationship	O
between	O
genotypes	O
and	O
normalized	O
phenotype	O
cluster	O
scores	O
were	O
analyzed	O
by	O
linear	O
regression	O
analysis	O
.	O
Three	O
phenotype	O
clusters	O
were	O
identified	O
.	O
There	O
was	O
some	O
overlap	O
in	O
symptoms	B-T184
between	O
phenotype	O
clusters	O
,	O
particularly	O
for	O
depression	B-T048
.	O
However	O
,	O
cluster	O
1	O
appears	O
to	O
be	O
characterized	O
by	O
speech	B-T047
disorder	I-T047
and	O
affective	O
behavior	B-T184
symptoms	I-T184
,	O
cluster	O
2	O
has	O
predominantly	O
hallucination	B-T048
symptoms	B-T184
and	O
cluster	O
3	O
has	O
mainly	O
delusion	B-T048
symptoms	B-T184
.	O
Interaction	O
of	O
five	O
SNPs	O
was	O
found	O
to	O
have	O
an	O
effect	O
on	O
cluster	O
1	O
symptoms	B-T184
;	O
ten	O
SNPs	O
on	O
cluster	O
2	O
symptoms	B-T184
;	O
and	O
eight	O
SNPs	O
on	O
cluster	O
3	O
symptoms	B-T184
.	O
The	O
interaction	O
of	O
specific	O
susceptibility	O
genes	O
is	O
likely	O
to	O
lead	O
to	O
specific	O
clinical	O
sub	O
-	O
phenotypes	O
of	O
schizophrenia	B-T048
.	O
Larger	O
patient	O
cohorts	O
with	O
more	O
extensive	O
clinical	O
data	O
will	O
improve	O
the	O
detection	B-T033
of	O
gene	O
interactions	O
and	O
the	O
resultant	O
schizophrenia	B-T048
clinical	O
phenotypes	O
.	O
      
Implementing	O
Non	O
-	O
Invasive	O
Prenatal	B-T060
Diagnosis	I-T060
(	O
NIPD	B-T060
)	O
in	O
a	O
National	O
Health	O
Service	O
Laboratory	O
;	O
From	O
Dominant	O
to	O
Recessive	O
Disorders	B-T047
Our	O
UK	O
National	O
Health	O
Service	O
regional	O
genetics	O
laboratory	O
offers	O
NIPD	B-T060
for	O
autosomal	O
dominant	O
and	O
de	O
novo	O
conditions	O
(	O
achondroplasia	B-T019
,	O
thanataphoric	B-T019
dysplasia	I-T019
,	O
Apert	B-T019
syndrome	I-T019
)	O
,	O
paternal	O
mutation	O
exclusion	O
for	O
cystic	B-T047
fibrosis	I-T047
and	O
a	O
range	O
of	O
bespoke	B-T060
tests	I-T060
.	O
NIPD	B-T060
avoids	O
the	O
risks	B-T033
associated	O
with	O
invasive	B-T060
testing	I-T060
,	O
making	O
prenatal	B-T060
diagnosis	I-T060
more	O
accessible	O
to	O
families	O
at	O
high	O
genetic	O
risk	O
.	O
However	O
,	O
the	O
challenge	O
remains	O
in	O
offering	O
definitive	O
diagnosis	B-T033
for	O
autosomal	B-T047
recessive	I-T047
diseases	I-T047
,	O
which	O
is	O
complicated	O
by	O
the	O
predominance	O
of	O
the	O
maternal	O
mutant	O
allele	O
in	O
the	O
cell	O
-	O
free	O
DNA	O
sample	O
and	O
thus	O
requires	O
a	O
variety	O
of	O
different	O
approaches	O
.	O
Validation	O
and	O
diagnostic	O
implementation	O
for	O
NIPD	B-T060
of	O
congenital	B-T047
adrenal	I-T047
hyperplasia	I-T047
(	O
CAH	B-T047
)	O
is	O
further	O
complicated	O
by	O
presence	B-T033
of	O
a	O
pseudogene	O
that	O
requires	O
a	O
different	O
approach	O
.	O
We	O
have	O
used	O
an	O
assay	B-T059
targeting	O
approximately	O
6700	O
heterozygous	O
SNPs	O
around	O
the	O
CAH	O
gene	O
(	O
CYP21A2	O
)	O
to	O
construct	O
the	O
high	B-T033
-	I-T033
risk	I-T033
parental	O
haplotypes	O
and	O
tested	O
this	O
approach	O
in	O
five	O
cases	O
,	O
showing	O
that	O
inheritance	O
of	O
the	O
parental	O
alleles	O
can	O
be	O
correctly	O
identified	O
using	O
NIPD	B-T060
.	O
We	O
are	O
evaluating	O
various	O
measures	O
of	O
the	O
fetal	B-T018
fraction	O
to	O
help	O
determine	O
inheritance	O
of	O
parental	O
mutations	O
.	O
We	O
are	O
currently	O
exploring	O
the	O
utility	O
of	O
an	O
NIPD	B-T060
multi	B-T059
-	I-T059
disorder	I-T059
panel	I-T059
for	O
autosomal	B-T047
recessive	I-T047
disease	I-T047
,	O
to	O
make	O
testing	O
more	O
widely	O
applicable	O
to	O
families	O
with	O
a	O
variety	O
of	O
serious	O
genetic	B-T047
conditions	I-T047
.	O
      
Comparison	O
of	O
Gasoline	O
Direct	O
-	O
Injection	O
(	O
GDI	O
)	O
and	O
Port	O
Fuel	O
Injection	O
(	O
PFI	O
)	O
Vehicle	O
Emissions	O
:	O
Emission	O
Certification	O
Standards	O
,	O
Cold	B-T033
-	I-T033
Start	I-T033
,	O
Secondary	O
Organic	O
Aerosol	O
Formation	O
Potential	O
,	O
and	O
Potential	O
Climate	O
Impacts	O
Recent	O
increases	O
in	O
the	O
Corporate	O
Average	O
Fuel	O
Economy	O
standards	O
have	O
led	O
to	O
widespread	O
adoption	O
of	O
vehicles	O
equipped	O
with	O
gasoline	O
direct	O
-	O
injection	O
(	O
GDI	O
)	O
engines	O
.	O
Changes	O
in	O
engine	O
technologies	O
can	O
alter	O
emissions	O
.	O
To	O
quantify	O
these	O
effects	O
,	O
we	O
measured	O
gas-	O
and	O
particle	O
-	O
phase	O
emissions	O
from	O
82	O
light	O
-	O
duty	O
gasoline	O
vehicles	O
recruited	O
from	O
the	O
California	O
in	O
-	O
use	O
fleet	O
tested	O
on	O
a	O
chassis	O
dynamometer	O
using	O
the	O
cold	B-T033
-	I-T033
start	I-T033
unified	O
cycle	O
.	O
The	O
fleet	O
included	O
15	O
GDI	O
vehicles	O
,	O
including	O
8	O
GDIs	O
certified	O
to	O
the	O
most	O
-	O
stringent	O
emissions	O
standard	O
,	O
superultra	O
-	O
low	O
-	O
emission	O
vehicles	O
(	O
SULEV	O
)	O
.	O
We	O
quantified	O
the	O
effects	O
of	O
engine	O
technology	O
,	O
emission	O
certification	O
standards	O
,	O
and	O
cold	B-T033
-	I-T033
start	I-T033
on	O
emissions	O
.	O
For	O
vehicles	O
certified	O
to	O
the	O
same	O
emissions	O
standard	O
,	O
there	O
is	O
no	O
statistical	O
difference	O
of	O
regulated	O
gas	O
-	O
phase	O
pollutant	O
emissions	O
between	O
PFIs	O
and	O
GDIs	O
.	O
However	O
,	O
GDIs	O
had	O
,	O
on	O
average	O
,	O
a	O
factor	O
of	O
2	O
higher	O
particulate	O
matter	O
(	O
PM	O
)	O
mass	O
emissions	O
than	O
PFIs	O
due	O
to	O
higher	O
elemental	O
carbon	O
(	O
EC	O
)	O
emissions	O
.	O
SULEV	O
certified	O
GDIs	O
have	O
a	O
factor	O
of	O
2	O
lower	O
PM	O
mass	O
emissions	O
than	O
GDIs	O
certified	O
as	O
ultralow	O
-	O
emission	O
vehicles	O
(	O
3.0	O
±	O
1.1	O
versus	O
6.3	O
±	O
1.1	O
mg	O
/	O
mi	O
)	O
,	O
suggesting	O
improvements	O
in	O
engine	O
design	O
and	O
calibration	O
.	O
Comprehensive	O
organic	O
speciation	O
revealed	O
no	O
statistically	O
significant	O
differences	O
in	O
the	O
composition	O
of	O
the	O
volatile	O
organic	O
compounds	O
emissions	O
between	O
PFI	O
and	O
GDIs	O
,	O
including	O
benzene	O
,	O
toluene	O
,	O
ethylbenzene	O
,	O
and	O
xylenes	O
(	O
BTEX	O
)	O
.	O
Therefore	O
,	O
the	O
secondary	O
organic	O
aerosol	O
and	O
ozone	O
formation	O
potential	O
of	O
the	O
exhaust	O
does	O
not	O
depend	O
on	O
engine	O
technology	O
.	O
Cold	B-T033
-	I-T033
start	I-T033
contributes	O
a	O
larger	O
fraction	O
of	O
the	O
total	O
unified	O
cycle	O
emissions	O
for	O
vehicles	O
meeting	O
more	O
-	O
stringent	O
emission	O
standards	O
.	O
Organic	O
gas	O
emissions	O
were	O
the	O
most	O
sensitive	O
to	O
cold	B-T033
-	I-T033
start	I-T033
compared	O
to	O
the	O
other	O
pollutants	O
tested	O
here	O
.	O
There	O
were	O
no	O
statistically	O
significant	O
differences	O
in	O
the	O
effects	O
of	O
cold	B-T033
-	I-T033
start	I-T033
on	O
GDIs	O
and	O
PFIs	O
.	O
For	O
our	O
test	O
fleet	O
,	O
the	O
measured	O
14.5	O
%	O
decrease	O
in	O
CO2	O
emissions	O
from	O
GDIs	O
was	O
much	O
greater	O
than	O
the	O
potential	O
climate	O
forcing	O
associated	O
with	O
higher	O
black	B-T121
carbon	I-T121
emissions	O
.	O
Thus	O
,	O
switching	O
from	O
PFI	O
to	O
GDI	O
vehicles	O
will	O
likely	O
lead	O
to	O
a	O
reduction	O
in	O
net	O
global	O
warming	O
.	O
      
Methods	O
,	O
tools	O
and	O
current	O
perspectives	O
in	O
proteogenomics	O
With	O
combined	O
technological	O
advancements	O
in	O
high	O
-	O
throughput	O
next	O
-	O
generation	O
sequencing	O
and	O
deep	B-T059
mass	I-T059
spectrometry	I-T059
-based	O
proteomics	O
,	O
proteogenomics	O
,	O
i.e.	O
,	O
the	O
integrative	O
analysis	O
of	O
proteomic	O
and	O
genomic	O
data	O
,	O
has	O
emerged	O
as	O
a	O
new	O
research	O
field	O
.	O
Early	O
efforts	O
in	O
the	O
field	O
were	O
focused	O
on	O
improving	O
protein	O
identification	O
using	O
sample	O
-	O
specific	O
genomic	O
and	O
transcriptomic	O
sequencing	O
data	O
.	O
More	O
recently	O
,	O
integrative	O
analysis	O
of	O
quantitative	O
measurements	O
from	O
genomic	O
and	O
proteomic	O
studies	O
have	O
identified	O
novel	O
insights	O
into	O
gene	O
expression	O
regulation	O
,	O
cell	O
signaling	O
,	O
and	O
disease	B-T047
.	O
Many	O
methods	O
and	O
tools	O
have	O
been	O
developed	O
or	O
adapted	O
to	O
enable	O
an	O
array	O
of	O
integrative	O
proteogenomic	O
approaches	O
and	O
in	O
this	O
article	O
,	O
we	O
systematically	O
classify	O
published	O
methods	O
and	O
tools	O
into	O
four	O
major	O
categories	O
,	O
(	O
1	O
)	O
Sequence	O
-centric	O
proteogenomics	O
;	O
(	O
2	O
)	O
Analysis	O
of	O
proteogenomic	O
relationships	O
;	O
(	O
3	O
)	O
Integrative	O
modeling	O
of	O
proteogenomic	O
data	O
;	O
and	O
(	O
4	O
)	O
Data	O
sharing	O
and	O
visualization	O
.	O
We	O
provide	O
a	O
comprehensive	O
review	O
of	O
methods	O
and	O
available	O
tools	O
in	O
each	O
category	O
and	O
highlight	O
their	O
typical	O
applications	O
.	O
      
Tissue	O
reservoirs	O
of	O
antiviral	B-T033
T	O
cell	O
immunity	O
in	O
persistent	O
human	O
CMV	B-T047
infection	I-T047
T	O
cell	O
responses	O
to	O
viruses	B-T005
are	O
initiated	O
and	O
maintained	O
in	O
tissue	O
sites	O
;	O
however	O
,	O
knowledge	O
of	O
human	O
antiviral	B-T033
T	O
cells	O
is	O
largely	O
derived	O
from	O
blood	O
.	O
Cytomegalovirus	B-T005
(	O
CMV	B-T005
)	O
persists	O
in	O
most	O
humans	O
,	O
requires	O
T	O
cell	O
immunity	O
to	O
control	O
,	O
yet	O
tissue	O
immune	O
responses	O
remain	O
undefined	O
.	O
Here	O
,	O
we	O
investigated	O
human	O
CMV	B-T005
CMV	B-T005
-specific	O
T	O
cells	O
,	O
virus	B-T005
persistence	O
and	O
CMV	B-T005
-associated	O
T	O
cell	O
homeostasis	O
in	O
blood	O
,	O
lymphoid	O
,	O
mucosa	O
l	O
and	O
secretory	O
tissues	O
of	O
44	O
CMV	B-T005
seropositive	O
and	O
28	O
seronegative	O
donors	O
.	O
CMV	B-T005
-specific	O
T	O
cells	O
were	O
maintained	O
in	O
distinct	O
distribution	O
patterns	O
,	O
highest	O
in	O
blood	O
,	O
bone	O
marrow	O
(	O
BM	O
)	O
,	O
or	O
lymph	B-T023
nodes	I-T023
(	O
LN	B-T023
)	O
,	O
with	O
the	O
frequency	O
and	O
function	O
in	O
blood	O
distinct	O
from	O
tissues	O
.	O
CMV	B-T005
genomes	O
were	O
detected	B-T033
predominantly	O
in	O
lung	B-T023
and	O
also	O
in	O
spleen	B-T023
,	O
BM	O
,	O
blood	O
and	O
LN	B-T023
.	O
High	O
frequencies	O
of	O
activated	O
CMV	B-T005
-specific	O
T	O
cells	O
were	O
found	O
in	O
blood	O
and	O
BM	O
samples	O
with	O
low	O
virus	O
detection	O
,	O
whereas	O
in	O
lung	B-T023
,	O
CMV	B-T005
-specific	O
T	O
cells	O
were	O
present	O
along	O
with	O
detectable	O
virus	B-T005
.	O
In	O
LNs	B-T023
,	O
CMV	B-T005
-specific	O
T	O
cells	O
exhibited	O
quiescent	O
phenotypes	O
independent	O
of	O
virus	B-T005
.	O
Overall	O
,	O
T	O
cell	O
differentiation	O
was	O
enhanced	O
in	O
sites	O
of	O
viral	O
persistence	O
with	O
age	O
.	O
Together	O
,	O
our	O
results	O
suggest	O
tissue	O
T	O
cell	O
reservoirs	O
for	O
CMV	B-T005
control	B-T058
shaped	O
by	O
both	O
viral	O
and	O
tissue	O
-	O
intrinsic	B-T121
factors	I-T121
,	O
with	O
global	O
effects	O
on	O
homeostasis	O
of	O
tissue	O
T	O
cells	O
over	O
the	O
lifespan	O
.	O
      
Unbiased	O
estimates	O
of	O
cerebrospinal	O
fluid	O
β	O
-	O
amyloid	O
1	O
-	O
42	O
cutoffs	O
in	O
a	O
large	O
memory	O
clinic	O
population	O
We	O
sought	O
to	O
define	O
a	O
cutoff	O
for	O
β	O
-	O
amyloid	O
1	O
-	O
42	O
in	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
,	O
a	O
key	O
marker	O
for	O
Alzheimer	B-T047
's	I-T047
disease	I-T047
(	O
AD	B-T047
)	O
,	O
with	O
data	O
-	O
driven	O
Gaussian	O
mixture	O
modeling	O
in	O
a	O
memory	O
clinic	O
population	O
.	O
We	O
performed	O
a	O
combined	O
cross	O
-	O
sectional	O
and	O
prospective	O
cohort	O
study	O
.	O
We	O
selected	O
2462	O
subjects	O
with	O
subjective	O
cognitive	O
decline	O
,	O
mild	B-T048
cognitive	I-T048
impairment	I-T048
,	O
AD	B-T047
-type	O
dementia	B-T048
,	O
and	O
dementia	B-T048
other	O
than	O
AD	B-T047
from	O
the	O
Amsterdam	O
Dementia	B-T048
Cohort	O
.	O
We	O
defined	O
CSF	O
β	O
-	O
amyloid	O
1	O
-	O
42	O
cutoffs	O
by	O
data	O
-	O
driven	O
Gaussian	O
mixture	O
modeling	O
in	O
the	O
total	O
population	O
and	O
in	O
subgroups	O
based	O
on	O
clinical	B-T060
diagnosis	I-T060
,	O
age	O
,	O
and	O
apolipoprotein	B-T059
E	I-T059
(	I-T059
APOE	I-T059
)	I-T059
genotype	I-T059
.	O
We	O
investigated	O
whether	O
abnormal	B-T033
β	O
-	O
amyloid	O
1	O
-	O
42	O
as	O
defined	O
by	O
the	O
data	O
-	O
driven	O
cutoff	O
could	O
better	O
predict	O
progression	O
to	O
AD	B-T047
-type	O
dementia	B-T048
than	O
abnormal	B-T033
β	O
-	O
amyloid	O
1	O
-	O
42	O
defined	O
by	O
a	O
clinical	B-T060
diagnosis	I-T060
-based	O
cutoff	O
using	O
Cox	O
proportional	O
hazards	O
regression	O
.	O
In	O
the	O
total	O
group	O
of	O
patients	O
,	O
we	O
found	O
a	O
cutoff	O
for	O
abnormal	B-T033
CSF	O
β	O
-	O
amyloid	O
1	O
-	O
42	O
of	O
680	O
pg	O
/	O
ml	O
(	O
95	O
%	O
CI	O
660	O
-	O
705	O
pg	O
/	O
ml	O
)	O
.	O
Similar	O
cutoffs	O
were	O
found	O
within	O
diagnostic	B-T033
and	O
APOE	B-T059
genotype	I-T059
subgroups	O
.	O
The	O
cutoff	O
was	O
higher	O
in	O
elderly	O
subjects	O
than	O
in	O
younger	O
subjects	O
.	O
The	O
data	O
-	O
driven	O
cutoff	O
was	O
higher	O
than	O
our	O
clinical	B-T060
diagnosis	I-T060
-based	O
cutoff	O
and	O
had	O
a	O
better	O
predictive	O
accuracy	O
for	O
progression	O
to	O
AD	B-T047
-type	O
dementia	B-T048
in	O
nondemented	O
subjects	O
(	O
HR	O
7.6	O
versus	O
5.2	O
,	O
p	O
<	O
0.01	O
)	O
.	O
Mixture	O
modeling	O
is	O
a	O
robust	O
method	O
to	O
determine	O
cutoffs	O
for	O
CSF	O
β	O
-	O
amyloid	O
1	O
-	O
42	O
.	O
It	O
might	O
better	O
capture	O
biological	O
changes	O
that	O
are	O
related	O
to	O
AD	B-T047
than	O
cutoffs	O
based	O
on	O
clinical	B-T060
diagnosis	I-T060
.	O
      
A	O
new	O
parametric	O
model	O
to	O
assess	O
delay	O
and	O
compression	O
of	O
mortality	O
A	O
decrease	O
in	O
mortality	O
across	O
all	O
ages	O
causes	O
a	O
shift	O
of	O
the	O
age	O
pattern	O
of	O
mortality	O
,	O
or	O
mortality	O
delay	O
,	O
while	O
differences	O
in	O
the	O
rate	O
of	O
decrease	O
across	O
ages	O
cause	O
a	O
change	O
in	O
the	O
shape	O
of	O
the	O
age	B-T033
-	I-T033
at	I-T033
-	I-T033
death	I-T033
distribution	O
,	O
mortality	O
compression	O
or	O
expansion	O
.	O
Evidence	O
exists	O
for	O
both	O
compression	O
and	O
delay	O
of	O
mortality	O
.	O
Existing	O
parametric	O
models	O
to	O
describe	O
the	O
full	O
age	O
pattern	O
of	O
mortality	O
are	O
not	O
able	O
to	O
capture	O
mortality	O
delay	O
versus	O
mortality	O
compression	O
.	O
More	O
recent	O
models	O
that	O
assess	O
delay	O
versus	O
compression	O
mostly	O
focused	O
on	O
the	O
adult	O
or	O
old	O
ages	O
alone	O
and	O
did	O
not	O
distinguish	O
mortality	O
compression	O
below	O
and	O
above	O
the	O
modal	O
age	O
at	O
death	B-T033
,	O
although	O
they	O
represent	O
different	O
mechanisms	O
.	O
This	O
paper	O
presents	O
a	O
new	O
parametric	O
model	O
that	O
describes	O
the	O
full	O
age	O
pattern	O
of	O
mortality	O
and	O
assesses	O
compression	O
-	O
at	O
different	O
stages	O
of	O
life	O
-	O
and	O
delay	O
of	O
mortality	O
:	O
the	O
CoDe	O
model	O
.	O
The	O
model	O
includes	O
10	O
parameters	O
,	O
of	O
which	O
five	O
are	O
constant	O
over	O
time	O
.	O
The	O
five	O
time	O
-varying	O
parameters	O
reflect	O
delay	O
of	O
mortality	O
and	O
compression	O
of	O
mortality	O
in	O
infancy	O
,	O
adolescence	O
,	O
young	O
adulthood	O
,	O
late	O
adulthood	O
,	O
and	O
old	O
age	O
.	O
The	O
model	O
describes	O
infant	O
and	O
background	O
mortality	O
by	O
two	O
simple	O
functions	O
,	O
uses	O
a	O
mixed	O
logistic	O
model	O
with	O
different	O
slopes	O
in	O
adult	O
,	O
middle	O
,	O
and	O
old	O
age	O
,	O
and	O
includes	O
the	O
modal	O
age	O
at	O
death	B-T033
as	O
a	O
parameter	O
to	O
account	O
for	O
the	O
delay	O
in	O
mortality	O
.	O
Applying	O
the	O
CoDe	O
model	O
to	O
age	O
-	O
specific	O
probabilities	O
of	O
death	B-T033
for	O
Japanese	O
,	O
French	O
,	O
American	O
,	O
and	O
Danish	O
men	O
and	O
women	O
between	O
1950	O
and	O
2010	O
showed	O
a	O
very	O
good	O
fit	O
of	O
the	O
full	O
age	O
pattern	O
of	O
mortality	O
.	O
Delay	O
of	O
mortality	O
explained	O
about	O
two	O
-	O
thirds	O
of	O
the	O
increase	O
in	O
life	O
expectancy	O
at	O
birth	O
,	O
whereas	O
compression	O
of	O
mortality	O
due	O
to	O
mortality	O
declines	O
in	O
young	B-T033
age	I-T033
explained	O
about	O
one	O
-	O
third	O
.	O
No	O
strong	O
compression	O
of	O
mortality	O
in	O
late	O
adulthood	O
age	O
was	O
observed	O
.	O
Mortality	O
compression	O
in	O
old	O
age	O
has	O
had	O
a	O
small	O
negative	O
impact	O
on	O
life	O
expectancy	O
.	O
The	O
CoDe	O
model	O
proved	O
a	O
valid	O
instrument	O
for	O
describing	O
the	O
full	O
age	O
pattern	O
of	O
mortality	O
and	O
for	O
disentangling	O
the	O
effects	O
of	O
mortality	O
delay	O
and	O
compression	O
-	O
at	O
different	O
stages	O
of	O
life	O
-	O
on	O
the	O
increase	O
in	O
life	O
expectancy	O
.	O
      
Non	O
-	O
toxigenic	O
environmental	O
Vibrio	B-T007
cholerae	I-T007
O1	I-T007
strain	B-T001
from	O
Haiti	O
provides	O
evidence	O
of	O
pre	O
-	O
pandemic	O
cholera	B-T047
in	O
Hispaniola	O
Vibrio	B-T007
cholerae	I-T007
is	O
ubiquitous	O
in	O
aquatic	O
environments	O
,	O
with	O
environmental	O
toxigenic	O
V.	B-T007
cholerae	I-T007
O1	I-T007
strains	B-T001
serving	O
as	O
a	O
source	B-T033
for	O
recurrent	O
cholera	B-T047
epidemics	I-T047
and	O
pandemic	O
disease	B-T047
.	O
However	O
,	O
a	O
number	O
of	O
questions	O
remain	O
about	O
long	O
-	O
term	O
survival	O
and	O
evolution	O
of	O
V.	B-T007
cholerae	I-T007
strains	B-T001
within	O
these	O
aquatic	O
environmental	O
reservoirs	O
.	O
Through	O
monitoring	O
of	O
the	O
Haitian	O
aquatic	O
environment	O
following	O
the	O
2010	O
cholera	B-T047
epidemic	I-T047
,	O
we	O
isolated	O
two	O
novel	O
non	O
-	O
toxigenic	O
(	O
ctxA	O
/	O
B	O
-	O
negative	B-T033
)	O
Vibrio	B-T007
cholerae	I-T007
O1	I-T007
.	O
These	O
two	O
isolates	O
underwent	O
whole	O
-	O
genome	O
sequencing	O
and	O
were	O
investigated	O
through	O
comparative	O
genomics	O
and	O
Bayesian	O
coalescent	O
analysis	O
.	O
These	O
isolates	O
cluster	O
in	O
the	O
evolutionary	O
tree	O
with	O
strains	B-T001
responsible	O
for	O
clinical	O
cholera	B-T047
,	O
possessing	O
genomic	O
components	O
of	O
6(th	O
)	O
and	O
7(th	O
)	O
pandemic	O
lineages	O
,	O
and	O
diverge	O
from	O
"	O
modern	O
"	O
cholera	B-T047
strains	B-T001
around	O
1548	O
C.E.	O
[	O
95	O
%	O
HPD	O
:	O
1532	O
-	O
1555	O
]	O
.	O
Vibrio	O
Pathogenicity	O
Island	O
(	O
VPI)-1	O
was	O
present	B-T033
;	O
however	O
,	O
SXT	O
/	O
R391	O
-	O
family	O
ICE	O
and	O
VPI-2	O
were	O
absent	O
.	O
Rugose	O
phenotype	O
conversion	O
and	O
vibriophage	B-T005
resistance	O
evidenced	O
adaption	O
for	O
persistence	O
in	O
aquatic	O
environments	O
.	O
The	O
identification	O
of	O
V.	B-T007
cholerae	I-T007
O1	I-T007
strains	B-T001
in	O
the	O
Haitian	O
environment	O
,	O
which	O
predate	O
the	O
first	O
reported	O
cholera	B-T047
pandemic	O
in	O
1817	O
,	O
broadens	O
our	O
understanding	O
of	O
the	O
history	O
of	O
pandemics	O
.	O
It	O
also	O
raises	O
the	O
possibility	O
that	O
these	O
and	O
similar	O
environmental	O
strains	B-T001
could	O
acquire	O
virulence	O
genes	O
from	O
the	O
2010	O
Haitian	O
epidemic	O
clone	O
,	O
including	O
the	O
cholera	O
toxin	O
producing	O
CTXϕ.	O
      
Alanine	O
Aminotransferase	O
Is	O
a	O
Marker	O
of	O
Lipotoxicity	B-T047
Consequences	O
and	O
Hyperandrogenemia	B-T033
in	O
Women	O
with	O
Polycystic	B-T047
Ovary	I-T047
Syndrome	I-T047
Several	O
studies	O
have	O
reported	O
higher	O
levels	O
of	O
Alanine	O
aminotransferase	O
(	O
ALT	O
)	O
in	O
women	O
with	O
polycystic	B-T047
ovary	I-T047
syndrome	I-T047
(	O
PCOS	B-T047
)	O
compared	O
with	O
control	O
subjects	O
.	O
Plasma	B-T059
ALT	I-T059
levels	I-T059
are	O
considered	O
a	O
marker	O
of	O
hepatic	O
lipotoxicity	B-T047
because	O
of	O
their	O
significant	O
associations	O
with	O
different	O
hepatic	O
metabolic	O
dysfunctions	O
,	O
such	O
as	O
hepatic	B-T047
steatosis	I-T047
and	O
hepatic	O
insulin	O
resistance	O
.	O
Retrospective	O
chart	O
review	O
aiming	O
to	O
assess	O
,	O
in	O
PCOS	B-T047
women	O
,	O
the	O
relationship	O
between	O
ALT	B-T059
levels	I-T059
and	O
measures	O
of	O
lipotoxicity	B-T047
consequences	O
that	O
are	O
available	O
clinically	O
,	O
both	O
during	O
fasting	B-T059
and	O
using	O
the	O
oral	B-T060
glucose	I-T060
tolerance	I-T060
test	I-T060
.	O
Women	O
(	O
n	O
=	O
132	O
)	O
with	O
PCOS	B-T047
,	O
were	O
in	O
average	O
27.9	O
years	O
of	O
age	O
,	O
with	O
a	O
mean	O
body	O
mass	O
index	O
of	O
34.1	O
kg	O
/	O
m(2	O
)	O
and	O
49	O
%	O
had	O
a	O
metabolic	B-T047
syndrome	I-T047
(	O
MetS	B-T047
)	O
.	O
ALT	B-T059
levels	I-T059
were	O
significantly	O
correlated	O
with	O
homeostatic	B-T059
model	I-T059
assessment	I-T059
for	I-T059
insulin	I-T059
resistance	I-T059
(	O
r	O
=	O
0.42	O
,	O
P	O
<	O
0.001	O
)	O
,	O
HDL	O
-	O
C	O
(	O
r	O
=	O
-0.31	O
,	O
P	O
<	O
0.001	O
)	O
,	O
Matsuda	O
index	O
(	O
-0.45	O
,	O
P	O
<	O
0.001	O
)	O
,	O
insulin	B-T060
secretion	I-T060
-	I-T060
sensitivity	I-T060
index-2	I-T060
(	O
-0.26	O
,	O
P	O
=	O
0.043	O
)	O
,	O
and	O
free	O
testosterone	O
(	O
0.38	O
,	O
P	O
<	O
0.001	O
)	O
,	O
but	O
not	O
with	O
fasting	O
glucose	O
and	O
triglyceride	O
levels	O
.	O
ALT	O
cutoff	O
≥24	O
IU	O
/	O
L	O
was	O
associated	O
with	O
all	O
these	O
parameters	O
,	O
including	O
fasting	O
glucose	O
(	O
P	O
=	O
0.021	O
)	O
and	O
triglyceride	O
levels	O
(	O
P	O
=	O
0.041	O
)	O
,	O
and	O
detected	O
more	O
women	O
with	O
the	O
MetS	B-T047
(	O
59.2	O
%	O
vs.	O
36.1	O
%	O
,	O
P	O
=	O
0.008	O
)	O
and	O
whole	O
-	O
body	O
insulin	O
resistance	O
(	O
Matsuda	O
index	O
<	O
12.3	O
L(2)·10	O
/	O
mmol(2	O
)	O
,	O
85.3	O
%	O
vs.	O
51.9	O
%	O
,	O
P	O
=	O
0.004	O
)	O
.	O
Plasma	B-T059
ALT	I-T059
levels	I-T059
seem	O
to	O
be	O
a	O
strong	O
predictor	O
not	O
only	O
of	O
liver	B-T023
lipotoxicity	B-T047
but	O
also	O
of	O
systemic	B-T047
lipotoxic	I-T047
consequences	O
and	O
hyperandrogenemia	B-T033
in	O
women	O
with	O
PCOS	B-T047
.	O
Although	O
it	O
requires	O
validation	O
in	O
another	O
study	O
,	O
an	O
ALT	O
cutoff	O
of	O
≥24	O
IU	O
/	O
L	O
may	O
help	O
clinicians	O
identify	O
women	O
with	O
increased	O
metabolic	O
risks	O
.	O
      
Secondary	B-T023
Ossification	I-T023
Center	I-T023
Appearance	O
and	O
Closure	B-T061
in	I-T061
the	I-T061
Pelvis	I-T061
and	O
Proximal	O
Femur	O
Variable	O
ossification	O
patterns	O
of	O
the	O
pelvis	B-T023
in	O
skeletally	O
immature	O
patients	O
can	O
make	O
the	O
interpretation	O
of	O
pelvic	B-T023
radiographs	B-T060
challenging	O
.	O
Inconsistencies	O
among	O
prior	O
studies	O
and	O
lack	O
of	O
sex	O
comparisons	O
underscore	O
the	O
need	O
for	O
a	O
more	O
comprehensive	O
characterization	O
of	O
the	O
secondary	B-T023
ossification	I-T023
centers	I-T023
.	O
This	O
study	O
evaluates	B-T058
the	O
chronology	O
and	O
sex	O
differences	O
for	O
appearance	O
and	O
closure	B-T061
of	I-T061
pelvic	I-T061
and	O
proximal	O
femoral	O
secondary	B-T023
ossification	I-T023
centers	I-T023
using	O
computed	B-T060
tomography	I-T060
(	O
CT	B-T060
)	O
.	O
Patients	O
who	O
underwent	O
abdominal	B-T060
and	O
pelvic	B-T060
CT	I-T060
scans	I-T060
between	O
January	O
2009	O
and	O
December	O
2014	O
at	O
2	O
tertiary	O
level	O
1	O
trauma	O
centers	O
were	O
retrospectively	O
reviewed	O
.	O
Patients	O
between	O
the	O
ages	O
of	O
2	O
and	O
32	O
years	O
with	O
adequate	O
imaging	B-T060
of	O
the	O
pelvis	B-T023
and	O
proximal	O
femurs	O
were	O
included	O
.	O
Patients	O
with	O
a	O
history	O
of	O
orthopaedic	O
trauma	O
or	O
pathology	O
affecting	O
ossification	O
were	O
excluded	O
.	O
CT	B-T060
scans	I-T060
were	O
assessed	O
for	O
the	O
appearance	O
and	O
closure	B-T061
of	O
the	O
following	O
secondary	B-T023
ossification	I-T023
centers	I-T023
:	O
anterior	B-T023
inferior	I-T023
iliac	I-T023
spine	I-T023
(	O
AIIS	B-T023
)	O
,	O
anterior	B-T023
superior	I-T023
iliac	I-T023
spine	I-T023
(	O
ASIS	B-T023
)	O
,	O
femoral	B-T023
head	I-T023
(	O
FH	B-T023
)	O
,	O
greater	B-T023
trochanter	I-T023
(	O
GT	B-T023
)	O
,	O
iliac	B-T023
crest	I-T023
(	O
IC	B-T023
)	O
,	O
ischial	B-T023
tuberosity	I-T023
(	O
IT	B-T023
)	O
,	O
lesser	B-T023
trochanter	I-T023
(	O
LT	B-T023
)	O
,	O
posterior	B-T023
superior	I-T023
iliac	I-T023
spine	I-T023
(	O
PSIS	B-T023
)	O
,	O
symphysis	O
pubis	O
(	O
SP	O
)	O
,	O
and	O
triradiate	O
cartilage	O
(	O
TRC	O
)	O
.	O
Basic	O
descriptive	O
statistics	O
are	O
reported	O
.	O
A	O
total	O
of	O
496	O
CT	B-T060
scans	I-T060
met	O
inclusion	O
criteria	O
(	O
240	O
males	O
and	O
256	O
females	O
)	O
.	O
The	O
order	O
of	O
appearance	O
of	O
the	O
secondary	B-T023
ossification	I-T023
centers	I-T023
was	O
:	O
(	O
male	O
)	O
GT	B-T023
,	O
LT	B-T023
,	O
AIIS	B-T023
,	O
IT	B-T023
,	O
ASIS	B-T023
,	O
PSIS	B-T023
,	O
IC	B-T023
,	O
and	O
SP	O
;	O
(	O
female	O
)	O
GT	B-T023
,	O
LT	B-T023
,	O
IT	B-T023
,	O
AIIS	B-T023
,	O
PSIS	B-T023
,	O
IC	B-T023
,	O
ASIS	B-T023
,	O
and	O
SP	O
.	O
The	O
order	O
of	O
closure	B-T061
was	O
similar	O
:	O
(	O
male	O
)	O
TRC	O
,	O
LT	B-T023
,	O
FH	B-T023
,	O
AIIS	B-T023
,	O
GT	B-T023
,	O
ASIS	B-T023
,	O
PSIS	B-T023
,	O
IT	B-T023
,	O
IC	B-T023
,	O
and	O
SP	O
;	O
(	O
female	O
)	O
LT	B-T023
,	O
TRC	O
,	O
AIIS	B-T023
,	O
FH	B-T023
,	O
GT	B-T023
,	O
ASIS	B-T023
,	O
PSIS	B-T023
,	O
IT	B-T023
,	O
IC	B-T023
,	O
and	O
SP	O
.	O
Female	O
ossification	B-T023
centers	I-T023
appeared	O
~1	O
to	O
2	O
years	O
before	O
males	O
in	O
all	O
locations	O
.	O
Female	O
ossification	B-T023
centers	I-T023
closed	O
~1	O
to	O
2	O
years	O
before	O
males	O
in	O
all	O
locations	O
except	O
TRC	O
,	O
IC	B-T023
,	O
and	O
SP	O
.	O
The	O
appearance	O
and	O
closure	B-T061
of	I-T061
the	I-T061
pelvis	I-T061
and	O
proximal	O
femur	O
secondary	B-T023
ossification	I-T023
centers	I-T023
follow	O
a	O
predictable	O
pattern	O
of	O
development	O
,	O
occurring	O
slightly	O
earlier	O
in	O
females	O
than	O
males	O
.	O
Knowledge	O
of	O
more	O
precise	O
ages	B-T033
of	I-T033
developmen	I-T033
t	O
and	O
sex	O
differences	O
better	O
characterize	O
this	O
complex	O
skeletal	O
development	O
.	O
Future	O
studies	O
may	O
use	O
secondary	B-T023
ossification	I-T023
centers	I-T023
to	O
further	O
evaluate	B-T058
skeletal	B-T060
maturity	I-T060
,	O
assess	O
pediatric	O
pathology	O
,	O
and	O
aid	O
surgical	B-T058
management	I-T058
.	O
Level	O
III	O
.	O
      
Evaluation	B-T058
of	O
MIF	O
-173	O
G	O
/	O
C	O
Polymorphism	O
in	O
Turkish	O
Patients	O
with	O
Ankylosing	B-T047
Spondylitis	I-T047
Ankylosing	B-T047
spondylitis	I-T047
(	O
AS	B-T047
)	O
is	O
a	O
chronic	B-T047
inflammatory	I-T047
disease	I-T047
mainly	O
affecting	O
the	O
spine	B-T023
and	O
sacroiliac	O
joints	O
.	O
Macrophage	O
migration	O
inhibitory	O
(	O
MIF	O
)	O
factor	O
is	O
a	O
regulatory	O
cytokine	O
that	O
inhibits	O
random	O
immune	O
cell	O
migration	O
.	O
MIF	O
gene	O
promoter	O
polymorphisms	O
play	O
a	O
role	O
in	O
the	O
progression	O
of	O
several	O
inflammatory	B-T047
disorders	I-T047
.	O
To	O
investigate	O
the	O
relationship	O
between	O
the	O
MIF	O
gene	O
-173	O
G	O
/	O
C	O
single	O
-	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
and	O
AS	B-T047
.	O
Cross	O
-	O
sectional	O
study	O
.	O
In	O
this	O
study	O
,	O
a	O
total	O
of	O
161	O
AS	B-T047
and	O
194	O
normal	O
controls	O
were	O
recruited	O
.	O
The	O
MIF	O
gene	O
-173	O
G	O
/	O
C	O
SNP	O
was	O
analyzed	O
by	O
polymerase	O
chain	O
reaction	O
using	O
the	O
restriction	B-T059
fragment	I-T059
length	I-T059
polymorphism	I-T059
method	I-T059
.	O
There	O
was	O
no	O
significant	O
difference	O
between	O
groups	O
in	O
terms	O
of	O
genotype	O
distribution	O
(	O
p>0.05	O
)	O
.	O
When	O
wild	O
-	O
type	O
G	O
/	O
G	O
and	O
G	O
/	O
C+C	O
/	O
C	O
genotypes	O
are	O
compared	O
in	O
terms	O
of	O
clinical	O
characteristics	O
,	O
there	O
is	O
a	O
significant	O
difference	O
between	O
the	O
average	O
age	O
and	O
the	O
duration	O
of	O
disease	O
in	O
AS	B-T047
patients	O
(	O
p<0.05	O
)	O
.	O
No	O
significant	O
relationship	O
between	O
AS	B-T047
disease	B-T047
and	O
MIF	O
-173	O
G	O
/	O
C	O
polymorphism	O
was	O
found	O
.	O
MIF	O
-173	O
G	O
/	O
C	O
polymorphism	O
(	O
C	O
allele	O
)	O
may	O
affect	O
the	O
time	O
of	O
onset	O
and	O
the	O
duration	O
of	O
disease	O
in	O
AS	B-T047
patients	O
.	O
      
Clinical	O
Experience	O
With	O
the	O
Subcutaneous	O
Implantable	O
Cardioverter	O
-	O
Defibrillator	O
in	O
Adults	O
With	O
Congenital	B-T019
Heart	I-T019
Disease	I-T019
Sudden	O
cardiac	O
death	O
is	O
a	O
major	O
contributor	O
to	O
mortality	O
for	O
adults	O
with	O
congenital	B-T019
heart	I-T019
disease	I-T019
.	O
The	O
subcutaneous	O
implantable	O
cardioverter	O
-	O
defibrillator	O
(	O
ICD	O
)	O
has	O
emerged	O
as	O
a	O
novel	O
tool	O
for	O
prevention	O
of	O
sudden	O
cardiac	O
death	O
,	O
but	O
clinical	B-T033
performance	I-T033
data	O
for	O
adults	O
with	O
congenital	B-T019
heart	I-T019
disease	I-T019
are	O
limited	O
.	O
A	O
retrospective	O
study	O
involving	O
7	O
centers	O
over	O
a	O
5-	O
year	O
period	O
beginning	O
in	O
2011	O
was	O
performed	O
.	O
Twenty	O
-	O
one	O
patients	O
(	O
median	O
33.9	O
years	O
)	O
were	O
identified	O
.	O
The	O
most	O
common	O
diagnosis	B-T033
was	O
single	B-T019
ventricle	I-T019
physiology	O
(	O
52	O
%	O
)	O
,	O
9	O
palliated	B-T061
by	O
Fontan	B-T061
operation	I-T061
and	O
2	O
by	O
aortopulmonary	B-T061
shunts	I-T061
:	O
d	B-T019
-	I-T019
transposition	I-T019
of	I-T019
the	I-T019
great	I-T019
arteries	I-T019
after	O
Mustard	B-T061
/	O
Senning	B-T061
(	O
n=2	O
)	O
,	O
tetralogy	B-T019
of	I-T019
Fallot	I-T019
(	O
n=2	O
)	O
,	O
aortic	B-T047
valve	I-T047
disease	I-T047
(	O
n=2	O
)	O
,	O
and	O
other	O
biventricular	O
surgery	B-T061
(	O
n=4	O
)	O
.	O
A	O
prior	O
cardiac	O
device	O
had	O
been	O
implanted	B-T061
in	O
7	O
(	O
33	O
%	O
)	O
.	O
The	O
ICD	O
indication	O
was	O
primary	B-T061
prevention	I-T061
in	O
67	O
%	O
and	O
secondary	B-T061
in	O
33	O
%	O
patient	O
s.	O
The	O
most	O
common	O
reason	O
for	O
subcutaneous	O
ICD	O
placement	B-T058
was	O
limited	O
transvenous	O
access	O
for	O
ventricular	O
lead	O
placement	B-T058
(	O
n=10	O
)	O
followed	O
by	O
intracardiac	B-T033
right	I-T033
-	I-T033
to	I-T033
-	I-T033
left	I-T033
shunt	I-T033
(	O
n=5	O
)	O
.	O
Ventricular	B-T047
arrhythmia	I-T047
was	O
induced	O
in	O
17	O
(	O
81	O
%	O
)	O
and	O
was	O
converted	O
with	O
≤80	O
Joules	O
in	O
all	O
.	O
There	O
was	O
one	O
implant	O
complication	O
related	O
to	O
infection	O
,	O
not	O
requiring	O
device	B-T061
removal	I-T061
.	O
Over	O
a	O
median	O
follow	B-T058
-	I-T058
up	I-T058
of	O
14	O
months	O
,	O
4	O
patients	O
(	O
21	O
%	O
)	O
received	O
inappropriate	B-T047
and	O
1	O
(	O
5	O
%	O
)	O
patient	O
received	O
appropriate	O
shocks	O
.	O
There	O
was	O
one	O
arrhythmic	B-T033
death	I-T033
related	O
to	O
asystole	B-T047
in	O
a	O
single	B-T019
ventricle	I-T019
patient	O
.	O
Subcutaneous	O
ICD	O
implantation	B-T061
is	O
feasible	O
for	O
adults	O
with	O
congenital	B-T019
heart	I-T019
disease	I-T019
patients	O
.	O
Most	O
candidates	O
have	O
single	B-T019
ventricle	I-T019
heart	B-T047
disease	I-T047
and	O
limited	O
transvenous	O
options	O
for	O
ICD	O
placement	B-T058
.	O
Despite	O
variable	O
anatomy	O
,	O
this	O
study	O
demonstrates	O
successful	O
conversion	O
of	O
induced	O
ventricular	B-T047
arrhythmia	I-T047
and	O
reasonable	B-T033
rhythm	O
discrimination	O
during	O
follow	B-T058
-	I-T058
up	I-T058
.	O
      
Limb	B-T023
remote	B-T061
ischaemic	I-T061
postconditioning	I-T061
-	O
induced	O
elevation	O
of	O
fibulin-5	O
confers	O
neuroprotection	O
to	O
rats	O
with	O
cerebral	B-T047
ischaemia	I-T047
/	O
reperfusion	O
injury	O
:	O
Activation	O
of	O
the	O
AKT	O
pathway	O
Limb	B-T023
remote	B-T061
ischaemic	I-T061
postconditioning	I-T061
(	O
RIPostC	B-T061
)	O
is	O
an	O
effective	O
and	O
well	O
-	O
acknowledged	O
treatment	B-T061
for	O
brain	O
ischaemia	O
injury	O
.	O
The	O
present	O
study	O
aimed	O
to	O
evaluate	O
the	O
role	O
of	O
fibulin-5	O
in	O
the	O
neuroprotection	O
of	O
RIPostC	B-T061
against	O
cerebral	B-T047
ischaemia	I-T047
/	O
reperfusion	O
(	O
I	O
/	O
R	O
)	O
injury	O
in	O
rats	O
.	O
The	O
middle	B-T020
cerebral	I-T020
artery	I-T020
occlusion	I-T020
(	O
MCAO	B-T020
)	O
model	O
was	O
established	O
in	O
rats	O
and	O
then	O
RIPostC	B-T061
was	O
carried	O
out	O
by	O
three	O
cycles	O
of	O
10	O
minutes	O
occlusion	B-T020
/10	O
minutes	O
release	O
of	O
the	O
bilateral	O
femoral	B-T023
artery	I-T023
at	O
the	O
beginning	O
of	O
the	O
reperfusion	B-T061
.	O
To	O
downregulate	O
the	O
fibulin-5	O
level	O
,	O
fibulin-5	O
siRNA	O
was	O
injected	B-T061
into	O
the	O
lateral	O
ventricle	O
24	O
hours	O
before	O
MCAO	B-T020
.	O
According	O
to	O
our	O
present	O
study	O
,	O
RIPostC	B-T061
attenuated	O
cerebral	B-T047
I	I-T047
/	O
R	O
injury	O
by	O
decreasing	B-T033
infarct	O
volume	O
,	O
improving	O
neurobehavioral	O
score	O
and	O
suppressing	O
blood	B-T023
brain	I-T023
barrier	I-T023
(	O
BBB	B-T023
)	O
leakage	O
.	O
Moreover	O
,	O
the	O
mRNA	O
and	O
protein	O
levels	O
of	O
fibulin-5	O
were	O
upregulated	O
by	O
RIPostC	B-T061
at	O
24	O
hours	O
and	O
72	O
hours	O
after	O
reperfusion	B-T061
RIPostC	B-T061
.	O
Downregulation	O
of	O
fibulin-5	O
attenuated	O
the	O
neuroprotection	O
of	O
RIPostC.	O
Finally	O
,	O
the	O
result	O
showed	O
that	O
fibulin-5	O
was	O
upregulated	O
by	O
RIPostC	B-T061
via	O
activation	O
of	O
the	O
PI3K	O
/	O
AKT	O
pathway	O
.	O
Taken	O
together	O
,	O
these	O
results	O
provide	O
evidence	O
that	O
upregulation	O
of	O
fibulin-5	O
is	O
involved	O
in	O
the	O
beneficial	O
effect	O
of	O
RIPostC	B-T061
against	O
cerebral	B-T047
I	I-T047
/	O
R	O
injury	O
.	O
      
Analysis	O
of	O
Low	O
-	O
Biomass	O
Microbial	B-T001
Communities	I-T001
in	O
the	O
Deep	O
Biosphere	O
Over	O
the	O
past	O
few	O
decades	O
,	O
the	O
subseafloor	O
biosphere	O
has	O
been	O
explored	O
by	O
scientific	O
ocean	O
drilling	O
to	O
depths	O
of	O
about	O
2.5	O
km	O
below	O
the	O
seafloor	O
.	O
Although	O
organic	O
-	O
rich	O
anaerobic	O
sedimentary	O
habitats	O
in	O
the	O
ocean	O
margins	O
harbor	O
large	O
numbers	O
of	O
microbial	B-T001
cells	I-T001
,	O
microbial	B-T001
populations	I-T001
in	O
ultraoligotrophic	O
aerobic	O
sedimentary	O
habitats	O
in	O
the	O
open	O
ocean	O
gyres	O
are	O
several	O
orders	O
of	O
magnitude	O
less	O
abundant	O
.	O
Despite	O
advances	O
in	O
cultivation	O
-	O
independent	O
molecular	O
ecological	O
techniques	O
,	O
exploring	O
the	O
low	O
-	O
biomass	O
environment	O
remains	O
technologically	O
challenging	O
,	O
especially	O
in	O
the	O
deep	O
subseafloor	O
biosphere	O
.	O
Reviewing	O
the	O
historical	O
background	O
of	O
deep	O
-	O
biosphere	O
analytical	O
methods	O
,	O
the	O
importance	O
of	O
obtaining	O
clean	O
samples	O
and	O
tracing	B-T033
contamination	O
,	O
as	O
well	O
as	O
methods	O
for	O
detecting	B-T033
microbial	B-T001
life	O
,	O
technological	O
aspects	O
of	O
molecular	O
microbiology	O
,	O
and	O
detecting	B-T033
subseafloor	O
metabolic	O
activity	O
will	O
be	O
discussed	O
.	O
      
The	O
Pre	O
-	O
Eclampsia	O
Ontology	O
:	O
A	O
Disease	O
Ontology	O
Representing	O
the	O
Domain	O
Knowledge	O
Specific	O
to	O
Pre	O
-	O
Eclampsia	O
Pre	O
-	O
eclampsia	O
(	O
PE	O
)	O
is	O
a	O
clinical	O
syndrome	O
characterized	O
by	O
new	O
-	O
onset	O
hypertension	O
and	O
proteinuria	B-T033
at	O
≥20	B-T033
weeks	I-T033
of	I-T033
gestation	I-T033
,	O
and	O
is	O
a	O
leading	O
cause	O
of	O
maternal	B-T033
and	O
perinatal	O
morbidity	O
and	O
mortality	O
.	O
Previous	O
studies	O
have	O
gathered	O
abundant	O
data	O
about	O
PE	O
such	O
as	O
risk	B-T033
factors	I-T033
and	O
pathological	O
findings	O
.	O
However	O
,	O
most	O
of	O
these	O
data	O
are	O
not	O
semantically	O
structured	O
.	O
Clinical	O
data	O
on	O
PE	O
patients	O
are	O
often	O
generated	O
with	O
semantic	O
heterogeneity	O
such	O
as	O
using	O
disparate	O
terminology	O
to	O
describe	O
the	O
same	O
phenomena	O
.	O
In	O
clinical	O
studies	O
,	O
interoperability	O
of	O
heterogenic	O
clinical	O
data	O
is	O
required	O
in	O
various	O
situations	O
.	O
In	O
such	O
a	O
situation	O
,	O
it	O
is	O
necessary	O
to	O
develop	O
an	O
interoperable	O
and	O
standardized	O
semantic	O
framework	O
to	O
research	O
the	O
pathology	O
of	O
PE	O
more	O
comprehensively	O
and	O
to	O
achieve	O
interoperability	O
of	O
heterogenic	O
clinical	O
data	O
of	O
PE	O
patients	O
.	O
In	O
this	O
study	O
,	O
we	O
developed	O
an	O
ontology	O
representing	O
clinical	O
features	O
,	O
treatments	B-T061
,	O
genetic	O
factors	O
,	O
environmental	O
factors	O
,	O
and	O
other	O
aspects	O
of	O
the	O
current	O
knowledge	O
in	O
the	O
domain	O
of	O
PE	O
.	O
We	O
call	O
this	O
pre	O
-	O
eclampsia	O
ontology	O
"	O
PEO	O
"	O
.	O
To	O
achieve	O
interoperability	O
with	O
other	O
ontologies	O
,	O
the	O
core	O
structure	O
of	O
PEO	O
was	O
compliant	O
with	O
the	O
hierarchy	O
of	O
the	O
Basic	O
Formal	O
Ontology	O
(	O
BFO	O
)	O
.	O
The	O
PEO	O
incorporates	O
a	O
wide	O
range	O
of	O
key	O
concepts	O
and	O
terms	O
of	O
PE	O
from	O
clinical	O
and	O
biomedical	O
research	O
in	O
structuring	O
the	O
knowledge	O
base	O
that	O
is	O
specific	O
to	O
PE	O
;	O
therefore	O
,	O
PEO	O
is	O
expected	O
to	O
enhance	O
PE	O
-specific	O
information	O
retrieval	O
and	O
knowledge	O
discovery	O
in	O
both	O
clinical	O
and	O
biomedical	O
research	O
fields	O
.	O
      
Antagonistic	O
Self	O
-	O
Organizing	O
Patterning	O
Systems	O
Control	O
Maintenance	O
and	O
Regeneration	O
of	O
the	O
Anteroposterior	O
Axis	O
in	O
Planarians	O
Planarian	O
flatworms	O
maintain	O
their	O
body	B-T017
plan	O
in	O
the	O
face	O
of	O
constant	O
internal	O
turnover	O
and	O
can	O
regenerate	O
from	O
arbitrary	O
tissue	O
fragments	O
.	O
Both	O
phenomena	O
require	O
self	O
-	O
maintaining	O
and	O
self	O
-	O
organizing	O
patterning	O
mechanisms	O
,	O
the	O
molecular	O
mechanisms	O
of	O
which	O
remain	O
poorly	O
understood	O
.	O
We	O
show	O
that	O
a	O
morphogenic	O
gradient	O
of	O
canonical	O
Wnt	O
signaling	O
patterns	O
gene	O
expression	O
along	O
the	O
planarian	O
anteroposterior	O
(	O
A	O
/	O
P	O
)	O
axis	O
.	O
Our	O
results	B-T033
demonstrate	O
that	O
gradient	O
formation	O
likely	O
occurs	O
autonomously	O
in	O
the	O
tail	B-T023
and	O
that	O
an	O
autoregulatory	O
module	O
of	O
Wnt	O
-mediated	O
Wnt	O
expression	O
both	O
shapes	O
the	O
gradient	O
at	O
steady	O
state	O
and	O
governs	O
its	O
re	O
-	O
establishment	O
during	O
regeneration	O
.	O
Functional	O
antagonism	O
between	O
the	O
tail	B-T023
Wnt	O
gradient	O
and	O
an	O
unknown	O
head	O
patterning	O
system	O
further	O
determines	O
the	O
spatial	O
proportions	O
of	O
the	O
planarian	O
A	O
/	O
P	O
axis	O
and	O
mediates	O
mutually	O
exclusive	O
molecular	O
fate	O
choices	O
during	O
regeneration	O
.	O
Overall	O
,	O
our	O
results	B-T033
suggest	O
that	O
the	O
planarian	O
A	O
/	O
P	O
axis	O
is	O
patterned	O
by	O
self	O
-	O
organizing	O
patterning	O
systems	O
deployed	O
from	O
either	O
end	O
that	O
are	O
functionally	O
coupled	O
by	O
mutual	O
antagonism	O
.	O
      
Questionable	O
diagnostic	O
benefit	O
of	O
the	O
commercially	O
available	O
panel	O
of	O
bee	O
venom	O
components	O
For	O
many	O
years	O
,	O
only	O
the	O
major	O
allergen	O
rApi	O
m	O
1	O
has	O
been	O
available	O
on	O
the	O
ImmunoCAP	O
system	O
for	O
routine	O
diagnosis	B-T033
of	O
bee	O
venom	O
(	O
BV	O
)	O
allergy	O
.	O
Now	O
,	O
there	O
are	O
five	O
components	O
available	O
,	O
and	O
we	O
aimed	O
to	O
detect	O
the	O
sensitivity	O
and	O
specificity	O
of	O
rApi	O
m	O
1	O
,	O
2	O
,	O
3	O
,	O
5	O
,	O
and	O
10	O
in	O
BV	O
-	O
allergic	O
patients	O
.	O
We	O
further	O
evaluated	O
the	O
sensitivity	O
of	O
rApi	O
m	O
1	O
and	O
2	O
of	O
an	O
alternative	O
platform	O
and	O
investigated	O
possible	O
differences	O
in	O
the	O
sensitization	O
profile	O
between	O
monosensitization	O
and	O
clinically	O
relevant	O
double	O
sensitization	O
.	O
Analysis	O
of	O
the	O
whole	O
panel	O
of	O
BV	O
allergens	O
of	O
the	O
CAP	O
system	O
still	O
resulted	O
in	O
a	O
lower	O
sensitivity	O
than	O
analysis	O
of	O
the	O
combination	O
of	O
rApi	O
m	O
1	O
and	O
2	O
of	O
the	O
Immulite	O
(	O
71.6	O
%	O
vs	O
85.8	O
%	O
)	O
.	O
Sensitization	O
rate	O
of	O
rApi	O
m	O
5	O
was	O
more	O
than	O
doubled	O
in	O
double	O
-	O
sensitized	O
patients	O
,	O
while	O
there	O
was	O
no	O
difference	O
for	O
rApi	O
m	O
2	O
.	O
The	O
benefit	O
of	O
the	O
commercially	O
available	O
panel	O
of	O
BV	O
components	O
is	O
questionable	O
,	O
due	O
to	O
the	O
insufficient	O
sensitivity	O
and	O
still	O
unavailable	O
important	O
cross	O
-	O
reacting	O
allergens	O
.	O
      
Treatment	B-T061
for	O
Rheumatoid	B-T047
Arthritis	I-T047
and	O
Risk	B-T033
of	O
Alzheimer	B-T047
's	I-T047
Disease	I-T047
:	O
A	O
Nested	O
Case	O
-	O
Control	O
Analysis	O
It	O
is	O
increasingly	O
becoming	O
accepted	O
that	O
inflammation	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
Alzheimer	B-T047
's	I-T047
disease	I-T047
(	O
AD	B-T047
)	O
,	O
as	O
several	O
immune	O
-related	O
genes	O
have	O
been	O
associated	O
with	O
AD	B-T047
.	O
Among	O
these	O
is	O
tumor	O
necrosis	O
factor	O
(	O
TNF)-α	O
,	O
a	O
proinflammatory	O
cytokine	O
known	O
to	O
play	O
an	O
important	O
role	O
in	O
autoimmune	B-T047
disorders	I-T047
,	O
including	O
rheumatoid	B-T047
arthritis	I-T047
(	O
RA	B-T047
)	O
.	O
Although	O
AD	B-T047
and	O
RA	B-T047
appear	O
to	O
involve	O
similar	O
pathological	O
mechanisms	O
through	O
the	O
production	O
of	O
TNF	O
-	O
α	O
,	O
the	O
relationship	O
between	O
AD	B-T047
and	O
RA	B-T047
remains	O
unknown	O
.	O
To	O
determine	O
the	O
relative	O
risk	O
of	O
AD	B-T047
among	O
RA	B-T047
patients	O
and	O
non-	O
RA	B-T047
patients	O
,	O
and	O
whether	O
anti	B-T061
-	I-T061
TNF	I-T061
therapy	I-T061
for	O
RA	B-T047
was	O
associated	O
with	O
a	O
lower	O
risk	B-T033
of	O
AD	B-T047
in	O
RA	B-T047
patients	O
.	O
We	O
performed	O
a	O
nested	O
case	O
-	O
control	O
study	O
of	O
more	O
than	O
8.5	O
million	O
commercially	O
insured	O
adults	O
(	O
aged	O
≥18	O
years	O
)	O
in	O
all	O
50	O
US	O
states	O
,	O
Puerto	O
Rico	O
,	O
and	O
US	O
Virgin	O
Islands	O
in	O
the	O
Verisk	O
Health	O
claims	O
database	O
.	O
We	O
derived	O
a	O
sub	O
-	O
cohort	O
of	O
subjects	O
with	O
a	O
diagnosis	B-T033
of	O
RA	B-T047
(	O
controls	O
)	O
,	O
or	O
RA	B-T047
and	O
AD	B-T047
(	O
cases	O
)	O
,	O
matching	O
cases	O
and	O
controls	O
based	O
on	O
age	O
,	O
sex	O
,	O
exposure	B-T058
assessment	I-T058
period	I-T058
,	O
and	O
methotrexate	B-T061
treatment	I-T061
.	O
We	O
also	O
assessed	B-T058
relative	I-T058
risk	I-T058
of	O
AD	B-T047
following	O
exposure	O
to	O
standard	O
RA	B-T047
therapies	B-T061
,	O
including	O
anti	B-T121
-	I-T121
TNF	I-T121
agents	I-T121
(	O
infliximab	B-T121
,	O
adalimumab	B-T121
,	O
etanercept	B-T121
)	O
,	O
methotrexate	B-T121
,	O
prednisone	B-T121
,	O
sulfasalazine	B-T121
,	O
and	O
rituximab	B-T121
.	O
Odds	O
ratios	O
were	O
adjusted	O
for	O
comorbidities	O
,	O
including	O
coronary	B-T047
artery	I-T047
disease	I-T047
,	O
diabetes	B-T047
mellitus	I-T047
,	O
and	O
peripheral	B-T047
vascular	I-T047
disease	I-T047
.	O
AD	B-T047
was	O
more	O
prevalent	O
(	O
p	O
<	O
0.0001	O
)	O
among	O
RA	B-T047
patients	O
(	O
0.79	O
%	O
)	O
than	O
among	O
those	O
without	O
RA	B-T047
(	O
0.11	O
%	O
)	O
.	O
Chronic	B-T033
conditions	I-T033
such	O
as	O
coronary	B-T047
artery	I-T047
disease	I-T047
(	O
odds	O
ratio	O
[	O
OR	O
]	O
1.48	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
1.04	O
-	O
2.05	O
;	O
p	O
=	O
0.03	O
)	O
,	O
diabetes	B-T047
(	O
OR	O
1.86	O
;	O
95	O
%	O
CI	O
1.32	O
-	O
2.62	O
;	O
p	O
=	O
0.0004	O
)	O
,	O
and	O
peripheral	B-T047
vascular	I-T047
disease	I-T047
(	O
OR	O
1.61	O
;	O
95	O
%	O
CI	O
1.06	O
-	O
2.43	O
;	O
p	O
=	O
0.02	O
)	O
significantly	O
increased	O
the	O
relative	O
risk	O
of	O
AD	B-T047
among	O
RA	B-T047
patients	O
.	O
Exposure	O
to	O
anti	B-T121
-	I-T121
TNF	I-T121
agents	I-T121
as	O
a	O
class	O
,	O
but	O
not	O
other	O
immunosuppressive	B-T121
drugs	I-T121
studied	O
,	O
was	O
associated	O
with	O
lowered	O
risk	B-T033
of	O
AD	B-T047
among	O
RA	B-T047
patients	O
(	O
unadjusted	O
OR	O
0.44	O
;	O
95	O
%	O
CI	O
0.22	O
-	O
0.87	O
;	O
p	O
=	O
0.02	O
;	O
adjusted	O
OR	O
0.45	O
;	O
95	O
%	O
CI	O
0.23	O
-	O
0.90	O
;	O
p	O
=	O
0.02	O
)	O
.	O
Sub	O
-	O
group	O
analysis	O
demonstrated	O
that	O
of	O
the	O
three	O
anti	B-T121
-	I-T121
TNF	I-T121
agents	I-T121
studied	O
,	O
only	O
etanercept	B-T121
(	O
unadjusted	O
OR	O
,	O
0.33	O
;	O
95	O
%	O
CI	O
0.08	O
-	O
0.94	O
;	O
p	O
=	O
0.03	O
;	O
adjusted	O
OR	O
0.30	O
;	O
95	O
%	O
CI	O
0.08	O
-	O
0.89	O
;	O
p	O
=	O
0.02	O
)	O
was	O
associated	O
with	O
a	O
decreased	O
risk	B-T033
of	O
AD	B-T047
in	O
RA	B-T047
patients	O
.	O
There	O
is	O
an	O
increased	O
risk	B-T033
of	O
AD	B-T047
in	O
the	O
studied	O
RA	B-T047
population	O
.	O
The	O
relative	O
risk	O
of	O
AD	B-T047
among	O
RA	B-T047
subjects	O
was	O
lowered	O
in	O
those	O
exposed	O
to	O
etanercept	B-T121
.	O
Anti	B-T061
-	I-T061
TNF	I-T061
therapy	I-T061
with	O
etanercept	B-T121
shows	O
promise	O
as	O
a	O
potential	O
treatment	B-T061
for	O
AD	B-T047
.	O
      
Development	O
of	O
an	O
automaton	O
model	O
of	O
rotational	O
activity	O
driving	O
atrial	B-T047
fibrillation	I-T047
Atrial	B-T047
fibrillation	I-T047
(	O
AF	B-T047
)	O
is	O
difficult	O
to	O
treat	B-T061
effectively	O
,	O
owing	O
to	O
uncertainty	B-T033
in	O
where	O
to	O
best	O
ablate	B-T061
to	O
eliminate	O
arrhythmogenic	O
substrate	O
.	O
A	O
model	O
providing	O
insight	O
into	O
the	O
electrical	O
activation	O
events	O
would	O
be	O
useful	O
to	O
guide	O
catheter	B-T061
ablation	I-T061
strategy	I-T061
.	O
Method	O
A	O
two	O
-	O
dimensional	O
,	O
576×576	O
node	O
automaton	O
was	O
developed	O
to	O
simulate	O
atrial	B-T023
electrical	O
activity	O
.	O
The	O
substrate	O
field	O
was	O
altered	O
by	O
the	O
presence	O
of	O
differing	O
refractory	O
period	O
at	O
varying	O
locations	O
.	O
Fibrosis	O
was	O
added	O
in	O
the	O
form	O
of	O
short	O
,	O
randomly	O
positioned	O
lines	O
of	O
conduction	O
block	B-T047
.	O
Larger	O
areas	O
of	O
block	O
were	O
used	O
to	O
simulate	O
ablation	B-T033
lesions	I-T033
.	O
Anisotropy	O
was	O
imposed	O
in	O
a	O
2:1	O
ratio	O
.	O
A	O
premature	O
electrical	O
impulse	O
from	O
one	O
of	O
four	O
grid	O
corners	O
was	O
utilized	O
to	O
initiate	O
activation	O
.	O
Rotational	O
activity	O
was	O
uninducible	O
when	O
refractory	O
patch	O
dimensions	O
were	O
less	O
than	O
20×20	O
mm	O
.	O
For	O
larger	O
refractory	O
regions	O
,	O
a	O
single	O
premature	O
stimulus	O
was	O
capable	O
of	O
inducing	O
an	O
average	O
of	O
1.19±1.10	O
rotors	O
,	O
which	O
often	O
formed	O
near	O
the	O
patch	O
edges	O
.	O
A	O
maximum	O
of	O
5	O
rotors	O
formed	O
when	O
refractory	O
patch	O
dimensions	O
approached	O
the	O
size	O
of	O
the	O
entire	O
left	B-T023
atrial	I-T023
virtual	O
field	O
.	O
Rotors	O
formed	O
along	O
a	O
refractory	O
patch	O
edge	O
,	O
after	O
wavefront	B-T033
arrival	I-T033
was	I-T033
delayed	I-T033
at	O
turning	O
points	O
or	O
due	O
to	O
the	O
presence	O
of	O
a	O
fiber	O
cluster	O
of	O
sufficient	O
size	O
.	O
However	O
,	O
rotational	O
activity	O
could	O
also	O
occur	O
around	O
a	O
large	O
fiber	O
cluster	O
without	O
the	O
need	O
of	O
spatially	O
variable	O
refractoriness	O
.	O
When	O
obstacles	O
to	O
conduction	O
were	O
lacking	O
in	O
size	O
,	O
nascent	O
rotors	O
drifted	O
and	O
either	O
extinguished	O
,	O
or	O
stabilized	B-T033
upon	O
anchoring	O
at	O
a	O
sufficiently	O
large	O
fiber	O
cluster	O
elsewhere	O
in	O
the	O
field	O
.	O
Transient	O
rotors	O
terminated	O
when	O
traversing	O
a	O
region	O
with	O
differing	O
refractory	O
periods	O
,	O
if	O
no	O
obstacle	O
to	O
conduction	O
was	O
present	O
to	O
sufficiently	O
delay	B-T033
wavefront	I-T033
arrival	I-T033
beyond	O
the	O
longest	O
refractory	O
period	O
.	O
Other	O
rotors	O
were	O
annihilated	O
when	O
a	O
nearby	O
rotor	O
with	O
faster	O
spin	O
rate	O
gradually	O
interrupted	O
the	O
activation	O
pathway	O
.	O
Elimination	O
of	O
anchors	B-T061
by	O
removal	B-T061
,	O
or	O
by	O
simulated	O
ablation	B-T061
over	O
a	O
sufficient	O
region	O
,	O
prevented	O
rotor	O
onset	O
at	O
a	O
particular	O
location	O
where	O
it	O
would	O
otherwise	O
form	O
.	O
The	O
presence	O
of	O
obstacles	O
to	O
conduction	O
and	O
spatial	B-T033
differences	I-T033
in	O
refractory	O
period	O
are	O
important	O
parameters	O
for	O
initiating	O
and	O
maintaining	O
rotational	O
activity	O
in	O
this	O
simulation	O
of	O
an	O
atrial	B-T023
substrate	O
.	O
      
Perineal	O
injuries	O
and	O
birth	B-T033
positions	I-T033
among	O
2992	O
women	O
with	O
a	O
low	B-T033
risk	I-T033
pregnancy	I-T033
who	O
opted	O
for	O
a	O
homebirth	B-T033
Whether	O
certain	O
birth	B-T033
positions	I-T033
are	O
associated	O
with	O
perineal	O
injuries	O
and	O
severe	O
perineal	O
trauma	O
(	O
SPT	O
)	O
is	O
still	O
unclear	B-T033
.	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
describe	O
the	O
prevalence	O
of	O
perineal	O
injuries	O
of	O
different	O
severity	O
in	O
a	O
low	O
-	O
risk	O
population	O
of	O
women	O
who	O
planned	O
to	O
give	O
birth	B-T033
at	I-T033
home	I-T033
and	O
to	O
compare	O
the	O
prevalence	O
of	O
perineal	O
injuries	O
,	O
SPT	O
and	O
episiotomy	B-T061
in	O
different	O
birth	B-T033
positions	I-T033
in	O
four	O
Nordic	O
countries	O
.	O
A	O
population	O
-based	O
prospective	O
cohort	O
study	O
of	O
planned	O
home	B-T033
births	I-T033
in	O
four	O
Nordic	O
countries	O
.	O
To	O
assess	O
medical	O
outcomes	O
a	O
questionnaire	O
completed	O
after	O
birth	O
by	O
the	O
attending	O
midwife	O
was	O
used	O
.	O
Descriptive	O
statistics	O
,	O
bivariate	O
analysis	O
and	O
logistic	O
regression	O
were	O
used	O
to	O
analyze	O
the	O
data	O
.	O
Two	O
thousand	O
nine	O
hundred	O
ninety	O
-	O
two	O
women	O
with	O
planned	O
home	B-T033
births	I-T033
,	O
who	O
birthed	O
spontaneously	O
at	O
home	O
or	O
after	O
transfer	B-T058
to	I-T058
hospital	I-T058
,	O
between	O
2008	O
and	O
2013	O
were	O
included	O
.	O
The	O
prevalence	O
of	O
SPT	O
was	O
0.7	O
%	O
and	O
the	O
prevalence	O
of	O
episiotomy	B-T061
was	O
1.0	O
%	O
.	O
There	O
were	O
differences	O
between	O
the	O
countries	O
regarding	O
all	O
maternal	B-T033
characteristics	O
.	O
No	O
association	O
between	O
flexible	O
sacrum	O
positions	O
and	O
sutured	O
perineal	O
injuries	O
was	O
found	O
(	O
OR	O
1.02	O
;	O
95	O
%	O
CI	O
0.86	O
-	O
1.21	O
)	O
or	O
SPT	O
(	O
OR	O
0.68	O
;	O
CI	O
95	O
%	O
0.26	O
-	O
1.79	O
)	O
.	O
Flexible	O
sacrum	O
positions	O
were	O
associated	O
with	O
fewer	O
episiotomies	B-T061
(	O
OR	O
0.20	O
;	O
CI	O
95	O
%	O
0.10	O
-	O
0.54	O
)	O
.	O
A	O
low	O
prevalence	O
of	O
SPT	O
and	O
episiotomy	B-T061
was	O
found	O
among	O
women	O
opting	O
for	O
a	O
home	B-T033
birth	I-T033
in	O
four	O
Nordic	O
countries	O
.	O
Women	O
used	O
a	O
variety	O
of	O
birth	B-T033
positions	I-T033
and	O
a	O
majority	O
gave	O
birth	O
in	O
flexible	O
sacrum	O
positions	O
.	O
No	O
associations	O
were	O
found	O
between	O
flexible	O
sacrum	O
positions	O
and	O
SPT	O
.	O
Flexible	O
sacrum	O
positions	O
were	O
associated	O
with	O
fewer	O
episiotomies	B-T061
.	O
      
Ophthalmic	B-T184
Manifestations	I-T184
of	O
Facial	O
Dog	O
Bites	O
in	O
Children	O
To	O
characterize	O
ophthalmic	B-T184
manifestations	I-T184
and	O
periocular	O
injuries	O
of	O
pediatric	O
facial	O
dog	O
bites	O
.	O
A	O
retrospective	O
review	O
of	O
all	O
children	O
younger	O
than	O
18	O
years	O
who	O
sought	O
medical	O
attention	O
after	O
a	O
dog	O
bite	O
to	O
the	O
face	O
between	O
January	O
1	O
,	O
2003	O
and	O
May	O
22	O
,	O
2014	O
was	O
performed	O
at	O
a	O
large	O
tertiary	O
pediatric	O
hospital	O
.	O
Data	O
on	O
type	O
and	O
location	B-T033
of	I-T033
injury	I-T033
,	O
surgical	B-T033
intervention	I-T033
,	O
and	O
complications	O
were	O
collected	O
.	O
A	O
total	O
of	O
1,989	O
children	O
aged	O
0.19	O
to	O
17	O
years	O
were	O
identified	O
with	O
dog	O
bite	O
s.	O
Dog	O
bite	O
s	O
to	O
the	O
face	O
occurred	O
in	O
most	O
patients	O
(	O
n	O
=	O
1	O
,	O
414	O
[	O
71	O
%	O
]	O
)	O
.	O
Of	O
those	O
children	O
with	O
facial	O
dog	O
bite	O
injuries	O
,	O
230	O
(	O
16	O
%	O
)	O
suffered	B-T048
ophthalmic	B-T184
manifestations	I-T184
.	O
The	O
average	O
age	O
was	O
4.3	O
years	O
.	O
Eyelid	O
injuries	O
occurred	O
in	O
227	O
(	O
99	O
%	O
)	O
of	O
children	O
,	O
47	O
(	O
20	O
%	O
)	O
sustained	O
canalicular	O
system	O
injuries	O
,	O
3	O
(	O
1.3	O
%	O
)	O
suffered	B-T048
corneal	O
abrasions	O
,	O
and	O
2	O
patients	O
sustained	O
facial	O
nerve	O
injury	O
resulting	O
in	O
lagophthalmos	B-T047
.	O
No	O
patients	O
suffered	B-T048
vision	B-T033
loss	I-T033
.	O
Complications	O
occurred	O
in	O
32	O
patients	O
(	O
14	O
%	O
)	O
,	O
with	O
the	O
most	O
common	O
being	O
epiphora	O
in	O
9	O
patients	O
(	O
28	O
%	O
)	O
,	O
upper	O
eyelid	O
ptosis	O
in	O
8	O
(	O
25	O
%	O
)	O
,	O
and	O
prominent	O
scar	B-T033
formation	I-T033
in	O
4	O
patients	O
(	O
13	O
%	O
)	O
.	O
Thirteen	O
children	O
(	O
5.7	O
%	O
)	O
needed	O
one	O
or	O
more	O
secondary	B-T061
procedure	I-T061
to	O
correct	O
complications	O
.	O
The	O
authors	O
report	O
the	O
clinical	O
features	O
and	O
management	O
on	O
the	O
largest	O
series	O
of	O
ophthalmic	O
and	O
periocular	O
injuries	O
associated	O
with	O
pediatric	O
facial	O
dog	O
bite	O
s.	O
These	O
injuries	O
occur	O
in	O
about	O
1	O
in	O
6	O
dog	O
bite	O
s	O
to	O
the	O
face	O
and	O
primarily	O
involve	O
the	O
ocular	B-T023
adnexa	I-T023
.	O
Despite	O
early	O
and	O
appropriate	O
surgical	B-T058
management	I-T058
,	O
complications	O
and	O
the	O
need	O
for	O
revision	B-T061
surgery	I-T061
are	O
relatively	O
common	O
.	O
      
Child	B-T033
death	I-T033
and	O
maternal	B-T033
psychosis	B-T048
-	I-T048
like	I-T048
experiences	I-T048
in	O
44	O
low-	O
and	O
middle	O
-	O
income	O
countries	O
:	O
The	O
role	O
of	O
depression	B-T048
Studies	O
on	O
the	O
effect	O
of	O
child	B-T033
death	I-T033
on	O
the	O
mental	O
wellbeing	O
of	O
women	O
in	O
low-	O
and	O
middle	O
-	O
income	O
countries	O
(	O
LMICs	O
)	O
are	O
scarce	O
despite	O
the	O
high	O
child	O
mortality	O
rates	O
.	O
Thus	O
,	O
the	O
aim	O
of	O
the	O
current	O
study	O
was	O
to	O
assess	O
the	O
association	O
between	O
child	B-T033
death	I-T033
and	O
psychosis	B-T048
-	I-T048
like	I-T048
experiences	I-T048
(	O
PLEs	B-T048
)	O
,	O
as	O
well	O
as	O
the	O
role	O
of	O
depression	B-T048
in	O
this	O
association	O
.	O
Data	O
from	O
44	O
LMICs	O
which	O
participated	O
in	O
the	O
World	O
Health	O
Survey	O
(	O
WHS	O
)	O
were	O
analyzed	O
.	O
A	O
total	O
of	O
59,444	O
women	O
who	O
ever	O
gave	O
birth	O
,	O
aged	O
18	O
-	O
49	O
years	O
,	O
without	O
a	O
self	O
-	O
reported	O
lifetime	O
psychosis	B-T060
diagnosis	I-T060
,	O
were	O
included	O
in	O
the	O
analysis	O
.	O
The	O
World	O
Mental	O
Health	O
Survey	O
version	O
of	O
the	O
Composite	O
International	O
Diagnostic	O
Interview	O
(	O
CIDI	O
)	O
was	O
used	O
to	O
establish	O
the	O
diagnosis	O
of	O
past	O
12-	O
month	O
DSM	O
-	O
IV	O
depression	B-T048
,	O
and	O
assess	O
four	O
positive	B-T184
psychotic	I-T184
symptoms	I-T184
.	O
Depression	B-T048
was	O
defined	O
as	O
self	O
-	O
reported	O
lifetime	O
depression	B-T060
diagnosis	I-T060
and/or	O
past	O
12-	O
month	O
depression	B-T048
.	O
Multivariable	O
logistic	O
regression	O
analyses	O
were	O
performed	O
.	O
After	O
adjustment	O
for	O
potential	O
confounders	O
,	O
women	O
who	O
experienced	O
child	B-T033
death	I-T033
had	O
higher	O
odds	O
for	O
all	O
types	O
of	O
PLEs	B-T048
(	O
when	O
unadjusted	O
for	O
depression	B-T048
)	O
(	O
OR	O
1.20	O
-	O
1.71	O
;	O
p<0.05	O
)	O
and	O
depression	B-T048
(	O
OR	O
=	O
1.64	O
;	O
95	O
%	O
CI	O
=	O
1.39	O
-	O
1.93	O
)	O
.	O
When	O
adjusted	O
for	O
depression	B-T048
,	O
only	O
delusion	B-T048
of	I-T048
control	I-T048
was	O
strongly	O
associated	O
with	O
child	B-T033
death	I-T033
(	O
OR	O
=	O
1.54	O
;	O
95	O
%	O
CI	O
=	O
1.20	O
-	O
1.97	O
)	O
.	O
Child	B-T033
death	I-T033
may	O
be	O
an	O
important	O
determinant	O
of	O
mental	O
wellbeing	O
among	O
women	O
in	O
LMICs	O
.	O
Given	O
the	O
known	O
adverse	O
health	O
outcomes	O
associated	O
with	O
PLEs	B-T048
and	O
depression	B-T048
,	O
as	O
well	O
as	O
the	O
co	O
-	O
occurrence	O
of	O
these	O
symptoms	B-T184
,	O
mental	B-T061
health	I-T061
care	I-T061
may	O
be	O
particularly	O
important	O
for	O
mothers	O
who	O
have	O
experienced	O
child	B-T033
loss	I-T033
in	O
LMICs	O
.	O
      
Appearance	O
Differences	O
Between	O
Lots	O
and	O
Brands	O
of	O
Similar	O
Shade	O
Designations	O
of	O
Dental	O
Composite	O
Resins	O
The	O
purposes	O
of	O
this	O
study	O
were	O
to	O
investigate	O
differences	O
in	O
two	O
inherent	O
appearance	O
characteristics	O
between	O
lots	O
of	O
an	O
enamel	O
dental	O
composite	O
resin	O
of	O
the	O
same	O
shade	O
and	O
brand	O
,	O
and	O
to	O
further	O
compare	O
these	O
differences	O
to	O
those	O
of	O
similar	O
shade	O
designation	O
of	O
a	O
different	O
brand	O
of	O
dental	O
composite	O
resins	O
.	O
Appearance	O
analyses	O
proceeded	O
for	O
three	O
different	O
lots	O
of	O
shades	O
A1	O
,	O
B2	O
,	O
and	O
D3	O
manufactured	O
by	O
one	O
company	O
and	O
for	O
one	O
lot	O
of	O
shade	O
EA1	O
manufactured	O
by	O
another	O
.	O
Samples	O
were	O
measured	O
on	O
black	O
,	O
white	O
,	O
and	O
gray	O
backings	O
using	O
spectroradiometry	B-T059
.	O
Kubelka	O
-	O
Munk	O
theory	O
was	O
used	O
to	O
determine	O
reflectivity	O
of	O
each	O
lot	O
studied	O
.	O
CIELAB	O
values	O
and	O
color	O
differences	O
between	O
shades	O
and	O
lots	O
were	O
analyzed	O
.	O
Translucency	O
indicators	O
were	O
compared	O
between	O
lots	O
over	O
thicknesses	O
from	O
0.5	O
to	O
3.0	O
mm	O
.	O
Differences	O
in	O
inherent	O
color	O
between	O
some	O
lots	O
of	O
same	O
shade	O
designations	O
within	O
a	O
brand	O
were	O
found	O
to	O
be	O
above	O
the	O
acceptability	O
threshold	O
.	O
Color	O
difference	O
between	O
an	O
enamel	O
composite	O
resin	O
of	O
shade	O
A1	O
and	O
a	O
composite	O
resin	O
of	O
shade	O
EA1	O
was	O
also	O
above	O
the	O
acceptability	O
threshold	O
.	O
Statistically	O
significant	O
differences	O
in	O
the	O
translucency	O
were	O
found	O
between	O
some	O
lots	O
of	O
one	O
shade	O
over	O
the	O
entire	O
range	O
of	O
thicknesses	O
studied	O
.	O
Appearance	O
analyses	O
indicate	O
substantial	O
variation	O
between	O
lots	O
of	O
same	O
shade	O
designations	O
as	O
well	O
as	O
between	O
brands	O
of	O
similar	O
shade	O
designations	O
.	O
Optical	O
principles	O
applied	O
to	O
important	O
clinical	O
appearance	O
attributes	O
are	O
described	O
which	O
characterize	O
inherent	O
appearance	O
attributes	O
and	O
provide	O
aid	O
in	O
the	O
appearance	O
matching	O
process	O
for	O
dental	O
composite	O
resins	O
used	O
in	O
restorative	B-T061
and	O
operative	B-T061
dental	I-T061
procedures	I-T061
.	O
(	O
J	O
Esthet	O
Restor	O
Dent	O
29	O
:	O
E6	O
-	O
E14	O
,	O
2017	O
)	O
.	O
      
SIRT2	O
Deacetylates	O
and	O
Inhibits	O
the	O
Peroxidase	O
Activity	O
of	O
Peroxiredoxin-1	O
to	O
Sensitize	O
Breast	O
Cancer	O
Cells	O
to	O
Oxidant	O
Stress	O
-	O
Inducing	O
Agents	O
SIRT2	O
is	O
a	O
protein	O
deacetylase	O
with	O
tumor	O
suppressor	O
activity	O
in	O
breast	B-T191
and	O
liver	B-T191
tumors	I-T191
where	O
it	O
is	O
mutated	O
;	O
however	O
,	O
the	O
critical	O
substrates	O
mediating	O
its	O
antitumor	B-T033
activity	I-T033
are	O
not	O
fully	O
defined	O
.	O
Here	O
we	O
demonstrate	O
that	O
SIRT2	O
binds	O
,	O
deacetylates	O
,	O
and	O
inhibits	O
the	O
peroxidase	O
activity	O
of	O
the	O
antioxidant	O
protein	O
peroxiredoxin	O
(	O
Prdx-1	O
)	O
in	O
breast	O
cancer	O
cells	O
.	O
Ectopic	O
overexpression	O
of	O
SIRT2	O
,	O
but	O
not	O
its	O
catalytically	O
dead	O
mutant	O
,	O
increased	O
intracellular	O
levels	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
induced	B-T121
by	I-T121
hydrogen	I-T121
peroxide	I-T121
,	I-T121
which	O
led	O
to	O
increased	O
levels	O
of	O
an	O
overoxidized	O
and	O
multimeric	O
form	O
of	O
Prdx-1	O
with	O
activity	O
as	O
a	O
molecular	O
chaperone	O
.	O
Elevated	O
levels	O
of	O
SIRT2	O
sensitized	O
breast	O
cancer	O
cells	O
to	O
intracellular	O
DNA	O
damage	O
and	O
cell	O
death	O
induced	O
by	O
oxidative	O
stress	O
,	O
as	O
associated	O
with	O
increased	O
levels	O
of	O
nuclear	O
FOXO3A	O
and	O
the	O
proapoptotic	O
BIM	O
protein	O
.	O
In	O
addition	O
,	O
elevated	O
levels	O
of	O
SIRT2	O
sensitized	O
breast	O
cancer	O
cells	O
to	O
arsenic	B-T121
trioxide	I-T121
,	O
an	O
approved	O
therapeutic	O
agent	O
,	O
along	O
with	O
other	O
intracellular	O
ROS	O
-	O
inducing	B-T121
agents	I-T121
.	O
Conversely	O
,	O
antisense	O
RNA	O
-	O
mediated	O
attenuation	O
of	O
SIRT2	O
reversed	O
ROS	O
-	O
induced	O
toxicity	O
as	O
demonstrated	O
in	O
a	O
zebrafish	O
embryo	B-T018
model	I-T018
system	I-T018
.	O
Collectively	O
,	O
our	O
findings	O
suggest	O
that	O
the	O
tumor	O
suppressor	O
activity	O
of	O
SIRT2	O
requires	O
its	O
ability	O
to	O
restrict	O
the	O
antioxidant	O
activity	O
of	O
Prdx-1	O
,	O
thereby	O
sensitizing	O
breast	O
cancer	O
cells	O
to	O
ROS	O
-	O
induced	O
DNA	O
damage	O
and	O
cell	O
cytotoxicity	O
.	O
Cancer	O
Res	O
;	O
76(18	O
)	O
;	O
5467	O
-	O
78	O
.	O
©	O
2016	O
AACR	O
.	O
      
Body	O
Diffusion	B-T060
Weighted	I-T060
Imaging	I-T060
Using	O
Non	B-T060
-	I-T060
CPMG	I-T060
Fast	I-T060
Spin	I-T060
Echo	I-T060
SS	B-T060
-	I-T060
FSE	I-T060
is	O
a	O
fast	O
technique	B-T060
that	O
does	O
not	O
suffer	O
from	O
off	B-T033
-	I-T033
resonance	I-T033
distortions	O
to	O
the	O
degree	O
that	O
EPI	B-T060
does	O
.	O
Unlike	O
EPI	B-T060
,	O
SS	B-T060
-	I-T060
FSE	I-T060
is	O
ill	O
-	O
suited	O
to	O
diffusion	B-T060
weighted	I-T060
imaging	I-T060
(	O
DWI	B-T060
)	O
due	O
to	O
the	O
Carr	B-T033
-	I-T033
Purcell	I-T033
-	I-T033
Meiboom	I-T033
-	I-T033
Geill	I-T033
(	I-T033
CPMG	I-T033
)	I-T033
condition	I-T033
.	O
Non	B-T033
-	I-T033
CPMG	I-T033
phase	O
cycling	O
does	O
accommodate	O
SS	B-T060
-	I-T060
FSE	I-T060
and	O
DWI	B-T060
but	O
places	O
constraints	O
on	O
reconstruction	O
,	O
which	O
are	O
resolved	B-T033
here	O
through	O
parallel	B-T060
imaging	I-T060
.	O
Additionally	O
,	O
improved	B-T033
echo	O
stability	O
can	O
be	O
achieved	O
by	O
using	O
short	O
duration	O
and	O
highly	O
selective	O
DIVERSE	O
radiofrequency	O
pulses	O
.	O
Here	O
,	O
signal	O
-	O
to	O
-	O
noise	O
ratio	O
(	O
SNR	O
)	O
comparisons	O
between	O
EPI	B-T060
and	O
nCPMG	B-T033
SS	B-T060
-	I-T060
FSE	I-T060
acquisitions	O
and	O
reconstruction	O
techniques	O
give	O
similar	O
values	O
.	O
Diffusion	B-T060
imaging	I-T060
with	O
nCPMG	B-T033
SS	B-T060
-	I-T060
FSE	I-T060
gives	O
similar	O
SNR	O
to	O
an	O
EPI	B-T060
acquisition	O
,	O
though	O
apparent	O
diffusion	O
coefficient	O
values	O
are	O
higher	O
than	O
seen	O
with	O
EPI	B-T060
.	O
In	O
vivo	O
images	O
have	O
good	O
image	O
quality	O
with	O
little	O
distortion	O
.	O
This	O
method	O
has	O
the	O
ability	O
to	O
capture	O
distortion	O
-	O
free	O
DWI	B-T060
images	O
near	O
areas	O
of	O
significant	O
off	B-T033
-	I-T033
resonance	I-T033
as	O
well	O
as	O
preserve	O
adequate	O
SNR	O
.	O
Parallel	B-T060
imaging	I-T060
and	O
DIVERSE	O
refocusing	O
RF	O
pulses	O
allow	O
shorter	O
ETL	O
compared	O
to	O
previous	O
implementations	O
and	O
thus	O
reduces	O
phase	O
encode	O
direction	O
blur	O
and	O
SAR	O
accumulation	B-T033
.	O
      
The	O
MEssaging	B-T058
for	I-T058
Diabetes	I-T058
Intervention	B-T061
Reduced	O
Barriers	O
to	O
Medication	B-T033
Adherence	I-T033
Among	O
Low	B-T033
-	I-T033
Income	I-T033
,	O
Diverse	O
Adults	O
With	O
Type	B-T047
2	I-T047
Nonadherence	B-T033
to	O
diabetes	B-T047
medication	B-T058
is	O
prevalent	O
and	O
costly	O
.	O
MEssaging	B-T058
for	I-T058
Diabetes	I-T058
(	O
MED	B-T058
)	O
,	O
a	O
mobile	B-T058
health	I-T058
(	O
mHealth	B-T058
)	O
intervention	B-T061
,	O
identified	O
and	O
addressed	O
user	O
-specific	O
barriers	O
to	O
medication	B-T033
adherence	I-T033
.	O
We	O
assessed	O
whether	O
MED	B-T058
reduced	O
users	O
'	O
targeted	O
barriers	O
and	O
if	O
barrier	O
reductions	O
were	O
associated	O
with	O
within	O
-	O
participant	O
improvements	O
in	O
adherence	O
or	O
glycemic	O
control	O
(	O
HbA1c	O
)	O
.	O
Adults	O
(	O
N	O
=	O
80	O
)	O
with	O
type	B-T047
2	I-T047
diabetes	I-T047
completed	O
self	O
-	O
report	O
measures	O
identifying	O
barriers	O
to	O
adherence	O
at	O
baseline	O
and	O
monthly	O
for	O
3	O
months	O
.	O
At	O
each	O
assessment	B-T058
,	O
17	O
barriers	O
were	O
assessed	O
and	O
ranked	O
for	O
each	O
user	O
.	O
Each	O
subsequent	O
month	O
,	O
users	O
received	O
daily	O
text	O
messages	O
addressing	O
their	O
3	O
highest	O
ranked	O
barriers	O
.	O
Targeted	O
barriers	O
were	O
different	O
for	O
each	O
participant	O
and	O
could	O
change	O
monthly	O
.	O
Paired	O
t	O
-	O
tests	O
assessed	O
within	O
-	O
participant	O
improvement	O
in	O
targeted	O
barriers	O
each	O
month	O
,	O
and	O
nested	O
regression	O
models	O
assessed	O
if	O
changes	O
in	O
a	O
participant	O
's	O
barrier	O
scores	O
were	O
associated	O
with	O
improvements	O
in	O
adherence	O
and	O
HbA1c	O
.	O
Participants	O
were	O
69	O
%	O
non	O
-	O
white	O
and	O
82	O
%	O
had	O
incomes	O
<	O
$	O
25K.	O
Average	O
HbA1c	O
was	O
8.2	O
±	O
2.0	O
%	O
.	O
Assessment	O
completion	O
rates	O
were	O
100	O
%	O
at	O
baseline	O
,	O
59	O
%	O
at	O
1	O
month	O
,	O
30	O
%	O
at	O
2	O
months	O
,	O
and	O
65	O
%	O
at	O
3	O
months	O
.	O
The	O
most	O
commonly	O
reported	O
barriers	O
were	O
the	O
cost	O
of	O
medications	B-T058
(	O
76	O
%	O
)	O
,	O
believing	O
medications	B-T058
are	O
harmful	O
(	O
58	O
%	O
)	O
,	O
and	O
lacking	O
information	O
about	O
medications	B-T058
(	O
53	O
%	O
)	O
.	O
Participants	O
'	O
barrier	O
scores	O
improved	O
each	O
month	O
and	O
barrier	O
improvement	O
predicted	O
adherence	O
assessed	O
via	O
nightly	O
adherence	O
assessment	O
text	O
messages	O
(	O
P	O
<	O
.001	O
)	O
.	O
Among	O
participants	O
who	O
completed	O
assessments	O
each	O
month	O
,	O
barrier	O
improvement	O
in	O
months	O
2	O
and	O
3	O
(	O
P	O
<	O
.05	O
)	O
predicted	O
HbA1c	O
improvement	O
.	O
Iterative	O
,	O
individual	O
tailoring	O
may	O
overcome	O
users	O
'	O
barriers	O
to	O
adherence	O
.	O
Attrition	O
is	O
a	O
challenge	O
for	O
mHealth	B-T058
interventions	B-T061
among	O
low	B-T033
-	I-T033
income	I-T033
patients	O
.	O
      
Neoadjuvant	B-T061
Chemotherapy	I-T061
of	O
Ovarian	B-T191
Cancer	I-T191
Results	O
in	O
Three	O
Patterns	O
of	O
Tumor	O
-	O
Infiltrating	O
Lymphocyte	O
Response	O
with	O
Distinct	O
Implications	O
for	O
Immunotherapy	B-T061
Purpose	O
:	O
Some	O
forms	O
of	O
chemotherapy	B-T061
can	O
enhance	O
antitumor	O
immunity	O
through	O
immunogenic	O
cell	O
death	O
,	O
resulting	O
in	O
increased	O
T	O
-	O
cell	O
activation	O
and	O
tumor	B-T191
infiltration	I-T191
.	O
Such	O
effects	O
could	O
potentially	O
sensitize	O
tumors	B-T191
to	O
immunotherapies	B-T061
,	O
including	O
checkpoint	O
blockade	O
.	O
We	O
investigated	O
whether	O
platinum	O
-	O
and	O
taxane	B-T121
-based	O
chemotherapy	B-T061
for	O
ovarian	B-T191
cancer	I-T191
induces	O
immunologic	O
changes	O
consistent	O
with	O
this	O
possibility	O
.	O
Experimental	O
Design	O
:	O
Matched	O
pre	O
-	O
and	O
post	O
-	O
neoadjuvant	B-T061
chemotherapy	I-T061
tumor	O
samples	O
from	O
26	O
high	B-T191
-	I-T191
grade	I-T191
serous	I-T191
carcinoma	I-T191
(	O
HGSC	B-T191
)	O
patients	O
were	O
analyzed	O
by	O
immunohistochemistry	B-T060
(	O
IHC	B-T060
)	O
for	O
a	O
large	O
panel	O
of	O
immune	O
cells	O
and	O
associated	O
factors	O
.	O
The	O
prognostic	O
significance	O
of	O
post	O
-	O
chemotherapy	B-T061
TIL	O
patterns	O
was	O
assessed	O
in	O
an	O
expanded	O
cohort	O
(	O
n	O
=	O
90).Results	O
:	O
Neoadjuvant	B-T061
chemotherapy	I-T061
was	O
associated	O
with	O
increased	O
densities	O
of	O
CD3	O
(	O
+	O
)	O
,	O
CD8	O
(	O
+	O
)	O
,	O
CD8	O
(	O
+	O
)	O
TIA-1	O
(	O
+	O
)	O
,	O
PD-1	O
(	O
+	O
)	O
and	O
CD20	O
(	O
+	O
)	O
TIL	O
.	O
Other	O
immune	O
subsets	O
and	O
factors	O
were	O
unchanged	O
,	O
including	O
CD79a	O
(	O
+	O
)	O
CD138	O
(	O
+	O
)	O
plasma	O
cells	O
,	O
CD68	O
(	O
+	O
)	O
macrophages	O
,	O
and	O
MHC	O
class	O
I	O
on	O
tumor	O
cells	O
.	O
Immunosuppressive	B-T047
cell	O
types	O
were	O
also	O
unchanged	O
,	O
including	O
FoxP3	O
(	O
+	O
)	O
PD-1	O
(	O
+	O
)	O
cells	O
(	O
putative	O
regulatory	O
T	O
cells	O
)	O
,	O
IDO-1	O
(	O
+	O
)	O
cells	O
,	O
and	O
PD	O
-	O
L1	O
(	O
+	O
)	O
cells	O
(	O
both	O
macrophages	O
and	O
tumor	O
cells	O
)	O
.	O
Hierarchical	O
clustering	O
revealed	O
three	O
response	O
patterns	O
:	O
(	O
i	O
)	O
TIL	O
(	O
high	O
)	O
tumors	B-T191
showed	O
increases	O
in	O
multiple	O
immune	O
markers	O
after	O
chemotherapy	B-T061
;	O
(	O
ii	O
)	O
TIL	O
(	O
low	O
)	O
tumors	O
underwent	O
similar	O
increases	O
,	O
achieving	O
patterns	O
indistinguishable	O
from	O
the	O
first	O
group	O
;	O
and	O
(	O
iii	O
)	O
TIL	O
(	O
negative	B-T033
)	O
cases	O
generally	O
remained	O
negative	B-T033
.	O
Despite	O
the	O
dramatic	O
increases	O
seen	O
in	O
the	O
first	O
two	O
patterns	O
,	O
post-	O
chemotherapy	B-T061
TIL	O
showed	O
limited	O
prognostic	O
significance	O
.	O
Conclusions	O
:	O
Chemotherapy	B-T061
augments	O
pre	O
-	O
existing	O
TIL	O
responses	O
but	O
fails	O
to	O
relieve	O
major	O
immune	B-T047
-	I-T047
suppressive	I-T047
mechanisms	I-T047
or	O
confer	O
significant	O
prognostic	O
benefit	O
.	O
Our	O
findings	O
provide	O
rationale	O
for	O
multipronged	O
approaches	O
to	O
immunotherapy	B-T061
tailored	O
to	O
the	O
baseline	O
features	O
of	O
the	O
tumor	O
microenvironment	O
.	O
Clin	O
Cancer	O
Res	O
;	O
23(4	O
)	O
;	O
925	O
-	O
34	O
.	O
©	O
2016	O
AACR	O
.	O
      
Co	B-T059
-	I-T059
ChIP	I-T059
enables	O
genome	O
-	O
wide	O
mapping	O
of	O
histone	O
mark	O
co	O
-	O
occurrence	O
at	O
single	O
-	O
molecule	O
resolution	O
Histone	O
modifications	O
play	O
an	O
important	O
role	O
in	O
chromatin	O
organization	O
and	O
transcriptional	O
regulation	O
,	O
but	O
despite	O
the	O
large	O
amount	O
of	O
genome	O
-	O
wide	O
histone	O
modification	O
data	O
collected	O
in	O
different	O
cells	O
and	O
tissues	O
,	O
little	O
is	O
known	O
about	O
co	O
-	O
occurrence	O
of	O
modifications	O
on	O
the	O
same	O
nucleosome	O
.	O
Here	O
we	O
present	O
a	O
genome	O
-	O
wide	O
quantitative	O
method	O
for	O
combinatorial	O
indexed	O
chromatin	B-T059
immunoprecipitation	I-T059
(	O
co	B-T059
-	I-T059
ChIP	I-T059
)	O
to	O
characterize	O
co	O
-	O
occurrence	O
of	O
histone	O
modifications	O
on	O
nucleosomes	O
.	O
Using	O
co	B-T059
-	I-T059
ChIP	I-T059
,	O
we	O
study	O
the	O
genome	O
-	O
wide	O
co	O
-	O
occurrence	O
of	O
14	O
chromatin	O
marks	O
(	O
70	O
pairwise	O
combinations	O
)	O
,	O
and	O
find	O
previously	O
undescribed	O
co	O
-	O
occurrence	O
patterns	O
,	O
including	O
the	O
co	O
-	O
occurrence	O
of	O
H3K9me1	O
and	O
H3K27ac	O
in	O
super	O
-	O
enhancers	O
.	O
Finally	O
,	O
we	O
apply	O
co	B-T059
-	I-T059
ChIP	I-T059
to	O
measure	O
the	O
distribution	O
of	O
the	O
bivalent	O
H3K4me3	O
-	O
H3K27me3	O
domains	O
in	O
two	O
distinct	O
mouse	O
embryonic	O
stem	O
cell	O
(	O
mESC	O
)	O
states	O
and	O
in	O
four	O
adult	O
tissues	O
.	O
We	O
observe	O
dynamic	O
changes	O
in	O
5,786	O
regions	O
and	O
discover	O
both	O
loss	O
and	O
de	O
novo	O
gain	O
of	O
bivalency	O
in	O
key	O
tissue	O
-	O
specific	O
regulatory	O
genes	O
,	O
suggesting	O
a	O
functional	O
role	O
for	O
bivalent	O
domains	O
during	O
different	O
stages	O
of	O
development	O
.	O
These	O
results	B-T033
show	O
that	O
co	B-T059
-	I-T059
ChIP	I-T059
can	O
reveal	O
the	O
complex	O
interactions	O
between	O
histone	O
modifications	O
.	O
      
Utilization	O
and	O
Outcomes	O
of	O
Sentinel	B-T060
Lymph	I-T060
Node	I-T060
Biopsy	I-T060
for	O
Vulvar	B-T191
Cancer	I-T191
To	O
examine	O
the	O
use	O
and	O
predictors	O
of	O
sentinel	B-T060
node	I-T060
biopsy	I-T060
in	O
women	O
with	O
vulvar	B-T191
cancer	I-T191
.	O
The	O
Perspective	O
database	O
,	O
an	O
all	O
-	O
payer	O
database	O
that	O
collects	O
data	O
from	O
more	O
than	O
500	O
hospitals	O
,	O
was	O
used	O
to	O
perform	O
a	O
retrospective	O
cohort	O
study	O
of	O
women	O
with	O
vulvar	B-T191
cancer	I-T191
who	O
underwent	O
vulvectomy	B-T061
and	O
lymph	B-T060
node	I-T060
assessment	I-T060
from	O
2006	O
to	O
2015	O
.	O
Multivariable	O
models	O
were	O
used	O
to	O
determine	O
factors	O
associated	O
with	O
sentinel	B-T060
node	I-T060
biopsy	I-T060
.	O
Length	O
of	O
stay	O
and	O
cost	O
were	O
compared	O
between	O
women	O
who	O
underwent	O
sentinel	B-T060
node	I-T060
biopsy	I-T060
and	O
lymphadenectomy	B-T061
.	O
Among	O
2,273	O
women	O
,	O
sentinel	B-T060
node	I-T060
biopsy	I-T060
was	O
utilized	O
in	O
618	O
(	O
27.2	O
%	O
)	O
and	O
1,655	O
(	O
72.8	O
%	O
)	O
underwent	O
inguinofemoral	B-T061
lymphadenectomy	I-T061
.	O
Performance	O
of	O
sentinel	B-T060
node	I-T060
biopsy	I-T060
increased	O
from	O
17.0	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
12.0	O
-	O
22.0	O
%	O
)	O
in	O
2006	O
to	O
39.1	O
%	O
(	O
95	O
%	O
CI	O
27.1	O
-	O
51.0	O
%	O
)	O
in	O
2015	O
.	O
In	O
a	O
multivariable	O
model	O
,	O
women	O
treated	O
more	O
recently	O
were	O
more	O
likely	O
to	O
have	O
undergone	O
sentinel	B-T060
node	I-T060
biopsy	I-T060
,	O
whereas	O
women	O
with	O
more	O
comorbidities	O
and	O
those	O
treated	O
at	O
rural	O
hospitals	O
were	O
less	O
likely	O
to	O
have	O
undergone	O
the	O
procedure	B-T060
.	O
The	O
median	O
length	O
of	O
stay	O
was	O
shorter	O
for	O
those	O
undergoing	O
sentinel	B-T060
node	I-T060
biopsy	I-T060
(	O
median	O
2	O
days	O
,	O
interquartile	O
range	O
1	O
-	O
3	O
)	O
compared	O
with	O
women	O
who	O
underwent	O
inguinofemoral	B-T061
lymphadenectomy	I-T061
(	O
median	O
3	O
days	O
,	O
interquartile	O
range	O
2	O
-	O
4	O
)	O
.	O
The	O
cost	O
of	O
sentinel	B-T060
node	I-T060
biopsy	I-T060
was	O
$	O
7,599	O
(	O
interquartile	O
range	O
$	O
5,739	O
-	O
9,922	O
)	O
compared	O
with	O
$	O
8,095	O
(	O
interquartile	O
range	O
$	O
5,917	O
-	O
11,281	O
)	O
for	O
lymphadenectomy	B-T061
.	O
The	O
use	O
of	O
sentinel	B-T060
node	I-T060
biopsy	I-T060
for	O
vulvar	B-T191
cancer	I-T191
has	O
more	O
than	O
doubled	O
since	O
2006	O
.	O
Sentinel	B-T060
lymph	I-T060
node	I-T060
biopsy	I-T060
is	O
associated	O
with	O
a	O
shorter	O
hospital	O
stay	O
and	O
decreased	O
cost	O
compared	O
with	O
inguinofemoral	B-T061
lymphadenectomy	I-T061
.	O
      
Recruitment	O
of	O
Minority	O
Adolescents	O
and	O
Young	O
Adults	O
into	O
Randomised	O
Clinical	O
Trials	O
:	O
Testing	O
the	O
Design	O
of	O
the	O
Technology	B-T058
Enhanced	I-T058
Community	I-T058
Health	I-T058
Nursing	I-T058
(	O
TECH	B-T058
-	I-T058
N	I-T058
)	O
Pelvic	B-T047
Inflammatory	I-T047
Disease	I-T047
Trial	O
Pelvic	B-T047
inflammatory	I-T047
disease	I-T047
(	O
PID	B-T047
)	O
disproportionately	O
affects	O
adolescent	O
and	O
young	O
adult	O
(	O
AYA	O
)	O
women	O
and	O
can	O
negatively	O
influence	O
reproductive	O
health	O
trajectories	O
.	O
Few	O
randomized	O
controlled	O
trials	O
(	O
RCTs	O
)	O
have	O
focused	O
on	O
strategies	O
to	O
improve	B-T033
outpatient	O
adherence	O
or	O
to	O
reduce	O
reproductive	O
morbidity	O
in	O
this	O
population	O
.	O
This	O
paper	O
describes	O
the	O
research	O
methods	O
and	O
preliminary	O
effectiveness	O
of	O
recruitment	O
,	O
retention	O
,	O
and	O
intervention	B-T058
strategies	O
employed	O
in	O
a	O
novel	O
RCT	O
designed	O
to	O
test	O
a	O
technology	B-T058
-	I-T058
enhanced	I-T058
community	I-T058
-	I-T058
health	I-T058
nursing	I-T058
(	O
TECH	B-T058
-	I-T058
N	I-T058
)	O
intervention	B-T058
among	O
urban	O
AYA	O
with	O
PID	B-T047
.	O
AYA	O
women	O
aged	O
13	O
-	O
25	O
years	O
were	O
recruited	O
during	O
acute	B-T047
PID	I-T047
visits	B-T058
in	O
outpatient	O
clinics	O
and	O
emergency	O
departments	O
(	O
ED	O
)	O
to	O
participate	B-T058
in	O
this	O
IRB	O
-	O
approved	O
trial	O
.	O
Participants	O
completed	O
an	O
audio	O
-	O
computerized	O
self	O
-	O
interview	O
(	O
ACASI	O
)	O
,	O
provided	O
vaginal	O
specimens	O
,	O
and	O
were	O
randomized	O
to	O
standard	O
treatment	B-T061
or	O
the	O
intervention	B-T058
.	O
Intervention	B-T058
participants	O
received	O
text	O
-	O
messaging	O
support	O
for	O
30	O
days	O
and	O
a	O
community	O
health	O
nurse	O
(	O
CHN	O
)	O
interventionist	O
performed	O
a	O
home	B-T058
visit	I-T058
with	I-T058
clinical	I-T058
assessment	I-T058
within	O
5	O
days	O
after	O
enrollment	B-T058
.	O
All	O
patients	O
received	O
a	O
full	O
course	O
of	O
medications	B-T058
and	O
completed	O
research	O
visits	B-T058
at	O
14-	O
days	O
(	O
adherence	O
)	O
,	O
30	O
days	O
and	O
90	O
days	O
with	O
by	O
an	O
outreach	O
worker	O
.	O
STI	B-T047
testing	O
performed	O
at	O
the	O
30	O
-	O
and	O
90-	O
day	O
visits	B-T058
.	O
Exploratory	O
analyses	O
using	O
descriptive	O
statistics	O
were	O
conducted	O
to	O
examine	O
recruitment	O
,	O
retention	O
,	O
and	O
follow	B-T058
-	I-T058
up	I-T058
data	O
to	O
test	O
the	O
overall	O
design	O
of	O
the	O
intervention	B-T058
.	O
In	O
the	O
first	O
48	O
months	O
,	O
64	O
%	O
of	O
463	O
patients	O
were	O
eligible	O
for	O
the	O
study	O
and	O
81.2	O
%	O
of	O
293	O
eligible	O
patients	O
were	O
recruited	O
for	O
the	O
study	O
(	O
63.3	O
%	O
)	O
;	O
238	O
(	O
81.2	O
%	O
)	O
of	O
eligible	O
patients	O
were	O
enrolled	B-T058
.	O
Most	O
participants	O
were	O
African	O
American	O
(	O
95.6	O
%	O
)	O
with	O
a	O
mean	O
age	O
of	O
18.6	O
(	O
2.3	O
)	O
.	O
Ninety	O
-	O
four	O
percent	O
of	O
individuals	O
assigned	O
to	O
the	O
TECH	B-T058
-	I-T058
N	I-T058
intervention	I-T058
completed	O
the	O
nursing	B-T058
visits	I-T058
.	O
All	O
completed	O
visits	B-T058
have	O
been	O
within	O
the	O
5-	O
day	O
window	O
and	O
over	O
90	O
%	O
of	O
patients	O
in	O
both	O
arms	O
have	O
been	O
retained	O
over	O
the	O
3-	O
month	O
follow	B-T058
-	I-T058
up	I-T058
period	O
.	O
Biological	O
data	O
suggests	O
a	O
shift	O
in	O
the	O
biological	O
milieu	O
with	O
the	O
predominance	O
of	O
Chlamydia	B-T047
trachomatis	I-T047
,	O
Mycoplasma	B-T047
genitalium	I-T047
,	O
and	O
Trichomonas	B-T047
vaginalis	I-T047
infections	I-T047
.	O
Preliminary	O
data	O
from	O
the	O
TECH	B-T058
-	I-T058
N	I-T058
study	O
demonstrated	O
that	O
urban	O
,	O
low	B-T033
-	I-T033
income	I-T033
,	O
minority	O
AYA	O
with	O
PID	B-T047
can	O
effectively	O
be	O
recruited	O
and	O
retained	O
to	O
participate	B-T058
in	O
sexual	O
and	O
reproductive	O
health	O
RCTs	O
with	O
sufficient	O
investment	O
in	O
the	O
design	O
and	O
infrastructure	O
of	O
the	O
study	O
.	O
Community	O
-based	O
sexual	O
health	O
interventions	B-T061
appear	O
to	O
be	O
both	O
feasible	O
and	O
acceptable	O
in	O
this	O
population	O
.	O
      
Biochemical	O
evidence	O
for	O
a	O
mitochondrial	O
genetic	O
modifier	O
in	O
the	O
phenotypic	O
manifestation	O
of	O
Leber	B-T047
's	I-T047
hereditary	I-T047
optic	I-T047
neuropathy	I-T047
-associated	O
mitochondrial	B-T019
DNA	I-T019
mutation	I-T019
Leber	B-T047
's	I-T047
hereditary	I-T047
optic	I-T047
neuropathy	I-T047
(	O
LHON	B-T047
)	O
is	O
the	O
most	O
common	O
mitochondrial	B-T047
disease	I-T047
.	O
Mitochondrial	O
modifiers	O
are	O
proposed	O
to	O
modify	O
the	O
phenotypic	O
expression	O
of	O
primary	O
LHON	B-T047
-associated	O
mitochondrial	O
DNA	O
(	O
mtDNA	O
)	O
mutations	B-T019
.	O
In	O
this	O
study	O
,	O
we	O
demonstrated	O
that	O
the	O
LHON	B-T047
susceptibility	O
allele	O
(	O
m.14502	O
T	O
>	O
C	O
,	O
p.	O
58I	O
>	O
V	O
)	O
in	O
the	O
ND6	O
gene	O
modulated	O
the	O
phenotypic	O
expression	O
of	O
primary	O
LHON	B-T047
-associated	O
m.11778	O
G	O
>	O
A	O
mutation	O
.	O
Twenty	O
-	O
two	O
Han	O
Chinese	O
pedigrees	O
carrying	O
m.14502	O
T	O
>	O
C	O
and	O
m.11778	O
G	O
>	O
A	O
mutations	O
exhibited	O
significantly	O
higher	O
penetrance	O
of	O
optic	B-T047
neuropathy	I-T047
than	O
those	O
carrying	O
only	O
m.11778	O
G	O
>	O
A	O
mutation	O
.	O
We	O
performed	O
functional	O
assays	B-T059
using	O
the	O
cybrid	O
cell	O
models	O
,	O
generated	O
by	O
fusing	O
mtDNA	O
-	O
less	O
ρ(o	O
)	O
cells	O
with	O
enucleated	O
cells	O
from	O
LHON	B-T047
patients	O
carrying	O
both	O
m.11778	O
G	O
>	O
A	O
and	O
m.14502	O
T	O
>	O
C	O
mutations	O
,	O
only	O
m.14502	O
T	O
>	O
C	O
or	O
m.11778	O
G	O
>	O
A	O
mutation	O
and	O
a	O
control	O
belonging	O
to	O
the	O
same	O
mtDNA	O
haplogroup	O
.	O
These	O
cybrids	O
cell	O
lines	O
bearing	O
m.14502	O
T	O
>	O
C	O
mutation	O
exhibited	O
mild	O
effects	O
on	O
mitochondrial	O
functions	O
compared	O
with	O
those	O
carrying	O
only	O
m.11778	O
G	O
>	O
A	O
mutation	O
.	O
However	O
,	O
more	O
severe	O
mitochondrial	O
dysfunctions	O
were	O
observed	O
in	O
cell	O
lines	O
bearing	O
both	O
m.14502	O
T	O
>	O
C	O
and	O
m.11778	O
G	O
>	O
A	O
mutations	O
than	O
those	O
carrying	O
only	O
m.11778	O
G	O
>	O
A	O
or	O
m.14502	O
T	O
>	O
C	O
mutation	O
.	O
In	O
particular	O
,	O
the	O
m.14502	O
T	O
>	O
C	O
mutation	O
altered	O
assemble	O
of	O
complex	O
I	O
,	O
thereby	O
aggravating	O
the	O
respiratory	O
phenotypes	O
associated	O
with	O
m.11778	O
G	O
>	O
A	O
mutation	O
,	O
resulted	O
in	O
a	O
more	O
defective	O
complex	O
I.	O
Furthermore	O
,	O
more	O
reductions	O
in	O
the	O
levels	O
of	O
mitochondrial	O
ATP	B-T121
and	O
increasing	O
production	O
of	O
reactive	O
oxygen	O
species	O
were	O
also	O
observed	O
in	O
mutant	O
cells	O
bearing	O
both	O
m.14502	O
T	O
>	O
C	O
and	O
m.11778	O
G	O
>	O
A	O
mutation	O
than	O
those	O
carrying	O
only	O
11778	O
G	O
>	O
A	O
mutation	O
.	O
Our	O
findings	O
provided	O
new	O
insights	O
into	O
the	O
pathophysiology	O
of	O
LHON	B-T047
that	O
were	O
manifested	O
by	O
interaction	O
between	O
primary	O
and	O
secondary	O
mtDNA	O
mutations	B-T019
.	O
      
Antiadipogenic	B-T033
Activity	I-T033
of	O
γ	O
-	O
Oryzanol	O
and	O
Its	O
Stability	O
in	O
Pigmented	O
Rice	O
γ	O
-	O
Oryzanol	O
,	O
a	O
prevalent	O
compound	O
in	O
pigmented	O
rice	O
varieties	O
,	O
has	O
been	O
reported	O
to	O
ameliorate	O
obesity	B-T047
-	I-T047
associated	I-T047
metabolic	I-T047
disorders	I-T047
.	O
Antiadipogenic	B-T033
activities	I-T033
of	O
γ	O
-	O
oryzanol	O
were	O
determined	O
in	O
human	O
adipose	O
-	O
derived	O
mesenchymal	O
stem	O
cells	O
and	O
mouse	O
-	O
derived	O
3T3	O
-	O
L1	O
cells	O
.	O
γ	O
-	O
Oryzanol	O
significantly	O
decreased	O
lipid	B-T033
accumulation	I-T033
and	O
reduced	O
glycerol-3	O
-	O
phosphate	O
dehydrogenase	O
activities	O
in	O
both	O
adipocytes	O
.	O
In	O
addition	O
,	O
γ	O
-	O
oryzanol	O
in	O
four	O
pigmented	O
rice	O
varieties	O
(	O
black	O
with	O
giant	O
embryo	O
,	O
brown	O
,	O
sugary	O
brown	O
,	O
and	O
red	O
)	O
was	O
stable	O
when	O
stored	O
at	O
4	O
°	O
C	O
and	O
also	O
at	O
room	O
temperature	O
for	O
22	O
weeks	O
,	O
whereas	O
other	O
bioactives	O
such	O
as	O
lutein	B-T121
and	O
β	B-T121
-	I-T121
carotene	I-T121
were	O
stable	O
only	O
at	O
-80	O
°	O
C	O
.	O
Furthermore	O
,	O
the	O
yield	O
of	O
γ	O
-	O
oryzanol	O
from	O
these	O
rice	O
varieties	O
was	O
significantly	O
increased	O
through	O
steaming	O
and	O
roasting	O
processes	O
.	O
Therefore	O
,	O
γ	O
-	O
oryzanol	O
exerts	O
antiadipogenic	B-T033
activity	I-T033
by	O
suppressing	O
adipocyte	O
differentiations	O
and	O
is	O
stable	O
in	O
pigmented	O
rice	O
for	O
an	O
extended	O
period	O
of	O
time	O
during	O
storage	O
and	O
after	O
cooking	O
.	O
Thus	O
,	O
the	O
intake	O
of	O
pigmented	O
rice	O
may	O
be	O
a	O
useful	O
strategy	O
for	O
preventing	O
obesity	B-T047
.	O
      
Firecracker	O
eye	B-T033
exposure	I-T033
:	O
experimental	O
study	O
and	O
simulation	O
Understanding	O
the	O
mechanisms	O
of	O
traumatic	O
ocular	O
injury	O
is	O
helpful	O
to	O
make	O
accurate	O
diagnoses	B-T033
before	O
the	O
symptoms	B-T184
emerge	O
and	O
to	O
develop	O
specific	O
eye	O
protection	O
.	O
The	O
comprehension	O
of	O
the	O
dynamics	O
of	O
primary	O
blast	O
injury	O
mechanisms	O
is	O
a	O
challenging	O
issue	B-T033
.	O
The	O
question	O
is	O
whether	O
the	O
pressure	O
wave	O
propagation	O
and	O
reflection	O
alone	O
could	O
cause	O
ocular	B-T033
damage	I-T033
.	O
To	O
date	O
,	O
there	O
are	O
dissenting	O
opinions	O
and	O
no	O
conclusive	O
evidence	O
thereupon	O
.	O
A	O
previous	O
numerical	B-T058
investigation	I-T058
of	O
blast	O
trauma	O
highlighted	O
the	O
dynamic	O
effect	O
of	O
pressure	O
propagation	O
and	O
its	O
amplification	O
by	O
the	O
geometry	O
of	O
the	O
bony	B-T023
orbit	I-T023
,	O
inducing	O
a	O
resonance	O
cavity	O
effect	O
and	O
a	O
standing	O
wave	O
hazardous	O
for	O
eye	B-T023
tissues	O
.	O
The	O
objective	O
of	O
the	O
current	O
work	O
is	O
to	O
find	O
experimental	O
evidence	O
of	O
the	O
numerically	O
identified	O
phenomenon	O
.	O
Therefore	O
,	O
tests	O
aimed	O
at	O
evaluating	B-T058
the	O
response	O
of	O
porcine	O
eyes	B-T023
to	O
blast	O
overpressure	O
generated	O
by	O
firecrackers	O
explosion	O
were	O
performed	O
.	O
The	O
orbital	O
cavity	O
effect	O
was	O
considered	O
mounting	O
the	O
enucleated	O
eyes	O
inside	O
a	O
dummy	O
orbit	O
.	O
The	O
experimental	O
measurements	O
obtained	O
during	O
the	O
explosion	O
tests	O
presented	O
in	O
this	O
paper	O
corroborate	O
the	O
numerical	O
evidence	O
of	O
a	O
high	O
-	O
frequency	O
pressure	O
amplification	O
,	O
enhancing	O
the	O
loading	O
on	O
the	O
ocular	B-T023
tissues	O
,	O
attributable	O
to	O
the	O
orbital	O
bony	O
walls	O
surrounding	O
the	O
eye	B-T023
.	O
      
Allogeneic	B-T061
stem	I-T061
cell	I-T061
transplantation	I-T061
for	O
adult	O
patients	O
with	O
acute	B-T191
lymphoblastic	I-T191
leukemia	I-T191
who	O
had	O
central	B-T033
nervous	I-T033
system	I-T033
involvement	I-T033
:	O
a	O
study	O
from	O
the	O
Adult	O
ALL	B-T191
Working	O
Group	O
of	O
the	O
Japan	O
Society	O
for	O
Hematopoietic	B-T061
Cell	I-T061
Transplantation	I-T061
The	O
prognosis	B-T058
for	O
adult	O
acute	B-T191
lymphoblastic	I-T191
leukemia	I-T191
(	O
ALL	B-T191
)	O
patients	O
with	O
central	B-T033
nervous	I-T033
system	I-T033
(	I-T033
CNS	I-T033
)	I-T033
involvement	I-T033
(	O
CNS+	B-T033
)	O
who	O
received	O
allogeneic	B-T061
hematopoietic	I-T061
stem	I-T061
cell	I-T061
transplantation	I-T061
(	O
allo	B-T061
-	I-T061
SCT	I-T061
)	O
remains	O
unclear	O
.	O
We	O
retrospectively	O
compared	O
the	O
outcomes	O
of	O
allo	B-T061
-	I-T061
SCT	I-T061
for	O
patients	O
with	O
CNS	B-T033
involvement	I-T033
and	O
for	O
patients	O
without	O
CNS	B-T033
involvement	I-T033
(	O
CNS-	B-T033
)	O
using	O
a	O
database	O
in	O
Japan	O
.	O
The	O
eligibility	O
criteria	O
for	O
this	O
study	O
were	O
as	O
follows	O
:	O
diagnosis	O
of	O
ALL	B-T191
,	O
aged	O
more	O
than	O
16	O
years	O
,	O
allo	B-T061
-	I-T061
SCT	I-T061
between	O
2005	O
and	O
2012	O
,	O
and	O
first	O
SCT	B-T061
.	O
Data	O
for	O
2582	O
patients	O
including	O
136	O
CNS+	O
patients	O
and	O
2446	O
CNS-	O
patients	O
were	O
used	O
for	O
analyses	O
.	O
As	O
compared	O
with	O
CNS-	O
patients	O
,	O
CNS+	O
patients	O
were	O
younger	O
,	O
had	O
worse	B-T033
disease	B-T047
status	O
at	O
SCT	B-T061
and	O
had	O
poorer	O
performance	O
status	O
(	O
PS	O
)	O
at	O
SCT	B-T061
(	O
P	O
<	O
0.01	O
)	O
.	O
Incidence	O
of	O
relapse	O
was	O
higher	O
in	O
CNS+	O
patients	O
(	O
P	O
=	O
0.02	O
)	O
,	O
and	O
incidence	O
of	O
CNS	O
relapse	O
was	O
also	O
higher	O
(	O
P	O
<	O
0.01	O
)	O
.	O
The	O
probability	O
of	O
3-	O
year	O
overall	O
survival	O
(	O
OS	O
)	O
was	O
better	O
in	O
CNS-	O
patients	O
(	O
P	O
<	O
0.01	O
)	O
by	O
univariate	O
analysis	O
.	O
However	O
,	O
in	O
patients	O
who	O
received	O
SCT	B-T061
in	O
CR	B-T033
,	O
there	O
was	O
no	B-T033
difference	I-T033
in	O
the	O
probability	O
of	O
OS	O
between	O
CNS+	B-T033
and	O
CNS-	B-T033
patients	O
(	O
P	O
=	O
0.38	O
)	O
and	O
CNS	B-T033
involvement	I-T033
did	O
not	O
have	O
an	O
unfavorable	O
effect	O
on	O
OS	O
by	O
multivariate	O
analysis	O
.	O
CNS+	O
patients	O
who	O
achieved	O
CR	B-T033
showed	O
OS	O
comparable	O
to	O
that	O
of	O
CNS-	O
patients	O
.	O
      
Gene	O
expression	O
reveals	O
evidence	O
for	O
EGFR	O
-dependent	O
proximal	B-T023
-	I-T023
distal	I-T023
limb	I-T023
patterning	O
in	O
a	O
myriapod	O
Evolution	O
of	O
segmented	B-T023
limbs	I-T023
is	O
one	O
of	O
the	O
key	O
innovations	O
of	O
Arthropoda	O
,	O
allowing	O
development	O
of	O
functionally	O
specific	O
specialized	O
head	O
and	O
trunk	O
appendages	B-T023
,	O
a	O
major	O
factor	O
behind	O
their	O
unmatched	O
evolutionary	O
success	O
.	O
Proximodistal	B-T023
limb	I-T023
patterning	O
is	O
controlled	O
by	O
two	O
regulatory	O
networks	O
in	O
the	O
vinegar	O
fly	O
Drosophila	O
melanogaster	O
,	O
and	O
other	O
insects	O
.	O
The	O
first	O
is	O
represented	O
by	O
the	O
function	O
of	O
the	O
morphogens	O
Wingless	O
(	O
Wg	O
)	O
and	O
Decapentaplegic	O
(	O
Dpp	O
)	O
;	O
the	O
second	O
by	O
the	O
EGFR	O
-	O
signaling	O
cascade	O
.	O
While	O
the	O
role	O
of	O
Wg	O
and	O
Dpp	O
has	O
been	O
studied	O
in	O
a	O
wide	O
range	O
of	O
arthropods	O
representing	O
all	O
main	O
branches	O
,	O
that	O
is	O
,	O
Pancrustacea	O
(=	O
Hexapoda	O
+	O
Crustacea	O
)	O
,	O
Myriapoda	O
and	O
Chelicerata	O
,	O
investigation	O
of	O
the	O
potential	O
role	O
of	O
EGFR	O
-	O
signaling	O
is	O
restricted	O
to	O
insects	O
(	O
Hexapoda	O
)	O
.	O
Gene	O
expression	O
analysis	O
of	O
Egfr	O
,	O
its	O
potential	O
ligands	O
,	O
and	O
putative	O
downstream	O
factors	O
in	O
the	O
pill	O
millipede	O
Glomeris	O
marginata	O
(	O
Myriapoda	O
:	O
Diplopoda	O
)	O
,	O
reveals	O
that	O
-	O
in	O
at	O
least	O
mandibulate	O
arthropods	O
-	O
EGFR	O
-	O
signaling	O
is	O
likely	O
a	O
conserved	O
regulatory	B-T033
mechanism	I-T033
in	O
proximodistal	B-T023
limb	I-T023
patterning	O
.	O
      
Impact	O
of	O
alcohol	O
use	O
on	O
EEG	B-T060
dynamics	I-T060
of	O
response	O
inhibition	O
:	O
a	O
cotwin	O
control	O
analysis	O
Research	O
indicates	O
that	O
alcohol	O
misuse	O
is	O
associated	O
with	O
behavioral	B-T048
disinhibition	I-T048
,	O
but	O
the	O
neurophysiological	O
mechanisms	O
governing	O
this	O
relationship	O
remain	O
largely	O
unknown	O
.	O
Recent	O
work	O
suggests	O
that	O
successful	O
inhibition	O
and	O
cognitive	O
control	O
involve	O
electrophysiological	B-T060
theta	I-T060
-	I-T060
band	I-T060
dynamics	I-T060
,	O
including	O
medial	O
frontal	O
cortex	O
(	O
MFC	O
)	O
power	O
enhancement	O
and	O
functional	O
connectivity	O
between	O
the	O
MFC	O
and	O
dorsal	B-T023
prefrontal	I-T023
cortex	I-T023
(	O
dPFC	B-T023
)	O
regions	O
,	O
which	O
may	O
be	O
disrupted	O
by	O
alcohol	O
misuse	O
.	O
In	O
addition	O
,	O
research	O
suggests	O
that	O
,	O
compared	O
to	O
men	O
,	O
women	O
are	O
at	O
heightened	O
risk	O
of	O
experiencing	O
the	O
negative	O
physical	O
and	O
neurocognitive	O
correlates	O
of	O
drinking	O
.	O
The	O
present	O
study	O
tested	O
the	O
hypothesis	O
that	O
alcohol	O
misuse	O
has	O
a	O
deleterious	O
effect	O
on	O
theta	B-T061
-	I-T061
band	I-T061
response	O
inhibition	O
EEG	B-T060
dynamics	I-T060
in	O
a	O
sample	O
of	O
300	O
24	O
-	O
year	O
-	O
old	O
same	O
-	O
sex	O
twins	O
.	O
A	O
cotwin	O
control	O
(	O
CTC	O
)	O
design	O
was	O
used	O
to	O
disentangle	O
premorbid	O
risk	O
for	O
alcohol	O
use	O
from	O
the	O
causal	O
effects	O
of	O
alcohol	O
exposure	O
.	O
Drinking	O
was	O
negatively	O
associated	O
with	O
theta	B-T061
-	I-T061
band	I-T061
MFC	O
power	O
and	O
MFC	O
-	O
dPFC	B-T023
connectivity	O
during	O
response	O
inhibition	O
,	O
and	O
this	O
effect	O
was	O
stronger	O
among	O
women	O
.	O
The	O
CTC	O
analysis	O
suggested	O
that	O
,	O
for	O
women	O
,	O
reduced	O
nogo	O
-	O
related	O
theta	B-T061
-	I-T061
band	I-T061
MFC	O
power	O
and	O
MFC	O
-	O
dPFC	B-T023
connectivity	O
were	O
both	O
consistent	O
with	O
the	O
potential	O
deleterious	O
causal	O
effects	O
of	O
alcohol	O
exposure	O
.	O
These	O
findings	O
suggest	O
that	O
diminished	O
theta	B-T061
-	I-T061
band	I-T061
MFC	O
power	O
and	O
MFC	O
-	O
dPFC	B-T023
connectivity	O
may	O
be	O
neurophysiological	O
mechanisms	O
underlying	O
alcohol	B-T048
-	I-T048
related	I-T048
disinhibition	I-T048
.	O
Although	O
preliminary	O
,	O
these	O
results	O
suggest	O
that	O
normative	B-T033
levels	I-T033
of	O
alcohol	O
use	O
during	O
emerging	O
adulthood	O
have	O
potential	O
sex	O
-	O
specific	O
causal	O
effects	O
on	O
response	O
inhibition	O
EEG	B-T060
dynamics	I-T060
,	O
and	O
thus	O
have	O
potentially	O
significant	O
public	O
health	O
implications	O
.	O
      
Cucurbitacin	B-T121
B	I-T121
Protects	O
Against	O
Pressure	B-T184
Overload	O
Induced	O
Cardiac	O
Hypertrophy	O
Lack	O
of	O
effective	O
anti	B-T121
-	I-T121
cardiac	I-T121
hypertrophy	I-T121
drugs	I-T121
creates	O
a	O
major	O
cause	O
for	O
the	O
increasing	O
prevalence	O
of	O
heart	B-T047
failure	I-T047
.	O
In	O
the	O
present	O
study	O
,	O
we	O
determined	O
the	O
anti	B-T033
-	I-T033
hypertrophy	I-T033
and	O
anti	B-T033
-	I-T033
fibrosis	I-T033
potential	O
of	O
a	O
natural	O
plant	O
triterpenoid	O
,	O
Cucurbitacin	B-T121
B	I-T121
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
Aortic	B-T061
banding	I-T061
(	O
AB	B-T061
)	O
was	O
performed	O
to	O
induce	O
cardiac	O
hypertrophy	O
.	O
After	O
1	O
week	O
of	O
surgery	B-T061
,	O
mice	O
were	O
receive	O
cucurbitacin	B-T121
B	I-T121
treatment	B-T061
(	O
Gavage	O
,	O
0.2	O
mg	O
/	O
kg	O
body	O
weight	O
/2	O
day	O
)	O
.	O
After	O
4	O
weeks	O
of	O
AB	B-T061
,	O
cucurbitacin	B-T121
B	I-T121
demonstrated	O
a	O
strong	O
anti	B-T033
-	I-T033
hypertrophy	I-T033
and	O
-fibrosis	B-T033
ability	O
as	O
evidenced	O
by	O
decreased	O
of	O
heart	B-T023
weight	O
,	O
myocardial	O
cell	O
cross	O
-	O
sectional	O
area	O
and	O
interstitial	O
fibrosis	O
,	O
ameliorated	O
of	O
systolic	O
and	O
diastolic	O
abnormalities	B-T033
,	O
normalized	O
in	O
gene	O
expression	O
of	O
hypertrophic	O
and	O
fibrotic	O
markers	O
,	O
reserved	O
microvascular	O
density	O
in	O
pressure	B-T184
overload	O
induced	O
hypertrophic	O
mice	O
.	O
Cucurbitacin	B-T121
B	I-T121
also	O
showed	O
significant	O
hypertrophy	O
inhibitory	B-T033
effect	I-T033
in	O
phenylephrine	B-T121
stimulated	O
cardiomyocytes	O
.	O
The	O
Cucurbitacin	B-T121
B	I-T121
-mediated	O
mitigated	O
cardiac	O
hypertrophy	O
was	O
attributable	O
to	O
the	O
increasing	O
level	O
of	O
autophagy	O
,	O
which	O
was	O
associated	O
with	O
the	O
blockade	O
of	O
Akt	O
/	O
mTOR	O
/	O
FoxO3a	O
signal	O
pathway	O
,	O
validated	O
by	O
SC79	O
,	O
MK2206	B-T121
,	O
and	O
3	O
-	O
MA	O
,	O
the	O
Akt	O
agonist	B-T121
,	O
inhibitor	O
and	O
autophagy	O
inhibitor	O
in	O
vitro	O
.	O
The	O
overexpression	O
of	O
constitutively	O
active	O
Akt	O
completely	O
abolished	O
the	O
Cucurbitacin	B-T121
B	I-T121
-mediated	O
protection	O
of	O
cardiac	O
hypertrophy	O
in	O
human	O
cardiomyocytes	O
AC16	O
.	O
Collectively	O
,	O
our	O
findings	O
suggest	O
that	O
cucurbitacin	B-T121
B	I-T121
protects	O
against	O
cardiac	O
hypertrophy	O
through	O
increasing	O
the	O
autophagy	O
level	O
in	O
cardiomyocytes	O
,	O
which	O
is	O
associated	O
with	O
the	O
inhibition	O
of	O
Akt	O
/	O
mTOR	O
/	O
FoxO3a	O
signal	O
axis	O
.	O
J.	O
Cell	O
.	O
Biochem	O
.	O
9999	O
:	O
1	O
-	O
12	O
,	O
2017	O
.	O
©	O
2017	O
Wiley	O
Periodicals	O
,	O
Inc.	O
      
Histomorphometric	B-T059
and	O
transcriptome	O
evaluation	B-T058
of	O
early	O
healing	B-T033
bone	I-T033
treated	B-T061
with	I-T061
a	O
novel	O
human	O
particulate	O
dentin	O
powder	O
Human	O
particulate	O
dentin	O
(	O
HPD	O
)	O
shows	O
potential	O
as	O
an	O
alternative	O
bone	B-T061
grafting	I-T061
material	O
.	O
However	O
,	O
the	O
mechanism	O
of	O
bone	B-T033
healing	I-T033
at	O
the	O
molecular	O
level	O
after	O
grafting	B-T061
with	O
HPD	O
is	O
unclear	O
.	O
This	O
study	O
assessed	O
the	O
histological	O
and	O
global	O
gene	O
expression	O
of	O
bone	O
tissues	O
grafted	O
with	O
HPD	O
.	O
The	O
HPD	O
was	O
prepared	B-T033
to	O
250	O
-	O
500	O
µm	O
in	O
size	O
.	O
X	B-T059
-	I-T059
ray	I-T059
diffraction	I-T059
(	O
XRD	B-T059
)	O
and	O
energy	B-T059
dispersive	I-T059
x	I-T059
-	I-T059
ray	I-T059
spectroscopy	I-T059
(	O
EDX	B-T059
)	O
were	O
performed	O
to	O
confirm	O
the	O
crystal	O
structure	O
,	O
organic	O
compound	O
residues	O
,	O
and	O
surface	O
morphology	O
,	O
respectively	O
.	O
Bony	O
defects	O
were	O
created	O
on	O
the	O
heads	O
of	O
24	O
New	O
Zealand	O
White	O
rabbits	O
.	O
Sterilized	O
HPD	O
was	O
used	O
as	O
the	O
grafting	O
material	O
.	O
The	O
quality	O
and	O
quantity	O
of	O
new	O
bone	O
formation	O
was	O
evaluated	B-T058
using	O
micro	B-T060
-	I-T060
CT	I-T060
and	O
histologic	O
analyses	O
during	O
the	O
8	O
week	O
experimental	O
periods	O
.	O
For	O
microarray	B-T059
assay	I-T059
,	O
bone	O
tissue	O
and	O
blood	O
samples	O
were	O
taken	O
at	O
3	O
,	O
5	O
and	O
7	O
d	O
post	O
-	O
implantation	O
.	O
The	O
results	O
of	O
XRD	B-T059
and	O
EDX	B-T059
showed	O
that	O
HPD	O
exhibited	O
physical	O
and	O
chemical	O
properties	O
similar	O
to	O
natural	O
hydroxyapatite	O
.	O
New	O
bone	O
formation	O
was	O
observed	O
after	O
HPD	O
implantation	B-T061
compared	O
to	O
the	O
controls	O
,	O
as	O
shown	O
on	O
hematoxylin	B-T059
and	I-T059
eosin	I-T059
staining	I-T059
and	O
micro	B-T060
-	I-T060
CT	I-T060
.	O
The	O
bone	O
volume	O
of	O
HPD	O
treated	O
animals	O
was	O
higher	O
than	O
that	O
of	O
the	O
control	O
group	O
at	O
all	O
observation	O
times	O
.	O
Microarray	B-T059
analysis	I-T059
showed	O
that	O
vascular	O
development	O
coupled	O
with	O
immune	O
and	O
inflammatory	O
related	O
genes	O
were	O
expressed	O
in	O
the	O
early	O
healing	O
stage	O
.	O
The	O
gene	O
coding	O
for	O
the	O
IL-1	B-T121
antagonist	I-T121
,	O
IL1RN	O
,	O
was	O
expressed	O
to	O
inhibit	O
the	O
inflammatory	O
response	O
,	O
and	O
at	O
the	O
same	O
time	O
,	O
the	O
CCL2	O
gene	O
was	O
activated	O
to	O
2.3	O
times	O
the	O
normal	O
level	O
.	O
BMP2	O
,	O
RUNX2	O
,	O
COL1A	O
,	O
and	O
OPN	O
expression	O
were	O
also	O
up	O
-	O
regulated	O
.	O
CCL2	O
predominated	O
in	O
osteoblastogenesis	O
of	O
the	O
HPD	O
-	O
treated	O
bony	O
defect	O
in	O
the	O
early	O
stage	O
of	O
healing	O
.	O
HPD	O
accelerated	O
bone	O
regeneration	O
and	O
augmentation	B-T033
.	O
These	O
results	O
suggested	O
that	O
HPD	O
provided	O
potential	O
as	O
a	O
bone	B-T061
graft	I-T061
resource	O
during	O
the	O
bone	B-T023
healing	O
process	O
.	O
      
A	O
novel	O
role	O
for	O
poly(C	O
)	O
binding	O
proteins	O
in	O
programmed	O
ribosomal	O
frameshifting	O
Translational	O
control	O
through	O
programmed	O
ribosomal	O
frameshifting	O
(	O
PRF	O
)	O
is	O
exploited	O
widely	O
by	O
viruses	B-T005
and	O
increasingly	O
documented	O
in	O
cellular	O
genes	O
.	O
Frameshifting	O
is	O
induced	O
by	O
mRNA	O
secondary	O
structures	O
that	O
compromise	O
ribosome	O
fidelity	O
during	O
decoding	O
of	O
a	O
heptanucleotide	O
'	O
slippery	O
'	O
sequence	O
.	O
The	O
nsp2	O
PRF	O
signal	O
of	O
porcine	B-T005
reproductive	I-T005
and	I-T005
respiratory	I-T005
syndrome	I-T005
virus	I-T005
is	O
distinctive	O
in	O
directing	O
both	O
-2	O
and	O
-1	O
PRF	O
and	O
in	O
its	O
requirement	O
for	O
a	O
trans	O
-	O
acting	O
protein	O
factor	O
,	O
the	O
viral	B-T005
replicase	O
subunit	O
nsp1β	O
.	O
Here	O
we	O
show	O
that	O
the	O
the	O
trans	O
-	O
activation	O
of	O
frameshifting	O
is	O
carried	O
out	O
by	O
a	O
protein	O
complex	O
composed	O
of	O
nsp1β	O
and	O
a	O
cellular	O
poly(C	O
)	O
binding	O
protein	O
(	O
PCBP	O
)	O
.	O
From	O
the	O
results	O
of	O
in	O
vitro	O
translation	O
and	O
electrophoretic	B-T059
mobility	I-T059
shift	I-T059
assays	I-T059
,	O
we	O
demonstrate	O
that	O
a	O
PCBP	O
/	O
nsp1β	O
complex	O
binds	O
to	O
a	O
C	O
-	O
rich	O
sequence	O
downstream	O
of	O
the	O
slippery	O
sequence	O
and	O
here	O
mimics	O
the	O
activity	O
of	O
a	O
structured	O
mRNA	O
stimulator	O
of	O
PRF	O
.	O
This	O
is	O
the	O
first	O
description	O
of	O
a	O
role	O
for	O
a	O
trans	O
-	O
acting	O
cellular	O
protein	O
in	O
PRF	O
.	O
The	O
discovery	O
broadens	O
the	O
repertoire	O
of	O
activities	O
associated	O
with	O
poly(C	O
)	O
binding	O
proteins	O
and	O
prototypes	O
a	O
new	O
class	O
of	O
virus	B-T005
-	O
host	B-T001
interactions	O
.	O
      
Liver	B-T047
Inflammation	I-T047
Relates	O
to	O
Decreased	O
Canalicular	B-T023
Bile	O
Transporter	O
Expression	O
in	O
Pediatric	O
Onset	O
Intestinal	B-T047
Failure	I-T047
Although	O
liver	B-T047
disease	I-T047
is	O
a	O
major	O
complication	O
of	O
parenteral	B-T061
nutrition	I-T061
(	O
PN	B-T061
)	O
for	O
intestinal	B-T047
failure	I-T047
(	O
IF	B-T047
)	O
,	O
its	O
pathogenesis	O
remains	O
unclear	O
.	O
We	O
investigated	O
potential	O
molecular	O
mechanisms	O
of	O
liver	O
injury	O
in	O
pediatric	O
onset	O
IF	B-T047
.	O
Liver	B-T023
expression	O
of	O
canalicular	B-T023
phospholipid	O
(	O
ABCB4	O
)	O
,	O
bile	O
acid	O
(	O
ABCB11	O
)	O
,	O
and	O
sterol	O
(	O
ABCG5/8	O
)	O
transporters	O
,	O
their	O
upstream	O
regulators	O
LXR	O
and	O
FXR	O
as	O
well	O
as	O
pro	O
-	O
inflammatory	O
cytokines	O
interleukin-6	O
(	O
IL6	O
)	O
and	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
were	O
investigated	O
among	O
patients	O
with	O
IF	B-T047
[	O
age	O
median	O
3.8	O
(	O
IQR	O
1.2	O
to	O
11	O
)	O
]	O
in	O
relation	O
to	O
biochemical	O
and	O
histologic	O
liver	O
injury	O
,	O
PN	B-T061
,	O
serum	O
plant	B-T121
sterols	I-T121
,	O
fibroblast	O
growth	O
factor	O
19	O
,	O
and	O
α	B-T121
-	I-T121
tocopherol	I-T121
.	O
Patients	O
receiving	O
PN	B-T061
currently	O
(	O
n	O
=	O
18	O
)	O
showed	O
more	O
advanced	O
liver	O
injury	O
than	O
patients	O
after	O
weaning	B-T033
off	O
PN	B-T061
(	O
n	O
=	O
30	O
)	O
.	O
Histologic	O
portal	B-T033
inflammation	I-T033
strongly	O
segregated	O
PN	B-T061
-	O
dependent	O
(	O
44	O
%	O
)	O
from	O
weaned	B-T033
off	O
patients	O
(	O
3	O
%	O
,	O
P	O
=	O
0.001	O
)	O
and	O
coupled	O
with	O
progression	O
of	O
cholestasis	B-T047
and	O
liver	B-T047
fibrosis	I-T047
.	O
Patients	O
with	O
portal	B-T033
inflammation	I-T033
demonstrated	O
markedly	O
induced	O
liver	B-T023
RNA	O
expression	O
of	O
IL6	O
and	O
TNF	O
,	O
repression	O
of	O
FXR	O
and	O
its	O
canalicular	B-T023
bile	O
transporter	O
target	O
gene	O
RNA	O
expression	O
,	O
including	O
ABCB4	O
and	O
ABCB11	O
as	O
well	O
as	O
decreased	O
protein	O
expression	O
of	O
ABCB11	O
and	O
ABCB4	O
.	O
Furthermore	O
,	O
upregulation	O
of	O
LXR	O
and	O
ABCG5/8	O
RNA	O
expression	O
was	O
suppressed	O
in	O
patients	O
with	O
portal	B-T033
inflammation	I-T033
.	O
Current	O
PN	B-T061
,	O
increased	O
serum	O
levels	O
of	O
plant	B-T121
sterols	I-T121
stigmasterol	O
,	O
avenasterol	B-T121
,	O
and	O
sitosterol	B-T121
along	O
with	O
serum	O
citrulline	B-T121
,	O
a	O
marker	O
of	O
enterocyte	O
mass	O
,	O
predicted	O
portal	B-T033
inflammation	I-T033
.	O
In	O
pediatric	O
onset	O
IF	B-T047
,	O
current	O
PN	B-T061
delivery	O
synergistically	O
with	O
intestinal	B-T023
compromise	B-T033
promote	O
liver	B-T047
inflammation	I-T047
,	O
which	O
associates	O
with	O
progression	O
of	O
biochemical	O
and	O
histologic	O
liver	O
injury	O
,	O
while	O
reducing	O
expression	O
of	O
canalicular	B-T023
bile	O
transporters	O
.	O
      
Mitochondrial	O
Ultrastructure	O
and	O
Glucose	O
Signaling	O
Pathways	O
Attributed	O
to	O
the	O
Kv1.3	O
Ion	O
Channel	O
Gene	O
-	O
targeted	O
deletion	O
of	O
the	O
potassium	O
channel	O
Kv1.3	O
(	O
Kv1.3(-∕-	O
)	O
)	O
results	O
i	O
n	O
"	O
S	O
uper	O
-	O
smeller	O
"	O
mice	O
with	O
a	O
se	O
nsory	O
p	O
h	O
enotype	O
t	O
hat	O
includes	O
an	O
increased	O
olfactory	O
ability	O
linked	O
to	O
changes	O
in	O
olfactory	O
circuitry	O
,	O
increased	O
abundance	O
of	O
olfactory	O
cilia	O
,	O
and	O
increased	O
expression	O
of	O
odorant	O
receptors	O
and	O
the	O
G	O
-	O
protein	O
,	O
Golf	O
.	O
Kv1.3(-∕-	O
)	O
mice	O
a	O
lso	O
have	O
a	O
metabolic	O
p	O
h	O
enotype	O
i	O
ncluding	O
lo	O
wer	O
b	O
o	O
dy	O
weight	O
a	O
nd	O
de	O
creased	O
a	O
d	O
iposity	O
,	O
in	O
creased	B-T033
total	I-T033
energy	I-T033
expenditure	I-T033
(	O
TEE	B-T033
)	O
,	O
increased	O
locomotor	O
activity	O
,	O
and	O
resistance	O
to	O
both	O
diet	O
-	O
and	O
genetic	O
-	O
induced	O
obesity	B-T047
.	O
We	O
explored	O
two	O
cellular	O
aspects	O
to	O
elucidate	O
the	O
mechanism	O
by	O
which	O
loss	O
of	O
Kv1.3	O
channel	O
in	O
the	O
olfactory	B-T023
bulb	I-T023
(	O
OB	B-T023
)	O
may	O
enhance	O
glucose	O
utilization	O
and	O
metabolic	O
rate	O
.	O
First	O
,	O
using	O
in	O
situ	O
hybridization	O
we	O
find	O
that	O
Kv1.3	O
and	O
the	O
insulin	B-T121
-	O
dependent	O
glucose	O
transporter	O
type	O
4	O
(	O
GLUT4	O
)	O
are	O
co	O
-	O
localized	O
to	O
the	O
mitral	B-T023
cell	O
layer	O
of	O
the	O
OB	B-T023
.	O
Disruption	O
of	O
Kv1.3	O
conduction	O
via	O
construction	O
of	O
a	O
pore	O
mutation	O
(	O
W386F	O
Kv1.3	O
)	O
was	O
sufficient	O
to	O
independently	O
translocate	O
GLUT4	O
to	O
the	O
plasma	O
membrane	O
in	O
HEK	O
293	O
cells	O
.	O
Because	O
olfactory	O
sensory	O
perception	O
and	O
the	O
maintenance	O
of	O
action	O
potential	O
(	O
AP	O
)	O
firing	O
frequency	O
by	O
mitral	B-T023
cells	O
of	O
the	O
OB	B-T023
is	O
highly	O
energy	O
demanding	O
and	O
Kv1.3	O
is	O
also	O
expressed	O
in	O
mitochondria	O
,	O
we	O
next	O
explored	O
the	O
structure	O
of	O
this	O
organelle	O
in	O
mitral	B-T023
cells	O
.	O
We	O
challenged	O
wildtype	O
(	O
WT	O
)	O
and	O
Kv1.3(-∕-	O
)	O
male	O
mice	O
with	O
a	O
m	O
oderately	B-T061
high	I-T061
-	I-T061
fat	I-T061
diet	I-T061
(	I-T061
M	O
HF	B-T061
,	I-T061
31.8	O
%	O
kcal	O
fat	O
)	O
for	O
4	O
months	O
and	O
then	O
examined	O
OB	B-T023
ultrastructure	O
using	O
transmission	B-T059
electron	I-T059
microscopy	I-T059
.	O
In	O
WT	O
mice	O
,	O
mitochondria	O
were	O
significantly	O
enlarged	O
following	O
diet	B-T047
-	I-T047
induced	I-T047
obesity	I-T047
(	O
DIO	B-T047
)	O
and	O
there	O
were	O
fewer	O
mitochondria	O
,	O
likely	O
due	O
to	O
mitophagy	O
.	O
Interestingly	O
,	O
mitochondria	O
were	O
significantly	O
smaller	O
in	O
Kv1.3(-∕-	O
)	O
mice	O
c	O
ompared	O
with	O
that	O
of	O
W	O
T	O
mice	O
.	O
Similar	O
to	O
their	O
m	O
etabolic	O
r	O
esistance	O
to	O
D	O
IO	B-T047
,	I-T047
the	O
K	O
v1.3(-∕-	O
)	O
mice	O
ha	O
d	O
unchanged	O
mit	O
ochondria	O
in	O
terms	O
of	O
cros	O
s	O
sectional	O
area	O
and	O
abundance	O
following	O
a	O
challenge	O
with	O
modified	B-T061
diet	I-T061
.	O
We	O
are	O
very	O
interested	O
to	O
understand	O
how	O
targeted	O
disruption	O
of	O
the	O
Kv1.3	O
channel	O
in	O
the	O
OB	B-T023
can	O
modify	O
TEE	B-T033
.	O
Our	O
study	O
demonstrates	O
that	O
Kv1.3	O
regulates	O
mitochondrial	O
structure	O
and	O
alters	O
glucose	O
utilization	O
;	O
two	O
important	O
metabolic	O
changes	O
that	O
could	O
drive	O
whole	O
system	O
changes	O
in	O
metabolism	O
initiated	O
at	O
the	O
OB	B-T023
.	O
      
Risk	O
and	O
protective	O
factors	O
associated	O
with	O
adolescent	O
girls	O
'	O
substance	B-T048
use	I-T048
:	O
Data	O
from	O
a	O
nationwide	O
Facebook	O
sample	O
Despite	O
overall	O
reductions	O
in	O
teenage	O
substance	B-T048
use	I-T048
,	O
adolescent	O
girls	O
'	O
rates	O
of	O
substance	B-T048
use	I-T048
remain	O
unacceptably	O
high	O
.	O
This	O
article	O
examines	O
whether	O
girls	O
'	O
substance	B-T048
use	I-T048
is	O
associated	O
with	O
general	O
risk	O
and	O
protective	O
factors	O
(	O
goal	O
setting	O
,	O
problem	O
solving	O
,	O
refusal	O
skills	O
,	O
peer	O
use	O
,	O
and	O
self	O
-	O
efficacy	O
)	O
and	O
gender	O
-	O
specific	O
risk	O
and	O
protective	O
factors	O
(	O
communication	O
style	O
,	O
coping	O
skills	O
,	O
self	O
-	O
esteem	O
,	O
body	O
image	O
,	O
perceived	B-T048
stress	I-T048
,	O
anxiety	B-T048
,	O
and	O
depression	B-T048
)	O
.	O
Cross	O
-	O
sectional	O
data	O
were	O
collected	O
in	O
2013	O
via	O
online	O
surveys	O
from	O
a	O
nationwide	O
sample	O
of	O
adolescent	O
girls	O
(	O
N	O
=	O
788	O
)	O
,	O
aged	O
13	O
and	O
14	O
years	O
,	O
who	O
were	O
recruited	O
through	O
Facebook	O
.	O
In	O
multivariate	O
analyses	O
,	O
controlling	O
for	O
correlates	O
of	O
adolescent	O
substance	B-T048
use	I-T048
,	O
11	O
of	O
the	O
13	O
general	O
and	O
gender	O
-	O
specific	O
risk	O
and	O
protective	O
factors	O
were	O
consistently	O
associated	O
with	O
past	O
-	O
month	O
alcohol	O
,	O
cigarette	O
,	O
and	O
other	O
drug	B-T048
use	I-T048
in	O
the	O
expected	O
direction	O
;	O
past	B-T048
-	I-T048
month	I-T048
marijuana	I-T048
use	I-T048
was	O
associated	O
with	O
8	O
of	O
the	O
13	O
factors	O
.	O
Refusal	O
skill	O
s	O
,	O
peer	O
use	O
,	O
coping	O
,	O
and	O
depressive	B-T033
mood	I-T033
were	O
most	O
consistently	O
and	O
strongly	O
associated	O
with	O
substance	B-T048
use	I-T048
.	O
Substance	B-T058
abuse	I-T058
prevention	I-T058
programs	B-T058
targeting	O
adolescent	O
girls	O
should	O
focus	O
on	O
such	O
general	O
risk	O
and	O
protective	O
factors	O
as	O
problem	O
solving	O
,	O
refusal	O
skill	O
s	O
,	O
peer	O
influences	O
,	O
and	O
self	O
-	O
efficacy	O
,	O
as	O
well	O
as	O
such	O
gender	O
-	O
specific	O
risk	O
and	O
protective	O
factors	O
as	O
communication	O
style	O
,	O
coping	O
,	O
self	O
-	O
esteem	O
,	O
body	O
image	O
,	O
perceived	B-T048
stress	I-T048
,	O
and	O
mood	B-T061
management	I-T061
.	O
      
Genetic	O
parameters	B-T033
for	O
tick	O
count	O
and	O
udder	B-T023
health	O
in	O
commercial	O
and	O
indigenous	O
ewes	O
in	O
South	O
Africa	O
The	O
genetics	O
of	O
tick	B-T047
infestation	I-T047
in	O
sheep	O
need	O
study	O
,	O
as	O
host	O
resistance	O
often	O
forms	O
part	O
of	O
integrated	O
pest	O
control	O
programs	O
.	O
Repeated	O
udder	B-T023
health	O
scores	O
,	O
site	O
-	O
specific	O
tick	O
count	O
,	O
mating	O
weight	O
and	O
reproduction	O
records	O
(	O
N=879	O
-	O
1204	O
)	O
were	O
recorded	O
annually	O
from	O
2010	O
to	O
2015	O
on	O
ewes	O
of	O
the	O
indigenous	O
Namaqua	O
Afrikaner	O
(	O
NA	O
)	O
fat	O
-	O
tailed	O
breed	O
,	O
as	O
well	O
as	O
the	O
commercial	O
Dorper	O
and	O
SA	O
Mutton	O
Merino	O
(	O
SAMM	O
)	O
breeds	O
.	O
Udder	B-T023
s	O
were	O
scored	O
subjectively	O
on	O
a	O
1	O
-	O
5	O
scale	O
(	O
1	O
-	O
udder	B-T023
intact	O
and	O
5	O
-	O
udder	B-T023
damaged	O
severely	O
)	O
and	O
ticks	B-T047
were	O
counted	O
on	O
three	O
locations	O
.	O
The	O
body	O
sites	O
counted	O
were	O
the	O
head	B-T023
and	I-T023
thoracic	I-T023
limb	I-T023
(	O
HTLTC	B-T023
)	O
,	O
udder	B-T023
-	I-T023
pelvic	I-T023
limb	I-T023
(	O
UPLTC	B-T023
)	O
and	O
perineum	B-T023
-	I-T023
breech	I-T023
-	I-T023
tail	I-T023
(	O
PBTTC	B-T023
)	O
.	O
These	O
counts	O
were	O
also	O
totaled	O
for	O
a	O
total	O
tick	O
count	O
(	O
TTC	O
)	O
.	O
Reproduction	O
traits	O
were	O
number	O
of	O
lambs	O
weaned	B-T033
per	O
ewe	B-T033
lambed	I-T033
and	O
total	O
weight	O
of	O
lamb	B-T033
weaned	I-T033
per	O
ewe	B-T033
lambed	I-T033
.	O
Udder	B-T023
health	O
scores	O
of	O
NA	O
ewes	O
were	O
lower	O
than	O
those	O
of	O
Dorpers	O
,	O
which	O
in	O
turn	O
had	O
lower	O
scores	O
than	O
SAMM	O
ewes	O
.	O
NA	O
ewes	O
had	O
lower	O
values	O
for	O
HTLTC	B-T023
,	O
UPLTC	B-T023
and	O
TTC	O
than	O
the	O
commercial	O
breeds	O
,	O
but	O
higher	O
values	O
for	O
PBTTC	B-T023
than	O
Dorpers	O
.	O
Heritability	B-T033
estimates	O
amounted	O
to	O
0.26±0.04	O
for	O
HTLTC	B-T023
,	O
0.53±0.04	O
for	O
UPLTC	B-T023
,	O
0.07±0.06	O
for	O
PBTTC	B-T023
,	O
0.44±0.06	O
for	O
TTC	O
and	O
0.61±0.03	O
for	O
udder	B-T023
health	O
score	O
.	O
Animal	O
permanent	O
environment	O
also	O
affected	O
PBTTC	B-T023
(	O
0.14±0.07	O
)	O
.	O
Significant	O
genetic	O
correlations	O
were	O
found	O
between	O
the	O
HTLTC	B-T023
and	O
UPLTC	B-T023
(	O
0.47±0.10	O
)	O
,	O
UPLTC	B-T023
and	O
udder	B-T023
health	O
score	O
(	O
0.52±0.07	O
)	O
,	O
HTLTC	B-T023
and	O
UPLTC	B-T023
(	O
0.24±0.11	O
)	O
as	O
well	O
as	O
UPLTC	B-T023
and	O
PBTTC	B-T023
(	O
-0.44±0.11	O
)	O
.	O
Heavier	O
ewes	O
had	O
higher	O
UPLTC	B-T023
(	O
0.38±0.09	O
)	O
,	O
TTC	O
(	O
0.33±0.09	O
)	O
and	O
impaired	O
udder	B-T023
health	O
(	O
0.21±0.08	O
)	O
.	O
Udder	B-T023
health	O
score	O
s	O
and	O
tick	O
counts	O
at	O
all	O
sites	O
were	O
not	O
related	O
to	O
reproduction	O
traits	O
.	O
The	O
indigenous	O
NA	O
breed	O
outperformed	O
the	O
commercial	O
breeds	O
with	O
lower	O
values	O
for	O
HTLTC	B-T023
,	O
UPLTC	B-T023
,	O
TTC	O
and	O
a	O
better	O
udder	B-T023
health	O
score	O
.	O
Mechanisms	O
contributing	O
to	O
the	O
better	O
performance	O
of	O
the	O
NA	O
breed	O
under	O
pastoral	B-T058
conditions	I-T058
and	O
the	O
scope	O
for	O
selection	O
for	O
tick	B-T047
tolerance	O
within	O
breeds	O
should	O
be	O
studied	O
further	O
.	O
      
Rubinstein	B-T047
-	I-T047
Taybi	I-T047
Syndrome	I-T047
Associated	O
with	O
Pituitary	B-T191
Macroadenoma	I-T191
:	O
A	O
Case	O
Report	O
Rubinstein	B-T047
-	I-T047
Taybi	I-T047
Syndrome	I-T047
(	O
RSTS	B-T047
)	O
is	O
an	O
autosomal	B-T047
dominant	I-T047
disorder	I-T047
that	O
is	O
classically	O
characterized	O
by	O
prenatal	O
and	O
postnatal	O
growth	O
restriction	O
,	O
microcephaly	B-T019
,	O
dysmorphic	B-T019
craniofacial	I-T019
features	I-T019
,	O
broad	B-T033
thumbs	I-T033
and	O
toes	B-T033
,	O
and	O
intellectual	B-T048
disability	I-T048
.	O
We	O
describe	O
the	O
first	O
reported	O
case	O
of	O
a	O
pituitary	B-T191
macroadenoma	I-T191
associated	O
with	O
RSTS	B-T047
.	O
A	O
39	O
-	O
year	O
-	O
old	O
Caucasian	O
female	O
with	O
a	O
past	B-T033
medical	I-T033
history	I-T033
of	O
RSTS	B-T047
diagnosed	B-T033
at	O
age	O
two	O
was	O
found	O
to	O
have	O
a	O
gadolinium	O
-enhancing	O
pituitary	B-T190
mass	I-T190
on	O
magnetic	B-T060
resonance	I-T060
imaging	I-T060
(	O
MRI	B-T060
)	O
of	O
the	O
brain	B-T023
three	O
years	O
ago	O
during	O
workup	O
for	O
migraine	B-T184
-	I-T184
like	I-T184
headaches	I-T184
.	O
Subsequent	O
serial	O
imaging	B-T060
showed	O
radiographic	O
evidence	O
of	O
growth	O
up	O
to	O
11.5	O
x	O
14.0	O
x	O
10.0	O
mm	O
in	O
size	O
.	O
The	O
pituitary	B-T023
sellar	B-T033
lesion	I-T033
was	O
resected	B-T061
through	O
an	O
endoscopic	O
transnasal	O
transsphenoidal	O
approach	O
and	O
was	O
found	O
to	O
be	O
a	O
thyrotroph	B-T191
adenoma	I-T191
.	O
RSTS	B-T047
is	O
a	O
rare	O
,	O
neurodevelopmental	B-T048
genetic	B-T047
disease	I-T047
where	O
most	O
patients	O
with	O
disabilities	O
survive	O
into	O
adulthood	O
.	O
The	O
disorder	B-T047
is	O
associated	O
with	O
an	O
increased	O
predisposition	O
for	O
development	O
of	O
nervous	B-T191
system	I-T191
tumors	I-T191
,	O
including	O
pituitary	B-T191
adenomas	I-T191
.	O
      
Water	O
pipe	O
(	O
Shisha	O
,	O
Hookah	O
,	O
Arghile	O
)	O
Smoking	O
and	O
Secondhand	O
Tobacco	O
Smoke	O
Effects	O
on	O
CYP1A2	O
and	O
CYP2A6	O
Phenotypes	O
as	O
Measured	O
by	O
Caffeine	B-T059
Urine	I-T059
Test	I-T059
Public	O
policies	O
to	O
stop	O
or	O
reduce	O
cigarette	O
smoking	O
and	O
exposure	O
to	O
secondhand	O
smoke	O
and	O
associated	O
diseases	O
have	O
yielded	O
successful	O
results	O
over	O
the	O
past	O
decade	O
.	O
Yet	O
,	O
the	O
growing	O
worldwide	O
popularity	O
of	O
another	O
form	O
of	O
tobacco	O
consumption	O
,	O
water	O
pipe	O
smoking	O
,	O
has	O
received	O
relatively	O
less	O
attention	O
.	O
To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
no	O
study	O
to	O
date	O
has	O
evaluated	O
the	O
effects	O
of	O
water	O
pipe	O
smoking	O
on	O
cytochrome	O
P450	O
(	O
CYP450	O
)	O
activities	O
and	O
drug	O
interaction	O
potential	O
in	O
humans	O
,	O
whereas	O
only	O
limited	O
information	O
is	O
available	O
on	O
the	O
impact	O
of	O
secondhand	O
smoke	O
on	O
drug	O
metabolism	O
.	O
In	O
a	O
sample	O
of	O
99	O
healthy	O
volunteers	O
(	O
28	O
water	O
pipe	O
smokers	O
,	O
30	O
secondhand	O
tobacco	O
smoke	O
exposed	O
persons	O
,	O
and	O
41	O
controls	O
)	O
,	O
we	O
systematically	O
compared	O
CYP1A2	O
and	O
CYP2A6	O
enzyme	O
activities	O
in	O
vivo	O
using	O
caffeine	B-T059
urine	I-T059
test	I-T059
.	O
The	O
median	O
self	O
-	O
reported	O
duration	O
of	O
water	O
pipe	O
smoking	O
was	O
7.5	O
h	O
/	O
week	O
and	O
3	O
years	O
of	O
exposure	O
in	O
total	O
.	O
The	O
secondhand	O
smoke	O
group	O
had	O
a	O
median	O
of	O
14	O
h	O
of	O
self	O
-	O
reported	O
weekly	O
exposure	O
to	O
tobacco	O
smoke	O
indoor	O
where	O
a	O
minimum	O
of	O
five	O
cigarettes	O
were	O
smoked	O
/	O
hour	O
for	O
a	O
total	O
of	O
3.5	O
years	O
(	O
median	O
)	O
.	O
Analysis	O
of	O
variance	O
did	O
not	O
find	O
a	O
significant	O
difference	O
in	O
CYP1A2	O
and	O
CYP2A6	O
activities	O
among	O
the	O
three	O
study	O
groups	O
(	O
p	O
>	O
0.05	O
)	O
.	O
Nor	O
was	O
there	O
a	O
significant	O
association	O
between	O
the	O
extent	O
of	O
water	O
pipe	O
or	O
secondhand	O
smoke	O
exposure	O
and	O
the	O
CYP1A2	O
and	O
CYP2A6	O
activities	O
(	O
p	O
>	O
0.05	O
)	O
.	O
Further	O
analysis	O
in	O
a	O
subsample	O
with	O
smoke	O
exposure	O
more	O
than	O
the	O
median	O
values	O
also	O
did	O
not	O
reveal	O
a	O
significant	O
difference	O
from	O
the	O
controls	O
.	O
Although	O
we	O
do	O
not	O
rule	O
out	O
an	O
appreciable	O
possible	O
impact	O
of	O
water	O
pipe	O
smoke	O
and	O
secondhand	O
smoke	O
on	O
in	O
vivo	O
activities	O
of	O
these	O
two	O
drug	O
metabolism	O
pathways	O
,	O
variability	O
in	O
smoke	O
constituents	O
from	O
different	O
tobacco	O
consumption	O
methods	O
(	O
e.g.	O
,	O
water	O
pipe	O
)	O
might	O
affect	O
drug	O
metabolism	O
in	O
ways	O
that	O
might	O
differ	O
from	O
that	O
of	O
cigarette	O
smoke	O
.	O
Further	O
studies	O
in	O
larger	O
prospective	O
samples	O
are	O
recommended	O
to	O
evaluate	O
water	O
pipe	O
and	O
secondhand	O
tobacco	O
smoke	O
effects	O
on	O
CYP450	O
function	O
,	O
particularly	O
at	O
higher	O
smoke	O
exposure	O
conditions	O
.	O
      
Self	O
-	O
assembled	O
polymeric	O
vectors	O
mixtures	O
:	O
characterization	O
of	O
the	O
polymorphism	O
and	O
existence	O
of	O
synergistic	O
effects	O
in	O
photodynamic	B-T061
therapy	I-T061
The	O
objective	O
of	O
this	O
work	O
was	O
to	O
assess	O
the	O
relation	O
between	O
the	O
purity	O
of	O
polymeric	O
self	O
-	O
assemblies	O
vectors	O
solution	O
and	O
their	O
photodynamic	B-T061
therapeutic	I-T061
efficiency	O
.	O
For	O
this	O
,	O
several	O
amphiphilic	B-T121
block	O
copolymers	O
of	O
poly(ethyleneoxide	O
-	O
b	O
-	O
ε	O
-	O
caprolactone	O
)	O
have	O
been	O
used	O
to	O
form	O
self	O
-	O
assemblies	O
with	O
different	O
morphologies	O
(	O
micelles	O
,	O
worm	O
-	O
like	O
micelles	O
or	O
vesicles	O
)	O
.	O
In	O
a	O
first	O
step	O
,	O
controlled	O
mixtures	O
of	O
preformed	O
micelles	O
and	O
vesicles	O
have	O
been	O
characterized	O
both	O
by	O
dynamic	B-T059
light	I-T059
scattering	I-T059
and	O
asymmetrical	B-T059
flow	I-T059
field	I-T059
flow	I-T059
fractionation	I-T059
(	O
AsFlFFF	B-T059
)	O
.	O
For	O
this	O
,	O
a	O
custom	O
-	O
made	O
program	O
,	O
STORMS	O
,	O
was	O
developed	O
to	O
analyze	O
DLS	B-T059
data	O
in	O
a	O
thorough	O
manner	O
by	O
providing	O
a	O
large	O
set	O
of	O
fitting	O
parameters	O
.	O
This	O
showed	O
that	O
DLS	B-T059
only	O
sensed	O
the	O
larger	O
vesicles	O
when	O
the	O
micelles	O
/	O
vesicles	O
ratio	O
was	O
80/20	O
w	O
/	O
w.	O
On	O
the	O
other	O
hand	O
,	O
AsFlFFF	B-T059
allowed	O
clear	O
detection	B-T033
of	O
the	O
presence	O
of	O
micelles	O
when	O
this	O
same	O
ratio	O
was	O
as	O
low	O
as	O
10/90	O
.	O
Subsequently	O
,	O
the	O
photodynamic	B-T061
therapy	I-T061
efficiency	O
of	O
various	O
controlled	O
mixtures	O
was	O
assessed	O
using	O
multicellular	O
spheroids	B-T033
when	O
a	O
photosensitizer	B-T121
,	O
pheophorbide	B-T121
a	I-T121
,	O
was	O
encapsulated	O
in	O
the	O
polymer	O
self	O
-	O
assemblies	O
.	O
Some	O
mixtures	O
were	O
shown	O
to	O
be	O
as	O
efficient	O
as	O
monomorphous	B-T033
systems	I-T033
.	O
In	O
some	O
cases	O
,	O
mixtures	O
were	O
found	O
to	O
exhibit	O
a	O
higher	O
PDT	B-T061
efficiency	O
compared	O
to	O
the	O
individual	O
nano	O
-	O
objects	O
,	O
revealing	O
a	O
synergistic	O
effect	O
for	O
the	O
efficient	O
delivery	O
of	O
the	O
photosensitizer	B-T121
.	O
Polymorphous	O
vectors	O
can	O
therefore	O
be	O
superior	O
in	O
therapeutic	O
applications	O
.	O
      
Multidetector	B-T060
CT	I-T060
of	O
expected	O
findings	B-T033
and	O
complications	O
after	O
contemporary	O
inguinal	B-T061
hernia	I-T061
repair	I-T061
surgery	B-T061
Inguinal	B-T061
hernia	I-T061
repair	I-T061
(	O
IHR	B-T061
)	O
with	O
prosthetic	O
mesh	O
implantation	B-T061
is	O
the	O
most	O
common	O
procedure	B-T061
in	O
general	B-T061
surgery	I-T061
,	O
and	O
may	O
be	O
performed	O
using	O
either	O
an	O
open	O
or	O
laparoscopic	O
approach	O
.	O
This	O
paper	O
provides	O
an	O
overview	O
of	O
contemporary	O
tension	O
-	O
free	O
IHR	B-T061
techniques	O
and	O
materials	O
,	O
and	O
illustrates	O
the	O
expected	O
postoperative	B-T033
imaging	O
findings	O
and	O
iatrogenic	O
injuries	O
.	O
Emphasis	O
is	O
placed	O
on	O
multidetector	B-T060
CT	I-T060
,	O
which	O
represents	O
the	O
ideal	O
modality	O
to	O
comprehensively	O
visualize	O
the	O
operated	O
groin	O
region	O
and	O
deeper	O
intra	B-T023
-	I-T023
abdominal	I-T023
structures	I-T023
.	O
CT	B-T060
consistently	O
depicts	O
seroma	O
,	O
mesh	O
infections	O
,	O
hemorrhages	O
,	O
bowel	B-T023
complications	O
and	O
urinary	B-T023
bladder	I-T023
injuries	O
,	O
and	O
thus	O
generally	O
provides	O
a	O
consistent	O
basis	O
for	O
therapeutic	O
choice	O
.	O
Since	O
radiologists	O
are	O
increasingly	O
requested	O
to	O
investigate	O
suspected	O
iatrogenic	O
complications	O
,	O
this	O
paper	O
aims	O
to	O
provide	O
an	O
increased	O
familiarity	O
with	O
early	O
CT	B-T060
studies	B-T060
after	O
IHR	B-T061
,	O
including	O
complications	O
and	O
normal	O
postoperative	B-T033
appearances	O
such	O
as	O
focal	O
pseudolesions	O
,	O
in	O
order	O
to	O
avoid	B-T058
misinterpretation	I-T058
and	O
inappropriate	O
management	B-T058
.	O
      
Breast	B-T061
Augmentation	I-T061
after	O
Conservation	B-T061
Surgery	I-T061
and	O
Radiation	B-T061
Therapy	I-T061
There	O
is	O
a	O
paucity	O
of	O
data	O
regarding	O
outcomes	O
for	O
patients	O
undergoing	O
breast	B-T061
augmentation	I-T061
with	O
implants	O
after	O
breast	B-T061
conservation	I-T061
surgery	I-T061
(	O
BCS	B-T061
)	O
and	O
radiotherapy	B-T061
.	O
This	O
retrospective	O
study	O
examined	O
outcomes	O
for	O
patients	O
with	O
breast	O
implant	O
-only	O
augmentation	B-T061
after	O
BCS	B-T061
and	O
radiotherapy	B-T061
.	O
Between	O
June	O
1998	O
and	O
December	O
2010	O
,	O
671	O
women	O
underwent	O
prosthetic	O
breast	B-T061
reconstruction	I-T061
.	O
Nineteen	O
patients	O
(	O
2.8	O
%	O
)	O
underwent	O
an	O
augmentation	B-T061
after	O
BCS	B-T061
and	O
radiotherapy	B-T061
.	O
The	O
mean	O
age	O
was	O
55.8	O
years	O
(	O
range	O
,	O
40	O
-	O
69	O
years	O
)	O
.	O
Sixteen	O
of	O
these	O
patients	O
underwent	O
one	B-T061
-	I-T061
stage	I-T061
implant	I-T061
-only	O
breast	B-T061
augmentation	I-T061
,	O
whereas	O
3	O
patients	O
underwent	O
two	B-T061
-	I-T061
stage	I-T061
expander	I-T061
and	O
then	O
implant	B-T061
augmentation	I-T061
.	O
All	O
surgeries	B-T061
were	O
successful	O
.	O
The	O
average	O
size	O
of	O
breast	O
implant	O
used	O
was	O
258.7	O
�	O
€‰g	O
.	O
Seven	O
patients	O
also	O
received	O
contralateral	O
augmentation	B-T061
with	O
an	O
average	O
implant	O
size	O
of	O
232.2	O
�	O
€‰g	O
.	O
One	O
patient	O
received	O
oral	O
antibiotics	B-T195
for	O
minor	O
wound	O
infection	O
.	O
Patients	O
were	O
judged	O
to	O
have	O
an	O
excellent	O
(	O
14/19	O
;	O
73.7	O
%	O
)	O
,	O
good	O
(	O
3/19	O
;	O
15.8	O
%	O
)	O
,	O
or	O
fair	O
(	O
2/19	O
;	O
10.5	O
%	O
)	O
cosmetic	B-T033
result	O
.	O
The	O
breasts	B-T023
of	O
selected	O
patients	O
with	O
breast	B-T191
cancer	I-T191
after	O
BCS	B-T061
and	O
radiotherapy	B-T061
.	O
with	O
asymmetry	O
can	O
be	O
adequately	O
augmented	O
with	O
breast	O
implants	O
alone	O
.	O
      
Variation	O
in	O
the	O
Intensity	O
of	O
Selection	O
on	O
Codon	O
Bias	O
over	O
Time	O
Causes	O
Contrasting	O
Patterns	O
of	O
Base	O
Composition	O
Evolution	O
in	O
Drosophila	O
Four	O
-	O
fold	O
degenerate	O
coding	O
sites	O
form	O
a	O
major	O
component	O
of	O
the	O
genome	O
,	O
and	O
are	O
often	O
used	O
to	O
make	O
inferences	O
about	O
selection	O
and	O
demography	O
,	O
so	O
that	O
understanding	O
their	O
evolution	O
is	O
important	O
.	O
Despite	O
previous	O
efforts	O
,	O
many	O
questions	O
regarding	O
the	O
causes	O
of	O
base	O
composition	O
changes	O
at	O
these	O
sites	O
in	O
Drosophila	O
remain	O
unanswered	O
.	O
To	O
shed	O
further	O
light	O
on	O
this	O
issue	B-T033
,	O
we	O
obtained	O
a	O
new	O
whole	O
-	O
genome	O
polymorphism	O
data	O
set	O
from	O
D.	O
simulans	O
.	O
We	O
analyzed	O
samples	O
from	O
the	O
putatively	O
ancestral	O
range	O
of	O
D.	O
simulans	O
,	O
as	O
well	O
as	O
an	O
existing	O
polymorphism	O
data	O
set	O
from	O
an	O
African	O
population	O
of	O
D.	O
melanogaster	O
.	O
By	O
using	O
D.	O
yakuba	O
as	O
an	O
outgroup	O
,	O
we	O
found	O
clear	O
evidence	O
for	O
selection	O
on	O
4	O
-	O
fold	O
sites	O
along	O
both	O
lineages	O
over	O
a	O
substantial	O
period	O
,	O
with	O
the	O
intensity	O
of	O
selection	O
increasing	O
with	O
GC	O
content	O
.	O
Based	O
on	O
an	O
explicit	O
model	O
of	O
base	O
composition	O
evolution	O
,	O
we	O
suggest	O
that	O
the	O
observed	O
AT-	O
biased	O
substitution	O
pattern	O
in	O
both	O
lineages	O
is	O
probably	O
due	O
to	O
an	O
ancestral	O
reduction	O
in	O
selection	O
intensity	O
,	O
and	O
is	O
unlikely	O
to	O
be	O
the	O
result	O
of	O
an	O
increase	O
in	O
mutational	O
bias	O
towards	O
AT	O
alone	O
.	O
By	O
using	O
two	O
polymorphism	B-T060
-	I-T060
based	I-T060
methods	I-T060
for	O
estimating	O
selection	O
coefficients	O
over	O
different	O
timescales	O
,	O
we	O
show	O
that	O
the	O
selection	O
intensity	O
on	O
codon	O
usage	O
has	O
been	O
rather	O
stable	O
in	O
D.	O
simulans	O
in	O
the	O
recent	O
past	O
,	O
but	O
the	O
long	O
-	O
term	O
estimates	O
in	O
D.	O
melanogaster	O
are	O
much	O
higher	O
than	O
the	O
short	O
-	O
term	O
ones	O
,	O
indicating	O
a	O
continuing	O
decline	O
in	O
selection	O
intensity	O
,	O
to	O
such	O
an	O
extent	O
that	O
the	O
short	O
-	O
term	O
estimates	O
suggest	O
that	O
selection	O
is	O
only	O
active	O
in	O
the	O
most	O
GC	O
-rich	O
parts	O
of	O
the	O
genome	O
.	O
Finally	O
,	O
we	O
provide	O
evidence	O
for	O
complex	O
evolutionary	O
patterns	O
in	O
the	O
putatively	O
neutral	O
short	O
introns	O
,	O
which	O
can	O
not	O
be	O
explained	O
by	O
the	O
standard	O
GC	O
-	O
biased	O
gene	O
conversion	O
model	O
.	O
These	O
results	O
reveal	O
a	O
dynamic	O
picture	O
of	O
base	O
composition	O
evolution	O
.	O
      
International	O
Liver	O
Transplant	O
Society	O
Practice	O
Guidelines	O
:	O
Diagnosis	B-T033
and	O
Management	B-T058
of	O
Hepatopulmonary	B-T047
Syndrome	I-T047
and	O
Portopulmonary	B-T047
Hypertension	I-T047
Two	O
distinct	O
pulmonary	B-T047
vascular	I-T047
disorders	I-T047
,	O
hepatopulmonary	B-T047
syndrome	I-T047
(	O
HPS	B-T047
)	O
and	O
portopulmonary	B-T047
hypertension	I-T047
(	O
POPH	B-T047
)	O
may	O
occur	O
as	O
a	O
consequence	O
of	O
hepatic	B-T023
parenchymal	I-T023
or	O
vascular	B-T033
abnormalities	I-T033
.	O
HPS	B-T047
and	O
POPH	B-T047
have	O
major	O
clinical	O
implications	B-T033
for	O
liver	B-T061
transplantation	I-T061
.	O
A	O
European	O
Respiratory	O
Society	O
Task	O
Force	O
on	O
Pulmonary	B-T047
-	I-T047
Hepatic	I-T047
Disorders	I-T047
convened	O
in	O
2002	O
to	O
standardize	O
the	O
diagnosis	B-T033
and	O
guide	O
management	O
of	O
these	O
disorders	B-T047
.	O
These	O
International	O
Liver	O
Transplant	O
Society	O
diagnostic	O
and	O
management	O
guidelines	O
are	O
based	O
on	O
that	O
task	O
force	O
consensus	O
and	O
should	O
continue	O
to	O
evolve	O
as	O
clinical	O
experience	O
dictates	O
.	O
Based	O
on	O
a	O
review	O
of	O
over	O
1000	O
published	O
HPS	B-T047
and	O
POPH	B-T047
articles	O
identified	O
via	O
a	O
MEDLINE	O
search	O
(	O
1985	O
-	O
2015	O
)	O
,	O
clinical	O
guidelines	O
were	O
based	O
on	O
,	O
selected	B-T058
single	I-T058
care	I-T058
reports	I-T058
,	O
small	O
series	O
,	O
registries	O
,	O
databases	O
,	O
and	O
expert	O
opinion	O
.	O
The	O
paucity	O
of	O
randomized	O
,	O
controlled	O
trials	O
in	O
either	O
of	O
these	O
disorders	B-T047
was	O
noted	O
.	O
Guidelines	O
are	O
presented	O
in	O
5	O
parts	O
;	O
I.	O
Definitions	O
/	O
Diagnostic	O
criteria	O
;	O
II	O
.	O
Hepatopulmonary	B-T047
syndrome	I-T047
;	O
III	O
.	O
Portopulmonary	B-T047
hypertension	I-T047
;	O
IV	O
.	O
Implications	B-T033
for	O
liver	B-T061
transplantation	I-T061
;	O
and	O
V.	O
Suggestions	O
for	O
future	O
clinical	O
research	O
.	O
      
Association	O
between	O
postpartum	B-T048
depression	I-T048
and	O
the	O
practice	O
of	O
exclusive	O
breastfeeding	O
in	O
the	O
first	O
three	O
months	O
of	O
life	O
To	O
investigate	O
the	O
association	O
between	O
postpartum	B-T048
depression	I-T048
and	O
the	O
occurrence	O
of	O
exclusive	O
breastfeeding	O
.	O
This	O
is	O
a	O
cross	O
-	O
sectional	O
study	O
conducted	O
in	O
the	O
states	O
of	O
the	O
Northeast	O
region	O
,	O
during	O
the	O
vaccination	B-T058
campaign	I-T058
in	O
2010	O
.	O
The	O
sample	O
consisted	O
of	O
2583	O
mother	O
-	O
child	O
pairs	O
,	O
with	O
children	O
aged	O
from	O
15	O
days	O
to	O
3	O
months	O
.	O
The	O
Edinburgh	O
Postnatal	O
Depression	O
Scale	O
was	O
used	O
to	O
screen	B-T058
for	O
postpartum	B-T048
depression	I-T048
.	O
The	O
outcome	O
was	O
lack	O
of	O
exclusive	O
breastfeeding	O
,	O
defined	O
as	O
the	O
occurrence	O
of	O
this	O
practice	O
in	O
the	O
24h	O
preceding	O
the	O
interview	O
.	O
Postpartum	B-T048
depression	I-T048
was	O
the	O
explanatory	O
variable	O
of	O
interest	O
and	O
the	O
covariates	O
were	O
:	O
socioeconomic	O
and	O
demographic	O
conditions	O
;	O
maternal	B-T058
health	I-T058
care	I-T058
;	O
prenatal	B-T058
,	O
delivery	B-T061
,	O
and	O
postnatal	B-T058
care	I-T058
;	O
and	O
the	O
child	O
's	O
biological	O
factors	O
.	O
Multivariate	O
logistic	O
regression	O
analysis	O
was	O
conducted	O
to	O
control	O
for	O
possible	O
confounding	O
factors	O
.	O
Exclusive	O
breastfeeding	O
was	O
observed	O
in	O
50.8	O
%	O
of	O
the	O
infants	O
and	O
11.8	O
%	O
of	O
women	O
had	O
symptoms	B-T184
of	O
postpartum	B-T048
depression	I-T048
.	O
In	O
the	O
multivariate	O
logistic	O
regression	O
analysis	O
,	O
a	O
higher	O
chance	O
of	O
exclusive	O
breastfeeding	O
absence	O
was	O
found	O
among	O
mothers	O
with	O
symptoms	B-T184
of	O
postpartum	B-T048
depression	I-T048
(	O
OR=1.67	O
;	O
p<0.001	O
)	O
,	O
among	O
younger	O
subjects	O
(	O
OR=1.89	O
;	O
p<0.001	O
)	O
,	O
those	O
who	O
reported	O
receiving	O
benefits	O
from	O
the	O
Bolsa	O
Família	O
Program	O
(	O
OR=1.25	O
;	O
p=0.016	O
)	O
,	O
and	O
those	O
started	O
antenatal	B-T058
care	I-T058
later	O
during	O
pregnancy	O
(	O
OR=2.14	O
;	O
p=0.032	O
)	O
.	O
Postpartum	B-T048
depression	I-T048
contributed	O
to	O
reducing	O
the	O
practice	O
of	O
exclusive	O
breastfeeding	O
.	O
Therefore	O
,	O
this	O
disorder	B-T047
should	O
be	O
included	O
in	O
the	O
prenatal	B-T058
and	O
early	O
postpartum	O
support	O
guidelines	O
for	O
breastfeeding	O
,	O
especially	O
in	O
low	O
socioeconomic	O
status	O
women	O
.	O
      
Discordance	O
in	O
pathology	O
report	O
after	O
central	B-T060
pathology	I-T060
review	I-T060
:	O
Implications	O
for	O
breast	B-T191
cancer	I-T191
adjuvant	B-T061
treatment	I-T061
Pathological	O
predictive	O
factors	O
are	O
the	O
most	O
important	O
markers	O
when	O
selecting	O
early	O
breast	B-T191
cancer	I-T191
adjuvant	B-T061
therapy	I-T061
.	O
In	O
randomized	O
clinical	O
trials	O
the	O
variability	O
in	O
pathology	O
report	O
after	O
central	B-T060
pathology	I-T060
review	I-T060
is	O
noteworthy	O
.	O
We	O
evaluated	O
the	O
discordance	O
rate	O
(	O
DR	O
)	O
and	O
inter	O
-	O
rater	O
agreement	O
between	O
local	O
and	O
central	O
histopathological	O
report	O
and	O
the	O
clinical	O
implication	O
on	O
treatment	B-T033
decision	I-T033
.	O
A	O
retrospective	O
analysis	O
was	O
conducted	O
in	O
a	O
series	O
of	O
consecutive	O
early	O
breast	B-T191
cancer	I-T191
tumors	I-T191
diagnosed	O
by	O
local	O
pathologists	O
and	O
subsequently	O
reviewed	O
at	O
the	O
Pathology	O
Division	O
of	O
European	O
Institute	O
of	O
Oncology	O
.	O
The	O
inter	O
-	O
rater	O
agreement	O
(	O
k	O
)	O
between	O
local	O
and	O
central	O
pathology	O
was	O
calculated	O
for	O
Ki-67	O
,	O
grading	O
,	O
hormone	O
receptors	O
(	O
ER	O
/	O
PgR	O
)	O
and	O
HER2	O
/	O
neu	O
.	O
The	O
Bland	O
-	O
Altman	O
plots	O
were	O
derived	O
to	O
determine	O
discrepancies	O
in	O
Ki-67	O
,	O
ER	O
and	O
PgR.	O
DR	O
was	O
calculated	O
for	O
ER	O
/	O
PgR	O
and	O
HER2	O
.	O
From	O
2007	O
to	O
2013	O
,	O
187	O
pathology	O
specimens	O
from	O
10	O
Cancer	O
Centers	O
were	O
reviewed	O
.	O
Substantial	O
agreement	O
was	O
observed	O
for	O
ER	O
(	O
k0.612	O
;	O
95	O
%	O
CI	O
,	O
0538	O
-	O
0.686	O
)	O
,	O
PgR	O
(	O
k0.659	O
;	O
95	O
%	O
CI	O
,	O
0580	O
-	O
0.737	O
)	O
,	O
Ki-67	O
(	O
k0.609	O
;	O
95	O
%	O
CI	O
,	O
0.534	O
-	O
0.684	O
)	O
and	O
grading	O
(	O
k0.669	O
;	O
95	O
%	O
CI	O
,	O
0.569	O
-	O
0.769	O
)	O
.	O
Moderate	O
agreement	O
was	O
found	O
for	O
HER2	O
(	O
k0.546	O
;	O
95	O
%	O
CI	O
,	O
0444	O
-	O
0.649	O
)	O
.	O
DR	O
was	O
9.5	O
%	O
(	O
negativity	O
to	O
positivity	O
)	O
and	O
31.7	O
%	O
(	O
positivity	O
to	O
negativity	O
)	O
for	O
HER2	O
and	O
26.2	O
%	O
(	O
negativity	O
to	O
positivity	O
)	O
and	O
12.5	O
%	O
(	O
positivity	O
to	O
negativity	O
)	O
for	O
ER	O
/	O
PgR.	O
According	O
to	O
changes	O
in	O
Her2	O
and	O
ER	O
/	O
PgR	O
status	O
,	O
23	O
(	O
12.2	O
%	O
)	O
and	O
33	O
(	O
17.6	O
%	O
)	O
systemic	O
prescription	B-T058
were	O
respectively	O
modified	O
.	O
In	O
our	O
retrospective	O
analysis	O
,	O
central	B-T060
pathological	I-T060
review	I-T060
has	O
a	O
significant	O
impact	O
in	O
the	O
decision	B-T058
-	I-T058
making	I-T058
process	I-T058
in	O
early	O
breast	B-T191
cancer	I-T191
,	O
as	O
shown	O
in	O
clinical	O
trials	O
.	O
Further	O
studies	O
are	O
warranted	O
to	O
confirm	O
these	O
provocative	O
results	O
.	O
      
The	O
Prevalence	O
and	O
Clinical	O
Relevance	O
of	O
ASA	B-T121
Nonresponse	B-T033
After	O
Cardiac	B-T061
Surgery	I-T061
We	O
aimed	O
to	O
identify	O
the	O
prevalence	O
of	O
acetylsalicylic	B-T121
acid	I-T121
(	O
ASA	B-T121
)	O
nonresponse	B-T033
in	O
patients	O
after	O
coronary	B-T061
artery	I-T061
bypass	I-T061
graft	I-T061
(	I-T061
CABG	I-T061
)	I-T061
surgery	I-T061
and	O
the	O
possible	O
consequences	O
for	O
the	O
rate	O
of	O
major	O
cardiovascular	B-T033
events	I-T033
.	O
This	O
prospective	O
,	O
observational	O
,	O
bicentric	O
cohort	O
study	O
was	O
conducted	O
in	O
two	O
German	O
University	O
hospitals	O
.	O
A	O
total	O
of	O
400	O
patients	O
(	O
200	O
in	O
each	O
study	O
center	O
)	O
undergoing	O
elective	B-T061
CABG	B-T061
surgery	I-T061
were	O
enrolled	O
after	O
written	O
informed	O
consent	O
.	O
Platelet	O
function	O
was	O
analyzed	O
on	O
day	O
3	O
(	O
d3	O
)	O
and	O
day	O
5	O
(	O
d5	O
)	O
postoperatively	O
following	O
stimulation	O
with	O
arachidonic	O
acid	O
(	O
ASPItest	B-T059
)	O
and	O
with	O
thrombin	O
receptor	O
-	O
activating	O
peptide	O
6	O
(	O
TRAPtest	B-T059
)	O
using	O
multiple	B-T059
electrode	I-T059
aggregometry	I-T059
(	O
Multiplate	B-T059
)	O
.	O
Individuals	O
with	O
an	O
ASPItest	B-T059
≥40	O
AU·min	O
were	O
categorized	O
as	O
ASA	B-T121
nonresponders	B-T033
.	O
A	O
1	O
-	O
year	O
follow	B-T058
-	I-T058
up	I-T058
recorded	O
the	O
combined	O
end	O
point	O
of	O
cardiovascular	B-T033
events	I-T033
,	O
hospital	B-T058
admissions	I-T058
,	O
or	O
deaths	B-T033
related	O
to	O
cardiovascular	B-T047
disease	I-T047
.	O
The	O
prevalence	O
of	O
ASA	B-T121
nonresponse	B-T033
was	O
51.5	O
%	O
on	O
d3	O
,	O
and	O
it	O
significantly	O
increased	O
to	O
71.3	O
%	O
on	O
d5	O
(	O
P	O
=	O
.0049	O
)	O
.	O
The	O
area	O
under	O
the	O
aggregation	B-T059
curve	I-T059
in	O
the	O
TRAPtest	B-T059
(	O
P	O
<	O
.0001	O
)	O
,	O
the	O
platelet	B-T059
count	I-T059
on	O
d5	O
(	O
P	O
=	O
.009	O
)	O
,	O
and	O
the	O
cardiopulmonary	B-T033
bypass	I-T033
time	I-T033
(	O
P	O
=	O
.01	O
)	O
were	O
identified	O
as	O
independent	O
predictors	O
of	O
an	O
ASA	B-T121
nonresponse	B-T033
.	O
A	O
1	O
-	O
year	O
follow	B-T058
-	I-T058
up	I-T058
recorded	O
54	O
events	O
fulfilling	O
criteria	O
for	O
the	O
combined	O
end	O
point	O
with	O
no	O
difference	O
between	O
ASA	B-T121
responders	B-T033
and	O
nonresponders	B-T033
.	O
This	O
study	O
indicates	O
a	O
high	O
incidence	O
of	O
perioperative	O
ASA	B-T121
nonresponse	B-T033
in	O
patients	O
following	O
CABG	B-T061
.	O
No	O
effect	O
on	O
the	O
incidence	O
of	O
cardiovascular	B-T033
events	I-T033
was	O
recorded	O
in	O
the	O
1	O
-	O
year	O
follow	B-T058
-	I-T058
up	I-T058
.	O
Therefore	O
,	O
a	O
randomized	O
dosage	O
adjustment	O
trial	O
should	O
elucidate	O
whether	O
a	O
tailored	O
ASA	B-T121
treatment	B-T061
after	O
CABG	B-T061
surgery	I-T061
represents	O
a	O
useful	O
concept	O
.	O
      
Halogenated	O
phenolic	O
compounds	O
in	O
wild	O
fish	O
from	O
Canadian	O
Areas	O
of	O
Concern	O
Concentrations	O
of	O
halogenated	O
phenolic	O
compounds	O
were	O
measured	O
in	O
the	O
plasma	O
of	O
brown	O
bullhead	O
(	O
Ameiurus	O
nebulosus	O
)	O
from	O
4	O
Canadian	O
Areas	O
of	O
Concern	O
(	O
AOCs	O
)	O
,	O
to	O
assess	O
exposure	O
to	O
suspected	O
thyroid	B-T023
-	O
disrupting	O
chemicals	O
.	O
Hydroxylated	O
polychlorinated	O
biphenyls	O
(	O
OH	O
-	O
PCBs	O
)	O
were	O
detected	O
in	O
every	O
sample	O
collected	O
in	O
3	O
of	O
the	O
AOCs	O
;	O
the	O
detection	B-T061
frequency	O
was	O
lower	O
in	O
samples	O
from	O
the	O
Detroit	O
River	O
AOC	O
.	O
The	O
OH	O
-	O
PCBs	O
most	O
frequently	O
detected	O
were	O
pentachloro	O
,	O
hexachloro	O
,	O
and	O
heptachloro	O
congeners	O
,	O
which	O
are	O
structurally	O
similar	O
to	O
thyroid	O
hormones	O
.	O
Pentachlorophenol	O
(	O
PCP	O
)	O
was	O
detected	O
at	O
highest	O
concentrations	O
(	O
1.8	O
ng	O
/	O
g	O
)	O
in	O
fish	O
from	O
Prince	O
Edward	O
Bay	O
,	O
the	O
Bay	O
of	O
Quinte	O
Lake	O
reference	O
site	O
,	O
and	O
Hillman	O
Marsh	O
(	O
the	O
Wheatley	O
Harbour	O
reference	O
site	O
)	O
,	O
suggesting	O
local	O
sources	O
of	O
contamination	O
.	O
Elevated	B-T059
PCP	I-T059
concentrations	I-T059
were	O
also	O
detected	O
in	O
the	O
plasma	O
of	O
brown	O
bullhead	O
from	O
exposed	O
sites	O
in	O
the	O
Toronto	O
and	O
Region	O
AOC	O
(	O
0.4	O
-	O
0.6	O
ng	O
/	O
g	O
)	O
.	O
Triclosan	B-T121
was	O
consistently	O
detected	O
in	O
the	O
Toronto	O
and	O
Region	O
AOC	O
(	O
0.05	O
-	O
0.9	O
ng	O
/	O
g	O
)	O
,	O
consistent	O
with	O
wastewater	O
emission	O
.	O
Greater	O
concentrations	O
were	O
occasionally	O
detected	O
in	O
the	O
plasma	O
of	O
brown	O
bullhead	O
from	O
the	O
Bay	O
of	O
Quinte	O
AOC	O
.	O
Concentrations	O
of	O
polybrominated	O
diphenyl	O
ethers	O
were	O
highest	O
in	O
the	O
Toronto	O
and	O
Region	O
AOC	O
,	O
and	O
at	O
2	O
of	O
the	O
Bay	O
of	O
Quinte	O
AOC	O
exposed	O
sites	O
near	O
Trenton	O
and	O
Belleville	O
.	O
Distribution	O
patterns	O
reflected	O
the	O
properties	O
and	O
usage	O
of	O
the	O
compounds	O
under	O
investigation	O
and	O
the	O
characteristics	O
of	O
each	O
AOC	O
.	O
Environ	O
Toxicol	O
Chem	O
2017;9999:1	O
-	O
8	O
.	O
©	O
2017	O
SETAC	O
.	O
      
Grade	O
Group	O
Underestimation	B-T033
in	O
Prostate	B-T060
Biopsy	I-T060
:	O
Predictive	O
Factors	O
and	O
Outcomes	B-T033
in	O
Candidates	O
for	O
Active	B-T058
Surveillance	I-T058
We	O
intended	O
to	O
analyze	O
the	O
outcomes	B-T033
and	O
predictive	O
factors	O
for	O
underestimating	O
the	O
prostate	B-T191
cancer	I-T191
(	O
PCa	B-T191
)	O
grade	O
group	O
(	O
GG	O
)	O
from	O
prostate	B-T060
biopsies	I-T060
in	O
a	O
large	O
monocentric	O
cohort	O
of	O
patients	O
treated	O
by	O
minimally	B-T061
invasive	I-T061
radical	I-T061
prostatectomy	I-T061
(	O
RP	B-T061
)	O
.	O
Using	O
a	O
monocentric	O
prospectively	O
maintained	O
database	O
,	O
we	O
included	O
3062	O
patients	O
who	O
underwent	O
minimally	B-T061
invasive	I-T061
RP	I-T061
between	O
2006	O
and	O
2013	O
.	O
We	O
explored	O
clinicopathologic	O
features	O
and	O
outcomes	B-T033
associated	O
with	O
a	O
GG	O
upgrade	O
from	O
biopsy	B-T060
to	O
RP	B-T061
.	O
Multivariate	O
logistic	O
regression	O
was	O
used	O
to	O
develop	O
and	O
validate	O
a	O
nomogram	O
to	O
predict	O
upgrading	O
for	O
GG1	O
.	O
Biopsy	B-T060
GG	O
was	O
upgraded	O
after	O
RP	B-T061
in	O
51.5	O
%	O
of	O
cases	O
.	O
Patients	O
upgraded	O
from	O
GG1	O
to	O
GG2	O
or	O
GG3	O
after	O
RP	B-T061
had	O
a	O
longer	O
time	O
to	O
biochemical	B-T033
recurrence	I-T033
than	O
those	O
with	O
GG2	O
or	O
GG3	O
respectively	O
,	O
on	O
both	O
biopsy	B-T060
and	O
RP	B-T061
,	O
but	O
a	O
shorter	O
time	O
to	O
biochemical	B-T033
recurrence	I-T033
than	O
those	O
who	O
remained	O
GG1	O
after	O
RP	O
(	O
P	O
<	O
.0001	O
)	O
.	O
In	O
multivariate	O
analyses	O
,	O
variables	O
predicting	O
upgrading	O
for	O
GG1	O
PCa	B-T191
were	O
age	O
(	O
P	O
=	O
.0014	O
)	O
,	O
abnormal	B-T060
digital	I-T060
rectal	I-T060
examination	I-T060
(	O
P	O
<	O
.0001	O
)	O
,	O
prostate	B-T023
prostate	B-T033
-specific	I-T033
antigen	I-T033
density	I-T033
(	O
P	O
<	O
.0001	O
)	O
,	O
percentage	B-T033
of	I-T033
positive	I-T033
cores	I-T033
(	O
P	O
<	O
.0001	O
)	O
,	O
and	O
body	O
mass	O
index	O
(	O
P	O
=	O
.037	O
)	O
.	O
A	O
nomogram	O
was	O
generated	O
and	O
validated	O
internally	O
.	O
Biopsy	B-T060
grading	B-T058
system	I-T058
is	O
misleading	O
in	O
approximately	O
50	O
%	O
of	O
cases	O
.	O
Upgrading	O
GG	O
from	O
biopsy	B-T060
to	O
RP	B-T061
may	O
have	O
consequences	O
on	O
clinical	B-T033
outcomes	I-T033
.	O
A	O
nomogram	O
using	O
clinicopathologic	O
features	O
could	O
aid	O
the	O
probability	O
of	O
needing	O
to	O
upgrade	O
GG1	O
patients	O
at	O
their	O
initial	O
evaluation	B-T058
.	O
      
A	O
trial	O
to	O
determine	O
whether	O
septic	O
shock	O
-	O
reversal	O
is	O
quicker	O
in	O
pediatric	O
patients	O
randomized	O
to	O
an	O
early	O
goal	B-T061
-	I-T061
directed	I-T061
fluid	I-T061
-	I-T061
sparing	I-T061
strategy	I-T061
versus	O
usual	B-T058
care	I-T058
(	O
SQUEEZE	O
):	O
study	O
protocol	O
for	O
a	O
pilot	O
randomized	O
controlled	O
trial	O
Current	O
pediatric	O
septic	O
shock	O
resuscitation	B-T061
guidelines	O
from	O
the	O
American	O
College	O
of	O
Critical	O
Care	O
Medicine	O
focus	O
on	O
the	O
early	O
and	O
goal	B-T061
-	I-T061
directed	I-T061
administration	I-T061
of	O
intravascular	O
fluid	O
followed	O
by	O
vasoactive	O
medication	B-T121
infusions	B-T061
for	O
persistent	O
and	O
fluid	B-T047
-	I-T047
refractory	I-T047
shock	I-T047
.	O
However	O
,	O
accumulating	B-T033
adult	O
and	O
pediatric	O
data	O
suggest	O
that	O
excessive	O
fluid	B-T061
administration	I-T061
is	O
associated	O
with	O
worse	B-T033
patient	O
outcomes	O
and	O
even	O
increased	B-T033
risk	I-T033
of	I-T033
death	I-T033
.	O
The	O
optimal	O
amount	O
of	O
intravascular	O
fluid	O
required	O
in	O
early	O
pediatric	O
septic	O
shock	O
resuscitation	B-T061
prior	O
to	O
the	O
initiation	O
of	O
vasoactive	O
support	O
remains	O
unanswered	O
.	O
The	O
SQUEEZE	O
Pilot	O
Trial	O
is	O
a	O
pragmatic	O
,	O
two	O
-	O
arm	O
,	O
parallel	O
-	O
group	O
,	O
open	O
-	O
label	O
,	O
prospective	O
pilot	O
randomized	O
controlled	O
trial	O
.	O
Participants	O
are	O
children	O
aged	O
29	O
days	O
to	O
under	O
18	O
years	O
with	O
suspected	O
or	O
confirmed	B-T033
septic	O
shock	O
and	O
a	O
need	O
for	O
ongoing	O
resuscitation	B-T061
.	O
Eligible	O
participants	O
are	O
enrolled	B-T058
under	O
an	O
exception	O
to	O
consent	O
process	O
and	O
randomly	O
assigned	O
via	O
concealed	O
allocation	O
to	O
either	O
the	O
Usual	B-T058
Care	I-T058
(	O
control	O
)	O
or	O
Fluid	B-T061
Sparing	I-T061
(	I-T061
intervention	I-T061
)	I-T061
resuscitation	I-T061
strategy	I-T061
.	O
The	O
primary	O
objective	O
of	O
this	O
pilot	O
trial	O
is	O
to	O
determine	O
feasibility	O
,	O
based	O
on	O
the	O
ability	O
to	O
enroll	B-T058
participants	O
and	O
to	O
adhere	O
to	O
the	O
study	O
protocol	O
.	O
The	O
primary	O
outcome	O
measure	O
by	O
which	O
success	O
will	O
be	O
determined	O
is	O
participant	O
enrollment	B-T058
rate	O
(	O
"	O
pass	O
"	O
defined	O
as	O
at	O
least	O
two	O
participants	O
/	O
site	O
/	O
month	O
,	O
recognizing	O
that	O
enrollment	B-T058
may	O
be	O
slower	O
during	O
the	O
run	O
-	O
in	O
phase	O
)	O
.	O
Secondary	O
objectives	O
include	O
assessing	O
(	O
1	O
)	O
appropriateness	O
of	O
eligibility	O
criteria	O
,	O
and	O
(	O
2	O
)	O
completeness	O
of	O
clinical	O
outcomes	O
to	O
inform	O
the	O
endpoints	O
for	O
the	O
planned	O
multisite	O
trial	O
.	O
To	O
support	O
the	O
nested	O
translational	O
study	O
,	O
SQUEEZE	O
-	O
D	O
,	O
we	O
will	O
also	O
evaluate	O
the	O
feasibility	O
of	O
describing	O
cell	O
-	O
free	O
DNA	O
(	O
a	O
procoagulant	O
molecule	O
with	O
prognostic	O
utility	O
)	O
in	O
blood	O
samples	O
obtained	O
from	O
children	O
enrolled	B-T058
into	O
the	O
SQUEEZE	O
Pilot	O
Trial	O
at	O
baseline	O
and	O
at	O
24	O
h.	O
The	O
optimal	O
degree	O
of	O
fluid	O
resuscitation	B-T061
and	O
the	O
timing	O
of	O
initiation	O
of	O
vasoactive	O
support	O
in	O
order	O
to	O
achieve	O
recommended	O
therapeutic	O
targets	O
in	O
children	O
with	O
septic	O
shock	O
remains	O
unanswered	O
.	O
No	O
prospective	O
study	O
to	O
date	O
has	O
examined	O
this	O
important	O
question	O
for	O
children	O
in	O
developed	O
countries	O
including	O
Canada	O
.	O
Recruitment	O
for	O
the	O
SQUEEZE	O
Pilot	O
Trial	O
opened	B-T033
on	O
6	O
January	O
2014	O
.	O
Findings	B-T033
will	O
inform	O
the	O
feasibility	O
of	O
the	O
planned	O
multicenter	O
trial	O
to	O
answer	O
our	O
overall	O
research	O
question	O
.	O
ClinicalTrials.gov	O
Identifier	O
NCT01973907	O
,	O
registered	O
on	O
23	O
October	O
2013	O
.	O
      
The	O
relationship	O
between	O
polymorphisms	O
of	O
BDNFOS	O
and	O
BDNF	O
genes	O
and	O
heroin	B-T048
addiction	I-T048
in	O
the	O
Han	O
Chinese	O
population	O
The	O
number	O
of	O
heroin	B-T121
addicts	O
is	O
increasing	O
in	O
the	O
world	O
.	O
Both	O
environmental	O
and	O
genetic	O
factors	O
both	O
play	O
critical	O
roles	O
in	O
the	O
process	O
of	O
heroin	B-T048
addiction	I-T048
.	O
We	O
aimed	O
to	O
investigate	O
the	O
associations	O
between	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
LIN7C	O
,	O
BDNFOS	O
and	O
BDNF	O
genes	O
and	O
drug	B-T048
addiction	I-T048
in	O
the	O
Han	O
Chinese	O
population	O
.	O
We	O
conducted	O
a	O
case	O
-	O
control	O
study	O
among	O
692	O
cases	O
and	O
700	O
healthy	O
controls	O
from	O
Xi'an	O
,	O
China	O
.	O
Eight	O
SNPs	O
were	O
selected	O
and	O
genotyped	B-T059
using	O
MassARRAY	O
technology	O
(	O
Sequenom	O
,	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
.	O
Odds	O
ratios	O
(	O
OR	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
CIs	O
)	O
were	O
calculated	O
by	O
unconditional	O
logistic	O
regression	O
adjusting	O
for	O
age	O
and	O
sex	O
.	O
Using	O
the	O
chi	O
-	O
squared	O
test	O
,	O
we	O
found	O
that	O
rs7481311	O
(	O
OR	O
=	O
1.275	O
,	O
95	O
%	O
CI	O
=	O
1.087	O
-	O
1.497	O
,	O
p	O
=	O
0.009	O
)	O
and	O
rs11030096	O
(	O
OR	O
=	O
1.227	O
,	O
95	O
%	O
CI	O
=	O
1.049	O
-	O
1.436	O
,	O
p	O
=	O
0.011	O
)	O
in	O
the	O
BNDFOS	O
were	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
heroin	B-T048
addiction	I-T048
.	O
By	O
contrast	O
,	O
rs988712	O
located	O
in	O
BDNFOS	O
showed	O
a	O
decreased	O
risk	O
of	O
heroin	B-T048
addiction	I-T048
(	O
OR	O
=	O
0.734	O
,	O
95	O
%	O
CI	O
=	O
0.582	O
-	O
0.925	O
,	O
p	O
=	O
0.003	O
)	O
.	O
By	O
genetic	O
model	O
analysis	O
,	O
we	O
found	O
that	O
the	O
'	O
T	O
'	O
allele	O
of	O
rs988712	O
in	O
BDNFOS	O
had	O
a	O
protective	O
role	O
for	O
heroin	B-T048
addiction	I-T048
in	O
the	O
additive	O
model	O
and	O
dominant	O
model	O
(	O
p	O
<	O
0.05	O
)	O
.	O
By	O
contrast	O
,	O
the	O
allele	O
'	O
T	O
'	O
of	O
rs7481311	O
in	O
BDNFOS	O
significantly	O
elevated	O
the	O
risk	O
of	O
heroin	B-T048
addiction	I-T048
in	O
the	O
additive	O
model	O
,	O
recessive	O
model	O
and	O
dominant	O
model	O
(	O
p	O
<	O
0.05	O
)	O
.	O
We	O
also	O
found	O
that	O
allele	O
'	O
C	O
'	O
of	O
rs11030096	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
addiction	B-T048
in	O
the	O
dominant	O
model	O
and	O
additive	O
model	O
(	O
p	O
<	O
0.05	O
)	O
.	O
Additionally	O
,	O
we	O
found	O
that	O
rs6265	O
,	O
rs11030104	O
and	O
rs10767664	O
in	O
BDNF	O
were	O
associated	O
with	O
a	O
decreased	O
risk	O
of	O
heroin	B-T048
addiction	I-T048
(	O
p	O
<	O
0.05	O
)	O
.	O
However	O
,	O
only	O
rs7481311	O
in	O
BDNFOS	O
remained	O
significant	O
after	O
Bonferroni	O
correction	O
(	O
p	O
<	O
0.00625	O
)	O
.	O
These	O
results	B-T033
suggest	O
that	O
polymorphisms	O
of	O
BDNFOS	O
play	O
an	O
important	O
role	O
in	O
heroin	B-T048
addiction	I-T048
susceptibility	O
in	O
the	O
Chinese	O
Han	O
population	O
.	O
      
Pathophysiology	O
,	O
treatment	B-T061
and	O
prevention	B-T061
of	O
ovarian	B-T047
hyperstimulation	I-T047
syndrome	I-T047
Severe	O
ovarian	B-T047
hyperstimulation	I-T047
syndrome	I-T047
(	O
OHSS	B-T047
)	O
is	O
an	O
iatrogenic	O
condition	O
that	O
affects	O
1	O
%	O
of	O
women	O
that	O
undergo	O
treatment	B-T061
with	O
assisted	B-T061
reproductive	I-T061
technology	I-T061
.	O
The	O
review	O
aims	O
to	O
summarize	O
recent	O
evidence	O
on	O
pathophysiology	O
,	O
treatment	B-T061
,	O
and	O
prevention	B-T061
of	O
OHSS	B-T047
.	O
The	O
pathophysiology	O
is	O
still	O
not	O
completely	O
understood	O
;	O
however	O
,	O
vascular	O
endothelial	O
growth	O
factor	O
is	O
likely	O
to	O
be	O
an	O
important	O
mediator	O
.	O
Human	B-T121
chorionic	I-T121
gonadotropin	I-T121
was	O
previously	O
thought	O
to	O
be	O
necessary	O
for	O
OHSS	B-T047
to	O
occur	O
;	O
however	O
,	O
recent	O
case	O
reports	O
have	O
proven	O
otherwise	O
.	O
The	O
contribution	O
of	O
an	O
attenuated	O
anti	B-T121
-	I-T121
Mullerian	I-T121
hormone	I-T121
signalling	O
pathway	O
and	O
CD11c	O
+	O
HLA	O
-	O
DR	O
+	O
dendritic	O
cells	O
and	O
associated	O
interleukins	O
has	O
been	O
explored	O
recently	O
as	O
contributors	O
to	O
pathogenesis	O
.	O
Treatment	B-T061
is	O
largely	O
supportive	B-T061
and	O
is	O
based	O
mainly	O
on	O
consensus	O
statements	O
rather	O
than	O
evidence	O
.	O
Therefore	O
,	O
it	O
is	O
important	O
to	O
prevent	O
this	O
condition	O
by	O
identifying	B-T058
women	O
at	O
risk	O
,	O
allowing	O
the	O
clinician	O
to	O
implement	O
preventive	O
strategies	O
,	O
including	O
the	O
use	O
of	O
GnRH	B-T121
antagonist	I-T121
cycles	O
with	O
agonist	B-T121
triggers	O
.	O
More	O
research	O
is	O
required	O
to	O
elucidate	O
the	O
pathophysiology	O
behind	O
the	O
condition	O
.	O
Clinicians	O
should	O
employ	O
strategies	O
to	O
prevent	B-T061
OHSS	B-T047
.	O
      
Pedicle	O
Screw	O
Combined	O
With	O
Lateral	O
Mass	O
Screw	O
Fixation	B-T061
in	O
the	O
Treatment	B-T061
of	O
Basilar	B-T019
Invagination	I-T019
and	O
Congenital	B-T019
C2	I-T019
-	I-T019
C3	I-T019
Fusion	I-T019
Clinical	B-T058
evaluation	I-T058
of	O
a	O
surgical	B-T061
fixation	B-T061
technique	O
featuring	O
combined	O
use	O
of	O
pedicle	O
screw	O
and	O
lateral	O
mass	O
screw	O
(	O
LMS	O
)	O
.	O
Introduction	O
of	O
a	O
novel	O
technique	O
for	O
the	O
treatment	B-T061
of	O
congenital	B-T019
C2	I-T019
-	I-T019
C3	I-T019
fusion	I-T019
and	O
basilar	B-T019
invagination	I-T019
(	O
BI	B-T019
)	O
.	O
Posterior	O
occipitocervical	O
fixation	B-T061
using	O
C2	O
pedicle	O
screw	O
was	O
widely	O
used	O
for	O
BI	B-T019
.	O
However	O
,	O
in	O
cases	O
where	O
BI	B-T019
is	O
concurrent	O
with	O
congenital	B-T019
C2	I-T019
-	I-T019
C3	I-T019
fusion	I-T019
,	O
the	O
C2	B-T023
pedicles	I-T023
tend	O
to	O
be	O
thinner	O
than	O
that	O
in	O
normal	O
population	O
and	O
hence	O
more	O
likely	O
to	O
fail	O
.	O
We	O
prompted	O
to	O
tackle	O
the	O
issue	B-T033
by	O
combining	O
the	O
pedicle	O
screw	O
with	O
the	O
additional	O
use	O
of	O
LMS	O
in	O
attempt	O
to	O
strengthen	O
the	O
fixation	B-T061
.	O
Twenty	O
-	O
five	O
patients	O
who	O
underwent	O
combined	O
pedicle	O
screw	O
with	O
LMS	O
fixation	B-T061
were	O
retrospectively	O
studied	O
.	O
The	O
instrument	O
position	O
,	O
fusion	O
status	O
,	O
and	O
complications	O
were	O
analyzed	O
.	O
None	O
had	O
spinal	O
cord	O
or	O
vertebral	O
artery	O
injury	O
.	O
The	O
average	O
follow	B-T058
-	I-T058
up	I-T058
time	O
was	O
20	O
months	O
.	O
Solid	O
fusion	O
was	O
achieved	O
in	O
23	O
patients	O
(	O
92	O
%	O
)	O
as	O
detected	O
radiologically	B-T060
.	O
Two	O
cases	O
suffered	O
from	O
recurred	O
BI	B-T019
and	O
instrument	O
failure	B-T033
but	O
eventually	O
achieved	O
solid	O
fusion	O
between	O
the	O
occiput	O
and	O
C2	B-T023
was	O
after	O
revision	B-T061
.	O
Among	O
all	O
25	O
patients	O
,	O
4	O
suffered	O
from	O
complications	O
including	O
instrument	O
s	O
failure	B-T033
,	O
cerebrospinal	B-T047
fluid	I-T047
leakage	I-T047
,	O
and	O
intracranial	O
infection	O
.	O
The	O
clinical	O
outcome	O
indicates	O
that	O
the	O
technique	O
is	O
reliable	O
for	O
the	O
treatment	B-T061
of	O
BI	B-T019
with	O
congenital	B-T019
C2	I-T019
-	I-T019
C3	I-T019
fusion	I-T019
.	O
      
Impact	O
of	O
diabetic	B-T047
ketoacidosis	I-T047
management	B-T058
in	O
the	O
medical	O
intensive	O
care	O
unit	O
after	O
order	O
set	O
implementation	O
To	O
determine	O
the	O
rate	O
of	O
compliance	B-T058
to	O
the	O
2006	O
and	O
2009	O
ADA	O
DKA	O
guidelines	O
in	O
the	O
medical	O
intensive	O
care	O
unit	O
(	O
MICU	O
)	O
at	O
a	O
large	O
academic	O
medical	O
centre	O
after	O
the	O
implementation	O
of	O
a	O
computerised	O
DKA	O
order	O
set	O
and	O
protocol	B-T061
.	O
Retrospective	O
chart	O
review	O
of	O
adult	O
patients	O
with	O
DKA	B-T047
admitted	B-T058
to	O
the	O
MICU	O
.	O
Results	O
of	O
pre	O
-	O
order	O
set	O
(	O
PRE	O
)	O
were	O
compared	O
to	O
those	O
of	O
data	O
post	O
-	O
order	O
set	O
(	O
POST	O
)	O
.	O
The	O
primary	O
outcome	O
was	O
a	O
composite	O
administration	B-T061
of	O
intravenous	B-T061
fluid	I-T061
resuscitation	I-T061
in	O
the	O
first	O
24	O
h	O
,	O
insulin	B-T121
bolus	B-T061
and	O
initial	O
insulin	B-T121
infusion	O
rate	O
.	O
Twelve	O
of	O
60	O
patients	O
(	O
20	O
%	O
)	O
in	O
the	O
PRE	O
group	O
received	O
treatment	B-T061
compliant	O
with	O
the	O
2006	O
guidelines	O
versus	O
14	O
of	O
55	O
patients	O
(	O
25.5	O
%	O
)	O
in	O
the	O
POST	O
group	O
(	O
OR	O
1.22	O
95	O
%	O
CI	O
0.44	O
to	O
3.4	O
,	O
P	O
=	O
0.51	O
)	O
.	O
Compliance	B-T058
to	O
the	O
2009	O
guidelines	O
was	O
significantly	O
higher	O
in	O
the	O
POST	O
group	O
(	O
31.7	O
%	O
versus	O
65.5	O
%	O
,	O
OR	O
4.44	O
95	O
%	O
CI	O
1.8	O
to	O
10.92	O
,	O
P	O
=	O
0.0004	O
)	O
.	O
Compliance	B-T058
for	O
individual	O
components	O
was	O
26.7	O
%	O
versus	O
70.9	O
%	O
for	O
fluid	B-T061
resuscitation	I-T061
(	O
P	O
=	O
0.0001	O
)	O
,	O
55	O
%	O
versus	O
49.1	O
%	O
for	O
insulin	B-T121
bolus	B-T061
(	O
P	O
=	O
0.58	O
)	O
and	O
60	O
%	O
versus	O
81.3	O
%	O
for	O
initial	O
insulin	B-T121
infusion	O
rate	O
(	O
P	O
=	O
0.014	O
)	O
,	O
respectively	O
.	O
Time	O
to	O
DKA	B-T047
resolution	O
was	O
decreased	O
(	O
P	O
=	O
0.04	O
)	O
,	O
and	O
hypoglycaemia	B-T047
was	O
increased	O
(	O
P	O
=	O
0.0022	O
)	O
.	O
Implementation	O
of	O
a	O
computerised	O
DKA	O
order	O
set	O
and	O
protocol	B-T061
was	O
associated	O
with	O
improved	B-T033
compliance	B-T058
to	O
the	O
2009	O
ADA	O
DKA	O
guidelines	O
,	O
24	O
-	O
h	O
fluid	B-T061
resuscitation	I-T061
,	O
initial	O
insulin	B-T121
infusion	O
rate	O
,	O
time	O
to	O
DKA	B-T047
resolution	O
and	O
appropriate	O
transition	O
to	O
subcutaneous	O
insulin	B-T121
.	O
However	O
,	O
patients	O
in	O
the	O
POST	O
implementation	O
group	O
were	O
more	O
likely	O
to	O
exhibit	O
hypoglycaemia	B-T047
.	O
Future	O
assessment	O
is	O
warranted	O
.	O
      
Volumetric	B-T060
absorptive	I-T060
microsampling	I-T060
at	O
home	O
as	O
an	O
alternative	O
tool	O
for	O
the	O
monitoring	B-T058
of	O
HbA1c	O
in	O
diabetes	B-T047
patients	O
Microsampling	O
techniques	O
have	O
several	O
advantages	O
over	O
traditional	O
blood	B-T060
collection	I-T060
.	O
Dried	B-T059
blood	I-T059
spot	I-T059
(	I-T059
DBS	I-T059
)	I-T059
sampling	I-T059
and	O
blood	B-T060
collection	I-T060
with	O
heparinized	O
capillaries	O
are	O
the	O
standard	O
techniques	B-T059
.	O
Volumetric	B-T060
absorptive	I-T060
microsampling	I-T060
(	O
VAMS	B-T060
)	O
is	O
a	O
novel	O
technique	B-T059
that	O
collects	O
a	O
fixed	O
volume	O
of	O
blood	O
by	O
applying	O
an	O
absorbent	O
tip	O
to	O
a	O
blood	O
drop	O
.	O
In	O
the	O
present	O
study	O
we	O
explored	O
the	O
feasibility	O
of	O
HbA1c	O
monitoring	B-T058
with	O
VAMS	B-T060
sampling	I-T060
at	O
home	O
and	O
analysis	O
in	O
the	O
laboratory	O
.	O
Diabetic	B-T047
patients	O
were	O
enrolled	O
in	O
this	O
study	O
during	O
consultation	B-T058
with	O
the	O
endocrinologist	O
.	O
A	O
venous	O
(	O
adults	O
)	O
or	O
capillary	O
(	O
children	O
)	O
sample	O
was	O
taken	O
for	O
immediate	O
HbA1c	O
analysis	O
.	O
DBS	B-T059
(	O
n=1	O
)	O
and	O
dried	B-T060
VAMS	I-T060
(	O
n=2	O
)	O
were	O
collected	O
at	O
home	O
and	O
sent	O
to	O
the	O
laboratory	O
.	O
For	O
25	O
pediatric	O
patients	O
one	O
VAMS	B-T060
was	O
collected	O
during	O
consultation	B-T058
for	O
immediate	O
analysis	O
(	O
without	O
drying	O
)	O
,	O
referred	O
to	O
as	O
"	O
wet	B-T060
VAMS	I-T060
"	O
.	O
HbA1c	O
analyses	O
were	O
performed	O
on	O
a	O
Tosoh	O
HLC-723	O
G8	O
high	O
-	O
performance	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
analyzer	O
.	O
The	O
median	O
time	O
between	O
sampling	B-T060
at	O
home	O
and	O
analysis	O
was	O
3	O
days	O
.	O
Results	O
of	O
HbA1c	O
in	O
dried	O
VAMS	B-T060
showed	O
a	O
poor	O
agreement	O
with	O
venous	O
/	O
capillary	O
blood	O
collected	O
in	O
hospital	O
(	O
concordance	O
correlation	O
coefficient	O
CCC	O
=	O
0.72	O
)	O
.	O
Similar	O
observations	O
were	O
found	O
with	O
standard	O
DBS	B-T059
.	O
An	O
excellent	O
agreement	O
was	O
obtained	O
between	O
HbA1c	O
results	O
on	O
wet	B-T060
VAMS	I-T060
(	O
CCC	O
=	O
0.996	O
)	O
and	O
standard	O
blood	O
samples	O
.	O
Patients	O
experienced	O
VAMS	B-T060
and	O
DBS	B-T059
as	O
easy	B-T033
and	O
convenient	O
to	O
use	O
.	O
Utilizing	O
equipment	O
standard	O
available	O
in	O
the	O
clinical	O
laboratory	O
,	O
the	O
use	O
of	O
home	O
-sampled	O
dried	B-T060
VAMS	I-T060
and	O
DBS	B-T059
is	O
not	O
a	O
reliable	O
tool	O
for	O
the	O
monitoring	B-T058
of	O
HbA1c	O
.	O
However	O
,	O
perfect	O
agreement	O
between	O
HbA1c	O
measured	O
on	O
wet	B-T060
VAMS	I-T060
and	O
capillary	O
microsamples	O
was	O
obtained	O
.	O
      
Effect	O
of	O
emodin	B-T121
on	O
mobility	O
signal	O
transduction	O
system	O
of	O
gallbladder	B-T023
smooth	O
muscle	O
in	O
Guinea	O
pig	O
with	O
cholelithiasis	B-T047
To	O
study	O
the	O
effect	O
of	O
emodin	B-T121
on	O
protein	O
and	O
gene	O
expressions	O
of	O
the	O
massagers	O
in	O
mobility	O
signal	O
transduction	O
system	O
of	O
cholecyst	B-T023
smooth	O
muscle	O
cells	O
in	O
guinea	O
pig	O
with	O
cholesterol	O
calculus	O
.	O
The	O
guinea	O
pigs	O
were	O
randomly	O
divided	O
into	O
4	O
groups	O
,	O
such	O
as	O
control	O
group	O
,	O
gall	B-T047
-	I-T047
stone	I-T047
(	O
GS	B-T047
)	O
group	O
,	O
emodin	B-T121
group	O
and	O
ursodeoxycholic	B-T121
acid	I-T121
(	O
UA	B-T121
)	O
group	O
.	O
Cholesterol	O
calculus	O
models	O
were	O
induced	O
in	O
guinea	O
pigs	O
of	O
GS	B-T047
,	O
emodin	B-T121
and	O
UA	B-T121
groups	O
by	O
lithogenic	O
diet	O
,	O
while	O
emodin	B-T121
or	O
UA	B-T121
were	O
given	O
to	O
the	O
corresponding	O
group	O
for	O
7	O
weeks	O
.	O
The	O
histomorphological	O
and	O
ultrastructure	O
change	O
of	O
gallbladder	B-T023
were	O
detected	B-T033
by	O
microscope	O
and	O
electron	O
microscope	O
,	O
the	O
content	O
of	O
plasma	O
cholecystokinin	B-T121
(	O
CCK	B-T121
)	O
and	O
[	B-T121
Ca(2+)]i	I-T121
were	O
analyzed	O
successively	O
by	O
radioimmunoassay	B-T059
and	O
flow	B-T059
cytometry	I-T059
.	O
The	O
protein	O
and	O
mRNA	O
of	O
Gsα	O
,	O
Giα	O
and	O
Cap	O
in	O
cholecyst	B-T023
cells	O
were	O
determined	O
by	O
western	B-T059
blotting	I-T059
and	O
real	O
time	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
.	O
Emodin	B-T121
or	O
UA	B-T121
can	O
relieve	O
pathogenic	B-T033
changes	O
in	O
epithelial	O
cells	O
and	O
muscle	O
cells	O
in	O
gallbladder	B-T023
of	O
guinea	O
pig	O
with	O
cholesterol	O
calculus	O
by	O
microscope	O
and	O
transmission	O
electron	O
microscope	O
.	O
In	O
the	O
cholecyst	B-T023
cells	O
of	O
GS	B-T047
group	O
,	O
CCK	B-T121
levels	O
in	O
plasma	O
and	O
[	B-T121
Ca(2+)]i	I-T121
decreased	O
,	O
the	O
protein	O
and	O
mRNA	O
of	O
GS	B-T047
were	O
down	O
-	O
regulated	O
,	O
the	O
protein	O
and	O
mRNA	O
of	O
Gi	O
and	O
Cap	O
were	O
up	O
-	O
regulated	O
.	O
Emodin	B-T121
significantly	O
decreased	O
the	O
formative	O
rate	O
of	O
gallstone	B-T047
,	O
improved	O
the	O
pathogenic	B-T033
change	O
in	O
epithelial	O
cells	O
and	O
muscle	O
cells	O
,	O
increased	O
CCK	B-T121
levels	O
in	O
plasma	O
and	O
[	B-T121
Ca(2+)]i	I-T121
in	O
cholecyst	B-T023
cells	O
,	O
enhanced	O
the	O
protein	O
and	O
mRNA	O
of	O
Gs	O
in	O
cholecyst	B-T023
cells	O
,	O
reduced	O
the	O
protein	O
and	O
mRNA	O
of	O
Gi	O
and	O
Cap	O
in	O
cholecyst	B-T023
cells	O
in	O
guinea	O
pig	O
with	O
cholesterol	O
calculus	O
.	O
The	O
dysfunction	O
of	O
gallbladder	O
contraction	O
gives	O
rise	O
to	O
the	O
disorders	B-T047
of	O
mobility	O
signal	O
transduction	O
system	O
in	O
cholecyst	B-T023
smooth	O
muscle	O
cells	O
,	O
including	O
low	O
content	O
of	O
plasma	O
CCK	B-T121
and	O
[	B-T121
Ca(2+)]i	I-T121
in	O
cholecyst	B-T023
cells	O
,	O
abnormal	O
protein	O
and	O
mRNA	O
of	O
Gs	O
,	O
Gi	O
and	O
Cap	O
.	O
Emodin	B-T121
can	O
enhance	O
the	O
contractibility	O
of	O
gallbladder	O
and	O
alleviate	O
cholestasis	B-T047
by	O
regulating	O
plasma	O
CCK	B-T121
levels	O
,	O
[	B-T121
Ca(2+)]i	I-T121
in	O
cholecyst	B-T023
cells	O
and	O
the	O
protein	O
and	O
mRNA	O
of	O
Gs	O
,	O
Gi	O
and	O
Cap	O
.	O
      
The	O
R2R3MYB	O
VvMYBPA1	O
from	O
grape	O
reprograms	O
the	O
phenylpropanoid	O
pathway	O
in	O
tobacco	O
flowers	O
This	O
work	O
shows	O
that	O
,	O
in	O
tobacco	O
,	O
the	O
ectopic	O
expression	O
of	O
VvMYBPA1	O
,	O
a	O
grape	O
regulator	O
of	O
proanthocyanidin	B-T121
biosynthesis	O
,	O
up-	O
or	O
down	O
-	O
regulates	O
different	O
branches	O
of	O
the	O
phenylproanoid	O
pathway	O
,	O
in	O
a	O
structure	O
-	O
specific	O
fashion	O
.	O
Proanthocyanidins	B-T121
are	O
flavonoids	O
of	O
paramount	O
importance	O
for	O
animal	O
and	O
human	O
diet	O
.	O
Research	O
interest	O
increasingly	O
tilts	O
towards	O
generating	O
crops	O
enriched	O
with	O
these	O
health	O
-promoting	O
compounds	O
.	O
Flavonoids	O
synthesis	O
is	O
regulated	O
by	O
the	O
MBW	O
transcriptional	O
complex	O
,	O
made	O
of	O
R2R3MYB	O
,	O
bHLH	O
and	O
WD40	O
proteins	O
,	O
with	O
the	O
MYB	O
components	O
liable	O
for	O
channeling	O
the	O
complex	O
towards	O
specific	O
branches	O
of	O
the	O
pathway	O
.	O
Hence	O
,	O
using	O
tobacco	O
as	O
a	O
model	O
,	O
here	O
,	O
we	O
tested	O
if	O
the	O
ectopic	O
expression	O
of	O
the	O
proanthocyanidin	B-T121
regulator	O
VvMYBPA1	O
from	O
grape	O
induces	O
the	O
biosynthesis	O
of	O
these	O
compounds	O
in	O
not	O
-	O
naturally	O
committed	O
cells	O
.	O
Here	O
,	O
we	O
show	O
,	O
via	O
targeted	O
transcriptomic	O
and	O
metabolic	O
analyses	O
of	O
primary	O
transgenic	O
lines	O
and	O
their	O
progeny	O
,	O
that	O
VvMYBPA1	O
alters	O
the	O
phenylpropanoid	O
pathway	O
in	O
tobacco	O
floral	O
organs	O
,	O
in	O
a	O
structure	O
-	O
specific	O
fashion	O
.	O
We	O
also	O
report	O
that	O
a	O
modest	O
VvMYBPA1	O
expression	O
is	O
sufficient	O
to	O
induce	O
the	O
expression	O
of	O
both	O
proanthocyanidin	B-T121
-specific	O
and	O
early	O
genes	O
of	O
the	O
phenylpropanoid	O
pathway	O
.	O
Consequently	O
,	O
proanthocyanidins	B-T121
and	O
chlorogenic	O
acids	O
are	O
induced	O
or	O
de	O
novo	O
synthetised	O
in	O
floral	O
limbs	O
,	O
tubes	O
and	O
stamens	O
.	O
Other	O
phenylpropanoid	O
branches	O
are	O
conversely	O
induced	O
or	O
depleted	O
according	O
to	O
the	O
floral	O
structure	O
.	O
Our	O
study	O
documents	O
a	O
novel	O
and	O
distinct	O
function	O
of	O
VvMYBPA1	O
with	O
respect	O
to	O
other	O
MYBs	O
regulating	O
proanthocyanidins	B-T121
.	O
Present	O
findings	O
may	O
have	O
major	O
implications	O
in	O
designing	O
strategies	O
for	O
enriching	O
crops	O
with	O
health	O
-promoting	O
compounds	O
.	O
      
Splicing	O
variants	O
of	O
ADAR2	O
and	O
ADAR2	O
-mediated	O
RNA	O
editing	O
in	O
glioma	B-T191
The	O
roles	O
of	O
alternative	O
splicing	O
and	O
RNA	O
editing	O
in	O
gene	O
regulation	O
and	O
transcriptome	O
diversity	O
are	O
well	O
documented	O
.	O
Adenosine	O
deaminases	O
acting	O
on	O
RNA	O
(	O
ADARs	O
)	O
are	O
responsible	O
for	O
adenosine	O
-	O
to	O
-	O
inosine	O
(	O
A	O
-	O
to	O
-	O
I	O
)	O
editing	O
and	O
exemplify	O
the	O
complex	O
association	O
between	O
RNA	O
editing	O
and	O
alternative	O
splicing	O
.	O
The	O
self	O
-	O
editing	O
activity	O
of	O
ADAR2	O
,	O
which	O
acts	O
on	O
its	O
own	O
pre	O
-	O
mRNA	O
,	O
leads	O
to	O
its	O
alternative	O
splicing	O
.	O
Alternative	O
splicing	O
occurs	O
independently	O
at	O
nine	O
splicing	O
sites	O
on	O
ADAR2	O
pre	O
-	O
mRNA	O
,	O
generating	O
numerous	O
alternative	O
splicing	O
variants	O
with	O
various	O
catalytic	O
activities	O
.	O
A	O
-	O
to	O
-	O
I	O
RNA	O
editing	O
is	O
important	O
in	O
a	O
range	O
of	O
physiological	O
processes	O
in	O
humans	O
and	O
is	O
associated	O
with	O
several	O
diseases	B-T047
,	O
including	O
amyotrophic	B-T047
lateral	I-T047
sclerosis	I-T047
,	O
mood	B-T048
disorders	I-T048
,	O
epilepsy	B-T047
and	O
glioma	B-T191
.	O
Reduced	O
editing	O
at	O
the	O
glutamine	B-T121
/	O
arginine	B-T121
site	O
of	O
the	O
AMPA	O
receptor	O
subunit	O
GluA2	O
in	O
glioma	B-T191
,	O
without	O
any	O
alteration	O
in	O
ADAR2	O
expression	O
,	O
is	O
a	O
notable	O
phenomenon	O
.	O
Several	O
studies	O
have	O
tried	O
to	O
explain	O
this	O
alteration	O
in	O
the	O
catalytic	O
activity	O
of	O
ADAR2	O
;	O
however	O
,	O
the	O
underlying	O
mechanism	O
remains	O
unclear	O
.	O
The	O
present	O
review	O
summarizes	O
the	O
relevant	O
literature	O
and	O
shares	O
experimental	B-T033
results	I-T033
concerning	O
ADAR2	O
alternative	O
splicing	O
.	O
In	O
particular	O
,	O
the	O
present	O
review	O
demonstrates	O
that	O
shifts	O
in	O
the	O
relative	O
abundance	O
of	O
the	O
active	O
and	O
inactive	O
splicing	O
variants	O
of	O
ADAR2	O
may	O
reduce	O
the	O
ADAR2	O
editing	O
activity	O
in	O
glioma	B-T191
.	O
Dominant	O
expression	O
of	O
ADAR2	O
splicing	O
variant	O
with	O
low	O
enzyme	O
activity	O
causes	O
reduced	O
RNA	O
editing	O
of	O
GluA2	O
subunit	O
at	O
the	O
glutamine	B-T121
/	O
arginine	B-T121
site	O
in	O
glioma	B-T191
.	O
      
Assessing	B-T058
the	O
learning	O
potential	O
of	O
an	O
interactive	O
digital	O
game	O
versus	O
an	O
interactive	O
-	O
style	O
didactic	O
lecture	O
:	O
the	O
continued	O
importance	O
of	O
didactic	O
teaching	O
in	O
medical	O
student	O
education	O
Games	O
with	O
educational	O
intent	O
offer	O
a	O
possible	B-T033
advantage	O
of	O
being	O
more	O
interactive	O
and	O
increasing	O
learner	O
satisfaction	O
.	O
We	O
conducted	O
a	O
two	O
-	O
armed	O
experiment	O
to	O
evaluate	B-T058
student	O
satisfaction	O
and	O
content	O
mastery	O
for	O
an	O
introductory	O
pediatric	O
radiology	O
topic	O
,	O
taught	O
by	O
either	O
an	O
interactive	O
digital	O
game	O
or	O
with	O
a	O
traditional	O
didactic	O
lecture	O
.	O
Medical	O
students	O
participating	O
in	O
a	O
fourth	O
-	O
year	O
radiology	O
elective	O
were	O
invited	O
to	O
participate	O
.	O
Student	O
cohorts	O
were	O
alternatively	O
given	O
a	O
faculty	O
-	O
supervised	O
1h	O
session	O
playing	O
a	O
simple	O
interactive	O
digital	O
Tic	O
-	O
tac	O
-	O
toe	O
quiz	O
module	O
on	O
pediatric	B-T060
gastrointestinal	I-T060
radiology	I-T060
or	O
a	O
1h	O
didactic	O
introductory	O
lecture	O
on	O
the	O
same	O
topic	O
.	O
Survey	O
questions	O
assessed	O
the	O
learners	O
'	O
perceived	O
ability	O
to	O
recall	O
the	O
material	O
as	O
well	O
as	O
their	O
satisfaction	O
with	O
the	O
educational	O
experience	O
.	O
Results	O
of	O
an	O
end	O
-	O
of	O
-	O
rotation	O
exam	O
were	O
reviewed	O
to	O
evaluate	B-T058
a	O
quantitative	O
measure	O
of	O
learning	O
between	O
groups	O
.	O
Survey	O
responses	O
were	O
analyzed	O
with	O
a	O
chi	O
-	O
squared	O
test	O
.	O
Exam	O
results	O
for	O
both	O
groups	O
were	O
analyzed	O
with	O
a	O
paired	O
Student	O
's	O
t	O
-	O
test	O
.	O
Students	O
in	O
the	O
lecture	O
group	O
had	O
higher	O
test	O
scores	O
compared	O
to	O
students	O
in	O
the	O
game	O
group	O
(	O
4.0/5	O
versus	O
3.6/5	O
,	O
P	O
=	O
0.045	O
)	O
.	O
Students	O
in	O
the	O
lecture	O
group	O
reported	B-T058
greater	O
understanding	O
and	O
recall	O
of	O
the	O
material	O
than	O
students	O
in	O
the	O
game	O
group	O
(	O
P	O
<	O
0.001	O
and	O
P	O
=	O
0.004	O
,	O
respectively	O
)	O
.	O
Students	O
in	O
the	O
lecture	O
group	O
perceived	O
the	O
lecture	O
to	O
be	O
more	O
enjoyable	B-T033
and	O
a	O
better	O
use	O
of	O
their	O
time	O
compared	O
to	O
those	O
in	O
the	O
game	O
group	O
(	O
P	O
=	O
0.04	O
and	O
P	O
<	O
0.001	O
,	O
respectively	O
)	O
.	O
There	O
was	O
no	O
statistically	O
significant	O
difference	B-T033
between	O
the	O
lecture	O
and	O
game	O
group	O
in	O
ability	O
to	O
maintain	O
interest	O
(	O
P	O
=	O
0.187	O
)	O
.	O
In	O
comparison	O
to	O
pre	O
-	O
survey	O
results	O
,	O
there	O
was	O
a	O
statistically	O
significant	O
decrease	O
in	O
interest	O
for	O
further	O
digital	O
interactive	O
materials	O
reported	B-T058
by	O
students	O
in	O
the	O
game	O
group	O
(	O
P	O
=	O
0.146	O
)	O
.	O
Our	O
experience	O
supported	O
the	O
use	O
of	O
a	O
traditional	O
lecture	O
over	O
a	O
digital	O
game	O
module	O
.	O
While	O
these	O
results	O
might	O
be	O
affected	O
by	O
the	O
specific	O
lecture	O
and	O
digital	O
content	O
in	O
any	O
given	O
comparison	O
,	O
a	O
digital	O
module	O
is	O
not	O
always	O
the	O
superior	O
option	O
.	O
      
The	O
use	O
of	O
informativity	O
in	O
the	O
development	O
of	O
robust	O
viromics	O
-based	O
examinations	O
Metagenomics	O
-based	O
studies	O
have	O
provided	O
insight	O
into	O
many	O
of	O
the	O
complex	O
microbial	B-T001
communities	I-T001
responsible	O
for	O
maintaining	B-T058
life	I-T058
on	I-T058
this	I-T058
planet	I-T058
.	O
Sequencing	O
efforts	O
often	O
uncover	O
novel	O
genetic	O
content	O
;	O
this	O
is	O
most	O
evident	O
for	O
phage	B-T005
communities	I-T005
,	O
in	O
which	O
upwards	O
of	O
90	O
%	O
of	O
all	O
sequences	B-T059
exhibit	O
no	O
similarity	O
to	O
any	O
sequence	B-T059
in	O
current	O
data	O
repositories	O
.	O
For	O
the	O
small	O
fraction	O
that	O
can	O
be	O
identified	O
,	O
the	O
top	O
BLAST	O
hit	O
is	O
generally	O
posited	O
as	O
being	O
representative	O
of	O
a	O
viral	O
taxon	O
present	O
in	O
the	O
sample	O
of	O
origin	O
.	O
Homology	O
-based	O
classification	O
,	O
however	O
,	O
can	O
be	O
misleading	O
as	O
sequence	O
repositories	O
capture	O
but	O
a	O
small	O
fraction	O
of	O
phage	B-T005
diversity	I-T005
.	O
Furthermore	O
,	O
lateral	O
gene	O
transfer	O
is	O
pervasive	O
within	O
phage	B-T005
communities	I-T005
.	O
As	O
such	O
,	O
the	O
presence	O
of	O
a	O
particular	O
gene	O
may	O
not	O
be	O
indicative	O
of	O
the	O
presence	O
of	O
a	O
particular	B-T005
viral	I-T005
species	I-T005
.	O
Rather	O
,	O
it	O
is	O
just	O
that	O
:	O
an	O
indication	O
of	O
the	O
presence	O
of	O
a	O
specific	O
gene	O
.	O
To	O
circumvent	O
this	O
limitation	O
,	O
we	O
have	O
developed	O
a	O
new	O
method	O
for	O
the	O
analysis	B-T059
of	I-T059
viral	I-T059
metagenomic	I-T059
datasets	I-T059
.	O
BLAST	O
hits	O
are	O
weighted	O
,	O
integrating	O
the	O
sequence	O
identity	O
and	O
length	O
of	O
alignments	O
as	O
well	O
as	O
a	O
taxonomic	O
signal	O
,	O
such	O
that	O
each	O
gene	O
is	O
evaluated	O
with	O
respect	O
to	O
its	O
information	O
content	O
.	O
Through	O
this	O
quantifiable	O
metric	O
,	O
predictions	O
of	O
viral	B-T001
community	I-T001
structure	O
can	O
be	O
made	O
with	O
confidence	O
.	O
As	O
a	O
proof	O
-	O
of	O
-	O
concept	O
,	O
the	O
approach	O
presented	O
here	O
was	O
implemented	O
and	O
applied	O
to	O
seven	O
freshwater	O
viral	O
metagenomes	O
.	O
While	O
providing	O
a	O
robust	O
method	O
for	O
evaluating	O
viral	O
metagenomic	O
data	O
,	O
the	O
tool	O
is	O
versatile	O
and	O
can	O
easily	O
be	O
customized	O
to	O
investigations	B-T058
of	O
any	O
environment	O
or	O
biome	B-T001
.	O
      
Size	O
matters	O
to	O
function	O
:	O
Brain	O
volume	O
correlates	O
with	O
intrinsic	O
brain	O
activity	O
across	O
healthy	O
individuals	O
A	O
fundamental	O
issue	O
in	O
neuroscience	O
is	O
to	O
understand	O
the	O
structural	O
substrates	O
of	O
neural	O
activities	O
.	O
Intrinsic	O
brain	O
activity	O
has	O
been	O
increasingly	O
recognized	O
as	O
an	O
important	O
functional	O
activity	O
mode	O
and	O
is	O
tightly	O
linked	O
with	O
various	O
cognitive	O
functions	O
.	O
Structurally	O
,	O
cognitive	O
functions	O
have	O
also	O
shown	O
a	O
relation	O
with	O
brain	O
volume	O
/	O
size	O
.	O
Therefore	O
,	O
an	O
association	O
between	O
intrinsic	O
brain	O
activities	O
and	O
brain	O
volume	O
/	O
size	O
can	O
be	O
hypothesized	O
,	O
and	O
brain	O
volume	O
/	O
size	O
may	O
impact	O
intrinsic	O
brain	O
activity	O
in	O
human	O
brains	B-T023
.	O
The	O
present	O
study	O
aimed	O
to	O
explicitly	O
investigate	O
this	O
brain	B-T023
structure	I-T023
-	O
function	O
relationship	O
using	O
two	O
large	O
independent	O
cohorts	O
of	O
176	O
and	O
236	O
young	O
adults	O
.	O
Structural	O
-	O
MRI	B-T060
was	O
performed	O
to	O
estimate	O
the	O
brain	O
volume	O
,	O
and	O
resting	B-T060
-	I-T060
state	I-T060
functional	I-T060
-	I-T060
MRI	I-T060
was	O
applied	O
to	O
extract	O
the	O
amplitude	O
of	O
low	O
-	O
frequency	O
fluctuations	O
(	O
ALFF	O
)	O
,	O
an	O
imaging	O
measure	O
of	O
intrinsic	O
brain	O
activity	O
.	O
Intriguingly	O
,	O
our	O
results	O
revealed	O
a	O
robust	O
linear	O
correlation	O
between	O
whole	O
-	O
brain	O
size	O
and	O
ALFF	O
.	O
Moreover	O
,	O
specific	O
brain	B-T023
lobes	I-T023
/	O
regions	O
,	O
including	O
the	O
frontal	B-T023
lobe	I-T023
,	O
the	O
left	B-T023
middle	I-T023
frontal	I-T023
gyrus	I-T023
,	O
anterior	B-T023
cingulate	I-T023
gyrus	I-T023
,	O
Rolandic	B-T023
operculum	I-T023
,	O
and	O
insula	B-T023
,	O
also	O
showed	O
a	O
reliable	O
,	O
positive	B-T033
volume	O
-	O
ALFF	O
correlation	O
in	O
the	O
two	O
cohorts	O
.	O
These	O
findings	O
offer	O
direct	O
,	O
empirical	O
evidence	O
of	O
a	O
strong	O
association	O
between	O
brain	O
size	O
/	O
volume	O
and	O
intrinsic	O
brain	O
activity	O
,	O
as	O
well	O
as	O
provide	O
novel	O
insight	O
into	O
the	O
structural	O
substrates	O
of	O
the	O
intrinsic	O
brain	O
activity	O
of	O
the	O
human	O
brain	B-T023
.	O
      
Macular	O
Ganglion	O
Cell	O
-	O
Inner	B-T023
Plexiform	I-T023
Layer	I-T023
Thickness	O
Is	O
Associated	O
with	O
Clinical	O
Progression	O
in	O
Mild	B-T047
Cognitive	I-T047
Impairment	I-T047
and	O
Alzheimers	B-T047
Disease	I-T047
We	O
investigated	O
the	O
association	O
of	O
the	O
macular	O
ganglion	O
cell	O
-	O
inner	B-T023
plexiform	I-T023
layer	I-T023
(	O
GCIPL	B-T023
)	O
and	O
peripapillary	B-T023
retinal	I-T023
nerve	I-T023
fiber	I-T023
layer	I-T023
(	O
RNFL	B-T023
)	O
thicknesses	O
with	O
disease	O
progression	O
in	O
mild	B-T047
cognitive	I-T047
impairment	I-T047
(	O
MCI	B-T047
)	O
and	O
Alzheimer	B-T047
's	I-T047
disease	I-T047
(	O
AD	B-T047
)	O
.	O
We	O
recruited	O
42	O
patients	O
with	O
AD	B-T047
,	O
26	O
with	O
MCI	B-T047
,	O
and	O
66	O
normal	O
elderly	O
controls	O
.	O
The	O
thicknesses	O
of	O
the	O
RNFL	B-T023
and	O
GCIPL	B-T023
were	O
measured	O
via	O
spectral	O
-	O
domain	O
optic	O
coherent	O
tomography	O
in	O
all	O
participants	O
at	O
baseline	O
.	O
The	O
patients	O
with	O
MCI	B-T047
or	O
AD	B-T047
underwent	O
clinical	O
and	O
neuropsychological	B-T060
tests	I-T060
at	O
baseline	O
and	O
once	O
every	O
year	O
thereafter	O
for	O
2	O
years	O
.	O
The	O
Clinical	O
Dementia	O
Rating	O
scale	O
-	O
Sum	O
of	O
Boxes	O
(	O
CDR	O
-	O
SB	O
)	O
score	O
exhibited	O
significant	O
negative	B-T033
relationships	O
with	O
the	O
average	B-T023
GCIPL	I-T023
thickness	O
(	O
β	O
=	O
-0.15	O
,	O
p	O
<	O
0.05	O
)	O
and	O
the	O
GCIPL	B-T023
thickness	O
in	O
the	O
superotemporal	O
,	O
superonasal	O
,	O
and	O
inferonasal	O
sectors	O
.	O
The	O
composite	O
memory	O
score	O
exhibited	O
significant	O
positive	B-T033
associations	O
with	O
the	O
average	B-T023
GCIPL	I-T023
thickness	O
and	O
the	O
GCIPL	B-T023
thickness	O
in	O
the	O
superotemporal	O
,	O
inferonasal	O
,	O
and	O
inferotemporal	O
sectors	O
.	O
The	O
temporal	B-T023
RNFL	I-T023
thickness	O
,	O
the	O
average	O
and	O
minimum	O
GCIPL	B-T023
thicknesses	O
,	O
and	O
the	O
GCIPL	B-T023
thickness	O
in	O
the	O
inferonasal	O
,	O
inferior	O
,	O
and	O
inferotemporal	O
sectors	O
at	O
baseline	O
were	O
significantly	O
reduced	O
in	O
MCI	B-T047
patients	O
who	O
were	O
converted	O
to	O
AD	B-T047
compared	O
to	O
stable	O
MCI	B-T047
patients	O
.	O
The	O
change	O
of	O
CDR	O
-	O
SB	O
from	O
baseline	O
to	O
2	O
years	O
exhibited	O
significant	O
negative	B-T033
associations	O
with	O
the	O
average	O
(	O
β	O
=	O
-0.150	O
,	O
p	O
=	O
0.006	O
)	O
and	O
minimum	B-T023
GCIPL	I-T023
thicknesses	O
as	O
well	O
as	O
GCIPL	B-T023
thickness	O
in	O
the	O
superotemporal	O
,	O
superior	O
,	O
superonasal	O
,	O
and	O
inferonasal	O
sectors	O
at	O
baseline	O
.	O
Our	O
data	O
suggest	O
that	O
macular	O
GCIPL	B-T023
thickness	O
represents	O
a	O
promising	O
biomarker	O
for	O
monitoring	O
the	O
progression	O
of	O
MCI	B-T047
and	O
AD	B-T047
.	O
      
Expressional	O
divergence	O
of	O
insect	O
GOX	O
genes	O
:	O
From	O
specialist	O
to	O
generalist	O
glucose	O
oxidase	O
Insect	O
herbivores	O
often	O
secrete	O
glucose	O
oxidase	O
(	O
GOX	O
)	O
onto	O
plants	O
to	O
counteract	O
plant	O
defenses	O
and	O
potential	O
pathogens	B-T001
.	O
Whether	O
generalist	O
herbivores	O
always	O
have	O
significantly	O
higher	O
GOX	O
activities	O
than	O
their	O
specialist	O
counterparts	O
at	O
any	O
comparable	O
stage	O
or	O
conditions	O
and	O
how	O
this	O
is	O
realized	O
remain	O
unknown	O
.	O
To	O
address	O
these	O
two	O
general	O
questions	O
,	O
we	O
subjected	O
larvae	O
of	O
a	O
pair	O
of	O
sister	O
species	O
differed	O
mainly	O
in	O
host	O
range	O
,	O
the	O
generalist	O
Helicoverpa	O
armigera	O
and	O
its	O
specialist	O
counterpart	O
Helicoverpa	O
assulta	O
,	O
to	O
the	O
same	O
sets	O
of	O
stage	O
,	O
protein	O
to	O
digestible	O
carbohydrate	O
(	O
P	O
:	O
C	O
)	O
ratio	O
,	O
allelochemical	O
or	O
host	O
plant	O
treatments	O
for	O
simultaneous	O
analyses	O
of	O
GOX	O
transcripts	O
and	O
activities	O
in	O
their	O
labial	B-T023
glands	I-T023
.	O
GOX	O
activity	O
and	O
transcripts	O
are	O
upregulated	O
concurrently	O
with	O
food	O
ingestion	O
and	O
body	O
growth	O
,	O
downregulated	O
with	O
stopping	O
ingestion	O
and	O
wandering	O
for	O
pupation	O
in	O
both	O
species	O
.	O
The	O
three	O
tested	O
host	O
plants	O
upregulated	O
GOX	O
transcripts	O
,	O
and	O
to	O
a	O
lesser	O
extent	O
,	O
GOX	O
activity	O
in	O
both	O
species	O
.	O
There	O
were	O
significant	O
differences	O
in	O
both	O
GOX	O
transcripts	O
and	O
activity	O
elicited	O
by	O
allelochemicals	O
,	O
but	O
only	O
in	O
GOX	O
transcripts	O
by	O
P	O
:	O
C	O
ratios	O
in	O
both	O
species	O
.	O
GOX	O
activities	O
were	O
higher	O
in	O
H.	O
armigera	O
than	O
H.	O
assulta	O
in	O
all	O
the	O
comparable	O
treatments	O
,	O
but	O
GOX	O
transcripts	O
were	O
significantly	O
higher	O
either	O
in	O
generalists	O
or	O
in	O
specialists	O
,	O
depending	O
on	O
the	O
developmental	O
stages	O
,	O
host	O
plants	O
,	O
P	O
:	O
C	O
ratio	O
and	O
allelochemicals	O
they	O
encounter	O
.	O
These	O
data	O
indicate	O
that	O
the	O
greater	O
GOX	O
activity	O
in	O
generalist	O
herbivores	O
is	O
not	O
achieved	O
by	O
greater	O
transcription	O
rate	O
,	O
but	O
by	O
greater	O
transcript	O
stability	O
,	O
greater	O
translation	O
rate	O
,	O
better	O
enzyme	O
stability	O
and/or	O
their	O
combination	O
.	O
      
Proteomics	O
analysis	B-T059
of	O
the	O
endogenous	O
,	O
constitutive	O
,	O
leaf	O
SUMOylome	O
SUMOylation	O
is	O
a	O
post	O
-	O
translational	O
modification	O
which	O
regulates	O
a	O
number	O
of	O
critical	O
biological	O
processes	O
in	O
,	O
for	O
example	O
mammals	O
,	O
yeast	O
and	O
plants	O
.	O
In	O
order	O
to	O
fully	O
understand	O
the	O
functional	B-T033
effects	I-T033
of	O
SUMOylation	O
an	O
essential	O
first	O
step	O
is	O
the	O
identification	O
of	O
endogenous	O
targets	O
for	O
SUMOylation	O
.	O
Here	O
we	O
report	O
the	O
results	O
of	O
using	O
a	O
recently	O
developed	O
proteomic	O
approach	O
based	O
on	O
the	O
use	O
of	O
3D	O
gels	O
to	O
identify	O
the	O
endogenous	O
SUMO	O
targets	O
in	O
leaves	O
of	O
Solanum	O
tuberosum	O
.	O
By	O
using	O
3D	O
gels	O
we	O
avoid	O
the	O
problem	O
of	O
co	O
-	O
migration	O
of	O
proteins	O
,	O
which	O
is	O
a	O
major	O
limitation	O
of	O
2D	O
gels	O
,	O
and	O
we	O
enable	O
the	O
use	O
of	O
the	O
highly	O
sensitive	O
CyDye	O
DIGE	O
fluor	O
saturation	O
dyes	O
.	O
Using	O
this	O
new	O
method	O
we	O
have	O
identified	O
39	O
individual	O
proteins	O
as	O
probable	O
SUMO	O
targets	O
in	O
leaves	O
of	O
Solanum	O
tuberosum	O
.	O
The	O
advantages	O
of	O
this	O
method	B-T059
compared	O
with	O
other	O
approaches	O
are	O
discussed	O
,	O
and	O
possible	B-T033
future	O
developments	O
are	O
outlined	O
.	O
The	O
authors	O
have	O
no	O
conflicts	O
of	O
interest	O
to	O
declare	O
.	O
All	O
authors	O
have	O
approved	O
the	O
manuscript	O
and	O
agree	B-T033
with	O
submission	O
to	O
Journal	O
of	O
Proteomics	O
.	O
      
'	O
You	O
ca	O
n't	O
be	O
a	O
person	O
and	O
a	O
docto	O
r	O
'	O
:	O
the	O
work	O
-	O
life	O
balance	O
of	O
doctors	O
in	O
training	O
-a	O
qualitative	O
study	O
Investigate	O
the	O
work	O
-	O
life	O
balance	O
of	O
doctors	O
in	O
training	O
in	O
the	O
UK	O
from	O
the	O
perspectives	O
of	O
trainers	O
and	O
trainees	O
.	O
Qualitative	O
semistructured	O
focus	O
groups	O
and	O
interviews	O
with	O
trainees	O
and	O
trainers	O
.	O
Postgraduate	O
medical	O
training	O
in	O
London	O
,	O
Yorkshire	O
and	O
Humber	O
,	O
Kent	O
,	O
Surrey	O
and	O
Sussex	O
,	O
and	O
Wales	O
during	O
the	O
junior	O
doctor	O
contract	O
dispute	O
at	O
the	O
end	O
of	O
2015	O
.	O
Part	O
of	O
a	O
larger	O
General	O
Medical	O
Council	O
study	O
about	O
the	O
fairness	O
of	O
postgraduate	O
medical	O
training	O
.	O
96	O
trainees	O
and	O
41	O
trainers	O
.	O
Trainees	O
comprised	O
UK	O
graduates	O
and	O
International	O
Medical	O
Graduates	O
,	O
across	O
all	O
stages	O
of	O
training	O
in	O
6	O
specialties	O
(	O
General	O
Practice	O
,	O
Medicine	O
,	O
Obstetrics	O
and	O
Gynaecology	O
,	O
Psychiatry	O
,	O
Radiology	O
,	O
Surgery	O
)	O
and	O
Foundation	O
.	O
Postgraduate	O
training	O
was	O
characterised	O
by	O
work	O
-	O
life	O
imbalance	O
.	O
Long	O
hours	O
at	O
work	O
were	O
typically	O
supplemented	O
with	O
revision	O
and	O
completion	O
of	O
the	O
e	O
-	O
portfolio	O
.	O
Trainees	O
regularly	O
moved	O
workplaces	O
which	O
could	O
disrupt	O
their	O
personal	O
lives	O
and	O
sometimes	O
led	O
to	O
separation	O
from	O
friends	O
and	O
family	O
.	O
This	O
made	O
it	O
challenging	O
to	O
cope	O
with	O
personal	O
pressures	O
,	O
the	O
stresses	B-T048
of	O
which	O
could	O
then	O
impinge	O
on	O
learning	O
and	O
training	O
,	O
while	O
also	O
leaving	O
trainees	O
with	O
a	O
lack	O
of	O
social	O
support	O
outside	O
work	O
to	O
buffer	O
against	O
the	O
considerable	O
stresses	B-T048
of	O
training	O
.	O
Low	O
morale	B-T033
and	O
harm	B-T033
to	O
well	B-T033
-	I-T033
being	I-T033
resulted	O
in	O
some	O
trainees	O
feeling	O
dehumanised	O
.	O
Work	O
-	O
life	O
imbalance	O
was	O
particularly	O
severe	O
for	O
those	O
with	O
children	O
and	O
especially	O
women	O
who	O
faced	O
a	O
lack	O
of	O
less	O
-	O
than	O
-	O
full	O
-	O
time	O
positions	O
and	O
discriminatory	O
attitudes	O
.	O
Female	O
trainees	O
frequently	O
talked	O
about	O
having	O
to	O
choose	O
a	O
specialty	O
they	O
felt	O
was	O
more	O
conducive	O
to	O
a	O
work	O
-	O
life	O
balance	O
such	O
as	O
General	O
Practice	O
.	O
The	O
proposed	O
junior	O
doctor	O
contract	O
was	O
felt	O
to	O
exacerbate	B-T033
existing	O
problems	B-T033
.	O
A	O
lack	O
of	O
work	O
-	O
life	O
balance	O
in	O
postgraduate	O
medical	O
training	O
negatively	O
impacted	O
on	O
trainees	O
'	O
learning	O
and	O
well	B-T033
-	I-T033
being	I-T033
.	O
Women	O
with	O
children	O
were	O
particularly	O
affected	O
,	O
suggesting	O
this	O
group	O
would	O
benefit	O
the	O
greatest	O
from	O
changes	O
to	O
improve	B-T033
the	O
work	O
-	O
life	O
balance	O
of	O
trainees	O
.	O
      
Exploring	O
Consumer	O
and	O
Patient	O
Knowledge	O
,	O
Behavior	O
,	O
and	O
Attitude	O
Toward	O
Medicinal	B-T121
and	O
Lifestyle	O
Products	O
Purchased	O
From	O
the	O
Internet	O
:	O
A	O
Web	O
-	O
Based	O
Survey	O
In	O
recent	O
years	O
,	O
lifestyle	O
products	O
have	O
emerged	O
to	O
help	O
improve	B-T033
people	O
's	O
physical	O
and	O
mental	O
performance	O
.	O
The	O
Internet	O
plays	O
a	O
major	O
role	O
in	O
the	O
spread	O
of	O
these	O
products	O
.	O
However	O
,	O
the	O
literature	O
has	O
reported	O
issues	O
regarding	O
the	O
authenticity	O
of	O
medicines	B-T121
purchased	O
from	O
the	O
Internet	O
and	O
the	O
impact	O
of	O
counterfeit	O
medicines	O
on	O
public	O
health	O
.	O
Little	O
or	O
no	O
data	O
are	O
available	O
on	O
the	O
authenticity	O
of	O
lifestyle	O
products	O
and	O
actual	O
toxicity	O
associated	O
with	O
their	O
use	O
and	O
misuse	B-T033
.	O
Our	O
aim	O
was	O
to	O
investigate	O
consumer	O
and	O
patient	O
attitudes	O
toward	O
the	O
purchase	O
of	O
lifestyle	O
products	O
from	O
the	O
Internet	O
,	O
their	O
knowledge	O
of	O
product	O
authenticity	O
and	O
toxicity	O
,	O
and	O
their	O
experiences	O
with	O
counterfeit	O
lifestyle	O
products	O
.	O
A	O
Web	O
-	O
based	O
study	O
was	O
performed	O
between	O
May	O
2014	O
and	O
May	O
2015	O
.	O
Uniform	O
collection	O
of	O
data	O
was	O
performed	O
through	O
an	O
anonymous	O
online	O
questionnaire	O
.	O
Participants	O
were	O
invited	O
worldwide	O
via	O
email	O
,	O
social	O
media	O
,	O
or	O
personal	O
communication	O
to	O
complete	O
the	O
online	O
questionnaire	O
.	O
A	O
total	O
of	O
320	O
participants	O
completed	O
the	O
questionnaire	O
.	O
The	O
results	O
of	O
the	O
questionnaire	O
showed	O
that	O
208	O
(	O
65.0	O
%	O
)	O
participants	O
purchased	O
lifestyle	O
products	O
from	O
the	O
Internet	O
mainly	O
due	O
to	O
convenience	O
and	O
reduced	O
cost	O
.	O
More	O
than	O
half	O
(	O
55.6	O
%	O
,	O
178/320	O
)	O
of	O
participants	O
purchased	O
cosmetic	O
products	O
,	O
whereas	O
only	O
a	O
minority	O
purchased	O
medicinal	B-T121
products	I-T121
.	O
Yet	O
,	O
62.8	O
%	O
(	O
201/320	O
)	O
of	O
participants	O
were	O
aware	O
of	O
the	O
presence	B-T033
of	O
counterfeit	O
lifestyle	O
products	O
from	O
the	O
Internet	O
,	O
and	O
11.9	O
%	O
(	O
38/320	O
)	O
experienced	O
counterfeit	O
products	O
.	O
In	O
only	O
0.9	O
%	O
(	O
3/320	O
)	O
of	O
those	O
cases	O
were	O
counterfeit	O
lifestyle	O
products	O
reported	B-T058
to	O
authorities	O
.	O
Moreover	O
,	O
7.2	O
%	O
(	O
23/320	O
)	O
of	O
the	O
participants	O
experienced	O
adverse	O
effects	O
due	O
to	O
counterfeit	O
lifestyle	O
products	O
.	O
In	O
summary	O
,	O
patients	O
experienced	O
counterfeit	O
lifestyle	O
products	O
that	O
resulted	O
in	O
adverse	O
effects	O
on	O
their	O
health	O
.	O
Although	O
certain	O
adverse	O
effects	O
were	O
reported	B-T058
in	O
this	O
study	O
,	O
counterfeit	O
products	O
were	O
underreported	B-T058
to	O
authorities	O
.	O
Further	O
public	O
awareness	O
campaigns	O
and	O
patient	O
education	O
are	O
needed	O
.	O
      
Geographical	O
Factors	O
Associated	O
With	O
Health	B-T033
Disparities	I-T033
in	O
Prostate	B-T191
Cancer	I-T191
Treatment	B-T061
variation	O
in	O
prostate	B-T191
cancer	I-T191
is	O
common	O
,	O
and	O
it	O
is	O
driven	O
by	O
clinical	O
and	O
clinician	O
factors	O
,	O
patient	O
preferences	O
,	O
availability	O
of	O
resources	O
,	O
and	O
access	O
to	O
physicians	O
and	O
treating	O
facilities	O
.	O
Most	O
research	O
on	O
treatment	B-T061
disparities	O
in	O
men	O
with	O
prostate	B-T191
cancer	I-T191
has	O
focused	O
on	O
race	O
and	O
socioeconomic	O
factors	O
.	O
However	O
,	O
the	O
geography	O
of	O
disparities	O
-	O
capturing	O
racial	B-T033
and	O
socioeconomic	B-T033
differences	I-T033
based	O
on	O
where	O
patients	O
live	O
-	O
can	O
provide	O
insight	O
into	O
barriers	O
to	O
care	B-T058
and	O
help	O
identify	O
outlier	O
areas	O
in	O
which	O
access	O
to	O
care	B-T058
,	O
health	O
resources	O
,	O
or	O
both	O
are	O
more	O
pronounced	O
.	O
Research	O
regarding	O
treatment	B-T061
patterns	O
and	O
disparities	O
in	O
prostate	B-T191
cancer	I-T191
using	O
the	O
Geographical	O
Information	O
System	O
(	O
GIS	O
)	O
was	O
searched	O
.	O
Studies	O
were	O
limited	O
to	O
English	O
-	O
language	O
articles	O
and	O
research	O
focused	O
on	O
US	O
populations	O
.	O
A	O
total	O
of	O
43	O
articles	O
were	O
found	O
;	O
of	O
those	O
,	O
30	O
provided	O
information	O
about	O
or	O
used	O
spatial	O
or	O
geographical	O
analyses	O
to	O
assess	O
and	O
describe	O
differences	O
or	O
disparities	O
in	O
prostate	B-T191
cancer	I-T191
and	O
its	O
treatment	B-T061
.	O
Two	O
additional	O
GIS	O
resources	O
were	O
included	O
.	O
The	O
research	O
on	O
geographical	O
and	O
spatial	O
determinants	O
of	O
prostate	B-T191
cancer	I-T191
disparities	O
was	O
reviewed	O
.	O
We	O
also	O
examined	O
geographical	O
analyses	O
at	O
the	O
state	O
level	O
,	O
focusing	O
on	O
Florida	O
.	O
Overall	O
,	O
we	O
described	O
a	O
geographical	O
framework	O
to	O
disparities	O
that	O
affect	O
men	O
with	O
prostate	B-T191
cancer	I-T191
and	O
reviewed	O
existing	O
published	O
evidence	O
supporting	O
the	O
interplay	O
of	O
geographical	O
factors	O
and	O
disparities	O
in	O
prostate	B-T191
cancer	I-T191
.	O
Disparities	O
in	O
prostate	B-T191
cancer	I-T191
are	O
common	O
and	O
persistent	O
,	O
and	O
notable	O
differences	O
in	O
treatment	B-T061
are	O
observable	O
across	O
racial	O
and	O
socioeconomic	O
strata	O
.	O
Geographical	O
analysis	O
provides	O
additional	O
information	O
about	O
where	O
disparate	O
groups	O
live	O
and	O
also	O
helps	O
to	O
map	O
access	O
to	O
care	B-T058
.	O
This	O
information	O
can	O
be	O
used	O
by	O
public	O
health	O
officials	O
,	O
health	O
-	O
systems	O
administrators	O
,	O
clinicians	O
,	O
and	O
policymakers	O
to	O
better	O
understand	O
and	O
respond	O
to	O
geographical	O
barriers	O
that	O
contribute	O
to	O
disparities	O
in	O
care	O
.	O
      
Utility	O
and	O
applicability	O
of	O
the	O
"	O
Childhood	O
Obesity	O
Risk	O
Evaluation	O
"	O
(	O
CORE)-index	O
in	O
predicting	O
obesity	B-T047
in	O
childhood	O
and	O
adolescence	O
in	O
Greece	O
from	O
early	O
life	O
:	O
the	O
"	O
National	O
Action	O
Plan	O
for	O
Public	O
Health	O
"	O
Early	O
identification	B-T058
of	O
infants	O
being	O
at	O
high	B-T033
risk	I-T033
to	O
become	O
obese	B-T047
at	O
their	O
later	O
childhood	O
or	O
adolescence	O
can	O
be	O
of	O
vital	O
importance	O
in	O
any	O
obesity	B-T047
prevention	O
initiative	B-T033
.	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
examine	O
the	O
utility	O
and	O
applicability	O
of	O
the	O
"	O
Childhood	O
Obesity	O
Risk	O
Evaluation	O
(	O
CORE	O
)	O
"	O
index	O
as	O
a	O
screening	B-T058
tool	O
for	O
the	O
early	O
prediction	O
of	O
obesity	B-T047
in	O
childhood	O
and	O
adolescence	O
.	O
Anthropometric	O
,	O
socio	O
-	O
demographic	O
data	O
were	O
collected	O
cross	O
-	O
sectionally	O
and	O
retrospectively	O
from	O
a	O
representative	O
sample	O
of	O
5946	O
children	O
,	O
and	O
adolescents	O
and	O
were	O
combined	O
for	O
calculating	O
the	O
CORE	O
-	O
index	O
score	O
.	O
Logistic	O
regression	O
analyses	O
were	O
performed	O
to	O
examine	O
the	O
associations	O
of	O
the	O
CORE	O
-	O
index	O
score	O
with	O
obesity	B-T047
by	O
gender	O
and	O
age	O
group	O
,	O
and	O
cut	O
-	O
off	O
point	O
analysis	O
was	O
also	O
applied	O
to	O
identify	O
the	O
optimal	O
value	O
of	O
the	O
CORE	O
-	O
index	O
score	O
that	O
differentiates	O
obese	B-T047
from	O
non	O
-	O
obese	O
children	O
.	O
Mean	O
CORE	O
-	O
index	O
score	O
in	O
the	O
total	O
sample	O
was	O
3.06	O
(	O
sd	O
1.92	O
)	O
units	O
(	O
range	O
0	O
-	O
11	O
units	O
)	O
.	O
Each	O
unit	O
increase	O
in	O
the	O
CORE	O
-	O
index	O
score	O
was	O
found	O
to	O
be	O
associated	O
with	O
a	O
30	O
%	O
(	O
95	O
%	O
C.I.	O
1.24	O
-	O
1.36	O
)	O
increased	O
likelihood	O
for	O
obesity	B-T047
in	O
childhood	O
or	O
adolescence	O
,	O
while	O
the	O
optimal	O
cut	O
-	O
off	O
value	O
of	O
the	O
CORE	O
-	O
index	O
score	O
that	O
predicted	O
obesity	B-T047
with	O
the	O
highest	O
possible	O
sensitivity	O
and	O
specificity	O
was	O
found	O
to	O
be	O
3.5	O
.	O
The	O
present	O
study	O
supports	O
the	O
utility	O
and	O
applicability	O
of	O
the	O
CORE	O
-	O
index	O
as	O
a	O
screening	B-T058
tool	O
for	O
the	O
early	O
identification	B-T058
of	O
infants	O
that	O
are	O
potentially	O
at	O
a	O
higher	B-T033
risk	I-T033
for	O
becoming	O
obese	B-T047
at	O
their	O
childhood	O
and	O
adolescence	O
.	O
This	O
tool	O
could	O
be	O
routinely	O
used	O
by	O
health	O
professionals	O
to	O
identify	O
infants	O
at	O
high	B-T033
risk	I-T033
and	O
provide	O
appropriate	O
counselling	B-T058
to	O
their	O
parents	O
and	O
caregivers	O
so	O
as	O
to	O
maximize	O
the	O
effectiveness	O
of	O
early	O
obesity	B-T047
prevention	O
initiatives	B-T033
.	O
What	O
is	O
known	O
?	O
•	O
Childhood	O
obesity	B-T047
has	O
reached	O
epidemic	O
proportions	O
worldwide	O
.	O
•	O
Certain	O
perinatal	B-T033
and	O
socio	B-T033
-	I-T033
demographic	I-T033
indices	I-T033
that	O
were	O
previously	O
identified	O
as	O
correlates	O
of	O
childhood	O
obesity	B-T047
in	O
children	O
were	O
combined	O
to	O
develop	O
the	O
CORE	O
-	O
index	O
,	O
a	O
screening	B-T058
tool	O
that	O
estimates	O
obesity	B-T047
risk	O
in	O
9	O
-	O
13	O
year	O
-	O
old	O
children	O
.	O
What	O
is	O
new	O
?	O
•	O
The	O
utility	O
and	O
applicability	O
of	O
the	O
CORE	O
-	O
index	O
as	O
screening	B-T058
tool	O
can	O
be	O
extended	O
to	O
the	O
age	O
range	O
of	O
6	O
-	O
15	O
years	O
.	O
•	O
The	O
CORE	O
-	O
index	O
is	O
a	O
cost	O
-	O
effective	O
screening	B-T058
tool	O
that	O
can	O
assist	O
health	O
professionals	O
in	O
initiating	O
obesity	B-T047
preventive	O
measures	O
from	O
early	O
life	O
.	O
      
Internet	O
Gaming	O
Disorder	B-T048
Explains	O
Unique	O
Variance	O
in	O
Psychological	B-T048
Distress	I-T048
and	O
Disability	B-T033
After	O
Controlling	O
for	O
Comorbid	B-T033
Depression	B-T048
,	O
OCD	B-T048
,	O
ADHD	B-T048
,	O
and	O
Anxiety	B-T033
This	O
study	O
extends	O
knowledge	O
about	O
the	O
relationship	O
of	O
Internet	B-T048
Gaming	I-T048
Disorder	I-T048
(	O
IGD	B-T048
)	O
to	O
other	O
established	O
mental	B-T048
disorders	I-T048
by	O
exploring	O
comorbidities	O
with	O
anxiety	B-T033
,	O
depression	B-T048
,	O
Attention	B-T048
Deficit	I-T048
Hyperactivity	I-T048
Disorder	I-T048
(	O
ADHD	B-T048
)	O
,	O
and	O
obsessive	B-T048
compulsive	I-T048
disorder	I-T048
(	O
OCD	B-T048
)	O
,	O
and	O
assessing	B-T058
whether	O
IGD	B-T048
accounts	O
for	O
unique	O
variance	O
in	O
distress	B-T033
and	O
disability	B-T033
.	O
An	O
online	O
survey	O
was	O
completed	O
by	O
a	O
convenience	O
sample	O
that	O
engages	O
in	O
Internet	O
gaming	O
(	O
N	O
=	O
404	O
)	O
.	O
Participants	O
meeting	O
criteria	O
for	O
IGD	B-T048
based	O
on	O
the	O
Personal	O
Internet	O
Gaming	O
Disorder	O
Evaluation-9	O
(	O
PIE-9	O
)	O
reported	O
higher	O
comorbidity	O
with	O
depression	B-T048
,	O
OCD	B-T048
,	O
ADHD	B-T048
,	O
and	O
anxiety	B-T033
compared	O
with	O
those	O
who	O
did	O
not	O
meet	O
the	O
IGD	B-T048
criteria	O
.	O
IGD	B-T048
explained	O
a	O
small	O
proportion	O
of	O
unique	O
variance	O
in	O
distress	B-T033
(	O
1	O
%	O
)	O
and	O
disability	B-T033
(	O
3	O
%	O
)	O
.	O
IGD	B-T048
accounted	O
for	O
a	O
larger	O
proportion	O
of	O
unique	O
variance	O
in	O
disability	B-T033
than	O
anxiety	B-T033
and	O
ADHD	B-T048
,	O
and	O
a	O
similar	O
proportion	O
to	O
depression	B-T048
.	O
Replications	O
with	O
clinical	O
samples	O
using	O
longitudinal	O
designs	O
and	O
structured	O
diagnostic	O
interviews	O
are	O
required	O
.	O
      
THSD7A	O
expression	O
in	O
human	O
cancer	B-T191
We	O
recently	O
described	O
a	O
case	O
of	O
a	O
Thrombospondin	O
Type-1	O
Domain	O
containing	O
7A	O
(	O
THSD7A	O
)	O
associated	O
membranous	B-T047
nephropathy	I-T047
in	O
a	O
female	O
patient	O
who	O
was	O
synchronously	O
suffering	B-T184
from	O
a	O
THSD7A	O
-	O
positive	B-T033
malignancy	O
.	O
We	O
here	O
investigated	O
the	O
role	O
of	O
THSD7A	O
as	O
a	O
new	O
potential	O
tumor	O
antigen	O
by	O
evaluating	O
over	O
20	O
000	O
tissue	O
spots	O
in	O
more	O
than	O
70	O
different	O
tumor	B-T033
entities	I-T033
by	O
immunohistochemistry	B-T060
using	O
tissue	O
microarrays	O
.	O
THSD7A	O
expression	O
was	O
highly	O
variable	O
in	O
different	B-T191
neoplasias	I-T191
with	O
differing	O
staining	O
patterns	O
.	O
Both	O
gain	B-T033
and	I-T033
loss	I-T033
of	O
THSD7A	O
expression	O
compared	O
to	O
expression	O
status	O
in	O
non	O
-	O
tumor	O
tissue	O
were	O
linked	O
to	O
tumor	O
-	O
specific	O
markers	O
in	O
the	O
different	O
tumor	B-T033
entities	I-T033
and	O
were	O
of	O
prognostic	O
value	O
.	O
The	O
potential	O
role	O
of	O
THSD7A	O
in	O
tumor	B-T033
development	I-T033
and	O
therapy	B-T061
needs	O
further	O
investigation	O
.	O
      
Impaired	B-T033
mobility	I-T033
,	O
depressed	B-T033
mood	I-T033
,	O
cognitive	B-T048
impairment	I-T048
and	O
polypharmacy	B-T033
are	O
independently	O
associated	O
with	O
disability	B-T033
in	O
older	O
cancer	B-T191
outpatients	O
:	O
The	O
prospective	O
Physical	B-T033
Frailty	I-T033
in	O
Elderly	O
Cancer	O
patients	O
(	O
PF	B-T033
-	O
EC	O
)	O
cohort	O
study	O
To	O
assess	O
the	O
prevalence	O
of	O
disability	B-T033
and	O
the	O
oncologic	B-T033
factors	I-T033
associated	O
with	O
disability	B-T033
in	O
older	O
outpatients	O
with	O
cancer	B-T191
.	O
The	O
Physical	B-T033
Frailty	I-T033
in	O
Elderly	O
Cancer	O
patients	O
(	O
PF	B-T033
-	O
EC	O
)	O
study	O
(	O
France	O
)	O
is	O
a	O
prospective	O
bicentric	O
observational	O
cohort	O
study	O
.	O
Two	O
hundred	O
and	O
ninety	O
outpatients	O
with	O
cancer	B-T191
were	O
included	O
.	O
A	O
cross	O
-	O
sectional	O
analysis	O
of	O
oncologic	B-T033
factors	I-T033
and	O
geriatric	O
variables	O
associated	O
with	O
disability	B-T033
that	O
were	O
collected	O
using	O
a	O
comprehensive	O
geriatric	B-T058
assessment	I-T058
(	O
CGA	B-T058
)	O
was	O
conducted	O
.	O
Disability	B-T033
was	O
defined	O
as	O
impairment	O
in	O
activities	O
of	O
daily	O
living	O
(	O
ADL	O
)	O
and/or	O
instrumental	B-T033
activities	I-T033
of	I-T033
daily	I-T033
living	I-T033
(	B-T033
IADL	I-T033
)	O
,	O
simplified	O
to	O
four	O
items	O
.	O
Univariate	O
and	O
multivariate	O
logistic	O
models	O
of	O
disabled	O
patients	O
were	O
performed	O
.	O
The	O
three	O
final	O
multivariate	O
models	O
were	O
compared	O
using	O
the	O
area	O
under	O
the	O
receiver	O
operating	O
characteristic	O
curve	O
(	O
AUC	O
/	O
ROC	O
)	O
of	O
the	O
logistic	O
model	O
.	O
The	O
mean	O
age	O
was	O
80.6years	O
,	O
and	O
51	O
%	O
of	O
the	O
patients	O
were	O
women	O
with	O
various	O
types	O
of	O
cancer	B-T191
.	O
The	O
prevalence	O
of	O
disability	B-T033
was	O
67.6	O
%	O
.	O
No	O
oncologic	B-T033
factors	I-T033
(	O
cancer	O
site	O
,	O
cancer	B-T191
extension	I-T191
)	O
were	O
associated	O
with	O
disability	B-T033
.	O
Impaired	B-T033
mobility	I-T033
,	O
poor	B-T033
functional	I-T033
status	I-T033
,	O
depressive	B-T033
mood	I-T033
,	O
cognitive	B-T048
impairment	I-T048
and	O
polypharmacy	B-T033
were	O
independently	O
associated	O
with	O
disability	B-T033
(	O
P<0.05	O
)	O
.	O
The	O
AUC	O
/	O
ROC	O
of	O
the	O
final	O
models	O
was	O
similar	O
.	O
Disability	B-T033
was	O
highly	O
prevalent	O
in	O
older	O
cancer	B-T191
outpatients	O
before	O
cancer	B-T061
treatment	I-T061
but	O
was	O
not	O
associated	O
with	O
oncologic	B-T033
factors	I-T033
.	O
Impaired	B-T033
mobility	I-T033
,	O
depressed	B-T033
mood	I-T033
,	O
cognitive	B-T048
impairment	I-T048
and	O
polypharmacy	B-T033
were	O
the	O
geriatric	O
variables	O
significantly	O
and	O
independently	O
associated	O
with	O
disability	B-T033
.	O
Identifying	O
these	O
factors	O
prior	O
to	O
cancer	B-T061
treatment	I-T061
could	O
enable	O
the	O
implementation	O
of	O
corrective	O
actions	O
to	O
improve	O
patient	O
autonomy	O
before	O
treatment	B-T061
and	O
during	O
follow	B-T058
-	I-T058
up	I-T058
.	O
      
Blood	O
Collection	O
Tubes	O
and	O
Storage	O
Temperature	O
Should	O
Be	O
Evaluated	O
when	O
Using	O
the	O
Siemens	O
ADVIA	O
Centaur	O
XP	O
for	O
Measuring	B-T059
25	I-T059
-	I-T059
Hydroxyvitamin	I-T059
D	I-T059
A	O
significant	O
bias	O
was	O
found	O
when	O
using	O
the	O
Siemens	O
ADVIA	O
Centaur	O
XP	O
system	O
for	O
measurement	B-T059
of	I-T059
25	I-T059
-	I-T059
hydroxyvitamin	I-T059
D	I-T059
(	O
25OHD	O
)	O
with	O
VACUETTE	O
®	O
tubes	O
with	O
Serum	O
Clot	O
Activator	O
and	O
Gel	O
.	O
Here	O
,	O
we	O
examined	O
whether	O
other	O
commonly	O
used	O
tubes	O
or	O
temperatures	O
affected	O
25OHD	B-T059
results	I-T059
obtained	O
with	O
the	O
Siemens	O
ADVIA	O
Centaur	O
XP	O
system	O
.	O
Serum	O
was	O
collected	O
into	O
five	O
types	O
of	O
vacuum	O
blood	O
collection	O
tubes	O
from	O
three	O
manufacturers	O
,	O
and	O
25OHD	B-T059
was	I-T059
analyzed	I-T059
using	O
the	O
Siemens	O
ADVIA	O
Centaur	O
XP	O
system	O
and	O
liquid	B-T059
chromatography	I-T059
tandem	I-T059
mass	I-T059
spectrometry	I-T059
(	O
LC	B-T059
-	I-T059
MS	I-T059
/	I-T059
MS	I-T059
)	O
immediately	O
or	O
after	O
storage	O
at	O
4	O
°	O
C	O
or	O
-80	O
°	O
C	O
for	O
48	O
h.	O
Significantly	O
higher	O
25OHD	B-T059
values	I-T059
were	O
found	O
when	O
using	O
the	O
Siemens	O
ADVIA	O
Centaur	O
XP	O
system	O
with	O
VACUETTE	O
®	O
tubes	O
with	O
serum	O
clot	O
activator	O
and	O
gel	O
and	O
VACUETTE	O
®	O
tubes	O
with	O
clot	O
activator	O
but	O
no	O
gel	O
compared	O
with	O
VACUETTE	O
®	O
tubes	O
with	O
no	O
additives	O
.	O
The	O
25OHD	B-T059
values	I-T059
in	O
all	O
of	O
these	O
tubes	O
were	O
not	O
significantly	O
different	O
from	O
those	O
obtained	O
by	O
LC	B-T059
-	I-T059
MS	I-T059
/	I-T059
MS	I-T059
.	O
Moreover	O
,	O
after	O
storage	O
at	O
-80	O
°	O
C	O
for	O
48	O
h	O
,	O
the	O
values	O
obtained	O
in	O
IMPROVEVACUTER	O
®	O
tubes	O
with	O
serum	O
clot	O
activator	O
and	O
ge	O
l	O
significantly	O
increased	O
,	O
with	O
a	O
mean	O
bias	O
of	O
74.6	O
%	O
compared	O
with	O
the	O
values	O
before	O
storage	O
,	O
on	O
analysis	O
with	O
the	O
Siemens	O
ADVIA	O
Centaur	O
XP	O
system	O
.	O
VACUETTE	O
®	O
tubes	O
containing	O
additives	O
significantly	O
affect	O
the	O
accuracy	O
of	O
25OHD	B-T059
results	I-T059
obtained	O
using	O
the	O
Siemens	O
ADVIA	O
Centaur	O
XP	O
system	O
.	O
Additionally	O
,	O
the	O
composition	O
of	O
serum	O
collected	O
in	O
IMPROVEVACUTER	O
®	O
tubes	O
was	O
affected	O
by	O
freezing	O
,	O
resulting	O
in	O
different	O
measurements	O
when	O
using	O
the	O
Siemens	O
25OHD	O
assay	O
platform	O
.	O
      
Shout	O
louder	O
about	O
poor	O
pay	O
It	O
seems	O
increasingly	O
clear	O
to	O
me	O
that	O
the	O
NHS	B-T058
pay	O
campaign	O
is	O
not	O
making	O
waves	O
either	O
in	O
the	O
NHS	B-T058
or	O
with	O
the	O
public	O
.	O
      
Extra	O
carbohydrate	O
binding	O
module	O
contributes	O
to	O
the	O
processivity	O
and	O
catalytic	O
activity	O
of	O
a	O
non	O
-	O
modular	O
hydrolase	O
family	O
5	O
endoglucanase	O
from	O
Fomitiporia	O
mediterranea	O
MF3/22	O
FmEG	O
from	O
Fomitiporia	O
mediterranea	O
is	O
a	O
non	O
-	O
modular	O
endoglucanase	O
composed	O
of	O
a	O
24	B-T121
-	I-T121
amino	I-T121
acids	I-T121
extension	O
and	O
13	B-T121
-	I-T121
amino	I-T121
acids	I-T121
linker	O
-	O
like	O
peptide	O
at	O
the	O
N	O
-	O
terminus	O
and	O
a	O
312	B-T121
-	I-T121
amino	I-T121
acids	I-T121
GH5	O
catalytic	O
domain	O
(	O
CD	O
)	O
at	O
the	O
C	O
-	O
terminus	O
.	O
In	O
this	O
study	O
,	O
six	O
FmEG	O
derivatives	O
with	O
deletion	O
of	O
N	O
-	O
terminal	O
fragments	O
or	O
fusion	O
with	O
an	O
extra	O
family	O
1	O
carbohydrate	O
-	O
binding	O
module	O
(	O
CBM1	O
)	O
was	O
constructed	O
in	O
order	O
to	O
evaluate	O
the	O
contribution	O
of	O
CBM1	O
to	O
FmEG	O
processivity	O
and	O
catalytic	O
activity	O
.	O
FmEG	O
showed	O
a	O
weak	O
processivity	O
and	O
released	O
cellobiose	O
(	O
G2	O
)	O
and	O
cellotriose	O
(	O
G3	O
)	O
as	O
main	O
end	O
products	O
,	O
and	O
cellotriose	O
(	O
G4	O
)	O
as	O
minor	O
end	O
product	O
from	O
filter	O
paper	O
(	O
FP	O
)	O
,	O
but	O
more	O
amount	O
of	O
G4	O
was	O
released	O
from	O
regenerated	O
amorphous	O
cellulose	O
(	O
RAC	O
)	O
.	O
All	O
derivatives	O
had	O
similar	O
activity	O
on	O
carboxymethylcellulose	B-T121
(	O
CMC	B-T121
)	O
with	O
the	O
same	O
optimal	O
pH	O
(	O
7.0	O
)	O
and	O
temperature	O
(	O
50	O
°	O
C	O
)	O
.	O
However	O
,	O
fusing	O
an	O
extra	O
CBM1	O
to	O
FmEG	O
△	O
24	O
or	O
FmEG	O
△	O
37	O
with	O
flexible	O
peptide	O
significantly	O
improved	O
its	O
processivity	O
and	O
catalytic	O
activity	O
to	O
FP	O
and	O
RAC	O
.	O
Overall	O
,	O
1.79-	O
and	O
1.84	O
-	O
fold	O
increases	O
in	O
the	O
soluble	O
/insoluble	O
product	O
ratio	O
on	O
FP	O
,	O
and	O
1.38-	O
and	O
1.39	O
-	O
fold	O
increases	O
on	O
RAC	O
,	O
compared	O
to	O
FmEG	O
△	O
24	O
,	O
were	O
recorded	O
for	O
CBM1	O
-	O
FmEG	O
△	O
24	O
and	O
CBM1	O
-linker-	O
FmEG	O
△	O
24	O
,	O
respectively	O
.	O
Meanwhile	O
,	O
they	O
displayed	O
2.64-	O
and	O
2.67	B-T033
-	I-T033
fold	I-T033
more	I-T033
activity	I-T033
on	O
RAC	O
,	O
and	O
1.68-	O
and	O
1.77	O
-	O
fold	O
on	O
FP	O
,	O
respectively	O
.	O
Similar	O
improvement	O
was	O
also	O
obtained	O
for	O
CBM1	O
-linker-	O
FmEG	O
△	O
37	O
as	O
compared	O
with	O
FmEG	O
△	O
37	O
.	O
Interestingly	O
,	O
fusion	O
of	O
an	O
extra	O
CBM1	O
with	O
FmEG	O
also	O
caused	O
an	O
alteration	O
of	O
cleavage	O
pattern	O
on	O
insoluble	O
celluloses	O
.	O
Our	O
results	O
suggest	O
that	O
such	O
improvements	O
in	O
processivity	O
and	O
catalytic	O
activity	O
may	O
arise	O
from	O
CBM1	O
binding	O
affinity	O
.	O
The	O
N	B-T121
-	I-T121
terminal	I-T121
24-	I-T121
or	I-T121
37	I-T121
-	I-T121
amino	I-T121
acids	I-T121
may	O
serve	O
as	O
linker	O
for	O
sufficient	O
spatial	O
separation	O
of	O
the	O
two	O
domains	O
required	O
for	O
processivity	O
and	O
catalytic	O
activity	O
.	O
In	O
addition	O
,	O
deletion	O
of	O
the	O
N	B-T121
-	I-T121
terminal	I-T121
24-	I-T121
or	I-T121
37	I-T121
-	I-T121
amino	I-T121
acids	I-T121
led	O
to	O
significant	O
reduction	O
in	O
thermostability	O
but	O
not	O
the	O
enzymatic	O
activity	O
.	O
      
Intensive	O
social	O
cognitive	B-T061
treatment	I-T061
(	O
can	O
do	O
treatment	O
)	O
with	O
participation	O
of	O
support	O
partners	O
in	O
persons	O
with	O
relapsing	B-T047
remitting	I-T047
multiple	I-T047
sclerosis	I-T047
:	O
observation	B-T058
of	O
improved	B-T033
self	O
-	O
efficacy	O
,	O
quality	O
of	O
life	O
,	O
anxiety	B-T033
and	O
depression	B-T048
1	O
year	O
later	O
In	O
persons	O
with	O
multiple	B-T047
sclerosis	I-T047
(	O
MS	B-T047
)	O
self	O
-	O
efficacy	O
positively	B-T033
affects	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O
HRQoL	O
)	O
and	O
physical	O
activity	O
.	O
In	O
a	O
previous	O
study	O
we	O
observed	O
that	O
6	O
months	O
after	O
an	O
intensive	O
3-	O
day	O
social	O
cognitive	B-T061
treatment	I-T061
(	O
Can	O
Do	O
treatment	O
)	O
with	O
the	O
participation	O
of	O
support	O
partners	O
,	O
self	O
-	O
efficacy	O
and	O
HRQoL	O
had	O
improved	B-T033
in	O
persons	O
with	O
relapsing	B-T047
remitting	I-T047
MS	I-T047
(	O
RRMS	B-T047
)	O
.	O
Given	O
the	O
chronic	O
nature	O
of	O
the	O
disease	O
,	O
it	O
is	O
important	O
to	O
know	O
whether	O
these	O
beneficial	O
changes	O
may	O
last	O
.	O
Can	O
Do	O
treatment	O
was	O
given	O
to	O
60	O
persons	O
with	O
MS	B-T047
and	O
their	O
support	O
partners	O
.	O
At	O
baseline	O
and	O
12	O
months	O
after	O
treatment	B-T061
self	O
-	O
efficacy	O
control	O
,	O
self	O
-	O
efficacy	O
function	O
,	O
physical	O
and	O
mental	O
HRQoL	O
,	O
anxiety	B-T033
,	O
depression	B-T048
and	O
fatigue	B-T184
were	O
assessed	O
via	O
self	O
-	O
report	O
questionnaires	O
.	O
Differences	O
were	O
tested	O
via	O
a	O
paired	O
t	O
test	O
.	O
Of	O
the	O
57	O
persons	O
with	O
MS	B-T047
that	O
completed	O
the	O
baseline	O
assessment	O
and	O
the	O
3-	O
day	O
treatment	O
,	O
38	O
filled	O
in	O
the	O
12th	O
month	O
questionnaires	O
(	O
response	B-T033
rate	O
66.7	O
%	O
)	O
,	O
22	O
with	O
RRMS	B-T047
and	O
14	O
with	O
progressive	O
MS	B-T047
.	O
In	O
the	O
RR	B-T047
group	O
self	O
-	O
efficacy	O
control	O
had	O
increased	O
by	O
20.2	O
%	O
and	O
physical	O
HRQoL	O
by	O
15.0	O
%	O
,	O
and	O
depression	B-T048
and	O
anxiety	B-T033
had	O
decreased	O
by	O
29.8	O
and	O
25.9	O
%	O
,	O
respectively	O
(	O
all	O
P	O
<	O
0.05	O
)	O
;	O
the	O
changes	O
in	O
mental	O
HRQoL	O
(	O
+17	O
%	O
)	O
and	O
fatigue	B-T184
(	O
-20	O
%	O
)	O
failed	O
to	O
be	O
statistically	O
significant	O
(	O
P	O
=	O
0.087	O
,	O
P	O
=	O
0.080	O
,	O
respectively	O
)	O
.	O
In	O
the	O
progressive	O
group	O
no	O
changes	O
suggestive	O
of	O
improvement	O
were	O
seen	O
.	O
The	O
findings	O
suggest	O
that	O
a	O
3-	O
day	O
intensive	O
social	O
cognitive	B-T061
treatment	I-T061
(	O
Can	O
Do	O
treatment	O
)	O
with	O
the	O
participation	O
of	O
support	O
partners	O
may	O
have	O
long	O
lasting	O
beneficial	O
effects	O
on	O
the	O
self	O
-	O
efficacy	O
and	O
HRQoL	O
in	O
persons	O
with	O
RRMS	B-T047
;	O
and	O
that	O
improvements	O
in	O
anxiety	B-T033
and	O
depression	B-T048
,	O
not	O
seen	O
in	O
the	O
6-	O
month	O
study	O
,	O
may	O
yet	O
develop	O
at	O
12	O
months	O
.	O
      
Map	O
learning	O
and	O
working	O
memory	O
:	O
Multimodal	O
learning	O
strategies	O
The	O
current	O
research	O
investigated	O
whether	O
learning	O
spatial	O
information	O
from	O
a	O
map	O
involves	O
different	O
modalities	O
,	O
which	O
are	O
managed	O
by	O
discrete	O
components	O
in	O
working	O
memory	O
.	O
In	O
four	O
experiments	O
,	O
participants	O
studied	O
a	O
map	O
either	O
while	O
performing	O
a	O
simultaneous	O
interference	O
task	O
(	O
high	O
cognitive	O
load	O
)	O
or	O
without	O
interference	O
(	O
low	O
cognitive	O
load	O
)	O
.	O
The	O
modality	O
of	O
interference	O
varied	O
between	O
experiments	O
.	O
Experiment	O
1	O
used	O
a	O
tapping	O
task	O
(	O
visuospatial	O
)	O
,	O
Experiment	O
2	O
a	O
backwards	O
counting	O
task	O
(	O
verbal	O
)	O
,	O
Experiment	O
3	O
an	O
articulatory	B-T048
suppression	B-T059
task	I-T059
(	O
verbal	O
)	O
and	O
Experiment	O
4	O
an	O
n	O
-	O
back	O
task	O
(	O
central	O
executive	O
)	O
.	O
Spatial	B-T033
recall	I-T033
was	O
assessed	O
in	O
two	O
tests	O
,	O
directional	O
judgements	O
and	O
map	O
drawing	O
.	O
Cognitive	O
load	O
was	O
found	O
to	O
affect	O
spatial	B-T033
recall	I-T033
detrimentally	O
regardless	O
of	O
interference	O
modality	O
.	O
The	O
findings	O
suggest	O
that	O
when	O
learning	O
maps	O
people	O
use	O
a	O
multimodal	O
learning	O
strategy	O
,	O
utilising	O
resources	O
from	O
all	O
components	O
of	O
working	O
memory	O
.	O
      
Creative	O
approach	O
for	O
successful	O
aging	O
:	O
A	O
pilot	O
study	O
of	O
an	O
intergenerational	O
health	B-T058
promotion	I-T058
program	I-T058
To	O
develop	O
and	O
evaluate	B-T058
the	O
effectiveness	O
of	O
an	O
intergenerational	O
health	B-T058
promotion	I-T058
program	I-T058
.	O
This	O
was	O
an	O
action	O
research	O
project	O
.	O
A	O
total	O
of	O
34	O
participants	O
attended	O
the	O
12-	O
week	O
program	B-T058
and	O
completed	O
the	O
pre	O
-	O
test	O
and	O
post	O
-	O
test	O
.	O
There	O
were	O
16	O
middle	O
-	O
aged	O
and	O
nine	O
older	O
adults	O
recruited	O
from	O
a	O
district	O
of	O
Taipei	O
,	O
and	O
nine	O
young	O
adults	O
recruited	O
from	O
the	O
principal	O
investigator	O
's	O
university	O
.	O
The	O
"	O
Attitudes	O
toward	O
Aging	O
Scale	O
"	O
and	O
the	O
"	O
Spiritual	O
Health	O
Scale	O
"	O
were	O
two	O
assessment	B-T058
instruments	O
used	O
in	O
the	O
study	O
.	O
The	O
results	B-T033
showed	O
that	O
there	O
were	O
significant	O
improvements	O
in	O
the	O
Attitudes	O
toward	O
Aging	O
Scale	O
for	O
the	O
young	O
adult	O
group	O
(	O
aged	O
18	O
-	O
29	O
years	O
)	O
and	O
in	O
the	O
Spiritual	O
Health	O
Scale	O
for	O
the	O
older	O
adult	O
group	O
(	O
aged	O
65	O
-	O
80	O
years	O
)	O
.	O
The	O
evaluation	B-T058
showed	O
that	O
participants	O
were	O
satisfied	O
with	O
the	O
program	B-T058
.	O
The	O
results	B-T033
of	O
the	O
present	O
study	O
provide	O
future	O
directions	O
for	O
successful	O
aging	O
and	O
intergenerational	O
learning	O
.	O
Geriatr	O
Gerontol	O
Int	O
2017	O
;	O
••	O
:	O
••-••.	O
      
Adoptively	O
transferred	O
natural	O
killer	O
cells	O
maintain	O
long	O
-	O
term	O
antitumor	B-T033
activity	I-T033
by	O
epigenetic	O
imprinting	O
and	O
CD4(+	O
)	O
T	O
cell	O
help	O
Natural	O
killer	O
(	O
NK	O
)	O
cell	O
infusions	B-T061
can	O
induce	O
remissions	O
in	O
subsets	O
of	O
patients	O
with	O
different	O
types	O
of	O
cancer	B-T191
.	O
The	O
optimal	O
strategies	O
for	O
NK	O
cell	O
activation	O
prior	O
to	O
infusion	B-T061
are	O
still	O
under	O
debate	O
.	O
There	O
is	O
recent	O
evidence	O
that	O
NK	O
cells	O
can	O
acquire	O
long	O
-	O
term	O
functional	O
competence	O
by	O
preactivation	O
with	O
the	O
cytokines	O
IL-12	B-T121
/	O
15	O
/	O
18	O
.	O
The	O
mechanisms	O
supporting	O
the	O
maintenance	O
of	O
long	O
-	O
term	O
NK	O
cell	O
antitumor	B-T033
activity	I-T033
are	O
incompletely	O
under	O
-	O
stood	O
.	O
Here	O
,	O
we	O
show	O
that	O
NK	O
cells	O
preactivated	O
in	B-T059
vitro	I-T059
with	O
IL-12	B-T121
/	O
15	O
/	O
18	O
,	O
but	O
not	O
with	O
IL-15	O
alone	O
,	O
maintained	O
high	O
antitumor	B-T033
activity	I-T033
even	O
1	O
mo	O
after	O
transfer	O
into	O
lymphopenic	B-T047
RAG-2(-/-	O
)	O
γc(-/-	O
)	O
mice	O
.	O
The	O
NK	O
cell	O
intrinsic	O
ability	O
for	O
IFNγ	B-T121
production	O
coincided	O
with	O
demethylation	O
of	O
the	O
conserved	O
non	O
-	O
coding	O
sequence	O
(	O
CNS	O
)	O
1	O
in	O
the	O
Ifng	O
locus	O
,	O
previously	O
shown	O
to	O
enhance	O
transcription	O
of	O
Ifng	O
.	O
In	O
a	O
xenograft	B-T050
melanoma	I-T050
mouse	I-T050
model	I-T050
,	O
human	O
IL-12	B-T121
/	O
15	O
/	O
18	O
-preactivated	O
NK	O
cells	O
rejected	O
tumors	B-T191
more	O
efficiently	O
.	O
In	O
RAG-2(-/-	O
)	O
γc(-/-	O
)	O
mice	O
,	O
co	O
-	O
transfer	O
of	O
CD4(+	O
)	O
T	O
cells	O
further	O
improved	O
the	O
long	O
-	O
term	O
competence	O
of	O
NK	O
cells	O
for	O
IFNγ	B-T121
production	O
that	O
was	O
dependent	O
on	O
IL-2	O
.	O
CD4(+	O
)	O
T	O
cell	O
activation	O
during	O
homeostatic	O
proliferation	O
required	O
macrophages	O
and	O
further	O
promoted	O
the	O
long	O
-	O
term	O
NK	O
cell	O
antitumor	B-T033
activity	I-T033
.	O
Thus	O
,	O
NK	O
cells	O
can	O
"	O
remember	O
"	O
a	O
previous	O
exposure	O
to	O
cytokines	O
by	O
epigenetic	O
imprinting	O
resulting	O
in	O
a	O
remarkable	O
stability	O
of	O
the	O
IFNγ	B-T121
-producing	O
phenotype	O
after	O
adoptive	O
transfer	O
.	O
In	O
addition	O
,	O
our	O
results	O
support	O
combination	O
of	O
cytokine	O
-preactivated	O
NK	O
cells	O
with	O
CD4(+	O
)	O
T	O
cell	O
activation	O
upon	O
lymphopenic	B-T047
conditioning	O
to	O
achieve	O
long	O
-	O
term	O
NK	O
cell	O
effector	O
function	O
for	O
cancer	B-T061
immunotherapy	I-T061
.	O
      
Multicentric	B-T191
Castleman	I-T191
disease	I-T191
of	O
hyaline	O
vascular	B-T023
variant	O
presenting	O
with	O
unusual	O
systemic	O
manifestations	O
:	O
a	O
case	O
report	O
Castleman	B-T191
disease	I-T191
is	O
a	O
rare	O
lymphoproliferative	B-T191
disorder	I-T191
presenting	O
with	O
localized	O
or	O
disseminated	O
lymphadenopathy	B-T047
and	O
systemic	O
manifestations	O
.	O
It	O
can	O
be	O
categorized	O
in	O
numerous	O
ways	O
,	O
such	O
as	O
unicentric	B-T047
versus	O
multicentric	B-T191
,	O
histopathological	O
variants	O
(	O
hyaline	O
-	O
vascular	B-T023
,	O
plasma	O
cell	O
,	O
and	O
mixed	O
)	O
,	O
or	O
subtypes	O
based	O
on	O
causative	B-T033
viral	B-T047
infections	I-T047
(	O
human	B-T005
immunodeficiency	I-T005
virus	I-T005
,	O
human	B-T005
herpesvirus-8	I-T005
,	O
or	O
Kaposi	B-T005
sarcoma	I-T005
herpesvirus	I-T005
)	O
.	O
Presentation	O
ranges	O
from	O
asymptomatic	B-T033
to	O
symptoms	B-T184
involving	O
multiple	O
organs	B-T023
.	O
Even	O
though	O
the	O
exact	O
mechanism	O
of	O
pathogenesis	O
is	O
unknown	O
,	O
treatment	O
is	O
directed	O
toward	O
possible	O
etiologies	O
such	O
as	O
interleukin-6	O
,	O
cluster	O
of	O
differentiation	O
20	O
,	O
and	O
viral	O
agents	O
.	O
A	O
36-	O
year	O
-old	O
Sri	O
Lankan	O
woman	O
presented	O
with	O
generalized	O
body	B-T184
swelling	I-T184
and	O
foamy	B-T184
urine	I-T184
of	O
2	O
weeks	O
'	O
duration	O
.	O
Examination	B-T058
revealed	O
pallor	B-T033
;	O
generalized	B-T033
edema	I-T033
;	O
axillary	O
,	O
cervical	O
,	O
and	O
inguinal	B-T047
lymphadenopathy	I-T047
;	O
hypertension	B-T047
;	O
and	O
hepatomegaly	B-T033
.	O
Investigations	B-T058
showed	O
bicytopenia	O
,	O
nephrotic	B-T033
range	I-T033
proteinuria	I-T033
with	O
hypoalbuminemia	B-T047
,	O
hypogammaglobulinemia	B-T047
,	O
and	O
features	O
of	O
hyaline	O
-	O
vascular	B-T023
type	O
Castleman	B-T191
disease	I-T191
in	O
a	O
lymph	B-T060
node	I-T060
biopsy	I-T060
.	O
She	O
was	O
managed	B-T058
with	O
rituximab	B-T121
and	O
had	O
good	O
clinical	O
improvement	O
.	O
Castleman	B-T191
disease	I-T191
has	O
a	O
broad	O
spectrum	O
of	O
clinical	O
manifestations	O
,	O
disease	B-T047
pathogeneses	O
,	O
and	O
associations	O
and/or	O
complications	O
.	O
Medical	O
professionals	O
need	O
to	O
be	O
familiar	O
with	O
this	O
spectrum	O
because	O
timely	O
diagnosis	B-T033
and	O
aggressive	B-T061
targeted	I-T061
therapy	I-T061
are	O
the	O
cornerstones	O
of	O
managing	O
these	O
patients	O
.	O
      
Dynamin	O
-	O
related	O
protein	O
1	O
mediates	O
low	B-T121
glucose	I-T121
-	O
induced	O
endothelial	B-T047
dysfunction	I-T047
in	O
human	O
arterioles	B-T023
Intensive	O
glycemic	O
regulation	O
has	O
resulted	O
in	O
an	O
increased	O
incidence	O
of	O
hypoglycemia	B-T047
.	O
Hypoglycemic	B-T047
burden	O
correlates	O
with	O
adverse	O
cardiovascular	O
complications	O
and	O
contributes	O
acutely	O
and	O
chronically	O
to	O
endothelial	B-T047
dysfunction	I-T047
.	O
Prior	O
data	O
indicate	O
that	O
mitochondrial	B-T033
dysfunction	I-T033
contributes	O
to	O
hypoglycemia	B-T047
-	O
induced	O
endothelial	B-T047
dysfunction	I-T047
,	O
but	O
the	O
mechanisms	O
behind	O
this	O
linkage	O
remain	O
unknown	O
.	O
We	O
attempt	O
to	O
determine	O
whether	O
clinically	O
relevant	O
low	B-T121
-	I-T121
glucose	I-T121
(	O
LG	B-T121
)	O
exposures	O
acutely	O
induce	O
endothelial	B-T047
dysfunction	I-T047
through	O
activation	O
of	O
the	O
mitochondrial	O
fission	O
process	O
.	O
Characterization	O
of	O
mitochondrial	B-T033
morphology	I-T033
was	O
carried	O
out	O
in	O
cultured	O
endothelial	O
cells	O
by	O
using	O
confocal	B-T059
microscopy	I-T059
.	O
Isolated	O
human	O
arterioles	B-T023
were	O
used	O
to	O
explore	O
the	O
effect	O
LG	B-T121
-	O
induced	O
mitochondrial	O
fission	O
has	O
on	O
the	O
formation	O
of	O
detrimental	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
,	O
bioavailability	O
of	O
nitric	B-T121
oxide	I-T121
(	O
NO	B-T121
)	O
,	O
and	O
endothelial	O
-	O
dependent	O
vascular	O
relaxation	O
.	O
Fluorescence	B-T059
microscopy	I-T059
was	O
employed	O
to	O
visualize	O
changes	O
in	O
mitochondrial	O
ROS	O
and	O
NO	B-T121
levels	O
and	O
videomicroscopy	B-T059
applied	O
to	O
measure	O
vasodilation	O
response	O
.	O
Pharmacological	O
disruption	O
of	O
the	O
profission	O
protein	O
Drp1	O
with	O
Mdivi-1	O
during	O
LG	B-T121
exposure	O
reduced	O
mitochondrial	O
fragmentation	O
among	O
vascular	O
endothelial	O
cells	O
(	O
LG	B-T121
:	O
0.469	O
;	O
LG	B-T121
+	O
Mdivi-1	O
:	O
0.276	O
;	O
P	O
=	O
0.003	O
)	O
,	O
prevented	O
formation	O
of	O
vascular	B-T023
ROS	O
(	O
LG	B-T121
:	O
2.036	O
;	O
LG	B-T121
+	O
Mdivi-1	O
:	O
1.774	O
;	O
P	O
=	O
0.005	O
)	O
,	O
increased	O
the	O
presence	B-T033
of	O
NO	B-T121
(	O
LG	B-T121
:	O
1.352	O
;	O
LG	B-T121
+	O
Mdivi-1	O
:	O
1.502	O
;	O
P	O
=	O
0.048	O
)	O
,	O
and	O
improved	B-T033
vascular	O
dilation	O
response	O
to	O
acetylcholine	B-T121
(	O
LG	B-T121
:	O
31.6	O
%	O
;	O
LG	B-T121
+	O
Mdivi-1	O
;	O
78.5	O
%	O
at	O
maximum	O
dose	O
;	O
P	O
<	O
0.001	O
)	O
.	O
Additionally	O
,	O
decreased	O
expression	O
of	O
Drp1	O
via	O
siRNA	O
knockdown	O
during	O
LG	B-T121
conditions	O
also	O
improved	B-T033
vascular	O
relaxation	O
.	O
Exposure	O
to	O
LG	B-T121
imparts	O
endothelial	B-T047
dysfunction	I-T047
coupled	O
with	O
altered	O
mitochondrial	O
phenotypes	O
among	O
isolated	O
human	O
arterioles	B-T023
.	O
Disruption	O
of	O
Drp1	O
and	O
subsequent	O
mitochondrial	O
fragmentation	O
events	O
prevents	O
impaired	O
vascular	O
dilation	O
,	O
restores	O
mitochondrial	O
phenotype	O
,	O
and	O
implicates	O
mitochondrial	O
fission	O
as	O
a	O
primary	O
mediator	O
of	O
LG	B-T121
-	O
induced	O
endothelial	B-T047
dysfunction	I-T047
.NEW	O
&	O
NOTEWORTHY	O
Acute	O
low	B-T121
-	I-T121
glucose	I-T121
exposure	O
induces	O
mitochondrial	O
fragmentation	O
in	O
endothelial	O
cells	O
via	O
Drp1	O
and	O
is	O
associated	O
with	O
impaired	O
endothelial	O
function	O
in	O
human	O
arterioles	B-T023
.	O
Targeting	O
of	O
Drp1	O
prevents	O
fragmentation	O
,	O
improves	O
vasofunction	O
,	O
and	O
may	O
provide	O
a	O
therapeutic	O
target	O
for	O
improving	O
cardiovascular	O
complications	O
among	O
diabetics	B-T033
.Listen	O
to	O
this	O
article	O
's	O
corresponding	O
podcast	O
@	O
http://ajpheart.podbean.com/e/mitochondrial-dynamics-impact-endothelial-function/.	O
      
Modifiable	O
Healthy	O
Lifestyle	O
Behaviors	O
:	O
10	O
-	O
Year	O
Health	O
Outcomes	O
From	O
a	O
Health	B-T058
Promotion	I-T058
Program	I-T058
Previous	O
studies	O
have	O
examined	O
the	O
impact	O
of	O
healthy	O
lifestyle	O
choices	O
on	O
health	O
-	O
related	O
outcomes	O
;	O
however	O
,	O
given	O
their	O
fragmented	O
,	O
often	O
cross	O
-	O
sectional	O
nature	O
,	O
assessing	B-T058
the	I-T058
relative	I-T058
impact	I-T058
of	O
daily	O
modifiable	O
behaviors	O
on	O
overall	O
long	O
-	O
term	O
outcomes	O
,	O
particularly	O
for	O
a	O
diverse	O
working	O
adult	O
population	O
,	O
remains	O
challenging	O
.	O
Relationships	O
between	O
ten	O
self	O
-	O
reported	O
healthy	O
lifestyle	O
behaviors	O
and	O
health	O
outcomes	O
during	O
the	O
subsequent	O
9	O
years	O
in	O
a	O
cohort	O
of	O
10,248	O
participants	O
enrolled	O
during	O
2003	O
in	O
a	O
voluntary	O
workplace	O
wellness	B-T058
program	I-T058
were	O
assessed	O
.	O
Cox	O
proportional	O
-	O
hazards	O
models	O
computed	O
hazard	O
ratios	O
(	O
HRs	O
)	O
for	O
lifestyle	O
characteristics	O
associated	O
with	O
time	O
to	O
one	O
of	O
seven	O
self	O
-	O
reported	O
chronic	B-T047
diseases	I-T047
or	O
death	O
.	O
Data	B-T033
were	I-T033
collected	I-T033
between	O
2003	O
and	O
2012	O
and	O
analyzed	O
between	O
2014	O
and	O
2016	O
.	O
Behaviors	O
that	O
most	O
significantly	O
affected	O
future	O
outcomes	O
were	O
low	B-T061
-	I-T061
fat	I-T061
diet	I-T061
,	O
aerobic	B-T061
exercise	I-T061
,	O
nonsmoking	B-T058
,	O
and	O
adequate	B-T033
sleep	I-T033
.	O
A	O
dose	O
-	O
response	O
effect	O
was	O
seen	O
between	O
dietary	B-T033
fat	I-T033
intake	I-T033
and	O
hypertension	B-T047
,	O
obesity	B-T047
,	O
diabetes	B-T047
,	O
heart	B-T047
disease	I-T047
,	O
and	O
hypercholesterolemia	B-T047
.	O
After	O
dietary	B-T033
fat	I-T033
intake	I-T033
,	O
aerobic	B-T061
exercise	I-T061
was	O
the	O
next	O
most	O
significant	O
behavior	O
associated	O
with	O
development	O
of	O
outcomes	O
.	O
Compared	O
with	O
sedentary	O
participants	O
,	O
those	O
who	O
exercised	O
4	O
days	O
per	O
week	O
were	O
less	O
likely	O
to	O
develop	O
new	O
-	O
onset	O
diabetes	O
(	O
HR	O
=	O
0.31	O
,	O
95	O
%	O
CI	O
=	O
0.20	O
,	O
0.48	O
)	O
;	O
heart	B-T047
disease	I-T047
(	O
HR	O
=	O
0.46	O
,	O
95	O
%	O
CI	O
=	O
0.27	O
,	O
0.80	O
)	O
;	O
and	O
hypercholesterolemia	B-T047
(	O
HR	O
=	O
0.61	O
,	O
95	O
%	O
CI	O
=	O
0.50	O
,	O
0.74	O
)	O
.	O
Low	B-T061
-	I-T061
fat	I-T061
diet	I-T061
and	O
adequate	B-T033
sleep	I-T033
were	O
more	O
significant	O
than	O
commonly	O
promoted	O
healthy	O
behaviors	O
,	O
such	O
as	O
eating	O
a	O
daily	O
breakfast	O
.	O
Modifiable	O
lifestyle	O
behaviors	O
targeted	O
in	O
health	B-T058
promotion	I-T058
programs	I-T058
should	O
be	O
prioritized	O
in	O
an	O
evidence	O
-	O
based	O
manner	O
.	O
Top	O
priorities	O
for	O
workplace	O
health	B-T058
promotion	I-T058
should	O
include	O
low	B-T061
-	I-T061
fat	I-T061
diet	I-T061
,	O
aerobic	B-T061
exercise	I-T061
,	O
nonsmoking	B-T058
,	O
and	O
adequate	B-T033
sleep	I-T033
.	O
      
Antenatal	O
consultation	B-T058
following	O
limb	B-T019
malformation	I-T019
discovery	O
using	O
ultrasound	B-T060
scan	I-T060
Our	O
unit	O
has	O
been	O
providing	O
antenatal	O
consultations	B-T058
for	O
30	O
years	O
following	O
the	O
discovery	O
of	O
limb	B-T019
malformation	I-T019
with	O
the	O
fetus	B-T018
.	O
Each	O
of	O
these	O
consultations	B-T058
is	O
specific	O
and	O
carried	B-T058
out	I-T058
by	O
a	O
multi	B-T058
-	I-T058
professional	I-T058
team	I-T058
.	O
It	O
requires	O
a	O
physical	O
and	O
rehabilitation	O
doctor	O
,	O
an	O
orthopedic	O
surgeon	O
,	O
an	O
occupational	O
therapist	O
for	O
upper	B-T019
limb	I-T019
malformation	I-T019
,	O
a	O
physiotherapist	O
for	O
lower	B-T019
malformation	I-T019
and	O
a	O
psychologist	O
.	O
This	O
multidisciplinary	O
consultation	B-T058
is	O
unique	O
because	O
of	O
each	O
pregnancy	O
story	O
,	O
because	O
of	O
each	O
patient	O
life	O
story	O
but	O
also	O
because	O
of	O
the	O
words	O
used	O
by	O
the	O
sonologist	O
when	O
announcing	O
the	O
diagnosis	B-T033
.	O
We	O
deal	O
with	O
couples	O
shocked	B-T033
by	O
the	O
prenatal	B-T060
diagnosis	I-T060
.	O
We	O
help	O
them	O
get	O
acceptance	O
of	O
the	O
child	O
to	O
be	O
born	O
and	O
to	O
forget	O
about	O
their	O
imaginary	O
child	O
.	O
Medical	B-T058
information	I-T058
is	O
often	O
perceived	O
as	O
being	O
"	O
a	O
surfeit	O
of	O
information	O
"	O
difficult	O
to	O
handle	O
by	O
the	O
couple	O
stunned	B-T033
by	O
the	O
overwhelming	O
diagnosis	B-T033
.	O
We	O
must	O
stress	O
that	O
it	O
is	O
critical	O
to	O
not	O
only	O
have	O
a	O
good	O
medical	B-T033
description	I-T033
of	O
the	O
malformations	B-T019
and	O
potential	B-T061
treatments	I-T061
but	O
also	O
a	O
good	O
psychological	B-T058
support	I-T058
(	O
parents	O
personal	O
life	O
story	O
,	O
self	O
-	O
defense	O
mechanism	O
,	O
guilt	O
feeling	O
)	O
.	O
The	O
ethical	O
aspect	O
of	O
this	O
consultation	B-T058
is	O
also	O
important	O
.	O
Team	B-T058
members	O
must	O
be	O
as	O
neutral	O
as	O
possible	B-T033
in	O
their	O
assessments	B-T058
in	O
order	O
to	O
let	O
the	O
couple	O
take	O
the	O
final	O
decision	O
:	O
the	O
continuation	B-T033
of	O
the	O
pregnancy	O
or	O
a	O
request	O
of	O
voluntary	O
termination	B-T061
of	I-T061
pregnancy	I-T061
.	O
These	O
prenatal	O
consultations	B-T058
highlight	O
the	O
importance	O
of	O
the	O
multidisciplinary	O
global	O
care	B-T058
.	O
      
The	O
cost	O
-	O
effectiveness	O
of	O
family	O
/	O
family	B-T061
-	I-T061
based	I-T061
therapy	I-T061
for	O
treatment	O
of	O
externalizing	B-T048
disorders	I-T048
,	O
substance	B-T048
use	I-T048
disorders	I-T048
and	O
delinquency	B-T048
:	O
a	O
systematic	O
review	O
Family	B-T061
therapy	I-T061
and	O
family	O
-	O
based	O
treatment	O
has	O
been	O
commonly	O
applied	O
in	O
children	O
and	O
adolescents	O
in	O
mental	B-T061
health	I-T061
care	I-T061
and	O
has	O
been	O
proven	O
to	O
be	O
effective	O
.	O
There	O
is	O
an	O
increased	O
interest	O
in	O
economic	O
evaluations	O
of	O
these	O
,	O
often	O
expensive	O
,	O
interventions	B-T061
.	O
The	O
aim	O
of	O
this	O
systematic	O
review	O
is	O
to	O
summarize	O
and	O
evaluate	B-T058
the	O
evidence	O
on	O
cost	O
-	O
effectiveness	O
of	O
family	O
/	O
family	B-T061
-	I-T061
based	I-T061
therapy	I-T061
for	O
externalizing	B-T048
disorders	I-T048
,	O
substance	B-T048
use	I-T048
disorders	I-T048
and	O
delinquency	B-T048
.	O
A	O
systematic	O
literature	O
search	O
was	O
performed	O
in	O
PubMed	O
,	O
Education	O
Resource	O
information	O
Centre	O
(	O
ERIC	O
)	O
,	O
Psycinfo	O
and	O
Cochrane	O
reviews	O
including	O
studies	B-T059
conducted	O
after	O
1990	O
and	O
before	O
the	O
first	O
of	O
August	O
of	O
2013	O
.	O
Full	O
economic	O
evaluations	O
investigating	O
family	O
/	O
family	B-T061
-	I-T061
based	I-T061
interventions	I-T061
for	O
adolescents	O
between	O
10	O
and	O
20	O
years	O
treated	O
for	O
substance	B-T048
use	I-T048
disorders	I-T048
,	O
delinquency	B-T048
or	O
externalizing	B-T048
disorders	I-T048
were	O
included	O
.	O
Seven	O
hundred	O
thirty	O
-	O
one	O
articles	O
met	O
the	O
search	O
criteria	O
and	O
51	O
studies	B-T059
were	O
initially	O
selected	O
.	O
The	O
final	O
selection	O
resulted	O
in	O
the	O
inclusion	O
of	O
11	O
studies	B-T059
.	O
The	O
quality	O
of	O
these	O
studies	B-T059
was	O
assessed	O
.	O
Within	O
the	O
identified	O
studies	B-T059
,	O
there	O
was	O
great	O
variation	O
in	O
the	O
specific	O
type	O
of	O
family	O
/	O
family	B-T061
-	I-T061
based	I-T061
interventions	I-T061
and	O
disorders	B-T047
.	O
According	O
to	O
the	O
outcomes	O
of	O
the	O
checklists	O
,	O
the	O
overall	O
quality	O
of	O
the	O
economic	O
evaluations	O
was	O
low	O
.	O
Results	O
varied	O
by	O
study	B-T059
.	O
Due	O
to	O
the	O
variations	O
in	O
setting	O
,	O
design	O
and	O
outcome	O
it	O
was	O
not	O
feasible	O
to	O
pool	O
results	O
using	O
a	O
meta	O
-	O
analysis	O
.	O
The	O
quality	O
of	O
the	O
identified	O
economic	O
evaluations	O
of	O
family	O
/	O
family	B-T061
-	I-T061
based	I-T061
therapy	I-T061
for	O
treatment	O
of	O
externalizing	B-T048
disorders	I-T048
,	O
adolescent	O
substance	B-T048
use	I-T048
disorders	I-T048
and	O
delinquency	B-T048
was	O
insufficient	O
to	O
determine	O
the	O
cost	O
-	O
effectiveness	O
.	O
Although	O
commonly	O
applied	O
,	O
family	O
/	O
family	B-T061
-	I-T061
based	I-T061
therapy	I-T061
is	O
costly	O
and	O
more	O
research	O
of	O
higher	O
quality	O
is	O
needed	O
.	O
      
Real	O
-	O
world	O
impact	O
of	O
non	B-T033
-	I-T033
breast	I-T033
cancer	I-T033
-	I-T033
specific	I-T033
death	I-T033
on	O
overall	O
survival	O
in	O
resectable	O
breast	B-T191
cancer	I-T191
The	O
real	O
-	O
world	O
occurrence	O
rate	O
of	O
non	B-T033
-	I-T033
breast	I-T033
cancer	I-T033
-	I-T033
specific	I-T033
death	I-T033
(	O
non	B-T033
-	I-T033
BCSD	I-T033
)	O
and	O
its	O
impact	O
on	O
patients	O
with	O
breast	B-T191
cancer	I-T191
are	O
poorly	O
recognized	O
.	O
Women	O
with	O
resectable	O
breast	B-T191
cancer	I-T191
from	O
1990	O
to	O
2007	O
in	O
the	O
Surveillance	O
,	O
Epidemiology	O
,	O
and	O
End	O
Results	O
database	O
(	O
n	O
=	O
199,963	O
)	O
were	O
analyzed	O
.	O
The	O
outcome	O
events	O
of	O
breast	B-T191
cancer	I-T191
were	O
classified	O
as	O
breast	O
cancer	O
-	O
specific	O
death	O
(	O
BCSD	O
)	O
,	O
non	B-T033
-	I-T033
BCSD	I-T033
,	O
or	O
survival	O
.	O
Binary	O
logistics	O
was	O
used	O
to	O
estimate	O
the	O
occurrence	O
rates	O
of	O
non	B-T033
-	I-T033
BCSD	I-T033
and	O
BCSD	O
with	O
different	O
clinicopathological	O
factors	O
.	O
The	O
Gray	O
method	O
was	O
used	O
to	O
measure	O
the	O
cumulative	O
incidence	O
of	O
non	B-T033
-	I-T033
BCSD	I-T033
and	O
BCSD	O
.	O
The	O
ratio	O
of	O
non	B-T033
-	I-T033
BCSDs	I-T033
to	O
all	O
causes	B-T033
of	I-T033
death	I-T033
and	O
stacked	O
cumulative	O
incidence	O
function	O
plots	O
were	O
used	O
to	O
present	O
the	O
impact	O
of	O
non	B-T033
-	I-T033
BCSD	I-T033
on	O
overall	O
survival	O
(	O
OS	O
)	O
.	O
Models	O
of	O
Cox	O
proportional	O
hazards	O
regression	O
and	O
competing	O
risk	O
regression	O
were	O
compared	O
to	O
highlight	O
the	O
suitable	O
model	O
.	O
There	O
were	O
12,879	O
non	B-T033
-	I-T033
BCSDs	I-T033
(	O
6.44	O
%	O
)	O
and	O
28,784	O
BCSDs	O
(	O
14.39	O
%	O
)	O
.	O
The	O
oldest	O
age	O
group	O
(	O
>	O
62	O
years	O
)	O
,	O
black	O
race	O
,	O
and	O
a	O
single	B-T033
or	I-T033
divorced	I-T033
marital	I-T033
status	I-T033
were	O
associated	O
with	O
more	O
non	B-T033
-	I-T033
BCSDs	I-T033
.	O
With	O
adjustments	O
for	O
age	O
,	O
a	O
hormone	B-T191
receptor	I-T191
-	I-T191
positive	I-T191
(	I-T191
HoR+	I-T191
)	I-T191
status	I-T191
was	O
no	O
longer	O
related	O
to	O
increased	O
non	B-T033
-	I-T033
BCSD	I-T033
s.	O
In	O
patients	O
with	O
grade	B-T047
1	I-T047
,	I-T047
stage	I-T047
I	I-T047
disease	I-T047
and	O
an	O
HoR+	B-T191
status	I-T191
as	O
well	O
as	O
the	O
oldest	O
subgroup	O
,	O
a	O
great	O
dilution	O
of	O
non	B-T033
-	I-T033
BCSD	I-T033
on	O
all	O
causes	B-T033
of	I-T033
death	I-T033
could	O
be	O
observed	O
,	O
and	O
this	O
led	O
to	O
incorrect	B-T033
interpretations	I-T033
.	O
The	O
inaccuracy	O
,	O
caused	O
by	O
the	O
commonly	O
used	O
Cox	O
proportional	O
hazards	O
model	O
,	O
could	O
be	O
corrected	O
by	O
a	O
competing	O
risk	O
model	O
.	O
OS	O
was	O
largely	O
impaired	O
by	O
non	B-T033
-	I-T033
BCSD	I-T033
during	O
early	O
breast	B-T191
cancer	I-T191
.	O
For	O
some	O
future	O
clinical	O
trial	O
planning	B-T058
,	O
especially	O
for	O
the	O
oldest	O
patients	O
and	O
those	O
with	O
HoR+	B-T191
breast	B-T191
cancer	I-T191
,	O
non	B-T033
-	I-T033
BCSD	I-T033
should	O
be	O
considered	O
a	O
competing	O
risk	O
event	O
.	O
Cancer	O
2017	O
.	O
©	O
2017	O
American	O
Cancer	O
Society	O
.	O
      
A	O
16	O
Yin	O
Yang	O
gene	O
expression	O
ratio	O
signature	O
for	O
ER+	B-T191
/	O
node-	B-T191
breast	I-T191
cancer	I-T191
Breast	B-T191
cancer	I-T191
is	O
one	O
of	O
the	O
leading	O
causes	O
of	O
cancer	B-T191
death	O
in	O
women	O
.	O
It	O
is	O
a	O
complex	O
and	O
heterogeneous	O
disease	B-T047
with	O
different	O
clinical	O
outcomes	O
.	O
Stratifying	O
patients	O
into	O
subgroups	O
with	O
different	O
outcomes	O
could	O
help	O
guide	O
clinical	B-T060
decision	I-T060
making	I-T060
.	O
In	O
this	O
study	O
,	O
we	O
used	O
two	O
opposing	O
groups	O
of	O
genes	O
,	O
Yin	O
and	O
Yang	O
,	O
to	O
develop	O
a	O
prognostic	O
expression	O
ratio	O
signature	O
.	O
Using	O
the	O
METABRIC	O
cohort	O
we	O
identified	O
a16-	O
gene	O
signature	O
capable	O
of	O
stratifying	O
breast	B-T191
cancer	I-T191
patients	O
into	O
four	O
risk	O
levels	O
with	O
intention	O
that	O
low	O
-	O
risk	O
patients	O
would	O
not	O
undergo	O
adjuvant	O
systemic	B-T061
therapy	I-T061
,	O
intermediate	O
-	O
low	O
-	O
risk	O
patients	O
will	O
be	O
treated	B-T061
with	I-T061
hormonal	B-T061
therapy	I-T061
only	O
,	O
and	O
intermediate	O
-high-	O
and	O
high	O
-	O
risk	O
groups	O
will	O
be	O
treated	B-T061
by	O
chemotherapy	B-T061
in	O
addition	O
to	O
the	O
hormonal	B-T061
therapy	I-T061
.	O
The	O
16-	O
gene	O
signature	O
for	O
four	O
risk	O
level	O
stratifications	O
of	O
breast	B-T191
cancer	I-T191
patients	O
has	O
been	O
validated	O
using	O
14	O
independent	O
datasets	O
.	O
Notably	O
,	O
the	O
low	O
-	O
risk	O
group	O
(	O
n	O
=	O
51	O
)	O
of	O
205	O
estrogen	B-T191
receptor	I-T191
-	I-T191
positive	I-T191
and	O
node	B-T191
negative	I-T191
(	O
ER+	B-T191
/	O
node-	B-T191
)	O
patients	O
from	O
three	O
different	O
datasets	O
who	O
had	O
not	O
had	O
any	O
systemic	O
adjuvant	B-T061
therapy	I-T061
had	O
100	O
%	O
15-	O
year	O
disease	O
-	O
specific	O
survival	O
rate	O
.	O
The	O
Concordance	O
Index	O
of	O
YMR	B-T060
for	O
ER+	B-T191
/	O
node	B-T191
negative	I-T191
patients	O
is	O
close	O
to	O
the	O
commercially	O
available	O
signatures	O
.	O
However	O
,	O
YMR	B-T060
showed	O
more	O
significance	O
(	O
HR	O
=	O
3.7	O
,	O
p	O
=	O
8.7e-12	O
)	O
in	O
stratifying	O
ER+	B-T191
/	O
node-	B-T191
subgroup	O
than	O
OncotypeDx	B-T060
(	O
HR	O
=	O
2.7	O
,	O
p	O
=	O
1.3e-7	O
)	O
,	O
MammaPrint	B-T059
(	O
HR	O
=	O
2.5	O
,	O
p	O
=	O
5.8e-7	O
)	O
,	O
rorS	B-T060
(	O
HR	O
=	O
2.4	O
,	O
p	O
=	O
1.4e-6	O
)	O
,	O
and	O
NPI	B-T060
(	O
HR	O
=	O
2.6	O
,	O
p	O
=	O
1.2e-6	O
)	O
.	O
YMR	B-T060
signature	O
may	O
be	O
developed	O
as	O
a	O
clinical	O
tool	O
to	O
select	O
a	O
subgroup	O
of	O
low	O
-	O
risk	O
ER+	B-T191
/	O
node-	B-T191
patients	O
who	O
do	O
not	O
require	O
any	O
adjuvant	O
hormonal	B-T061
therapy	I-T061
(	O
AHT	B-T061
)	O
.	O
      
Results	O
of	O
an	O
International	O
Postmarketing	O
Surveillance	O
Study	O
of	O
pl	B-T121
-	I-T121
VEGF165	I-T121
Safety	O
and	O
Efficacy	O
in	O
210	O
Patients	O
with	O
Peripheral	B-T047
Arterial	I-T047
Disease	I-T047
The	O
effective	O
treatment	B-T061
of	O
chronic	O
lower	B-T023
limb	I-T023
ischemia	O
is	O
one	O
of	O
the	O
most	O
challenging	O
issues	O
confronting	O
vascular	O
surgeons	O
.	O
Current	O
pharmacological	O
therapies	B-T061
play	O
an	O
auxiliary	O
role	O
and	O
can	O
not	O
prevent	O
disease	O
progression	O
,	O
and	O
new	O
treatment	B-T061
methods	I-T061
are	O
needed	O
.	O
pl	B-T121
-	I-T121
VEGF165	I-T121
,	O
a	O
gene	B-T061
therapy	I-T061
drug	B-T121
,	O
was	O
approved	O
in	O
Russia	O
for	O
the	O
treatment	B-T061
of	O
atherosclerotic	O
peripheral	B-T047
arterial	I-T047
disease	I-T047
(	O
PAD	B-T047
)	O
after	O
clinical	O
studies	O
in	O
2011	O
.	O
The	O
study	O
drug	B-T121
is	O
an	O
original	O
gene	O
construction	O
in	O
which	O
pl	B-T121
-	I-T121
VEGF165	I-T121
1.2	O
mg	O
is	O
the	O
active	O
substance	O
.	O
This	O
postmarketing	O
surveillance	O
study	O
was	O
undertaken	O
to	O
evaluate	O
the	O
safety	O
(	O
identification	O
of	O
uncommon	O
side	O
effects	O
)	O
and	O
efficacy	O
of	O
gene	B-T061
therapy	I-T061
in	O
patients	O
in	O
routine	O
clinical	O
practice	O
.	O
In	O
total	O
,	O
210	O
patients	O
with	O
stage	O
II	O
-	O
III	O
chronic	O
limb	B-T023
ischemia	O
(	O
according	O
to	O
the	O
Fontaine	O
classification	O
modified	O
by	O
AV	O
Pokrovsky	O
)	O
in	O
33	O
healthcare	O
facilities	O
in	O
Russia	O
and	O
the	O
Ukraine	O
were	O
enrolled	O
in	O
the	O
study	O
.	O
The	O
control	O
group	O
(	O
n	O
=	O
60	O
)	O
received	O
conservative	B-T061
therapy	I-T061
without	O
prostaglandins	B-T121
and	O
prostacyclins	B-T121
,	O
and	O
the	O
treatment	O
group	O
(	O
n	O
=	O
150	O
)	O
received	O
treatment	B-T061
with	O
pl	B-T121
-	I-T121
VEGF165	I-T121
as	O
two	O
intramuscular	O
injections	O
for	O
a	O
total	O
dose	O
of	O
2.4	O
mg	O
.	O
Pain	B-T033
-	I-T033
free	I-T033
walking	I-T033
distance	I-T033
(	O
PWD	B-T033
)	O
(	O
the	O
primary	O
efficacy	O
criterion	O
for	O
Fontaine	O
stages	O
II	O
-	O
III	O
)	O
,	O
blood	B-T033
flow	I-T033
linear	I-T033
velocity	I-T033
(	O
BFLV	B-T033
)	O
,	O
and	O
ankle	O
-	O
brachial	O
index	O
(	O
ABI	O
)	O
were	O
monitored	O
for	O
6	O
months	O
.	O
The	O
safety	O
of	O
pl	B-T121
-	I-T121
VEGF165	I-T121
gene	O
transfer	O
in	O
terms	O
of	O
the	O
trial	O
protocol	O
was	O
initially	O
evaluated	O
6	O
months	O
after	O
the	O
start	O
of	O
the	O
study	O
;	O
adverse	O
events	O
(	O
AEs	O
)	O
and	O
serious	O
adverse	O
events	O
(	O
SAEs	O
)	O
were	O
recorded	O
during	O
both	O
routine	O
visits	B-T058
and	O
unscheduled	O
requests	O
for	O
medical	B-T058
care	I-T058
.	O
Overall	O
,	O
PWD	B-T033
increased	O
by	O
177	O
%	O
,	O
from	O
100.3	O
±	O
6.9	O
to	O
277.1	O
±	O
16.2	O
m	O
(	O
p	O
=	O
0.0001	O
)	O
,	O
in	O
the	O
treatment	O
group	O
,	O
whereas	O
the	O
mean	O
value	O
was	O
unchanged	O
in	O
the	O
control	O
group	O
(	O
p	O
=	O
0.218	O
)	O
.	O
Both	O
BFLV	B-T033
and	O
ABI	O
values	O
increased	O
by	O
24	O
%	O
(	O
p	O
=	O
0.0001	O
)	O
in	O
the	O
treatment	O
group	O
but	O
decreased	O
in	O
the	O
control	O
group	O
.	O
The	O
greatest	O
therapeutic	O
effect	O
was	O
observed	O
for	O
stage	O
III	O
disease	B-T047
:	O
PWD	B-T033
increased	O
by	O
683	O
%	O
(	O
p	O
=	O
0.0001	O
)	O
.	O
No	B-T033
angiogenic	B-T061
therapy	I-T061
-related	O
AEs	O
or	O
side	O
effects	O
were	O
recorded	O
,	O
and	O
target	O
limb	B-T061
salvage	I-T061
was	O
96	O
and	O
97	O
%	O
in	O
the	O
treatment	O
and	O
control	O
groups	O
,	O
respectively	O
.	O
The	O
results	O
obtained	O
in	O
this	O
study	O
are	O
not	O
significantly	O
different	O
from	O
those	O
observed	O
in	O
the	O
phase	O
IIb	O
/	O
III	O
registration	O
clinical	O
study	O
completed	O
in	O
2011	O
.	O
pl	B-T121
-	I-T121
VEGF165	I-T121
intramuscular	O
gene	O
transfer	O
is	O
an	O
effective	O
treatment	B-T061
for	O
moderate	O
to	O
severe	O
claudication	B-T047
due	O
to	O
chronic	O
lower	B-T023
limb	I-T023
ischemia	O
in	O
routine	O
clinical	O
practice	O
.	O
ClinicalTrials.gov	O
identifier	O
:	O
NCT02369809	O
.	O
      
Optomechanical	O
Control	O
of	O
Quantum	O
Yield	O
in	O
Trans	O
-	O
Cis	O
Ultrafast	O
Photoisomerization	O
of	O
a	O
Retinal	B-T121
Chromophore	O
Model	O
The	O
quantum	O
yield	O
of	O
a	O
photochemical	O
reaction	O
is	O
one	O
of	O
the	O
most	O
fundamental	O
quantities	O
in	O
photochemistry	O
,	O
as	O
it	O
measures	O
the	O
efficiency	O
of	O
the	O
transduction	O
of	O
light	O
energy	O
into	O
chemical	O
energy	O
.	O
Nature	O
has	O
evolved	O
photoreceptors	O
in	O
which	O
the	O
reactivity	O
of	O
a	O
chromophore	O
is	O
enhanced	O
by	O
its	O
molecular	O
environment	O
to	O
achieve	O
high	O
quantum	O
yields	O
.	O
The	O
retinal	B-T121
chromophore	O
sterically	O
constrained	O
inside	O
rhodopsin	O
proteins	O
represents	O
an	O
outstanding	O
example	O
of	O
such	O
a	O
control	O
.	O
In	O
a	O
more	O
general	O
framework	O
,	O
mechanical	O
forces	O
acting	O
on	O
a	O
molecular	O
system	O
can	O
strongly	O
modify	O
its	O
reactivity	O
.	O
Herein	O
,	O
we	O
show	O
that	O
the	O
exertion	O
of	O
tensile	O
forces	O
on	O
a	O
simplified	O
retinal	B-T121
chromophore	O
model	O
provokes	O
a	O
substantial	O
and	O
regular	O
increase	O
in	O
the	O
trans	O
-	O
to	O
-	O
cis	O
photoisomerization	O
quantum	O
yield	O
in	O
a	O
counterintuitive	O
way	O
,	O
as	O
these	O
extension	O
forces	O
facilitate	O
the	O
formation	O
of	O
the	O
more	O
compressed	O
cis	O
photoisomer	O
.	O
A	O
rationale	O
for	O
the	O
mechanochemical	O
effect	O
on	O
this	O
photoisomerization	O
mechanism	O
is	O
also	O
proposed	O
.	O
      
Ultrasonography	B-T060
for	O
acute	B-T047
appendicitis	I-T047
-	O
the	O
way	O
it	O
looks	O
today	O
Despite	O
sophisticated	O
physical	B-T058
examination	I-T058
and	O
laboratory	B-T059
support	I-T059
,	O
diagnosis	B-T033
of	O
acute	B-T047
appendicitis	I-T047
remained	O
challenging	O
in	O
clinical	O
practice	O
with	O
a	O
negative	B-T061
appendectomy	I-T061
rate	O
of	O
15	O
-	O
30	O
%	O
.	O
As	O
a	O
remarkable	O
clue	O
and	O
as	O
early	O
as	O
1986	O
,	O
ultrasonography	B-T060
(	O
US	B-T060
)	O
has	O
been	O
proven	O
a	O
reliable	O
diagnostic	B-T060
method	I-T060
that	O
is	O
also	O
explicitly	O
helpful	O
in	O
difficult	O
cases	O
with	O
atypical	O
presentation	O
and	O
enables	O
to	O
rule	O
out	O
many	O
differential	B-T060
diagnoses	I-T060
.Recent	O
publications	O
emphasized	O
the	O
role	O
of	O
multidetector	B-T060
computed	I-T060
tomography	I-T060
(	O
CT	B-T060
)	O
resulting	O
in	O
a	O
significant	O
reduction	O
of	O
false	O
negative	O
findings	O
at	O
operation	B-T061
.	O
Extensive	O
as	O
well	O
as	O
uncritical	B-T061
application	I-T061
of	O
this	O
method	O
even	O
in	O
children	O
inevitably	O
causes	O
substantial	O
radiation	O
exposure	O
,	O
a	O
sequel	O
to	O
either	O
pure	O
ignorance	O
or	O
unqualified/	O
inadequate	O
performance	O
of	O
US	B-T060
in	O
this	O
particular	O
situation	O
,	O
which	O
in	O
turn	O
can	O
be	O
considered	O
sequel	O
to	O
either	O
egocentric	B-T033
or	O
economic	O
preponderance	O
.Recent	O
data	O
shed	O
new	O
light	O
on	O
the	O
role	O
of	O
US	B-T060
(	O
and	O
CT	B-T060
)	O
in	O
acute	B-T047
appendicitis	I-T047
.	O
Therefore	O
,	O
1	O
generation	O
after	O
US	B-T060
with	I-T060
graded	I-T060
compression	I-T060
was	O
etched	O
in	O
stone	O
as	O
the	O
method	O
of	O
choice	O
for	O
diagnosing	B-T033
acute	B-T047
appendicitis	I-T047
(	O
Puylaert	O
)	O
,	O
a	O
visual	O
arousal	O
fostering	O
its	O
role	O
and	O
performance	O
in	O
clinical	O
medicine	O
appears	O
justified	O
.	O
      
Construction	O
of	O
an	O
Acetylcholinesterase	O
Sensor	O
Based	O
on	O
Synthesized	O
Paramagnetic	O
Nanoparticles	O
,	O
a	O
Simple	O
Tool	O
for	O
Neurotoxic	O
Compounds	O
Assay	B-T059
Magnetic	O
particles	O
(	O
MPs	O
)	O
have	O
been	O
widely	O
used	O
in	O
biological	O
applications	O
in	O
recent	O
years	O
as	O
a	O
carrier	O
for	O
various	O
molecules	O
.	O
Their	O
big	O
advantage	O
is	O
in	O
repeated	O
use	O
of	O
immobilized	O
molecules	O
including	O
enzymes	O
.	O
Acetylcholinesterase	O
(	O
AChE	O
)	O
is	O
an	O
enzyme	O
playing	O
crucial	O
role	O
in	O
neurotransmission	O
and	O
the	O
enzyme	O
is	O
targeted	O
by	O
various	O
molecules	O
like	O
Alzheimer	B-T047
's	I-T047
drugs	B-T121
,	O
pesticides	O
and	O
warfare	O
agents	O
.	O
In	O
this	O
work	O
,	O
an	O
electrochemical	O
biosensor	O
having	O
AChE	O
immobilized	O
onto	O
MPs	O
and	O
stabilized	B-T033
through	O
glutaraldehyde	O
(	O
GA	O
)	O
molecule	O
was	O
proposed	O
for	O
assay	B-T059
of	O
the	O
neurotoxic	O
compounds	O
.	O
The	O
prepared	O
nanoparticles	O
were	O
modified	O
by	O
pure	O
AChE	O
and	O
they	O
were	O
used	O
for	O
the	O
measurement	O
anti	B-T033
-	I-T033
Alzheimer	I-T033
's	I-T033
drug	B-T121
galantamine	B-T121
and	O
carbamate	B-T121
pesticide	I-T121
carbofuran	O
with	O
limit	O
of	O
detection	B-T033
1.5	O
µM	O
and	O
20	O
nM	O
,	O
respectively	O
.	O
All	O
measurements	O
were	O
carried	O
out	O
using	O
screen	O
-	O
printed	O
sensor	O
with	O
carbon	O
working	O
,	O
silver	O
reference	O
,	O
and	O
carbon	O
auxiliary	O
electrode	O
.	O
Standard	B-T059
Ellman	I-T059
's	I-T059
assay	I-T059
was	O
used	O
for	O
validation	O
measurement	O
of	O
both	O
inhibitors	O
.	O
Part	O
of	O
this	O
work	O
was	O
the	O
elimination	O
of	O
reversible	O
inhibitors	O
represented	O
by	O
galantamine	B-T121
from	O
the	O
active	O
site	O
of	O
AChE.	O
For	O
this	O
purpose	O
,	O
we	O
used	O
a	O
lower	O
pH	O
to	O
get	O
the	O
original	O
activity	O
of	O
AChE	O
after	O
inhibition	O
by	O
galantamine	B-T121
.	O
We	O
also	O
observed	O
decarbamylation	O
of	O
the	O
AChE	O
-	O
carbofuran	O
adduct	O
.	O
Influence	O
of	O
organic	O
solvents	O
to	O
AChE	O
as	O
well	O
as	O
repeatability	O
of	O
measurement	O
with	O
MPs	O
with	O
AChE	O
was	O
also	O
established	O
.	O
      
Endurance	B-T033
based	O
personalized	O
fitness	O
planner	O
Endurance	B-T033
is	O
an	O
important	O
factor	O
of	O
cardiovascular	O
fitness	O
indicating	O
the	O
capacity	O
of	O
an	O
individual	O
to	O
perform	O
exercise	O
for	O
a	O
longer	O
duration	O
with	O
increased	O
intensity	O
.	O
Various	O
subject	O
specific	O
and	O
exercise	O
related	O
parameters	O
affect	O
endurance	B-T033
of	O
an	O
individual	O
.	O
In	O
this	O
work	O
,	O
we	O
propose	O
a	O
statistical	O
technique	O
to	O
model	O
endurance	B-T033
as	O
a	O
function	O
of	O
these	O
factors	O
incorporating	O
the	O
serial	O
dependence	O
of	O
observations	O
generated	O
by	O
individuals	O
over	O
time	O
.	O
The	O
proposed	O
model	O
provides	O
a	O
device	O
to	O
predict	O
future	O
endurance	B-T033
of	O
a	O
test	O
subject	O
following	O
particular	O
exercise	B-T061
regime	I-T061
.	O
This	O
facilitates	O
a	O
test	O
user	O
with	O
a	O
fitness	O
planner	O
with	O
the	O
provision	O
to	O
fix	O
exercise	B-T061
regimes	I-T061
to	O
reach	O
a	O
set	O
fitness	O
goal	O
.	O
      
A	O
thermophilic	B-T001
-like	O
ene	O
-	O
reductase	O
originating	O
from	O
an	O
acidophilic	O
iron	B-T007
oxidizer	I-T007
Ene	O
-	O
reductases	O
originating	O
from	O
extremophiles	B-T001
are	O
gaining	O
importance	O
in	O
the	O
field	O
of	O
biocatalysis	O
due	O
to	O
higher	O
-	O
stability	O
properties	O
.	O
The	O
genome	O
of	O
the	O
acidophilic	O
iron	B-T007
-	I-T007
oxidizing	I-T007
bacterium	I-T007
"	O
Ferrovum	B-T007
"	I-T007
sp	I-T007
.	I-T007
JA12	I-T007
was	O
found	O
to	O
harbor	O
a	O
thermophilic	B-T001
-like	O
ene	O
-	O
reductase	O
(	O
FOYE-1	O
)	O
.	O
The	O
foye-1	O
gene	O
was	O
ligated	O
into	O
a	O
pET16bp	O
expression	O
vector	O
system	O
,	O
and	O
the	O
enzyme	O
was	O
produced	O
in	O
Escherichia	B-T007
coli	I-T007
BL21	O
(	O
DE3	O
;	O
pLysS	O
)	O
cells	O
in	O
yields	O
of	O
10	O
mg	O
L(-1	O
)	O
.	O
FOYE-1	O
showed	O
remarkable	O
activity	O
and	O
rates	O
on	O
N	O
-	O
phenylmaleimide	O
and	O
N	O
-	O
phenyl-2	O
-	O
methylmaleimide	O
(	O
up	O
to	O
89	O
U	O
mg(-1	O
)	O
,	O
>	O
97	O
%	O
conversion	O
,	O
95	O
%	O
(	O
R)-selective	O
)	O
with	O
both	O
nicotinamide	O
cofactors	O
,	O
NADPH	O
and	O
NADH	B-T121
.	O
The	O
catalytic	O
efficiency	O
with	O
NADPH	O
was	O
27	O
times	O
higher	O
compared	O
to	O
NADH	B-T121
.	O
At	O
the	O
temperature	O
maximum	O
(	O
50	O
°	O
C	O
)	O
and	O
pH	O
optimum	O
(	O
6.5	O
)	O
,	O
activity	O
was	O
almost	O
doubled	O
to	O
160	O
U	O
mg(-1	O
)	O
.	O
These	O
findings	B-T033
accomplish	O
FOYE-1	O
for	O
a	O
valuable	O
biocatalyst	O
in	O
the	O
synthesis	O
of	O
succinimides	B-T121
.	O
The	O
appearance	O
of	O
a	O
thermophilic	B-T001
-like	O
ene	O
-	O
reductase	O
in	O
an	O
acidic	O
habitat	O
is	O
discussed	O
with	O
respect	O
to	O
its	O
phylogenetic	O
placement	O
and	O
to	O
the	O
genomic	O
neighborhood	O
of	O
the	O
encoding	O
gene	O
,	O
awarding	O
FOYE-1	O
a	O
putative	O
involvement	O
in	O
a	O
quorum	O
-	O
sensing	O
process	O
.	O
      
Growth	O
differentiation	O
factor	O
15	O
is	O
a	O
myomitokine	O
governing	O
systemic	O
energy	O
homeostasis	O
Reduced	O
mitochondrial	O
electron	O
transport	O
chain	O
activity	O
promotes	O
longevity	O
and	O
improves	B-T033
energy	O
homeostasis	O
via	O
cell	O
-	O
autonomous	O
and	O
-	O
non	O
-	O
autonomous	O
factors	O
in	O
multiple	O
model	O
systems	O
.	O
This	O
mitohormetic	O
effect	O
is	O
thought	O
to	O
involve	O
the	O
mitochondrial	O
unfolded	O
protein	O
response	O
(	O
UPR(mt	O
)	O
)	O
,	O
an	O
adaptive	O
stress	O
-	O
response	O
pathway	O
activated	O
by	O
mitochondrial	O
proteotoxic	O
stress	O
.	O
Using	O
mice	O
with	O
skeletal	O
muscle	O
-	O
specific	O
deficiency	O
of	O
Crif1	O
(	O
muscle	O
-	O
specific	O
knockout	O
[	O
MKO	O
]	O
)	O
,	O
an	O
integral	O
protein	O
of	O
the	O
large	O
mitoribosomal	O
subunit	O
(	O
39S	O
)	O
,	O
we	O
identified	O
growth	O
differentiation	O
factor	O
15	O
(	O
GDF15	O
)	O
as	O
a	O
UPR(mt	O
)	O
-associated	O
cell	O
-	O
non	O
-	O
autonomous	O
myomitokine	O
that	O
regulates	O
systemic	O
energy	O
homeostasis	O
.	O
MKO	O
mice	O
were	O
protected	B-T033
against	O
obesity	B-T047
and	O
sensitized	O
to	O
insulin	B-T121
,	O
an	O
effect	O
associated	O
with	O
elevated	O
GDF15	O
secretion	O
after	O
UPR(mt	O
)	O
activation	O
.	O
In	O
ob	O
/	O
ob	O
mice	O
,	O
administration	O
of	O
recombinant	O
GDF15	O
decreased	O
body	O
weight	O
and	O
improved	B-T033
insulin	O
sensitivity	O
,	O
which	O
was	O
attributed	O
to	O
elevated	O
oxidative	O
metabolism	O
and	O
lipid	O
mobilization	O
in	O
the	O
liver	B-T023
,	O
muscle	O
,	O
and	O
adipose	O
tissue	O
.	O
Thus	O
,	O
GDF15	O
is	O
a	O
potent	O
mitohormetic	O
signal	O
that	O
safeguards	O
against	O
the	O
onset	B-T033
of	I-T033
obesity	I-T033
and	O
insulin	O
resistance	O
.	O
      
Estimation	O
of	O
the	O
HIV-1	B-T005
backward	O
mutation	O
rate	O
from	O
transmitted	O
drug	O
-	O
resistant	O
strains	B-T001
One	O
of	O
the	O
serious	O
threats	O
facing	O
the	O
administration	O
of	O
antiretroviral	B-T061
therapy	I-T061
to	O
human	B-T005
immunodeficiency	I-T005
virus	I-T005
(	O
HIV-1	B-T005
)	O
infected	B-T047
patients	O
is	O
the	O
reported	O
increasing	O
prevalence	O
of	O
transmitted	O
drug	O
resistance	O
.	O
However	O
,	O
given	O
that	O
HIV-1	B-T005
drug	O
-	O
resistant	O
strains	B-T001
are	O
often	O
less	O
fit	O
than	O
the	O
wild	O
-	O
type	O
strains	B-T001
,	O
it	O
is	O
expected	O
that	O
drug	O
-	O
resistant	O
strains	B-T001
that	O
are	O
present	O
during	O
the	O
primary	O
phase	O
of	O
the	O
HIV-1	B-T047
infection	I-T047
are	O
replaced	O
by	O
the	O
fitter	O
wild	O
-	O
type	O
strains	B-T001
.	O
This	O
replacement	O
of	O
HIV-1	B-T033
resistant	I-T033
mutations	O
involves	O
the	O
emergence	O
of	O
wild	O
-	O
type	O
strains	B-T001
by	O
a	O
process	O
of	O
backward	O
mutation	O
.	O
How	O
quickly	O
the	O
replacement	O
happens	O
is	O
dependent	O
on	O
the	O
class	O
of	O
HIV-1	B-T005
mutation	O
group	O
.	O
We	O
estimate	O
the	O
backward	O
mutation	O
rates	O
and	O
relative	O
fitness	O
of	O
various	O
mutational	O
groups	O
known	O
to	O
confer	O
HIV-1	B-T005
drug	O
resistance	O
.	O
We	O
do	O
this	O
by	O
fitting	O
a	O
stochastic	O
model	O
to	O
data	O
for	O
individuals	O
who	O
were	O
originally	O
infected	B-T033
by	O
an	O
HIV-1	B-T005
strain	B-T001
carrying	O
any	O
one	O
of	O
the	O
known	O
drug	O
resistance	O
-conferring	O
mutations	O
and	O
observed	O
over	O
a	O
period	O
of	O
time	O
to	O
see	O
whether	O
the	O
resistant	O
strain	B-T001
is	O
replaced	O
.	O
To	O
do	O
this	O
,	O
we	O
seek	O
a	O
distribution	O
,	O
generated	O
from	O
simulations	O
of	O
the	O
stochastic	O
model	O
,	O
that	O
best	O
describes	O
the	O
observed	O
(	O
clinical	O
data	O
)	O
replacement	O
times	O
of	O
a	O
given	O
mutation	O
.	O
We	O
found	O
that	O
Lamivudine	B-T195
/	I-T195
Emtricitabine	I-T195
-associated	O
mutations	O
have	O
a	O
distinctly	O
higher	O
,	O
backward	O
mutation	O
rate	O
and	O
low	O
relative	O
fitness	O
compared	O
to	O
the	O
other	O
classes	O
(	O
as	O
has	O
been	O
reported	O
before	O
)	O
while	O
protease	B-T121
inhibitors	I-T121
-associated	O
mutations	O
have	O
a	O
slower	O
backward	O
mutation	O
rate	O
and	O
high	O
relative	O
fitness	O
.	O
For	O
the	O
other	O
mutation	O
classes	O
,	O
we	O
found	O
more	O
uncertainty	O
in	O
their	O
estimates	O
.	O
      
TANGO	O
-	O
a	O
screening	B-T058
tool	I-T058
to	O
identify	O
comorbidities	O
on	O
the	O
causal	O
pathway	O
of	O
nocturia	B-T047
To	O
develop	O
a	O
robust	B-T058
screening	I-T058
metric	I-T058
for	O
use	O
in	O
identifying	O
non	O
-	O
lower	O
urinary	B-T023
tract	I-T023
comorbidities	O
pertinent	O
to	O
the	O
multidisciplinary	B-T060
assessment	I-T060
of	O
patients	O
with	O
nocturia	B-T047
.	O
Variables	O
having	O
a	O
significant	O
risk	O
association	O
with	O
nocturia	B-T047
of	O
greater	O
than	O
once	O
per	O
night	O
were	O
identified	O
.	O
Discriminating	O
items	O
from	O
validated	O
and	O
reliable	O
tools	B-T058
measuring	O
these	O
comorbidities	O
were	O
identified	O
.	O
A	O
self	O
-	O
completed	O
57	O
-	O
item	O
questionnaire	O
was	O
developed	O
and	O
a	O
medical	O
checklist	O
and	O
pertinent	O
clinical	B-T033
measures	I-T033
added	O
.	O
Pre	O
-	O
determined	O
criteria	O
were	O
applied	O
to	O
retain	O
or	O
remove	O
items	O
in	O
the	O
development	O
of	O
the	O
Short	O
-	O
Form	O
(	O
SF	O
)	O
screening	B-T058
tool	I-T058
.	O
The	O
tool	B-T058
was	O
administered	O
to	O
252	O
individuals	O
with	O
nocturia	B-T047
who	O
were	O
attending	O
either	O
a	O
tertiary	O
level	O
Sleep	O
,	O
Continence	B-T061
,	O
Falls	B-T033
or	O
Rehabilitation	B-T058
service	I-T058
for	O
routine	B-T058
care	I-T058
.	O
Data	B-T033
collected	I-T033
were	O
subjected	O
to	O
descriptive	O
analysis	O
;	O
criteria	O
were	O
applied	O
to	O
reduce	O
the	O
number	O
of	O
items	O
.	O
Using	O
pre	O
-	O
determined	O
domains	O
,	O
a	O
nocturia	B-T047
screening	B-T058
metric	I-T058
,	O
entitled	O
TANGO	O
,	O
was	O
generated	O
.	O
The	O
acronym	O
TANGO	O
stands	O
for	O
Targeting	O
the	O
individual	O
's	O
Aetiology	O
of	O
Nocturia	B-T047
to	O
Guide	O
Outcomes	O
.	O
The	O
demographic	O
characteristics	O
of	O
the	O
sample	O
are	O
described	O
,	O
along	O
with	O
item	O
endorsement	O
levels	O
.	O
The	O
statistical	O
and	O
structural	O
framework	O
to	O
justify	O
deleting	O
or	O
retaining	O
of	O
items	O
from	O
the	O
TANGO	O
Long	O
-	O
Form	O
to	O
the	O
SF	O
is	O
presented	O
.	O
The	O
resultant	O
TANGO	O
-	O
SF	O
patient	O
-completed	O
nocturia	B-T047
screening	B-T058
tool	I-T058
is	O
reported	O
.	O
A	O
novel	O
all	O
-	O
cause	O
diagnostic	O
metric	O
for	O
identifying	O
co	O
-	O
existing	O
morbidities	O
of	O
clinical	O
relevance	O
to	O
nocturia	B-T047
in	O
patients	O
who	O
present	O
across	O
disciplines	B-T058
and	O
medical	O
specialties	O
has	O
been	O
developed	O
.	O
TANGO	O
has	O
the	O
potential	O
to	O
improve	O
practice	O
and	O
smooth	O
inequalities	O
associated	O
with	O
a	O
siloed	O
approach	O
to	O
assessment	B-T058
and	O
subsequent	O
care	O
of	O
patients	O
with	O
nocturia	B-T047
.	O
      
Survey	O
of	O
Neonatal	O
Intensive	O
Care	O
Unit	O
Nurse	O
Attitudes	O
Toward	O
Therapeutic	B-T061
Hypothermia	I-T061
Treatment	I-T061
The	O
traumatic	O
experiences	O
of	O
parent	O
s	O
of	O
babies	O
treated	B-T061
with	I-T061
therapeutic	B-T061
hypothermia	I-T061
(	O
TH	B-T061
)	O
have	O
been	O
described	O
.	O
No	O
research	O
has	O
assessed	O
neonatal	O
intensive	O
care	O
unit	O
(	O
NICU	O
)	O
nurse	O
experience	O
in	O
providing	O
care	O
to	O
hypothermic	B-T033
babies	O
and	O
emotional	O
support	O
to	O
their	O
parents	O
.	O
To	O
assess	O
NICU	O
nurse	O
attitudes	O
to	O
the	O
provision	O
of	O
TH	B-T061
with	O
respect	O
to	O
perceptions	O
about	O
baby	O
pain	B-T184
/	O
sedation	B-T061
,	O
need	O
for	O
nurse	O
and	O
parent	O
education	O
,	O
decision	O
making	O
about	O
initiation	O
of	O
TH	B-T061
,	O
and	O
barriers	O
to	O
best	O
care	O
.	O
A	O
survey	O
was	O
electronically	O
sent	O
to	O
219	O
nurses	O
at	O
2	O
affiliated	O
academic	O
level	O
III	O
NICUs	O
:	O
1	O
rural	O
and	O
1	O
urban	O
location	O
.	O
There	O
were	O
17	O
questions	O
where	O
responses	O
were	O
selected	O
from	O
a	O
preset	O
list	O
and	O
7	O
opportunities	O
for	O
nurses	O
to	O
provide	O
free	O
text	O
responses	O
.	O
The	O
response	O
rate	O
was	O
38	O
%	O
(	O
N	O
=	O
83	O
)	O
.	O
Overwhelming	O
similarities	O
between	O
the	O
urban	O
and	O
rural	O
institutions	O
were	O
found	O
with	O
NICU	O
nurses	O
expressing	O
understanding	O
of	O
the	O
indications	O
for	O
initiating	O
TH	B-T061
,	O
agreement	O
that	O
TH	B-T061
improves	O
long	O
-	O
term	O
outcomes	O
and	O
that	O
the	O
benefits	O
of	O
TH	B-T061
outweigh	O
the	O
risks	O
.	O
Nurses	O
at	O
the	O
urban	O
institution	O
more	O
frequently	O
expressed	O
concerns	O
surrounding	O
inadequate	O
treatment	B-T061
of	O
baby	O
pain	B-T184
/	O
sedation	B-T061
,	O
and	O
nurses	O
at	O
both	O
institutions	O
strongly	O
emphasized	O
the	O
need	O
for	O
more	O
nurse	O
and	O
parent	O
education	O
about	O
TH	B-T061
and	O
improved	O
timeliness	O
of	O
decision	O
making	O
for	O
initiation	O
of	O
TH	B-T061
.	O
NICU	O
nurses	O
specifically	O
want	O
to	O
learn	O
more	O
about	O
outcomes	O
of	O
babies	O
after	O
treatment	B-T061
with	O
TH	B-T061
and	O
feel	O
that	O
parents	O
need	O
more	O
education	O
about	O
TH	B-T061
.	O
Research	O
is	O
urgently	O
needed	O
to	O
better	O
understand	O
the	O
implications	O
of	O
TH	B-T061
treatment	I-T061
for	O
parent	O
-	O
baby	O
bonding	O
.	O
      
Quantitative	B-T060
Susceptibility	I-T060
Mapping	I-T060
using	O
Structural	O
Feature	O
based	O
Collaborative	O
Reconstruction	O
(	O
SFCR	O
)	O
in	O
the	O
Human	O
Brain	B-T023
The	O
reconstruction	O
of	O
MR	O
quantitative	B-T060
susceptibility	I-T060
mapping	I-T060
(	O
QSM	B-T060
)	O
from	O
local	O
phase	O
measurements	O
is	O
an	O
ill	O
posed	O
inverse	O
problem	O
and	O
different	O
regularization	O
strategies	O
incorporating	O
a	O
priori	O
information	O
extracted	O
from	O
magnitude	O
and	O
phase	O
images	O
have	O
been	O
proposed	O
.	O
However	O
,	O
the	O
anatomy	B-T017
observed	O
in	O
magnitude	O
and	O
phase	O
images	O
does	O
not	O
always	O
coincide	O
spatially	O
with	O
that	O
in	O
susceptibility	O
maps	O
,	O
which	O
could	O
give	O
erroneous	O
estimation	O
in	O
the	O
reconstructed	O
susceptibility	O
map	O
.	O
In	O
this	O
paper	O
,	O
we	O
develop	O
a	O
structural	O
feature	O
based	O
collaborative	O
reconstruction	O
(	O
SFCR	O
)	O
method	O
for	O
QSM	B-T060
including	O
both	O
magnitude	O
and	O
susceptibility	O
based	O
information	O
.	O
The	O
SFCR	O
algorithm	O
is	O
composed	O
of	O
two	O
consecutive	O
steps	O
corresponding	O
to	O
complementary	O
reconstruction	O
models	O
,	O
each	O
with	O
a	O
structural	O
feature	O
based	O
l1	O
norm	O
constraint	O
and	O
a	O
voxel	O
fidelity	O
based	O
l2	O
norm	O
constraint	O
,	O
which	O
allows	O
both	O
the	O
structure	O
edges	O
and	O
tiny	O
features	O
to	O
be	O
recovered	O
,	O
whereas	O
the	O
noise	O
and	O
artifacts	O
could	O
be	O
reduced	O
.	O
In	O
the	O
M	O
-	O
step	O
,	O
the	O
initial	O
susceptibility	O
map	O
is	O
reconstructed	O
by	O
employing	O
a	O
k	O
-	O
space	O
based	O
compressed	O
sensing	O
model	O
incorporating	O
magnitude	O
prior	O
.	O
In	O
the	O
S	O
-	O
step	O
,	O
the	O
susceptibility	O
map	O
is	O
fitted	O
in	O
spatial	O
domain	O
using	O
weighted	O
constraints	O
derived	O
from	O
the	O
initial	O
susceptibility	O
map	O
from	O
the	O
M	O
-	O
step	O
.	O
Simulations	O
and	O
in	O
vivo	O
human	O
experiments	O
at	O
7	O
T	O
MRI	B-T060
show	O
that	O
the	O
SFCR	O
method	O
provides	O
high	O
quality	O
susceptibility	O
maps	O
with	O
improved	O
RMSE	O
and	O
MSSIM	O
.	O
Finally	O
,	O
the	O
susceptibility	O
values	O
of	O
deep	O
gray	O
matter	O
are	O
analyzed	O
in	O
multiple	O
head	O
positions	O
,	O
with	O
the	O
supine	O
position	O
most	O
approximate	O
to	O
the	O
gold	O
standard	O
COSMOS	O
result	O
.	O
      
Doctor	O
Competence	O
and	O
the	O
Demand	B-T061
for	O
Healthcare	B-T058
:	O
Evidence	O
from	O
Rural	O
China	O
The	O
agency	O
problem	B-T033
between	O
patients	O
and	O
doctors	O
has	O
long	O
been	O
emphasised	O
in	O
the	O
health	O
economics	O
literature	O
,	O
but	O
the	O
empirical	O
evidence	O
on	O
whether	O
patients	O
can	O
evaluate	O
and	O
respond	O
to	O
better	O
quality	B-T058
care	I-T058
remains	O
mixed	O
and	O
inconclusive	O
.	O
Using	O
household	O
data	O
linked	O
to	O
an	O
assessment	O
of	O
village	O
doctors	O
'	O
clinical	O
competence	O
in	O
rural	O
China	O
,	O
we	O
show	O
that	O
there	O
is	O
no	O
correlation	O
between	O
doctor	O
competence	O
and	O
patients	O
'	O
healthcare	B-T058
utilisation	O
,	O
with	O
confidence	O
intervals	O
reasonably	O
tight	O
around	O
zero	O
.	O
Household	O
perceptions	O
of	O
quality	O
are	O
an	O
important	O
determinant	O
of	O
care	O
-	O
seeking	O
behaviour	O
,	O
yet	O
patients	O
appear	O
unable	B-T033
to	O
recognise	O
more	O
competent	O
doctors	O
-	O
there	O
is	O
no	O
relationship	O
between	O
doctor	O
competence	O
and	O
perceptions	O
of	O
quality	O
.	O
Copyright	O
©	O
2016	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd.	O
JOURNAL	O
ARTICLE	O
      
The	O
flavor	O
and	O
nutritional	O
characteristic	O
of	O
four	O
strawberry	O
varieties	O
cultured	O
in	O
soilless	O
system	O
Strawberry	O
fruits	O
(	O
cv	O
.	O
Benihoppe	O
,	O
Tochiotome	O
,	O
Sachinoka	O
,	O
and	O
Guimeiren	O
)	O
were	O
harvested	O
and	O
evaluated	O
the	O
flavor	O
and	O
nutritional	O
parameters	O
.	O
By	O
principal	O
component	O
analysis	O
and	O
hierarchical	O
clustering	O
analysis	O
,	O
differences	O
were	O
observed	O
based	O
on	O
the	O
volatile	O
compounds	O
composition	O
,	O
sugar	B-T121
and	O
acid	O
concentration	O
,	O
sweetness	O
,	O
and	O
total	B-T121
soluble	I-T121
sugars	I-T121
/	O
total	O
organic	O
acids	O
of	O
the	O
four	O
varieties	O
.	O
A	O
total	O
of	O
37	O
,	O
48	O
,	O
65	O
,	O
and	O
74	O
volatile	O
compounds	O
were	O
identified	O
and	O
determined	O
in	O
cv	O
.	O
Benihoppe	O
,	O
Tochiotome	O
,	O
Sachinoka	O
,	O
and	O
Guimeiren	O
strawberry	O
fruits	O
extracted	B-T061
by	O
head	B-T059
-	I-T059
space	I-T059
solid	I-T059
-	I-T059
phase	I-T059
microextraction	I-T059
(	O
HS	B-T059
-	I-T059
SPME	I-T059
)	O
,	O
respectively	O
.	O
Esters	O
significantly	O
dominated	O
the	O
chemical	O
composition	O
of	O
the	O
four	O
varieties	O
.	O
Furaneol	O
was	O
detected	O
in	O
cultivars	O
of	O
Sachinoka	O
and	O
Guimeiren	O
,	O
but	O
mesifuran	O
was	O
only	O
found	O
in	O
cv	O
.	O
Tochiotome	O
.	O
Tochiotome	O
and	O
Sachinoka	O
showed	O
higher	O
content	O
of	O
linalool	B-T121
and	O
(	O
E)-nerolidol	O
.	O
Sachinoka	O
showed	O
the	O
highest	O
content	O
of	O
total	B-T121
sugars	I-T121
and	O
total	O
acids	O
.	O
Guimeiren	O
showed	O
higher	O
sweetness	O
index	O
than	O
the	O
other	O
three	O
cultivars	O
.	O
Firmness	O
of	O
Tochiotome	O
was	O
highest	O
among	O
all	O
the	O
varieties	O
.	O
The	O
highest	O
total	O
soluble	O
solids	O
TSS	O
value	O
was	O
found	O
in	O
cv	O
.	O
Sachinoka	O
,	O
followed	O
by	O
the	O
Guimeiren	O
and	O
Tochiotome	O
varieties	O
.	O
Sachinoka	O
had	O
the	O
highest	O
titratable	O
acidity	O
TA	O
value	O
.	O
The	O
content	O
of	O
ascorbic	B-T121
acid	I-T121
(	O
AsA	B-T121
)	O
of	O
cv	O
.	O
Tochiotome	O
was	O
higher	O
than	O
the	O
others	O
,	O
but	O
there	O
was	O
no	B-T033
significant	I-T033
difference	O
in	O
cultivars	O
of	O
Benihoppe	O
,	O
Tochiotome	O
,	O
and	O
Sachinoka	O
.	O
Fructose	B-T121
and	O
glucose	B-T121
were	O
the	O
major	O
sugars	B-T121
in	O
all	O
cultivars	O
.	O
Citric	B-T121
acid	I-T121
was	O
the	O
major	O
organic	O
acid	O
in	O
cv	O
.	O
Tochiotome	O
,	O
cv	O
.	O
Sachinoka	O
,	O
and	O
cv	O
.	O
Guimeiren	O
.	O
Tochiotome	O
had	O
higher	O
ratios	O
of	O
TSS	O
/	O
TA	O
and	O
total	B-T121
sugars	I-T121
/	O
total	O
organic	O
acids	O
than	O
others	O
,	O
arising	O
from	O
its	O
lower	O
acid	O
content	O
.	O
The	O
order	O
of	O
the	O
comprehensive	O
evaluation	O
score	O
was	O
Sachinoka	O
>	O
Guimeiren	O
>	O
Tochiotome	O
>	O
Benihoppe	O
.	O
      
Tead1	O
regulates	O
the	O
expression	O
of	O
Peripheral	O
Myelin	O
Protein	O
22	O
during	O
Schwann	O
cell	O
development	O
Schwann	O
cells	O
are	O
myelinating	O
glia	O
in	O
the	O
peripheral	O
nervous	O
system	O
that	O
form	O
the	O
myelin	O
sheath	O
.	O
A	O
major	O
cause	O
of	O
peripheral	B-T047
neuropathy	I-T047
is	O
a	O
copy	O
number	O
variant	O
involving	O
the	O
Peripheral	O
Myelin	O
Protein	O
22	O
(	O
PMP22	O
)	O
gene	O
,	O
which	O
is	O
located	O
within	O
a	O
1.4	O
-	O
Mb	O
duplication	O
on	O
chromosome	O
17	O
associated	O
with	O
the	O
most	O
common	O
form	O
of	O
Charcot	B-T047
-	I-T047
Marie	I-T047
-	I-T047
Tooth	I-T047
Disease	I-T047
(	O
CMT1A	B-T047
)	O
.	O
Rodent	B-T050
models	I-T050
of	O
CMT1A	B-T047
have	O
been	O
used	O
to	O
show	O
that	O
reducing	O
Pmp22	O
overexpression	O
mitigates	O
several	O
aspects	O
of	O
a	O
CMT1A	B-T047
-related	O
phenotype	O
.	O
Mechanistic	O
studies	O
of	O
Pmp22	O
regulation	O
identified	O
enhancers	O
regulated	O
by	O
the	O
Sox10	O
(	O
SRY	O
sex	O
determining	O
region	O
Y	O
-	O
box	O
10	O
)	O
and	O
Egr2	O
/	O
Krox20	O
(	O
Early	O
growth	O
response	O
protein	O
2	O
)	O
transcription	O
factors	O
in	O
myelinated	O
nerves	O
.	O
However	O
,	O
relatively	O
little	O
is	O
known	O
regarding	O
how	O
other	O
transcription	O
factors	O
induce	O
Pmp22	O
expression	O
during	O
Schwann	O
cell	O
development	O
and	O
myelination	O
.	O
Here	O
,	O
we	O
examined	O
Pmp22	O
enhancers	O
as	O
a	O
function	O
of	O
cell	O
type	O
-	O
specificity	O
,	O
nerve	O
injury	O
and	O
development	O
.	O
While	O
Pmp22	O
enhancers	O
marked	O
by	O
active	O
histone	O
modifications	O
were	O
lost	O
or	O
remodeled	O
after	O
injury	O
,	O
we	O
found	O
that	O
these	O
enhancers	O
were	O
permissive	O
in	O
early	O
development	O
prior	O
to	O
Pmp22	O
upregulation	O
.	O
Pmp22	O
enhancers	O
contain	O
binding	O
motifs	O
for	O
TEA	O
domain	O
(	O
Tead	O
)	O
transcription	O
factors	O
of	O
the	O
Hippo	O
signaling	O
pathway	O
.	O
We	O
discovered	O
that	O
Tead1	O
and	O
co	O
-	O
activators	O
Yap	O
and	O
Taz	O
are	O
required	O
for	O
Pmp22	O
expression	O
,	O
as	O
well	O
as	O
for	O
the	O
expression	O
of	O
Egr2	O
Tead1	O
directly	O
binds	O
Pmp22	O
and	O
Egr2	O
enhancers	O
early	O
in	O
development	O
and	O
Tead1	O
binding	O
is	O
induced	O
during	O
myelination	O
,	O
correlating	O
with	O
Pmp22	O
expression	O
.	O
The	O
data	O
identify	O
Tead1	O
as	O
a	O
novel	O
regulator	O
of	O
Pmp22	O
expression	O
during	O
development	O
in	O
concert	O
with	O
Sox10	O
and	O
Egr2	O
.	O
      
Proliferation	O
-Related	O
Activity	O
in	O
Endothelial	O
Cells	O
Is	O
Enhanced	O
by	O
Micropower	O
Plasma	O
Nonthermal	B-T058
plasma	I-T058
has	O
received	O
a	O
lot	O
of	O
attention	O
as	O
a	O
medical	O
treatment	O
technique	O
in	O
recent	O
years	O
.	O
It	O
can	O
easily	O
create	O
various	O
reactive	O
chemical	O
species	O
(	O
ROS	O
)	O
and	O
is	O
harmless	O
to	O
living	O
body	O
.	O
Although	O
plasma	O
at	O
gas	O
-	O
liquid	O
interface	O
has	O
a	O
potential	O
for	O
a	O
biomedical	B-T058
application	I-T058
,	O
the	O
interactions	O
between	O
the	O
gas	O
-	O
liquid	O
plasma	O
and	O
living	O
cells	O
remain	O
unclear	O
.	O
Here	O
,	O
we	O
show	O
characteristics	O
of	O
a	O
micropower	O
plasma	O
with	O
0.018	O
W	O
of	O
the	O
power	O
input	O
,	O
generated	O
at	O
gas	O
-	O
liquid	O
interface	O
.	O
We	O
also	O
provide	O
the	O
evidence	O
of	O
plasma	O
-induced	O
enhancement	O
in	O
proliferation	O
activity	O
of	O
endothelial	O
cells	O
.	O
The	O
plasma	O
produced	O
H2O2	B-T121
,	O
HNO2	O
,	O
and	O
HNO3	O
in	O
phosphate	B-T121
buffered	I-T121
saline	O
containing	O
Mg(++	O
)	O
and	O
Ca(++	B-T121
)	I-T121
(	O
PBS	B-T121
(	O
+	O
)	O
)	O
,	O
and	O
their	O
concentration	O
increased	O
linearly	O
during	O
600	O
-	O
second	O
discharge	O
.	O
The	O
value	O
of	O
pH	O
in	O
PBS	B-T121
(	O
+	O
)	O
against	O
the	O
plasma	O
discharge	O
time	O
was	O
stable	O
at	O
about	O
7.0	O
.	O
Temperature	O
in	O
PBS	B-T121
(	O
+	O
)	O
rose	O
monotonically	O
,	O
and	O
its	O
rise	O
was	O
up	O
to	O
0.8	O
°	O
C	O
at	O
the	O
bottom	O
of	O
a	O
cell	O
-	O
cultured	O
dish	O
by	O
the	O
plasma	O
discharge	O
for	O
600	O
s.	O
Short	O
-	O
time	O
treatment	O
of	O
the	O
plasma	O
enhanced	O
proliferation	O
activity	O
of	O
endothelial	O
cells	O
.	O
In	O
contrast	O
,	O
the	O
treatment	O
of	O
H2O2	B-T121
does	O
not	O
enhance	O
the	O
cell	O
proliferation	O
.	O
Thus	O
,	O
the	O
ROS	O
production	O
and	O
the	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
κB	O
)	O
activation	O
due	O
to	O
the	O
plasma	O
treatment	O
might	O
be	O
related	O
to	O
enhancement	O
of	O
the	O
cell	O
proliferation	O
.	O
Our	O
results	O
may	O
potentially	O
provide	O
the	O
basis	O
for	O
developing	O
the	O
biomedical	B-T058
applications	I-T058
using	O
the	O
gas	O
-	O
liquid	O
plasma	O
.	O
      
Application	B-T058
of	O
Laparoscopic	B-T060
Lumbar	B-T061
Discectomy	I-T061
and	O
Artificial	B-T061
Disc	I-T061
Replacement	I-T061
:	O
At	O
Least	O
Two	O
Years	O
of	O
Follow	B-T058
-	I-T058
Up	I-T058
This	O
prospective	O
observational	O
study	O
included	O
22	O
patients	O
who	O
were	O
diagnosed	B-T033
with	O
symptomatic	O
degenerative	B-T047
disc	I-T047
disease	I-T047
treated	O
via	O
artificial	B-T061
disc	I-T061
replacement	I-T061
(	O
ADR	B-T061
)	O
with	O
a	O
laparoscopic	B-T060
technique	O
.	O
The	O
current	O
study	O
aimed	O
to	O
assess	O
the	O
safety	O
and	O
efficacy	O
of	O
ADR	B-T061
using	O
a	O
laparoscopic	B-T060
technique	O
for	O
lumbar	B-T020
disc	I-T020
herniation	I-T020
.	O
Symptomatic	O
degenerative	B-T047
disc	I-T047
disease	I-T047
is	O
the	O
major	O
cause	O
of	O
low	B-T184
back	I-T184
pain	I-T184
with	O
lumbar	O
segmental	O
instability	B-T033
.	O
ADR	B-T061
has	O
increased	O
in	O
popularity	O
as	O
an	O
alternative	O
treatment	O
for	O
lumbar	B-T020
disc	I-T020
herniation	I-T020
.	O
However	O
,	O
the	O
traditional	O
approach	O
to	O
spinal	B-T061
surgery	I-T061
carries	O
the	O
risk	O
of	O
catastrophic	B-T047
bleeding	O
from	O
injury	O
to	O
major	O
vessels	B-T023
,	O
as	O
well	O
as	O
iatrogenic	O
injury	O
to	O
the	O
viscera	B-T023
and	O
associated	B-T023
structures	I-T023
.	O
Therefore	O
,	O
laparoscopic	B-T060
lumbar	B-T061
discectomy	I-T061
and	O
ADR	B-T061
may	O
represent	O
a	O
useful	O
alternative	O
.	O
Twenty	O
-	O
two	O
patients	O
(	O
8	O
males	O
and	O
14	O
females	O
)	O
who	O
were	O
diagnosed	B-T033
with	O
symptomatic	O
degenerative	B-T047
disc	I-T047
disease	I-T047
were	O
included	O
in	O
this	O
study	O
.	O
Seven	O
cases	O
involved	O
the	O
L4/5	O
level	O
,	O
and	O
15	O
cases	O
involved	O
the	O
L5	O
/	O
S1	O
level	O
.	O
All	O
patients	O
were	O
ineffective	O
after	O
at	O
least	O
6	O
months	O
of	O
conservative	B-T061
treatments	I-T061
;	O
all	O
patients	O
were	O
informed	O
of	O
the	O
surgery	B-T061
before	O
the	O
operation	B-T061
and	O
provided	O
consent	O
.	O
Three	O
-	O
dimensional	O
computed	B-T060
tomographic	I-T060
angiography	I-T060
(	O
3D	O
-	O
CTA	B-T060
)	O
of	O
the	O
iliac	B-T023
great	O
blood	B-T023
vessels	I-T023
was	O
completed	O
before	O
the	O
surgery	B-T061
.	O
All	O
surgical	B-T061
procedures	I-T061
were	O
performed	O
under	O
a	O
laparoscope	O
.	O
All	O
patients	O
were	O
followed	B-T058
up	I-T058
.	O
All	O
surgeries	B-T061
were	O
successfully	O
completed	O
.	O
The	O
average	O
operation	B-T061
time	O
was	O
120	O
minutes	O
(	O
range	O
110	O
-	O
150	O
min	O
)	O
,	O
and	O
the	O
average	O
hemorrhage	O
was	O
145	O
mL	O
(	O
range	O
80	O
-	O
360	O
mL	O
)	O
.	O
All	O
cases	O
underwent	O
X	B-T060
-	I-T060
rays	I-T060
at	O
3	O
days	O
,	O
3	O
months	O
,	O
6	O
months	O
,	O
1	O
year	O
,	O
and	O
the	O
final	O
postoperative	B-T058
follow	B-T058
-	I-T058
up	I-T058
.	O
The	O
outcome	O
indicated	O
that	O
there	O
was	O
no	O
mobilization	O
,	O
displacement	O
,	O
or	O
subsidence	O
in	O
all	O
patients	O
with	O
the	O
exception	O
of	O
one	O
case	O
with	O
prosthesis	O
migration	O
.	O
The	O
follow	B-T058
-	I-T058
up	I-T058
time	O
was	O
43.8	O
months	O
(	O
range	O
24	O
-	O
64	O
months	O
)	O
.	O
The	O
mean	O
visual	O
analog	O
scale	O
(	O
VAS	O
)	O
and	O
Oswestry	B-T033
scores	I-T033
were	O
decreased	O
postoperatively	O
.	O
The	O
mean	O
improvement	O
rate	O
of	O
the	O
VAS	O
score	O
was	O
73.5	O
%	O
.	O
Lumbar	O
ADR	B-T061
using	O
a	O
laparoscope	O
represents	O
a	O
novel	O
,	O
minimally	O
invasive	O
treatment	O
for	O
symptomatic	O
degenerative	B-T047
disc	I-T047
disease	I-T047
and	O
severe	O
lumbar	B-T047
discogenic	I-T047
pain	I-T047
.	O
      
Hospitalist	O
Co	O
-	O
management	O
of	O
Pediatric	O
Orthopaedic	B-T061
Surgical	O
Patients	O
at	O
a	O
Community	O
Hospital	O
The	O
benefits	O
of	O
hospitalist	O
co	O
-	O
management	O
of	O
pediatric	O
surgical	O
patients	O
include	O
bettering	O
patient	B-T058
safety	I-T058
,	O
decreasing	B-T033
negative	O
patient	O
outcomes	O
,	O
providing	O
comprehensive	B-T058
medical	I-T058
care	I-T058
,	O
and	O
establishing	O
a	O
dedicated	O
resource	O
to	O
patients	O
for	O
postoperative	B-T058
care	I-T058
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
characterize	O
the	O
nature	O
of	O
patients	O
co	O
-	O
managed	O
by	O
a	O
pediatric	O
hospitalist	O
.	O
The	O
authors	O
hypothesize	O
that	O
hospitalist	O
co	O
-	O
management	O
is	O
safe	B-T033
and	O
efficacious	O
in	O
pediatric	O
orthopaedic	B-T061
surgical	O
patients	O
who	O
are	O
admitted	B-T058
to	O
a	O
community	O
hospital	O
.	O
A	O
retrospective	O
review	O
was	O
performed	O
of	O
all	O
pediatric	O
orthopaedic	B-T061
surgical	O
patients	O
admitted	B-T058
to	O
a	O
community	O
hospital	O
who	O
were	O
co	O
-	O
managed	O
by	O
a	O
pediatric	O
hospitalist	O
.	O
Indications	O
for	O
hospitalization	B-T058
included	O
pain	B-T061
control	I-T061
,	O
antibiotic	B-T061
infusion	I-T061
,	O
and	O
need	O
for	O
neurovascular	B-T058
monitoring	I-T058
.	O
Parameters	O
of	O
postoperative	B-T058
care	I-T058
and	O
co	O
-	O
management	O
were	O
assessed	O
,	O
including	O
presence	B-T033
of	O
complications	O
,	O
medication	B-T061
introduction	I-T061
or	O
adjustment	O
by	O
the	O
hospitalist	O
,	O
follow	B-T058
-	I-T058
up	I-T058
adherence	O
,	O
and	O
readmission	B-T058
/	O
complication	O
rates	O
after	O
discharge	B-T058
.	O
Thirty	O
-	O
two	O
patients	O
were	O
assessed	O
with	O
an	O
average	O
age	O
of	O
8.8	O
years	O
.	O
Twenty	O
-	O
five	O
percent	O
of	O
patients	O
had	O
an	O
associated	O
comorbidity	O
,	O
including	O
asthma	B-T047
,	O
attention	B-T048
deficit	I-T048
disorder	I-T048
,	O
and/or	O
autism	B-T048
.	O
The	O
pediatric	O
hospitalist	O
added	O
pain	B-T061
medication	I-T061
to	O
the	O
original	O
postoperative	B-T058
orders	I-T058
placed	O
by	O
the	O
orthopaedics	O
team	O
in	O
44	O
percent	O
of	O
patients	O
(	O
14	O
of	O
the	O
32	O
)	O
either	O
for	O
breakthrough	B-T184
pain	I-T184
or	O
better	O
long	O
-	O
term	O
coverage	O
.	O
Additionally	O
,	O
25	O
percent	O
of	O
patients	O
had	O
pain	B-T061
medication	I-T061
adjusted	O
from	O
the	O
original	O
dosing	O
and	O
schedule	B-T058
.	O
The	O
hospitalist	O
team	O
contacted	O
the	O
surgeon	O
about	O
the	O
four	O
patients	O
(	O
12.5	O
percent	O
)	O
.	O
In	O
three	O
of	O
the	O
cases	O
,	O
the	O
surgeon	O
was	O
contacted	O
to	O
discuss	O
pain	B-T061
medication	I-T061
,	O
and	O
one	O
patient	O
woke	O
up	O
agitated	O
from	O
anesthesia	B-T061
,	O
necessitating	O
a	O
visit	O
from	O
the	O
surgeon	O
on	O
the	O
pediatrics	O
floor	O
.	O
The	O
length	O
of	O
stay	O
was	O
one	O
day	O
for	O
all	O
patients	O
.	O
The	O
hospitalists	O
rounded	O
on	O
and	O
discharged	B-T058
patients	I-T058
the	O
subsequent	O
morning	O
.	O
All	O
patients	O
were	O
given	O
a	O
follow	O
-	O
up	O
appointment	O
and	O
schedule	O
by	O
the	O
hospitalist	O
team	O
,	O
and	O
every	O
patient	O
followed	B-T058
up	I-T058
accordingly	O
within	O
ten	O
days	O
of	O
discharge	B-T058
.	O
No	O
complications	O
or	O
hospital	B-T058
readmissions	I-T058
occurred	O
within	O
thirty	O
days	O
of	O
discharge	B-T058
.	O
Hospitalist	O
co	O
-	O
management	O
of	O
pediatric	O
orthopaedic	B-T061
surgical	O
patients	O
in	O
a	O
community	O
hospital	O
allows	O
for	O
better	O
medical	O
comorbidity	O
and	O
medication	B-T058
management	I-T058
.	O
Hospitalist	O
s	O
can	O
provide	O
closer	O
observation	O
during	O
the	O
inpatient	O
stay	O
and	O
help	O
streamline	O
communication	O
between	O
providers	O
and	O
patients	O
while	O
allowing	O
the	O
surgeon	O
the	O
ability	O
to	O
be	O
more	O
mobile	O
.	O
Co	O
-	O
management	O
is	O
safe	B-T033
and	O
efficacious	O
in	O
pediatric	O
orthopaedic	B-T061
surgical	O
patients	O
who	O
are	O
admitted	B-T058
to	O
a	O
community	O
hospital	O
.	O
      
A	O
Giant	O
Aneurysmal	B-T047
Bone	I-T047
Cyst	I-T047
in	O
the	O
Mandibular	B-T023
Condyle	I-T023
Aneurysmal	B-T047
bone	I-T047
cyst	I-T047
(	O
ABC	B-T047
)	O
is	O
a	O
rare	O
,	O
rapidly	O
expanding	O
,	O
locally	O
destructive	O
,	O
and	O
easily	B-T033
misdiagnosed	B-T033
lesion	B-T033
.	O
An	O
ABC	B-T047
of	O
the	O
condyle	B-T023
is	O
rare	O
.	O
This	O
report	O
presents	O
a	O
25-	O
year	O
-	O
old	O
female	O
with	O
a	O
giant	O
ABC	B-T047
in	O
the	O
left	O
mandibular	B-T023
condyle	I-T023
.	O
This	O
patient	O
was	O
treated	B-T061
with	I-T061
surgical	B-T061
resection	I-T061
of	O
the	O
affected	O
bone	B-T023
and	O
immediate	O
mandibular	B-T061
reconstruction	I-T061
using	O
autologous	O
bone	B-T023
.	O
Follow	B-T058
-	I-T058
up	I-T058
to	I-T058
date	I-T058
showed	O
no	O
signs	B-T033
of	O
recurrence	O
.	O
The	O
clinical	O
feature	O
,	O
imaging	O
finding	O
,	O
pathogenesis	O
,	O
and	O
treatment	B-T061
methods	I-T061
of	O
ABCs	B-T047
are	O
discussed	O
.	O
      
Double	O
strand	O
break	O
induction	O
and	O
kinetics	O
indicate	O
preserved	O
hypersensitivity	O
in	O
keratinocytes	O
to	O
subtherapeutic	O
doses	O
for	O
7	O
weeks	O
of	O
radiotherapy	B-T061
Previously	O
we	O
reported	O
that	O
hyper	O
-	O
radiosensitivity	O
(	O
HRS	O
)	O
was	O
evidenced	O
by	O
quantifying	O
DNA	O
double	O
strand	O
break	O
(	O
DSB	O
)	O
foci	O
in	O
epidermis	O
biopsies	B-T060
collected	O
after	O
delivering	O
radiotherapeutic	O
one	O
and	O
five	O
dose	O
fractions	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
HRS	O
was	O
preserved	O
throughout	O
a	O
7-	O
week	O
radiotherapy	B-T061
treatment	B-T061
,	O
and	O
also	O
to	O
examine	O
the	O
rate	O
of	O
foci	O
decline	O
and	O
foci	O
persistence	O
between	O
dose	O
fractions	O
.	O
42	O
patients	O
with	O
prostate	B-T191
cancer	I-T191
received	O
7-	O
week	O
fractionated	O
radiotherapy	B-T061
treatment	I-T061
(	O
RT	B-T061
)	O
with	O
daily	O
dose	O
fractions	O
of	O
0.05	O
-	O
1.10Gy	O
to	O
the	O
skin	O
.	O
Before	O
RT	B-T061
,	O
and	O
at	O
several	O
times	O
throughout	O
treatment	B-T061
,	O
skin	B-T060
biopsies	I-T060
(	O
n=452	O
)	O
were	O
collected	O
at	O
30min	O
,	O
and	O
2	O
,	O
3	O
,	O
24	O
,	O
and	O
72h	O
after	O
dose	O
fractions	O
.	O
DSB	O
-	O
foci	O
markers	O
,	O
γH2AX	O
and	O
53BP1	O
,	O
were	O
labelled	O
in	O
epidermal	O
keratinocytes	O
with	O
immunofluorescence	B-T059
and	O
immunohistochemical	B-T059
staining	I-T059
.	O
Foci	O
were	O
counted	O
both	O
with	O
digital	B-T060
image	I-T060
analysis	I-T060
and	O
manually	O
.	O
HRS	O
in	O
keratinocytes	O
was	O
evidenced	O
by	O
the	O
dose	O
-	O
response	O
relationships	O
of	O
DSB	O
foci	O
,	O
observed	O
throughout	O
the	O
treatment	O
course	O
,	O
independent	O
of	O
sampling	B-T060
time	O
and	O
quantification	O
method	O
.	O
Foci	O
observed	O
at	O
24h	O
after	O
dose	O
fractions	O
indicated	O
considerable	O
DSB	O
persistence	O
.	O
Accordingly	O
,	O
foci	O
significantly	O
accumulated	O
after	O
5	O
consecutive	O
dose	O
fractions	O
.	O
For	O
doses	O
below	O
0.3Gy	O
,	O
persistent	O
foci	O
could	O
be	O
observed	O
even	O
at	O
72h	O
after	O
damage	O
induction	O
.	O
A	O
comparison	O
of	O
γH2AX	O
and	O
53BP1	O
quantifications	O
in	O
double	O
-	O
staine	O
d	O
biopsies	B-T060
showed	O
similar	O
HRS	O
dose	O
-	O
response	O
relationships	O
.	O
These	O
results	O
represented	O
the	O
first	O
evidence	O
of	O
preserved	O
HRS	O
,	O
assessed	O
by	O
γH2AX	O
-	O
and	O
53BP1	O
-labelled	O
DSB	O
foci	O
,	O
throughout	O
a	O
7-	O
week	O
treatment	O
course	O
with	O
daily	O
repeated	O
subtherapeutic	O
dose	O
fractions	O
.	O
      
Geographical	B-T033
variations	I-T033
in	O
incidence	O
,	O
management	B-T058
and	O
survival	O
of	O
hepatocellular	B-T191
carcinoma	I-T191
in	O
a	O
Western	O
country	O
Information	O
on	O
the	O
incidence	O
,	O
management	B-T058
,	O
and	O
prognosis	B-T058
of	O
hepatocellular	B-T191
carcinoma	I-T191
(	O
HCC	B-T191
)	O
is	O
derived	O
from	O
population	O
samples	O
,	O
regional	O
data	O
,	O
or	O
registries	O
.	O
Comprehensive	O
national	O
evaluations	B-T058
within	O
a	O
given	O
country	O
are	O
lacking	O
.	O
This	O
study	O
aimed	O
to	O
investigate	O
regional	O
variations	O
in	O
HCC	B-T191
care	O
within	O
France	O
.	O
This	O
observational	O
study	O
analysed	O
data	O
from	O
French	O
administrative	O
databases	O
for	O
more	O
than	O
30,000	O
patients	O
with	O
HCC	B-T191
diagnosed	B-T033
between	O
2009	O
and	O
2012	O
,	O
and	O
followed	O
-	O
up	O
until	O
2013	O
.	O
The	O
incidence	O
of	O
HCC	B-T191
,	O
access	O
to	O
surgery	B-T061
,	O
and	O
survival	O
,	O
at	O
both	O
the	O
national	O
level	O
and	O
two	O
geographical	O
levels	O
(	O
the	O
21	O
French	O
regions	O
and	O
95	O
French	O
departments	O
into	O
which	O
France	O
is	O
divided	O
administratively	O
)	O
,	O
were	O
determined	O
.	O
The	O
influence	O
on	O
outcome	O
of	O
the	O
structure	O
of	O
the	O
hospital	O
where	O
HCC	B-T191
was	O
first	O
managed	O
was	O
assessed	O
.	O
At	O
the	O
national	O
level	O
,	O
the	O
median	O
survival	O
was	O
9.4	O
months	O
and	O
only	O
22.8	O
%	O
of	O
patients	O
had	O
curative	B-T033
treatment	I-T033
.	O
There	O
were	O
marked	O
variations	O
between	O
regions	O
and	O
departments	O
in	O
incidence	O
,	O
access	O
to	O
curative	B-T033
treatment	I-T033
(	O
range	O
1.3	O
-	O
28.8	O
%	O
and	O
8.1	O
-	O
32.3	O
%	O
respectively	O
)	O
,	O
and	O
in	O
median	O
survival	O
(	O
range	O
5.7	O
-	O
12.1	O
and	O
4.3	O
-	O
16.5	O
months	O
respectively	O
)	O
.	O
The	O
administrative	O
type	O
and	O
annual	O
HCC	B-T191
-	O
caseload	O
of	O
the	O
hospital	O
where	O
patients	O
were	O
first	O
admitted	B-T058
also	O
had	O
an	O
independent	O
influence	O
on	O
treatment	B-T061
and	O
survival	O
.	O
Despite	O
full	O
insurance	O
coverage	O
for	O
all	O
citizens	O
,	O
national	O
measures	O
to	O
reduce	O
inequities	O
in	O
the	O
management	B-T058
of	O
cancer	O
patients	O
,	O
standardised	O
recommendations	O
for	O
HCC	B-T191
surveillance	B-T061
and	O
management	B-T058
,	O
the	O
percentage	O
of	O
patients	O
undergoing	O
curative	B-T033
treatment	I-T033
and	O
their	O
survival	O
may	O
vary	O
four	O
-	O
fold	O
depending	O
on	O
their	O
postcode	B-T033
.	O
The	O
hospital	O
in	O
which	O
patients	O
are	O
first	O
managed	O
has	O
a	O
clear	O
influence	O
on	O
accessibility	O
to	O
both	O
good	O
care	O
and	O
survival	O
.	O
Population	O
-	O
based	O
studies	O
have	O
highlighted	O
large	O
and	O
sometimes	O
unexpected	O
differences	O
between	O
countries	O
in	O
the	O
survival	O
of	O
patients	O
with	O
malignancy	B-T191
.	O
As	O
these	O
differences	O
are	O
considered	O
to	O
indicate	O
the	O
overall	O
effectiveness	O
of	O
health	O
systems	O
,	O
in	O
addition	O
to	O
the	O
incidence	O
of	O
the	O
cancer	B-T191
or	O
quality	O
of	O
registration	B-T058
,	O
variations	O
within	O
a	O
given	O
country	O
should	O
be	O
minimal	O
.	O
However	O
,	O
similar	O
to	O
between	O
countries	O
differences	O
,	O
this	O
study	O
shows	O
differences	O
within	O
the	O
same	O
country	O
in	O
the	O
incidence	O
,	O
curative	B-T033
treatment	I-T033
rate	O
,	O
and	O
survival	O
of	O
patients	O
with	O
HCC	B-T191
.	O
Evidence	O
that	O
access	O
to	O
care	O
and	O
survival	O
varies	O
within	O
a	O
country	O
can	O
strengthen	O
the	O
impetus	O
for	O
government	O
and	O
clinicians	O
to	O
address	O
these	O
disparities	O
.	O
      
Evaluation	O
of	O
DNMT1	O
gene	O
expression	O
profile	O
and	O
methylation	O
of	O
its	O
promoter	O
region	O
in	O
patients	O
with	O
ankylosing	B-T047
spondylitis	I-T047
Ankylosing	B-T047
spondylitis	I-T047
(	O
AS	B-T047
)	O
is	O
an	O
autoimmune	B-T047
disease	I-T047
with	O
a	O
chronic	B-T047
inflammatory	I-T047
arthritis	I-T047
.	O
The	O
critical	O
role	O
of	O
methylation	O
in	O
the	O
biology	O
of	O
immunocytes	O
has	O
increasingly	O
been	O
surveyed	O
to	O
discover	O
disease	B-T047
etiology	O
.	O
DNA	O
methyltransferase	O
1	O
(	O
DNMT1	O
)	O
is	O
an	O
enzyme	O
,	O
which	O
establishes	O
and	O
regulates	O
patterns	O
of	O
methylated	O
cytosine	O
residues	O
.	O
The	O
aim	O
of	O
the	O
current	O
investigation	B-T058
was	O
to	O
unveil	O
if	O
methylation	O
circumstances	O
of	O
CpG	O
sites	O
in	O
DNMT1	O
promoter	O
could	O
affect	O
the	O
mRNA	O
expression	O
level	O
of	O
this	O
gene	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
from	O
AS	B-T047
patients	O
.	O
PBMCs	O
were	O
isolated	O
from	O
whole	O
blood	O
of	O
40	O
AS	B-T047
patients	O
and	O
40	O
healthy	O
individuals	O
.	O
Total	O
RNA	O
and	O
DNA	O
contents	O
of	O
leukocytes	O
were	O
extracted	B-T061
.	O
Afterward	O
,	O
quantitative	O
analysis	O
was	O
carried	O
out	O
by	O
real	O
-	O
time	O
PCR	O
using	O
the	O
SYBR	O
Green	O
PCR	O
Master	O
Mix	O
.	O
Finally	O
,	O
to	O
determine	O
the	O
methylation	O
level	O
,	O
PCR	O
products	O
of	O
bisulfite	O
-	O
treated	O
DNA	O
from	O
patients	O
and	O
controls	O
were	O
sequenced	B-T059
.	O
Compared	O
with	O
healthy	O
controls	O
,	O
expression	O
level	O
of	O
DNMT1	O
in	O
AS	B-T047
patients	O
was	O
significantly	O
downregulated	O
.	O
Methylation	O
of	O
DNMT1	O
promoter	O
was	O
significantly	O
higher	O
in	O
AS	B-T047
patients	O
in	O
comparison	O
to	O
controls	O
.	O
While	O
a	O
negative	B-T033
correlation	O
between	O
methylation	O
and	O
expression	O
level	O
of	O
DNMT1	O
was	O
observed	O
in	O
AS	B-T047
patients	O
,	O
both	O
methylation	O
and	O
expression	O
level	O
of	O
DNMT1	O
did	O
not	O
correlate	O
with	O
clinical	O
manifestations	O
.	O
Considering	O
the	O
observation	O
that	O
decreased	O
expression	O
level	O
of	O
DNMT1	O
was	O
associated	O
with	O
hypermethylation	O
of	O
DNMT1	O
promoter	O
in	O
PBMCs	O
from	O
AS	B-T047
patients	O
,	O
this	O
survey	O
suggests	O
that	O
dysregulation	O
of	O
DNMT1	O
expression	O
through	O
altered	O
methylation	O
level	O
of	O
other	O
target	O
genes	O
would	O
probably	O
contribute	O
to	O
AS	B-T047
development	O
.	O
      
Psychological	O
factors	O
associated	O
with	O
NAFLD	B-T047
/	O
NASH	B-T047
:	O
a	O
systematic	O
review	O
Nonalcoholic	B-T047
fatty	I-T047
liver	I-T047
disease	I-T047
(	O
NAFLD	B-T047
)	O
represents	O
one	O
of	O
the	O
most	O
common	O
chronic	B-T047
liver	I-T047
diseases	I-T047
worldwide	O
.	O
So	O
far	O
,	O
the	O
pathogenesis	O
of	O
NAFLD	B-T047
and	O
its	O
more	O
severe	O
variant	O
nonalcoholic	B-T047
steatohepatitis	I-T047
(	O
NASH	B-T047
)	O
is	O
yet	O
unclear	O
,	O
with	O
many	O
mechanisms	O
being	O
proposed	O
as	O
possible	O
causes	O
.	O
This	O
article	O
aims	O
to	O
review	O
the	O
psychological	O
factors	O
associated	O
with	O
NAFLD	B-T047
/	O
NASH	B-T047
.	O
Three	O
main	O
categories	O
of	O
factors	O
have	O
been	O
investigated	O
:	O
emotional	B-T033
,	O
cognitive	O
and	O
behavioral	O
.	O
Five	O
electronic	O
databases	O
were	O
searched	O
,	O
limited	O
to	O
studies	O
published	O
in	O
the	O
English	O
language	O
,	O
during	O
the	O
period	O
2005	O
-	O
2015	O
:	O
PubMed	O
,	O
Thomson	O
ISI	O
-	O
Web	O
of	O
Science	O
,	O
Scopus	O
,	O
ProQuest	O
,	O
and	O
ScienceDirect	O
.	O
Results	O
indicated	O
the	O
most	O
relevant	O
emotional	B-T033
factors	O
to	O
be	O
depression	B-T048
and	O
anxiety	B-T033
.	O
The	O
areas	O
of	O
investigation	O
for	O
cognitive	O
functioning	O
concern	O
those	O
contents	O
and	O
processes	O
related	O
to	O
the	O
ability	O
to	O
initiate	O
and	O
maintain	O
lifestyle	O
changes	O
.	O
The	O
most	O
important	O
behavioral	O
factors	O
identified	O
are	O
physical	O
activity	O
,	O
nutrition	O
/	O
food	O
intake	O
and	O
substance	O
consumption	O
:	O
coffee	O
,	O
alcohol	O
,	O
cigarettes	O
.	O
Some	O
of	O
the	O
factors	O
identified	O
act	O
as	O
protective	O
factors	O
,	O
other	O
as	O
vulnerability	B-T033
factors	I-T033
.	O
NAFLD	B-T047
/	O
NASH	B-T047
may	O
be	O
considered	O
a	O
cognitive	B-T048
-	I-T048
behavioral	I-T048
disease	I-T048
,	O
the	O
most	O
effective	O
management	B-T058
being	O
lifestyle	O
changes	O
,	O
with	O
emphasis	O
on	O
diet	O
and	O
exercise	O
.	O
      
WDR26	O
promotes	O
mitophagy	O
of	O
cardiomyocytes	O
induced	O
by	O
hypoxia	O
through	O
Parkin	O
translocation	O
Myocardial	B-T047
ischemia	I-T047
is	O
a	O
heart	B-T023
condition	O
caused	O
by	O
reduction	O
of	O
blood	O
flow	O
to	O
the	O
heart	B-T023
,	O
preventing	O
heart	B-T023
from	O
receiving	O
enough	O
oxygen	B-T121
.	O
Myocardial	B-T047
ischemia	I-T047
is	O
the	O
most	O
common	O
cause	B-T033
of	I-T033
death	I-T033
globally	O
.	O
Heart	B-T023
ischemic	B-T061
preconditioning	I-T061
(	O
IPC	B-T061
)	O
has	O
a	O
protective	O
effect	O
against	O
myocardial	O
cell	O
death	O
induced	O
by	O
ischemia	O
and	O
ischemia	O
-	O
reperfusion	O
injury	O
.	O
WDR26	O
has	O
recently	O
been	O
identified	O
as	O
a	O
protein	O
that	O
is	O
increased	O
following	O
rat	O
cardiac	B-T023
IPC	B-T061
.	O
WDR26	O
can	O
promote	O
the	O
proliferation	O
of	O
H9c2	O
cells	O
and	O
protect	O
cardiomyocytes	O
against	O
oxidative	O
stress	O
through	O
inhibiting	O
apoptosis	O
.	O
However	O
,	O
its	O
role	O
in	O
myocardial	B-T047
ischemia	I-T047
is	O
unclear	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
explore	O
the	O
role	O
of	O
WDR26	O
in	O
myocardial	B-T047
ischemia	I-T047
and	O
H9c2	O
cell	O
hypoxia	O
.	O
Our	O
results	O
showed	O
that	O
WDR26	O
is	O
induced	O
by	O
myocardial	B-T047
ischemia	I-T047
and	O
H9c2	O
cell	O
hypoxia	O
.	O
WDR26	O
protects	O
H9c2	O
cells	O
against	O
hypoxia	O
injury	O
through	O
inhibiting	O
LDH	O
release	O
and	O
increasing	O
cell	O
viability	O
.	O
WDR26	O
promotes	O
hypoxia	O
-	O
induced	O
autophagy	O
in	O
hypoxia	O
of	O
H9c2	O
cells	O
.	O
We	O
further	O
demonstrated	O
that	O
in	O
H9c2	O
cell	O
hypoxia	O
,	O
WDR26	O
increases	O
mitochondrial	O
membrane	O
potential	O
,	O
thereby	O
increases	O
Parkin	O
translocation	O
of	O
mitochondria	O
.	O
After	O
Parkin	O
is	O
translocated	O
at	O
mitochondria	O
,	O
WDR26	O
can	O
increase	O
mitochondria	O
l	O
protein	O
ubiquitination	O
in	O
hypoxia	O
of	O
H9c2	O
cells	O
.	O
WDR26	O
is	O
a	O
mediator	O
of	O
response	O
to	O
hypoxia	O
,	O
and	O
WDR26	O
plays	O
an	O
important	O
role	O
in	O
hypoxia	O
-mediated	O
autophagy	O
and	O
mitophagy	O
.	O
This	O
study	O
provides	O
novel	O
insights	O
into	O
the	O
protective	O
role	O
of	O
WDR26	O
in	O
cardiomyocyte	O
injury	O
during	O
hypoxia	O
.	O
WDR26	O
may	O
serve	O
as	O
a	O
potential	O
target	O
for	O
the	O
treatment	B-T061
of	O
myocardial	B-T047
ischemia	I-T047
.	O
      
Targeting	O
the	O
ecology	O
within	O
:	O
The	O
role	O
of	O
the	O
gut	O
-	O
brain	O
axis	O
and	O
human	O
microbiota	B-T001
in	O
drug	B-T048
addiction	I-T048
Despite	O
major	O
advances	O
in	O
our	O
understanding	O
of	O
the	O
brain	B-T023
using	O
traditional	O
neuroscience	O
,	O
reliable	O
and	O
efficacious	O
treatments	B-T061
for	O
drug	B-T048
addiction	I-T048
have	O
remained	B-T033
elusive	I-T033
.	O
Hence	O
,	O
the	O
time	O
has	O
come	O
to	O
utilize	O
novel	O
approaches	O
,	O
particularly	O
those	O
drawing	O
upon	O
contemporary	O
advances	O
in	O
fields	O
outside	O
of	O
established	O
neuroscienc	O
e	O
and	O
psychiatry	O
.	O
Put	O
another	O
way	O
,	O
the	O
time	O
has	O
come	O
for	O
a	O
paradigm	O
shift	O
in	O
the	O
addiction	B-T048
sciences	O
.	O
Apropos	O
,	O
a	O
revolution	O
in	O
the	O
area	O
of	O
human	O
health	O
is	O
underway	O
,	O
which	O
is	O
occurring	O
at	O
the	O
nexus	O
between	O
enteric	O
microbiology	O
and	O
neuroscience	O
.	O
It	O
has	O
become	O
increasingly	O
clear	O
that	O
the	O
human	O
microbiota	B-T001
(	O
the	O
vast	O
ecology	O
of	O
bacteria	B-T007
residing	O
within	O
the	O
human	O
organism	B-T001
)	O
,	O
plays	O
an	O
important	O
role	O
in	O
health	O
and	O
disease	B-T047
.	O
This	O
is	O
not	O
surprising	O
,	O
as	O
it	O
has	O
been	O
estimated	O
that	O
bacteria	B-T007
living	O
in	O
the	O
human	O
body	O
(	O
approximately	O
1	O
kg	O
of	O
mass	O
,	O
roughly	O
equivalent	O
to	O
that	O
of	O
the	O
human	O
brain	B-T023
)	O
outnumber	O
human	O
cells	O
10	O
to	O
1	O
.	O
While	O
advances	O
in	O
the	O
understanding	O
of	O
the	O
role	O
of	O
microbiota	B-T001
in	O
other	O
areas	O
of	O
human	O
health	O
have	O
yielded	O
intriguing	O
results	O
(	O
e.g.	O
,	O
Clostridium	B-T047
difficile	I-T047
,	O
irritable	B-T047
bowel	I-T047
syndrome	I-T047
,	O
autism	B-T048
,	O
etc	O
.	O
)	O
,	O
to	O
date	O
,	O
no	O
systematic	O
programs	O
of	O
research	O
have	O
examined	B-T033
the	O
role	O
of	O
microbiota	B-T001
in	O
drug	B-T048
addiction	I-T048
.	O
The	O
current	O
hypothesis	O
,	O
therefore	O
,	O
is	O
that	O
gut	B-T184
dysbiosis	I-T184
plays	O
a	O
key	O
role	O
in	O
addictive	B-T048
disorders	B-T047
.	O
In	O
the	O
context	O
of	O
this	O
hypothesis	O
,	O
this	O
paper	O
provides	O
a	O
rationale	O
for	O
future	O
research	O
to	O
target	O
the	O
"	O
gut	B-T023
-	O
brain	B-T023
axis	O
"	O
in	O
addiction	B-T048
.	O
A	O
brief	O
background	O
of	O
the	O
gut	B-T023
-	O
brain	B-T023
axis	O
is	O
provided	O
,	O
along	O
with	O
a	O
series	O
of	O
hypothesis	O
-	O
driven	O
ideas	O
outlining	O
potential	O
treatments	B-T061
for	O
addiction	B-T048
via	O
manipulations	B-T033
of	O
the	O
"	O
ecology	O
within	O
.	O
"	O
      
Assessment	B-T058
of	O
cerebral	B-T023
blood	O
perfusion	O
reserve	O
with	O
acetazolamide	B-T121
using	O
3D	B-T060
spiral	I-T060
ASL	I-T060
MRI	I-T060
:	O
Preliminary	O
experience	O
in	O
pediatric	O
patients	O
To	O
demonstrate	O
the	O
clinical	O
feasibility	O
of	O
a	O
new	O
non	B-T060
-	I-T060
Cartesian	I-T060
cylindrically	I-T060
-	I-T060
distributed	I-T060
spiral	I-T060
3D	I-T060
pseudo	I-T060
-	I-T060
continuous	I-T060
arterial	I-T060
spin	I-T060
labeling	I-T060
(	I-T060
pCASL	I-T060
)	I-T060
magnetic	I-T060
resonance	I-T060
imaging	I-T060
(	I-T060
MRI	I-T060
)	I-T060
pulse	O
sequence	O
in	O
pediatric	O
patients	O
in	O
quantifying	O
cerebral	B-T033
blood	I-T033
flow	I-T033
(	O
CBF	B-T033
)	O
response	O
to	O
an	O
acetazolamide	B-T121
(	I-T121
ACZ	I-T121
)	I-T121
vasodilator	I-T121
challenge	O
.	O
MRI	B-T060
exams	I-T060
were	O
performed	O
on	O
two	O
3	O
Tesla	O
Philips	O
Ingenia	O
systems	O
using	O
32	O
channel	O
head	O
coil	O
arrays	O
.	O
After	O
local	O
institutional	O
review	O
board	O
approval	O
,	O
the	O
3D	B-T060
spiral	I-T060
-	I-T060
based	I-T060
pCASL	I-T060
technique	I-T060
was	O
added	O
to	O
a	O
standard	O
brain	B-T060
MRI	I-T060
exam	I-T060
and	O
evaluated	O
in	O
13	O
pediatric	O
patients	O
(	O
average	O
age	O
:	O
11.7±6.4years	O
,	O
range	O
:	O
1.4	O
-	O
22.2years	O
)	O
.	O
All	O
patients	O
were	O
administered	B-T058
ACZ	B-T121
for	O
clinically	B-T033
indicated	I-T033
reasons	O
.	O
Quantitative	O
whole	B-T060
-	I-T060
brain	I-T060
CBF	I-T060
measurements	I-T060
were	O
computed	O
pre	O
-	O
and	O
post	O
-	O
ACZ	B-T121
to	O
assess	O
cerebrovascular	O
reserve	O
.	O
3D	B-T060
spiral	I-T060
pCASL	I-T060
data	O
were	O
successfully	O
reconstructed	O
in	O
all	O
13	O
cases	O
.	O
In	O
11	O
patients	O
,	O
CBF	B-T033
increased	O
2.8	O
%	O
to	O
93.2	O
%	O
after	O
administration	B-T058
of	I-T058
ACZ	B-T121
.	O
In	O
the	O
two	O
remaining	O
patients	O
,	O
CBF	B-T033
decreased	O
by	O
2.4	O
to	O
6.0	O
%	O
after	O
ACZ	B-T121
.	O
The	O
group	O
average	O
change	O
in	O
CBF	B-T033
due	O
to	O
ACZ	B-T121
was	O
approximately	O
25.0	O
%	O
and	O
individual	O
changes	O
were	O
statistically	O
significant	O
(	O
p<0.01	O
)	O
in	O
all	O
patients	O
using	O
a	O
paired	O
t	O
-	O
test	O
analysis	O
.	O
CBF	B-T033
perfusion	O
data	O
were	O
diagnostically	O
useful	O
in	O
supporting	O
conventional	O
MR	B-T060
angiography	I-T060
and	O
clinical	O
findings	O
.	O
3D	B-T060
cylindrically	I-T060
-	I-T060
distributed	I-T060
spiral	I-T060
pCASL	I-T060
MRI	I-T060
provides	O
a	O
robust	O
approach	O
to	O
assess	B-T058
cerebral	B-T033
blood	I-T033
flow	I-T033
and	O
reserve	O
in	O
pediatric	O
patients	O
.	O
      
Group	O
III	O
/	O
IV	O
muscle	O
afferents	O
limit	O
the	O
intramuscular	O
metabolic	O
perturbation	O
during	O
whole	B-T017
body	I-T017
exercise	O
in	O
humans	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	B-T059
the	O
role	O
of	O
group	O
III	O
/	O
IV	O
muscle	O
afferents	O
in	O
limiting	O
the	O
endurance	B-T033
exercise	O
-	O
induced	O
metabolic	O
perturbation	O
assayed	B-T059
in	O
muscle	O
biopsy	O
samples	O
taken	O
from	O
locomotor	O
muscle	O
.	O
Lumbar	O
intrathecal	O
fentanyl	B-T121
was	O
used	O
to	O
attenuate	O
the	O
central	O
projection	O
of	O
μ	O
-	O
opioid	O
receptor	O
-	O
sensitive	O
locomotor	O
muscle	O
afferents	O
during	O
a	O
5	O
km	O
cycling	O
time	O
trial	O
.	O
The	O
findings	B-T033
suggest	O
that	O
the	O
central	O
projection	O
of	O
group	O
III	O
/	O
IV	O
muscle	O
afferent	O
feedback	O
constrains	O
voluntary	O
neural	O
'	O
drive	O
'	O
to	O
working	O
locomotor	O
muscle	O
and	O
limits	O
the	O
exercise	O
-	O
induced	O
intramuscular	O
metabolic	O
perturbation	O
.	O
Therefore	O
,	O
the	O
CNS	O
might	O
regulate	O
the	O
degree	O
of	O
metabolic	O
perturbation	O
within	O
locomotor	O
muscle	O
and	O
thereby	O
limit	O
peripheral	O
fatigue	B-T184
.	O
It	O
appears	O
that	O
the	O
group	O
III	O
/	O
IV	O
muscle	O
afferents	O
are	O
an	O
important	O
neural	O
link	O
in	O
this	O
regulatory	O
mechanism	O
,	O
which	O
probably	O
serves	O
to	O
protect	B-T033
locomotor	O
muscle	O
from	O
the	O
potentially	O
severe	O
functional	B-T033
impairment	I-T033
as	O
a	O
consequence	O
of	O
severe	O
intramuscular	O
metabolic	O
disturbance	O
.	O
To	O
investigate	O
the	O
role	O
of	O
metabo	O
-	O
and	O
mechanosensitive	O
group	O
III	O
/	O
IV	O
muscle	O
afferents	O
in	O
limiting	O
the	O
intramuscular	O
metabolic	O
perturbation	O
during	O
whole	B-T017
body	I-T017
endurance	B-T033
exercise	O
,	O
eight	O
subjects	O
performed	O
5	O
km	O
cycling	O
time	O
trials	O
under	B-T033
control	I-T033
conditions	I-T033
(	O
CTRL	B-T033
)	O
and	O
with	O
lumbar	O
intrathecal	O
fentanyl	B-T121
impairing	O
lower	B-T023
limb	I-T023
muscle	O
afferent	O
feedback	O
(	O
FENT	O
)	O
.	O
Vastus	B-T023
lateralis	I-T023
muscle	O
biopsies	O
were	O
obtained	O
before	O
and	O
immediately	O
after	O
exercise	O
.	O
Motoneuronal	O
output	B-T060
was	I-T060
estimated	I-T060
through	O
vastus	B-T023
lateralis	I-T023
surface	I-T023
electromyography	B-T060
(	O
EMG	B-T060
)	O
.	O
Exercise	O
-	O
induced	O
changes	O
in	O
intramuscular	O
metabolites	O
were	O
determine	B-T059
d	O
using	O
liquid	O
and	O
gas	B-T059
chromatography	I-T059
-	I-T059
mass	I-T059
spectrometry	I-T059
.	O
Quadriceps	B-T023
fatigue	B-T184
was	O
quantified	O
by	O
pre	O
-	O
to	O
post	O
-	O
exercise	O
changes	O
in	O
potentiated	O
quadriceps	O
twitch	O
torque	O
(	O
ΔQTsingle	O
)	O
evoked	O
by	O
electrical	O
femoral	B-T023
nerve	I-T023
stimulation	B-T061
.	O
Although	O
motoneuronal	O
output	O
was	O
21	O
±	O
12	O
%	O
higher	O
during	O
FENT	O
compared	O
to	O
CTRL	B-T033
(	O
P	O
<	O
0.05	O
)	O
,	O
time	O
to	O
complete	O
the	O
time	O
trial	O
was	O
similar	O
(	O
∼8.8	O
min	O
)	O
.	O
Compared	O
to	O
CTRL	B-T033
,	O
power	O
output	O
during	O
FENT	O
was	O
10	O
±	O
4	O
%	O
higher	O
in	O
the	O
first	B-T033
half	I-T033
of	O
the	O
time	O
trial	O
,	O
but	O
11	O
±	O
5	O
%	O
lower	O
in	O
the	O
second	B-T033
half	I-T033
(	O
both	O
P	O
<	O
0.01	O
)	O
.	O
The	O
exercise	O
-	O
induced	O
increase	O
in	O
intramuscular	O
inorganic	B-T121
phosphate	I-T121
,	O
H(+	O
)	O
,	O
adenosine	O
diphosphate	O
,	O
lactate	O
and	O
phosphocreatine	B-T121
depletion	O
was	O
55	O
±	O
30	O
,	O
62	O
±	O
18	O
,	O
129	O
±	O
63	O
,	O
47	O
±	O
14	O
(	O
P	O
<	O
0.001	O
)	O
and	O
27	O
±	O
14	O
%	O
(	O
P	O
<	O
0.01	O
)	O
greater	O
in	O
FENT	O
than	O
CTRL	B-T033
.	O
ΔQTsingle	O
was	O
greater	O
following	O
FENT	O
than	O
CTRL	B-T033
(	O
-52	O
±	O
2	O
vs	O
-31	O
±	O
1	O
%	O
,	O
P	O
<	O
0.001	O
)	O
and	O
this	O
difference	O
was	O
positively	B-T033
correlated	O
with	O
the	O
difference	O
in	O
inorganic	B-T121
phosphate	I-T121
(	O
r(2	O
)	O
=	O
0.79	O
;	O
P	O
<	O
0.01	O
)	O
and	O
H(+	O
)	O
(	O
r(2	O
)	O
=	O
0.92	O
;	O
P	O
<	O
0.01	O
)	O
.	O
In	O
conclusion	O
,	O
during	O
whole	B-T017
body	I-T017
exercise	O
,	O
group	O
III	O
/	O
IV	O
muscle	O
afferents	O
provide	O
feedback	O
to	O
the	O
CNS	O
which	O
,	O
in	O
turn	O
,	O
constrains	O
motoneuronal	O
output	O
to	O
the	O
active	O
skeletal	O
muscle	O
.	O
This	O
regulatory	O
mechanism	O
limits	O
the	O
exercise	O
-	O
induced	O
intramuscular	O
metabolic	O
perturbation	O
,	O
preventing	O
an	O
abnormal	B-T033
homeostatic	I-T033
challenge	B-T058
and	O
excessive	O
peripheral	O
fatigue	B-T184
.	O
      
High	O
Diversity	O
of	O
Planctomycetes	B-T007
in	O
Soils	O
of	O
Two	O
Lichen	O
-Dominated	O
Sub	O
-	O
Arctic	O
Ecosystems	O
of	O
Northwestern	O
Siberia	O
A	O
wide	O
variety	O
of	O
terrestrial	O
ecosystems	O
in	O
tundra	O
have	O
a	O
ground	O
vegetation	O
cover	O
composed	O
of	O
reindeer	O
lichens	O
(	O
genera	O
Cladonia	O
and	O
Cetraria	O
)	O
.	O
The	O
microbial	B-T001
communities	O
of	O
two	O
lichen	O
-dominated	O
ecosystems	O
typical	O
of	O
the	O
sub	O
-	O
arctic	O
zone	O
of	O
northwestern	O
Siberia	O
,	O
that	O
is	O
a	O
forested	O
tundra	O
soil	O
and	O
a	O
shallow	O
acidic	O
peatland	O
,	O
were	O
examined	O
in	O
our	O
study	O
.	O
As	O
revealed	O
by	O
molecular	O
analyses	O
,	O
soil	O
and	O
peat	O
layers	O
just	O
beneath	O
the	O
lichen	O
cover	O
were	O
abundantly	O
colonized	B-T033
by	O
bacteria	B-T007
from	O
the	O
phylum	O
Planctomycetes	B-T007
.	O
Highest	O
abundance	O
of	O
planctomycetes	B-T007
detected	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
was	O
in	O
the	O
range	O
2.2	O
-	O
2.7	O
×	O
10(7	O
)	O
cells	O
per	O
gram	O
of	O
wet	O
weight	O
.	O
16S	O
rRNA	O
gene	O
fragments	O
from	O
the	O
Planctomycetes	B-T007
comprised	O
8	O
-	O
13	O
%	O
of	O
total	O
16S	O
rRNA	O
gene	O
reads	O
retrieved	O
using	O
Illumina	O
pair	O
-	O
end	O
sequencing	O
from	O
the	O
soil	O
and	O
peat	O
samples	O
.	O
Lichen	O
-associated	O
assemblages	O
of	O
planctomycetes	B-T007
displayed	O
unexpectedly	O
high	O
diversity	O
,	O
with	O
a	O
total	O
of	O
89,662	O
reads	O
representing	O
1723	O
operational	O
taxonomic	O
units	O
determined	O
at	O
97	O
%	O
sequence	O
identity	O
.	O
The	O
soil	O
of	O
forested	O
tundra	O
was	O
dominated	O
by	O
uncultivated	O
members	O
of	O
the	O
family	O
Planctomycetaceae	B-T007
(	O
53	O
-	O
71	O
%	O
of	O
total	O
Planctomycetes	B-T007
-like	O
reads	O
)	O
,	O
while	O
sequences	O
affiliated	O
with	O
the	O
Phycisphaera	B-T007
-	I-T007
related	I-T007
group	I-T007
WD2101	I-T007
(	O
recently	O
assigned	O
to	O
the	O
order	O
Tepidisphaerales	B-T007
)	O
were	O
most	O
abundant	O
in	O
peat	O
(	O
28	O
-	O
51	O
%	O
of	O
total	O
reads	O
)	O
.	O
Representatives	O
of	O
the	O
Isosphaera	B-T007
-	O
Singulisphaera	B-T007
group	I-T007
(	O
14	O
-	O
28	O
%	O
of	O
total	O
reads	O
)	O
and	O
the	O
lineages	O
defined	O
by	O
the	O
genera	O
Gemmata	B-T007
(	O
1	O
-	O
4	O
%	O
)	O
and	O
Planctopirus	B-T007
-	O
Rubinisphaera	B-T007
(	O
1	O
-	O
3	O
%	O
)	O
were	O
present	O
in	O
both	O
habitats	O
.	O
Two	O
strains	O
of	O
Singulisphaera	B-T007
-	I-T007
like	I-T007
bacteria	I-T007
were	O
isolated	O
from	O
studied	O
soil	O
and	O
peat	O
samples	O
.	O
These	O
planctomycetes	B-T007
displayed	O
good	O
tolerance	O
of	O
low	O
temperatures	O
(	O
4	O
-	O
15	O
°	O
C	O
)	O
and	O
were	O
capable	O
of	O
growth	O
on	O
a	O
number	O
of	O
polysaccharides	B-T121
,	O
including	O
lichenan	O
,	O
a	O
characteristic	O
component	O
of	O
lichen	O
-derived	O
phytomass	O
.	O
      
A	O
Novel	O
Potent	O
Anticancer	B-T121
Compound	I-T121
Optimized	O
from	O
a	O
Natural	O
Oridonin	B-T121
Scaffold	O
Induces	O
Apoptosis	O
and	O
Cell	O
Cycle	O
Arrest	O
through	O
the	O
Mitochondrial	O
Pathway	O
The	O
cytotoxicity	O
of	O
the	O
natural	O
ent	B-T121
-	I-T121
kaurene	I-T121
diterpenoid	I-T121
,	O
oridonin	B-T121
,	O
has	O
been	O
extensively	O
studied	O
.	O
However	O
,	O
the	O
application	O
of	O
oridonin	B-T121
for	O
cancer	B-T061
therapy	I-T061
was	O
hampered	O
primarily	O
by	O
its	O
moderate	O
potency	O
.	O
In	O
this	O
study	O
,	O
a	O
series	O
of	O
oridonin	B-T121
A	O
-	O
ring	O
modified	O
analogues	O
,	O
and	O
their	O
derivatives	O
bearing	O
various	O
substituents	O
on	O
14	O
-	O
OH	O
position	O
,	O
were	O
designed	O
,	O
synthesized	O
,	O
and	O
evaluated	B-T058
for	O
anticancer	B-T121
efficacy	O
.	O
Some	O
of	O
the	O
derivatives	O
were	O
significantly	O
more	O
potent	O
than	O
oridonin	B-T121
against	O
both	O
drug	B-T121
-	O
sensitive	O
and	O
drug	O
-	O
resistant	O
cancer	O
cells	O
.	O
The	O
most	O
potent	O
compound	B-T121
,	I-T121
13p	I-T121
,	O
was	O
200	O
-	O
fold	O
more	O
efficacious	O
than	O
oridonin	B-T121
in	O
MCF-7	O
cancer	O
cells	O
.	O
Furthermore	O
,	O
13p	B-T121
induced	O
apoptosis	O
and	O
cell	O
cycle	O
arrest	O
at	O
the	O
G2	O
/	O
M	O
phase	O
.	O
A	O
decrease	O
in	O
mitochondrial	O
membrane	O
potential	O
and	O
an	O
increase	O
in	O
Bax	O
/	O
Bcl-2	O
ratio	O
,	O
accompanied	O
by	O
activated	O
caspase-3	O
cleavage	O
,	O
were	O
observed	O
in	O
MCF-7	O
cells	O
after	O
treatment	B-T061
with	O
13p	B-T121
,	O
suggesting	O
that	O
the	O
mitochondrial	O
pathway	O
was	O
involved	O
in	O
the	O
13p	B-T121
-mediated	O
apoptosis	O
.	O
Moreover	O
,	O
13p	B-T121
significantly	O
inhibited	O
tumor	B-T191
growth	I-T191
in	O
mouse	O
xenograft	B-T050
models	I-T050
and	O
had	O
no	B-T184
observable	I-T184
toxic	I-T184
effect	I-T184
.	O
      
Genome	O
-	O
Wide	O
Detection	O
of	O
Selective	O
Signatures	O
in	O
Chicken	O
through	O
High	O
Density	O
SNPs	O
Chicken	O
is	O
recognized	O
as	O
an	O
excellent	O
model	O
for	O
studies	O
of	O
genetic	O
mechanism	O
of	O
phenotypic	O
and	O
genomic	O
evolution	O
,	O
with	O
large	O
effective	O
population	O
size	O
and	O
strong	O
human	O
-driven	O
selection	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
performed	O
Extended	O
Haplotype	O
Homozygosity	O
(	O
EHH	O
)	O
tests	O
to	O
identify	O
significant	O
core	O
regions	O
employing	O
600	O
K	O
SNP	O
Chicken	O
chip	O
in	O
an	O
F2	O
population	O
of	O
1,534	O
hens	O
,	O
which	O
was	O
derived	O
from	O
reciprocal	B-T059
crosses	I-T059
between	O
White	O
Leghorn	O
and	O
Dongxiang	O
chicken	O
.	O
Results	O
indicated	O
that	O
a	O
total	O
of	O
49,151	O
core	O
regions	O
with	O
an	O
average	O
length	O
of	O
9.79	O
Kb	O
were	O
identified	O
,	O
which	O
occupied	O
approximately	O
52.15	O
%	O
of	O
genome	O
across	O
all	O
autosomes	O
,	O
and	O
806	O
significant	O
core	O
regions	O
attracted	O
us	O
mostly	O
.	O
Genes	O
in	O
candidate	O
regions	O
may	O
experience	O
positive	B-T059
selection	I-T059
and	O
were	O
considered	O
to	O
have	O
possible	O
influence	O
on	O
beneficial	O
economic	O
traits	O
.	O
A	O
panel	O
of	O
genes	O
including	O
AASDHPPT	O
,	O
GDPD5	O
,	O
PAR3	O
,	O
SOX6	O
,	O
GPC1	O
and	O
a	O
signal	O
pathway	O
of	O
AKT1	O
were	O
detected	B-T033
with	O
the	O
most	O
extreme	O
P	O
-	O
values	O
.	O
Further	O
enrichment	O
analyses	O
indicated	O
that	O
these	O
genes	O
were	O
associated	O
with	O
immune	O
function	O
,	O
sensory	O
organ	O
development	O
and	O
neurogenesis	O
,	O
and	O
may	O
have	O
experienced	O
positive	B-T059
selection	I-T059
in	O
chicken	O
.	O
Moreover	O
,	O
some	O
of	O
core	O
regions	O
exactly	O
overlapped	O
with	O
genes	O
excavated	O
in	O
our	O
previous	O
GWAS	O
,	O
suggesting	O
that	O
these	O
genes	O
have	O
undergone	O
positive	B-T059
selection	I-T059
may	O
affect	O
egg	O
production	O
.	O
Findings	O
in	O
our	O
study	O
could	O
draw	O
a	O
comparatively	O
integrate	O
genome	O
-	O
wide	O
map	O
of	O
selection	O
signature	O
in	O
the	O
chicken	O
genome	O
,	O
and	O
would	O
be	O
worthy	O
for	O
explicating	O
the	O
genetic	O
mechanisms	O
of	O
phenotypic	O
diversity	O
in	O
poultry	O
breeding	O
.	O
      
A	O
novel	O
method	O
for	O
interactive	O
multi	O
-	O
objective	O
dose	B-T058
-	I-T058
guided	I-T058
patient	I-T058
positioning	I-T058
In	O
intensity	B-T061
-	I-T061
modulated	I-T061
radiation	I-T061
therapy	I-T061
(	O
IMRT	B-T061
)	O
,	O
3D	O
in	O
-	O
room	O
imaging	B-T060
data	O
is	O
typically	O
utilized	O
for	O
accurate	O
patient	O
alignment	O
on	O
the	O
basis	O
of	O
anatomical	O
landmarks	O
.	O
In	O
the	O
presence	O
of	O
non	O
-	O
rigid	O
anatomical	O
changes	O
,	O
it	O
is	O
often	O
not	O
obvious	O
which	O
patient	B-T033
position	I-T033
is	O
most	O
suitable	O
.	O
Thus	O
,	O
dose	O
-guided	O
patient	O
alignment	O
is	O
an	O
interesting	O
approach	O
to	O
use	O
available	O
in	O
-	O
room	O
imaging	B-T060
data	O
for	O
up	O
-	O
to	O
-	O
date	O
dose	O
calculation	O
,	O
aimed	O
at	O
finding	B-T033
the	O
position	O
that	O
yields	O
the	O
optimal	O
dose	O
distribution	O
.	O
This	O
contribution	O
presents	O
the	O
first	O
implementation	O
of	O
dose	O
-guided	O
patient	O
alignment	O
as	O
multi	O
-	O
criteria	O
optimization	O
problem	O
.	O
User	O
-	O
defined	O
clinical	O
objectives	O
are	O
employed	O
for	O
setting	O
up	O
a	O
multi	O
-	O
objective	O
problem	O
.	O
Using	O
pre	O
-	O
calculated	O
dose	O
distributions	O
at	O
a	O
limited	O
number	O
of	O
patient	B-T058
shifts	I-T058
and	O
dose	O
interpolation	O
,	O
a	O
continuous	O
space	O
of	O
Pareto	B-T058
-	I-T058
efficient	I-T058
patient	I-T058
shifts	I-T058
becomes	O
accessible	O
.	O
Pareto	O
sliders	O
facilitate	O
interactive	O
browsing	O
of	O
the	O
possible	O
shifts	O
with	O
real	O
-	O
time	O
dose	O
display	O
to	O
the	O
user	O
.	O
Dose	O
interpolation	O
accuracy	O
is	O
validated	O
and	O
the	O
potential	O
of	O
multi	O
-	O
objective	O
dose	B-T058
-	I-T058
guided	I-T058
positioning	I-T058
demonstrated	O
for	O
three	O
head	B-T191
and	I-T191
neck	I-T191
(	O
H&N	B-T191
)	O
and	O
three	O
prostate	B-T191
cancer	I-T191
patients	O
.	O
Dose	B-T058
-	I-T058
guided	I-T058
positioning	I-T058
is	O
compared	O
to	O
replanning	O
for	O
all	O
cases	O
.	O
A	O
delineated	O
replanning	O
CT	B-T060
served	O
as	O
surrogate	O
for	O
in	O
-	O
room	O
imaging	B-T060
data	O
.	O
Dose	O
interpolation	O
accuracy	O
was	O
high	O
.	O
Using	O
a	O
[	O
Formula	O
:	O
see	O
text	O
]	O
dose	O
difference	O
criterion	O
,	O
a	O
median	O
pass	O
-	O
rate	O
of	O
95.7	O
%	O
for	O
H&N	B-T191
and	O
99.6	O
%	O
for	O
prostate	B-T191
cases	I-T191
was	O
determined	O
in	O
a	O
comparison	O
to	O
exact	O
dose	O
calculations	O
.	O
For	O
all	O
patients	O
,	O
dose	B-T058
-	I-T058
guided	I-T058
positioning	I-T058
allowed	O
to	O
find	O
a	O
clinically	O
preferable	O
dose	O
distribution	O
compared	O
to	O
bony	O
anatomy	O
based	O
alignment	O
.	O
For	O
all	O
H&N	B-T191
cases	O
,	O
mean	O
dose	O
to	O
the	O
spared	O
parotid	B-T023
glands	I-T023
was	O
below	O
[	O
Formula	O
:	O
see	O
text	O
]	O
(	O
up	O
to	O
[	O
Formula	O
:	O
see	O
text	O
]	O
with	O
bony	O
alignment	O
)	O
and	O
clinical	O
target	O
volume	O
(	O
CTV	O
)	O
[	O
Formula	O
:	O
see	O
text	O
]	O
above	O
99.1	O
%	O
(	O
compared	O
to	O
95.1	O
%	O
)	O
.	O
For	O
all	O
prostate	B-T191
patients	O
,	O
CTV	O
[	O
Formula	O
:	O
see	O
text	O
]	O
was	O
above	O
98.9	O
%	O
(	O
compared	O
to	O
88.5	O
%	O
)	O
and	O
[	O
Formula	O
:	O
see	O
text	O
]	O
to	O
the	O
rectum	O
below	O
[	O
Formula	O
:	O
see	O
text	O
]	O
(	O
compared	O
to	O
56.1	O
%	O
)	O
.	O
Replanning	O
yielded	O
improved	O
results	O
for	O
the	O
H&N	B-T191
cases	O
.	O
For	O
the	O
prostate	B-T191
cases	I-T191
,	O
differences	O
to	O
dose	B-T058
-	I-T058
guided	I-T058
positioning	I-T058
were	O
minor	O
.	O
      
Wnt-5a	O
/	O
Frizzled9	O
receptor	O
signaling	O
through	O
the	O
Gαo	O
/	O
Gβγ	O
complex	O
regulates	O
dendritic	O
spine	O
formation	O
Wnt	O
ligands	O
play	O
crucial	O
roles	O
in	O
the	O
development	O
and	O
regulation	O
of	O
synapse	O
structure	O
and	O
function	O
.	O
Specifically	O
,	O
Wnt-5a	O
acts	O
as	O
a	O
secreted	O
growth	O
factor	O
that	O
regulates	O
dendritic	O
spine	O
formation	O
in	O
rodent	O
hippocampal	B-T023
neurons	O
,	O
resulting	O
in	O
postsynaptic	O
development	O
that	O
promotes	O
the	O
clustering	O
of	O
the	O
postsynaptic	O
density	O
protein-95	O
(	O
PSD-95	O
)	O
.	O
Here	O
,	O
we	O
focused	O
on	O
the	O
early	O
events	O
occurring	O
after	O
the	O
interaction	O
between	O
Wnt-5a	O
and	O
its	O
Frizzled	O
receptor	O
at	O
the	O
neuronal	O
cell	O
surface	O
.	O
Additionally	O
,	O
we	O
studied	O
the	O
role	O
of	O
heterotrimeric	O
G	O
proteins	O
in	O
Wnt-5a	O
-dependent	O
synaptic	O
development	O
.	O
We	O
report	O
that	O
Frizzled9	O
(	O
FZD9	O
)	O
,	O
a	O
Wnt	O
receptor	O
related	O
to	O
Williams	B-T047
'	I-T047
syndrome	I-T047
,	O
is	O
localized	O
in	O
the	O
postsynaptic	O
region	O
,	O
where	O
it	O
interacts	O
with	O
Wnt-5a	O
.	O
Functionally	O
,	O
FZD9	O
is	O
required	O
for	O
the	O
Wnt-5a	O
-mediated	O
increase	O
in	O
dendritic	O
spine	O
density	O
.	O
FZD9	O
forms	O
a	O
pre	O
-	O
coupled	O
complex	O
with	O
Gαo	O
under	O
basal	O
conditions	O
that	O
dissociates	O
after	O
Wnt-5a	O
stimulation	O
.	O
Accordingly	O
,	O
we	O
found	O
that	O
G	O
-	O
protein	O
inhibition	O
abrogates	O
Wnt-5a	O
-dependent	O
pathway	O
in	O
hippocampal	B-T023
neurons	O
.	O
In	O
particular	O
,	O
the	O
activation	O
of	O
Gαo	O
appears	O
to	O
be	O
a	O
key	O
factor	O
controlling	O
the	O
Wnt-5a	O
-	O
induced	O
dendritic	O
spine	O
density	O
.	O
In	O
addition	O
,	O
we	O
found	O
that	O
Gβγ	O
is	O
required	O
for	O
the	O
Wnt-5a	O
-mediated	O
increase	O
in	O
cytosolic	O
calcium	B-T121
levels	O
and	O
spinogenesis	O
.	O
Our	O
findings	O
reveal	O
that	O
FZD9	O
and	O
heterotrimeric	O
G	O
proteins	O
regulate	O
Wnt-5a	O
signaling	O
and	O
dendritic	O
spines	O
in	O
cultured	O
hippocampal	B-T023
neurons	O
.	O
      
Treated	B-T061
Prevalence	O
of	O
Attention	B-T048
-	I-T048
Deficit	I-T048
/	I-T048
Hyperactivity	I-T048
Disorder	I-T048
Increased	O
from	O
2009	O
to	O
2015	O
Among	O
School	O
-	O
Aged	O
Children	O
and	O
Adolescents	O
in	O
the	O
United	O
States	O
The	O
purpose	O
of	O
this	O
brief	O
is	O
to	O
describe	O
changes	O
in	O
the	O
treated	B-T061
prevalence	O
of	O
medically	O
managed	B-T058
attention	B-T048
-	I-T048
deficit	I-T048
/	I-T048
hyperactivity	I-T048
disorder	I-T048
(	O
ADHD	B-T048
)	O
among	O
insured	O
school	O
-	O
aged	O
children	O
and	O
adolescents	O
in	O
the	O
United	O
States	O
from	O
2009	O
to	O
2015	O
.	O
We	O
examine	B-T033
the	O
differences	O
between	O
those	O
with	O
employer	O
-	O
sponsored	O
insurance	O
(	O
ESI	O
)	O
and	O
with	O
Medicaid	B-T058
insurance	I-T058
.	O
We	O
utilized	O
two	O
large	O
longitudinal	O
administrative	O
datasets	O
containing	O
medical	O
and	O
drug	B-T121
claims	B-T058
data	O
on	O
individuals	O
with	O
ESI	O
and	O
Medicaid	B-T058
insurance	I-T058
from	O
Truven	O
Health	O
MarketScan	O
(	O
®	O
)	O
Administrative	O
Claims	O
Databases	O
.	O
Treated	B-T061
prevalence	O
was	O
measured	O
as	O
the	O
percentage	O
of	O
school	O
-	O
aged	O
children	O
and	O
adolescents	O
enrolled	O
in	O
a	O
calendar	O
year	O
who	O
met	O
the	O
criteria	O
for	O
medically	O
managed	B-T058
ADHD	B-T048
in	O
the	O
same	O
calendar	O
year	O
.	O
Subjects	O
were	O
eligible	O
for	O
inclusion	O
if	O
they	O
were	O
aged	O
6	O
-	O
17	O
years	O
and	O
were	O
continuously	O
enrolled	O
during	O
a	O
calendar	O
year	O
.	O
The	O
annual	O
prevalence	O
of	O
treated	B-T061
ADHD	B-T048
among	O
school	O
-	O
aged	O
children	O
and	O
adolescents	O
with	O
ESI	O
increased	O
from	O
4.5	O
%	O
in	O
2009	O
to	O
6.7	O
%	O
in	O
2015	O
.	O
Among	O
those	O
with	O
Medicaid	B-T058
it	O
increased	O
from	O
11.3	O
%	O
in	O
2009	O
to	O
13.3	O
%	O
in	O
2012	O
,	O
and	O
fell	O
after	O
2012	O
,	O
remaining	O
steady	O
from	O
2013	O
through	O
2015	O
.	O
Treated	B-T061
prevalence	O
of	O
ADHD	B-T048
increased	O
continuously	O
over	O
time	O
among	O
school	O
-	O
aged	O
children	O
and	O
adolescents	O
with	O
ESI	O
,	O
but	O
declined	O
slightly	O
after	O
2012	O
among	O
those	O
in	O
the	O
Medicaid	B-T058
sample	I-T058
.	O
      
Quantification	O
of	O
urinary	O
mono	O
-	O
hydroxylated	O
metabolites	O
of	O
polycyclic	O
aromatic	O
hydrocarbons	O
by	O
on	B-T059
-	I-T059
line	I-T059
solid	I-T059
phase	I-T059
extraction	I-T059
-	O
high	B-T059
performance	I-T059
liquid	I-T059
chromatography	I-T059
-	I-T059
tandem	I-T059
mass	I-T059
spectrometry	I-T059
Human	O
exposure	O
to	O
polycyclic	O
aromatic	O
hydrocarbons	O
(	O
PAHs	O
)	O
can	O
be	O
assessed	O
through	O
monitoring	B-T058
of	O
urinary	O
mono	O
-	O
hydroxylated	O
PAHs	O
(	O
OH	O
-	O
PAHs	O
)	O
.	O
Gas	B-T059
chromatography	I-T059
(	O
GC	B-T059
)	O
has	O
been	O
widely	O
used	O
to	O
separate	O
OH	O
-	O
PAHs	O
before	O
quantification	O
by	O
mass	B-T059
spectrometry	I-T059
in	O
biomonitoring	O
studies	O
.	O
However	O
,	O
because	O
GC	B-T059
requires	O
derivatization	O
,	O
it	O
can	O
be	O
time	O
consuming	O
.	O
We	O
developed	O
an	O
on	B-T059
-	I-T059
line	I-T059
solid	I-T059
phase	I-T059
extraction	I-T059
coupled	O
to	O
isotope	O
dilution	O
-	O
high	B-T059
performance	I-T059
liquid	I-T059
chromatography	I-T059
-	I-T059
tandem	I-T059
mass	I-T059
spectrometry	I-T059
(	O
on	B-T059
-	I-T059
line	I-T059
-	I-T059
SPE	I-T059
-	O
HPLC	B-T059
-	I-T059
MS	I-T059
/	O
MS	B-T059
)	O
method	O
for	O
the	O
quantification	O
in	O
urine	O
of	O
1	B-T121
-	I-T121
OH	I-T121
-	I-T121
naphthalene	I-T121
,	O
2	B-T121
-	I-T121
OH	I-T121
-	I-T121
naphthalene	I-T121
,	O
2	O
-	O
OH	O
-	O
fluorene	O
,	O
3	O
-	O
OH	O
-	O
fluorene	O
,	O
1	O
-	O
OH	O
-	O
phenanthrene	O
,	O
the	O
sum	O
of	O
2	O
-	O
OH	O
and	O
3	O
-	O
OH	O
-	O
phenanthrene	O
,	O
4	O
-	O
OH	O
-	O
phenanthrene	O
,	O
and	O
1	O
-	O
OH	O
-	O
pyrene	O
.	O
The	O
method	O
,	O
which	O
employed	B-T033
a	O
96-	O
well	O
plate	O
platform	O
and	O
on	B-T059
-	I-T059
line	I-T059
SPE	I-T059
,	O
showed	O
good	O
sensitivity	O
(	O
i.e.	O
,	O
limits	O
of	O
detection	B-T061
ranged	O
from	O
0.007	O
to	O
0.09	O
ng	O
/	O
mL	O
)	O
and	O
used	O
only	O
100	O
μL	O
of	O
urine	O
.	O
Accuracy	O
,	O
calculated	B-T059
from	O
the	O
recovery	O
percentage	O
at	O
three	O
spiking	O
levels	O
,	O
varied	O
from	O
94	O
to	O
113	O
%	O
,	O
depending	O
on	O
the	O
analyte	O
.	O
The	O
inter	O
-	O
and	O
intra	O
-	O
day	O
precision	O
,	O
calculated	B-T059
from	O
20	O
repeated	O
measurements	O
of	O
two	O
quality	O
control	O
materials	O
,	O
varied	O
from	O
5.2	O
to	O
16.7	O
%	O
.	O
Adequate	O
method	O
performance	O
was	O
also	O
confirmed	O
by	O
acceptable	O
recovery	O
(	O
83	O
-	O
102	O
%	O
)	O
of	O
two	O
NIST	O
standard	O
reference	O
materials	O
(	O
3672	O
and	O
3673	O
)	O
.	O
This	O
high	O
-	O
throughput	O
on	B-T059
-	I-T059
line	I-T059
-	I-T059
SPE	I-T059
-	O
HPLC	B-T059
-	I-T059
MS	I-T059
/	O
MS	B-T059
method	O
can	O
be	O
applied	O
in	O
large	O
-	O
scale	O
epidemiological	O
studies	O
.	O
Graphical	O
abstract	O
Example	O
LC	O
-	O
MS	O
chromatogram	O
of	O
urinary	O
mono	O
-	O
hydroxylated	O
PAH	O
metabolites	O
.	O
      
Remitting	B-T047
Seronegative	I-T047
Symmetrical	I-T047
Synovitis	I-T047
With	I-T047
Pitting	I-T047
Edema	I-T047
:	O
Appearance	O
on	O
FDG	B-T060
PET	I-T060
/	I-T060
CT	I-T060
Remitting	B-T047
seronegative	I-T047
symmetrical	I-T047
synovitis	I-T047
with	I-T047
pitting	I-T047
edema	I-T047
(	O
RS3PE	B-T047
)	O
is	O
a	O
rare	B-T047
condition	I-T047
in	O
the	O
elderly	O
and	O
can	O
appear	O
as	O
a	O
first	O
presentation	O
of	O
various	O
types	O
of	O
rheumatic	B-T047
and	O
malignant	B-T047
diseases	I-T047
.	O
We	O
presented	O
a	O
62-	O
year	O
-old	O
man	O
with	O
the	O
diagnosis	B-T033
of	O
RS3PE	B-T047
based	O
on	O
the	O
clinical	B-T184
sign	I-T184
and	O
laboratory	O
data	O
.	O
Because	O
of	O
the	O
possibility	O
of	O
associated	O
malignancies	B-T191
in	O
RS3PE	B-T047
,	O
FDG	B-T060
PET	I-T060
/	I-T060
CT	I-T060
was	O
performed	O
to	O
exclude	O
occult	B-T191
tumors	I-T191
.	O
The	O
images	O
showed	O
multiple	O
,	O
symmetrically	B-T033
,	O
diffusely	O
increased	O
F	O
-	O
FDG	O
uptake	O
in	O
the	O
soft	O
tissue	O
around	O
joints	O
and	O
bones	B-T023
in	O
the	O
shoulders	O
,	O
hips	B-T023
,	O
knees	B-T023
,	O
and	O
ankles	O
.	O
      
A	O
comparison	O
of	O
the	O
localization	O
of	O
rectal	B-T191
carcinomas	I-T191
according	O
to	O
the	O
general	O
rules	O
of	O
the	O
Japanese	O
classification	O
of	O
colorectal	O
carcinoma	O
(	O
JCCRC	O
)	O
and	O
Western	O
guidelines	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
localization	O
of	O
rectal	B-T191
cancers	I-T191
as	O
classified	O
according	O
to	O
the	O
general	O
rules	O
of	O
the	O
Japanese	O
classification	O
of	O
colorectal	O
carcinoma	O
(	O
JCCRC	O
)	O
and	O
also	O
according	O
to	O
the	O
European	O
Society	O
for	O
Medical	O
Oncology	O
(	O
ESMO	O
)	O
and	O
the	O
National	O
Comprehensive	O
Cancer	O
Network	O
(	O
NCCN	O
)	O
guidelines	O
,	O
which	O
are	O
based	O
on	O
rigid	B-T060
endoscopic	I-T060
measurements	O
.	O
The	O
medical	O
records	O
of	O
patients	O
scheduled	O
to	O
receive	O
curative	B-T061
surgery	I-T061
for	O
histologically	O
proven	O
rectal	B-T191
adenocarcinoma	I-T191
during	O
2009	O
-	O
2015	O
were	O
investigated	O
(	O
n	O
=	O
230	O
)	O
.	O
Rigid	B-T060
proctoscopy	I-T060
was	O
performed	O
in	O
patients	O
with	O
rectal	B-T191
cancer	I-T191
located	O
in	O
the	O
upper	O
(	O
Ra	O
)	O
or	O
lower	O
(	O
Rb	O
)	O
division	B-T061
using	O
double	B-T060
-	I-T060
contrast	I-T060
barium	I-T060
enema	I-T060
.	O
The	O
median	O
values	O
of	O
height	O
from	O
the	O
anal	B-T023
verge	I-T023
were	O
7.5	O
cm	O
(	O
range	O
2	O
-	O
12	O
)	O
and	O
3	O
cm	O
(	O
0	O
-	O
9.5	O
)	O
on	O
rigid	B-T060
proctoscopy	I-T060
for	O
cancers	B-T191
assigned	O
as	O
Ra	O
and	O
Rb	O
,	O
respectively	O
.	O
All	O
159	O
cancers	B-T191
at	O
Ra	O
or	O
Rb	O
were	O
located	O
within	O
12	O
cm	O
from	O
the	O
anal	B-T023
verge	I-T023
by	O
rigid	B-T060
proctoscopy	I-T060
,	O
while	O
only	O
79.7	O
%	O
of	O
Ra	O
or	O
82.1	O
%	O
of	O
Rb	O
cancers	B-T191
were	O
located	O
in	O
the	O
mid	O
(	O
5.1	O
-	O
10	O
cm	O
)	O
or	O
low	O
(	O
≤5	O
cm	O
)	O
rectum	B-T023
,	O
respectively	O
.	O
Ra	O
and	O
Rb	O
cancers	B-T191
are	O
deemed	O
to	O
be	O
rectal	B-T191
cancers	I-T191
according	O
to	O
NCCN	O
guidelines	O
,	O
but	O
these	O
classifications	O
are	O
not	O
interchangeable	O
with	O
mid-	O
and	O
low	O
-	O
rectal	B-T191
cancers	I-T191
,	O
respectively	O
,	O
according	O
to	O
the	O
ESMO	O
guidelines	O
.	O
      
ANTI	B-T033
ANGIOGENIC	I-T033
EFFECT	I-T033
OF	O
CHEBULAGIC	B-T121
ACID	I-T121
INVOLVES	O
INHIBITION	O
OF	O
VEGFR2	O
AND	O
GSK3β	O
DEPENDENT	O
SIGNALING	O
PATHWAYS	O
Inhibition	O
of	O
angiogenesis	O
is	O
a	O
useful	O
strategy	O
to	O
prevent	O
cancer	B-T191
growth	I-T191
,	O
which	O
targets	O
new	O
vessels	B-T023
that	O
grow	O
to	O
nourish	O
actively	O
proliferating	O
tumor	O
cells	O
.	O
Endothelial	O
cells	O
can	O
use	O
a	O
number	O
of	O
different	O
pathways	O
to	O
cause	O
angiogenesis	O
and	O
each	O
step	O
in	O
these	O
pathways	O
can	O
be	O
targeted	O
.	O
The	O
use	O
of	O
multi	B-T121
targeted	I-T121
drugs	I-T121
is	O
gaining	O
much	O
importance	O
in	O
this	O
scenario	O
.	O
Our	O
previous	O
results	O
have	O
shown	O
the	O
anti	B-T033
angiogenic	I-T033
effect	I-T033
of	O
Chebulagic	B-T121
acid	I-T121
-	O
a	O
benzopyran	O
tannin	B-T121
present	O
in	O
the	O
fruits	O
of	O
Terminalia	O
chebula	O
.	O
The	O
present	O
study	O
was	O
designed	O
to	O
examine	O
the	O
molecular	O
mechanism	O
of	O
the	O
anti	B-T033
angiogenic	I-T033
effect	I-T033
of	O
chebulagic	B-T121
acid	I-T121
.	O
Results	O
of	O
our	O
investigations	O
using	O
molecular	O
docking	O
studies	O
and	O
HUVECs	O
in	O
culture	B-T059
suggested	O
that	O
Chebulagic	B-T121
acid	I-T121
inhibited	O
GSK-3β	O
dependent	O
β	O
-	O
catenin	O
phosphorylation	O
,	O
an	O
important	O
mediator	O
of	O
VE	O
-	O
cadherin	O
/	O
β	O
-	O
catenin	O
signaling	O
and	O
VEGFR2	O
phosphorylation	O
which	O
is	O
an	O
important	O
step	O
involved	O
in	O
VEGF	O
signaling	O
.	O
Chebulagic	B-T121
acid	I-T121
inhibits	O
angiogenesis	O
by	O
blocking	O
both	O
VEGF	O
/	O
VEGFR2	O
and	O
cell	O
-	O
cell	O
contact	O
dependent	O
downstream	O
signaling	O
pathway	O
.	O
      
Nodal	O
skip	B-T033
metastasis	B-T191
in	O
thoracic	B-T191
esophageal	I-T191
squamous	I-T191
cell	I-T191
carcinoma	I-T191
:	O
a	O
cohort	O
study	O
Nodal	O
skip	B-T033
metastasis	B-T191
is	O
a	O
prognostic	O
factor	O
in	O
some	O
sites	O
of	O
malignancies	B-T191
,	O
but	O
its	O
role	O
in	O
esophageal	B-T191
cancer	I-T191
is	O
still	O
unclear	B-T033
.	O
The	O
present	O
study	O
aimed	O
to	O
investigate	O
occurrence	O
and	O
effect	O
of	O
nodal	O
skip	B-T033
metastases	O
in	O
thoracic	B-T191
esophageal	I-T191
squamous	I-T191
cell	I-T191
carcinoma	I-T191
.	O
All	O
578	O
patients	O
undergoing	O
esophagectomy	B-T061
for	O
thoracic	B-T191
esophageal	I-T191
squamous	I-T191
cell	I-T191
carcinoma	I-T191
at	O
the	O
Center	O
for	O
Esophageal	O
Diseases	O
located	O
in	O
Padova	O
between	O
January	O
1992	O
and	O
December	O
2010	O
were	O
retrospectively	O
evaluated	O
.	O
Selection	O
criteria	O
were	O
R0	B-T033
resection	I-T033
,	O
pathological	O
M0	B-T033
stage	I-T033
and	O
pathological	O
lymph	B-T033
node	I-T033
involvement	I-T033
.	O
Patients	O
receiving	O
neoadjuvant	B-T061
therapy	I-T061
were	O
excluded	O
.	O
The	O
selection	O
identified	O
88	O
patients	O
with	O
lymph	B-T033
node	I-T033
involvement	I-T033
confirmed	O
by	O
pathological	O
evaluation	B-T058
.	O
Sixteen	O
patients	O
(	O
18.2	O
%	O
)	O
had	O
nodal	O
skip	B-T033
metastasis	B-T191
.	O
Adjusting	O
for	O
the	O
number	O
of	O
lymph	B-T191
node	I-T191
metastases	I-T191
,	O
patient	O
with	O
nodal	O
skip	B-T033
metastasis	B-T191
had	O
similar	O
5	O
-	O
year	O
overall	O
survival	O
(	O
14	O
%	O
vs.	O
13	O
%	O
,	O
p	O
=	O
0.93	O
)	O
and	O
5	O
-	O
year	O
disease	O
free	O
survival	O
(	O
14	O
%	O
vs.	O
9	O
%	O
,	O
p	O
=	O
0.48	O
)	O
compared	O
to	O
patients	O
with	O
both	O
peritumoral	O
and	O
distant	O
lymph	B-T191
node	I-T191
metastases	I-T191
.	O
The	O
risk	O
difference	O
of	O
nodal	O
skip	B-T033
metastasis	B-T191
was	O
:	O
-24.1	O
%	O
(	O
95	O
%	O
C.I.	O
-43.1	O
%	O
to	O
-5.2	O
%	O
)	O
in	O
patients	O
with	O
more	O
than	O
one	O
lymph	B-T191
node	I-T191
metastasis	I-T191
compared	O
to	O
those	O
with	O
one	O
lymph	B-T191
node	I-T191
metastasis	I-T191
;	O
-2.3	O
%	O
(	O
95	O
%	O
C.I.	O
-29.8	O
%	O
to	O
25.2	O
%	O
)	O
in	O
middle	O
thoracic	B-T023
esophagus	I-T023
and	O
-23.0	O
%	O
(	O
95	O
%	O
C.I.	O
-47.8	O
%	O
to	O
1.8	O
%	O
)	O
in	O
lower	O
thoracic	B-T023
esophagus	I-T023
compared	O
to	O
upper	O
thoracic	B-T023
esophagus	I-T023
;	O
18.1	O
%	O
(	O
95	O
%	O
C.I.	O
3.2	O
%	O
to	O
33.0	O
%	O
)	O
in	O
clinical	O
N0	B-T033
stage	I-T033
vs.	O
clinical	O
N+	B-T033
stage	I-T033
.	O
Nodal	O
skip	B-T033
metastasis	B-T191
is	O
a	O
common	O
pattern	O
of	O
metastatic	B-T033
lymph	I-T033
involvement	I-T033
in	O
thoracic	B-T191
esophageal	I-T191
squamous	I-T191
cell	I-T191
carcinoma	I-T191
.	O
However	O
,	O
neither	O
overall	O
survival	O
nor	O
disease	O
free	O
survival	O
are	O
associated	O
with	O
nodal	O
skip	B-T033
metastasis	B-T191
occurrence	O
.	O
      
Activation	O
of	O
general	O
control	O
nonderepressible	O
2	O
kinase	O
protects	B-T033
human	O
glomerular	O
endothelial	O
cells	O
from	O
harmful	O
high	B-T033
-	I-T033
glucose	I-T033
-	O
induced	O
molecular	O
pathways	O
Considering	O
the	O
referred	O
beneficial	O
effects	O
of	O
protein	O
restriction	O
on	O
diabetic	B-T047
nephropathy	I-T047
(	O
DN	B-T047
)	O
and	O
the	O
role	O
of	O
renal	B-T023
endothelium	O
in	O
its	O
pathogenesis	O
,	O
we	O
evaluated	B-T058
the	O
effect	O
of	O
general	O
control	O
nonderepressible	O
2	O
(	O
GCN2	O
)	O
kinase	O
activation	O
,	O
a	O
sensor	O
of	O
amino	B-T121
acid	I-T121
deprivation	O
,	O
on	O
known	O
detrimental	O
molecular	O
pathways	O
in	O
primary	O
human	O
glomerular	O
endothelial	O
cells	O
(	O
GEnC	O
)	O
.	O
GEnC	O
were	O
cultured	B-T059
under	O
normal	O
or	O
high	B-T047
-glucose	I-T047
conditions	I-T047
in	O
the	O
presence	O
or	O
not	O
of	O
the	O
GCN2	O
kinase	O
activator	O
,	O
tryptophanol	O
.	O
Glucose	O
transporter	O
1	O
(	O
GLUT1	O
)	O
expression	O
was	O
assessed	O
by	O
western	B-T059
blotting	I-T059
and	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
using	O
a	O
fluorogenic	O
probe	O
.	O
Activities	O
of	O
glyceraldehyde	O
3	O
-	O
phosphate	O
dehydrogenase	O
(	O
GAPDH	O
)	O
and	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
were	O
assessed	O
by	O
commercial	B-T059
activity	I-T059
assays	I-T059
,	O
sorbitol	B-T121
colorimetrically	B-T059
,	O
methylglyoxal	O
by	O
ELISA	B-T059
and	O
O	O
-	O
linked	O
β	O
-	O
N	O
-	O
acetyl	O
glucosamine	O
(	O
O	O
-	O
GlcNAc)-modified	O
proteins	O
by	O
western	B-T059
blotting	I-T059
.	O
High	B-T033
glucose	I-T033
induced	O
GLUT1	O
expression	O
,	O
increased	O
ROS	O
and	O
inhibited	O
GAPDH	O
.	O
Also	O
it	O
increased	O
the	O
polyol	O
pathway	O
product	O
sorbitol	B-T121
,	O
PKC	O
activity	O
,	O
the	O
level	O
of	O
the	O
O	O
-	O
GlcNAc	O
-	O
modified	O
proteins	O
that	O
produced	O
by	O
the	O
hexosamine	O
pathway	O
and	O
the	O
advanced	O
glycation	O
endproducts	O
'	O
precursor	O
methylglyoxal	O
.	O
Co	B-T058
-	I-T058
treatment	I-T058
of	O
GEnC	O
with	O
tryptophanol	O
restored	O
the	O
above	O
high	B-T033
-	I-T033
glucose	I-T033
-	O
induced	O
alterations	O
.	O
Activation	O
of	O
GCN2	O
kinase	O
protects	O
GEnC	O
from	O
high	B-T033
-	I-T033
glucose	I-T033
-	O
induced	O
harmful	O
molecular	O
pathways	O
.	O
By	O
inhibiting	O
concurrently	O
many	O
pathways	O
involved	O
in	O
DN	B-T047
pathogenesis	O
,	O
GCN2	O
kinase	O
may	O
serve	O
as	O
a	O
pharmaceutical	O
target	O
for	O
the	O
treatment	B-T061
of	O
DN	B-T047
.	O
      
BJN	O
Awards	O
2016	O
:	O
IV	B-T061
therapy	I-T061
Claire	O
Rickard	O
Professor	O
of	O
Nursing	O
,	O
National	O
Health	O
and	O
Medical	O
Research	O
Council	O
(	O
NHMRC	O
)	O
Centre	O
of	O
Research	O
Excellence	O
in	O
Nursing	O
,	O
Griffith	O
University	O
,	O
was	O
awarded	O
second	O
place	O
in	O
the	O
BJN	O
Awards	O
2016	O
for	O
IV	B-T061
Therapy	I-T061
Nurse	O
of	O
the	O
Year	O
.	O
Here	O
she	O
talks	O
about	O
the	O
she	O
has	O
done	O
to	O
be	O
recognised	O
in	O
this	O
field	B-T058
.	O
      
Visualization	B-T060
of	O
the	O
Intimal	B-T023
Flap	I-T023
in	O
Intracranial	B-T190
Arterial	I-T190
Dissection	I-T190
Using	O
High	B-T059
-	I-T059
Resolution	I-T059
3	B-T060
T	I-T060
MRI	I-T060
Presence	B-T033
of	O
an	O
intimal	B-T023
flap	I-T023
is	O
a	O
critical	O
imaging	O
finding	O
in	O
diagnosing	B-T033
intracranial	B-T190
artery	I-T190
dissection	I-T190
(	O
ICAD	B-T190
)	O
.	O
Recent	O
reports	O
showed	O
that	O
high	B-T059
-	I-T059
resolution	I-T059
magnetic	B-T060
resonance	I-T060
imaging	I-T060
(	O
MRI	B-T060
)	O
was	O
better	O
at	O
identifying	O
intimal	B-T023
flaps	I-T023
as	O
compared	O
with	O
routine	O
MRI	B-T060
techniques	I-T060
used	O
in	O
clinical	O
settings	O
.	O
However	O
,	O
no	O
current	O
standardized	O
sequence	O
for	O
high	B-T059
-	I-T059
resolution	I-T059
MRI	B-T060
without	O
gadolinium	O
enhancement	O
produces	O
images	O
of	O
satisfactory	O
quality	O
with	O
clinically	O
tolerable	O
scanning	B-T060
times	O
.	O
This	O
study	O
evaluated	B-T058
a	O
nonenhanced	B-T060
high	I-T060
-	I-T060
resolution	I-T060
fast	I-T060
spin	I-T060
echo	I-T060
(	I-T060
HR	I-T060
-	I-T060
FSE	I-T060
)	I-T060
MRI	I-T060
sequence	O
for	O
visualizing	O
intimal	B-T023
flaps	I-T023
in	O
patients	O
with	O
ICAD	B-T190
.	O
Three	O
patients	O
with	O
ICAD	B-T190
underwent	O
plain	O
MRI	B-T060
examination	O
using	O
a	O
2	O
-	O
dimensional	O
T2	B-T060
-	I-T060
weighted	I-T060
FSE	I-T060
imaging	I-T060
sequence	O
optimized	O
for	O
our	O
3	O
T	O
system	O
(	O
in	O
-	O
plane	O
pixel	O
size	O
,	O
.23	O
mm	O
×	O
.23	O
mm	O
;	O
slice	O
thickness	O
3	O
mm	O
with	O
no	O
interslice	O
gap	O
)	O
,	O
as	O
well	O
as	O
scanning	B-T060
with	O
conventional	O
modalities	O
,	O
including	O
CT	B-T060
angiography	I-T060
,	O
magnetic	B-T060
resonance	I-T060
angiography	I-T060
,	O
and	O
digital	B-T060
subtraction	I-T060
angiography	I-T060
.	O
We	O
assessed	O
whether	O
these	O
imaging	O
methods	O
could	O
visualize	O
an	O
intimal	B-T023
flap	I-T023
and/or	O
double	B-T033
lumen	I-T033
sign	I-T033
in	O
the	O
participants	O
and	O
compared	O
the	O
results	B-T033
between	O
HR	B-T060
-	I-T060
FSE	I-T060
and	O
the	O
other	O
modalities	O
.	O
HR	B-T060
-	I-T060
FSE	I-T060
images	O
clearly	O
showed	O
intimal	B-T023
flaps	I-T023
and	O
double	B-T033
lumen	I-T033
signs	I-T033
in	O
all	O
3	O
patients	O
,	O
whereas	O
the	O
conventional	O
modalities	O
identified	O
a	O
double	B-T033
lumen	I-T033
sign	I-T033
in	O
only	O
2	O
of	O
the	O
3	O
patients	O
.	O
The	O
present	O
method	O
of	O
optimized	O
HR	B-T060
-	I-T060
FSE	I-T060
imaging	I-T060
with	O
a	O
3	O
T	O
system	O
improved	B-T033
visualization	B-T060
of	O
intimal	B-T023
flaps	I-T023
and	O
should	O
thus	O
be	O
considered	O
for	O
assessing	O
patients	O
with	O
suspected	O
ICAD	B-T190
that	O
can	O
not	O
be	O
definitively	O
diagnosed	B-T033
by	O
conventional	O
imaging	O
modalities	O
.	O
      
Alleviation	O
of	O
hepatic	O
fat	B-T033
accumulation	I-T033
by	O
betaine	B-T121
involves	O
reduction	O
of	O
homocysteine	O
via	O
up	O
-	O
regulation	O
of	O
betaine	O
-	O
homocysteine	O
methyltransferase	O
(	O
BHMT	O
)	O
We	O
investigated	O
the	O
anti	O
-	O
lipogenic	O
effect	O
of	O
betaine	B-T121
in	O
rats	O
fed	O
methionine	B-T121
and	O
choline	B-T121
-	O
deficient	O
diet	O
(	O
MCD	O
)	O
.	O
Intake	O
of	O
MCD	O
for	O
3	O
wk	O
resulted	O
in	O
a	O
significant	O
accumulation	B-T033
of	O
hepatic	O
lipids	O
,	O
which	O
was	O
prevented	O
by	O
betaine	B-T121
supplementation	B-T061
in	O
drinking	O
water	O
(	O
1	O
%	O
)	O
.	O
Phosphorylation	O
of	O
AMP	O
-	O
activated	O
protein	O
kinase	O
(	O
AMPK	O
)	O
,	O
acetyl	O
-	O
CoA	O
carboxylase	O
(	O
ACC	O
)	O
,	O
sterol	O
regulatory	O
element	O
-	O
binding	O
protein	O
1c	O
(	O
SREBP-1c	O
)	O
,	O
and	O
liver	O
kinase	O
B1	O
(	O
LKB1	O
)	O
was	O
inhibited	O
by	O
MCD	O
intake	O
,	O
and	O
these	O
changes	O
were	O
all	O
inhibited	O
by	O
betaine	B-T121
feeding	B-T058
.	O
Meanwhile	O
,	O
betaine	B-T121
supplementation	B-T061
reversed	O
the	O
reduction	O
of	O
methionine	O
and	O
S	O
-	O
adenosylmethionine	O
(	O
SAM	O
)	O
,	O
and	O
the	O
elevation	O
of	O
homocysteine	B-T059
levels	I-T059
in	O
the	O
liver	B-T023
,	I-T023
which	O
could	O
be	O
attributable	O
to	O
the	O
induction	O
of	O
betaine	O
-	O
homocysteine	O
methyltransfease	O
(	O
BHMT	O
)	O
and	O
methionine	O
adenosyltransferase	O
(	O
MAT	O
)	O
.	O
Different	O
cell	O
lines	O
were	O
used	O
to	O
clarify	O
the	O
role	O
of	O
homocysteine	O
on	O
activation	O
of	O
the	O
AMPK	O
pathway	O
.	O
Homocysteine	O
treatment	O
decreased	O
pAMPK	O
,	O
pACC	O
,	O
pSREBP-1c	O
and	O
pLKB1	O
in	O
HepG2	O
cells	O
.	O
Metformin	B-T121
-	O
induced	O
activation	O
of	O
AMPK	O
was	O
also	O
inhibited	O
by	O
homocysteine	O
.	O
Treatment	O
with	O
hydroxylamine	O
,	O
a	O
cystathionine	O
β	O
-	O
synthase	O
inhibitor	B-T121
,	O
resulted	O
in	O
a	O
reduction	O
of	O
pAMPK	O
,	O
pACC	O
and	O
pSREBP-1c	O
,	O
accompanied	O
by	O
an	O
elevation	O
of	O
intracellular	O
homocysteine	O
.	O
Betaine	B-T121
treatment	B-T061
prevented	O
the	O
homocysteine	O
-	O
induced	O
reduction	O
of	O
pAMPK	O
,	O
pACC	O
,	O
pSREBP-1c	O
and	O
pLKB1	O
in	O
H4IIE	O
cells	O
,	O
but	O
not	O
in	O
HepG2	O
cells	O
.	O
Also	O
the	O
elevation	O
of	O
cellular	O
homocysteine	O
and	O
inhibition	O
of	O
protein	O
expression	O
of	O
BHMT	O
were	O
prevented	O
by	O
betaine	B-T121
only	O
in	O
H4IIE	O
cells	O
which	O
express	O
BHMT	O
.	O
The	O
results	O
suggest	O
that	O
the	O
beneficial	O
effect	O
of	O
betaine	B-T121
against	O
hepatic	O
lipid	O
accumulation	B-T033
may	O
be	O
attributed	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
the	O
depletion	O
of	O
homocysteine	O
via	O
up	O
-	O
regulation	O
of	O
BHMT	O
in	O
hepatocytes	O
.	O
      
Everolimus	B-T121
for	O
Treatment	B-T061
of	O
Pseudomyogenic	B-T191
Hemangioendothelioma	I-T191
Pseudomyogenic	B-T191
hemangioendothelioma	I-T191
(	O
PMH	B-T191
)	O
is	O
a	O
recently	O
described	O
vascular	B-T191
neoplasm	I-T191
that	O
occurs	O
most	O
commonly	O
in	O
the	O
soft	O
tissue	O
of	O
the	O
distal	O
extremities	O
of	O
young	O
adults	O
.	O
Metastatic	O
PMH	B-T191
can	O
be	O
fatal	O
and	O
there	O
are	O
no	O
effective	O
medications	B-T121
.	O
We	O
describe	O
a	O
case	O
of	O
a	O
15	O
-	O
year	O
-	O
old	O
boy	O
with	O
metastatic	O
PMH	B-T191
,	O
who	O
responded	O
to	O
treatment	O
with	O
everolimus	B-T121
,	O
a	O
mammalian	B-T121
target	I-T121
of	I-T121
rapamycin	I-T121
inhibitor	I-T121
.	O
Immunohistochemistry	B-T060
showed	O
that	O
mammalian	O
target	O
of	O
rapamycin	O
was	O
expressed	O
in	O
PMH	B-T191
biopsy	O
specimens	O
,	O
which	O
may	O
explain	O
the	O
reduction	O
in	O
PMH	B-T191
tumor	O
size	O
following	O
treatment	B-T061
.	O
      
Physicians	O
'	O
knowledge	O
on	O
the	O
work	B-T047
-	I-T047
related	I-T047
chronic	B-T047
obstructive	I-T047
pulmonary	I-T047
disease	I-T047
Chronic	B-T047
obstructive	I-T047
pulmonary	I-T047
disease	I-T047
(	O
COPD	B-T047
)	O
may	O
be	O
induced	O
by	O
the	O
work	O
environment	O
conditions	O
.	O
According	O
to	O
the	O
estimates	O
,	O
10	O
-	O
20	O
%	O
of	O
all	O
COPD	B-T047
cases	O
are	O
associated	O
with	O
occupational	O
exposure	O
to	O
dusts	O
and	O
irritant	O
gases	O
.	O
However	O
,	O
in	O
2014	O
,	O
only	O
11	O
cases	O
of	O
work	B-T047
-	I-T047
related	I-T047
COPD	B-T047
were	O
recognized	O
in	O
Poland	O
.	O
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
analyze	O
the	O
reasons	O
for	O
the	O
low	O
incidence	O
of	O
work	B-T047
-	I-T047
related	I-T047
COPD	B-T047
in	O
the	O
context	O
of	O
pulmonologists	O
'	O
knowledge	O
about	O
occupational	O
risk	B-T033
factors	I-T033
and	O
procedures	O
on	O
reporting	B-T058
suspected	B-T047
occupational	B-T047
diseases	I-T047
.	O
A	O
survey	O
included	O
94	O
pulmonologists	O
randomly	O
selected	O
out	O
of	O
225	O
specialists	O
registered	O
at	O
the	O
Local	O
Physicians	O
Chamber	O
in	O
Łódź	O
.	O
The	O
study	O
was	O
performed	O
anonymously	O
with	O
the	O
use	O
of	O
original	O
questionnaire	O
.	O
More	O
than	O
a	O
half	O
of	O
the	O
surveyed	O
pulmonologists	O
identified	O
environmental	O
risk	B-T033
factors	I-T033
for	O
COPD	B-T047
correctly	O
,	O
while	O
only	O
23.4	O
%	O
properly	O
identified	O
the	O
main	O
occupational	O
risk	B-T033
factors	I-T033
as	O
the	O
cause	O
of	O
COPD	B-T047
.	O
Only	O
58.5	O
%	O
of	O
the	O
pulmonologists	O
always	O
asked	O
their	O
patients	O
suffering	B-T033
from	O
COPD	B-T047
about	O
their	O
job	O
/	O
profession	O
and	O
60.6	O
%	O
of	O
them	O
did	O
not	O
have	O
any	O
knowledge	O
about	O
procedures	O
on	O
reporting	B-T058
suspected	B-T047
occupational	B-T047
diseases	I-T047
.	O
The	O
physicians	O
rarely	O
ask	O
patients	O
suffering	B-T033
from	O
COPD	B-T047
about	O
their	O
job	O
/	O
profession	O
and	O
the	O
relationship	O
between	O
their	O
ailments	B-T184
and	O
occupational	O
exposure	O
.	O
What	O
is	O
more	O
,	O
they	O
do	O
not	O
know	O
legal	O
regulations	O
on	O
proper	O
referral	B-T058
of	I-T058
a	I-T058
patient	I-T058
with	O
a	O
suspected	B-T047
case	O
of	O
occupational	B-T047
disease	I-T047
.	O
The	O
results	O
of	O
the	O
study	O
clearly	O
indicate	O
that	O
there	O
is	O
an	O
urgent	O
need	O
for	O
increasing	O
pulmonologists	O
'	O
knowledge	O
on	O
work	B-T047
-	I-T047
related	I-T047
COPD	B-T047
.	O
Med	O
Pr	O
2016;67(3):375	O
-	O
384	O
.	O
      
When	O
emotion	O
and	O
expression	B-T033
diverge	O
:	O
The	O
social	O
costs	O
of	O
Parkinson	B-T047
's	I-T047
disease	I-T047
Patients	O
with	O
Parkinson	B-T047
's	I-T047
disease	I-T047
(	O
PD	B-T047
)	O
are	O
perceived	O
more	O
negatively	B-T033
than	O
their	O
healthy	O
peers	O
,	O
yet	O
it	O
remains	O
unclear	O
what	O
factors	O
contribute	O
to	O
this	O
negative	B-T033
social	O
perception	O
.	O
Based	O
on	O
a	O
cohort	O
of	O
17	O
PD	B-T047
patients	O
and	O
20	O
healthy	O
controls	O
,	O
we	O
assessed	O
how	O
naïve	O
raters	O
judge	O
the	O
emotion	O
and	O
emotional	B-T033
intensity	O
displayed	O
in	O
dynamic	O
facial	B-T033
expressions	I-T033
as	O
adults	O
with	O
and	O
without	O
PD	B-T047
watched	O
emotionally	O
evocative	O
films	O
(	O
Experiment	O
1	O
)	O
,	O
and	O
how	O
age	O
-matched	O
peers	O
naïve	O
to	O
patients	O
'	O
disease	B-T047
status	O
judge	O
their	O
social	O
desirability	O
along	O
various	O
dimensions	O
from	O
audiovisual	O
stimuli	O
(	O
interview	O
excerpts	O
)	O
recorded	O
after	O
certain	O
films	O
(	O
Experiment	O
2	O
)	O
.	O
In	O
Experiment	O
1	O
,	O
participants	O
with	O
PD	B-T047
were	O
rated	O
as	O
significantly	O
more	O
facially	B-T033
expressive	I-T033
than	O
healthy	O
controls	O
;	O
moreover	O
,	O
ratings	O
demonstrated	O
that	O
PD	B-T047
patients	O
were	O
routinely	O
mistaken	O
for	O
experiencing	O
a	O
negative	B-T033
emotion	O
,	O
whereas	O
controls	O
were	O
rated	O
as	O
displaying	O
a	O
more	O
positive	B-T033
emotion	O
than	O
they	O
reported	B-T058
feeling	O
.	O
In	O
Experiment	O
2	O
,	O
results	O
showed	O
that	O
age	O
-	O
peers	O
rated	O
PD	B-T047
patients	O
as	O
significantly	O
less	O
socially	O
desirable	O
than	O
control	O
participants	O
.	O
Specifically	O
,	O
PD	B-T047
patients	O
were	O
rated	O
as	O
less	O
involved	O
,	O
interested	O
,	O
friendly	O
,	O
intelligent	O
,	O
optimistic	B-T033
,	O
attentive	O
,	O
and	O
physically	O
attractive	O
than	O
healthy	O
controls	O
.	O
Taken	O
together	O
,	O
our	O
results	O
point	O
to	O
a	O
disconnect	O
between	O
how	O
PD	B-T047
patients	O
report	B-T058
feeling	O
and	O
attributions	O
that	O
others	O
make	O
about	O
their	O
emotions	O
and	O
social	O
characteristics	O
,	O
underlining	O
significant	O
social	O
challenges	O
of	O
the	O
disease	B-T047
.	O
In	O
particular	O
,	O
changes	O
in	O
the	O
ability	O
to	O
modulate	O
the	O
expression	B-T033
of	O
negative	B-T033
emotions	O
may	O
contribute	O
to	O
the	O
negative	B-T033
social	O
impressions	O
that	O
many	O
PD	B-T047
patients	O
face	O
.	O
      
Talking	O
or	O
Keeping	O
Silent	O
About	O
Parental	O
Mental	B-T033
Health	I-T033
Problems	I-T033
-A	O
Grounded	O
Theory	O
of	O
Parents	O
'	O
Decision	O
Making	O
and	O
Experiences	O
with	O
Their	O
Children	O
This	O
grounded	O
theory	O
study	O
explored	O
parents	O
'	O
experiences	O
of	O
responding	O
to	O
their	O
children	O
's	O
need	O
for	O
understanding	O
parental	O
mental	O
health	O
concerns	O
.	O
Fifteen	O
parents	O
with	O
severe	O
and	O
enduring	O
mental	B-T033
health	I-T033
difficulties	I-T033
participated	O
in	O
the	O
study	O
.	O
The	O
findings	B-T033
suggest	O
four	O
main	O
social	O
processes	O
that	O
influence	O
parents	O
'	O
talk	O
with	O
their	O
children	O
about	O
parental	O
mental	B-T033
health	I-T033
issues	I-T033
,	O
namely	O
"	O
Protecting	O
and	O
being	O
protected	O
,	O
"	O
"	O
Responding	O
to	O
children	O
's	O
search	O
for	O
understanding	O
,	O
"	O
"	O
Prioritizing	O
family	O
life	O
,	O
"	O
and	O
"	O
Relating	O
to	O
others	O
.	O
"	O
Implications	O
of	O
the	O
findings	B-T033
for	O
clinical	B-T058
practice	I-T058
and	O
future	O
research	O
are	O
considered	O
.	O
In	O
particular	O
,	O
the	O
need	O
for	O
more	O
family	B-T058
-	I-T058
orientated	I-T058
services	I-T058
where	O
parents	O
experience	O
parental	O
mental	B-T033
health	I-T033
problems	I-T033
is	O
highlighted	O
.	O
      
Dexmedetomidine	B-T121
Effect	O
on	O
Emergence	B-T048
Agitation	I-T048
and	O
Delirium	B-T048
in	O
Children	O
Undergoing	O
Laparoscopic	B-T061
Hernia	I-T061
Repair	I-T061
:	O
a	O
Preliminary	O
Study	O
Objective	O
To	O
evaluate	O
the	O
safety	O
and	O
efficacy	O
of	O
dexmedetomidine	B-T121
(	O
Dex	B-T121
)	O
to	O
prevent	O
emergence	B-T048
agitation	I-T048
(	O
EA	B-T048
)	O
and	O
delirium	B-T048
(	O
ED	B-T048
)	O
in	O
children	O
undergoing	O
laparoscopic	B-T061
hernia	I-T061
repair	I-T061
under	O
general	B-T061
anesthesia	I-T061
.	O
Methods	O
100	O
children	O
(	O
1	O
-	O
5	O
years	O
,	O
10	O
-	O
25	O
kg	O
)	O
were	O
randomized	O
into	O
four	O
groups	O
:	O
controls	O
(	O
saline	O
)	O
and	O
intravenous	O
Dex	B-T121
at	O
0.25	O
,	O
0.5	O
,	O
and	O
1.0	O
µg	O
/	O
kg	O
(	O
D1	O
,	O
D2	O
,	O
D3	O
,	O
respectively	O
)	O
.	O
Dex	B-T121
/	O
saline	O
infusion	B-T061
was	O
started	O
following	O
anesthesia	B-T121
.	O
EA	B-T048
and	O
ED	B-T048
were	O
evaluated	O
on	O
a	O
5	O
-	O
point	O
scale	O
.	O
Results	O
For	O
the	O
C	O
,	O
D1	O
,	O
D2	O
,	O
and	O
D3	O
groups	O
,	O
respectively	O
,	O
EA	B-T048
frequencies	O
were	O
45.8	O
%	O
,	O
30.4	O
%	O
,	O
12	O
%	O
,	O
4	O
%	O
;	O
ED	B-T048
frequencies	O
29.1	O
%	O
,	O
13	O
%	O
,	O
4	O
%	O
,	O
4	O
%	O
;	O
CHIPPS	O
scores	O
8	O
,	O
6	O
,	O
3	O
,	O
3	O
;	O
sevoflurane	B-T121
doses	O
from	O
13.2	O
±	O
3.4	O
(	O
controls	O
)	O
to	O
9.4	O
±	O
3.5	O
ml	O
(	O
D3	O
)	O
.	O
Intervals	O
until	O
mask	O
removal	O
/	O
spontaneous	O
eye	O
opening	O
were	O
significantly	O
longer	O
for	O
D2	O
and	O
D3	O
than	O
controls	O
.	O
PACU	O
stay	O
was	O
longer	O
for	O
D3	O
.	O
Conclusions	O
There	O
was	O
significantly	O
less	O
postoperative	O
EA	B-T048
and	O
pain	B-T184
,	O
with	O
less	O
sevoflurane	B-T121
required	O
,	O
using	O
Dex	B-T121
.	O
      
Stress	B-T048
and	O
binge	O
drinking	O
:	O
A	O
toxic	O
combination	O
for	O
the	O
teenage	O
brain	B-T023
Young	O
adult	O
university	O
students	O
frequently	O
binge	O
on	O
alcohol	O
and	O
have	O
high	O
stress	B-T033
levels	I-T033
.	O
Based	O
on	O
findings	O
in	O
rodents	O
,	O
we	O
predicted	O
that	O
heavy	B-T033
current	I-T033
alcohol	I-T033
use	I-T033
and	O
elevated	O
stress	B-T048
and	O
depression	B-T033
scores	I-T033
would	O
be	O
associated	O
with	O
deficits	O
on	O
high	O
interference	O
memory	O
tasks	O
,	O
while	O
early	B-T033
onset	I-T033
,	O
prolonged	O
binge	O
patterns	O
would	O
lead	O
to	O
broader	O
cognitive	B-T048
deficits	I-T048
on	O
tests	O
of	O
associative	O
encoding	O
and	O
executive	O
functions	O
.	O
We	O
developed	O
the	O
Concentration	O
Memory	O
Task	O
,	O
a	O
novel	O
computerized	O
version	O
of	O
the	O
Concentration	O
card	O
game	O
with	O
a	O
high	O
degree	O
of	O
interference	O
.	O
We	O
found	O
that	O
young	O
adults	O
with	O
elevated	O
stress	B-T033
,	O
depression	B-T033
,	O
and	O
alcohol	O
consumption	O
scores	O
were	O
impaired	O
in	O
the	O
Concentration	O
Memory	O
Task	O
.	O
We	O
also	O
analyzed	O
data	O
from	O
a	O
previous	O
study	O
,	O
and	O
found	O
that	O
higher	O
alcohol	O
consumption	O
scores	O
were	O
associated	O
with	O
impaired	O
performance	O
on	O
another	O
high	O
interference	O
memory	O
task	O
,	O
based	O
on	O
Kirwan	O
and	O
Stark	O
's	O
Mnemonic	O
Similarity	O
Test	O
.	O
On	O
the	O
other	O
hand	O
,	O
adolescent	O
onset	O
of	O
binge	O
drinking	O
predicted	O
poorer	O
performance	O
on	O
broader	O
range	O
of	O
memory	O
tests	O
,	O
including	O
a	O
more	O
systematic	O
test	O
of	O
spatial	O
recognition	O
memory	O
,	O
and	O
an	O
associative	O
learning	O
task	O
.	O
Our	O
results	B-T033
are	O
broadly	O
consistent	O
with	O
findings	O
in	O
rodents	O
that	O
acute	O
alcohol	O
and	O
stress	B-T048
exposure	O
suppress	O
neurogenesis	O
in	O
the	O
adult	O
hippocampus	B-T023
,	O
which	O
in	O
turn	O
impairs	O
performance	O
in	O
high	O
interference	O
memory	O
tasks	O
,	O
while	O
adolescent	O
onset	O
binge	O
drinking	O
causes	O
more	O
extensive	O
brain	O
damage	O
and	O
cognitive	B-T048
deficits	I-T048
.	O
      
Voriconazole	B-T121
metabolism	O
is	O
influenced	O
by	O
severe	O
inflammation	O
:	O
a	O
prospective	O
study	O
During	O
an	O
infection	O
or	O
inflammation	O
,	O
several	O
drug	B-T121
-	O
metabolizing	O
enzymes	O
in	O
the	O
liver	B-T023
are	O
down	O
-	O
regulated	O
,	O
including	O
cytochrome	O
P450	O
iso	O
-	O
enzymes	O
.	O
Since	O
voriconazole	B-T121
is	O
extensively	O
metabolized	O
by	O
cytochrome	O
P450	O
iso	O
-	O
enzymes	O
,	O
the	O
metabolism	O
of	O
voriconazole	B-T121
can	O
be	O
influenced	O
during	O
inflammation	O
via	O
reduced	O
clearance	O
of	O
the	O
drug	O
,	O
resulting	O
in	O
higher	O
voriconazole	B-T121
trough	O
concentrations	O
.	O
To	O
investigate	O
prospectively	O
the	O
influence	O
of	O
inflammation	O
on	O
voriconazole	B-T121
metabolism	O
and	O
voriconazole	B-T121
trough	O
concent	O
ratio	O
ns	O
.	O
A	O
prospective	O
observational	O
study	O
was	O
performed	O
at	O
the	O
University	O
Medical	O
Center	O
Groningen	O
.	O
Patients	O
were	O
eligible	O
for	O
inclusion	O
if	O
they	O
were	O
≥18	O
years	O
old	O
and	O
treated	B-T061
with	I-T061
voriconazole	B-T121
.	O
Voriconazole	B-T121
and	O
voriconazole	B-T121
-	I-T121
N	I-T121
-	I-T121
oxide	I-T121
concentrations	O
were	O
determined	O
in	O
discarded	O
blood	O
samples	O
.	O
To	O
determine	O
the	O
degree	O
of	O
inflammation	O
,	O
C	B-T059
-	I-T059
reactive	I-T059
protein	I-T059
(	I-T059
CRP	I-T059
)	I-T059
concentrations	I-T059
were	O
used	O
.	O
Subsequently	O
,	O
a	O
longitudinal	O
data	O
analysis	O
was	O
performed	O
to	O
assess	B-T058
the	O
effect	O
of	O
inflammation	O
on	O
the	O
metabolic	O
ratio	O
and	O
voriconazole	B-T121
trough	O
concentration	O
.	O
Thirty	O
-	O
four	O
patients	O
were	O
included	O
.	O
In	O
total	O
489	O
voriconazole	B-T121
trough	O
concentrations	O
were	O
included	O
in	O
the	O
longitudinal	O
data	O
analysis	O
.	O
This	O
analysis	O
showed	O
that	O
inflammation	O
,	O
reflected	O
by	O
CRP	B-T059
concentrations	I-T059
,	O
significantly	O
influence	O
d	O
the	O
metabolic	O
ratio	O
,	O
voriconazole	B-T121
trough	O
concentration	O
and	O
voriconazole	B-T121
-	I-T121
N	I-T121
-	I-T121
oxide	I-T121
concentration	O
(	O
all	O
P	O
<	O
0.001	O
)	O
,	O
when	O
corrected	O
for	O
other	O
factors	O
that	O
could	O
influence	O
voriconazole	B-T121
metabolism	O
.	O
The	O
metabolic	O
ratio	O
was	O
decreased	O
by	O
0.99229(N	O
)	O
and	O
the	O
voriconazole	B-T121
-	I-T121
N	I-T121
-	I-T121
oxide	I-T121
concentration	O
by	O
0.99775(N	O
)	O
,	O
while	O
the	O
voriconazole	B-T121
trough	O
concentration	O
was	O
increased	O
by	O
1.005321(N	O
)	O
,	O
where	O
N	O
is	O
the	O
difference	O
in	O
CRP	O
units	O
(	O
in	O
mg	O
/	O
L	O
)	O
.	O
This	O
study	O
shows	O
that	O
voriconazole	B-T121
metabolism	O
is	O
decreased	O
during	O
inflammation	O
,	O
resulting	O
in	O
higher	O
voriconazole	B-T121
trough	O
concentration	O
s.	O
Therefore	O
,	O
frequent	O
monitoring	B-T058
of	O
voriconazole	B-T121
serum	O
concentrations	O
is	O
recommended	O
during	O
and	O
following	O
severe	O
inflammation	O
.	O
      
Recombinant	O
protein	O
transduction	O
domain	O
-	O
Cu	O
/	O
Zn	O
superoxide	O
dismutase	O
alleviates	O
bone	B-T191
cancer	I-T191
pain	B-T184
via	O
peroxiredoxin	O
4	O
modulation	O
and	O
antioxidation	O
Bone	B-T191
cancer	I-T191
pain	B-T184
(	O
BCP	B-T184
)	O
is	O
a	O
serious	O
chronic	O
clinical	O
condition	O
and	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
were	O
considered	O
to	O
be	O
involved	O
in	O
its	O
development	O
and	O
persistency	O
.	O
Normally	O
,	O
superoxide	B-T121
dismutase	I-T121
(	O
SOD	B-T121
)	O
converts	O
superoxide	O
anions	O
to	O
hydrogen	B-T121
peroxide	I-T121
(	O
H2O2	B-T121
)	O
and	O
H2O2	B-T121
is	O
then	O
naturalized	O
to	O
be	O
water	B-T121
by	O
peroxiredoxin	O
4	O
.	O
We	O
reported	O
previously	O
that	O
recombinant	O
protein	O
transduction	O
domain	O
(	O
PTD)-	O
Cu	O
/	O
Zn	O
SOD	O
effectively	O
scavenged	O
excessive	O
ROS	O
and	O
prevented	O
cardiomyocytes	O
from	O
hypoxia	O
-	O
reoxygenation	O
damage	O
.	O
However	O
,	O
whether	O
PTD	O
-	O
Cu	O
/	O
Zn	O
SOD	O
would	O
prevent	O
BCP	B-T184
development	O
is	O
unknown	O
.	O
In	O
the	O
current	O
study	O
,	O
we	O
found	B-T033
that	O
an	O
implanted	O
carcinoma	B-T191
in	O
the	O
rat	O
tibia	B-T023
induced	O
remarkable	O
hyperalgesia	B-T184
,	O
increased	O
H2O2	B-T121
levels	O
and	O
decreased	O
SOD	B-T121
and	O
peroxiredoxin	O
4	O
levels	O
.	O
After	O
administration	O
of	O
recombinant	O
PTD	O
-	O
Cu	O
/	O
Zn	O
SOD	O
to	O
these	O
tumor	O
-	O
burden	O
rats	O
,	O
their	O
hyperalgesia	B-T184
was	O
significantly	O
attenuated	O
and	O
peroxiredoxin	O
4	O
expression	O
was	O
significantly	O
increased	O
.	O
In	O
addition	O
,	O
an	O
increased	O
expression	O
of	O
N	O
-	O
methyl	O
-	O
d	O
-	O
aspartic	O
acid	O
(	O
NMDA	O
)	O
receptors	O
and	O
a	O
decreased	O
expression	O
of	O
γ	O
-	O
aminobutyric	O
acid	O
(	O
GABA	O
)	O
receptors	O
in	O
this	O
cancer	B-T184
pain	I-T184
were	O
prevented	O
by	O
PTD	O
-	O
Cu	O
/	O
Zn	O
SOD	O
administration	O
or	O
peroxiredoxin	O
4	O
overexpression	O
.	O
Our	O
data	O
suggested	O
that	O
reactive	O
oxygen	O
species	O
,	O
at	O
least	O
in	O
part	O
,	O
play	O
a	O
role	O
in	O
cancer	B-T191
metastatic	I-T191
pain	B-T184
development	O
and	O
persistency	O
which	O
can	O
be	O
attenuated	O
by	O
the	O
adminstration	O
of	O
recombinant	O
PTD	O
-	O
Cu	O
/	O
Zn	O
SOD	O
via	O
the	O
peroxiredoxin	O
4	O
modulation	O
from	O
oxidative	O
stress	O
.	O
      
Effects	O
of	O
a	O
specific	O
blend	O
of	O
essential	O
oils	O
on	O
apparent	O
nutrient	O
digestion	O
,	O
rumen	B-T023
fermentation	O
and	O
rumen	B-T023
microbial	B-T001
populations	I-T001
in	O
sheep	O
fed	O
a	O
50:50	O
alfalfa	O
hay	O
:	O
concentrate	O
diet	O
An	O
experiment	O
was	O
conducted	O
to	O
investigate	O
the	O
effects	O
of	O
a	O
specific	O
mixture	O
of	O
essential	O
oils	O
(	O
MEO	O
)	O
,	O
containing	O
thyme	O
,	O
clove	B-T121
and	O
cinnamon	O
EO	O
,	O
on	O
rumen	B-T023
microbial	O
fermentation	O
,	O
nutrient	O
apparent	O
digestibility	B-T033
and	O
blood	O
metabolites	O
in	O
fistulated	O
sheep	O
.	O
Six	O
sheep	O
fitted	O
with	O
ruminal	B-T190
fistulas	I-T190
were	O
used	O
in	O
a	O
repeated	O
measurement	O
design	O
with	O
two	O
24	O
-	O
d	O
periods	O
to	O
investigate	O
the	O
effect	O
of	O
adding	O
MEO	O
at	O
0	O
(	O
control	O
)	O
,	O
0.8	O
,	O
and	O
1.6	O
mL	O
/	O
d	O
on	O
apparent	O
nutrient	O
digestibility	B-T033
,	O
rumen	B-T023
fermentation	O
characteristics	O
,	O
rumen	B-T023
microbial	B-T001
population	I-T001
and	O
blood	O
chemical	O
metabolites	O
.	O
Animals	O
were	O
fed	O
with	O
a	O
50:50	O
alfalfa	O
hay	O
:	O
concentrate	O
diet	O
.	O
Ruminal	O
pH	O
,	O
total	O
volatile	O
fatty	O
acids	O
(	O
VFA	O
)	O
concentration	O
,	O
molar	O
proportion	O
of	O
individual	O
VFA	O
,	O
acetate	O
:	O
propionate	O
ratio	O
and	O
methane	O
production	O
were	O
not	O
affected	O
with	O
MEO	O
.	O
Relative	O
to	O
the	O
control	O
,	O
Small	O
peptides	O
plus	O
amino	O
acid	O
nitrogen	O
and	O
large	O
peptides	O
nitrogen	O
concentration	O
in	O
rumen	O
fluid	O
were	O
not	O
affected	O
with	O
MEO	O
supplementation	B-T061
;	O
while	O
,	O
rumen	O
fluid	O
ammonia	B-T121
nitrogen	O
concentration	O
at	O
0	O
and	O
6	O
h	O
after	O
morning	O
feeding	O
in	O
sheep	O
fed	O
with	O
1.6	O
mL	O
/	O
d	O
of	O
MEO	O
was	O
lower	O
(	O
p<0.05	O
)	O
compared	O
to	O
the	O
control	O
and	O
0.8	O
mL	O
/	O
d	O
of	O
MEO	O
.	O
At	O
0	O
h	O
after	O
morning	O
feeding	O
,	O
ammonia	B-T121
nitrogen	O
concentration	O
was	O
higher	O
(	O
p<0.05	O
)	O
in	O
sheep	O
fed	O
0.8	O
mL	O
/	O
d	O
of	O
MEO	O
relative	O
to	O
1.6	O
mL	O
/	O
d	O
and	O
control	O
diet	O
.	O
Ruminal	O
protozoa	O
and	O
hyper	B-T007
ammonia	I-T007
producing	I-T007
(	I-T007
HAP	I-T007
)	I-T007
bacteria	I-T007
counts	B-T059
were	O
not	O
affected	O
by	O
addition	O
of	O
MEO	O
in	O
the	O
diet	O
.	O
Relative	O
to	O
the	O
control	O
,	O
no	O
changes	O
were	O
observed	O
in	O
the	O
red	B-T059
and	O
white	O
blood	O
cells	O
,	O
hemoglobin	B-T059
,	O
hematocrit	B-T033
,	O
glucose	B-T059
,	O
beta	O
-	O
hydroxybutyric	O
acid	O
,	O
cholesterol	B-T059
,	O
total	B-T059
protein	I-T059
,	O
albumin	B-T059
,	O
blood	B-T059
urea	I-T059
nitrogen	I-T059
and	O
aspartate	B-T059
aminotransferase	I-T059
and	O
alanine	B-T059
aminotransferase	I-T059
concentration	O
.	O
Apparent	O
total	B-T033
tract	I-T033
digestibility	I-T033
of	O
dry	O
matter	O
,	O
crude	O
proten	O
,	O
organic	O
matter	O
,	O
and	O
neutral	O
detergent	O
fiber	O
were	O
not	O
influenced	O
by	O
MEO	O
supplementation	B-T061
.	O
The	O
results	O
of	O
the	O
present	O
study	O
suggested	O
that	O
supplementation	B-T061
of	O
MEO	O
may	O
have	O
limited	O
effects	O
on	O
apparent	O
nutrient	O
digestibility	B-T033
,	O
ruminal	O
fermentation	O
and	O
protozoa	O
and	O
HAP	B-T007
bacteria	I-T007
count	B-T059
,	O
blood	O
cells	O
and	O
metabolites	O
.	O
      
Uveitis	B-T047
in	O
children	O
The	O
review	O
provides	O
updates	O
on	O
novel	O
risk	O
markers	O
for	O
the	O
development	O
of	O
pediatric	O
inflammatory	B-T047
uveitis	I-T047
and	O
a	O
severe	O
disease	O
course	O
,	O
on	O
treatment	B-T061
of	O
refractory	B-T033
disease	I-T033
,	O
and	O
on	O
the	O
measurement	O
of	O
visual	O
outcomes	O
.	O
There	O
are	O
several	O
new	O
genetic	O
markers	O
,	O
biomarkers	O
,	O
and	O
clinical	O
factors	O
that	O
may	O
influence	O
a	O
child	O
's	O
uveitis	B-T047
disease	O
course	O
.	O
It	O
is	O
important	O
to	O
identify	O
children	O
at	O
risk	O
for	O
poor	O
visual	O
outcomes	O
and	O
who	O
are	O
refractory	O
to	O
traditional	B-T061
therapy	I-T061
.	O
Racial	B-T033
disparities	I-T033
have	O
recently	O
been	O
reported	O
.	O
We	O
describe	O
agents	O
of	O
potential	O
benefit	O
.	O
In	O
addition	O
,	O
we	O
discuss	O
the	O
importance	O
of	O
patient	O
reported	O
outcomes	O
in	O
this	O
population	O
.	O
Uveitis	B-T047
can	O
lead	O
to	O
vision	O
-	O
threatening	O
complications	O
.	O
Timely	B-T061
and	I-T061
aggressive	I-T061
treatment	I-T061
of	O
children	O
identified	O
to	O
be	O
at	O
risk	O
for	O
a	O
severe	O
uveitis	O
course	O
may	O
lead	O
to	O
improved	O
outcomes	O
.	O
      
Synthesis	O
and	O
characterization	O
of	O
acetylated	O
amylose	O
and	O
development	O
of	O
inclusion	O
complexes	O
with	O
rifampicin	B-T195
Amylose	O
(	O
AM	O
)	O
tends	O
to	O
form	O
single	O
helical	O
inclusion	O
complexes	O
with	O
suitable	O
agents	O
.	O
These	O
complexes	O
are	O
considered	O
promising	O
biomaterial	O
carrier	O
since	O
the	O
guest	O
molecules	O
can	O
be	O
released	O
later	O
,	O
leading	O
to	O
many	O
applications	O
,	O
especially	O
in	O
the	O
pharmaceutical	O
industry	O
.	O
Rifampicin	B-T195
(	O
RIF	B-T195
)	O
has	O
long	O
been	O
recognized	O
as	O
an	O
active	O
drug	B-T121
against	O
Mycobacterium	B-T007
tuberculosis	I-T007
,	O
however	O
,	O
the	O
administration	B-T061
of	O
RIF	B-T195
in	O
high	O
dosages	O
can	O
originate	O
unwanted	O
side	O
-	O
effects	O
.	O
Due	O
to	O
the	O
fact	O
that	O
the	O
use	O
of	O
native	O
amylose	O
(	O
AM	O
)	O
in	O
the	O
formation	O
of	O
complexes	O
is	O
limited	O
by	O
their	O
low	O
water	O
solubility	O
,	O
it	O
was	O
acetylated	O
with	O
a	O
medium	O
degree	O
of	O
substitution	O
(	O
DS	O
)	O
,	O
allowing	O
solubilizing	O
(	O
0.5gL(-1	O
)	O
)	O
acetylated	O
amylose	O
(	O
AMA	O
)	O
in	O
water	B-T121
at	O
neutral	O
pH	O
,	O
in	O
opposition	O
to	O
that	O
observed	O
with	O
native	O
amylose	O
(	O
trace	O
solubility	O
)	O
.	O
The	O
resulting	O
acetylated	O
amylose	O
was	O
characterized	O
by	O
means	O
of	O
Fourier	O
Transform	O
Infrared	O
(	O
FT	O
-	O
IR	O
)	O
spectroscopy	O
and	O
Scanning	B-T059
Electron	I-T059
Microscopy	I-T059
(	O
SEM	B-T059
)	O
.	O
FT	O
-	O
IR	O
results	O
indicated	B-T033
that	O
the	O
acetylation	O
of	O
anhydroglucose	B-T121
units	O
of	O
amylose	O
corresponds	O
to	O
a	O
low	O
DS	O
,	O
whereas	O
SEM	B-T059
results	O
suggested	O
that	O
the	O
smooth	O
surfaces	O
of	O
amylose	O
granules	O
were	O
changed	O
into	O
rougher	O
surfaces	O
after	O
acetylation	O
.	O
Ultraviolet	B-T059
absorption	I-T059
spectroscopy	I-T059
(	O
UV	B-T059
-	I-T059
vis	I-T059
)	O
analysis	O
confirmed	O
the	O
formation	O
and	O
allowed	O
the	O
quantification	O
of	O
both	O
native	O
(	O
AM	O
-	O
RIF	B-T195
)	O
and	O
acetylated	O
(	O
AMA	O
-	O
RIF	B-T195
)	O
amylose	O
inclusion	O
complexes	O
.	O
Their	O
characterization	O
in	O
solution	O
was	O
performed	O
by	O
dynamic	B-T059
light	I-T059
scattering	I-T059
(	O
DLS	B-T059
)	O
and	O
zeta	O
potential	O
(	O
ZP	O
)	O
measurements	O
.	O
The	O
average	O
size	O
of	O
inclusion	O
complexes	O
as	O
determined	O
by	O
DLS	B-T059
,	O
ranged	O
between	O
70	O
and	O
100	O
nm	O
.	O
Besides	O
,	O
ZP	O
analysis	O
showed	O
that	O
both	O
complexes	O
are	O
more	O
stable	O
in	O
the	O
presence	B-T033
of	O
RIF	B-T195
.	O
This	O
study	O
may	O
lead	O
to	O
the	O
development	O
of	O
an	O
effective	O
method	O
for	O
the	O
preparation	O
of	O
amylose	O
inclusion	O
complexes	O
,	O
which	O
is	O
beneficial	O
to	O
their	O
further	O
application	O
in	O
drug	O
delivery	O
systems	O
.	O
      
On	O
the	O
identity	O
of	O
the	O
Palearctic	O
species	O
of	O
the	O
wolf	O
spider	O
genus	O
<	O
i	O
>	O
Trebacosa	O
<	O
/i>(Araneae	O
:	O
Lycosidae	O
)	O
In	O
this	O
paper	O
we	O
propose	O
Trebacosa	O
brunhesi	O
Villepoux	O
,	O
2007	O
as	O
a	O
junior	O
synonym	O
of	O
Trebacosa	O
europaea	O
Szinetár	O
&	O
Kan	O
-	O
csal	O
,	O
2007	O
based	O
on	O
the	O
examination	O
of	O
specimens	O
from	O
all	O
the	O
localities	O
from	O
where	O
those	O
species	O
are	O
known	O
.	O
Illustration	O
of	O
the	O
type	O
species	O
of	O
the	O
genus	O
,	O
Trebacosa	O
marxi	O
(	O
Stone	O
,	O
1890	O
)	O
and	O
specimens	O
from	O
all	O
known	O
localities	O
of	O
T.	O
europaea	O
are	O
given	O
to	O
show	O
both	O
the	O
inter-	O
and	O
the	O
intraspecific	O
differences	O
of	O
the	O
genus	O
.	O
Scanning	B-T059
electron	I-T059
micrographs	I-T059
were	O
used	O
to	O
illustrate	O
the	O
detailed	O
structure	O
of	O
the	O
female	B-T023
's	I-T023
genitalia	I-T023
.	O
      
Neuroticism	B-T048
and	O
Fatigue	B-T184
3	O
Months	O
After	O
Ischemic	B-T047
Stroke	I-T047
:	O
A	O
Cross	O
-	O
Sectional	O
Study	O
To	O
examine	B-T033
the	O
relation	O
between	O
neuroticism	B-T048
and	O
fatigue	B-T184
in	O
Chinese	O
patients	O
with	O
stroke	B-T047
.	O
Cross	O
-	O
sectional	O
study	O
.	O
Acute	O
stroke	O
unit	O
.	O
Survivors	O
of	O
ischemic	B-T047
stroke	I-T047
(	O
N=191	O
)	O
recruited	O
from	O
the	O
acute	O
stroke	O
unit	O
between	O
May	O
1	O
,	O
2010	O
,	O
and	O
September	O
1	O
,	O
2011	O
.	O
Not	O
applicable	O
.	O
The	O
personality	B-T033
trait	I-T033
of	O
neuroticism	B-T048
was	O
measured	O
with	O
the	O
neuroticism	B-T048
subscale	O
of	O
the	O
Chinese	O
version	O
of	O
the	O
NEO	B-T060
Five	I-T060
-	I-T060
Factor	I-T060
Inventory	I-T060
.	O
The	O
level	O
of	O
fatigue	B-T184
was	O
measured	O
with	O
the	O
Fatigue	O
Assessment	O
Scale	O
.	O
The	O
National	O
Institutes	O
of	O
Health	O
Stroke	O
Scale	O
,	O
Geriatric	O
Depression	O
Scale	O
,	O
Barthel	O
Index	O
,	O
and	O
Mini	B-T060
-	I-T060
Mental	I-T060
State	I-T060
Examination	I-T060
were	O
administered	O
to	O
obtain	O
demographic	O
and	O
clinical	O
information	O
.	O
Fatigue	O
severity	O
3	O
months	O
after	O
stroke	B-T047
positively	O
correlated	O
with	O
Geriatric	O
Depression	O
Scale	O
and	O
NEO	B-T060
Five	I-T060
-	I-T060
Factor	I-T060
Inventory	I-T060
neuroticism	B-T048
scores	O
and	O
negatively	B-T033
correlated	O
with	O
the	O
Barthel	O
Index	O
score	O
.	O
Neuroticism	B-T048
,	O
independent	B-T033
of	O
depressive	B-T184
symptoms	I-T184
,	O
is	O
a	O
predictor	O
of	O
fatigue	O
severity	O
3	O
months	O
after	O
stroke	B-T047
.	O
Interventions	O
such	O
as	O
psychological	O
screening	O
programs	O
are	O
warranted	O
for	O
early	O
detection	B-T061
of	O
patients	O
at	O
high	B-T033
risk	I-T033
of	I-T033
poststroke	B-T047
depression	I-T047
.	O
      
Extended	O
use	O
of	O
Prostate	B-T059
Health	I-T059
Index	I-T059
and	O
percentage	O
of	O
[	O
-2]pro	O
-	O
prostate	O
-	O
specific	O
antigen	O
in	O
Chinese	O
men	O
with	O
prostate	O
specific	O
antigen	O
10	O
-	O
20	O
ng	O
/	O
mL	O
and	O
normal	O
digital	B-T060
rectal	I-T060
examination	I-T060
We	O
investigated	O
the	O
extended	O
use	O
of	O
Prostate	B-T059
Health	I-T059
Index	I-T059
(	O
PHI	B-T059
)	O
and	O
percentage	O
of	O
[	O
-2]pro	O
-	O
prostate	O
-	O
specific	O
antigen	O
(	O
%	O
p2PSA	O
)	O
in	O
Chinese	O
men	O
with	O
prostate	O
-	O
specific	O
antigen	O
(	O
PSA	O
)	O
10	O
-	O
20	O
ng	O
/	O
mL	O
and	O
normal	O
digital	B-T060
rectal	I-T060
examination	I-T060
(	O
DRE	B-T060
)	O
.	O
All	O
consecutive	O
Chinese	O
men	O
with	O
PSA	O
10	O
-	O
20	O
ng	O
/	O
mL	O
and	O
normal	O
DRE	B-T060
who	O
agreed	O
for	O
transrectal	B-T060
ultrasound	I-T060
TRUS	B-T060
(	O
TRUS)-guided	O
10	O
-	O
core	O
prostate	B-T060
biopsy	I-T060
were	O
recruited	O
.	O
Blood	O
samples	O
were	O
taken	O
immediately	O
before	O
TRUS	B-T060
-guided	O
prostate	B-T060
biopsy	I-T060
.	O
The	O
performances	O
of	O
total	B-T059
PSA	I-T059
(	O
tPSA	B-T059
)	O
,	O
%	O
free	B-T059
-	I-T059
to	I-T059
-	I-T059
total	I-T059
PSA	I-T059
(	O
%	O
fPSA	B-T059
)	O
,	O
%	O
p2PSA	O
,	O
and	O
PHI	B-T059
were	O
compared	O
using	O
logistic	O
regression	O
,	O
receiver	O
operating	O
characteristic	O
,	O
and	O
decision	O
curve	O
analyses	O
(	O
DCA	O
)	O
.	O
From	O
2008	O
to	O
2015	O
,	O
312	O
consecutive	O
Chinese	O
men	O
were	O
included	O
.	O
Among	O
them	O
,	O
53	O
out	O
of	O
312	O
(	O
17.0	O
%	O
)	O
men	O
were	O
diagnosed	B-T033
to	O
have	O
prostate	B-T191
cancer	I-T191
on	O
biopsy	B-T060
.	O
The	O
proportions	O
of	O
men	O
with	O
positive	B-T033
biopsies	I-T033
biopsies	B-T060
were	O
6.7	O
%	O
in	O
PHI	B-T059
<	O
35	O
,	O
22.8	O
%	O
in	O
PHI	B-T059
35	O
-	O
55	O
,	O
and	O
54.5	O
%	O
in	O
PHI	B-T059
>	O
55	O
(	O
chi	O
-	O
square	O
test	O
,	O
p<0.001	O
)	O
.	O
The	O
area	O
under	O
curves	O
(	O
AUC	O
)	O
of	O
the	O
base	O
model	O
including	O
age	O
,	O
tPSA	B-T059
and	O
status	O
of	O
initial	O
/	O
repeated	O
biopsy	B-T060
was	O
0.64	O
.	O
Adding	O
%	O
p2PSA	O
and	O
PHI	B-T059
to	O
the	O
base	O
model	O
improved	B-T033
the	O
AUC	O
to	O
0.79	O
(	O
p<0.001	O
)	O
and	O
0.78	O
(	O
p<0.001	O
)	O
,	O
respectively	O
,	O
and	O
provided	O
net	O
clinical	O
benefit	O
in	O
DCA	O
.	O
The	O
positive	B-T033
biopsy	I-T033
biopsy	B-T060
rates	O
of	O
Gleason	O
7	O
or	O
above	O
prostate	B-T191
cancers	I-T191
were	O
2.2	O
%	O
for	O
PHI	B-T059
<	O
35	O
,	O
7.9	O
%	O
for	O
PHI	B-T059
35	O
-	O
55	O
,	O
and	O
36.4	O
%	O
for	O
PHI	B-T059
>	O
55	O
(	O
chi	O
-	O
square	O
test	O
,	O
p<0.001	O
)	O
.	O
By	O
utilizing	O
the	O
PHI	B-T059
cutoff	O
of	O
35	O
to	O
men	O
with	O
PSA	O
10	O
-	O
20	O
ng	O
/	O
mL	O
and	O
normal	O
DRE	B-T060
,	O
57.1	O
%	O
(	O
178	O
of	O
312	O
)	O
biopsies	B-T060
could	O
be	O
avoided	O
.	O
Both	O
PHI	B-T059
and	O
%	O
p2PSA	O
performed	O
well	O
in	O
predicting	O
prostate	B-T191
cancer	I-T191
and	O
high	B-T191
grade	I-T191
prostate	I-T191
cancer	I-T191
.	O
The	O
use	O
of	O
PHI	B-T059
and	O
%	O
p2PSA	O
should	O
be	O
extended	O
to	O
Chinese	O
men	O
with	O
PSA	O
10	O
-	O
20	O
ng	O
/	O
mL	O
and	O
normal	O
DRE	B-T060
.	O
      
Development	O
and	O
Evaluation	O
of	O
the	O
ADHD	B-T048
Cognitions	O
Scale	O
for	O
Adults	O
The	O
clinical	O
literature	O
on	O
ADHD	B-T048
in	O
adults	O
suggests	O
that	O
"	O
overly	O
positive	O
"	O
or	O
optimistic	O
cognitions	O
may	O
contribute	O
to	O
impairment	O
and	O
failure	O
to	O
use	O
self	O
-	O
regulation	O
skills	O
in	O
this	O
population	O
,	O
yet	O
the	O
research	O
literature	O
on	O
this	O
topic	O
is	O
limited	O
.	O
We	O
developed	O
the	O
ADHD	B-T048
Cognitions	O
Scale	O
(	O
ACS	O
)	O
,	O
a	O
brief	O
self	O
-	O
report	O
measure	O
of	O
ADHD	B-T048
-related	O
thoughts	O
,	O
and	O
evaluated	O
its	O
psychometric	O
properties	O
.	O
We	O
collected	O
self	O
-	O
report	O
measures	O
,	O
inculding	O
the	O
ACS	O
,	O
from	O
two	O
large	O
community	O
samples	O
(	O
Ns	O
=	O
262	O
,	O
304	O
)	O
.	O
The	O
measure	O
demonstrated	O
a	O
one	O
-	O
factor	O
solution	O
that	O
replicated	O
in	O
the	O
second	O
sample	O
.	O
Evidence	O
of	O
good	O
internal	O
consistency	O
and	O
also	O
convergent	O
and	O
divergent	O
validity	O
was	O
obtained	O
for	O
both	O
samples	O
.	O
Scores	O
on	O
the	O
ACS	O
correlated	O
with	O
functional	B-T033
impairment	I-T033
,	O
time	B-T033
management	I-T033
problems	I-T033
,	O
and	O
avoidant	B-T033
coping	I-T033
strategies	O
.	O
With	O
additional	O
study	O
,	O
the	O
ACS	O
may	O
be	O
useful	O
to	O
identify	O
and	O
track	O
maladaptive	B-T033
ADHD	B-T048
-related	O
cognitions	O
during	O
cognitive	B-T061
-	I-T061
behavioral	I-T061
treatment	I-T061
,	O
and	O
to	O
further	O
study	O
the	O
role	O
of	O
these	O
thoughts	O
in	O
ADHD	B-T048
ADHD	B-T033
-related	I-T033
impairment	I-T033
.	O
      
Immature	O
stages	O
and	O
larval	O
chaetotaxy	O
of	O
Notofairchildia	O
stenygros	O
(	O
Quate	O
&	O
Alexander	O
)	O
(	O
Diptera	O
:	O
Psychodidae	O
:	O
Bruchomyiinae	O
)	O
Some	O
authors	O
have	O
hypothesized	O
that	O
Bruchomyiinae	O
is	O
"	O
the	O
most	O
plesiomorphic	O
subfamily	O
of	O
Psychodidae	O
"	O
and	O
its	O
members	O
"	O
are	O
among	O
the	O
most	O
primitive	O
living	O
Diptera	O
"	O
.	O
Although	O
Bruchomyiinae	O
is	O
of	O
no	B-T033
medical	O
importance	O
,	O
it	O
is	O
of	O
great	O
evolutionary	O
significance	O
,	O
having	O
long	O
been	O
placed	O
as	O
the	O
sister	O
group	O
of	O
Phlebotominae	O
.	O
In	O
general	O
,	O
species	O
of	O
this	O
subfamily	O
are	O
rarely	O
collected	O
in	O
their	O
natural	O
environment	O
;	O
therefore	O
,	O
adults	O
and	O
,	O
even	O
more	O
so	O
,	O
the	O
immature	O
stages	O
of	O
these	O
flies	O
are	O
poorly	O
known	O
.	O
We	O
describe	O
the	O
egg	O
,	O
larvae	O
and	O
pupae	O
of	O
Notofairchildia	O
stenygros	O
and	O
provide	O
nomenclatural	O
notes	O
on	O
larval	O
chaetotaxy	O
based	O
on	O
analyses	O
using	O
scanning	B-T059
electron	I-T059
microscopy	I-T059
(	O
SEM	B-T059
)	O
and	O
optic	B-T059
microscopy	I-T059
.	O
The	O
morphology	O
of	O
immature	O
Nt	O
.	O
stenygros	O
is	O
compared	O
with	O
other	O
Bruchomyiinae	O
and	O
Psychodidae	O
species	O
,	O
especially	O
with	O
species	O
of	O
Phlebotominae	O
that	O
are	O
superficially	O
similar	O
to	O
Bruchomyiinae	O
.	O
Results	B-T033
of	O
this	O
study	O
revealed	O
striking	O
morphological	O
differences	O
between	O
the	O
immature	O
stages	O
of	O
Bruchomyiinae	O
and	O
Phlebotominae	O
;	O
the	O
former	O
are	O
lacking	O
abdominal	O
pseudopods	O
and	O
microtrichia	B-T023
on	O
the	O
cephalic	O
integument	O
,	O
both	O
of	O
which	O
are	O
present	O
in	O
the	O
larvae	O
of	O
Phlebotominae	O
.	O
These	O
morphological	O
differences	O
observed	O
in	O
the	O
immature	O
stages	O
between	O
members	O
of	O
the	O
two	O
subfamilies	O
support	O
the	O
findings	B-T033
of	O
recent	O
molecular	B-T059
studies	I-T059
indicating	O
that	O
Bruchomyiinae	O
and	O
Phlebtominae	O
are	O
evolutionarily	O
not	O
closely	O
related	O
.	O
Notofairchildia	O
stenygros	O
is	O
now	O
the	O
fourth	O
species	O
of	O
Bruchomyiinae	O
for	O
which	O
the	O
immature	O
stages	O
are	O
described	O
.	O
      
An	O
HIV	B-T005
-	O
tailored	B-T058
quit	O
-	O
smoking	O
counselling	B-T058
pilot	O
intervention	B-T061
targeting	O
depressive	B-T184
symptoms	I-T184
plus	O
Nicotine	B-T061
Replacement	I-T061
Therapy	I-T061
Cardiovascular	B-T047
disease	I-T047
(	O
CVD	B-T047
)	O
rates	O
among	O
people	O
living	O
with	O
HIV	O
/	O
AIDS	O
(	O
PHAs	O
)	O
are	O
high	O
.	O
Rates	O
of	O
cigarette	O
smoking	O
,	O
a	O
leading	O
contributor	O
to	O
CVD	B-T047
among	O
PHAs	O
,	O
are	O
40	O
-	O
70	O
%	O
(	O
2	O
-	O
3	O
times	O
higher	O
than	O
the	O
general	O
population	O
)	O
.	O
Furthermore	O
,	O
PHAs	O
have	O
high	O
rates	O
of	O
depression	B-T048
(	O
40	O
-	O
60	O
%	O
)	O
,	O
a	O
risk	B-T033
factor	I-T033
for	O
smoking	O
cessation	O
relapse	O
.	O
The	O
current	O
pilot	O
study	O
examined	B-T033
the	O
effectiveness	O
of	O
a	O
specifically	O
tailored	B-T058
5-	O
session	O
smoking	O
cessation	O
counselling	B-T058
programme	I-T058
for	O
PHAs	O
,	O
which	O
addressed	O
depression	B-T048
,	O
in	O
combination	O
with	O
Nicotine	B-T061
Replacement	I-T061
Therapy	I-T061
(	O
NRT	B-T061
)	O
in	O
a	O
cohort	O
of	O
PHA	O
smokers	B-T033
(	O
n	O
=	O
50	O
)	O
.	O
At	O
6-	O
month	O
follow	B-T058
-	I-T058
up	I-T058
,	O
28	O
%	O
of	O
participants	O
demonstrated	O
biochemically	O
verified	O
abstinence	B-T061
from	O
smoking	O
.	O
This	O
result	B-T033
compares	O
favourably	O
to	O
other	O
quit	O
-	O
smoking	O
intervention	B-T061
studies	O
,	O
particularly	O
given	O
the	O
high	O
percentage	O
of	O
HIV+	O
smokers	B-T033
with	O
depression	B-T048
.	O
At	O
study	O
baseline	O
,	O
52	O
%	O
of	O
HIV+	O
smokers	B-T033
scored	O
above	O
the	O
clinical	O
cut	O
-	O
off	O
for	O
depression	B-T048
on	O
the	O
Centre	O
for	O
Epidemiological	O
Studies	O
-	O
Depression	O
(	O
CES	O
-	O
D	O
)	O
scale	O
.	O
HIV+	O
smokers	B-T033
with	O
depression	B-T048
at	O
study	O
baseline	O
demonstrated	O
quantitatively	O
lower	O
depression	B-T048
at	O
6-	O
month	O
follow	B-T058
-	I-T058
up	I-T058
with	O
a	O
large	O
effect	O
size	O
(	O
d	O
=	O
1	O
)	O
,	O
though	O
it	O
did	O
not	O
reach	O
statistical	O
significance	O
(	O
p	O
=	O
.058	O
)	O
.	O
Furthermore	O
,	O
those	O
with	O
depression	B-T048
were	O
no	O
more	O
likely	O
to	O
relapse	O
than	O
those	O
without	O
depression	B-T048
(	O
p	O
=	O
.33	O
)	O
,	O
suggesting	O
that	O
our	O
counselling	B-T058
programme	I-T058
adequately	O
addressed	O
this	O
significant	O
barrier	O
to	O
smoking	O
cessation	O
among	O
PHAs	O
.	O
Our	O
pilot	O
study	O
indicates	O
the	O
importance	O
of	O
tailored	B-T058
programmes	I-T058
to	O
help	O
PHAs	O
quit	O
smoking	O
,	O
the	O
significance	O
of	O
addressing	O
depressive	B-T184
symptoms	I-T184
,	O
and	O
the	O
need	O
for	O
tailored	B-T058
counselling	I-T058
programmes	I-T058
to	O
enhance	O
quit	O
rates	O
among	O
PHAs	O
.	O
      
The	O
relationship	O
between	O
anthropometry	O
and	O
body	O
composition	O
from	O
computed	B-T060
tomography	I-T060
:	O
The	O
Mediators	O
of	O
Atherosclerosis	B-T047
in	O
South	O
Asians	O
Living	O
in	O
America	O
Study	O
Few	O
studies	O
examine	O
the	O
relationships	O
between	O
anthropometry	O
and	O
the	O
body	O
composition	O
measures	O
they	O
approximate	O
,	O
or	O
whether	O
they	O
differ	O
by	O
sex	O
,	O
and	O
no	O
studies	O
have	O
examined	O
these	O
relationships	O
in	O
South	O
Asians	O
living	O
in	O
the	O
US	O
.	O
We	O
conducted	O
a	O
cross	O
-	O
sectional	O
study	O
of	O
871	O
participants	O
in	O
the	O
Mediators	O
of	O
Atherosclerosis	B-T047
in	O
South	O
Asians	O
Living	O
in	O
America	O
(	O
MASALA	O
)	O
Study	O
who	O
had	O
BMI	O
<	O
40	O
kg	O
/	O
m(2	O
)	O
and	O
underwent	O
abdominal	B-T060
CT	I-T060
scans	I-T060
for	O
measurement	O
of	O
visceral	O
and	O
subcutaneous	O
fat	O
.	O
Linear	O
regression	O
was	O
used	O
to	O
model	O
the	O
associations	O
between	O
anthropometric	O
measures	O
and	O
naturally	O
log	O
-	O
transformed	O
body	O
composition	O
measures	O
.	O
All	O
measures	O
of	O
anthropometry	O
,	O
except	O
height	O
,	O
were	O
significantly	O
associated	O
with	O
visceral	O
fat	O
and	O
had	O
a	O
significant	O
non	O
-	O
linear	O
component	O
(	O
p	O
<	O
.05	O
)	O
.	O
The	O
only	O
associations	O
for	O
visceral	O
fat	O
that	O
exhibited	O
significant	O
heterogeneity	O
by	O
sex	O
were	O
waist	O
circumference	O
(	O
%	O
difference	O
in	O
visceral	O
fat	O
slope	O
:	O
women	O
1.92	O
,	O
men	O
2.74	O
,	O
p	O
=	O
.007	O
for	O
interaction	O
)	O
and	O
waist	O
-	O
to	O
-	O
hip	O
ratio	O
(	O
women	O
25.9	O
,	O
men	O
717.4	O
,	O
p	O
<	O
.001	O
)	O
.	O
Except	O
for	O
height	O
,	O
all	O
measures	O
of	O
anthropometry	O
were	O
significantly	O
associated	O
with	O
subcutaneous	O
fat	O
,	O
had	O
a	O
significant	O
quadratic	O
component	O
,	O
and	O
significant	O
heterogeneity	O
by	O
sex	O
(	O
weight	O
(	O
kg	O
):	O
2.74	O
for	O
women	O
,	O
4.08	O
for	O
men	O
;	O
BMI	O
(	O
kg	O
/	O
m(2	O
)	O
):	O
10.3	O
,	O
14.0	O
;	O
waist	O
circumference	O
(	O
cm	O
):	O
1.51	O
,	O
3.36	O
;	O
hip	O
circumference	O
(	O
cm	O
):	O
2.53	O
,	O
4.50	O
)	O
with	O
p	O
<	O
.001	O
for	O
each	O
.	O
In	O
MASALA	O
participants	O
,	O
the	O
relationships	O
of	O
anthropometric	O
measures	O
with	O
visceral	O
and	O
subcutaneous	O
fat	O
appear	O
similar	O
to	O
other	O
race	O
/	O
ethnic	O
groups	O
,	O
but	O
with	O
weaker	O
non	O
-	O
linearity	O
and	O
heterogeneity	O
by	O
sex	O
.	O
Given	O
these	O
results	O
,	O
researchers	O
should	O
consider	O
separate	O
models	O
by	O
sex	O
for	O
US	O
South	O
Asians	O
when	O
approximating	O
subcutaneous	O
fat	O
or	O
when	O
using	O
waist	O
circumference	O
to	O
approximate	O
visceral	O
fat	O
.	O
      
Interaction	O
-	O
driven	O
distinctive	O
electronic	O
states	O
of	O
artificial	O
atoms	O
at	O
the	O
ZnO	B-T121
interface	O
We	O
have	O
investigated	O
the	O
electronic	O
states	O
of	O
planar	O
quantum	O
dots	O
at	O
the	O
ZnO	B-T121
interface	O
containing	O
a	O
few	O
interacting	O
electrons	O
in	O
an	O
externally	O
applied	O
magnetic	O
field	O
.	O
The	O
electron	O
-	O
electron	O
interaction	O
effects	O
are	O
expected	O
to	O
be	O
much	O
stronger	O
in	O
this	O
case	O
than	O
in	O
traditional	O
semiconductor	O
quantum	O
systems	O
,	O
such	O
as	O
in	O
GaAs	O
or	O
InAs	O
quantum	O
dots	O
.	O
In	O
order	O
to	O
highlight	O
that	O
stronger	O
Coulomb	O
effects	O
in	O
the	O
ZnO	B-T121
quantum	O
dots	O
,	O
we	O
have	O
compared	O
the	O
energy	O
spectra	O
and	O
the	O
magnetization	O
in	O
this	O
system	O
to	O
those	O
of	O
the	O
InAs	O
quantum	O
dots	O
.	O
We	O
have	O
found	O
that	O
in	O
the	O
ZnO	B-T121
quantum	O
dots	O
the	O
signatures	O
of	O
stronger	O
Coulomb	O
interaction	O
manifests	O
in	O
an	O
unique	O
ground	O
state	O
that	O
has	O
very	O
different	O
properties	O
than	O
the	O
corresponding	O
ones	O
in	O
the	O
InAs	O
dot	O
.	O
Our	O
results	O
for	O
the	O
magnetization	O
also	O
exhibits	O
behaviors	O
never	O
before	O
observed	O
in	O
a	O
quantum	O
dot	O
for	O
a	O
realistic	O
set	O
of	O
parameters	O
.	O
We	O
have	O
found	O
a	O
stronger	O
temperature	O
dependence	O
and	O
other	O
unexpected	O
features	O
,	O
such	O
as	O
paramagnetic	O
-	O
like	O
behavior	O
at	O
high	O
temperatures	O
for	O
a	O
quantum	O
-	O
dot	O
helium	B-T121
.	O
      
Dynamics	O
of	O
bacterial	O
class	B-T007
Bacilli	I-T007
in	O
the	O
deepest	O
valley	O
lake	O
of	O
Kashmir	O
-the	O
Manasbal	O
Lake	O
In	O
recognition	O
of	O
the	O
importance	O
of	O
bacteria	B-T007
as	O
ecological	O
indicators	O
of	O
the	O
aquatic	O
systems	O
a	O
comprehensive	O
and	O
systematic	O
analysis	O
was	O
carried	O
out	O
on	O
Manasbal	O
Lake	O
,	O
the	O
deepest	O
spring	O
fed	O
valley	O
lake	O
of	O
Kashmir	O
.	O
The	O
main	O
objective	O
envisaged	O
was	O
to	O
analyze	O
bacterial	O
community	O
composition	O
(	O
BCC	O
)	O
and	O
for	O
this	O
purpose	O
systematic	O
and	O
regular	O
sampling	O
of	O
waters	B-T121
from	O
ten	O
different	O
sampling	O
stations	O
,	O
predetermined	O
in	O
the	O
Lake	O
according	O
to	O
differences	O
in	O
degree	O
of	O
human	O
interference	O
and	O
also	O
as	O
zones	O
of	O
special	O
ecological	O
interests	O
were	O
selected	O
.	O
The	O
isolated	O
species	O
were	O
identified	O
according	O
to	O
Bergey	O
's	O
Manual	O
specification	O
by	O
examining	O
their	O
micro	O
and	O
macro	O
morphological	O
characteristics	O
and	O
biochemical	O
characteristics	O
on	O
different	O
culture	O
media	O
.	O
Further	O
confirmation	B-T033
was	O
done	O
by	O
sequencing	O
the	O
16s	O
rRNA	O
gene	O
by	O
using	O
universal	O
bacterial	O
primers	O
27F	O
and	O
1429R.	O
From	O
all	O
the	O
sampling	O
stations	O
the	O
class	B-T007
Bacilli	I-T007
showed	O
a	O
maximum	O
relative	O
abundance	O
with	O
a	O
contribution	O
of	O
16	O
bacterial	O
species	O
.	O
The	O
whole	O
process	O
resulted	O
in	O
the	O
identification	O
of	O
Bacillus	B-T007
aerius	I-T007
,	O
Bacillus	B-T007
altitudinis	I-T007
,	O
Bacillus	B-T007
anthracis	I-T007
,	O
Bacillus	B-T007
cereus	I-T007
,	O
Bacillus	B-T007
ginsengisoli	I-T007
,	O
Bacillus	B-T007
pumilus	I-T007
,	O
Bacillus	B-T007
safensis	I-T007
,	O
Bacillus	B-T007
stratosphericus	I-T007
,	O
Bacillus	B-T007
subtilis	I-T007
,	O
Bacillus	B-T007
tequilensis	I-T007
,	O
Bacillus	B-T007
thermocopriae	I-T007
,	O
Bacillus	B-T007
thuringiensis	I-T007
,	O
Brevibacillus	B-T007
agri	I-T007
strain	I-T007
,	O
Lysinibacillus	B-T007
boronitolerans	I-T007
,	O
Lysinibacillus	B-T007
pakistanensis	I-T007
and	O
Lysinibacillus	B-T007
sphaericus	I-T007
.	O
      
A	O
method	O
of	O
providing	O
engaging	O
formative	O
feedback	O
to	O
large	O
cohort	O
first	O
-	O
year	O
physiology	O
and	O
anatomy	O
students	O
A	O
growing	O
body	O
of	O
evidence	O
demonstrates	O
a	O
critical	O
role	O
for	O
effective	O
,	O
meaningful	O
feedback	O
to	O
enhance	O
student	O
learning	O
.	O
Effective	O
feedback	O
can	O
become	O
part	O
of	O
the	O
learning	O
cycle	O
that	O
is	O
not	O
only	O
a	O
learning	O
opportunity	O
for	O
the	O
student	O
but	O
can	O
also	O
be	O
used	O
to	O
inform	O
the	O
teacher	O
and	O
ongoing	O
curriculum	O
development	O
.	O
Feedback	O
is	O
considered	O
particularly	O
important	O
during	O
the	O
first	O
year	O
of	O
university	O
and	O
can	O
even	O
be	O
viewed	O
as	O
a	O
retention	O
strategy	O
that	O
can	O
help	O
attenuate	O
student	O
performance	B-T048
anxieties	I-T048
and	O
solidify	O
perceptions	O
of	O
academic	O
support	O
.	O
Unfortunately	O
,	O
the	O
provision	O
of	O
individualized	O
,	O
timely	O
feedback	O
can	O
be	O
particularly	O
challenging	O
in	O
first	O
-	O
year	O
courses	O
as	O
they	O
tend	O
to	O
be	O
large	O
and	O
diverse	O
cohort	O
classes	O
that	O
pose	O
challenges	O
of	O
time	O
and	O
logistics	O
.	O
Various	O
forms	O
of	O
generic	O
feedback	O
can	O
provide	O
rapid	O
and	O
cost	O
-	O
effect	O
feedback	O
to	O
large	O
cohorts	O
but	O
may	O
be	O
of	O
limited	O
benefit	O
to	O
students	O
other	O
than	O
signaling	O
weaknesses	B-T033
in	O
knowledge	O
.	O
The	O
present	B-T033
study	O
describes	O
a	O
method	O
that	O
was	O
used	O
to	O
provide	O
formative	O
task	O
-	O
related	O
feedback	O
to	O
a	O
large	O
cohort	O
of	O
first	O
-	O
year	O
physiology	O
and	O
anatomy	O
students	O
.	O
Based	O
on	O
student	O
evaluations	B-T058
presented	O
in	O
this	O
study	O
,	O
this	O
method	O
provided	O
feedback	O
in	O
a	O
manner	O
that	O
engaged	O
students	O
,	O
uncovered	O
underlying	B-T033
misconceptions	I-T033
,	O
facilitated	O
peer	O
discussion	O
,	O
and	O
provided	O
opportunity	O
for	O
new	O
instruction	O
while	O
allowing	O
the	O
lecturer	O
to	O
recognize	O
common	O
gaps	O
in	O
knowledge	O
and	O
inform	O
ongoing	O
curriculum	O
development	O
.	O
      
Validation	O
of	O
the	O
Neogen	B-T121
®	I-T121
Fentanyl	I-T121
ELISA	B-T059
Kit	O
for	O
Blood	O
and	O
Urine	O
The	O
Neogen	B-T121
®	I-T121
Fentanyl	I-T121
ready	O
-	O
to	O
-	O
use	O
enzyme	B-T059
-	I-T059
linked	I-T059
immunosorbent	I-T059
assay	I-T059
kit	O
was	O
validated	O
following	O
the	O
Scientific	O
Working	O
Group	O
for	O
Forensic	O
Toxicology	O
Standard	O
Practices	O
for	O
Method	O
Validation	O
in	O
Forensic	O
Toxicology	O
Laboratory	O
Guidelines	O
.	O
Two	O
decision	O
points	O
,	O
0.5	O
and	O
1	O
ng	O
/	O
mL	O
,	O
were	O
successfully	O
validated	O
for	O
whole	O
blood	O
.	O
For	O
urine	O
,	O
two	O
decision	O
points	O
,	O
1	O
and	O
5	O
ng	O
/	O
mL	O
,	O
were	O
also	O
successfully	O
validated	O
.	O
The	O
validation	O
included	O
the	O
evaluation	B-T058
of	O
sensitivity	O
,	O
precision	O
,	O
specificity	O
,	O
carryover	O
,	O
plate	O
drift	O
,	O
ruggedness	O
/	O
robustness	O
and	O
a	O
case	O
sample	O
evaluation	B-T058
.	O
The	O
empirically	O
determined	O
limit	O
of	O
detection	O
was	O
0.25	O
ng	O
/	O
mL	O
for	O
blood	O
and	O
0.5	O
ng	O
/	O
mL	O
for	O
urine	O
.	O
Precision	O
was	O
determined	O
at	O
five	O
different	O
concentrations	O
ranging	O
from	O
0.25	O
to	O
1.5	O
ng	O
/	O
mL	O
with	O
15	O
replicates	O
at	O
each	O
level	O
for	O
whole	O
blood	O
and	O
demonstrated	O
a	O
<	O
2.4	O
%	O
coefficient	O
of	O
variation	O
(	O
CV	O
)	O
.	O
In	O
urine	O
,	O
the	O
CV	O
was	O
<	O
5.6	O
%	O
at	O
six	O
different	O
concentrations	O
from	O
0.5	O
to	O
7.5	O
ng	O
/	O
mL	O
with	O
15	O
replicates	O
at	O
each	O
level	O
.	O
Cross	O
-	O
reactivity	O
was	O
evaluated	B-T058
for	O
norfentanyl	O
,	O
acetyl	B-T121
fentanyl	I-T121
,	O
4	O
-	O
anilino	O
-	O
N	O
-	O
phenethylpiperidine	O
,	O
beta	B-T121
-	I-T121
hydroxythiofentanyl	I-T121
,	O
butyryl	B-T121
fentanyl	I-T121
and	O
furanyl	B-T121
fentanyl	I-T121
.	O
      
Receipt	O
of	O
thyroid	B-T047
hormone	I-T047
deficiency	I-T047
treatment	B-T061
and	O
risk	O
of	O
herpes	B-T047
zoster	I-T047
Thyroid	O
hormone	O
(	O
TH	O
)	O
has	O
been	O
suggested	O
to	O
control	O
herpes	B-T005
virus	I-T005
gene	O
expression	O
and	O
replication	O
in	O
neurons	O
via	O
epigenetics	O
through	O
its	O
nuclear	O
receptors	O
.	O
It	O
has	O
previously	O
been	O
shown	O
that	O
patients	O
with	O
hypothyroidism	B-T047
are	O
predisposed	O
to	O
herpes	B-T047
zoster	I-T047
(	O
HZ	B-T047
)	O
,	O
suggesting	O
that	O
the	O
TH	B-T047
deficiency	I-T047
may	O
be	O
a	O
risk	B-T033
factor	I-T033
for	O
varicella	B-T005
zoster	I-T005
virus	I-T005
(	O
VZV	B-T005
)	O
reactivation	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
test	O
the	O
hypothesis	O
that	O
TH	B-T061
treatment	I-T061
will	O
ameliorate	O
the	O
complication	O
of	O
HZ	B-T047
.	O
This	O
study	O
investigated	O
the	O
hypothesis	O
by	O
enquiring	O
into	O
a	O
comprehensive	O
medical	O
database	O
at	O
Kaiser	O
Permanente	O
Southern	O
California	O
(	O
KPSC	O
)	O
to	O
verify	O
whether	O
patients	O
taking	O
TH	O
medication	B-T058
experience	O
a	O
reduction	O
in	O
HZ	B-T047
occurrence	O
.	O
It	O
was	O
shown	O
by	O
Kaplan	O
-	O
Meier	O
analysis	O
that	O
hypothyroidism	B-T047
patients	O
taking	O
TH	O
medicines	B-T121
had	O
a	O
lower	O
risk	O
of	O
HZ	B-T047
.	O
The	O
fully	O
adjusted	O
analysis	O
indicated	O
that	O
patients	O
receiving	O
medication	B-T058
for	O
the	O
treatment	B-T061
of	O
TH	B-T047
deficiency	I-T047
exhibited	O
a	O
reduced	O
risk	O
of	O
HZ	B-T047
(	O
hazard	O
ratio	O
0.60	O
,	O
95	O
%	O
confidence	O
interval	O
0.51	O
-	O
0.71	O
)	O
.	O
This	O
lower	O
risk	O
of	O
HZ	B-T047
was	O
significant	O
in	O
all	O
age	O
groups	O
except	O
the	O
18	O
-	O
39	O
years	O
cohort	O
.	O
In	O
addition	O
,	O
female	O
patients	O
taking	O
TH	B-T061
treatment	I-T061
exhibited	O
a	O
lower	O
risk	O
than	O
their	O
male	O
counterparts	O
.	O
Together	O
these	O
findings	B-T033
support	O
the	O
hypothesis	O
that	O
a	O
constant	O
level	O
of	O
TH	O
will	O
provide	O
a	O
degree	O
of	O
protection	O
from	O
contracting	O
HZ	B-T047
.	O
More	O
studies	O
are	O
underway	O
to	O
evaluate	B-T058
the	I-T058
laboratory	I-T058
data	I-T058
for	O
an	O
analysis	O
of	O
hormonal	O
effects	O
on	O
individuals	O
.	O
      
The	O
effects	O
of	O
paternal	O
high	O
-	O
fat	O
diet	O
exposure	O
on	O
offspring	O
metabolism	O
with	O
epigenetic	O
changes	O
in	O
the	O
mouse	O
adiponectin	O
and	O
leptin	O
gene	O
promoters	O
Recent	O
studies	O
have	O
demonstrated	O
that	O
epigenetic	O
changes	O
resulting	O
from	O
malnutrition	B-T047
might	O
play	O
important	O
roles	O
in	O
transgenerational	O
links	O
with	O
metabolic	B-T047
diseases	I-T047
.	O
Previously	O
,	O
we	O
observed	O
that	O
exposure	O
to	O
a	O
high	O
-	O
fat	O
diet	O
(	O
HFD	O
)	O
in	O
utero	O
caused	O
a	O
metabolic	O
syndrome	B-T047
-like	O
phenomenon	O
through	O
epigenetic	O
modifications	O
of	O
the	O
adiponectin	O
and	O
leptin	O
genes	O
that	O
persisted	O
for	O
multiple	O
generations	O
.	O
Recent	O
etiological	O
studies	O
indicated	B-T033
that	O
paternal	O
BMI	O
had	O
effects	O
on	O
offspring	O
BMI	O
that	O
were	O
independent	O
of	O
but	O
additive	O
to	O
maternal	B-T033
BMI	O
effects	O
.	O
Thus	O
,	O
we	O
examined	O
whether	O
paternal	O
HFD	O
-	O
induced	O
obesity	B-T047
affected	O
the	O
metabolic	O
status	O
of	O
offspring	O
through	O
epigenetic	O
changes	O
in	O
the	O
adiponectin	O
and	O
leptin	O
genes	O
.	O
Additionally	O
,	O
we	O
investigated	O
whether	O
a	O
normal	O
diet	O
during	O
subsequent	O
generations	O
abolished	O
the	O
epigenetic	O
changes	O
associated	O
with	O
paternal	O
HFD	O
exposure	O
before	O
conception	O
.	O
We	O
observed	O
the	O
effects	O
of	O
paternal	O
HFD	O
exposure	O
before	O
conception	O
over	O
multiple	O
generations	O
on	O
offspring	O
metabolic	O
traits	O
,	O
including	O
weight	B-T033
and	O
fat	B-T121
gain	O
,	O
glucose	B-T047
intolerance	I-T047
,	O
hypertriglyceridemia	B-T047
,	O
abnormal	O
adipocytokine	O
levels	O
,	O
hypertension	B-T047
,	O
and	O
adiponectin	O
and	O
leptin	O
gene	O
expression	O
and	O
epigenetic	O
changes	O
.	O
Normal	O
diet	O
consumption	O
by	O
male	O
offspring	O
during	O
the	O
subsequent	O
generation	O
following	O
paternal	O
HFD	O
exposure	O
diminished	O
whereas	O
consumption	O
for	O
two	O
generations	O
completely	O
abolished	O
the	O
effect	O
of	O
paternal	O
HFD	O
exposure	O
on	O
metabolic	O
traits	O
and	O
adipocytokine	O
promoter	O
epigenetic	O
changes	O
in	O
the	O
offspring	O
.	O
The	O
effects	O
of	O
paternal	O
HFD	O
exposure	O
on	O
offspring	O
were	O
relatively	O
weaker	O
than	O
those	O
following	O
HFD	O
exposure	O
in	O
utero	O
.	O
However	O
,	O
paternal	O
HFD	O
exposure	O
had	O
an	O
additive	O
metabolic	O
effect	O
for	O
two	O
generations	O
,	O
suggesting	O
that	O
both	O
paternal	O
and	O
maternal	B-T033
nutrition	O
might	O
affect	O
offspring	O
metabolism	O
through	O
epigenetic	O
modifications	O
of	O
adipocytokine	O
genes	O
for	O
multiple	O
generations	O
.	O
      
Parks	O
as	O
Social	O
and	O
Cultural	O
Spaces	O
Among	O
U.S	O
.-	O
and	O
Foreign	O
-	O
Born	O
Latinas	O
Parks	O
provide	O
opportunities	O
for	O
people	O
to	O
engage	O
in	O
activities	O
that	O
can	O
promote	O
physical	O
and	O
emotional	B-T033
well	O
-	O
being	O
.	O
Using	O
focus	O
groups	O
and	O
personal	O
interviews	O
conducted	O
in	O
selected	O
neighborhoods	O
of	O
a	O
Northeastern	O
city	O
with	O
a	O
high	O
rate	O
of	O
obesity	B-T047
,	O
we	O
examined	B-T033
perceptions	O
of	O
barriers	O
and	O
facilitators	O
regarding	O
the	O
use	O
of	O
parks	O
and	O
park	O
features	O
that	O
would	O
promote	O
physical	O
activity	O
among	O
Latina	O
women	O
(	O
N	O
=	O
39	O
)	O
.	O
Foreign	O
-	O
born	O
Latinas	O
emphasized	O
the	O
environmental	O
characteristics	O
of	O
parks	O
and	O
the	O
types	O
of	O
amenities	O
that	O
can	O
support	O
preferred	O
cultural	O
and	O
social	O
activities	O
,	O
while	O
U.S.	O
-	O
born	O
Latinas	O
emphasized	O
the	O
use	O
of	O
parks	O
for	O
physical	O
activity	O
and	O
weight	O
management	O
.	O
Most	O
striking	O
were	O
the	O
different	O
ways	O
in	O
which	O
foreign	O
-	O
born	O
participants	O
conceptualized	O
parks	O
as	O
sociocultural	O
family	O
centers	O
,	O
extending	O
more	O
common	O
conceptualizations	O
centered	O
on	O
exercise	O
or	O
individual	O
health	O
gain	O
.	O
These	O
findings	O
suggest	O
the	O
need	O
for	O
new	O
policies	O
that	O
incorporate	O
culturally	O
specific	O
park	O
programming	O
to	O
promote	O
national	O
goals	O
of	O
increasing	O
levels	O
of	O
physical	O
activity	O
for	O
health	O
.	O
      
Metabolomic	O
analysis	O
of	O
glycerophospholipid	O
signatures	O
of	O
inflammation	O
treated	B-T061
with	I-T061
non	B-T121
-	I-T121
steroidal	I-T121
anti	I-T121
-	I-T121
inflammatory	I-T121
drugs	I-T121
-induced-	O
RAW264.7	O
cells	O
using	O
(	B-T060
1)H	I-T060
NMR	I-T060
and	O
U	B-T059
-	I-T059
HPLC	I-T059
/	O
Q	B-T059
-	I-T059
TOF	I-T059
-	I-T059
MS	I-T059
Non	B-T060
-	I-T060
destructive	I-T060
proton	I-T060
nuclear	I-T060
magnetic	I-T060
resonance	I-T060
(	I-T060
(	I-T060
1)H	I-T060
NMR	I-T060
)	I-T060
spectroscopy	I-T060
and	O
highly	O
sensitive	O
ultra	B-T059
-	I-T059
performance	I-T059
liquid	I-T059
chromatography	I-T059
quadrupole	B-T059
time	I-T059
-	I-T059
of	I-T059
-	I-T059
flight	I-T059
mass	I-T059
spectrometry	I-T059
(	O
U	B-T059
-	I-T059
HPLC	I-T059
/	O
Q	B-T059
-	I-T059
TOF	I-T059
-	I-T059
MS	I-T059
)	O
coupled	O
to	O
data	O
processing	O
methods	O
were	O
applied	O
to	O
analyze	O
the	O
metabolic	O
profiling	O
changes	O
of	O
glycerophospholipids	O
(	O
GPLs	O
)	O
in	O
RAW264.7	O
cells	O
from	O
inflammation	O
to	O
prognosis	B-T058
.	O
Analysis	O
of	O
(	B-T060
1)H	I-T060
NMR	I-T060
was	O
shown	O
that	O
the	O
models	O
were	O
grouped	O
successfully	O
,	O
illustrating	O
that	O
all	O
of	O
them	O
had	O
significant	O
differences	O
.	O
Based	O
on	O
the	O
highly	O
simple	O
,	O
accurate	O
,	O
non	O
-	O
targeted	O
and	O
non	O
-	O
destructively	O
advantages	O
of	O
(	B-T060
1)H	I-T060
NMR	I-T060
,	O
it	O
could	O
be	O
used	O
as	O
a	O
new	O
screening	O
tool	O
of	O
anti	B-T121
-	I-T121
inflammatory	I-T121
drugs	I-T121
in	O
the	O
metabolic	O
profiling	O
of	O
GPLs	O
.	O
58	O
GPLs	O
were	O
identified	O
by	O
U	B-T059
-	I-T059
HPLC	I-T059
/	O
Q	B-T059
-	I-T059
TOF	I-T059
-	I-T059
MS	I-T059
,	O
and	O
19	O
components	O
were	O
firstly	O
identified	O
in	O
this	O
study	O
compared	O
with	O
our	O
previous	O
results	O
.	O
In	O
addition	O
,	O
ten	O
potential	O
biomarkers	O
were	O
proved	O
,	O
of	O
which	O
phosphatidylcholine	B-T121
(	O
PC	B-T121
)	O
(	O
16:0/18:1	O
)	O
and	O
(	O
18:0/18:1	O
)	O
changed	O
consistently	O
in	O
three	O
drug	O
-	O
induced	O
groups	O
and	O
might	O
be	O
the	O
important	O
biomarkers	O
.	O
Compared	O
with	O
(	B-T060
1)H	I-T060
NMR	I-T060
,	O
U	B-T059
-	I-T059
HPLC	I-T059
/	O
Q	B-T059
-	I-T059
TOF	I-T059
-	I-T059
MS	I-T059
showed	O
higher	O
sensitivity	O
and	O
specificity	O
and	O
was	O
more	O
suitable	O
for	O
the	O
determination	B-T059
of	O
biomarkers	O
apart	O
from	O
the	O
deficiency	O
of	O
time	O
-	O
consuming	O
sample	B-T059
preparation	I-T059
steps	I-T059
and	O
unambiguous	O
metabolite	O
identification	O
.	O
Therefore	O
,	O
it	O
is	O
feasible	O
to	O
analyze	O
the	O
changes	O
of	O
GPLs	O
during	O
inflammation	O
by	O
combining	O
(	B-T060
1)H	I-T060
NMR	I-T060
spectroscopy	I-T060
with	O
U	B-T059
-	I-T059
HPLC	I-T059
/	O
Q	B-T059
-	I-T059
TOF	I-T059
-	I-T059
MS	I-T059
.	O
The	O
metabolic	O
profiling	O
of	O
GPLs	O
provides	O
valuable	O
evidence	O
for	O
inflammation	O
diagnosis	B-T033
and	O
prognosis	B-T058
,	O
and	O
might	O
unravel	O
the	O
mechanisms	O
involved	O
in	O
inflammation	O
progression	O
.	O
      
Multi	O
-	O
drug	O
-	O
resistant	O
Acinetobacter	B-T007
calcoaceticus	I-T007
-	I-T007
Acinetobacter	I-T007
baumannii	I-T007
complex	I-T007
infection	O
outbreak	O
in	O
dogs	O
and	O
cats	O
in	O
a	O
veterinary	O
hospital	O
Members	O
of	O
the	O
Acinetobacter	B-T007
calcoaceticus	I-T007
-	I-T007
Acinetobacter	I-T007
baumannii	I-T007
complex	I-T007
cause	O
severe	O
outbreaks	O
in	O
humans	O
,	O
and	O
are	O
increasingly	O
reported	B-T058
in	O
animals	O
.	O
A	O
retrospective	O
study	O
,	O
describing	O
a	O
severe	O
outbreak	O
in	O
dogs	O
and	O
cats	O
caused	O
by	O
a	O
multidrug	B-T007
resistant	I-T007
member	I-T007
of	O
the	O
Acinetobacter	B-T007
calcoaceticus	I-T007
-	I-T007
Acinetobacter	I-T007
baumannii	I-T007
complex	I-T007
in	O
a	O
veterinary	O
hospital	O
,	O
between	O
July	O
2010	O
and	O
November	O
2012	O
.	O
The	O
study	O
included	O
19	O
dogs	O
and	O
4	O
cats	O
.	O
Acinetobacter	B-T007
calcoaceticus	I-T007
-	I-T007
Acinetobacter	I-T007
baumannii	I-T007
complex	I-T007
bacteria	I-T007
were	O
isolated	O
from	O
urine	O
(	O
9	O
animals	O
)	O
,	O
respiratory	O
tract	O
(	O
11	O
)	O
,	O
tissues	O
(	O
3	O
)	O
and	O
blood	O
(	O
1	O
)	O
.	O
The	O
most	O
common	O
infection	O
-	O
associated	B-T033
findings	I-T033
included	O
fever	B-T184
,	O
purulent	B-T184
discharge	I-T184
from	O
endotracheal	O
tubes	O
,	O
hypotension	B-T033
,	O
and	O
neutropaenia	B-T047
.	O
Infection	O
s	O
led	O
to	O
pneumonia	B-T047
,	O
urinary	B-T047
tract	I-T047
infection	I-T047
,	O
cellulitis	O
and	O
sepsis	B-T047
.	O
Infection	O
was	O
transmitted	O
in	O
the	O
intensive	O
care	O
unit	O
,	O
where	O
22	O
of	O
23	O
animals	O
were	O
initially	O
hospitalised	B-T058
.	O
The	O
mortality	O
rate	O
was	O
70	O
%	O
(	O
16	O
of	O
23	O
animals	O
)	O
,	O
and	O
was	O
higher	O
in	O
cases	O
of	O
respiratory	B-T047
infection	I-T047
compared	O
to	O
other	O
infections	O
.	O
Aggressive	O
environmental	O
cleaning	O
and	O
disinfection	B-T061
,	O
with	O
staff	O
education	O
for	O
personal	O
hygiene	O
and	O
antisepsis	B-T061
,	O
sharply	O
decreased	O
the	O
infection	O
incidence	O
.	O
Health	O
care	O
-	O
associated	O
outbreaks	O
with	O
multidrug	O
resistant	O
Acinetobacter	B-T007
calcoaceticus	I-T007
-	I-T007
Acinetobacter	I-T007
baumannii	I-T007
complex	I-T007
in	O
dogs	O
and	O
cats	O
are	O
potentially	O
highly	O
fatal	O
and	O
difficult	O
to	O
eradicate	B-T061
,	O
warranting	O
monitoring	B-T058
,	O
antiseptic	B-T121
techniques	O
and	O
judicious	O
antibiotic	B-T195
use	O
.	O
      
Overcoming	O
structural	O
inequalities	O
in	O
oral	B-T058
health	I-T058
:	O
the	O
role	O
of	O
dental	B-T058
curricula	O
To	O
date	O
the	O
role	O
of	O
health	O
professional	O
schools	O
in	O
addressing	O
oral	B-T058
health	I-T058
inequalities	O
have	O
been	O
minimal	O
,	O
as	O
attempts	O
have	O
focused	O
principally	O
upon	O
systemic	O
reform	O
and	O
broader	O
societal	O
obligations	O
.	O
Professionalism	O
is	O
a	O
broad	O
competency	O
that	O
is	O
taught	O
throughout	O
dental	O
schools	O
and	O
encompasses	O
a	O
range	O
of	O
attributes	O
.	O
Professionalism	O
as	O
a	O
competency	O
draws	O
some	O
debate	O
and	O
appears	O
to	O
be	O
a	O
shifting	O
phenomenon	O
.	O
We	O
may	O
ask	O
if	O
professionalism	O
in	O
the	O
dental	B-T058
curricula	O
may	O
be	O
better	O
addressed	O
by	O
social	O
accountability	O
?	O
Social	O
accountability	O
directs	O
oral	B-T058
health	I-T058
professional	O
curricula	O
(	O
education	O
,	O
research	O
,	O
and	O
service	B-T058
activities	I-T058
)	O
towards	O
addressing	O
the	O
priority	O
health	O
concerns	O
of	O
the	O
community	O
,	O
in	O
our	O
case	O
oral	B-T058
health	I-T058
inequalities	O
.	O
Although	O
working	O
toward	O
dental	O
schools	O
becoming	O
more	O
socially	O
accountable	O
seems	O
like	O
a	O
sensible	O
way	O
to	O
address	O
oral	B-T058
health	I-T058
inequalities	O
,	O
it	O
might	O
have	O
limitations	O
.	O
We	O
will	O
consider	O
some	O
of	O
the	O
challenges	O
in	O
the	O
dental	B-T058
curricula	O
by	O
considering	O
some	O
of	O
the	O
political	O
,	O
structural	O
,	O
social	O
and	O
ethical	O
factors	O
that	O
influence	O
our	O
institutions	O
and	O
our	O
graduates	O
.	O
      
Caries	B-T047
with	O
Dental	B-T047
Fluorosis	I-T047
and	O
Oral	O
Health	O
Behaviour	O
Among	O
12	O
-	O
Year	O
School	O
Children	O
in	O
Moderate	O
-	O
Fluoride	O
Drinking	O
Water	O
Community	O
in	O
Quetta	O
,	O
Pakistan	O
To	O
determine	O
the	O
prevalence	O
of	O
dental	B-T047
caries	I-T047
and	O
its	O
relationship	O
with	O
dental	B-T047
fluorosis	I-T047
,	O
oral	O
health	O
behaviour	O
and	O
dietary	B-T033
behaviour	I-T033
among	O
12	O
-	O
year	O
school	O
children	O
in	O
moderate	O
-	O
fluoride	O
drinking	O
water	O
community	O
in	O
Quetta	O
,	O
Pakistan	O
.	O
Cross	O
-	O
sectional	O
study	O
.	O
Government	O
and	O
private	O
schools	O
of	O
Quetta	O
,	O
from	O
November	O
2012	O
to	O
February	O
2013	O
.	O
Atotal	O
of	O
349	O
children	O
aged	O
12	O
-	O
year	O
from	O
14	O
randomly	O
selected	O
schools	O
were	O
included	O
.	O
The	O
data	O
collection	O
was	O
done	O
on	O
questionnaire	O
designed	O
for	O
children	O
.	O
Dental	B-T047
caries	I-T047
status	O
was	O
examined	B-T033
by	O
using	O
WHO	O
criteria	O
.	O
Dental	B-T047
caries	I-T047
was	O
found	O
in	O
81	O
children	O
(	O
23.2	O
%	O
)	O
with	O
mean	O
DMFT	O
0.61	O
.	O
Boys	O
had	O
1.6	O
times	O
more	O
chance	O
to	O
have	O
dental	B-T047
caries	I-T047
than	O
girls	O
.	O
Dental	B-T047
fluorosis	I-T047
was	O
found	O
in	O
63.6	O
%	O
of	O
children	O
with	O
majority	O
of	O
moderate	O
degree	O
(	O
50.5	O
%	O
)	O
.	O
Dental	B-T047
fluorosis	I-T047
status	O
was	O
found	O
significantly	O
associated	O
with	O
dental	B-T047
caries	I-T047
status	O
in	O
children	O
.	O
The	O
children	O
who	O
had	O
mild	O
,	O
moderate	O
and	O
severe	O
fluorosis	B-T047
,	O
had	O
4	O
times	O
more	O
chances	O
to	O
develop	O
caries	B-T047
than	O
those	O
who	O
did	O
not	O
have	O
fluorosis	B-T047
.	O
There	O
was	O
no	O
significant	O
association	O
between	O
children	O
's	O
caries	B-T047
status	O
and	O
use	O
of	O
paste	O
,	O
brushing	B-T061
habit	I-T061
,	O
miswak	O
,	O
and	O
visit	O
to	O
the	O
dentist	O
.	O
The	O
use	O
of	O
pastries	O
and	O
juices	O
had	O
a	O
direct	O
relation	O
with	O
the	O
children	O
's	O
dental	B-T047
caries	I-T047
status	O
.	O
Dental	B-T047
caries	I-T047
in	O
children	O
of	O
Quetta	O
is	O
not	O
so	O
much	O
frequent	O
as	O
compared	O
to	O
the	O
fluoride	B-T121
deficient	O
countries	O
.	O
However	O
,	O
the	O
high	O
prevalence	O
of	O
moderate	O
dental	B-T047
fluorosis	I-T047
and	O
consumption	O
of	O
pastries	O
and	O
juices	O
resulted	O
in	O
dental	B-T047
caries	I-T047
.	O
      
The	O
NCAM1	O
gene	O
set	O
is	O
linked	O
to	O
depressive	B-T184
symptoms	I-T184
and	O
their	O
brain	B-T023
structural	I-T023
correlates	O
in	O
healthy	O
individuals	O
Depressive	B-T184
symptoms	I-T184
exist	O
on	O
a	O
continuum	O
,	O
the	O
far	O
end	O
of	O
which	O
is	O
found	O
in	O
depressive	B-T048
disorders	I-T048
.	O
Utilizing	O
the	O
continuous	B-T059
spectrum	I-T059
of	O
depressive	B-T184
symptoms	I-T184
may	O
therefore	O
contribute	O
to	O
the	O
understanding	O
of	O
the	O
biological	B-T033
underpinnings	I-T033
of	O
depression	B-T048
.	O
Gene	B-T059
set	I-T059
enrichment	I-T059
analysis	I-T059
(	O
GSEA	B-T059
)	O
is	O
an	O
important	O
tool	O
for	O
the	O
identification	O
of	O
gene	O
groups	O
linked	O
to	O
complex	O
traits	O
,	O
and	O
was	O
applied	O
in	O
the	O
present	O
study	O
on	O
genome	O
-	O
wide	O
association	O
study	O
(	O
GWAS	O
)	O
data	B-T033
of	I-T033
depression	I-T033
scores	I-T033
and	O
their	O
brain	B-T023
-	I-T023
level	I-T023
structural	I-T023
correlates	O
in	O
healthy	O
young	O
individuals	O
.	O
On	O
symptom	B-T033
level	I-T033
(	O
i.e.	O
depression	B-T033
scores	I-T033
)	O
,	O
robust	O
enrichment	O
was	O
identified	O
for	O
two	O
gene	O
sets	O
:	O
NCAM1	O
Interactions	O
and	O
Collagen	O
Formation	O
.	O
Depression	B-T033
scores	I-T033
were	O
also	O
associated	O
with	O
decreased	O
fractional	O
anisotropy	O
(	O
FA	O
)	O
-	O
a	O
brain	B-T023
white	I-T023
matter	I-T023
property	I-T023
-	O
within	B-T023
the	I-T023
forceps	I-T023
minor	I-T023
and	O
the	O
left	B-T023
superior	I-T023
temporal	I-T023
longitudinal	I-T023
fasciculus	I-T023
.	O
Within	O
each	O
of	O
these	O
tracts	O
,	O
mean	O
FA	O
value	O
of	O
depression	B-T033
score	I-T033
-	O
associated	O
voxels	O
was	O
used	O
as	O
a	O
phenotype	O
in	O
a	O
subsequent	O
GSEA	B-T059
.	O
The	O
NCAM1	O
Interactions	O
gene	O
set	O
was	O
significantly	O
enriched	O
in	O
these	O
tracts	O
.	O
By	O
linking	O
the	O
NCAM1	O
Interactions	O
gene	O
set	O
to	O
depression	B-T033
scores	I-T033
and	O
their	O
structural	B-T023
brain	I-T023
correlates	O
in	O
healthy	O
participants	O
,	O
the	O
current	O
study	O
contributes	O
to	O
the	O
understanding	O
of	O
the	O
molecular	B-T033
underpinnings	I-T033
of	O
depressive	B-T184
symptomatology	I-T184
.	O
      
Minimally	B-T061
invasive	I-T061
treatment	I-T061
of	O
difficult	O
bleeding	O
lesions	B-T033
of	O
the	O
small	B-T023
bowel	I-T023
Bleeding	O
lesions	B-T033
of	O
the	O
small	B-T023
bowel	I-T023
are	O
often	O
difficult	O
to	O
identify	O
due	O
to	O
the	O
obscure	B-T033
symptomatology	B-T184
.	O
Localizing	O
these	O
lesions	B-T033
requires	O
specific	O
techniques	O
.	O
The	O
Double	B-T060
-	I-T060
balloon	I-T060
enteroscopy	I-T060
(	O
DBE	B-T060
)	O
could	O
be	O
used	O
to	O
precisely	O
localize	O
and	O
mark	O
lesions	B-T033
,	O
so	O
that	O
a	O
minimally	B-T061
invasive	I-T061
surgical	I-T061
treatment	I-T061
could	O
be	O
performed	O
.	O
Twenty	O
robot	O
-	O
assisted	O
small	B-T061
bowel	I-T061
procedures	I-T061
are	O
presented	O
using	O
a	O
combination	O
of	O
DBE	B-T060
for	O
localization	O
and	O
robotic	B-T061
resection	I-T061
.	O
There	O
were	O
10	O
jejunal	B-T061
resections	I-T061
and	O
10	O
ileal	B-T061
resections	I-T061
.	O
Mean	O
age	O
was	O
58.7	O
years	O
.	O
Mean	O
operative	O
time	O
was	O
153.4	O
minutes	O
,	O
mean	O
blood	B-T033
loss	I-T033
of	O
46	O
mL.	O
No	O
conversion	B-T061
-	I-T061
to	I-T061
-	I-T061
open	I-T061
and	O
there	O
were	O
4	O
post	O
-	O
operative	O
complications	O
.	O
The	O
90-	O
day	O
mortality	O
was	O
nil	O
and	O
the	O
median	O
length	O
of	O
stay	O
was	O
4.1	O
days	O
.	O
Final	O
pathology	O
was	O
consistent	O
with	O
malignancy	B-T191
in	O
10	O
cases	O
.	O
The	O
combination	O
of	O
double	B-T060
-	I-T060
balloon	I-T060
enteroscopy	I-T060
and	O
robotic	B-T061
technology	I-T061
allows	O
accurate	O
identification	O
and	O
selective	O
treatment	O
of	O
lesions	B-T033
that	O
could	O
be	O
otherwise	O
difficult	O
to	O
treat	O
in	O
a	O
minimally	B-T061
invasive	I-T061
fashion	I-T061
.	O
      
Blur	O
perception	O
throughout	O
the	O
visual	O
field	O
in	O
myopia	B-T047
and	O
emmetropia	B-T033
We	O
evaluated	B-T058
the	O
ability	O
of	O
emmetropic	B-T033
and	O
myopic	B-T047
observers	O
to	O
detect	B-T033
and	O
discriminate	O
blur	O
across	O
the	O
retina	B-T023
under	O
monocular	O
or	O
binocular	O
viewing	O
conditions	O
.	O
We	O
recruited	O
39	O
young	O
(	O
23	O
-	O
30	O
years	O
)	O
healthy	B-T033
adults	I-T033
(	O
n	O
=	O
19	O
myopes	B-T047
)	O
with	O
best	O
-	O
corrected	O
visual	O
acuity	O
0.0	O
LogMAR	O
(	O
20/20	O
)	O
or	O
better	O
in	O
each	O
eye	B-T023
and	O
no	B-T033
binocular	I-T033
or	O
accommodative	B-T033
dysfunction	I-T033
.	O
Monocular	O
and	O
binocular	O
blur	O
discrimination	O
thresholds	O
were	O
measured	O
as	O
a	O
function	O
of	O
pedestal	O
blur	O
using	O
naturalistic	O
stimuli	O
with	O
an	O
adaptive	B-T060
4AFC	I-T060
procedure	I-T060
.	O
Stimuli	O
were	O
presented	O
in	O
a	O
46	O
°	O
diameter	O
window	O
at	O
40	O
cm	O
.	O
Gaussian	O
blur	O
pedestals	O
were	O
confined	O
to	O
an	O
annulus	O
at	O
either	O
0	O
°	O
,	O
4	O
°	O
,	O
8	O
°	O
,	O
or	O
12	O
°	O
eccentricity	O
,	O
with	O
a	O
blur	O
increment	O
applied	O
to	O
only	O
one	O
quadrant	O
of	O
the	O
image	O
.	O
The	O
adaptive	B-T060
procedure	I-T060
efficiently	O
estimated	O
a	O
dipper	B-T033
shaped	I-T033
blur	O
discrimination	O
threshold	O
function	O
with	O
two	O
parameters	O
:	O
intrinsic	O
blur	O
and	O
blur	O
sensitivity	O
.	O
The	O
amount	O
of	O
intrinsic	O
blur	O
increased	O
for	O
retinal	O
eccentricities	O
beyond	O
4	O
°	O
(	O
p	O
<	O
0.001	O
)	O
and	O
was	O
lower	O
in	O
binocular	O
than	O
monocular	O
conditions	O
(	O
p	O
<	O
0.001	O
)	O
,	O
but	O
was	O
similar	O
across	O
refractive	O
groups	O
(	O
p	O
=	O
0.47	O
)	O
.	O
Blur	O
sensitivity	O
decreased	O
with	O
retinal	O
eccentricity	O
(	O
p	O
<	O
0.001	O
)	O
and	O
was	O
highest	O
for	O
binocular	O
viewing	O
,	O
but	O
only	O
for	O
central	O
vision	O
(	O
p	O
<	O
0.05	O
)	O
.	O
Myopes	B-T047
showed	O
worse	B-T033
blur	O
sensitivity	O
than	O
emmetropes	B-T033
monocularly	O
(	O
p	O
<	O
0.05	O
)	O
but	O
not	O
binocularly	O
(	O
p	O
=	O
0.66	O
)	O
.	O
As	O
expected	O
,	O
blur	O
perception	O
worsens	B-T033
in	O
the	O
visual	O
periphery	O
and	O
binocular	O
summation	O
is	O
most	O
evident	O
in	O
central	O
vision	O
.	O
Furthermore	O
,	O
myopes	B-T047
exhibit	O
a	O
monocular	O
impairment	O
in	O
blur	O
sensitivity	O
that	O
improves	B-T033
under	O
binocular	O
conditions	O
.	O
Implications	O
for	O
the	O
development	O
of	O
myopia	B-T047
are	O
discussed	O
.	O
      
CAGEd	O
-	O
oPOSSUM	O
:	O
motif	O
enrichment	O
analysis	O
from	O
CAGE	O
-derived	O
TSSs	O
With	O
the	O
emergence	O
of	O
large	O
-	O
scale	O
Cap	O
Analysis	O
of	O
Gene	O
Expression	O
(	O
CAGE	O
)	O
datasets	O
from	O
individual	O
labs	O
and	O
the	O
FANTOM	O
consortium	O
,	O
one	O
can	O
now	O
analyze	O
the	O
cis	O
-	O
regulatory	O
regions	O
associated	O
with	O
gene	O
transcription	O
at	O
an	O
unprecedented	O
level	O
of	O
refinement	O
.	O
By	O
coupling	O
transcription	O
factor	O
binding	O
site	O
(	O
TFBS	O
)	O
enrichment	O
analysis	O
with	O
CAGE	O
-derived	O
genomic	O
regions	O
,	O
CAGEd	O
-	O
oPOSSUM	O
can	O
identify	O
TFs	O
that	O
act	O
as	O
key	O
regulators	O
of	O
genes	O
involved	O
in	O
specific	O
mammalian	O
cell	O
and	O
tissue	O
types	O
.	O
The	O
webtool	O
allows	O
for	O
the	O
analysis	O
of	O
CAGE	O
-derived	O
transcription	O
start	O
sites	O
(	O
TSSs	O
)	O
either	O
provided	O
by	O
the	O
user	O
or	O
selected	O
from	O
∼1300	O
mammalian	O
samples	O
from	O
the	O
FANTOM5	O
project	O
with	O
pre	O
-	O
computed	O
TFBS	O
predicted	O
with	O
JASPAR	O
TF	O
binding	O
profiles	O
.	O
The	O
tool	O
helps	O
power	O
insights	O
into	O
the	O
regulation	O
of	O
genes	O
through	O
the	O
study	O
of	O
the	O
specific	O
usage	O
of	O
TSSs	O
within	O
specific	O
cell	O
types	O
and/or	O
under	O
specific	O
conditions	O
.	O
The	O
CAGEd	O
-	O
oPOSUM	O
web	O
tool	O
is	O
implemented	O
in	O
Perl	O
,	O
MySQL	O
and	O
Apache	O
and	O
is	O
available	O
at	O
http://cagedop.cmmt.ubc.ca/CAGEd_oPOSSUM	O
CONTACTS	O
:	O
anthony.mathelier@ncmm.uio.no	O
or	O
wyeth@cmmt.ubc.ca	O
Supplementary	O
information	O
:	O
Supplementary	O
data	O
are	O
available	O
at	O
Bioinformatics	O
online	O
.	O
      
Is	O
Modern	O
Medical	B-T058
Management	I-T058
Changing	O
Ultimate	O
Patient	O
Outcomes	O
in	O
Inflammatory	B-T047
Bowel	I-T047
Disease	I-T047
?	O
The	O
impact	O
of	O
modern	O
medical	B-T058
management	I-T058
of	O
inflammatory	B-T047
bowel	I-T047
disease	I-T047
(	O
IBD	B-T047
)	O
on	O
surgical	B-T058
necessity	I-T058
and	O
outcomes	O
remains	O
unclear	B-T033
.	O
We	O
hypothesized	O
that	O
surgery	B-T061
rates	O
have	O
decreased	O
while	O
outcomes	O
have	O
worsened	B-T033
due	O
to	O
operating	B-T061
on	O
"	O
sicker	B-T184
"	O
patients	O
since	O
the	O
introduction	O
of	O
biologic	B-T061
medications	I-T061
.	O
The	O
Nationwide	O
Inpatient	O
Sample	O
and	O
ICD-9	O
-	O
CM	O
codes	O
were	O
used	O
to	O
identify	O
inpatient	O
admissions	B-T058
for	O
Crohn	B-T047
's	I-T047
disease	I-T047
and	O
ulcerative	B-T047
colitis	I-T047
.	O
Trends	O
in	O
IBD	B-T047
nutrition	B-T033
,	O
surgeries	B-T061
,	O
and	O
postoperative	O
complications	O
were	O
determined	O
.	O
There	O
were	O
191,743	O
admissions	B-T058
for	O
IBD	B-T047
during	O
the	O
study	O
period	O
.	O
Surgery	B-T061
rates	O
were	O
largely	O
unchanged	B-T033
over	O
the	O
study	O
period	O
,	O
ranging	O
from	O
9	O
to	O
12	O
%	O
of	O
admissions	B-T058
in	O
both	O
Crohn	B-T047
's	I-T047
disease	I-T047
and	O
ulcerative	B-T047
colitis	I-T047
.	O
The	O
rate	O
of	O
poor	B-T047
nutrition	I-T047
increased	O
by	O
67	O
%	O
in	O
ulcerative	B-T047
colitis	I-T047
and	O
by	O
83	O
%	O
in	O
Crohn	B-T047
's	I-T047
disease	I-T047
.	O
Rates	O
of	O
postoperative	O
anastomotic	O
leak	O
(	O
10.2	O
-	O
13.9	O
%	O
)	O
were	O
unchanged	B-T033
over	O
the	O
years	O
.	O
Postoperative	O
infection	O
rates	O
decreased	O
by	O
17	O
%	O
in	O
Crohn	B-T047
's	I-T047
disease	I-T047
(	O
18	O
%	O
in	O
2003	O
to	O
15	O
%	O
in	O
2012	O
;	O
P	O
<	O
0.001	O
)	O
but	O
did	O
not	O
show	O
a	O
trend	B-T033
in	O
any	O
direction	O
in	O
ulcerative	B-T047
colitis	I-T047
.	O
Rates	O
of	O
IBD	B-T047
surgery	O
have	O
remained	O
stable	O
while	O
postoperative	O
infectious	O
complications	O
have	O
remained	O
stable	O
or	O
decreased	O
since	O
the	O
implementation	B-T058
of	O
biologic	B-T061
therapies	I-T061
.	O
We	O
identified	O
an	O
increase	O
in	O
poor	B-T047
nutrition	I-T047
in	O
surgical	O
patients	O
.	O
      
Source	O
apportionment	O
and	O
heavy	O
metal	O
health	B-T061
risk	I-T061
(	O
HMHR	B-T061
)	O
quantification	O
from	O
sources	B-T033
in	O
a	O
southern	O
city	O
in	O
China	O
,	O
using	O
an	O
ME2	O
-	O
HMHR	B-T061
model	O
Heavy	O
metals	O
(	O
Cr	O
,	O
Co	O
,	O
Ni	O
,	O
As	B-T121
,	O
Cd	O
,	O
and	O
Pb	O
)	O
can	O
be	O
bound	O
to	O
PM	O
adversely	O
affecting	O
human	O
health	O
.	O
Quantifying	O
the	O
source	B-T033
impacts	O
on	O
heavy	O
metals	O
can	O
provide	O
source	B-T033
-	O
specific	O
estimates	O
of	O
the	O
heavy	O
metal	O
health	B-T061
risk	I-T061
(	O
HMHR	B-T061
)	O
to	O
guide	O
effective	O
development	O
of	O
strategies	O
to	O
reduce	O
such	O
risks	O
from	O
exposure	O
to	O
heavy	O
metals	O
in	O
PM2.5	O
(	O
particulate	O
matter	O
(	O
PM	O
)	O
with	O
aerodynamic	O
diameter	O
less	O
than	O
or	O
equal	O
to	O
2.5	O
μm	O
)	O
.	O
In	O
this	O
study	O
,	O
a	O
method	O
combining	O
Multilinear	O
Engine	O
2	O
(	O
ME2	O
)	O
and	O
a	O
risk	B-T058
assessment	I-T058
model	O
is	O
developed	O
to	O
more	O
effectively	O
quantify	O
source	B-T033
contributions	O
to	O
HMHR	B-T061
,	O
including	O
heavy	O
metal	O
non	B-T033
-	I-T033
cancer	I-T033
risk	I-T033
(	O
non	B-T033
-	I-T033
HMCR	I-T033
)	O
and	O
cancer	O
risk	O
(	O
HMCR	O
)	O
.	O
The	O
combined	O
model	O
(	O
called	O
ME2	O
-	O
HMHR	O
)	O
has	O
two	O
steps	O
:	O
step1	O
,	O
source	B-T033
contributions	O
to	O
heavy	O
metals	O
are	O
estimated	O
by	O
employing	O
the	O
ME2	O
model	O
;	O
step2	O
,	O
the	O
source	B-T033
contributions	O
in	O
step	O
1	O
are	O
introduced	O
into	O
the	O
risk	B-T058
assessment	I-T058
model	O
to	O
calculate	O
the	O
source	B-T033
contributions	O
to	O
HMHR	B-T061
.	O
The	O
approach	O
was	O
applied	O
to	O
Huzou	O
,	O
China	O
and	O
five	O
significant	O
sources	B-T033
were	O
identified	O
.	O
Soil	O
dust	O
is	O
the	O
largest	O
source	B-T033
of	O
non	B-T033
-	I-T033
HMCR	I-T033
.	O
For	O
HMCR	O
,	O
the	O
source	B-T033
contributions	O
of	O
soil	O
dust	O
,	O
coal	O
combustion	O
,	O
cement	B-T033
dust	I-T033
,	O
vehicle	O
,	O
and	O
secondary	O
sources	B-T033
are	O
1.0	O
×	O
10(-4	O
)	O
,	O
3.7	O
×	O
10(-5	O
)	O
,	O
2.7	O
×	O
10(-6	O
)	O
,	O
1.6	O
×	O
10(-6	O
)	O
and	O
1.9	O
×	O
10(-9	O
)	O
,	O
respectively	O
.	O
The	O
soil	O
dust	O
is	O
the	O
largest	O
contributor	O
to	O
HMCR	O
,	O
being	O
driven	O
by	O
the	O
high	O
impact	O
of	O
soil	O
dust	O
on	O
PM2.5	O
and	O
the	O
abundance	O
of	O
heavy	O
metals	O
in	O
soil	O
dust	O
.	O
      
Intravascular	O
Inflammation	O
Triggers	O
Intracerebral	O
Activated	O
Microglia	O
and	O
Contributes	O
to	O
Secondary	O
Brain	O
Injury	O
After	O
Experimental	O
Subarachnoid	B-T047
Hemorrhage	I-T047
(	O
eSAH	B-T047
)	O
Activation	O
of	O
innate	O
immunity	O
contributes	O
to	O
secondary	O
brain	O
injury	O
after	O
experimental	O
subarachnoid	B-T047
hemorrhage	I-T047
(	O
eSAH	B-T047
)	O
.	O
Microglia	O
accumulation	B-T033
and	O
activation	O
within	O
the	O
brain	B-T023
has	O
recently	O
been	O
shown	O
to	O
induce	O
neuronal	O
cell	O
death	O
after	O
eSAH	B-T047
.	O
In	O
isolated	O
mouse	O
brain	B-T023
capillaries	B-T023
after	O
eSAH	B-T047
,	O
we	O
show	O
a	O
significantly	O
increased	O
gene	O
expression	O
for	O
intercellular	O
adhesion	O
molecule-1	O
(	O
ICAM-1	O
)	O
and	O
P	O
-	O
selectin	O
.	O
Hence	O
,	O
we	O
hypothesized	O
that	O
extracerebral	O
intravascular	O
inflammatory	O
processes	O
might	O
initiate	O
the	O
previously	O
reported	B-T058
microglia	O
accumulation	B-T033
within	O
the	O
brain	B-T023
tissue	I-T023
.	O
We	O
therefore	O
induced	O
eSAH	B-T047
in	O
knockout	O
mice	O
for	O
ICAM-1	O
(	O
ICAM-1(-/-	O
)	O
)	O
and	O
P	O
-	O
selectin	O
glycoprotein	O
ligand-1	O
(	O
PSGL-1(-/-	O
)	O
)	O
to	O
find	O
a	O
significant	O
decrease	O
in	O
neutrophil	O
-	O
endothelial	O
interaction	O
within	O
the	O
first	O
7	O
days	O
after	O
the	O
bleeding	O
in	O
a	O
chronic	O
cranial	O
window	O
model	O
.	O
This	O
inhibition	O
of	O
neutrophil	O
recruitment	O
to	O
the	O
endothelium	O
results	O
in	O
significantly	O
ameliorated	B-T033
microglia	O
accumulation	B-T033
and	O
neuronal	O
cell	O
death	O
in	O
knockout	O
animals	O
in	O
comparison	O
to	O
controls	O
.	O
Our	O
results	O
suggest	O
an	O
outside	O
-	O
in	O
activation	O
of	O
the	O
CNS	O
innate	O
immune	O
system	O
at	O
the	O
vessel	O
/	O
brain	B-T023
interface	O
following	O
eSAH	B-T047
.	O
Microglia	O
cells	O
,	O
as	O
part	O
of	O
the	O
brain	B-T023
's	I-T023
innate	O
immune	O
system	O
,	O
are	O
triggered	O
by	O
an	O
inflammatory	O
reaction	O
in	O
the	O
microvasculature	O
after	O
eSAH	B-T047
,	O
thus	O
contributing	O
to	O
neuronal	O
cell	O
death	O
.	O
This	O
finding	O
offers	O
a	O
whole	O
range	O
of	O
new	O
research	O
targets	O
,	O
as	O
well	O
as	O
possible	O
therapy	O
options	O
for	O
patients	O
suffering	O
from	O
eSAH	B-T047
.	O
      
Early	O
assessment	B-T058
of	O
bilateral	B-T061
inguinal	I-T061
hernia	I-T061
repair	I-T061
:	O
A	O
comparison	O
between	O
the	O
laparoscopic	B-T061
total	I-T061
extraperitoneal	I-T061
and	O
Stoppa	B-T061
approaches	I-T061
The	O
present	O
clinical	O
trial	O
was	O
designed	O
to	O
compare	O
the	O
results	O
of	O
bilateral	B-T061
inguinal	I-T061
hernia	I-T061
repair	I-T061
between	O
patients	O
who	O
underwent	O
the	O
conventional	O
Stoppa	B-T061
technique	I-T061
and	O
laparoscopic	B-T061
total	I-T061
extraperitoneal	I-T061
repair	I-T061
(	O
LTE	B-T061
)	O
with	O
a	O
single	O
mesh	O
and	O
without	O
staple	B-T061
fixation	I-T061
.	O
This	O
controlled	O
,	O
randomised	O
clinical	O
trial	O
was	O
conducted	O
at	O
General	O
Surgery	O
and	O
Trauma	O
of	O
the	O
Clinics	O
Hospital	O
,	O
Medical	O
School	O
,	O
the	O
University	O
of	O
Sγo	O
Paulo	O
between	O
September	O
2010	O
and	O
February	O
2011	O
.	O
Totally	O
,	O
50	O
male	O
patients	O
,	O
with	O
a	O
bilateral	B-T190
inguinal	I-T190
hernia	I-T190
,	O
older	O
than	O
25	O
years	O
were	O
considered	O
eligible	O
for	O
the	O
study	O
.	O
The	O
following	O
parameters	O
were	O
analysed	O
during	O
the	O
early	O
post	O
-	O
operative	O
period	O
:	O
(	O
1	O
)	O
The	O
intensity	O
of	O
surgical	B-T033
trauma	I-T033
,	O
operation	O
time	O
,	O
C	O
-	O
reactive	O
protein	O
(	O
CRP	O
)	O
levels	O
,	O
white	B-T059
blood	I-T059
cell	I-T059
count	I-T059
,	O
bleeding	O
and	O
pain	O
intensity	O
;	O
(	O
2	O
)	O
quality	O
of	O
life	O
assessment	B-T058
;	O
and	O
(	O
3	O
)	O
post	O
-	O
operative	O
complications	O
.	O
LTE	B-T061
procedure	I-T061
was	O
longer	O
than	O
the	O
Stoppa	B-T061
procedure	I-T061
(	O
134.6	O
min	O
΁	O
38.3	O
vs.	O
90.6	O
min	O
΁	O
41.3	O
;	O
P	O
<	O
0.05	O
)	O
.	O
The	O
levels	O
of	O
CRP	O
were	O
higher	O
in	O
the	O
Stoppa	B-T061
group	O
(	O
P	O
<	O
0.05	O
)	O
but	O
the	O
number	O
of	O
leucocytes	O
,	O
haematocrit	B-T033
,	O
and	O
haemoglobin	O
were	O
similar	O
between	O
the	O
groups	O
(	O
P	O
>	O
0.05	O
)	O
.	O
There	O
was	O
no	B-T033
difference	I-T033
in	O
pain	B-T184
during	O
the	O
1	O
st	O
and	O
7	O
th	O
post	B-T033
-	I-T033
operative	I-T033
,	O
physical	B-T033
functioning	I-T033
,	O
physical	O
limitation	O
,	O
the	O
impact	O
of	O
pain	B-T184
on	O
daily	O
activities	O
,	O
and	O
the	O
Carolinas	O
Comfort	O
Scale	O
during	O
the	O
7	O
th	O
and	O
15	O
th	O
post	B-T033
-	I-T033
operative	I-T033
(	O
P	O
>	O
0.05	O
)	O
.	O
Complications	O
occurred	O
in	O
88	O
%	O
of	O
Stoppa	B-T061
group	O
(	O
22	O
patients	O
)	O
and	O
64	O
%	O
in	O
LTE	B-T061
group	O
(	O
16	O
patients	O
)	O
(	O
P	O
<	O
0.05	O
)	O
.	O
The	O
comparative	O
study	O
between	O
the	O
Stoppa	B-T061
and	O
LTE	B-T061
approaches	O
for	O
the	O
bilateral	B-T061
inguinal	I-T061
hernia	I-T061
repair	I-T061
demonstrated	O
that	O
:	O
(	O
1	O
)	O
The	O
LTE	B-T061
approach	O
showed	O
less	O
surgical	B-T033
trauma	I-T033
despite	O
the	O
longer	O
operation	O
time	O
;	O
(	O
2	O
)	O
Quality	O
of	O
life	O
during	O
the	O
early	O
post	O
-	O
operative	O
period	O
were	O
similar	O
;	O
and	O
(	O
3	O
)	O
Complication	O
rates	O
were	O
higher	O
in	O
the	O
Stoppa	B-T061
group	O
.	O
      
Spectral	B-T059
fingerprints	I-T059
of	O
large	O
-	O
scale	O
cortical	B-T023
dynamics	O
during	O
ambiguous	O
motion	O
perception	O
Ambiguous	O
stimuli	O
have	O
been	O
widely	O
used	O
to	O
study	O
the	O
neuronal	O
correlates	O
of	O
consciousness	O
.	O
Recently	O
,	O
it	O
has	O
been	O
suggested	O
that	O
conscious	O
perception	O
might	O
arise	O
from	O
the	O
dynamic	O
interplay	O
of	O
functionally	O
specialized	O
but	O
widely	O
distributed	O
cortical	B-T023
areas	I-T023
.	O
While	O
previous	O
research	O
mainly	O
focused	O
on	O
phase	O
coupling	O
as	O
a	O
correlate	O
of	O
cortical	B-T023
communication	O
,	O
more	O
recent	O
findings	O
indicated	O
that	O
additional	O
coupling	O
modes	O
might	O
coexist	O
and	O
possibly	O
subserve	O
distinct	O
cortical	O
functions	O
.	O
Here	O
,	O
we	O
studied	O
two	O
coupling	O
modes	O
,	O
namely	O
phase	O
and	O
envelope	O
coupling	O
,	O
which	O
might	O
differ	O
in	O
their	O
origins	O
,	O
putative	O
functions	O
and	O
dynamics	O
.	O
Therefore	O
,	O
we	O
recorded	O
128	O
-	O
channel	O
EEG	B-T060
while	O
participants	O
performed	O
a	O
bistable	B-T060
motion	I-T060
task	I-T060
and	O
utilized	O
state	O
-	O
of	O
-	O
the	O
-	O
art	O
source	O
-	O
space	O
connectivity	O
analysis	O
techniques	O
to	O
study	O
the	O
functional	O
relevance	O
of	O
different	O
coupling	O
modes	O
for	O
cortical	B-T023
communication	O
.	O
Our	O
results	O
indicate	O
that	O
gamma	O
-	O
band	O
phase	O
coupling	O
in	O
extrastriate	O
visual	B-T023
cortex	I-T023
might	O
mediate	O
the	O
integration	O
of	O
visual	B-T060
tokens	I-T060
into	O
a	O
moving	O
stimulus	O
during	O
ambiguous	O
visual	B-T060
stimulation	I-T060
.	O
Furthermore	O
,	O
our	O
results	O
suggest	O
that	O
long	O
-	O
range	O
fronto	O
-	O
occipital	O
gamma	O
-	O
band	O
envelope	O
coupling	O
sustains	O
the	O
horizontal	O
percept	O
during	O
ambiguous	O
motion	O
perception	O
.	O
Additionally	O
,	O
our	O
results	O
support	O
the	O
idea	O
that	O
local	B-T023
parieto	I-T023
-	I-T023
occipital	I-T023
alpha	O
-	O
band	O
phase	O
coupling	O
controls	O
the	O
inter-	O
hemispheric	O
information	O
transfer	O
.	O
These	O
findings	O
provide	O
correlative	O
evidence	O
for	O
the	O
notion	O
that	O
synchronized	O
oscillatory	O
brain	O
activity	O
reflects	O
the	O
processing	O
of	O
sensory	O
input	O
as	O
well	O
as	O
the	O
information	O
integration	O
across	O
several	O
spatiotemporal	O
scales	O
.	O
The	O
results	O
indicate	O
that	O
distinct	O
coupling	O
modes	O
are	O
involved	O
in	O
different	O
cortical	B-T023
computations	O
and	O
that	O
the	O
rich	O
spatiotemporal	O
correlation	O
structure	B-T023
of	I-T023
the	I-T023
brain	I-T023
might	O
constitute	O
the	O
functional	O
architecture	O
for	O
cortical	B-T023
processing	O
and	O
specific	O
multi	O
-	O
site	O
communication	O
.	O
Hum	O
Brain	O
Mapp	O
37:4099	O
-	O
4111	O
,	O
2016	O
.	O
©	O
2016	O
Wiley	O
Periodicals	O
,	O
Inc.	O
      
Effect	O
of	O
Hepatitis	B-T047
C	I-T047
Virus	I-T047
Coinfection	I-T047
on	O
the	O
Content	O
of	O
CD4(+	O
)	O
and	O
CD8(+	O
)	O
T	O
Cell	O
Subpopulations	O
in	O
HIV	B-T005
-	O
Infected	B-T033
Patients	O
Receiving	O
Antiretroviral	B-T061
Therapy	I-T061
We	O
studied	O
the	O
effect	O
of	O
hepatitis	B-T047
C	I-T047
virus	I-T047
coinfection	I-T047
on	O
T	O
cell	O
subpopulations	O
in	O
HIV	B-T005
-	O
infected	B-T033
patients	O
receiving	O
antiretroviral	B-T061
therapy	I-T061
.	O
Coinfection	B-T047
with	O
hepatitis	B-T005
C	I-T005
virus	I-T005
was	O
followed	O
by	O
a	O
decrease	O
in	O
the	O
number	O
of	O
naive	O
CD4(+	O
)	O
T	O
cells	O
and	O
an	O
increase	O
in	O
the	O
count	O
of	O
central	O
CD8(+	O
)	O
memory	O
T	O
cells	O
in	O
these	O
patients	O
.	O
Hepatitis	B-T005
C	I-T005
virus	I-T005
had	O
no	O
effect	O
on	O
the	O
number	O
of	O
CD4(+	O
)	O
memory	O
T	O
cells	O
(	O
main	O
target	O
for	O
HIV	B-T005
)	O
.	O
This	O
can	O
explain	O
the	O
absence	O
of	O
strong	O
negative	B-T033
effect	O
of	O
hepatitis	B-T005
C	I-T005
virus	I-T005
on	O
the	O
course	O
of	O
HIV	B-T005
infection	O
.	O
      
Impact	O
of	O
Blood	B-T061
Transfusions	I-T061
on	O
Survival	O
of	O
Locally	O
Advanced	O
Cervical	B-T191
Cancer	I-T191
Patients	O
Undergoing	O
Neoadjuvant	B-T061
Chemotherapy	I-T061
Plus	O
Radical	B-T061
Surgery	I-T061
Transfusions	B-T061
represent	O
one	O
of	O
the	O
main	O
progresses	O
of	O
modern	O
medicine	O
.	O
However	O
,	O
accumulating	O
evidence	O
supports	O
that	O
transfusions	B-T061
correlate	O
with	O
worse	O
survival	O
outcomes	O
in	O
patients	O
affected	O
by	O
solid	B-T191
cancers	I-T191
.	O
In	O
the	O
present	O
study	O
,	O
we	O
aimed	O
to	O
investigate	O
the	O
effects	O
of	O
perioperative	O
blood	B-T061
transfusion	I-T061
in	O
locally	O
advanced	O
cervical	B-T191
cancer	I-T191
.	O
Data	O
of	O
consecutive	O
patients	O
affected	O
by	O
locally	O
advanced	O
cervical	B-T191
cancer	I-T191
scheduled	O
to	O
undergo	O
neoadjuvant	B-T061
chemotherapy	I-T061
plus	O
radical	B-T061
surgery	I-T061
were	O
retrospectively	O
searched	O
to	O
test	O
the	O
impact	O
of	O
perioperative	O
transfusions	B-T061
on	O
survival	O
outcomes	O
.	O
Five-	O
year	O
survival	O
outcomes	O
were	O
evaluated	O
using	O
Kaplan	O
-	O
Meier	O
and	O
Cox	O
models	O
.	O
The	O
study	O
included	O
275	O
patients	O
.	O
Overall	O
,	O
170	O
(	O
62	O
%	O
)	O
patients	O
had	O
blood	B-T061
transfusion	I-T061
.	O
Via	O
univariate	O
analysis	O
,	O
we	O
observed	O
that	O
transfusion	B-T061
correlated	O
with	O
an	O
increased	O
risk	O
of	O
developing	O
recurrence	B-T191
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
,	O
2.2	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
1.09	O
-	O
4.40	O
;	O
P	O
=	O
0.02	O
)	O
.	O
Other	O
factors	O
associated	O
with	O
5-	O
year	O
disease	O
-	O
free	O
survival	O
were	O
noncomplete	B-T033
clinical	B-T033
response	I-T033
after	O
neoadjuvant	B-T061
chemotherapy	I-T061
(	O
HR	O
,	O
2.99	O
;	O
95	O
%	O
CI	O
,	O
0.92	O
-	O
9.63	O
;	O
P	O
=	O
0.06	O
)	O
and	O
pathological	B-T033
(	O
P	O
=	O
0.03	O
)	O
response	B-T033
at	O
neoadjuvant	B-T061
chemotherapy	I-T061
as	O
well	O
as	O
parametrial	O
(	O
P	O
=	O
0.004	O
)	O
,	O
vaginal	B-T023
(	O
P	O
<	O
0.001	O
)	O
,	O
and	O
lymph	B-T023
node	I-T023
(	O
P	O
=	O
0.002	O
)	O
involvements	O
.	O
However	O
,	O
via	O
multivariate	O
analysis	O
,	O
only	O
vaginal	B-T023
(	O
HR	O
,	O
3.07	O
;	O
95	O
%	O
CI	O
,	O
1.20	O
-	O
7.85	O
;	O
P	O
=	O
0.01	O
)	O
and	O
lymph	B-T023
node	I-T023
involvements	O
(	O
HR	O
,	O
2.4	O
;	O
95	O
%	O
CI	O
,	O
1.00	O
-	O
6.06	O
;	O
P	O
=	O
0.05	O
)	O
correlate	O
with	O
worse	O
disease	O
-	O
free	O
survival	O
.	O
No	O
association	O
with	O
worse	O
outcomes	O
was	O
observed	O
for	O
patients	O
undergoing	O
blood	B-T061
transfusion	I-T061
(	O
HR	O
,	O
2.71	O
;	O
95	O
%	O
CI	O
,	O
0.91	O
-	O
8.03	O
;	O
P	O
=	O
0.07	O
)	O
.	O
Looking	O
at	O
factors	O
influencing	O
overall	O
survival	O
,	O
we	O
observed	O
that	O
lymph	B-T023
node	I-T023
status	O
(	O
P	O
=	O
0.01	O
)	O
and	O
vaginal	B-T023
involvement	O
(	O
P	O
=	O
0.06	O
)	O
were	O
independently	O
associated	O
with	O
survival	O
.	O
The	O
role	O
of	O
blood	B-T061
transfusions	I-T061
in	O
increasing	O
the	O
risk	O
of	O
developing	O
recurrence	B-T191
in	O
LAAC	B-T191
patients	O
treated	B-T061
by	O
neoadjuvant	B-T061
chemotherapy	I-T061
plus	O
radical	B-T061
surgery	I-T061
remains	O
unclear	B-T033
;	O
further	O
prospective	O
studies	O
are	O
warranted	O
.	O
      
How	O
Should	O
I	O
Study	O
for	O
the	O
Exam	O
?	O
Self	O
-	O
Regulated	O
Learning	O
Strategies	O
and	O
Achievement	O
in	O
Introductory	O
Biology	O
In	O
college	O
introductory	O
science	O
courses	O
,	O
students	O
are	O
challenged	O
with	O
mastering	O
large	O
amounts	O
of	O
disciplinary	O
content	O
while	O
developing	O
as	O
autonomous	O
and	O
effective	O
learners	O
.	O
Self	O
-	O
regulated	O
learning	O
(	O
SRL	O
)	O
is	O
the	O
process	O
of	O
setting	O
learning	O
goals	O
,	O
monitoring	O
progress	O
toward	O
them	O
,	O
and	O
applying	O
appropriate	O
study	O
strategies	O
.	O
SRL	O
characterizes	O
successful	O
,	O
"	O
expert	O
"	O
learners	O
,	O
and	O
develops	O
with	O
time	O
and	O
practice	O
.	O
In	O
a	O
large	O
,	O
undergraduate	O
introductory	O
biology	O
course	O
,	O
we	O
investigated	O
:	O
1	O
)	O
what	O
SRL	O
strategies	O
students	O
reported	O
using	O
the	O
most	O
when	O
studying	O
for	O
exams	O
,	O
2	O
)	O
which	O
strategies	O
were	O
associated	O
with	O
higher	O
achievement	O
and	O
with	O
grade	O
improvement	B-T033
on	O
exams	O
,	O
and	O
3	O
)	O
what	O
study	O
approaches	O
students	O
proposed	O
to	O
use	O
for	O
future	O
exams	O
.	O
Higher	O
-	O
achieving	O
students	O
,	O
and	O
students	O
whose	O
exam	O
grades	O
improved	B-T033
in	O
the	O
first	B-T033
half	I-T033
of	O
the	O
semester	O
,	O
reported	O
using	O
specific	O
cognitive	O
and	O
metacognitive	O
strategies	O
significantly	O
more	O
frequently	O
than	O
their	O
lower	O
-	O
achieving	O
peers	O
.	O
Lower	O
-	O
achieving	O
students	O
more	O
frequently	O
reported	O
that	O
they	O
did	O
not	O
implement	O
their	O
planned	O
strategies	O
or	O
,	O
if	O
they	O
did	O
,	O
still	O
did	O
not	O
improve	O
their	O
outcomes	O
.	O
These	O
results	O
suggest	O
that	O
many	O
students	O
entering	O
introductory	O
biology	O
have	O
limited	O
knowledge	O
of	O
SRL	O
strategies	O
and/or	O
limited	O
ability	O
to	O
implement	O
them	O
,	O
which	O
can	O
impact	O
their	O
achievement	O
.	O
Course	O
-specific	O
interventions	B-T058
that	O
promote	O
SRL	O
development	O
should	O
be	O
considered	O
as	O
integral	O
pedagogical	O
tools	O
,	O
aimed	O
at	O
fostering	O
development	O
of	O
students	O
'	O
lifelong	O
learning	O
skills	O
.	O
      
Haemoglobinopathies	B-T047
and	O
β	B-T047
-	I-T047
Thalassaemia	I-T047
among	O
the	O
Tribals	O
Working	O
in	O
the	O
Tea	O
Gardens	O
of	O
Assam	O
,	O
India	O
Prevalence	O
of	O
haemoglobinopathies	B-T047
and	O
β	B-T047
-	I-T047
thalassaemia	I-T047
are	O
very	O
high	O
in	O
India	O
but	O
information	O
about	O
its	O
status	O
among	O
the	O
tribals	O
working	O
in	O
the	O
tea	O
gardens	O
of	O
Assam	O
is	O
very	O
less	O
.	O
The	O
present	O
study	O
was	O
carried	O
out	O
to	O
determine	O
the	O
prevalence	O
of	O
haemoglobinopathies	B-T047
and	O
β	B-T047
-	I-T047
thalassaemia	I-T047
among	O
the	O
tribals	O
working	O
in	O
the	O
tea	O
gardens	O
of	O
Assam	O
.	O
A	O
total	O
1204	O
samples	O
from	O
the	O
tribals	O
working	O
in	O
tea	O
gardens	O
of	O
Assam	O
were	O
analysed	O
for	O
both	O
Complete	B-T059
Blood	I-T059
Count	I-T059
(	O
CBC	B-T059
)	O
and	O
High	B-T059
Pressure	I-T059
Liquid	I-T059
Chromatography	I-T059
(	O
HPLC	B-T059
)	O
for	O
detection	B-T061
of	O
haemoglobinopathies	B-T047
and	O
β	B-T047
-	I-T047
thalassaemia	I-T047
.	O
This	O
study	O
showed	O
that	O
the	O
prevalence	O
of	O
sickle	B-T047
cell	I-T047
anaemia	I-T047
and	O
β	B-T047
-	I-T047
thalassaemia	I-T047
were	O
very	O
high	O
among	O
this	O
population	O
.	O
Our	O
results	O
indicated	B-T033
a	O
higher	O
prevalence	O
of	O
β	B-T047
-	I-T047
thalassaemia	I-T047
(	O
3.07	O
%	O
)	O
among	O
the	O
Munda	O
ethnic	O
group	O
and	O
higher	O
prevalence	O
of	O
sickle	B-T047
cell	I-T047
anaemia	I-T047
(	O
4.73	O
%	O
)	O
among	O
the	O
Lohar	O
ethnic	O
group	O
.	O
This	O
was	O
the	O
first	O
study	O
to	O
report	O
the	O
presence	B-T033
of	O
HbE	O
among	O
the	O
tribals	O
working	O
in	O
the	O
tea	O
gardens	O
of	O
Assam	O
.	O
Based	O
on	O
the	O
present	O
findings	B-T033
,	O
sickle	B-T047
cell	I-T047
anaemia	I-T047
and	O
β	B-T047
-	I-T047
thalassaemia	I-T047
were	O
major	O
health	O
problem	B-T033
for	O
the	O
tribals	O
working	O
in	O
the	O
tea	O
gardens	O
of	O
Assam	O
.	O
Proper	O
diagnostic	B-T058
facilities	I-T058
for	O
haemoglobinopathy	B-T047
and	O
thalassaemia	B-T047
should	O
be	O
established	O
in	O
these	O
areas	O
,	O
including	O
establishment	O
of	O
haemoglobinopathy	B-T047
and	O
thalassaemia	B-T047
database	O
collection	O
,	O
haematological	O
analysis	O
laboratories	O
,	O
genetic	O
counselling	O
clinics	O
,	O
prenatal	O
diagnosis	O
centres	O
and	O
neonatal	O
screening	O
centres	O
.	O
      
Assessing	O
sex	O
-	O
differences	O
and	O
the	O
effect	O
of	O
timing	O
of	O
vaccination	B-T061
on	O
immunogenicity	O
,	O
reactogenicity	B-T033
and	O
efficacy	B-T033
of	I-T033
vaccines	I-T033
in	O
young	O
children	O
:	O
study	O
protocol	O
for	O
an	O
individual	O
participant	O
data	O
meta	O
-	O
analysis	O
of	O
randomised	O
controlled	O
trials	O
Disease	B-T047
incidence	O
differs	O
between	O
males	O
and	O
females	O
for	O
some	O
infectious	B-T047
or	O
inflammatory	B-T047
diseases	I-T047
.	O
Sex	O
-	O
differences	O
in	O
immune	O
responses	O
to	O
some	O
vaccines	B-T121
have	O
also	O
been	O
observed	O
,	O
mostly	O
to	O
viral	B-T121
vaccines	I-T121
in	O
adults	O
.	O
Little	O
evidence	O
is	O
available	O
on	O
whether	O
sex	O
-	O
differences	O
occur	O
in	O
response	B-T033
to	O
immunisation	B-T061
in	O
infancy	O
even	O
though	O
this	O
is	O
the	O
age	O
group	O
in	O
which	O
most	O
vaccines	B-T121
are	O
administered	O
.	O
Factors	O
other	O
than	O
sex	O
,	O
such	O
as	O
timing	O
or	O
coadministration	B-T061
of	O
other	O
vaccines	B-T121
,	O
can	O
also	O
influence	O
the	O
immune	O
response	O
to	O
vaccination	B-T061
.	O
Individual	O
participant	O
data	O
meta	O
-	O
analysis	O
of	O
randomised	O
controlled	O
trials	O
of	O
vaccines	B-T121
in	O
healthy	O
infants	O
and	O
young	O
children	O
will	O
be	O
conducted	O
.	O
Fully	O
anonymised	O
data	O
from	O
∼170	O
randomised	O
controlled	O
trials	O
of	O
v	O
accines	B-T121
for	O
diphtheria	B-T047
,	O
tetanus	B-T047
,	O
Bordetella	B-T007
pertussis	I-T007
,	O
polio	B-T047
,	O
Haemophilus	B-T007
influenzae	I-T007
type	I-T007
B	I-T007
,	O
hepatitis	B-T047
B	I-T047
,	O
Streptococcus	B-T007
pneumoniae	I-T007
,	O
Neisseria	B-T007
meningitidis	I-T007
,	O
measles	B-T047
,	O
mumps	B-T047
,	O
rubella	B-T047
,	O
varicella	B-T047
and	O
rotavirus	B-T005
will	O
be	O
combined	O
for	O
analysis	O
.	O
Outcomes	O
include	O
measures	O
of	O
immunogenicity	O
(	O
immunoglobulins	O
)	O
,	O
reactogenicity	B-T033
,	O
safety	O
and	O
disease	B-T047
-specific	O
clinical	O
efficacy	O
.	O
Data	O
from	O
trials	O
of	O
vaccines	B-T121
containing	O
similar	O
components	O
will	O
be	O
combined	O
in	O
hierarchical	O
models	O
and	O
the	O
effect	O
of	O
sex	O
and	O
timing	O
of	O
vaccinations	B-T061
estimated	O
for	O
each	O
outcome	O
separately	O
.	O
Systematic	O
reviews	O
of	O
published	O
estimates	O
of	O
sex	O
-	O
differences	O
can	O
not	O
adequately	O
answer	B-T061
questions	I-T061
in	O
this	O
field	O
since	O
such	O
comparisons	O
are	O
never	O
the	O
main	O
purpose	O
of	O
a	O
clinical	O
trial	O
,	O
thus	O
a	O
large	O
degree	O
of	O
reporting	B-T058
bias	O
exists	O
in	O
the	O
published	O
literature	O
.	O
Recent	O
improvements	O
in	O
the	O
widespread	O
availability	O
of	O
individual	O
participant	O
data	O
from	O
randomised	O
controlled	O
trials	O
makes	O
it	O
feasible	O
to	O
conduct	O
extensive	O
individual	O
participant	O
data	O
meta	O
-	O
analyses	O
which	O
were	O
previously	O
impossible	B-T033
,	O
thereby	O
reducing	O
the	O
effect	O
of	O
publication	O
or	O
reporting	B-T058
bias	O
on	O
the	O
understanding	O
of	O
the	O
infant	O
immune	O
response	O
.	O
Preliminary	O
results	O
will	O
be	O
available	O
in	O
2016	O
with	O
final	O
results	O
available	O
in	O
2019	O
.	O
No	O
ethics	O
review	O
is	O
required	O
for	O
secondary	O
analyses	O
of	O
anonymised	O
data	O
.	O
      
Patient	O
-	O
Physician	O
Discordance	O
in	O
Global	O
Assessment	O
in	O
Rheumatoid	B-T047
Arthritis	I-T047
:	O
A	O
Systematic	O
Literature	O
Review	O
With	O
Meta	O
-	O
Analysis	O
The	O
integration	O
of	O
the	O
patient	O
in	O
therapeutic	O
decision	O
-	O
making	O
is	O
important	O
in	O
the	O
management	B-T058
of	O
rheumatoid	B-T047
arthritis	I-T047
(	O
RA	B-T047
)	O
,	O
but	O
the	O
patient	O
opinion	O
regarding	O
disease	B-T047
status	O
may	O
differ	O
from	O
the	O
physician	O
's	O
opinion	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
in	O
the	O
published	O
literature	O
the	O
frequency	O
and	O
drivers	O
of	O
patient	O
-	O
physician	O
discordance	O
in	O
global	O
assessment	O
in	O
RA	B-T047
.	O
A	O
systematic	O
literature	O
review	O
of	O
all	O
articles	O
published	O
up	O
to	O
January	O
2015	O
in	O
Medline	O
or	O
Embase	O
,	O
reporting	O
discordance	O
in	O
RA	B-T047
,	O
was	O
conducted	O
by	O
2	O
investigators	O
.	O
Discordance	O
was	O
defined	O
based	O
on	O
the	O
absolute	O
difference	O
of	O
patient	O
global	O
(	O
PGA	O
)	O
and	O
physician	O
global	O
assessments	O
(	O
PhGA	O
)	O
on	O
0	O
-	O
10	O
-	O
cm	O
scales	O
.	O
The	O
frequency	O
of	O
discordance	O
and	O
its	O
predictors	B-T033
were	O
collected	O
in	O
each	O
study	O
.	O
Frequencies	O
of	O
discordance	O
were	O
pooled	O
by	O
meta	O
-	O
analysis	O
using	O
random	O
effect	O
.	O
In	O
all	O
,	O
12	O
studies	O
were	O
selected	O
(	O
i.e.	O
,	O
11,879	O
patients	O
):	O
weighted	O
mean	O
±	O
SD	O
age	O
was	O
55.1	O
±	O
13.9	O
years	O
,	O
weighted	O
mean	O
±	O
SD	O
disease	O
duration	O
was	O
10.4	O
±	O
9.3	O
years	O
,	O
and	O
80.7	O
%	O
were	O
women	O
.	O
The	O
value	O
of	O
the	O
difference	O
   	O
      
Changes	O
in	O
Cardiovascular	O
Health	O
Status	O
and	O
the	O
Risk	O
of	O
New	O
-	O
Onset	O
Hypertension	O
in	O
Kailuan	O
Cohort	O
Study	O
American	O
Heart	O
Association	O
cardiovascular	O
health	O
metrics	O
are	O
intimately	O
related	O
to	O
cardiovascular	B-T047
diseases	I-T047
.	O
Acting	O
as	O
a	O
key	O
independent	O
risk	B-T033
factor	I-T033
for	O
high	O
morbidity	O
and	O
mortality	O
of	O
cardiovascular	B-T047
diseases	I-T047
,	O
hypertension	B-T047
and	O
its	O
relationship	O
between	O
health	O
status	O
get	O
urgent	O
attention	O
.	O
While	O
the	O
influence	O
of	O
individual	O
health	O
status	O
changes	O
and	O
the	O
future	O
risk	O
of	O
new	O
-	O
onset	O
hypertension	O
is	O
rarely	O
understood	O
,	O
the	O
present	O
study	O
applied	O
this	O
construct	O
to	O
assess	B-T058
the	O
changes	O
of	O
cardiovascular	O
health	O
status	O
and	O
the	O
morbidity	O
of	O
hypertension	B-T047
in	O
Kailuan	O
cohort	O
study	O
in	O
north	O
China	O
.	O
The	O
Cardiovascular	O
Health	O
Score	O
(	O
CHS	O
)	O
was	O
evaluated	B-T058
by	O
the	O
follow	B-T058
-	I-T058
ups	I-T058
of	O
2006	O
-	O
2007	O
,	O
2008	O
-	O
2009	O
,	O
2010	O
-	O
2011	O
and	O
2012	O
-	O
2013	O
.	O
The	O
study	O
population	O
(	O
n	O
=	O
19381	O
)	O
was	O
divided	O
into	O
5	O
groups	O
based	O
on	O
the	O
changes	O
in	O
their	O
CHS	O
score	O
between	O
the	O
first	O
two	O
follow	B-T058
-	I-T058
ups	I-T058
(	O
△	O
CHS	O
)	O
of	O
2006	O
-	O
2007	O
and	O
2008	O
-	O
2009	O
(	O
≤-2	O
,	O
-1	O
,	O
0	O
,	O
1	O
,	O
≥2	O
)	O
.	O
The	O
morbidity	O
of	O
hypertension	B-T047
was	O
collected	O
during	O
2010	O
-	O
2011	O
and	O
2012	O
-	O
2013	O
follow	B-T058
-	I-T058
ups	I-T058
.	O
Data	O
analysis	O
showed	O
that	O
during	O
a	O
median	O
follow	B-T058
-	I-T058
up	I-T058
of	O
3.79±0.96	O
years	O
,	O
morbidity	O
of	O
hypertension	B-T047
had	O
a	O
graded	O
relationship	O
with	O
△	O
CHS	O
.	O
As	O
△	O
CHS	O
scored	O
from	O
low	O
to	O
high	O
,	O
the	O
standardized	B-T058
morbidity	O
of	O
hypertension	B-T047
for	O
all	O
participants	O
were	O
81.40	O
,	O
75.47	O
,	O
68.37	O
,	O
71.43	O
and	O
83.13	O
per	O
1000	O
person	O
-	O
year	O
,	O
respectively	O
.	O
An	O
increased	O
△	O
CHS	O
score	O
of	O
1	O
was	O
associated	O
with	O
a	O
10	O
%	O
decrease	O
in	O
the	O
future	O
risk	O
of	O
new	O
-	O
onset	O
hypertension	O
(	O
HR	O
:	O
0.90	O
,	O
95	O
%	O
CI	O
:	O
0.88	O
-	O
0.92	O
)	O
.	O
In	O
conclusion	O
,	O
there	O
was	O
a	O
strong	O
inverse	O
relationship	O
between	O
the	O
incidence	O
of	O
new	O
-	O
onset	O
hypertension	O
and	O
elevation	O
of	O
cardiovascular	O
health	O
metrics	O
.	O
Population	O
-wide	O
prevention	O
,	O
especially	O
the	O
promotion	B-T058
of	O
lifestyle	O
improvements	O
,	O
is	O
critical	O
to	O
reducing	O
the	O
morbidity	O
of	O
new	O
-	O
onset	O
hypertension	O
.	O
      
Management	B-T058
and	O
Case	O
Outcome	O
of	O
Gastric	B-T020
Impaction	I-T020
in	O
Four	O
Raptors	O
:	O
A	O
Case	O
Series	O
Four	O
captive	O
raptors	O
,	O
an	O
American	O
kestrel	O
(	O
Falco	O
sparverius	O
)	O
,	O
peregrine	O
falcon	O
(	O
Falco	O
peregrinus	O
)	O
,	O
golden	O
eagle	O
(	O
Aquila	O
chrysaetos	O
)	O
,	O
and	O
barn	O
owl	O
(	O
Tyto	O
alba	O
)	O
,	O
were	O
diagnosed	B-T033
with	O
ventricular	B-T023
and/or	O
proventricular	B-T023
foreign	O
material	O
impactions	O
consisting	O
of	O
artificial	O
turf	O
substrate	O
,	O
paper	O
and	O
plastic	O
substrate	O
,	O
grass	O
,	O
and	O
newspaper	O
.	O
Partial	B-T047
or	I-T047
total	I-T047
anorexia	I-T047
was	O
reported	O
in	O
all	O
birds	O
and	O
decreased	O
casting	B-T061
in	O
2	O
birds	O
.	O
Survey	O
radiographs	B-T060
confirmed	O
presence	O
of	O
gastric	B-T023
enlargement	B-T061
in	O
all	O
4	O
birds	O
.	O
The	O
kestrel	O
and	O
eagle	O
were	O
treated	O
unsuccessfully	O
with	O
gastroscopy	B-T060
and	O
gastric	B-T061
lavage	I-T061
,	O
respectively	O
,	O
followed	O
by	O
surgical	B-T033
intervention	I-T033
to	O
remove	O
the	O
ventricular	B-T023
impactions	O
.	O
Both	O
birds	O
died	B-T033
of	I-T033
undetermined	I-T033
causes	I-T033
after	O
surgery	O
.	O
The	O
peregrine	O
falcon	O
died	B-T033
before	B-T061
medical	I-T061
or	O
surgical	B-T033
intervention	I-T033
was	O
started	O
,	O
and	O
the	O
owl	O
was	O
managed	O
successfully	O
with	O
oral	B-T200
mineral	I-T200
oil	I-T200
and	O
liquid	B-T061
diet	I-T061
to	O
facilitate	O
egestion	O
of	O
the	O
foreign	O
material	O
as	O
a	O
pellet	O
.	O
Lead	O
poisoning	O
was	O
suspected	O
as	O
the	O
predisposing	O
cause	O
for	O
foreign	O
body	O
ingestion	O
in	O
the	O
eagle	O
,	O
but	O
underlying	O
causes	O
for	O
pica	B-T048
in	O
the	O
other	O
birds	O
were	O
not	O
determined	O
.	O
Radiographs	B-T060
can	O
provide	O
useful	O
diagnostic	B-T058
information	I-T058
in	O
sick	B-T184
raptors	O
that	O
exhibit	B-T184
vomiting	I-T184
or	O
changes	B-T033
in	I-T033
appetite	I-T033
or	O
casting	B-T061
frequency	I-T061
,	O
and	O
may	O
help	O
guide	O
treatment	B-T061
decisions	I-T061
of	O
impacted	O
birds	O
.	O
Careful	O
consideration	B-T033
of	O
substrate	O
,	O
enrichment	O
items	O
,	O
and	O
access	O
to	O
potential	O
foreign	O
material	O
that	O
could	O
be	O
ingested	O
may	O
be	O
the	O
best	O
pre	O
-	O
emptive	O
management	B-T058
strategy	I-T058
in	O
captive	O
raptors	O
.	O
      
A	O
tanshinone	B-T121
I	I-T121
derivative	O
enhances	O
the	O
activities	O
of	O
antibiotics	B-T195
against	O
Staphylococcus	B-T007
aureus	I-T007
in	O
vitro	O
and	O
in	O
vivo	O
Infections	O
caused	O
by	O
Staphylococcus	B-T007
aureus	I-T007
are	O
prevalent	O
.	O
The	O
dramatically	O
reduced	O
discovery	O
of	O
new	O
antibiotics	B-T195
,	O
as	O
well	O
as	O
the	O
persistent	O
emergence	O
of	O
resistant	B-T007
bacteria	I-T007
,	O
represents	O
a	O
major	O
health	O
problem	B-T033
in	O
both	O
hospital	O
and	O
community	O
settings	O
.	O
Using	O
antibiotic	B-T195
enhancers	O
to	O
rescue	O
existing	O
classes	O
of	O
antibiotics	B-T195
is	O
an	O
attractive	O
strategy	O
.	O
In	O
this	O
study	O
,	O
16	B-T121
-	I-T121
aldehyde	I-T121
tanshinone	I-T121
I	I-T121
(	O
ALT	B-T121
)	O
was	O
synthesized	O
and	O
bacteriostatic	O
activity	O
was	O
explored	O
.	O
In	O
addition	O
,	O
synergistic	O
or	O
additive	O
activity	O
between	O
ALT	B-T121
and	O
aminoglycoside	B-T195
antibiotics	I-T195
or	O
β	B-T195
-	I-T195
lactam	I-T195
antibiotics	I-T195
in	O
vitro	O
was	O
identified	O
.	O
Moreover	O
,	O
ALT	B-T121
was	O
documented	O
to	O
augment	O
clearance	O
of	O
streptomycin	B-T195
(	O
STR	B-T195
)	O
and	O
ampicillin	B-T195
(	O
AMP	B-T195
)	O
against	O
S.	B-T007
aureus	I-T007
in	O
a	O
murine	B-T050
infection	I-T050
model	I-T050
.	O
Primary	O
mechanistic	O
insight	O
indicated	O
that	O
ALT	B-T121
could	O
damage	O
the	O
bacterial	B-T007
cell	O
membrane	O
,	O
leading	O
to	O
accumulation	B-T033
of	O
antibiotics	B-T195
inside	O
bacterial	B-T007
cells	I-T007
.	O
This	O
finding	O
might	O
be	O
useful	O
for	O
treating	O
infections	O
caused	O
by	O
S.	B-T007
aureus	I-T007
and	O
expand	O
the	O
scope	O
of	O
application	O
of	O
tanshinones	B-T121
.	O
      
Are	O
Eyes	B-T023
a	O
Mirror	O
of	O
the	O
Soul	O
?	O
What	O
Eye	B-T023
Wrinkles	B-T190
Reveal	O
about	O
a	O
Horse	O
's	O
Emotional	O
State	O
Finding	O
valid	O
indicators	O
of	O
emotional	O
states	O
is	O
one	O
of	O
the	O
biggest	O
challenges	O
in	O
animal	O
welfare	O
science	O
.	O
Here	O
,	O
we	O
investigated	O
in	O
horses	O
whether	O
variation	O
in	O
the	O
expression	O
of	O
eye	B-T023
wrinkles	B-T190
caused	O
by	O
contraction	O
of	O
the	O
inner	B-T023
eyebrow	I-T023
raiser	O
reflects	O
emotional	B-T033
valence	I-T033
.	O
By	O
confronting	O
horses	O
with	O
positive	B-T033
and	O
negative	B-T033
conditions	O
,	O
we	O
aimed	O
to	O
induce	O
positive	B-T033
and	O
negative	B-T033
emotional	O
states	O
,	O
hypothesising	O
that	O
positive	B-T033
emotions	O
would	O
reduce	O
whereas	O
negative	B-T033
emotions	O
would	O
increase	O
eye	B-T023
wrinkle	B-T190
expression	O
.	O
Sixteen	O
horses	O
were	O
individually	O
exposed	O
in	O
a	O
balanced	O
order	O
to	O
two	O
positive	B-T033
(	O
grooming	O
,	O
food	O
anticipation	O
)	O
and	O
two	O
negative	B-T033
condition	O
s	O
(	O
food	O
competition	O
,	O
waving	O
a	O
plastic	O
bag	O
)	O
.	O
Each	O
condition	O
lasted	O
for	O
60	O
seconds	O
and	O
was	O
preceded	O
by	O
a	O
60	O
second	O
control	O
phase	O
.	O
Throughout	O
both	O
phases	O
,	O
pictures	O
of	O
the	O
eyes	B-T023
were	O
taken	O
,	O
and	O
for	O
each	O
horse	O
four	O
pictures	O
per	O
condition	O
and	O
phase	O
were	O
randomly	O
selected	O
.	O
Pictures	O
were	O
scored	O
in	O
random	O
order	O
and	O
by	O
two	O
experimenters	O
blind	O
to	O
condition	O
and	O
phase	O
for	O
six	O
outcome	O
measures	O
:	O
qualitative	O
impression	O
,	O
eyelid	B-T023
shape	O
,	O
markedness	O
of	O
the	O
wrinkles	B-T190
,	O
presence	B-T033
of	O
eye	B-T023
white	I-T023
,	O
number	O
of	O
wrinkles	B-T190
,	O
and	O
the	O
angle	O
between	O
the	O
line	O
through	O
the	O
eyeball	B-T023
and	O
the	O
highest	O
wrinkle	B-T190
.	O
The	O
angle	O
decreased	O
during	O
grooming	O
and	O
increased	O
during	O
food	O
competition	O
compared	O
to	O
control	O
phase	O
s	O
,	O
whereas	O
the	O
two	O
phases	O
did	O
not	O
differ	O
during	O
food	O
anticipation	O
and	O
the	O
plastic	O
bag	O
condition	O
.	O
No	O
effects	O
on	O
the	O
other	O
outcome	O
measures	O
were	O
detected	B-T033
.	O
Taken	O
together	O
,	O
we	O
have	O
defined	O
a	O
set	O
of	O
measures	O
to	O
assess	O
eye	B-T023
wrinkle	B-T190
expression	O
reliably	O
,	O
of	O
which	O
one	O
measure	O
was	O
affected	O
by	O
the	O
conditions	O
the	O
horses	O
were	O
exposed	O
to	O
.	O
Variation	O
in	O
eye	B-T023
wrinkle	B-T190
expression	O
might	O
provide	O
valuable	O
information	O
on	O
horse	O
welfare	O
but	O
further	O
validation	O
of	O
specific	O
measures	O
across	O
different	O
conditions	O
is	O
needed	O
.	O
      
Opportunities	O
for	O
genomic	O
prediction	O
for	O
fertility	O
using	O
endocrine	O
and	O
classical	O
fertility	O
traits	O
in	O
dairy	O
cattle	O
Endocrine	O
fertility	O
traits	O
,	O
defined	O
from	O
progesterone	B-T121
concentration	O
levels	O
in	O
milk	O
,	O
have	O
been	O
suggested	O
as	O
alternative	O
indicators	O
for	O
fertility	O
in	O
dairy	O
cows	O
because	O
they	O
are	O
less	O
biased	O
by	O
farm	O
management	O
decisions	O
and	O
more	O
directly	O
reflect	O
a	O
cow	O
's	O
reproductive	O
physiology	O
than	O
classical	O
traits	O
derived	O
from	O
insemination	O
and	O
calving	O
data	O
.	O
To	O
determine	O
the	O
potential	O
use	O
of	O
endocrine	O
fertility	O
traits	O
in	O
genomic	O
evaluations	O
,	O
the	O
improvement	O
in	O
accuracy	O
from	O
using	O
endocrine	O
fertility	O
traits	O
concurrent	O
with	O
classical	O
traits	O
in	O
the	O
genomic	O
prediction	O
of	O
fertility	O
was	O
quantified	O
.	O
The	O
impact	O
of	O
recording	O
all	O
traits	O
on	O
all	O
training	O
animals	O
was	O
also	O
investigated	O
.	O
Endocrine	O
and	O
classical	O
fertility	O
records	O
were	O
available	O
on	O
5,339	O
lactations	O
from	O
2,447	O
Holstein	O
cows	O
in	O
Ireland	O
,	O
the	O
Netherlands	O
,	O
Sweden	O
,	O
and	O
the	O
United	O
Kingdom	O
.	O
The	O
endocrine	O
traits	O
were	O
commencement	O
of	O
luteal	O
activity	O
(	O
C	O
-	O
LA	O
)	O
and	O
proportion	O
of	O
samples	O
with	O
luteal	O
activity	O
(	O
PLA	O
)	O
;	O
the	O
classical	O
trait	O
was	O
the	O
interval	O
from	O
calving	O
to	O
first	O
service	O
(	O
CFS	O
)	O
.	O
The	O
interval	O
from	O
C	O
-	O
LA	O
to	O
first	O
service	O
(	O
C	O
-	O
LAFS	O
)	O
,	O
which	O
is	O
a	O
combination	O
of	O
an	O
endocrine	O
trait	O
and	O
a	O
classical	O
trait	O
,	O
was	O
also	O
investigated	O
.	O
The	O
target	O
(	O
breeding	O
goal	O
)	O
trait	O
for	O
fertility	O
was	O
CFS	O
or	O
C	O
-	O
LAFS	O
,	O
whereas	O
C	O
-	O
LA	O
and	O
PLA	O
served	O
as	O
predictor	O
traits	O
.	O
Genomic	O
EBV	O
(	O
GEBV	O
)	O
for	O
fertility	O
were	O
derived	O
using	O
genomic	O
BLUP	O
in	O
bivariate	O
models	O
with	O
85,485	O
SNP	O
.	O
Genomic	O
EBV	O
for	O
the	O
separate	O
fertility	O
traits	O
were	O
also	O
computed	O
,	O
in	O
univariate	O
models	O
.	O
The	O
accuracy	O
of	O
GEBV	O
was	O
evaluated	O
by	O
5	O
-	O
fold	O
cross	O
-	O
validation	O
.	O
The	O
highest	O
accuracy	O
of	O
GEBV	O
was	O
achieved	O
using	O
bivariate	O
predictions	O
,	O
where	O
both	O
an	O
endocrine	O
fertility	O
trait	O
and	O
the	O
classical	O
fertility	O
trait	O
were	O
used	O
.	O
Accuracy	O
of	O
GEBV	O
for	O
predicting	O
adjusted	O
phenotypes	O
for	O
CFS	O
in	O
the	O
univariate	O
model	O
was	O
0.04	O
,	O
but	O
when	O
predicting	O
CFS	O
using	O
a	O
bivariate	O
model	O
with	O
C	O
-	O
LA	O
,	O
the	O
accuracy	O
increased	O
to	O
0.14	O
when	O
all	O
training	O
animals	O
were	O
phenotyped	O
for	O
C	O
-	O
LA	O
and	O
(	O
or	O
not	O
)	O
for	O
CFS	O
.	O
On	O
phenotyping	O
all	O
training	O
animals	O
for	O
both	O
C	O
-	O
LA	O
and	O
CFS	O
,	O
accuracy	O
for	O
CFS	O
increased	O
to	O
0.18	O
;	O
however	O
,	O
when	O
validation	O
animals	O
were	O
also	O
phenotyped	O
for	O
C	O
-	O
LA	O
,	O
there	O
was	O
no	B-T033
substantial	O
increase	O
in	O
accuracy	O
.	O
When	O
predicting	O
CFS	O
in	O
bivariate	O
analysis	O
with	O
PLA	O
,	O
accuracy	O
ranged	O
from	O
0.07	O
to	O
0.14	O
.	O
This	O
first	O
study	O
on	O
genomic	O
predictions	O
for	O
fertility	O
using	O
endocrine	O
traits	O
suggests	O
some	O
improvement	O
in	O
the	O
accuracy	O
of	O
prediction	O
over	O
using	O
only	O
the	O
classical	O
traits	O
.	O
Further	O
studies	O
with	O
larger	O
training	O
populations	O
may	O
show	O
greater	O
improvements	O
.	O
      
Modeling	O
the	O
hospital	O
safety	O
partnership	B-T058
preferences	O
of	O
patients	O
and	O
their	O
families	O
:	O
a	O
discrete	O
choice	O
conjoint	O
experiment	O
Patients	O
and	O
their	O
families	O
play	O
an	O
important	O
role	O
in	O
efforts	O
to	O
improve	O
health	B-T058
service	I-T058
safety	O
.	O
The	O
objective	O
of	O
this	O
study	O
is	O
to	O
understand	O
the	O
safety	O
partnership	B-T058
preferences	O
of	O
patients	O
and	O
their	O
families	O
.	O
We	O
used	O
a	O
discrete	O
choice	O
conjoint	O
experiment	O
to	O
model	O
the	O
safety	O
partnership	B-T058
preferences	O
of	O
1,084	O
patients	O
or	O
those	O
such	O
as	O
parents	O
acting	O
on	O
their	O
behalf	O
.	O
Participants	O
made	O
choices	O
between	O
hypothetical	O
safety	O
partnerships	B-T058
composed	O
by	O
experimentally	O
varying	O
15	O
four	O
-	O
level	O
partnership	B-T058
design	O
attributes	O
.	O
Participants	O
preferred	O
an	O
approach	O
to	O
safety	O
based	O
on	O
partnerships	B-T058
between	O
patients	O
and	O
staff	O
rather	O
than	O
a	O
model	O
delegating	O
responsibility	O
for	O
safety	O
to	O
hospital	O
staff	O
.	O
They	O
valued	O
the	O
opportunity	O
to	O
participate	O
in	O
point	O
of	O
service	O
safety	O
partnerships	B-T058
,	O
such	O
as	O
identity	O
and	O
medication	B-T058
double	I-T058
checks	I-T058
,	O
that	O
might	O
afford	O
an	O
immediate	O
risk	O
reduction	O
.	O
Latent	O
class	O
analysis	O
yielded	O
two	O
segments	O
.	O
Actively	O
engaged	O
participants	O
(	O
73.3	O
%	O
)	O
comprised	O
outpatients	O
with	O
higher	O
education	O
,	O
who	O
anticipated	B-T033
more	O
benefits	O
to	O
safety	O
partnerships	B-T058
,	O
were	O
more	B-T033
confident	I-T033
in	O
their	O
ability	O
to	O
contribute	O
,	O
and	O
were	O
more	O
intent	O
on	O
participating	O
.	O
They	O
were	O
more	O
likely	O
to	O
prefer	O
a	O
personal	O
engagement	B-T058
strategy	O
,	O
valued	O
scientific	O
evidence	O
,	O
preferred	O
a	O
more	O
active	O
approach	O
to	O
safety	O
education	O
,	O
and	O
advocated	O
disclosure	O
of	O
errors	O
.	O
The	O
passively	O
engaged	O
segment	O
(	O
26.7	O
%	O
)	O
anticipated	B-T033
fewer	O
benefits	O
,	O
were	O
less	O
confident	O
in	O
their	O
ability	O
to	O
contribute	O
,	O
and	O
were	O
less	O
intent	O
on	O
participating	O
.	O
They	O
were	O
more	O
likely	O
to	O
prefer	O
an	O
engagement	B-T058
strategy	O
based	O
on	O
signage	O
.	O
They	O
preferred	O
that	O
staff	O
explain	O
why	O
they	O
thought	O
patients	O
should	O
help	O
make	O
care	B-T058
safer	O
and	O
decide	O
whether	O
errors	O
were	O
disclosed	O
.	O
Inpatients	O
,	O
those	O
with	O
immigrant	B-T033
backgrounds	I-T033
,	O
and	O
those	O
with	O
less	B-T033
education	I-T033
were	O
more	O
likely	O
to	O
be	O
in	O
this	O
segment	O
.	O
Health	B-T058
services	I-T058
need	O
to	O
communicate	O
information	O
regarding	O
risks	O
,	O
ask	O
about	O
partnership	B-T058
preferences	O
,	O
create	O
opportunities	O
respecting	O
individual	O
differences	O
,	O
and	O
ensure	O
a	O
positive	B-T033
response	I-T033
when	O
patients	O
raise	O
safety	O
concerns	O
.	O
      
Succinic	B-T121
acid	I-T121
production	O
by	O
immobilized	O
cultures	B-T059
using	O
spent	O
sulphite	O
liquor	O
as	O
fermentation	O
medium	O
Spent	O
sulphite	O
liquor	O
(	O
SSL	O
)	O
was	O
used	O
as	O
carbon	O
source	B-T033
for	O
the	O
production	O
of	O
succinic	B-T121
acid	I-T121
using	O
immobilized	O
cultures	B-T059
of	O
Actinobacillus	B-T007
succinogenes	I-T007
and	O
Basfia	B-T007
succiniciproducens	I-T007
on	O
two	O
different	O
supports	O
,	O
delignified	B-T121
cellulosic	I-T121
material	I-T121
(	O
DCM	B-T121
)	O
and	O
alginate	O
beads	O
.	O
Fed	B-T059
-	I-T059
batch	I-T059
immobilized	I-T059
cultures	I-T059
with	O
A.	B-T007
succinogenes	I-T007
in	O
alginates	O
resulted	O
in	O
higher	O
sugar	B-T121
to	O
succinic	B-T121
acid	I-T121
conversion	O
yield	O
(	O
0.81g	O
/	O
g	O
)	O
than	O
the	O
respective	O
yield	O
achieved	O
(	O
0.65g	O
/	O
g	O
)	O
when	O
DCM	B-T121
immobilized	O
cultures	B-T059
were	O
used	O
.	O
The	O
final	O
succinic	B-T121
acid	I-T121
concentration	O
and	O
yield	O
achieved	O
in	O
fed	B-T059
-	I-T059
batch	I-T059
with	O
immobilized	O
cultures	B-T059
of	O
B.	B-T007
succiniciproducens	I-T007
in	O
alginates	O
(	O
45g	O
/	O
L	O
and	O
0.66g	O
/	O
g	O
)	O
were	O
higher	O
than	O
A.	B-T007
succinogenes	I-T007
immobilized	O
cultures	B-T059
(	O
35.4g	O
/	O
L	O
and	O
0.61g	O
/	O
g	O
)	O
using	O
nano	O
-	O
filtrated	O
SSL	O
as	O
fermentation	O
medium	O
.	O
Immobilized	O
cultures	B-T059
of	O
B.	B-T007
succiniciproducens	I-T007
in	O
alginate	O
beads	O
were	O
reused	O
in	O
four	O
sequential	B-T059
fed	I-T059
-	I-T059
batch	I-T059
fermentations	O
of	O
nano	O
-	O
filtrated	O
SSL	O
leading	O
to	O
the	O
production	O
of	O
64.7	O
g	O
of	O
succinic	B-T121
acid	I-T121
with	O
a	O
yield	O
range	O
of	O
0.42	O
-	O
0.67g	O
/	O
g	O
and	O
productivity	O
range	O
of	O
0.29	O
-	O
0.65g	O
/	O
L	O
/	O
h.	O
The	O
immobilized	O
cultures	B-T059
improved	O
the	O
efficiency	O
of	O
succinic	B-T121
acid	I-T121
production	O
as	O
compared	O
to	O
free	B-T059
cell	I-T059
cultures	I-T059
.	O
      
Four	O
-	O
Dimensional	O
Graded	O
Consciousness	O
Both	O
the	O
multidimensional	O
phenomenon	O
and	O
the	O
polysemous	O
notion	O
of	O
consciousness	O
continue	O
to	O
prove	O
resistant	O
to	O
consistent	O
measurement	O
and	O
unambiguous	O
definition	O
.	O
This	O
is	O
hardly	O
surprising	O
,	O
given	O
that	O
there	O
is	O
no	B-T033
agreement	I-T033
even	O
as	O
regards	O
the	O
most	O
fundamental	O
issues	B-T033
they	O
involve	O
.	O
One	O
of	O
the	O
basic	O
disagreements	O
present	O
in	O
the	O
continuing	O
debate	O
about	O
consciousness	O
pertains	O
to	O
its	O
gradational	O
nature	O
.	O
The	O
general	O
aim	O
of	O
this	O
article	O
is	O
to	O
show	O
how	O
consciousness	O
might	O
be	O
graded	O
and	O
multidimensional	O
at	O
the	O
same	O
time	O
.	O
We	O
therefore	O
focus	O
on	O
the	O
question	O
of	O
what	O
it	O
is	O
,	O
exactly	O
,	O
that	O
is	O
or	O
could	O
be	O
graded	O
in	O
cases	O
of	O
consciousness	O
,	O
and	O
how	O
we	O
can	O
measure	O
it	O
.	O
Ultimately	O
,	O
four	O
different	O
gradable	O
aspects	O
of	O
consciousness	O
will	O
be	O
described	O
:	O
quality	O
,	O
abstractness	O
,	O
complexity	O
and	O
usefulness	O
,	O
which	O
belong	O
to	O
four	O
different	O
dimensions	O
,	O
these	O
being	O
understood	O
,	O
respectively	O
,	O
as	O
phenomenal	O
,	O
semantic	O
,	O
physiological	O
,	O
and	O
functional	O
.	O
Consequently	O
,	O
consciousness	O
may	O
be	O
said	O
to	O
vary	O
with	O
respect	O
to	O
phenomenal	O
quality	O
,	O
semantic	O
abstraction	O
,	O
physiological	O
complexity	O
,	O
and	O
functional	O
usefulness	O
.	O
It	O
is	O
hoped	O
that	O
such	O
a	O
four	O
-	O
dimensional	O
approach	O
will	O
help	O
to	O
clarify	O
and	O
justify	O
claims	O
about	O
the	O
hierarchical	O
nature	O
of	O
consciousness	O
.	O
The	O
approach	O
also	O
proves	O
explanatorily	O
advantageous	O
,	O
as	O
it	O
enables	O
us	O
not	O
only	O
to	O
draw	O
attention	O
to	O
certain	O
new	O
and	O
important	O
differences	O
in	O
respect	O
of	O
subjective	O
measures	O
of	O
awareness	O
and	O
to	O
justify	O
how	O
a	O
given	O
creature	O
may	O
be	O
ranked	O
higher	O
in	O
one	O
dimension	O
of	O
consciousness	O
and	O
lower	O
in	O
terms	O
of	O
another	O
,	O
but	O
also	O
allows	O
for	O
innovative	O
explanations	O
of	O
a	O
variety	O
of	O
well	O
-	O
known	O
phenomena	O
(	O
amongst	O
these	O
,	O
the	O
interpretations	O
of	O
blindsight	O
and	O
locked	B-T047
-	I-T047
in	I-T047
syndrome	I-T047
will	O
be	O
briefly	O
outlined	O
here	O
)	O
.	O
Moreover	O
,	O
a	O
4D	O
framework	O
makes	O
possible	O
many	O
predictions	O
and	O
hypotheses	O
that	O
may	O
be	O
experimentally	O
tested	O
(	O
We	O
point	O
out	O
a	O
few	O
such	O
possibilities	O
pertaining	O
to	O
interdimensional	O
dependencies	O
)	O
.	O
      
Impact	O
of	O
femoral	B-T023
artery	I-T023
puncture	B-T058
using	O
digital	B-T060
subtraction	I-T060
angiography	I-T060
and	O
road	O
mapping	O
on	O
vascular	B-T047
and	O
bleeding	O
complications	O
after	O
transfemoral	O
transcatheter	B-T061
aortic	I-T061
valve	I-T061
implantation	I-T061
The	O
use	O
of	O
large	O
-	O
diameter	O
sheaths	O
carries	O
the	O
risk	O
of	O
significant	O
vascular	B-T047
and	O
bleeding	O
complications	O
after	O
transfemoral	O
transcatheter	B-T061
aortic	I-T061
valve	I-T061
implantation	I-T061
(	O
TAVI	B-T061
)	O
.	O
In	O
this	O
analysis	O
,	O
we	O
sought	O
to	O
assess	B-T058
the	O
impact	O
of	O
a	O
modified	O
femoral	B-T023
artery	I-T023
puncture	B-T058
technique	O
using	O
digital	B-T060
subtraction	I-T060
angiography	I-T060
(	O
DSA	B-T060
)	O
and	O
road	O
mapping	O
during	O
transfemoral	O
TAVI	B-T061
on	O
periprocedural	O
vascular	B-T023
and	O
bleeding	O
events	O
.	O
This	O
is	O
a	O
retrospective	O
analysis	O
of	O
transfemoral	O
TAVI	B-T061
patients	O
included	O
in	O
a	O
prospective	O
institutional	O
database	O
.	O
The	O
modified	O
femoral	B-T023
artery	I-T023
puncture	B-T058
technique	O
using	O
DSA	B-T060
-derived	O
road	O
mapping	O
guidance	O
was	O
introduced	O
in	O
October	O
2012	O
.	O
Before	O
the	O
introduction	O
of	O
this	O
technique	O
,	O
vascular	B-T023
puncture	B-T058
was	O
acquired	O
based	O
on	O
an	O
integration	O
of	O
angiographic	B-T060
data	O
,	O
the	O
bony	O
iliofemoral	B-T023
landmarks	O
and	O
a	O
radiopaque	O
object	O
.	O
Consecutive	O
patients	O
who	O
underwent	O
TAVI	B-T061
with	O
the	O
road	O
mapping	O
technique	O
(	O
RM	O
group	O
,	O
n=160	O
)	O
were	O
compared	O
with	O
consecutive	O
patients	O
who	O
underwent	O
TAVI	B-T061
without	O
road	O
mapping	O
(	O
control	O
group	O
,	O
n=160	O
)	O
prior	O
to	O
its	O
introduction	O
.	O
A	O
standardised	O
strategy	O
of	O
periprocedural	B-T061
anticoagulation	I-T061
was	O
adopted	O
in	O
both	O
groups	O
as	O
well	O
as	O
the	O
use	O
of	O
a	O
single	O
suture	O
-	O
based	O
closure	O
device	O
.	O
All	O
endpoints	O
were	O
defined	O
according	O
to	O
the	O
VARC-2	O
criteria	O
for	O
event	O
definition	O
.	O
The	O
mean	O
age	O
in	O
the	O
RM	O
group	O
was	O
80±7.7	O
years	O
compared	O
to	O
81±5.9	O
years	O
in	O
the	O
control	O
group	O
(	O
p=0.19	O
)	O
,	O
and	O
females	O
were	O
equally	O
distributed	O
between	O
both	O
groups	O
(	O
63.1	O
%	O
vs.	O
58.1	O
%	O
,	O
p=0.36	O
)	O
.	O
The	O
baseline	O
logistic	O
EuroSCORE	O
was	O
20.7±14.4	O
%	O
vs.	O
24.9±15.2	O
%	O
in	O
the	O
RM	O
and	O
control	O
group	O
,	O
respectively	O
(	O
p=0.01	O
)	O
.	O
Notably	O
,	O
sheath	O
size	O
was	O
significantly	O
larger	O
in	O
the	O
RM	O
compared	O
to	O
the	O
control	O
group	O
due	O
to	O
the	O
more	O
frequent	O
use	O
of	O
the	O
20	O
Fr	O
sheath	O
(	O
23.8	O
%	O
vs.	O
1.8	O
%	O
,	O
p<0.001	O
,	O
respectively	O
)	O
associated	O
with	O
the	O
more	O
frequent	O
implantation	B-T061
of	O
the	O
29	O
mm	O
Edwards	O
SAPIEN	O
XT	O
valve	O
in	O
the	O
RM	O
group	O
(	O
43.8	O
%	O
vs.	O
7	O
%	O
,	O
respectively	O
,	O
p<0.001	O
)	O
.	O
Despite	O
the	O
latter	O
finding	O
,	O
both	O
major	O
vascular	B-T047
complications	I-T047
and	O
major	O
bleeding	O
at	O
30	O
days	O
were	O
significantly	O
lower	O
in	O
the	O
RM	O
group	O
compared	O
to	O
the	O
control	O
group	O
(	O
4.3	O
%	O
vs.	O
11.8	O
%	O
,	O
p=0.01	O
,	O
and	O
14.4	O
%	O
vs.	O
25.6	O
%	O
,	O
p=0.01	O
)	O
.	O
An	O
analysis	O
limited	O
to	O
access	O
site	O
-	O
related	O
complications	O
also	O
revealed	O
lower	O
events	O
in	O
the	O
road	O
map	O
group	O
but	O
did	O
not	O
reach	O
statistical	O
significance	O
(	O
8.1	O
%	O
vs.	O
13.8	O
%	O
,	O
p=0.1	O
)	O
.	O
Other	O
forms	O
of	O
vascular	B-T047
and	O
bleeding	O
complications	O
as	O
well	O
as	O
all	O
-	O
cause	O
mortality	O
were	O
comparable	O
in	O
both	O
groups	O
.	O
A	O
modified	O
femoral	B-T023
artery	I-T023
puncture	B-T058
technique	O
using	O
DSA	B-T060
and	O
road	O
mapping	O
was	O
associated	O
with	O
a	O
reduction	O
in	O
major	O
vascular	B-T047
and	O
bleeding	O
complications	O
after	O
transfemoral	O
TAVI	B-T061
,	O
and	O
provides	O
a	O
simple	O
and	O
effective	O
strategy	O
for	O
potentially	O
improving	O
patient	O
outcomes	O
.	O
      
Truncated	O
Bovine	O
Integrin	O
Alpha	O
-	O
v	O
/	O
Beta-6	O
as	O
a	O
Universal	O
Capture	O
Ligand	O
for	O
FMD	B-T047
Diagnosis	B-T033
Foot	B-T047
-	I-T047
and	I-T047
-	I-T047
mouth	I-T047
disease	I-T047
(	O
FMD	B-T047
)	O
is	O
endemic	B-T047
in	O
many	O
regions	O
of	O
the	O
world	O
and	O
is	O
one	O
of	O
the	O
most	O
prevalent	O
epizootic	O
animal	B-T047
diseases	I-T047
.	O
FMD	B-T047
affects	O
livestock	O
,	O
such	O
as	O
cattle	O
,	O
sheep	O
,	O
goats	O
and	O
pigs	O
,	O
and	O
causes	O
enormous	O
economic	O
losses	O
due	O
to	O
reduced	O
productivity	O
and	O
trade	O
restrictions	O
.	O
Preparedness	B-T033
and	O
early	B-T060
diagnosis	I-T060
are	O
essential	O
for	O
effective	B-T058
control	I-T058
of	O
FMD	B-T047
.	O
Many	O
diagnostic	B-T059
assays	I-T059
are	O
dependent	O
on	O
raising	O
high	O
-	O
affinity	O
,	O
anti	B-T005
-	I-T005
FMD	I-T005
virus	I-T005
(	O
FMDV	B-T005
)	O
serotype	O
-	O
specific	O
antibodies	O
in	O
small	O
animals	O
(	O
rabbits	O
and	O
guinea	O
pigs	O
)	O
that	O
give	O
broad	O
virus	B-T005
coverage	O
.	O
Here	O
we	O
show	O
that	O
soluble	O
,	O
truncated	O
forms	O
of	O
bovine	O
αvβ6	O
bind	O
FMDV	B-T005
in	O
an	O
authentic	O
RGD	O
and	O
divalent	O
cation	O
dependent	O
interaction	O
and	O
can	O
be	O
used	O
as	O
the	O
trapping	O
reagent	O
in	O
a	O
FMDV	B-T005
sandwich	B-T059
ELISA	I-T059
.	O
In	O
addition	O
,	O
inclusion	O
of	O
FLAG	O
or	O
His	B-T121
tags	I-T121
facilitates	O
simple	O
purification	B-T059
without	O
the	O
loss	O
of	O
virus	O
binding	O
.	O
We	O
also	O
provide	O
evidence	O
that	O
when	O
combined	O
with	O
a	O
guinea	O
pig	O
polyclonal	O
serum	O
,	O
or	O
serotype	O
-	O
specific	O
monoclonal	O
antibodies	O
,	O
the	O
integrin	O
can	O
be	O
used	O
to	O
detect	B-T033
viruses	B-T005
representative	O
of	O
all	O
FMDV	B-T005
serotypes	I-T005
.	O
We	O
also	O
show	O
that	O
recombinant	B-T005
FMDV	I-T005
empty	B-T017
capsids	I-T017
,	O
with	O
stabilising	O
disulphide	O
bonds	O
,	O
can	O
serve	O
as	O
an	O
antigen	O
in	O
the	O
ELISA	B-T059
and	O
can	O
therefore	O
replace	O
inactivated	O
virus	O
antigen	O
as	O
a	O
positive	O
control	O
for	O
the	O
assay	B-T059
.	O
Our	O
results	O
demonstrate	O
the	O
potential	O
use	O
of	O
bovine	O
αvβ6	O
and	O
FMDV	B-T005
empty	B-T017
capsids	I-T017
in	O
FMD	B-T047
diagnostic	B-T059
assays	I-T059
.	O
      
Impact	O
of	O
Clinical	O
Trial	O
Results	O
on	O
the	O
Temporal	O
Trends	O
of	O
Carotid	B-T061
Endarterectomy	I-T061
and	O
Stenting	B-T061
From	O
2002	O
to	O
2014	O
Randomized	O
trials	O
provide	O
conflicting	O
data	O
for	O
the	O
efficacy	O
of	O
carotid	B-T061
-	I-T061
artery	I-T061
stenting	I-T061
compared	O
with	O
endarterectomy	B-T061
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
impact	O
of	O
conflicting	O
clinical	O
trial	O
publications	O
on	O
the	O
utilization	O
rates	O
of	O
carotid	B-T061
revascularization	I-T061
procedures	I-T061
.	O
We	O
conducted	O
a	O
population	O
-	O
level	O
time	O
-	O
series	O
analysis	O
of	O
all	O
individuals	O
who	O
underwent	O
carotid	B-T061
endarterectomy	I-T061
and	O
stenting	B-T061
in	O
Ontario	O
,	O
Canada	O
(	O
2002	O
-	O
2014	O
)	O
.	O
The	O
primary	O
analysis	O
examined	O
temporal	O
changes	O
in	O
the	O
rates	O
of	O
carotid	B-T061
revascularization	I-T061
procedures	I-T061
after	O
publications	O
of	O
major	O
randomized	O
trials	O
.	O
Secondary	O
analyses	O
examined	O
changes	O
in	O
overall	O
and	O
age	O
,	O
sex	O
,	O
carotid	B-T184
-	I-T184
artery	I-T184
symptom	I-T184
,	O
and	O
operator	O
specialty	O
-	O
specific	O
procedure	O
rates	O
.	O
A	O
total	O
of	O
16	O
772	O
patients	O
were	O
studied	O
(	O
14	O
394	O
endarterectomy	B-T061
[	O
86	O
%	O
]	O
;	O
2378	O
stenting	B-T061
[	O
14	O
%	O
]	O
)	O
.	O
The	O
overall	O
rate	O
of	O
carotid	B-T061
revascularization	I-T061
decreased	O
from	O
6.0	O
procedures	B-T061
per	O
100	O
000	O
individuals	O
≥40	O
years	O
old	O
in	O
April	O
2002	O
to	O
4.3	O
procedures	B-T061
in	O
the	O
first	O
quarter	O
of	O
2014	O
(	O
29	O
%	O
decrease	O
;	O
P<0.001	O
)	O
.	O
The	O
rate	O
of	O
endarterectomy	B-T061
decreased	O
by	O
36	O
%	O
(	O
P<0.001	O
)	O
,	O
whereas	O
the	O
rate	O
of	O
carotid	B-T061
-	I-T061
artery	I-T061
stenting	I-T061
increased	O
by	O
72	O
%	O
(	O
P=0.006	O
)	O
.	O
We	O
observed	O
a	O
marked	O
increase	O
(	O
P=0.01	O
)	O
in	O
stenting	B-T061
after	O
publication	O
of	O
the	O
SAPPHIRE	O
trial	O
(	O
Stenting	O
and	O
Angioplasty	O
With	O
Protection	O
in	O
Patients	O
at	O
High	O
Risk	O
for	O
Endarterectomy	O
)	O
in	O
2004	O
,	O
whereas	O
stenting	B-T061
remained	O
relatively	O
unchanged	B-T033
after	O
subsequent	O
randomized	O
trials	O
published	O
in	O
2006	O
(	O
P=0.11	O
)	O
and	O
2010	O
(	O
P=0.34	O
)	O
.	O
In	O
contrast	O
,	O
endarterectomy	B-T061
decreased	O
after	O
trials	O
published	O
in	O
2006	O
(	O
P=0.04	O
)	O
and	O
2010	O
(	O
P=0.005	O
)	O
.	O
Although	O
the	O
overall	O
rates	O
of	O
carotid	B-T061
revascularization	I-T061
and	O
endarterectomy	B-T061
have	O
fallen	O
since	O
2002	O
,	O
the	O
rate	O
of	O
carotid	B-T061
-	I-T061
artery	I-T061
stenting	I-T061
has	O
risen	O
since	O
the	O
publication	O
of	O
stenting	B-T061
-favorable	O
SAPPHIRE	O
trial	O
.	O
Subsequent	O
conflicting	O
randomized	O
trials	O
were	O
associated	O
with	O
a	O
decreasing	B-T033
rate	I-T033
of	O
carotid	B-T061
endarterectomy	I-T061
.	O
      
Unintentional	O
insecticide	O
poisoning	O
by	O
age	O
:	O
an	O
analysis	O
of	O
Queensland	O
Poisons	O
Information	O
Centre	O
calls	B-T058
Data	O
from	O
the	O
Queensland	O
Poisons	O
Information	O
Centre	O
(	O
QPIC	O
)	O
was	O
assessed	O
to	O
determine	O
mechanisms	O
of	O
acute	O
insecticide	O
poisoning	O
in	O
young	O
children	O
(	O
<	O
5	O
years	O
)	O
and	O
whether	O
age	O
affects	O
insecticide	O
-	O
poisoning	O
patterns	O
.	O
Records	O
of	O
all	O
insecticide	B-T058
-	I-T058
related	I-T058
calls	I-T058
placed	O
to	O
QPIC	O
in	O
2014	O
were	O
obtained	O
.	O
A	O
stratified	O
analysis	O
of	O
call	B-T058
patterns	O
by	O
age	O
was	O
conducted	O
.	O
Of	O
743	O
insecticide	B-T058
-	I-T058
related	I-T058
calls	I-T058
received	O
by	O
QPIC	O
364	O
(	O
49.0	O
%	O
)	O
were	O
for	O
young	O
children	O
.	O
The	O
number	O
of	O
calls	B-T058
peaked	O
in	O
children	O
aged	O
one	O
.	O
Ant	O
and	O
cockroach	O
baits	O
accounted	O
for	O
39.0	O
%	O
of	O
calls	B-T058
.	O
Sprays	O
,	O
which	O
were	O
found	B-T033
to	O
contain	O
not	O
only	O
pyrethroids	O
,	O
pyrethrins	O
and/or	O
piperonly	B-T121
butoxide	I-T121
but	O
also	O
the	O
organophosphate	O
diazinon	O
,	O
accounted	O
for	O
25.8	O
%	O
of	O
calls	B-T058
.	O
Mouthing	O
or	O
ingesting	O
a	O
pest	O
-	O
control	O
product	O
and	O
consuming	O
an	O
item	O
/	O
insect	O
after	O
treatment	O
were	O
common	O
mechanisms	O
for	O
children	O
under	O
the	O
age	O
of	O
two	O
.	O
Topical	O
exposure	O
to	O
sprays	O
,	O
via	O
direct	O
application	O
,	O
typically	O
by	O
the	O
child	O
or	O
an	O
older	O
sibling	O
,	O
peaked	O
in	O
children	O
aged	O
two	O
.	O
In	O
12.3	O
%	O
of	O
calls	B-T058
medical	B-T058
attention	I-T058
for	O
the	O
child	O
was	O
already	O
sought	O
or	O
advised	B-T058
by	I-T058
QPIC	O
.	O
Normal	O
behaviours	O
associated	O
with	O
child	O
development	O
,	O
particularly	O
mouthing	O
behaviours	O
,	O
explained	O
the	O
peak	O
of	O
exposure	O
in	O
one	O
-	O
year	O
-	O
olds	O
.	O
This	O
finding	B-T033
should	O
guide	O
strategies	O
to	O
minimise	O
poisonings	O
in	O
this	O
vulnerable	O
population	O
.	O
      
ACR	O
Appropriateness	O
Criteria	O
(	O
®	O
)	O
Radiologic	O
Management	B-T058
of	O
Mesenteric	B-T047
Ischemia	I-T047
Mesenteric	B-T047
vascular	I-T047
insufficiency	I-T047
is	O
a	O
serious	O
medical	B-T033
condition	I-T033
that	O
may	O
lead	O
to	O
bowel	B-T047
infarction	I-T047
,	O
morbidity	O
,	O
and	O
mortality	O
that	O
may	O
approach	O
50	O
%	O
.	O
Recommended	O
therapy	B-T061
for	O
acute	B-T047
mesenteric	I-T047
ischemia	I-T047
includes	O
aspiration	B-T061
embolectomy	B-T061
,	O
transcatheter	B-T061
thrombolysis	B-T061
,	O
and	O
angioplasty	B-T061
with	O
or	O
without	O
stenting	B-T061
for	O
the	O
treatment	B-T061
of	O
underlying	O
arterial	B-T190
stenosis	I-T190
.	O
Nonocclusive	B-T047
mesenteric	I-T047
ischemia	I-T047
may	O
respond	O
to	O
transarterial	B-T061
infusion	I-T061
of	O
vasodilators	B-T121
such	O
as	O
nitroglycerin	B-T121
,	O
papaverine	B-T121
,	O
glucagon	B-T121
,	O
and	O
prostaglandin	B-T121
E1	I-T121
.	O
Recommended	O
therapy	B-T061
for	O
chronic	B-T047
mesenteric	I-T047
ischemia	I-T047
includes	O
angioplasty	B-T061
with	O
or	O
without	O
stent	B-T061
placement	I-T061
and	O
,	O
if	O
an	O
endovascular	B-T061
approach	I-T061
is	O
not	O
possible	O
,	O
surgical	B-T061
bypass	I-T061
or	O
endarterectomy	B-T061
.	O
The	O
diagnosis	B-T033
of	O
median	B-T047
arcuate	I-T047
ligament	I-T047
syndrome	I-T047
is	O
controversial	O
,	O
but	O
surgical	B-T061
release	O
may	O
be	O
appropriate	O
depending	O
on	O
the	O
clinical	O
situation	O
.	O
Venous	O
mesenteric	B-T047
ischemia	I-T047
may	O
respond	O
to	O
systemic	O
anticoagulation	B-T061
alone	O
.	O
Transhepatic	O
or	O
transjugular	O
superior	B-T023
mesenteric	I-T023
vein	I-T023
catheterization	B-T060
and	I-T060
thrombolytic	I-T060
infusion	I-T060
can	O
be	O
offered	O
depending	O
on	O
the	O
severity	O
of	O
symptoms	B-T184
,	O
condition	B-T033
of	I-T033
the	I-T033
patient	I-T033
,	O
and	O
response	O
to	O
systemic	O
anticoagulation	B-T061
.	O
Adjunct	O
transjugular	B-T061
intrahepatic	I-T061
portosystemic	I-T061
shunt	I-T061
creation	I-T061
can	O
be	O
considered	O
for	O
outflow	O
improvement	O
.	O
The	O
American	O
College	O
of	O
Radiology	O
Appropriateness	O
Criteria	O
are	O
evidence	O
-	O
based	O
guidelines	O
for	O
specific	O
clinical	B-T033
conditions	I-T033
that	O
are	O
reviewed	O
annually	O
by	O
a	O
multidisciplinary	O
expert	O
panel	O
.	O
The	O
guideline	O
development	O
and	O
revision	O
include	O
an	O
extensive	O
analysis	O
of	O
current	O
medical	O
literature	O
from	O
peer	O
-	O
reviewed	O
journals	O
and	O
the	O
application	O
of	O
well	O
-	O
established	O
methodologies	O
(	O
RAND	O
/	O
UCLA	O
Appropriateness	O
Method	O
and	O
Grading	O
of	O
Recommendations	O
Assessment	O
,	O
Development	O
,	O
and	O
Evaluation	O
or	O
GRADE	O
)	O
to	O
rate	O
the	O
appropriateness	O
of	O
imaging	B-T060
and	O
treatment	B-T061
procedures	I-T061
for	O
specific	O
clinical	O
scenarios	O
.	O
In	O
those	O
instances	O
where	O
evidence	O
is	O
lacking	O
or	O
equivocal	O
,	O
expert	O
opinion	O
may	O
supplement	O
the	O
available	O
evidence	O
to	O
recommend	O
imaging	B-T060
or	O
treatment	B-T061
.	O
      
The	O
CLASP2	O
Protein	O
Interaction	O
Network	O
in	O
Adipocytes	O
Links	O
CLIP2	O
to	O
AGAP3	O
,	O
CLASP2	O
to	O
G2L1	O
,	O
MARK2	O
,	O
and	O
SOGA1	O
,	O
and	O
Identifies	O
SOGA1	O
as	O
a	O
Microtubule	O
-	O
Associated	O
Protein	O
CLASP2	O
is	O
a	O
microtubule	O
-	O
associated	O
protein	O
that	O
undergoes	O
insulin	B-T121
-	O
stimulated	O
phosphorylation	O
and	O
co	O
-	O
localization	O
with	O
reorganized	O
actin	O
and	O
GLUT4	O
at	O
the	O
plasma	O
membrane	O
.	O
To	O
gain	O
insight	O
to	O
the	O
role	O
of	O
CLASP2	O
in	O
this	O
system	O
,	O
we	O
developed	O
and	O
successfully	O
executed	O
a	O
streamlined	O
interactome	O
approach	O
and	O
built	O
a	O
CLASP2	O
protein	O
network	O
in	O
3T3	O
-	O
L1	O
adipocytes	O
.	O
Using	O
two	O
different	O
commercially	O
available	O
antibodies	O
for	O
CLASP2	O
and	O
an	O
antibody	O
for	O
epitope	O
-tagged	O
,	O
overexpressed	O
CLASP2	O
,	O
we	O
performed	O
multiple	O
affinity	B-T059
purification	I-T059
coupled	O
with	O
mass	B-T059
spectrometry	I-T059
(	O
AP	B-T059
-	O
MS	B-T059
)	O
experiments	O
in	O
combination	O
with	O
label	B-T033
-	I-T033
free	I-T033
quantitative	O
proteomics	O
and	O
analyzed	O
the	O
data	O
with	O
the	O
bioinformatics	O
tool	O
Significance	O
Analysis	O
of	O
Interactome	O
(	O
SAINT	O
)	O
.	O
We	O
discovered	O
that	O
CLASP2	O
co	O
-	O
immunoprecipitates	O
(	O
co	O
-	O
IPs	O
)	O
the	O
novel	O
protein	O
SOGA1	O
,	O
the	O
microtubule	O
-	O
associated	O
protein	O
kinase	O
MARK2	O
,	O
and	O
the	O
microtubule	O
/	O
actin	O
-	O
regulating	O
protein	O
G2L1	O
.	O
The	O
GTPase	O
-	O
activating	O
proteins	O
AGAP1	O
and	O
AGAP3	O
were	O
also	O
enriched	O
in	O
the	O
CLASP2	O
interactome	O
,	O
although	O
subsequent	O
AGAP3	O
and	O
CLIP2	O
interactome	O
analysis	O
suggests	O
a	O
preference	O
of	O
AGAP3	O
for	O
CLIP2	O
.	O
Follow	O
-	O
up	O
MARK2	O
interactome	O
analysis	O
confirmed	B-T033
reciprocal	O
co	O
-	O
IP	O
of	O
CLASP2	O
and	O
also	O
revealed	O
MARK2	O
can	O
co	O
-	O
IP	O
SOGA1	O
,	O
glycogen	O
synthase	O
,	O
and	O
glycogenin	O
.	O
Investigating	O
the	O
SOGA1	O
interactome	O
confirmed	B-T033
SOGA1	O
can	O
reciprocal	O
co	O
-	O
IP	O
both	O
CLASP2	O
and	O
MARK2	O
as	O
well	O
as	O
glycogen	O
synthase	O
and	O
glycogenin	O
.	O
SOGA1	O
was	O
confirmed	B-T033
to	O
colocalize	O
with	O
CLASP2	O
and	O
also	O
with	O
tubulin	O
,	O
which	O
identifies	O
SOGA1	O
as	O
a	O
new	O
microtubule	O
-	O
associated	O
protein	O
.	O
These	O
results	B-T033
introduce	O
the	O
metabolic	O
function	O
of	O
these	O
proposed	O
novel	O
protein	O
networks	O
and	O
their	O
relationship	O
with	O
microtubules	O
as	O
new	O
fields	O
of	O
cytoskeleton	O
-	O
associated	O
protein	O
biology	O
.	O
      
Photosensitizer	B-T121
Decorated	O
Red	O
Blood	O
Cells	O
as	O
an	O
Ultra	O
-	O
Sensitive	O
Light	O
-	O
Responsive	O
Drug	O
Delivery	O
System	O
Red	O
blood	O
cells	O
(	O
RBCs	O
)	O
,	O
the	O
most	O
abundant	O
type	O
of	O
cells	O
in	O
our	O
blood	O
,	O
have	O
shown	O
promises	O
as	O
a	O
natural	O
drug	O
delivery	O
system	O
(	O
DDS	O
)	O
with	O
inherent	O
biocompatibility	O
.	O
Herein	O
,	O
we	O
uncover	O
that	O
a	O
photosensitizer	B-T121
,	O
chlorin	B-T121
e6	I-T121
(	O
Ce6	B-T121
)	O
,	O
could	O
be	O
decorated	O
into	O
the	O
membrane	O
of	O
RBCs	O
upon	O
simple	O
mixing	O
,	O
without	O
affecting	O
the	O
membrane	O
integrity	O
and	O
stability	O
in	O
dark	O
.	O
Upon	O
light	O
irradiation	O
with	O
a	O
rather	O
low	O
power	O
density	O
,	O
the	O
generated	O
singlet	O
oxygen	O
by	O
Ce6	B-T121
as	O
the	O
result	O
of	O
photodynamic	O
effect	O
would	O
lead	O
to	O
rather	O
efficient	O
disruption	O
of	O
RBC	O
membrane	O
.	O
With	O
doxorubicin	B-T195
(	O
DOX	B-T195
DOX	B-T195
)	O
,	O
a	O
typical	O
chemotherapy	B-T061
drug	B-T121
,	O
as	O
the	O
model	O
,	O
we	O
engineer	O
a	O
unique	O
type	O
of	O
light	O
-	O
responsive	O
RBC	O
-	O
based	O
DDS	O
by	O
decorating	O
Ce6	B-T121
on	O
the	O
cell	O
membrane	O
and	O
loading	O
DOX	B-T195
inside	O
cells	O
.	O
The	O
light	O
triggered	O
cell	O
membrane	O
break	O
down	O
would	O
thus	O
trigger	O
instant	O
release	O
of	O
DOX	B-T195
,	O
enabling	O
light	B-T061
-	I-T061
controlled	I-T061
chemotherapy	I-T061
with	O
great	O
specificity	O
.	O
Beyond	O
that	O
,	O
our	O
RBC	O
system	O
could	O
also	O
be	O
utilized	O
for	O
loading	O
of	O
larger	O
biomolecules	O
such	O
as	O
enzymes	O
,	O
whose	O
release	O
as	O
well	O
as	O
catalytic	O
function	O
is	O
also	O
controlled	O
by	O
light	O
.	O
Our	O
work	O
thus	O
presents	O
a	O
unique	O
type	O
of	O
biocompatible	O
cell	O
-	O
based	O
DDS	O
that	O
can	O
be	O
precisely	O
controlled	O
by	O
mild	O
external	O
stimuli	O
,	O
promising	O
not	O
only	O
for	O
cancer	B-T061
therapy	I-T061
but	O
also	O
for	O
other	O
potential	O
applications	O
in	O
biotechnologies	O
.	O
      
High	O
Occurrence	O
of	O
Non	B-T191
-	I-T191
Clear	I-T191
Cell	I-T191
Renal	I-T191
Cell	I-T191
Carcinoma	I-T191
in	O
Oman	O
It	O
is	O
conventionally	O
accepted	O
that	O
renal	B-T191
cell	I-T191
carcinoma	I-T191
(	O
RCC	B-T191
)	O
occurs	O
in	O
older	O
patients	O
and	O
the	O
clear	B-T191
cell	I-T191
type	I-T191
is	O
the	O
most	O
common	O
histology	O
.	O
However	O
,	O
ethnic	O
variations	O
exist	O
and	O
this	O
study	O
was	O
carried	O
out	O
to	O
determine	O
the	O
epidemiological	O
pattern	O
of	O
RCC	B-T191
in	O
Oman	O
.	O
Ninety	O
RCC	B-T191
patients	O
who	O
presented	O
to	O
a	O
tertiary	O
care	O
center	O
in	O
the	O
Sultanate	O
of	O
Oman	O
from	O
2010	O
to	O
2014	O
were	O
studied	O
.	O
The	O
main	B-T033
findings	I-T033
were	O
that	O
the	O
median	O
age	O
of	O
presentation	O
was	O
low	O
,	O
more	O
patients	O
presented	O
with	O
localized	O
stage	O
,	O
and	O
there	O
was	O
a	O
higher	O
incidence	O
of	O
non	B-T191
-	I-T191
clear	I-T191
(	O
especially	O
papillary	B-T191
)	O
histology	O
.	O
Data	O
from	O
other	O
Gulf	O
countries	O
and	O
possible	O
reasons	O
for	O
the	O
different	O
profile	O
are	O
discussed	O
.	O
      
Modeling	O
the	O
flux	O
of	O
metabolites	O
in	O
the	O
juvenile	O
hormone	O
biosynthesis	O
pathway	O
using	O
generalized	O
additive	O
models	O
and	O
ordinary	O
differential	O
equations	O
Juvenile	O
hormone	O
(	O
JH	O
)	O
regulates	O
development	O
and	O
reproductive	O
maturation	O
in	O
insects	O
.	O
The	O
corpora	B-T023
allata	I-T023
(	O
CA	B-T023
)	O
from	O
female	O
adult	O
mosquitoes	O
synthesize	O
fluctuating	O
levels	O
of	O
JH	O
,	O
which	O
have	O
been	O
linked	O
to	O
the	O
ovarian	O
development	O
and	O
are	O
influenced	O
by	O
nutritional	O
signals	O
.	O
The	O
rate	O
of	O
JH	O
biosynthesis	O
is	O
controlled	O
by	O
the	O
rate	O
of	O
flux	O
of	O
isoprenoids	O
in	O
the	O
pathway	O
,	O
which	O
is	O
the	O
outcome	O
of	O
a	O
complex	O
interplay	O
of	O
changes	O
in	O
precursor	O
pools	O
and	O
enzyme	O
levels	O
.	O
A	O
comprehensive	O
study	O
of	O
the	O
changes	O
in	O
enzymatic	O
activities	O
and	O
precursor	O
pool	O
sizes	O
have	O
been	O
previously	O
reported	O
for	O
the	O
mosquito	O
Aedes	O
aegypti	O
JH	O
biosynthesis	O
pathway	O
.	O
In	O
the	O
present	O
studies	O
,	O
we	O
used	O
two	O
different	O
quantitative	O
approaches	O
to	O
describe	O
and	O
predict	O
how	O
changes	O
in	O
the	O
individual	O
metabolic	O
reactions	O
in	O
the	O
pathway	O
affect	O
JH	O
synthesis	O
.	O
First	O
,	O
we	O
constructed	O
generalized	O
additive	O
models	O
(	O
GAMs	O
)	O
that	O
described	O
the	O
association	O
between	O
changes	O
in	O
specific	O
metabolite	O
concentrations	O
with	O
changes	O
in	O
enzymatic	O
activities	O
and	O
substrate	O
concentrations	O
.	O
Changes	O
in	O
substrate	O
concentrations	O
explained	O
50	O
%	O
or	O
more	O
of	O
the	O
model	O
deviances	O
in	O
7	O
of	O
the	O
13	O
metabolic	O
steps	O
analyzed	O
.	O
Addition	O
of	O
information	O
on	O
enzymatic	O
activities	O
almost	O
always	O
improved	O
the	O
fitness	O
of	O
GAMs	O
built	O
solely	O
based	O
on	O
substrate	O
concentrations	O
.	O
GAMs	O
were	O
validated	O
using	O
experimental	O
data	O
that	O
were	O
not	O
included	O
when	O
the	O
model	O
was	O
built	O
.	O
In	O
addition	O
,	O
a	O
system	O
of	O
ordinary	O
differential	O
equations	O
(	O
ODE	O
)	O
was	O
developed	O
to	O
describe	O
the	O
instantaneous	O
changes	O
in	O
metabolites	O
as	O
a	O
function	O
of	O
the	O
levels	O
of	O
enzymatic	O
catalytic	O
activities	O
.	O
The	O
results	O
demonstrated	O
the	O
ability	O
of	O
the	O
models	O
to	O
predict	O
changes	O
in	O
the	O
flux	O
of	O
metabolites	O
in	O
the	O
JH	O
pathway	O
,	O
and	O
can	O
be	O
used	O
in	O
the	O
future	O
to	O
design	O
and	O
validate	O
experimental	O
manipulations	O
of	O
JH	O
synthesis	O
.	O
      
Human	O
brucellosis	B-T047
in	O
South	O
Africa	O
:	O
Public	O
health	O
and	O
diagnostic	O
pitfalls	O
Human	O
brucellosis	B-T047
in	O
South	O
Africa	O
(	O
SA	O
)	O
is	O
under	O
-	O
diagnosed	O
and	O
under	B-T033
-	I-T033
reported	I-T033
.	O
This	O
is	O
because	O
many	O
clinicians	O
have	O
little	O
or	O
no	O
experience	O
in	O
managing	O
affected	O
patients	O
,	O
and	O
in	O
part	O
because	O
of	O
the	O
nonspecific	O
and	O
insidious	O
nature	O
of	O
the	O
disease	O
.	O
A	O
case	O
of	O
human	O
brucellosis	B-T047
caused	O
by	O
Brucella	B-T007
melitensis	I-T007
in	O
a	O
patient	O
from	O
the	O
Western	O
Cape	O
Province	O
of	O
SA	O
is	O
described	O
,	O
and	O
the	O
resulting	O
exposure	O
of	O
staff	O
members	O
at	O
two	O
medical	O
microbiology	O
laboratories	O
,	O
as	O
well	O
as	O
the	O
public	B-T058
health	I-T058
investigation	I-T058
that	O
was	O
conducted	O
,	O
are	O
discussed	O
.	O
This	O
article	O
aims	O
to	O
highlight	O
the	O
need	O
for	O
strengthening	O
integration	O
between	O
public	O
health	O
,	O
medical	B-T058
and	O
veterinary	O
services	O
and	O
exposing	O
deficiencies	O
in	O
public	O
health	O
,	O
veterinary	O
and	O
laboratory	O
practices	O
.	O
      
Request	O
and	O
fulfillment	O
of	O
postpartum	O
tubal	B-T061
ligation	I-T061
in	O
patients	O
after	O
high	O
-	O
risk	O
pregnancy	O
Female	B-T061
sterilization	I-T061
is	O
one	O
of	O
the	O
most	O
prevalent	O
methods	O
of	O
contraception	B-T061
in	O
the	O
United	O
States	O
.	O
Prior	O
studies	O
have	O
shown	O
that	O
nearly	O
half	O
of	O
postpartum	O
tubal	B-T061
ligation	I-T061
(	O
PPTL	B-T061
)	O
requests	O
go	O
unfulfilled	O
.	O
This	O
study	O
seeks	O
to	O
establish	O
whether	O
obstetric	O
or	O
medical	O
risk	O
status	O
influences	O
patients	O
'	O
request	O
for	O
or	O
subsequent	O
completion	O
of	O
PPTL	B-T061
.	O
This	O
study	O
was	O
a	O
retrospective	O
cohort	O
study	O
of	O
women	O
delivering	O
at	O
a	O
university	O
hospital	O
in	O
2009	O
-	O
2010	O
who	O
received	O
prenatal	B-T058
care	I-T058
in	O
the	O
faculty	O
and	O
resident	O
clinics	O
.	O
High	B-T033
-	I-T033
risk	I-T033
status	O
was	O
defined	O
by	O
Society	O
for	O
Maternal	O
-	O
Fetal	O
Medicine	O
guidelines	O
.	O
Documentation	O
of	O
contraceptive	O
plan	O
and	O
administration	B-T061
of	O
contraceptive	B-T061
methods	I-T061
was	O
abstracted	O
from	O
patient	O
records	O
.	O
Subsequent	O
pregnancies	O
through	O
March	O
1	O
,	O
2013	O
,	O
were	O
abstracted	O
.	O
Of	O
3063	O
participants	O
(	O
2048	O
low	O
risk	O
and	O
1015	O
high	B-T033
risk	I-T033
)	O
,	O
231	O
requested	O
PPTL	B-T061
(	O
7.5	O
%	O
)	O
.	O
This	O
was	O
more	O
likely	O
among	O
high	B-T033
-	I-T033
risk	I-T033
patients	O
than	O
low	O
-	O
risk	O
patients	O
(	O
10.0	O
%	O
vs.	O
6.3	O
%	O
,	O
p<.001	O
)	O
,	O
those	O
with	O
public	O
insurance	O
(	O
13.8	O
%	O
vs.	O
3.2	O
%	O
,	O
p<.001	O
)	O
and	O
those	O
with	O
an	O
unintended	B-T033
index	I-T033
pregnancy	I-T033
(	O
13.8	O
%	O
vs.	O
4.1	O
%	O
,	O
p<.001	O
)	O
.	O
Of	O
the	O
patients	O
requesting	O
PPTL	B-T061
,	O
118	O
(	O
51.1	O
%	O
)	O
underwent	O
the	O
procedure	B-T061
immediately	O
postpartum	O
.	O
Completion	O
was	O
not	O
associated	O
with	O
high	B-T033
-	I-T033
risk	I-T033
status	O
(	O
54.0	O
%	O
)	O
,	O
or	O
with	O
race	O
,	O
insurance	O
status	O
or	O
parity	B-T033
.	O
Among	O
113	O
women	O
with	O
an	O
unfulfilled	O
PPTL	B-T061
request	O
,	O
there	O
were	O
17	O
subsequent	O
pregnancies	O
(	O
15.0	O
%	O
)	O
during	O
the	O
27	O
months	O
of	O
follow	B-T058
-	I-T058
up	I-T058
.	O
Though	O
women	O
with	O
high	O
-	O
risk	O
pregnancies	O
were	O
more	O
likely	O
to	O
request	O
PPTL	B-T061
,	O
they	O
were	O
not	O
more	O
likely	O
to	O
complete	O
the	O
procedure	B-T061
.	O
Over	O
one	O
third	O
of	O
high	B-T033
-	I-T033
risk	I-T033
patients	O
'	O
requests	O
were	O
unfulfilled	O
,	O
indicating	O
that	O
significant	O
barriers	O
may	O
remain	O
.	O
Though	O
women	O
with	O
high	O
-	O
risk	O
pregnancies	O
were	O
more	O
likely	O
to	O
request	O
PPTL	B-T061
,	O
they	O
were	O
not	O
more	O
likely	O
to	O
complete	O
the	O
procedure	B-T061
.	O
Providers	O
should	O
consider	O
these	O
procedures	B-T061
urgent	O
,	O
especially	O
in	O
high	B-T033
-	I-T033
risk	I-T033
women	O
,	O
and	O
advocate	O
for	O
their	O
patients	O
'	O
access	O
to	O
this	O
procedure	B-T061
.	O
      
Extract	O
of	O
Caulis	O
Spatholobi	O
,	O
a	O
novel	O
blocker	B-T121
targeting	O
tumor	O
cell	O
‑induced	O
platelet	O
aggregation	O
,	O
inhibits	O
breast	B-T191
cancer	I-T191
metastasis	B-T191
Metastasis	B-T191
of	O
breast	B-T191
cancer	I-T191
is	O
the	O
vital	O
step	O
for	O
malignant	B-T191
progression	I-T191
.	O
During	O
such	O
a	O
process	O
,	O
hematogenous	B-T191
metastasis	I-T191
is	O
an	O
indispensable	O
approach	O
for	O
the	O
dissemination	O
of	O
cancer	O
cells	O
.	O
A	O
platelet	O
,	O
contributes	O
to	O
hypercoagulable	B-T047
state	I-T047
,	O
and	O
is	O
also	O
identified	O
the	O
crucial	O
factor	O
in	O
the	O
coagulation	O
system	O
for	O
supporting	O
metastasis	B-T191
.	O
Therefore	O
,	O
the	O
relationship	O
of	O
a	O
platelet	O
and	O
a	O
tumor	O
cell	O
plays	O
a	O
critical	O
role	O
in	O
tumor	O
cell	O
metastasis	B-T191
.	O
Consequently	O
,	O
inhibiting	O
tumor	O
cell	O
‑induced	O
platelet	O
aggregation	O
(	O
TCIPA	O
)	O
is	O
recongnized	O
as	O
a	O
crucial	O
target	O
on	O
suppression	O
of	O
tumor	B-T191
metastasis	I-T191
such	O
as	O
aspirin	B-T121
(	O
ASA	B-T121
)	O
.	O
Under	O
such	O
circumstance	O
,	O
here	O
we	O
report	O
that	O
,	O
through	O
dissociating	O
the	O
tumor‑platelet	O
(	O
T‑P	O
)	O
complex	O
,	O
80	O
%	O
ethanol	B-T121
extracts	O
of	O
Caulis	O
Spatholobi	O
(	O
SET	O
)	O
successfully	O
alleviated	O
the	O
hypercoagulation	B-T047
state	I-T047
,	O
thereby	O
reducing	O
tumor	B-T191
metastasis	I-T191
and	O
improving	O
the	O
prospects	O
of	O
survival	O
in	O
breast	B-T023
cancer	O
cell	O
model	O
.	O
Through	O
MTT	B-T059
and	O
anti‑aggregation	B-T059
assay	I-T059
stimulated	I-T059
by	I-T059
ADP	I-T059
,	O
we	O
detected	O
the	O
optimum	O
treatment	O
time	O
and	O
the	O
optimum	O
dose	O
of	O
SET	O
.	O
By	O
using	O
confocal	B-T059
microscopy	I-T059
,	O
we	O
observed	O
that	O
SET	O
can	O
strongly	O
block	O
the	O
formation	O
of	O
T‑P	O
complex	O
i	O
n	O
vitro	O
.	O
The	O
result	O
was	O
further	O
quantified	O
and	O
confirmed	O
by	O
the	O
FACS	B-T059
analysis	I-T059
.	O
The	O
fluorescent	O
value	O
of	O
T‑P	O
complex	O
was	O
obviously	O
decreased	O
in	O
the	O
drug‑treated	O
groups	O
.	O
In	O
vivo	O
,	O
4T1	O
cells	O
were	O
injected	B-T061
through	O
the	O
mouse	O
tail	B-T023
vein	I-T023
for	O
dynamic	B-T060
visualization	I-T060
by	O
small	O
animal	O
imaging	O
system	O
.	O
The	O
metastatic	O
intensity	O
was	O
quantified	O
and	O
the	O
survival	O
curve	O
was	O
analyzed	O
.	O
Additionally	O
,	O
general	O
observation	O
and	O
hematoxylin	B-T059
and	I-T059
eosin	I-T059
(	I-T059
H&E	I-T059
)	I-T059
staining	I-T059
of	O
lung	B-T023
tissue	O
was	O
performed	O
.	O
SET	O
exerted	O
an	O
obvious	O
effect	O
on	O
the	O
inhibition	O
of	O
metastasis	B-T191
and	O
increasing	O
the	O
survival	O
rate	O
of	O
mice	O
.	O
For	O
the	O
molecular	O
mechanism	O
study	O
of	O
anti‑TCIPA	B-T059
,	O
zymography	O
and	O
R	O
T‑PCR	O
assay	O
preliminarily	O
revealed	O
the	O
molecular	O
mechanism	O
of	O
SET	O
in	O
the	O
regulation	O
of	O
P	O
‑T	O
interaction	O
.	O
Collectively	O
,	O
through	O
drug	O
efficacy	O
identification	O
and	O
pharmacological	O
revealing	O
,	O
we	O
have	O
obtained	O
a	O
promising	O
candidate	O
for	O
the	O
interference	O
of	O
breast	B-T023
metastasis	B-T191
by	O
suppressing	O
TCIPA	O
,	O
which	O
will	O
be	O
beneficial	O
for	O
clinical	O
cancer	B-T061
treatment	I-T061
.	O
      
Advanced	O
age	O
is	O
not	O
a	O
barrier	O
to	O
creating	O
a	O
functional	O
arteriovenous	B-T020
fistula	I-T020
:	O
a	O
retrospective	O
study	O
Arteriovenous	B-T020
fistulas	I-T020
(	O
AVFs	B-T020
)	O
are	O
the	O
recommended	O
form	O
of	O
vascular	O
access	O
for	O
hemodialysis	B-T061
.	O
However	O
,	O
controversy	O
exists	O
regarding	O
whether	O
AVFs	B-T020
are	O
suitable	O
for	O
elderly	O
patients	O
.	O
Single	O
-	O
center	O
retrospective	O
review	O
to	O
investigate	O
the	O
impact	O
of	O
age	O
on	O
AVF	B-T020
outcomes	O
.	O
Five	O
hundred	O
and	O
twenty	O
-	O
five	O
patients	O
with	O
AVF	B-T020
creation	O
were	O
stratified	O
based	O
on	O
age	O
<	O
65	O
,	O
65	O
-	O
75	O
,	O
and	O
>	O
75	O
years	O
.	O
AVF	B-T020
outcomes	O
including	O
primary	O
failure	O
,	O
AVF	B-T020
patency	O
(	O
primary	O
,	O
secondary	O
,	O
and	O
functional	O
)	O
,	O
and	O
AVF	B-T020
complications	O
were	O
studied	O
for	O
3	O
years	O
following	O
AVF	B-T020
creation	O
.	O
The	O
cohort	O
was	O
63	O
%	O
male	O
,	O
44	O
%	O
Caucasian	O
,	O
and	O
55	O
%	O
had	O
diabetes	B-T047
or	O
cardiovascular	B-T047
disease	I-T047
.	O
39	O
%	O
were	O
aged	O
<	O
65	O
years	O
,	O
33	O
%	O
65	O
-	O
75	O
years	O
,	O
and	O
28	O
%	O
were	O
aged	O
>	O
75	O
years	O
.	O
No	O
differences	O
in	O
rates	O
of	O
primary	O
failure	O
,	O
loss	O
of	O
primary	O
patency	O
,	O
complications	O
,	O
or	O
need	O
for	O
intervention	B-T061
were	O
observed	O
between	O
age	O
groups	O
.	O
There	O
was	O
a	O
significant	O
association	O
of	O
age	O
with	O
secondary	O
patency	O
and	O
functional	O
patency	O
,	O
with	O
age	O
>	O
75	O
being	O
an	O
independent	O
risk	B-T033
factor	I-T033
for	O
shortened	O
lifespan	O
of	O
the	O
fistula	O
.	O
For	O
patients	O
aged	O
>	O
75	O
years	O
,	O
secondary	O
patency	O
at	O
3	O
years	O
was	O
64	O
%	O
compared	O
to	O
75%-78	O
%	O
for	O
younger	O
patients	O
.	O
Functional	O
patency	O
at	O
2	O
years	O
was	O
69	O
%	O
for	O
those	O
aged	O
>	O
75	O
years	O
compared	O
to	O
78%-81	O
%	O
for	O
younger	O
patients	O
.	O
We	O
found	O
no	O
difference	O
in	O
AVF	B-T020
maturation	O
,	O
primary	O
patency	O
,	O
complications	O
,	O
or	O
interventions	B-T061
in	O
those	O
over	O
the	O
age	O
of	O
75	O
compared	O
to	O
younger	O
counterparts	O
.	O
While	O
secondary	O
and	O
functional	O
patency	O
rates	O
were	O
significantly	O
lower	O
in	O
those	O
aged	O
>	O
75	O
years	O
,	O
the	O
magnitude	O
of	O
difference	O
is	O
likely	O
not	O
clinically	O
relevant	O
.	O
Therefore	O
,	O
we	O
recommend	O
that	O
advanced	O
age	O
alone	O
should	O
not	O
preclude	O
patients	O
from	O
AVF	B-T020
creation	O
.	O
      
Activation	O
of	O
transcription	O
enforces	O
the	O
formation	O
of	O
distinct	O
nuclear	O
bodies	O
in	O
zebrafish	O
embryos	B-T018
Nuclear	O
bodies	O
are	O
cellular	O
compartments	O
that	O
lack	O
lipid	O
bilayers	O
and	O
harbor	O
specific	O
RNAs	O
and	O
proteins	O
.	O
Recent	O
proposals	O
that	O
nuclear	O
bodies	O
form	O
through	O
liquid	O
-	O
liquid	O
phase	O
separation	O
leave	O
the	O
question	O
of	O
how	O
different	O
nuclear	O
bodies	O
maintain	O
their	O
distinct	O
identities	O
unanswered	O
.	O
Here	O
we	O
investigate	O
Cajal	O
bodies	O
(	O
CBs	O
)	O
,	O
histone	O
locus	O
bodies	O
(	O
HLBs	O
)	O
and	O
nucleoli	O
-	O
involved	O
in	O
assembly	O
of	O
the	O
splicing	O
machinery	O
,	O
histone	O
mRNA	O
3	O
'	O
end	O
processing	O
,	O
and	O
rRNA	O
processing	O
,	O
respectively	O
-	O
in	O
the	O
embryos	B-T018
of	O
the	O
zebrafish	O
,	O
Danio	O
rerio	O
.	O
We	O
take	O
advantage	O
of	O
the	O
transcriptional	O
silence	O
of	O
the	O
1	O
-	O
cell	O
embryo	B-T018
and	O
follow	O
nuclear	O
body	O
appearance	O
as	O
zygotic	B-T018
transcription	O
becomes	O
activated	O
.	O
CBs	O
are	O
present	O
from	O
fertilization	O
onwards	O
,	O
while	O
HLB	O
and	O
nucleolar	O
components	O
formed	O
foci	O
several	O
hours	O
later	O
when	O
histone	O
genes	O
and	O
rDNA	O
became	O
active	O
.	O
HLB	O
formation	O
was	O
blocked	O
by	O
transcription	O
inhibition	O
,	O
suggesting	O
nascent	O
histone	O
transcripts	O
recruit	O
HLB	O
components	O
like	O
U7	O
snRNP	O
.	O
Surprisingly	O
,	O
we	O
found	O
that	O
U7	O
base	O
-	O
pairing	O
with	O
nascent	O
histone	O
transcripts	O
was	O
not	O
required	O
for	O
localization	O
to	O
HLBs	O
.	O
Rather	O
,	O
the	O
type	O
of	O
Sm	O
ring	O
assembled	O
on	O
U7	O
determined	O
its	O
targeting	O
to	O
HLBs	O
or	O
CBs	O
;	O
the	O
spliceosomal	O
Sm	O
ring	O
targeted	O
snRNAs	O
to	O
CBs	O
while	O
the	O
specialized	O
U7	O
Sm	O
-	O
ring	O
localized	O
to	O
HLBs	O
,	O
demonstrating	O
the	O
contribution	O
of	O
protein	O
constituents	O
to	O
the	O
distinction	O
among	O
nuclear	O
bodies	O
.	O
Thus	O
,	O
nucleolar	O
,	O
HLB	O
,	O
and	O
CB	O
components	O
can	O
mix	O
in	O
early	O
embryogenesis	O
when	O
transcription	O
is	O
naturally	O
or	O
artificially	O
silenced	O
.	O
These	O
data	O
support	O
a	O
model	O
in	O
which	O
transcription	O
of	O
specific	O
gene	O
loci	O
nucleates	O
nuclear	O
body	O
components	O
with	O
high	O
specificity	O
and	O
fidelity	O
to	O
perform	O
distinct	O
regulatory	O
functions	O
.	O
      
Gain	O
-	O
of	O
-	O
function	O
mutation	O
in	O
SCN5A	O
causes	O
ventricular	B-T047
arrhythmias	I-T047
and	O
early	B-T033
onset	I-T033
atrial	B-T047
fibrillation	I-T047
Mutations	O
in	O
SCN5A	O
,	O
the	O
gene	O
encoding	O
the	O
α	O
-	O
subunit	O
of	O
the	O
cardiac	B-T023
sodium	O
channel	O
(	O
NaV1.5	O
)	O
,	O
are	O
associated	O
with	O
a	O
broad	O
spectrum	O
of	O
inherited	O
cardiac	B-T033
arrhythmia	I-T033
disorders	I-T033
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
identify	O
the	O
genetic	O
and	O
functional	O
determinants	O
underlying	O
a	O
Dutch	O
family	O
that	O
presented	O
with	O
a	O
combined	O
phenotype	O
of	O
ventricular	B-T047
arrhythmias	I-T047
with	O
a	O
likely	O
adrenergic	O
component	O
,	O
either	O
in	O
isolation	O
or	O
in	O
combination	O
with	O
a	O
mildly	O
decreased	O
heart	O
function	O
and	O
early	B-T033
onset	I-T033
(	O
<	O
55	O
years	O
)	O
atrial	B-T047
fibrillation	I-T047
.	O
We	O
performed	O
next	O
generation	O
sequencing	O
in	O
the	O
proband	O
of	O
a	O
two-	O
generation	O
Dutch	O
family	O
and	O
demonstrated	O
a	O
novel	O
missense	O
mutation	O
in	O
SCN5A-(p	O
.	O
M1851V	O
)	O
which	O
co	O
-	O
segregated	O
with	O
the	O
clinical	O
phenotype	O
in	O
the	O
family	O
.	O
We	O
functionally	O
evaluated	O
the	O
putative	O
genetic	O
defect	O
by	O
patch	O
clamp	O
electrophysiological	B-T060
studies	I-T060
in	O
human	B-T018
embryonic	I-T018
kidney	O
cells	O
transfected	O
with	O
mutant	O
or	O
wild	O
-	O
type	O
Nav1.5	O
.	O
The	O
current	O
inactivation	O
was	O
slower	O
and	O
recovery	O
from	O
inactivation	O
was	O
faster	O
in	O
SCN5A	O
-	O
M1851V	O
channels	O
.	O
The	O
voltage	O
dependence	O
of	O
inactivation	O
was	O
shifted	O
towards	O
more	O
positive	B-T033
potentials	O
and	O
consequently	O
,	O
a	O
larger	O
TTX	O
-	O
sensitive	O
window	O
current	O
was	O
observed	O
in	O
SCN5A	O
-	O
M1851V	O
channels	O
.	O
Furthermore	O
,	O
a	O
higher	O
upstroke	O
velocity	O
was	O
observed	O
for	O
the	O
SCN5A	O
-	O
M1851V	O
channels	O
,	O
while	O
the	O
depolarization	O
voltage	O
was	O
more	O
negative	B-T033
,	O
both	O
indicating	O
increased	O
excitability	O
.	O
This	O
mutation	O
leads	O
to	O
a	O
gain	O
-	O
of	O
-	O
function	O
mechanism	O
based	O
on	O
increased	O
channel	O
availability	O
and	O
increased	O
window	O
current	O
,	O
fitting	O
the	O
observed	O
clinical	O
phenotype	O
of	O
(	O
likely	O
adrenergic	O
-	O
induced	O
)	O
ventricular	B-T047
arrhythmias	I-T047
and	O
atrial	B-T047
fibrillation	I-T047
.	O
These	O
findings	B-T033
further	O
expand	O
the	O
range	O
of	O
cardiac	B-T033
arrhythmias	I-T033
associated	O
with	O
mutations	O
in	O
SCN5A.	O
      
Assessment	B-T058
the	O
Exposure	O
Level	O
of	O
Rare	O
Earth	O
Elements	O
in	O
Workers	O
Producing	O
Cerium	B-T121
,	O
Lanthanum	O
Oxide	O
Ultrafine	O
and	O
Nanoparticles	O
In	O
order	O
to	O
assess	B-T058
occupational	O
exposure	O
level	O
of	O
15	O
rare	O
earth	O
elements	O
(	O
REEs	O
)	O
and	O
identify	O
the	O
associated	O
influence	O
,	O
we	O
used	O
inductively	B-T059
coupled	I-T059
plasma	I-T059
mass	I-T059
spectrometry	I-T059
(	O
ICP	B-T059
-	I-T059
MS	I-T059
)	O
based	O
on	O
closed	O
-	O
vessel	O
microwave	O
-	O
assisted	O
wet	O
digestion	O
procedure	O
to	O
determinate	B-T059
the	O
concentration	O
of	O
Y	O
,	O
La	O
,	O
Ce	B-T121
,	O
Pr	O
,	O
Nd	O
,	O
Sm	B-T121
,	O
Eu	O
,	O
Gd	O
,	O
Tb	O
,	O
Dy	O
,	O
Ho	O
,	O
Er	O
,	O
Tm	O
,	O
Yb	B-T121
and	O
Lu	O
in	O
urinary	O
samples	O
obtained	O
from	O
workers	O
producing	O
ultrafine	O
and	O
nanoparticles	O
containing	O
cerium	B-T121
and	O
lanthanum	O
oxide	O
.	O
The	O
results	O
suggest	O
that	O
La	O
and	O
Ce	B-T121
were	O
the	O
primary	O
component	O
,	O
together	O
accounting	O
for	O
97	O
%	O
of	O
total	O
REEs	O
in	O
workers	O
.	O
The	O
urinary	O
levels	O
of	O
La	O
,	O
and	O
Ce	B-T121
among	O
the	O
workers	O
(	O
6.36	O
,	O
15.32	O
μg.g(-1	O
)	O
creatinine	O
,	O
respectively	O
)	O
were	O
significantly	O
enriched	O
compared	O
to	O
those	O
levels	O
measured	O
in	O
the	O
control	O
subjects	O
(	O
1.52	O
,	O
4.04	O
μg.g(-1	O
)	O
creatinine	O
,	O
respectively	O
)	O
(	O
p	O
<	O
0.05	O
)	O
.	O
This	O
study	O
simultaneously	O
identified	O
the	O
associated	O
individual	O
factors	O
,	O
the	O
results	O
indicate	O
that	O
the	O
concentrations	O
in	O
over	O
5	O
years	O
group	O
(	O
11.64	O
±	O
10.93	O
for	O
La	O
,	O
27.83	O
±	O
24.38	O
for	O
Ce	B-T121
)	O
were	O
significantly	O
elevated	O
compared	O
to	O
1	O
-	O
5	O
years	O
group	O
(	O
2.58	O
±	O
1.51	O
for	O
La	O
,	O
6.87	O
±	O
3.90	O
for	O
Ce	B-T121
)	O
(	O
p	O
<	O
0.05	O
)	O
.	O
Compared	O
the	O
urinary	O
levels	O
of	O
La	O
and	O
Ce	B-T121
at	O
the	O
separation	O
and	O
packaging	O
locations	O
(	O
9.10	O
±	O
9.51	O
for	O
La	O
,	O
22.29	O
±	O
21.01	O
for	O
Ce	B-T121
)	O
with	O
the	O
other	O
locations	O
(	O
2.85	O
±	O
0.98	O
for	O
La	O
,	O
6.37	O
±	O
2.12	O
for	O
Ce	B-T121
)	O
,	O
the	O
results	O
show	O
urinary	O
concentrations	O
were	O
significantly	O
higher	O
in	O
workers	O
at	O
separation	O
and	O
packaging	O
locations	O
(	O
p	O
<	O
0.01	O
)	O
.	O
Inter	O
-	O
individual	O
variation	O
in	O
levels	O
of	O
La	O
and	O
Ce	B-T121
in	O
urine	O
is	O
the	O
result	O
of	O
multi	O
-	O
factorial	O
comprehensive	O
action	O
.	O
Further	O
researches	O
should	O
focus	O
on	O
the	O
multiple	O
factors	O
contributing	O
to	O
the	O
REEs	O
levels	O
of	O
the	O
occupationally	O
exposed	O
workers	O
.	O
      
Orai1	O
-Mediated	O
Antimicrobial	B-T121
Secretion	O
from	O
Pancreatic	B-T023
Acini	I-T023
Shapes	O
the	O
Gut	B-T001
Microbiome	I-T001
and	O
Regulates	O
Gut	B-T023
Innate	O
Immunity	O
The	O
gut	B-T001
microbiome	I-T001
participates	O
in	O
numerous	O
physiologic	O
functions	O
and	O
communicates	B-T033
intimately	O
with	O
the	O
host	B-T001
immune	O
system	O
.	O
Antimicrobial	B-T121
peptides	I-T121
are	O
critica	O
l	O
components	O
of	O
intestinal	B-T023
innate	O
immunity	O
.	O
We	O
report	O
a	O
prominent	O
role	O
for	O
antimicrobials	O
secreted	O
by	O
pancreatic	B-T023
acini	I-T023
in	O
shaping	O
the	O
gut	B-T001
microbiome	I-T001
that	O
is	O
essential	O
for	O
intestinal	B-T023
innate	O
immunity	O
,	O
barrier	O
function	O
,	O
and	O
survival	O
.	O
Deletion	O
of	O
the	O
Ca(2	O
+	O
)	O
channel	O
Orai1	O
in	O
pancreatic	B-T023
acini	I-T023
of	O
adult	O
mice	O
resulted	O
in	O
60%-70	O
%	O
mortality	O
within	O
3	O
weeks	O
.	O
Despite	O
robust	O
activation	O
of	O
the	O
intestinal	O
innate	O
immune	O
response	O
,	O
mice	O
lacking	O
acinar	O
Orai1	O
exhibited	O
intestinal	B-T023
bacterial	O
outgrowth	O
and	O
dysbiosis	B-T184
,	O
ultimately	O
causing	O
systemic	O
translocation	O
,	O
inflammation	O
,	O
and	O
death	O
.	O
While	O
digestive	B-T121
enzyme	I-T121
supplementation	B-T061
was	O
ineffective	O
,	O
treatments	B-T061
constraining	O
bacterial	O
outgrowth	O
(	O
purified	O
liquid	B-T061
diet	I-T061
,	O
broad	B-T195
-	I-T195
spectrum	I-T195
antibiotics	I-T195
)	O
rescued	O
survival	O
,	O
feeding	O
,	O
and	O
weight	B-T033
gain	I-T033
.	O
Pancreatic	O
levels	O
of	O
cathelicidin	O
-related	O
antimicrobial	B-T121
peptide	I-T121
(	O
CRAMP	B-T121
)	O
were	O
reduced	O
,	O
and	O
supplement	O
of	O
synthetic	O
CRAMP	B-T121
prevented	O
intestinal	B-T047
disease	I-T047
.	O
These	O
findings	B-T033
reveal	O
a	O
critical	O
role	O
for	O
antimicrobial	B-T121
pancreatic	O
secretion	O
in	O
gut	B-T023
innate	O
immunity	O
.	O
      
Genome	O
-	O
wide	O
association	O
mapping	O
in	O
winter	O
barley	O
for	O
grain	O
yield	O
and	O
culm	O
cell	O
wall	O
polymer	O
content	O
using	O
the	O
high	O
-	O
throughput	O
CoMPP	B-T059
technique	I-T059
A	O
collection	O
of	O
112	O
winter	O
barley	O
varieties	O
(	O
Hordeum	O
vulgare	O
L.	O
)	O
was	O
grown	O
in	O
the	O
field	O
for	O
two	O
years	O
(	O
2008/09	O
and	O
2009/10	O
)	O
in	O
northern	O
Italy	O
and	O
grain	O
and	O
straw	O
yields	O
recorded	O
.	O
In	O
the	O
first	O
year	O
of	O
the	O
trial	O
,	O
a	O
severe	O
attack	O
of	O
barley	B-T005
yellow	I-T005
mosaic	I-T005
virus	I-T005
(	O
BaYMV	B-T005
)	O
strongly	O
influenced	O
final	O
performances	O
with	O
an	O
average	O
reduction	O
of	O
~	O
50	O
%	O
for	O
grain	O
and	O
straw	O
harvested	O
in	O
comparison	O
to	O
the	O
second	O
year	O
.	O
The	O
genetic	B-T059
determination	I-T059
(	O
GD	B-T059
)	O
for	O
grain	O
yield	O
was	O
0.49	O
and	O
0.70	O
,	O
for	O
the	O
two	O
years	O
respectively	O
,	O
and	O
for	O
straw	O
yield	O
GD	B-T059
was	O
low	O
in	O
2009	O
(	O
0.09	O
)	O
and	O
higher	O
in	O
2010	O
(	O
0.29	O
)	O
.	O
Cell	O
wall	O
polymers	O
in	O
culms	O
were	O
quantified	O
by	O
means	O
of	O
the	O
monoclonal	O
antibodies	O
LM6	O
,	O
LM11	O
,	O
JIM13	O
and	O
BS-400	O
-	O
3	O
and	O
the	O
carbohydrate	O
-	O
binding	O
module	O
CBM3a	O
using	O
the	O
high	O
-	O
throughput	O
CoMPP	B-T059
technique	I-T059
.	O
Of	O
these	O
,	O
LM6	O
,	O
which	O
detects	B-T033
arabinan	O
components	O
,	O
showed	O
a	O
relatively	O
high	O
GD	B-T059
in	O
both	O
years	O
and	O
a	O
significantly	O
negative	B-T033
correlation	O
with	O
grain	O
yield	O
(	O
GYLD	O
)	O
.	O
Overall	O
,	O
heritability	O
(	O
H2	O
)	O
was	O
calculated	O
for	O
GYLD	O
,	O
LM6	O
and	O
JIM	O
and	O
resulted	O
to	O
be	O
0.42	O
,	O
0.32	O
and	O
0.20	O
,	O
respectively	O
.	O
A	O
total	O
of	O
4,976	O
SNPs	O
from	O
the	O
9	O
K	O
iSelect	O
array	O
were	O
used	O
in	O
the	O
study	O
for	O
the	O
analysis	O
of	O
population	O
structure	O
,	O
linkage	O
disequilibrium	O
(	O
LD	O
)	O
and	O
genome	O
-	O
wide	O
association	O
study	O
(	O
GWAS	O
)	O
.	O
Marker	O
-	O
trait	O
associations	O
(	O
MTA	O
)	O
were	O
analyzed	O
for	O
grain	O
yield	O
and	O
cell	O
wall	O
determination	O
by	O
LM6	O
and	O
JIM13	O
as	O
these	O
were	O
the	O
traits	O
showing	O
significant	O
correlations	O
between	O
the	O
years	O
.	O
A	O
single	O
QTL	O
for	O
GYLD	O
containing	O
three	O
MTAs	O
was	O
found	O
on	O
chromosome	O
3H	O
located	O
close	O
to	O
the	O
Hv	O
-	O
eIF4E	O
gene	O
,	O
which	O
is	O
known	O
to	O
regulate	O
resistance	O
to	O
BaYMV	B-T005
.	O
Subsequently	O
the	O
QTL	O
was	O
shown	O
to	O
be	O
tightly	O
linked	O
to	O
rym4	O
,	O
a	O
locus	O
for	O
resistance	O
to	O
the	O
virus	B-T005
.	O
GWAs	O
on	O
arabinans	O
quantified	O
by	O
LM6	O
resulted	O
in	O
the	O
identification	O
of	O
major	O
QTLs	O
closely	O
located	O
on	O
3H	O
and	O
hypotheses	O
regarding	O
putative	O
candidate	O
genes	O
were	O
formulated	O
through	O
the	O
study	O
of	O
gene	O
expression	O
levels	O
based	O
on	O
bioinformatics	O
tools	O
.	O
      
Extracellular	O
Potassium	O
and	O
Seizures	B-T184
:	O
Excitation	O
,	O
Inhibition	O
and	O
the	O
Role	O
of	O
Ih	O
Seizure	B-T184
activity	I-T184
leads	O
to	O
increases	O
in	O
extracellular	O
potassium	O
concentration	O
(	O
[	O
K	B-T121
[	O
Formula	O
:	O
see	O
text]]o	O
)	O
,	O
which	O
can	O
result	O
in	O
changes	O
in	O
neuronal	O
passive	O
and	O
active	O
membrane	O
properties	O
as	O
well	O
as	O
in	O
population	O
activities	O
.	O
In	O
this	O
study	O
,	O
we	O
examined	O
how	O
extracellular	O
potassium	O
modulates	O
seizure	B-T184
activities	I-T184
using	O
an	O
acute	O
4	B-T121
-	I-T121
AP	I-T121
induced	O
seizure	B-T184
model	O
in	O
the	O
neocortex	B-T023
,	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O
Moderately	O
elevated	O
[	O
K	B-T121
[	O
Formula	O
:	O
see	O
text]]o	O
up	O
to	O
9[Formula	O
:	O
see	O
text]mM	O
prolonged	O
seizure	B-T184
durations	O
and	O
shortened	O
interictal	O
intervals	O
as	O
well	O
as	O
depolarized	O
the	O
neuronal	O
resting	O
membrane	O
potential	O
(	O
RMP	O
)	O
.	O
However	O
,	O
when	O
[	O
K	B-T121
[	O
Formula	O
:	O
see	O
text]]o	O
reached	O
higher	O
than	O
9[Formula	O
:	O
see	O
text]mM	O
,	O
seizure	B-T184
like	I-T184
events	I-T184
(	O
SLEs	B-T184
)	O
were	O
blocked	O
and	O
neurons	O
went	O
into	O
a	O
depolarization	O
-	O
blocked	O
state	O
.	O
Spreading	O
depression	B-T048
was	O
never	O
observed	O
as	O
the	O
blockade	O
of	O
ictal	B-T184
events	I-T184
could	O
be	O
reversed	O
within	O
1	O
-	O
2[Formula	O
:	O
see	O
text]min	O
after	O
the	O
raised	O
[	O
K	B-T121
[	O
Formula	O
:	O
see	O
text]]o	O
was	O
changed	O
back	O
to	O
control	O
levels	O
.	O
This	O
concentration	O
-dependent	O
dual	O
effect	O
of	O
[	O
K	B-T121
[	O
Formula	O
:	O
see	O
text]]o	O
was	O
observed	O
using	O
in	O
vivo	O
and	O
in	O
vitro	O
mouse	O
brain	O
preparations	O
as	O
well	O
as	O
in	O
human	O
neocortical	B-T023
tissue	O
resected	O
during	O
epilepsy	B-T047
surgery	B-T061
.	O
Blocking	O
the	O
Ih	O
current	O
,	O
mediated	O
by	O
hyperpolarization	O
-	O
activated	O
cyclic	O
nucleotide	O
-	O
gated	O
(	O
HCN	O
)	O
channels	O
,	O
modulated	O
the	O
elevated	O
[	O
K	B-T121
[	O
Formula	O
:	O
see	O
text]]o	O
influence	O
on	O
SLEs	B-T184
by	O
promoting	O
the	O
high	O
[	O
K	B-T121
[	O
Formula	O
:	O
see	O
text]]o	O
inhibitory	O
actions	O
.	O
These	O
results	O
demonstrate	O
biphasic	O
actions	O
of	O
raised	O
[	O
K	B-T121
[	O
Formula	O
:	O
see	O
text]]o	O
on	O
neuronal	O
excitability	B-T184
and	O
seizure	B-T184
activity	I-T184
.	O
      
Medication	B-T061
Intervention	I-T061
for	O
Chronic	B-T047
Kidney	I-T047
Disease	I-T047
Patients	O
Transitioning	O
from	O
Hospital	O
to	O
Home	O
:	O
Study	O
Design	O
and	O
Baseline	O
Characteristics	O
The	O
hospital	B-T058
readmission	I-T058
rate	O
in	O
the	O
population	O
with	O
chronic	B-T047
kidney	I-T047
disease	I-T047
(	O
CKD	B-T047
)	O
is	O
high	O
and	O
strategies	O
to	O
reduce	O
this	O
risk	O
are	O
urgently	O
needed	O
.	O
The	O
CKD	B-T047
-	O
Medication	B-T061
Intervention	I-T061
Trial	I-T061
(	O
CKD	B-T047
-	O
MIT	B-T061
;	O
www.clinicaltrials.gov	O
;	O
NCTO1459770	O
)	O
is	O
a	O
single	O
-	O
blind	O
(	O
investigators	O
)	O
,	O
randomized	O
,	O
clinical	O
trial	O
conducted	O
at	O
Providence	B-T058
Health	I-T058
Care	I-T058
in	O
Spokane	O
,	O
Washington	O
.	O
Study	O
participants	O
are	O
hospitalized	O
patients	O
with	O
CKD	B-T047
stages	O
3	O
-	O
5	O
(	O
not	O
treated	B-T061
with	I-T061
kidney	B-T061
replacement	I-T061
therapy	I-T061
)	O
and	O
acute	O
illness	O
.	O
The	O
study	O
intervention	O
is	O
a	O
pharmacist	O
-	O
led	O
,	O
home	B-T058
-	I-T058
based	I-T058
,	O
medication	B-T058
management	I-T058
intervention	B-T061
delivered	O
within	O
7	O
days	O
after	O
hospital	B-T058
discharge	I-T058
.	O
The	O
primary	O
outcome	O
is	O
a	O
composite	O
of	O
hospital	B-T058
readmissions	I-T058
and	O
visits	O
to	O
emergency	O
departments	O
and	O
urgent	O
care	O
centers	O
for	O
90	O
days	O
following	O
hospital	B-T058
discharge	I-T058
.	O
Secondary	O
outcomes	O
are	O
achievements	O
of	O
guideline	O
-	O
based	O
targets	O
for	O
CKD	B-T047
risk	B-T033
factors	I-T033
and	O
complications	O
.	O
Enrollment	B-T058
began	O
in	O
February	O
2012	O
and	O
ended	O
in	O
May	O
2015	O
.	O
At	O
baseline	O
,	O
the	O
age	O
of	O
participants	O
was	O
69	O
±	O
11	O
years	O
(	O
mean	O
±	O
SD	O
)	O
,	O
50	O
%	O
(	O
77	O
of	O
155	O
)	O
were	O
women	O
,	O
83	O
%	O
(	O
117	O
of	O
141	O
)	O
had	O
hypertension	B-T047
and	O
56	O
%	O
(	O
79	O
of	O
141	O
)	O
had	O
diabetes	B-T047
.	O
At	O
baseline	O
,	O
the	O
estimated	B-T059
glomerular	I-T059
filtration	I-T059
rate	O
was	O
41	O
±	O
14	O
ml	O
/	O
min/1.73	O
m2	O
and	O
urine	B-T059
albumin	I-T059
-	I-T059
to	I-T059
-	I-T059
creatinine	I-T059
ratio	I-T059
was	O
43	O
mg	O
/	O
g	O
(	O
interquartile	O
range	O
8	O
-	O
528	O
mg	O
/	O
g	O
)	O
.	O
The	O
most	O
frequent	O
diagnosis	O
category	O
for	O
the	O
index	O
hospital	B-T058
admission	I-T058
was	O
cardiovascular	B-T047
diseases	I-T047
at	O
34	O
%	O
(	O
53	O
of	O
155	O
)	O
,	O
but	O
the	O
most	O
common	O
single	B-T033
diagnosis	I-T033
for	O
admission	B-T058
was	O
community	O
-	O
acquired	O
acute	B-T047
kidney	I-T047
injury	I-T047
at	O
10	O
%	O
(	O
16	O
of	O
155	O
)	O
.	O
Participants	O
in	O
CKD	B-T047
-	O
MIT	B-T061
are	O
typical	O
of	O
acutely	O
ill	O
hospitalized	O
patients	O
with	O
CKD	B-T047
.	O
A	O
medication	B-T058
management	I-T058
intervention	B-T061
after	O
hospital	B-T058
discharge	I-T058
is	O
under	O
study	O
to	O
reduce	O
post	O
-	O
hospitalization	B-T058
acute	B-T058
care	I-T058
utilization	O
and	O
to	O
improve	O
CKD	B-T047
management	B-T058
.	O
      
Form	O
and	O
function	O
in	O
gene	O
regulatory	O
networks	O
:	O
the	O
structure	O
of	O
network	O
motifs	O
determines	O
fundamental	O
properties	O
of	O
their	O
dynamical	O
state	O
space	O
Network	O
motifs	O
have	O
been	O
studied	O
extensively	O
over	O
the	O
past	O
decade	O
,	O
and	O
certain	O
motifs	O
,	O
such	O
as	O
the	O
feed	O
-	O
forward	O
loop	O
,	O
play	O
an	O
important	O
role	O
in	O
regulatory	O
networks	O
.	O
Recent	O
studies	O
have	O
used	O
Boolean	O
network	O
motifs	O
to	O
explore	O
the	O
link	O
between	O
form	O
and	O
function	O
in	O
gene	O
regulatory	O
networks	O
and	O
have	O
found	O
that	O
the	O
structure	O
of	O
a	O
motif	O
does	O
not	O
strongly	O
determine	O
its	O
function	O
,	O
if	O
this	O
is	O
defined	O
in	O
terms	O
of	O
the	O
gene	O
expression	O
patterns	O
the	O
motif	O
can	O
produce	O
.	O
Here	O
,	O
we	O
offer	O
a	O
different	O
,	O
higher	O
-	O
level	O
definition	O
of	O
the	O
'	O
function	O
'	O
of	O
a	O
motif	O
,	O
in	O
terms	O
of	O
two	O
fundamental	O
properties	O
of	O
its	O
dynamical	O
state	O
space	O
as	O
a	O
Boolean	O
network	O
.	O
One	O
is	O
the	O
basin	O
entropy	O
,	O
which	O
is	O
a	O
complexity	O
measure	O
of	O
the	O
dynamics	O
of	O
Boolean	O
networks	O
.	O
The	O
other	O
is	O
the	O
diversity	O
of	O
cyclic	O
attractor	O
lengths	O
that	O
a	O
given	O
motif	O
can	O
produce	O
.	O
Using	O
these	O
two	O
measures	O
,	O
we	O
examine	O
all	O
104	O
topologically	O
distinct	O
three	O
-	O
node	O
motifs	O
and	O
show	O
that	O
the	O
structural	O
properties	O
of	O
a	O
motif	O
,	O
such	O
as	O
the	O
presence	O
of	O
feedback	O
loops	O
and	O
feed	O
-	O
forward	O
loops	O
,	O
predict	O
fundamental	O
characteristics	O
of	O
its	O
dynamical	O
state	O
space	O
,	O
which	O
in	O
turn	O
determine	O
aspects	O
of	O
its	O
functional	O
versatility	O
.	O
We	O
also	O
show	O
that	O
these	O
higher	O
-	O
level	O
properties	O
have	O
a	O
direct	O
bearing	O
on	O
real	O
regulatory	O
networks	O
,	O
as	O
both	O
basin	O
entropy	O
and	O
cycle	O
length	O
diversity	O
show	O
a	O
close	O
correspondence	O
with	O
the	O
prevalence	O
,	O
in	O
neural	O
and	O
genetic	O
regulatory	O
networks	O
,	O
of	O
the	O
13	O
connected	O
motifs	O
without	O
self	O
-	O
interactions	O
that	O
have	O
been	O
studied	O
extensively	O
in	O
the	O
literature	O
.	O
      
A	O
comparison	O
of	O
two	O
comorbidity	O
indices	O
for	O
predicting	O
inpatient	O
rehabilitation	B-T061
outcomes	O
Comorbid	B-T033
conditions	I-T033
are	O
important	O
in	O
health	B-T058
care	I-T058
.	O
The	O
best	O
comorbidity	O
index	O
for	O
predicting	O
the	O
impact	O
of	O
comorbidities	O
on	O
rehabilitation	B-T061
outcomes	O
has	O
not	O
been	O
determined	O
.	O
Compare	O
the	O
associations	O
of	O
comorbidity	O
measured	O
using	O
the	O
Charlson	O
Comorbidity	O
Index	O
(	O
CCI	O
)	O
and	O
the	O
Cumulative	O
Index	O
Rating	O
Scale	O
(	O
CIRS	O
)	O
with	O
key	O
rehabilitation	B-T061
outcomes	O
.	O
Aim	O
was	O
to	O
determine	O
whether	O
either	O
of	O
these	O
comorbidity	O
indices	O
helped	O
explain	O
the	O
variation	O
in	O
key	O
rehabilitation	B-T061
outcomes	O
.	O
Prospective	O
open	O
-	O
cohort	O
study	O
.	O
Inpatient	O
rehabilitation	B-T061
ward	O
,	O
Melbourne	O
,	O
Australia	O
.	O
Adults	O
admitted	B-T058
for	O
inpatient	O
rehabilitation	B-T061
(	O
n=280	O
)	O
.	O
The	O
main	O
outcomes	O
were	O
demographic	O
(	O
e.g.	O
age	O
,	O
gender	O
,	O
discharge	B-T058
destination	O
)	O
and	O
clinical	O
outcomes	O
(	O
reason	B-T033
for	O
rehabilitation	B-T061
,	O
length	O
of	O
stay	O
,	O
Functional	O
Independence	O
Measure	O
,	O
CCI	O
and	O
CIRS	O
)	O
.	O
A	O
series	O
of	O
regression	O
analyses	O
were	O
performed	O
to	O
determine	O
the	O
influence	O
of	O
comorbidity	O
on	O
three	O
dependent	O
variables	O
:	O
LOS	O
in	O
rehabilitation	B-T061
;	O
2	O
)	O
the	O
change	O
in	O
Functional	O
Independence	O
Measure	O
-	O
motor	O
score	O
between	O
rehabilitation	B-T061
discharge	B-T058
and	O
admission	B-T058
;	O
and	O
3	O
)	O
the	O
discharge	B-T058
destination	O
(	O
home	O
vs	O
other	O
)	O
.	O
The	O
mean	O
age	O
was	O
57.7	O
years	O
,	O
there	O
were	O
slightly	O
more	O
females	O
(	O
51	O
%	O
)	O
,	O
most	O
(	O
95	O
%	O
)	O
patients	O
previously	O
lived	B-T033
at	I-T033
home	I-T033
with	O
family	O
or	O
other	O
relatives	O
(	O
63	O
%	O
)	O
.	O
The	O
most	O
common	O
reason	B-T033
for	O
rehabilitation	B-T061
was	O
orthopaedic	B-T061
or	O
other	O
conditions	O
(	O
52	O
%	O
)	O
and	O
most	O
(	O
80	O
%	O
)	O
people	O
were	O
discharged	B-T058
home	O
.	O
The	O
median	O
LOS	O
was	O
27	O
days	O
.	O
There	O
were	O
100	O
(	O
35.7	O
%	O
)	O
patients	O
who	O
had	O
no	O
comorbidity	O
recorded	O
using	O
the	O
CCI	O
,	O
112	O
(	O
40.0	O
%	O
)	O
and	O
26	O
(	O
9.3	O
%	O
)	O
who	O
three	O
or	O
more	O
.	O
All	O
patients	O
had	O
at	O
least	O
one	O
comorbidity	O
recorded	O
with	O
the	O
CIRS	O
,	O
and	O
264	O
(	O
94.3	O
%	O
)	O
had	O
3	O
or	O
more	O
comorbidities	O
.	O
There	O
was	O
little	O
or	O
no	O
difference	O
between	O
the	O
CCI	O
or	O
CIRS	O
in	O
terms	O
of	O
their	O
ability	O
to	O
explain	O
the	O
variance	O
in	O
LOS	O
(	O
adjusted	O
R2	O
=	O
0.38	O
with	O
and	O
without	O
comorbidities	O
)	O
,	O
change	O
in	O
disability	B-T033
during	O
rehabilitation	B-T061
(	O
adjusted	O
R2	O
=	O
0.31	O
-	O
0.33	O
with	O
and	O
without	O
comorbidities	O
)	O
or	O
the	O
discharge	B-T058
destination	O
(	O
AUC=0.72	O
without	O
comorbidities	O
;	O
0.73	O
-	O
0.74	O
with	O
comorbidities	O
)	O
beyond	O
that	O
accounted	O
for	O
by	O
demographic	O
and	O
clinical	O
information	O
.	O
Neither	O
the	O
CIRS	O
nor	O
the	O
CCI	O
in	O
our	O
patient	O
sample	O
provide	O
additional	O
information	O
that	O
explains	O
the	O
impact	O
of	O
comorbidities	O
on	O
key	O
rehabilitation	B-T061
outcomes	O
.	O
Further	O
research	O
is	O
needed	O
to	O
determine	O
the	O
most	O
appropriate	O
measure	O
of	O
comorbidity	O
of	O
relevance	O
to	O
inpatient	O
rehabilitation	B-T061
outcomes	O
.	O
      
Loss	O
of	O
control	O
over	O
alcohol	O
seeking	O
in	O
rats	O
depends	O
on	O
individual	O
vulnerability	B-T033
and	O
duration	O
of	O
alcohol	O
consumption	O
experience	O
Alcohol	B-T048
use	I-T048
disorder	I-T048
(	O
AUD	B-T048
)	O
is	O
characterized	O
by	O
excessive	B-T033
alcohol	I-T033
use	I-T033
and	O
persistent	O
alcohol	O
seeking	O
despite	O
knowledge	O
of	O
its	O
negative	O
consequences	O
.	O
Importantly	O
,	O
AUD	B-T048
typically	O
develops	O
after	O
chronic	O
excessive	B-T033
alcohol	I-T033
use	I-T033
in	O
a	O
subgroup	O
of	O
individuals	O
who	O
drink	B-T033
alcohol	I-T033
,	O
suggesting	O
that	O
AUD	B-T048
results	O
from	O
an	O
interaction	O
between	O
individual	O
vulnerability	B-T033
and	O
prolonged	O
alcohol	O
exposure	O
.	O
The	O
present	O
study	O
assessed	O
the	O
contribution	O
of	O
prolonged	O
exposure	O
to	O
alcohol	O
and	O
individual	O
levels	O
of	O
alcohol	O
intake	O
to	O
the	O
development	O
of	O
loss	O
of	O
control	O
over	O
alcohol	O
seeking	O
in	O
a	O
conditioned	O
suppression	O
model	O
.	O
To	O
investigate	O
the	O
impact	O
of	O
prolonged	O
alcohol	O
exposure	O
,	O
conditioned	O
suppression	O
of	O
alcohol	O
seeking	O
was	O
assessed	O
after	O
2	O
and	O
4	O
months	O
of	O
intermittent	O
alcohol	O
access	O
(	O
IAA	O
)	O
in	O
a	O
subgroup	O
of	O
rats	O
drinking	O
moderate	O
amounts	O
of	O
alcohol	O
.	O
We	O
observed	O
that	O
suppression	O
of	O
alcohol	O
seeking	O
was	O
reduced	O
after	O
4	O
months	O
compared	O
with	O
2	O
months	O
of	O
IAA	O
.	O
The	O
influence	O
of	O
individual	O
levels	O
of	O
alcohol	O
intake	O
on	O
loss	O
of	O
control	O
over	O
alcohol	O
seeking	O
was	O
subsequently	O
determined	O
by	O
assessing	O
conditioned	O
suppression	O
in	O
subgroups	O
of	O
low	O
and	O
high	O
alcohol	O
drinking	O
rats	O
.	O
Unlike	O
the	O
low	O
alcohol	O
drinking	O
rats	O
,	O
the	O
high	O
alcohol	O
drinking	O
rats	O
showed	O
aversion	O
-	O
resistant	O
alcohol	O
seeking	O
after	O
2	O
months	O
of	O
IAA	O
,	O
although	O
both	O
groups	O
showed	O
comparable	O
levels	O
of	O
conditioned	O
freezing	O
.	O
These	O
findings	O
show	O
that	O
the	O
development	O
of	O
loss	O
of	O
control	O
over	O
alcohol	O
seeking	O
,	O
a	O
key	O
characteristic	O
of	O
AUD	B-T048
in	O
humans	O
,	O
is	O
dependent	O
on	O
both	O
the	O
extent	O
of	O
alcohol	O
exposure	O
and	O
the	O
individual	O
's	O
propensity	O
to	O
consume	O
alcohol	O
.	O
      
Identification	O
of	O
protective	O
B	O
-	O
cell	O
epitopes	O
within	O
the	O
novel	O
malaria	B-T121
vaccine	I-T121
candidate	O
P.	O
falciparum	O
Schizont	O
Egress	O
Antigen-1	O
Naturally	O
-acquired	O
antibodies	O
to	O
PfSEA-1A	O
are	O
associated	O
with	O
protection	O
against	O
severe	O
malaria	B-T047
in	O
children	O
.	O
Vaccination	B-T061
of	O
mice	O
with	O
PbSEA-1A	O
decreases	O
parasitemia	B-T047
and	O
prolongs	O
survival	O
following	O
Plasmodium	O
berghei	O
ANKA	O
challenge	O
.	O
To	O
enhance	O
the	O
immunogenicity	O
of	O
PfSEA-1A	O
,	O
we	O
identified	O
five	O
linear	O
,	O
B	O
-	O
cell	O
epitopes	O
using	O
peptide	O
microarrays	O
probed	O
with	O
anti	B-T121
-	I-T121
sera	I-T121
from	O
rPfSEA-1A	O
-	O
vaccinated	B-T033
non	O
-	O
human	O
primates	O
.	O
We	O
evaluated	B-T058
the	O
relationship	O
between	O
epitope	O
-specific	O
antibody	O
levels	O
and	O
protection	O
from	O
parasitemia	B-T047
in	O
a	O
longitudinal	O
treatment	B-T061
-	O
reinfection	O
cohort	O
in	O
Western	O
Kenya	O
.	O
Antibodies	O
to	O
three	O
epitopes	O
were	O
associated	O
with	O
16	O
-	O
17	O
%	O
decreased	O
parasitemia	B-T047
over	O
an	O
18-	O
week	O
high	O
transmission	O
season	O
.	O
We	O
are	O
currently	O
designing	O
immunogens	B-T121
to	O
enhance	O
antibody	O
responses	O
to	O
these	O
three	O
epitopes	O
.	O
      
A	O
single	O
session	O
of	O
exhaustive	O
exercise	O
markedly	O
decreases	O
circulating	O
levels	O
of	O
guanidinoacetic	B-T121
acid	I-T121
in	O
healthy	O
men	O
and	O
women	O
We	O
evaluated	B-T058
the	O
effects	O
of	O
exercise	O
on	O
circulating	O
concentrations	O
of	O
guanidinoacetic	B-T121
acid	I-T121
(	O
GAA	B-T121
)	O
and	O
creatine	O
in	O
23	O
healthy	O
volunteers	O
subjected	O
to	O
running	O
to	O
exhaustion	B-T184
and	O
free	O
-	O
weight	O
bench	O
-	O
press	O
to	O
volitional	O
failure	O
.	O
Blood	O
was	O
taken	O
before	O
and	O
following	O
each	O
exercise	O
session	O
.	O
Running	O
induced	O
a	O
significant	O
decrease	O
in	O
serum	O
GAA	B-T121
by	O
20.1	O
%	O
(	O
P	O
<	O
0.001	O
)	O
,	O
while	O
free	O
-	O
weight	O
exercise	O
reduced	O
GAA	B-T121
by	O
11.7	O
%	O
(	O
P	O
<	O
0.001	O
)	O
,	O
suggesting	O
the	O
possible	O
use	O
of	O
serum	O
GAA	B-T121
as	O
a	O
novel	O
biomarker	O
of	O
exhaustion	B-T184
.	O
      
Risk	B-T033
Factors	I-T033
of	O
Neurological	B-T184
Deterioration	I-T184
in	O
Patients	O
with	O
Cerebral	B-T047
Infarction	I-T047
due	O
to	O
Large	B-T047
-	I-T047
Artery	I-T047
Atherosclerosis	I-T047
In	O
some	O
patients	O
with	O
acute	O
ischemic	B-T047
stroke	I-T047
,	O
neurological	B-T184
deterioration	I-T184
(	O
ND	B-T184
)	O
is	O
observed	O
,	O
and	O
it	O
is	O
difficult	O
to	O
predict	O
at	O
the	O
time	O
of	O
admission	O
.	O
Especially	O
in	O
some	O
patients	O
with	O
large	B-T047
-	I-T047
artery	I-T047
atherosclerosis	I-T047
(	O
LAA	B-T047
)	O
,	O
aggressive	O
medical	B-T058
treatments	I-T058
and	O
surgical	B-T058
interventions	I-T058
might	O
be	O
helpful	O
to	O
prevent	O
ND	B-T184
.	O
Therefore	O
,	O
we	O
investigated	O
factors	O
associated	O
with	O
ND	B-T184
in	O
patients	O
with	O
LAA	B-T047
.	O
We	O
studied	O
patients	O
with	O
LAA	B-T047
who	O
were	O
admitted	B-T058
to	I-T058
our	I-T058
hospital	I-T058
.	O
We	O
divided	O
them	O
into	O
2	O
groups	O
with	O
(	O
group	O
1	O
)	O
and	O
without	O
deterioration	O
(	O
group	O
2	O
)	O
,	O
and	O
evaluated	B-T058
their	O
medical	O
records	O
,	O
risk	B-T033
factors	I-T033
,	O
and	O
radiological	O
findings	B-T033
,	O
such	O
as	O
number	O
of	O
diffusion	O
-	O
positive	B-T033
lesion	B-T033
and	O
degree	O
of	O
stenosis	O
.	O
Our	O
study	O
population	O
consisted	O
of	O
171	O
patients	O
;	O
71	O
(	O
41.5	O
%	O
)	O
did	O
and	O
100	O
(	O
58.5	O
%	O
)	O
did	O
not	O
suffer	B-T048
deterioration	O
.	O
By	O
univariate	O
analysis	O
,	O
blood	O
pressure	O
(	O
BP	O
)	O
,	O
heart	O
rate	O
,	O
National	B-T033
Institutes	I-T033
of	I-T033
Health	I-T033
Stroke	I-T033
Scale	I-T033
(	I-T033
NIHSS	I-T033
)	I-T033
score	I-T033
,	O
number	O
of	O
diffusion	O
-	O
positive	B-T033
lesion	B-T033
,	O
count	B-T059
of	I-T059
red	I-T059
blood	I-T059
cell	I-T059
,	O
high	O
-	O
density	O
lipoprotein	O
,	O
and	O
degree	O
of	O
stenosis	O
differed	O
significantly	O
between	O
the	O
2	O
groups	O
.	O
By	O
multivariate	O
analysis	O
,	O
systolic	O
BP	O
(	O
≥170	O
mm	O
Hg	O
,	O
odds	O
ratio	O
:	O
7.20	O
,	O
P	O
<	O
.001	O
)	O
was	O
associated	O
with	O
ND	B-T184
.	O
Furthermore	O
,	O
number	O
of	O
diffusion	B-T060
-	I-T060
weighted	I-T060
image	I-T060
DWI	B-T060
(	O
DWI)-	O
positive	B-T033
lesion	B-T033
(	O
≥8	O
)	O
,	O
degree	O
of	O
stenosis	O
(	O
>	O
80.0	O
%	O
)	O
,	O
and	O
NIHSS	B-T033
score	I-T033
(	O
≥4	O
)	O
were	O
also	O
independent	O
factors	O
associated	O
with	O
ND	B-T184
.	O
High	B-T047
BP	I-T047
,	O
severity	O
of	O
neurological	B-T033
deficit	I-T033
at	O
the	O
time	O
of	O
admission	O
,	O
and	O
radiological	O
findings	B-T033
,	O
such	O
as	O
degree	O
of	O
stenosis	O
and	O
number	O
of	O
DWI	B-T060
-	O
positive	B-T033
lesion	B-T033
,	O
are	O
independently	B-T033
associated	O
with	O
ND	B-T184
in	O
patients	O
with	O
LAA	B-T047
.	O
      
A	O
Recombinant	O
Human	O
Anti	O
-	O
Platelet	O
scFv	O
Antibody	O
Produced	O
in	O
Pichia	O
pastoris	O
for	O
Atheroma	O
Targeting	O
Cells	O
of	O
the	O
innate	O
and	O
adaptive	O
immune	O
system	O
are	O
key	O
factors	O
in	O
the	O
progression	O
of	O
atherosclerotic	O
plaque	O
,	O
leading	O
to	O
plaque	B-T033
instability	B-T033
and	O
rupture	O
,	O
potentially	O
resulting	O
in	O
acute	O
atherothrombotic	B-T020
events	O
such	O
as	O
coronary	B-T047
artery	I-T047
disease	I-T047
,	O
cerebrovascular	B-T047
disease	I-T047
and	O
peripheral	B-T047
arterial	I-T047
disease	I-T047
.	O
Here	O
,	O
we	O
describe	O
the	O
cloning	O
,	O
expression	O
,	O
purification	O
,	O
and	O
immunoreactivity	O
assessment	B-T058
of	O
a	O
recombinant	B-T001
single	O
-	O
chain	O
variable	O
fragment	O
(	O
scFv	O
)	O
derived	O
from	O
a	O
human	O
anti	O
-	O
αIIbβ3	O
antibody	O
(	O
HuAb	O
)	O
selected	O
to	O
target	O
atheromatous	O
lesions	B-T033
for	O
the	O
presence	B-T033
of	O
platelets	O
.	O
Indeed	O
,	O
platelets	O
within	O
atheroma	O
plaques	O
have	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
inflammation	O
,	O
in	O
platelet	O
-	O
leucocyte	O
aggregates	O
and	O
in	O
thrombi	O
formation	O
and	O
might	O
thus	O
be	O
considered	O
relevant	O
biomarkers	O
of	O
atherosclerotic	O
progression	O
.	O
The	O
DNA	O
sequence	O
that	O
encodes	O
the	O
anti	O
-	O
αIIbβ3	O
TEG4	O
scFv	O
previously	O
obtained	O
from	O
a	O
phage	O
-	O
display	O
selection	O
on	O
activated	O
platelets	O
,	O
was	O
inserted	O
into	O
the	O
eukaryote	O
vector	O
(	O
pPICZαA	O
)	O
in	O
fusion	O
with	O
a	O
tag	O
sequence	O
encoding	O
2	O
cysteines	O
useable	O
for	O
specific	O
probes	O
grafting	B-T059
experiments	I-T059
.	O
The	O
recombinant	O
protein	O
was	O
expressed	O
at	O
high	O
yields	O
in	O
Pichia	O
pastoris	O
(	O
30	O
mg	O
/	O
L	O
culture	O
)	O
.	O
The	O
advantage	O
of	O
P.	O
pastoris	O
as	O
an	O
expression	O
system	O
is	O
the	O
production	O
and	O
secretion	O
of	O
recombinant	O
proteins	O
in	O
the	O
supernatant	O
,	O
ruling	O
out	O
the	O
difficulties	O
encountered	O
when	O
scFv	O
are	O
produced	O
in	O
the	O
cytoplasm	O
of	O
bacteria	B-T007
(	O
low	O
yield	O
,	O
low	O
solubility	O
and	O
reduced	O
affinity	O
)	O
.	O
The	O
improved	B-T033
conditions	O
allowed	O
for	O
the	O
recovery	O
of	O
highly	O
purified	O
and	O
biologically	O
active	O
scFv	O
fragments	O
ready	O
to	O
be	O
grafted	O
in	O
a	O
site	O
-directed	O
way	O
to	O
nanoparticles	O
for	O
the	O
imaging	B-T060
of	O
atherosclerotic	O
plaques	O
involving	O
inflammatory	O
processes	O
and	O
thus	O
at	O
high	B-T033
risk	I-T033
of	I-T033
instability	B-T033
.	O
      
Novel	O
insights	O
into	O
development	O
of	O
diabetic	B-T033
bladder	B-T047
disorder	I-T047
provided	O
by	O
metabolomic	O
analysis	O
of	O
the	O
rat	O
nondiabetic	O
and	O
diabetic	B-T033
detrusor	B-T023
and	O
urothelial	O
layer	O
There	O
are	O
at	O
present	O
no	O
published	O
studies	O
providing	O
a	O
global	O
overview	O
of	O
changes	O
in	O
bladder	B-T023
metabolism	O
resulting	O
from	O
diabetes	B-T047
.	O
Such	O
studies	O
have	O
the	O
potential	O
to	O
provide	O
mechanistic	O
insight	O
into	O
the	O
development	O
of	O
diabetic	B-T033
bladder	B-T047
disorder	I-T047
(	I-T047
DBD	I-T047
)	I-T047
.	O
In	O
the	O
present	O
study	O
,	O
we	O
compared	O
the	O
metabolome	O
of	O
detrusor	B-T023
and	O
urothelial	O
layer	O
in	O
a	O
1	O
-	O
mo	O
streptozotocin	B-T195
-induced	O
rat	O
model	B-T050
of	O
type	B-T047
1	I-T047
diabetes	I-T047
with	O
nondiabetic	O
controls	O
.	O
Our	O
studies	O
revealed	O
that	O
diabetes	B-T047
caused	O
both	O
common	O
and	O
differential	O
changes	O
in	O
the	O
detrusor	B-T023
and	O
urothelial	O
layer	O
's	O
metabolome	O
.	O
Diabetes	B-T047
resulted	O
in	O
similar	O
changes	O
in	O
the	O
levels	O
of	O
previously	O
described	O
diabetic	B-T047
markers	O
in	O
both	O
tissues	O
,	O
such	O
as	O
glucose	B-T121
,	O
lactate	B-T121
,	O
2	O
-	O
hydroxybutyrate	O
,	O
branched	O
-	O
chain	O
amino	O
acid	O
degradation	O
products	O
,	O
bile	O
acids	O
,	O
and	O
1,5	O
-	O
anhydroglucitol	O
,	O
as	O
well	O
as	O
markers	O
of	O
oxidative	O
stress	O
.	O
In	O
the	O
detrusor	B-T023
(	O
but	O
not	O
the	O
urothelial	O
layer	O
)	O
,	O
diabetes	B-T047
caused	O
activation	O
of	O
the	O
pentose	O
-	O
phosphate	O
and	O
polyol	O
pathways	O
,	O
concomitant	O
with	O
a	O
reduction	O
in	O
the	O
TCA	O
cycle	O
and	O
β	O
-	O
oxidation	O
.	O
Changes	O
in	O
detrusor	B-T023
energy	O
-	O
generating	O
pathways	O
resulted	O
in	O
an	O
accumulation	O
of	O
sorbitol	B-T121
that	O
,	O
through	O
generation	O
of	O
advanced	O
glycation	O
end	O
products	O
,	O
is	O
likely	O
to	O
play	O
a	O
central	O
role	O
in	O
the	O
development	O
of	O
DBD	B-T047
.	O
In	O
the	O
diabetic	B-T033
urothelial	O
layer	O
there	O
was	O
decreased	O
flux	O
of	O
glucose	B-T121
via	O
glycolysis	O
and	O
changes	O
in	O
lipid	O
metabolism	O
,	O
particularly	O
prostaglandin	B-T121
synthesis	O
,	O
which	O
also	O
potentially	O
contributes	O
to	O
detrusor	B-T023
dysfunction	O
.	O
      
Penile	B-T020
Erosion	I-T020
in	O
a	O
Paraplegic	B-T047
Man	O
With	O
Indwelling	O
Urinary	O
Catheter	O
and	O
Scrotal	B-T033
Edema	I-T033
The	O
chronic	O
use	O
of	O
urinary	O
indwelling	O
catheters	O
is	O
a	O
common	O
practice	O
in	O
the	O
setting	O
of	O
long	O
-	O
term	O
patient	B-T058
care	I-T058
and	O
is	O
associated	O
with	O
numerous	O
complications	O
.	O
More	O
awareness	O
about	O
urogenital	O
trauma	O
from	O
urinary	B-T061
catheterization	I-T061
is	O
needed	O
,	O
as	O
it	O
is	O
as	O
common	O
as	O
symptomatic	O
urinary	B-T047
tract	I-T047
infections	I-T047
.	O
There	O
are	O
a	O
number	O
of	O
preventable	O
measures	O
that	O
can	O
be	O
taken	O
to	O
decrease	O
the	O
risk	O
of	O
mechanical	O
trauma	O
to	O
the	O
urethra	B-T023
and	O
glans	B-T023
penis	I-T023
caused	O
by	O
chronic	O
catheterization	B-T061
.	O
We	O
present	O
a	O
case	O
of	O
a	O
27-	O
year	O
old	O
paraplegic	B-T047
male	O
needing	O
a	O
chronic	O
indwelling	O
catheter	O
that	O
acquired	O
ventral	O
penile	B-T020
erosion	I-T020
while	O
being	O
cared	O
for	O
in	O
the	O
ICU	O
setting	O
.	O
      
Straight	B-T023
configuration	I-T023
saphenous	I-T023
vein	I-T023
transposition	B-T061
to	O
popliteal	B-T023
artery	I-T023
for	O
vascular	O
access	O
The	O
saphenous	B-T023
vein	I-T023
is	O
commonly	O
used	O
as	O
a	O
vascular	B-T023
graft	I-T023
in	O
peripheral	B-T023
artery	I-T023
surgery	B-T061
but	O
rarely	O
used	O
for	O
vascular	O
access	O
.	O
The	O
literature	O
on	O
straight	B-T023
configuration	I-T023
saphenous	I-T023
vein	I-T023
transposition	B-T061
to	O
the	O
popliteal	B-T023
artery	I-T023
is	O
scarce	O
.	O
Here	O
we	O
present	O
two	O
cases	O
of	O
straight	B-T023
configuration	I-T023
saphenous	I-T023
vein	I-T023
transposition	B-T061
to	O
the	O
popliteal	B-T023
artery	I-T023
for	O
vascular	O
access	O
,	O
the	O
surgical	B-T060
technique	I-T060
and	O
respective	O
follow	B-T058
-	I-T058
up	I-T058
.	O
Two	O
young	O
men	O
,	O
aged	O
29	O
and	O
36	O
years	O
,	O
were	O
chosen	O
for	O
lower	B-T061
-	I-T061
limb	I-T061
vascular	I-T061
access	I-T061
for	O
hemodialysis	B-T061
.	O
The	O
first	O
patient	O
was	O
paraplegic	B-T047
since	O
birth	O
.	O
He	O
used	O
his	O
arms	O
to	O
move	O
so	O
upper	O
extremity	O
vascular	O
access	O
was	O
avoided	O
.	O
The	O
second	O
patient	O
presented	O
with	O
an	O
infected	B-T033
upper	O
extremity	O
arteriovenous	O
graft	O
(	O
AVG	O
)	O
and	O
after	O
multiple	O
closed	O
AVFs	B-T190
he	O
had	O
no	O
more	O
available	O
arm	B-T023
veins	I-T023
.	O
Both	O
patients	O
received	O
autologous	O
lower	B-T023
extremity	I-T023
straight	B-T023
configuration	I-T023
saphenous	I-T023
vein	I-T023
transpositions	B-T061
to	O
the	O
popliteal	B-T023
artery	I-T023
under	O
spinal	B-T061
anesthesia	I-T061
in	O
May	O
and	O
October	O
2012	O
,	O
respectively	O
.	O
Cannulation	B-T061
of	O
the	O
fistula	B-T190
was	O
allowed	O
after	O
one	O
month	O
.	O
There	O
were	O
no	B-T184
early	I-T184
complications	I-T184
.	O
Slight	B-T033
swelling	I-T033
on	O
the	O
leg	B-T023
appeared	O
in	O
one	O
of	O
the	O
patients	O
.	O
Both	O
fistulas	B-T190
were	O
still	O
functional	O
after	O
36	O
and	O
32	O
months	O
,	O
respectively	O
.	O
The	O
straight	B-T023
configuration	I-T023
saphenous	I-T023
vein	I-T023
transposition	B-T061
to	O
popliteal	B-T023
artery	I-T023
is	O
simple	O
to	O
perform	O
,	O
offers	O
a	O
long	O
and	O
straight	O
segment	O
for	O
cannulation	B-T061
and	O
may	O
be	O
a	O
suitable	O
autologous	O
vascular	O
access	O
in	O
selected	O
patients	O
.	O
      
DNA	O
annealing	O
by	O
Redβ	O
is	O
insufficient	O
for	O
homologous	O
recombination	O
and	O
the	O
additional	O
requirements	O
involve	O
intra-	O
and	O
inter	O
-	O
molecular	O
interactions	O
Single	O
strand	O
annealing	O
proteins	O
(	O
SSAPs	O
)	O
like	O
Redβ	O
initiate	O
homologous	O
recombination	O
by	O
annealing	O
complementary	O
DNA	O
strands	O
.	O
We	O
show	O
that	O
C	O
-	O
terminally	O
truncated	O
Redβ	O
,	O
whilst	O
still	O
able	O
to	O
promote	O
annealing	O
and	O
nucleoprotein	O
filament	O
formation	O
,	O
is	O
unable	O
to	O
mediate	O
homologous	O
recombination	O
.	O
Mutations	O
of	O
the	O
C	O
-	O
terminal	O
domain	O
were	O
evaluated	O
using	O
both	O
single	O
-	O
and	O
double	O
stranded	O
(	O
ss	O
and	O
ds	O
)	O
substrates	O
in	O
recombination	O
assays	B-T059
.	O
Mutations	B-T059
of	O
critical	B-T121
amino	I-T121
acids	I-T121
affected	O
either	O
dsDNA	O
recombination	O
or	O
both	O
ssDNA	O
and	O
dsDNA	O
recombination	O
indicating	O
two	O
separable	O
functions	O
,	O
one	O
of	O
which	O
is	O
critical	O
for	O
dsDNA	O
recombination	O
and	O
the	O
second	O
for	O
recombination	O
per	O
se	O
.	O
As	O
evaluated	O
by	O
co	B-T059
-	I-T059
immunoprecipitation	I-T059
experiments	I-T059
,	O
the	O
dsDNA	O
recombination	O
function	O
relates	O
to	O
the	O
Redα	O
-	O
Redβ	O
protein	O
-	O
protein	O
interaction	O
,	O
which	O
requires	O
not	O
only	O
contacts	O
in	O
the	O
C	O
-	O
terminal	O
domain	O
but	O
also	O
a	O
region	O
near	O
the	O
N	O
-	O
terminus	O
.	O
Because	O
the	O
nucleoprotein	O
filament	O
formed	O
with	O
C	O
-	O
terminally	O
truncated	O
Redβ	O
has	O
altered	O
properties	O
,	O
the	O
second	O
C	O
-	O
terminal	O
function	O
could	O
be	O
due	O
to	O
an	O
interaction	O
required	O
for	O
functional	O
filaments	O
.	O
Alternatively	O
the	O
second	O
C	O
-	O
terminal	O
function	O
could	O
indicate	O
a	O
requirement	O
for	O
a	O
Redβ	O
-	O
host	O
factor	O
interaction	O
.	O
These	O
data	O
further	O
advance	O
the	O
model	O
for	O
Red	O
recombination	O
and	O
the	O
proposition	O
that	O
Redβ	O
and	O
RAD52	O
SSAPs	O
share	O
ancestral	O
and	O
mechanistic	O
roots	O
.	O
      
Supramolecular	O
Recognition	O
of	O
Amino	B-T121
Acids	I-T121
by	O
Twisted	O
Cucurbit[14]uril	O
Binding	O
interactions	O
between	O
twisted	O
cucurbit[14]uril	O
(	O
tQ[14	O
]	O
)	O
and	O
twenty	O
standard	O
amino	B-T121
acids	I-T121
(	B-T121
AAs	I-T121
)	I-T121
have	O
been	O
investigated	O
by	O
NMR	B-T060
spectroscopy	I-T060
and	O
isothermal	B-T059
titration	I-T059
calorimetry	I-T059
(	B-T059
ITC	I-T059
)	I-T059
in	O
aqueous	B-T121
HCl	O
solutions	O
and	O
in	O
DMSO	B-T121
.	O
The	O
results	O
showed	O
that	O
tQ[14	O
]	O
displays	O
clear	O
binding	O
affinity	O
for	O
AAs	B-T121
with	O
a	O
positively	O
charged	O
side	O
chain	O
or	O
containing	O
an	O
aromatic	O
ring	O
,	O
but	O
weaker	O
binding	O
affinity	O
for	O
AAs	B-T121
with	O
hydrophobic	O
or	O
polar	O
side	O
chains	O
,	O
with	O
the	O
binding	O
mode	O
depending	O
on	O
the	O
type	O
of	O
side	O
chain	O
present	O
in	O
the	O
AAs	B-T121
.	O
      
Downregulation	O
of	O
Endothelial	O
Transient	O
Receptor	O
Potential	O
Vanilloid	O
Type	O
4	O
Channel	O
and	O
Small	O
-	O
Conductance	O
of	O
Ca2	O
+	O
-Activated	O
K+	O
Channels	O
Underpins	O
Impaired	O
Endothelium	O
-	O
Dependent	O
Hyperpolarization	O
in	O
Hypertension	B-T047
Endothelium	O
-	O
dependent	O
hyperpolarization	O
(	O
EDH)-mediated	O
responses	B-T033
are	O
impaired	O
in	O
hypertension	B-T047
,	O
but	O
the	O
underlying	O
mechanisms	O
have	O
not	O
yet	O
been	O
determined	O
.	O
The	O
activation	O
of	O
small-	O
and	O
intermediate	O
-	O
conductance	O
of	O
Ca(2+)-activated	O
K(+	O
)	O
channels	O
(	O
SKCa	O
and	O
IKCa	O
)	O
underpins	O
EDH	O
-mediated	O
responses	B-T033
.	O
It	O
was	O
recently	O
reported	O
that	O
Ca(2	O
+	O
)	O
influx	O
through	O
endothelial	O
transient	O
receptor	O
potential	O
vanilloid	O
type	O
4	O
channel	O
(	O
TRPV4	O
)	O
is	O
a	O
prerequisite	O
for	O
the	O
activation	O
of	O
SKCa	O
/	O
IKCa	O
in	O
endothelial	O
cells	O
in	O
specific	O
beds	O
.	O
Here	O
,	O
we	O
attempted	O
to	O
determine	O
whether	O
the	O
impairment	O
of	O
EDH	O
in	O
hypertension	B-T047
is	O
attributable	O
to	O
the	O
dysfunction	O
of	O
TRPV4	O
and	O
S	O
/	O
IKCa	O
,	O
using	O
isolated	O
superior	B-T023
mesenteric	I-T023
arteries	I-T023
of	O
20	O
-	O
week	O
-	O
old	O
stroke	O
-	O
prone	O
spontaneously	O
hypertensive	O
rats	O
(	O
SHRSP	O
)	O
and	O
age	O
-	O
matched	O
Wistar	O
-	O
Kyoto	O
(	O
WKY	O
)	O
rats	O
.	O
In	O
the	O
WKY	O
arteries	B-T023
,	O
EDH	O
-mediated	O
responses	B-T033
were	O
reduced	O
by	O
a	O
combination	O
of	O
SKCa	O
/	O
IKCa	O
blockers	B-T121
(	O
apamin	O
plus	O
TRAM-34	B-T121
;	O
1-[(2	B-T121
-	I-T121
chlorophenyl)diphenylmethl]-1H	I-T121
-	I-T121
pyrazole	I-T121
)	O
and	O
by	O
the	O
blockade	O
of	O
TRPV4	O
with	O
the	O
selective	O
antagonist	O
RN-1734	O
or	O
HC-067047	B-T121
.	O
In	O
the	O
SHRSP	O
arteries	B-T023
,	O
EDH	O
-	O
mediated	O
hyperpolarization	O
and	O
relaxation	O
were	O
significantly	O
impaired	O
when	O
compared	O
with	O
WKY	O
.	O
GSK1016790A	O
,	O
a	O
selective	O
TRPV4	O
activator	B-T121
,	O
evoked	O
robust	O
hyperpolarization	O
and	O
relaxation	O
in	O
WKY	O
arteries	B-T023
.	O
In	O
contrast	O
,	O
in	O
SHRSP	O
arteries	B-T023
,	O
the	O
GSK1016790A	O
-evoked	O
hyperpolarization	O
was	O
small	O
and	O
relaxation	O
was	O
absent	O
.	O
Hyperpolarization	O
and	O
relaxation	O
to	O
cyclohexyl-[2-(3,5	B-T121
-	I-T121
dimethyl	I-T121
-	I-T121
pyrazol-1	I-T121
-	I-T121
yl)-6	I-T121
-	I-T121
methyl	I-T121
-	I-T121
pyrimidin-4	I-T121
-	I-T121
yl]-amine	I-T121
,	O
a	O
selective	O
SKCa	O
activator	B-T121
,	O
were	O
marginally	O
decreased	O
in	O
SHRSP	O
arteries	B-T023
compared	O
with	O
WKY	O
arteries	B-T023
.	O
The	O
expression	O
of	O
endothelial	O
TRPV4	O
and	O
SKCa	O
protein	O
was	O
significantly	O
decreased	O
in	O
the	O
SHRSP	O
mesenteric	B-T023
arteries	I-T023
compared	O
with	O
those	O
of	O
WKY	O
,	O
whereas	O
function	O
and	O
expression	O
of	O
IKCa	O
were	O
preserved	O
in	O
SHRSP	O
arteries	B-T023
.	O
These	O
findings	B-T033
suggest	O
that	O
EDH	O
-mediated	O
responses	B-T033
are	O
impaired	O
in	O
superior	B-T023
mesenteric	I-T023
arteries	I-T023
of	O
SHRSP	O
because	O
of	O
a	O
reduction	B-T061
in	O
both	O
TRPV4	O
and	O
SKCa	O
input	O
to	O
EDH	O
.	O
      
Silent	O
strain	O
of	O
caregiving	O
:	O
exploring	O
the	O
best	B-T033
predictors	I-T033
of	O
distress	B-T033
in	O
family	O
carers	O
of	O
geriatric	O
patients	O
The	O
aim	O
of	O
this	O
article	O
was	O
to	O
identify	O
the	O
best	B-T033
predictors	I-T033
of	O
distress	B-T033
suffered	I-T033
by	O
family	O
carers	O
(	O
FCs	O
)	O
of	O
geriatric	O
patients	O
.	O
A	O
cross	O
-	O
sectional	O
study	O
of	O
100	O
FC	O
-	O
geriatric	O
patient	O
dyads	O
was	O
conducted	O
.	O
The	O
negative	B-T033
impact	I-T033
of	I-T033
care	I-T033
(	O
NIoC	B-T033
)	O
subscale	O
of	O
the	O
COPE	O
index	O
was	O
dichotomized	O
to	O
identify	O
lower	B-T033
stress	I-T033
(	O
score	O
of	O
≤15	O
on	O
the	O
scale	O
)	O
and	O
higher	B-T033
stress	I-T033
(	O
score	O
of	O
≥16	O
on	O
the	O
scale	O
)	O
exerted	O
on	O
FCs	O
by	O
the	O
process	B-T058
of	I-T058
providing	I-T058
care	I-T058
.	O
The	O
set	O
of	O
explanatory	O
variables	B-T033
comprised	O
a	O
wide	O
range	O
of	O
sociodemographic	O
and	O
care	B-T058
-	I-T058
related	I-T058
attributes	I-T058
,	O
including	O
patient	B-T033
-	I-T033
related	I-T033
results	I-T033
from	O
comprehensive	O
geriatric	B-T058
assessments	I-T058
and	O
disease	B-T047
profiles	B-T058
.	O
The	O
best	O
combination	O
of	O
explanatory	O
variables	B-T033
that	O
provided	O
the	O
highest	O
predictive	O
powe	O
r	O
for	O
distress	B-T033
among	O
FCs	O
in	O
the	O
multiple	O
logistic	O
regression	O
(	O
LR	O
)	O
model	O
was	O
determined	O
according	O
to	O
statistical	O
information	O
criteria	O
.	O
The	O
statistical	O
robustness	O
of	O
the	O
observed	O
relationships	O
and	O
the	O
discriminative	O
power	O
of	O
the	O
model	O
were	O
verified	O
with	O
the	O
cross	O
-	O
validation	O
method	O
.	O
The	O
mean	O
age	O
of	O
FCs	O
was	O
57.2	O
(	O
±10.6	O
)	O
years	O
,	O
whereas	O
that	O
of	O
geriatric	O
patients	O
was	O
81.7	O
(	O
±6.4	O
)	O
years	O
.	O
Despite	O
the	O
broad	O
initial	O
set	O
of	O
potential	O
explanatory	O
variables	B-T033
,	O
only	O
five	O
predictors	B-T033
were	O
jointly	O
selected	O
for	O
the	O
best	O
statistical	O
model	O
.	O
A	O
higher	O
level	O
of	O
distress	B-T033
was	O
independently	O
predicted	O
by	O
lower	B-T058
self	I-T058
-	I-T058
evaluation	I-T058
of	I-T058
health	I-T058
;	O
worse	O
self	O
-	O
appraisal	O
of	O
coping	O
well	O
as	O
a	O
caregiver	O
;	O
lower	O
sense	O
of	O
general	B-T058
support	I-T058
;	O
more	O
hours	O
of	O
care	O
per	O
week	O
;	O
and	O
the	O
motor	B-T033
retardation	I-T033
of	O
the	O
cared	O
-for	O
person	O
measured	O
with	O
the	O
speed	O
of	O
the	O
Timed	B-T060
Up	I-T060
and	I-T060
Go	I-T060
(	I-T060
TUG	I-T060
)	I-T060
test	I-T060
.	O
Worse	O
performance	O
on	O
the	O
TUG	B-T060
test	I-T060
was	O
only	O
the	O
patient	O
-related	O
predictor	B-T033
of	O
distress	B-T033
among	O
the	O
variables	B-T033
NIoC	B-T033
examined	O
as	O
contributors	O
to	O
the	O
higher	O
NIoC.	O
Enhancing	O
the	O
mobility	B-T061
of	I-T061
geriatric	I-T061
patients	I-T061
through	O
suitably	O
tailored	O
kinesitherapeutic	B-T061
methods	I-T061
during	O
their	O
hospital	O
stay	O
may	O
mitigate	O
the	O
burden	O
endured	O
by	O
FCs	O
.	O
      
Inflammatory	O
and	O
Oxidative	O
Stress	O
Markers	O
in	O
Experimental	O
Allergic	B-T047
Asthma	I-T047
Ovalbumin	O
-	O
induced	O
allergic	B-T047
lung	I-T047
inflammation	I-T047
(	O
ALI	B-T047
)	O
is	O
a	O
condition	O
believed	O
to	O
be	O
mediated	O
by	O
cytokines	O
,	O
extracellular	O
matrix	O
remodeling	O
,	O
and	O
redox	O
imbalance	B-T184
.	O
In	O
this	O
study	O
,	O
we	O
evaluated	B-T058
pulmonary	O
function	O
together	O
with	O
inflammatory	O
markers	O
as	O
interleukin-4	O
(	O
IL-4	O
)	O
,	O
myeloperoxidase	O
(	O
MPO	O
)	O
,	O
eosinophil	O
cells	O
,	O
and	O
redox	O
markers	O
in	O
the	O
lungs	B-T023
of	O
BALB	O
/	O
c	O
mice	O
after	O
ovalbumin	O
(	O
OVA	O
)	O
sensitization	O
and	O
challenge	B-T059
.	O
Our	O
results	O
showed	O
an	O
increase	O
in	O
bronchial	B-T047
hyperresponsiveness	I-T047
stimulated	O
by	O
methacholine	B-T121
(	O
Mch	B-T121
)	O
,	O
inflammatory	O
cell	O
influx	O
,	O
especially	O
eosinophils	O
together	O
with	O
an	O
increase	O
of	O
high	O
mobility	O
group	O
box	O
1	O
(	O
HMGB1	O
)	O
and	O
altered	O
lipid	O
peroxidation	O
(	O
LP	O
)	O
and	O
antioxidant	B-T121
defenses	O
in	O
the	O
OVA	O
group	O
compared	O
to	O
the	O
control	O
group	O
(	O
p	O
≤	O
0.5	O
)	O
.	O
Thus	O
,	O
we	O
demonstrated	O
that	O
OVA	O
-	O
induced	O
ALI	B-T047
altered	O
redox	O
status	O
concomitantly	O
with	O
impaired	O
lung	O
function	O
,	O
which	O
was	O
associated	O
with	O
HMGB1	O
expression	O
and	O
proteolytic	O
remodeling	O
.	O
Taken	O
together	O
all	O
results	O
found	O
here	O
,	O
we	O
may	O
suggest	O
HMGB1	O
is	O
an	O
important	O
therapeutic	O
target	O
for	O
asthma	B-T047
,	O
once	O
orchestrates	O
the	O
redox	O
signaling	O
,	O
inflammation	O
,	O
and	O
remodeling	O
that	O
contribute	O
to	O
the	O
disease	B-T047
development	O
.	O
      
Case	O
Report	O
of	O
Necrotizing	B-T047
Fasciitis	I-T047
Associated	O
with	O
Streptococcus	B-T007
pneumoniae	I-T007
Necrotizing	B-T047
fasciitis	I-T047
,	O
caused	O
by	O
Streptococcus	B-T007
pneumoniae	I-T007
,	O
is	O
an	O
extremely	O
rare	O
and	O
life	B-T033
-	I-T033
threatening	I-T033
bacterial	B-T007
soft	B-T047
tissue	I-T047
infection	I-T047
.	O
We	O
report	B-T058
a	O
case	O
of	O
early	O
necrotizing	B-T047
fasciitis	I-T047
associated	O
with	O
Streptococcus	B-T007
pneumoniae	I-T007
infection	O
in	O
a	O
26-	O
year	O
-old	O
man	O
who	O
was	O
immunocompromised	B-T033
with	O
mixed	B-T047
connective	I-T047
tissue	I-T047
disease	I-T047
.	O
The	O
patient	O
presented	O
with	O
acute	O
,	O
painful	B-T184
,	O
erythematous	O
,	O
and	O
edematous	O
skin	O
lesions	B-T033
of	O
his	O
right	O
lower	O
back	O
,	O
which	O
rapidly	O
progressed	O
to	O
the	O
right	B-T023
knee	I-T023
.	O
The	O
patient	O
underwent	O
surgical	B-T060
exploration	I-T060
,	O
and	O
a	O
diagnosis	B-T033
of	O
necrotizing	B-T047
fasciitis	I-T047
was	O
confirmed	O
by	O
pathological	O
evidence	O
of	O
necrosis	O
of	O
the	O
fascia	O
and	O
neutrophil	O
infiltration	O
in	O
tissue	B-T060
biopsies	I-T060
.	O
Cultures	B-T059
of	O
fascial	O
tissue	B-T060
biopsies	I-T060
and	O
blood	O
samples	O
were	O
positive	B-T033
for	O
Streptococcus	B-T007
pneumoniae	I-T007
.	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	B-T058
of	O
necrotizing	B-T047
fasciitis	I-T047
resulting	O
from	O
Streptococcus	B-T007
pneumoniae	I-T007
diagnosed	B-T033
at	O
early	O
phase	O
;	O
the	O
patient	O
recovered	O
well	O
without	O
surgical	B-T061
debridement	I-T061
.	O
      
Spinal	B-T023
load	O
in	O
nurses	O
during	O
emergency	O
lifting	O
of	O
obese	B-T047
patients	O
:	O
preliminary	O
results	O
Nurses	O
are	O
exposed	O
to	O
the	O
risk	O
of	O
injury	O
while	O
handling	B-T033
patients	O
.	O
This	O
is	O
particularly	O
true	O
for	O
obese	B-T047
patients	O
.	O
The	O
goal	O
of	O
this	O
paper	O
is	O
to	O
estimate	O
the	O
spinal	B-T023
loads	O
and	O
the	O
related	O
risk	O
of	O
injury	O
to	O
nurses	O
while	O
lifting	O
obese	B-T047
patients	O
from	O
the	O
floor	O
with	O
a	O
bariatric	O
sheet	O
during	O
a	O
hospital	O
emergency	O
.	O
Six	O
male	O
nurses	O
participated	O
in	O
this	O
study	O
.	O
The	O
biomechanical	B-T060
analysis	I-T060
focused	O
on	O
the	O
lifting	O
strategy	O
.	O
Thirty	O
obese	B-T047
in	O
-	O
patients	O
were	O
enrolled	O
to	O
take	O
part	O
in	O
the	O
experimental	O
study	O
and	O
divided	O
into	O
three	O
groups	O
according	O
to	O
their	O
Body	O
Mass	O
Index	O
(	O
BMI	O
)	O
.	O
Three	B-T060
-	I-T060
dimensional	I-T060
motion	I-T060
analysis	I-T060
was	O
conducted	O
using	O
an	O
optoelectronic	O
system	O
.	O
The	O
trunk	O
kinematics	O
and	O
the	O
loading	O
on	O
the	O
spines	B-T023
of	O
the	O
operating	O
nurses	O
were	O
computed	B-T059
.	O
Our	O
data	O
showed	O
that	O
when	O
the	O
nurse	O
was	O
operating	O
from	O
the	O
central	O
handle	O
,	O
his	O
trunk	O
was	O
more	O
flexed	O
at	O
the	O
end	O
of	O
the	O
lift	O
with	O
a	O
reduced	O
range	O
of	O
motion	O
.	O
The	O
values	O
were	O
higher	O
when	O
the	O
nurse	O
lifted	O
patients	O
with	O
higher	O
BMIs	O
.	O
All	O
kinetic	O
parameters	O
and	O
tension	O
in	O
the	O
lumbar	B-T023
muscles	I-T023
at	O
the	O
end	O
of	O
the	O
movement	O
were	O
characterised	O
by	O
lower	O
values	O
for	O
the	O
nurse	O
placed	O
beside	O
the	O
patient	O
's	O
head	O
or	O
feet	B-T023
if	O
compared	O
to	O
the	O
operator	O
positioned	O
beside	O
the	O
central	O
handle	O
in	O
all	O
patient	O
groups	O
.	O
Our	O
preliminary	O
data	O
suggest	O
that	O
only	O
the	O
reaction	O
load	O
on	O
the	O
spine	B-T023
of	O
the	O
nurse	O
holding	O
the	O
central	O
handle	O
,	O
closest	O
to	O
the	O
patient	O
's	O
centre	O
of	O
mass	O
,	O
seems	O
to	O
exceed	O
the	O
recommended	O
safety	O
limits	O
.	O
      
Hyperandrogenemia	B-T033
in	O
women	O
with	O
polycystic	B-T047
ovary	I-T047
syndrome	I-T047
:	O
prevalence	O
,	O
characteristics	O
and	O
association	O
with	O
body	O
mass	O
index	O
Hyperandrogenemia	B-T033
is	O
one	O
of	O
the	O
major	O
diagnostic	O
features	O
for	O
the	O
diagnosis	B-T033
of	O
polycystic	B-T047
ovary	I-T047
syndrome	I-T047
(	O
PCOS	B-T047
)	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
estimate	O
the	O
prevalence	O
and	O
the	O
characteristics	O
of	O
hyperandrogenemia	B-T033
in	O
women	O
with	O
PCOS	B-T047
and	O
to	O
investigate	O
the	O
association	O
of	O
clinical	O
and	O
biochemical	O
characteristics	O
with	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
according	O
to	O
the	O
presence	B-T033
of	O
hyperandrogenemia	B-T033
.	O
We	O
studied	O
266	O
women	O
diagnosed	B-T033
with	O
PCOS	B-T047
.	O
Hyperandrogenemia	B-T033
was	O
defined	O
by	O
testosterone	B-T121
(	O
T	B-T121
)	O
and/or	O
free	O
testosterone	O
(	O
FT	O
)	O
and/or	O
∆4	B-T121
androstenedione	I-T121
(	O
Δ4	B-T121
-	I-T121
A	I-T121
)	O
higher	O
than	O
75	O
%	O
of	O
the	O
upper	O
limits	O
of	O
each	O
hormone	O
.	O
Patients	O
were	O
stratified	O
in	O
two	O
groups	O
according	O
to	O
a	O
BMI	O
threshold	O
of	O
25	O
kg	O
/	O
m2	O
.	O
Hyperandrogenemia	B-T033
was	O
present	B-T033
in	O
78.2	O
%	O
of	O
the	O
patients	O
.	O
Elevated	O
levels	O
of	O
T	B-T121
were	O
found	O
in	O
58.4	O
%	O
,	O
while	O
elevated	O
levels	O
of	O
FT	O
and	O
Δ4	B-T121
-	I-T121
A	I-T121
were	O
found	O
in	O
42.5	O
%	O
and	O
34.1	O
%	O
of	O
patients	O
.	O
In	O
normal	B-T033
weight	I-T033
women	O
(	O
BMI	O
≤25	O
kg	O
/	O
m2	O
)	O
with	O
hyperandrogenemia	B-T033
lower	O
values	O
of	O
hip	O
circumference	O
and	O
HOMA	B-T059
-	I-T059
IR	I-T059
and	O
increased	O
levels	O
of	O
T	B-T121
,	O
FT	O
,	O
Δ4	B-T121
-	I-T121
A	I-T121
,	O
17	B-T121
-	I-T121
hydroxyprogesterone	I-T121
(	O
17	B-T121
-	I-T121
OHP	I-T121
)	O
,	O
dehydroepiandrosterone	B-T121
sulfate	I-T121
(	O
DHEAS	B-T121
)	O
,	O
white	O
blood	O
cells	O
(	O
WBC	O
)	O
and	O
neutrophils	O
were	O
observed	O
compared	O
to	O
women	O
without	O
hyperandrogenemia	B-T033
.	O
Also	O
,	O
in	O
overweight	B-T184
women	O
higher	O
levels	O
of	O
T	B-T121
,	O
FT	O
,	O
Δ4	B-T121
-	I-T121
A	I-T121
,	O
17	B-T121
-	I-T121
OHP	I-T121
,	O
DHEAS	B-T121
and	O
cortisol	B-T121
were	O
measured	O
,	O
while	O
lower	O
thyroid	B-T059
-	I-T059
stimulating	I-T059
hormone	I-T059
(	I-T059
TSH	I-T059
)	I-T059
levels	I-T059
were	O
comparable	O
to	O
women	O
without	O
hyperandrogenemia	B-T033
.	O
This	O
study	O
showed	O
high	O
prevalence	O
of	O
hyperandrogenemia	B-T033
in	O
PCOS	B-T047
women	O
.	O
Women	O
with	O
BMI	O
≤25	O
kg	O
/	O
m2	O
have	O
significant	O
differences	O
in	O
androgens	B-T121
,	O
WBC	O
,	O
neutrophils	O
and	O
HOMA	B-T059
-	I-T059
IR	I-T059
and	O
women	O
with	O
BMI	O
≥25	O
kg	O
/	O
m2	O
in	O
androgens	B-T121
,	O
TSH	B-T121
and	O
cortisol	B-T121
according	O
to	O
the	O
presence	B-T033
or	O
not	O
of	O
hyperandrogenemia	B-T033
.	O
      
Predictors	O
and	O
Moderators	O
of	O
Spontaneous	O
Pretend	O
Play	O
in	O
Children	O
with	O
and	O
without	O
Autism	B-T048
Spectrum	I-T048
Disorder	I-T048
Although	O
pretend	O
play	O
has	O
long	O
been	O
linked	O
to	O
children	O
's	O
normative	O
cognitive	O
development	O
,	O
inconsistent	O
findings	B-T033
call	O
for	O
greater	O
rigor	O
in	O
examining	O
this	O
relation	O
(	O
Lillard	O
et	O
al	O
.	O
,	O
2013	O
)	O
.	O
Spontaneous	O
pretend	O
play	O
is	O
often	O
impacted	O
in	O
atypical	O
development	O
,	O
notably	O
in	O
autism	B-T048
spectrum	I-T048
disorder	I-T048
(	O
ASD	B-T048
)	O
.	O
Since	O
ASD	B-T048
traits	O
exist	O
along	O
a	O
continuum	O
in	O
the	O
general	O
population	O
,	O
investigating	O
how	O
pretend	O
play	O
varies	O
across	O
the	O
range	O
of	O
ASD	B-T048
symptoms	B-T184
by	O
indexing	O
variations	O
in	O
ASD	B-T048
traits	O
in	O
both	O
typically	O
developing	O
and	O
ASD	B-T048
populations	O
may	O
provide	O
insight	O
into	O
how	O
ASD	B-T048
symptoms	B-T184
may	O
influence	O
the	O
relation	O
between	O
pretend	O
play	O
and	O
associated	O
processes	O
in	O
cognitive	O
development	O
.	O
This	O
study	O
used	O
rigorous	O
observational	O
methods	O
to	O
assess	O
spontaneous	O
pretend	O
play	O
.	O
Specifically	O
,	O
5-	O
min	O
free	B-T058
-	I-T058
play	I-T058
sessions	I-T058
with	O
two	O
discrete	O
toy	O
sets	O
were	O
double	O
-	O
coded	O
by	O
blinded	O
coders	O
(	O
coder	O
assignment	O
counterbalanced	O
)	O
.	O
Key	O
facets	O
of	O
pretense	O
development	O
[	O
attribution	O
of	O
pretend	O
properties	O
(	O
APP	O
)	O
,	O
object	O
substitution	O
(	O
OS	O
)	O
,	O
imaginary	O
objects	O
]	O
were	O
examined	O
.	O
These	O
facets	O
of	O
pretend	O
play	O
production	O
were	O
then	O
analyzed	O
in	O
relation	O
to	O
ASD	B-T048
symptoms	B-T184
,	O
as	O
well	O
as	O
plausible	O
,	O
long	O
-	O
theorized	O
correlates	O
[	O
theory	O
of	O
mind	O
(	O
ToM	O
)	O
,	O
verbal	O
ability	O
,	O
familiarity	O
,	O
and	O
interest	O
in	O
specific	O
toys	O
]	O
.	O
Forty	O
children	O
(	O
Mage	O
=	O
6;5	O
,	O
SDage	O
=	O
1.45	O
;	O
29	O
males	O
)	O
,	O
six	O
of	O
whom	O
met	O
the	O
threshold	O
for	O
ASD	B-T048
diagnosis	B-T033
via	O
parent	O
-reported	O
ASD	B-T048
symptoms	B-T184
,	O
participated	O
in	O
play	B-T058
sessions	I-T058
and	O
completed	O
measures	O
of	O
verbal	O
IQ	O
and	O
ToM.	O
Besides	O
the	O
measure	O
of	O
child	O
ASD	B-T048
symptoms	B-T184
,	O
parents	O
completed	O
a	O
survey	O
of	O
their	O
child	O
's	O
interest	O
in	O
and	O
familiarity	O
with	O
the	O
play	B-T058
session	I-T058
toys	O
.	O
Overall	O
,	O
greater	O
ToM	O
predicted	O
more	O
APP	O
,	O
and	O
more	O
interest	O
in	O
the	O
toys	O
presented	O
predicted	O
more	O
OS	O
.	O
In	O
terms	O
of	O
overall	O
pretend	O
play	O
production	O
,	O
two	O
results	O
were	O
counterintuitive	O
.	O
First	O
,	O
among	O
children	O
with	O
more	O
ASD	B-T048
symptoms	B-T184
,	O
verbal	O
ability	O
marginally	O
negatively	O
predicted	O
pretend	O
play	O
production	O
.	O
Second	O
,	O
among	O
children	O
with	O
fewer	O
ASD	B-T048
symptoms	B-T184
,	O
ToM	O
negatively	O
predicted	O
pretend	O
play	O
production	O
.	O
Further	O
probing	O
revealed	O
that	O
the	O
negative	O
effect	O
of	O
ASD	B-T048
symptoms	B-T184
on	O
pretend	O
play	O
was	O
simultaneously	O
moderated	O
by	O
both	O
variables	O
:	O
low	O
ToM	O
and	O
high	O
verbal	O
ability	O
both	O
related	O
to	O
less	O
pretend	O
play	O
production	O
among	O
children	O
with	O
more	O
ASD	B-T048
symptoms	B-T184
.	O
Implications	O
for	O
assessment	O
and	O
subsequent	O
treatment	B-T061
for	O
pretend	O
ability	O
among	O
children	O
with	O
varying	O
degrees	O
of	O
ASD	B-T048
symptoms	B-T184
,	O
as	O
well	O
as	O
for	O
future	O
research	O
,	O
are	O
discussed	O
.	O
      
Binding	O
of	O
Pollutants	O
to	O
Biomolecules	O
:	O
A	O
Simulation	O
Study	O
A	O
number	O
of	O
cases	O
around	O
the	O
world	O
have	O
been	O
reported	O
where	O
animals	O
were	O
found	B-T033
dead	I-T033
or	O
dying	O
with	O
symptoms	B-T184
resembling	O
a	O
thiamine	B-T047
(	B-T047
vitamin	I-T047
B	I-T047
)	I-T047
deficiency	I-T047
,	O
and	O
for	O
some	O
of	O
these	O
,	O
a	O
link	O
to	O
pollutants	O
has	O
been	O
suggested	O
.	O
Here	O
,	O
we	O
investigate	B-T058
whether	O
biomolecules	O
involved	O
in	O
thiamin	O
binding	O
and	O
transport	O
could	O
be	O
blocked	O
by	O
a	O
range	O
of	O
different	O
pollutants	O
.	O
We	O
used	O
in	O
silico	O
docking	O
of	O
five	O
compound	O
classes	O
(	O
25	O
compounds	O
in	O
total	O
)	O
to	O
each	O
of	O
five	O
targets	O
(	O
prion	O
protein	O
,	O
ECF	O
-	O
type	O
ABC	O
transporter	O
,	O
thi	O
-	O
box	O
riboswitch	O
receptor	O
,	O
thiamin	O
pyrophosphokinase	O
,	O
and	O
YKoF	O
protein	O
)	O
and	O
subsequently	O
performed	O
molecular	O
dynamics	O
(	O
MD	O
)	O
simulations	O
to	O
assess	O
the	O
stability	O
of	O
the	O
complexes	O
.	O
The	O
compound	O
classes	O
were	O
thiamin	O
analogues	O
(	O
control	O
)	O
,	O
pesticides	O
,	O
veterinary	O
medicines	B-T121
,	O
polychlorinated	O
biphenyls	O
,	O
and	O
dioxins	O
,	O
all	O
of	O
which	O
are	O
prevalent	O
in	O
the	O
environment	O
to	O
some	O
extent	O
.	O
A	O
few	O
anthropogenic	O
compounds	O
were	O
found	O
to	O
bind	O
the	O
ECF	O
-	O
type	O
ABC	O
transporter	O
,	O
but	O
none	B-T033
binds	I-T033
stably	I-T033
to	O
prion	O
protein	O
.	O
For	O
the	O
riboswitch	O
,	O
most	O
compounds	O
remained	O
in	O
their	O
binding	O
pockets	O
during	O
50	O
ns	O
of	O
MD	O
simulation	O
,	O
indicating	O
that	O
RNA	O
provides	O
a	O
promiscuous	O
binding	O
site	O
.	O
In	O
both	O
YKoF	O
and	O
thiamin	O
pyrophosphokinase	O
(	O
TPK	O
)	O
,	O
most	O
compounds	O
remain	O
tightly	O
bound	O
.	O
However	O
,	O
TPK	O
biomolecules	O
undergo	O
pollutant	O
-	O
induced	O
conformational	O
changes	O
.	O
Although	O
most	O
compounds	O
are	O
found	O
to	O
bind	O
to	O
some	O
of	O
these	O
targets	O
,	O
a	O
larger	O
data	O
set	O
is	O
needed	O
along	O
with	O
more	O
quantitative	O
methods	O
like	O
free	O
energy	O
perturbation	O
calculations	O
before	O
firm	O
conclusions	O
can	O
be	O
drawn	O
.	O
This	O
study	O
is	O
in	O
part	O
a	O
test	O
bed	O
for	O
large	O
-	O
scale	O
quantitative	O
computational	B-T059
screening	I-T059
of	O
interactions	O
between	O
biological	O
entities	O
and	O
pollutant	O
molecules	O
.	O
      
Comparing	O
the	O
effects	O
of	O
different	O
dynamic	B-T061
sitting	I-T061
strategies	I-T061
in	O
wheelchair	O
seating	O
on	O
lumbar	O
-	O
pelvic	O
angle	O
Prolonged	O
static	B-T033
sitting	I-T033
in	O
a	O
wheelchair	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
lower	B-T184
back	I-T184
pain	I-T184
.	O
The	O
wheelchair	O
seating	O
system	O
is	O
a	O
key	O
factor	O
of	O
this	O
risk	O
because	O
it	O
affects	O
spinal	O
loading	O
in	O
the	O
sitting	B-T033
position	I-T033
.	O
In	O
this	O
study	O
,	O
7	O
dynamic	B-T061
sitting	I-T061
strategies	I-T061
(	O
DSSs	B-T061
)	O
are	O
examined	B-T033
:	O
lumbar	B-T061
prominent	I-T061
dynamic	I-T061
sitting	I-T061
(	O
LPDS	B-T061
)	O
,	O
back	B-T061
reclined	I-T061
dynamic	I-T061
sitting	I-T061
(	O
BRDS	B-T061
)	O
,	O
femur	B-T061
upward	I-T061
dynamic	I-T061
sitting	I-T061
(	O
FUDS	B-T061
)	O
,	O
lumbar	B-T061
prominent	I-T061
with	I-T061
back	I-T061
reclined	I-T061
dynamic	I-T061
sitting	I-T061
(	O
LBDS	B-T061
)	O
,	O
lumbar	B-T061
prominent	I-T061
with	I-T061
femur	I-T061
upward	I-T061
dynamic	I-T061
sitting	I-T061
(	O
LFDS	B-T061
)	O
,	O
back	B-T061
reclined	I-T061
with	I-T061
femur	I-T061
upward	I-T061
dynamic	I-T061
sitting	I-T061
(	O
BFDS	B-T061
)	O
,	O
and	O
lumbar	B-T061
prominent	I-T061
with	I-T061
back	I-T061
reclined	I-T061
with	I-T061
femur	I-T061
upward	I-T061
dynamic	I-T061
sitting	I-T061
(	O
LBFDS	B-T061
)	O
.	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
analyze	O
the	O
biomechanical	O
effects	O
of	O
these	O
sitting	B-T061
strategies	I-T061
on	O
lumbar	O
-	O
pelvic	O
angles	O
.	O
Twenty	O
able	B-T033
-	I-T033
bodied	I-T033
participants	O
were	O
recruited	O
for	O
the	O
study	O
.	O
All	O
participants	O
performed	O
LPDS	B-T061
,	O
BRDS	B-T061
,	O
FUDS	B-T061
,	O
LBDS	B-T061
,	O
LFDS	B-T061
,	O
BFDS	B-T061
,	O
and	O
LBFDS	B-T061
in	O
a	O
random	O
order	O
.	O
All	O
lumbar	O
-	O
pelvic	O
angle	O
parameters	O
,	O
including	O
the	O
static	O
lumbar	O
angle	O
,	O
static	O
pelvic	B-T023
angle	I-T023
,	O
lumbar	B-T033
range	I-T033
of	I-T033
motion	I-T033
,	O
and	O
pelvic	B-T033
range	I-T033
of	I-T033
motion	I-T033
were	O
measured	O
and	O
compared	O
.	O
Results	O
show	O
that	O
LBDS	B-T061
and	O
LBFDS	B-T061
enabled	O
the	O
most	O
beneficial	O
lumbar	O
movements	O
,	O
although	O
the	O
difference	O
between	O
the	O
2	O
strategies	O
was	O
nonsignificant	B-T033
.	O
BRDS	B-T061
and	O
BFDS	B-T061
enabled	O
the	O
most	O
beneficial	O
pelvic	B-T061
movements	I-T061
,	O
although	O
the	O
difference	O
between	O
the	O
2	O
strategies	O
was	O
nonsignificant	B-T033
.	O
Among	O
all	O
the	O
upright	O
DSSs	B-T061
,	O
LPDS	B-T061
and	O
LFDS	B-T061
enabled	O
the	O
most	O
beneficial	O
lumbar	O
and	O
pelvic	B-T061
movements	I-T061
,	O
although	O
no	B-T033
significant	I-T033
difference	O
was	O
observed	O
between	O
these	O
2	O
strategies	O
.	O
We	O
identified	O
the	O
effects	O
and	O
differences	O
among	O
7	O
DSSs	B-T061
on	O
lumbar	O
-	O
pelvic	O
angles	O
.	O
Wheelchair	O
users	O
can	O
choose	O
the	O
most	O
suitable	O
DSS	B-T061
that	O
meets	O
their	O
needs	O
.	O
These	O
findings	B-T033
may	O
serve	O
as	O
a	O
reference	O
for	O
practicing	O
physicians	O
or	O
wheelchair	O
users	O
to	O
choose	O
an	O
appropriate	O
dynamic	O
wheelchair	O
seating	O
system	O
.	O
ISRCTN12389808	O
,	O
18th	O
November	O
2016	O
,	O
retrospectively	O
registered	O
.	O
      
Propranolol	B-T121
Effects	O
on	O
Decompression	B-T047
Sickness	I-T047
in	O
a	O
Simulated	O
DISSUB	O
Rescue	O
in	O
Swine	O
Disabled	O
submarine	O
(	O
DISSUB	O
)	O
survivors	O
may	O
face	O
elevated	B-T033
CO2	I-T033
levels	I-T033
and	O
inert	O
gas	O
saturation	O
,	O
putting	O
them	O
at	O
risk	O
for	O
CO2	O
toxicity	O
and	O
decompression	B-T047
sickness	I-T047
(	O
DCS	B-T047
)	O
.	O
Propranolol	B-T121
was	O
shown	O
to	O
reduce	B-T059
CO2	I-T059
production	I-T059
in	O
an	O
experimental	O
DISSUB	O
model	O
in	O
humans	O
but	O
its	O
effects	O
on	O
DCS	B-T047
in	O
a	O
DISSUB	O
rescue	O
scenario	O
are	O
unknown	O
.	O
A	O
100	O
%	O
oxygen	O
prebreathe	O
(	O
OPB	O
)	O
reduces	O
DCS	B-T047
incidence	O
and	O
severity	O
and	O
is	O
incorporated	O
into	O
some	O
DISSUB	O
rescue	O
protocols	O
.	O
We	O
used	O
a	O
swine	O
model	O
of	O
DISSUB	O
rescue	O
to	O
study	O
the	O
effect	O
of	O
propranolol	B-T121
on	O
DCS	B-T047
incidence	O
and	O
mortality	O
with	O
and	O
without	O
an	O
OPB	O
.	O
In	O
Experiment	O
1	O
,	O
male	O
Yorkshire	O
Swine	O
(	O
70	O
kg	O
)	O
were	O
pressurized	O
to	O
2.8	O
ATA	O
for	O
22	O
h.	O
Propranolol	B-T121
1.0	O
mg	O
·	O
kg-1	O
(	O
IV	O
)	O
was	O
administered	O
at	O
21.25	O
h.	O
At	O
22	O
h	O
,	O
the	O
animal	O
was	O
rapidly	O
decompressed	O
and	O
observed	O
for	O
DCS	B-T047
type	O
,	O
onset	O
time	O
,	O
and	O
mortality	O
.	O
Experimental	O
animals	O
(	O
N	O
=	O
21	O
;	O
69	O
±	O
4.1	O
kg	O
)	O
,	O
PROP1.0	B-T121
,	O
were	O
compared	O
to	O
PROP1.0	B-T121
-	O
OPB45	O
(	O
N	O
=	O
8	O
;	O
69	O
±	O
2.8	O
kg	O
)	O
with	O
the	O
same	O
dive	O
profile	O
,	O
except	O
for	O
a	O
45	O
min	O
OPB	O
prior	O
to	O
decompression	O
.	O
In	O
Experiment	O
2	O
,	O
the	O
same	O
methodology	O
was	O
used	O
with	O
the	O
following	O
changes	O
:	O
swine	O
pressurized	O
to	O
2.8	O
ATA	O
for	O
28	O
h	O
;	O
experimental	O
group	O
(	O
N	O
=	O
25	O
;	O
67	O
±	O
3.3	O
kg	O
)	O
,	O
PROP0.5	B-T121
bis	O
,	O
propranolol	B-T121
0.5	O
mg	O
·	O
kg-1	O
bis	O
(	O
twice	O
)	O
(	O
IV	O
)	O
was	O
administered	O
at	O
22	O
h	O
and	O
26	O
h.	O
Control	O
animals	O
(	O
N	O
=	O
25	O
;	O
67	O
±	O
3.9	O
kg	O
)	O
received	O
normal	B-T121
saline	I-T121
.	O
OPB	O
reduced	O
mortality	O
in	O
PROP1.0	B-T121
-	O
OBP45	O
compared	O
to	O
PROP1.0	B-T121
(	O
0	O
%	O
vs.	O
71	O
%	O
)	O
.	O
PROP0.5	B-T121
bis	O
had	O
increased	O
mortality	O
compared	O
to	O
CONTROL	O
(	O
60-%	O
vs.	O
4	O
%	O
)	O
.	O
Administration	O
of	O
beta	B-T121
blockers	I-T121
prior	O
to	O
saturation	O
decompression	O
appears	O
to	O
increase	O
DCS	B-T047
and	O
worsen	O
mortality	O
in	O
a	O
swine	O
model	O
;	O
however	O
,	O
their	O
effects	O
in	O
bounce	O
diving	O
remain	O
unknown	O
.	O
Forbes	O
AS	O
,	O
Regis	O
DP	O
,	O
HallAA	O
,	O
Mahon	O
RT	O
,	O
Cronin	O
WA	O
.	O
Propranolol	O
effects	O
on	O
decompression	O
sickness	O
in	O
a	O
simulated	O
DISSUB	O
rescue	O
in	O
swine	O
.	O
Aerosp	O
Med	O
Hum	O
Perform	O
.	O
2017	O
;	O
88(4):385	O
-	O
391	O
.	O
      
Silk	B-T121
fibroin	I-T121
based	O
carrier	O
system	O
for	O
delivery	O
of	O
fibrinogen	B-T121
and	O
thrombin	B-T121
as	O
coagulant	B-T121
supplements	O
The	O
control	O
of	O
bleeding	O
is	O
one	O
of	O
the	O
most	O
important	O
interventions	B-T061
after	O
a	O
traumatic	O
injury	O
.	O
Hemostatic	B-T121
devices	I-T121
delivering	O
blood	O
clotting	O
accelerating	O
agents	B-T121
such	O
as	O
fibrinogen	B-T121
are	O
increasingly	O
used	O
due	O
to	O
their	O
efficacy	O
and	O
their	O
ease	O
of	O
application	B-T058
.	O
In	O
the	O
present	O
study	O
,	O
we	O
describe	O
a	O
method	O
to	O
incorporate	O
the	O
coagulant	B-T121
supplements	O
fibrinogen	B-T121
and	O
thrombin	B-T121
in	O
silk	B-T121
protein	I-T121
sponges	O
by	O
mixing	O
the	O
coagulants	B-T121
with	O
an	O
aqueous	B-T121
silk	B-T121
solution	O
,	O
followed	O
by	O
molding	B-T059
,	O
freeze	B-T059
-	I-T059
drying	I-T059
and	O
water	B-T059
annealing	I-T059
.	O
In	O
this	O
combination	O
system	O
we	O
demonstrate	O
the	O
delivery	O
of	O
fibrinogen	B-T121
while	O
maintaining	O
its	O
hemostatic	O
potential	O
.	O
Concentration	O
ratios	O
of	O
silk	B-T121
to	O
fibrinogen	B-T121
of	O
1.0%/2.8	O
%	O
,	O
2.3%/1.5	O
%	O
and	O
3.0%/0.8	O
%	O
were	O
used	O
.	O
The	O
thrombin	B-T121
-induced	O
fibrin	B-T121
polymeric	O
network	O
filled	O
the	O
space	O
in	O
and	O
next	O
to	O
the	O
silk	B-T121
spongy	O
structure	O
but	O
also	O
remained	O
interconnected	O
to	O
the	O
silk	B-T121
,	O
providing	O
an	O
intact	O
network	O
.	O
The	O
mechanical	O
characterization	O
of	O
the	O
fibrinogen	O
-	O
releasing	O
silk	B-T121
sponges	O
before	O
and	O
after	O
the	O
induction	O
of	O
the	O
fibrinogen	B-T121
polymerization	O
demonstrated	O
that	O
the	O
fibrin	B-T121
network	O
resulted	O
in	O
reduced	O
permanent	O
deformation	O
from	O
21.1	O
%	O
to	O
6.5	O
%	O
,	O
19.6	O
%	O
to	O
5.7	O
%	O
and	O
12.7	O
%	O
to	O
9.4	O
%	O
for	O
the	O
2.8	O
%	O
,	O
1.5	O
%	O
and	O
0.8	O
%	O
fibrinogen	B-T121
-containing	O
silk	B-T121
sponges	O
,	O
respectively	O
.	O
Moreover	O
,	O
the	O
fibrin	B-T121
formation	O
lead	O
to	O
a	O
more	O
linear	O
elastic	O
behavior	O
over	O
longer	O
strain	O
ranges	O
.	O
In	O
combination	O
,	O
the	O
Calcein	B-T121
-	I-T121
AM	I-T121
/	O
PI	O
stainings	O
and	O
MTT	O
assay	O
results	O
indicate	O
uniform	O
cell	O
adhesion	O
on	O
the	O
surface	O
and	O
cytocompatibility	O
of	O
the	O
silk	B-T121
/	O
fibrin	B-T121
sponges	O
,	O
respectively	O
.	O
Moreover	O
,	O
the	O
co	O
-	O
delivery	O
of	O
thrombin	B-T121
with	O
fibrinogen	B-T121
via	O
silk	B-T121
as	O
carrier	O
material	O
is	O
described	O
,	O
offering	O
a	O
more	O
mechanically	O
robust	O
and	O
durable	O
system	O
while	O
preserving	O
hemostatic	O
features	O
of	O
the	O
coagulant	B-T121
substances	I-T121
for	O
the	O
generation	O
of	O
hemostatic	B-T121
devices	I-T121
.	O
This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O
All	O
rights	O
reserved	O
.	O
      
Naphthohydroquinones	B-T121
,	O
naphthoquinones	O
,	O
anthraquinones	B-T121
,	O
and	O
a	O
naphthohydroquinone	B-T121
dimer	O
isolated	O
from	O
the	O
aerial	O
parts	O
of	O
Morinda	O
parvifolia	O
and	O
their	O
cytotoxic	O
effects	O
through	O
up	O
-	O
regulation	O
of	O
p53	O
Five	O
unknown	O
compounds	B-T121
,	O
morindaparvins	B-T121
C	I-T121
-	I-T121
G	I-T121
,	O
consisting	O
of	O
naphthohydroquinones	B-T121
,	O
a	O
naphthoquinone	O
,	O
an	O
anthraquinone	B-T121
,	O
and	O
a	O
naphthohydroquinone	B-T121
dimer	O
,	O
together	O
with	O
three	O
known	O
quinones	O
and	O
seven	O
other	O
known	O
compounds	B-T121
,	O
were	O
isolated	O
from	O
the	O
aerial	O
parts	O
of	O
Morinda	O
parvifolia	O
.	O
The	O
structures	O
of	O
morindaparvins	B-T121
C	I-T121
,	O
D	B-T121
,	O
E	B-T121
,	O
F	B-T121
,	O
and	O
G	B-T121
were	O
elucidated	O
on	O
the	O
basis	O
of	O
spectroscopic	B-T059
or	O
X	B-T059
-	I-T059
ray	I-T059
diffraction	I-T059
analysis	I-T059
as	O
methyl	B-T121
4	I-T121
-	I-T121
hydroxy-1,6	I-T121
-	I-T121
dimethoxy	I-T121
-	I-T121
naphthalene-2	I-T121
-	I-T121
carboxylate	I-T121
,	O
methyl	B-T121
4,8	I-T121
-	I-T121
dihydroxy-1	I-T121
-	I-T121
methoxy	I-T121
-	I-T121
naphthalene-2	I-T121
-	I-T121
carboxylate	I-T121
,	O
3	B-T121
-	I-T121
amino-6	I-T121
-	I-T121
methoxy-2	I-T121
-	I-T121
methoxycarbonyl-1,4	I-T121
-	I-T121
naphthoquinone	I-T121
,	O
1,4	B-T121
-	I-T121
dihydroxy-7	I-T121
-	I-T121
hydroxymethyl	I-T121
-	I-T121
anthraquinone	I-T121
,	O
and	O
dimethyl	B-T121
1,1'-dihydroxy-4,4',7,7'-tetramethoxy-2,2'-binaphthalene-3,3'-dicarboxylate	I-T121
,	O
respectively	O
.	O
Naphthoquinones	O
and	O
naphthohydroquinone	B-T121
dimers	O
were	O
previously	O
unknown	O
in	O
the	O
genus	O
Morinda	O
.	O
In	O
addition	O
,	O
the	O
compounds	B-T121
were	O
tested	O
for	O
cytotoxicity	O
against	O
four	O
human	O
cancer	O
cell	O
lines	O
HeLa	O
,	O
A2780	O
,	O
Ketr3	O
and	O
MCF-7	O
and	O
their	O
effects	O
on	O
p53	O
-	O
activated	O
transcription	O
.	O
Three	O
naphthoquinones	O
had	O
moderate	O
cytotoxic	O
effects	O
with	O
IC50	O
values	O
ranging	O
from	O
1.51	O
to	O
9.56	O
μM	O
,	O
through	O
up	O
-	O
regulation	O
of	O
p53	O
transcriptional	O
activity	O
.	O
      
Treatment	B-T061
of	O
erythematotelangiectatic	B-T047
rosacea	I-T047
with	O
the	O
fractionation	B-T061
of	O
high	O
-	O
fluence	O
,	O
long	O
-	O
pulsed	O
595	O
-	O
nm	O
pulsed	O
dye	O
laser	O
Various	O
lasers	O
have	O
been	O
used	O
for	O
the	O
treatment	B-T061
of	O
erythematotelangiectatic	B-T047
rosacea	I-T047
(	O
ETR	B-T047
)	O
that	O
does	O
not	O
respond	O
to	O
systemic	B-T061
or	O
topical	B-T061
therapy	I-T061
.	O
The	O
pulsed	O
dye	O
lasers	O
(	O
PDLs	O
)	O
are	O
an	O
effective	O
option	O
for	O
ETR	B-T047
,	O
and	O
the	O
purpuragenic	B-T047
fluence	O
proved	O
to	O
be	O
superior	O
until	O
now	O
.	O
Given	O
that	O
purpura	B-T047
and	O
subsequent	O
possible	O
postinflammatory	O
hyperpigmentation	O
(	O
PIH	O
)	O
are	O
occasionally	O
unbearable	O
in	O
some	O
patients	O
,	O
and	O
several	O
studies	O
using	O
the	O
low	O
nonpurpuragenic	B-T033
fluence	O
were	O
reported	O
.	O
To	O
deliver	O
the	O
sufficient	O
high	O
fluence	O
of	O
a	O
PDL	O
without	O
generating	O
purpura	B-T047
,	O
we	O
designed	O
the	O
fractionation	B-T061
of	O
high	O
fluence	O
using	O
five	O
passes	O
and	O
longer	O
pulse	O
duration	O
(	O
6	O
milliseconds	O
)	O
of	O
a	O
PDL	O
in	O
succession	O
.	O
A	O
total	O
of	O
eight	O
patients	O
with	O
ETR	B-T047
were	O
enrolled	O
in	O
this	O
study	O
;	O
all	O
patients	O
were	O
treated	O
with	O
PDL	O
10	O
times	O
at	O
2	O
-	O
week	O
intervals	O
.	O
Erythema	B-T047
and	O
telangiectasia	B-T047
scores	O
,	O
as	O
well	O
as	O
improvement	O
,	O
were	O
assessed	O
by	O
two	O
physicians	O
using	O
the	O
digital	O
photographs	O
.	O
Moderate	O
-	O
to	O
-	O
marked	O
improvement	O
was	O
achieved	O
in	O
most	O
of	O
the	O
patients	O
,	O
and	O
erythema	B-T047
and	O
telangiectasia	B-T047
scores	O
were	O
significantly	O
decreased	O
.	O
Purpura	B-T047
and	O
PIH	O
were	O
not	O
reported	O
in	O
all	O
patients	O
.	O
The	O
fractionation	B-T061
of	O
high	O
-	O
fluence	O
,	O
long	O
-	O
pulsed	O
595	O
nm	O
PDL	O
is	O
a	O
very	O
safe	O
and	O
effective	O
treatment	B-T061
for	O
ETR	B-T047
.	O
      
Minimally	O
invasive	O
percutaneous	B-T061
nephrolithotomy	I-T061
improves	O
stone	O
-	O
free	O
rates	O
for	O
impacted	O
proximal	O
ureteral	B-T047
stones	I-T047
:	O
A	O
systematic	O
review	O
and	O
meta	O
-	O
analysis	O
Urinary	B-T047
stones	I-T047
are	O
common	O
medical	O
disorders	B-T047
and	O
the	O
treatment	O
of	O
impacted	B-T047
proximal	I-T047
ureteral	I-T047
stones	I-T047
(	O
IPUS	B-T047
)	O
is	O
still	O
a	O
challenge	O
for	O
urologists	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
efficacy	O
and	O
safety	O
of	O
minimally	O
invasive	O
percutaneous	B-T061
nephrolithotomy	I-T061
(	O
MI	O
-	O
PCNL	B-T061
)	O
and	O
ureteroscopic	B-T061
lithotripsy	I-T061
(	O
URL	B-T061
)	O
in	O
the	O
treatment	O
of	O
IPUS	B-T047
via	O
a	O
meta	O
-	O
analysis	O
.	O
We	O
collected	O
studies	O
using	O
PubMed	O
,	O
Embase	O
,	O
and	O
Cochrane	O
Library	O
from	O
1978	O
to	O
November	O
2016	O
and	O
analyzed	O
them	O
using	O
Stata	O
12.0	O
and	O
RevMan	O
5.3	O
.	O
Odds	O
ratios	O
(	O
OR	O
s	O
)	O
and	O
standard	O
mean	O
difference	O
(	O
SMD	O
)	O
were	O
calculated	O
for	O
binary	O
and	O
continuous	O
variables	O
respectively	O
,	O
accompanied	O
with	O
95	O
%	O
confidence	O
intervals	O
(	O
CIs	O
)	O
.	O
All	O
study	O
procedures	O
followed	O
the	O
PRISMA	O
guidelines	O
.	O
Five	O
prospective	O
studies	O
were	O
included	O
in	O
our	O
meta	O
-	O
analysis	O
,	O
with	O
242	O
MI	O
-	O
PCNL	B-T061
and	O
256	O
URL	B-T061
cases	O
.	O
MI	O
-	O
PCNL	B-T061
was	O
associated	O
with	O
a	O
longer	O
postoperative	O
hospital	O
stay	O
than	O
URL	B-T061
(	O
SMD	O
,	O
3.14	O
;	O
95	O
%	O
CI	O
,	O
1.27	O
to	O
5.55	O
)	O
.	O
However	O
,	O
no	O
significant	O
difference	O
was	O
observed	O
in	O
operative	O
time	O
(	O
SMD	O
,	O
-0.38	O
;	O
95	O
%	O
CI	O
,	O
-3.15	O
to	O
2.38	O
)	O
.	O
In	O
addition	O
,	O
MI	O
-	O
PCNL	B-T061
had	O
higher	O
initial	O
(	O
OR	O
,	O
11.12	O
;	O
95	O
%	O
CI	O
,	O
5.56	O
to	O
22.24	O
)	O
and	O
overall	O
stone	O
-	O
free	O
rates	O
(	O
OR	O
,	O
8.70	O
;	O
95	O
%	O
CI	O
,	O
3.23	O
to	O
23.45	O
)	O
than	O
URL	B-T061
,	O
along	O
with	O
lower	O
possibilities	O
of	O
surgical	B-T061
conversion	I-T061
(	O
OR	O
,	O
0.11	O
;	O
95	O
%	O
CI	O
,	O
0.03	O
to	O
0.49	O
)	O
and	O
postoperative	O
shock	B-T061
wave	I-T061
lithotripsy	I-T061
(	O
OR	O
,	O
0.06	O
;	O
95	O
%	O
CI	O
,	O
0.02	O
to	O
0.18	O
)	O
.	O
Regarding	O
complications	O
,	O
no	O
significant	O
differences	O
were	O
observed	O
between	O
MI	O
-	O
PCNL	B-T061
and	O
URL	B-T061
(	O
OR	O
,	O
1.39	O
;	O
95	O
%	O
CI	O
,	O
0.93	O
to	O
2.10	O
)	O
,	O
except	O
for	O
hematuria	B-T047
(	O
OR	O
,	O
4.80	O
;	O
95	O
%	O
CI	O
,	O
1.45	O
to	O
15.94	O
)	O
.	O
MI	O
-	O
PCNL	B-T061
is	O
optimal	O
and	O
should	O
be	O
considered	O
as	O
the	O
preferred	O
treatment	B-T061
method	I-T061
for	O
IPUS	B-T047
,	O
as	O
it	O
has	O
better	O
efficacy	O
and	O
a	O
safety	O
profile	O
similar	O
to	O
that	O
of	O
URL	B-T061
.	O
However	O
,	O
further	O
high	O
quality	O
studies	O
with	O
larger	O
sample	O
size	O
are	O
required	O
in	O
future	O
.	O
      
Safe	O
with	O
Self	O
-	O
Injury	O
:	O
A	O
Practical	O
Guide	O
to	O
Understanding	O
,	O
Responding	O
and	O
Harm	B-T061
-	I-T061
reduction	I-T061
Inckle	O
Kay	O
Safe	O
with	O
Self	O
-	O
Injury	O
:	O
A	O
Practical	O
Guide	O
to	O
Understanding	O
,	O
Responding	O
and	O
Harm	B-T061
-	I-T061
reduction	I-T061
274pp	O
£	O
23.99	O
PCCS	O
Books	O
9781910919163	O
1910919160	O
[	O
Formula	O
:	O
see	O
text	O
The	O
author	O
begins	O
her	O
book	O
with	O
a	O
concise	O
exploration	O
of	O
the	O
stereotypes	O
and	O
truths	O
of	O
self	O
-	O
harm	O
.	O
In	O
the	O
following	O
seven	O
chapters	O
,	O
she	O
sets	O
out	O
a	O
grounded	O
and	O
often	O
challenging	O
view	O
of	O
how	O
self	O
-	O
harm	O
is	O
understood	O
from	O
differing	O
perspectives	O
.	O
      
Association	O
of	O
Toll	O
-	O
Like	O
Receptor	O
4	O
on	O
Human	O
Monocyte	O
Subsets	O
and	O
Vulnerability	B-T033
Characteristics	O
of	O
Coronary	B-T023
Plaque	B-T033
as	O
Assessed	O
by	O
64	B-T060
-	I-T060
Slice	I-T060
Multidetector	I-T060
Computed	I-T060
Tomography	I-T060
Although	O
Toll	O
-	O
like	O
receptor	O
4	O
(	O
TLR-4	O
)	O
is	O
involved	O
in	O
monocyte	O
activation	O
in	O
patients	O
with	O
accelerated	O
forms	O
of	O
atherosclerosis	B-T047
,	O
the	O
relationship	O
between	O
the	O
expression	O
of	O
TLR-4	O
on	O
circulating	O
monocyte	O
s	O
and	O
coronary	B-T023
plaque	B-T033
vulnerability	B-T033
has	O
not	O
previously	O
been	O
evaluated	B-T058
.	O
We	O
investigated	O
this	O
relationship	O
using	O
64	B-T060
-	I-T060
slice	I-T060
multidetector	I-T060
computed	I-T060
tomography	I-T060
(	O
MDCT	B-T060
)	O
in	O
patients	O
with	O
stable	B-T047
angina	I-T047
pectoris	I-T047
SAP	B-T047
(	O
SAP).Methods	O
and	O
Results	O
:	O
We	O
enrolled	O
65	O
patients	O
with	O
SAP	B-T047
who	O
underwent	O
MDCT	B-T060
.	O
Three	O
monocyte	O
subsets	O
(	O
CD14(++)CD16(-	O
)	O
,	O
CD14(++)CD16(+	O
)	O
,	O
and	O
CD14(+)CD16(+	O
)	O
)	O
and	O
expression	O
of	O
TLR-4	O
were	O
measured	O
by	O
flow	B-T059
cytometry	I-T059
.	O
Intracoronary	B-T023
plaques	B-T033
were	O
assessed	O
by	O
64	B-T060
-	I-T060
slice	I-T060
MDCT	I-T060
.	O
We	O
defined	O
vulnerability	B-T033
of	O
intracoronary	B-T023
plaques	B-T033
according	O
to	O
the	O
presence	O
of	O
positive	O
remodeling	O
(	O
remodeling	B-T033
index	I-T033
>	O
1.05	O
)	O
and/or	O
low	O
CT	B-T060
attenuation	O
(	O
<	O
35	O
HU	O
)	O
.	O
The	O
circulating	O
CD14(++)CD16(+)monocytes	O
more	O
frequently	O
expressed	O
TLR-4	O
than	O
CD14(++)CD16(-	O
)	O
and	O
CD14(+)CD16(+)monocytes	O
(	O
P<0.001	O
)	O
.	O
The	O
relative	O
proportion	O
of	O
the	O
expression	O
of	O
TLR-4	O
on	O
CD14(++)CD16(+)monocytes	O
was	O
significantly	O
greater	O
in	O
patients	O
with	O
vulnerable	B-T033
plaque	I-T033
compared	O
with	O
those	O
without	O
(	O
10.4	O
[	O
4.1	O
-	O
14.5	O
]	O
%	O
vs.	O
4.5	O
[	O
2.8	O
-	O
7.8	O
]	O
%	O
,	O
P=0.012	O
)	O
.	O
In	O
addition	O
,	O
the	O
relative	O
proportion	O
of	O
TLR-4	O
expression	O
on	O
CD14(++)CD16(+)monocytes	O
positively	O
correlated	O
with	O
the	O
remodeling	B-T033
index	I-T033
(	O
r=0.28	O
,	O
P=0.025	O
)	O
and	O
negatively	O
correlated	O
with	O
CT	B-T060
attenuation	O
value	O
(	O
r=-0.31	O
,	O
P=0.013	O
)	O
.	O
Upregulation	O
of	O
TLR-4	O
on	O
CD14(++)CD16(+)monocytes	O
might	O
be	O
associated	O
with	O
coronary	B-T023
plaque	B-T033
vulnerability	B-T033
in	O
patients	O
with	O
SAP	B-T047
.	O
      
Evolution	O
:	O
Enhanced	O
Footing	O
for	O
Snake	O
Limb	O
Development	O
Two	O
groups	O
have	O
studied	O
the	O
loss	O
of	O
limbs	B-T023
in	O
snake	O
evolution	O
by	O
focusing	O
on	O
a	O
long	B-T033
-	I-T033
distance	I-T033
cis	O
-	O
acting	O
enhancer	O
of	O
Sonic	O
Hedgehog	O
.	O
They	O
find	O
a	O
progressive	O
degeneration	O
of	O
binding	O
sites	O
for	O
key	O
transcription	O
factors	O
,	O
mirroring	O
the	O
progressive	O
limblessness	O
occurring	O
in	O
these	O
reptiles	O
.	O
      
Methamphetamine	O
,	O
3,4	B-T121
-	I-T121
methylenedioxymethamphetamine	I-T121
(	O
MDMA	B-T121
)	O
and	O
3,4	O
-	O
methylenedioxypyrovalerone	O
(	O
MDPV	O
)	O
induce	O
differential	O
cytotoxic	O
effects	O
in	O
bovine	O
brain	B-T023
microvessel	B-T023
endothelial	O
cells	O
Designer	O
drugs	O
such	O
as	O
synthetic	B-T121
psychostimulants	I-T121
are	O
indicative	O
of	O
a	O
worldwide	O
problem	B-T033
of	O
drug	B-T048
abuse	I-T048
and	O
addiction	B-T048
.	O
In	O
addition	O
to	O
methamphetamine	O
(	O
METH	O
)	O
,	O
these	O
drugs	O
include	O
3,4	B-T121
-	I-T121
methylenedioxy	I-T121
-	I-T121
methamphetamine	I-T121
(	O
MDMA	B-T121
)	O
and	O
commercial	O
preparations	O
of	O
synthetic	B-T121
cathinones	I-T121
including	O
3,4	O
-	O
methylenedioxypyrovalerone	O
(	O
MDPV	O
)	O
,	O
typically	O
referred	O
to	O
as	O
"	O
bath	B-T121
salts	I-T121
.	O
"	O
These	O
psychostimulants	B-T121
exert	O
neurotoxic	O
effects	O
by	O
altering	O
monoamine	O
systems	O
in	O
the	O
brain	B-T023
.	O
Additionally	O
,	O
METH	O
and	O
MDMA	B-T121
adversely	O
affect	O
the	O
integrity	O
of	O
the	O
blood	B-T023
-	I-T023
brain	I-T023
barrier	I-T023
(	O
BBB	B-T023
):	O
there	O
are	O
no	O
current	O
reports	O
on	O
the	O
effects	O
of	O
MDPV	O
on	O
the	O
BBB	B-T023
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
effects	O
of	O
METH	O
,	O
MDMA	B-T121
and	O
MDPV	O
on	O
bovine	O
brain	B-T023
microvessel	B-T023
endothelial	O
cells	O
(	O
bBMVECs	O
)	O
,	O
an	O
accepted	O
in	O
vitro	O
model	O
of	O
the	O
BBB	B-T023
.	O
Confluent	O
bBMVEC	O
monolayers	B-T023
were	O
treated	O
with	O
METH	O
,	O
MDMA	B-T121
and	O
MDPV	O
(	O
0.5mM-2.5mM	O
)	O
for	O
24h	O
.	O
METH	O
and	O
MDMA	B-T121
increased	O
lactate	O
dehydrogenase	O
release	O
only	O
at	O
the	O
highest	O
concentration	O
(	O
2.5mM	O
)	O
,	O
whereas	O
MDPV	O
induced	O
cytotoxicity	O
at	O
all	O
concentration	O
s.	O
MDMA	B-T121
and	O
METH	O
decreased	O
cellular	O
proliferation	O
only	O
at	O
2.5mM	O
,	O
with	O
similar	O
effects	O
observed	O
after	O
MDPV	O
exposures	O
starting	O
at	O
1mM.	O
Only	O
MDPV	O
increased	O
reactive	O
oxygen	O
species	O
production	O
at	O
all	O
concentrations	O
tested	O
whereas	O
all	O
3	O
drugs	O
increased	O
nitric	B-T121
oxide	I-T121
production	O
.	O
Morphological	O
analysis	O
revealed	O
different	O
patterns	O
of	O
compound	O
-	O
induced	O
cell	O
damage	O
.	O
METH	O
induced	O
vacuole	O
formatio	O
n	O
at	O
1mM	O
and	O
disruption	O
of	O
the	O
monolayer	B-T023
at	O
2.5mM.	O
MDMA	B-T121
induced	O
disruption	O
of	O
the	O
endothelial	O
monolayer	B-T023
from	O
1mM	O
without	O
vacuolization	B-T033
.	O
On	O
the	O
other	O
hand	O
,	O
MDPV	O
induced	O
monolayer	B-T023
disruption	O
at	O
doses	O
≥0.5mM	O
without	O
vacuole	O
formation	O
;	O
at	O
2.5mM	O
,	O
the	O
few	O
remaining	O
cells	O
lacked	O
endothelial	O
morphology	O
.	O
These	O
data	O
suggest	O
that	O
even	O
though	O
these	O
synthetic	B-T121
psychostimulants	I-T121
alter	O
monoaminergic	O
systems	O
,	O
they	O
each	O
induce	O
BBB	B-T023
toxicity	O
by	O
different	O
mechanisms	O
with	O
MDPV	O
being	O
the	O
most	O
toxic	O
.	O
      
The	O
anatomical	O
mummies	O
of	O
Mombello	O
:	O
detection	B-T033
of	O
cocaine	O
,	O
nicotine	O
,	O
and	O
caffeine	B-T121
in	O
the	O
hair	B-T023
of	O
psychiatric	O
patients	O
of	O
the	O
early	O
20th	O
century	O
The	O
Mombello	O
Psychiatric	O
Hospital	O
in	O
Limbiate	O
,	O
near	O
Milan	O
,	O
replaced	O
the	O
old	O
Senavra	O
Hospital	O
as	O
the	O
Psychiatric	O
Hospital	O
for	O
the	O
Province	O
of	O
Milan	O
in	O
the	O
19th	O
century	O
.	O
During	O
the	O
early	O
20th	O
century	O
,	O
bodies	O
of	O
several	O
Mombello	O
patients	O
were	O
dissected	O
and	O
preserved	B-T059
by	O
Giuseppe	O
Paravicini	O
,	O
an	O
anatomist	O
who	O
operated	O
within	O
the	O
asylum	O
.	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
examine	O
and	O
memorialize	O
this	O
important	O
assemblage	O
.	O
To	O
this	O
end	O
,	O
we	O
were	O
allowed	O
to	O
sample	O
the	O
head	B-T023
hair	I-T023
of	O
six	O
such	O
preparations	O
for	O
toxicological	O
analysis	O
.	O
By	O
means	O
of	O
high	B-T059
performance	I-T059
liquid	I-T059
chromatography	I-T059
,	O
cocaine	O
and	O
its	O
main	O
metabolite	O
,	O
benzoylecgonine	B-T121
,	O
were	O
detected	B-T033
in	O
two	O
out	O
of	O
six	O
hair	O
samples	O
.	O
The	O
concentrations	O
for	O
cocaine	O
were	O
0.151	O
and	O
0.09ng	O
/	O
mg	O
and	O
for	O
benzoylecgonine	B-T121
0.103	O
and	O
0.147ng	O
/	O
mg	O
,	O
respectively	O
.	O
Given	O
that	O
cocaine	O
was	O
a	O
commonly	O
used	O
medicine	B-T121
,	O
beginning	O
in	O
the	O
mid-19th	O
century	O
and	O
persisting	O
into	O
the	O
20th	O
century	O
,	O
it	O
is	O
not	O
surprising	O
that	O
some	O
patients	O
may	O
have	O
ingested	O
this	O
drug	B-T121
.	O
In	O
addition	O
to	O
the	O
detection	B-T033
of	O
cocaine	O
,	O
these	O
analyses	O
also	O
provided	O
evidence	O
of	O
nicotine	O
and	O
caffeine	B-T121
intake	O
.	O
      
A	O
Randomized	O
Controlled	O
Noninferiority	O
Trial	O
of	O
Single	O
Dose	O
of	O
Oral	B-T200
Dexamethasone	I-T200
Versus	O
5	O
Days	O
of	O
Oral	B-T200
Prednisone	I-T200
in	O
Acute	O
Adult	O
Asthma	B-T047
Oral	B-T200
dexamethasone	I-T200
demonstrates	O
bioavailability	O
similar	O
to	O
that	O
of	O
oral	B-T200
prednisone	I-T200
but	O
has	O
a	O
longer	O
half	O
-	O
life	O
.	O
We	O
evaluate	O
whether	O
a	O
single	O
dose	O
of	O
oral	B-T200
dexamethasone	I-T200
plus	O
4	O
days	O
of	O
placebo	O
is	O
not	O
inferior	O
to	O
5	O
days	O
of	O
oral	B-T200
prednisone	I-T200
in	O
treatment	O
of	O
adults	O
with	O
mild	B-T033
to	O
moderate	B-T033
asthma	B-T033
exacerbations	I-T033
to	O
prevent	O
relapse	O
defined	O
as	O
an	O
unscheduled	O
return	O
visit	O
for	O
additional	B-T033
treatment	I-T033
for	O
persistent	B-T047
or	O
worsening	O
asthma	B-T047
within	O
14	O
days	O
.	O
Adult	O
emergency	O
department	O
patients	O
(	O
aged	O
18	O
to	O
55	O
years	O
)	O
were	O
randomized	O
to	O
receive	O
either	O
a	O
single	O
dose	O
of	O
12	O
mg	O
of	O
oral	B-T200
dexamethasone	I-T200
with	O
4	O
days	O
of	O
placebo	O
or	O
a	O
5-	O
day	O
course	O
of	O
oral	B-T200
prednisone	I-T200
60	O
mg	O
a	O
day	O
.	O
Outcomes	O
including	O
relapse	O
were	O
assessed	O
by	O
a	O
follow	B-T058
-	I-T058
up	I-T058
telephone	I-T058
interview	I-T058
at	O
2	O
weeks	O
.	O
One	O
hundred	O
seventy	O
-	O
three	O
dexamethasone	B-T121
and	O
203	O
prednisone	B-T121
subjects	O
completed	O
the	O
study	O
regimen	O
and	O
telephone	B-T058
follow	I-T058
-	I-T058
up	I-T058
.	O
The	O
dexamethasone	B-T121
group	O
by	O
a	O
small	O
margin	O
surpassed	O
the	O
preset	O
8	O
%	O
difference	O
between	O
groups	O
for	O
noninferiority	O
in	O
relapse	O
rates	O
within	O
14	O
days	O
(	O
12.1	O
%	O
versus	O
9.8	O
%	O
;	O
difference	O
2.3	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
-4.1	O
%	O
to	O
8.6	O
%	O
)	O
.	O
Subjects	O
in	O
the	O
2	O
groups	O
had	O
similar	O
rates	O
of	O
hospitalization	B-T058
for	O
their	O
relapse	O
visit	B-T058
(	O
dexamethasone	B-T121
3.4	O
%	O
versus	O
prednisone	B-T121
2.9	O
%	O
;	O
difference	O
0.5	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
-4.1	O
%	O
to	O
3.1	O
%	O
)	O
.	O
Adverse	O
effect	O
rates	O
were	O
generally	O
the	O
same	O
in	O
the	O
2	O
groups	O
.	O
A	O
single	O
dose	O
of	O
oral	B-T200
dexamethasone	I-T200
did	O
not	O
demonstrate	O
noninferiority	O
to	O
prednisone	B-T121
for	O
5	O
days	O
by	O
a	O
very	O
small	O
margin	O
for	O
treatment	O
of	O
adults	O
with	O
mild	B-T033
to	O
moderate	B-T033
asthma	B-T033
exacerbations	I-T033
.	O
Enhanced	O
compliance	B-T033
and	O
convenience	O
may	O
support	O
the	O
use	O
of	O
dexamethasone	B-T121
regardless	O
.	O
      
ATP	B-T121
release	O
from	O
bladder	O
urothelium	O
and	O
serosa	O
in	O
a	O
rat	O
model	B-T050
of	O
partial	B-T047
bladder	I-T047
outlet	I-T047
obstruction	I-T047
Overactive	B-T047
bladder	I-T047
is	O
one	O
of	O
the	O
major	O
health	B-T033
problem	I-T033
especially	O
in	O
elderly	O
people	O
.	O
Adenosine	B-T121
triphosphate	I-T121
(	O
ATP	B-T121
)	O
is	O
released	O
from	O
urinary	O
bladder	O
cells	O
and	O
acts	O
as	O
a	O
smooth	O
muscle	O
contraction	O
and	O
sensory	O
signal	O
in	O
micturition	O
but	O
little	O
is	O
known	O
about	O
the	O
role	O
of	O
ATP	B-T121
release	O
in	O
the	O
pathophysiology	O
of	O
overactive	B-T047
bladder	I-T047
.	O
To	O
assess	O
the	O
relationship	O
between	O
ATP	B-T121
and	O
overactive	B-T047
bladder	I-T047
,	O
we	O
used	O
a	O
partial	B-T047
bladder	I-T047
outlet	I-T047
obstruction	I-T047
(	O
pBOO	B-T047
)	O
model	B-T050
in	O
rats	O
.	O
The	O
bladder	B-T023
caused	O
several	O
changes	O
by	O
pBOO	B-T047
:	O
An	O
increase	O
in	O
bladder	B-T023
weight	O
,	O
hypertrophy	O
of	O
sub	O
-	O
urothelium	O
and	O
sub	O
-	O
serosal	O
area	O
,	O
and	O
frequent	O
non	O
-	O
voiding	O
bladder	O
contraction	O
during	O
urine	O
storage	O
.	O
Basal	O
ATP	B-T121
release	O
from	O
urothelium	O
and	O
serosa	O
of	O
pBOO	B-T047
rats	O
was	O
significantly	O
higher	O
than	O
that	O
of	O
normal	O
rats	O
.	O
Distention	B-T033
induced	O
ATP	B-T121
release	O
from	O
urothelium	O
of	O
normal	O
and	O
pBOO	B-T047
rats	O
had	O
no	O
significant	O
change	O
.	O
However	O
,	O
distention	B-T033
-	O
induced	O
ATP	B-T121
release	O
from	O
serosa	O
of	O
pBOO	B-T047
rats	O
was	O
higher	O
than	O
that	O
of	O
normal	O
.	O
These	O
findings	O
may	O
identify	O
ATP	B-T121
especially	O
released	O
from	O
serosa	O
as	O
one	O
of	O
causes	O
of	O
non	O
-	O
voiding	O
contractions	O
and	O
overactive	B-T047
bladder	I-T047
symptoms	B-T184
.	O
      
Percentile	O
categorization	O
of	O
QT	B-T033
interval	I-T033
as	O
an	O
approach	O
for	O
identifying	B-T058
adult	O
patients	O
at	O
risk	O
for	O
cardiovascular	O
death	O
The	O
results	O
from	O
studies	O
of	O
the	O
association	O
of	O
QT	B-T033
prolongation	I-T033
with	O
cardiovascular	O
death	O
(	O
CVD	O
)	O
have	O
been	O
inconsistent	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
major	O
correction	O
formulas	O
to	O
percentile	O
values	O
of	O
QT	O
for	O
heart	O
rate	O
ranges	O
as	O
to	O
their	O
ability	O
to	O
remove	O
the	O
relationship	O
of	O
QT	O
to	O
heart	O
rate	O
and	O
to	O
predict	O
CVD	O
.	O
Participants	O
were	O
16,531	O
veterans	O
who	O
had	O
an	O
initial	O
ECG	B-T033
at	O
the	O
Veterans	O
Affairs	O
Medical	O
Center	O
,	O
Palo	O
Alto	O
,	O
between	O
March	O
31	O
,	O
1987	O
,	O
and	O
December	O
20	O
,	O
1999	O
,	O
and	O
were	O
followed	O
for	O
CVD	O
.	O
The	O
4	O
major	O
correction	O
formulas	O
(	O
Bazett	O
,	O
Fridericia	O
,	O
Framingham	O
,	O
and	O
Hodges	O
)	O
were	O
used	O
to	O
correct	O
QT	B-T033
interval	I-T033
.	O
In	O
addition	O
,	O
the	O
percentiles	O
for	O
heart	O
rate	O
ranges	O
as	O
proposed	O
by	O
Schwartz	O
were	O
calculated	O
.	O
During	O
median	O
follow	O
-	O
up	O
of	O
17.8	O
years	O
,	O
455	O
CVD	O
events	O
occurred	O
.	O
When	O
compared	O
to	O
the	O
other	O
equations	O
,	O
QTc	O
Bazett	O
had	O
the	O
greatest	O
dependence	O
on	O
heart	O
rate	O
(	O
R(2	O
)	O
=	O
0.18	O
)	O
.	O
The	O
hazard	O
ratio	O
(	O
95	O
%	O
confidence	O
interval	O
)	O
for	O
CVD	O
was	O
2.08	O
(	O
1.28	O
-	O
3.9	O
)	O
for	O
the	O
98th	O
percentile	O
of	O
QT	B-T033
interval	I-T033
by	O
heart	O
rate	O
ranges	O
,	O
2.05	O
(	O
1.27	O
-	O
3.33	O
)	O
for	O
QTc	O
Bazett	O
,	O
1.39	O
(	O
0.44	O
-	O
4.34	O
)	O
for	O
QTc	O
Fridericia	O
,	O
1.05	O
(	O
0.26	O
-	O
4.24	O
)	O
for	O
QTc	O
Hodges	O
,	O
and	O
1.12	O
(	O
0.28	O
-	O
4.52	O
)	O
for	O
QTc	O
Framingham	O
.	O
The	O
hazard	O
ratio	O
of	O
QTc	O
Bazett	O
was	O
significantly	O
higher	O
than	O
the	O
other	O
formulas	O
except	O
for	O
the	O
98th	O
percentile	O
method	O
.	O
The	O
Framingham	O
,	O
Hodges	O
,	O
and	O
Fridericia	O
equations	O
remove	O
the	O
effect	O
of	O
heart	O
rate	O
on	O
QT	B-T033
interval	I-T033
significantly	O
better	O
than	O
the	O
Bazett	O
equation	O
.	O
Using	O
QT	B-T033
-	I-T033
interval	I-T033
percentiles	O
based	O
on	O
heart	O
rate	O
provides	O
a	O
consistent	O
approach	O
both	O
for	O
identifying	O
those	O
whose	O
QT	B-T033
intervals	I-T033
prolong	O
due	O
to	O
drugs	B-T061
or	O
other	O
stressors	O
and	O
for	O
assessing	O
CVD	O
risk	O
.	O
      
A	O
numerical	O
study	O
on	O
the	O
application	O
of	O
the	O
functionally	O
graded	O
materials	O
in	O
the	O
stent	O
design	O
Undesirable	O
deformation	O
of	O
the	O
stent	O
can	O
induce	O
a	O
significant	O
amount	O
of	O
injure	O
not	O
only	O
to	O
the	O
blood	B-T023
vessel	I-T023
but	O
also	O
to	O
the	O
plaque	B-T033
.	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
reduce	B-T033
/	I-T033
minimize	I-T033
these	O
undesirable	O
deformations	O
by	O
the	O
application	O
of	O
Functionally	O
Graded	O
Materials	O
(	O
FGM	O
)	O
.	O
To	O
do	O
this	O
,	O
Finite	O
Element	O
(	O
FE	O
)	O
method	O
was	O
employed	B-T033
to	O
simulate	O
the	O
expansion	O
of	O
a	O
stent	O
and	O
the	O
corresponding	O
displacement	O
of	O
the	O
stenosis	O
plaque	B-T033
.	O
Three	O
hyperelastic	O
plaque	B-T033
types	O
as	O
well	O
as	O
five	O
elastoplastic	O
stents	O
were	O
simulated	O
.	O
Dogboning	O
,	O
foreshortening	B-T033
,	O
maximum	O
stress	B-T033
in	O
the	O
plaque	B-T033
,	O
and	O
the	O
pressure	O
which	O
is	O
needed	O
to	O
fully	O
expand	O
the	O
stent	O
for	O
different	O
stent	O
materials	O
,	O
were	O
acquired	O
.	O
While	O
all	O
FGMs	O
had	O
lower	O
dogboning	O
in	O
comparison	O
to	O
the	O
stents	O
made	O
of	O
the	O
uniform	O
materials	O
,	O
the	O
stent	O
with	O
the	O
lowest	O
heterogeneous	O
index	O
displayed	O
the	O
lowest	O
amount	O
of	O
dogboning	O
.	O
Steel	O
stent	O
showed	O
the	O
lowest	O
foreshortening	B-T033
and	O
fully	O
expansion	O
pressure	O
but	O
the	O
difference	O
was	O
much	O
lower	O
than	O
that	O
the	O
one	O
for	O
dogboning	O
.	O
Therefore	O
,	O
the	O
FGM	O
with	O
the	O
heterogeneous	O
index	O
of	O
0.5	O
is	O
expected	O
to	O
exhibit	O
the	O
most	O
suitable	O
results	O
.	O
In	O
addition	O
,	O
the	O
results	O
revealed	O
that	O
the	O
material	O
parameters	O
has	O
crucial	O
effects	O
on	O
the	O
deformation	O
of	O
the	O
stent	O
and	O
,	O
as	O
a	O
result	O
,	O
as	O
a	O
design	O
point	O
of	O
view	O
the	O
FGM	O
parameters	O
can	O
be	O
tailored	O
to	O
achieve	O
the	O
goal	O
of	O
the	O
biomechanical	O
optimization	O
.	O
      
Tracking	O
children	O
with	O
acute	B-T191
lymphoblastic	I-T191
leukemia	I-T191
who	O
abandoned	O
therapy	B-T061
:	O
Experience	O
,	O
challenges	B-T058
,	O
parental	O
perspectives	O
,	O
and	O
impact	O
of	O
treatment	B-T061
subsidies	B-T058
and	O
intensified	B-T058
counseling	I-T058
Refusal	O
for	O
treatment	O
and	O
therapy	B-T061
abandonment	B-T033
are	O
important	O
reasons	O
for	O
unfavorable	O
outcome	O
of	O
childhood	O
acute	B-T191
lymphoblastic	I-T191
leukemia	I-T191
(	O
ALL	B-T191
)	O
in	O
resource	O
-poor	O
countries	O
.	O
The	O
present	O
study	O
,	O
conducted	O
on	O
children	O
with	O
ALL	B-T191
whose	O
treatment	B-T061
was	O
abandoned	O
,	O
attempted	O
to	O
track	O
all	O
these	O
children	O
to	O
ascertain	O
the	O
causes	O
and	O
outcome	O
of	O
therapy	B-T061
abandonment	B-T033
/	O
refusal	O
.	O
In	O
order	O
to	O
improve	O
outcome	O
of	O
ALL	B-T191
,	O
measures	O
to	O
prevent	O
abandonment	B-T033
were	O
introduced	O
in	O
the	O
form	O
of	O
treatment	B-T061
subsidies	B-T058
and	O
intensified	B-T058
multistage	I-T058
counseling	I-T058
.	O
Of	O
the	O
77	O
(	O
of	O
418	O
)	O
children	O
abandoning	O
therapy	B-T061
,	O
17	O
(	O
22	O
%	O
)	O
refused	O
upfront	O
,	O
whereas	O
the	O
rest	O
abandoned	O
during	O
various	O
phases	O
of	O
chemotherapy	B-T061
.	O
Only	O
39	O
(	O
50.6	O
%	O
)	O
of	O
these	O
77	O
families	O
could	O
be	O
subsequently	O
contacted	O
.	O
Financial	B-T033
problems	I-T033
,	O
too	O
many	O
dependents	O
at	O
home	O
,	O
and	O
wrong	O
perceptions	O
about	O
cancer	B-T191
led	O
to	O
abandonment	B-T033
in	O
majority	O
.	O
Children	B-T033
abandoning	I-T033
treatment	I-T033
before	O
completion	O
of	O
induction	B-T061
had	O
a	O
significantly	O
shorter	O
survival	O
than	O
who	O
abandoned	O
post	O
induction	O
(	O
P	O
<	O
.0001	O
)	O
.	O
Intensified	B-T058
preabandonment	I-T058
counseling	I-T058
and	O
subsidized	O
treatment	B-T061
led	O
to	O
significant	O
reduction	O
in	O
abandonment	O
rates	O
(	O
P	O
<	O
.0001	O
)	O
.	O
      
Green	O
and	O
rapid	O
synthesis	O
of	O
silver	O
nanoparticles	O
using	O
Borago	O
officinalis	O
leaf	O
extract	O
:	O
anticancer	B-T033
and	O
antibacterial	B-T033
activities	I-T033
This	O
study	O
highlights	O
the	O
facile	O
,	O
reliable	O
,	O
cost	O
effective	O
,	O
and	O
ecofriendly	O
synthesis	O
of	O
silver	O
nanoparticles	O
(	O
AgNPs	O
)	O
using	O
Borago	O
officinalis	O
leaves	O
extract	O
efficiently	O
.	O
The	O
biosynthesis	O
of	O
AgNPs	O
was	O
verified	O
by	O
UV	O
-	O
Vis	O
spectrum	O
which	O
showed	O
the	O
surface	O
plasmon	O
resonance	O
(	O
SPR	O
)	O
band	O
at	O
422	O
nm	O
.	O
Transmission	B-T059
electron	I-T059
microscope	I-T059
(	I-T059
TEM	I-T059
)	I-T059
analysis	I-T059
revealed	O
that	O
the	O
particles	O
were	O
spherical	O
,	O
hexagonal	O
,	O
and	O
irregular	O
in	O
shape	O
and	O
had	O
size	O
ranging	O
from	O
30	O
to	O
80	O
nm	O
.	O
The	O
energy	B-T059
dispersive	I-T059
X	I-T059
-	I-T059
ray	I-T059
spectroscopy	I-T059
(	O
EDX	B-T059
)	O
and	O
elemental	B-T059
mapping	I-T059
have	O
displayed	O
the	O
purity	O
and	O
maximum	O
distribution	O
of	O
silver	O
in	O
the	O
AgNPs	O
.	O
The	O
crystalline	O
nature	O
of	O
AgNPs	O
had	O
been	O
identified	O
using	O
X	B-T059
-	I-T059
ray	I-T059
diffraction	I-T059
(	O
XRD	B-T059
)	O
and	O
selected	B-T059
area	I-T059
diffraction	I-T059
pattern	I-T059
(	O
SAED	O
)	O
.	O
The	O
particle	O
size	O
analysis	O
revealed	O
that	O
the	O
Z	O
-	O
average	O
diameter	O
of	O
the	O
AgNPs	O
was	O
50.86	O
nm	O
with	O
polydispersity	O
index	O
(	O
PDI	O
)	O
0.136	O
.	O
Zeta	O
potential	O
analysis	O
displayed	O
the	O
colloidal	O
stability	O
of	O
AgNPs	O
.	O
This	O
work	O
also	O
showed	O
the	O
efficacy	O
of	O
AgNPs	O
against	O
lung	B-T023
cancer	O
cell	O
lines	O
(	O
A549	O
)	O
and	O
cervical	B-T023
cancer	O
cell	O
line	O
(	O
HeLa	O
)	O
,	O
in	O
vitro	O
.	O
The	O
AgNPs	O
showed	O
cytotoxicity	O
to	O
the	O
A549	O
and	O
HeLa	O
cancer	O
cell	O
line	O
at	O
the	O
concentrations	O
5	O
and	O
2	O
μg	O
/	O
ml	O
.	O
The	O
AgNPs	O
were	O
also	O
explored	O
for	O
the	O
antibacterial	B-T033
activity	I-T033
including	O
biofilm	B-T007
inhibition	O
against	O
pathogenic	B-T033
bacteria	B-T007
.	O
The	O
B.	O
officinalis	O
leaves	O
extract	O
can	O
be	O
used	O
efficiently	O
for	O
green	O
synthesis	O
AgNPs	O
.	O
The	O
biosynthesized	O
AgNPs	O
demonstrated	O
potentials	O
as	O
anticancer	B-T121
and	O
antibacterial	B-T195
agents	I-T195
.	O
This	O
work	O
provides	O
helpful	O
insight	O
into	O
the	O
development	O
of	O
new	O
anticancer	B-T121
and	O
antimicrobial	B-T121
agents	I-T121
.	O
      
Elastin	O
Is	O
Differentially	O
Regulated	O
by	O
Pressure	B-T061
Therapy	I-T061
in	O
a	O
Porcine	O
Model	O
of	O
Hypertrophic	B-T020
Scar	I-T020
Beneficial	O
effects	O
of	O
pressure	B-T061
therapy	I-T061
for	O
hypertrophic	B-T020
scars	I-T020
have	O
been	O
reported	O
,	O
but	O
the	O
mechanisms	O
of	O
action	O
are	O
not	O
fully	O
understood	O
.	O
This	O
study	O
evaluated	O
elastin	O
and	O
its	O
contribution	O
to	O
scar	B-T020
pliability	O
.	O
The	O
relationship	O
between	O
changes	O
in	O
Vancouver	O
Scar	O
Scale	O
(	O
VSS	O
)	O
scores	O
of	O
pressure	B-T061
-	I-T061
treated	I-T061
scars	B-T020
and	O
differential	O
regulation	O
of	O
elastin	O
was	O
assessed	O
.	O
Hypertrophic	B-T020
scars	I-T020
were	O
created	O
and	O
assessed	O
weekly	O
using	O
VSS	O
and	O
biopsy	B-T060
procurement	B-T033
.	O
Pressure	B-T061
treatment	I-T061
began	O
on	O
day	O
70	O
postinjury	O
.	O
Treated	B-T061
scars	B-T020
were	O
compared	O
with	O
untreated	O
shams	B-T061
.	O
Treatment	B-T061
lasted	O
2	O
weeks	O
,	O
through	O
day	O
84	O
,	O
and	O
scars	B-T020
were	O
assessed	O
weekly	O
through	O
day	O
126	O
.	O
Transcript	O
and	O
protein	O
levels	O
of	O
elastin	O
were	O
quantified	O
.	O
Pressure	B-T061
treatment	I-T061
resulted	O
in	O
lower	O
VSS	O
scores	O
compared	O
with	O
sham	B-T061
-	I-T061
treated	I-T061
scars	B-T020
.	O
Pliability	O
(	O
VSSP	O
)	O
was	O
a	O
key	O
contributor	O
to	O
this	O
difference	O
.	O
At	O
day	O
70	O
pretreatment	O
,	O
VSSP	O
=	O
2	O
.	O
Without	B-T061
treatment	I-T061
,	O
sham	B-T061
-	I-T061
treated	I-T061
scars	B-T020
became	O
less	O
pliable	O
,	O
while	O
pressure	B-T061
-	I-T061
treated	I-T061
scars	B-T020
became	O
more	O
pliable	O
.	O
The	O
percentage	O
of	O
elastin	O
in	O
scars	B-T020
at	O
day	O
70	O
was	O
higher	O
than	O
in	O
uninjured	O
skin	O
.	O
Following	O
treatment	B-T061
,	O
the	O
percentage	O
of	O
elastin	O
increased	O
and	O
continued	O
to	O
increase	O
through	O
day	O
126	O
.	O
Untreated	O
sham	B-T061
scars	B-T020
did	O
not	O
show	O
a	O
similar	O
increase	O
.	O
Quantification	O
of	O
Verhoeff	B-T059
-	I-T059
Van	I-T059
Gieson	I-T059
staining	I-T059
corroborated	O
the	O
findings	B-T033
and	O
immunofluorescence	B-T059
revealed	O
the	O
alignment	O
of	O
elastin	O
fibers	O
.	O
Pressure	B-T061
treatment	I-T061
results	O
in	O
increased	O
protein	O
level	O
expression	O
of	O
elastin	O
compared	O
with	O
sham	B-T061
-untreated	O
scars	B-T020
.	O
These	O
findings	B-T033
further	O
characterize	O
the	O
extracellular	O
matrix	O
's	O
response	O
to	O
the	O
application	O
of	O
pressure	O
as	O
a	O
scar	B-T020
treatment	B-T061
,	O
which	O
will	O
contribute	O
to	O
the	O
refinement	O
of	O
rehabilitation	O
practices	O
and	O
ultimately	O
improvements	O
in	O
functional	O
and	O
psychosocial	O
outcomes	O
for	O
patients	O
.	O
      
A	O
novel	O
rapid	O
analysis	O
using	O
mass	B-T059
spectrometry	I-T059
to	O
evaluate	O
downstream	O
refolding	O
of	O
recombinant	B-T121
human	I-T121
insulin	I-T121
-	I-T121
like	I-T121
growth	I-T121
factor-1	I-T121
(	O
mecasermin	B-T121
)	O
Mecasermin	B-T121
is	O
used	O
to	O
treat	O
elevated	B-T047
blood	I-T047
sugar	I-T047
as	O
well	O
as	O
growth	B-T121
hormone	I-T121
-	O
resistant	O
Laron	B-T047
-	I-T047
type	I-T047
dwarfism	I-T047
.	O
Mecasermin	B-T121
isolated	O
from	O
inclusion	O
bodies	O
in	O
extracts	O
of	O
E.coli	B-T007
must	O
be	O
refolded	O
to	O
acquire	O
sufficient	O
activity	O
.	O
However	O
,	O
there	O
is	O
no	O
rapid	O
analytical	O
method	O
for	O
monitoring	O
refolding	O
during	O
the	O
purification	B-T059
process	O
.	O
We	O
prepared	O
mecasermin	B-T121
drug	B-T121
product	I-T121
,	O
in	O
-	O
process	O
samples	O
during	O
the	O
oxidation	O
of	O
mecasermin	B-T121
,	O
forced	O
-	O
reduced	O
mecasermin	B-T121
,	O
and	O
aerially	O
oxidized	O
mecasermin	B-T121
after	O
forced	O
reduction	O
.	O
Desalted	O
mecasermin	B-T121
samples	O
were	O
analyzed	O
using	O
MALDI	B-T059
-	I-T059
ISD	I-T059
.	O
The	O
peak	O
intensity	O
ratio	O
of	O
product	O
to	O
precursor	O
ion	O
was	O
determined	O
.	O
The	O
charge	O
state	O
distribution	O
(	O
CSD	O
)	O
of	O
mecasermin	B-T121
ions	O
was	O
evaluated	O
using	O
ESI	B-T059
-	I-T059
MS	I-T059
coupled	O
with	O
SEC	O
-	O
mode	O
HPLC	B-T059
.	O
The	O
drift	O
time	O
and	O
collision	O
cross	O
-	O
sectional	O
areas	O
(	O
CCS	O
)	O
of	O
mecasermin	B-T121
ions	O
were	O
evaluated	O
using	O
ESI	B-T059
-	I-T059
IMS	I-T059
-	I-T059
MS	I-T059
coupled	O
with	O
SEC	O
-	O
mode	O
HPLC	B-T059
.	O
MALDI	B-T059
-	I-T059
ISD	I-T059
data	O
,	O
CSD	O
values	O
determined	O
using	O
ESI	B-T059
-	I-T059
MS	I-T059
,	O
and	O
the	O
CCS	O
acquired	O
using	O
ESI	B-T059
-	I-T059
IMS	I-T059
-	I-T059
MS	I-T059
revealed	O
the	O
relationship	O
between	O
the	O
folded	O
and	O
unfolded	O
proteoforms	O
of	O
forced	O
-	O
reduced	O
mecasermin	B-T121
and	O
aerially	O
oxidized	O
mecasermin	B-T121
with	O
the	O
free	O
-	O
SH	O
:	O
protein	O
ratio	O
of	O
mecasermin	B-T121
drug	B-T121
product	I-T121
.	O
The	O
collision	O
cross	O
-	O
sectional	O
area	O
,	O
which	O
is	O
determined	O
using	O
ESI	B-T059
-	I-T059
IMS	I-T059
-	I-T059
MS	I-T059
,	O
provided	O
proteoform	O
information	O
through	O
rapid	O
monitoring	O
(	O
<	O
2	O
min	O
)	O
of	O
in	O
-	O
process	O
samples	O
during	O
the	O
manufacture	O
of	O
mecasermin	B-T121
.	O
ESI	B-T059
-	I-T059
IMS	I-T059
-	I-T059
MS	I-T059
coupled	O
with	O
SEC	O
-	O
mode	O
HPLC	B-T059
is	O
a	O
rapid	O
and	O
robust	O
method	O
for	O
analyzing	O
the	O
free	O
-	O
SH	O
:	O
protein	O
ratio	O
of	O
mecasermin	B-T121
that	O
allows	O
evaluating	O
and	O
monitoring	O
proteoform	O
changes	O
during	O
the	O
oxidation	O
of	O
mecasermin	B-T121
.	O
ESI	B-T059
-	I-T059
IMS	I-T059
-	I-T059
MS	I-T059
is	O
applicable	O
as	O
a	O
process	O
analytical	O
technology	O
tool	O
for	O
identifying	O
the	O
"	O
critical	O
quality	O
attributes	O
"	O
and	O
implementing	O
"	O
quality	O
by	O
design	O
"	O
for	O
manufacturing	O
mecasermin	B-T121
.	O
      
Modification	O
of	O
Mechanical	O
Properties	O
,	O
Polymerization	O
Temperature	O
,	O
and	O
Handling	O
Time	O
of	O
Polymethylmethacrylate	O
Cement	O
for	O
Enhancing	O
Applicability	O
in	O
Vertebroplasty	B-T061
Polymethylmethacrylate	O
(	O
PMMA	O
)	O
bone	O
cement	O
is	O
a	O
popular	O
bone	B-T023
void	O
filler	O
for	O
vertebroplasty	B-T061
.	O
However	O
,	O
the	O
use	O
of	O
PMMA	O
has	O
some	O
drawbacks	O
,	O
including	O
the	O
material	O
's	O
excessive	O
stiffness	O
,	O
exothermic	O
polymerization	O
,	O
and	O
short	O
handling	O
time	O
.	O
This	O
study	O
aimed	O
to	O
create	O
an	O
ideal	O
modified	O
bone	O
cement	O
to	O
solve	O
the	O
above	O
-	O
mentioned	O
problems	B-T033
.	O
Modified	O
bone	O
cements	O
were	O
prepared	O
by	O
combining	O
PMMA	O
with	O
three	O
different	O
volume	O
fractions	O
of	O
castor	B-T121
oil	I-T121
(	O
5	O
%	O
,	O
10	O
%	O
,	O
and	O
15	O
%	O
)	O
.	O
The	O
peak	O
polymerization	O
temperatures	O
,	O
times	O
to	O
achieve	O
the	O
peak	O
polymerization	O
temperature	O
,	O
porosities	O
,	O
densities	O
,	O
modulus	O
and	O
maximum	O
compression	O
strengths	O
of	O
standard	O
(	O
without	O
castor	B-T121
oil	I-T121
)	O
,	O
and	O
modified	O
cements	O
were	O
investigated	O
following	O
storage	O
at	O
ambient	O
temperature	O
(	O
22	O
°	O
C	O
)	O
or	O
under	O
precooling	O
conditions	O
(	O
3	O
°	O
C	O
)	O
.	O
Six	O
specimens	O
were	O
tested	O
in	O
each	O
group	O
of	O
the	O
aforementioned	O
parameters	O
.	O
Increasing	O
castor	B-T121
oil	I-T121
content	O
and	O
precooling	O
treatment	O
effectively	O
decreased	O
the	O
peak	O
polymerization	O
temperatures	O
and	O
increased	O
the	O
duration	O
to	O
achieve	O
the	O
peak	O
polymerization	O
temperature	O
(	O
P	O
<	O
0.05	O
)	O
.	O
Furthermore	O
,	O
the	O
mechanical	O
properties	O
of	O
the	O
material	O
,	O
including	O
density	O
,	O
modulus	O
,	O
and	O
maximum	O
compression	O
strength	O
,	O
decreased	O
with	O
increasing	O
castor	B-T121
oil	I-T121
content	O
.	O
However	O
,	O
preparation	O
temperature	O
(	O
room	O
temperature	O
versus	O
precooling	O
)	O
had	O
no	O
significant	O
effect	O
(	O
P	O
>	O
0.05	O
)	O
on	O
these	O
mechanical	O
properties	O
.	O
In	O
conclusion	O
,	O
the	O
addition	O
of	O
castor	B-T121
oil	I-T121
to	O
PMMA	O
followed	O
by	O
precooling	O
created	O
an	O
ideal	O
modified	O
bone	O
cement	O
with	O
a	O
low	O
modulus	O
,	O
low	O
polymerization	O
temperature	O
,	O
and	O
long	O
handling	O
time	O
,	O
enhancing	O
its	O
applicability	O
and	O
safety	O
for	O
vertebroplasty	B-T061
.	O
      
Novel	O
Strategy	O
to	O
Expand	O
Super	O
-	O
Charged	O
NK	O
Cells	O
with	O
Significant	O
Potential	O
to	O
Lyse	O
and	O
Differentiate	O
Cancer	O
Stem	O
Cells	O
:	O
Differences	O
in	O
NK	O
Expansion	O
and	O
Function	O
between	O
Healthy	O
and	O
Cancer	O
Patients	O
Natural	O
killer	O
(	O
NK	O
)	O
cells	O
are	O
known	O
to	O
target	O
cancer	O
stem	O
cells	O
and	O
undifferentiated	B-T191
tumors	I-T191
.	O
In	O
this	O
paper	O
,	O
we	O
provide	O
a	O
novel	O
strategy	O
for	O
expanding	O
large	O
numbers	O
of	O
super	O
-	O
charged	O
NK	O
cells	O
with	O
significant	O
potential	O
to	O
lyse	O
and	O
differentiate	O
cancer	O
stem	O
cells	O
and	O
demonstrate	O
the	O
differences	O
in	O
the	O
dynamics	O
of	O
NK	O
cell	O
expansion	O
between	O
healthy	O
donors	O
and	O
cancer	O
patients	O
.	O
Decline	B-T033
in	I-T033
cytotoxicity	I-T033
and	O
lower	O
interferon	O
(	O
IFN)-γ	O
secretion	O
by	O
osteoclast	O
(	O
OC)-expanded	O
NK	O
cells	O
from	O
cancer	O
patients	O
correlates	O
with	O
faster	O
expansion	O
of	O
residual	O
contaminating	O
T	O
cells	O
within	O
purified	O
NK	O
cells	O
,	O
whereas	O
healthy	O
donors	O
'	O
OCs	O
continue	O
expanding	O
super	O
-	O
charged	O
NK	O
cells	O
while	O
limiting	O
T	O
cell	O
expansion	O
for	O
up	O
to	O
60	O
days	O
.	O
Similar	O
to	O
patient	O
NK	O
cells	O
,	O
NK	O
cells	O
from	O
tumor	B-T191
-bearing	O
BLT	B-T050
-	I-T050
humanized	I-T050
mice	I-T050
promote	O
faster	O
expansion	O
of	O
residual	O
T	B-T033
cells	I-T033
resulting	I-T033
in	I-T033
decreased	I-T033
numbers	I-T033
and	O
function	O
of	O
NK	O
cells	O
,	O
whereas	O
NK	O
cells	O
from	O
mice	O
with	O
no	B-T033
tumor	B-T191
continue	O
expanding	O
NK	O
cells	O
and	O
retain	O
their	O
cytotoxicity	O
.	O
In	O
addition	O
,	O
dendritic	O
cells	O
(	O
DCs	O
)	O
in	O
contrast	O
to	O
OCs	O
are	O
found	O
to	O
promote	O
faster	O
expansion	O
of	O
residual	O
T	O
cells	O
within	O
purified	O
NK	O
cells	O
resulting	O
in	O
the	O
decline	B-T033
in	I-T033
NK	I-T033
cell	I-T033
numbers	I-T033
from	O
healthy	O
individuals	O
.	O
Addition	O
of	O
anti	O
-	O
CD3	O
mAb	O
inhibits	O
T	O
cell	O
proliferation	O
while	O
enhancing	O
NK	O
cell	O
expansion	O
;	O
however	O
,	O
expanding	O
NK	O
cells	O
have	O
lower	O
cytotoxicity	O
but	O
higher	O
secretion	O
of	O
IFN	O
-	O
γ	O
.	O
Expansion	O
and	O
functional	O
activation	O
of	O
super	O
-	O
charged	O
NK	O
cells	O
by	O
OCs	O
is	O
dependent	O
on	O
interleukin	B-T121
(	I-T121
IL)-12	I-T121
and	O
IL-15	O
.	O
Thus	O
,	O
in	O
this	O
report	O
,	O
we	O
not	O
only	O
provide	O
a	O
novel	O
strategy	O
to	O
expand	O
super	O
-	O
charged	O
NK	O
cells	O
,	O
but	O
also	O
demonstrate	O
that	O
rapid	O
and	O
sustained	O
expansion	O
of	O
residual	O
T	O
cells	O
within	O
the	O
purified	O
NK	O
cells	O
during	O
expansion	O
with	O
DCs	O
or	O
OCs	O
could	O
be	O
a	O
potential	O
mechanism	O
by	O
which	O
the	O
numbers	O
and	O
function	O
of	O
NK	B-T033
cells	I-T033
decline	I-T033
in	O
cancer	O
patients	O
and	O
in	O
BLT	B-T050
-	I-T050
humanized	I-T050
mice	I-T050
.	O
      
Genetically	O
encoded	O
calcium	O
indicators	O
for	O
studying	O
long	O
-	O
term	O
calcium	B-T121
dynamics	O
during	O
apoptosis	O
Intracellular	O
calcium	O
release	O
is	O
essential	O
for	O
regulating	O
almost	O
all	O
cellular	O
functions	O
.	O
Specific	O
spatio	O
-	O
temporal	O
patterns	O
of	O
cytosolic	O
calcium	B-T121
elevations	O
are	O
critical	O
determinants	O
of	O
cell	O
fate	O
in	O
response	O
to	O
pro	O
-	O
apoptotic	O
cellular	O
stressors	O
.	O
As	O
the	O
apoptotic	O
program	O
can	O
take	O
hours	O
or	O
days	O
,	O
measurement	O
of	O
long	O
-	O
term	O
calcium	B-T121
dynamics	O
are	O
essential	O
for	O
understanding	O
the	O
mechanistic	O
role	O
of	O
calcium	B-T121
in	O
apoptotic	O
cell	O
death	O
.	O
Due	O
to	O
the	O
technical	O
limitations	O
of	O
using	O
calcium	B-T121
-	O
sensitive	O
dyes	O
to	O
measure	O
cytosolic	O
calcium	B-T121
little	O
is	O
known	O
about	O
long	O
-	O
term	O
calcium	B-T121
dynamics	O
in	O
living	O
cells	O
after	O
treatment	B-T061
with	O
apoptosis	O
-	O
inducing	O
drugs	B-T121
.	O
Genetically	O
encoded	O
calcium	O
indicators	O
could	O
potentially	O
overcome	O
some	O
of	O
the	O
limitations	O
of	O
calcium	B-T121
-	O
sensitive	O
dyes	O
.	O
Here	O
,	O
we	O
compared	O
the	O
performance	O
of	O
the	O
genetically	O
encoded	O
calcium	B-T121
indicators	O
GCaMP6s	O
and	O
GCaMP6f	O
with	O
the	O
ratiometric	O
dye	O
Fura-2	O
.	O
GCaMP6s	O
performed	O
as	O
well	O
or	O
better	O
than	O
Fura-2	O
in	O
detecting	O
agonist	B-T121
-	O
induced	O
calcium	B-T121
transients	O
.	O
We	O
then	O
examined	O
the	O
utility	O
of	O
GCaMP6s	O
for	O
continuously	O
measuring	O
apoptotic	O
calcium	B-T059
release	I-T059
over	O
the	O
course	O
of	O
ten	O
hours	O
after	O
treatment	B-T061
with	O
staurosporine	B-T121
.	O
We	O
found	O
that	O
GCaMP6s	O
was	O
suitable	O
for	O
measuring	O
apoptotic	O
calcium	B-T059
release	I-T059
over	O
long	O
time	O
courses	O
and	O
revealed	O
significant	O
heterogeneity	O
in	O
calcium	B-T059
release	I-T059
dynamics	O
in	O
individual	O
cells	O
challenged	O
with	O
staurosporine	B-T121
.	O
Our	O
results	O
suggest	O
GCaMP6s	O
is	O
an	O
excellent	O
indicator	O
for	O
monitoring	B-T058
long	O
-	O
term	O
changes	O
cytosolic	O
calcium	B-T121
during	O
apoptosis	O
.	O
      
Anti	O
-	O
inflammatory	O
effect	O
of	O
Yu	B-T121
-	I-T121
Ping	I-T121
-	I-T121
Feng	I-T121
-	I-T121
San	I-T121
via	O
TGF	B-T121
-	I-T121
β1	I-T121
signaling	O
suppression	O
in	O
rat	O
model	B-T050
of	O
COPD	B-T047
Yu	B-T121
-	I-T121
Ping	I-T121
-	I-T121
Feng	I-T121
-	I-T121
San	I-T121
(	O
YPFS	B-T121
)	O
is	O
a	O
classical	O
traditional	O
Chinese	B-T121
medicine	I-T121
that	O
is	O
widely	O
used	O
for	O
treatment	O
of	O
the	O
diseases	B-T047
in	O
respiratory	O
systems	O
,	O
including	O
chronic	B-T047
obstructive	I-T047
pulmonary	I-T047
disease	I-T047
(	O
COPD	B-T047
)	O
recognized	O
as	O
chronic	B-T047
inflammatory	I-T047
disease	I-T047
.	O
However	O
,	O
the	O
molecular	O
mechanism	O
remains	O
unclear	O
.	O
Here	O
we	O
detected	O
the	O
factors	O
involved	O
in	O
transforming	B-T121
growth	I-T121
factor	I-T121
beta	I-T121
1	I-T121
(	O
TGF	B-T121
-	I-T121
β1	I-T121
β1)/	O
Smad2	O
signaling	O
pathway	O
and	O
inflammatory	O
cytokines	O
,	O
to	O
clarify	O
whether	O
YPFS	B-T121
could	O
attenuate	O
inflammatory	O
response	O
dependent	O
on	O
TGF	B-T121
-	I-T121
β1	I-T121
/	O
Smad2	O
signaling	O
in	O
COPD	B-T047
rats	O
or	O
cigarette	O
smoke	O
extract	O
(	O
CSE)-	O
treated	O
human	O
bronchial	O
epithelial	O
(	O
Beas-2B	O
)	O
cells	O
.	O
The	O
COPD	B-T047
rat	O
model	B-T050
was	O
established	O
by	O
exposure	O
to	O
cigarette	O
smoke	O
and	O
intratracheal	O
instillation	O
of	O
lipopolysaccharide	O
,	O
YPFS	B-T121
was	O
administered	O
to	O
the	O
animals	O
.	O
The	O
efficacy	O
of	O
YPFS	B-T121
was	O
evaluated	O
by	O
comparing	O
the	O
severity	O
of	O
pulmonary	O
pathological	O
damage	O
,	O
pro	O
-	O
inflammation	O
cytokines	O
,	O
collagen	O
related	O
genes	O
and	O
the	O
activation	O
of	O
TGF	B-T121
-	I-T121
β1	I-T121
/	O
Smad2	O
signaling	O
pathway	O
.	O
Furthermore	O
,	O
CSE	O
-	O
treated	O
cells	O
were	O
employed	O
to	O
confirm	O
whether	O
the	O
effect	O
of	O
YPFS	B-T121
was	O
dependent	O
on	O
the	O
TGF	B-T121
-	I-T121
β1	I-T121
/	O
Smad2	O
signaling	O
via	O
knockdown	O
Smad2	O
(	O
Si	O
-	O
RNA	O
)	O
,	O
or	O
pretreatment	O
with	O
the	O
inhibitor	O
of	O
TGF	B-T121
-	I-T121
β1	I-T121
.	O
Administration	O
of	O
YPFS	B-T121
effectively	O
alleviated	O
injury	O
of	O
lung	O
,	O
suppressed	O
releasing	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
and	O
collagen	O
deposition	O
in	O
COPD	B-T047
animals	O
(	O
P<0.05	O
)	O
,	O
whereas	O
exogenous	B-T121
TGF	I-T121
-	I-T121
β1	I-T121
promoted	O
releasing	O
of	O
IL-1β	O
,	O
IL-6	O
,	O
TNFα	O
(	O
P<0.05	O
)	O
.	O
Administration	O
YPFS	B-T121
reduced	O
inflammatory	O
response	O
significantly	O
,	O
also	O
down	O
-	O
regulated	O
TGF	B-T121
-	I-T121
β1	I-T121
/	O
Smad2	O
signaling	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O
Unexpectedly	O
,	O
knockdown	O
Smad2	O
or	O
inhibition	O
of	O
TGF	B-T121
-	I-T121
β1	I-T121
abolished	O
anti	O
-	O
inflammatory	O
effect	O
of	O
YPFS	B-T121
in	O
CSE	O
-	O
treated	O
cells	O
.	O
YPFS	B-T121
accomplished	O
anti	O
-	O
inflammatory	O
effects	O
mainly	O
by	O
suppressing	O
phosphorylation	O
of	O
Smad2	O
,	O
TGF	B-T121
-	I-T121
β1	I-T121
/	O
Smad2	O
signaling	O
pathway	O
was	O
required	O
for	O
YPFS	B-T121
-mediated	O
anti	O
-	O
inflammation	O
in	O
COPD	B-T047
rats	O
or	O
CSE	O
-	O
treated	O
Beas-2B	O
cells	O
.	O
      
Evidence	O
of	O
toothpick	O
groove	O
formation	O
in	O
Neandertal	O
anterior	O
and	O
posterior	O
teeth	B-T023
During	O
the	O
microscopic	B-T059
examination	I-T059
of	O
the	O
Neandertal	O
dentitions	B-T023
from	O
El	O
Sidrón	O
(	O
Spain	O
)	O
and	O
Hortus	O
(	O
France	O
)	O
,	O
we	O
found	O
unusual	O
fine	O
parallel	O
microstriations	O
on	O
the	O
mesial	O
and	O
distal	O
sides	O
of	O
all	O
tooth	B-T023
types	O
,	O
near	O
the	O
cervix	O
.	O
As	O
its	O
appearance	O
was	O
similar	O
to	O
toothpick	O
grooves	O
described	O
in	O
other	O
Homo	O
species	O
,	O
it	O
could	O
correspond	O
to	O
early	O
stages	O
on	O
its	O
formation	O
.	O
To	O
test	O
this	O
hypothesis	O
we	O
developed	O
an	O
experimental	O
replication	O
of	O
a	O
groove	O
using	O
grass	O
stalks	O
.	O
Comparisons	O
between	O
204	O
isolated	O
Neandertal	O
teeth	B-T023
and	O
the	O
two	O
experimental	O
dental	O
specimens	O
corroborate	O
that	O
the	O
marks	B-T184
correspond	O
to	O
initial	O
stages	O
of	O
toothpick	O
groove	O
formation	O
,	O
and	O
we	O
propose	O
a	O
five	O
-	O
grade	O
recording	O
scale	O
that	O
summarized	O
the	O
groove	O
formation	O
process	O
.	O
Using	O
this	O
new	O
recording	O
procedure	O
,	O
we	O
found	O
that	O
Hortus	O
individuals	O
have	O
higher	O
incidence	O
of	O
this	O
trait	O
(	O
eight	O
individuals	O
out	O
of	O
nine	O
)	O
than	O
the	O
El	O
Sidrón	O
individuals	O
(	O
nine	O
out	O
of	O
11	O
)	O
.	O
Toothpick	O
grooves	O
from	O
El	O
Sidrón	O
show	O
the	O
earliest	O
stages	O
of	O
development	O
,	O
whereas	O
the	O
grooves	O
found	O
on	O
Hortus	O
Neandertals	O
were	O
well	O
-	O
developed	O
.	O
Toothpick	O
grooves	O
were	O
also	O
found	O
in	O
21	O
incisors	B-T023
and	O
canines	B-T023
.	O
These	O
differences	O
could	O
be	O
due	O
to	O
the	O
more	O
advanced	O
occlusal	O
dental	O
wear	O
in	O
Hortus	O
individuals	O
,	O
maybe	O
age	O
-related	O
and	O
with	O
a	O
more	O
meat	O
-based	O
diet	O
maybe	O
favoring	O
the	O
inclusion	O
of	O
food	O
debris	O
and	O
thus	O
probing	O
as	O
the	O
cleaning	O
methodology	O
.	O
Our	O
results	O
allow	O
the	O
identification	O
and	O
characterization	O
of	O
incipient	O
toothpick	O
grooves	O
on	O
the	O
human	O
fossil	O
record	O
and	O
contribute	O
to	O
increase	O
our	O
knowledge	O
on	O
Neandertals	O
behavioral	O
and	O
oral	B-T033
care	I-T033
habits	I-T033
.	O
      
The	O
value	O
of	O
transesophageal	B-T060
echocardiography	I-T060
for	O
embolic	B-T047
strokes	I-T047
of	I-T047
undetermined	I-T047
source	I-T047
Our	O
aim	O
was	O
to	O
evaluate	O
the	O
diagnostic	B-T060
yield	I-T060
of	O
transesophageal	B-T060
echocardiography	I-T060
(	O
TEE	B-T060
)	O
in	O
consecutive	O
patients	O
with	O
ischemic	B-T047
stroke	I-T047
(	O
IS	B-T047
)	O
fulfilling	O
the	O
diagnostic	O
criteria	O
of	O
embolic	B-T047
strokes	I-T047
of	I-T047
undetermined	I-T047
source	I-T047
(	O
ESUS	B-T047
)	O
.	O
We	O
prospectively	O
evaluated	O
consecutive	O
patients	O
with	O
acute	O
IS	B-T047
satisfying	O
ESUS	B-T047
criteria	O
who	O
underwent	O
in-	O
hospital	O
TEE	B-T060
examination	I-T060
in	O
3	O
tertiary	O
care	O
stroke	O
centers	O
during	O
a	O
12	O
-	O
month	O
period	O
.	O
We	O
also	O
performed	O
a	O
systematic	O
review	O
and	O
meta	O
-	O
analysis	O
estimating	O
the	O
cumulative	O
effect	O
of	O
TEE	B-T060
findings	B-T033
on	O
therapeutic	O
management	O
for	O
secondary	B-T061
stroke	I-T061
prevention	I-T061
among	O
different	O
IS	B-T047
subgroups	O
.	O
We	O
identified	O
61	O
patients	O
with	O
ESUS	B-T047
who	O
underwent	B-T058
investigation	I-T058
with	O
TEE	B-T060
(	O
mean	O
age	O
44	O
±	O
12	O
years	O
,	O
49	O
%	O
men	O
,	O
median	O
NIH	O
Stroke	O
Scale	O
score	O
=	O
5	O
points	O
[	O
interquartile	O
range	O
:	O
3	O
-	O
8	O
]	O
)	O
.	O
TEE	B-T060
revealed	O
additional	O
findings	B-T033
in	O
52	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
:	O
40%-65	O
%	O
)	O
of	O
the	O
study	O
population	O
.	O
TEE	B-T060
findings	B-T033
changed	O
management	O
(	O
initiation	O
of	O
anticoagulation	B-T061
therapy	I-T061
,	O
administration	B-T061
of	O
IV	B-T061
antibiotic	I-T061
therapy	I-T061
,	O
and	O
patent	B-T061
foramen	I-T061
ovale	I-T061
closure	I-T061
)	O
in	O
10	O
(	O
16	O
%	O
[	O
95	O
%	O
CI	O
:	O
9%-28	O
%	O
]	O
)	O
patients	O
.	O
The	O
pooled	O
rate	O
of	O
reported	O
anticoagulation	B-T061
therapy	I-T061
attributed	O
to	O
abnormal	B-T033
TEE	B-T060
findings	B-T033
among	O
3,562	O
acute	O
IS	B-T047
patients	O
included	O
in	O
the	O
meta	O
-	O
analysis	O
(	O
12	O
studies	O
)	O
was	O
8.7	O
%	O
(	O
95	O
%	O
CI	O
:	O
7.3%-10.4	O
%	O
)	O
.	O
In	O
subgroup	O
analysis	O
,	O
the	O
rates	O
of	O
initiation	O
of	O
anticoagulation	B-T061
therapy	I-T061
on	O
the	O
basis	O
of	O
TEE	B-T060
investigation	O
did	O
not	O
differ	O
(	O
p	O
=	O
0.315	O
)	O
among	O
patients	O
with	O
cryptogenic	O
stroke	O
(	O
6.9	O
%	O
[	O
95	O
%	O
CI	O
:	O
4.9%-9.6	O
%	O
]	O
)	O
,	O
ESUS	B-T047
(	O
8.1	O
%	O
[	O
95	O
%	O
CI	O
:	O
3.4%-18.1	O
%	O
]	O
)	O
,	O
and	O
IS	B-T047
(	O
9.4	O
%	O
[	O
95	O
%	O
CI	O
:	O
7.5%-11.8	O
%	O
]	O
)	O
.	O
Abnormal	O
TEE	B-T060
findings	B-T033
may	O
decisively	O
affect	O
the	O
selection	O
of	O
appropriate	O
therapeutic	B-T061
strategy	I-T061
in	O
approximately	O
1	O
of	O
7	O
patients	O
with	O
ESUS	B-T047
.	O
      
Treating	O
the	O
binge	B-T048
or	O
the	O
(	B-T023
fat	I-T023
)	I-T023
body	I-T023
?	O
Representations	O
of	O
fatness	B-T033
in	O
a	O
gold	O
standard	O
psychological	O
treatment	O
manual	O
for	O
binge	B-T048
eating	I-T048
disorder	I-T048
This	O
article	O
reports	B-T058
the	O
results	O
of	O
a	O
Foucauldian	O
-informed	O
discourse	O
analysis	O
exploring	O
representations	O
of	O
fatness	B-T033
embedded	O
within	O
an	O
empirically	O
based	O
psychological	O
treatment	O
manual	O
for	O
binge	B-T048
eating	I-T048
disorder	I-T048
,	O
a	O
condition	O
characterized	O
by	O
overvaluation	O
of	O
weight	O
and	O
shape	O
.	O
Analyses	O
indicate	B-T033
that	O
the	O
manual	O
prioritizes	O
weight	B-T033
loss	I-T033
with	O
relatively	O
less	O
emphasis	O
placed	O
on	O
treating	O
the	O
diagnostic	O
symptoms	B-T184
and	O
underlying	O
mechanisms	O
of	O
binge	B-T048
eating	I-T048
disorder	I-T048
.	O
We	O
raise	O
critical	B-T033
concerns	I-T033
about	O
these	O
observations	O
and	O
link	O
our	O
findings	B-T033
to	O
mainstream	O
psychology	O
's	O
adoption	O
of	O
the	O
medical	O
framing	O
of	O
fatness	B-T033
as	O
obesity	B-T047
within	O
the	O
"	O
gold	O
standard	O
"	O
approach	O
to	O
intervention	B-T058
.	O
We	O
recommend	O
that	O
psychology	O
as	O
a	O
discipline	B-T058
abandons	O
the	O
weight	B-T033
loss	I-T033
imperative	O
associated	O
with	O
binge	B-T048
eating	I-T048
disorder	I-T048
and	O
fat	B-T023
bodies	I-T023
.	O
We	O
recommend	O
that	O
practitioners	O
locate	O
the	O
problem	B-T033
of	O
fat	O
shame	O
in	O
society	O
as	O
opposed	O
to	O
the	O
individual	O
person	O
's	O
body	O
and	O
provide	O
individuals	O
with	O
tools	O
to	O
identify	O
and	O
resist	O
fat	B-T033
stigma	I-T033
and	O
oppression	O
,	O
rather	O
than	O
provide	O
them	O
with	O
tools	O
to	O
reshape	O
their	O
bodies	O
.	O
      
Lipid	B-T059
levels	I-T059
and	O
risk	O
of	O
recurrent	O
venous	O
thrombosis	O
:	O
results	O
from	O
the	O
MEGA	O
follow	O
-	O
up	O
study	O
Essentials	O
The	O
role	O
of	O
lipid	B-T059
levels	I-T059
in	O
the	O
risk	O
of	O
recurrent	O
venous	O
thrombosis	O
is	O
unclear	B-T033
.	O
Lipids	O
were	O
assessed	O
in	O
patients	O
with	O
a	O
first	O
venous	O
thrombosis	O
(	O
n	O
=	O
2106	O
)	O
followed	O
for	O
6.9	O
years	O
.	O
Lipids	O
were	O
not	O
associated	O
with	O
recurrence	O
,	O
overall	O
or	O
in	O
patients	O
with	O
unprovoked	O
first	O
events	O
.	O
Testing	B-T059
lipid	I-T059
levels	I-T059
is	O
not	O
useful	O
to	O
identify	O
patients	O
at	O
an	O
increased	O
risk	O
of	O
recurrence	O
.	O
Background	O
Knowledge	O
of	O
risk	B-T033
factors	I-T033
for	O
recurrent	O
venous	O
thrombosis	O
may	O
guide	O
decisions	O
on	O
duration	O
of	O
anticoagulation	B-T061
.	O
The	O
association	O
between	O
lipid	B-T059
levels	I-T059
and	O
first	O
venous	O
thrombosis	O
has	O
been	O
studied	O
extensively	O
.	O
However	O
,	O
data	O
on	O
the	O
role	O
of	O
lipids	O
in	O
the	O
risk	O
of	O
recurrence	O
are	O
scarce	O
.	O
Objective	O
To	O
assess	O
the	O
association	O
between	O
lipid	B-T059
levels	I-T059
and	O
recurrent	O
venous	O
thrombosis	O
.	O
Patients	O
/Methods	O
Patients	O
with	O
a	O
first	O
venous	O
thrombosis	O
from	O
the	O
MEGA	O
study	O
were	O
included	O
.	O
Follow	B-T058
-	I-T058
up	I-T058
started	O
at	O
the	O
date	O
of	O
end	O
of	O
anticoagulant	B-T061
treatment	I-T061
.	O
Percentile	O
categories	O
of	O
total	O
/	O
low	O
-	O
density	O
lipoprotein	O
/	O
high	O
-	O
density	O
lipoprotein	O
cholesterol	O
,	O
triglycerides	O
and	O
apolipoproteins	O
B	O
and	O
A1	O
were	O
established	O
(	O
<	O
10th	O
,	O
10th-25th	O
,	O
25th-75th	O
[	O
reference	O
]	O
,	O
75th-90th	O
,	O
>	O
90th	O
percentile	O
)	O
.	O
Lipids	O
were	O
measured	O
at	O
least	O
3	O
months	O
after	O
discontinuing	B-T033
anticoagulation	B-T061
.	O
Results	O
Of	O
2106	O
patients	O
followed	O
for	O
a	O
median	O
of	O
6.9	O
years	O
,	O
326	O
developed	O
recurrence	O
(	O
incidence	O
rate	O
,	O
2.7/100	O
patient	O
-	O
years	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
2.5	O
-	O
3.1	O
)	O
.	O
With	O
hazard	O
ratios	O
ranging	O
from	O
0.88	O
(	O
95	O
%	O
CI	O
,	O
0.55	O
-	O
1.42	O
)	O
to	O
1.33	O
(	O
95	O
%	O
CI	O
,	O
0.86	O
-	O
2.04	O
)	O
in	O
the	O
highest	O
percentile	O
category	O
vs.	O
the	O
reference	O
,	O
we	O
found	O
no	O
association	O
across	O
percentile	O
categories	O
between	O
recurrence	O
and	O
lipid	B-T059
levels	I-T059
in	O
age-	O
and	O
sex	O
-adjusted	O
models	O
,	O
nor	O
after	O
further	O
adjustments	O
for	O
body	O
mass	O
index	O
,	O
diabetes	B-T047
,	O
estrogen	B-T121
and	O
statin	B-T121
use	O
,	O
and	O
duration	O
of	O
anticoagulation	B-T061
.	O
Subgroup	O
analyses	O
stratified	O
by	O
unprovoked	O
or	O
provoked	O
first	O
events	O
,	O
location	O
(	O
deep	B-T047
vein	I-T047
thrombosis	I-T047
or	O
pulmonary	B-T047
embolism	I-T047
)	O
and	O
sex	O
also	O
did	O
not	O
reveal	O
an	O
association	O
with	O
any	O
of	O
the	O
lipid	B-T059
levels	I-T059
studied	O
.	O
Conclusions	O
Testing	B-T059
lipid	I-T059
levels	I-T059
did	O
not	O
identify	O
patients	O
at	O
an	O
increased	O
risk	O
of	O
recurrent	O
venous	O
thrombosis	O
in	O
this	O
study	O
,	O
including	O
those	O
with	O
unprovoked	O
first	O
events	O
,	O
and	O
these	O
should	O
not	O
influence	O
decisions	O
on	O
duration	O
of	O
anticoagulation	B-T061
.	O
      
The	O
burden	O
of	O
HPV	B-T005
-related	O
diseases	B-T047
in	O
Italy	O
,	O
2001	O
-	O
12	O
Human	B-T047
papillomavirus	I-T047
(	I-T047
HPV	I-T047
)	I-T047
infection	I-T047
is	O
the	O
main	O
cause	O
of	O
cervical	B-T191
cancer	I-T191
and	O
plays	O
a	O
relevant	O
role	O
in	O
the	O
development	O
of	O
genital	B-T047
warts	I-T047
and	O
of	O
the	O
cancer	B-T191
of	O
penis	B-T023
and	O
anus	B-T023
,	O
head	O
/	O
neck	O
,	O
oropharynx	O
and	O
genitourinary	O
system	O
.	O
The	O
aim	O
of	O
this	O
study	O
is	O
the	O
evaluation	O
of	O
hospitalizations	B-T058
due	O
to	O
HPV	B-T047
-	I-T047
related	I-T047
pathologies	I-T047
in	O
2001	O
-	O
12	O
in	O
Italy	O
.	O
The	O
national	B-T058
hospital	I-T058
discharge	I-T058
forms	O
were	O
provided	O
by	O
the	O
Ministry	O
of	O
Health	O
.	O
The	O
HPV	B-T005
-related	O
hospitalizations	B-T058
were	O
identified	O
using	O
specific	O
diagnostic	O
codes	O
,	O
accordingly	O
to	O
the	O
ICD-9	O
-	O
CM	O
coding	O
system	O
.	O
The	O
proportion	O
of	O
hospitalizations	B-T058
of	O
potentially	O
HPV	B-T047
-	I-T047
related	I-T047
pathologies	I-T047
,	O
obtained	O
from	O
the	O
literature	O
,	O
was	O
evaluated	O
as	O
well	O
as	O
the	O
hospitalization	O
rates	O
(	O
hr	O
)	O
and	O
their	O
trend	O
over	O
time	O
.	O
Uterine	B-T191
cervical	I-T191
cancer	I-T191
and	O
CIN	B-T191
III	I-T191
accounted	O
for	O
40	O
%	O
of	O
hospitalizations	B-T058
(	O
hr	O
:	O
15.6/100	O
000	O
and	O
17.6/100	O
000	O
,	O
respectively	O
)	O
.	O
Head	O
/	O
neck	O
and	O
oropharynx	O
pathologies	O
accounted	O
for	O
24.5	O
%	O
of	O
cases	O
(	O
hr	O
:	O
16/100	O
000	O
and	O
3.9/100	O
000	O
,	O
in	O
males	O
and	O
females	O
,	O
respectively	O
)	O
,	O
followed	O
by	O
genital	B-T047
warts	I-T047
(	O
17.3	O
%	O
of	O
hospitalizations	B-T058
;	O
hr	O
:	O
7.5/100	O
000	O
in	O
males	O
and	O
8.52/100	O
000	O
in	O
females	O
)	O
,	O
anal	B-T191
(	O
8.1	O
%	O
of	O
hospitalizations	B-T058
)	O
,	O
genitourinary	B-T191
(	O
7.7	O
%	O
)	O
and	O
penis	B-T191
cancers	I-T191
(	O
2.2	O
%	O
)	O
.	O
The	O
study	O
,	O
even	O
if	O
limited	O
to	O
the	O
evaluation	O
of	O
hospitalizations	B-T058
,	O
points	O
out	O
how	O
HPV	B-T047
-	I-T047
related	I-T047
pathologies	I-T047
continue	O
to	O
be	O
a	O
relevant	O
public	O
health	O
issue	B-T033
in	O
Italy	O
with	O
a	O
high	O
impact	O
on	O
population	O
.	O
      
Air	O
pollution	O
characteristics	O
and	O
health	B-T061
risks	I-T061
in	O
Henan	O
Province	O
,	O
China	O
Events	O
of	O
severe	O
air	O
pollution	O
occurred	O
frequently	O
in	O
China	O
recently	O
,	O
thus	O
understanding	O
of	O
the	O
air	O
pollution	O
characteristics	O
and	O
its	O
health	O
risks	O
is	O
very	O
important	O
.	O
In	O
this	O
work	O
,	O
we	O
analyzed	O
a	O
two	O
-	O
year	O
dataset	O
(	O
March	O
2014	O
-	O
February	O
2016	O
)	O
including	O
daily	O
concentrations	O
of	O
six	O
criteria	O
pollutants	O
(	O
PM2.5	O
,	O
PM10	O
,	O
CO	O
,	O
SO2	O
,	O
NO2	O
,	O
and	O
O3	O
)	O
from	O
18	O
cities	O
in	O
Henan	O
province	O
.	O
Results	O
reveal	O
the	O
serious	O
air	O
pollution	O
status	O
in	O
Henan	O
province	O
,	O
especially	O
the	O
northern	O
part	O
,	O
and	O
Zhengzhou	O
is	O
the	O
city	O
with	O
the	O
worst	O
air	O
quality	O
.	O
Annual	O
average	O
PM2.5	O
concentrations	O
exceed	O
the	O
second	O
grade	O
of	O
Chinese	O
Ambient	O
Air	O
Quality	O
Standard	O
(	O
75μg	O
/	O
m(3	O
)	O
)	O
at	O
both	O
2014	O
and	O
2015	O
.	O
PM2.5	O
is	O
typically	O
the	O
major	O
pollutant	O
,	O
but	O
ozone	O
pollution	O
can	O
be	O
significant	O
during	O
summer	O
.	O
Furthermore	O
,	O
as	O
the	O
commonly	O
used	O
air	O
quality	O
index	O
(	O
AQI	O
)	O
neglects	O
the	O
mutual	O
health	O
effects	O
from	O
multiple	O
pollutants	O
,	O
we	O
introduced	O
the	O
aggregate	O
air	O
quality	O
index	O
(	O
AAQI	O
)	O
and	O
health	O
-	O
risk	O
based	O
air	O
quality	O
index	O
(	O
HAQI	O
)	O
to	O
evaluate	B-T061
the	I-T061
health	I-T061
risks	I-T061
.	O
Results	O
show	O
that	O
based	O
on	O
HAQI	O
,	O
the	O
current	O
AQI	O
system	O
likely	O
significantly	O
underestimate	O
the	O
health	O
risks	O
of	O
air	O
pollution	O
,	O
highlighting	O
that	O
the	O
general	O
public	O
may	O
need	O
stricter	O
health	B-T058
protection	I-T058
measures	I-T058
.	O
The	O
population	O
-weighted	O
two	O
-	O
year	O
average	O
HAQI	O
data	O
further	O
demonstrates	O
that	O
all	O
population	O
in	O
the	O
studied	O
cities	O
in	O
Henan	O
province	O
live	O
with	O
polluted	O
air	O
-	O
72	O
%	O
of	O
the	O
population	O
is	O
exposed	O
to	O
air	O
that	O
is	O
unhealthy	B-T033
for	O
sensitive	O
people	O
,	O
while	O
28	O
%	O
of	O
people	O
is	O
exposed	O
to	O
air	O
that	O
can	O
be	O
harmful	O
to	O
healthy	O
people	O
;	O
and	O
the	O
health	O
risks	O
are	O
much	O
greater	O
during	O
winter	O
than	O
during	O
other	O
seasons	O
.	O
Future	O
works	O
should	O
further	O
improve	O
the	O
HAQI	O
algorithm	O
,	O
and	O
validate	O
the	O
links	O
between	O
the	O
clinical	O
/	O
epidemiologic	O
data	O
and	O
the	O
HAQI	O
values	O
.	O
      
In	O
Search	O
of	O
the	O
E.	B-T007
coli	I-T007
Compounds	O
that	O
Change	O
the	O
Antibiotic	B-T195
Production	O
Pattern	O
of	O
Streptomyces	B-T007
coelicolor	I-T007
During	O
Inter	O
-	O
species	O
Interaction	O
The	O
aim	O
of	O
this	O
work	O
was	O
to	O
investigate	O
the	O
interaction	O
between	O
E.coli	B-T007
and	O
Streptomyces	B-T007
coelicolor	I-T007
A3	I-T007
(	I-T007
2	I-T007
)	I-T007
for	O
the	O
increased	O
production	O
of	O
undecylprodigiosin	B-T121
and	O
identify	O
the	O
E.	B-T007
coli	I-T007
actives	O
mediating	O
this	O
inter	O
-	O
species	O
interaction	O
.	O
The	O
antibiotics	B-T195
of	O
interest	O
were	O
the	O
red	B-T121
-	I-T121
pigmented	I-T121
undecylprodigiosin	I-T121
and	O
blue	O
-	O
pigmented	O
actinorhodin	B-T195
.	O
Pure	O
cultures	B-T059
of	O
S.	B-T007
coelicolor	I-T007
in	O
a	O
defined	O
medium	O
produced	O
higher	O
concentrations	O
of	O
actinorhodin	B-T195
compared	O
to	O
those	O
of	O
undecylprodigiosin	B-T121
.	O
The	O
latter	O
however	O
,	O
is	O
more	O
important	O
due	O
to	O
its	O
immunosuppressive	O
and	O
antitumor	O
properties	O
.	O
As	O
a	O
strategy	O
to	O
increase	O
undecylprodigiosin	B-T121
production	O
,	O
we	O
added	O
separately	O
,	O
live	O
cells	O
and	O
heat	O
-	O
killed	O
cells	O
of	O
E.	B-T007
coli	I-T007
C600	I-T007
,	O
and	O
the	O
cell	O
-	O
free	O
supernatant	O
of	O
E.	B-T007
coli	I-T007
culture	B-T059
to	O
S.	B-T007
coelicolor	I-T007
cultures	B-T059
in	I-T059
shake	I-T059
flasks	I-T059
.	O
The	O
interaction	O
with	O
live	O
cells	O
of	O
E.	B-T007
coli	I-T007
altered	O
the	O
antibiotic	B-T195
production	O
pattern	O
and	O
undecylprodigiosin	B-T121
production	O
was	O
enhanced	O
by	O
3.5	O
-	O
fold	O
compared	O
to	O
the	O
pure	B-T059
cultures	I-T059
of	O
S.	B-T007
coelicolor	I-T007
and	O
actinorhodin	B-T195
decreased	O
by	O
15	O
-	O
fold	O
.	O
The	O
heat	O
-	O
killed	O
cells	O
of	O
E.	B-T007
coli	I-T007
however	O
,	O
had	O
no	O
effect	O
on	O
antibiotic	B-T195
production	O
.	O
In	O
all	O
cases	O
,	O
growth	O
and	O
glucose	B-T033
consumption	I-T033
of	O
S.	B-T007
coelicolor	I-T007
remained	O
almost	O
the	O
same	O
as	O
those	O
observed	O
in	O
the	O
pure	B-T059
culture	I-T059
indicating	O
that	O
the	O
changes	O
in	O
antibiotic	B-T195
production	O
were	O
not	O
due	O
to	O
nutritional	O
stress	B-T033
.	O
Results	O
with	O
cell	O
-	O
free	O
supernatant	O
of	O
E.	B-T007
coli	I-T007
culture	B-T059
indicated	O
that	O
the	O
interaction	O
between	O
S.	B-T007
coelicolor	I-T007
and	O
E.	B-T007
coli	I-T007
was	O
mediated	O
via	O
diffusible	O
molecule(s	O
)	O
.	O
Using	O
a	O
set	O
of	O
extraction	B-T059
procedures	I-T059
and	O
agar	B-T059
-	I-T059
well	I-T059
diffusion	I-T059
bioassays	I-T059
,	O
we	O
isolated	O
and	O
preliminarily	O
identified	O
a	O
class	O
of	O
compounds	O
.	O
For	O
the	O
preliminary	O
verification	O
,	O
we	O
added	O
the	O
compound	O
which	O
was	O
the	O
common	O
chemical	O
structural	O
moiety	O
in	O
this	O
class	O
of	O
compounds	O
to	O
the	O
pure	O
S.	B-T007
coelicolor	I-T007
cultures	B-T059
.	O
We	O
observed	O
similar	O
effects	O
on	O
antibiotic	B-T195
production	O
as	O
with	O
the	O
live	O
E.	B-T007
coli	I-T007
cells	O
and	O
their	O
supernatant	O
indicating	O
that	O
this	O
class	O
of	O
compounds	O
secreted	O
by	O
E.	B-T007
coli	I-T007
indeed	O
could	O
act	O
as	O
actives	O
during	O
interspecies	O
interaction	O
and	O
increase	O
the	O
production	O
of	O
undecylprodigiosin	B-T121
.	O
      
Pediatric	O
Orthopaedic	O
Trauma	O
and	O
Associated	O
Injuries	O
of	O
Snowmobile	B-T033
,	O
ATV	O
,	O
and	O
Dirtbike	O
Accidents	O
:	O
A	O
19	O
-	O
Year	O
Experience	O
at	O
a	O
Level	O
1	O
Pediatric	O
Trauma	O
Center	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
type	O
and	O
severity	O
of	O
orthopaedic	O
and	O
associated	O
injuries	O
for	O
snowmobile	B-T033
,	O
All	O
-	O
terrain	O
vehicles	O
(	O
ATV	O
)	O
and	O
motorized	O
dirtbike	O
accidents	O
in	O
a	O
pediatric	O
patient	O
population	O
.	O
A	O
total	O
of	O
758	O
patients	O
who	O
presented	O
following	O
either	O
snowmobile	O
(	O
n=87	O
)	O
,	O
ATV	O
-	O
related	O
(	O
n=308	O
)	O
or	O
dirtbike	O
(	O
n=363)-related	O
trauma	O
at	O
our	O
institution	O
between	O
1996	O
and	O
2015	O
were	O
retrospectively	O
reviewed	O
.	O
A	O
total	O
of	O
441	O
axial	O
and	O
appendicular	O
fractures	O
occurred	O
requiring	O
533	O
procedures	O
.	O
Snowmobile	B-T033
and	O
dirtbike	O
accidents	O
were	O
associated	O
with	O
a	O
higher	O
rate	O
of	O
fractures	O
(	O
63	O
%	O
,	O
64	O
%	O
)	O
than	O
the	O
ATV	O
group	O
(	O
50	O
%	O
)	O
(	O
P=0.0008	O
)	O
.	O
Snowmobile	O
injuries	O
had	O
the	O
highest	O
rate	O
of	O
spinal	O
(	O
23	O
%	O
)	O
and	O
lower	O
extremity	O
fractures	O
(	O
53	O
%	O
)	O
(	O
P=0.0004	O
)	O
.	O
Snowmobile	O
and	O
dirtbike	O
cohorts	O
had	O
higher	O
rate	O
of	O
femur	O
fractures	O
(	O
22	O
%	O
,	O
17	O
%	O
,	O
P=0.001	O
)	O
whereas	O
the	O
ATV	O
cohort	O
had	O
higher	O
rates	O
of	O
upper	B-T023
extremity	I-T023
(	O
18	O
%	O
)	O
,	O
hand	B-T023
(	O
11	O
%	O
)	O
,	O
scapula	B-T023
(	O
4.6	O
%	O
)	O
,	O
and	O
open	O
fractures	O
(	O
28.6	O
%	O
)	O
(	O
P<0.01	O
)	O
.	O
Head	O
trauma	O
was	O
the	O
most	O
commonly	O
associated	O
injury	O
in	O
275	O
patients	O
with	O
the	O
highest	O
rate	O
in	O
the	O
ATV	O
group	O
(	O
44	O
%	O
)	O
who	O
also	O
had	O
the	O
highest	O
rate	O
of	O
no	O
helmet	O
use	O
(	O
76	O
%	O
)	O
.	O
Snowmobile	O
and	O
ATV	O
patients	O
had	O
higher	O
Injury	O
Severity	O
Score	O
(	O
11.3	O
,	O
9.6	O
)	O
than	O
dirtbike	O
patients	O
(	O
7.8	O
)	O
(	O
P=0.001	O
)	O
.	O
ATV	O
patients	O
were	O
found	O
to	O
be	O
younger	O
(	O
11.8	O
y	O
)	O
compared	O
with	O
snowmobile	O
(	O
13.2	O
y	O
)	O
and	O
dirtbike	O
(	O
13.5	O
y	O
)	O
(	O
P<0.01	O
)	O
.	O
Pediatric	O
snowmobile	B-T033
,	O
ATV	O
and	O
dirtbike	O
accidents	O
result	O
in	O
severe	O
orthopaedic	O
and	O
associated	O
injuries	O
with	O
each	O
vehicle	O
demonstrating	O
significantly	O
different	O
injury	O
patterns	O
.	O
Injury	B-T061
prevention	I-T061
should	O
focus	O
on	O
improved	O
safety	B-T058
mechanisms	I-T058
,	O
protective	O
gear	O
,	O
safe	O
areas	O
for	O
off	O
-	O
road	O
vehicle	O
use	O
and	O
strict	O
laws	O
with	O
minimum	O
age	O
requirements	O
LEVEL	O
OF	O
EVIDENCE	O
:	O
:	O
Level	O
IV	O
.	O
      
Did	O
FIDELIS	O
projects	O
contribute	O
to	O
the	O
detection	B-T033
of	O
new	O
smear	B-T059
-	O
positive	B-T033
pulmonary	B-T047
tuberculosis	I-T047
cases	O
in	O
China	O
?	O
Setting	O
:	O
The	O
first	O
phase	O
of	O
the	O
Fund	O
for	O
Innovative	O
DOTS	O
Expansion	O
through	O
Local	O
Initiatives	O
to	O
Stop	O
TB	O
(	O
FIDELIS	O
)	O
projects	O
in	O
China	O
started	O
in	O
2003	O
.	O
Objective	O
:	O
To	O
determine	O
whether	O
the	O
FIDELIS	O
projects	O
contribute	O
d	O
to	O
the	O
increased	O
case	O
detection	B-T033
rate	O
for	O
new	O
smear	B-T059
-	O
positive	B-T033
pulmonary	B-T047
tuberculosis	I-T047
(	O
PTB	B-T047
)	O
in	O
China	O
.	O
Methods	O
:	O
We	O
compared	O
the	O
case	O
notification	O
rates	O
(	O
CNRs	O
)	O
in	O
the	O
intervention	O
year	O
with	O
those	O
of	O
the	O
previous	O
year	O
in	O
the	O
FIDELIS	O
areas	O
,	O
then	O
compared	O
the	O
difference	O
between	O
the	O
CNRs	O
of	O
the	O
intervention	O
year	O
and	O
the	O
previous	O
year	O
in	O
the	O
FIDELIS	O
areas	O
with	O
those	O
in	O
the	O
non	B-T033
-	I-T033
FI	I-T033
-	I-T033
DELIS	I-T033
areas	O
within	O
the	O
province	O
.	O
Results	O
:	O
There	O
was	O
an	O
increase	O
in	O
the	O
CNR	O
in	O
the	O
intervention	O
year	O
compared	O
with	O
the	O
previous	O
year	O
for	O
all	O
the	O
project	O
sites	O
.	O
The	O
differences	O
between	O
the	O
CNR	O
in	O
the	O
intervention	O
year	O
and	O
the	O
previous	O
year	O
ranged	O
from	O
6.4	O
to	O
31.1	O
per	O
100	O
000	O
population	O
in	O
the	O
FIDELIS	O
areas	O
and	O
from	O
2.9	O
to	O
20.4/100	O
000	O
in	O
the	O
non	B-T033
-	I-T033
FIDELIS	I-T033
areas	O
.	O
Differences	O
-in-	O
differences	O
analysis	O
shows	O
that	O
the	O
differences	O
in	O
the	O
CNRs	O
in	O
the	O
FIDELIS	O
areas	O
were	O
not	O
statistically	O
significantly	O
different	O
from	O
those	O
in	O
the	O
non-	O
FIDELIS	O
areas	O
(	O
P	O
=	O
0.393	O
)	O
.	O
Conclusion	O
:	O
The	O
FIDELIS	O
projects	O
may	O
have	O
contributed	O
to	O
the	O
increase	O
in	O
case	O
detection	B-T033
of	O
new	O
smear	B-T059
-	O
positive	B-T033
PTB	B-T047
in	O
China	O
,	O
but	O
the	O
level	O
of	O
evidence	O
is	O
low	O
.	O
      
Shining	O
the	O
light	O
on	O
the	O
dark	O
side	O
of	O
medical	O
leadership	O
-	O
a	O
qualitative	O
study	O
in	O
Australia	O
Purpose	O
The	O
paper	O
aims	O
to	O
explore	O
the	O
beliefs	O
of	O
doctors	O
in	O
leadership	O
roles	O
of	O
the	O
concept	O
of	O
"	O
the	O
dark	O
side	O
"	O
,	O
using	O
data	O
collected	O
from	O
interviews	O
carried	O
out	O
with	O
45	O
doctors	O
in	O
medical	O
leadership	O
roles	O
across	O
Australia	O
.	O
The	O
paper	O
looks	O
at	O
the	O
beliefs	O
from	O
the	O
perspectives	O
of	O
doctors	O
who	O
are	O
already	O
in	O
leadership	O
roles	O
themselves	O
;	O
to	O
identify	O
potential	O
barriers	B-T033
they	O
might	O
have	O
encountered	O
and	O
to	O
arrive	O
at	O
better	O
-	O
informed	O
strategies	O
to	O
engage	O
more	O
doctors	O
in	O
the	O
leadership	O
of	O
the	O
Australian	O
health	O
system	O
.	O
The	O
research	O
question	O
is	O
:	O
"	O
What	O
are	O
the	O
beliefs	O
of	O
medical	O
leaders	O
that	O
form	O
the	O
key	O
themes	O
or	O
dimensions	O
of	O
the	O
negative	O
perception	O
of	O
the	O
'	O
dark	O
side	O
'	O
?	O
"	O
.	O
Design	O
/	O
methodology	O
/	O
approach	O
The	O
paper	O
analysed	O
data	O
from	O
two	O
similar	O
qualitative	O
studies	O
examining	O
medical	O
leadership	O
and	O
engagement	O
in	O
Australia	O
by	O
the	O
same	O
author	O
,	O
in	O
collaboration	O
with	O
other	O
researchers	O
,	O
which	O
used	O
in	O
-	O
depth	O
semi	O
-	O
structured	O
interviews	O
with	O
45	O
purposively	O
sampled	O
senior	O
medical	O
leaders	O
in	O
leadership	O
roles	O
across	O
Australia	O
in	O
health	B-T058
services	I-T058
,	O
private	O
and	O
public	O
hospitals	O
,	O
professional	O
associations	O
and	O
health	O
departments	O
.	O
The	O
data	O
were	O
analysed	O
using	O
deductive	O
and	O
inductive	O
approaches	O
through	O
a	O
coding	O
framework	O
based	O
on	O
the	O
interview	O
data	O
and	O
literature	O
review	O
,	O
with	O
all	O
sections	O
of	O
coded	O
data	O
grouped	O
into	O
themes	O
.	O
Findings	O
Medical	O
leaders	O
had	O
four	O
key	O
beliefs	O
about	O
the	O
"	O
dark	O
side	O
"	O
as	O
perceived	O
through	O
the	O
eyes	B-T023
of	O
their	O
own	O
past	O
clinical	O
experience	O
and/or	O
their	O
clinical	O
colleagues	O
.	O
These	O
four	O
beliefs	O
or	O
dimensions	O
of	O
the	O
negative	O
perception	O
colloquially	O
known	O
as	O
"	O
the	O
dark	O
side	O
"	O
are	O
the	O
belief	O
that	O
they	O
lack	O
both	O
managerial	O
and	O
clinical	O
credibility	O
,	O
they	O
have	O
confused	O
identities	O
,	O
they	O
may	O
be	O
in	O
conflict	O
with	O
clinicians	O
,	O
their	O
clinical	O
colleagues	O
lack	O
insight	O
into	O
the	O
complexities	O
of	O
medical	O
leadership	O
and	O
,	O
as	O
a	O
result	O
,	O
doctors	O
are	O
actively	O
discouraged	O
from	O
making	O
the	O
transition	O
from	O
clinical	O
practice	O
to	O
medical	O
leadership	O
roles	O
in	O
the	O
first	O
place	O
.	O
Research	O
limitations	O
/	O
implications	O
This	O
research	O
was	O
conducted	O
within	O
the	O
Western	O
developed	O
-	O
nation	O
setting	O
of	O
Australia	O
and	O
only	O
involved	O
interviews	O
with	O
doctors	O
in	O
medical	O
leadership	O
roles	O
.	O
The	O
findings	O
are	O
therefore	O
limited	O
to	O
the	O
doctors	O
'	O
own	O
perceptions	O
of	O
themselves	O
based	O
on	O
their	O
past	O
experiences	O
and	O
beliefs	O
.	O
Future	O
research	O
involving	O
doctors	O
who	O
have	O
not	O
chosen	O
to	O
transition	O
to	O
leadership	O
roles	O
,	O
or	O
other	O
health	O
practitioners	O
in	O
other	O
settings	O
,	O
may	O
provide	O
a	O
broader	O
perspective	O
.	O
Also	O
,	O
this	O
research	O
was	O
exploratory	O
and	O
descriptive	B-T033
in	O
nature	O
using	O
qualitative	O
methods	O
,	O
and	O
quantitative	O
research	O
can	O
be	O
carried	O
out	O
in	O
the	O
future	O
to	O
extend	O
this	O
research	O
for	O
statistical	O
generalisation	O
.	O
Practical	O
implications	O
The	O
paper	O
includes	O
implications	O
for	O
health	O
organisations	O
,	O
training	O
providers	O
,	O
medical	O
employers	O
and	O
health	O
departments	O
and	O
describes	O
a	O
multi	O
-	O
prong	O
strategy	O
to	O
address	O
this	O
important	O
issue	O
.	O
Originality	O
/	O
value	O
This	O
paper	O
fulfils	O
an	O
identified	O
need	O
to	O
study	O
the	O
concept	O
of	O
"	O
moving	O
to	O
the	O
dark	O
side	O
"	O
as	O
a	O
negative	O
perception	O
of	O
medical	O
leadership	O
and	O
contributes	O
to	O
the	O
evidence	O
in	O
this	O
under-	O
researched	O
area	O
.	O
This	O
paper	O
has	O
used	O
data	O
from	O
two	O
similar	O
studies	O
,	O
combined	O
together	O
for	O
the	O
first	O
time	O
,	O
with	O
new	O
analysis	O
and	O
coding	O
,	O
looking	O
at	O
the	O
concept	O
of	O
the	O
"	O
dark	O
side	O
"	O
to	O
discover	O
new	O
emergent	O
findings	O
.	O
      
A	O
randomized	O
trial	O
of	O
Plasma	B-T121
-	I-T121
Lyte	I-T121
A	I-T121
and	O
0.9	B-T121
%	I-T121
sodium	I-T121
chloride	I-T121
in	O
acute	B-T047
pediatric	I-T047
gastroenteritis	I-T047
Compare	O
the	O
efficacy	O
and	O
safety	O
of	O
Plasma	B-T121
-	I-T121
Lyte	I-T121
A	I-T121
(	O
PLA	B-T121
)	O
versus	O
0.9	B-T121
%	I-T121
sodium	I-T121
chloride	I-T121
(	O
NaCl	B-T121
)	O
intravenous	B-T061
(	I-T061
IV	I-T061
)	I-T061
fluid	I-T061
replacement	I-T061
in	O
children	O
with	O
moderate	O
to	O
severe	B-T047
dehydration	I-T047
secondary	O
to	O
acute	B-T047
gastroenteritis	I-T047
(	O
AGE	B-T047
)	O
.	O
Prospective	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
study	O
conducted	O
at	O
eight	O
pediatric	O
emergency	O
departments	O
(	O
EDs	O
)	O
in	O
the	O
US	O
and	O
Canada	O
(	O
NCT#01234883	O
)	O
.	O
The	O
primary	O
outcome	O
measure	O
was	O
serum	O
bicarbonate	O
level	O
at	O
4	O
h.	O
Secondary	O
outcomes	O
included	O
safety	O
and	O
tolerability	O
.	O
The	O
hypothesis	O
was	O
that	O
PLA	B-T121
would	O
be	O
superior	O
to	O
0.9	B-T121
%	I-T121
NaCl	I-T121
in	O
improvement	B-T059
of	I-T059
4	I-T059
-	I-T059
h	I-T059
bicarbonate	I-T059
.	O
Patients	O
(	O
n	O
=	O
100	O
)	O
aged	O
≥6	O
months	O
to	O
<	O
11	O
years	O
with	O
AGE	B-T047
-induced	O
moderate	O
-	O
to-	O
severe	B-T047
dehydration	I-T047
were	O
enrolled	O
.	O
Patients	O
with	O
a	O
baseline	O
bicarbonate	O
level	O
≤22	O
mEq	O
/	O
L	O
formed	O
the	O
modified	O
intent	O
to	O
treat	O
(	O
mITT	O
)	O
group	O
.	O
At	O
baseline	O
,	O
the	O
treatment	B-T061
groups	O
were	O
comparable	O
except	O
that	O
the	O
PLA	B-T121
group	O
was	O
older	O
.	O
At	O
hour	O
4	O
,	O
the	O
PLA	B-T121
group	O
had	O
greater	O
increases	B-T033
in	I-T033
serum	I-T033
bicarbonate	I-T033
from	O
baseline	O
than	O
did	O
the	O
0.9	B-T121
%	I-T121
NaCl	I-T121
group	O
(	O
mean	O
±	O
SD	O
at	O
4	O
h	O
:	O
18	O
±	O
3.74	O
vs	O
18.0	O
±	O
3.67	O
;	O
change	O
from	O
baseline	O
of	O
1.6	O
and	O
0.0	O
,	O
respectively	O
;	O
P	O
=	O
.004	O
)	O
.	O
Both	O
treatment	B-T061
groups	O
received	O
similar	O
fluid	O
volumes	O
.	O
The	O
PLA	B-T121
group	O
had	O
less	O
abdominal	B-T184
pain	I-T184
and	O
better	O
dehydration	B-T047
scores	O
at	O
hour	O
2	O
(	O
both	O
P	O
=	O
.03	O
)	O
but	O
not	O
at	O
hour	O
4	O
(	O
P	O
=	O
0.15	O
and	O
0.08	O
,	O
respectively	O
)	O
.	O
No	O
patient	O
experienced	O
clinically	O
relevant	O
worsening	O
of	O
laboratory	O
findings	O
or	O
physical	B-T058
examination	I-T058
,	O
and	O
hospital	O
admission	O
rates	O
were	O
similar	O
.	O
One	O
patient	O
in	O
each	O
treatment	B-T061
group	O
developed	O
hyponatremia	B-T047
.	O
Four	O
patients	O
developed	O
hyperkalemia	B-T033
(	O
PLA	B-T121
:1	O
,	O
0.9	B-T121
%	I-T121
NaCl	I-T121
:3	O
)	O
.	O
In	O
comparison	O
with	O
0.9	B-T121
%	I-T121
NaCl	I-T121
,	O
PLA	B-T121
for	O
rehydration	B-T061
in	O
children	O
with	O
AGE	B-T047
was	O
well	O
tolerated	O
and	O
led	O
to	O
more	O
rapid	O
improvement	B-T059
in	I-T059
serum	I-T059
bicarbonate	I-T059
and	O
dehydration	B-T047
score	O
.	O
NCT#01234883	O
(	O
Registration	O
Date	O
:	O
November	O
3	O
,	O
2010	O
)	O
.	O
      
The	O
relationships	O
between	O
symptoms	B-T184
and	O
quality	O
of	O
life	O
over	O
the	O
course	O
of	O
cognitive	B-T061
-	I-T061
behavioral	I-T061
therapy	I-T061
for	O
panic	B-T048
disorder	I-T048
in	O
Japan	O
This	O
study	O
examined	B-T033
the	O
relationships	O
between	O
changes	O
in	O
symptoms	B-T184
and	O
changes	O
in	O
quality	O
of	O
life	O
(	O
QOL	O
)	O
during	O
cognitive	B-T061
-	I-T061
behavioral	I-T061
therapy	I-T061
(	O
CBT	B-T061
)	O
for	O
panic	B-T048
disorder	I-T048
(	O
PD	B-T048
)	O
.	O
We	O
treated	O
198	O
PD	B-T048
patients	O
with	O
group	O
CBT	B-T061
in	O
Japan	O
.	O
Using	O
multiple	O
regression	O
analysis	O
,	O
we	O
examined	B-T033
the	O
associations	O
between	O
changes	O
in	O
QOL	O
and	O
changes	O
in	O
PD	B-T048
symptoms	B-T184
or	O
comorbid	B-T184
psychological	I-T184
symptoms	I-T184
during	O
CBT	B-T061
.	O
Changes	O
in	O
anticipatory	B-T033
anxiety	I-T033
,	O
agoraphobic	B-T048
fear	I-T048
/	O
avoidance	O
,	O
and	O
somatization	B-T048
were	O
significant	O
predictors	O
of	O
changes	O
in	O
some	O
aspects	O
of	O
QOL	O
.	O
It	O
might	O
be	O
useful	O
to	O
decrease	O
somatization	B-T048
,	O
anticipatory	B-T033
anxiety	I-T033
,	O
and	O
agoraphobic	B-T048
fear	I-T048
to	O
improve	O
QOL	O
in	O
CBT	B-T061
for	O
PD	B-T048
.	O
      
PRESENCE	B-T033
OF	I-T033
CITRININ	B-T195
IN	O
GRAINS	O
AND	O
ITS	O
POSSIBLE	B-T033
HEALTH	O
EFFECTS	O
Citrinin	B-T195
is	O
a	O
mycotoxin	O
produced	O
by	O
several	O
species	O
of	O
the	O
genera	O
Aspergillus	O
,	O
Penicillium	O
and	O
Monascus	O
and	O
it	O
occurs	O
mainly	O
in	O
stored	O
grain	O
.	O
Citrinin	B-T195
is	O
generally	O
formed	O
after	O
harvest	O
and	O
occurs	O
mainly	O
in	O
stored	O
grains	O
,	O
it	O
also	O
occurs	O
in	O
other	O
plant	O
products	O
.	O
Often	O
,	O
the	O
co	O
-	O
occurrence	O
with	O
other	O
mycotoxins	O
is	O
observed	O
,	O
especially	O
ochratoxin	B-T121
A	I-T121
,	O
which	O
is	O
usually	O
associated	O
with	O
endemic	B-T047
nephropathy	I-T047
.	O
At	O
the	O
European	O
Union	O
level	O
,	O
systematic	O
monitoring	B-T058
of	O
Citrinin	B-T195
in	O
grains	O
began	O
with	O
the	O
aim	O
of	O
determining	O
its	O
highest	O
permissible	O
amount	O
in	O
food	O
.	O
Thus	O
,	O
far	O
the	O
systematic	O
monitoring	B-T058
of	O
the	O
above	B-T195
mentioned	I-T195
mycotoxin	I-T195
in	O
Croatia	O
is	O
yet	O
to	O
begin	O
.	O
The	O
main	O
goal	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
presence	B-T033
of	I-T033
Citrinin	B-T195
in	O
grains	O
sampled	O
in	O
the	O
area	O
of	O
Međimurje	O
,	O
Osijek	O
-	O
Baranja	O
,	O
Vukovar	O
-	O
Srijem	O
and	O
Brod	O
-	O
Posavina	O
County	O
.	O
For	O
the	O
purpose	O
of	O
identification	O
and	O
quantification	O
of	O
citrinin	B-T195
,	O
high	B-T059
performance	I-T059
liquid	I-T059
chromatograph	I-T059
(	I-T059
HPLC	I-T059
)	I-T059
with	I-T059
fluorescence	I-T059
was	O
used	B-T033
(	O
Calibration	O
curve	O
k	O
>	O
0.999	O
;	O
Intra	O
assay	O
CV	O
=	O
2.1	O
%	O
;	O
Inter	O
assay	O
CV	O
=	O
4.3	O
%	O
;	O
LOQ	O
<	O
1	O
μg	O
/	O
kg	O
)	O
.	O
From	O
the	O
area	O
of	O
Međimurje	O
County	O
,	O
10	O
samples	O
of	O
corn	O
and	O
10	O
samples	O
of	O
wheat	O
were	O
analyzed	O
.	O
None	O
of	O
the	O
samples	O
contained	O
Citrinin	B-T195
(	O
<	O
1	O
μg	O
/	O
kg	O
)	O
.	O
From	O
the	O
area	O
of	O
Osijek	O
-	O
Baranja	O
and	O
Vukovar	O
-	O
Srijem	O
County	O
,	O
15	O
samples	O
from	O
each	O
County	O
were	O
analyzed	O
.	O
The	O
mean	O
value	O
for	O
the	O
samples	O
of	O
Osijek	O
-	O
Baranja	O
County	O
was	O
19.63	O
μg	O
/	O
kg	O
(	O
median	O
=	O
15.8	O
μg	O
/	O
kg	O
)	O
,	O
while	O
for	O
Vukovar	O
-	O
Srijem	O
County	O
the	O
mean	O
value	O
of	O
citrinin	B-T195
was	O
14,6	O
μg	O
/	O
kg	O
(	O
median	O
=	O
1.23	O
μg	O
/	O
kg	O
)	O
.	O
From	O
5	O
analyzed	O
samples	O
from	O
Brod	O
-	O
Posavina	O
County	O
,	O
one	O
of	O
the	O
samples	O
contained	O
citrinin	B-T195
in	O
the	O
amount	O
of	O
23.8	O
μg	O
/	O
kg	O
,	O
while	O
the	O
registered	B-T058
amount	O
s	O
in	O
the	O
other	O
samples	O
were	O
<	O
1	O
μg	O
/	O
kg	O
.	O
The	O
results	O
show	O
that	O
grains	O
from	O
several	O
Counties	O
contain	O
certain	O
amounts	O
of	O
Citrinin	B-T195
possibly	O
indicating	B-T033
a	O
significant	O
intake	O
of	O
citrinin	B-T195
in	O
humans	O
.	O
It	O
must	O
be	O
stated	O
that	O
grains	O
and	O
grain	O
-	O
based	O
products	O
are	O
the	O
basis	O
of	O
everyday	O
diet	O
of	O
all	O
age	O
groups	O
,	O
especially	O
small	O
children	O
,	O
where	O
higher	O
intake	O
of	O
citrinin	B-T195
can	O
occur	O
.	O
Consequently	O
,	O
we	O
emphasize	O
the	O
need	O
for	O
systematic	O
analysis	O
of	O
larger	O
amount	O
of	O
samples	O
,	O
from	O
both	O
large	O
grains	O
and	O
small	O
grains	O
,	O
especially	O
in	O
the	O
area	O
of	O
Brod	O
-	O
Posavina	O
County	O
,	O
in	O
order	O
to	O
obtain	O
more	O
realistic	O
notion	O
of	O
citrinin	B-T195
contamination	O
of	O
grains	O
and	O
to	O
asses	O
the	O
health	O
risk	O
in	O
humans	O
.	O
      
Mitochondrial	O
pyruvate	O
dehydrogenase	O
phosphatase	O
1	O
regulates	O
the	O
early	O
differentiation	O
of	O
cardiomyocytes	O
from	O
mouse	O
embryonic	O
stem	O
cells	O
Mitochondria	O
are	O
crucial	O
for	O
maintaining	O
the	O
properties	O
of	O
embryonic	O
stem	O
cells	O
(	O
ESCs	O
)	O
and	O
for	O
regulating	O
their	O
subsequent	O
differentiation	O
into	O
diverse	O
cell	O
lineages	O
,	O
including	O
cardiomyocytes	O
.	O
However	O
,	O
mitochondrial	O
regulators	O
that	O
manage	O
the	O
rate	O
of	O
differentiation	O
or	O
cell	O
fate	O
have	O
been	O
rarely	O
identified	O
.	O
This	O
study	O
aimed	O
to	O
determine	O
the	O
potential	O
mitochondrial	O
factor	O
that	O
controls	O
the	O
differentiation	O
of	O
ESCs	O
into	O
cardiac	O
myocytes	O
.	O
We	O
induced	O
cardiomyocyte	O
differentiation	O
from	O
mouse	O
ESCs	O
(	O
mESCs	O
)	O
and	O
performed	O
microarray	B-T059
assays	I-T059
to	O
assess	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
expression	O
changes	O
at	O
differentiation	B-T033
day	I-T033
8	I-T033
(	O
D8	B-T033
)	O
compared	O
with	O
undifferentiated	O
mESCs	O
(	O
D0	O
)	O
.	O
Among	O
the	O
differentially	O
expressed	O
genes	O
,	O
Pdp1	O
expression	O
was	O
significantly	O
decreased	O
(	O
27	O
-	O
fold	O
)	O
on	O
D8	B-T033
compared	O
to	O
D0	O
,	O
which	O
was	O
accompanied	O
by	O
suppressed	O
mitochondrial	O
indices	O
,	O
including	O
ATP	B-T121
levels	O
,	O
membrane	O
potential	O
,	O
ROS	O
and	O
mitochondrial	O
Ca(2	O
+	O
)	O
.	O
Notably	O
,	O
Pdp1	O
overexpression	O
significantly	O
enhanced	O
the	O
mitochondrial	O
indices	O
and	O
pyruvate	O
dehydrogenase	O
activity	O
and	O
reduced	O
the	O
expression	O
of	O
cardiac	O
differentiation	O
marker	O
mRNA	O
and	O
the	O
cardiac	O
differentiation	O
rate	O
compared	O
to	O
a	O
mock	O
control	O
.	O
In	O
confirmation	O
of	O
this	O
,	O
a	O
knockdown	O
of	O
the	O
Pdp1	O
gene	O
promoted	O
the	O
expression	O
of	O
cardiac	O
differentiation	O
marker	O
mRNA	O
and	O
the	O
cardiac	O
differentiation	O
rate	O
.	O
In	O
conclusion	O
,	O
our	O
results	O
suggest	O
that	O
mitochondrial	O
PDP1	O
is	O
a	O
potential	O
regulator	O
that	O
controls	O
cardiac	O
differentiation	O
at	O
an	O
early	O
differentiation	O
stage	O
in	O
ESCs	O
.	O
      
Validity	O
and	O
reliability	O
of	O
fluoroscopy	B-T060
for	O
digital	B-T060
radiography	I-T060
:	O
a	O
new	O
way	O
to	O
evaluate	B-T058
diaphragmatic	B-T023
mobility	O
Fluoroscopy	B-T060
is	O
considered	O
the	O
most	O
accurate	O
method	O
to	O
evaluate	B-T058
the	O
diaphragm	B-T023
,	O
yet	O
most	O
existing	O
methods	O
for	O
measuring	O
diaphragmatic	B-T023
mobility	O
using	O
fluoroscopy	B-T060
are	O
complex	O
.	O
To	O
assess	O
the	O
validity	O
and	O
reliability	O
of	O
a	O
new	O
evaluation	O
method	O
of	O
diaphragmatic	B-T023
motion	O
using	O
fluoroscopy	B-T060
by	O
digital	B-T060
radiography	I-T060
of	O
healthy	O
adults	O
.	O
Twenty	O
-	O
six	O
adults	O
were	O
evaluated	B-T058
,	O
according	O
to	O
the	O
parameters	O
:	O
anthropometry	O
and	O
pulmonary	B-T060
function	I-T060
test	I-T060
.	O
The	O
evaluation	B-T058
of	O
diaphragm	B-T023
mobility	O
by	O
means	O
of	O
fluoroscopy	B-T060
by	O
digital	B-T060
radiography	I-T060
method	O
was	O
randomly	O
conducted	O
by	O
two	O
raters	O
(	O
A	O
and	O
B	O
)	O
.	O
The	O
Pearson	O
correlation	O
coefficient	O
and	O
the	O
intraclass	O
correlation	O
coefficient	O
(	O
ICC	O
)	O
were	O
used	O
to	O
assess	O
the	O
concurrent	O
validity	O
.	O
The	O
inter	O
-	O
rater	O
and	O
intra	O
-	O
rater	O
reliability	O
of	O
the	O
measurement	O
of	O
diaphragmatic	B-T023
motion	O
was	O
determined	O
using	O
ICC	O
and	O
a	O
confidence	O
interval	O
of	O
95	O
%	O
.	O
There	O
was	O
a	O
relationship	O
in	O
the	O
assessment	B-T058
of	O
the	O
concurrent	O
validity	O
.	O
There	O
was	O
good	O
inter	O
-	O
rater	O
reliability	O
for	O
right	O
hemidiaphragm	B-T023
mobility	O
and	O
moderate	O
reliability	O
for	O
left	B-T023
hemidiaphragm	I-T023
in	O
the	O
first	O
assessment	B-T058
.	O
In	O
the	O
second	O
assessment	B-T058
,	O
there	O
was	O
good	O
reliability	O
for	O
the	O
mobility	O
of	O
both	O
hemidiaphragms	B-T023
.	O
There	O
was	O
good	O
intra	O
-	O
rater	O
reliability	O
in	O
the	O
mobility	O
of	O
both	O
hemidiaphragms	B-T023
for	O
raters	O
A	O
and	O
B.	O
The	O
evaluation	B-T058
of	O
diaphragmatic	B-T023
motion	O
using	O
fluoroscopy	B-T060
by	O
digital	B-T060
radiography	I-T060
proved	O
to	O
be	O
a	O
valid	O
and	O
reliable	O
method	O
of	O
healthy	O
adults	O
.	O
      
Capsular	O
Polysaccharide	O
Types	O
and	O
Virulence	O
-	O
Related	O
Traits	O
of	O
Epidemic	O
KPC	B-T047
-	O
Producing	O
Klebsiella	B-T007
pneumoniae	I-T007
Isolates	O
in	O
a	O
Chinese	O
University	O
Hospital	O
Klebsiella	B-T007
pneumoniae	I-T007
is	O
an	O
important	O
human	O
pathogen	B-T001
associated	O
with	O
a	O
variety	O
of	O
diseases	B-T047
and	O
the	O
prevalence	O
of	O
blaKPC	O
carrying	O
K.	B-T007
pneumoniae	I-T007
(	O
KPC	B-T007
-	I-T007
Kp	I-T007
)	O
is	O
rapidly	O
increasing	O
.	O
Capsule	O
is	O
an	O
important	O
virulence	O
factor	O
in	O
K.	B-T007
pneumoniae	I-T007
.	O
In	O
this	O
study	O
,	O
we	O
determined	O
to	O
first	O
systematically	O
characterize	O
capsular	O
polysaccharide	O
(	O
CPS	O
)	O
and	O
virulence	O
traits	O
in	O
KPC	B-T007
-	I-T007
Kp	I-T007
strains	B-T001
.	O
A	O
total	O
of	O
56	O
KPC	B-T007
-	I-T007
Kp	I-T007
isolates	O
were	O
recovered	O
from	O
clinical	O
samples	O
in	O
a	O
Chinese	O
hospital	O
,	O
which	O
were	O
assigned	O
to	O
clonal	O
lineages	O
by	O
multilocus	O
sequence	O
typing	O
(	O
MLST	O
)	O
.	O
Capsule	O
typing	B-T058
(	O
wzi	B-T059
sequencing	I-T059
and	O
wzc	O
polymerase	O
chain	O
reaction	O
[	O
PCR	O
]	O
)	O
and	O
virulence	O
genes	O
were	O
characterized	O
by	O
molecular	B-T059
approaches	I-T059
.	O
The	O
virulence	O
of	O
these	O
strains	B-T001
was	O
determined	O
by	O
biofilm	O
formation	O
,	O
serum	O
killing	O
resistance	O
,	O
phagocytosis	O
,	O
and	O
infection	O
models	O
.	O
Six	O
different	O
STs	B-T033
were	O
found	B-T033
among	O
56	O
KPC	B-T007
-	I-T007
Kp	I-T007
isolates	O
:	O
76.8	O
%	O
(	O
43	O
of	O
56	O
isolates	O
)	O
belonged	O
to	O
ST11	B-T033
,	O
6	B-T033
isolates	O
belonged	O
to	O
ST147	B-T033
,	O
4	O
isolates	O
belonged	O
to	O
ST15	B-T033
,	O
1	O
isolate	O
belonged	O
to	O
ST1456	B-T033
,	O
1	O
isolate	O
belonged	O
to	O
ST65	B-T033
,	O
and	O
1	O
isolate	O
was	O
ST23	B-T033
.	O
Based	O
on	O
the	O
wzi	B-T059
gene	I-T059
DNA	I-T059
sequences	I-T059
and	O
wzc	O
PCR	O
,	O
these	O
56	O
strains	B-T001
were	O
classified	O
as	O
capsular	O
type	O
wzi47	O
-	O
K47	O
(	O
n	O
=	O
37	O
)	O
,	O
wzi64	O
-	O
K64	O
(	O
n	O
=	O
8)	O
,	O
wzi8	O
-	O
K8	O
(	O
n	O
=	O
4	O
)	O
,	O
wzi37	O
-	O
K37	O
(	O
n	O
=	O
4	O
)	O
,	O
wzi53	O
-	O
K53	O
(	O
n	O
=	O
1	O
)	O
,	O
wzi125	O
-	O
K2	O
(	O
n	O
=	O
1	O
)	O
,	O
and	O
wzi1	O
-	O
K1	O
(	O
n	O
=	O
1	O
)	O
.	O
Heterogeneity	O
was	O
detected	B-T033
in	O
biofilm	O
formation	O
and	O
phagocytosis	O
among	O
different	O
CPS	O
types	O
.	O
ST11	B-T033
strains	B-T001
were	O
less	O
virulent	O
than	O
other	O
ST	B-T033
strains	B-T001
.	O
KPC	B-T007
-	I-T007
Kp	I-T007
strains	B-T001
exhibit	O
variability	O
of	O
virulence	O
-	O
associated	O
traits	O
.	O
Differences	O
were	O
associated	O
with	O
the	O
ST	B-T033
types	O
and	O
CPS	O
.	O
      
Persistent	O
effects	O
of	O
pre	O
-	O
Columbian	O
plant	O
domestication	O
on	O
Amazonian	O
forest	O
composition	O
The	O
extent	O
to	O
which	O
pre	O
-	O
Columbian	O
societies	O
altered	O
Amazonian	O
landscapes	O
is	O
hotly	O
debated	O
.	O
We	O
performed	O
a	O
basin	O
-	O
wide	O
analysis	O
of	O
pre	O
-	O
Columbian	O
impacts	O
on	O
Amazonian	O
forests	O
by	O
overlaying	O
known	O
archaeological	O
sites	O
in	O
Amazonia	O
with	O
the	O
distributions	O
and	O
abundances	O
of	O
85	O
woody	O
species	O
domesticated	O
by	O
pre	O
-	O
Columbian	O
peoples	O
.	O
Domesticated	O
species	O
are	O
five	O
times	O
more	O
likely	O
than	O
nondomesticated	O
species	O
to	O
be	O
hyperdominant	O
.	O
Across	O
the	O
basin	O
,	O
the	O
relative	O
abundance	O
and	O
richness	O
of	O
domesticated	O
species	O
increase	O
in	O
forests	O
on	O
and	O
around	O
archaeological	O
sites	O
.	O
In	O
southwestern	O
and	O
eastern	O
Amazonia	O
,	O
distance	O
to	O
archaeological	O
sites	O
strongly	O
influences	O
the	O
relative	O
abundance	O
and	O
richness	O
of	O
domesticated	O
species	O
.	O
Our	O
analyses	O
indicate	O
that	O
modern	O
tree	O
communities	O
in	O
Amazonia	O
are	O
structured	O
to	O
an	O
important	O
extent	O
by	O
a	O
long	O
history	O
of	O
plant	O
domestication	O
by	O
Amazonian	O
peoples	O
.	O
      
Engineering	O
the	O
ribosomal	O
DNA	O
in	O
a	O
megabase	O
synthetic	O
chromosome	O
We	O
designed	O
and	O
synthesized	O
a	O
976,067	O
-	O
base	O
pair	O
linear	O
chromosome	O
,	O
synXII	O
,	O
based	O
on	O
native	O
chromosome	O
XII	O
in	O
Saccharomyces	O
cerevisiae	O
SynXII	O
was	O
assembled	O
using	O
a	O
two	O
-	O
step	O
method	O
,	O
specified	O
by	O
successive	O
megachunk	O
integration	O
and	O
meiotic	O
recombination	O
-	O
mediated	O
assembly	O
,	O
producing	O
a	O
functional	O
chromosome	O
in	O
S.	O
cerevisiae	O
.	O
Minor	O
growth	O
defect	O
"	O
bugs	O
"	O
detected	B-T033
in	O
synXII	O
,	O
caused	O
by	O
deletion	O
of	O
tRNA	O
genes	O
,	O
were	O
rescued	O
by	O
introducing	O
an	O
ectopic	O
copy	O
of	O
a	O
single	O
tRNA	O
gene	O
.	O
The	O
ribosomal	O
gene	O
cluster	O
(	O
rDNA	O
)	O
on	O
synXII	O
was	O
left	O
intact	O
during	O
the	O
assembly	O
process	O
and	O
subsequently	O
replaced	O
by	O
a	O
modified	O
rDNA	O
unit	O
used	O
to	O
regenerate	O
rDNA	O
at	O
three	O
distinct	O
chromosomal	O
locations	O
.	O
The	O
signature	O
sequences	O
within	O
rDNA	O
,	O
which	O
can	O
be	O
used	O
to	O
determine	O
species	O
identity	B-T033
,	O
were	O
swapped	O
to	O
generate	O
a	O
Saccharomyces	O
synXII	O
strain	B-T001
that	O
would	O
be	O
identified	O
as	O
Saccharomyces	O
bayanus	O
by	O
standard	O
DNA	O
barcoding	O
procedures	O
.	O
      
Left	B-T023
ventricular	I-T023
rotational	O
mechanics	O
in	O
infants	O
with	O
hypoxic	B-T047
ischemic	I-T047
encephalopathy	I-T047
and	O
preterm	O
infants	O
at	O
36	O
weeks	O
postmenstrual	O
age	O
:	O
A	O
comparison	O
with	O
healthy	O
term	O
controls	O
There	O
is	O
a	O
paucity	O
of	O
data	O
on	O
left	B-T023
ventricle	I-T023
(	O
LV	B-T023
)	O
rotational	O
physiology	O
in	O
neonates	O
.	O
We	O
aimed	O
to	O
assess	O
rotational	O
mechanics	O
in	O
infants	O
with	O
hypoxic	B-T047
ischemic	I-T047
encephalopathy	I-T047
(	O
HIE	B-T047
)	O
and	O
premature	O
infants	O
(	O
<	O
32	O
weeks	O
)	O
at	O
36	O
weeks	O
postmenstrual	O
age	O
(	O
PMA	O
)	O
(	O
preterm	O
group	O
)	O
and	O
compare	O
them	O
with	O
healthy	O
term	O
controls	O
(	O
term	O
controls	O
)	O
.	O
We	O
also	O
compared	O
the	O
parameters	O
in	O
preterm	O
infants	O
with	O
and	O
without	O
chronic	B-T047
lung	I-T047
disease	I-T047
(	O
CLD	B-T047
)	O
.	O
Echocardiography	B-T060
was	O
performed	O
within	O
48	O
hours	O
of	O
birth	O
or	O
at	O
36	O
weeks	O
PMA	O
.	O
LV	B-T023
basal	O
and	O
apical	O
rotation	O
,	O
twist	O
(	O
and	O
torsion	O
=	O
twist	O
/	O
LV	O
length	O
)	O
,	O
twist	O
rate	O
(	O
LVTR	O
)	O
,	O
and	O
untwist	O
rate	O
(	O
LVUTR	O
)	O
were	O
measured	O
.	O
One	O
-	O
way	O
ANOVA	O
was	O
used	O
to	O
compare	O
values	O
.	O
There	O
was	O
no	O
difference	O
in	O
gestation	O
(	O
40.0	O
[	O
39.1	O
-	O
40.3	O
]	O
vs	O
39.9	O
[	O
39.0	O
-	O
40.9	O
]	O
,	O
P>.05	O
)	O
or	O
birthweight	O
(	O
3.7	O
[	O
3.4	O
-	O
4.1	O
]	O
vs	O
3.5	O
[	O
3.2	O
-	O
3.9	O
]	O
,	O
P>.05	O
)	O
between	O
the	O
HIE	B-T047
group	O
(	O
n=16	O
)	O
and	O
term	O
controls	O
(	O
n=30	O
)	O
.	O
The	O
preterm	O
group	O
(	O
n=35	O
)	O
had	O
a	O
gestation	O
and	O
weight	O
of	O
36.0	O
[	O
34.6	O
-	O
36.3	O
]	O
weeks	O
and	O
2.3	O
[	O
2.0	O
-	O
2.4	O
]	O
kg	O
.	O
The	O
HIE	B-T047
group	O
had	O
lower	O
twist	O
,	O
torsion	O
,	O
LVTR	O
,	O
and	O
LVUTR	O
than	O
the	O
other	O
two	O
groups	O
.	O
The	O
preterm	O
group	O
had	O
a	O
more	O
negative	O
(	O
clockwise	O
)	O
basal	O
rotation	O
while	O
the	O
term	O
group	O
had	O
a	O
more	O
positive	O
(	O
counterclockwise	O
)	O
apical	O
rotation	O
.	O
Preterm	O
infants	O
with	O
CLD	B-T047
had	O
higher	O
apical	O
rotation	O
,	O
twist	O
,	O
and	O
torsion	O
when	O
compared	O
to	O
infants	O
without	O
CLD	B-T047
.	O
Infants	O
with	O
HIE	B-T047
have	O
reduced	O
rotational	O
mechanics	O
.	O
Preterm	O
infants	O
at	O
36	O
weeks	O
PMA	O
have	O
comparable	O
measurements	O
of	O
twist	O
to	O
term	O
infants	O
.	O
This	O
is	O
achieved	O
by	O
predominant	O
basal	O
rather	O
than	O
apical	O
rotation	O
.	O
Infants	O
with	O
CLD	B-T047
have	O
increased	O
apical	O
rotation	O
.	O
      
Mimicking	O
the	O
cell	O
membrane	O
:	O
bio	O
-	O
inspired	O
simultaneous	O
functions	O
with	O
monovalent	O
anion	O
selectivity	O
and	O
antifouling	O
properties	O
of	O
anion	O
exchange	O
membrane	O
A	O
new	O
bio	O
-	O
inspired	O
method	O
was	O
applied	O
in	O
this	O
study	O
to	O
simultaneously	O
improve	O
the	O
monovalent	O
anion	O
selectivity	O
and	O
antifouling	O
properties	O
of	O
anion	O
exchange	O
membranes	O
(	O
AEMs	O
)	O
.	O
Three	O
-	O
layer	O
architecture	O
was	O
developed	O
by	O
deposition	O
of	O
polydopamine	B-T121
(	O
PDA	B-T121
)	O
and	O
electro	O
-	O
deposition	O
of	O
N	B-T121
-	I-T121
O	I-T121
-	I-T121
sulfonic	I-T121
acid	I-T121
benzyl	I-T121
chitosan	I-T121
(	O
NSBC	B-T121
)	O
.	O
The	O
innermost	O
and	O
outermost	O
layers	O
were	O
PDA	B-T121
with	O
different	O
deposition	O
time	O
.	O
The	O
middle	O
layer	O
was	O
prepared	O
by	O
NSBC	B-T121
.	O
Fourier	O
transform	O
infrared	O
spectroscopy	O
and	O
scanning	B-T059
electron	I-T059
microscopy	I-T059
confirmed	O
that	O
PDA	B-T121
and	O
NSBC	B-T121
were	O
successfully	O
modified	O
on	O
the	O
surfaces	O
of	O
AEMs	O
.	O
The	O
contact	O
angle	O
of	O
the	O
membranes	O
indicated	O
an	O
improved	O
hydrophilicity	O
of	O
the	O
modified	O
membranes	O
.	O
A	O
series	O
of	O
electrodialysis	O
experiments	O
in	O
which	O
Cl(-	O
)	O
/	O
SO4(2-	O
)	O
separation	O
was	O
studied	O
,	O
demonstrating	O
the	O
monovalent	O
anion	O
selectivity	O
of	O
the	O
samples	O
.	O
The	O
Cl(-	O
)	O
/	O
SO4(2-	O
)	O
permselectivity	O
of	O
the	O
modified	O
membranes	O
can	O
reach	O
up	O
to	O
2.20	O
,	O
higher	O
than	O
that	O
of	O
the	O
commercial	O
membrane	O
(	O
only	O
0.78	O
)	O
during	O
90	O
minutes	O
in	O
electrodialysis	O
(	O
ED	O
)	O
.	O
The	O
increase	O
value	O
of	O
the	O
resistance	O
of	O
the	O
membranes	O
was	O
also	O
measured	O
to	O
evaluate	O
the	O
antifouling	O
properties	O
.	O
Sodium	B-T121
dodecyl	I-T121
benzene	I-T121
sulfonate	I-T121
(	O
SDBS	B-T121
)	O
was	O
used	O
as	O
the	O
fouling	O
material	O
in	O
the	O
ED	O
process	O
and	O
the	O
membrane	O
area	O
resistance	O
of	O
modified	O
membrane	O
increase	O
value	O
of	O
was	O
only	O
0.08	O
Ωcm(2	O
)	O
30	O
minutes	O
later	O
.	O
      
Help	O
end	O
the	O
HIV	B-T005
epidemic	O
After	O
many	O
delays	O
,	O
the	O
public	B-T061
consultation	I-T061
on	O
HIV	B-T061
prevention	I-T061
tool	O
PrEP	B-T061
(	O
pre	B-T061
-	I-T061
exposure	I-T061
prophylaxis	I-T061
)	O
is	O
finally	O
here	O
.	O
Now	O
is	O
the	O
time	O
to	O
mobilise	O
-	O
help	O
end	O
the	O
HIV	B-T005
epidemic	O
by	O
responding	O
to	O
this	O
NHS	B-T058
England	I-T058
consultation	I-T058
before	O
23	O
September	O
.	O
      
New	O
directions	O
for	O
psychiatric	B-T061
rehabilitation	I-T061
in	O
the	O
USA	O
American	O
researchers	O
have	O
led	O
the	O
world	O
in	O
developing	O
,	O
evaluating	B-T058
,	O
and	O
disseminating	O
evidence	O
-based	O
psychiatric	B-T061
rehabilitation	I-T061
practices	O
for	O
people	O
with	O
serious	O
mental	B-T048
illness	I-T048
.	O
Paradoxically	O
,	O
however	O
,	O
the	O
USA	O
lags	O
behind	O
most	O
industrialized	O
nations	O
in	O
providing	O
access	O
to	O
high	B-T058
-	I-T058
quality	I-T058
mental	B-T058
health	I-T058
and	O
psychiatric	B-T058
services	I-T058
.	O
This	O
essay	O
examines	O
several	O
evidence	O
-	O
based	O
practices	O
developed	O
in	O
the	O
USA	O
,	O
the	O
spread	O
of	O
these	O
practices	B-T058
,	O
the	O
barriers	B-T033
to	O
ensuring	O
availability	O
to	O
people	O
who	O
could	O
benefit	O
from	O
these	O
services	B-T058
,	O
and	O
some	O
promising	O
directions	O
for	O
overcoming	O
the	O
barriers	B-T033
.	O
Factors	O
influencing	O
the	O
growth	O
and	O
sustainment	O
of	O
effective	O
client	O
-centred	O
practices	B-T058
include	O
the	O
availability	O
of	O
adequate	O
and	O
stable	O
funding	O
,	O
committed	O
leadership	O
,	O
and	O
the	O
influence	O
of	O
vested	O
interests	O
.	O
Two	O
strategies	O
for	O
promoting	O
the	O
spread	O
and	O
sustainment	O
of	O
well	O
-	O
implemented	O
evidence	O
-	O
based	O
practices	O
are	O
the	O
adoption	O
of	O
fidelity	O
scales	O
and	O
learning	O
communities	O
.	O
      
Dabigatran	B-T121
:	O
A	O
new	O
oral	B-T121
anticoagulant	I-T121
.	O
Guidelines	O
to	O
follow	O
in	O
oral	B-T061
surgery	I-T061
procedures	I-T061
.	O
A	O
systematic	O
review	O
of	O
the	O
literature	O
Dabigatran	B-T121
is	O
a	O
newly	O
commercialized	O
drug	B-T121
that	O
is	O
replacing	O
other	O
anticoagulants	B-T121
in	O
the	O
prevention	O
of	O
venous	B-T047
thromboembolism	I-T047
,	O
stroke	B-T047
and	O
systemic	O
arterial	O
valve	O
embolism	O
.	O
It	O
acts	O
directly	O
on	O
thrombin	B-T121
presenting	O
in	O
a	O
dynamic	O
and	O
predictable	O
way	O
,	O
which	O
does	O
not	O
require	O
monitoring	O
these	O
patients	O
.	O
Therefore	O
,	O
we	O
consider	O
the	O
need	O
to	O
assess	O
whether	O
their	O
use	O
increases	O
the	O
risk	B-T033
of	I-T033
bleeding	I-T033
involved	O
before	O
any	O
dental	B-T061
treatment	I-T061
.	O
We	O
performed	O
a	O
systematic	O
review	O
with	O
a	O
bibliographic	O
search	O
in	O
PubMed	O
/	O
Medline	O
along	O
with	O
the	O
Cochrane	O
Library	O
.	O
We	O
excluded	O
articles	O
dealing	O
with	O
all	O
anticoagulants	B-T121
other	O
than	O
dabigatran	B-T121
,	O
and	O
works	O
about	O
surgical	B-T061
treatments	I-T061
in	O
anatomical	O
locations	O
other	O
than	O
the	O
oral	O
cavity	O
.	O
We	O
included	O
a	O
total	O
of	O
13	O
papers	O
of	O
which	O
1	O
was	O
a	O
randomized	O
clinical	O
trial	O
,	O
9	O
narrative	O
literature	O
reviews	O
,	O
1	O
case	O
series	O
,	O
2	O
clinical	O
cases	O
and	O
1	O
expert	O
opinion	O
.	O
Because	O
we	O
did	O
not	O
obtain	O
any	O
properly	O
designed	O
clinical	O
trials	O
,	O
we	O
were	O
unable	O
to	O
conduct	O
a	O
meta	O
-	O
analysis	O
.	O
Currently	O
,	O
there	O
is	O
no	O
consensus	O
on	O
the	O
procedure	B-T061
to	O
be	O
followed	O
in	O
patients	O
taking	O
dabigatran	B-T121
.	O
However	O
,	O
all	O
authors	O
agree	O
to	O
treat	O
each	O
case	O
individually	O
in	O
accordance	O
to	O
the	O
risk	O
of	O
embolism	O
,	O
postoperative	O
bleeding	O
and	O
renal	O
function	O
.	O
Also	O
,	O
it	O
is	O
necessary	O
to	O
perform	O
minimally	O
invasive	B-T061
interventions	I-T061
,	O
and	O
take	O
the	O
appropriate	O
local	O
anti	B-T061
-	I-T061
hemolytic	I-T061
measures	I-T061
.	O
      
Anemia	B-T047
complicating	O
type	B-T047
2	I-T047
diabetes	I-T047
:	O
Prevalence	O
,	O
risk	B-T033
factors	I-T033
and	O
prognosis	B-T058
To	O
determine	O
the	O
prevalence	O
,	O
risk	B-T033
factors	I-T033
and	O
prognosis	B-T058
of	O
anemia	B-T047
in	O
representative	O
community	O
-	O
based	O
patients	O
with	O
type	B-T047
2	I-T047
diabetes	I-T047
.	O
Data	O
from	O
the	O
Fremantle	O
Diabetes	O
Study	O
Phase	O
II	O
(	O
FDS2	O
;	O
n=1551	O
,	O
mean	O
age	O
65.7years	O
,	O
51.9	O
%	O
males	O
)	O
and	O
Busselton	O
Diabetes	O
Study	O
(	O
BDS	O
;	O
n=186	O
,	O
mean	O
age	O
70.2years	O
,	O
50.0	O
%	O
males	O
)	O
cohorts	O
,	O
and	O
from	O
186	O
matched	O
BDS	O
participants	O
without	O
diabetes	B-T047
,	O
were	O
analyzed	O
.	O
The	O
prevalence	O
of	O
anemia	B-T047
(	O
hemoglobin	O
≤130g	O
/	O
L	O
males	O
,	O
≤120g	O
/	O
L	O
females	O
)	O
was	O
determined	O
in	O
each	O
sample	O
.	O
In	O
FDS2	O
,	O
associates	O
of	O
anemia	B-T047
were	O
assessed	O
using	O
multiple	O
logistic	O
regression	O
and	O
Cox	O
proportional	O
hazards	O
modeling	O
identified	O
predictors	B-T033
of	O
death	O
during	O
4.3±1.2years	O
post	O
-	O
recruitment	O
.	O
The	O
prevalence	O
of	O
anemia	B-T047
at	O
baseline	O
was	O
11.5	O
%	O
in	O
FDS2	O
participants	O
,	O
17.8	O
%	O
in	O
BDS	O
type	O
2	O
patients	O
and	O
5.4	O
%	O
in	O
BDS	O
participants	O
without	O
diabetes	B-T047
.	O
In	O
FDS2	O
,	O
163	O
of	O
178	O
patients	O
with	O
anemia	B-T047
(	O
91.6	O
%	O
)	O
had	O
at	O
least	O
one	O
other	O
risk	B-T033
factor	I-T033
(	O
serum	B-T059
vitamin	I-T059
B12	I-T059
<	O
140pmol	O
/	O
L	O
,	O
serum	B-T033
ferritin	I-T033
<	O
30μg	O
/	O
L	O
and/or	O
transferrin	B-T059
saturation	I-T059
<	O
20	O
%	O
,	O
serum	B-T059
testosterone	I-T059
<	O
10nmol	O
/	O
L	O
(	O
males	O
)	O
,	O
glitazone	B-T121
therapy	B-T061
,	O
estimated	B-T059
glomerular	I-T059
filtration	I-T059
rate	I-T059
(	O
eGFR	B-T059
)	O
<	O
60mL	O
/	O
min	O
1.73m(2	O
)	O
,	O
malignancy	B-T191
,	O
hemoglobinopathy	B-T047
)	O
.	O
More	O
anemic	B-T033
than	O
non	B-T033
-	I-T033
anemic	I-T033
FDS2	O
patients	O
died	O
(	O
28.7	O
%	O
versus	O
8.0	O
%	O
;	O
P<0.001	O
)	O
.	O
After	O
adjustment	O
for	O
other	O
independent	O
predictors	B-T033
(	O
age	O
as	O
time	O
-	O
scale	O
,	O
male	O
sex	O
,	O
Aboriginality	B-T033
,	O
marital	O
status	O
,	O
smoking	O
,	O
eGFR	B-T059
)	O
,	O
anemia	B-T047
was	O
associated	O
with	O
a	O
57	O
%	O
increase	O
in	O
mortality	O
(	O
P=0.015	O
)	O
.	O
Type	B-T047
2	I-T047
diabetes	I-T047
at	O
least	O
doubles	O
the	O
risk	O
of	O
anemia	B-T047
but	O
other	O
mostly	O
modifiable	O
risk	B-T033
factors	I-T033
are	O
usually	O
present	B-T033
.	O
Anemia	B-T047
is	O
associated	O
with	O
an	O
increased	B-T033
risk	I-T033
of	I-T033
death	I-T033
after	O
adjustment	O
for	O
other	O
predictors	B-T033
.	O
      
Integrating	O
molecular	O
QTL	O
data	O
into	O
genome	O
-	O
wide	O
genetic	O
association	O
analysis	O
:	O
Probabilistic	O
assessment	O
of	O
enrichment	O
and	O
colocalization	O
We	O
propose	O
a	O
novel	O
statistical	O
framework	O
for	O
integrating	O
the	O
result	O
from	O
molecular	O
quantitative	O
trait	O
loci	O
(	O
QTL	O
)	O
mapping	O
into	O
genome	O
-	O
wide	O
genetic	O
association	O
analysis	O
of	O
complex	O
traits	O
,	O
with	O
the	O
primary	O
objectives	O
of	O
quantitatively	O
assessing	O
the	O
enrichment	O
of	O
the	O
molecular	O
QTLs	O
in	O
complex	O
trait	O
-	O
associated	O
genetic	O
variants	O
and	O
the	O
colocalizations	O
of	O
the	O
two	O
types	O
of	O
association	O
signals	O
.	O
We	O
introduce	O
a	O
natural	O
Bayesian	O
hierarchical	O
model	O
that	O
treats	O
the	O
latent	O
association	O
status	O
of	O
molecular	O
QTLs	O
as	O
SNP	O
-	O
level	O
annotations	O
for	O
candidate	O
SNPs	O
of	O
complex	O
traits	O
.	O
We	O
detail	O
a	O
computational	O
procedure	O
to	O
seamlessly	O
perform	O
enrichment	O
,	O
fine	O
-	O
mapping	O
and	O
colocalization	O
analyses	O
,	O
which	O
is	O
a	O
distinct	O
feature	O
compared	O
to	O
the	O
existing	O
colocalization	O
analysis	O
procedures	O
in	O
the	O
literature	O
.	O
The	O
proposed	O
approach	O
is	O
computationally	O
efficient	O
and	O
requires	O
only	O
summary	O
-	O
level	O
statistics	O
.	O
We	O
evaluate	O
and	O
demonstrate	O
the	O
proposed	O
computational	O
approach	O
through	O
extensive	O
simulation	O
studies	O
and	O
analyses	O
of	O
blood	O
lipid	O
data	O
and	O
the	O
whole	O
blood	O
eQTL	O
data	O
from	O
the	O
GTEx	O
project	O
.	O
In	O
addition	O
,	O
a	O
useful	O
utility	O
from	O
our	O
proposed	O
method	O
enables	O
the	O
computation	O
of	O
expected	O
colocalization	O
signals	O
using	O
simple	O
characteristics	O
of	O
the	O
association	O
data	O
.	O
Using	O
this	O
utility	O
,	O
we	O
further	O
illustrate	O
the	O
importance	O
of	O
enrichment	O
analysis	O
on	O
the	O
ability	O
to	O
discover	O
colocalized	O
signals	O
and	O
the	O
potential	O
limitations	O
of	O
currently	O
available	O
molecular	O
QTL	O
data	O
.	O
The	O
software	O
pipeline	O
that	O
implements	O
the	O
proposed	O
computation	O
procedures	O
,	O
enloc	O
,	O
is	O
freely	O
available	O
at	O
https://github.com/xqwen/integrative	O
.	O
      
Mucosa	O
-	O
associated	O
biohydrogenating	B-T001
microbes	I-T001
protect	O
the	O
simulated	O
colon	O
microbiome	B-T001
from	O
stress	B-T033
associated	O
with	O
high	O
concentrations	O
of	O
poly	O
-	O
unsaturated	O
fat	O
Polyunsaturated	O
fatty	O
acids	O
(	O
PUFAs	O
)	O
may	O
affect	O
colon	O
microbiome	B-T001
homeostasis	O
by	O
exerting	O
(	O
specific	O
)	O
antimicrobial	B-T195
effects	O
and/or	O
interfering	O
with	O
mucosal	O
biofilm	O
formation	O
at	O
the	O
gut	B-T023
mucosal	I-T023
interface	I-T023
.	O
We	O
used	O
standardized	B-T059
batch	I-T059
incubations	I-T059
and	O
the	O
Mucosal	O
-	O
Simulator	O
of	O
the	O
Human	O
Microbial	O
Intestinal	O
Ecosystem	O
(	O
M	O
-	O
SHIME	O
)	O
to	O
show	O
the	O
in	O
vitro	O
luminal	O
and	O
mucosal	O
effects	O
of	O
the	O
main	O
PUFA	O
in	O
the	O
Western	B-T061
diet	I-T061
,	O
linoleic	B-T121
acid	I-T121
(	O
LA	B-T121
)	O
.	O
High	O
concentrations	O
of	O
LA	B-T121
were	O
found	O
to	O
decrease	O
butyrate	O
production	O
and	O
Faecalibacterium	B-T007
prausnitzii	I-T007
numbers	O
dependent	O
on	O
LA	B-T121
biohydrogenation	O
to	O
vaccenic	O
acid	O
(	O
VA	O
)	O
and	O
stearic	B-T121
acid	I-T121
(	O
SA	B-T121
)	O
.	O
In	O
faecal	O
batch	B-T059
incubations	I-T059
,	O
LA	B-T121
biohydrogenation	O
and	O
butyrate	O
production	O
were	O
positively	O
correlated	O
and	O
SA	B-T121
did	O
not	O
inhibit	O
butyrate	O
production	O
.	O
In	O
the	O
M	O
-	O
SHIME	O
,	O
addition	O
of	O
a	O
mucosal	O
environment	O
stimulated	O
biohydrogenation	O
to	O
SA	B-T121
and	O
protected	O
F.	B-T007
prausnitzii	I-T007
from	O
inhibition	O
by	O
LA	B-T121
.	O
This	O
was	O
probably	O
due	O
to	O
the	O
preference	O
of	O
two	O
biohydrogenating	O
genera	O
Roseburia	B-T007
and	O
Pseudobutyrivibrio	B-T007
for	O
the	O
mucosal	O
niche	O
.	O
Co	B-T059
-	I-T059
culture	I-T059
batch	B-T059
incubations	I-T059
using	O
Roseburia	B-T007
hominis	I-T007
and	O
F.	B-T007
prausnitzii	I-T007
validated	O
these	O
observations	O
.	O
Correlations	O
networks	O
further	O
uncovered	O
the	O
central	O
role	O
of	O
Roseburia	B-T007
and	O
Pseudobutyrivibrio	B-T007
in	O
protecting	O
luminal	O
and	O
mucosal	B-T059
SHIME	I-T059
microbiota	I-T059
from	O
LA	B-T121
-	O
induced	B-T033
stress	I-T033
.	O
Our	O
results	O
confirm	O
how	O
cross	O
-	O
shielding	O
interactions	O
provide	O
resilience	O
to	O
the	O
microbiome	B-T001
and	O
demonstrate	O
the	O
importance	O
of	O
biohydrogenating	O
,	O
mucosal	O
bacteria	B-T007
for	O
recovery	O
from	O
LA	B-T121
stress	B-T033
.	O
      
Establishment	O
and	O
application	O
of	O
a	O
flow	B-T059
cytometry	I-T059
-based	O
method	O
for	O
detecting	B-T033
histone	O
acetylation	O
levels	O
Histone	B-T121
deacetylase	I-T121
inhibitors	I-T121
,	O
which	O
have	O
also	O
received	O
attention	O
in	O
AIDS	B-T047
and	O
other	O
diseases	B-T047
,	O
are	O
a	O
new	O
class	O
of	O
anticancer	B-T121
drugs	I-T121
developed	O
in	O
recent	O
years	O
.	O
However	O
,	O
there	O
is	O
still	O
a	O
lack	O
of	O
a	O
unified	O
and	O
reliable	O
method	O
for	O
detecting	B-T033
histone	O
acetylation	O
levels	O
in	O
basic	O
and	O
clinical	O
research	O
.	O
In	O
this	O
study	O
,	O
we	O
developed	O
a	O
flow	B-T059
cytometry	I-T059
-based	O
method	O
to	O
detect	B-T061
detect	B-T033
histone	O
acetylation	O
levels	O
by	O
comparing	O
different	O
sample	O
processing	O
temperature	O
(	O
on	O
ice	O
vs.	O
room	B-T033
temperature	I-T033
room	B-T033
temperature	I-T033
)	O
,	O
permeabilization	O
method	O
(	O
intracellular	O
vs.	O
nuclear	O
)	O
,	O
antibody	O
dose	O
(	O
antibody	B-T059
titration	I-T059
)	O
and	O
antibody	O
incubation	O
time	O
(	O
time	O
gradient	O
)	O
using	O
whole	O
blood	O
and	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O
In	O
addition	O
,	O
we	O
applied	O
this	O
optimized	O
method	O
in	O
in	O
vitro	O
experiment	O
and	O
clinical	O
trial	O
of	O
Chidamide	B-T121
(	O
the	O
only	O
China	O
FDA	O
approved	O
HDACi	O
)	O
,	O
the	O
result	O
of	O
which	O
confirmed	B-T033
that	O
the	O
flow	B-T059
cytometry	I-T059
-based	O
method	O
for	O
detecting	B-T033
histone	O
acetylation	O
levels	O
is	O
a	O
reliable	O
,	O
fast	O
and	O
convenient	O
method	O
which	O
can	O
be	O
used	O
in	O
basic	O
and	O
clinical	O
research	O
.	O
      
Data	O
-Driven	O
Implementation	O
of	O
Alarm	O
Reduction	O
Interventions	B-T061
in	O
a	O
Cardiovascular	O
Surgical	O
ICU	O
Alarm	B-T033
fatigue	I-T033
in	O
the	O
ICU	O
setting	O
has	O
been	O
well	O
documented	B-T058
in	O
the	O
literature	O
.	O
The	O
ICU	O
's	O
high	O
-	O
intensity	O
environment	O
requires	O
staff	O
's	O
vigilant	O
attention	O
,	O
and	O
distraction	O
from	O
false	O
and	O
non	O
-	O
actionable	O
alarms	O
pulls	O
staff	O
away	O
from	O
important	O
tasks	O
,	O
creates	O
dissatisfaction	O
,	O
and	O
is	O
a	O
potential	O
patient	B-T058
safety	I-T058
risk	O
if	O
alarms	O
are	O
missed	O
or	O
ignored	O
.	O
This	O
project	O
was	O
intended	O
to	O
improve	O
patient	B-T058
safety	I-T058
by	O
optimizing	O
alarm	O
systems	O
in	O
a	O
cardiovascular	O
surgical	O
intensive	O
care	O
unit	O
(	O
CVSICU	O
)	O
.	O
Specific	O
aims	O
were	O
to	O
examine	B-T033
nurses	O
'	O
attitudes	O
toward	O
clinical	O
alarm	O
signals	O
,	O
assess	O
nurses	O
'	O
ability	O
to	O
discriminate	O
audible	O
alarm	O
signals	O
,	O
and	O
implement	O
a	O
bundled	O
set	O
of	O
best	O
practices	O
for	O
monitor	B-T033
alarm	I-T033
reduction	O
without	O
undermining	O
patient	B-T058
safety	I-T058
.	O
CVSICU	O
nurses	O
completed	O
an	O
alarm	O
perception	O
survey	O
and	O
participated	O
in	O
alarm	O
discriminability	O
testing	O
.	O
Nurse	O
survey	O
data	O
and	O
baseline	O
monitor	O
alarm	O
data	O
were	O
used	O
to	O
select	O
targeted	O
alarm	O
reduction	O
interventions	B-T061
,	O
which	O
were	O
progressively	O
phased	O
in	O
.	O
Monitor	O
alarm	O
data	O
and	O
cardiorespiratory	B-T033
event	I-T033
data	O
were	O
trended	O
over	O
one	O
year	O
.	O
Five	O
of	O
the	O
most	O
frequent	O
CVSICU	O
monitor	B-T033
alarm	I-T033
types-	O
pulse	B-T060
oximetry	I-T060
,	O
heart	O
rate	O
,	O
systolic	B-T033
and	O
diastolic	B-T047
blood	I-T047
pressure	I-T047
,	O
pulse	B-T060
oximetry	I-T060
sensor	O
,	O
and	O
ventricular	B-T047
tachycardia	I-T047
>	O
2	O
-	O
were	O
targeted	O
.	O
After	O
implementation	O
,	O
there	O
was	O
a	O
61	O
%	O
reduction	O
in	O
average	O
alarms	O
per	O
monitored	O
bed	O
and	O
a	O
downward	O
trend	O
in	O
cardiorespiratory	B-T033
events	I-T033
.	O
To	O
reduce	O
alarm	B-T033
fatigue	I-T033
it	O
is	O
important	O
to	O
decrease	O
alarm	O
burden	O
through	O
targeted	O
interventions	B-T061
.	O
Methods	O
to	O
reduce	O
non	O
-	O
actionable	O
alarms	O
include	O
adding	O
short	O
delays	O
to	O
allow	O
alarm	O
self	O
-	O
correction	O
,	O
adjusting	O
default	O
alarm	O
threshold	O
limits	O
,	O
providing	O
alarm	O
notification	B-T058
through	O
a	O
secondary	O
device	O
,	O
and	O
teaching	O
staff	O
to	O
optimize	O
alarm	O
settings	O
for	O
individual	O
patients	O
.	O
      
Prospective	O
study	O
of	O
dietary	O
Non	B-T059
Enzymatic	I-T059
Antioxidant	I-T059
Capacity	I-T059
on	O
the	O
risk	O
of	O
hip	O
fracture	O
in	O
the	O
elderly	O
Dietary	O
antioxidants	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
prevention	O
of	O
bone	B-T047
loss	I-T047
and	O
associated	O
fractures	O
by	O
reducing	O
levels	O
of	O
oxidative	O
stress	O
.	O
We	O
prospectively	O
investigated	O
the	O
association	O
between	O
dietary	O
Non	B-T059
Enzymatic	I-T059
Antioxidant	I-T059
Capacity	I-T059
(	O
NEAC	B-T059
)	O
and	O
the	O
risk	O
of	O
hip	O
fracture	O
and	O
whether	O
this	O
effect	O
was	O
modified	O
by	O
smoking	O
.	O
In	O
the	O
Swedish	O
National	O
March	O
Cohort	O
13,409	O
men	O
and	O
women	O
over	O
the	O
age	O
of	O
55	O
who	O
had	O
not	O
experienced	O
cancer	B-T191
,	O
cardiovascular	B-T047
disease	I-T047
or	O
hip	O
fracture	O
,	O
were	O
followed	O
through	O
record	O
-	O
linkages	O
from	O
1997	O
through	O
2010	O
.	O
NEAC	B-T059
was	O
assessed	O
by	O
a	O
validated	O
food	O
frequency	O
questionnaire	O
collected	O
at	O
baseline	O
.	O
We	O
categorized	O
the	O
distribution	O
of	O
NEAC	B-T059
into	O
sex	O
-	O
specific	O
quartiles	O
and	O
used	O
multivariable	O
adjusted	O
Cox	O
proportional	O
hazards	O
regression	O
models	O
to	O
estimate	O
hazard	O
ratios	O
(	O
HRs	O
)	O
with	O
95	O
%	O
confidence	O
intervals	O
(	O
95	O
%	O
CI	O
)	O
.	O
During	O
a	O
mean	O
follow	B-T058
-	I-T058
up	I-T058
time	O
of	O
12.4years	O
,	O
we	O
identified	O
491	O
incident	O
cases	O
of	O
first	O
hip	O
fracture	O
.	O
Subjects	O
in	O
the	O
highest	O
quartile	O
of	O
dietary	O
NEAC	B-T059
had	O
a	O
39	O
%	O
lower	B-T033
risk	I-T033
of	O
incident	O
hip	O
fracture	O
compared	O
to	O
those	O
in	O
the	O
lowest	O
quartile	O
(	O
HR	O
:	O
0.61	O
;	O
95	O
%	O
CI	O
:	O
0.44	O
-	O
0.85	O
)	O
.	O
The	O
association	O
was	O
non	O
-	O
linear	O
(	O
p	O
for	O
non	O
-	O
linearity	O
:	O
0.004	O
)	O
with	O
a	O
potential	O
threshold	O
between	O
the	O
first	O
and	O
the	O
second	O
quartile	O
and	O
no	O
further	O
risk	O
reduction	O
at	O
higher	O
levels	O
of	O
dietary	O
NEAC	B-T059
.	O
Due	O
to	O
a	O
low	O
smoking	O
prevalence	O
in	O
our	O
study	O
population	O
,	O
we	O
had	O
limited	O
power	O
to	O
detect	O
effect	O
modification	O
between	O
dietary	O
NEAC	B-T059
and	O
smoking	O
on	O
a	O
multiplicative	O
or	O
additive	O
scale	O
.	O
Higher	O
dietary	O
NEAC	B-T059
intake	O
is	O
associated	O
with	O
lower	O
risk	O
of	O
hip	O
fracture	O
in	O
the	O
elderly	O
.	O
      
Effect	O
of	O
alpha	B-T121
lipoic	I-T121
acid	I-T121
on	O
in	O
vitro	O
development	O
of	O
bovine	O
secondary	B-T023
preantral	I-T023
follicles	I-T023
The	O
present	O
study	O
aimed	O
to	O
evaluate	B-T058
the	O
in	O
vitro	O
effect	O
of	O
alpha	B-T121
lipoic	I-T121
acid	I-T121
(	O
ALA	B-T121
)	O
addition	O
to	O
the	O
culture	O
medium	O
on	O
the	O
development	O
of	O
the	O
bovine	O
secondary	B-T023
preantral	I-T023
follicles	I-T023
.	O
Bovine	O
secondary	B-T023
preantral	I-T023
follicles	I-T023
were	O
collected	O
and	O
divided	O
into	O
two	O
groups	O
depending	O
on	O
their	O
size	O
(	O
80	O
-	O
100	O
μm	O
and	O
100	O
-	O
110	O
μm	O
)	O
.	O
They	O
were	O
cultured	O
in	O
vitro	O
for	O
15	O
days	O
(	O
D	O
)	O
using	O
different	O
media	O
including	O
at	O
three	O
different	O
doses	O
of	O
ALA	B-T121
.	O
The	O
genes	O
expression	O
levels	O
of	O
follicle	O
-	O
stimulating	O
hormone	O
beta	O
-	O
subunit	O
(	O
FSHR	O
)	O
,	O
insulin	O
-	O
like	O
growth	O
factor	O
(	O
IGF-1	O
)	O
,	O
Activin	O
,	O
luteinizing	O
hormone	O
/	O
choriogonadotropin	O
receptor	O
,	O
bone	O
morphogenetic	O
protein	O
receptor	O
type	O
IA	O
,	O
transforming	O
growth	O
factor	O
beta	O
receptor	O
1	O
,	O
growth	O
differentiation	O
factor	O
9	O
,	O
BCL2	O
-	O
associated	O
X	O
protein	O
(	O
BAX	O
)	O
,	O
and	O
C	O
-	O
Myc	O
were	O
studied	O
using	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
.	O
The	O
protein	O
expression	O
levels	O
of	O
FSHR	O
,	O
IGF-1	O
,	O
and	O
BAX	O
were	O
measured	O
using	O
Western	B-T059
blot	I-T059
analysis	I-T059
.	O
The	O
results	O
of	O
the	O
present	O
work	O
revealed	O
that	O
in	O
vitro	O
addition	O
of	O
ALA	B-T121
-	O
induced	O
significant	O
increase	O
in	O
the	O
growth	O
and	O
development	O
of	O
secondary	B-T023
preantral	I-T023
follicles	I-T023
throughout	O
the	O
culture	B-T059
period	O
as	O
compared	O
to	O
control	O
.	O
The	O
FSHR	O
,	O
IGF-1	O
,	O
luteinizing	O
hormone	O
/	O
choriogonadotropin	O
receptor	O
,	O
bone	O
morphogenetic	O
protein	O
receptor	O
type	O
IA	O
,	O
transforming	O
growth	O
factor	O
beta	O
receptor	O
1	O
,	O
growth	O
differentiation	O
factor	O
9	O
,	O
and	O
Activin	O
A	O
genes	O
were	O
upregulated	O
in	O
ALA	B-T121
-	O
treated	O
follicles	B-T023
as	O
compared	O
to	O
the	O
control	O
.	O
On	O
contrary	O
,	O
preapoptotic	O
genes	O
BAX	O
and	O
C	O
-	O
Myc	O
were	O
downregulated	O
in	O
treated	O
follicles	B-T023
compared	O
to	O
control	O
ones	O
.	O
The	O
protein	O
levels	O
of	O
FSHR	O
and	O
IGF-1	O
were	O
highly	O
expressed	O
in	O
treated	O
follicles	B-T023
compared	O
to	O
control	O
;	O
however	O
,	O
BAX	O
protein	O
was	O
downregulated	O
in	O
the	O
treated	O
follicles	B-T023
groups	O
.	O
The	O
addition	O
of	O
ALA	B-T121
to	O
the	O
culture	O
medium	O
enhances	O
secondary	B-T023
preantral	I-T023
follicles	I-T023
development	O
and	O
growth	O
.	O
      
Terahertz	B-T059
identification	I-T059
and	O
quantification	O
of	O
neurotransmitter	O
and	O
neurotrophy	O
mixture	O
Terahertz	B-T059
spectroscopy	I-T059
has	O
been	O
widely	O
used	O
for	O
investigating	O
the	O
fingerprint	B-T059
spectrum	I-T059
of	O
different	O
substances	O
.	O
For	O
cancerous	B-T191
tissues	O
,	O
the	O
greatest	O
difficulty	O
is	O
the	O
absorption	O
peaks	O
of	O
various	O
substances	O
contained	O
in	O
tissues	O
overlap	O
with	O
each	O
other	O
,	O
which	O
are	O
hard	O
to	O
identify	O
and	O
quantitative	O
analyze	O
.	O
As	O
a	O
result	O
,	O
it	O
is	O
very	O
hard	O
to	O
measure	O
the	O
presence	O
of	O
cancer	O
cell	O
and	O
then	O
to	O
diagnose	B-T033
accurately	O
.	O
In	O
this	O
paper	O
,	O
we	O
select	O
three	O
typical	O
neurotransmitters	O
(	O
γ	O
-	O
aminobutyric	O
acid	O
,	O
L	B-T121
-	I-T121
glutamic	I-T121
acid	I-T121
,	O
dopamine	B-T121
hydrochloride	I-T121
)	O
and	O
two	O
typical	O
metabolites	O
(	O
inositol	B-T121
and	O
creatine	O
)	O
in	O
neurons	O
to	O
measure	O
their	O
terahertz	B-T059
spectra	I-T059
with	O
different	O
mixture	O
ratios	O
.	O
By	O
choosing	O
characteristic	O
absorption	O
peaks	O
,	O
removing	O
baseline	O
and	O
using	O
the	O
least	O
square	O
method	O
,	O
we	O
can	O
identify	O
the	O
components	O
and	O
proportions	O
of	O
each	O
mixture	O
,	O
where	O
the	O
goodness	O
of	O
fit	O
to	O
practical	O
situation	O
is	O
up	O
to	O
94	O
%	O
.	O
These	O
results	O
provide	O
important	O
evidences	O
for	O
identifying	O
nerve	O
substances	O
and	O
obtaining	O
exact	O
quantitative	O
analysis	O
.	O
      
Utility	O
of	O
a	O
mHealth	O
App	O
for	O
Self	B-T058
-	I-T058
Management	I-T058
and	O
Education	O
of	O
Cardiac	B-T047
Diseases	I-T047
in	O
Spanish	O
Urban	O
and	O
Rural	O
Areas	O
Analyze	O
the	O
utility	O
of	O
a	O
mobile	O
health	O
app	O
named	O
HeartKeeper	O
in	O
several	O
groups	O
of	O
population	O
and	O
obtain	O
conclusions	O
to	O
be	O
applied	O
to	O
other	O
similar	O
apps	O
.	O
A	O
questionnaire	O
has	O
been	O
designed	O
to	O
evaluate	O
the	O
usage	O
and	O
utility	O
of	O
the	O
HeartKeeper	O
app	O
.	O
The	O
questionnaire	O
information	O
was	O
collected	O
by	O
collaborating	O
cardiologists	O
from	O
32	O
patients	O
before	O
and	O
after	O
they	O
used	O
the	O
app	O
.	O
Patients	O
were	O
randomly	O
selected	O
with	O
established	O
quotas	O
within	O
interest	O
groups	O
,	O
so	O
that	O
men	O
and	O
women	O
,	O
patients	O
older	O
or	O
younger	O
than	O
60	O
years	O
old	O
and	O
patients	O
living	O
in	O
urban	O
or	O
rural	O
areas	O
were	O
equally	O
represented	O
.	O
Using	O
the	O
appropriate	O
statistical	O
techniques	O
we	O
see	O
that	O
the	O
HeartKeeper	O
app	O
was	O
useful	O
for	O
patients	O
as	O
they	O
qualify	O
with	O
70	O
points	O
(	O
out	O
of	O
100	O
)	O
the	O
overall	B-T033
opinion	I-T033
of	O
the	O
app	O
,	O
it	O
helps	O
them	O
remember	O
more	O
easily	O
taking	O
their	O
pills	O
with	O
a	O
mean	O
improvement	O
of	O
20.94	O
points	O
(	O
p	O
<	O
0.001	O
)	O
and	O
they	O
perceive	O
a	O
global	O
improvement	O
of	O
their	O
health	O
(	O
8.28	O
points	O
,	O
p	O
<	O
0.001	O
)	O
.	O
We	O
also	O
observe	O
that	O
these	O
improvements	O
do	O
not	O
depend	O
,	O
in	O
general	O
,	O
on	O
the	O
area	O
(	O
urban	O
or	O
rural	O
)	O
where	O
the	O
patient	O
comes	O
from	O
or	O
on	O
their	O
sex	O
.	O
Although	O
older	O
patients	O
needed	O
more	O
help	O
to	O
use	O
the	O
app	O
and	O
used	O
it	O
slightly	O
less	O
frequently	O
,	O
the	O
improvements	O
on	O
several	O
measures	O
considered	O
,	O
such	O
as	O
remembering	O
taking	O
pills	O
,	O
breathing	B-T184
problems	I-T184
or	O
trouble	B-T184
developing	I-T184
activities	I-T184
,	O
depend	O
significantly	O
(	O
p	O
<	O
0.05	O
)	O
on	O
age	O
with	O
older	O
patients	O
reporting	O
higher	O
improvements	O
than	O
younger	O
ones	O
.	O
The	O
results	O
obtained	O
with	O
the	O
sample	O
of	O
patients	O
considered	O
in	O
this	O
research	O
prove	O
the	O
utility	O
of	O
the	O
HeartKeeper	O
app	O
.	O
This	O
utility	O
is	O
similar	O
in	O
urban	O
and	O
rural	O
areas	O
and	O
for	O
patients	O
of	O
both	O
sexes	O
and	O
,	O
to	O
some	O
extent	O
,	O
depends	O
on	O
the	O
age	O
of	O
the	O
patient	O
with	O
older	O
patients	O
reporting	O
slightly	O
lower	O
frequency	O
of	O
use	O
but	O
higher	O
health	O
improvements	O
than	O
younger	O
ones	O
.	O
      
Generation	O
of	O
High	O
-	O
Quality	O
SWATH	O
(	O
®	O
)	O
Acquisition	O
Data	O
for	O
Label	B-T033
-	I-T033
free	I-T033
Quantitative	O
Proteomics	O
Studies	O
Using	O
TripleTOF	O
(	O
®	O
)	O
Mass	O
Spectrometers	O
Data	O
-	O
independent	O
acquisition	O
is	O
a	O
powerful	O
mass	B-T059
spectrometry	I-T059
technique	I-T059
that	O
enables	O
comprehensive	O
MS	B-T059
and	O
MS	O
/	O
MS	O
analysis	O
of	O
all	O
detectable	O
species	O
,	O
providing	O
an	O
information	O
rich	O
data	O
file	O
that	O
can	O
be	O
mined	O
deeply	O
.	O
Here	O
,	O
we	O
describe	O
how	O
to	O
acquire	O
high	O
-	O
quality	O
SWATH	O
(	O
®	O
)	O
Acquisition	O
data	O
to	O
be	O
used	O
for	O
large	O
quantitative	O
proteomic	O
studies	O
.	O
We	O
specifically	O
focus	O
on	O
using	O
variable	O
sized	O
Q1	O
windows	O
for	O
acquisition	O
of	O
MS	O
/	O
MS	O
data	O
for	O
generating	O
higher	O
specificity	O
quantitative	O
data	O
.	O
      
Characterisation	O
of	O
methicillin	B-T007
-	I-T007
resistant	I-T007
Staphylococcus	I-T007
aureus	I-T007
clinical	O
isolates	O
from	O
animals	O
in	O
New	O
Zealand	O
,	O
2012	O
-	O
2013	O
,	O
and	O
subclinical	O
colonisation	B-T033
in	O
dogs	O
and	O
cats	O
in	O
Auckland	O
To	O
characterise	O
methicillin	B-T007
-	I-T007
resistant	I-T007
Staphylococcus	I-T007
aureus	I-T007
(	O
MRSA	B-T007
)	O
isolates	O
from	O
infection	B-T047
sites	I-T047
in	O
animals	O
in	O
New	O
Zealand	O
and	O
assess	O
the	O
prevalence	O
of	O
subclinical	O
MRSA	B-T033
colonisation	I-T033
in	O
dogs	O
and	O
cats	O
attending	O
veterinary	O
clinics	O
in	O
Auckland	O
.	O
MRSA	B-T007
isolates	O
from	O
clinical	O
specimens	O
obtained	O
by	O
the	O
main	O
New	O
Zealand	O
veterinary	O
diagnostic	O
laboratories	O
between	O
June	O
2012	O
and	O
June	O
2013	O
,	O
were	O
genotypically	O
characterised	O
by	O
DNA	O
microarray	O
hybridisation	O
analysis	O
and	O
spa	O
typing	B-T059
.	O
In	O
addition	O
,	O
nasal	B-T023
or	O
perineal	B-T023
skin	I-T023
swabs	O
collected	O
from	O
a	O
cross	O
-	O
sectional	O
sample	O
of	O
dogs	O
(	O
n=361	O
)	O
and	O
cats	O
(	O
n=225	O
)	O
attending	O
29	O
veterinary	O
clinics	O
in	O
Auckland	O
during	O
the	O
same	O
period	O
were	O
analysed	O
for	O
MRSA	B-T007
by	O
culture	B-T059
.	O
Eight	O
MRSA	B-T007
clinical	O
isolates	O
were	O
submitted	O
for	O
characterisation	O
by	O
the	O
participating	O
laboratories	O
.	O
The	O
isolates	O
originated	O
from	O
five	O
dogs	O
,	O
including	O
two	O
isolates	O
from	O
the	O
same	O
dog	O
,	O
one	O
foal	O
,	O
and	O
one	O
isolate	O
had	O
no	O
identification	O
of	O
the	O
source	B-T033
.	O
The	O
strain	B-T001
-	O
types	O
identified	O
were	O
AK3	B-T007
(	I-T007
ST-5	I-T007
SCCmecIV	I-T007
t045	O
;	O
n=1	O
)	O
,	O
USA500	B-T007
(	I-T007
ST8	I-T007
SCCmecIV	I-T007
t064	O
;	O
n=1	O
)	O
,	O
WSPP	B-T007
(	I-T007
ST30	I-T007
SCCmecIV	I-T007
t019	O
;	O
n=1	O
)	O
,	O
Rhine	B-T007
Hesse	I-T007
(	I-T007
ST5	I-T007
SCCmecII	I-T007
t002	O
;	O
n=2	O
)	O
,	O
and	O
EMRSA-15	B-T007
(	I-T007
ST22	I-T007
SCCmecIV	I-T007
t032	O
;	O
n=3	O
)	O
.	O
No	O
MRSA	B-T007
were	O
isolated	O
from	O
586	O
cultured	O
swabs	O
.	O
Methicillin	B-T007
-	I-T007
susceptible	I-T007
S.	I-T007
aureus	I-T007
were	O
detected	B-T033
in	O
9/257	O
(	O
3.5	O
%	O
)	O
swabs	O
and	O
non	B-T007
-	I-T007
aureus	I-T007
staphylococci	I-T007
in	O
22/257	O
(	O
8.5	O
%	O
)	O
swabs	O
.	O
The	O
estimated	O
true	O
MRSA	B-T007
subclinical	O
colonisation	B-T033
prevalence	O
was	O
0	O
%	O
,	O
with	O
an	O
upper	O
95	O
%	O
CI	O
boundary	O
of	O
1.9	O
%	O
for	O
cats	O
and	O
1.4	O
%	O
for	O
dogs	O
.	O
The	O
modest	O
number	O
of	O
MRSA	B-T007
isolates	O
submitted	O
for	O
this	O
study	O
by	O
the	O
participating	O
laboratories	O
suggests	O
clinical	O
MRSA	B-T047
infection	I-T047
in	O
animals	O
in	O
New	O
Zealand	O
continues	O
to	O
be	O
sporadic	O
.	O
The	O
wide	O
variety	O
of	O
strain	B-T001
-	O
types	O
found	O
mirrored	O
the	O
evolving	O
strain	B-T001
-	O
type	O
diversity	O
observed	O
in	O
humans	O
.	O
We	O
can	O
not	O
rule	O
out	O
bias	O
due	O
to	O
the	O
non	O
-	O
random	O
sampling	O
of	O
dogs	O
and	O
cats	O
,	O
but	O
the	O
apparent	O
colonisation	B-T033
prevalence	O
of	O
0	O
%	O
was	O
consistent	O
with	O
the	O
low	O
prevalence	O
of	O
subclinical	O
colonisation	B-T033
in	O
humans	O
in	O
New	O
Zealand	O
.	O
These	O
similarities	O
indicate	O
the	O
epidemiology	O
of	O
animal	O
and	O
human	O
MRSA	B-T047
infections	I-T047
are	O
linked	O
.	O
In	O
the	O
last	O
decade	O
,	O
the	O
prevalence	O
of	O
human	O
MRSA	B-T047
infections	I-T047
in	O
New	O
Zealand	O
has	O
steadily	O
increased	O
.	O
This	O
is	O
the	O
second	O
published	O
study	O
of	O
MRSA	B-T007
in	O
animals	O
in	O
New	O
Zealand	O
.	O
The	O
results	O
indicate	O
clinical	O
MRSA	B-T047
infection	I-T047
in	O
animals	O
remains	O
sporadic	O
,	O
but	O
the	O
diversification	O
of	O
the	O
strain	B-T001
-	O
types	O
may	O
pose	O
new	O
therapeutic	O
challenges	O
to	O
veterinarians	O
,	O
due	O
to	O
their	O
diverse	O
resistome	O
.	O
      
Fluoranthene	B-T121
degradation	O
and	O
binding	O
mechanism	O
study	O
based	O
on	O
the	O
active	O
-	O
site	O
structure	O
of	O
ring	O
-	O
hydroxylating	O
dioxygenase	O
in	O
Microbacterium	B-T007
paraoxydans	I-T007
JPM1	I-T007
In	O
this	O
study	O
,	O
a	O
gram	B-T007
-	I-T007
positive	I-T007
fluoranthene	I-T007
-	I-T007
degrading	I-T007
bacterial	I-T007
strain	B-T001
was	O
isolated	O
from	O
crude	O
oil	O
in	O
Dagang	O
Oilfield	O
and	O
identified	O
as	O
Microbacterium	B-T007
paraoxydans	I-T007
JPM1	I-T007
by	O
the	O
analysis	O
of	O
16S	O
rDNA	O
sequence	O
.	O
After	O
25	O
days	O
of	O
incubation	B-T059
,	O
the	O
strain	B-T001
JPM1	B-T007
could	O
degrade	O
91.78	O
%	O
of	O
the	O
initial	O
amount	O
of	O
fluoranthene	B-T121
.	O
Moreover	O
,	O
four	O
metabolites	O
9	O
-	O
fluorenone-1	O
-	O
carboxylic	O
acid	O
,	O
9	O
-	O
fluorenone	O
,	O
phthalic	O
acid	O
,	O
and	O
benzoic	B-T121
acid	I-T121
were	O
detected	O
in	O
the	O
culture	O
solution	O
.	O
The	O
gene	O
sequence	O
encoding	O
the	O
aromatic	O
-	O
ring	O
-	O
hydroxylating	O
dioxygenase	O
was	O
amplified	O
in	O
the	O
strain	B-T001
JPM1	B-T007
by	O
PCR	O
.	O
Based	O
on	O
the	O
translated	O
protein	O
sequence	O
,	O
a	O
homology	O
modeling	O
method	O
was	O
applied	O
to	O
build	O
the	O
crystal	O
structure	O
of	O
dioxygenase	O
.	O
Subsequently	O
,	O
the	O
interaction	O
mechanism	O
between	O
fluoranthene	B-T121
and	O
the	O
active	O
site	O
of	O
dioxygenase	O
was	O
simulated	O
and	O
analyzed	O
by	O
molecular	O
docking	O
.	O
Consequently	O
,	O
a	O
feasible	O
degrading	O
pathway	O
of	O
fluoranthene	B-T121
in	O
the	O
strain	B-T001
JPM1	B-T007
was	O
proposed	O
based	O
on	O
the	O
metabolites	O
and	O
the	O
interaction	O
analyses	O
.	O
Additionally	O
,	O
the	O
thermodynamic	O
analysis	O
showed	O
that	O
the	O
strain	B-T001
JPM1	B-T007
had	O
high	O
tolerance	O
for	O
fluoranthene	B-T121
,	O
and	O
the	O
influence	O
of	O
fluoranthene	B-T121
for	O
the	O
bacterial	B-T007
growth	O
activity	O
was	O
negligible	O
under	O
100	O
to	O
400	O
mg	O
L(-1	O
)	O
concentrations	O
.	O
Taken	O
together	O
,	O
this	O
study	O
indicates	O
that	O
the	O
strain	B-T001
JPM1	B-T007
has	O
high	O
potential	O
for	O
further	O
study	O
in	O
bioremediation	O
of	O
polycyclic	O
aromatic	O
hydrocarbon	O
(	O
PAH)-	O
contaminated	O
sites	O
.	O
      
Nonylphenol	O
diethoxylate	O
inhibits	O
apoptosis	O
induced	O
in	O
PC12	O
cells	O
Nonylphenol	O
and	O
short	O
-	O
chain	O
nonylphenol	O
ethoxylates	O
such	O
as	O
NP2	O
EO	O
are	O
present	B-T033
in	O
aquatic	O
environment	O
as	O
wastewater	O
contaminants	O
,	O
and	O
their	O
toxic	O
effects	O
on	O
aquatic	B-T001
species	I-T001
have	O
been	O
reported	O
.	O
Apoptosis	O
has	O
been	O
shown	O
to	O
be	O
induced	O
by	O
serum	O
deprivation	O
or	O
copper	B-T121
treatment	O
.	O
To	O
understand	O
the	O
toxicity	O
of	O
nonylphenol	O
diethoxylate	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
NP2	O
EO	O
on	O
apoptosis	O
induced	O
by	O
serum	O
deprivation	O
and	O
copper	B-T121
by	O
using	O
PC12	O
cell	O
system	O
.	O
Nonylphenol	O
diethoxylate	O
itself	O
showed	O
no	O
toxicity	O
and	O
recovered	O
cell	O
viability	O
from	O
apoptosis	O
.	O
In	O
addition	O
,	O
nonylphenol	O
diethoxylate	O
decreased	O
DNA	O
fragmentation	O
caused	O
by	O
apoptosis	O
in	O
PC12	O
cells	O
.	O
This	O
phenomenon	O
was	O
confirmed	O
after	O
treating	O
apoptotic	O
PC12	O
cells	O
with	O
nonylphenol	O
diethoxylate	O
,	O
whereas	O
the	O
cytochrome	O
c	O
release	O
into	O
the	O
cytosol	O
decreased	O
as	O
compared	O
to	O
that	O
in	O
apoptotic	O
cells	O
not	O
treated	O
with	O
nonylphenol	O
diethoxylate	O
s.	O
Furthermore	O
,	O
Bax	O
contents	O
in	O
apoptotic	O
cells	O
were	O
reduced	O
after	O
exposure	O
to	O
nonylphenol	O
diethoxylate	O
.	O
Thus	O
,	O
nonylphenol	O
diethoxylate	O
has	O
the	O
opposite	O
effect	O
on	O
apoptosis	O
in	O
PC12	O
cells	O
compared	O
to	O
nonylphenol	O
,	O
which	O
enhances	O
apoptosis	O
induced	O
by	O
serum	O
deprivation	O
.	O
The	O
difference	O
in	O
structure	O
of	O
the	O
two	O
compounds	O
is	O
hypothesized	O
to	O
be	O
responsible	O
for	O
this	O
phenomenon	O
.	O
These	O
results	B-T033
indicated	O
that	O
nonylphenol	O
diethoxylate	O
has	O
capability	O
to	O
affect	O
cell	O
differentiation	O
and	O
development	O
and	O
has	O
potentially	O
harmful	O
effect	O
on	O
organisms	B-T001
because	O
of	O
its	O
unexpected	O
impact	O
on	O
apoptosis	O
.	O
©	O
2015	O
Wiley	O
Periodicals	O
,	O
Inc.	O
Environ	O
Toxicol	O
31	O
:	O
1389	O
-	O
1398	O
,	O
2016	O
.	O
      
Activation	O
of	O
ephrinB	O
-	O
EphB	O
receptor	O
signalling	O
in	O
rat	B-T023
spinal	I-T023
cord	I-T023
contributes	O
to	O
maintenance	O
of	O
diabetic	B-T033
neuropathic	B-T033
pain	I-T033
Diabetic	B-T033
neuropathic	B-T033
pain	I-T033
(	O
DNP	B-T033
)	O
is	O
severe	O
and	O
intractable	O
in	O
clinic	O
.	O
The	O
specific	O
cellular	O
and	O
molecular	O
mechanisms	O
underlying	O
DNP	B-T033
remain	O
elusive	O
and	O
its	O
treatment	O
are	O
limited	O
.	O
We	O
investigated	O
roles	O
of	O
EphB1	O
receptor	O
in	O
the	O
development	O
of	O
DNP	B-T033
.	O
Diabetic	B-T033
neuropathic	B-T033
pain	I-T033
was	O
produced	O
in	O
male	O
,	O
adult	O
,	O
Sprague	O
-	O
Dawley	O
rats	O
by	O
a	O
single	O
i.p	O
.	O
streptozotocin	B-T195
(	O
STZ	B-T195
)	O
or	O
alloxan	O
.	O
Western	B-T059
blot	I-T059
analysis	I-T059
and	O
immunohistochemistry	B-T060
were	O
used	O
to	O
analyse	O
expression	O
of	O
EphB1	O
receptor	O
as	O
well	O
as	O
the	O
activation	O
of	O
the	O
glial	O
cells	O
and	O
the	O
pro	O
-	O
inflammatory	O
cytokines	O
in	O
the	O
spinal	B-T023
cord	I-T023
.	O
DNP	B-T033
manifested	O
as	O
mechanical	B-T184
allodynia	I-T184
,	O
which	O
was	O
determined	O
by	O
measuring	O
incidence	O
of	O
foot	B-T023
withdrawal	O
in	O
response	O
to	O
mechanical	O
indentation	O
of	O
the	O
hind	O
paw	B-T023
by	O
an	O
electro	O
von	O
Frey	O
filament	O
.	O
Diabetic	B-T033
neuropathic	B-T033
pain	I-T033
and	O
high	B-T033
blood	I-T033
glucose	I-T033
were	O
exhibited	O
simultaneously	O
in	O
around	O
70	O
%	O
of	O
animals	O
that	O
received	O
i.p	O
.	O
STZ	B-T195
or	O
alloxan	O
.	O
Phosphorylation	O
of	O
EphB1	O
,	O
activation	O
of	O
the	O
astrocytes	O
and	O
microglial	O
cells	O
,	O
and	O
level	O
of	O
tumour	O
necrosis	O
factor	O
(	O
TNF)-α	O
and	O
interleukin	O
(	O
IL)-1β	O
in	O
the	O
spinal	B-T023
cord	I-T023
were	O
significantly	O
increased	O
in	O
rats	O
with	O
DNP	B-T033
.	O
Spinal	O
blocking	O
EphB1	O
receptor	O
activation	O
in	O
the	O
late	O
phase	O
after	O
STZ	B-T195
injection	B-T061
significantly	O
suppressed	O
the	O
established	O
mechanical	B-T184
allodynia	I-T184
as	O
well	O
as	O
activation	O
of	O
the	O
astrocytes	O
and	O
microglial	O
cells	O
and	O
activity	O
of	O
TNF	O
-	O
α	O
and	O
IL-1β	O
.	O
However	O
,	O
spinal	O
treatment	O
of	O
EphB1	O
-	O
Fc	O
in	O
the	O
early	O
phase	O
after	O
STZ	B-T195
injection	B-T061
did	O
not	O
prevent	O
the	O
induction	O
of	O
DNP	B-T033
.	O
EphB1	O
receptor	O
activation	O
in	O
the	O
spinal	B-T023
cord	I-T023
is	O
critical	O
to	O
the	O
maintenance	O
,	O
but	O
not	O
induction	O
of	O
diabetic	B-T033
pain	B-T184
.	O
EphB1	O
receptor	O
may	O
be	O
a	O
potential	O
target	O
for	O
relieving	B-T061
the	O
established	O
diabetic	B-T033
pain	B-T184
.	O
Activation	O
of	O
EphB1	O
receptor	O
in	O
the	O
spinal	B-T023
cord	I-T023
is	O
critical	O
to	O
maintaining	O
the	O
established	O
diabetic	B-T033
neuropathic	B-T033
pain	I-T033
,	O
but	O
not	O
to	O
diabetic	B-T033
pain	B-T184
induction	O
.	O
Spinal	O
blocking	O
EphB1	O
receptor	O
activation	O
suppresses	O
ongoing	O
diabetic	B-T033
neuropathic	B-T033
pain	I-T033
.	O
      
Conservation	O
of	O
the	O
Red	O
Kite	O
Milvus	O
milvus	O
(	O
Aves	O
:	O
Accipitriformes	O
)	O
Is	O
Not	O
Affected	O
by	O
the	O
Establishment	O
of	O
a	O
Broad	O
Hybrid	B-T001
Zone	O
with	O
the	O
Black	O
Kite	O
Milvus	O
migrans	O
migrans	O
in	O
Central	O
Europe	O
Among	O
Accipitriformes	O
sensu	O
stricto	O
,	O
only	O
a	O
few	O
species	O
have	O
been	O
reported	O
to	O
form	O
hybrid	B-T001
zones	O
;	O
these	O
include	O
the	O
red	O
kite	O
Milvus	O
milvus	O
and	O
black	O
kite	O
Milvus	O
migrans	O
migrans	O
.	O
M.	O
milvus	O
is	O
endemic	O
to	O
the	O
western	O
Palearctic	O
and	O
has	O
an	O
estimated	O
total	O
population	O
of	O
20	O
-	O
24,000	O
breeding	O
pairs	O
.	O
The	O
species	O
was	O
in	O
decline	O
until	O
the	O
1970s	O
due	O
to	O
persecution	O
and	O
has	O
declined	O
again	O
since	O
the	O
1990s	O
due	O
to	O
ingestion	O
of	O
rodenticide	O
-	O
treated	O
baits	O
,	O
illegal	O
poisoning	O
and	O
changes	O
in	O
agricultural	O
practices	O
,	O
particularly	O
in	O
its	O
core	O
range	O
.	O
Whereas	O
F1	O
M.	O
milvus	O
×	O
M.	O
migr	O
.	O
migrans	O
hybrid	B-T001
offspring	O
have	O
been	O
found	O
,	O
F2	O
and	O
F3	O
hybrids	B-T001
have	O
only	O
rarely	O
been	O
reported	O
,	O
with	O
low	O
nesting	O
success	O
rates	O
of	O
F1	O
hybrids	B-T001
and	O
partial	O
hybrid	B-T001
sterility	O
likely	O
playing	O
a	O
role	O
.	O
Here	O
,	O
we	O
analyzed	O
the	O
mitochondrial	O
(	O
CO1	O
and	O
CytB	O
)	O
and	O
nuclear	O
(	O
Myc	O
)	O
DNA	O
loci	O
of	O
184	O
M.	O
milvus	O
,	O
124	O
M.	O
migr	O
.	O
migrans	O
and	O
3	O
F1	O
hybrid	B-T001
individuals	O
collected	O
across	O
central	O
Europe	O
.	O
In	O
agreement	O
with	O
previous	O
studies	O
,	O
we	O
found	O
low	O
heterozygosity	O
in	O
M.	O
milvus	O
regardless	O
of	O
locus	O
.	O
We	O
found	O
that	O
populations	O
of	O
both	O
examined	B-T033
species	O
were	O
characterized	O
by	O
a	O
high	O
gene	O
flow	O
within	O
populations	O
,	O
with	O
all	O
of	O
the	O
major	O
haplotypes	O
distributed	O
across	O
the	O
entire	O
examined	B-T033
area	O
.	O
Few	O
haplotypes	O
displayed	O
statistically	O
significant	O
aggregation	O
in	O
one	O
region	O
over	O
another	O
.	O
We	O
did	O
not	O
find	O
mitochondrial	O
DNA	O
of	O
one	O
species	O
in	O
individuals	O
with	O
the	O
plumage	B-T023
of	O
the	O
other	O
species	O
,	O
except	O
in	O
F1	O
hybrids	B-T001
,	O
which	O
agrees	O
with	O
Haldane´s	O
Rule	O
.	O
It	O
remains	O
to	O
be	O
investigated	O
by	O
genomic	O
methods	O
whether	O
occasional	O
gene	O
flow	O
occurs	O
through	O
the	O
paternal	O
line	O
,	O
as	O
the	O
examined	B-T033
Myc	O
gene	O
displayed	O
only	O
marginal	O
divergence	O
between	O
M.	O
milvus	O
and	O
M.	O
migr	O
.	O
migrans	O
.	O
The	O
central	O
Europe	O
an	O
population	O
of	O
M.	O
milvus	O
is	O
clearly	O
subject	O
to	O
free	O
intraspecific	O
gene	O
flow	O
,	O
which	O
has	O
direct	O
implications	O
when	O
considering	O
the	O
origin	O
of	O
individuals	O
in	O
M.	O
milvus	O
re	O
-	O
introduction	O
programs	O
.	O
      
Tissue	O
MicroRNA	O
profiles	O
as	O
diagnostic	O
and	O
prognostic	O
biomarkers	O
in	O
patients	O
with	O
resectable	B-T061
pancreatic	B-T191
ductal	I-T191
adenocarcinoma	I-T191
and	O
periampullary	B-T191
cancers	I-T191
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
validate	O
previously	O
described	O
diagnostic	O
and	O
prognostic	O
microRNA	O
expression	O
profiles	O
in	O
tissue	O
samples	O
from	O
patients	O
with	O
pancreatic	B-T191
cancer	I-T191
and	O
other	O
periampullary	B-T191
cancers	I-T191
.	O
Expression	O
of	O
46	O
selected	O
microRNAs	O
was	O
studied	O
in	O
formalin	B-T121
-fixed	O
paraffin	O
-	O
embedded	O
tissue	O
from	O
patients	O
with	O
resected	B-T061
pancreatic	B-T191
ductal	I-T191
adenocarcinoma	I-T191
(	O
n	O
=	O
165	O
)	O
,	O
ampullary	B-T191
cancer	I-T191
(	O
n=59	O
)	O
,	O
duodenal	B-T191
cancer	I-T191
(	O
n	O
=	O
6	O
)	O
,	O
distal	O
common	B-T191
bile	I-T191
duct	I-T191
cancer	I-T191
(	O
n	O
=	O
21	O
)	O
,	O
and	O
gastric	B-T191
cancer	I-T191
(	O
n	O
=	O
20	O
)	O
;	O
chronic	B-T047
pancreatitis	I-T047
(	O
n	O
=	O
39	O
)	O
;	O
and	O
normal	B-T033
pancreas	I-T033
(	O
n	O
=	O
35	O
)	O
.	O
The	O
microRNAs	O
were	O
analyzed	O
by	O
PCR	O
using	O
the	O
Fluidigm	O
platform	O
.	O
Twenty	O
-	O
two	O
microRNAs	O
were	O
significantly	O
differently	O
expressed	O
in	O
patients	O
with	O
pancreatic	B-T191
cancer	I-T191
when	O
compared	O
to	O
healthy	O
controls	O
and	O
chronic	B-T047
pancreatitis	I-T047
patients	O
;	O
17	O
miRNAs	O
were	O
upregulated	O
(	O
miR-21	O
-	O
5p	O
,	O
-	O
23a-3p	O
,	O
-	O
31	O
-	O
5p	O
,	O
-	O
34c-5p	O
,	O
-	O
93	O
-	O
3p	O
,	O
-	O
135b-3p	O
,	O
-	O
155	O
-	O
5p	O
,	O
-	O
186	O
-	O
5p	O
,	O
-	O
196b-5p	O
,	O
-	O
203	O
,	O
-	O
205	O
-	O
5p	O
,	O
-	O
210	O
,	O
-	O
222	O
-	O
3p	O
,	O
-	O
451	O
,	O
-	O
492	O
,	O
-	O
614	O
,	O
and	O
miR-622	O
)	O
and	O
5	O
were	O
downregulated	O
(	O
miR-122	O
-	O
5p	O
,	O
-	O
130b-3p	O
,	O
-	O
216b	O
,	O
-	O
217	O
,	O
and	O
miR-375	O
)	O
.	O
MicroRNAs	O
were	O
grouped	O
into	O
diagnostic	O
indices	O
of	O
varying	O
complexity	O
.	O
Ten	O
microRNAs	O
associated	O
with	O
prognosis	B-T058
were	O
identified	O
(	O
let-7	O
g	O
,	O
miR-29a-5p	O
,	O
-	O
34a-5p	O
,	O
-	O
125a-3p	O
,	O
-	O
146a-5p	O
,	O
-	O
187	O
,	O
-	O
205	O
-	O
5p	O
,	O
-	O
212	O
-	O
3p	O
,	O
-	O
222	O
-	O
5p	O
,	O
and	O
miR-450b-5p	O
)	O
.	O
Prognostic	O
indices	O
based	O
on	O
differences	O
in	O
expression	O
of	O
2	O
different	O
microRNAs	O
were	O
constructed	O
for	O
pancreatic	B-T191
and	O
ampullary	B-T191
cancer	I-T191
combined	O
and	O
separately	O
(	O
30	O
,	O
5	O
,	O
and	O
21	O
indices	O
)	O
.	O
The	O
study	O
confirms	O
that	O
pancreatic	B-T191
cancer	I-T191
tissue	O
has	O
a	O
microRNA	O
expression	O
profile	O
that	O
is	O
different	O
from	O
that	O
of	O
other	O
periampullary	B-T191
cancers	I-T191
,	O
chronic	B-T047
pancreatitis	I-T047
,	O
and	O
normal	B-T033
pancreas	I-T033
.	O
We	O
identified	O
prognostic	O
microRNAs	O
and	O
microRNA	O
indices	O
that	O
were	O
associated	O
with	O
shorter	O
overall	O
survival	O
in	O
patients	O
with	O
radically	O
resected	B-T061
pancreatic	B-T191
cancer	I-T191
.	O
      
In	O
Vivo	O
Three	O
-	O
Dimensional	O
Patellar	B-T023
Mechanics	O
:	O
Normal	O
Knees	B-T023
Compared	O
with	O
Domed	O
and	O
Anatomic	O
Patellar	B-T023
Components	O
Patellofemoral	O
complications	O
are	O
a	O
major	O
cause	O
of	O
revision	B-T061
surgery	I-T061
following	O
total	B-T061
knee	I-T061
arthroplasty	I-T061
(	O
TKA	B-T061
)	O
.	O
High	O
forces	O
occurring	O
at	O
the	O
patellofemoral	O
articulation	O
coupled	O
with	O
a	O
small	O
patellofemoral	O
contact	O
area	O
pose	O
substantial	O
design	O
challenges	O
.	O
In	O
this	O
study	O
,	O
the	O
three	O
-	O
dimensional	O
(	O
3D	O
)	O
in	O
vivo	O
mechanics	O
of	O
domed	O
and	O
anatomically	O
shaped	O
patellar	B-T023
components	O
were	O
compared	O
with	O
those	O
of	O
native	O
patellae	B-T023
.	O
Ten	O
normal	O
knees	B-T023
,	O
10	O
treated	B-T061
with	I-T061
an	O
LCS	B-T061
-	I-T061
PS	I-T061
(	I-T061
low	I-T061
contact	I-T061
stress	I-T061
-	I-T061
posterior	I-T061
stabilized	I-T061
)	I-T061
TKA	I-T061
(	O
anatomically	O
shaped	O
patellar	B-T023
component	O
)	O
,	O
and	O
10	O
treated	B-T061
with	I-T061
a	O
PFC	B-T061
Sigma	I-T061
RP	I-T061
-	I-T061
PS	I-T061
(	I-T061
press	I-T061
-	I-T061
fit	I-T061
condylar	I-T061
Sigma	I-T061
rotating	I-T061
platform	I-T061
-	I-T061
posterior	I-T061
stabilized	I-T061
)	I-T061
TKA	I-T061
(	O
domed	O
patellar	B-T023
component	O
)	O
were	O
analyzed	O
under	O
fluoroscopic	B-T060
surveillance	O
while	O
the	O
patient	O
performed	O
a	O
weight	B-T033
-	I-T033
bearing	I-T033
deep	O
knee	B-T033
bend	I-T033
from	O
full	O
knee	B-T033
extension	I-T033
to	O
maximum	O
knee	B-T033
flexion	I-T033
.	O
Relevant	O
bone	O
geometries	O
were	O
segmented	O
out	O
from	O
computed	B-T060
tomography	I-T060
(	O
CT	B-T060
)	O
scans	B-T060
,	O
and	O
computer	O
-	O
assisted	O
-	O
design	O
(	O
CAD	O
)	O
models	O
of	O
the	O
implanted	O
components	O
were	O
obtained	O
from	O
the	O
manufacturer	O
.	O
Three	O
-	O
dimensional	O
patellofemoral	O
kinematics	O
were	O
obtained	O
using	O
a	O
3D	O
-to-	O
2D	O
registration	O
process	O
.	O
Contact	O
mechanics	O
were	O
calculated	O
using	O
a	O
distance	O
map	O
between	O
the	O
articulating	B-T023
patellar	I-T023
and	O
femoral	O
surfaces	O
.	O
Both	O
patellar	B-T023
component	O
designs	O
exhibited	O
good	O
rotational	O
kinematics	O
and	O
tracked	O
well	O
within	O
the	O
femoral	B-T023
trochlea	I-T023
when	O
compared	O
with	O
the	O
normal	O
patella	B-T023
.	O
The	O
contact	O
areas	O
in	O
the	O
TKA	B-T061
groups	O
peaked	O
at	O
60	O
°	O
of	O
knee	B-T033
flexion	I-T033
(	O
mean	O
and	O
standard	O
deviation	O
,	O
201	O
±	O
63.4	O
mm	O
for	O
the	O
LCS	O
-	O
PS	O
group	O
and	O
218	O
±	O
95.4	O
mm	O
for	O
the	O
Sigma	O
RP	O
-	O
PS	O
group	O
)	O
,	O
and	O
the	O
areas	O
were	O
substantially	O
smaller	O
than	O
those	O
previously	O
reported	O
for	O
the	O
normal	O
patella	B-T023
.	O
Contact	O
points	O
in	O
the	O
TKA	B-T061
groups	O
stayed	O
close	O
to	O
the	O
center	O
of	O
the	O
patellar	B-T023
components	O
.	O
Both	O
designs	O
performed	O
satisfactorily	O
,	O
although	O
patellofemoral	O
contact	O
areas	O
were	O
reduced	O
in	O
comparison	O
with	O
those	O
in	O
the	O
native	O
patella	B-T023
.	O
Therapeutic	O
Level	O
III	O
.	O
See	O
Instructions	O
for	O
Authors	O
for	O
a	O
complete	O
description	O
of	O
levels	O
of	O
evidence	O
.	O
      
Most	O
Americans	O
Have	O
Good	O
Health	O
,	O
Little	O
Unmet	B-T033
Need	I-T033
,	O
And	O
Few	O
Health	O
Care	O
Expenses	O
The	O
distribution	O
of	O
health	O
care	O
expenditures	O
remains	O
highly	O
concentrated	O
,	O
but	O
most	O
Americans	O
use	O
few	O
health	O
care	O
resources	O
and	O
have	O
low	O
out	O
-	O
of	O
-	O
pocket	O
spending	O
.	O
More	O
than	O
93	O
percent	O
of	O
"	O
low	O
spenders	O
"	O
(	O
those	O
in	O
the	O
bottom	O
half	O
of	O
the	O
population	O
)	O
believe	O
they	O
have	O
received	O
all	O
needed	O
care	B-T058
in	O
a	O
timely	O
manner	O
.	O
The	O
low	O
spending	O
by	O
the	O
majority	O
of	O
the	O
population	O
has	O
remained	O
almost	O
unchanged	O
during	O
the	O
thirty	O
-	O
seven-	O
year	O
period	O
examined	B-T033
.	O
      
Precise	O
prediction	O
of	O
activators	B-T121
for	O
the	O
human	O
constitutive	O
androstane	O
receptor	O
using	O
structure	O
-based	O
three	O
-	O
dimensional	O
quantitative	O
structure	O
-	O
activity	O
relationship	O
methods	O
The	O
constitutive	O
androstane	O
receptor	O
(	O
CAR	O
,	O
NR1I3	O
)	O
regulates	O
the	O
expression	O
of	O
numerous	O
drug	O
-	O
metabolizing	O
enzymes	O
and	O
transporters	O
.	O
The	O
upregulation	O
of	O
various	O
enzymes	O
,	O
including	O
CYP2B6	O
,	O
by	O
CAR	O
activators	B-T121
is	O
a	O
critical	O
problem	O
leading	O
to	O
clinically	O
severe	O
drug	O
-	O
drug	O
interactions	O
(	O
DDIs	O
)	O
.	O
To	O
date	O
,	O
however	O
,	O
few	O
effective	O
computational	O
approaches	O
for	O
identifying	O
CAR	O
activators	O
exist	O
.	O
In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
develop	O
three	O
-	O
dimensional	O
quantitative	O
structure	O
-	O
activity	O
relationship	O
(	O
3D	O
-	O
QSAR	O
)	O
models	O
to	O
predict	O
the	O
CAR	O
activating	O
potency	O
of	O
compounds	B-T121
emerging	O
in	O
the	O
drug	O
-	O
discovery	O
process	O
.	O
Models	O
were	O
constructed	O
using	O
comparative	O
molecular	O
field	O
analysis	O
(	O
CoMFA	O
)	O
based	O
on	O
the	O
molecular	O
alignments	O
of	O
ligands	O
binding	O
to	O
CAR	O
,	O
which	O
were	O
obtained	O
from	O
ensemble	O
ligand	O
-	O
docking	O
using	O
28	B-T121
compounds	I-T121
as	O
a	O
training	O
set	O
.	O
The	O
CoMFA	O
model	O
,	O
modified	O
by	O
adding	O
a	O
lipophilic	O
parameter	O
with	O
calculated	O
logD7.4	O
(	O
S+logD7.4	O
)	O
,	O
demonstrated	O
statistically	O
good	O
predictive	O
ability	O
(	O
r(2	O
)	O
=	O
0.99	O
,	O
q(2	O
)	O
=	O
0.74	O
)	O
.	O
We	O
also	O
confirmed	O
the	O
excellent	O
predictability	O
of	O
the	O
3D	O
-	O
QSAR	O
model	O
for	O
CAR	O
activation	O
(	O
r(2)pred	O
=	O
0.71	O
)	O
using	O
seven	O
compounds	B-T121
as	O
a	O
test	O
set	O
for	O
external	O
validation	O
.	O
Collectively	O
,	O
our	O
results	O
indicate	O
that	O
the	O
3D	O
-	O
QSAR	O
model	O
developed	O
in	O
this	O
study	O
provides	O
precise	O
prediction	O
of	O
CAR	O
activating	O
potency	O
and	O
,	O
thus	O
,	O
should	O
be	O
useful	O
for	O
selecting	O
drug	B-T121
candidates	I-T121
with	O
minimized	O
DDI	O
risk	O
related	O
to	O
enzyme	O
-	O
induction	O
in	O
the	O
early	O
drug	O
-	O
discovery	O
stage	O
.	O
      
Delicaflavone	B-T121
induces	O
autophagic	O
cell	O
death	O
in	O
lung	B-T191
cancer	I-T191
via	O
Akt	O
/	O
mTOR	O
/	O
p70S6	O
K	O
signaling	O
pathway	O
Searching	O
for	O
potential	O
anticancer	B-T121
agents	I-T121
from	O
natural	B-T033
sources	I-T033
is	O
an	O
effective	O
strategy	O
for	O
developing	O
novel	O
chemotherapeutic	B-T121
agents	I-T121
.	O
In	O
this	O
study	O
,	O
data	O
supporting	O
the	O
in	O
vitro	O
and	O
in	O
vivo	O
anticancer	B-T033
effects	I-T033
of	O
delicaflavone	B-T121
,	O
a	O
rarely	O
occurring	O
biflavonoid	O
from	O
Selaginella	O
doederleinii	O
,	O
were	O
reported	O
.	O
Delicaflavone	B-T121
exhibited	O
favorable	O
anticancer	B-T033
properties	O
,	O
as	O
shown	O
by	O
the	O
MTT	O
assay	O
and	O
xenograft	B-T050
model	I-T050
of	O
human	O
non	B-T191
-	I-T191
small	I-T191
cell	I-T191
lung	I-T191
cancer	I-T191
in	O
male	O
BALB	O
/	O
c	O
nude	O
mice	O
without	O
observable	O
adverse	O
effect	O
.	O
By	O
transmission	B-T059
electron	I-T059
microscopy	I-T059
with	O
acridine	O
orange	O
and	O
Cyto	O
-	O
ID	O
®	O
Autophagy	O
detection	O
dyes	O
,	O
Western	B-T059
blot	I-T059
analysis	O
,	O
and	O
RT	O
-	O
PCR	O
assay	O
,	O
we	O
confirmed	O
that	O
delicaflavone	B-T121
induces	O
autophagic	O
cell	O
death	O
by	O
increasing	O
the	O
ratio	O
of	O
LC3	O
-	O
II	O
to	O
LC3	O
-	O
I	O
,	O
which	O
are	O
autophagy	O
-	O
related	O
proteins	O
,	O
and	O
promoting	O
the	O
generation	O
of	O
acidic	O
vesicular	O
organelles	O
and	O
autolysosomes	O
in	O
the	O
cytoplasm	O
of	O
human	O
lung	B-T191
cancer	I-T191
A549	O
and	O
PC-9	O
cells	O
in	O
a	O
time	O
-	O
and	O
dose	O
-	O
dependent	O
manner	O
.	O
Delicaflavone	B-T121
downregulated	O
the	O
expression	B-T033
of	I-T033
phospho	I-T033
-	I-T033
Akt	I-T033
,	O
phospho	O
-	O
mTOR	O
,	O
and	O
phospho	O
-	O
p70S6	O
K	O
in	O
a	O
time	O
-	O
and	O
dose	O
-	O
dependent	O
manner	O
,	O
suggesting	O
that	O
it	O
induced	O
autophagy	O
by	O
inhibiting	O
the	O
Akt	O
/	O
mTOR	O
/	O
p70S6	O
K	O
pathway	O
in	O
A549	O
and	O
PC-9	O
cells	O
.	O
Delicaflavone	B-T121
is	O
a	O
potential	O
anticancer	B-T121
agent	I-T121
that	O
can	O
induce	O
autophagic	O
cell	O
death	O
in	O
human	O
non	B-T191
-	I-T191
small	I-T191
cell	I-T191
lung	I-T191
cancer	I-T191
via	O
the	O
Akt	O
/	O
mTOR	O
/	O
p70S6	O
K	O
signaling	O
pathway	O
.	O
Delicaflavone	B-T121
showed	O
anti	B-T033
-	I-T033
lung	I-T033
cancer	I-T033
effects	I-T033
in	O
vitro	O
and	O
in	O
vivo	O
.	O
Delicaflavone	B-T121
induced	O
autophagic	O
cell	O
death	O
via	O
Akt	O
/	O
mTOR	O
/	O
p70S6	O
K	O
signaling	O
pathway	O
.	O
Delicaflavone	B-T121
did	O
not	O
show	O
observable	O
side	O
effects	O
in	O
a	O
xenograft	B-T050
mouse	I-T050
model	I-T050
.	O
Delicaflavone	B-T121
may	O
represent	O
a	O
potential	O
therapeutic	O
agent	O
for	O
lung	B-T191
cancer	I-T191
.	O
Delicaflavone	B-T121
showed	O
anti	B-T033
-	I-T033
lung	I-T033
cancer	I-T033
effects	I-T033
in	O
vitro	O
and	O
in	O
vivo	O
.	O
Delicaflavone	B-T121
induced	O
autophagic	O
cell	O
death	O
via	O
Akt	O
/	O
mTOR	O
/	O
p70S6	O
K	O
signaling	O
pathway	O
.	O
Delicaflavone	B-T121
did	O
not	O
show	O
observable	O
side	O
effects	O
in	O
a	O
xenograft	B-T050
mouse	I-T050
model	I-T050
.	O
Delicaflavone	B-T121
may	O
represent	O
a	O
potential	O
therapeutic	O
agent	O
for	O
lung	B-T191
cancer	I-T191
.	O
      
Complete	O
Genome	O
Sequences	O
of	O
Three	O
Outbreak	O
-Associated	O
Legionella	B-T007
pneumophila	I-T007
Isolates	O
We	O
report	O
here	O
the	O
complete	O
genome	O
sequences	O
of	O
three	O
Legionella	B-T007
pneumophila	I-T007
isolates	O
that	O
are	O
associated	O
with	O
a	O
Legionnaires	B-T047
'	I-T047
disease	I-T047
outbreak	O
in	O
New	O
York	O
in	O
2012	O
.	O
Two	O
clinical	O
isolates	O
(	O
D7630	B-T007
and	O
D7632	B-T007
)	O
and	O
one	O
environmental	O
isolate	O
(	O
D7631	B-T007
)	O
were	O
recovered	O
from	O
this	O
outbreak	O
.	O
A	O
single	O
isolate	O
-	O
specific	O
virulence	O
gene	O
was	O
found	O
in	O
D7632	B-T007
.	O
These	O
isolates	O
were	O
included	O
in	O
a	O
large	O
study	O
evaluating	B-T058
the	O
genomic	O
resolution	O
of	O
various	O
bioinformatics	O
approaches	O
for	O
L.	B-T007
pneumophila	I-T007
serogroup	O
1	O
isolates	O
.	O
      
Coupling	O
of	O
TRPV6	O
and	O
TMEM16A	O
in	O
epithelial	O
principal	O
cells	O
of	O
the	O
rat	B-T023
epididymis	I-T023
The	O
epididymis	B-T023
establishes	O
a	O
congenial	O
environment	O
for	O
sperm	O
maturation	O
and	O
protection	B-T033
.	O
Its	O
fluid	O
is	O
acidic	O
,	O
and	O
the	O
calcium	B-T121
concentration	O
is	O
low	O
and	O
declines	O
along	O
the	O
length	O
of	O
the	O
epididymal	B-T023
tubule	I-T023
.	O
However	O
,	O
our	O
knowledge	O
of	O
ionic	O
currents	O
and	O
mechanisms	O
of	O
calcium	O
homeostasis	O
in	O
rat	B-T023
epididymal	I-T023
epithelial	O
cells	O
remains	O
enigmatic	O
.	O
In	O
this	O
study	O
,	O
to	O
better	O
understand	O
calcium	O
regulation	O
in	O
the	O
epididymis	B-T023
,	O
we	O
use	O
the	O
patch	O
-	O
clamp	O
method	O
to	O
record	O
from	O
single	O
rat	O
cauda	B-T023
epididymal	I-T023
principal	O
cells	O
.	O
We	O
detect	B-T033
a	O
constitutively	O
active	O
Ca(2	B-T121
+	I-T121
)	I-T121
current	O
with	O
characteristics	O
that	O
match	O
the	O
epithelial	O
calcium	O
channel	O
TRPV6	O
.	O
Electrophysiological	B-T060
and	O
pharmacological	B-T060
data	I-T060
also	O
reveal	O
a	O
constitutively	O
active	O
calcium	O
-	O
activated	O
chloride	O
conductance	O
(	O
CaCC	O
)	O
.	O
Removal	O
of	O
extracellular	O
calcium	B-T121
attenuates	O
not	O
only	O
the	O
TRPV6	O
-like	O
conductance	O
,	O
but	O
also	O
the	O
CaCC	O
.	O
Lanthanide	O
block	O
is	O
time	O
dependent	O
such	O
that	O
the	O
TRPV6	O
-like	O
component	O
is	O
inhibited	O
first	O
,	O
followed	O
by	O
the	O
CaCC	O
.	O
The	O
putative	O
CaCC	O
blocker	B-T121
niflumic	B-T121
acid	I-T121
partially	O
inhibits	O
whole	O
-	O
cell	O
currents	O
,	O
whereas	O
La(3	O
+	O
)	O
almost	O
abolishes	O
whole	O
-	O
cell	O
currents	O
in	O
principal	O
cells	O
.	O
Membrane	O
potential	O
measurements	O
reveal	O
an	O
interplay	O
between	O
La(3	O
+	O
)	O
-	O
sensitive	O
ion	O
channels	O
and	O
those	O
that	O
are	O
sensitive	O
to	O
the	O
specific	O
TMEM16A	O
inhibitor	O
tannic	B-T121
acid	I-T121
.	O
In	O
vivo	O
perfusion	B-T061
of	O
the	O
cauda	B-T023
epididymal	I-T023
tubule	I-T023
shows	O
a	O
substantial	O
rate	O
of	O
Ca(2	B-T121
+	I-T121
)	I-T121
reabsorption	O
from	O
the	O
luminal	O
side	O
,	O
which	O
is	O
dose	O
-	O
dependently	O
suppressed	O
by	O
ruthenium	O
red	O
,	O
a	O
putative	O
blocker	B-T121
of	O
epithelial	O
Ca(2	O
+	O
)	O
channels	O
and	O
CaCC	O
.	O
Finally	O
,	O
we	O
discover	O
messenger	O
RNA	O
for	O
both	O
TRPV6	O
and	O
TMEM16A	O
in	O
the	O
rat	B-T023
epididymis	I-T023
and	O
show	O
that	O
their	O
proteins	O
colocalize	O
in	O
the	O
apical	O
membrane	O
of	O
principal	O
cells	O
.	O
Collectively	O
,	O
these	O
data	O
provide	O
evidence	O
for	O
a	O
coupling	O
mechanism	O
between	O
TRPV6	O
and	O
TMEM16A	O
in	O
principal	O
cells	O
that	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
calcium	O
homeostasis	O
in	O
the	O
epididymis	B-T023
.	O
      
How	O
Integrated	B-T059
Management	I-T059
Strategies	I-T059
Promote	O
Protein	O
Quality	O
of	O
Cotton	O
Embryos	O
:	O
High	O
Levels	O
of	O
Soil	O
Available	O
N	O
,	O
N	O
Assimilation	O
and	O
Protein	O
Accumulation	B-T033
Rate	O
Cottonseed	O
is	O
widely	O
used	O
as	O
a	O
source	B-T033
of	O
ruminant	O
feed	O
and	O
for	O
industrial	O
purposes	O
.	O
Therefore	O
,	O
there	O
is	O
a	O
tremendous	O
need	O
to	O
improve	B-T033
the	O
nutritional	O
value	O
of	O
cotton	O
embryos	O
.	O
In	O
this	O
study	O
,	O
a	O
conventional	B-T059
management	I-T059
(	O
CM	B-T059
)	O
and	O
two	O
integrated	O
cotton	O
management	B-T059
strategies	I-T059
(	O
IMS1	B-T059
,	O
IMS2	B-T059
)	O
were	O
performed	O
at	O
two	O
soil	O
fertility	B-T033
levels	O
to	O
study	O
the	O
relationships	O
among	O
soil	O
N	O
,	O
N	O
assimilation	O
,	O
embryonic	O
protein	O
accumulation	B-T033
and	O
protein	O
quality	O
.	O
The	O
levels	B-T059
of	I-T059
proteins	I-T059
,	O
essential	B-T059
amino	I-T059
acids	I-T059
,	O
and	O
semi	B-T059
-	I-T059
essential	I-T059
amino	I-T059
acids	I-T059
,	O
especially	O
those	O
of	O
glutamate	B-T059
,	O
lysine	B-T059
,	O
and	O
methionine	B-T059
,	O
were	O
higher	O
in	O
IMS1	B-T059
and	O
IMS2	B-T059
embryos	O
than	O
in	O
CM	B-T059
embryos	O
.	O
These	O
changes	O
were	O
significantly	O
positively	B-T033
correlated	O
with	O
the	O
soil	O
-	O
available	O
N	B-T059
content	I-T059
,	O
glutamine	O
synthetase	O
activity	O
and	O
peak	O
value	O
of	O
protein	O
accumulation	B-T033
rate	O
and	O
were	O
negatively	B-T033
correlated	O
with	O
the	O
free	O
amino	B-T059
acid	I-T059
level	I-T059
.	O
These	O
results	B-T033
illustrated	O
that	O
integrated	B-T059
management	I-T059
strategies	I-T059
,	O
especially	O
the	O
rates	O
and	O
timing	O
of	O
N	O
application	O
,	O
raise	O
the	O
level	O
of	O
soil	O
available	O
N	O
,	O
which	O
is	O
beneficial	O
for	O
N	O
assimilation	O
in	O
developing	O
cotton	O
embryos	O
.	O
The	O
protein	B-T059
content	I-T059
was	O
limited	O
by	O
the	O
rate	O
of	O
protein	O
accumulation	B-T033
rather	O
than	O
by	O
the	O
free	O
amino	B-T059
acid	I-T059
content	I-T059
.	O
The	O
combination	O
of	O
target	O
yield	O
fertilization	O
,	O
a	O
growth	O
-driven	O
N	O
application	O
schedule	O
,	O
a	O
high	O
plant	O
density	O
and	O
the	O
seedling	O
raising	O
with	O
bio	O
-	O
organic	O
fertilizer	O
can	O
substantially	O
improve	B-T033
protein	O
quality	O
in	O
cotton	O
embryos	O
,	O
especially	O
at	O
a	O
soil	O
with	O
low	O
soil	O
organic	O
matter	O
and	O
total	O
nitrogen	O
.	O
      
Two	O
known	O
and	O
one	O
new	O
species	O
of	O
Draconematidae	O
and	O
Epsilonematida	O
(	O
Nematoda	O
,	O
Desmodorida	O
)	O
from	O
the	O
White	O
Sea	O
,	O
North	O
Russia	O
Morphological	O
descriptions	O
of	O
three	O
"	O
walking	O
nematode	O
"	O
species	O
found	O
for	O
the	O
first	O
time	O
in	O
the	O
White	O
Sea	O
are	O
presented	O
.	O
Draconema	O
ophicephalum	O
(	O
Claparède	O
,	O
1863	O
)	O
(	O
Draconematidae	O
)	O
and	O
Epsilonema	O
steineri	O
Chitwood	O
,	O
1935	O
(	O
Epsilonematidae	O
)	O
,	O
both	O
known	O
from	O
insufficient	O
material	O
and	O
females	O
only	O
,	O
are	O
re	O
-	O
described	O
and	O
problems	B-T033
of	O
their	O
taxonomic	O
identification	O
as	O
well	O
as	O
species	O
compositions	O
of	O
respective	O
genera	O
are	O
discussed	O
.	O
The	O
new	O
species	O
Prochaetosoma	O
marisalbi	O
sp	O
.	O
n.	O
(	O
Draconematidae	O
)	O
differs	O
from	O
other	O
Prochaetosoma	O
species	O
except	O
P.	O
longicapitatum	O
(	O
Allgén	O
,	O
1935	O
)	O
in	O
that	O
the	O
pharyngeal	B-T023
bulb	B-T017
lumen	O
is	O
not	B-T033
cuticularised	I-T033
,	O
from	O
P.	O
longicapitatum	O
by	O
shape	B-T017
of	I-T017
body	I-T017
and	O
rostrum	O
,	O
greater	O
number	O
of	O
cephalic	O
adhesive	O
tubes	O
,	O
and	O
from	O
P.	O
maertensi	O
Decraemer	O
,	O
1989	O
by	O
having	O
a	O
relatively	O
longer	O
tail	B-T023
,	O
fewer	O
anterior	O
adhesive	O
tubes	O
and	O
longer	O
spicules	O
,	O
besides	O
lacking	O
cuticular	O
thickening	O
in	O
the	O
pharyngeal	B-T023
bulb	B-T017
.	O
Draconema	O
hoonsooi	O
,	O
D.	O
youngeouni	O
,	O
P.rochaetosoma	O
beomseomense	O
,	O
P.	O
brevicaudatum	O
,	O
P.	O
byungilli	O
,	O
P.	O
cracense	O
,	O
P.	O
saheungi	O
,	O
P.	O
sujungi	O
,	O
P.	O
supseomense	O
erected	O
by	O
Rho	O
&	O
Min	O
(	O
2011	O
)	O
are	O
considered	O
as	O
invalid	O
species	O
while	O
Prochaetosoma	O
arcticum	O
,	O
P.	O
lugubre	O
and	O
Epsilonema	O
cygnoides	O
are	O
assumed	O
as	O
species	O
inquirenda	O
.	O
From	O
a	O
phylogenetic	O
tree	O
based	O
on	O
the	O
18S	O
rRNA	O
gene	O
,	O
all	O
three	O
White	O
Sea	O
species	O
adjoin	O
to	O
unidentified	O
species	O
of	O
their	O
respective	O
genera	O
.	O
      
Automated	O
basal	B-T191
cell	I-T191
carcinoma	I-T191
detection	O
in	O
high	B-T060
-	I-T060
definition	I-T060
optical	I-T060
coherence	I-T060
tomography	I-T060
Basal	B-T191
cell	I-T191
carcinoma	I-T191
(	O
BCC	B-T191
)	O
is	O
the	O
most	O
common	O
non	B-T191
-	I-T191
melanoma	I-T191
skin	I-T191
cancer	I-T191
.	O
Conventional	O
diagnosis	O
of	O
BCC	B-T191
requires	O
invasive	O
biopsies	B-T060
.	O
Recently	O
,	O
a	O
high	B-T060
-	I-T060
definition	I-T060
optical	I-T060
coherence	I-T060
tomography	I-T060
(	O
HD	B-T060
-	I-T060
OCT	I-T060
)	O
technique	O
has	O
been	O
developed	O
,	O
which	O
provides	O
a	O
non	O
-	O
invasive	O
in	B-T059
vivo	I-T059
imaging	I-T059
method	I-T059
of	O
skin	O
.	O
Good	O
agreements	O
of	O
BCC	B-T191
features	O
between	O
HD	B-T060
-	I-T060
OCT	I-T060
images	O
and	O
histopathological	O
architecture	O
have	O
been	O
found	O
.	O
Therefore	O
it	O
is	O
possible	O
to	O
automatically	O
detect	O
BCC	B-T191
using	O
HD	B-T060
-	I-T060
OCT	I-T060
.	O
This	O
paper	O
presents	O
a	O
novel	O
BCC	B-T191
detection	B-T060
method	I-T060
that	O
consists	O
of	O
four	O
steps	O
:	O
graph	O
based	O
skin	O
surface	O
segmentation	B-T058
,	O
surface	O
flattening	O
,	O
deep	O
feature	O
extraction	O
and	O
the	O
BCC	B-T191
classification	O
.	O
The	O
effectiveness	O
of	O
the	O
proposed	O
method	O
is	O
well	O
demonstrated	O
on	O
a	O
dataset	O
of	O
5,040	O
images	O
.	O
It	O
can	O
therefore	O
serve	O
as	O
an	O
automatic	O
tool	O
for	O
screening	O
BCC	B-T191
.	O
      
Long	O
Non	O
-	O
Coding	O
RNA	O
SNHG6	O
as	O
a	O
Potential	O
Biomarker	O
for	O
Hepatocellular	B-T191
Carcinoma	I-T191
Long	O
Non	O
-	O
coding	O
RNAs	O
(	O
lncRNAs	O
)	O
refer	O
to	O
all	O
non	O
-	O
protein	O
coding	O
transcripts	O
longer	O
than	O
200	O
nucleotides	O
.	O
Their	O
critical	O
roles	O
in	O
different	O
biological	O
pathways	O
have	O
been	O
already	O
well	O
established	O
.	O
Altered	O
expression	O
of	O
lncRNAs	O
can	O
be	O
involved	O
in	O
the	O
cancer	B-T191
initiation	I-T191
and/or	O
progression	B-T191
.	O
Since	O
patients	O
with	O
hepatocellular	B-T191
carcinoma	I-T191
(	O
HCC	B-T191
)	O
are	O
usually	O
diagnosed	B-T033
in	O
late	O
stages	O
,	O
developing	O
diagnostic	B-T060
methods	I-T060
seems	O
to	O
be	O
essential	O
.	O
In	O
this	O
study	O
,	O
the	O
expression	O
levels	O
of	O
different	O
lncRNAs	O
were	O
systematically	O
analysed	O
in	O
different	O
genomic	O
and	O
transcriptome	O
datasets	O
.	O
The	O
analyses	O
showed	O
that	O
SNHG6	O
is	O
among	O
the	O
lncRNAs	O
with	O
distinctive	O
dysregulation	O
of	O
expression	O
and	O
copy	O
number	O
variation	O
in	O
HCC	B-T191
tumors	I-T191
compared	O
with	O
normal	O
tissues	O
.	O
The	O
results	O
also	O
suggest	O
that	O
the	O
dysregulation	O
of	O
SNHG6	O
is	O
highly	O
cancer	B-T191
type	O
specific	O
.	O
Through	O
co	O
-	O
occurrence	O
analyses	O
,	O
we	O
found	O
that	O
SNHG6	O
and	O
its	O
related	O
co	O
-	O
expressed	O
genes	O
on	O
8q	O
are	O
involved	O
in	O
the	O
structural	O
integrity	O
of	O
ribosome	O
and	O
translation	O
.	O
This	O
comprehensive	O
in	O
silico	O
analysis	O
,	O
provides	O
a	O
resource	O
for	O
investigating	O
SNHG6	O
in	O
hepatocellular	B-T191
carcinoma	I-T191
and	O
lays	O
the	O
groundwork	O
for	O
design	O
of	O
next	O
researches	O
.	O
      
Identification	O
and	O
SAR	O
Evaluation	B-T058
of	O
Hemozoin	O
-	O
Inhibiting	O
Benzamides	O
Active	O
against	O
Plasmodium	O
falciparum	O
Quinoline	O
antimalarials	B-T121
target	O
hemozoin	O
formation	O
causing	O
a	O
cytotoxic	O
accumulation	B-T033
of	O
ferriprotoporphyrin	O
IX	O
(	O
Fe(III)PPIX	O
)	O
.	O
Well	O
-	O
developed	O
SAR	O
models	O
exist	O
for	O
β	O
-	O
hematin	O
inhibition	O
,	O
parasite	O
activity	O
,	O
and	O
cellular	O
mechanisms	O
for	O
this	O
compound	O
class	O
,	O
but	O
no	O
comparably	O
detailed	O
investigations	B-T033
exist	O
for	O
other	O
hemozoin	O
inhibiting	O
chemotypes	B-T121
.	O
Here	O
,	O
benzamide	O
analogues	O
based	O
on	O
previous	O
HTS	B-T059
hits	O
have	O
been	O
purchased	O
or	O
synthesized	O
.	O
Only	O
derivatives	O
containing	O
an	O
electron	O
deficient	O
aromatic	O
ring	O
and	O
capable	O
of	O
adopting	O
flat	O
conformations	O
,	O
optimal	O
for	O
π	O
-	O
π	O
interactions	O
with	O
Fe(III)PPIX	O
,	O
inhibited	O
β	O
-	O
hematin	O
formation	O
.	O
The	O
two	O
most	O
potent	O
analogues	O
showed	O
nanomolar	O
parasite	O
activity	O
,	O
with	O
little	O
CQ	B-T121
cross	O
-	O
resistance	O
,	O
low	O
cytotoxicity	O
,	O
and	O
high	O
in	O
vitro	O
microsomal	O
stability	O
.	O
Selected	O
analogues	O
inhibited	O
hemozoin	O
formation	O
in	O
Plasmodium	O
falciparum	O
causing	O
high	O
levels	O
of	O
free	O
heme	O
.	O
In	O
contrast	O
to	O
quinolines	O
,	O
introduction	O
of	O
amine	O
side	O
chains	O
did	O
not	O
lead	O
to	O
benzamide	O
accumulation	B-T033
in	O
the	O
parasite	O
.	O
These	O
data	O
reveal	O
complex	O
relationships	O
between	O
heme	O
binding	O
,	O
free	O
heme	O
levels	O
,	O
cellular	O
accumulation	O
,	O
and	O
in	O
vitro	O
activity	O
of	O
potential	O
novel	O
antimalarials	B-T121
.	O
      
Comparing	O
the	O
bulking	O
effect	O
of	O
calcium	B-T121
hydroxyapatite	I-T121
and	O
Deflux	B-T121
injection	B-T061
into	O
the	O
bladder	B-T023
neck	I-T023
for	O
improvement	O
of	O
urinary	O
incontinence	O
in	O
bladder	B-T047
exstrophy	I-T047
-	I-T047
epispadias	I-T047
complex	I-T047
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
efficacy	O
of	O
the	O
endoscopic	B-T061
injection	I-T061
of	O
calcium	B-T121
hydroxyapatite	I-T121
(	O
CaHA	B-T121
)	O
into	O
the	O
bladder	B-T023
neck	I-T023
(	O
BN	B-T023
)	O
region	O
of	O
patients	O
with	O
urinary	O
incontinence	O
and	O
bladder	B-T047
exstrophy	I-T047
-	I-T047
epispadias	I-T047
complex	I-T047
(	O
BEEC	B-T047
)	O
.	O
We	O
designed	O
a	O
retrospective	O
cohort	O
study	O
in	O
which	O
we	O
retrospectively	O
studied	O
medical	O
charts	O
of	O
female	O
and	O
male	O
patients	O
of	O
BEEC	B-T047
who	O
had	O
undergone	O
CaHA	B-T121
or	O
Deflux	B-T121
injection	B-T061
for	O
continence	B-T061
improvement	I-T061
between	O
2009	O
and	O
2014	O
.	O
Sixteen	O
incontinent	B-T047
patients	O
with	O
a	O
mean	O
±	O
SD	O
age	O
of	O
8.09	O
±	O
3.5	O
years	O
received	O
an	O
endoscopic	B-T061
submucosal	I-T061
injection	I-T061
of	O
5.4	O
ml	O
of	O
pure	O
CaHA	B-T121
powder	O
with	O
autologous	O
plasma	O
(	O
group	O
A	O
)	O
.	O
Patients	O
in	O
group	O
B	O
(	O
N	O
=	O
21	O
)	O
,	O
control	O
group	O
,	O
with	O
a	O
mean	O
±	O
SD	O
age	O
of	O
7.51	O
±	O
2.8	O
years	O
received	O
Deflux	B-T121
injection	B-T061
(	O
5.1	O
ml	O
)	O
.	O
The	O
mean	O
follow	B-T058
-	I-T058
up	I-T058
after	O
injection	B-T061
was	O
38	O
±	O
5.2	O
and	O
33	O
±	O
4.1	O
months	O
in	O
groups	O
A	O
and	O
B	O
,	O
respectively	O
.	O
No	O
post	O
-	O
injection	O
complication	O
was	O
detected	B-T033
in	O
none	O
of	O
the	O
patients	O
during	O
the	O
follow	B-T058
-	I-T058
up	I-T058
.	O
Eleven	O
patients	O
(	O
68.75	O
%	O
)	O
in	O
group	O
A	O
became	O
socially	O
dry	O
following	O
1	O
-	O
2	O
injections	B-T061
,	O
the	O
degree	O
of	O
incontinence	B-T047
was	O
improved	O
in	O
4	O
patients	O
(	O
25	O
%	O
)	O
,	O
and	O
there	O
was	O
no	B-T033
change	I-T033
in	O
one	O
patient	O
(	O
6.25	O
%	O
)	O
.	O
However	O
,	O
Deflux	B-T121
injection	B-T061
resulted	O
in	O
complete	O
dryness	O
in	O
14	O
(	O
66.66	O
%	O
)	O
,	O
improvement	O
in	O
the	O
degree	O
of	O
incontinence	B-T047
in	O
5	O
(	O
23.81	O
%	O
)	O
and	O
no	B-T033
change	I-T033
in	O
2	O
patients	O
(	O
9.52	O
%	O
)	O
,	O
leading	O
to	O
no	B-T033
significant	I-T033
difference	I-T033
in	O
continence	B-T061
achievement	I-T061
between	O
CaHA	B-T121
and	O
Deflux	B-T121
groups	O
(	O
p	O
=	O
0.9	O
)	O
.	O
The	O
statistical	O
analysis	O
was	O
not	B-T033
significantly	I-T033
different	I-T033
in	O
terms	O
of	O
bladder	B-T033
capacity	I-T033
(	O
p	O
=	O
0.7	O
)	O
or	O
Q	O
max	O
(	O
p	O
=	O
0.8	O
)	O
.	O
The	O
preliminary	O
results	O
of	O
this	O
study	O
revealed	O
that	O
CaHA	B-T121
may	O
be	O
applied	O
as	O
an	O
affordable	O
bulking	B-T121
agent	I-T121
in	O
treatment	B-T061
of	O
urinary	O
incontinence	O
in	O
BEEC	B-T047
.	O
      
Real	O
role	O
of	O
β	B-T121
-	I-T121
blockers	I-T121
in	O
regression	O
of	O
left	B-T033
ventricular	I-T033
mass	I-T033
in	O
hypertension	B-T047
patients	O
:	O
Bayesian	O
network	O
meta	O
-	O
analysis	O
Left	B-T047
ventricular	I-T047
hypertrophy	I-T047
(	O
LVH	B-T047
)	O
is	O
commonly	O
present	O
in	O
patients	O
with	O
hypertension	B-T047
(	O
HT	B-T047
)	O
.	O
According	O
to	O
the	O
expert	O
consensus	O
document	O
from	O
American	O
,	O
angiotensin	B-T121
-	I-T121
converting	I-T121
enzyme	I-T121
inhibitor	I-T121
(	O
ACEI	B-T121
)	O
and	O
angiotensin	B-T121
receptor	I-T121
blockers	I-T121
(	O
ARBs	B-T121
)	O
were	O
recommended	O
as	O
1st	O
-	O
line	O
therapeutic	B-T121
drugs	I-T121
.	O
However	O
,	O
none	O
noticed	O
the	O
different	O
efficacy	O
between	O
fat	B-T121
-	I-T121
soluble	I-T121
and	I-T121
selective	I-T121
β1	I-T121
-	I-T121
receptor	I-T121
blockers	I-T121
(	O
FS	B-T121
-	I-T121
β	I-T121
-	I-T121
B	I-T121
)	O
and	O
other	O
β	B-T121
-	I-T121
blockers	I-T121
on	O
regression	O
of	O
LVH	B-T047
before	O
.	O
The	O
aim	O
of	O
this	O
analysis	O
was	O
to	O
compare	O
the	O
efficacy	O
of	O
FS	B-T121
-	I-T121
β	I-T121
-	I-T121
B	I-T121
with	O
the	O
other	O
4	O
different	O
classes	O
of	O
antihypertensive	B-T121
drugs	I-T121
(	O
ACEI	B-T121
,	O
ARBs	B-T121
,	O
calcium	B-T121
channel	I-T121
blockers	I-T121
[	O
CCBs	B-T121
]	O
,	O
and	O
diuretics	B-T121
)	O
on	O
regression	O
of	O
LVH	B-T047
.	O
Relative	O
trials	O
were	O
identified	O
in	O
the	O
PubMed	O
,	O
Web	O
of	O
Science	O
,	O
OVID	O
EBM	O
Reviews	O
and	O
Cochrane	O
databases	O
,	O
and	O
the	O
relevant	O
papers	O
were	O
examined	O
.	O
We	O
performed	O
both	O
traditional	O
and	O
Bayesian	O
meta	O
-	O
analysis	O
of	O
randomized	O
controlled	O
trials	O
(	O
RCTs	O
)	O
about	O
the	O
regression	O
of	O
LVH	B-T047
.	O
Sensitivity	O
analysis	O
and	O
regression	O
analysis	O
were	O
performed	O
to	O
explore	O
possible	O
sources	O
of	O
heterogeneity	O
.	O
Inconsistency	O
analysis	O
was	O
performed	O
to	O
check	O
whether	O
the	O
analysis	O
of	O
the	O
trials	O
in	O
the	O
network	O
was	O
indeed	O
consistent	O
.	O
A	O
total	O
of	O
41	O
RCTs	O
involving	O
2566	O
patients	O
with	O
HT	B-T047
and	O
LVH	B-T047
were	O
included	O
in	O
this	O
analysis	O
.	O
Bayesian	O
network	O
meta	O
-	O
analysis	O
indicated	O
no	O
statistically	O
significant	O
differences	O
between	O
these	O
groups	O
:	O
FS	B-T121
-	I-T121
β	I-T121
-	I-T121
B	I-T121
and	O
ACEI	B-T121
(	O
MD	O
,	O
-7.09	O
;	O
95	O
%	O
CI	O
,	O
-14.99	O
,	O
1.27	O
)	O
;	O
FS	B-T121
-	I-T121
β	I-T121
-	I-T121
B	I-T121
and	O
ARB	B-T121
(	O
MD	O
,	O
-2.66	O
;	O
95	O
%	O
Cl	O
,	O
-12.02	O
,	O
6.31	O
)	O
.	O
Although	O
FS	B-T121
-	I-T121
β	I-T121
-	I-T121
B	I-T121
showed	O
greater	O
efficacy	O
when	O
compared	O
with	O
diuretic	B-T121
(	O
MD	O
,	O
13.04	O
;	O
95	O
%	O
CI	O
,	O
3.38	O
,	O
22.59	O
)	O
or	O
CCB	B-T121
(	O
MD	O
,	O
10.90	O
;	O
95	O
%	O
CI	O
,	O
1.98	O
,	O
19.49	O
)	O
.	O
The	O
probabilities	O
of	O
being	O
among	O
the	O
most	O
efficacious	O
treatments	B-T061
were	O
:	O
FS	B-T121
-	I-T121
β	I-T121
-	I-T121
B	I-T121
(	O
72	O
%	O
)	O
,	O
ARB	B-T121
(	O
27	O
%	O
)	O
,	O
ACEI	B-T121
(	O
0.01	O
%	O
)	O
,	O
CCB	B-T121
(	O
0.00	O
%	O
)	O
,	O
and	O
diuretic	B-T121
(	O
0.00	O
%	O
)	O
.	O
Evidence	O
from	O
our	O
analysis	O
reveals	O
that	O
FS	B-T121
-	I-T121
β	I-T121
-	I-T121
B	I-T121
have	O
potential	O
to	O
become	O
1st	O
-	O
line	O
therapeutic	B-T121
drugs	I-T121
in	O
HT	B-T047
and	O
LVH	B-T047
patients	O
.	O
However	O
,	O
the	O
real	O
efficacy	O
of	O
FS	B-T121
-	I-T121
β	I-T121
-	I-T121
B	I-T121
on	O
regression	O
of	O
LVH	B-T047
should	O
be	O
confirmed	O
by	O
further	O
large	O
,	O
high	O
quality	O
trials	O
considering	O
the	O
limitation	O
of	O
the	O
study	O
number	O
.	O
      
Simultaneous	O
edited	O
MRS	B-T060
of	O
GABA	O
and	O
glutathione	O
Edited	O
MRS	B-T060
allows	O
the	O
detection	B-T061
of	O
low	O
-	O
concentration	O
metabolites	O
,	O
whose	O
signals	O
are	O
not	O
resolved	O
in	O
the	O
MR	B-T060
spectrum	I-T060
.	O
Tailored	O
acquisitions	O
can	O
be	O
designed	O
to	O
detect	B-T061
,	O
for	O
example	O
,	O
the	O
inhibitory	O
neurotransmitter	O
γ	O
-	O
aminobutyric	O
acid	O
(	O
GABA	O
)	O
,	O
or	O
the	O
reduction	O
-	O
oxidation	O
(	O
redox	O
)	O
compound	O
glutathione	O
(	O
GSH	O
)	O
,	O
and	O
single	O
-	O
voxel	O
edited	O
experiments	O
are	O
generally	O
acquired	O
at	O
a	O
rate	O
of	O
one	O
metabolite	O
-	O
per	O
-	O
experiment	O
.	O
We	O
demonstrate	O
that	O
simultaneous	O
detection	B-T061
of	O
the	O
overlapping	O
signals	O
of	O
GABA	O
and	O
GSH	O
is	O
possible	O
using	O
Hadamard	B-T059
Encoding	I-T059
and	I-T059
Reconstruction	I-T059
of	I-T059
Mega	I-T059
-	I-T059
Edited	I-T059
Spectroscopy	I-T059
(	O
HERMES	B-T059
)	O
.	O
HERMES	B-T059
applies	O
orthogonal	O
editing	O
encoding	O
(	O
following	O
a	O
Hadamard	O
scheme	O
)	O
,	O
such	O
that	O
GSH-	O
and	O
GABA	O
-	O
edited	O
difference	O
spectra	O
can	O
be	O
reconstructed	O
from	O
a	O
single	O
multiplexed	O
experiment	O
.	O
At	O
a	O
TE	O
of	O
80ms	O
,	O
20	O
-	O
ms	O
editing	O
pulses	O
are	O
applied	O
at	O
4.56ppm	O
(	O
on	O
GSH),1.9ppm	O
(	O
on	O
GABA	O
)	O
,	O
both	O
offsets	O
(	O
using	O
a	O
dual	O
-	O
lobe	O
cosine	O
-	O
modulated	O
pulse	O
)	O
or	O
neither	O
.	O
Hadamard	O
combinations	O
of	O
the	O
four	O
sub	O
-	O
experiments	O
yield	O
GABA	O
and	O
GSH	O
difference	O
spectra	O
.	O
It	O
is	O
shown	O
that	O
HERMES	B-T059
gives	O
excellent	O
separation	O
of	O
the	O
edited	O
GABA	O
and	O
GSH	O
signals	O
in	O
phantoms	O
,	O
and	O
resulting	O
edited	O
lineshapes	O
agree	B-T033
well	O
with	O
separate	O
Mescher	B-T059
-	I-T059
Garwood	I-T059
Point	I-T059
-	I-T059
resolved	I-T059
Spectroscopy	I-T059
(	O
MEGA	B-T059
-	I-T059
PRESS	I-T059
)	O
acquisitions	O
.	O
In	O
vivo	O
,	O
the	O
quality	O
and	O
signal	O
-	O
to	O
-	O
noise	O
ratio	O
(	O
SNR	O
)	O
of	O
HERMES	B-T059
spectra	O
are	O
similar	O
to	O
those	O
of	O
sequentially	O
acquired	O
MEGA	B-T059
-	I-T059
PRESS	I-T059
spectra	O
,	O
with	O
the	O
benefit	O
of	O
saving	O
half	O
the	O
acquisition	O
time	O
.	O
      
Draft	O
Genome	O
Sequences	O
of	O
15	O
Isolates	O
of	O
Listeria	B-T007
monocytogenes	I-T007
Serotype	I-T007
1/2a	I-T007
,	O
Subgroup	O
ST204	B-T001
Listeria	B-T007
monocytogenes	I-T007
sequence	B-T001
type	I-T001
204	I-T001
(	I-T001
ST204	I-T001
)	I-T001
strains	I-T001
have	O
been	O
isolated	O
from	O
a	O
range	O
of	O
food	O
,	O
environmental	O
,	O
and	O
clinical	O
sources	B-T033
in	O
Australia	O
.	O
This	O
study	O
describes	O
the	O
draft	O
genome	O
sequences	O
of	O
15	O
isolates	O
collected	O
from	O
meat	O
and	O
dairy	O
associated	O
sources	O
.	O
      
Suppressed	O
translation	O
and	O
ULK1	O
degradation	O
as	O
potential	O
mechanisms	O
of	O
autophagy	O
limitation	O
under	O
prolonged	O
starvation	B-T033
Macroautophagy	O
/	O
autophagy	O
is	O
a	O
well	O
-	O
organized	O
process	O
of	O
intracellular	O
degradation	O
,	O
which	O
is	O
rapidly	O
activated	O
under	O
starvation	B-T033
conditions	O
.	O
Recent	O
data	O
demonstrate	O
a	O
transcriptional	O
upregulation	O
of	O
several	O
autophagy	O
genes	O
as	O
a	O
mechanism	O
that	O
controls	O
autophagy	O
in	O
response	O
to	O
starvation	B-T033
.	O
Here	O
we	O
report	O
that	O
despite	O
the	O
significant	O
upregulation	O
of	O
mRNA	O
of	O
the	O
essential	O
autophagy	O
initiation	O
gene	O
ULK1	O
,	O
its	O
protein	O
level	O
is	O
rapidly	O
reduced	O
under	O
starvation	B-T033
.	O
Although	O
both	O
autophagic	O
and	O
proteasomal	O
systems	O
contribute	O
to	O
the	O
degradation	O
of	O
ULK1	O
,	O
under	O
prolonged	O
nitrogen	O
deprivation	O
,	O
its	O
level	O
was	O
still	O
reduced	O
in	O
ATG7	O
knockout	O
cells	O
,	O
and	O
only	O
initially	O
stabilized	O
in	O
cells	O
treated	O
with	O
the	O
lysosomal	O
or	O
proteasomal	B-T121
inhibitors	I-T121
.	O
We	O
demonstrate	O
that	O
under	O
starvation	B-T033
,	O
protein	O
translation	O
is	O
rapidly	O
diminished	O
and	O
,	O
similar	O
to	O
treatments	B-T061
with	O
the	O
proteosynthesis	B-T121
inhibitors	I-T121
cycloheximide	B-T195
or	O
anisomycin	B-T195
,	O
is	O
associated	O
with	O
a	O
significant	O
reduction	O
of	O
ULK1	O
.	O
Furthermore	O
,	O
it	O
was	O
found	O
that	O
inhibition	O
of	O
the	O
mitochondrial	O
respiratory	O
complexes	O
or	O
the	O
mitochondrial	O
ATP	O
synthase	O
function	O
that	O
could	O
also	O
take	O
place	O
in	O
the	O
absence	O
of	O
substrates	O
,	O
promote	O
upregulation	O
of	O
ULK1	O
mRNA	O
and	O
protein	O
expression	O
in	O
an	O
AMPK	O
-	O
dependent	O
manner	O
in	O
U1810	O
lung	O
cancer	O
cells	O
growing	O
in	O
complete	O
culture	O
medium	O
.	O
These	O
inhibitors	O
could	O
also	O
drastically	O
increase	O
the	O
ULK1	O
protein	O
in	O
U1810	O
cells	O
with	O
knockout	O
of	O
ATG13	O
,	O
where	O
the	O
ULK1	O
expression	O
is	O
significantly	O
diminished	O
.	O
However	O
,	O
such	O
upregulation	O
of	O
ULK1	O
protein	O
is	O
negligible	O
under	O
starvation	B-T033
conditions	O
,	O
further	O
signifying	O
the	O
contribution	O
of	O
translation	O
and	O
suggesting	O
that	O
transcriptional	O
upregulation	O
of	O
ULK1	O
protein	O
will	O
be	O
diminished	O
under	O
such	O
conditions	O
.	O
Thus	O
,	O
we	O
propose	O
a	O
model	O
where	O
inhibition	O
of	O
protein	O
translation	O
,	O
together	O
with	O
the	O
degradation	O
systems	O
,	O
limit	O
autophagy	O
during	O
starvation	B-T033
.	O
      
Combination	B-T121
of	O
telmisartan	B-T121
with	O
sildenafil	B-T121
ameliorate	O
progression	O
of	O
diabetic	B-T047
nephropathy	I-T047
in	O
streptozotocin	B-T195
-	O
induced	O
diabetic	B-T033
model	O
Diabetic	B-T047
nephropathy	I-T047
(	O
DN	B-T047
)	O
is	O
a	O
leading	O
cause	O
of	O
end	B-T047
-	I-T047
stage	I-T047
renal	I-T047
disease	I-T047
in	O
the	O
world	O
.	O
Several	O
signaling	O
pathways	O
are	O
involved	O
in	O
the	O
pathogenesis	O
of	O
DN	B-T047
including	O
elevation	O
in	O
level	O
of	O
angiotensin	B-T121
II	I-T121
,	O
formation	O
of	O
advanced	O
glycation	O
end	O
products	O
(	O
AGE	O
)	O
,	O
activation	O
of	O
protein	O
kinase	O
c	O
(	O
PKC	O
)	O
,	O
and	O
lipid	B-T033
accumulation	I-T033
.	O
These	O
pathways	O
activate	O
one	O
another	O
mutually	O
leading	O
to	O
oxidative	O
stress	O
,	O
increasing	O
expression	O
of	O
transforming	B-T121
growth	I-T121
factor	I-T121
beta-1	I-T121
(	O
TGF	B-T121
-	I-T121
β	I-T121
1	I-T121
)	O
and	O
release	O
of	O
interleukins	O
and	O
adhesion	O
molecules	O
,	O
so	O
the	O
aim	O
of	O
this	O
study	O
is	O
to	O
interrupt	O
more	O
than	O
pathogenic	B-T033
pathway	O
to	O
ameliorate	O
the	O
progression	O
of	O
DN	B-T047
.	O
In	O
the	O
present	O
study	O
,	O
white	O
male	O
rats	O
(	O
N=48	O
)	O
were	O
divided	O
into	O
six	O
groups	O
(	O
8	O
rats	O
each	O
)	O
,	O
the	O
first	O
two	O
groups	O
served	O
as	O
normal	O
control	O
and	O
a	O
control	O
vehicle	O
group	O
while	O
the	O
remaining	O
four	O
groups	O
were	O
rendered	O
diabetic	B-T033
by	O
a	O
single	O
intraperitoneal	B-T061
injection	I-T061
of	O
Streptozotocin	B-T195
(	O
STZ	B-T195
)	O
and	O
being	O
left	O
for	O
4	O
weeks	O
to	O
develop	O
DN	B-T047
.	O
Thereafter	O
,	O
the	O
rats	O
were	O
divided	O
into	O
DN	B-T047
group	O
,	O
DN	B-T047
group	O
receiving	O
Telmisartan	B-T121
or	O
Sildenafil	B-T121
or	O
Telmisartan	B-T121
Sildenafil	B-T121
combination	B-T121
.	O
After	O
the	O
specified	O
treatment	O
period	O
,	O
urine	O
samples	O
were	O
collected	O
(	O
using	O
metabolic	O
cages	O
)	O
to	O
measure	O
proteinuria	B-T033
,	O
animals	O
were	O
then	O
euthanized	O
,	O
blood	O
and	O
tissue	O
samples	O
were	O
collected	O
for	O
measurement	B-T059
of	I-T059
Blood	I-T059
glucose	I-T059
,	O
BUN	B-T059
,	O
S.Cr	B-T059
,	O
LDL	B-T059
,	O
NO	B-T059
,	O
TGF	B-T059
-	I-T059
β1	I-T059
,	O
IL-1β	B-T059
,	O
AGEPs	B-T059
,	O
and	O
SOD	B-T059
.	O
The	O
combination	B-T061
therapy	I-T061
showed	O
significant	O
decrease	O
in	O
BUN	O
,	O
S.Cr	O
,	O
LDL	O
,	O
TGF	B-T121
-	I-T121
β1	I-T121
,	O
IL-1β	O
,	O
Proteinuria	B-T033
and	O
AGEPs	O
and	O
significant	O
increase	O
in	O
SOD	B-T121
and	O
NO	B-T121
.	O
The	O
findings	O
showed	O
that	O
combination	B-T061
therapy	I-T061
was	O
able	O
to	O
ameliorate	O
DN	B-T047
and	O
that	O
the	O
effects	O
were	O
superior	O
to	O
the	O
single	O
drugs	B-T121
alone	O
.	O
      
CXCL5	O
Plays	O
a	O
Promoting	O
Role	O
in	O
Osteosarcoma	B-T191
Cell	B-T191
Migration	I-T191
and	I-T191
Invasion	I-T191
in	O
Autocrine	O
-	O
and	O
Paracrine	O
-Dependent	O
Manners	O
CXCL5	O
,	O
a	O
CXC	O
-	O
type	O
chemokine	O
,	O
is	O
an	O
important	O
attractant	O
for	O
granulocytic	O
immune	O
cells	O
by	O
binding	O
to	O
its	O
receptor	O
CXCR2	O
.	O
Recently	O
,	O
CXCL5	O
/	O
CXCR2	O
has	O
been	O
found	O
to	O
play	O
an	O
oncogenic	O
role	O
in	O
many	O
human	O
cancers	B-T191
.	O
However	O
,	O
the	O
exact	O
role	O
of	O
CXCL5	O
in	O
osteosarcoma	B-T191
cell	B-T191
migration	I-T191
and	I-T191
invasion	I-T191
has	O
not	O
been	O
revealed	O
.	O
Here	O
we	O
found	O
that	O
the	O
protein	O
expression	O
of	O
CXCL5	O
was	O
significantly	O
increased	O
in	O
osteosarcoma	B-T191
tissues	O
compared	O
with	O
that	O
in	O
matched	O
adjacent	O
nontumor	O
tissues	O
.	O
Moreover	O
,	O
the	O
expression	O
of	O
CXCL5	O
was	O
significantly	O
associated	O
with	O
advanced	O
clinical	O
stage	O
and	O
metastasis	O
.	O
Further	O
investigation	O
showed	O
that	O
the	O
CXCL5	O
expression	O
levels	O
were	O
also	O
significantly	O
increased	O
in	O
osteosarcoma	B-T191
cell	O
lines	O
,	O
including	O
Saos-2	O
,	O
MG63	O
,	O
U2OS	O
,	O
and	O
SW1353	O
,	O
when	O
compared	O
with	O
those	O
in	O
normal	O
osteoblast	O
hFoB1.19	O
cells	O
.	O
U2OS	O
cells	O
were	O
further	O
transfected	O
with	O
CXCL5	O
-	O
specific	O
siRNA	O
or	O
overexpression	O
plasmid	O
.	O
Knockdown	O
of	O
CXCL5	O
significantly	O
suppressed	O
U2OS	O
cell	B-T191
migration	I-T191
and	I-T191
invasion	I-T191
.	O
On	O
the	O
contrary	O
,	O
overexpression	O
of	O
CXLC5	O
remarkably	O
promoted	O
the	O
migration	B-T191
and	I-T191
invasion	I-T191
of	O
U2OS	O
cells	O
.	O
Interestingly	O
,	O
both	O
exogenous	O
CXCL5	O
treatment	O
and	O
the	O
conditioned	O
medium	O
of	O
CXCL5	O
-	O
overexpressing	O
hFoB1.19	O
cells	O
could	O
also	O
enhance	O
the	O
migration	B-T191
and	I-T191
invasion	I-T191
of	O
U2OS	O
cells	O
,	O
suggesting	O
that	O
the	O
promoting	O
role	O
of	O
CXCL5	O
in	O
U2OS	O
cell	B-T191
migration	I-T191
and	I-T191
invasion	I-T191
is	O
also	O
in	O
a	O
paracrine	O
-dependent	O
manner	O
.	O
According	O
to	O
these	O
data	O
,	O
our	O
study	O
demonstrates	O
that	O
CXCL5	O
is	O
upregulated	O
in	O
osteosarcoma	B-T191
and	O
may	O
play	O
an	O
oncogenic	O
role	O
in	O
osteosarcoma	B-T191
metastasis	O
.	O
Therefore	O
,	O
CXCL5	O
may	O
become	O
a	O
potential	O
therapeutic	O
target	O
for	O
osteosarcoma	B-T191
treatment	O
.	O
      
Fading	O
With	O
Time	O
of	O
PD	O
-	O
L1	O
Immunoreactivity	O
in	O
Non	B-T191
-	I-T191
Small	I-T191
Cells	I-T191
Lung	I-T191
Cancer	I-T191
Tissues	O
:	O
A	O
Methodological	O
Study	O
Blockade	O
of	O
inhibitory	O
immune	O
checkpoints	O
is	O
currently	O
arising	O
as	O
a	O
potential	O
immunologic	O
option	O
for	O
tumor	B-T061
therapy	I-T061
.	O
Inhibition	O
of	O
programmed	O
cell	O
death	O
protein	O
1	O
and/or	O
its	O
specific	O
ligand	O
programmed	O
death	O
-	O
ligand	O
1	O
(	O
PD	O
-	O
L1	O
)	O
was	O
effective	O
in	O
clinical	O
trials	O
in	O
advanced	O
melanoma	B-T191
,	O
non	B-T191
-	I-T191
small	I-T191
cell	I-T191
lung	I-T191
cancer	I-T191
(	O
NSCLC	B-T191
)	O
bladder	B-T191
and	O
kidney	B-T191
cancer	I-T191
.	O
The	O
predictive	O
role	O
of	O
the	O
immunohistochemical	B-T059
(	O
IHC	B-T059
)	O
expression	O
of	O
PD	O
-	O
L1	O
is	O
highly	O
debated	O
.	O
Different	O
reagents	O
,	O
clones	O
,	O
cutoffs	O
of	O
cell	O
expression	O
and	O
subjective	O
interpretation	B-T033
of	O
PD	O
-	O
L1	O
immunoreactivity	O
in	O
epithelial	O
cells	O
and	O
lymphocytes	O
are	O
the	O
main	O
issue	B-T033
.	O
In	O
this	O
study	O
we	O
selected	O
58	O
consecutive	O
NSCLC	B-T191
surgical	O
specimens	O
that	O
underwent	O
pathologic	B-T060
examination	I-T060
from	O
January	O
2014	O
to	O
July	O
2015	O
.	O
Using	O
a	O
tissue	O
microarray	B-T059
approach	I-T059
we	O
evaluated	O
the	O
IHC	B-T059
expression	I-T059
of	O
PD	O
-	O
L1	O
in	O
tumor	O
-	O
infiltrating	O
lymphocytes	O
and	O
tumor	O
cells	O
(	O
TCs	O
)	O
and	O
compared	O
the	O
ICH	B-T059
staining	I-T059
with	O
tumor	O
histology	O
,	O
grade	O
and	O
the	O
age	O
of	O
the	O
tissue	O
blocks	O
.	O
The	O
main	O
new	O
finding	B-T033
was	O
the	O
fading	O
of	O
PD	O
-	O
L1	O
IHC	B-T059
expression	I-T059
in	O
TCs	O
in	O
tissues	O
processed	O
in	O
2014	O
compared	O
with	O
2015	O
.	O
PD	O
-	O
L1	O
expression	O
in	O
tumor	O
-	O
infiltrating	O
lymphocytes	O
in	O
the	O
2	O
years	O
was	O
similar	O
.	O
We	O
also	O
found	O
a	O
significant	O
higher	O
immunoreactivity	O
of	O
TCs	O
in	O
high	O
grade	O
NSCLC	B-T191
and	O
in	O
the	O
squamous	B-T191
carcinoma	I-T191
histotype	O
compared	O
with	O
low	O
grade	O
tumors	O
and	O
the	O
adenocarcinoma	B-T191
histology	O
(	O
P=0.013	O
)	O
.	O
We	O
demonstrated	O
that	O
the	O
IHC	B-T059
evaluation	I-T059
of	O
PD	O
-	O
L1	O
in	O
NSCLC	B-T191
archival	O
tissues	O
is	O
feasible	O
and	O
can	O
be	O
implemented	O
in	O
a	O
routine	O
pathology	O
setting	O
,	O
but	O
it	O
should	O
be	O
carefully	O
assessed	O
in	O
tissue	O
blocks	O
older	O
than	O
1	O
year	O
.	O
      
Comparison	O
of	O
sonoelastography	B-T060
with	O
sonourethrography	B-T060
and	O
retrograde	B-T060
urethrography	I-T060
in	O
the	O
evaluation	B-T058
of	O
male	O
anterior	B-T190
urethral	I-T190
strictures	I-T190
Retrograde	B-T060
urethrography	I-T060
(	O
RUG	B-T060
)	O
is	O
the	O
most	O
common	O
and	O
preferred	O
imaging	O
modality	O
for	O
imaging	B-T060
of	O
the	O
anterior	B-T190
urethral	I-T190
strictures	I-T190
despite	O
its	O
well	O
-	O
known	O
limitations	O
and	O
disadvantages	O
.	O
Sonourethrography	B-T060
(	O
SUG	B-T060
)	O
was	O
introduced	O
in	O
1988	O
to	O
overcome	O
the	O
limitations	O
of	O
RUG	B-T060
and	O
to	O
provide	O
more	O
accurate	O
results	O
.	O
As	O
proper	O
selection	O
of	O
imaging	O
modality	O
is	O
very	O
important	O
for	O
planning	O
the	O
treatment	O
,	O
various	O
advances	O
in	O
this	O
area	O
are	O
required	O
.	O
One	O
of	O
the	O
major	O
factors	O
for	O
recurrence	O
of	O
stricture	B-T047
disease	I-T047
is	O
spongiofibrosis	O
.	O
Sonoelastography	B-T060
(	O
SE	B-T060
)	O
is	O
a	O
newer	O
technique	O
,	O
tried	O
in	O
various	O
other	O
pathologies	O
.	O
In	O
this	O
study	O
,	O
we	O
have	O
used	O
this	O
technique	O
for	O
the	O
first	O
time	O
to	O
assess	O
its	O
efficacy	O
in	O
the	O
evaluation	O
of	O
anterior	B-T190
urethral	I-T190
stricture	I-T190
disease	I-T190
by	O
comparison	O
with	O
RUG	B-T060
and	O
SUG	B-T060
.	O
Between	O
August	O
2014	O
and	O
May	O
2015	O
,	O
77	O
patients	O
with	O
clinical	O
features	O
of	O
anterior	B-T190
urethral	I-T190
stricture	I-T190
disease	I-T190
were	O
included	O
in	O
the	O
study	O
and	O
evaluated	O
by	O
RUG	B-T060
followed	O
by	O
SUG	B-T060
and	O
SE	B-T060
for	O
stricture	B-T047
location	O
,	O
length	O
,	O
depth	O
of	O
spongiofibrosis	O
and	O
periurethral	O
pathologies	O
.	O
The	O
results	O
were	O
then	O
correlated	O
with	O
operative	O
and	O
histopathological	O
findings	O
.	O
Overall	O
diagnostic	O
accuracy	O
of	O
SE	B-T060
,	O
SUG	B-T060
,	O
and	O
RGU	B-T060
for	O
the	O
estimation	O
of	O
stricture	B-T047
location	O
,	O
and	O
length	O
were	O
estimated	O
92.68	O
%	O
vs.	O
91.54	O
%	O
,	O
79	O
%	O
vs.	O
78.87	O
%	O
and	O
80.48	O
%	O
vs.	O
43.66	O
%	O
,	O
respectively	O
,	O
while	O
for	O
depth	O
of	O
spongiofibrosis	O
SE	B-T060
,	O
and	O
SUG	B-T060
had	O
accuracy	O
rates	O
of	O
87.3	O
%	O
,	O
48	O
%	O
,	O
respectively	O
.	O
The	O
mean	O
length	O
measured	O
on	O
SE	B-T060
was	O
nearest	O
to	O
the	O
mean	O
intra	O
-	O
operative	O
stricture	B-T047
length	O
(	O
21.34	O
+	O
11.8	O
mm	O
)	O
.	O
SE	B-T060
findings	O
significantly	O
correlated	O
with	O
the	O
colour	B-T033
of	I-T033
bladder	I-T033
mucosa	I-T033
on	O
cystoscopic	B-T060
examination	I-T060
(	O
p=0.003	O
)	O
whereas	O
the	O
association	O
was	O
non	O
-	O
significant	O
(	O
p=0.127	O
)	O
for	O
difficulty	O
in	O
incision	B-T061
.	O
While	O
a	O
nonsignificant	O
correlation	O
existed	O
between	O
SUG	B-T060
findings	O
related	O
both	O
to	O
the	O
colour	B-T033
of	I-T033
the	I-T033
bladder	I-T033
mucosa	I-T033
and	O
difficulty	O
in	O
incision	B-T061
on	O
cystoscopy	B-T060
,	O
SE	B-T060
findings	O
had	O
a	O
significant	O
association	O
(	O
p<0.001	O
)	O
with	O
histopathology	O
findings	O
for	O
severe	O
degree	B-T060
of	I-T060
fibrosis	I-T060
.	O
Sonoelastography	B-T060
estimates	O
stricture	O
site	O
and	O
length	O
better	O
in	O
comparison	O
with	O
RUG	B-T060
and	O
SUG	B-T060
.	O
It	O
estimates	O
degree	O
of	O
spongiofibrosis	O
which	O
serves	O
as	O
an	O
important	O
prognostic	O
factor	O
for	O
stricture	O
recurrence	O
more	O
accurately	O
than	O
SUG	B-T060
.	O
      
The	O
Effect	O
of	O
l	B-T121
-	I-T121
Arginine	I-T121
on	O
Dural	O
Healing	O
After	O
Experimentally	O
Induced	O
Dural	B-T023
Defect	O
in	O
a	O
Rat	O
Model	O
Incomplete	O
repair	O
of	O
the	O
dura	B-T023
mater	I-T023
may	O
result	O
in	O
numerous	O
complications	O
such	O
as	O
cerebrospinal	B-T047
fluid	I-T047
leakage	I-T047
and	O
meningitis	B-T047
.	O
For	O
this	O
reason	O
,	O
accurate	O
repair	O
of	O
the	O
dura	B-T023
mater	I-T023
is	O
essential	O
.	O
In	O
this	O
study	O
,	O
the	O
effect	O
of	O
systemic	O
and	O
local	O
supplementation	O
of	O
l	B-T121
-	I-T121
arginine	I-T121
on	O
dural	O
healing	O
was	O
evaluated	O
.	O
Thirty	O
male	O
Wistar	O
rats	O
were	O
used	O
and	O
divided	O
into	O
control	O
,	O
local	O
,	O
and	O
systemic	O
l	B-T121
-	I-T121
arginine	I-T121
groups	O
,	O
with	O
10	O
rats	O
in	O
each	O
.	O
In	O
each	O
group	O
,	O
a	O
5	O
-	O
mm	O
experimental	B-T061
incision	I-T061
was	O
made	O
at	O
the	O
lumbar	O
segment	O
of	O
the	O
dura	O
mater	O
and	O
cerebrospinal	B-T047
fluid	I-T047
leakage	I-T047
was	O
induced	O
.	O
Each	O
group	O
was	O
divided	O
into	O
2	O
subgroups	O
and	O
at	O
the	O
end	O
of	O
the	O
first	O
and	O
sixth	O
weeks	O
,	O
the	O
rats	O
were	O
killed	B-T058
and	O
the	O
damaged	O
segments	O
of	O
the	O
dura	B-T023
were	O
separated	O
,	O
histologically	O
evaluated	O
and	O
the	O
dural	O
healing	O
indicators	O
including	O
cell	O
types	O
,	O
granulation	O
tissue	O
formation	O
,	O
collagen	O
deposit	O
,	O
and	O
vascularization	O
were	O
compared	O
between	O
groups	O
.	O
The	O
systematic	O
supplementation	O
of	O
l	B-T121
-	I-T121
arginine	I-T121
showed	O
a	O
significant	O
effect	O
in	O
dural	O
healing	O
compared	O
with	O
the	O
control	O
group	O
.	O
After	O
the	O
first	O
week	O
,	O
granulation	O
formation	O
increased	O
considerably	O
(	O
P	O
<	O
0.031	O
)	O
,	O
and	O
after	O
6	O
weeks	O
,	O
collagen	O
deposition	O
and	O
neovascularization	O
were	O
significantly	O
different	O
compared	O
with	O
the	O
control	O
group	O
(	O
P	O
<	O
0.030	O
;	O
P	O
<	O
0.009	O
)	O
.	O
In	O
comparison	O
between	O
different	O
groups	O
at	O
the	O
end	O
of	O
the	O
first	O
and	O
sixth	O
weeks	O
,	O
maximum	O
changes	O
in	O
healing	O
indicators	O
were	O
observed	O
in	O
the	O
systemic	O
group	O
and	O
the	O
least	O
variations	O
were	O
related	O
to	O
the	O
control	O
group	O
.	O
The	O
systemic	O
supplementation	O
of	O
l	B-T121
-	I-T121
arginine	I-T121
may	O
accelerate	O
dural	O
healing	O
by	O
increasing	O
the	O
level	O
of	O
granulation	O
tissue	O
formation	O
,	O
collagen	O
deposition	O
,	O
and	O
vascularization	O
.	O
      
Zoonotic	B-T001
and	O
Non	B-T033
-	I-T033
zoonotic	I-T033
Parasites	O
of	O
Wild	O
Rodents	O
in	O
Turkman	O
Sahra	O
,	O
Northeastern	O
Iran	O
This	O
study	O
was	O
conducted	O
to	O
collect	O
informative	O
data	O
on	O
the	O
parasitic	B-T047
infection	I-T047
of	O
wild	O
rodents	O
,	O
emphasizing	O
on	O
finding	B-T033
parasites	O
,	O
which	O
have	O
medical	O
importance	O
to	O
human	O
.	O
During	O
2012	O
-	O
2014	O
,	O
a	O
total	O
number	O
of	O
91	O
wild	O
rodents	O
were	O
captured	O
from	O
rural	O
areas	O
of	O
Turkmen	O
Sahra	O
,	O
Golestan	O
Province	O
,	O
using	O
handmade	O
traps	O
.	O
Animals	O
were	O
anesthetized	B-T033
,	O
surveyed	O
for	O
any	O
ectoparasite	O
and	O
then	O
their	O
carcasses	B-T021
were	O
carefully	O
dissected	O
for	O
examination	B-T033
of	O
endoparsites	O
.	O
Four	O
species	O
of	O
rodents	O
including	O
Mus	O
musculus	O
(	O
52.75	O
%	O
)	O
,	O
Rattus	O
norvegicus	O
(	O
38.46	O
%	O
)	O
,	O
Rhombomys	O
opimus	O
(	O
4.40	O
%	O
)	O
and	O
Meriones	O
libycus	O
(	O
4.40	O
%	O
)	O
were	O
captured	O
.	O
Parasitic	B-T047
infestation	I-T047
was	O
detected	B-T033
in	O
38.5	O
%	O
of	O
sampled	O
rodents	O
.	O
Parasite	B-T047
infestation	I-T047
rates	O
of	O
sampled	O
rodents	O
was	O
Hymenolepis	O
diminuta	O
=	O
7.7	O
%	O
,	O
Cryptosporidium	O
spp	O
=	O
6.6	O
%	O
,	O
Trichuris	O
spp	O
.=	O
5.5	O
%	O
,	O
Cysticercus	O
fasciolaris	O
=	O
2.20	O
%	O
,	O
Angiostrongylus	O
spp	O
.=	O
2.20	O
%	O
,	O
Capillaria	O
sp	O
.=	O
1.09	O
%	O
,	O
Rhipicephalus	O
spp	O
.	O
=	O
8.70	O
%	O
,	O
Nosopsyllus	O
fasciatus	O
=	O
1.09	O
%	O
,	O
and	O
Laelaps	O
nuttalli	O
=	O
3.29	O
%	O
.	O
Among	O
10	O
genera	O
/	O
species	O
of	O
identified	O
parasites	O
,	O
at	O
least	O
8	O
of	O
them	O
were	O
zoonotic	B-T001
with	O
public	O
health	O
importance	O
.	O
L.	O
nuttalli	O
and	O
N.	O
fasciatus	O
were	O
the	O
only	O
two	O
non	B-T033
-	I-T033
zoonotic	I-T033
detected	B-T033
parasites	O
in	O
this	O
survey	O
.	O
Harboring	O
a	O
wide	O
variety	O
of	O
zoonotic	B-T001
parasites	O
in	O
sampled	O
wild	O
rodents	O
particularly	O
when	O
they	O
live	O
nearby	O
villages	O
,	O
represents	O
a	O
potential	O
risk	O
to	O
native	O
inhabitants	O
.	O
Hence	O
,	O
controlling	O
rodents	O
'	O
population	O
in	O
residential	O
regions	O
and	O
improving	B-T033
awareness	O
of	O
local	O
people	O
about	O
the	O
risk	O
of	O
disease	O
transmission	O
through	O
rodents	O
seems	O
to	O
be	O
entirely	O
necessary	O
.	O
      
Improving	O
Care	B-T058
Transitions	I-T058
Across	O
Healthcare	B-T058
Settings	O
Through	O
a	O
Human	B-T033
Factors	I-T033
Approach	O
After	O
more	O
than	O
two	O
decades	O
of	O
research	O
focused	O
on	O
care	B-T058
transition	I-T058
improvement	O
and	O
intervention	B-T061
development	O
,	O
unfavorable	B-T033
outcome	I-T033
measures	O
associated	O
with	O
care	B-T058
transitions	I-T058
across	O
healthcare	B-T058
settings	O
persist	O
.	O
Readmissions	O
rates	O
remain	O
an	O
important	O
outcome	O
to	O
target	O
for	O
intervention	B-T061
,	O
adverse	O
events	O
associated	O
with	O
care	B-T058
transitions	I-T058
continue	O
to	O
be	O
an	O
issue	B-T033
,	O
and	O
patients	O
are	O
often	O
dissatisfied	O
with	O
the	O
quality	O
of	O
their	O
care	O
.	O
Currently	O
,	O
interventions	B-T061
to	O
improve	O
care	B-T058
transitions	I-T058
are	O
disease	B-T047
specific	O
,	O
require	O
substantial	O
financial	B-T058
investments	I-T058
in	O
training	O
allied	O
healthcare	O
professionals	O
,	O
or	O
focus	O
primarily	O
on	O
hospital	B-T058
-	I-T058
based	I-T058
discharge	I-T058
planning	I-T058
with	O
mixed	O
results	O
.	O
This	O
complex	O
situation	O
requires	O
a	O
method	O
of	O
evaluation	O
that	O
can	O
provide	O
a	O
comprehensive	O
,	O
in	O
-	O
depth	O
,	O
and	O
context	O
-	O
driven	O
investigation	B-T058
of	O
potential	B-T033
risks	I-T033
to	O
safe	O
care	B-T058
transitions	I-T058
across	O
healthcare	B-T058
settings	O
,	O
which	O
can	O
lead	O
to	O
the	O
creation	O
of	O
effective	O
,	O
usable	O
,	O
and	O
sustainable	O
interventions	B-T061
.	O
A	O
systems	O
'	O
approach	O
known	O
as	O
Human	O
Factors	O
and	O
Ergonomics	O
(	O
HFE	O
)	O
evaluates	O
the	O
factors	O
in	O
a	O
system	O
that	O
affect	O
human	O
performance	O
.	O
This	O
article	O
describes	O
how	O
HFE	O
can	O
complement	O
and	O
further	O
strengthen	O
efforts	O
to	O
improve	O
care	B-T058
transitions	I-T058
.	O
      
Autoantibodies	O
to	O
MOG	O
in	O
a	O
distinct	O
subgroup	O
of	O
adult	O
multiple	B-T047
sclerosis	I-T047
To	O
evaluate	B-T058
the	O
presence	O
of	O
antibodies	O
to	O
conformation	O
-intact	O
myelin	O
oligodendrocyte	O
glycoprotein	O
(	O
MOG	O
)	O
in	O
a	O
subgroup	O
of	O
adult	O
patients	O
with	O
clinically	O
definite	O
multiple	B-T047
sclerosis	I-T047
(	O
MS	B-T047
)	O
preselected	O
for	O
a	O
specific	O
clinical	O
phenotype	O
including	O
severe	O
spinal	B-T023
cord	I-T023
,	O
optic	B-T023
nerve	I-T023
,	O
and	O
brainstem	B-T023
involvement	O
.	O
Antibodies	O
to	O
MOG	O
were	O
investigated	O
using	O
a	O
cell	B-T059
-	I-T059
based	I-T059
assay	I-T059
in	O
3	O
groups	O
of	O
patients	O
:	O
104	O
preselected	O
patients	O
with	O
MS	B-T047
(	O
group	O
1	O
)	O
,	O
55	O
age	O
-	O
and	O
sex	O
-matched	O
,	O
otherwise	O
unselected	O
patients	O
with	O
MS	B-T047
(	O
group	O
2	O
)	O
,	O
and	O
in	O
22	O
brain	B-T060
-	I-T060
biopsied	I-T060
patients	O
with	O
demyelinating	B-T047
diseases	I-T047
of	O
the	O
CNS	O
(	O
n	O
=	O
19	O
with	O
MS	B-T047
)	O
,	O
4	O
of	O
whom	O
classified	O
as	O
MS	B-T047
type	I-T047
II	I-T047
(	O
group	O
3	O
)	O
.	O
Recognized	O
epitopes	O
were	O
identified	O
with	O
mutated	O
variants	O
of	O
MOG	O
.	O
Antibodies	O
to	O
MOG	O
were	O
found	O
in	O
about	O
5	O
%	O
(	O
5/104	O
)	O
of	O
preselected	O
adult	O
patients	O
with	O
MS	B-T047
.	O
In	O
contrast	O
,	O
in	O
groups	O
2	O
and	O
3	O
,	O
none	O
of	O
the	O
patients	O
tested	O
positive	O
for	O
MOG	O
antibodies	O
.	O
Patients	O
with	O
MS	B-T047
with	O
antibodies	O
to	O
MOG	O
predominantly	O
manifested	O
with	O
concomitant	O
severe	O
brainstem	B-T023
and	O
spinal	B-T023
cord	I-T023
involvement	O
and	O
had	O
a	O
severe	O
disease	O
course	O
with	O
high	O
relapse	O
rates	O
and	O
failure	B-T033
to	O
several	O
disease	B-T061
-	I-T061
modifying	I-T061
therapies	I-T061
.	O
Three	O
of	O
them	O
had	O
been	O
treated	B-T061
with	I-T061
plasma	B-T061
exchange	I-T061
with	O
a	O
favorable	O
response	O
.	O
All	O
anti	O
-	O
MOG	O
-positive	O
patients	O
with	O
MS	B-T047
showed	O
typical	O
MS	B-T047
lesions	B-T033
on	O
brain	B-T060
MRI	I-T060
.	O
Longitudinal	O
analysis	O
up	O
to	O
9	O
years	O
revealed	O
fluctuations	B-T184
and	O
reappearance	O
of	O
anti	O
-	O
MOG	O
reactivity	O
.	O
Epitope	B-T059
mapping	I-T059
indicated	O
interindividual	O
heterogeneity	O
,	O
yet	O
intraindividual	O
stability	O
of	O
the	O
antibody	O
response	O
.	O
Antibodies	O
to	O
MOG	O
can	O
be	O
found	O
in	O
a	O
distinct	O
subgroup	O
of	O
adult	O
MS	B-T047
with	O
a	O
specific	O
clinical	O
phenotype	O
and	O
may	O
indicate	O
disease	B-T047
heterogeneity	O
.	O
      
Activation	O
of	O
the	O
orphan	O
receptor	O
GPR55	O
by	O
lysophosphatidylinositol	O
promotes	O
metastasis	B-T191
in	O
triple	B-T191
-	I-T191
negative	I-T191
breast	I-T191
cancer	I-T191
The	O
orphan	O
G	O
protein	O
-	O
coupled	O
receptor	O
GPR55	O
has	O
been	O
directly	O
or	O
indirectly	O
related	O
to	O
basic	O
alterations	O
that	O
drive	O
malignant	O
growth	O
:	O
uncontrolled	O
cancer	O
cell	O
proliferation	O
,	O
sustained	O
angiogenesis	O
,	O
and	O
cancer	O
cell	O
adhesion	O
and	O
migration	O
.	O
However	O
,	O
little	O
is	O
known	O
about	O
the	O
involvement	O
of	O
this	O
receptor	O
in	O
metastasis	B-T191
.	O
Here	O
,	O
we	O
show	O
that	O
elevated	O
GPR55	O
expression	O
in	O
human	O
tumors	B-T191
is	O
associated	O
with	O
the	O
aggressive	B-T191
basal	I-T191
/	O
triple	B-T191
-	I-T191
negative	I-T191
breast	I-T191
cancer	I-T191
population	O
,	O
higher	O
probability	O
to	O
develop	O
metastases	B-T191
,	O
and	O
therefore	O
poor	O
patient	O
prognosis	B-T058
.	O
Activation	O
of	O
GPR55	O
by	O
its	O
proposed	O
endogenous	O
ligand	O
lysophosphatidylinositol	O
confers	O
pro	O
-	O
invasive	O
features	O
on	O
breast	O
cancer	O
cells	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
Specifically	O
,	O
this	O
effect	O
is	O
elicited	O
by	O
coupling	O
to	O
Gq/11	O
heterotrimeric	O
proteins	O
and	O
the	O
subsequent	O
activation	O
,	O
through	O
ERK	O
,	O
of	O
the	O
transcription	O
factor	O
ETV4	O
/	O
PEA3	O
.	O
Together	O
,	O
these	O
data	O
show	O
that	O
GPR55	O
promotes	O
breast	B-T191
cancer	I-T191
metastasis	B-T191
,	O
and	O
supports	O
the	O
notion	O
that	O
this	O
orphan	O
receptor	O
may	O
constitute	O
a	O
new	O
therapeutic	O
target	O
and	O
potential	O
biomarker	O
in	O
the	O
highly	O
aggressive	O
triple	O
-	O
negative	O
subtype	O
.	O
      
A	O
pilot	O
study	O
exploring	O
the	O
relationship	O
between	O
self	O
-	O
compassion	O
,	O
self	O
-	O
judgement	O
,	O
self	O
-	O
kindness	O
,	O
compassion	O
,	O
professional	O
quality	O
of	O
life	O
and	O
wellbeing	B-T033
among	O
UK	O
community	O
nurses	O
Compassion	B-T048
fatigue	I-T048
and	O
burnout	B-T048
can	O
impact	O
on	O
performance	O
of	O
nurses	O
.	O
This	O
paper	O
explores	O
the	O
relationship	O
between	O
self	O
-	O
compassion	O
,	O
self	O
-	O
judgement	O
,	O
self	O
-	O
kindness	O
,	O
compassion	O
,	O
professional	O
quality	O
of	O
life	O
,	O
and	O
wellbeing	B-T033
among	O
community	O
nurses	O
.	O
To	O
measure	O
associations	O
between	O
self	O
-	O
compassion	O
,	O
compassion	B-T048
fatigue	I-T048
,	O
wellbeing	B-T033
,	O
and	O
burnout	B-T048
in	O
community	O
nurses	O
.	O
Quantitative	O
data	O
were	O
collected	O
using	O
standardised	O
psychometric	O
questionnaires	O
:	O
(	O
1	O
)	O
Professional	O
Quality	O
of	O
Life	O
Scale	O
;	O
(	O
2	O
)	O
Self	O
-	O
Compassion	O
Scale	O
;	O
(	O
3	O
)	O
short	O
Warwick	O
Edinburgh	O
Mental	O
Wellbeing	O
Scale	O
;	O
(	O
4	O
)	O
Compassion	O
For	O
Others	O
Scale	O
,	O
used	O
to	O
measure	O
relationships	O
between	O
self	O
-	O
compassion	O
,	O
compassion	B-T048
fatigue	I-T048
,	O
wellbeing	B-T033
,	O
and	O
burnout	B-T048
.	O
A	O
cross	O
sectional	O
sample	O
of	O
registered	O
community	O
nurses	O
(	O
n=37	O
)	O
studying	O
for	O
a	O
postgraduate	O
diploma	B-T033
at	O
a	O
University	O
in	O
the	O
North	O
of	O
England	O
took	O
part	O
in	O
this	O
study	O
.	O
Results	O
show	O
that	O
community	O
nurses	O
who	O
score	O
high	O
on	O
measures	O
of	O
self	O
-	O
compassion	O
and	O
wellbeing	B-T033
,	O
also	O
report	O
less	O
burnout	B-T048
.	O
Greater	O
compassion	O
satisfaction	O
was	O
also	O
positively	B-T033
associated	O
with	O
compassion	O
for	O
others	O
,	O
and	O
wellbeing	B-T033
,	O
whilst	O
also	O
being	O
negatively	B-T033
correlated	O
with	O
burnout	B-T048
.	O
High	O
levels	O
of	O
self	O
-	O
compassion	O
were	O
linked	O
with	O
lower	O
levels	O
of	O
burnout	B-T048
.	O
Furthermore	O
when	O
community	O
nurses	O
have	O
greater	O
compassion	O
satisfaction	O
they	O
also	O
report	O
more	O
compassion	O
for	O
others	O
,	O
increased	O
wellbeing	B-T033
,	O
and	O
less	O
burnout	B-T048
.	O
The	O
implications	O
of	O
this	O
are	O
discussed	O
alongside	O
suggestions	O
for	O
the	O
promotion	O
of	O
greater	O
compassion	O
      
Evaluation	O
of	O
an	O
international	O
educational	O
programme	O
for	O
health	O
care	O
professionals	O
on	O
best	O
practice	O
in	O
the	O
management	O
of	O
a	O
perinatal	O
death	O
:	O
IMproving	O
Perinatal	O
mortality	O
Review	O
and	O
Outcomes	O
Via	O
Education	O
(	O
IMPROVE	O
)	O
Stillbirths	B-T033
and	O
neonatal	B-T033
deaths	I-T033
are	O
devastating	O
events	O
for	O
both	O
parents	O
and	O
clinicians	O
and	O
are	O
global	O
public	O
health	O
concerns	O
.	O
Careful	O
clinical	B-T058
management	I-T058
after	O
these	O
deaths	O
is	O
required	O
,	O
including	O
appropriate	O
investigation	B-T058
and	O
assessment	B-T058
to	O
determine	O
cause	O
(	O
s	O
)	O
to	O
prevent	O
future	O
losses	O
,	O
and	O
to	O
improve	O
bereavement	B-T058
care	I-T058
for	O
families	O
.	O
An	O
educational	O
programme	O
for	O
health	O
care	O
professionals	O
working	O
in	O
maternal	B-T033
and	O
child	B-T058
health	I-T058
has	O
been	O
designed	O
to	O
address	O
these	O
needs	O
according	O
to	O
the	O
Perinatal	O
Society	O
of	O
Australia	O
and	O
New	O
Zealand	O
Guideline	O
for	O
Perinatal	O
Mortality	O
:	O
IMproving	O
Perinatal	O
mortality	O
Review	O
and	O
Outcomes	O
Via	O
Education	O
(	O
IMPROVE	O
)	O
.	O
The	O
programme	O
has	O
a	O
major	O
focus	O
on	O
stillbirth	B-T033
and	O
is	O
delivered	O
as	O
six	O
interactive	O
skills	O
-based	O
stations	O
.	O
We	O
aimed	O
to	O
determine	O
participants	O
'	O
pre-	O
and	O
post	O
-	O
programme	O
knowledge	O
of	O
and	O
confidence	O
in	O
the	O
management	O
of	O
perinatal	O
deaths	O
,	O
along	O
with	O
satisfaction	O
with	O
the	O
programme	O
.	O
We	O
also	O
aimed	O
to	O
determine	O
suitability	O
for	O
international	O
use	O
.	O
The	O
IMPROVE	O
programme	O
was	O
delivered	O
to	O
health	O
professionals	O
in	O
maternity	O
hospitals	O
in	O
all	O
seven	O
Australian	O
states	O
and	O
territories	O
and	O
modified	O
for	O
use	O
internationally	O
with	O
piloting	O
in	O
Vietnam	O
,	O
Fiji	O
,	O
and	O
the	O
Netherlands	O
(	O
with	O
the	O
assistance	B-T058
of	O
the	O
International	O
Stillbirth	O
Alliance	O
,	O
ISA	O
)	O
.	O
Modifications	O
were	O
made	O
to	O
programme	O
materials	O
in	O
consultation	B-T058
with	O
local	O
teams	O
and	O
included	O
translation	O
for	O
the	O
Vietnam	O
programme	O
.	O
Participants	O
completed	O
pre-	O
and	O
post	O
-	O
programme	O
evaluation	O
questionnaires	O
on	O
knowledge	O
and	O
confidence	O
on	O
six	O
key	O
components	O
of	O
perinatal	O
death	O
management	O
as	O
well	O
as	O
a	O
satisfaction	O
questionnaire	O
.	O
Over	O
the	O
period	O
May	O
2012	O
to	O
May	O
2015	O
,	O
30	O
IMPROVE	O
workshops	O
were	O
conducted	O
,	O
including	O
26	O
with	O
758	O
participants	O
in	O
Australia	O
and	O
four	O
with	O
136	O
participants	O
internationally	O
.	O
Evaluations	O
showed	O
a	O
significant	O
improvement	O
between	O
pre-	O
and	O
post	O
-	O
programme	O
knowledge	O
and	O
confidence	O
in	O
all	O
six	O
stations	O
and	O
overall	O
,	O
and	O
a	O
high	O
degree	O
of	O
satisfaction	O
in	O
all	O
settings	O
.	O
The	O
IMPROVE	O
programme	O
has	O
been	O
well	O
received	O
in	O
Australia	O
and	O
in	O
three	O
different	O
international	O
settings	O
and	O
is	O
now	O
being	O
made	O
available	O
through	O
ISA	O
.	O
Future	O
research	O
is	O
required	O
to	O
determine	O
whether	O
the	O
immediate	O
improvements	O
in	O
knowledge	O
are	O
sustained	O
with	O
less	O
causes	O
of	O
death	O
being	O
classified	O
as	O
unknown	O
,	O
changes	O
in	O
clinical	O
practice	O
and	O
improvement	O
in	O
parents	O
'	O
experiences	O
with	O
care	O
.	O
The	O
suitability	O
for	O
this	O
programme	O
in	O
low	B-T033
-	I-T033
income	I-T033
countries	O
also	O
needs	O
to	O
be	O
established	O
.	O
      
RELIABILITY	O
AND	O
VALIDITY	O
OF	O
THE	O
DIABETES	B-T058
EATING	I-T058
PROBLEM	I-T058
SURVEY	I-T058
-	I-T058
REVISED	I-T058
ON	O
TURKISH	O
CHILDREN	O
AND	O
ADOLESCENTS	O
WITH	O
TYPE	B-T047
1	I-T047
DIABETES	I-T047
MELLITUS	I-T047
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
reliability	O
and	O
validity	O
of	O
Turkish	O
version	O
of	O
Diabetes	B-T058
Eating	I-T058
Problem	I-T058
Survey	I-T058
-	I-T058
Revised	I-T058
(	O
DEPS	B-T058
-	I-T058
R	I-T058
)	O
for	O
children	O
and	O
adolescent	O
with	O
Type	B-T047
1	I-T047
Diabetes	I-T047
Mellitus	I-T047
.	O
A	O
total	O
of	O
200	O
children	O
and	O
adolescents	O
with	O
type	B-T047
1	I-T047
diabetes	I-T047
,	O
ages	O
9	O
-	O
18	O
years	O
,	O
completed	O
the	O
DEPS	B-T058
-	I-T058
R	I-T058
Turkish	O
version	O
.	O
In	O
addition	O
to	O
tests	O
of	O
validity	O
,	O
confirmatory	O
factor	O
analysis	O
was	O
conducted	O
to	O
investigate	O
the	O
factor	O
structure	O
of	O
the	O
16	O
-	O
item	O
Turkish	O
version	O
of	O
DEPS	B-T058
-	I-T058
R	I-T058
R.	O
The	O
Turkish	O
version	O
of	O
DEPS	B-T058
-	I-T058
R	I-T058
demonstrated	O
satisfactory	O
Cronbach	O
's	O
∝	O
(	O
0.847	O
)	O
and	O
was	O
significantly	O
correlated	O
with	O
ag	O
e	O
(	O
r=0.194	O
;	O
p<0.01	O
)	O
,	O
hemoglobin	O
A1c	O
levels	O
(	O
r=0.303	O
;	O
p<0.01	O
)	O
and	O
BMI	O
-	O
SDS	O
(	O
r=0.412	O
;	O
p<0.01	O
)	O
indicating	O
criterion	O
validity	O
.	O
Median	O
DEPS	B-T058
-	I-T058
R	I-T058
scores	O
of	O
Turkish	O
version	O
for	O
the	O
total	O
samples	O
,	O
females	O
and	O
males	O
were	O
as	O
follows	O
:	O
11.0	O
,	O
11.5	O
and	O
10.5	O
respectively	O
.	O
Disturbed	B-T048
eating	I-T048
behaviors	I-T048
and	O
insulin	B-T121
restriction	O
were	O
associated	O
with	O
poor	O
metabolic	O
control	O
.	O
A	O
short	O
,	O
self	O
-	O
administered	O
diabetes	B-T047
specific	O
screening	B-T058
tool	O
for	O
disordered	B-T048
eating	I-T048
behavior	I-T048
can	O
be	O
used	O
routinely	O
in	O
the	O
clinical	O
care	B-T058
of	O
adolescents	O
with	O
type	B-T047
1	I-T047
diabetes	I-T047
.	O
The	O
Turkish	O
version	O
of	O
DEPS	B-T058
-	I-T058
R	I-T058
is	O
a	O
valid	O
screening	B-T058
tool	O
for	O
disordered	B-T048
eating	I-T048
behaviors	I-T048
in	O
type	B-T047
1	I-T047
diabetes	I-T047
and	O
it	O
is	O
potentially	O
important	O
to	O
early	O
detect	O
disordered	B-T048
eating	I-T048
behaviors	I-T048
.	O
      
Perioperative	B-T058
Management	I-T058
of	O
Severe	B-T033
Hypertension	I-T033
during	O
Laparoscopic	B-T061
Surgery	I-T061
for	O
Pheochromocytoma	B-T191
Phaeochromocytoma	B-T191
is	O
a	O
catecholamine	O
-	O
secreting	O
vascular	B-T191
tumour	I-T191
that	O
is	O
derived	O
from	O
chromaffin	O
cell	O
.	O
Lethal	B-T033
cardiovascular	O
complications	O
,	O
such	O
as	O
serious	O
hypertension	B-T047
,	O
myocardial	B-T047
infarction	I-T047
and	O
aortic	B-T047
dissection	I-T047
,	O
may	O
occur	O
because	O
of	O
uncontrolled	B-T191
catecholamine	I-T191
release	I-T191
.	O
Each	O
stage	O
of	O
anaesthesia	B-T061
management	I-T061
has	O
vital	O
importance	O
because	O
of	O
this	O
destructive	B-T191
catecholamine	I-T191
secretion	I-T191
that	O
may	O
occur	O
during	O
induction	B-T061
,	O
perioperative	O
stage	O
and	O
surgical	B-T061
manipulation	I-T061
.	O
In	O
this	O
study	O
,	O
we	O
report	O
regarding	O
the	O
preoperative	B-T058
preparation	I-T058
and	O
severe	B-T058
,	I-T058
persistent	I-T058
hypertension	I-T058
attack	I-T058
management	I-T058
with	O
a	O
combination	O
of	O
α	B-T121
-	I-T121
adrenergic	I-T121
blockade	I-T121
,	O
β	B-T121
-	I-T121
adrenergic	I-T121
blockade	I-T121
,	O
sodium	B-T121
nitroprusside	I-T121
and	O
remifentanil	B-T121
in	O
a	O
patient	O
who	O
underwent	O
laparoscopic	B-T061
surgery	I-T061
for	O
phaeochromocytoma	B-T191
.	O
      
Association	O
of	O
leukemia	O
inhibitory	O
factor	O
gene	O
polymorphism	O
and	O
in	O
vitro	O
fertilization	O
outcome	O
in	O
a	O
population	O
in	O
northern	O
Iran	O
Several	O
studies	O
have	O
been	O
demonstrated	O
that	O
endometrial	O
leukemia	O
inhibitory	O
factor	O
(	O
LIF	O
)	O
is	O
important	O
in	O
embryo	O
implantation	O
.	O
LIF	O
is	O
a	O
secreted	O
glycoprotein	O
with	O
a	O
variety	O
of	O
biological	O
functions	O
including	O
stimulation	O
of	O
cell	O
proliferation	O
,	O
differentiation	O
and	O
survival	O
that	O
are	O
all	O
essential	O
for	O
blastocyete	B-T018
development	O
and	O
implantation	O
.	O
The	O
LIF	O
receptor	O
activates	O
several	O
signaling	O
pathways	O
in	O
diverse	O
cell	O
types	O
,	O
including	O
Jak	O
/	O
STAT	O
,	O
MAPK	O
and	O
PI3	O
-	O
kinase	O
pathways	O
in	O
the	O
endometrium	B-T023
of	O
fertile	O
woman	O
.	O
It	O
has	O
been	O
suggested	O
that	O
the	O
initial	O
lower	O
expression	O
of	O
LIF	O
in	O
proliferative	O
phase	O
may	O
be	O
one	O
of	O
the	O
causes	O
for	O
multiple	O
failure	O
of	O
implantation	B-T061
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
association	O
between	O
maternal	B-T033
genotype	O
of	O
SNP	O
3951C	O
/	O
T	O
LIF	O
and	O
in	B-T061
vitro	I-T061
fertilization	I-T061
and	O
embryo	B-T061
transfer	I-T061
(	O
IVF	B-T061
-	O
ET	B-T061
)	O
outcome	O
in	O
infertile	O
women	O
.	O
This	O
case	O
-	O
control	O
study	O
was	O
comprised	O
of	O
infertile	O
patients	O
(	O
n=70	O
)	O
and	O
women	O
having	O
one	O
healthy	B-T033
child	I-T033
as	O
controls	O
(	O
n=73	O
)	O
.	O
Genotyping	B-T059
for	O
SNP-3951C	O
/	O
T	O
was	O
performed	O
by	O
PCR	B-T059
/	I-T059
RFLP	I-T059
.	O
Allele	O
and	O
genotype	O
distribution	O
did	O
not	O
differ	O
significantly	O
between	O
patients	O
and	O
controls	O
(	O
P>0.05	O
)	O
.	O
The	O
LIF	O
genotype	O
frequencies	O
amongst	O
the	O
70	O
cases	O
were	O
C	O
/	O
C	O
=	O
40	O
%	O
,	O
C	O
/	O
T	O
=	O
52.8	O
%	O
and	O
T	O
/	O
T	O
=	O
7.2	O
%	O
;	O
the	O
C	O
and	O
T	O
allele	O
frequencies	O
were	O
66	O
%	O
and	O
34	O
%	O
,	O
respectively	O
.	O
The	O
LIF	O
genotype	O
frequencies	O
amongst	O
the	O
73	O
controls	O
were	O
C	O
/	O
C	O
=	O
45.20	O
%	O
,	O
C	O
/	O
T	O
=	O
50.70	O
%	O
and	O
T	O
/	O
T	O
=	O
4.1	O
%	O
;	O
the	O
C	O
and	O
T	O
allele	O
frequencies	O
were	O
70	O
%	O
and	O
30	O
%	O
,	O
respectively	O
.	O
In	O
conclusion	O
,	O
the	O
results	O
of	O
this	O
study	O
indicate	O
that	O
SNP	O
3951C	O
/	O
T	O
of	O
LIF	O
may	O
not	O
be	O
associated	O
with	O
IVF	B-T061
-	O
ET	B-T061
outcome	O
in	O
this	O
population	O
.	O
Although	O
more	O
studies	O
should	O
be	O
considered	O
with	O
larger	O
number	O
of	O
patients	O
and	O
control	O
subjects	O
to	O
confirm	O
our	O
results	O
.	O
      
A	O
novel	O
mechanical	O
simulator	O
for	O
cannulation	B-T061
and	O
sphincterotomy	B-T061
after	O
Billroth	B-T061
II	I-T061
or	O
Roux	B-T061
-	I-T061
en	I-T061
-	I-T061
Y	I-T061
reconstruction	I-T061
In	O
patients	O
with	O
Billroth	B-T061
II	I-T061
(	O
B	B-T061
II	I-T061
)	O
or	O
Roux	B-T061
-	I-T061
en	I-T061
-	I-T061
Y	I-T061
anatomy	B-T017
,	O
endoscopic	B-T060
retrograde	I-T060
cholangiopancreatography	I-T060
(	O
ERCP	B-T060
)	O
is	O
demanding	O
.	O
Here	O
,	O
we	O
describe	O
a	O
novel	O
simulator	O
with	O
simulated	O
fluoroscopy	B-T060
for	O
cannulation	B-T061
and	O
sphincterotomy	B-T061
training	O
in	O
such	O
situations	O
.	O
A	O
custom	O
-	O
made	O
simulation	O
system	O
was	O
built	O
based	O
upon	O
a	O
common	O
chassis	O
of	O
a	O
series	O
of	O
previously	O
described	O
ERCP	B-T060
simulators	O
.	O
The	O
papilla	B-T023
is	O
made	O
out	O
of	O
organic	O
material	O
and	O
can	O
be	O
cut	O
by	O
high	O
frequency	O
current	O
.	O
The	O
advancement	O
of	O
guidewires	O
and	O
other	O
instruments	O
within	O
transparent	O
mock	O
bile	B-T023
ducts	I-T023
can	O
be	O
viewed	O
in	O
the	O
window	O
of	O
the	O
simulator	O
without	O
the	O
need	O
for	O
fluoroscopy	B-T060
.	O
The	O
ERCP	B-T060
B	B-T061
II	I-T061
/	O
Roux	B-T061
-	I-T061
en	I-T061
-	I-T061
Y	I-T061
simulation	O
system	O
was	O
first	O
evaluated	B-T058
during	O
an	O
ERCP	B-T060
course	O
.	O
There	O
were	O
no	O
technical	O
problems	O
related	O
to	O
the	O
novel	O
simulator	O
during	O
the	O
course	O
.	O
After	O
sphincterotomy	B-T061
,	O
the	O
organic	O
papillae	B-T023
could	O
easily	O
be	O
exchanged	O
within	O
a	O
few	O
seconds	O
.	O
Overall	O
,	O
the	O
novel	O
B	B-T061
II	I-T061
/	O
Roux	B-T061
-	I-T061
en	I-T061
-	I-T061
Y	I-T061
simulator	O
achieved	O
favorable	O
results	O
by	O
trainees	O
and	O
expert	O
endoscopists	O
in	O
all	O
categories	O
assessed	O
.	O
The	O
new	O
B	B-T061
II	I-T061
/	O
Roux	B-T061
-	I-T061
en	I-T061
-	I-T061
Y	I-T061
mechanical	O
simulator	O
is	O
simple	O
and	O
practicable	O
.	O
A	O
first	O
evaluation	B-T058
during	O
an	O
ERCP	B-T060
course	O
showed	O
promising	O
results	O
.	O
      
Overall	O
Quality	O
Properties	O
of	O
Kiwifruit	O
Treated	B-T061
by	I-T061
Cinnamaldehyde	B-T121
and	O
Citral	B-T121
:	O
Microbial	B-T001
,	O
Antioxidant	O
Capacity	O
during	O
Cold	B-T059
Storage	I-T059
This	O
work	O
was	O
undertaken	O
to	O
evaluate	B-T058
the	O
microbiological	O
characteristics	O
and	O
antioxidant	O
and	O
physiological	O
activities	O
in	O
kiwifruits	O
(	O
Actinida	O
deliciosa	O
var	O
.	O
Qinmei	O
)	O
with	O
/	O
without	O
cinnamaldehyde	B-T121
(	O
C1	O
)	O
and	O
citral	B-T121
(	O
C2	O
)	O
fumigation	O
treatments	O
(	O
5	O
μL	O
/	O
L	O
)	O
during	O
0	O
,	O
3	O
,	O
6	O
,	O
9	O
,	O
and	O
12	O
d	O
of	O
storage	O
at	O
4	O
°	O
C	O
.	O
Essential	O
oils	O
(	O
EOs	O
)	O
treatment	O
lowered	O
the	O
total	O
viable	O
counts	O
,	O
yeast	O
,	O
and	O
mold	O
to	O
1.54	O
,	O
2.36	O
,	O
and	O
2.05	O
log	O
CFU	O
/	O
g	O
,	O
respectively	O
.	O
Moreover	O
,	O
EOs	O
improved	O
the	O
antioxidant	O
activities	O
of	O
kiwifruit	O
.	O
They	O
enhanced	O
phenolics	B-T121
and	O
flavonoids	O
content	O
in	O
fruit	O
tissue	O
by	O
49.48	O
%	O
at	O
day	O
3	O
and	O
56.93	O
%	O
at	O
day	O
6	O
,	O
respectively	O
.	O
In	O
addition	O
,	O
ascorbic	B-T121
acid	I-T121
in	O
treated	O
groups	O
had	O
the	O
lower	O
losing	O
rate	O
.	O
Similarly	O
,	O
MDA	O
(	O
malondialdehyde	O
)	O
,	O
H2	B-T121
O2	I-T121
(	O
hydrogen	B-T121
peroxide	I-T121
)	O
,	O
and	O
(	O
•	O
)	O
O2(-	O
)	O
(	O
superoxide	O
anion	O
)	O
production	O
were	O
effectively	O
decreased	O
in	O
the	O
range	O
of	O
27.27	O
%	O
to	O
54.38	O
%	O
.	O
Physicochemical	O
characteristics	O
showed	O
that	O
kiwifruits	O
from	O
treated	O
group	O
maintained	O
higher	O
levels	O
of	O
flesh	O
luminosity	O
and	O
firmness	O
.	O
EOs	O
also	O
decreased	O
the	O
levels	O
of	O
reducing	O
sugar	O
by	O
45.97	O
%	O
at	O
day	O
3	O
,	O
and	O
increased	O
the	O
content	O
of	O
soluble	O
protein	O
and	O
hydrolyzed	O
amino	B-T121
acid	I-T121
.	O
Therefore	O
,	O
postharvest	O
EOs	O
treatment	O
has	O
positive	O
effects	O
on	O
delaying	O
senescence	O
and	O
enhancing	O
antioxidant	O
capacities	O
in	O
kiwifruit	O
.	O
      
Simultaneous	O
thrombosis	O
of	O
multiple	B-T023
coronary	I-T023
arteries	I-T023
in	O
a	O
patient	O
with	O
rheumatoid	B-T047
arthritis	I-T047
We	O
present	O
a	O
case	O
of	O
simultaneous	O
coronary	B-T047
thrombosis	I-T047
of	I-T047
the	I-T047
left	I-T047
main	I-T047
,	O
the	O
left	B-T023
anterior	I-T023
descending	I-T023
artery	I-T023
and	O
the	O
right	B-T023
coronary	I-T023
artery	I-T023
in	O
a	O
patient	O
,	O
recently	O
diagnosed	B-T060
with	O
rheumatoid	B-T047
arthritis	I-T047
.	O
      
Effects	O
of	O
Application	O
of	O
Social	O
Marketing	O
Theory	O
and	O
the	O
Health	B-T058
Belief	I-T058
Model	I-T058
in	O
Promoting	O
Cervical	B-T061
Cancer	I-T061
Screening	I-T061
among	O
Targeted	O
Women	O
in	O
Sisaket	O
Province	O
,	O
Thailand	O
Cervical	B-T191
cancer	I-T191
is	O
a	O
major	O
public	B-T033
health	I-T033
problem	I-T033
in	O
Thailand	O
,	O
being	O
ranked	O
second	O
only	O
to	O
breast	B-T191
cancer	I-T191
.	O
Thai	O
women	O
have	O
been	O
reported	B-T058
to	O
have	O
a	O
low	O
rate	O
of	O
cervical	B-T061
cancer	I-T061
screening	I-T061
(	O
27.7	O
%	O
of	O
the	O
80	O
%	O
goal	O
of	O
WHO	O
)	O
.	O
We	O
therefore	O
aimed	O
to	O
apply	O
the	O
social	O
marketing	O
theory	O
and	O
health	B-T058
belief	I-T058
model	I-T058
in	O
promoting	O
cervical	B-T061
cancer	I-T061
screening	I-T061
in	O
Kanthararom	O
District	O
,	O
Sisaket	O
Province	O
.	O
A	O
total	O
of	O
92	O
from	O
974	O
targeted	O
women	O
aged	O
3060	O
years	O
were	O
randomly	O
divided	O
into	O
two	O
groups	O
.	O
The	O
experimental	O
group	O
underwent	O
application	O
of	O
social	O
marketing	O
theory	O
and	O
a	O
health	B-T058
belief	I-T058
model	I-T058
program	O
promoting	O
cervical	B-T061
cancer	I-T061
screening	I-T061
while	O
the	O
control	O
group	O
received	O
normal	B-T058
services	I-T058
.	O
Two	O
research	O
tools	O
were	O
used	O
:	O
(	O
1	O
)	O
application	O
of	O
social	O
marketing	O
theory	O
and	O
health	B-T058
belief	I-T058
model	I-T058
program	O
and	O
(	O
2	O
)	O
questionnaire	O
used	O
to	O
evaluate	O
perceptions	O
of	O
cervical	B-T191
cancer	I-T191
.	O
Descriptive	O
and	O
inferential	O
statistics	O
including	O
paired	O
sample	O
ttest	O
and	O
independent	O
ttest	O
were	O
used	O
to	O
analyze	O
the	O
data	O
.	O
After	O
the	O
program	O
had	O
been	O
used	O
,	O
the	O
mean	B-T033
score	I-T033
of	O
perception	O
of	O
cervical	B-T191
cancer	I-T191
of	O
experimental	O
group	O
was	O
at	O
a	O
higher	O
level	O
(	O
x=4.09	O
;	O
S.D.	O
=	O
0.30	O
)	O
,	O
than	O
in	O
the	O
control	O
group	O
(	O
x=3.82	O
;	O
S.D.	O
=	O
0.20	O
)	O
with	O
statistical	O
significance	O
(	O
p<0.001	O
)	O
.	O
This	O
research	O
demonstrated	O
an	O
appropriate	O
communication	O
process	O
in	O
behavioral	O
modification	O
to	O
prevent	O
cervical	B-T191
cancer	I-T191
.	O
It	O
can	O
be	O
recommended	O
that	O
this	O
program	O
featuring	O
social	O
marketing	O
and	O
the	O
health	B-T058
belief	I-T058
model	I-T058
be	O
used	O
to	O
promote	O
cervical	B-T061
cancer	I-T061
screening	I-T061
in	O
targeted	O
women	O
and	O
it	O
can	O
be	O
promoted	O
as	O
a	O
guideline	O
for	O
other	O
health	B-T058
services	I-T058
,	O
especially	O
in	O
health	B-T058
promotion	I-T058
and	O
disease	B-T061
prevention	I-T061
.	O
      
Active	O
packaging	O
of	O
chicken	O
meats	O
with	O
modified	O
atmosphere	O
including	O
oxygen	B-T121
scavengers	O
The	O
effects	O
of	O
modified	O
atmosphere	O
packaging	O
(	O
MAP	O
-70	O
%	O
CO2	O
/30	O
%	O
N2	O
)	O
and	O
iron	B-T121
-based	O
oxygen	B-T121
scavengers	O
(	O
OS	O
)	O
with	O
various	O
absorption	O
capacities	O
(	O
Ageless	O
(	O
®	O
)	O
ss100	O
,	O
ss300	O
,	O
and	O
ss500	O
)	O
as	O
an	O
active	O
packaging	O
system	O
on	O
microbiological	O
and	O
oxidative	O
changes	O
in	O
chicken	O
thigh	O
meats	O
were	O
evaluated	O
during	O
refrigerated	O
storage	O
(	O
4	O
°	O
C	O
)	O
for	O
19	O
d	O
at	O
3-	O
day	O
intervals	O
.	O
Total	O
aerobic	O
mesophilic	O
bacteria	O
counts	O
exceeded	O
the	O
acceptability	O
limit	O
at	O
d	O
7	O
in	O
the	O
control	O
group	O
without	O
MAP	O
(	O
AIR	O
)	O
,	O
and	O
at	O
d	O
19	O
in	O
MAP	O
and	O
OS	O
containing	O
samples	O
.	O
OS	O
utilization	O
resulted	O
in	O
around	O
1.5	O
and	O
1.0	O
log	O
unit	O
reductions	O
in	O
Pseudomonas	B-T007
spp	I-T007
.	I-T007
counts	O
at	O
d	O
7	O
and	O
d	O
10	O
of	O
storage	O
,	O
respectively	O
,	O
as	O
compared	O
with	O
AIR	O
and	O
MAP	O
groups	O
(	O
P	O
<	O
0.05	O
)	O
.	O
MAP	O
and	O
OS	O
groups	O
had	O
fewer	O
(	O
P	O
<	O
0.05	O
)	O
coliform	O
counts	O
than	O
did	O
the	O
AIR	O
group	O
,	O
with	O
an	O
approximately	O
1.0	O
log	O
reduction	O
observed	O
at	O
d	O
10	O
.	O
Although	O
in	O
some	O
cases	O
OS	O
utilization	O
resulted	O
in	O
lower	O
TBARS	O
values	O
and	O
carbonyl	O
and	O
sulphydryl	O
contents	O
,	O
particularly	O
during	O
later	O
stages	O
of	O
refrigerated	O
storage	O
as	O
compared	O
to	O
AIR	O
and	O
MAP	O
groups	O
,	O
in	O
general	O
,	O
these	O
effects	O
were	O
not	O
always	O
apparent	O
.	O
The	O
results	O
of	O
this	O
study	O
suggested	O
that	O
MAP	O
suppressed	O
microbiological	O
growth	O
and	O
retarded	O
lipid	O
and	O
protein	O
oxidation	O
in	O
chicken	O
thigh	O
meats	O
,	O
with	O
a	O
9-	O
day	O
shelf	O
-	O
life	O
extention	O
with	O
insignificant	O
effects	O
of	O
OS	O
.	O
      
Grapevine	O
Subtilase	O
Family	O
:	O
Update	O
on	O
New	O
Sequences	O
and	O
Nomenclature	O
Proposal	O
In	O
grapevine	O
,	O
serine	O
peptidases	O
from	O
the	O
subtilase	O
family	O
were	O
recently	O
associated	O
to	O
Plasmopara	O
viticola	O
resistance	O
.	O
This	O
family	O
in	O
grapevine	O
,	O
first	O
characterized	O
in	O
2014	O
,	O
was	O
re	O
-	O
analyzed	O
last	O
year	O
and	O
82	O
subtilase	O
genes	O
were	O
identified	O
.	O
However	O
,	O
in	O
November	O
of	O
2016	O
,	O
the	O
National	O
Center	O
for	O
Biotechnology	O
Information	O
database	O
(	O
NCBI	O
)	O
made	O
a	O
new	O
public	O
release	O
of	O
the	O
grapevine	O
genome	O
annotation	O
based	O
on	O
new	O
sequencing	O
data	O
and	O
better	O
prediction	O
algorithms	O
.	O
As	O
a	O
consequence	O
,	O
some	O
gene	O
annotations	O
and	O
lengths	O
changed	O
.	O
Here	O
we	O
present	O
an	O
update	O
to	O
the	O
grapevine	O
subtilase	O
gene	O
family	O
sequences	O
(	O
SBT	O
)	O
,	O
namely	O
sequence	O
identifiers	O
,	O
bioinformatic	O
predictions	O
and	O
recommend	O
a	O
nomenclature	O
for	O
the	O
grapevine	O
SBT	O
genes	O
.	O
Our	O
results	O
show	O
that	O
grapevine	O
subtilase	O
gene	O
family	O
is	O
now	O
constituted	O
by	O
87	O
subtilase	O
genes	O
encoding	O
for	O
109	O
subtilase	O
proteins	O
and	O
,	O
despite	O
the	O
reported	O
alterations	O
,	O
expression	O
data	O
on	O
subtilases	O
associated	O
to	O
grapevine	O
resistance	O
to	O
P.	O
viticola	O
pathosystem	B-T001
did	O
not	O
suffer	O
any	O
alteration	O
.	O
      
Associations	O
between	O
human	B-T121
breast	I-T121
milk	I-T121
hormones	O
and	O
adipocytokines	O
and	O
infant	O
growth	O
and	O
body	O
composition	O
in	O
the	O
first	B-T033
6	I-T033
months	I-T033
of	I-T033
life	I-T033
Much	O
is	O
to	O
be	O
learnt	O
about	O
human	B-T121
breast	I-T121
milk	I-T121
(	O
HBM	B-T121
)	O
.	O
The	O
purpose	O
of	O
this	O
study	O
is	O
to	O
extend	O
our	O
knowledge	O
of	O
HBM	B-T121
by	O
investigating	O
the	O
role	O
of	O
maternal	B-T033
body	O
mass	O
index	O
(	O
BMI	O
)	O
,	O
sex	O
and	O
stage	O
of	O
lactation	O
(	O
month	O
1	O
vs.	O
6	O
)	O
on	O
HBM	B-T121
insulin	B-T121
,	O
glucose	B-T121
,	O
leptin	O
,	O
IL-6	O
and	O
TNF	O
-	O
α	O
and	O
their	O
associations	O
with	O
infant	O
body	O
composition	O
.	O
Thirty	O
-	O
seven	O
exclusively	O
breastfeeding	B-T033
infants	I-T033
(	O
n	O
=	O
37	O
;	O
16	O
♀	O
,	O
21	O
♂	O
)	O
,	O
and	O
their	O
mothers	B-T033
(	O
19	O
-	O
47	O
kg	O
m(-2	O
)	O
)	O
were	O
studied	O
at	O
1	O
and	O
6	O
months	O
of	O
lactation	O
.	O
Infants	O
had	O
body	O
composition	O
measured	O
(	O
using	O
dual	B-T060
-	I-T060
energy	I-T060
X	I-T060
-	I-T060
ray	I-T060
absorptiometry	I-T060
)	O
and	O
HBM	B-T121
collected	O
.	O
A	O
significant	O
interaction	O
between	O
maternal	B-T033
BMI	O
and	O
infant	O
sex	O
on	O
insulin	B-T059
levels	I-T059
(	O
p	O
=	O
0.0322	O
)	O
was	O
observed	O
such	O
that	O
insulin	O
was	O
229	O
%	O
higher	O
in	O
obese	B-T047
mothers	O
nursing	O
female	B-T033
infants	I-T033
than	O
in	O
normal	B-T033
weight	I-T033
mothers	O
nursing	O
female	B-T033
infants	I-T033
and	O
179	O
%	O
higher	O
than	O
obese	B-T047
mothers	O
nursing	O
male	B-T033
infants	I-T033
.	O
For	O
leptin	O
,	O
a	O
significant	O
association	O
with	O
BMI	O
category	O
was	O
observed	O
(	O
p	O
<	O
0.0001	O
)	O
such	O
that	O
overweight	B-T184
and	O
obese	B-T047
mothers	O
had	O
96.5	O
%	O
and	O
315.1	O
%	O
higher	B-T033
leptin	I-T033
levels	I-T033
than	O
normal	B-T033
weight	I-T033
mothers	O
,	O
respectively	O
.	O
Leptin	O
was	O
also	O
found	O
to	O
have	O
a	O
significant	O
(	O
p	O
=	O
0.0004	O
)	O
33.7	O
%	O
decrease	O
from	O
months	O
1	O
to	O
6	O
,	O
controlling	O
for	O
BMI	O
category	O
and	O
sex	O
.	O
A	O
significant	O
inverse	O
relationship	O
between	O
month	O
1	O
leptin	O
levels	O
and	O
infant	B-T033
length	I-T033
(	O
p	O
=	O
0.0257	O
)	O
,	O
percent	B-T033
fat	I-T033
(	O
p	O
=	O
0.0223	O
)	O
,	O
total	O
fat	O
mass	O
(	O
p	O
=	O
0.0226	O
)	O
and	O
trunk	O
fat	O
mass	O
(	O
p	O
=	O
0.0111	O
)	O
at	O
month	O
6	O
was	O
also	O
found	O
.	O
No	O
associations	O
or	O
interactions	O
were	O
observed	O
for	O
glucose	B-T121
,	O
TNF	O
-	O
α	O
or	O
IL-6	O
.	O
These	O
data	O
demonstrate	O
that	O
maternal	B-T033
BMI	O
,	O
infant	O
sex	O
and	O
stage	O
of	O
lactation	O
affect	O
the	O
compositional	O
make	O
-	O
up	O
of	O
insulin	B-T121
and	O
leptin	O
.	O
      
Bilateral	O
sternal	B-T023
infusion	B-T061
of	O
ropivacaine	B-T121
and	O
length	O
of	O
stay	O
in	O
ICU	O
after	O
cardiac	B-T061
surgery	I-T061
with	O
increased	O
respiratory	O
risk	O
:	O
A	O
randomised	O
controlled	O
trial	O
The	O
continuous	O
bilateral	O
infusion	B-T061
of	O
a	O
local	B-T121
anaesthetic	I-T121
solution	O
around	O
the	O
sternotomy	B-T061
wound	O
(	O
bilateral	O
sternal	B-T023
)	O
is	O
an	O
innovative	O
technique	O
for	O
reducing	O
pain	B-T184
after	O
sternotomy	B-T061
.	O
To	O
assess	O
the	O
effects	O
of	O
the	O
technique	O
on	O
the	O
need	O
for	O
intensive	B-T058
care	I-T058
in	O
cardiac	O
patients	O
at	O
increased	O
risk	O
of	O
respiratory	O
complications	O
.	O
Randomised	O
,	O
observer	O
-	O
blind	O
controlled	O
trial	O
.	O
Single	O
centre	O
,	O
French	O
University	O
Hospital	O
.	O
In	O
total	O
,	O
120	O
adults	O
scheduled	O
for	O
open	B-T061
-	I-T061
heart	I-T061
surgery	I-T061
,	O
with	O
one	O
of	O
the	O
following	O
conditions	O
:	O
age	O
more	O
than	O
75	O
years	O
,	O
BMI	O
>	O
30	O
kg	O
m	O
,	O
chronic	B-T047
obstructive	I-T047
pulmonary	I-T047
disease	I-T047
,	O
active	O
smoking	O
habit	O
.	O
Either	O
a	O
bilateral	O
sternal	B-T023
infusion	B-T061
of	O
0.2	O
%	O
ropivacaine	B-T121
(	O
3	O
ml	O
h	O
through	O
each	O
catheter	O
;	O
'	O
intervention	O
'	O
group	O
)	O
,	O
or	O
standardised	O
care	O
only	O
(	O
'	O
control	O
'	O
group	O
)	O
.	O
Analgesia	B-T061
was	O
provided	O
with	O
paracetamol	B-T121
and	O
self	O
-	O
administered	O
intravenous	O
morphine	B-T121
.	O
The	O
length	O
of	O
time	O
to	O
readiness	B-T033
for	O
discharge	B-T058
from	O
ICU	O
,	O
blindly	O
assessed	O
by	O
a	O
committee	O
of	O
experts	O
.	O
No	O
effect	O
was	O
found	O
between	O
groups	O
for	O
the	O
primary	O
outcome	O
(	O
P	O
=	O
0.680	O
,	O
intention	O
to	O
treat	O
)	O
;	O
the	O
median	O
values	O
were	O
42.4	O
and	O
37.7	O
h	O
,	O
respectively	O
for	O
the	O
control	O
and	O
intervention	O
groups	O
(	O
P	O
=	O
0.873	O
)	O
.	O
Similar	O
nonsignificant	O
trends	O
were	O
noted	O
for	O
other	O
postoperative	B-T033
delays	O
.	O
Significant	O
effects	O
favouring	O
the	O
intervention	B-T061
were	O
noted	O
for	O
dynamic	B-T184
pain	I-T184
,	O
patient	O
satisfaction	O
,	O
occurrence	B-T184
of	I-T184
nausea	I-T184
and	O
vomiting	B-T184
,	O
occurrence	O
of	O
delirium	B-T048
or	O
mental	B-T048
confusion	I-T048
and	O
occurrence	O
of	O
pulmonary	O
complications	O
.	O
In	O
12	O
patients	O
,	O
although	O
no	O
symptoms	B-T184
actually	O
occurred	O
,	O
the	O
total	O
ropivacaine	O
plasma	O
level	O
exceeded	O
the	O
lowest	O
value	O
for	O
which	O
neurological	B-T184
symptoms	I-T184
have	O
been	O
observed	O
in	O
healthy	O
volunteers	O
.	O
Because	O
of	O
a	O
small	O
size	O
effect	O
,	O
and	O
despite	O
significant	O
analgesic	B-T033
effects	I-T033
,	O
this	O
strategy	O
failed	O
to	O
reduce	O
the	O
time	O
spent	O
in	O
ICU	O
.	O
EudraCT	O
(	O
N	O
°	O
:	O
2012	O
-	O
005225	O
-	O
69	O
)	O
;	O
ClinicalTrials.gov	O
(	O
NCT01828788	O
)	O
.	O
      
Dual	B-T059
-	I-T059
color	I-T059
STED	I-T059
microscopy	I-T059
reveals	O
a	O
sandwich	O
structure	O
of	O
Bassoon	O
and	O
Piccolo	O
in	O
active	O
zones	O
of	O
adult	O
and	O
aged	O
mice	O
Presynaptic	O
active	O
zones	O
play	O
a	O
pivotal	O
role	O
as	O
synaptic	O
vesicle	O
release	O
sites	O
for	O
synaptic	O
transmission	O
,	O
but	O
the	O
molecular	O
architecture	O
of	O
active	O
zones	O
in	O
mammalian	O
neuromuscular	O
junctions	O
(	O
NMJs	O
)	O
at	O
sub	O
-	O
diffraction	O
limited	O
resolution	O
remains	O
unknown	O
.	O
Bassoon	O
and	O
Piccolo	O
are	O
active	O
zone	O
specific	O
cytosolic	O
proteins	O
essential	O
for	O
active	O
zone	O
assembly	O
in	O
NMJs	O
,	O
ribbon	O
synapses	O
,	O
and	O
brain	B-T023
synapses	O
.	O
These	O
proteins	O
are	O
thought	O
to	O
colocalize	O
and	O
share	O
some	O
functions	O
at	O
active	O
zones	O
.	O
Here	O
,	O
we	O
report	O
an	O
unexpected	O
finding	O
of	O
non	O
-	O
overlapping	O
localization	O
of	O
these	O
two	O
proteins	O
in	O
mouse	O
NMJs	O
revealed	O
using	O
dual	O
-	O
color	O
stimulated	O
emission	O
depletion	O
(	O
STED	O
)	O
super	B-T059
resolution	I-T059
microscopy	I-T059
.	O
Piccolo	O
puncta	B-T033
sandwiched	O
Bassoon	O
puncta	B-T033
and	O
aligned	O
in	O
a	O
Piccolo	O
-	O
Bassoon	O
-	O
Piccolo	O
structure	O
in	O
adult	O
NMJs	O
.	O
P	O
/	O
Q	O
-	O
type	O
voltage	O
-	O
gated	O
calcium	O
channel	O
(	O
VGCC	O
)	O
puncta	B-T033
colocalized	O
with	O
Bassoon	O
puncta	B-T033
.	O
The	O
P	O
/	O
Q	O
-	O
type	O
VGCC	O
and	O
Bassoon	O
protein	O
levels	O
decreased	O
significantly	O
in	O
NMJs	O
from	O
aged	O
mouse	O
.	O
In	O
contrast	O
,	O
the	O
Piccolo	O
levels	O
in	O
NMJs	O
from	O
aged	O
mice	O
were	O
comparable	O
to	O
levels	O
in	O
adult	O
mice	O
.	O
This	O
study	O
revealed	O
the	O
molecular	O
architecture	O
of	O
active	O
zones	O
in	O
mouse	O
NMJs	O
at	O
sub	O
-	O
diffraction	O
limited	O
resolution	O
,	O
and	O
described	O
the	O
selective	O
degeneration	O
mechanism	O
of	O
active	O
zone	O
proteins	O
in	O
NMJs	O
from	O
aged	O
mice	O
.	O
Interestingly	O
,	O
the	O
localization	O
pattern	O
of	O
active	O
zone	O
proteins	O
described	O
herein	O
is	O
similar	O
to	O
active	O
zone	O
structures	O
described	O
using	O
electron	B-T059
microscope	I-T059
tomography	I-T059
.	O
      
Description	O
of	O
Ancylomarina	B-T007
subtilis	I-T007
gen	I-T007
.	I-T007
nov	I-T007
.	I-T007
,	I-T007
sp	I-T007
.	I-T007
nov	I-T007
.	I-T007
,	O
isolated	O
from	O
coastal	O
sediment	O
,	O
proposal	O
of	O
Marinilabiliales	B-T007
ord	I-T007
.	I-T007
nov	I-T007
.	I-T007
and	O
transfer	O
of	O
Marinilabiliaceae	B-T007
,	O
Prolixibacteraceae	B-T007
and	O
Marinifilaceae	B-T007
to	O
the	O
order	O
Marinilabiliales	B-T007
A	O
Gram	B-T007
-	I-T007
stain	I-T007
-	I-T007
negative	I-T007
,	O
facultatively	B-T007
anaerobic	I-T007
,	O
moderately	O
halophilic	O
,	O
filamentous	O
,	O
non	B-T007
-	I-T007
motile	I-T007
bacterium	I-T007
,	O
designated	O
FA102	B-T007
T	I-T007
,	O
was	O
isolated	O
from	O
marine	O
sediment	O
of	O
the	O
coast	O
of	O
Weihai	O
,	O
China	O
.	O
Phylogenetic	O
analysis	O
based	O
on	O
16S	O
rRNA	O
gene	O
sequences	O
showed	O
that	O
strain	O
FA102	B-T007
T	I-T007
formed	O
a	O
distinct	O
evolutionary	O
lineage	O
within	O
the	O
family	O
Marinifilaceae	B-T007
and	O
its	O
closest	B-T033
relative	I-T033
was	O
Marinifilum	B-T007
fragile	I-T007
JCM	I-T007
15579	I-T007
T	I-T007
(	O
93.2	O
%	O
sequence	O
similarity	O
)	O
.	O
The	O
DNA	O
G+C	O
content	O
of	O
the	O
novel	O
strain	O
was	O
36.5	O
mol%	O
.	O
The	O
predominant	O
cellular	O
fatty	O
acids	O
and	O
respiratory	O
quinone	O
were	O
iso	B-T121
-	I-T121
C15:0	I-T121
and	O
iso	B-T121
-	I-T121
C15:0	I-T121
3	I-T121
-	I-T121
OH	I-T121
,	O
and	O
MK-7	B-T121
,	O
respectively	O
.	O
On	O
the	O
basis	O
of	O
the	O
phylogenetic	O
,	O
phenotypic	O
and	O
physiological	O
data	O
,	O
strain	O
FA102	B-T007
T	I-T007
represents	O
a	O
novel	O
genus	O
and	O
species	O
,	O
for	O
which	O
the	O
name	O
Ancylomarina	B-T007
subtilis	I-T007
gen	I-T007
.	I-T007
nov	I-T007
.	I-T007
,	I-T007
sp	I-T007
.	I-T007
nov	I-T007
.	I-T007
is	O
proposed	O
.	O
The	O
type	O
strain	O
of	O
Ancylomarina	B-T007
subtilis	I-T007
is	O
FA102	B-T007
T	I-T007
(=	O
KCTC	B-T007
42257	I-T007
T	I-T007
=	O
DSM	B-T007
28825	I-T007
T	I-T007
=	O
CICC	B-T007
10902	I-T007
T	I-T007
)	O
.	O
Furthermore	O
,	O
a	O
new	O
order	O
named	O
Marinilabiliales	B-T007
is	O
proposed	O
to	O
accommodate	B-T033
three	O
families	O
previously	O
classified	O
in	O
the	O
order	O
Bacteroidales	B-T007
.	O
Marinilabiliales	B-T007
ord	I-T007
.	I-T007
nov	I-T007
.	I-T007
encompasses	O
the	O
families	O
Marinilabiliaceae	B-T007
,	O
Prolixibacteraceae	B-T007
and	O
Marinifilaceae	B-T007
.	O
      
Stepwise	O
cyclopropanation	O
on	O
the	O
polycyclopropanated	B-T121
polyketide	I-T121
formation	O
in	O
jawsamycin	B-T195
biosynthesis	O
Jawsamycin	B-T195
is	O
a	O
polyketide	B-T121
-	O
nucleoside	O
hybrid	O
with	O
a	O
unique	O
polycyclopropane	B-T121
moiety	O
on	O
a	O
single	O
polyketide	B-T121
chain	I-T121
.	O
The	O
unexpected	O
isolation	O
of	O
cyclopropane	B-T121
deficient	O
jawsamycin	B-T195
analogs	O
allowed	O
us	O
to	O
propose	O
a	O
stepwise	O
cyclopropanation	O
mechanism	O
for	O
the	O
enzymatic	O
synthesis	O
of	O
this	O
polyketide	B-T121
.	O
The	O
concise	O
timing	O
of	O
the	O
cyclopropanation	O
could	O
be	O
regulated	O
by	O
a	O
delicate	O
balance	O
between	O
reaction	O
rates	O
of	O
the	O
condensation	O
and	O
cyclopropanation	O
reactions	O
.	O
      
Liquid	B-T059
chromatography	I-T059
-	I-T059
tandem	I-T059
mass	I-T059
spectrometry	I-T059
quantification	O
of	O
acetamiprid	O
and	O
thiacloprid	B-T121
residues	O
in	O
butterbur	O
grown	O
under	O
regulated	O
conditions	O
An	O
analytical	O
method	O
was	O
developed	O
to	O
quantify	O
the	O
residual	O
levels	O
of	O
the	O
neonicotinoid	O
insecticides	O
,	O
acetamiprid	O
and	O
thiacloprid	B-T121
,	O
in	O
field	O
-	O
incurred	O
butterbur	O
samples	O
using	O
liquid	B-T059
chromatography	I-T059
-	I-T059
tandem	I-T059
mass	I-T059
spectrometry	I-T059
(	O
LC	B-T059
-	I-T059
MS	I-T059
/	I-T059
MS	I-T059
)	O
.	O
Samples	O
were	O
extracted	B-T059
with	O
acetonitrile	O
and	O
partitioned	O
with	O
dichloromethane	B-T121
.	O
After	O
partitioning	O
,	O
purification	O
was	O
conducted	O
using	O
a	O
Florisil	O
(	O
®	O
)	O
cartridge	O
.	O
Linearity	O
of	O
a	O
matrix	O
-	O
matched	O
calibration	O
curve	O
of	O
the	O
two	O
compounds	O
over	O
a	O
concentration	O
range	O
of	O
0.004	O
-	O
0.4μg	O
/	O
g	O
was	O
excellent	O
,	O
with	O
determination	O
coefficients	O
(	O
R(2))≥0.9998	O
.	O
The	O
limits	O
of	O
detection	O
(	O
LOD	O
)	O
and	O
quantitation	O
(	O
LOQ	O
)	O
for	O
both	O
acetamiprid	O
and	O
thiacloprid	B-T121
were	O
0.0006	O
and	O
0.002mg	O
/	O
kg	O
,	O
respectively	O
.	O
The	O
average	O
recoveries	O
for	O
acetamiprid	O
and	O
thiacloprid	B-T121
at	O
two	O
spiking	O
levels	O
(	O
0.02	O
and	O
0.1mg	O
/	O
kg	O
,	O
i.e.	O
,	O
10×	O
LOQ	O
and	O
50×	O
LOQ	O
)	O
were	O
between	O
78.23	O
to	O
82.17	O
%	O
,	O
with	O
relative	O
standard	O
deviations	O
(	O
RSDs)≤7.22	O
%	O
.	O
The	O
method	O
was	O
successfully	O
applied	O
to	O
field	O
-	O
incurred	O
samples	O
treated	O
with	O
a	O
commercial	O
pesticide	O
product	O
,	O
either	O
once	O
(	O
zero	O
or	O
7	O
days	O
before	O
harvest	O
)	O
or	O
twice	O
(	O
0	O
and	O
7	O
,	O
7	O
and	O
14	O
,	O
or	O
14	O
and	O
21	O
days	O
before	O
harvest	O
)	O
.	O
The	O
highest	O
and	O
lowest	O
residues	O
were	O
obtained	O
for	O
the	O
7	O
and	O
0	O
days	O
'	O
treatment	O
and	O
the	O
21	O
and	O
14	O
days	O
'	O
treatment	O
,	O
respectively	O
.	O
The	O
developed	O
method	O
is	O
simple	O
and	O
accurate	O
and	O
can	O
be	O
extrapolated	O
to	O
other	O
leafy	O
vegetables	O
.	O
      
Evaluation	O
of	O
the	O
relationship	O
between	O
the	O
static	O
measurement	O
of	O
transverse	O
arch	O
flexibility	O
of	O
the	O
forefoot	B-T023
and	O
gait	B-T033
parameters	O
in	O
healthy	O
subjects	O
[	O
Purpose	O
]	O
To	O
investigate	O
the	O
relationship	O
between	O
the	O
static	O
measurement	O
of	O
the	O
transverse	O
arch	O
of	O
the	O
forefoot	B-T023
,	O
using	O
a	O
3	O
-	O
dimensional	O
(	O
3D	O
)	O
foot	O
scanner	O
,	O
and	O
kinetics	O
and	O
kinematics	O
of	O
gait	B-T033
parameters	O
in	O
the	O
sagittal	O
plane	O
.	O
[	O
Subjects	O
and	O
Methods	O
]	O
Twenty	O
healthy	O
subjects	O
participated	O
in	O
this	O
study	O
.	O
The	O
transverse	O
arch	O
of	O
the	O
forefoot	B-T023
was	O
measured	O
under	O
three	O
conditions	O
as	O
follows	O
:	O
condition	O
1	O
,	O
sitting	B-T033
;	O
condition	O
2	O
,	O
standing	O
;	O
and	O
condition	O
3	O
,	O
foot	B-T023
forward	O
and	O
lower	B-T023
leg	I-T023
tilting	O
anteriorly	O
to	O
the	O
maximum	O
position	O
with	O
heel	O
contact	O
.	O
Gait	B-T033
parameters	O
were	O
recorded	O
using	O
a	O
3D	O
motion	O
analysis	O
system	O
and	O
force	O
plate	O
.	O
Correlation	O
coefficients	O
between	O
TAF	O
for	O
each	O
comparison	O
of	O
conditions	O
and	O
gait	B-T033
parameters	O
were	O
calculated	O
using	O
the	O
Spearman	O
correlation	O
analysis	O
.	O
[	O
Results	O
]	O
Rates	O
of	O
the	O
transverse	O
arch	O
of	O
the	O
forefoot	B-T023
width	O
and	O
height	O
between	O
condition	O
2	O
and	O
condition	O
3	O
were	O
significantly	O
correlated	O
with	O
the	O
anterior	O
and	O
posterior	O
component	O
of	O
ground	O
reaction	O
forces	O
,	O
the	O
hip	O
joint	O
extension	O
angle	O
,	O
and	O
the	O
ankle	O
plantar	O
flexion	O
moment	O
.	O
[	O
Conclusion	O
]	O
Our	O
study	O
's	O
findings	B-T033
indicated	B-T033
that	O
increased	O
stiffness	B-T184
of	O
the	O
transverse	O
arch	O
of	O
the	O
forefoot	B-T023
was	O
related	O
to	O
the	O
increase	O
in	O
ankle	O
plantar	O
moment	O
,	O
and	O
decreased	O
stiffness	B-T184
of	O
the	O
transverse	O
arch	O
of	O
the	O
forefoot	B-T023
was	O
related	O
to	O
the	O
increase	O
in	O
hip	O
joint	O
extension	O
angle	O
during	O
gait	B-T033
.	O
      
Initial	O
clinical	O
results	O
with	O
the	O
ThermoCool	O
®	O
SmartTouch	O
®	O
Surround	O
Flow	O
catheter	O
The	O
Biosense	O
Webster	O
ThermoCool	O
(	O
®	O
)	O
SmartTouch	O
(	O
®	O
)	O
Surround	O
Flow	O
(	O
STSF	O
)	O
catheter	O
is	O
a	O
recently	O
developed	O
ablation	B-T061
catheter	O
incorporating	O
Surround	O
Flow	O
(	O
SF	O
)	O
technology	O
to	O
ensure	O
efficient	O
cooling	O
and	O
force	O
sensing	O
to	O
quantify	O
tissue	O
contact	O
.	O
In	O
our	O
unit	O
,	O
it	O
superseded	O
the	O
ThermoCool	O
(	O
®	O
)	O
SF	O
catheter	O
from	O
the	O
time	O
of	O
its	O
introduction	O
in	O
May	O
2015	O
.	O
Procedure	B-T061
-related	O
data	O
were	O
collected	O
prospectively	O
for	O
the	O
first	O
100	O
ablation	B-T061
procedures	I-T061
performed	O
in	O
our	O
department	O
using	O
the	O
STSF	O
catheter	O
.	O
From	O
a	O
database	O
of	O
654	O
procedures	B-T061
performed	O
in	O
our	O
unit	O
using	O
the	O
SF	O
catheter	O
,	O
we	O
selected	O
one	O
to	O
match	O
each	O
STSF	B-T061
procedure	I-T061
,	O
matching	O
for	O
procedure	O
type	O
,	O
operator	O
experience	O
,	O
patient	O
age	O
,	O
and	O
gender	O
.	O
The	O
groups	O
were	O
well	O
matched	O
for	O
patient	O
age	O
,	O
gender	O
,	O
and	O
procedure	O
type	O
.	O
Procedure	O
duration	O
was	O
similar	O
in	O
both	O
groups	O
(	O
mean	O
225.5	O
vs.	O
221.4	O
min	O
,	O
IQR	O
106.5	O
vs.	O
91.5	O
,	O
P	O
=	O
0.55	O
)	O
,	O
but	O
fluoroscopy	O
duration	O
was	O
shorter	O
in	O
the	O
STSF	O
group	O
(	O
mean	O
25.8	O
vs.	O
30.0	O
,	O
IQR	O
19.6	O
vs.	O
18.5	O
,	O
P	O
=	O
0.03	O
)	O
.	O
No	B-T033
complication	I-T033
occurred	O
in	O
the	O
STSF	O
group	O
.	O
Complications	O
occurred	O
in	O
two	O
cases	O
in	O
the	O
SF	O
group	O
(	O
one	O
pericardial	B-T047
effusion	I-T047
requiring	O
drainage	B-T061
and	O
one	O
need	O
for	O
permanent	O
pacing	B-T061
)	O
.	O
Complete	B-T033
procedural	I-T033
success	I-T033
was	O
achieved	O
in	O
98	O
cases	O
in	O
the	O
STSF	O
group	O
and	O
94	O
cases	O
in	O
the	O
SF	O
group	O
(	O
P	O
=	O
0.15	O
)	O
.	O
The	O
composite	O
endpoint	O
of	O
procedure	O
failure	O
or	O
acute	O
complication	O
was	O
less	O
common	O
in	O
the	O
STSF	O
group	O
(	O
2	O
vs.	O
8	O
,	O
P	O
=	O
0.05	O
)	O
.	O
The	O
STSF	O
catheter	O
is	O
safe	O
and	O
effective	O
in	O
treating	O
a	O
range	O
of	O
arrhythmias	B-T033
.	O
Compared	O
with	O
the	O
SF	O
catheter	O
,	O
it	O
shows	O
a	O
trend	O
towards	O
improved	O
safety	O
-	O
efficacy	O
balance	O
.	O
      
Diagnosis	B-T033
of	O
retinal	B-T023
health	O
in	O
digital	B-T060
fundus	I-T060
images	I-T060
using	O
continuous	O
wavelet	O
transform	O
(	O
CWT	O
)	O
and	O
entropies	O
Vision	O
is	O
paramount	O
to	O
humans	O
to	O
lead	O
an	O
active	O
personal	O
and	O
professional	O
life	O
.	O
The	O
prevalence	O
of	O
ocular	B-T047
diseases	I-T047
is	O
rising	O
,	O
and	O
diseases	B-T047
such	O
as	O
glaucoma	B-T047
,	O
Diabetic	B-T047
Retinopathy	I-T047
(	O
DR	B-T047
)	O
and	O
Age	B-T047
-	I-T047
related	I-T047
Macular	I-T047
Degeneration	I-T047
(	O
AMD	B-T047
)	O
are	O
the	O
leading	O
causes	O
of	O
blindness	B-T033
in	O
developed	O
countries	O
.	O
Identifying	O
these	O
diseases	B-T047
in	O
mass	B-T058
screening	I-T058
programmes	I-T058
is	O
time	O
-	O
consuming	O
,	O
labor	O
-intensive	O
and	O
the	O
diagnosis	B-T033
can	O
be	O
subjective	O
.	O
The	O
use	O
of	O
an	O
automated	B-T060
computer	I-T060
aided	I-T060
diagnosis	I-T060
system	I-T060
will	O
reduce	O
the	O
time	O
taken	O
for	O
analysis	O
and	O
will	O
also	O
reduce	O
the	O
inter	O
-	O
observer	O
subjective	O
variabilities	O
in	O
image	B-T060
interpretation	I-T060
.	O
In	O
this	O
work	O
,	O
we	O
propose	O
one	O
such	O
system	O
for	O
the	O
automatic	O
classification	O
of	O
normal	O
from	O
abnormal	B-T033
(	O
DR	B-T047
,	O
AMD	B-T047
,	O
glaucoma	B-T047
)	O
images	O
.	O
We	O
had	O
a	O
total	O
of	O
404	O
normal	O
and	O
1082	O
abnormal	B-T033
fundus	B-T060
images	I-T060
in	O
our	O
database	O
.	O
As	O
the	O
first	O
step	O
,	O
2D	O
-	O
Continuous	O
Wavelet	O
Transform	O
(	O
CWT	O
)	O
decomposition	O
on	O
the	O
fundus	B-T060
images	I-T060
of	O
two	O
classes	O
was	O
performed	O
.	O
Subsequently	O
,	O
energy	O
features	O
and	O
various	O
entropies	O
namely	O
Yager	O
,	O
Renyi	O
,	O
Kapoor	O
,	O
Shannon	O
,	O
and	O
Fuzzy	O
were	O
extracted	O
from	O
the	O
decomposed	O
images	O
.	O
Then	O
,	O
adaptive	O
synthetic	O
sampling	O
approach	O
was	O
applied	O
to	O
balance	O
the	O
normal	O
and	O
abnormal	B-T033
datasets	O
.	O
Next	O
,	O
the	O
extracted	O
features	O
were	O
ranked	O
according	O
to	O
the	O
significances	O
using	O
Particle	O
Swarm	O
Optimization	O
(	O
PSO	O
)	O
.	O
Thereupon	O
,	O
the	O
ranked	O
and	O
selected	O
features	O
were	O
used	O
to	O
train	O
the	O
random	O
forest	O
classifier	O
using	O
stratified	O
10	O
-	O
fold	O
cross	O
validation	O
.	O
Overall	O
,	O
the	O
proposed	O
system	O
presented	O
a	O
performance	O
rate	O
of	O
92.48	O
%	O
,	O
and	O
a	O
sensitivity	O
and	O
specificity	O
of	O
89.37	O
%	O
and	O
95.58	O
%	O
respectively	O
using	O
15	O
features	O
.	O
This	O
novel	O
system	O
shows	O
promise	O
in	O
detecting	O
abnormal	B-T033
fundus	B-T060
images	I-T060
,	O
and	O
hence	O
,	O
could	O
be	O
a	O
valuable	O
adjunct	O
eye	B-T023
health	O
screening	B-T058
tool	I-T058
that	O
could	O
be	O
employed	O
in	O
polyclinics	O
,	O
and	O
thereby	O
reduce	O
the	O
workload	O
of	O
specialists	O
at	O
hospitals	O
.	O
      
Pre	O
-	O
hospital	O
policies	O
for	O
the	O
care	B-T058
of	I-T058
patients	I-T058
with	O
acute	B-T047
coronary	I-T047
syndromes	I-T047
in	O
India	O
:	O
A	O
policy	O
document	O
analysis	O
Ischemic	B-T184
heart	I-T184
disease	I-T184
is	O
the	O
leading	O
cause	B-T033
of	I-T033
death	I-T033
in	O
India	O
.	O
In	O
high	B-T033
-	I-T033
income	I-T033
countries	O
,	O
pre	B-T058
-	I-T058
hospital	I-T058
systems	I-T058
of	I-T058
care	I-T058
have	O
been	O
developed	O
to	O
manage	B-T058
acute	O
manifestations	O
of	O
ischemic	B-T184
heart	I-T184
disease	I-T184
,	O
such	O
as	O
acute	B-T047
coronary	I-T047
syndrome	I-T047
(	O
ACS	B-T047
)	O
.	O
However	O
,	O
it	O
is	O
unknown	O
whether	O
guidelines	O
,	O
policies	O
,	O
regulations	O
,	O
or	O
laws	O
exist	O
to	O
guide	O
pre	O
-	O
hospital	O
ACS	B-T047
care	B-T058
in	O
India	O
.	O
We	O
undertook	O
a	O
nation	O
-	O
wide	O
document	O
analysis	O
to	O
address	O
this	O
gap	O
in	O
knowledge	O
.	O
From	O
November	O
2014	O
to	O
May	O
2016	O
,	O
we	O
searched	O
for	O
publicly	O
available	O
emergency	B-T061
care	I-T061
guidelines	O
and	O
legislation	O
addressing	O
pre	O
-	O
hospital	O
ACS	B-T047
care	B-T058
in	O
all	O
29	O
Indian	O
states	O
and	O
7	O
Union	O
Territories	O
via	O
Internet	O
search	O
and	O
direct	O
correspondence	O
.	O
We	O
found	B-T033
two	O
documents	O
addressing	O
pre	O
-	O
hospital	O
ACS	B-T047
care	B-T058
.	O
Though	O
India	O
has	O
legislation	O
mandating	O
acute	B-T058
care	I-T058
for	O
emergencies	O
such	O
as	O
trauma	O
,	O
regulations	O
or	O
laws	O
to	O
guide	O
pre	O
-	O
hospital	O
ACS	B-T047
care	B-T058
are	O
largely	O
absent	O
.	O
Policy	O
makers	O
urgently	O
need	O
to	O
develop	O
comprehensive	O
,	O
multi	O
-	O
stakeholder	O
policies	O
for	O
pre	O
-	O
hospital	O
emergency	O
cardiovascular	B-T058
care	I-T058
in	O
India	O
.	O
      
Potential	O
drug	O
-	O
drug	O
interactions	O
among	O
prescriptions	B-T058
for	O
elderly	O
patients	O
in	O
primary	B-T058
health	I-T058
care	I-T058
Elderly	O
patients	O
are	O
at	O
high	B-T033
risk	I-T033
from	O
drug	O
-	O
drug	O
interactions	O
(	O
DDIs	O
)	O
.	O
This	O
study	O
evaluates	B-T058
the	O
potential	O
DDIs	O
in	O
Turkish	O
elderly	O
patients	O
at	O
a	O
primary	B-T058
health	I-T058
care	I-T058
outpatient	O
clinic	O
.	O
Online	O
database	O
systems	O
were	O
used	O
to	O
examine	O
DDIs	O
on	O
the	O
prescriptions	B-T058
of	O
patients	O
(	O
n	O
=	O
1206	O
)	O
.	O
The	O
clinical	B-T033
severity	I-T033
of	O
DDIs	O
was	O
classified	O
by	O
the	O
Lexi	O
-	O
Interact	O
Online	O
database	O
.	O
Of	O
the	O
5059	O
prescriptions	B-T058
,	O
33	O
%	O
were	O
found	O
to	O
have	O
DDIs	O
.	O
We	O
detected	B-T033
29	O
(	O
0.9	O
%	O
)	O
A	O
,	O
380	O
(	O
11.8	O
%	O
)	O
B	O
,	O
2494	O
(	O
77.7	O
%	O
)	O
C	O
,	O
289	O
(	O
9	O
%	O
)	O
D	O
,	O
and	O
18	O
(	O
0.6	O
%	O
)	O
X	O
risk	O
rating	O
category	O
DDIs	O
among	O
the	O
prescriptions	B-T058
.	O
Prescriptions	B-T058
of	O
female	O
patients	O
and	O
patients	O
aged	O
between	O
65	O
and	O
72	O
years	O
showed	O
significantly	O
higher	O
number	O
of	O
DDIs	O
.	O
The	O
frequency	O
of	O
DDIs	O
increased	O
both	O
with	O
the	O
number	O
of	O
drugs	B-T121
and	O
combined	O
preparations	O
per	O
prescription	B-T058
.	O
Acetylsalicylic	B-T121
acid	I-T121
and	O
salbutamol	B-T121
were	O
the	O
most	O
frequently	O
prescribed	B-T058
drugs	B-T121
contributing	O
to	O
clinically	B-T033
important	I-T033
DDIs	O
.	O
Additionally	O
,	O
acetylsalicylic	B-T121
acid	I-T121
and	O
escitalopram	B-T121
,	O
which	O
interact	O
with	O
each	O
other	O
,	O
were	O
found	O
on	O
the	O
list	O
of	O
Beers	O
criteria	O
.	O
The	O
most	O
predicted	B-T033
clinical	I-T033
outcomes	I-T033
of	O
DDIs	O
were	O
increase	O
in	O
therapeutic	O
efficacy	O
and	O
adverse	O
/	O
toxic	B-T033
reactions	I-T033
.	O
Conclusions	O
:	O
Prediction	O
of	O
DDIs	O
in	O
elderly	O
patients	O
will	O
provide	O
better	O
prescribing	B-T058
and	O
drug	O
safety	O
.	O
Use	O
of	O
nonsteroidal	B-T121
anti	I-T121
-	I-T121
inflammatory	I-T121
agents	I-T121
,	O
selective	B-T121
serotonin	I-T121
reuptake	I-T121
inhibitors	I-T121
,	O
and	O
beta-2	B-T121
adrenergic	I-T121
receptor	I-T121
agonists	I-T121
should	O
be	O
closely	O
monitored	O
.	O
      
Anatomical	O
subgroup	O
analysis	O
of	O
the	O
MERIDIAN	O
cohort	O
:	O
Posterior	B-T033
fossa	I-T033
abnormalities	I-T033
To	O
assess	B-T058
the	O
diagnostic	O
and	O
clinical	O
contribution	O
of	O
in	B-T060
utero	I-T060
magnetic	I-T060
resonance	I-T060
(	I-T060
iuMR	I-T060
)	I-T060
imaging	I-T060
in	O
fetuses	B-T018
diagnosed	B-T033
with	O
abnormalities	B-T033
of	I-T033
the	I-T033
posterior	I-T033
fossa	I-T033
as	O
the	O
only	O
intracranial	B-T033
abnormality	I-T033
recognised	O
on	O
antenatal	B-T060
ultrasonography	I-T060
(	O
USS	B-T060
)	O
.	O
We	O
report	O
a	O
sub	O
-	O
group	O
analysis	O
of	O
fetuses	B-T018
with	O
abnormalities	B-T033
of	I-T033
the	I-T033
posterior	I-T033
fossa	I-T033
diagnosed	B-T033
on	O
antenatal	B-T060
USS	I-T060
(	O
with	O
or	O
without	O
ventriculomegaly	O
)	O
from	O
the	O
MERIDIAN	O
cohort	O
who	O
had	O
iuMR	B-T060
imaging	I-T060
within	O
2	O
weeks	O
of	O
USS	B-T060
and	O
outcome	O
reference	O
data	O
were	O
available	O
.	O
The	O
diagnostic	O
accuracy	O
of	O
USS	B-T060
and	O
iuMR	B-T060
are	O
reported	O
as	O
well	O
as	O
indicators	O
of	O
diagnostic	O
confidence	O
and	O
effects	O
on	O
prognosis	B-T058
and	O
clinical	B-T058
management	I-T058
.	O
Abnormalities	B-T033
confined	I-T033
to	I-T033
the	I-T033
posterior	I-T033
fossa	I-T033
according	O
to	O
USS	B-T060
were	O
found	O
in	O
81	O
fetuses	B-T018
(	O
67	O
with	O
parenchymal	O
and	O
14	O
with	O
CSF	O
-containing	O
lesions	B-T033
)	O
.	O
The	O
overall	O
diagnostic	O
accuracy	O
for	O
detecting	B-T033
an	O
isolated	O
posterior	B-T033
fossa	I-T033
abnormality	I-T033
was	O
65	O
%	O
for	O
USS	B-T060
and	O
88	O
%	O
for	O
iuMR	B-T060
(	O
difference	O
=	O
22	O
%	O
,	O
95	O
%	O
CI	O
:	O
14.0	O
to	O
30.5	O
%	O
,	O
p	O
<	O
0.0001	O
)	O
.	O
There	O
was	O
an	O
improvement	O
in	O
'	O
appropriate	O
'	O
diagnostic	O
confidence	O
as	O
assessed	B-T058
by	O
a	O
score	O
-	O
based	O
weighted	O
average	O
'	O
method	O
(	O
p	O
<	O
0.0001	O
)	O
and	O
a	O
three	O
-	O
fold	O
reduction	B-T061
in	O
'	O
high	O
confidence	O
but	O
incorrect	O
diagnoses	B-T033
'	O
was	O
achieved	O
by	O
using	O
iuMR	B-T060
imaging	I-T060
.	O
The	O
prognostic	B-T058
information	I-T058
given	O
to	O
the	O
women	O
after	O
iuMR	B-T060
imaging	I-T060
changed	O
in	O
44	O
%	O
of	O
cases	O
and	O
the	O
overall	O
effect	O
of	O
iuMR	B-T060
on	O
clinical	B-T058
management	I-T058
was	O
considered	O
to	O
be	O
'	O
significant	O
'	O
,	O
'	O
major	O
'	O
or	O
'	O
decisive	B-T033
'	O
in	O
35	O
%	O
of	O
cases	O
.	O
Our	O
data	O
suggests	O
that	O
any	O
woman	O
whose	O
fetus	B-T018
has	O
a	O
posterior	B-T033
fossa	I-T033
abnormality	I-T033
as	O
the	O
only	O
intracranial	B-T033
finding	I-T033
on	O
USS	B-T060
should	O
have	O
iuMR	B-T060
imaging	I-T060
for	O
further	O
evaluation	B-T058
.	O
This	O
is	O
on	O
the	O
basis	O
of	O
improved	B-T033
diagnostic	O
accuracy	O
and	O
confidence	O
which	O
has	O
substantial	O
effects	O
on	O
the	O
prognostic	B-T058
information	I-T058
given	O
to	O
women	O
and	O
changes	O
in	O
clinical	B-T058
management	I-T058
.	O
      
Estradiol	B-T121
prodrugs	O
(	O
EP	O
)	O
for	O
efficient	O
oral	B-T061
estrogen	O
treatment	O
and	O
abolished	O
effects	O
on	O
estrogen	B-T121
modulated	O
liver	O
functions	O
Oral	B-T061
compared	O
to	O
parenteral	B-T061
estrogen	O
administration	O
is	O
characterized	O
by	O
reduced	O
systemic	O
but	O
prominent	O
hepatic	O
estrogenic	B-T033
effects	I-T033
on	O
lipids	O
,	O
hemostatic	O
factors	O
,	O
GH	B-T121
-/	O
IGF	O
I	O
axis	O
,	O
angiotensinogen	O
.	O
In	O
order	O
to	O
avoid	O
such	O
adverse	O
metabolic	O
effects	O
of	O
oral	B-T061
treatment	I-T061
,	O
estradiol	B-T121
(	O
E2	B-T121
)	O
prodrugs	O
(	O
EP	O
)	O
were	O
designed	O
which	O
bypass	O
the	O
liver	B-T023
tissue	I-T023
as	O
inactive	O
molecules	O
.	O
Carbone17	O
-	O
OH	O
sulfonamide	O
[	O
-O2	O
-	O
NH2	O
]	O
substituted	O
esters	O
of	O
E2	B-T121
(	O
EC508	B-T121
,	O
others	O
)	O
were	O
synthesized	O
and	O
tested	O
for	O
carbonic	O
anhydrase	O
II	O
(	O
CA	O
-	O
II	O
)	O
binding	O
.	O
CA	O
II	O
in	O
erythrocytes	O
is	O
thought	O
to	O
oppose	O
extraction	O
of	O
EP	O
from	O
portal	O
vein	O
blood	O
during	O
liver	B-T023
passage	O
.	O
Ovariectomized	B-T033
(	O
OVX	B-T033
,	O
day	O
minus	O
14	O
)	O
rats	O
were	O
orally	B-T061
treated	I-T061
once	O
daily	O
from	O
day	O
1	O
-	O
3	O
.	O
Sacrifice	O
day	O
4	O
.	O
Uteri	B-T023
were	O
dissected	O
and	O
weighed	B-T059
.	O
Cholesterol	B-T059
fractions	I-T059
and	O
angiotensinogen	B-T059
were	O
determined	O
in	O
plasma	O
.	O
Oral	B-T200
E2	I-T200
and	O
ethinyl	B-T121
estradiol	I-T121
(	O
EE	B-T121
)	O
generated	O
dose	O
related	O
uterine	B-T023
growth	O
and	O
important	O
hepatic	O
estrogenic	B-T033
effects	I-T033
.	O
EP	O
induced	O
uterine	O
growth	O
at	O
about	O
hundred	O
-	O
fold	O
lower	O
doses	O
.	O
This	O
was	O
possible	O
with	O
almost	O
absent	O
effects	O
on	O
plasma	O
cholesterol	O
or	O
angiotensinogen	O
.	O
Preliminary	O
pharmacokinetic	O
studies	O
with	O
EC508	B-T121
used	O
intravenous	O
and	O
oral	B-T061
administration	I-T061
in	O
male	O
rats	O
.	O
Resulting	O
blood	O
levels	O
revealed	O
complete	O
oral	B-T061
bioavailability	O
.	O
Further	O
high	O
blood	O
-	O
but	O
low	O
plasma	O
concentrations	O
indicated	O
erythrocyte	O
binding	O
of	O
EC508	B-T121
in	O
vivo	O
as	O
potential	O
mechanism	O
of	O
low	O
extraction	O
at	O
liver	B-T023
passage	O
.	O
Very	O
high	O
systemic	O
estrogenicity	B-T121
combined	O
with	O
markedly	O
lower	O
or	O
absent	O
adverse	O
hepatic	O
estrogenic	B-T033
effects	I-T033
is	O
evidence	O
for	O
a	O
systemic	O
release	O
of	O
E2	B-T121
from	O
sulfonamide	O
EP	O
.	O
In	O
conclusion	O
,	O
tested	O
oral	B-T061
EP	O
bypass	O
the	O
liver	B-T023
in	O
erythrocytes	O
furnishing	O
systemic	O
estradiol	B-T121
at	O
hydrolysis	O
.	O
This	O
mechanism	O
avoids	O
the	O
hepatic	O
estrogenic	O
impact	O
of	O
conventional	O
oral	B-T061
estrogen	B-T061
therapy	I-T061
.	O
      
Nutrient	B-T058
intake	I-T058
of	O
infants	O
and	O
toddlers	O
in	O
the	O
United	O
Arab	O
Emirates	O
:	O
the	O
Feeding	O
Infants	O
and	O
Toddlers	O
Study	O
This	O
descriptive	O
study	O
evaluated	O
the	O
nutrient	O
adequacy	O
of	O
the	O
diet	O
of	O
infants	O
(	O
aged	O
6	O
-	O
11.9	O
months	O
)	O
and	O
toddlers	O
(	O
aged	O
12	O
-	O
24	O
months	O
)	O
in	O
the	O
United	O
Arab	O
Emirates	O
.	O
A	O
random	O
sample	O
of	O
1000	O
infants	O
and	O
toddlers	O
was	O
recruited	O
from	O
2	O
cities	O
(	O
Al	O
Ain	O
and	O
Dubai	O
)	O
from	O
March	O
2011	O
to	O
February	O
2012	O
and	O
their	O
usual	O
nutrient	B-T058
intake	I-T058
was	O
determined	O
using	O
24	O
-	O
hour	O
recall	O
.	O
In	O
all	O
,	O
54.2	O
%	O
of	O
infants	O
and	O
25.2	O
%	O
of	O
toddlers	O
were	O
breastfeeding	O
.	O
Mean	O
energy	O
intake	O
of	O
infant	O
girls	O
in	O
Al	O
Ain	O
and	O
Dubai	O
was	O
747	O
(	O
SD	O
189	O
)	O
kcal	O
and	O
773	O
(	O
SD	O
215	O
)	O
kcal	O
respectively	O
and	O
810.5	O
(	O
SD	O
232.2	O
)	O
kcal	O
and	O
821.9	O
(	O
SD	O
262	O
)	O
kcal	O
for	O
boys	O
.	O
In	O
toddlers	O
,	O
mean	O
energy	O
intake	O
for	O
girls	O
in	O
Al	O
Ain	O
and	O
Dubai	O
was	O
1032.8	O
(	O
SD	O
252	O
)	O
kcal	O
and	O
1013	O
(	O
SD	O
339.1	O
)	O
kcal	O
respectively	O
and	O
1057.2	O
(	O
SD	O
201.8	O
)	O
kcal	O
and	O
1030.3	O
(	O
SD	O
341.7	O
)	O
kcal	O
for	O
boys	O
.	O
Iron	B-T033
intake	I-T033
was	O
low	O
in	O
both	O
groups	O
.	O
Mean	O
body	O
mass	O
index	O
and	O
body	O
weight	O
and	O
height	O
were	O
similar	O
to	O
World	O
Health	O
Organization	O
figures	O
but	O
significant	O
numbers	O
of	O
infants	O
and	O
toddlers	O
of	O
both	O
sexes	O
were	O
over	B-T184
-	O
or	O
underweight	B-T033
.	O
Although	O
mean	O
energy	O
and	O
macronutrient	O
intakes	B-T058
were	O
comparable	O
to	O
the	O
RDA	O
,	O
significant	O
numbers	O
were	O
over	B-T047
-	O
or	O
underfed	B-T047
.	O
      
Dobutamine	B-T060
Stress	I-T060
Echocardiography	I-T060
:	O
Impact	O
of	O
Abnormal	B-T033
Blood	O
Potassium	O
Levels	O
on	O
Cardiac	B-T033
Arrhythmias	I-T033
Guidelines	O
suggest	O
that	O
an	O
abnormal	B-T033
blood	O
potassium	O
level	O
is	O
a	O
relative	O
contraindication	O
to	O
performing	O
dobutamine	B-T060
stress	I-T060
echocardiography	I-T060
(	O
DSE	B-T060
)	O
.	O
However	O
,	O
this	O
has	O
not	O
been	O
previously	O
studied	O
.	O
We	O
reviewed	O
a	O
consecutive	O
series	O
of	O
patients	O
who	O
had	O
potassium	O
testing	O
within	O
48	O
hours	O
of	O
undergoing	O
DSE	B-T060
for	O
the	O
evaluation	B-T058
of	O
myocardial	B-T047
ischemia	I-T047
over	O
a	O
10-	O
year	O
period	O
(	O
N	O
=	O
13,198	O
)	O
.	O
Normal	O
potassium	O
range	O
in	O
our	O
laboratory	O
is	O
3.6	O
-	O
5.2	O
mmol	O
/	O
L.	O
Hemolyzed	B-T033
samples	I-T033
were	O
not	O
included	O
.	O
The	O
association	O
of	O
potassium	B-T033
levels	I-T033
with	O
the	O
development	O
of	O
supraventricular	O
and	O
ventricular	B-T047
arrhythmias	I-T047
was	O
assessed	O
.	O
The	O
incidence	O
of	O
clinically	O
significant	O
arrhythmias	B-T033
was	O
very	O
low	O
(	O
supraventricular	B-T047
tachycardia	I-T047
/	O
atrial	B-T047
fibrillation	I-T047
,	O
4.9	O
%	O
;	O
nonsustained	O
ventricular	O
tachycardia	O
,	O
2.9	O
%	O
;	O
sustained	B-T047
ventricular	I-T047
tachycardia	I-T047
or	O
ventricular	B-T047
fibrillation	I-T047
,	O
0.1	O
%	O
)	O
,	O
confirming	O
the	O
overall	O
safety	O
of	O
DSE	B-T060
.	O
Most	O
arrhythmias	B-T033
(	O
88	O
%	O
)	O
occurred	O
in	O
patients	O
with	O
normal	O
potassium	B-T033
levels	I-T033
,	O
and	O
arrhythmia	B-T033
rates	O
remained	O
low	O
in	O
patients	O
with	O
potassium	O
abnormalities	B-T033
.	O
Patients	O
with	O
hyperkalemia	B-T033
had	O
a	O
lower	O
risk	O
of	O
developing	O
mild	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
,	O
0.39	O
;	O
95	O
%	O
CI	O
,	O
0.22	O
-	O
0.71	O
)	O
and	O
severe	O
(	O
OR	O
,	O
0.13	O
;	O
95	O
%	O
CI	O
,	O
0.01	O
-	O
0.68	O
)	O
supraventricular	O
arrhythmias	O
as	O
well	O
as	O
mild	O
ventricular	B-T047
arrhythmias	I-T047
(	O
OR	O
,	O
0.58	O
;	O
95	O
%	O
CI	O
,	O
0.40	O
-	O
0.83	O
)	O
.	O
Even	O
though	O
events	O
were	O
rare	O
,	O
patients	O
with	O
severe	O
hypokalemia	B-T033
(	O
potassium	B-T033
levels	I-T033
≤	O
3.1	O
mmol	O
/	O
L	O
)	O
had	O
an	O
increased	O
risk	O
of	O
supraventricular	O
arrhythmia	O
and	O
ventricular	B-T047
ectopy	I-T047
.	O
DSE	B-T060
is	O
safe	O
even	O
in	O
the	O
setting	O
of	O
abnormalities	B-T033
in	O
blood	O
potassium	O
concentrations	O
,	O
and	O
hence	O
cancellation	O
of	O
DSE	B-T060
in	O
patients	O
with	O
potassium	O
abnormalities	B-T033
does	O
not	O
appear	O
warranted	O
.	O
Elevated	O
potassium	B-T033
levels	I-T033
are	O
associated	O
with	O
lower	O
rates	O
of	O
clinically	O
significant	O
supraventricular	O
and	O
ventricular	B-T047
arrhythmias	I-T047
.	O
While	O
remaining	O
at	O
relatively	O
low	O
risk	O
,	O
patients	O
with	O
very	O
low	O
potassium	B-T033
levels	I-T033
(	O
≤3.1	O
mmol	O
/	O
L	O
)	O
at	O
the	O
time	O
of	O
DSE	B-T060
have	O
a	O
modestly	O
increased	O
risk	O
of	O
arrhythmia	B-T033
.	O
Consideration	O
could	O
be	O
given	O
to	O
correcting	O
severe	O
hypokalemia	B-T033
prior	O
to	O
DSE	B-T060
.	O
      
Experimental	O
study	O
in	O
pulmonary	B-T023
artery	I-T023
sealing	B-T061
with	O
a	O
vessel	O
-	O
sealing	O
device	O
The	O
development	O
of	O
vessel	O
-	O
sealing	O
devices	O
will	O
facilitate	O
safety	O
in	O
video	B-T061
-	I-T061
assisted	I-T061
thoracoscopic	I-T061
surgery	I-T061
.	O
Our	O
objective	O
was	O
to	O
evaluate	O
the	O
feasibility	O
and	O
safety	O
of	O
sealing	B-T061
pulmonary	B-T023
arteries	I-T023
with	O
the	O
Enseal	O
tissue	O
-	O
sealing	O
device	O
.	O
Pulmonary	B-T023
arteries	I-T023
from	O
beagle	O
dogs	O
(	O
mean	O
body	O
weight	O
13.1	O
kg	O
,	O
range	O
10.5	O
-	O
15.4	O
kg	O
)	O
were	O
divided	O
into	O
3	O
groups	O
according	O
to	O
the	O
in	O
-	O
vivo	O
sealing	O
method	O
used	O
(	O
Enseal	O
,	O
ligation	B-T061
,	O
and	O
proximal	O
ligation	B-T061
plus	O
distal	O
Enseal	O
)	O
and	O
extracted	O
to	O
evaluate	O
the	O
pressure	O
tolerance	O
up	O
to	O
75	O
mm	O
Hg	O
at	O
the	O
sealed	O
end	O
.	O
A	O
left	O
lower	O
lobectomy	B-T061
was	O
performed	O
to	O
evaluate	O
chronic	O
-	O
phase	O
durability	O
of	O
the	O
sealed	O
stumps	O
in	O
a	O
survival	O
model	O
.	O
Two	O
or	O
three	O
branches	O
of	O
the	O
pulmonary	B-T023
arteries	I-T023
in	O
each	O
dog	O
were	O
allocated	O
to	O
each	O
of	O
the	O
3	O
groups	O
.	O
After	O
the	O
scheduled	O
survival	O
period	O
,	O
the	O
pulmonary	B-T023
arteries	I-T023
were	O
sampled	O
.	O
Pressure	O
tolerance	O
at	O
the	O
sealed	O
end	O
was	O
evaluated	O
in	O
91	O
pulmonary	B-T023
artery	I-T023
sections	O
.	O
All	O
sealed	O
ends	O
showed	O
pressure	O
tolerance	O
>	O
75	O
mm	O
Hg	O
.	O
A	O
left	O
lower	O
lobectomy	B-T061
was	O
performed	O
in	O
13	O
dogs	O
in	O
which	O
35	O
pulmonary	B-T023
artery	I-T023
sections	O
had	O
been	O
allocated	O
into	O
the	O
3	O
groups	O
.	O
No	B-T033
sealing	B-T061
failure	O
was	O
found	O
,	O
and	O
pathological	O
findings	B-T033
showed	O
healing	O
and	O
persistent	O
hemostasis	O
at	O
all	O
sealed	O
ends	O
of	O
the	O
pulmonary	B-T023
arteries	I-T023
after	O
2	O
and	O
4	O
weeks	O
of	O
the	O
survival	O
period	O
.	O
Pulmonary	B-T023
arteries	I-T023
sealed	O
in	O
vivo	O
with	O
the	O
Enseal	O
device	O
showed	O
pressure	O
tolerance	O
>	O
75	O
mm	O
Hg	O
in	O
the	O
acute	O
phase	O
,	O
and	O
persistent	O
hemostasis	O
after	O
2	O
or	O
4	O
weeks	O
.	O
Pulmonary	B-T023
artery	I-T023
sealing	B-T061
with	O
the	O
Enseal	O
device	O
is	O
feasible	O
and	O
safe	O
in	O
thoracic	B-T061
surgery	I-T061
settings	O
.	O
      
Anticholinergic	B-T121
premedication	B-T061
to	O
prevent	O
bradycardia	O
in	O
combined	O
spinal	B-T061
anesthesia	I-T061
and	O
dexmedetomidine	B-T121
sedation	B-T061
:	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
study	O
When	O
dexmedetomidine	B-T121
is	O
used	O
in	O
patients	O
undergoing	O
spinal	B-T061
anesthesia	I-T061
,	O
high	O
incidence	O
of	O
bradycardia	O
in	O
response	O
to	O
parasympathetic	O
activation	O
is	O
reported	O
.	O
Therefore	O
,	O
we	O
aimed	O
to	O
evaluate	O
the	O
effectiveness	O
of	O
atropine	B-T121
premedication	B-T061
for	O
preventing	O
the	O
incidence	O
of	O
bradycardia	O
and	O
the	O
hemodynamic	O
effect	O
on	O
patients	O
undergoing	O
spinal	B-T061
anesthesia	I-T061
with	O
sedation	B-T061
by	O
dexmedetomidine	B-T121
.	O
Randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
study	O
.	O
Operating	O
room	O
.	O
One	O
hundred	O
fourteen	O
patients	B-T121
(	O
age	O
range	O
,	O
2	O
-	O
65	O
years	O
;	O
American	O
Society	O
of	O
Anesthesiology	O
class	O
I	O
-	O
II	O
)	O
participated	O
in	O
this	O
study	O
,	O
willing	O
to	O
be	O
sedated	O
and	O
to	O
undergo	O
spinal	B-T061
anesthesia	I-T061
.	O
The	O
patients	B-T121
were	O
divided	O
into	O
2	O
groups	O
:	O
group	O
A	O
and	O
group	O
C.	O
After	O
performing	O
spinal	B-T061
anesthesia	I-T061
,	O
dexmedetomidine	B-T121
was	O
infused	B-T061
at	O
a	O
loading	O
dose	O
of	O
0.6	O
μg	O
/	O
kg	O
for	O
10	O
minutes	O
,	O
followed	O
by	O
an	O
infusion	B-T061
at	O
0.25	O
μg/(kg	O
h	O
)	O
.	O
Simultaneously	O
with	O
the	O
loading	O
dose	O
of	O
dexmedetomidine	B-T121
,	O
patients	B-T121
in	O
group	O
A	O
received	O
an	O
intravenous	O
bolus	O
of	O
0.5	O
mg	O
atropine	B-T121
,	O
whereas	O
patients	B-T121
in	O
group	O
C	O
received	O
an	O
intravenous	B-T061
normal	I-T061
saline	I-T061
bolus	B-T061
.	O
Data	O
on	O
administration	B-T061
of	O
atropine	B-T121
and	O
ephedrine	B-T121
were	O
collected	O
.	O
Hemodynamic	B-T059
data	O
including	O
heart	O
rate	O
,	O
systolic	O
blood	O
pressure	O
,	O
diastolic	O
blood	O
pressure	O
(	O
DBP	O
)	O
,	O
and	O
mean	B-T033
blood	I-T033
pressure	I-T033
(	O
MBP	B-T033
)	O
were	O
also	O
recorded	O
.	O
The	O
incidence	O
of	O
bradycardia	O
requiring	O
atropine	B-T121
treatment	B-T061
was	O
significantly	O
higher	O
in	O
group	O
C	O
than	O
group	O
A	O
(	O
P=.035	O
)	O
.	O
However	O
,	O
the	O
incidence	O
of	O
hypotension	B-T033
needing	O
ephedrine	B-T121
treatment	B-T061
showed	O
no	B-T033
significant	I-T033
difference	I-T033
between	O
the	O
2	O
groups	O
(	O
P=.7	O
)	O
.	O
Systolic	O
blood	O
pressure	O
and	O
heart	O
rate	O
showed	O
no	B-T033
significant	I-T033
differences	I-T033
between	O
the	O
2	O
groups	O
(	O
P=.138	O
and	O
.464	O
,	O
respectively	O
)	O
.	O
However	O
,	O
group	O
A	O
showed	O
significant	O
increases	O
in	O
DBP	O
and	O
MBP	B-T033
,	O
and	O
group	O
C	O
did	O
not	O
(	O
P=.014	O
and	O
.008	O
,	O
respectively	O
)	O
.	O
Prophylactic	B-T061
atropine	B-T121
reduces	O
the	O
incidence	O
of	O
bradycardia	O
in	O
patients	B-T121
undergoing	O
spinal	B-T061
anesthesia	I-T061
with	O
dexmedetomidine	B-T121
sedation	B-T061
.	O
However	O
,	O
DBP	O
and	O
MBP	B-T033
showed	O
significant	O
increases	O
in	O
patients	B-T121
when	O
prophylactic	B-T061
atropine	B-T121
was	O
administrated	B-T061
.	O
Therefore	O
,	O
atropine	B-T121
premedication	B-T061
should	O
be	O
administered	B-T061
cautiously	O
.	O
      
Changes	O
in	O
parenting	O
strategies	O
after	O
a	O
young	O
person	O
's	O
self	O
-	O
harm	O
:	O
a	O
qualitative	O
study	O
When	O
faced	O
with	O
the	O
discovery	O
of	O
their	O
child	O
's	O
self	O
-	O
harm	O
,	O
mothers	O
and	O
fathers	O
may	O
re	B-T058
-	I-T058
evaluate	I-T058
their	O
parenting	O
strategies	O
.	O
This	O
can	O
include	O
changes	O
to	O
the	O
amount	O
of	O
support	O
they	O
provide	O
their	O
child	O
and	O
changes	O
to	O
the	O
degree	O
to	O
which	O
they	O
control	O
and	O
monitor	O
their	O
child	O
.	O
We	O
conducted	O
an	O
in	O
-	O
depth	O
qualitative	O
study	O
with	O
37	O
parents	O
of	O
young	O
people	O
who	O
had	O
self	O
-	O
harmed	O
in	O
which	O
we	O
explored	O
how	O
and	O
why	O
their	O
parenting	O
changed	O
after	O
the	O
discovery	O
of	O
self	O
-	O
harm	O
.	O
Early	O
on	O
,	O
parents	O
often	O
found	O
themselves	O
"	O
walking	O
on	O
eggshells	O
"	O
so	O
as	O
not	O
to	O
upset	O
their	O
child	O
,	O
but	O
later	O
they	O
felt	O
more	O
able	O
to	O
take	O
some	O
control	O
.	O
Parents	O
'	O
reactions	O
to	O
the	O
self	O
-	O
harm	O
often	O
depended	O
on	O
how	O
they	O
conceptualised	O
it	O
:	O
as	O
part	O
of	O
adolescence	O
,	O
as	O
a	O
mental	B-T048
health	I-T048
issue	I-T048
or	O
as	O
"	O
naughty	O
behaviour	O
"	O
.	O
Parenting	O
of	O
other	O
children	O
in	O
the	O
family	O
could	O
also	O
be	O
affected	O
,	O
with	O
parents	O
worrying	O
about	O
less	O
of	O
their	O
time	O
being	O
available	O
for	O
siblings	O
.	O
Many	O
parents	O
developed	O
specific	O
strategies	O
they	O
felt	O
helped	O
them	O
to	O
be	O
more	O
effective	O
parents	O
,	O
such	O
as	O
learning	O
to	O
avoid	O
blaming	O
themselves	O
or	O
their	O
child	O
for	O
the	O
self	O
-	O
harm	O
and	O
developing	O
new	O
ways	O
to	O
communicate	B-T033
with	O
their	O
child	O
.	O
Parents	O
were	O
generally	O
eager	O
to	O
pass	O
their	O
knowledge	O
on	O
to	O
other	O
people	O
in	O
the	O
same	O
situation	O
.	O
Parents	O
reported	O
changes	O
in	O
their	O
parenting	O
behaviours	O
after	O
the	O
discovery	O
of	O
a	O
child	O
's	O
self	O
-	O
harm	O
.	O
Professionals	O
involved	O
in	O
the	O
care	O
of	O
young	O
people	O
who	O
self	O
-	O
harm	O
might	O
use	O
this	O
information	O
in	O
supporting	O
and	O
advising	O
parents	O
.	O
      
Fine	O
Mapping	O
of	O
Carbon	O
Assimilation	O
Rate	O
8	O
,	O
a	O
Quantitative	O
Trait	O
Locus	O
for	O
Flag	O
Leaf	O
Nitrogen	O
Content	O
,	O
Stomatal	O
Conductance	O
and	O
Photosynthesis	O
in	O
Rice	O
Increasing	O
the	O
rate	O
of	O
leaf	O
photosynthesis	O
is	O
one	O
important	O
approach	O
for	O
increasing	O
grain	O
yield	O
in	O
rice	O
(	O
Oryza	O
sativa	O
)	O
.	O
Exploiting	O
the	O
natural	O
variation	O
in	O
CO2	O
assimilation	O
rate	O
(	O
A	O
)	O
between	O
rice	O
cultivars	O
using	O
quantitative	O
genetics	O
is	O
one	O
promising	O
means	O
to	O
identify	O
genes	O
contributing	O
to	O
higher	O
photosynthesis	O
.	O
In	O
this	O
study	O
,	O
we	O
determined	O
precise	O
location	O
of	O
Carbon	O
Assimilation	O
Rate	O
8	O
(	O
CAR8	O
)	O
by	O
crossing	O
a	O
high	O
-	O
yielding	O
indica	O
cultivar	O
with	O
a	O
Japanese	O
commercial	O
cultivar	O
.	O
Fine	O
mapping	O
suggested	O
that	O
CAR8	O
encodes	O
a	O
putative	O
Heme	O
Activator	O
Protein	O
3	O
(	O
OsHAP3	O
)	O
subunit	O
of	O
a	O
CCAAT	O
-	O
box	O
-	O
binding	O
transcription	O
factor	O
called	O
OsHAP3H.	O
Sequencing	O
analysis	O
revealed	O
that	O
the	O
indica	O
allele	O
of	O
CAR8	O
has	O
a	O
1	O
-	O
bp	O
deletion	O
at	O
322	O
bp	O
from	O
the	O
start	O
codon	O
,	O
resulting	O
in	O
a	O
truncated	O
protein	O
of	O
125	O
amino	B-T121
acids	I-T121
.	O
In	O
addition	O
,	O
CAR8	O
is	O
identical	O
to	O
DTH8	O
/	O
Ghd8	O
/	O
LHD1	O
,	O
which	O
was	O
reported	O
to	O
control	O
rice	O
flowering	O
date	O
.	O
The	O
increase	O
of	O
A	O
is	O
largely	O
due	O
to	O
an	O
increase	O
of	O
RuBP	O
regeneration	O
rate	O
via	O
increased	O
leaf	O
nitrogen	O
content	O
,	O
and	O
partially	O
explained	O
by	O
reduced	O
stomatal	O
limitation	O
via	O
increased	O
stomatal	O
conductance	O
relative	O
to	O
A.	O
This	O
allele	O
also	O
increases	O
hydraulic	O
conductivity	O
,	O
which	O
would	O
promote	O
higher	O
stomatal	O
conductance	O
.	O
This	O
indicates	O
that	O
CAR8	O
affects	O
multiple	O
physiological	O
aspects	O
relating	O
to	O
photosynthesis	O
.	O
The	O
detailed	O
analysis	O
of	O
molecular	O
functions	O
of	O
CAR8	O
would	O
help	O
to	O
understand	O
the	O
association	O
between	O
photosynthesis	O
and	O
flowering	O
and	O
demonstrate	O
specific	O
genetic	O
mechanisms	O
that	O
can	O
be	O
exploited	O
to	O
improve	B-T033
photosynthesis	O
in	O
rice	O
and	O
potentially	O
other	O
crops	O
.	O
      
Associations	O
of	O
Body	O
Mass	O
Index	O
and	O
Physical	O
Activity	O
With	O
Sexual	B-T047
Dysfunction	I-T047
in	O
Breast	B-T191
Cancer	I-T191
Survivors	O
Sexual	B-T047
dysfunction	I-T047
is	O
a	O
common	O
and	O
distressing	B-T033
consequence	O
of	O
breast	B-T191
cancer	I-T191
(	O
BC	B-T191
)	O
treatment	B-T061
.	O
In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
sexual	O
functioning	O
of	O
BC	B-T191
patients	O
and	O
its	O
association	O
with	O
women	O
's	O
personal	O
characteristics	O
and	O
cancer	B-T061
treatments	I-T061
.	O
In	O
this	O
cross	O
-	O
sectional	O
study	O
,	O
sexual	O
function	O
was	O
assessed	O
using	O
the	O
Female	O
Sexual	O
Function	O
Index	O
(	O
FSFI	O
)	O
.	O
The	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O
HRQOL	O
)	O
was	O
measured	O
using	O
the	O
European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
(	O
EORTC	O
)	O
QLQ	O
-	O
C30	O
and	O
its	O
breast	O
module	O
BR-23	O
.	O
Of	O
the	O
235	O
participants	O
approached	O
,	O
216	O
participants	O
were	O
included	O
in	O
the	O
study	O
.	O
Of	O
these	O
,	O
63	O
patients	O
reported	O
no	B-T033
sexual	I-T033
activity	I-T033
in	O
the	O
last	O
month	O
and	O
thus	O
were	O
analyzed	O
only	O
in	O
relation	O
to	O
the	O
sexual	O
desire	O
domain	O
of	O
FSFI	O
.	O
A	O
total	O
of	O
154	O
(	O
71.3	O
%	O
)	O
patients	O
were	O
classified	O
with	O
hypoactive	B-T048
sexual	I-T048
desire	I-T048
disorder	I-T048
(	O
HSDD	B-T048
)	O
.	O
From	O
those	O
patients	O
reporting	O
sexual	O
activity	O
in	O
the	O
last	O
month	O
,	O
63.3	O
%	O
(	O
97	O
out	O
of	O
153	O
)	O
were	O
classified	O
with	O
sexual	B-T047
dysfunction	I-T047
.	O
Using	O
hierarchical	O
logistic	O
regression	O
,	O
the	O
variance	O
explained	O
(	O
change	O
in	O
R	O
(	O
2	O
)	O
)	O
by	O
the	O
addition	O
of	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
and	O
mild	O
to	O
moderate	O
physical	O
activity	O
in	O
the	O
prediction	O
models	O
of	O
sexual	B-T047
dysfunction	I-T047
and	O
HSDD	B-T048
were	O
6.8	O
and	O
7.2	O
%	O
,	O
respectively	O
.	O
Age	O
,	O
BMI	O
,	O
and	O
physical	O
activity	O
were	O
independently	O
associated	O
with	O
sexual	B-T047
dysfunction	I-T047
and	O
HSDD	B-T048
.	O
Additionally	O
,	O
BC	B-T191
patients	O
with	O
sexual	B-T047
dysfunction	I-T047
reported	O
lower	O
scores	O
on	O
global	O
HRQOL	O
,	O
role	O
functioning	O
,	O
and	O
fatigue	B-T184
.	O
Based	O
on	O
our	O
findings	B-T033
,	O
BC	B-T191
survivors	O
should	O
be	O
encouraged	O
to	O
practice	O
regular	O
physical	O
activity	O
and	O
to	O
lose	O
weight	O
in	O
order	O
to	O
avoid	O
sexual	B-T047
dysfunction	I-T047
.	O
However	O
,	O
future	O
clinical	O
trials	O
are	O
needed	O
to	O
confirm	O
these	O
findings	B-T033
.	O
      
Comparison	O
of	O
alkaline	O
phosphatase	O
activity	O
of	O
MC3T3	O
-	O
E1	O
cells	O
cultured	O
on	O
different	O
Ti	O
surfaces	O
:	O
modified	O
sandblasted	O
with	O
large	O
grit	O
and	O
acid	O
-	O
etched	O
(	O
MSLA	O
)	O
,	O
laser	O
-	O
treated	O
,	O
and	O
laser	O
and	O
acid	O
-	O
treated	O
Ti	O
surfaces	O
In	O
this	O
study	O
,	O
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	B-T058
the	O
effect	O
of	O
implant	O
surface	O
treatment	O
on	O
cell	O
differentiation	O
of	O
osteoblast	O
cells	O
.	O
For	O
this	O
purpose	O
,	O
three	O
surfaces	O
were	O
compared	O
:	O
(	O
1	O
)	O
a	O
modified	O
SLA	O
(	O
MSLA	O
:	O
sand	O
-	O
blasted	O
with	O
large	O
grit	O
,	O
acid	O
-	O
etched	O
,	O
and	O
immersed	O
in	O
0.9	O
%	O
NaCl	B-T121
)	O
,	O
(	O
2	O
)	O
a	O
laser	O
treatment	O
(	O
LT	O
:	O
laser	O
treatment	O
)	O
titanium	O
surface	O
and	O
(	O
3	O
)	O
a	O
laser	O
and	O
acid	O
-	O
treated	O
(	O
LAT	O
:	O
laser	O
treatment	O
,	O
acid	O
-	O
etched	O
)	O
titanium	O
surface	O
.	O
The	O
MSLA	O
surfaces	O
were	O
considered	O
as	O
the	O
control	O
group	O
,	O
and	O
LT	O
and	O
LAT	O
surfaces	O
as	O
test	O
groups	O
.	O
Alkaline	O
phosphatase	O
expression	O
(	O
ALP	O
)	O
was	O
used	O
to	O
quantify	O
osteoblastic	O
differentiation	O
of	O
MC3T3	O
-	O
E1	O
cell	O
.	O
Surface	O
roughness	O
was	O
evaluated	B-T058
by	O
a	O
contact	O
profilometer	O
(	O
URFPAK	O
-	O
SV	O
;	O
Mitutoyo	O
,	O
Kawasaki	O
,	O
Japan	O
)	O
and	O
characterized	O
by	O
two	O
parameters	O
:	O
mean	O
roughness	O
(	O
Ra	O
)	O
and	O
maximum	O
peak	O
-	O
to	O
-	O
valley	O
height	O
(	O
Rt	O
)	O
.	O
Scanning	O
electron	O
microscope	O
revealed	O
that	O
MSLA	O
(	O
control	O
group	O
)	O
surface	O
was	O
not	O
as	O
rough	O
as	O
LT	O
,	O
LAT	O
surface	O
(	O
test	O
groups	O
)	O
.	O
Alkaline	O
phosphatase	O
expression	O
,	O
the	O
measure	O
of	O
osteoblastic	O
differentiation	O
,	O
and	O
total	O
ALP	O
expression	O
by	O
surface	O
-	O
adherent	O
cells	O
were	O
found	O
to	O
be	O
highest	O
at	O
21	O
days	O
for	O
all	O
three	O
surfaces	O
tested	O
(	O
P<.05	O
)	O
.	O
Furthermore	O
,	O
ALP	O
expression	O
levels	O
of	O
MSLA	O
and	O
LAT	O
surfaces	O
were	O
significantly	O
higher	O
than	O
expression	O
levels	O
of	O
LT	O
surface	O
-	O
adherent	O
cells	O
at	O
7	O
,	O
14	O
,	O
and	O
21	O
days	O
,	O
respectively	O
(	O
P<.05	O
)	O
.	O
However	O
,	O
ALP	O
expression	O
levels	O
between	O
MSLA	O
and	O
LAT	O
surface	O
were	O
equal	O
at	O
7	O
,	O
14	O
,	O
and	O
21	O
days	O
(	O
P>.05	O
)	O
.	O
This	O
study	O
suggested	O
that	O
MSLA	O
and	O
LAT	O
surfaces	O
exhibited	O
more	O
favorable	O
environment	O
for	O
osteoblast	O
differentiation	O
when	O
compared	O
with	O
LT	O
surface	O
,	O
the	O
results	O
that	O
are	O
important	O
for	O
implant	O
surface	O
modification	O
studies	O
.	O
      
Alanine	O
to	O
Serine	B-T121
Variant	O
at	O
Position	O
986	O
of	O
Calcium	O
Sensing	O
Receptor	O
and	O
Colorectal	B-T191
Cancer	I-T191
Risk	O
With	O
regard	O
to	O
the	O
effect	O
of	O
calcium	B-T121
against	O
colorectal	B-T191
cancer	I-T191
(	O
CRC	B-T191
)	O
and	O
considering	O
the	O
key	O
role	O
of	O
calcium	O
sensing	O
receptor	O
(	O
CaSR	O
)	O
in	O
calcium	B-T121
homeostasis	I-T121
,	O
this	O
study	O
investigated	O
whether	O
CaSR	O
gene	O
rs1801725	O
or	O
A986S	O
variant	O
was	O
associated	O
with	O
susceptibility	O
to	O
CRC	B-T191
risk	O
.	O
This	O
study	O
was	O
conducted	O
as	O
a	O
case	O
-	O
control	O
study	O
and	O
303	O
cases	O
with	O
CRC	B-T191
and	O
354	O
controls	O
were	O
enrolled	O
.	O
All	O
657	O
subjects	O
were	O
genotyped	O
for	O
CaSR	O
gene	O
A986S	O
variant	O
using	O
PCR	O
-	O
RFLP	B-T059
method	I-T059
.	O
No	B-T033
significant	I-T033
difference	O
was	O
observed	O
for	O
the	O
A986S	O
variant	O
of	O
CaSR	O
gene	O
in	O
either	O
genotype	O
or	O
allele	O
frequencies	O
between	O
the	O
cases	O
and	O
the	O
controls	O
and	O
this	O
lack	O
of	O
difference	O
remained	O
non	O
-	O
significant	O
even	O
after	O
adjustment	O
for	O
age	O
,	O
BMI	O
,	O
sex	O
,	O
smoking	O
status	O
,	O
and	O
family	B-T033
history	I-T033
of	O
CRC	B-T191
.	O
No	O
evidence	O
for	O
the	O
effect	O
modification	B-T033
of	O
the	O
association	O
A986S	O
variant	O
and	O
CRC	B-T191
by	O
BMI	O
,	O
sex	O
,	O
or	O
tumor	O
site	O
was	O
also	O
observed	O
.	O
Furthermore	O
,	O
the	O
risk	O
of	O
obesity	B-T047
in	O
relation	O
to	O
the	O
A986S	O
variant	O
in	O
the	O
controls	O
and	O
the	O
cases	O
was	O
separately	O
analyzed	O
and	O
we	O
observed	O
no	B-T033
significant	I-T033
difference	I-T033
between	O
normal	B-T033
weight	I-T033
(	O
BMI	O
<	O
25kg	O
/	O
m(2	O
)	O
)	O
and	O
overweight	B-T184
/	O
obese	B-T047
(	O
BMI	O
≥	O
25kg	O
/	O
m(2	O
)	O
)	O
subjects	O
.	O
Our	O
findings	B-T033
do	O
not	O
support	O
a	O
role	O
for	O
effect	O
of	O
the	O
CaSR	O
gene	O
A986S	O
variant	O
on	O
CRC	B-T191
risk	O
;	O
nevertheless	O
,	O
this	O
finding	B-T033
requires	O
confirmation	B-T033
and	O
the	O
role	O
of	O
the	O
gene	O
variant	O
in	O
carcinogenesis	B-T191
needs	O
to	O
be	O
further	O
investigated	O
.	O
      
Biogeography	O
and	O
Character	O
Evolution	O
of	O
the	O
Ciliate	O
Genus	O
Euplotes	O
(	O
Spirotrichea	O
,	O
Euplotia	O
)	O
,	O
with	O
Description	O
of	O
Euplotes	O
curdsi	O
sp	O
.	O
nov	O
Ciliates	O
comprise	O
a	O
diverse	O
and	O
ecologically	O
important	O
phylum	O
of	O
unicellular	B-T001
protists	I-T001
.	O
One	O
of	O
the	O
most	O
specious	O
and	O
best	O
-	O
defined	O
genera	O
is	O
Euplotes	O
,	O
which	O
constitutes	O
more	O
than	O
70	O
morphospecies	O
,	O
many	O
of	O
which	O
have	O
never	O
been	O
molecularly	O
tested	O
.	O
The	O
increasing	O
number	O
of	O
described	O
Euplotes	O
taxa	O
emphasizes	O
the	O
importance	O
for	O
detailed	O
characterizations	O
of	O
new	O
ones	O
,	O
requiring	O
standardized	O
morphological	O
observations	O
,	O
sequencing	O
of	O
molecular	O
markers	O
and	O
careful	O
comparison	O
with	O
previous	O
literature	O
.	O
Here	O
we	O
describe	O
Euplotes	O
curdsi	O
sp	O
.	O
nov	O
.	O
,	O
distinguishable	O
by	O
the	O
combination	O
of	O
the	O
following	O
features	O
:	O
45	O
-	O
65	O
μm	O
length	O
,	O
oval	O
or	O
elongated	O
shape	O
with	O
both	O
ends	O
rounded	O
,	O
narrow	O
peristome	O
with	O
25	O
-	O
34	O
adoral	O
membranelles	O
,	O
conspicuous	O
paroral	O
membrane	O
,	O
double	O
-	O
eurystomus	O
dorsal	O
argyrome	O
type	O
,	O
6	O
-	O
7	O
dorsolateral	O
kineties	O
and	O
10	O
frontoventral	O
cirri	O
.	O
Three	O
populations	O
of	O
the	O
novel	O
species	O
have	O
been	O
found	O
in	O
brackish	O
and	O
marine	O
samples	O
in	O
the	O
Mediterranean	O
and	O
the	O
White	O
Sea	O
.	O
We	O
provide	O
the	O
SSU	O
rRNA	O
gene	O
sequences	O
of	O
these	O
populations	O
,	O
and	O
an	O
updated	O
phylogeny	O
of	O
the	O
genus	O
Euplotes	O
.	O
Using	O
the	O
molecular	O
phylogenetic	O
tree	O
,	O
we	O
inferred	O
aspects	O
of	O
the	O
biogeographical	O
history	O
of	O
the	O
genus	O
and	O
the	O
evolution	O
of	O
its	O
most	O
important	O
taxonomic	O
characters	O
in	O
order	O
to	O
provide	O
a	O
frame	O
for	O
future	O
descriptions	O
.	O
Ultimately	O
,	O
these	O
data	O
reveal	O
recurrent	O
trends	O
of	O
freshwater	O
invasion	O
and	O
highlight	O
the	O
dynamic	O
,	O
yet	O
convergent	O
,	O
morphological	O
evolution	O
of	O
Euplotes	O
.	O
      
Progressive	O
subcortical	O
calcifications	O
secondary	O
to	O
venous	B-T047
hypertension	I-T047
in	O
an	O
intracranial	O
dural	B-T190
arteriovenous	I-T190
fistula	I-T190
Intracranial	O
dural	B-T190
arteriovenous	I-T190
fistulas	I-T190
(	O
dAVF	B-T190
)	O
are	O
acquired	B-T033
lesions	I-T033
,	O
with	O
the	O
most	O
commonly	O
reported	B-T058
findings	B-T033
on	O
CT	B-T060
haemorrhage	O
or	O
focal	O
oedema	O
.	O
We	O
describe	O
a	O
case	O
of	O
progressive	O
subcortical	O
calcification	O
on	O
CT	B-T060
secondary	O
to	O
venous	B-T047
hypertension	I-T047
from	O
a	O
high	O
grade	O
dAVF	B-T190
.	O
      
pH	O
-Dependent	O
Transmembrane	O
Activity	O
of	O
Peptide	O
-Functionalized	O
Gold	B-T121
Nanostars	I-T121
for	O
Computed	B-T060
Tomography	I-T060
/	O
Photoacoustic	B-T060
Imaging	I-T060
and	O
Photothermal	B-T061
Therapy	I-T061
Progress	O
in	O
multifunctional	O
nanomaterials	O
for	O
tumor	B-T061
therapy	I-T061
mostly	O
depends	O
on	O
the	O
development	O
of	O
tumor	B-T191
-	O
targeting	O
delivery	B-T061
strategies	I-T061
.	O
One	O
approach	O
is	O
to	O
explore	O
a	O
pH	O
-responsive	O
strategy	O
to	O
target	O
the	O
slightly	O
acidic	O
solid	O
tumor	O
microenvironment	O
.	O
A	O
novel	O
class	O
of	O
pH	O
(	O
low	O
)	O
insertion	O
peptides	O
(	O
pHLIPs	O
)	O
with	O
pH	O
-dependent	O
transmembrane	O
activity	O
can	O
fold	O
and	O
rapidly	O
insert	O
into	O
the	O
lipid	O
bilayer	O
of	O
tumor	O
cells	O
triggered	O
by	O
acidity	O
,	O
facilitating	O
the	O
cellular	O
internalization	O
of	O
nanomaterials	O
synchronously	O
.	O
Here	O
,	O
we	O
innovatively	O
decorated	O
gold	B-T121
nanostars	I-T121
(	O
GNSs	B-T121
)	O
with	O
pHLIPs	O
(	O
GNS	B-T121
-	O
pHLIP	O
)	O
to	O
improve	O
their	O
targeting	O
ability	O
and	O
photothermal	B-T061
therapeutic	I-T061
(	O
PTT	B-T061
)	O
efficiency	O
.	O
The	O
obtained	O
GNS	B-T121
-	O
pHLIP	O
exhibited	O
the	O
excellent	O
characteristics	O
of	O
uniform	O
size	O
and	O
good	O
biocompatibility	O
.	O
As	O
compared	O
to	O
GNS	B-T121
-	O
mPEG	O
,	O
the	O
cellular	O
internalization	O
of	O
GNS	B-T121
-	O
pHLIP	O
was	O
1	O
-	O
fold	O
higher	O
after	O
a	O
2	O
h	O
incubation	O
with	O
cells	O
in	O
media	O
at	O
pH	O
6.4	O
than	O
at	O
pH	O
7.4	O
.	O
Moreover	O
,	O
the	O
tumor	B-T191
accumulation	B-T033
of	O
the	O
GNS	B-T121
-	O
pHLIP	O
was	O
3	O
-	O
fold	O
higher	O
than	O
that	O
of	O
GNS	B-T121
-	O
mPEG	O
after	O
intravenous	O
injection	O
into	O
MCF-7	O
breast	B-T191
tumor	I-T191
animal	B-T050
models	I-T050
for	O
24	O
h.	O
Furthermore	O
,	O
GNS	B-T121
-	O
pHLIP	O
exhibited	O
stronger	O
signals	O
than	O
the	O
GNS	B-T121
-	O
mPEG	O
through	O
computed	B-T060
tomography	I-T060
(	O
CT	B-T060
)	O
and	O
photoacoustic	B-T060
(	I-T060
PA	I-T060
)	I-T060
imaging	I-T060
.	O
Simultaneously	O
,	O
the	O
desirable	O
targeting	O
efficiency	O
significantly	O
improved	O
the	O
PTT	B-T061
efficacy	O
to	O
tumors	B-T191
,	O
with	O
low	O
side	O
effects	O
on	O
normal	O
tissues	O
.	O
The	O
results	O
clearly	O
demonstrate	O
that	O
the	O
GNS	B-T121
-	O
pHLIP	O
successfully	O
took	O
advantage	O
of	O
the	O
tumor	B-T191
-	O
targeting	O
ability	O
of	O
pHLIPs	O
and	O
the	O
good	O
characteristics	O
of	O
GNS	B-T121
GNS	B-T121
s	I-T121
,	O
which	O
may	O
contribute	O
to	O
the	O
study	O
of	O
tumor	B-T191
imaging	B-T060
and	O
therapy	B-T061
.	O
      
Retirement	B-T033
crisis	B-T033
warnings	O
becoming	O
a	O
reality	O
The	O
figures	O
are	O
startling	B-T033
:	O
the	O
number	O
of	O
NHS	O
staff	O
applying	O
to	O
retire	B-T033
has	O
surged	O
by	O
a	O
quarter	O
since	O
2012	O
.	O
The	O
potential	O
consequences	O
are	O
alarming	O
;	O
a	O
serious	O
shortage	O
of	O
nurses	O
and	O
other	O
healthcare	O
professionals	O
now	O
seems	O
inevitable	O
.	O
      
Parallel	O
-	O
processing	O
continuous	O
-	O
flow	O
device	O
for	O
optimization	O
-	O
free	O
polymerase	O
chain	O
reaction	O
A	O
parallel	O
-	O
processing	O
four	O
-	O
station	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
device	O
has	O
been	O
developed	O
,	O
which	O
performs	O
continuous	O
-	O
flow	O
PCR	O
without	O
optimization	O
of	O
the	O
annealing	O
temperature	O
.	O
Since	O
the	O
annealing	O
temperature	O
of	O
each	O
station	O
can	O
be	O
controlled	O
independently	O
,	O
the	O
device	O
covers	O
an	O
annealing	O
temperature	O
range	O
of	O
50	O
-	O
68	O
°	O
C	O
,	O
which	O
is	O
wide	O
enough	O
to	O
perform	O
PCR	O
for	O
any	O
DNA	O
fragment	O
regardless	O
of	O
its	O
optimum	O
annealing	O
condition	O
.	O
This	O
arrangement	O
lets	O
us	O
continuously	O
obtain	O
an	O
amplified	O
amount	O
of	O
a	O
DNA	O
fragment	O
at	O
least	O
from	O
one	O
of	O
the	O
stations	O
.	O
The	O
device	O
consists	O
of	O
four	O
identical	O
cylindrical	O
stations	O
(	O
diameter	O
20	O
mm	O
,	O
height	O
55	O
mm	O
)	O
.	O
A	O
polytetrafluoroethylene	O
capillary	O
reactor	O
(	O
length	O
2	O
m	O
,	O
I.D.	O
100	O
μm	O
,	O
O.D.	O
400	O
μm	O
)	O
is	O
wound	O
helically	O
up	O
around	O
each	O
station	O
.	O
The	O
whole	O
assembly	O
is	O
designed	O
to	O
minimize	O
the	O
number	O
of	O
heating	O
blocks	O
(	O
for	O
providing	O
temperatures	O
of	O
denaturation	O
,	O
annealing	O
,	O
and	O
extension	O
)	O
to	O
be	O
seven	O
and	O
to	O
shape	O
a	O
compact	B-T033
cube	O
(	O
height	O
55	O
mm	O
,	O
base	O
60	O
mm	O
×	O
60	O
mm	O
)	O
.	O
The	O
reproducibility	O
for	O
continuous	O
-	O
flow	O
PCR	O
is	O
reasonably	O
high	O
(	O
run	O
-to-	O
run	O
and	O
station	O
-to-	O
station	O
relative	O
standard	O
deviation	O
of	O
their	O
amplification	O
is	O
lower	O
than	O
6	O
%	O
and	O
about	O
4	O
%	O
,	O
respectively	O
)	O
.	O
Performance	O
on	O
the	O
optimization	O
-	O
free	O
DNA	O
amplification	O
has	O
been	O
evaluated	B-T058
with	O
four	O
DNA	O
samples	O
with	O
different	O
annealing	O
conditions	O
and	O
product	O
sizes	O
(	O
323	O
,	O
608	O
,	O
828	O
,	O
and	O
1101	O
bp	O
)	O
,	O
which	O
has	O
demonstrated	O
that	O
in	O
all	O
cases	O
,	O
PCR	O
is	O
successful	O
at	O
least	O
on	O
one	O
station	O
.	O
In	O
addition	O
,	O
three	O
DNA	O
fragment	O
s	O
with	O
different	O
lengths	O
(	O
323	O
,	O
1101	O
,	O
and	O
2836	O
bp	O
)	O
have	O
been	O
successfully	O
amplified	O
in	O
a	O
segmented	O
-	O
flow	O
mode	O
without	O
the	O
carry	O
-	O
over	O
contamination	O
between	O
segments	O
.	O
This	O
result	O
suggests	O
that	O
this	O
device	O
could	O
serve	O
as	O
the	O
PCR	O
module	O
of	O
a	O
continuous	O
-	O
flow	O
high	B-T060
-	I-T060
throughput	I-T060
on	I-T060
-	I-T060
line	I-T060
total	I-T060
DNA	I-T060
analysis	I-T060
system	O
integrating	O
all	O
necessary	O
modules	O
from	O
cell	O
lysis	O
/	O
DNA	O
extraction	O
to	O
PCR	O
product	O
analysis	O
.	O
      
A	O
Fast	O
Peak	O
-	O
Searching	O
Algorithm	O
for	O
Ultrasonic	B-T060
Elastography	I-T060
Tissue	B-T060
axial	I-T060
strain	I-T060
estimation	I-T060
with	I-T060
ultrasound	I-T060
elastography	I-T060
has	O
become	O
a	O
hot	O
field	O
in	O
recent	O
years	O
.	O
However	O
,	O
for	O
keypoints	O
tracking	O
-	O
based	O
elastography	O
algorithms	O
,	O
locating	B-T033
extrema	O
in	O
multimodal	O
ultrasonic	O
radiofrequency	O
signals	O
is	O
still	O
a	O
challenging	O
problem	B-T033
.	O
In	O
this	O
paper	O
,	O
a	O
new	O
method	O
is	O
proposed	O
to	O
locate	B-T033
the	O
local	O
maxima	O
and	O
minima	O
of	O
the	O
RF	O
signals	O
directly	O
without	O
derivation	O
operation	O
.	O
This	O
algorithm	O
can	O
accurately	O
locate	B-T033
extrema	O
even	O
if	O
disturbed	O
peaks	O
resulting	O
from	O
different	O
noise	O
exist	O
.	O
Furthermore	O
,	O
the	O
new	O
algorithm	O
can	O
speed	O
up	O
approximately	O
79	O
%	O
of	O
the	O
implementation	O
process	O
as	O
compared	O
with	O
the	O
standard	O
cross	O
-	O
correlation	O
method	O
on	O
the	O
same	O
computing	O
platform	O
.	O
In	O
addition	O
,	O
the	O
elastographic	O
signal	O
-	O
to	O
-	O
noise	O
ratio	O
and	O
the	O
contrast	O
-	O
to	O
-	O
noise	O
ratio	O
are	O
also	O
significantly	O
improved	O
with	O
this	O
new	O
method	O
.	O
      
The	O
Loop	O
2	O
Region	O
of	O
Ribosomal	O
Protein	O
uS5	O
Influences	O
Spectinomycin	B-T195
Sensitivity	B-T033
,	O
Translational	O
Fidelity	O
,	O
and	O
Ribosome	O
Biogenesis	O
Ribosomal	O
protein	O
uS5	O
is	O
an	O
essential	O
component	O
of	O
the	O
small	O
ribosomal	O
subunit	O
that	O
is	O
involved	O
in	O
subunit	O
assembly	O
,	O
maintenance	O
of	O
translational	O
fidelity	O
,	O
and	O
the	O
ribosome	O
's	O
response	O
to	O
the	O
antibiotic	B-T195
spectinomycin	I-T195
.	O
While	O
many	O
of	O
the	O
characterized	O
uS5	O
mutations	O
that	O
affect	O
decoding	O
map	O
to	O
its	O
interface	O
with	O
uS4	O
,	O
more	O
recent	O
work	O
has	O
shown	O
that	O
residues	O
distant	O
from	O
the	O
uS4	O
-	O
uS5	O
interface	O
can	O
also	O
affect	O
the	O
decoding	O
process	O
.	O
We	O
targeted	O
one	O
such	O
interface	O
-	O
remote	O
area	O
,	O
the	O
loop	O
2	O
region	O
(	O
residues	O
20	O
to	O
31	O
)	O
,	O
for	O
mutagenesis	O
in	O
Escherichia	B-T007
.	I-T007
coli	I-T007
and	O
generated	O
21	O
unique	O
mutants	O
.	O
A	O
majority	O
of	O
the	O
loop	O
2	O
alterations	O
confer	O
resistance	O
to	O
spectinomycin	B-T195
and	O
affect	O
the	O
fidelity	O
of	O
translation	O
.	O
However	O
,	O
only	O
a	O
minority	O
show	O
altered	O
rRNA	O
processing	O
or	O
ribosome	O
biogenesis	O
defects	O
.	O
      
Mechanisms	O
of	O
replacement	O
of	O
circulating	O
viruses	B-T005
by	O
seasonal	B-T047
and	O
pandemic	B-T005
influenza	I-T005
A	I-T005
viruses	I-T005
Seasonal	B-T047
influenza	I-T047
causes	O
annual	O
epidemics	O
by	O
the	O
accumulation	B-T033
of	O
antigenic	O
changes	O
.	O
Pandemic	B-T047
influenza	I-T047
occurs	O
through	O
a	O
major	O
antigenic	O
change	O
of	O
the	O
influenza	B-T005
A	I-T005
virus	I-T005
,	O
which	O
can	O
originate	O
from	O
other	O
hosts	B-T001
.	O
Although	O
new	O
antigenic	O
variants	O
of	O
the	O
influenza	B-T005
A	I-T005
virus	I-T005
replace	O
formerly	O
circulating	O
seasonal	B-T005
and	O
pandemic	B-T005
viruses	I-T005
,	O
replacement	O
mechanisms	O
remain	O
poorly	O
understood	O
.	O
A	O
stochastic	O
individual	O
-	O
based	O
SEIR	O
(	O
susceptible	O
-	O
exposed	O
-	O
infectious	O
-	O
recovered	O
)	O
model	O
with	O
two	O
viral	B-T001
strains	I-T001
(	O
formerly	O
circulating	O
old	B-T001
strain	I-T001
and	O
newly	B-T001
emerged	I-T001
strain	I-T001
)	O
was	O
developed	O
for	O
simulations	O
to	O
elucidate	O
the	O
replacement	O
mechanisms	O
.	O
Factors	O
and	O
conditions	O
of	O
virus	B-T005
and	O
host	B-T001
populations	O
affecting	O
the	O
replacement	O
were	O
identified	O
.	O
Replacement	O
is	O
more	O
likely	O
to	O
occur	O
in	O
tropical	O
regions	O
than	O
temperate	O
regions	O
.	O
The	O
magnitude	O
of	O
the	O
ongoing	O
epidemic	O
by	O
the	O
old	B-T001
strain	I-T001
,	O
herd	O
immunity	O
against	O
the	O
old	B-T001
strain	I-T001
,	O
and	O
timing	O
of	O
appearance	O
of	O
the	O
new	B-T001
strain	I-T001
are	O
not	O
that	O
important	O
for	O
replacement	O
.	O
It	O
is	O
probable	O
that	O
the	O
frequency	O
of	O
replacement	O
by	O
a	O
pandemic	B-T005
virus	I-T005
is	O
higher	O
than	O
a	O
seasonal	B-T005
virus	I-T005
because	O
of	O
the	O
high	O
initial	O
susceptibility	O
and	O
high	O
basic	O
reproductive	O
number	O
of	O
the	O
pandemic	B-T005
virus	I-T005
.	O
The	O
findings	O
of	O
this	O
study	O
on	O
replacement	O
mechanisms	O
could	O
lead	O
to	O
a	O
better	O
understanding	O
of	O
virus	O
transmission	O
dynamics	O
and	O
may	O
possibly	O
be	O
helpful	O
in	O
establishing	O
an	O
effective	O
strategy	O
to	O
mitigate	O
the	O
impact	O
of	O
seasonal	B-T047
and	O
pandemic	B-T047
influenza	I-T047
.	O
      
Determinants	O
of	O
On	O
-	O
Road	O
Driving	O
in	O
Multiple	B-T047
Sclerosis	I-T047
To	O
investigate	O
the	O
cognitive	O
,	O
visual	O
,	O
and	O
motor	B-T033
deficits	I-T033
underlying	O
poor	O
performance	O
on	O
different	O
dimensions	B-T033
of	O
on	O
-	O
road	O
driving	O
in	O
individuals	O
with	O
multiple	B-T047
sclerosis	I-T047
(	O
MS	B-T047
)	O
.	O
Prospective	O
cross	O
-	O
sectional	O
study	O
.	O
MS	O
clinic	O
and	O
driving	O
simulator	O
lab	O
.	O
Active	O
drivers	O
(	O
N=102	O
)	O
with	O
various	O
types	O
of	O
MS	B-T047
.	O
Not	O
applicable	O
.	O
Off	O
-	O
road	O
cognitive	O
,	O
visual	O
,	O
and	O
motor	O
functions	O
,	O
as	O
well	O
as	O
13	O
specific	O
driving	O
skills	O
.	O
These	O
skills	O
were	O
categorized	O
into	O
hierarchic	O
clusters	O
of	O
operational	O
,	O
tactical	O
,	O
visuo	O
-	O
integrative	O
,	O
and	O
mixed	O
driving	O
.	O
Stepwise	O
regression	O
analysis	O
was	O
used	O
to	O
determine	O
the	O
off	O
-	O
road	O
functions	O
influencing	O
performance	O
on	O
the	O
on	O
-	O
road	O
test	O
and	O
each	O
cluster	O
.	O
Visuospatial	O
function	O
(	O
P=.002	O
)	O
,	O
inhibition	O
(	O
P=.008	O
)	O
,	O
binocular	B-T033
acuity	I-T033
(	O
P=.04	O
)	O
,	O
vertical	B-T060
visual	I-T060
field	I-T060
(	O
P=.02	O
)	O
,	O
and	O
stereopsis	O
(	O
P=.03	O
)	O
best	O
determined	O
variance	O
in	O
total	O
on	O
-	O
road	O
score	O
(	O
unadjusted	O
R(2)=.37	O
)	O
.	O
Attentional	B-T033
shift	I-T033
(	O
P=.0004	O
)	O
,	O
stereopsis	O
(	O
P=.007	O
)	O
,	O
glare	B-T060
recovery	I-T060
(	O
P=.047	O
)	O
,	O
and	O
use	O
of	O
assistive	O
devices	O
(	O
P=.03	O
)	O
best	O
predicted	O
the	O
operational	O
cluster	O
(	O
unadjusted	O
R(2)=.28	O
)	O
.	O
Visuospatial	O
function	O
(	O
P=.002	O
)	O
,	O
inhibition	O
(	O
P=.002	O
)	O
,	O
reasoning	O
(	O
P=.003	O
)	O
,	O
binocular	B-T033
acuity	I-T033
(	O
P=.04	O
)	O
,	O
and	O
stereopsis	O
(	O
P=.005	O
)	O
best	O
determined	O
the	O
tactical	O
cluster	O
(	O
unadjusted	O
R(2)=.41	O
)	O
.	O
The	O
visuo	O
-	O
integrative	O
mode	O
l	O
(	O
unadjusted	O
R(2)=.12	O
)	O
comprised	O
binocular	B-T033
acuity	I-T033
(	O
P=.007	O
)	O
and	O
stereopsis	O
(	O
P=.045	O
)	O
.	O
Inhibition	O
(	O
P=.0001	O
)	O
and	O
binocular	B-T033
acuity	I-T033
(	O
P=.001	O
)	O
provided	O
the	O
best	O
model	O
of	O
the	O
mixed	O
cluster	O
(	O
unadjusted	O
R(2)=.25	O
)	O
.	O
Our	O
results	O
provide	O
more	O
insights	O
into	O
the	O
specific	O
impairments	O
that	O
influence	O
different	O
dimensions	O
of	O
on	O
-	O
road	O
driving	O
and	O
may	O
be	O
used	O
as	O
a	O
framework	O
for	O
targeted	O
driving	O
intervention	B-T061
programs	I-T061
in	O
MS	B-T047
.	O
      
Evaluation	B-T058
of	O
Choroidal	B-T023
Thickness	O
in	O
Patients	O
with	O
Pseudoexfoliation	B-T047
Syndrome	I-T047
and	O
Pseudoexfoliation	B-T047
Glaucoma	I-T047
Purpose	O
.	O
To	O
compare	O
the	O
macular	O
and	O
peripapillary	O
choroidal	B-T023
thickness	O
in	O
eyes	B-T023
with	O
pseudoexfoliation	B-T047
(	I-T047
PEX	I-T047
)	I-T047
syndrome	I-T047
and	O
PEX	B-T047
glaucoma	I-T047
with	O
the	O
normal	O
eyes	B-T023
of	O
healthy	O
controls	O
.	O
Materials	O
and	O
Methods	O
.	O
In	O
this	O
prospective	O
study	O
,	O
30	O
eyes	B-T023
of	O
30	O
patients	O
with	O
PEX	B-T047
syndrome	I-T047
,	O
28	O
eyes	B-T023
of	O
28	O
patients	O
with	O
PEX	B-T047
glaucoma	I-T047
,	O
and	O
30	O
eyes	B-T023
of	O
30	O
age	O
-matched	O
healthy	O
subjects	O
were	O
enrolled	O
.	O
Choroidal	B-T023
thicknesses	O
in	O
the	O
macular	O
and	O
peripapillary	O
areas	O
were	O
measured	O
by	O
using	O
spectral	O
domain	O
optical	O
coherence	O
tomography	O
.	O
Results	O
.	O
Gender	O
,	O
age	O
,	O
and	O
axial	O
length	O
did	O
not	B-T033
significantly	I-T033
differ	O
between	O
the	O
groups	O
(	O
all	O
,	O
p	O
>	O
0.05	O
)	O
.	O
The	O
mean	O
values	O
of	O
choroidal	B-T023
thickness	O
in	O
the	O
macular	O
and	O
peripapillary	O
areas	O
(	O
except	O
the	O
superior	O
quadrant	O
)	O
in	O
the	O
patients	O
with	O
PEX	B-T047
syndrome	I-T047
and	O
PEX	B-T047
glaucoma	I-T047
were	O
lower	O
compared	O
with	O
controls	O
(	O
all	O
p	O
<	O
0.05	O
)	O
.	O
The	O
mean	O
values	O
of	O
the	O
macular	O
and	O
peripapillary	O
choroidal	B-T023
thickness	O
in	O
the	O
PEX	B-T047
glaucoma	I-T047
group	O
were	O
lower	O
compared	O
with	O
PEX	B-T047
syndrome	I-T047
group	O
;	O
however	O
this	O
difference	O
was	O
not	B-T033
significant	I-T033
.	O
Conclusions	O
.	O
The	O
findings	B-T033
of	O
this	O
study	O
revealed	O
that	O
macular	O
and	O
peripapillary	O
choroidal	B-T023
thicknesses	O
were	O
decreased	O
in	O
PEX	B-T047
syndrome	I-T047
and	O
PEX	B-T047
glaucoma	I-T047
cases	O
.	O
The	O
role	O
of	O
choroid	B-T023
in	O
the	O
development	O
of	O
glaucomatous	B-T047
damage	O
in	O
patients	O
with	O
PEX	B-T047
syndrome	I-T047
remains	O
unclear	B-T033
.	O
      
Plasmodium	O
falciparum	O
Choline	O
Kinase	O
Inhibition	O
Leads	O
to	O
a	O
Major	O
Decrease	O
in	O
Phosphatidylethanolamine	B-T121
Causing	O
Parasite	O
Death	O
Malaria	B-T047
is	O
a	O
life	B-T033
-	I-T033
threatening	I-T033
disease	B-T047
caused	O
by	O
different	O
species	O
of	O
the	O
protozoan	O
parasite	O
Plasmodium	O
,	O
with	O
P.	O
falciparum	O
being	O
the	O
deadliest	O
.	O
Increasing	O
parasitic	O
resistance	O
to	O
existing	O
antimalarials	B-T121
makes	O
the	O
necessity	O
of	O
novel	O
avenues	O
to	O
treat	B-T061
this	O
disease	B-T047
an	O
urgent	O
priority	O
.	O
The	O
enzymes	O
responsible	O
for	O
the	O
synthesis	O
of	O
phosphatidylcholine	B-T121
and	O
phosphatidylethanolamine	B-T121
are	O
attractive	O
drug	O
targets	O
to	O
treat	B-T061
malaria	B-T047
as	O
their	O
selective	O
inhibition	O
leads	O
to	O
an	O
arrest	O
of	O
the	O
parasite	O
's	O
growth	O
and	O
cures	B-T033
malaria	B-T047
in	O
a	O
mouse	B-T050
model	I-T050
.	O
We	O
present	O
here	O
a	O
detailed	O
study	O
that	O
reveals	O
a	O
mode	O
of	O
action	O
for	O
two	O
P.	O
falciparum	O
choline	O
kinase	O
inhibitors	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
The	O
compounds	O
present	O
distinct	O
binding	O
modes	O
to	O
the	O
choline	B-T121
/	O
ethanolamine	O
-	O
binding	O
site	O
of	O
P.	O
falciparum	O
choline	O
kinase	O
,	O
reflecting	O
different	O
types	O
of	O
inhibition	O
.	O
Strikingly	O
,	O
these	O
compounds	O
primarily	O
inhibit	O
the	O
ethanolamine	O
kinase	O
activity	O
of	O
the	O
P.	O
falciparum	O
choline	O
kinase	O
,	O
leading	O
to	O
a	O
severe	O
decrease	O
in	O
the	O
phosphatidylethanolamine	B-T121
levels	O
within	O
P.	O
falciparum	O
,	O
which	O
explains	O
the	O
resulting	O
growth	O
phenotype	O
and	O
the	O
parasites	O
death	O
.	O
These	O
studies	O
provide	O
an	O
understanding	O
of	O
the	O
mode	O
of	O
action	O
,	O
and	O
act	O
as	O
a	O
springboard	O
for	O
continued	O
antimalarial	O
development	O
efforts	O
selectively	O
targeting	O
P.	O
falciparum	O
choline	O
kinase	O
.	O
      
Effect	O
of	O
Successive	B-T061
Administration	I-T061
of	O
Vancomycin	B-T195
and	O
Amikacin	B-T195
on	O
Auditory	O
Function	O
of	O
Immature	O
Animals	O
Effect	O
of	O
successive	B-T061
administration	I-T061
vancomycin	B-T195
and	O
amikacin	B-T195
in	O
therapeutic	O
doses	O
on	O
immature	O
auditory	O
organ	O
was	O
compared	O
to	O
single	O
administration	B-T058
of	O
the	O
same	O
drugs	B-T121
in	O
chronic	O
experiments	O
on	O
immature	O
rabbits	O
by	O
recording	O
of	O
short	O
-	O
latency	O
auditory	O
brainstem	O
response	O
(	O
ABR	O
)	O
and	O
distortion	B-T060
product	I-T060
otoacoustic	I-T060
emission	I-T060
(	O
DPOAE	B-T060
)	O
.	O
Drug	B-T058
administration	I-T058
always	O
increased	O
significantly	O
the	O
ABR	O
peak	O
I	O
threshold	O
.	O
Ototoxic	O
antibiotics	B-T195
did	O
not	O
change	O
DPOAE	B-T060
,	O
but	O
selectively	O
affected	O
activity	B-T033
of	O
outer	O
hair	O
cells	O
.	O
No	B-T033
enhancement	O
of	O
the	O
ototoxic	O
effects	O
was	O
observed	O
after	O
successive	B-T061
administration	I-T061
of	O
the	O
two	O
antibiotics	B-T195
.	O
      
Congenital	B-T019
anomalies	I-T019
following	O
use	O
of	O
isotretinoin	B-T121
:	O
Emphasis	O
on	O
its	O
legal	O
aspects	O
We	O
described	O
a	O
neonate	O
with	O
severe	O
and	O
multiple	B-T019
abnormalities	I-T019
following	O
use	O
of	O
isotretinoin	B-T121
,	O
in	O
spite	O
of	O
the	O
mother	O
's	O
previous	O
knowledge	O
of	O
drug	O
complications	O
.	O
Initial	O
physical	B-T058
examination	I-T058
after	O
delivery	B-T061
showed	O
congenital	B-T019
absence	I-T019
of	O
both	B-T023
eyes	I-T023
and	O
both	O
auricles	B-T023
as	O
well	O
as	O
anal	B-T019
atresia	I-T019
and	O
a	O
cleft	B-T019
palate	I-T019
.	O
Due	O
to	O
severe	O
respiratory	B-T184
distress	I-T184
and	O
atresia	B-T019
of	O
the	O
anus	B-T023
,	O
the	O
neonate	O
was	O
admitted	O
to	O
a	O
neonatal	O
intensive	O
care	O
unit	O
and	O
underwent	O
reconstructive	B-T061
surgery	I-T061
.	O
The	O
drug	B-T121
should	O
not	O
have	O
been	O
used	O
during	O
pregnancy	O
.	O
Using	O
this	O
drug	B-T121
within	O
pregnancy	O
with	O
awareness	O
of	O
its	O
side	O
effects	O
may	O
have	O
legal	O
consequences	O
.	O
      
Chitosan	B-T121
-functionalised	O
poly(2	O
-	O
hydroxyethyl	O
methacrylate	O
)	O
core	O
-	O
shell	O
microgels	O
as	O
drug	O
delivery	O
carriers	O
:	O
salicylic	B-T121
acid	I-T121
loading	O
and	O
release	O
This	O
work	O
presents	O
the	O
evaluation	O
of	O
chitosan	B-T121
-functionalised	O
poly(2	O
-	O
hydroxyethyl	O
methacrylate	O
)	O
(	O
CS	B-T121
/	O
PHEMA	O
)	O
core	O
-	O
shell	O
microgels	O
as	O
drug	O
delivery	O
carriers	O
.	O
CS	B-T121
/	O
PHEMA	O
microgels	O
were	O
prepared	O
by	O
emulsifier	O
-	O
free	O
emulsion	O
polymerisation	O
with	O
N	O
,	O
N	O
'	O
-methylenebisacrylamide	O
(	O
MBA	O
)	O
as	O
a	O
crosslinker	O
.	O
The	O
study	O
on	O
drug	O
loading	O
,	O
using	O
salicylic	B-T121
acid	I-T121
(	O
SA	B-T121
)	O
as	O
a	O
model	B-T121
drug	I-T121
,	O
was	O
performed	O
.	O
The	O
results	O
showed	O
that	O
the	O
encapsulation	O
efficiency	O
(	O
EE	O
)	O
increased	O
as	O
drug	B-T121
-to-	O
microgel	O
ratio	O
was	O
increased	O
.	O
Higher	O
EE	O
can	O
be	O
achieved	O
with	O
the	O
increase	O
in	O
degree	O
of	O
crosslinking	O
,	O
by	O
increasing	O
the	O
amount	O
of	O
MBA	O
from	O
0.01	O
g	O
to	O
0.03	O
g.	O
In	O
addition	O
,	O
the	O
highest	O
EE	O
(	O
61.1	O
%	O
)	O
was	O
observed	O
at	O
pH	O
3	O
.	O
The	O
highest	O
release	O
of	O
SA	O
(	O
60	O
%	O
)	O
was	O
noticed	O
at	O
pH	O
2.4	O
,	O
while	O
the	O
lowest	O
one	O
(	O
49.4	O
%	O
)	O
was	O
obtained	O
at	O
pH	O
7.4	O
.	O
Moreover	O
,	O
the	O
highest	O
release	O
of	O
SA	O
was	O
enhanced	O
by	O
the	O
presence	O
of	O
0.2	O
M	O
NaCl	B-T121
.	O
The	O
pH	O
-	O
and	O
ionic	O
-	O
sensitivity	O
of	O
CS	B-T121
/	O
PHEMA	O
could	O
be	O
useful	O
as	O
a	O
sustained	B-T121
release	I-T121
delivery	I-T121
device	I-T121
,	O
especially	O
for	O
oral	O
delivery	O
.	O
      
Disease	B-T047
Activity	I-T047
and	O
Increased	B-T033
Risk	I-T033
of	I-T033
Cardiovascular	O
Death	O
among	O
Patients	O
with	O
Psoriatic	B-T047
Arthritis	I-T047
Recent	O
studies	O
indicate	O
increased	O
cardiovascular	B-T047
(	I-T047
CV	I-T047
)	I-T047
morbidity	I-T047
and	O
mortality	O
in	O
patients	O
with	O
psoriatic	B-T047
arthritis	I-T047
(	O
PsA	B-T047
)	O
,	O
but	O
results	O
are	O
inconsistent	O
.	O
This	O
prompted	O
our	O
investigation	O
of	O
the	O
mortality	O
rate	O
,	O
cause	B-T033
of	I-T033
death	I-T033
,	O
and	O
incidence	O
of	O
acute	O
CV	B-T033
events	I-T033
PsA	B-T047
in	O
patients	O
from	O
northern	O
Sweden	O
with	O
PsA.	O
Patients	O
with	O
established	O
PsA	B-T047
(	O
464	O
)	O
were	O
included	O
.	O
To	O
calculate	O
standardized	O
mortality	O
ratio	O
(	O
SMR	O
)	O
and	O
standardized	O
incidence	O
ratio	O
(	O
SIR	O
)	O
for	O
CV	B-T033
events	I-T033
,	O
data	O
were	O
extracted	O
from	O
the	O
National	O
Causes	O
of	O
Death	O
Register	O
and	O
the	O
National	O
Inpatient	O
Care	O
Register	O
in	O
Sweden	O
,	O
and	O
compared	O
with	O
the	O
general	O
population	O
.	O
The	O
study	O
period	O
was	O
1995	O
-	O
2011	O
.	O
To	O
study	O
the	O
effect	O
of	O
inflammatory	O
activity	O
,	O
a	O
composite	O
disease	B-T060
activity	I-T060
index	I-T060
(	O
DAI	B-T060
)	O
was	O
used	O
.	O
The	O
SMR	O
(	O
95	O
%	O
CI	O
)	O
for	O
overall	O
mortality	O
and	O
diseases	B-T047
of	I-T047
the	I-T047
circulatory	I-T047
system	I-T047
(	O
International	O
Classification	O
of	O
Diseases	O
,	O
10th	O
edition	O
;	O
I00	O
-	O
I99	O
)	O
was	O
1.22	O
(	O
0.89	O
-	O
1.63	O
)	O
and	O
1.64	O
(	O
1.02	O
-	O
2.52	O
)	O
,	O
respectively	O
.	O
In	O
regression	O
analysis	O
,	O
DAI	B-T060
was	O
significantly	O
associated	O
with	O
death	B-T033
(	O
OR	O
1.99	O
,	O
95	O
%	O
CI	O
1.41	O
-	O
2.80	O
)	O
when	O
adjusted	O
for	O
age	O
and	O
sex	O
(	O
p	O
<	O
0.001	O
)	O
,	O
and	O
remained	O
significant	O
after	O
stratifying	O
patients	O
into	O
the	O
2	O
major	O
causes	B-T033
of	I-T033
death	I-T033
:	O
diseases	B-T047
of	I-T047
the	I-T047
circulatory	I-T047
system	I-T047
and	O
malignant	B-T191
neoplasms	I-T191
.	O
Peripheral	B-T047
and	O
axial	B-T033
disease	I-T033
was	O
associated	O
with	O
death	B-T033
(	O
OR	O
4.02	O
,	O
95	O
%	O
CI	O
1.84	O
-	O
8.84	O
,	O
p	O
<	O
0.001	O
)	O
compared	O
with	O
peripheral	B-T047
disease	I-T047
only	O
.	O
The	O
SIR	O
(	O
95	O
%	O
CI	O
)	O
for	O
a	O
CV	B-T033
event	I-T033
(	O
myocardial	B-T047
infarction	I-T047
or	O
stroke	O
)	O
was	O
0.597	O
(	O
0.40	O
-	O
0.86	O
)	O
;	O
this	O
association	O
was	O
only	O
significant	O
in	O
men	O
.	O
Patients	O
with	O
PsA	B-T047
had	O
a	O
small	O
but	O
significant	O
increase	O
in	O
SMR	O
for	O
death	B-T033
due	O
to	O
diseases	B-T047
of	I-T047
the	I-T047
circulatory	I-T047
system	I-T047
compared	O
with	O
the	O
general	O
population	O
.	O
Among	O
patients	O
,	O
death	B-T033
was	O
associated	O
with	O
DAI	B-T060
,	O
as	O
well	O
as	O
axial	B-T033
involvement	I-T033
in	O
combination	O
with	O
peripheral	B-T047
disease	I-T047
,	O
indicating	O
more	O
aggressive	O
disease	O
phenotypes	O
.	O
      
Attributable	O
risk	O
of	O
ambient	O
PM10	O
on	O
daily	O
mortality	O
and	O
years	O
of	O
life	O
lost	O
in	O
Chengdu	O
,	O
China	O
Attributable	O
risk	O
is	O
an	O
important	O
indicator	O
for	O
planning	B-T058
and	O
evaluating	B-T058
public	I-T058
health	I-T058
interventions	I-T058
.	O
However	O
,	O
most	O
current	O
measures	O
of	O
the	O
attributable	O
risk	O
of	O
air	O
pollutants	O
have	O
not	O
considered	O
temporal	O
relationships	O
between	O
exposure	O
and	O
risk	O
.	O
More	O
importantly	O
,	O
limited	O
information	O
is	O
available	O
regarding	O
the	O
attributable	O
risk	O
due	O
to	O
ambient	O
air	O
pollutants	O
in	O
basin	O
regions	O
like	O
the	O
Sichuan	O
Basin	O
,	O
China	O
.	O
To	O
quantify	O
the	O
association	O
between	O
PM10	O
and	O
deaths	B-T033
in	O
the	O
Basin	O
region	O
,	O
we	O
used	O
a	O
measure	O
proposed	O
recently	O
within	O
the	O
framework	O
of	O
the	O
distributed	O
lag	O
non	O
-	O
linear	O
model	O
to	O
estimate	O
the	O
attributable	O
risk	O
in	O
Chengdu	O
,	O
China	O
.	O
Meanwhile	O
,	O
we	O
examined	O
the	O
association	O
between	O
PM10	O
and	O
years	O
of	O
life	O
lost	O
(	O
YLL	O
)	O
.	O
Our	O
analysis	O
showed	O
that	O
population	O
-	O
attributable	O
fractions	O
for	O
non	O
-	O
accidental	O
,	O
respiratory	O
,	O
and	O
cardiovascular	O
mortality	O
were	O
0.569	O
%	O
(	O
95	O
%	O
CI	O
:	O
-3.474	O
%	O
,	O
4.374	O
%	O
)	O
,	O
0.695	O
%	O
(	O
95	O
%	O
CI	O
:	O
-5.260	O
%	O
,	O
6.457	O
%	O
)	O
,	O
and	O
0.631	O
%	O
(	O
95	O
%	O
CI	O
:	O
-6.973	O
%	O
,	O
7.390	O
%	O
)	O
,	O
respectively	O
.	O
On	O
average	O
,	O
a	O
1μg	O
/	O
m(3	O
)	O
increase	O
in	O
PM10	O
was	O
associated	O
with	O
cumulative	O
increases	O
of	O
0.26893	O
,	O
0.30437	O
,	O
and	O
0.21924	O
YLL	O
for	O
non	O
-	O
accidental	O
,	O
respiratory	O
,	O
and	O
cardiovascular	O
mortality	O
,	O
respectively	O
,	O
referring	O
to	O
20μg	O
/	O
m(3	O
)	O
.	O
In	O
addition	O
,	O
we	O
found	O
an	O
inverse	O
U	O
-	O
shaped	O
pattern	O
for	O
the	O
cumulative	O
risk	O
with	O
350μg	O
/	O
m(3	O
)	O
as	O
the	O
reverse	O
point	O
.	O
With	O
a	O
1μg	O
/	O
m(3	O
)	O
increase	O
in	O
PM10	O
,	O
YLL	O
changed	O
more	O
significantly	O
than	O
mortality	O
.	O
Moreover	O
,	O
PM10	O
demonstrated	O
remarkable	O
effects	O
on	O
YLL	O
among	O
men	O
and	O
the	O
elderly	O
.	O
      
Prognostic	O
value	O
of	O
GLUT-1	O
expression	O
in	O
oral	B-T191
squamous	I-T191
cell	I-T191
carcinoma	I-T191
:	O
A	O
prisma	O
-	O
compliant	O
meta	O
-	O
analysis	O
A	O
variety	O
of	O
studies	O
have	O
evaluated	B-T058
the	O
correlation	O
between	O
glucose	O
transporter-1	O
(	O
GLUT-1	O
)	O
expression	O
and	O
prognosis	B-T058
of	O
oral	B-T191
squamous	I-T191
cell	I-T191
carcinoma	I-T191
(	O
OSCC	B-T191
)	O
;	O
however	O
,	O
the	O
results	O
were	O
inconsistent	O
and	O
inconclusive	O
.	O
A	O
meta	O
-	O
analysis	O
was	O
performed	O
to	O
assess	B-T058
the	O
prognostic	O
significance	O
of	O
GLUT-1	O
in	O
OSCC	B-T191
.	O
Electronic	O
databases	O
of	O
PubMed	O
,	O
Embase	O
,	O
and	O
Web	O
of	O
Science	O
were	O
searched	O
for	O
relevant	O
studies	O
.	O
The	O
last	O
search	O
was	O
updated	O
on	O
July	O
2016	O
.	O
Odds	O
ratio	O
(	O
OR	O
)	O
and	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
were	O
pooled	O
to	O
evaluate	B-T058
the	O
relationship	O
between	O
GLUT-1	O
and	O
clinical	B-T033
features	I-T033
and	O
hazard	O
ratio	O
(	O
HR	O
)	O
and	O
95	O
%	O
CI	O
were	O
combined	O
to	O
measure	O
the	O
effect	O
of	O
GLUT-1	O
on	O
overall	O
survival	O
(	O
OS	O
)	O
.	O
P	O
value	O
<	O
0.05	O
was	O
considered	O
as	O
statistically	O
significant	O
.	O
A	O
total	O
of	O
13	O
studies	O
with	O
1301	O
subjects	O
were	O
included	O
for	O
meta	O
-	O
analysis	O
.	O
The	O
pooled	O
data	O
showed	O
that	O
high	O
GLUT-1	O
expression	O
was	O
associated	O
with	O
advanced	O
tumor	O
stages	O
(	O
n	O
=	O
7	O
,	O
OR	O
=	O
2.99	O
,	O
95	O
%	O
CI	O
:	O
2.01	O
-	O
4.46	O
,	O
P	O
<	O
0.001	O
)	O
,	O
higher	O
tumor	O
grade	O
(	O
n	O
=	O
5	O
,	O
OR	O
=	O
3.34	O
,	O
95	O
%	O
CI	O
:	O
1.12	O
-	O
9.94	O
,	O
P	O
=	O
0.031	O
)	O
,	O
tumor	O
size	O
(	O
n	O
=	O
5	O
,	O
OR	O
=	O
3.36	O
,	O
95	O
%	O
CI	O
:	O
2.04	O
-	O
5.51	O
,	O
P	O
<	O
0.001	O
)	O
,	O
lymph	B-T033
node	I-T033
metastasis	I-T033
(	O
n	O
=	O
5	O
,	O
OR	O
=	O
3.15	O
,	O
95	O
%	O
CI	O
:	O
1.89	O
-	O
5.25	O
,	O
P	O
<	O
0.001	O
)	O
,	O
tobacco	O
use	O
(	O
n	O
=	O
3	O
,	O
OR	O
=	O
2.18	O
,	O
95	O
%	O
CI	O
:	O
1.18	O
-	O
4.01	O
,	O
P	O
=	O
0.013	O
)	O
,	O
and	O
distant	O
metastasis	O
(	O
n	O
=	O
2	O
,	O
OR	O
=	O
3.06	O
,	O
95	O
%	O
CI	O
:	O
1.19	O
-	O
7.9	O
,	O
P	O
=	O
0.02	O
)	O
.	O
Furthermore	O
,	O
increased	O
GLUT-1	O
expression	O
was	O
also	O
correlated	O
with	O
shorter	O
OS	O
(	O
n	O
=	O
8	O
,	O
HR	O
=	O
1.88	O
,	O
95	O
%	O
CI	O
:	O
1.51	O
-	O
2.33	O
,	O
P	O
<	O
0.001	O
)	O
.	O
No	O
significant	O
publication	O
bias	O
was	O
detected	B-T033
in	O
this	O
meta	O
-	O
analysis	O
.	O
GLUT-1	O
overexpression	O
was	O
in	O
connection	O
with	O
aggressive	B-T033
clinical	I-T033
features	I-T033
and	O
worse	O
OS	O
in	O
OSCC	B-T191
.	O
However	O
,	O
further	O
studies	O
are	O
still	O
needed	O
to	O
verify	O
whether	O
GLUT-1	O
could	O
serve	O
as	O
a	O
prognostic	O
biomarker	O
for	O
OSCC	B-T191
.	O
      
Early	O
high	O
school	O
engagement	O
in	O
students	O
with	O
attention	B-T048
/	I-T048
deficit	I-T048
hyperactivity	I-T048
disorder	I-T048
Students	O
with	O
attention	B-T048
/	I-T048
deficit	I-T048
hyperactivity	I-T048
disorder	I-T048
(	O
ADHD	B-T048
)	O
continue	O
to	O
languish	O
behind	O
their	O
peers	O
with	O
regard	O
to	O
academic	O
achievement	O
and	O
education	B-T033
attainment	I-T033
.	O
School	O
engagement	O
is	O
potentially	O
modifiable	O
,	O
and	O
targeting	O
engagement	O
may	O
be	O
a	O
means	O
to	O
improve	O
education	O
outcomes	O
.	O
To	O
investigate	O
school	O
engagement	O
for	O
students	O
with	O
ADHD	B-T048
during	O
the	O
crucial	O
high	O
school	O
transition	O
period	O
and	O
to	O
identify	O
factors	O
associated	O
with	O
low	B-T033
school	I-T033
engagement	I-T033
.	O
Participants	O
are	O
adolescents	O
(	O
12	O
-	O
15	O
years	O
)	O
in	O
the	O
first	O
and	O
third	O
year	O
of	O
high	O
school	O
with	O
diagnosed	O
ADHD	B-T048
(	O
n	O
=	O
130	O
)	O
.	O
Participants	O
were	O
recruited	O
from	O
21	O
paediatric	O
practices	O
.	O
Cross	O
-	O
sectional	O
study	O
assessing	O
school	O
engagement	O
.	O
Data	O
were	O
collected	O
through	O
direct	O
assessment	B-T058
and	O
child	O
,	O
parent	O
,	O
and	O
teacher	O
surveys	O
.	O
School	O
engagement	O
is	O
measured	O
as	O
student	O
attitudes	O
to	O
school	O
(	O
cognitive	O
and	O
emotional	O
)	O
and	O
suspension	B-T033
rates	O
(	O
behavioural	O
)	O
.	O
Multivariable	O
regression	O
analyses	O
examined	O
student	O
,	O
family	O
,	O
and	O
school	O
factors	O
affecting	O
engagement	O
.	O
In	O
comparison	O
with	O
state	O
data	O
,	O
students	O
with	O
ADHD	B-T048
in	O
the	O
first	O
year	O
of	O
high	O
school	O
were	O
less	O
motivated	O
(	O
p	O
<	O
.01	O
)	O
and	O
less	O
connected	O
to	O
peers	O
(	O
p	O
<	O
.01	O
)	O
.	O
Overall	O
,	O
there	O
was	O
no	O
discordance	O
in	O
third	O
year	O
attitudes	O
.	O
There	O
were	O
high	B-T033
rates	I-T033
of	I-T033
suspension	I-T033
in	O
both	O
years	O
in	O
comparison	O
to	O
state	O
-	O
wide	O
suspensions	B-T033
(	O
21	O
%	O
vs.	O
6	O
%	O
,	O
p	O
<	O
.01	O
)	O
.	O
Explanatory	O
factors	O
for	O
poor	O
attitudes	O
include	O
adolescent	O
depression	B-T048
,	O
poor	O
adolescent	O
supervision	B-T061
,	O
and	O
devaluing	O
education	O
.	O
Conduct	O
problems	O
and	O
increased	O
hyperactivity	B-T048
were	O
related	O
to	O
increased	B-T033
likelihood	I-T033
of	I-T033
being	I-T033
suspended	I-T033
,	O
whilst	O
higher	O
cognitive	O
ability	O
,	O
family	O
socio	O
-	O
economic	O
status	O
,	O
and	O
independent	O
schools	O
reduced	O
risk	O
.	O
Potentially	O
modifiable	O
individual	O
and	O
family	O
factors	B-T033
including	O
adolescent	O
depression	B-T048
,	O
behavioural	B-T048
problems	I-T048
,	O
education	O
values	O
,	O
and	O
family	O
supervision	B-T061
could	O
be	O
targeted	O
to	O
better	O
manage	O
the	O
high	O
school	O
transition	O
for	O
students	O
with	O
ADHD	B-T048
.	O
      
Electronic	O
tongues	O
to	O
assess	O
wine	O
sensory	O
descriptors	O
This	O
work	O
reports	O
the	O
application	O
of	O
an	O
electronic	O
tongue	O
as	O
a	O
tool	O
towards	O
the	O
analysis	O
of	O
wine	O
in	O
tasks	O
such	O
as	O
its	O
discrimination	O
based	O
on	O
the	O
maturing	O
in	O
barrels	O
or	O
the	O
prediction	O
of	O
the	O
global	O
scores	O
assigned	O
by	O
a	O
sensory	O
panel	O
.	O
To	O
this	O
aim	O
,	O
red	O
wine	O
samples	O
were	O
first	O
analysed	O
with	O
the	O
voltammetric	O
sensor	O
array	O
,	O
without	O
performing	O
any	O
sample	O
pretreatment	O
.	O
Afterwards	O
,	O
obtained	O
responses	O
were	O
preprocessed	O
employing	O
fast	O
Fourier	O
transform	O
(	O
FFT	O
)	O
for	O
the	O
compression	O
and	O
reduction	O
of	O
signal	O
complexity	O
,	O
and	O
obtained	O
coefficients	O
were	O
then	O
used	O
as	O
inputs	O
to	O
build	O
the	O
qualitative	O
and	O
quantitative	O
models	O
employing	O
either	O
linear	O
discriminant	O
analysis	O
(	O
LDA	O
)	O
or	O
partial	O
least	O
squares	O
regression	O
(	O
PLS	O
)	O
,	O
respectively	O
.	O
Satisfactory	O
results	B-T033
were	O
obtained	O
overall	O
,	O
with	O
a	O
classification	O
rate	O
of	O
100	O
%	O
in	O
the	O
discrimination	O
of	O
the	O
type	O
of	O
barrel	O
used	O
during	O
wine	O
maturing	O
,	O
a	O
normalized	O
NRMSE	O
of	O
0.077	O
in	O
the	O
estimation	O
of	O
ageing	O
time	O
(	O
months	O
)	O
or	O
0.11	O
in	O
the	O
prediction	O
of	O
the	O
scores	O
(	O
0	O
-	O
10	O
)	O
from	O
a	O
trained	O
sensory	O
panel	O
(	O
all	O
for	O
the	O
external	O
test	O
subset	O
)	O
.	O
      
Serum	O
vascular	O
endothelial	O
growth	O
factor	O
receptor-3	O
levels	O
in	O
patients	O
with	O
esophageal	B-T191
squamous	I-T191
cell	I-T191
cancer	I-T191
Esophageal	B-T191
cancer	I-T191
is	O
one	O
of	O
the	O
most	O
aggressive	O
tumors	B-T191
of	I-T191
the	I-T191
gastrointestinal	I-T191
tract	I-T191
.	O
In	O
this	O
study	O
,	O
we	O
quantified	O
the	O
serum	O
vascular	O
endothelial	O
growth	O
factor-3	O
(	O
VEGFR-3	O
)	O
expression	O
in	O
patients	O
with	O
esophageal	B-T191
squamous	I-T191
cell	I-T191
carcinoma	I-T191
(	O
ESCC	B-T191
)	O
to	O
evaluate	O
the	O
role	O
of	O
VEGFR-3	O
in	O
ESCC	B-T191
.	O
Ninety	O
five	O
patients	O
with	O
ESCC	B-T191
were	O
studied	O
.	O
Pre	O
-	O
therapy	O
and	O
preoperative	O
samples	O
were	O
stored	O
and	O
ELISA	B-T059
was	O
used	O
to	O
designate	O
the	O
concentrations	O
of	O
VEGFR-3	O
.	O
The	O
serum	O
values	O
of	O
VEGFR-3	O
were	O
significantly	O
higher	O
in	O
patients	O
with	O
ESCC	B-T191
than	O
in	O
healthy	O
donors	O
(	O
p<0.0001	O
)	O
.	O
The	O
results	O
imply	O
a	O
very	O
good	O
sensitivity	O
of	O
VEGFR-3	O
in	O
ESCC	B-T191
.	O
VEGFR-3	O
may	O
be	O
a	O
good	O
diagnostic	O
biomarker	O
for	O
ESCC	B-T191
.	O
Biomarker	O
,	O
ESCC	B-T191
,	O
VEGFR-3	O
.	O
      
Influence	O
of	O
Surface	O
Properties	O
on	O
Adhesion	O
Forces	O
and	O
Attachment	O
of	O
Streptococcus	B-T007
mutans	I-T007
to	O
Zirconia	B-T121
In	O
Vitro	O
Zirconia	B-T121
is	O
becoming	O
a	O
prevalent	O
material	O
in	O
dentistry	O
.	O
However	O
,	O
any	O
foreign	O
bodies	O
inserted	B-T058
may	O
provide	O
new	O
niches	O
for	O
the	O
bacteria	B-T007
in	O
oral	O
cavity	O
.	O
The	O
object	O
of	O
this	O
study	O
was	O
to	O
explore	O
the	O
effect	O
of	O
surface	O
properties	O
including	O
surface	B-T033
roughness	I-T033
and	O
hydrophobicity	O
on	O
the	O
adhesion	O
and	O
biofilm	O
formation	O
of	O
Streptococcus	B-T007
mutans	I-T007
(	O
S.	B-T007
mutans	I-T007
)	O
to	O
zirconia	B-T121
.	O
Atomic	B-T059
force	I-T059
microscopy	I-T059
was	O
employed	O
to	O
determine	O
the	O
zirconia	B-T121
surface	O
morphology	O
and	O
the	O
adhesion	O
forces	O
between	O
the	O
S.	B-T007
mutans	I-T007
and	O
zirconia	B-T121
.	O
The	O
results	O
showed	O
that	O
the	O
surface	B-T033
roughness	I-T033
was	O
nanoscale	O
and	O
significantly	O
different	O
among	O
tested	O
groups	O
(	O
P	O
<	O
0.05	O
):	O
Coarse	O
(	O
23.94	O
±	O
2.52	O
nm	O
)	O
>	O
Medium	O
(	O
17.00	O
±	O
3.81	O
nm	O
)	O
>	O
Fine	O
(	O
11.89	O
±	O
1.68	O
nm	O
)	O
.	O
The	O
contact	O
angles	O
of	O
the	O
Coarse	O
group	O
were	O
the	O
highest	O
,	O
followed	O
by	O
the	O
Medium	O
and	O
the	O
Fine	O
groups	O
.	O
Increasing	O
the	O
surface	B-T033
roughness	I-T033
and	O
hydrophobicity	O
resulted	O
in	O
an	O
increase	O
of	O
adhesion	O
forces	O
and	O
early	O
attachment	O
(	O
2	O
h	O
and	O
4	O
h	O
)	O
of	O
S.	B-T007
mutans	I-T007
on	O
the	O
zirconia	B-T121
but	O
no	O
influence	O
on	O
the	O
further	O
development	O
of	O
biofilm	B-T007
(	O
6	O
h~24	O
h	O
)	O
.	O
Our	O
findings	O
suggest	O
that	O
the	O
surface	B-T033
roughness	I-T033
in	O
nanoscale	O
and	O
hydrophobicity	O
of	O
zirconia	B-T121
had	O
influence	O
on	O
the	O
S.	B-T007
mutans	I-T007
initial	O
adhesion	O
force	O
and	O
early	O
attachment	O
instead	O
of	O
whole	O
stages	O
of	O
biofilm	O
formation	O
.	O
      
Antigen	O
specificity	O
determines	O
anti	O
-	O
red	O
blood	O
cell	O
IgG	O
-	O
Fc	O
alloantibody	O
glycosylation	O
and	O
thereby	O
severity	O
of	O
haemolytic	B-T047
disease	I-T047
of	I-T047
the	I-T047
fetus	I-T047
and	I-T047
newborn	I-T047
Haemolytic	B-T047
disease	I-T047
of	I-T047
the	I-T047
fetus	I-T047
and	I-T047
newborn	I-T047
(	O
HDFN	B-T047
)	O
is	O
a	O
severe	O
disease	B-T047
in	O
which	O
fetal	B-T018
red	O
blood	O
cells	O
(	O
RBC	O
)	O
are	O
destroyed	O
by	O
maternal	O
anti	O
-	O
RBC	O
IgG	O
alloantibodies	O
.	O
HDFN	B-T047
is	O
most	O
often	O
caused	O
by	O
anti	O
-	O
D	O
but	O
may	O
also	O
occur	O
due	O
to	O
anti	O
-	O
K	O
,	O
-c	O
-	O
or	O
-E.	O
We	O
recently	O
found	O
N	O
-	O
linked	O
glycosylation	O
of	O
anti	O
-	O
D	O
to	O
be	O
skewed	O
towards	O
low	O
fucosylation	O
,	O
thereby	O
increasing	O
the	O
affinity	O
to	O
IgG	O
-	O
Fc	O
receptor	O
IIIa	O
and	O
IIIb	O
,	O
which	O
correlated	O
with	O
HDFN	B-T047
disease	B-T047
severity	O
.	O
Here	O
,	O
we	O
analysed	O
230	O
pregnant	O
women	O
with	O
anti	O
-	O
c	O
,	O
-E	O
or	O
-K	O
alloantibodies	O
from	O
a	O
prospective	O
screening	B-T058
cohort	I-T058
and	O
investigated	O
the	O
type	O
of	O
Fc	O
-	O
tail	O
glycosylation	O
of	O
these	O
antibodies	O
in	O
relation	O
to	O
the	O
trigger	O
of	O
immunisation	B-T061
and	O
pregnancy	B-T033
outcome	I-T033
.	O
Anti	O
-	O
c	O
,	O
-E	O
and	O
-K	O
show	O
-	O
independent	O
of	O
the	O
event	O
that	O
had	O
led	O
to	O
immunisation	B-T061
-	O
a	O
different	O
kind	O
of	O
Fc	O
-	O
glycosylation	O
compared	O
to	O
that	O
of	O
the	O
total	O
IgG	B-T121
IgG	B-T121
fraction	I-T121
,	O
but	O
with	O
less	O
pronounced	O
differences	O
compared	O
to	O
anti	O
-	O
D.	O
High	O
Fc	O
-	O
galactosylation	O
and	O
sialylation	O
of	O
anti	O
-	O
c	O
correlated	O
with	O
HDFN	B-T047
disease	B-T047
severity	O
,	O
while	O
low	O
anti	O
-	O
K	O
Fc	O
-	O
fucosylation	O
correlated	O
with	O
severe	O
fetal	B-T047
anaemia	I-T047
.	O
IgG	O
-	O
Fc	O
glycosylation	O
of	O
anti	O
-	O
RBC	O
antibodies	O
is	O
shaped	O
depending	O
on	O
the	O
antigen	O
.	O
These	O
features	O
influence	O
their	O
clinical	O
potency	O
and	O
may	O
therefore	O
be	O
used	O
to	O
predict	O
severity	O
and	O
identify	O
those	O
needing	O
treatment	O
.	O
      
Significance	O
of	O
uterine	B-T191
corpus	I-T191
tumor	I-T191
invasion	B-T033
in	O
early	O
-	O
stage	O
cervical	B-T191
cancer	I-T191
To	O
examine	O
characteristics	O
and	O
survival	O
outcomes	O
of	O
women	O
with	O
surgically	B-T061
-	I-T061
treated	I-T061
cervical	B-T191
cancer	I-T191
exhibiting	O
uterine	B-T191
corpus	I-T191
tumor	I-T191
invasion	B-T033
.	O
We	O
utilized	O
The	O
Surveillance	O
,	O
Epidemiology	O
,	O
and	O
End	O
Results	O
Program	O
to	O
identify	O
cervical	B-T191
cancer	I-T191
patients	O
who	O
underwent	O
hysterectomy	B-T061
between	O
1973	O
and	O
2003	O
.	O
Logistic	O
regression	O
models	O
were	O
used	O
to	O
identify	O
risk	B-T033
factors	I-T033
for	O
uterine	B-T191
corpus	I-T191
tumor	I-T191
invasion	B-T033
on	O
multivariable	O
analysis	O
.	O
Association	O
of	O
uterine	B-T191
corpus	I-T191
tumor	I-T191
invasion	B-T033
and	O
cause	O
-	O
specific	O
survival	O
(	O
CSS	O
)	O
from	O
cervical	B-T191
cancer	I-T191
was	O
examined	O
with	O
Cox	O
proportional	O
hazard	O
regression	O
models	O
on	O
multivariable	O
analysis	O
.	O
We	O
identified	O
837	O
(	O
4.9	O
%	O
)	O
cases	O
of	O
uterine	B-T191
corpus	I-T191
invasion	B-T033
and	O
16,237	O
(	O
95.1	O
%	O
)	O
cases	O
of	O
non	O
-	O
invasion	O
.	O
Median	O
follow	B-T058
-	I-T058
up	I-T058
time	O
was	O
14.0	O
years	O
.	O
There	O
were	O
1642	O
deaths	O
due	O
to	O
cervical	B-T191
cancer	I-T191
.	O
Uterine	B-T191
corpus	I-T191
invasion	B-T033
was	O
independently	O
associated	O
with	O
older	O
age	O
,	O
non	O
-	O
squamous	O
histology	O
,	O
high	B-T191
-	I-T191
grade	I-T191
tumors	I-T191
,	O
large	O
tumor	O
size	O
,	O
and	O
nodal	O
metastasis	B-T191
on	O
multivariable	O
analysis	O
(	O
all	O
,	O
P	O
<	O
0.001	O
)	O
.	O
On	O
univariable	O
analysis	O
,	O
uterine	B-T191
corpus	I-T191
tumor	I-T191
invasion	B-T033
was	O
significantly	O
associated	O
with	O
decreased	O
CSS	O
compared	O
to	O
the	O
non	O
-	O
invasion	O
(	O
5	O
-	O
year	O
rates	O
,	O
79.0	O
%	O
versus	O
94.5	O
%	O
,	O
P	O
<	O
0.001	O
)	O
.	O
After	O
controlling	O
for	O
other	O
significant	O
prognostic	O
factors	O
,	O
uterine	B-T191
corpus	I-T191
tumor	I-T191
invasion	B-T033
remained	O
an	O
independent	O
prognostic	O
factor	O
for	O
decreased	O
CSS	O
(	O
adjusted	O
-	O
hazard	O
ratio	O
1.45	O
,	O
95	O
%	O
confidence	O
interval	O
1.21	O
-	O
1.74	O
)	O
.	O
Among	O
stage	O
T1b	O
cases	O
(	O
n	O
=	O
6730	O
)	O
,	O
uterine	B-T191
corpus	I-T191
tumor	I-T191
invasion	B-T033
remained	O
an	O
independent	O
prognostic	O
factor	O
for	O
decreased	O
CSS	O
(	O
adjusted	O
-	O
hazard	O
ratio	O
1.95	O
,	O
95%CI	O
1.47	O
-	O
2.60	O
)	O
.	O
Uterine	B-T191
corpus	I-T191
tumor	I-T191
invasion	B-T033
was	O
significantly	O
associated	O
with	O
decreased	O
CSS	O
in	O
stage	O
T1b1	O
disease	B-T191
(	O
74.5	O
%	O
versus	O
90.7	O
%	O
,	O
P	O
<	O
0.001	O
)	O
and	O
in	O
stage	O
T1b2	O
disease	B-T191
(	O
67.0	O
%	O
versus	O
79.5	O
%	O
,	O
P	O
=	O
0.01	O
)	O
.	O
Uterine	B-T191
corpus	I-T191
tumor	I-T191
invasion	B-T033
is	O
an	O
independent	O
prognostic	O
factor	O
for	O
decreased	O
survival	O
of	O
women	O
with	O
early	O
-	O
stage	O
cervical	B-T191
cancer	I-T191
.	O
      
Temporal	O
Stability	O
of	O
Heavy	B-T033
Drinking	I-T033
Days	O
and	O
Drinking	O
Reductions	B-T061
Among	O
Heavy	O
Drinkers	O
in	O
the	O
COMBINE	O
Study	O
Recently	O
,	O
the	O
Food	O
and	O
Drug	O
Administration	O
(	O
FDA	O
)	O
proposed	O
to	O
expand	O
the	O
options	O
for	O
primary	O
end	O
points	O
in	O
the	O
development	O
of	O
medications	B-T058
for	O
alcohol	B-T048
use	I-T048
disorder	I-T048
to	O
include	O
either	O
abstinence	B-T061
from	O
alcohol	O
or	O
a	O
nonabstinent	B-T033
outcome	O
:	O
no	O
heavy	B-T033
drinking	I-T033
days	O
(	O
with	O
a	O
heavy	B-T033
drinking	I-T033
day	O
defined	O
as	O
more	O
than	O
3	O
drinks	O
per	O
day	O
for	O
women	O
and	O
more	O
than	O
4	O
drinks	O
per	O
day	O
for	O
men	O
[	O
>	O
3/>4	O
cutoff	O
]	O
)	O
.	O
The	O
FDA	O
also	O
suggested	O
that	O
6	O
months	O
would	O
be	O
the	O
most	O
appropriate	O
length	O
for	O
a	O
clinical	O
trial	O
to	O
demonstrate	O
the	O
stability	O
of	O
this	O
nonabstinent	B-T033
drinking	O
outcome	O
.	O
However	O
,	O
few	O
alcohol	O
clinical	O
trials	O
have	O
examined	B-T033
the	O
stability	O
of	O
nonheavy	B-T033
drinking	I-T033
during	O
and	O
after	B-T058
treatment	I-T058
.	O
In	O
a	O
secondary	O
analysis	O
of	O
the	O
COMBINE	O
study	O
data	O
(	O
n	O
=	O
1,383	O
)	O
,	O
we	O
examined	B-T033
transitions	O
in	O
heavy	B-T033
drinking	I-T033
days	O
during	O
the	O
course	O
of	O
treatment	O
(	O
months	O
1	O
through	O
4	O
)	O
,	O
during	O
the	O
transition	O
out	O
of	O
treatment	B-T061
(	O
months	O
4	O
through	O
7	O
)	O
,	O
and	O
up	O
to	O
12	O
months	O
afterward	O
(	O
months	O
13	O
through	O
16	O
)	O
using	O
latent	O
variable	O
mixture	O
models	O
.	O
Heavy	B-T033
drinking	I-T033
and	O
nonheavy	B-T033
drinking	I-T033
were	O
relatively	O
stable	O
in	O
consecutive	O
months	O
(	O
minimum	O
agreement	O
[	O
kappa	O
]	O
=	O
0.64	O
for	O
months	O
1	O
to	O
2	O
)	O
.	O
Most	O
individuals	O
were	O
stable	O
low	O
-	O
risk	O
drinkers	B-T033
/	O
abstainers	O
or	O
heavy	O
drinkers	O
by	O
the	O
end	O
of	O
treatment	B-T061
,	O
as	O
characterized	O
by	O
a	O
10	O
%	O
probability	O
(	O
or	O
less	O
)	O
of	O
transitioning	O
out	O
of	O
either	O
a	O
no	O
heavy	B-T033
drinking	I-T033
state	O
or	O
a	O
heavy	B-T033
drinking	I-T033
state	O
.	O
More	O
than	O
two	O
-	O
thirds	O
of	O
the	O
heavy	O
drinkers	O
who	O
exceeded	O
the	O
heavy	B-T033
drinking	I-T033
threshold	O
during	O
treatment	O
reported	B-T058
,	O
on	O
average	O
,	O
a	O
64	O
%	O
reduction	B-T061
in	O
drinking	B-T033
frequency	I-T033
and	O
a	O
38	O
%	O
reduction	B-T061
in	O
drinking	O
intensity	O
from	O
pretreatment	O
drinking	O
levels	O
.	O
The	O
results	O
show	O
stability	O
of	O
no	O
heavy	B-T033
drinking	I-T033
as	O
an	O
outcome	O
within	O
the	O
first	O
4	O
months	O
of	O
treatment	B-T061
and	O
that	O
the	O
>	O
3/>4	O
drink	O
cutoff	O
may	O
mask	O
substantial	O
reductions	B-T061
in	O
alcohol	O
consumption	O
among	O
some	O
patients	O
.	O
Future	O
studies	O
should	O
explore	O
the	O
clinical	O
utility	O
of	O
reduction	B-T061
end	O
points	O
.	O
      
Quantitative	O
analysis	O
of	O
cell	O
proliferation	O
by	O
a	O
dye	B-T060
dilution	I-T060
assay	I-T060
:	O
Application	O
to	O
cell	O
lines	O
and	O
cocultures	B-T059
Cell	O
proliferation	O
represents	O
one	O
of	O
the	O
most	O
fundamental	O
processes	O
in	O
biological	O
systems	O
,	O
thus	O
the	O
quantitative	O
analysis	O
of	O
cell	O
proliferation	O
is	O
important	O
in	O
many	O
biological	O
applications	O
such	O
as	O
drug	B-T059
screening	I-T059
,	O
production	O
of	O
biologics	B-T121
,	O
and	O
assessment	B-T058
of	O
cytotoxicity	O
.	O
Conventional	O
proliferation	O
assays	O
mainly	O
quantify	O
cell	B-T059
number	I-T059
based	O
on	O
a	O
calibration	O
curve	O
of	O
a	O
homogeneous	O
cell	O
population	O
,	O
and	O
therefore	O
are	O
not	O
applicable	O
for	O
the	O
analysis	O
of	O
cocultured	O
cells	O
.	O
Moreover	O
,	O
these	O
assays	B-T059
measure	O
cell	O
proliferation	O
indirectly	O
,	O
based	O
on	O
cellular	O
metabolic	O
activity	O
or	O
DNA	O
content	O
.	O
To	O
overcome	O
these	O
shortcomings	O
,	O
a	O
dye	B-T060
dilution	I-T060
assay	I-T060
employing	O
fluorescent	O
cell	O
tracking	O
dyes	O
that	O
are	O
retained	O
within	O
cells	O
was	O
applied	O
and	O
was	O
diluted	O
proportionally	O
by	O
subsequent	O
cell	O
divisions	O
.	O
Here	O
,	O
it	O
was	O
demonstrated	O
that	O
this	O
assay	B-T059
could	O
be	O
implemented	O
to	O
quantitatively	O
analyze	O
the	O
cell	O
proliferation	O
of	O
different	O
types	O
of	O
cell	O
lines	O
,	O
and	O
to	O
concurrently	O
analyze	O
the	O
proliferation	O
of	O
two	O
types	O
of	O
cell	O
lines	O
in	O
coculture	B-T059
by	O
utilizing	O
cell	O
tracking	O
dyes	O
with	O
different	O
spectral	O
characteristics	O
.	O
The	O
mean	O
division	O
time	O
estimated	O
by	O
the	O
dye	B-T060
dilution	I-T060
assay	I-T060
is	O
compared	O
with	O
the	O
population	O
doubling	O
time	O
obtained	O
from	O
conventional	O
methods	O
and	O
values	O
from	O
literature	O
.	O
Additionally	O
,	O
dye	O
transfer	O
between	O
cocultured	O
cells	O
was	O
investigated	O
and	O
it	O
was	O
found	O
that	O
it	O
is	O
a	O
characteristic	O
of	O
the	O
cells	O
rather	O
than	O
a	O
characteristic	O
of	O
the	O
dye	O
.	O
It	O
was	O
suggested	O
that	O
this	O
method	O
can	O
be	O
easily	O
combined	O
with	O
other	O
flow	B-T059
cytometric	I-T059
analyses	I-T059
of	O
cellular	O
properties	O
,	O
providing	O
valuable	O
information	O
on	O
cell	O
status	O
under	O
diverse	O
conditions	O
.	O
©	O
2017	O
International	O
Society	O
for	O
Advancement	O
of	O
Cytometry	O
.	O
      
Iterative	B-T033
Development	O
and	O
Evaluation	B-T058
of	O
a	O
Pharmacogenomic	O
-Guided	O
Clinical	O
Decision	O
Support	O
System	O
for	O
Warfarin	O
Dosing	O
Pharmacogenomic	O
-guided	O
dosing	O
has	O
the	O
potential	O
to	O
improve	O
patient	O
outcomes	O
but	O
its	O
implementation	O
has	O
been	O
met	O
with	O
clinical	O
challenges	B-T058
.	O
Our	O
objective	O
was	O
to	O
develop	O
and	O
evaluate	B-T058
a	O
clinical	O
decision	O
support	O
system	O
(	O
CDSS	O
)	O
for	O
pharmacogenomic	O
-guided	O
warfarin	O
dosing	O
designed	O
for	O
physicians	O
and	O
pharmacists	O
.	O
Twelve	O
physicians	O
and	O
pharmacists	O
completed	O
6	O
prescribing	B-T058
tasks	O
using	O
simulated	O
patient	O
scenarios	O
in	O
two	O
iterations	B-T033
(	O
development	O
and	O
validation	O
phases	O
)	O
of	O
a	O
newly	O
developed	O
pharmacogenomic	O
-driven	O
CDSS	O
prototype	O
.	O
For	O
each	O
scenario	O
,	O
usability	O
was	O
measured	O
via	O
efficiency	O
,	O
recorded	O
as	O
time	O
to	O
task	O
completion	O
,	O
and	O
participants	O
'	O
perceived	O
satisfaction	O
which	O
were	O
compared	O
using	O
Kruskal	O
-	O
Wallis	O
and	O
Mann	O
Whitney	O
U	O
tests	O
,	O
respectively	O
.	O
Debrief	O
interviews	O
were	O
conducted	O
and	O
qualitatively	B-T059
analyzed	I-T059
.	O
Usability	O
findings	O
from	O
the	O
first	O
(	O
i.e.	O
development	O
)	O
iteration	B-T033
were	O
incorporated	O
into	O
the	O
CDSS	O
design	O
for	O
the	O
second	O
(	O
i.e.	O
validation	O
)	O
iteration	B-T033
.	O
During	O
the	O
CDSS	O
validation	O
iteration	B-T033
,	O
participants	O
took	O
more	O
time	O
to	O
complete	O
tasks	O
with	O
a	O
median	O
(	O
IQR	O
)	O
of	O
183	O
(	O
124	O
-	O
247	O
)	O
seconds	O
versus	O
101	O
(	O
73.5	O
-	O
197	O
)	O
seconds	O
in	O
the	O
development	O
iteration	B-T033
(	O
p=0.01	O
)	O
.	O
This	O
increase	O
in	O
time	O
on	O
task	O
was	O
due	O
to	O
the	O
increase	O
in	O
time	O
spent	O
in	O
the	O
CDSS	O
corresponding	O
to	O
several	O
design	O
changes	O
.	O
Efficiency	O
differences	O
that	O
were	O
observed	O
between	O
pharmacists	O
and	O
physicians	O
in	O
the	O
development	O
iteration	B-T033
were	O
eliminated	O
in	O
the	O
validation	O
iteration	B-T033
.	O
The	O
increased	O
use	O
of	O
the	O
CDSS	O
corresponded	O
to	O
a	O
greater	O
acceptance	O
of	O
CDSS	O
recommended	O
doses	O
in	O
the	O
validation	O
iteration	B-T033
(	O
4	O
%	O
in	O
the	O
first	O
iteration	B-T033
vs.	O
37.5	O
%	O
in	O
the	O
second	O
iteration	B-T033
,	O
p<0.001	O
)	O
.	O
Overall	O
satisfaction	O
did	O
not	O
change	O
statistically	O
between	O
the	O
iterations	B-T033
but	O
the	O
qualitative	B-T059
analysis	I-T059
revealed	O
greater	O
trust	O
in	O
the	O
second	O
prototype	O
.	O
A	O
pharmacogenomic	O
-guided	O
CDSS	O
has	O
been	O
developed	O
using	O
warfarin	B-T121
as	O
the	O
test	O
drug	B-T121
.	O
The	O
final	O
CDSS	O
prototype	O
was	O
trusted	O
by	O
prescribers	O
and	O
significantly	O
increased	O
the	O
time	O
using	O
the	O
tool	B-T033
and	O
acceptance	O
of	O
the	O
recommended	O
doses	O
.	O
This	O
study	O
is	O
an	O
important	O
step	O
toward	O
incorporating	O
pharmacogenomics	O
into	O
CDSS	O
design	O
for	O
clinical	O
testing	O
.	O
      
Morphogenetic	O
Alterations	O
of	O
Alternaria	O
alternata	O
Exposed	O
to	O
Dicarboximide	O
Fungicide	O
,	O
Iprodione	O
Fungicide	O
-	O
resistant	O
Alternaria	O
alternata	O
impede	O
the	O
practical	O
control	O
of	O
the	O
Alternaria	B-T047
diseases	I-T047
in	O
crop	O
fields	O
.	O
This	O
study	O
aimed	O
to	O
investigate	O
cytological	O
fungicide	O
resistance	O
mechanisms	O
of	O
A.	O
alternata	O
against	O
dicarboximide	O
fungicide	O
iprodione	O
.	O
A.	O
alternata	O
isolated	O
from	O
cactus	O
brown	O
spot	O
was	O
cultured	B-T059
on	O
potato	O
-	O
dextrose	O
agar	O
(	O
PDA	O
)	O
with	O
or	O
without	O
iprodione	O
,	O
and	O
the	O
fungal	B-T059
cultures	I-T059
with	O
different	O
growth	O
characteristics	O
from	O
no	O
,	O
initial	O
and	O
full	O
growth	O
were	O
observed	O
by	O
light	B-T059
and	O
electron	B-T059
microscopy	I-T059
.	O
Mycelia	O
began	O
to	O
grow	O
from	O
one	O
day	O
after	O
incubation	O
(	O
DAI	O
)	O
and	O
continued	O
to	O
be	O
in	O
full	O
growth	O
(	O
control	O
-	O
growth	O
,	O
Con	O
-	O
G	O
)	O
on	O
PDA	O
without	O
fungicide	O
,	O
while	O
on	O
PDA	O
with	O
iprodione	O
,	O
no	O
fungal	O
growth	O
(	O
iprodione	O
-	O
no	O
growth	O
,	O
Ipr	O
-	O
N	O
)	O
occurred	O
for	O
the	O
first	O
3	O
DAI	O
,	O
but	O
once	O
the	O
initial	O
growth	O
(	O
iprodione	O
-	O
initial	O
growth	O
,	O
Ipr	O
-	O
I	O
)	O
began	O
at	O
4	O
-	O
5	O
DAI	O
,	O
the	O
colonies	O
grew	O
and	O
expanded	O
continuously	O
to	O
be	O
in	O
full	O
growth	O
(	O
iprodione	O
-	O
growth	O
,	O
Ipr	O
-	O
G	O
)	O
,	O
suggesting	O
Ipr	O
-	O
I	O
may	O
be	O
a	O
turning	O
moment	O
of	O
the	O
morphogenetic	O
changes	O
resisting	O
fungicidal	O
toxicity	O
.	O
Con	O
-	O
G	O
formed	O
multicellular	O
conidia	O
with	O
cell	O
walls	O
and	O
septa	O
and	O
intact	O
dense	O
cytoplasm	O
.	O
In	O
Ipr	O
-	O
N	O
,	O
fungal	O
sporulation	O
was	O
inhibited	O
by	O
forming	O
mostly	O
undeveloped	B-T033
unicellular	O
conidia	O
with	O
degraded	B-T033
and	O
necrotic	O
cytoplasm	O
.	O
However	O
,	O
in	O
Ipr	O
-	O
I	O
,	O
conspicuous	O
cellular	O
changes	O
occurred	O
during	O
sporulation	O
by	O
forming	O
multicellular	O
conidia	O
with	O
double	B-T033
layered	I-T033
(	O
thickened	B-T033
)	O
cell	O
walls	O
and	O
accumulation	B-T033
of	O
proliferated	O
lipid	O
bodies	O
in	O
the	O
conidial	O
cytoplasm	O
,	O
which	O
may	O
inhibit	O
the	O
penetration	O
of	O
the	O
fungicide	O
into	O
conidial	O
cells	O
,	O
reducing	O
fungicide	O
-	O
associated	O
toxicity	O
,	O
and	O
may	O
be	O
utilized	O
as	O
energy	O
and	O
nutritional	O
sources	B-T033
,	O
respectively	O
,	O
for	O
the	O
further	O
fungal	O
growth	O
to	O
form	O
mature	O
colonies	O
as	O
in	O
Ipr	O
-	O
G	O
that	O
formed	O
multicellular	O
conidia	O
with	O
cell	O
walls	O
and	O
intact	O
cytoplasm	O
with	O
lipid	O
bodies	O
as	O
in	O
Con	O
-	O
G.	O
      
Effect	O
of	O
peritoneal	B-T058
lavage	I-T058
solution	O
temperature	O
on	O
body	O
temperature	O
in	O
anaesthetised	B-T033
cats	O
and	O
small	O
dogs	O
A	O
prospective	O
,	O
randomised	O
,	O
non	O
-	O
blinded	O
,	O
clinical	O
study	O
to	O
assess	O
the	O
effect	O
of	O
peritoneal	B-T058
lavage	I-T058
using	O
warmed	O
fluid	O
on	O
body	O
temperature	O
in	O
anesthetised	B-T033
cats	O
and	O
dogs	O
of	O
less	O
than	O
10	O
kg	O
body	B-T033
mass	I-T033
undergoing	O
coeliotomy	B-T061
.	O
A	O
standardised	O
anaesthetic	O
protocol	O
was	O
used	O
.	O
Oesophageal	B-T058
and	O
rectal	B-T033
temperatures	I-T033
were	O
measured	O
at	O
various	O
time	O
points	O
.	O
At	O
the	O
end	O
of	O
surgery	B-T061
,	O
group	O
1	O
patients	O
(	O
n=10	O
)	O
were	O
lavaged	B-T061
with	O
200	O
ml	O
/	O
kg	O
sterile	O
isotonic	B-T121
saline	I-T121
at	O
34±1	O
°	O
C	O
and	O
group	O
2	O
(	O
n=10	O
)	O
at	O
40±1	O
°	O
C	O
.	O
Groups	O
were	O
similar	O
with	O
respect	O
to	O
age	O
,	O
mass	O
,	O
body	B-T033
condition	I-T033
and	O
surgical	B-T061
incision	I-T061
length	O
.	O
Duration	O
of	O
anaesthesia	B-T061
,	O
surgical	B-T061
procedures	I-T061
and	O
peritoneal	B-T058
lavage	I-T058
was	O
similar	O
between	O
groups	O
.	O
Linear	O
regression	O
showed	O
no	B-T033
significant	I-T033
change	I-T033
in	O
oesophageal	B-T058
temperature	I-T058
during	O
the	O
lavage	B-T061
period	O
for	O
group	O
1	O
(	O
P=0.64	O
)	O
,	O
but	O
a	O
significant	O
increase	O
for	O
group	O
2	O
patients	O
(	O
P<0.0001	O
)	O
,	O
with	O
mean	O
temperature	O
changes	O
of	O
-0.5	O
°	O
C	O
(	O
from	O
(	O
36.3	O
°	O
C	O
to	O
35.9	O
°	O
C	O
)	O
and	O
+0.9	O
°	O
C	O
(	O
from	O
35.4	O
°	O
C	O
to	O
36.3	O
°	O
C	O
)	O
,	O
respectively	O
.	O
Similar	O
results	B-T033
were	O
found	O
for	O
rectal	B-T033
temperature	I-T033
,	O
with	O
mean	O
changes	O
of	O
-0.5	O
°	O
C	O
and	O
+0.8	O
°	O
C	O
(	O
P=0.922	O
and	O
0.045	O
)	O
,	O
respectively	O
.	O
The	O
use	O
of	O
isotonic	B-T121
crystalloid	B-T121
solution	I-T121
for	O
peritoneal	B-T058
lavage	I-T058
at	O
a	O
temperature	O
of	O
40±1	O
°	O
C	O
significantly	O
warms	O
small	O
animal	O
patients	O
,	O
when	O
applied	O
in	O
a	O
clinical	O
setting	O
,	O
compared	O
with	O
lavage	B-T061
solution	O
at	O
34±1	O
°	O
C	O
.	O
      
Reversible	O
Humidity	O
Sensitive	O
Clothing	O
for	O
Personal	B-T061
Thermoregulation	I-T061
Two	O
kinds	O
of	O
humidity	O
-	O
induced	O
,	O
bendable	O
smart	O
clothing	O
have	O
been	O
designed	O
to	O
reversibly	O
adapt	O
their	O
thermal	O
insulation	O
functionality	O
.	O
The	O
first	O
design	O
mimics	O
the	O
pores	B-T023
in	O
human	O
skin	O
,	O
in	O
which	O
pre	O
-	O
cut	O
flaps	O
open	O
to	O
produce	O
pores	B-T023
in	O
Nafion	O
sheets	O
when	O
humidity	O
increases	O
,	O
as	O
might	O
occur	O
during	O
human	B-T033
sweating	I-T033
thus	O
permitting	O
air	O
flow	O
and	O
reducing	O
both	O
the	O
humidity	O
level	O
and	O
the	O
apparent	O
temperature	O
.	O
Like	O
the	O
smart	O
human	B-T023
sweating	I-T023
pores	I-T023
,	O
the	O
flaps	O
can	O
close	O
automatically	O
after	O
the	O
perspiration	B-T033
to	O
keep	O
the	O
wearer	O
warm	O
.	O
The	O
second	O
design	O
involves	O
thickness	O
adjustable	O
clothes	O
by	O
inserting	O
the	O
bent	O
polymer	O
sheets	O
between	O
two	O
fabrics	O
.	O
As	O
the	O
humidity	O
increases	O
,	O
the	O
sheets	O
become	O
thinner	O
,	O
thus	O
reducing	O
the	O
gap	O
between	O
the	O
two	O
fabrics	O
to	O
reduce	O
the	O
thermal	O
insulation	O
.	O
The	O
insulation	O
layer	O
can	O
recover	O
its	O
original	O
thickness	O
upon	O
humidity	O
reduction	O
to	O
restore	O
its	O
warmth	O
-	O
preservation	O
function	O
.	O
Such	O
humidity	O
sensitive	O
smart	O
polymer	O
materials	O
can	O
be	O
utilized	O
to	O
adjust	O
personal	O
comfort	O
,	O
and	O
be	O
effective	O
in	O
reducing	B-T033
energy	I-T033
consumption	I-T033
for	O
building	O
heating	O
or	O
cooling	O
with	O
numerous	O
smart	O
design	O
.	O
      
SARS	B-T047
-	O
CoV	B-T005
fusion	O
peptides	O
induce	O
membrane	O
surface	O
ordering	O
and	O
curvature	O
Viral	O
membrane	O
fusion	O
is	O
an	O
orchestrated	O
process	O
triggered	O
by	O
membrane	O
-	O
anchored	O
viral	O
fusion	O
glycoproteins	O
.	O
The	O
S2	O
subunit	O
of	O
the	O
spike	O
glycoprotein	O
from	O
severe	B-T047
acute	I-T047
respiratory	I-T047
syndrome	I-T047
(	O
SARS	B-T047
)	O
coronavirus	B-T005
(	O
CoV	B-T005
)	O
contains	O
internal	O
domains	O
called	O
fusion	O
peptides	O
(	O
FP	O
)	O
that	O
play	O
essential	O
roles	O
in	O
virus	O
entry	O
.	O
Although	O
membrane	O
fusion	O
has	O
been	O
broadly	O
studied	O
,	O
there	O
are	O
still	O
major	O
gaps	O
in	O
the	O
molecular	O
details	O
of	O
lipid	O
rearrangements	O
in	O
the	O
bilayer	O
during	O
fusion	O
peptide	O
-	O
membrane	O
interactions	O
.	O
Here	O
we	O
employed	O
differential	B-T059
scanning	I-T059
calorimetry	I-T059
(	O
DSC	B-T059
)	O
and	O
electron	B-T059
spin	I-T059
resonance	I-T059
(	O
ESR	B-T059
)	O
to	O
gather	O
information	O
on	O
the	O
membrane	O
fusion	O
mechanism	O
promoted	O
by	O
two	O
putative	O
SARS	B-T047
FPs	O
.	O
DSC	B-T059
data	O
showed	O
the	O
peptides	O
strongly	O
perturb	O
the	O
structural	O
integrity	O
of	O
anionic	O
vesicles	O
and	O
support	O
the	O
hypothesis	O
that	O
the	O
peptides	O
generate	O
opposing	O
curvature	O
stresses	O
on	O
phosphatidylethanolamine	O
membranes	O
.	O
ESR	B-T059
showed	O
that	O
both	O
FPs	O
increase	O
lipid	O
packing	O
and	O
head	O
group	O
ordering	O
as	O
well	O
as	O
reduce	O
the	O
intramembrane	O
water	O
content	O
for	O
anionic	O
membranes	O
.	O
Therefore	O
,	O
bending	O
moment	O
in	O
the	O
bilayer	O
could	O
be	O
generated	O
,	O
promoting	O
negative	O
curvature	O
.	O
The	O
significance	O
of	O
the	O
ordering	O
effect	O
,	O
membrane	O
dehydration	B-T033
,	O
changes	O
in	O
the	O
curvature	O
properties	O
and	O
the	O
possible	O
role	O
of	O
negatively	O
charged	O
phospholipids	O
in	O
helping	O
to	O
overcome	O
the	O
high	O
kinetic	O
barrier	O
involved	O
in	O
the	O
different	O
stages	O
of	O
the	O
SARS	B-T047
-	O
CoV	B-T005
-mediated	O
membrane	O
fusion	O
are	O
discussed	O
.	O
      
Juicer	O
Provides	O
a	O
One	O
-	O
Click	O
System	O
for	O
Analyzing	O
Loop	B-T059
-	I-T059
Resolution	I-T059
Hi	I-T059
-	I-T059
C	I-T059
Experiments	I-T059
Hi	B-T059
-	I-T059
C	I-T059
experiments	I-T059
explore	O
the	O
3D	O
structure	O
of	O
the	O
genome	O
,	O
generating	O
terabases	O
of	O
data	O
to	O
create	O
high	B-T059
-	I-T059
resolution	I-T059
contact	O
maps	O
.	O
Here	O
,	O
we	O
introduce	O
Juicer	O
,	O
an	O
open	O
-	O
source	O
tool	O
for	O
analyzing	O
terabase	O
-	O
scale	O
Hi	O
-	O
C	O
datasets	O
.	O
Juicer	O
allows	O
users	O
without	O
a	O
computational	O
background	O
to	O
transform	O
raw	O
sequence	O
data	O
into	O
normalized	O
contact	O
maps	O
with	O
one	O
click	O
.	O
Juicer	O
produces	O
a	O
hic	O
file	O
containing	O
compressed	O
contact	O
matrices	O
at	O
many	O
resolutions	O
,	O
facilitating	O
visualization	O
and	O
analysis	O
at	O
multiple	O
scales	O
.	O
Structural	O
features	O
,	O
such	O
as	O
loops	O
and	O
domains	O
,	O
are	O
automatically	O
annotated	O
.	O
Juicer	O
is	O
available	O
as	O
open	O
source	O
software	O
at	O
http://aidenlab.org/juicer/.	O
      
Impact	O
of	O
antibiotic	B-T195
de	B-T061
-	I-T061
escalation	I-T061
on	O
clinical	O
outcomes	O
in	O
community	O
-	O
acquired	O
pneumococcal	B-T047
pneumonia	I-T047
Although	O
antibiotic	B-T195
de	B-T061
-	I-T061
escalation	I-T061
is	O
regarded	O
as	O
a	O
measure	O
that	O
reduces	O
selection	O
pressure	O
,	O
adverse	O
drug	O
effects	O
and	O
costs	O
,	O
evidence	O
supporting	O
this	O
practice	O
in	O
community	B-T047
-	I-T047
acquired	I-T047
pneumococcal	I-T047
pneumonia	I-T047
(	O
CAPP	B-T047
)	O
is	O
lacking	O
.	O
We	O
carried	O
out	O
a	O
retrospective	O
analysis	O
of	O
prospectively	O
collected	O
data	O
of	O
a	O
cohort	O
of	O
hospitalized	O
adults	O
with	O
CAPP	B-T047
.	O
Pneumococcal	B-T047
aetiology	O
was	O
established	O
in	O
patients	O
with	O
one	O
or	O
more	O
positive	B-T033
cultures	I-T033
for	O
Streptococcus	B-T007
pneumoniae	I-T007
obtained	O
from	O
blood	O
,	O
sterile	O
fluids	O
or	O
sputum	O
,	O
and/or	O
a	O
positive	B-T033
urinary	B-T059
antigen	I-T059
test	I-T059
.	O
De	B-T061
-	I-T061
escalation	I-T061
therapy	I-T061
was	O
considered	O
when	O
the	O
initial	O
antibiotic	B-T061
therapy	I-T061
was	O
narrowed	O
to	O
penicillin	B-T195
,	O
amoxicillin	B-T195
or	O
amoxicillin	B-T121
/	I-T121
clavulanate	I-T121
within	O
the	O
first	O
72	O
h	O
after	O
admission	B-T058
.	O
The	O
primary	O
outcomes	O
were	O
30	O
day	O
mortality	O
and	O
length	O
of	O
hospital	O
stay	O
(	O
LOS	O
)	O
.	O
Adjustment	O
for	O
confounders	O
was	O
performed	O
with	O
multivariate	O
and	O
propensity	O
score	O
analyses	O
.	O
Of	O
1410	O
episodes	O
of	O
CAPP	B-T047
,	O
antibiotic	B-T195
de	B-T061
-	I-T061
escalation	I-T061
within	O
the	O
first	O
72	O
h	O
after	O
admission	B-T058
was	O
performed	O
in	O
166	O
cases	O
.	O
After	O
adjustment	O
,	O
antibiotic	B-T195
de	B-T061
-	I-T061
escalation	I-T061
was	O
not	O
associated	O
with	O
a	O
higher	O
risk	O
of	O
mortality	O
(	O
OR	O
=	O
0.83	O
,	O
95	O
%	O
CI	O
=	O
0.24	O
-	O
2.81	O
)	O
,	O
but	O
it	O
was	O
found	O
to	O
be	O
a	O
protective	O
factor	O
for	O
prolonged	O
LOS	O
(	O
above	O
the	O
median	O
)	O
(	O
OR	O
=	O
0.46	O
,	O
95	O
%	O
CI	O
=	O
0.30	O
-	O
0.70	O
)	O
.	O
Similar	O
results	O
were	O
found	O
in	O
patients	O
classified	O
into	O
high	B-T033
-	I-T033
risk	I-T033
pneumonia	B-T047
severity	O
index	O
classes	O
(	O
IV	O
-	O
V	O
)	O
,	O
those	O
with	O
clinical	B-T033
instability	I-T033
and	O
those	O
with	O
bacteraemia	B-T047
.	O
No	B-T033
significant	I-T033
differences	I-T033
were	O
documented	B-T058
in	O
adverse	O
drug	O
reactions	O
or	O
readmission	B-T058
(	O
<	O
30	O
days	O
)	O
.	O
Antibiotic	B-T195
de	B-T061
-	I-T061
escalation	I-T061
seems	O
to	O
be	O
safe	O
and	O
effective	O
in	O
reducing	O
the	O
duration	O
of	O
LOS	O
,	O
and	O
did	O
not	O
adversely	O
affect	O
outcomes	O
of	O
patients	O
with	O
CAPP	B-T047
,	O
even	O
those	O
with	O
bacteraemia	B-T047
and	O
severe	B-T047
disease	I-T047
,	O
and	O
those	O
who	O
were	O
clinically	B-T033
unstable	I-T033
.	O
      
Signs	B-T184
of	O
dysarthria	B-T048
in	O
adults	O
with	O
22q11.2	B-T047
deletion	I-T047
syndrome	I-T047
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
how	O
adults	O
with	O
22q11.2	B-T047
deletion	I-T047
syndrome	I-T047
(	O
22q11DS	B-T047
)	O
performed	O
on	O
dysarthria	B-T048
and	O
intelligibility	O
tests	B-T060
compared	O
with	O
a	O
control	O
group	O
.	O
Ten	O
participants	O
with	O
confirmed	O
22q11.2	O
deletion	O
,	O
five	O
males	O
and	O
five	O
females	O
with	O
a	O
mean	O
age	O
of	O
31	O
years	O
(	O
range	O
:	O
19	O
-	O
49	O
)	O
,	O
were	O
compared	O
with	O
a	O
control	O
group	O
matched	O
for	O
gender	O
and	O
age	O
(	O
five	O
males	O
and	O
five	O
females	O
,	O
mean	O
age	O
:	O
32	O
years	O
,	O
range	O
:	O
19	O
-	O
49	O
)	O
.	O
Assessment	O
of	O
non	B-T060
-	I-T060
verbal	I-T060
and	I-T060
verbal	I-T060
tasks	I-T060
reflecting	O
respiration	O
,	O
phonation	O
,	O
oral	O
motor	O
function	O
,	O
velopharyngeal	B-T059
function	I-T059
,	O
articulation	O
,	O
and	O
prosody	B-T033
was	O
performed	O
as	O
well	O
as	O
the	O
Swedish	O
Test	O
of	O
Intelligibility	O
(	O
STI	O
)	O
.	O
All	O
assessments	O
were	O
made	O
by	O
two	O
raters	O
;	O
inter	O
-	O
rater	O
and	O
intra	O
-	O
rater	O
reliability	O
was	O
acceptable	O
.	O
The	O
participants	O
with	O
22q11DS	B-T047
had	O
significantly	O
more	O
problems	B-T033
than	O
the	O
control	O
group	O
on	O
all	O
investigated	O
dimensions	O
except	O
the	O
STI	O
.	O
Overall	O
,	O
the	O
severity	O
of	O
their	O
speech	B-T033
deviation	I-T033
was	O
rated	O
as	O
mild	O
to	O
moderate	O
.	O
The	O
largest	O
difficulties	O
were	O
found	O
regarding	O
speech	O
respiration	O
,	O
phonation	O
,	O
oral	O
motor	O
function	O
,	O
and	O
velopharyngeal	B-T059
function	I-T059
.	O
The	O
results	O
of	O
the	O
present	O
study	O
suggest	O
that	O
a	O
neurological	O
etiology	O
could	O
be	O
added	O
to	O
the	O
previously	O
described	O
structural	O
etiology	O
explaining	O
the	O
speech	B-T033
difficulties	I-T033
found	O
in	O
22q11DS	B-T047
.	O
Signs	B-T184
of	O
difficulties	O
in	O
both	O
speech	O
motor	O
planning	O
and	O
speech	O
motor	O
programming	O
were	O
found	O
.	O
Further	O
studies	O
are	O
needed	O
to	O
confirm	O
the	O
results	O
,	O
as	O
are	O
studies	O
of	O
the	O
association	O
between	O
structural	B-T033
brain	I-T033
abnormalities	I-T033
and	O
neurological	B-T184
speech	I-T184
symptoms	I-T184
.	O
For	O
clinical	O
purposes	O
,	O
it	O
is	O
important	O
that	O
clinicians	O
have	O
knowledge	O
about	O
the	O
variable	O
speech	B-T184
symptoms	I-T184
that	O
may	O
occur	O
in	O
individuals	O
with	O
22q11DS	B-T047
and	O
that	O
they	O
be	O
aware	O
of	O
the	O
complexity	O
of	O
the	O
etiology	O
of	O
such	O
speech	B-T184
symptoms	I-T184
.	O
©	O
2017	O
Wiley	O
Periodicals	O
,	O
Inc.	O
      
Regulation	O
of	O
ABCA1	O
and	O
ABCG1	O
gene	O
expression	O
in	O
the	O
intraabdominal	O
adipose	O
tissue	O
Tissue	O
specific	O
expression	O
of	O
genes	O
encoding	O
cholesterol	O
transporters	O
ABCA1	O
and	O
ABCG1	O
as	O
well	O
as	O
genes	O
encoding	O
the	O
most	O
important	O
transcriptional	O
regulators	O
of	O
adipogenesis	O
-	O
LXRa	O
,	O
LXRb	O
,	O
PPARg	O
and	O
RORa	O
has	O
been	O
investigated	O
in	O
intraabdominal	O
adipose	O
tissue	O
(	O
IAT	O
)	O
samples	O
.A	O
direct	O
correlation	O
between	O
the	O
content	O
of	O
ABCA1	O
and	O
ABCG1	O
proteins	O
with	O
RORa	O
protein	O
level	O
(	O
r=0.480	O
,	O
p<0.05	O
;	O
r=0.435	O
,	O
p<0.05	O
,	O
respectively	O
)	O
suggests	O
the	O
role	O
of	O
the	O
transcription	O
factor	O
RORa	O
in	O
the	O
regulation	O
of	O
IAT	O
ABCA1	O
and	O
ABCG1	O
protein	O
levels	O
.	O
ABCA1	O
and	O
ABCG1	O
gene	O
expression	O
positively	O
correlated	O
with	O
obesity	B-T047
indicators	O
such	O
as	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
(	O
r=0.522	O
,	O
p=0.004	O
;	O
r=0.594	O
,	O
p=0.001	O
,	O
respectively	O
)	O
and	O
waist	O
circumference	O
(	O
r=0.403	O
,	O
p=0.033	O
;	O
r=0.474	O
,	O
p=0.013	O
,	O
respectively	O
)	O
.	O
The	O
development	O
of	O
obesity	B-T047
is	O
associated	O
with	O
decreased	O
IAT	O
levels	O
of	O
RORa	O
and	O
LXRb	O
mRNA	O
(	O
p=0.016	O
and	O
p=0.002	O
,	O
respectively	O
)	O
.	O
These	O
data	O
suggest	O
that	O
the	O
nuclear	O
factor	O
RORa	O
can	O
play	O
a	O
significant	O
role	O
in	O
the	O
regulation	O
of	O
cholesterol	O
metabolism	O
and	O
control	O
IAT	O
expression	O
of	O
ABCA1	O
and	O
ABCG1	O
,	O
while	O
the	O
level	O
of	O
IAT	O
LXRb	O
gene	O
expression	O
may	O
be	O
an	O
important	O
factor	O
associated	O
with	O
the	O
development	O
of	O
obesity	B-T047
.	O
      
Entropy	O
-	O
driven	O
reactions	O
in	O
living	O
cells	O
for	O
assay	B-T059
let-7a	O
microRNA	O
Imaging	B-T060
of	O
microRNA	O
(	O
miRNA	O
)	O
in	O
living	O
cells	O
could	O
facilitate	O
the	O
monitoring	O
of	O
the	O
expression	O
and	O
distribution	O
of	O
miRNA	O
and	O
research	O
on	O
miRNA	O
-related	O
diseases	B-T047
.	O
Given	O
the	O
low	O
expression	O
levels	O
and	O
even	O
down	O
-	O
regulation	O
of	O
cellular	O
miRNA	O
that	O
is	O
associated	O
with	O
some	O
diseases	B-T047
,	O
enzyme	O
-	O
free	O
amplification	O
strategies	O
are	O
imperative	O
for	O
intracellular	O
miRNA	O
assay	B-T059
.	O
In	O
this	O
work	O
,	O
we	O
report	O
an	O
entropy	O
-	O
driven	O
reaction	O
for	O
amplification	O
assay	B-T059
miRNA	O
with	O
a	O
detection	O
limit	O
of	O
0.27	O
pM.	O
The	O
resulting	O
signal	O
amplification	O
provides	O
excellent	O
recognition	O
and	O
signal	O
enhancement	O
of	O
specific	O
miRNA	O
s	O
in	O
living	O
cells	O
.	O
This	O
method	O
supplies	O
accurate	O
information	O
regarding	O
cellular	O
miRNA	O
-related	O
biological	O
events	O
and	O
provides	O
a	O
new	O
tool	O
for	O
highly	O
sensitive	O
and	O
simultaneous	O
imaging	B-T060
of	O
multiple	O
low	O
-	O
level	O
biomarkers	O
,	O
thereby	O
improving	O
the	O
accuracy	O
of	O
early	B-T060
disease	I-T060
diagnosis	I-T060
.	O
      
Audiovisual	O
integration	O
supports	O
face	O
-	O
name	O
associative	O
memory	O
formation	O
Prior	O
multisensory	O
experience	O
influences	O
how	O
we	O
perceive	O
our	O
environment	O
,	O
and	O
hence	O
how	O
memories	O
are	O
encoded	O
for	O
subsequent	O
retrieval	O
.	O
This	O
study	O
investigated	O
if	O
audiovisual	O
(	O
AV	O
)	O
integration	O
and	O
associative	O
memory	O
formation	O
rely	O
on	O
overlapping	O
or	O
distinct	O
processes	O
.	O
Our	O
functional	O
magnetic	B-T060
resonance	I-T060
imaging	I-T060
results	O
demonstrate	O
that	O
the	O
neural	O
mechanisms	O
underlying	O
AV	O
integration	O
and	O
associative	O
memory	O
overlap	O
substantially	O
.	O
In	O
particular	O
,	O
activity	O
in	O
anterior	O
superior	O
temporal	O
sulcus	O
(	O
STS	O
)	O
is	O
increased	O
during	O
AV	O
integration	O
and	O
also	O
determines	O
the	O
success	O
of	O
novel	O
AV	O
face	O
-	O
name	O
association	O
formation	O
.	O
Dynamic	O
causal	O
modeling	O
results	O
further	O
demonstrate	O
how	O
the	O
anterior	O
STS	O
interacts	O
with	O
the	O
associative	O
memory	O
system	O
to	O
facilitate	O
successful	O
memory	O
formation	O
for	O
AV	O
face	O
-	O
name	O
associations	O
.	O
Specifically	O
,	O
the	O
connection	O
of	O
fusiform	B-T023
gyrus	I-T023
to	O
anterior	O
STS	O
is	O
enhanced	O
while	O
the	O
reverse	O
connection	O
is	O
reduced	O
when	O
participants	O
subsequently	O
remembered	O
both	O
face	O
and	O
name	O
.	O
Collectively	O
,	O
our	O
results	O
demonstrate	O
how	O
multisensory	O
associative	O
memories	O
can	O
be	O
formed	O
for	O
subsequent	O
retrieval	O
.	O
      
Environmental	O
factors	O
and	O
hypertension	B-T047
Environmental	O
factors	O
are	O
a	O
major	O
cause	O
of	O
poor	B-T033
health	I-T033
worldwide	O
.	O
The	O
most	O
solid	O
evidence	O
is	O
for	O
air	O
pollution	O
,	O
leading	O
to	O
increased	O
disability	O
-	O
adjusted	O
life	O
years	O
.	O
Outdoor	O
temperature	O
and	O
other	O
seasonal	O
climate	O
changes	O
may	O
also	O
influence	O
cardiovascular	O
health	O
,	O
according	O
to	O
their	O
direct	O
modulation	O
of	O
air	O
pollution	O
.	O
Moreover	O
,	O
an	O
increasing	O
body	O
of	O
evidence	O
associates	O
environmental	O
exposure	O
to	O
noise	O
with	O
poor	B-T033
cardiovascular	I-T033
outcome	I-T033
,	O
and	O
in	O
particular	O
with	O
hypertension	B-T047
.	O
This	O
review	O
is	O
aimed	O
at	O
reviewing	O
current	O
evidence	O
about	O
the	O
role	O
of	O
these	O
environmental	O
factors	O
in	O
cardiovascular	B-T047
disease	I-T047
and	O
specifically	O
hypertension	B-T047
.	O
In	O
particular	O
,	O
the	O
impact	O
of	O
air	O
pollution	O
,	O
with	O
its	O
short	O
-	O
term	O
and	O
long	O
-	O
term	O
effects	O
,	O
the	O
outdoor	O
temperature	O
and	O
noise	O
pollution	O
will	O
be	O
investigated	O
.	O
People	O
belonging	O
to	O
low	O
social	O
classes	O
,	O
as	O
well	O
as	O
children	O
,	O
women	O
,	O
older	O
people	O
and	O
those	O
with	O
established	O
cardiovascular	B-T047
diseases	I-T047
,	O
seem	O
to	O
have	O
a	O
greater	O
susceptibility	O
to	O
the	O
effects	O
of	O
environmental	B-T033
stressors	I-T033
,	O
recalling	O
the	O
concept	O
of	O
"	O
environmental	O
justice	O
"	O
.	O
The	O
accumulating	O
strong	O
scientific	O
evidence	O
may	O
thus	O
support	O
public	O
health	O
policies	O
aimed	O
at	O
reducing	O
social	O
inequalities	O
in	O
cardiovascular	O
health	O
.	O
      
Staphylococcus	B-T007
pseudintermedius	I-T007
Human	O
Infection	O
Cases	O
in	O
Spain	O
:	O
Dog	O
-to-	O
Human	O
Transmission	O
Staphylococcus	B-T007
pseudintermedius	I-T007
is	O
an	O
opportunistic	B-T001
pathogen	I-T001
that	O
has	O
been	O
identified	O
as	O
infectious	B-T001
agent	I-T001
or	O
colonizer	B-T033
mainly	O
in	O
dogs	O
.	O
S.	B-T007
pseudintermedius	I-T007
has	O
been	O
also	O
detected	B-T033
in	O
humans	O
and	O
more	O
specifically	O
in	O
people	O
in	O
contact	O
with	O
dogs	O
.	O
In	O
this	O
study	O
,	O
the	O
possible	B-T033
S.	B-T007
pseudintermedius	I-T007
pet	O
-to-	O
human	O
transmission	O
was	O
analyzed	O
in	O
four	O
clinical	O
human	O
cases	O
.	O
Two	O
patients	O
were	O
dog	O
owners	O
and	O
S.	B-T007
pseudintermedius	I-T007
was	O
also	O
detected	B-T033
as	O
colonizer	B-T033
in	O
these	O
healthy	O
animals	O
.	O
S.	B-T007
pseudintermedius	I-T007
isolates	O
from	O
patients	O
and	O
dogs	O
of	O
the	O
same	O
household	O
showed	O
identical	O
pulsed	B-T059
-	I-T059
field	I-T059
gel	I-T059
electrophoresis	I-T059
patterns	O
,	O
sequence	B-T033
types	I-T033
(	O
STs	B-T033
)	O
,	O
and	O
antimicrobial	O
resistance	O
phenotypes	O
and	O
genotypes	O
,	O
and	O
were	O
methicillin	O
susceptible	O
.	O
Resistance	O
to	O
erythromycin	B-T195
,	O
clindamycin	B-T195
,	O
tetracycline	B-T195
,	O
trimetoprim	B-T121
-	I-T121
sulfamethoxazole	I-T121
,	O
and/or	O
ciprofloxacin	B-T121
was	O
identified	O
among	O
S.	B-T007
pseudintermedius	I-T007
strains	B-T001
.	O
The	O
lineages	O
ST241	B-T033
and	O
the	O
new	O
ST521	B-T033
were	O
detected	B-T033
in	O
the	O
strains	B-T001
of	O
the	O
two	O
dog	O
-	O
owner	O
patients	O
,	O
respectively	O
.	O
The	O
strains	B-T001
from	O
the	O
other	O
two	O
patients	O
presented	O
two	O
new	O
STs	B-T033
,	O
ST719	B-T033
and	O
ST720	B-T033
.	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
description	O
of	O
human	O
infections	O
caused	O
by	O
S.	B-T007
pseudintermedius	I-T007
in	O
Spain	O
.	O
      
It	O
's	O
not	O
All	O
Doom	O
and	O
Gloom	O
:	O
Prune	B-T047
Belly	I-T047
Syndrome	I-T047
Associated	B-T019
with	I-T019
VACTERL	I-T019
Prune	B-T047
belly	I-T047
syndrome	I-T047
is	O
a	O
rare	O
abnormality	B-T033
;	O
its	O
association	B-T019
with	I-T019
VACTERL	I-T019
is	O
even	O
rarer	O
.	O
This	O
association	B-T019
has	O
been	O
reported	B-T058
in	O
literature	O
a	O
few	O
times	O
since	O
first	O
reported	B-T058
in	O
1993	O
and	O
so	O
far	O
the	O
majority	O
have	O
either	O
been	O
stillbirths	B-T033
or	I-T033
died	I-T033
shortly	I-T033
after	I-T033
birth	I-T033
.	O
We	O
present	O
a	O
case	O
of	O
Prune	B-T047
belly	I-T047
syndrome	I-T047
associated	B-T019
with	I-T019
VACTERL	I-T019
who	O
is	O
now	O
one	O
year	O
old	O
.	O
      
Synthesis	O
of	O
Some	O
Unique	O
Carbamate	O
Derivatives	O
bearing	O
2	O
-	O
Furoyl-1	O
-	O
piperazine	O
as	O
a	O
Valuable	O
Therapeutic	B-T121
Agents	I-T121
The	O
aim	O
of	O
the	O
research	O
work	O
was	O
to	O
synthesize	O
different	O
biologically	O
active	O
carbamate	O
derivatives	O
bearing	O
2	O
-	O
furoyl-1	O
-	O
piperazine	O
and	O
having	O
modest	O
toxicity	O
.	O
The	O
synthesis	O
was	O
completed	O
as	O
a	O
multiple	O
sequence	O
.	O
The	O
structural	O
confirmation	B-T033
of	O
all	O
the	O
synthesized	O
compounds	O
was	O
obtained	O
by	O
EI	B-T059
-	I-T059
MS	I-T059
,	O
IR	B-T059
and	O
1H	B-T060
-	I-T060
NMR	I-T060
spectral	O
data	O
.	O
The	O
enzyme	O
inhibition	O
and	O
antibacterial	B-T033
potential	I-T033
of	O
the	O
synthesized	O
compounds	O
was	O
evaluated	B-T058
.	O
To	O
find	O
the	O
utility	O
of	O
the	O
prepared	O
compounds	O
as	O
possible	O
therapeutic	B-T121
agents	I-T121
their	O
cytotoxicity	O
was	O
also	O
checked	O
.	O
All	O
the	O
compounds	O
were	O
active	O
against	O
acetylcholinesterase	O
enzyme	O
,	O
especially	O
12	O
and	O
14	O
showed	O
very	O
good	O
inhibitory	O
potential	O
relative	O
to	O
Eserine	B-T121
,	O
a	O
reference	O
standard	O
.	O
Almost	O
all	O
the	O
compounds	O
showed	O
good	O
activities	O
against	O
both	O
Gram	B-T007
-	I-T007
positive	I-T007
and	O
Gram	B-T007
-	I-T007
negative	I-T007
bacterial	I-T007
strains	I-T007
.	O
      
Like	O
Father	O
,	O
Like	O
Daughter	O
-	O
inherited	O
cutis	B-T019
aplasia	I-T019
occurring	O
in	O
a	O
family	O
with	O
Marfan	B-T047
syndrome	I-T047
:	O
a	O
case	O
report	O
We	O
present	O
the	O
case	O
of	O
a	O
newborn	O
with	O
co	O
-	O
occurrence	O
of	O
Marfan	B-T047
syndrome	I-T047
and	O
aplasia	B-T019
cutis	I-T019
congenita	I-T019
(	O
ACC	B-T019
)	O
and	O
a	O
family	B-T033
history	I-T033
significant	O
for	O
Marfan	B-T047
syndrome	I-T047
and	O
ACC	B-T019
in	O
the	O
father	O
.	O
This	O
case	O
details	O
a	O
previously	O
unreported	O
mutation	O
in	O
Marfan	B-T047
syndrome	I-T047
and	O
describes	O
a	O
novel	O
coinheritance	O
of	O
Marfan	B-T047
syndrome	I-T047
and	O
ACC	B-T019
.	O
      
Surrogate	O
inaccuracy	O
in	O
predicting	O
older	O
adults	O
'	O
desire	O
for	O
life	B-T061
-	I-T061
sustaining	I-T061
interventions	I-T061
in	O
the	O
event	O
of	O
decisional	O
incapacity	O
:	O
is	O
it	O
due	O
in	O
part	O
to	O
erroneous	O
quality	B-T060
-	I-T060
of	I-T060
-	I-T060
life	I-T060
assessments	I-T060
?	O
Family	O
members	O
are	O
often	O
called	O
upon	O
to	O
make	O
decisions	O
for	O
an	O
incapacitated	O
relative	O
.	O
Yet	O
they	O
have	O
difficulty	O
predicting	O
a	O
loved	O
one	O
's	O
desire	O
to	O
receive	O
treatments	B-T061
in	O
hypothetical	O
situations	O
.	O
We	O
tested	O
the	O
hypothesis	O
that	O
this	O
difficulty	O
could	O
in	O
part	O
be	O
explained	O
by	O
discrepant	O
quality	B-T060
-	I-T060
of	I-T060
-	I-T060
life	I-T060
assessments	I-T060
.	O
The	O
data	O
come	O
from	O
235	O
community	O
-	O
dwelling	O
adults	O
aged	O
70	O
years	O
and	O
over	O
who	O
rated	O
their	O
quality	O
of	O
life	O
and	O
desire	O
for	O
specified	O
interventions	B-T061
in	O
four	O
health	B-T033
states	I-T033
(	O
current	B-T033
state	I-T033
,	O
mild	O
to	O
moderate	O
stroke	B-T047
,	O
incurable	O
brain	B-T191
cancer	I-T191
,	O
and	O
severe	O
dementia	B-T048
)	O
.	O
All	O
ratings	O
were	O
made	O
on	O
Likert	O
-	O
type	O
scales	O
.	O
Using	O
identical	O
rating	O
scales	O
,	O
a	O
surrogate	O
chosen	O
by	O
the	O
older	O
adult	O
was	O
asked	O
to	O
predict	O
the	O
latter	O
's	O
responses	O
.	O
Linear	O
mixed	O
models	O
were	O
fitted	O
to	O
determine	O
whether	O
differences	O
in	O
quality	O
-	O
of	O
-	O
life	O
ratings	O
between	O
the	O
older	O
adult	O
and	O
surrogate	O
were	O
associated	O
with	O
surrogates	O
'	O
inaccuracy	O
in	O
predicting	O
desire	O
for	O
treatment	B-T061
.	O
The	O
difference	O
in	O
quality	O
-	O
of	O
-	O
life	O
ratings	O
was	O
a	O
significant	O
predictor	O
of	O
prediction	O
inaccuracy	O
for	O
the	O
three	O
hypothetical	O
health	B-T033
states	I-T033
(	O
p	O
<	O
0.01	O
)	O
and	O
nearly	O
significant	O
for	O
the	O
current	B-T033
health	I-T033
state	I-T033
(	O
p	O
=	O
0.077	O
)	O
.	O
All	O
regression	O
coefficients	O
were	O
negative	B-T033
,	O
implying	O
that	O
the	O
more	O
the	O
surrogate	O
overestimated	O
quality	O
of	O
life	O
compared	O
to	O
the	O
older	O
adult	O
,	O
the	O
more	O
he	O
or	O
she	O
overestimated	O
the	O
older	O
adult	O
's	O
desire	O
to	O
be	O
treated	O
.	O
Discrepant	O
quality	O
-	O
of	O
-	O
life	O
ratings	O
are	O
associated	O
with	O
surrogates	O
'	O
difficulty	O
in	O
predicting	O
desire	O
for	O
life	B-T061
-	I-T061
sustaining	I-T061
interventions	I-T061
in	O
hypothetical	O
situations	O
.	O
This	O
finding	O
underscores	O
the	O
importance	O
of	O
discussing	O
anticipated	O
quality	O
of	O
life	O
in	O
states	O
of	O
cognitive	O
decline	O
,	O
to	O
better	O
prepare	O
family	O
members	O
for	O
making	O
difficult	O
decisions	O
for	O
their	O
loved	O
ones	O
.	O
ISRCTN89993391	O
.	O
      
Propulsion	O
strategy	O
in	O
the	O
gait	B-T033
of	O
primary	O
school	O
children	O
;	O
the	O
effect	O
of	O
age	O
and	O
speed	O
The	O
strategy	O
used	O
to	O
generate	O
power	O
for	O
forward	O
propulsion	O
in	O
walking	O
and	O
running	O
has	O
recently	O
been	O
highlighted	O
as	O
a	O
marker	O
of	O
gait	B-T033
maturation	O
and	O
elastic	O
energy	O
recycling	O
.	O
This	O
study	O
investigated	B-T058
ankle	O
and	O
hip	B-T023
power	O
generation	O
as	O
a	O
propulsion	O
strategy	O
(	O
PS	O
)	O
during	O
the	O
late	B-T033
stance	I-T033
/	O
early	B-T033
swing	I-T033
phases	I-T033
of	O
walking	O
and	O
running	O
in	O
typically	O
developing	O
(	O
TD	O
)	O
children	O
(	O
15	O
:	O
six	O
to	O
nine	O
years	O
;	O
17	O
:	O
nine	O
to	O
13	O
years	O
)	O
using	O
three	O
-	O
dimensional	O
gait	B-T060
analysis	I-T060
.	O
Peak	O
ankle	O
power	O
generation	O
at	O
push	O
-	O
off	O
(	O
peakA2	O
)	O
,	O
peak	O
hip	B-T023
power	O
generation	O
in	O
early	B-T033
swing	I-T033
(	O
peakH3	O
)	O
and	O
propulsion	O
strategy	O
(	O
PS	O
)	O
[	O
peakA2	O
/	O
(	O
peakA2+peakH3	O
)	O
]	O
were	O
calculated	O
to	O
provide	O
the	O
relative	O
contribution	O
of	O
ankle	O
power	O
to	O
total	O
propulsion	O
.	O
Mean	O
PS	O
values	O
decreased	O
as	O
speed	O
increased	O
for	O
comfortable	O
walking	O
(	O
p<0.001	O
)	O
,	O
fast	O
walking	O
(	O
p<0.001	O
)	O
and	O
fast	O
running	O
(	O
p<0.001	O
)	O
,	O
and	O
less	O
consistently	O
during	O
jogging	O
(	O
p=0.054	O
)	O
.	O
PS	O
varied	O
with	O
age	O
(	O
p<0.001	O
)	O
only	O
during	O
fast	O
walking	O
.	O
At	O
any	O
speed	O
of	O
fast	O
walking	O
,	O
older	O
children	O
generated	O
more	O
peakA2	O
(	O
p=0.001	O
)	O
and	O
less	O
peakH3	O
(	O
p=0.001	O
)	O
than	O
younger	O
children	O
.	O
While	O
the	O
kinetics	O
of	O
running	O
propulsion	O
appear	O
to	O
be	O
developed	O
by	O
age	O
six	O
years	O
,	O
the	O
skills	O
of	O
fast	O
walking	O
appeared	O
to	O
require	O
additional	O
neuromuscular	O
maturity	O
.	O
These	O
findings	B-T033
support	O
the	O
concept	O
that	O
running	O
is	O
a	O
skill	O
that	O
matures	O
early	O
for	O
TD	O
children	O
.	O
      
Participation	O
in	O
and	O
adherence	O
to	O
physical	O
exercise	O
after	O
completion	O
of	O
primary	B-T191
cancer	I-T191
treatment	B-T061
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
identify	O
demographic	O
,	O
clinical	O
,	O
psychosocial	O
,	O
physical	O
and	O
environmental	O
factors	O
that	O
are	O
associated	O
with	O
participation	O
in	O
and	O
adherence	O
to	O
a	O
combined	O
resistance	O
and	O
endurance	B-T061
exercise	I-T061
program	O
among	O
cancer	O
survivors	O
,	O
shortly	O
after	O
completion	O
of	O
primary	B-T191
cancer	I-T191
treatment	B-T061
.	O
Data	O
from	O
the	O
randomized	B-T033
controlled	O
Resistance	O
and	O
Endurance	O
exercise	O
After	O
ChemoTherapy	O
(	O
REACT	O
)	O
study	O
were	O
used	O
for	O
this	O
study	O
.	O
The	O
participants	O
of	O
the	O
REACT	O
study	O
were	O
randomly	O
allocated	O
to	O
either	O
a	O
high	O
intensity	O
(	O
HI	O
)	O
or	O
low	O
-to-	O
moderate	O
intensity	O
(	O
LMI	O
)	O
exercise	O
program	O
.	O
Patients	O
'	O
participation	O
rate	O
was	O
defined	O
as	O
the	O
cancer	O
survivors	O
'	O
decision	O
to	O
participate	O
in	O
the	O
REACT	O
study	O
.	O
Exercise	O
adherence	O
reflected	O
participants	O
'	O
attendance	O
to	O
the	O
scheduled	O
exercise	O
sessions	O
and	O
their	O
compliance	O
to	O
the	O
prescribed	B-T058
exercises	O
.	O
High	O
session	O
attendance	O
rates	O
were	O
defined	O
as	O
attending	O
at	O
least	O
80	O
%	O
of	O
the	O
sessions	O
.	O
High	O
compliance	O
rates	O
were	O
defined	O
as	O
performing	O
at	O
least	O
of	O
90	O
%	O
of	O
the	O
prescribed	B-T058
exercise	O
across	O
all	O
sessions	O
.	O
Correlates	O
of	O
exercise	O
adherence	O
were	O
studied	O
separately	O
for	O
HI	O
and	O
LMI	O
exercise	O
.	O
Demographic	O
,	O
clinical	O
,	O
and	O
physical	O
factors	O
were	O
assessed	O
using	O
self	O
-	O
reported	O
questionnaires	O
.	O
Relevant	O
clinical	O
information	O
was	O
extracted	O
from	O
medical	O
records	O
.	O
Multivariable	O
logistic	O
regression	O
analyses	O
were	O
applied	O
to	O
identify	O
correlates	O
that	O
were	O
significantly	O
associated	O
with	O
participation	O
,	O
high	O
session	O
attendance	O
,	O
high	O
compliance	O
with	O
resistance	O
and	O
high	O
compliance	O
with	O
endurance	B-T061
exercises	I-T061
.	O
Participants	O
were	O
more	B-T033
likely	I-T033
to	O
have	O
higher	O
education	O
,	O
be	O
non	B-T033
-	I-T033
smokers	I-T033
,	O
have	O
lower	O
psychological	B-T048
distress	I-T048
,	O
higher	O
outcome	O
expectations	O
,	O
and	O
perceive	O
more	O
exercise	O
barriers	O
than	O
non	O
-	O
participants	O
.	O
In	O
HI	O
exercise	O
,	O
higher	O
self	O
-	O
efficacy	O
was	O
significantly	O
associated	O
with	O
high	O
session	O
attendance	O
and	O
high	O
compliance	O
with	O
endurance	B-T061
exercises	I-T061
,	O
and	O
lower	O
psychological	B-T048
distress	I-T048
was	O
significantly	O
associated	O
with	O
high	O
compliance	O
with	O
resistance	O
exercise	O
s.	O
In	O
LMI	O
exercise	O
,	O
being	O
a	O
non	B-T033
-	I-T033
smoker	I-T033
was	O
significantly	O
associated	O
with	O
high	O
compliance	O
with	O
resistance	O
exercises	O
and	O
higher	O
BMI	O
was	O
significantly	O
associated	O
with	O
high	O
compliance	O
with	O
resistance	O
and	O
endurance	B-T061
exercises	I-T061
.	O
Furthermore	O
,	O
breast	O
cancer	O
survivors	O
were	O
less	O
likely	O
to	O
report	B-T058
high	O
compliance	O
with	O
resistance	O
and	O
endurance	B-T061
exercises	I-T061
in	O
LMI	O
exercise	O
compared	O
to	O
survivors	O
of	O
other	O
types	O
of	O
cancer	B-T191
.	O
The	O
discriminative	O
ability	O
of	O
the	O
multivariable	O
models	O
ranged	O
from	O
0.62	O
to	O
0.75	O
.	O
Several	O
demographic	O
,	O
clinical	O
and	O
psychosocial	O
factors	O
were	O
associated	O
with	O
participation	O
in	O
and	O
adherence	O
to	O
exercise	O
among	O
cancer	O
survivors	O
.	O
Psychosocial	O
factors	O
were	O
more	O
strongly	O
associated	O
with	O
adherence	O
in	O
HI	O
than	O
LMI	O
exercise	O
.	O
This	O
study	O
was	O
registered	O
at	O
the	O
Netherlands	O
Trial	O
Register	O
[	O
NTR2153	O
]	O
on	O
the	O
5(th	O
)	O
of	O
January	O
2010	O
.	O
      
ISX-9	O
can	O
potentiate	O
cell	O
proliferation	O
and	O
neuronal	O
commitment	O
in	O
the	O
rat	O
dentate	B-T023
gyrus	I-T023
Adult	O
hippocampal	B-T023
neurogenesis	O
can	O
be	O
modulated	O
by	O
various	O
physiological	O
and	O
pathological	O
conditions	O
,	O
including	O
stress	B-T033
,	O
affective	B-T048
disorders	I-T048
,	O
and	O
several	O
neurological	O
conditions	O
.	O
Given	O
the	O
proposed	O
role	O
of	O
this	O
form	O
of	O
structural	O
plasticity	O
in	O
the	O
functioning	O
of	O
the	O
hippocampus	B-T023
(	O
namely	O
learning	O
and	O
memory	O
and	O
affective	O
behaviors	O
)	O
,	O
it	O
is	O
believed	O
that	O
alterations	O
in	O
hippocampal	B-T023
neurogenesis	O
might	O
underlie	O
some	O
of	O
the	O
behavioral	O
deficits	O
associated	O
with	O
these	O
psychiatric	O
and	O
neurological	O
conditions	O
.	O
Thus	O
,	O
the	O
search	O
for	O
compounds	B-T121
that	O
can	O
reverse	O
these	O
deficits	O
with	O
minimal	O
side	O
effects	O
has	O
become	O
a	O
recognized	O
priority	O
.	O
In	O
the	O
present	O
study	O
we	O
tested	O
the	O
pro	O
-	O
neurogenic	O
effects	O
of	O
isoxazole	O
9	O
(	O
Isx-9	O
)	O
,	O
a	O
small	O
synthetic	O
molecule	O
that	O
has	O
been	O
recently	O
identified	O
through	O
the	O
screening	B-T059
of	I-T059
chemical	I-T059
libraries	I-T059
in	O
stem	B-T059
cell	I-T059
-	I-T059
based	I-T059
assays	I-T059
.	O
We	O
found	O
that	O
administration	B-T061
of	O
Isx-9	O
for	O
14days	O
was	O
able	O
to	O
potentiate	O
cell	O
proliferation	O
and	O
increase	O
the	O
number	O
of	O
immature	O
neurons	O
in	O
the	O
hippocampal	B-T023
DG	B-T023
of	O
adult	O
rats	O
.	O
In	O
addition	O
,	O
Isx-9	O
treatment	B-T061
was	O
able	O
to	O
completely	O
reverse	O
the	O
marked	O
reduction	O
in	O
these	O
initial	O
stages	O
of	O
the	O
neurogenic	O
process	O
observed	O
in	O
vehicle	O
-	O
treated	O
animals	O
(	O
which	O
were	O
submitted	O
to	O
repeated	O
handling	B-T059
and	O
exposure	O
to	O
daily	O
intraperitoneal	B-T061
injections	I-T061
)	O
.	O
Based	O
on	O
these	O
results	O
,	O
we	O
recommend	O
that	O
future	O
neurogenesis	O
studies	O
that	O
require	O
repeated	O
handling	B-T059
and	O
manipulation	B-T061
of	O
animals	O
should	O
include	O
a	O
naïve	O
(	O
non	O
-	O
manipulated	O
)	O
control	O
to	O
determine	O
the	O
baseline	O
levels	O
of	O
hippocampal	B-T023
cell	O
proliferation	O
and	O
neuronal	O
differentiation	O
.	O
Overall	O
,	O
these	O
findings	B-T033
demonstrate	O
that	O
Isx-9	O
is	O
a	O
promising	O
synthetic	O
compound	B-T121
for	O
the	O
mitigation	O
of	O
stress	B-T033
-	O
induced	O
deficits	O
in	O
adult	O
hippocampal	B-T023
neurogenesis	O
.	O
Future	O
studies	O
are	O
thus	O
warranted	O
to	O
evaluate	B-T058
the	O
pro	O
-	O
neurogenic	O
properties	O
of	O
Isx-9	O
in	O
animal	O
models	O
of	O
affective	B-T048
and	O
neurological	B-T047
disorders	I-T047
associated	O
with	O
impaired	O
hippocampal	B-T023
structural	O
plasticity	O
.	O
      
Anger	O
and	O
aggression	O
in	O
borderline	B-T048
personality	I-T048
disorder	I-T048
and	O
attention	B-T048
deficit	I-T048
hyperactivity	I-T048
disorder	I-T048
-	O
does	O
stress	B-T033
matter	O
?	O
The	O
impact	O
of	O
stress	B-T033
on	O
anger	O
and	O
aggression	O
in	O
Borderline	B-T048
Personality	I-T048
Disorder	I-T048
(	O
BPD	B-T048
)	O
and	O
Attention	B-T048
Deficit	I-T048
Hyperactivity	I-T048
Disorder	I-T048
(	O
ADHD	B-T048
)	O
has	O
not	O
been	O
thoroughly	O
investigated	O
.	O
The	O
goal	O
of	O
this	O
study	O
was	O
to	O
investigate	O
different	O
aspects	O
of	O
anger	O
and	O
aggression	O
in	O
patients	O
with	O
these	O
disorders	B-T047
.	O
Twenty	O
-	O
nine	O
unmedicated	B-T033
female	O
BPD	B-T048
patients	O
,	O
28	O
ADHD	B-T048
patients	O
and	O
30	O
healthy	O
controls	O
(	O
HC	O
)	O
completed	O
self	O
-	O
reports	O
measuring	O
trait	O
anger	O
,	O
aggression	O
and	O
emotion	O
regulation	O
capacities	O
.	O
A	O
modified	O
version	O
of	O
the	O
Point	O
Subtraction	O
Aggression	O
Paradigm	O
and	O
a	O
state	O
anger	O
measurement	O
were	O
applied	O
under	O
resting	O
and	O
stress	O
conditions	O
.	O
Stress	B-T033
was	O
induced	O
by	O
the	O
Mannheim	B-T060
Multicomponent	I-T060
Stress	I-T060
Test	I-T060
(	O
MMST	B-T060
)	O
.	O
Both	O
patient	O
groups	O
scored	O
significantly	O
higher	O
on	O
all	O
self	O
-	O
report	O
measures	O
compared	O
to	O
HCs	O
.	O
Compared	O
to	O
ADHD	B-T048
patients	O
,	O
BPD	B-T048
patients	O
reported	O
higher	O
trait	O
aggression	O
and	O
hostility	O
,	O
a	O
stronger	O
tendency	O
to	O
express	O
anger	O
when	O
provoked	O
and	O
to	O
direct	O
anger	O
inwardly	O
.	O
Furthermore	O
,	O
BPD	B-T048
patients	O
exhibited	O
higher	O
state	O
anger	O
than	O
HCs	O
and	O
ADHD	B-T048
patients	O
under	O
both	O
conditions	O
and	O
showed	O
a	O
stress	O
-	O
dependent	O
anger	O
increase	O
.	O
At	O
the	O
behavioral	O
level	O
,	O
no	O
significant	O
effects	O
were	O
found	O
.	O
In	O
BPD	B-T048
patients	O
,	O
aggression	O
and	O
anger	O
were	O
positively	O
correlated	O
with	O
emotion	O
regulation	O
deficits	O
.	O
Our	O
findings	B-T033
suggest	O
a	O
significant	O
impact	O
of	O
stress	B-T033
on	O
self	O
-	O
perceived	O
state	O
anger	O
in	O
BPD	B-T048
patients	O
but	O
not	O
on	O
aggressive	O
behavior	O
towards	O
others	O
in	O
females	O
with	O
BPD	B-T048
or	O
ADHD	B-T048
.	O
However	O
,	O
it	O
appears	O
to	O
be	O
pronounced	O
inwardly	O
directed	O
anger	O
which	O
is	O
of	O
clinical	O
importance	O
in	O
BPD	B-T048
patients	O
.	O
      
Blastocystis	O
subtyping	O
and	O
its	O
association	O
with	O
intestinal	B-T047
parasites	I-T047
in	O
children	O
from	O
different	O
geographical	O
regions	O
of	O
Colombia	O
Blastocystis	O
is	O
a	O
common	O
enteric	B-T033
protist	I-T033
colonizing	I-T033
probably	O
more	O
than	O
1	O
billion	O
people	O
with	O
a	O
large	O
variety	O
of	O
non	B-T001
-	I-T001
human	I-T001
hosts	I-T001
.	O
Remarkable	O
genetic	O
diversity	O
has	O
been	O
observed	O
,	O
leading	O
to	O
the	O
subdivision	O
of	O
the	O
genus	O
into	O
multiple	O
subtypes	O
(	O
ST	O
)	O
,	O
some	O
of	O
which	O
are	O
exclusively	O
found	O
in	O
non	B-T001
-	I-T001
human	I-T001
hosts	I-T001
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
distribution	O
of	O
Blastocystis	O
STs	O
/	O
18S	O
alleles	O
in	O
symptomatic	O
(	O
abdominal	B-T184
pain	I-T184
,	O
anal	B-T184
pruritus	I-T184
,	O
diarrhea	B-T184
,	O
headache	B-T184
,	O
nauseas	B-T184
and/or	O
vomit	B-T184
)	O
and	O
asymptomatic	B-T033
children	O
from	O
nine	O
geographical	O
regions	O
of	O
Colombia	O
.	O
A	O
total	O
of	O
2026	O
fecal	B-T058
samples	I-T058
were	O
collected	O
as	O
part	O
of	O
a	O
national	O
survey	O
to	O
estimate	O
the	O
frequency	O
of	O
intestinal	B-T047
parasites	I-T047
in	O
children	O
.	O
A	O
set	O
of	O
256	O
samples	O
that	O
were	O
Blastocystis	O
positive	O
was	O
finally	O
selected	O
.	O
The	O
samples	O
were	O
submitted	O
to	O
DNA	O
extraction	O
,	O
Real	O
Time	O
PCR	O
and	O
sequencing	B-T059
using	O
Blastocystis	B-T047
-specific	O
primers	O
targeting	O
the	O
small	O
subunit	O
rRNA	O
gene	O
for	O
ST	B-T059
identification	I-T059
.	O
DNA	O
of	O
Ascaris	O
lumbricoides	O
(	O
16.4	O
%	O
)	O
,	O
Trichuris	O
trichiura	O
(	O
8.2	O
%	O
)	O
,	O
hookworms	O
(	O
Necator	O
americanus	O
/	O
Ancylostoma	O
duodenale	O
)	O
(	O
7.3	O
%	O
)	O
,	O
Giardia	O
duodenalis	O
(	O
23.1	O
%	O
)	O
,	O
Entamoeba	O
complex	O
(	O
82	O
%	O
)	O
,	O
Entamoeba	O
coli	O
(	O
55	O
%	O
)	O
,	O
Hymenolepis	O
nana	O
(	O
0.8	O
%	O
)	O
,	O
Endolimax	O
nana	O
(	O
33.2	O
%	O
)	O
and	O
Neobalantidium	O
coli	O
(	O
2.7	O
%	O
)	O
was	O
detected	O
in	O
the	O
Blastocystis	O
-	O
positive	B-T033
samples	I-T033
.	O
We	O
detected	O
ST1	O
(	O
21.4	O
%	O
)	O
,	O
ST2	O
(	O
19.5	O
%	O
)	O
,	O
ST3	O
(	O
55.5	O
%	O
)	O
,	O
ST4	O
(	O
0.8	O
%	O
)	O
,	O
ST6	O
(	O
2	O
%	O
)	O
and	O
ST7	O
(	O
0.8	O
%	O
)	O
;	O
alleles	O
1	O
,	O
2	O
,	O
4	O
,	O
81	O
,	O
82	O
and	O
83	O
for	O
ST1	O
;	O
alleles	O
9	O
,	O
11	O
,	O
12	O
,	O
15	O
,	O
67	O
,	O
71	O
and	O
73	O
for	O
ST2	O
;	O
alleles	O
34	O
,	O
36	O
,	O
38	O
,	O
45	O
,	O
49	O
,	O
55	O
,	O
134	O
and	O
128	O
for	O
ST3	O
;	O
allele	O
42	O
for	O
ST4	O
;	O
allele	O
122	O
for	O
ST6	O
,	O
and	O
allele	O
142	O
for	O
ST7	O
.	O
Further	O
studies	O
implementing	O
high	B-T059
-	I-T059
resolution	I-T059
molecular	O
markers	O
are	O
necessary	O
to	O
understand	O
the	O
dynamics	O
of	O
Blastocystis	O
transmission	O
and	O
the	O
role	O
of	O
this	O
Stramenopila	O
in	O
health	O
and	O
disease	O
.	O
      
What	O
Is	O
the	O
Real	O
Impact	O
of	O
Urinary	O
Incontinence	O
on	O
Female	B-T048
Sexual	I-T048
Dysfunction	I-T048
?	O
A	O
Case	O
Control	O
Study	O
Urinary	O
incontinence	O
(	O
UI	O
)	O
has	O
been	O
associated	O
with	O
negative	B-T033
effects	O
on	O
women	O
's	O
sexuality	O
.	O
Women	O
's	O
sexuality	O
and	O
sexual	O
function	O
are	O
a	O
complex	O
issue	B-T033
,	O
and	O
the	O
role	O
of	O
UI	O
is	O
not	O
completely	O
clear	O
.	O
To	O
assess	O
the	O
impact	O
of	O
UI	O
on	O
female	O
sexual	O
function	O
by	O
comparing	O
this	O
population	O
with	O
a	O
control	O
group	O
of	O
continent	O
women	O
.	O
We	O
performed	O
a	O
case	O
-	O
control	O
study	O
from	O
August	O
2012	O
to	O
September	O
2013	O
.	O
We	O
evaluated	B-T058
continent	O
and	O
incontinent	O
women	O
(	O
age	O
range	O
=	O
30	O
-	O
70	O
years	O
)	O
for	O
their	O
sexuality	O
.	O
All	O
patients	O
were	O
evaluated	B-T058
by	O
anamnesis	O
,	O
physical	B-T058
examination	I-T058
,	O
and	O
self	O
-	O
report	O
quality	O
-	O
of	O
-	O
life	O
questionnaires	O
.	O
In	O
addition	O
,	O
incontinent	O
women	O
underwent	O
a	O
1	O
-	O
hour	O
pad	B-T060
test	I-T060
.	O
Patients	O
without	O
sexual	O
activity	O
were	O
evaluated	B-T058
for	O
the	O
role	O
of	O
UI	O
in	O
their	O
sexual	O
abstinence	O
.	O
Sexual	O
abstinence	O
was	O
defined	O
as	O
the	O
absence	B-T033
of	I-T033
sexual	I-T033
activity	I-T033
for	O
more	O
than	O
6	O
months	O
.	O
All	O
sexually	B-T033
active	I-T033
women	O
completed	O
the	O
self	O
-	O
report	O
Sexuality	O
Quotient	O
-	O
Female	O
Version	O
(	O
SQ	O
-	O
F	O
)	O
questionnaire	O
.	O
A	O
total	O
of	O
356	O
women	O
were	O
included	O
in	O
the	O
study	O
(	O
incontinent	O
,	O
n	O
=	O
243	O
;	O
continent	O
,	O
n	O
=	O
113	O
)	O
.	O
Sexual	O
abstinence	O
was	O
found	O
in	O
162	O
women	O
(	O
45	O
%	O
)	O
.	O
Incontinent	O
women	O
presented	O
a	O
higher	O
prevalence	O
(	O
P	O
<	O
.001	O
)	O
of	O
sexual	O
abstinence	O
than	O
their	O
counterparts	O
(	O
129	O
[	O
53	O
%	O
]	O
and	O
33	O
[	O
29.2	O
%	O
]	O
,	O
respectively	O
)	O
.	O
Age	O
,	O
marital	O
status	O
,	O
and	O
UI	O
were	O
found	O
to	O
be	O
isolated	O
predictive	O
factors	O
for	O
more	O
sexual	O
abstinence	O
in	O
incontinent	O
women	O
.	O
Sexually	B-T033
active	I-T033
women	O
(	O
incontinent	O
,	O
n	O
=	O
114	O
;	O
continent	O
,	O
n	O
=	O
80	O
)	O
presented	O
similar	O
demographic	O
data	O
.	O
Despite	O
a	O
similar	O
frequency	O
of	O
sexual	O
activity	O
,	O
incontinent	O
women	O
had	O
less	O
sexual	B-T048
desire	I-T048
,	O
foreplay	B-T033
,	O
harmony	O
with	O
a	O
partner	O
,	O
sexual	O
comfort	O
,	O
and	O
sexual	O
satisfaction	O
than	O
their	O
counterparts	O
.	O
Women	O
with	O
greater	O
urinary	B-T033
leakage	I-T033
during	O
the	O
1	O
-	O
hour	O
pad	B-T060
test	I-T060
(	O
weight	O
>	O
11	O
g	O
)	O
had	O
the	O
worst	O
sexual	O
function	O
(	O
SQ	O
-	O
F	O
)	O
score	O
.	O
Women	O
with	O
UI	O
were	O
more	O
likely	O
to	O
be	O
sexual	O
abstinent	O
than	O
continent	O
women	O
.	O
Furthermore	O
,	O
women	O
with	O
UI	O
showed	O
less	O
sexual	B-T048
desire	I-T048
,	O
sexual	O
comfort	O
,	O
and	O
sexual	O
satisfaction	O
than	O
their	O
counterparts	O
despite	O
having	O
a	O
similar	O
frequency	O
of	O
sexual	O
activity	O
.	O
      
The	O
Demand	O
for	O
Cigarettes	O
in	O
Tanzania	O
and	O
Implications	O
for	O
Tobacco	O
Taxation	O
Policy	O
The	O
study	O
attempts	O
to	O
estimate	O
the	O
demand	O
for	O
cigarettes	O
in	O
Tanzania	O
and	O
presents	O
simulation	O
results	O
on	O
the	O
effect	O
of	O
the	O
cigarette	O
excise	O
tax	O
on	O
smoking	O
participation	O
,	O
government	O
revenue	O
,	O
and	O
related	O
topics	O
.	O
After	O
briefly	O
summarizing	O
the	O
magnitude	O
and	O
spread	O
of	O
cigarette	B-T033
consumption	I-T033
in	O
the	O
country	O
,	O
the	O
paper	O
reviews	O
some	O
empirical	O
estimates	O
from	O
African	O
and	O
other	O
countries	O
.	O
The	O
2008	O
Tanzanian	O
household	O
budget	O
survey	O
was	O
used	O
to	O
estimate	O
the	O
demand	O
for	O
cigarettes	O
in	O
Tanzania	O
.	O
The	O
descriptive	O
statistics	O
suggest	O
that	O
the	O
smoking	O
prevalence	O
for	O
Tanzania	O
is	O
15.35	O
percent	O
with	O
low	O
variability	O
across	O
expenditure	O
(	O
income	O
)	O
groups	O
.	O
Smoking	O
intensity	O
and	O
per	O
capita	O
consumption	O
were	O
estimated	O
at	O
7.08	O
cigarettes	O
and	O
1.33	O
cigarettes	O
,	O
respectively	O
,	O
a	O
relatively	O
low	O
value	O
.	O
A	O
two	O
-	O
part	O
demand	O
equation	O
model	O
was	O
used	O
to	O
estimate	O
various	O
elasticities	O
.	O
For	O
the	O
overall	O
equation	O
,	O
the	O
price	O
elasticities	O
of	O
smoking	O
participation	O
,	O
smoking	O
intensity	O
,	O
and	O
total	O
elasticity	O
were	O
estimated	O
at	O
-0.879	O
,	O
-0.853	O
,	O
and	O
-1.732	O
,	O
respectively	O
.	O
Compared	O
to	O
similar	O
results	O
in	O
other	O
developing	O
countries	O
,	O
the	O
estimates	O
appear	O
quite	O
high	O
.	O
When	O
estimated	O
by	O
expenditure	O
(	O
income	O
)	O
groups	O
,	O
the	O
magnitude	O
of	O
the	O
elasticity	O
appears	O
higher	O
among	O
high	O
expenditure	O
groups	O
than	O
among	O
low	O
expenditure	O
groups	O
.	O
Two	O
simulation	O
exercises	O
were	O
undertaken	O
.	O
First	O
,	O
the	O
effect	O
of	O
different	O
excise	O
rates	O
on	O
smoking	O
participation	O
rate	O
,	O
cigarette	B-T033
consumption	I-T033
,	O
tax	O
revenue	O
,	O
and	O
related	O
responses	O
was	O
estimated	O
and	O
highlighted	O
.	O
Second	O
,	O
the	O
same	O
exercise	O
was	O
undertaken	O
to	O
determine	O
the	O
effect	O
of	O
a	O
given	O
increase	O
in	O
the	O
cigarette	O
excise	O
tax	O
on	O
various	O
expenditure	O
groups	O
.	O
The	O
overall	O
results	O
suggest	O
that	O
an	O
increase	O
in	O
the	O
excise	O
tax	O
on	O
cigarettes	O
in	O
Tanzania	O
would	O
reduce	O
cigarette	B-T033
consumption	I-T033
and	O
increase	O
government	O
tax	O
revenue	O
.	O
      
Visual	O
Confidence	O
Visual	O
confidence	O
refers	O
to	O
an	O
observer	O
's	O
ability	O
to	O
judge	O
the	O
accuracy	O
of	O
her	O
perceptual	O
decisions	O
.	O
Even	O
though	O
confidence	O
judgments	O
have	O
been	O
recorded	O
since	O
the	O
early	O
days	O
of	O
psychophysics	O
,	O
only	O
recently	O
have	O
they	O
been	O
recognized	O
as	O
essential	O
for	O
a	O
deeper	O
understanding	O
of	O
visual	O
perception	O
.	O
The	O
reluctance	O
to	O
study	O
visual	O
confidence	O
may	O
have	O
come	O
in	O
part	O
from	O
obtaining	O
convincing	O
experimental	O
evidence	O
in	O
favor	O
of	O
metacognitive	O
abilities	O
rather	O
than	O
just	O
perceptual	O
sensitivity	O
.	O
Some	O
effort	O
has	O
thus	O
been	O
dedicated	O
to	O
offer	O
different	O
experimental	O
paradigms	O
to	O
study	O
visual	O
confidence	O
in	O
humans	O
and	O
nonhuman	O
animals	O
.	O
To	O
understand	O
the	O
origins	O
of	O
confidence	O
judgments	O
,	O
investigators	O
have	O
developed	O
two	O
competing	O
frameworks	O
.	O
The	O
approach	O
based	O
on	O
signal	O
decision	O
theory	O
is	O
popular	O
but	O
fails	O
to	O
account	O
for	O
response	O
times	O
.	O
In	O
contrast	O
,	O
the	O
approach	O
based	O
on	O
accumulation	O
of	O
evidence	O
models	O
naturally	O
includes	O
the	O
dynamics	O
of	O
perceptual	O
decisions	O
.	O
These	O
models	O
can	O
explain	O
a	O
range	O
of	O
results	O
,	O
including	O
the	O
apparently	O
paradoxical	O
dissociation	B-T048
between	O
performance	O
and	O
confidence	O
that	O
is	O
sometimes	O
observed	O
.	O
      
An	O
attenuated	O
Mycobacterium	B-T007
tuberculosis	I-T007
clinical	O
strain	B-T001
with	O
a	O
defect	O
in	O
ESX-1	O
secretion	O
induces	O
minimal	O
host	B-T001
immune	O
responses	O
and	O
pathology	O
Although	O
Mycobacterium	B-T007
tuberculosis	I-T007
(	I-T007
M.tb	I-T007
)	I-T007
DK9897	I-T007
is	O
an	O
attenuated	O
strain	B-T001
,	O
it	O
was	O
isolated	O
from	O
a	O
patient	O
with	O
extrapulmonary	B-T047
tuberculosis	I-T047
and	O
vaccination	B-T061
with	O
a	O
subunit	B-T121
vaccine	I-T121
(	O
H56	B-T121
)	O
induced	O
poor	O
protection	B-T033
against	O
it	O
.	O
Both	O
attenuation	O
and	O
lack	O
of	O
protection	B-T033
are	O
because	O
M.tb	B-T007
DK9897	I-T007
can	O
not	O
secrete	O
the	O
EsxA	O
virulence	O
factor	O
nor	O
induce	O
a	O
host	O
response	O
against	O
it	O
.	O
Genome	O
sequencing	O
identified	O
a	O
frameshift	O
mutation	O
in	O
the	O
eccCa1	O
gene	O
.	O
Since	O
the	O
encoded	O
EccCa1	O
protein	O
provides	O
energy	O
for	O
ESX-1	O
secretion	O
,	O
it	O
suggested	O
a	O
defect	O
in	O
the	O
ESX-1	O
type	O
VII	O
secretion	O
system	O
.	O
Genetic	O
complementation	O
with	O
a	O
plasmid	O
carrying	O
the	O
M.tb	B-T007
H37Rv	I-T007
sequence	O
of	O
eccCa1	O
-	O
eccCb1	O
-	O
pe35	O
re	O
-	O
established	O
EsxA	O
secretion	O
,	O
host	B-T001
specific	O
EsxA	O
T	O
-	O
cell	O
responses	O
,	O
and	O
increased	O
strain	B-T001
virulence	O
.	O
The	O
ESX-1	O
secretion	O
defect	O
prevents	O
several	O
virulence	O
factors	O
from	O
being	O
functional	O
during	O
infection	O
and	O
therefore	O
attenuates	O
M.tb	B-T007
.	O
It	O
precludes	O
specific	O
T	O
-	O
cell	O
responses	O
against	O
strong	O
antigens	O
and	O
we	O
found	O
very	O
little	O
in	O
vivo	O
cytokine	O
production	O
,	O
gross	O
pathology	O
or	O
granuloma	O
formation	O
in	O
lungs	B-T023
from	O
M.tb	B-T007
DK9897	I-T007
infected	B-T033
animals	I-T033
.	O
This	O
coincides	O
with	O
M.tb	B-T007
DK9897	I-T007
being	O
unable	O
to	O
disrupt	O
the	O
phagosome	O
membrane	O
and	O
make	O
contact	O
to	O
the	O
cytosol	O
.	O
      
Benthic	O
injury	O
dose	O
-	O
response	O
models	O
for	O
polychlorinated	O
biphenyl	O
-	O
contaminated	O
sediment	O
using	O
equilibrium	O
partitioning	O
The	O
study	O
goal	O
was	O
to	O
develop	O
a	O
sediment	O
polychlorinated	O
biphenyl	O
(	O
PCB	O
)	O
dose	O
-	O
response	O
model	O
based	O
on	O
benthic	B-T001
invertebrate	I-T001
effects	O
to	O
PCBs	O
.	O
The	O
authors	O
used	O
an	O
equilibrium	O
partitioning	O
(	O
EqP	O
)	O
approach	O
to	O
generate	O
predicted	O
PCB	O
sediment	O
effect	O
concentrations	O
(	O
largely	O
Aroclor	O
1254	O
)	O
associated	O
with	O
a	O
gradient	O
of	O
toxic	O
effects	O
in	O
benthic	B-T001
organisms	I-T001
from	O
effects	O
observed	O
in	O
aquatic	O
toxicity	O
studies	O
.	O
The	O
present	O
study	O
differs	O
from	O
all	O
other	O
EqP	O
collective	O
sediment	O
investigations	O
in	O
that	O
the	O
authors	O
examined	O
a	O
common	O
dose	O
-	O
response	O
gradient	O
of	O
effects	O
for	O
PCBs	O
rather	O
than	O
a	O
single	O
,	O
protective	O
value	O
.	O
The	O
authors	O
reviewed	O
the	O
chronic	O
aquatic	O
toxicity	O
literature	O
to	O
identify	O
measured	O
aqueous	O
PCB	O
concentrations	O
and	O
associated	O
benthic	B-T001
invertebrate	I-T001
effects	O
.	O
The	O
authors	O
control	O
-	O
normalized	O
the	O
aquatic	O
toxic	O
effect	O
data	O
and	O
expressed	O
results	O
from	O
various	O
studies	O
as	O
a	O
common	O
metric	O
,	O
percent	O
injury	O
.	O
Then	O
,	O
they	O
calculated	O
organic	O
carbon	O
-normalized	O
sediment	O
PCB	O
concentrations	O
(	O
mg	O
/	O
kg	O
organic	O
carbon	O
)	O
from	O
the	O
aqueous	O
PCB	O
toxicity	O
data	O
set	O
using	O
EqP	O
theory	O
based	O
on	O
the	O
US	O
Environmental	O
Protection	O
Agency	O
's	O
(	O
EPIWEB	O
4.1	O
)	O
derivation	O
of	O
the	O
water	O
-	O
organic	O
carbon	O
partition	O
coefficient	O
(	O
KOC	O
)	O
.	O
Lastly	O
,	O
the	O
authors	O
constructed	O
a	O
nonlinear	O
dose	O
-	O
response	O
numerical	O
model	O
for	O
these	O
synoptic	O
sediment	O
PCB	O
concentrations	O
and	O
biological	O
effects	O
:	O
Y	O
=	O
100/1	O
+	O
10(([logEC50	O
-	O
logX	O
]	O
×	O
[	O
Hill	O
slope	O
]	O
)	O
)	O
(	O
EC50	O
=	O
median	O
effective	O
concentration	O
)	O
.	O
These	O
models	O
were	O
used	O
to	O
generate	O
"	O
look	O
-	O
up	O
"	O
tables	O
reporting	O
percent	O
injury	O
in	O
benthic	O
biota	O
for	O
a	O
range	O
of	O
Aroclor	O
-specific	O
sediment	O
concentrations	O
.	O
For	O
example	O
,	O
the	O
model	O
using	O
the	O
EPIWEB	O
KOC	O
estimate	O
predicts	O
mean	O
benthic	O
injury	O
of	O
23.3	O
%	O
,	O
46.0	O
%	O
,	O
70.6	O
%	O
,	O
87.1	O
%	O
,	O
and	O
95	O
%	O
for	O
hypothetical	O
sediment	O
concentrations	O
of	O
1	O
mg	O
/	O
kg	O
,	O
2	O
mg	O
/	O
kg	O
,	O
4	O
mg	O
/	O
kg	O
,	O
8	O
mg	O
/	O
kg	O
,	O
and	O
16	O
mg	O
/	O
kg	O
dry	O
weight	O
of	O
Aroclor	O
1254	O
,	O
respectively	O
(	O
at	O
1	O
%	O
organic	O
carbon	O
)	O
.	O
The	O
authors	O
recommend	O
the	O
model	O
presented	O
for	O
screening	O
but	O
suggest	O
,	O
when	O
possible	O
,	O
determining	O
a	O
site	O
-	O
specific	O
KOC	O
that	O
,	O
along	O
with	O
the	O
tables	O
and	O
equations	O
,	O
allows	O
users	O
to	O
create	O
their	O
own	O
protective	O
dose	O
-	O
response	O
sediment	O
concentration	O
.	O
Environ	O
Toxicol	O
Chem	O
2017;36:1311	O
-	O
1329	O
.	O
©	O
2016	O
SETAC	O
.	O
      
Elucidating	O
a	O
chemical	O
defense	O
mechanism	O
of	O
Antarctic	O
sponges	O
:	O
A	O
computational	B-T059
study	I-T059
In	O
2000	O
,	O
a	O
novel	O
secondary	O
metabolite	O
(	O
erebusinone	O
,	O
Ereb	O
)	O
was	O
isolated	O
from	O
the	O
Antarctic	O
sea	O
sponge	O
,	O
Isodictya	O
erinacea	O
.	O
The	O
bioactivity	O
of	O
Ereb	O
was	O
investigated	O
,	O
and	O
it	O
was	O
found	O
to	O
inhibit	O
molting	O
when	O
fed	O
to	O
the	O
arthropod	O
species	O
Orchomene	O
plebs	O
.	O
Xanthurenic	O
acid	O
(	O
XA	O
)	O
is	O
a	O
known	O
endogenous	O
molt	O
regulator	O
present	O
in	O
arthropods	O
.	O
Experimental	O
studies	O
have	O
confirmed	O
that	O
XA	O
inhibits	O
molting	O
by	O
binding	O
to	O
either	O
(	O
or	O
both	O
)	O
of	O
two	O
P450	O
enzymes	O
(	O
CYP315a1	O
or	O
CYP314a1	O
)	O
that	O
are	O
responsible	O
for	O
the	O
final	O
two	O
hydroxylations	O
in	O
the	O
production	O
of	O
the	O
molt	O
-	O
inducing	O
hormone	O
,	O
20	O
-	O
hydroxyecdysone	O
(	O
20E	O
)	O
.	O
The	O
lack	O
of	O
crystal	O
structures	O
and	O
biochemical	B-T059
assays	I-T059
for	O
CYP315a1	O
or	O
CYP314a1	O
,	O
has	O
prevented	O
further	O
experimental	O
exploration	O
of	O
XA	O
and	O
Ereb	O
's	O
molt	O
inhibition	O
mechanisms	O
.	O
Herein	O
,	O
a	O
wide	O
array	O
of	O
computational	O
techniques	O
-	O
homology	O
modeling	O
,	O
molecular	O
dynamics	O
simulations	O
,	O
binding	O
site	O
bioinformatics	O
,	O
flexible	O
receptor	O
-	O
flexible	O
ligand	O
docking	O
,	O
and	O
molecular	O
mechanics	O
-	O
generalized	O
Born	O
surface	O
area	O
calculations	O
-	O
have	O
been	O
employed	O
to	O
elucidate	O
the	O
structure	O
-	O
function	O
relationships	O
between	O
the	O
aforementioned	O
P450s	O
and	O
the	O
two	O
described	O
small	O
molecule	O
inhibitors	O
(	O
Ereb	O
and	O
XA	O
)	O
.	O
Results	O
indicate	O
that	O
Ereb	O
likely	O
targets	O
CYP315a1	O
by	O
interacting	O
with	O
a	O
network	O
of	O
aromatic	O
residues	O
in	O
the	O
binding	O
site	O
,	O
while	O
XA	O
may	O
inhibit	O
both	O
CYP315a1	O
and	O
CYP314a1	O
because	O
of	O
its	O
aromatic	O
,	O
as	O
well	O
as	O
charged	O
nature	O
.	O
      
Multidrug	O
Resistance	O
of	O
Acinetobacter	B-T007
Baumannii	I-T007
in	O
Ladoke	O
Akintola	O
University	O
Teaching	O
Hospital	O
,	O
Osogbo	O
,	O
Nigeria	O
Acinetobacter	B-T007
baumannii	I-T007
is	O
a	O
ubiquitous	O
pathogen	B-T001
that	O
has	O
emerged	O
as	O
a	O
major	O
cause	O
of	O
healthcare	O
-	O
associated	O
infections	O
at	O
Ladoke	O
Akintola	O
University	O
Teaching	O
Hospital	O
.	O
Isolates	O
were	O
assayed	B-T059
according	O
to	O
standard	O
protocol	O
.	O
The	O
isolates	O
were	O
subjected	O
to	O
molecular	O
techniques	O
to	O
detect	O
blaOXA	O
,	O
blaTEM	O
,	O
blaCTX	O
-	O
M	O
,	O
and	O
blaSHV	O
genes	O
in	O
strains	B-T007
of	O
the	O
A.	B-T007
baumannii	I-T007
isolates	O
.	O
The	O
prevalence	O
of	O
A.	B-T007
baumannii	I-T007
was	O
8.5	O
%	O
and	O
was	O
most	O
prevalent	O
among	O
patients	O
in	O
the	O
age	O
group	O
51	O
-	O
60	O
(	O
36	O
%	O
)	O
;	O
the	O
male	O
patients	O
(	O
63.6	O
%	O
)	O
were	O
more	O
infected	B-T033
than	O
their	O
female	O
counterparts	O
.	O
Patients	O
(	O
72.7	O
%	O
)	O
in	O
the	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
were	O
most	O
infected	B-T033
with	O
this	O
organism	B-T001
.	O
The	O
isolates	O
showed	O
100	O
%	O
resistance	O
to	O
both	O
amikacin	B-T195
and	O
ciprofloxacin	B-T121
and	O
90.9	O
%	O
to	O
both	O
ceftriaxone	B-T195
and	O
ceftazidime	B-T195
,	O
while	O
resistance	O
to	O
the	O
other	O
antibiotics	B-T195
used	O
in	O
this	O
study	O
were	O
:	O
piperacillin	B-T195
(	O
81.8	O
%	O
)	O
,	O
imipenem	B-T195
(	O
72.7	O
%	O
)	O
,	O
gentamycin	B-T195
(	O
72.2	O
%	O
)	O
,	O
and	O
meropenem	B-T195
(	O
63.6	O
%	O
)	O
.	O
None	O
of	O
the	O
isolates	O
was	O
,	O
however	O
,	O
resistant	O
to	O
colistin	B-T195
.	O
PCR	O
results	O
showed	O
that	O
blaOXA	O
,	O
blaTEM	O
,	O
and	O
blaCTX	O
-	O
M	O
genes	O
were	O
positive	B-T033
in	O
some	O
isolates	O
,	O
while	O
blaSHV	O
was	O
not	B-T033
detected	I-T033
in	O
any	O
of	O
the	O
isolates	O
.	O
This	O
study	O
has	O
revealed	O
that	O
the	O
strains	B-T007
of	O
A.	B-T007
baumannii	I-T007
isolated	O
are	O
multiple	O
drug	O
resistant	O
.	O
Regular	O
monitoring	B-T058
,	O
judicious	O
prescription	B-T058
,	O
and	O
early	O
detection	B-T061
of	O
resistance	O
to	O
these	O
antibiotics	B-T195
are	O
,	O
therefore	O
,	O
necessary	O
to	O
check	O
further	O
dissemination	O
of	O
the	O
organism	B-T001
.	O
      
Causes	B-T033
of	I-T033
Death	I-T033
among	O
Children	O
Aged	O
5	O
to	O
14	O
Years	O
Old	O
from	O
2008	O
to	O
2013	O
in	O
Kersa	O
Health	O
and	O
Demographic	O
Surveillance	O
System	O
(	O
Kersa	O
HDSS	O
)	O
,	O
Ethiopia	O
The	O
global	O
burden	O
of	O
mortality	O
among	O
children	O
is	O
still	O
very	O
huge	O
though	O
its	O
trend	O
has	O
started	O
declining	O
following	O
the	O
improvements	O
in	O
the	O
living	O
standard	O
.	O
It	O
presents	O
serious	O
challenges	B-T058
to	O
the	O
well	O
-	O
being	O
of	O
children	O
in	O
many	O
African	O
countries	O
.	O
Today	O
,	O
Sub	O
-	O
Saharan	O
Africa	O
alone	O
accounts	O
for	O
about	O
50	O
%	O
of	O
global	O
child	O
mortality	O
.	O
The	O
overall	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
magnitude	O
and	O
distribution	O
of	O
causes	B-T033
of	I-T033
death	I-T033
among	O
children	O
aged	O
5	O
to	O
14	O
year	O
olds	O
in	O
the	O
population	O
of	O
Kersa	O
HDSS	O
using	O
verbal	O
autopsy	B-T060
method	O
for	O
the	O
period	O
2008	O
to	O
2013	O
.	O
Kersa	O
Health	O
and	O
Demographic	O
Surveillance	O
System	O
(	O
Kersa	O
HDSS	O
)	O
was	O
established	O
in	O
September	O
2007	O
.	O
The	O
center	O
consists	O
of	O
10	O
rural	O
and	O
2	O
urban	O
kebeles	O
which	O
were	O
selected	O
randomly	O
from	O
38	O
kebeles	O
in	O
the	O
district	O
.	O
Thus	O
this	O
study	O
was	O
conducted	O
in	O
Kersa	O
HDSS	O
and	O
data	O
was	O
taken	O
from	O
Kersa	O
HDSS	O
database	O
.	O
The	O
study	O
population	O
included	O
all	O
children	O
aged	O
5	O
to	O
14	O
years	O
registered	O
during	O
the	O
period	O
of	O
2008	O
to	O
2013	O
in	O
Kersa	O
HDSS	O
using	O
age	O
specific	O
VA	O
questionnaires	O
.	O
Data	O
were	O
extracted	O
from	O
SPSS	O
database	O
and	O
analyzed	O
using	O
STATA	O
.	O
A	O
total	O
of	O
229	O
deaths	B-T033
were	O
recorded	O
over	O
the	O
period	O
of	O
six	O
years	O
with	O
a	O
crude	O
death	O
rate	O
of	O
219.6	O
per	O
100,000	O
population	O
of	O
this	O
age	O
group	O
over	O
the	O
study	O
period	O
.	O
This	O
death	O
rate	O
was	O
217.5	O
and	O
221.5	O
per	O
100,000	O
populations	O
for	O
females	O
and	O
males	O
,	O
respectively	O
.	O
75	O
%	O
of	O
deaths	B-T033
took	O
place	O
at	O
home	O
.	O
The	O
study	O
identified	O
severe	O
malnutrition	B-T047
(	O
33.9	O
%	O
)	O
,	O
intestinal	B-T047
infectious	I-T047
diseases	I-T047
(	O
13.8	O
%	O
)	O
and	O
acute	B-T047
lower	I-T047
respiratory	I-T047
infections	I-T047
(	O
9.2	O
%	O
)	O
to	O
be	O
the	O
three	O
most	O
leading	O
causes	B-T033
of	I-T033
death	I-T033
.	O
In	O
broad	O
causes	B-T033
of	I-T033
death	I-T033
classification	O
,	O
injuries	O
have	O
been	O
found	O
to	O
be	O
the	O
second	O
most	O
cause	B-T033
of	I-T033
death	I-T033
next	O
to	O
communicable	B-T047
diseases	I-T047
(	O
56.3	O
%	O
)	O
attributing	O
to	O
13.1	O
%	O
of	O
the	O
total	O
deaths	B-T033
.	O
In	O
specific	O
causes	B-T033
of	I-T033
death	I-T033
classification	O
severe	O
malnutrition	B-T047
,	O
intestinal	B-T047
infectious	I-T047
diseases	I-T047
and	O
acute	B-T047
lower	I-T047
respiratory	I-T047
infections	I-T047
were	O
the	O
three	O
leading	O
causes	B-T033
of	I-T033
death	I-T033
where	O
,	O
in	O
broad	O
causes	B-T033
of	I-T033
death	I-T033
communicable	B-T047
diseases	I-T047
and	O
injuries	O
were	O
among	O
the	O
leading	O
causes	B-T033
of	I-T033
death	I-T033
.	O
Hence	O
,	O
concerned	O
bodies	O
should	O
take	O
measures	O
to	O
avert	O
the	O
situation	O
of	O
mortality	O
from	O
these	O
causes	B-T033
of	I-T033
death	I-T033
and	O
further	O
inferential	O
analysis	O
into	O
the	O
prevention	B-T061
and	O
management	B-T058
of	O
infectious	B-T047
diseases	I-T047
should	O
also	O
be	O
taken	O
.	O
      
Acute	B-T191
Ph	I-T191
-	I-T191
negative	I-T191
lymphoblastic	I-T191
leukemias	I-T191
in	O
adults	O
:	O
Risk	B-T033
factors	I-T033
in	O
the	O
use	O
of	O
the	O
ALL-2009	O
protocol	O
to	O
analyze	O
well	O
-	O
known	O
risk	B-T033
factors	I-T033
(	O
RFs	B-T033
)	O
,	O
such	O
as	O
age	O
,	O
immunophenotype	B-T059
,	O
baseline	O
leukocytosis	O
,	O
enhanced	O
lactate	O
dehydrogenase	O
(	O
LDH	O
)	O
activity	O
,	O
time	O
to	O
achieve	O
complete	O
remission	B-T033
,	O
a	O
risk	O
group	O
,	O
and	O
cytogenetic	O
abnormalities	O
)	O
in	O
patients	O
with	O
acute	B-T191
lymphoblastic	I-T191
leukemia	I-T191
(	O
ALL	B-T191
)	O
in	O
the	O
use	O
of	O
the	O
ALL-2009	O
protocol	O
.	O
The	O
protocol	O
covered	O
298	O
patients	O
(	O
137	O
women	O
(	O
including	O
13	O
pregnant	O
women	O
)	O
and	O
161	O
men	O
)	O
aged	O
15	O
to	O
55	O
years	O
(	O
median	O
age	O
28	O
years	O
)	O
with	O
Ph	B-T191
-	I-T191
negative	I-T191
ALL	I-T191
.	O
The	O
phenotype	O
was	O
unknown	O
in	O
6	O
patients	O
.	O
Three	O
(	O
1	O
%	O
)	O
were	O
ascertained	O
to	O
have	O
a	O
biphenotypic	O
variant	O
.	O
182	O
(	O
62.4	O
%	O
)	O
patients	O
were	O
found	O
to	O
have	O
B	B-T191
-	I-T191
cell	I-T191
ALL	I-T191
(	O
early	O
pre	B-T191
-	I-T191
B	I-T191
ALL	I-T191
(	O
n=51	O
)	O
;	O
common	O
ALL	B-T191
(	O
n=92	O
)	O
,	O
and	O
pre	B-T191
-	I-T191
B	I-T191
ALL	I-T191
(	O
n=39	O
)	O
;	O
107	O
(	O
36.6	O
%	O
)	O
patients	O
had	O
T	B-T191
-	I-T191
cell	I-T191
ALL	I-T191
(	O
early	O
T	B-T191
-	I-T191
ALL	I-T191
(	O
n=56	O
)	O
;	O
thymic	B-T023
T	B-T191
-	I-T191
ALL	I-T191
(	O
n=41	O
)	O
,	O
and	O
mature	O
T	B-T191
-	I-T191
ALL	I-T191
(	O
n=10	O
)	O
.	O
According	O
to	O
the	O
baseline	O
clinical	O
and	O
laboratory	O
parameters	B-T033
(	O
leukocytosis	O
of	O
30·109	O
/	O
l	O
and	O
more	O
for	O
B	B-T191
-	I-T191
ALL	I-T191
;	O
and	O
that	O
of	O
100·109	O
/	O
l	O
and	O
more	O
for	O
T	B-T191
-	I-T191
ALL	I-T191
;	O
phenotype	O
В	O
-	O
I	O
for	O
B	B-T191
-	I-T191
ALL	I-T191
,	O
phenotype	O
Т	O
-	O
I	O
-	O
II	O
-	O
IV	O
for	O
T	B-T191
-	I-T191
ALL	I-T191
;	O
LDH	O
activity	O
was	O
more	O
than	O
twice	O
the	O
normal	O
values	O
;	O
the	O
presence	B-T033
of	O
translocation	O
t(4;11	O
)	O
)	O
,	O
the	O
high	O
-	O
risk	O
group	O
included	O
most	O
patients	O
with	O
B	B-T191
-	I-T191
ALL	I-T191
(	O
n=110	O
(	O
72.8	O
%	O
)	O
)	O
and	O
T	B-T191
-	I-T191
ALL	I-T191
(	O
n=76	O
(	O
76	O
%	O
)	O
)	O
.	O
Thirty	O
-	O
five	O
patients	O
with	O
T	B-T191
-	I-T191
ALL	I-T191
underwent	O
autologous	B-T061
bone	I-T061
marrow	I-T061
transplantation	I-T061
(	O
BMT	B-T061
)	O
.	O
Allogeneic	B-T061
BMT	I-T061
was	O
performed	O
in	O
18	O
(	O
7	O
%	O
)	O
of	O
the	O
258	O
patients	O
who	O
had	O
undergone	O
an	O
induction	O
phase	O
.	O
Five	O
-	O
year	O
overall	O
survival	O
for	O
all	O
the	O
patients	O
included	O
in	O
the	O
investigation	B-T058
was	O
59	O
%	O
;	O
relapse	B-T061
-	I-T061
free	I-T061
survival	O
was	O
65	O
%	O
,	O
which	O
was	O
significantly	O
different	O
in	O
the	O
patients	O
with	O
B	B-T191
-	I-T191
ALL	I-T191
and	O
in	O
those	O
with	O
T	B-T191
-	I-T191
ALL	I-T191
:	O
the	O
overall	O
survival	O
rates	O
were	O
53.3	O
and	O
67.5	O
%	O
(	O
p=0.1	O
)	O
;	O
the	O
relapse	O
-	O
free	O
survival	O
was	O
56	O
and	O
79	O
%	O
(	O
p=0.005	O
)	O
,	O
respectively	O
.	O
Multivariate	O
analysis	O
including	O
the	O
well	O
-	O
known	O
RFs	B-T033
demonstrated	O
that	O
the	O
latter	O
for	O
T	B-T191
-	I-T191
ALL	I-T191
were	O
of	O
no	O
independent	O
prognostic	O
value	O
and	O
only	O
the	O
patient	O
's	O
age	O
was	O
identified	O
for	O
B	B-T191
-	I-T191
ALL	I-T191
(	O
p=0.013	O
)	O
.	O
A	O
lower	O
chemotherapeutic	B-T121
load	O
and	O
a	O
small	O
number	O
of	O
allogeneic	B-T061
BMTs	I-T061
did	O
not	O
affect	O
total	O
positive	O
treatment	B-T061
results	O
in	O
adult	O
patients	O
with	O
ALL	B-T191
,	O
by	O
complying	O
with	O
the	O
principle	O
achieving	O
the	O
continuity	O
of	O
cytostatic	B-T121
effects	O
and	O
by	O
preserving	O
the	O
total	O
cytostatic	B-T121
loading	O
dose	O
.	O
The	O
results	O
of	O
the	O
Russian	O
investigation	B-T058
casts	O
some	O
doubt	O
on	O
the	O
necessity	O
of	O
using	O
very	O
intensive	O
consolidation	O
cycles	O
and	O
performing	O
a	O
large	O
number	O
of	O
allogeneic	B-T061
BMTs	I-T061
in	O
adult	O
patients	O
with	O
ALL	B-T191
.	O
      
Social	O
cognition	O
in	O
schizophrenia	B-T048
:	O
Factor	O
structure	O
of	O
emotion	O
processing	O
and	O
theory	O
of	O
mind	O
Factor	O
analytic	O
studies	O
examining	O
social	O
cognition	O
in	O
schizophrenia	B-T048
have	O
yielded	O
inconsistent	O
results	O
most	O
likely	O
due	O
to	O
the	O
varying	O
number	O
and	O
quality	O
of	O
measures	O
.	O
With	O
the	O
recent	O
conclusion	O
of	O
Phase	O
3	O
of	O
the	O
Social	O
Cognition	O
Psychometric	B-T060
Evaluation	I-T060
(	I-T060
SCOPE	I-T060
)	I-T060
Study	I-T060
,	O
the	O
most	O
psychometrically	B-T060
sound	B-T060
measures	I-T060
of	O
social	O
cognition	O
have	O
been	O
identified	O
.	O
Therefore	O
,	O
the	O
aims	O
of	O
the	O
present	O
study	O
were	O
to	O
:	O
1	O
)	O
examine	B-T033
the	O
factor	O
structure	O
of	O
social	O
cognition	O
in	O
schizophrenia	B-T048
through	O
the	O
utilization	O
of	O
psychometrically	B-T060
sound	B-T060
measures	I-T060
,	O
2	O
)	O
examine	B-T033
the	O
stability	O
of	O
the	O
factor	O
structure	O
across	O
two	O
study	O
visits	O
,	O
3	O
)	O
compare	O
the	O
factor	O
structure	O
of	O
social	O
cognition	O
in	O
schizophrenia	B-T048
to	O
that	O
in	O
healthy	O
controls	O
,	O
and	O
4	O
)	O
examine	B-T033
the	O
relationship	O
between	O
the	O
factors	O
and	O
relevant	O
outcome	O
measures	O
including	O
social	O
functioning	O
and	O
symptoms	B-T184
.	O
Results	O
supported	O
a	O
one	O
-	O
factor	O
model	O
for	O
the	O
patient	O
and	O
healthy	O
control	O
samples	O
at	O
both	O
visits	B-T058
visits	B-T058
.	O
This	O
single	O
factor	O
was	O
significantly	O
associated	O
with	O
negative	B-T184
symptoms	I-T184
in	O
the	O
schizophrenia	B-T048
sample	O
and	O
with	O
social	O
functioning	O
in	O
both	O
groups	O
at	O
both	O
study	O
visits	B-T058
.	O
      
Transcriptomic	O
insights	O
into	O
the	O
allelopathic	O
effects	O
of	O
the	O
garlic	O
allelochemical	O
diallyl	B-T121
disulfide	I-T121
on	O
tomato	O
roots	O
Garlic	O
is	O
an	O
allelopathic	O
crop	O
that	O
can	O
alleviate	O
the	O
obstacles	O
to	O
continuous	O
cropping	O
of	O
vegetable	O
crops	O
.	O
Diallyl	B-T121
disulfide	I-T121
(	O
DADS	B-T121
)	O
,	O
one	O
of	O
the	O
most	O
important	O
allelochemicals	O
in	O
garlic	O
,	O
promotes	O
tomato	O
root	O
growth	O
.	O
Therefore	O
,	O
the	O
global	O
transcriptome	O
profiles	O
of	O
DADS	B-T121
-	O
treated	O
tomato	O
roots	O
over	O
time	O
were	O
investigated	O
to	O
reveal	O
the	O
potential	O
growth	O
-	O
promoting	O
mechanisms	O
.	O
We	O
detected	B-T033
1828	O
,	O
1296	O
and	O
1190	O
differentially	O
expressed	O
genes	O
(	O
DEGs	O
)	O
in	O
the	O
4	O
,	O
24	O
and	O
48	O
h	O
samples	O
,	O
respectively	O
.	O
Most	O
DEGs	O
involved	O
in	O
assimilatory	O
sulfate	O
reduction	O
and	O
glutathione	O
metabolism	O
were	O
up	O
-	O
regulated	O
after	O
short	O
-	O
term	O
(	O
4	O
h	O
)	O
DADS	B-T121
treatment	O
.	O
In	O
addition	O
,	O
increased	B-T033
activity	I-T033
of	I-T033
defensive	I-T033
enzymes	I-T033
and	O
up	O
-	O
regulation	O
of	O
six	O
peroxidase	O
genes	O
were	O
observed	O
,	O
suggesting	O
that	O
DADS	B-T121
could	O
induce	O
tomato	O
resistance	O
.	O
In	O
plant	O
-	O
pathogen	O
interactions	O
,	O
DEGs	O
related	O
to	O
calcium	O
signaling	O
were	O
primarily	O
inhibited	O
,	O
while	O
those	O
encoding	O
pathogenesis	O
-	O
related	O
proteins	O
were	O
primarily	O
up	O
-	O
regulated	O
.	O
Although	O
plant	O
hormone	O
synthesis	O
and	O
signal	O
transduction	O
were	O
both	O
significantly	O
affected	O
by	O
DADS	B-T121
,	O
the	O
expression	O
trends	O
of	O
the	O
genes	O
in	O
these	O
two	O
pathways	O
were	O
conflicting	O
.	O
This	O
research	O
provides	O
comprehensive	O
information	O
concerning	O
the	O
changes	O
in	O
the	O
tomato	O
root	O
transcriptome	O
affected	O
by	O
DADS	B-T121
and	O
may	O
help	O
direct	O
further	O
studies	O
on	O
DADS	B-T121
-	O
responsive	O
genes	O
to	O
enhance	O
the	O
current	O
understanding	O
of	O
the	O
mechanisms	O
by	O
which	O
DADS	B-T121
alleviates	O
the	O
obstacles	O
to	O
continuous	O
cropping	O
.	O
      
Cognitive	B-T048
impairment	I-T048
in	O
first	O
-	O
episode	O
drug	O
-	O
naïve	O
patients	O
with	O
schizophrenia	B-T048
:	O
Relationships	O
with	O
serum	O
concentrations	O
of	O
brain	O
-	O
derived	O
neurotrophic	O
factor	O
and	O
glial	O
cell	O
line	O
-	O
derived	O
neurotrophic	O
factor	O
Evidence	O
suggests	O
that	O
brain	O
-	O
derived	O
neurotrophic	O
factor	O
(	O
BDNF	O
)	O
and	O
glial	O
cell	O
line	O
-derived	O
neurotrophic	O
factor	O
(	O
GDNF	O
)	O
are	O
important	O
in	O
the	O
regulation	O
of	O
synaptic	O
plasticity	O
,	O
which	O
plays	O
a	O
key	O
role	O
in	O
the	O
cognitive	O
processes	O
in	O
psychiatric	B-T048
disorders	I-T048
.	O
Our	O
work	O
aimed	O
at	O
exploring	O
the	O
associations	O
between	O
serum	O
BDNF	O
and	O
GDNF	O
levels	O
and	O
cognitive	O
functions	O
in	O
first	O
-	O
episode	O
drug	O
-	O
naïve	O
(	O
FEDN	O
)	O
patients	O
with	O
schizophrenia	B-T048
.	O
The	O
BDNF	O
and	O
GDNF	O
levels	O
of	O
58	O
FEDN	O
patients	O
and	O
55	O
age	O
-	O
and	O
sex	O
-matched	O
healthy	O
controls	O
were	O
measured	O
and	O
test	O
subjects	O
were	O
examined	O
using	O
several	O
neurocognitive	B-T060
tests	I-T060
including	O
the	O
verbal	B-T060
fluency	I-T060
test	I-T060
(	O
VFT	B-T060
)	O
,	O
the	O
trail	O
making	O
test	O
(	O
TMT	O
)	O
,	O
the	O
digit	O
span	O
test	O
(	O
DST	O
)	O
,	O
and	O
the	O
Stroop	B-T060
test	I-T060
.	O
Patients	O
performed	O
significantly	O
worse	O
than	O
controls	O
in	O
nearly	O
all	O
neurocognitive	B-T060
performances	I-T060
except	O
the	O
forward	O
subscale	O
part	O
of	O
the	O
DST	O
.	O
BDNF	O
levels	O
were	O
inversely	O
correlated	O
to	O
TMT	O
-	O
part	O
B	O
scores	O
and	O
positively	O
correlated	O
to	O
VFT	B-T060
-	I-T060
action	I-T060
in	O
the	O
FEDN	O
group	O
.	O
GDNF	O
levels	O
showed	O
a	O
positive	O
correlation	O
with	O
VFT	O
-	O
action	O
scores	O
and	O
a	O
negative	O
correlation	O
with	O
TMT	O
-	O
part	O
B	O
scores	O
of	O
these	O
patients	O
.	O
Current	O
data	O
suggests	O
that	O
cognitive	B-T048
dysfunction	I-T048
widely	O
exists	O
in	O
the	O
early	O
stages	O
of	O
schizophrenia	B-T048
.	O
BDNF	O
and	O
GDNF	O
may	O
be	O
jointly	O
contributed	O
to	O
the	O
pathological	O
mechanisms	O
involved	O
in	O
cognitive	B-T048
impairment	I-T048
in	O
FEDN	O
patients	O
with	O
schizophrenia	B-T048
.	O
      
Investigation	O
of	O
argyrophilic	O
nucleolar	O
organizing	O
region	O
Ischemia	O
/	O
reperfusion	O
(	O
I	O
/	O
R	O
)	O
injury	O
is	O
a	O
complex	O
event	O
frequently	O
observed	O
in	O
vascular	B-T061
surgery	I-T061
and	O
can	O
cause	O
functional	O
and	O
structural	O
cell	O
damage	O
.	O
Nucleolar	O
-	O
organizing	O
regions	O
(	O
NORs	O
)	O
are	O
sites	O
of	O
the	O
ribosomal	O
genes	O
located	O
on	O
chromosomes	O
and	O
can	O
be	O
stained	B-T059
with	O
silver	O
when	O
they	O
are	O
active	O
.	O
Thus	O
these	O
proteins	O
are	O
named	O
as	O
argyrophilic	O
-	O
NOR	O
(	O
AgNOR)-associated	O
proteins	O
.	O
We	O
aimed	O
to	O
investigate	O
any	O
possible	O
effects	O
of	O
renal	B-T023
I	O
/	O
R	O
injury	O
on	O
the	O
NOR	O
protein	O
synthesis	O
and	O
association	O
between	O
the	O
AgNOR	O
proteins	O
amount	O
and	O
histopathological	B-T033
injuring	I-T033
score	I-T033
.	O
Nine	O
female	O
wistar	O
-	O
albino	O
rats	O
with	O
weight	O
of	O
200	O
-	O
250	O
g	O
were	O
included	O
into	O
the	O
study	O
.	O
The	O
animals	O
were	O
randomly	O
divided	O
in	O
two	O
groups	O
,	O
a	O
Control	O
Group	O
and	O
an	O
I	O
/	O
R	O
Group	O
.	O
In	O
I	O
/	O
R	O
group	O
,	O
rats	O
were	O
subjected	O
to	O
45	O
minutes	O
of	O
renal	B-T023
pedicle	I-T023
occlusion	O
followed	O
by	O
24	O
hours	O
of	O
reperfusion	O
.	O
In	O
the	O
control	O
group	O
no	O
drug	B-T061
injections	I-T061
or	O
ischemia	O
reperfusion	O
were	O
performed	O
in	O
animals	O
.	O
Then	O
histopathological	B-T033
injury	I-T033
score	I-T033
,	O
mean	B-T033
AgNOR	I-T033
number	I-T033
and	O
total	B-T033
AgNOR	I-T033
area	I-T033
/	O
nuclear	B-T033
area	I-T033
(	O
TAA	B-T033
/	O
NA	B-T033
)	O
were	O
detected	B-T033
for	O
each	O
rat	O
.	O
The	O
differences	O
between	O
control	O
and	O
I	O
/	O
R	O
groups	O
were	O
significant	O
for	O
histopathological	B-T033
injury	I-T033
scores	I-T033
(	O
p	O
=	O
0.016	O
)	O
.	O
Also	O
the	O
differences	O
between	O
control	O
group	O
and	O
I	O
/	O
R	O
group	O
were	O
significant	O
for	O
mean	B-T033
AgNOR	I-T033
number	I-T033
(	O
p	O
=	O
0.000	O
)	O
and	O
TAA	O
/	O
NA	O
ratio	O
(	O
p	O
=	O
0.000	O
)	O
.	O
Additionally	O
,	O
there	O
was	O
a	O
positive	O
correlation	O
between	O
TAA	O
/	O
NA	O
ratio	O
and	O
histopathological	B-T033
injury	I-T033
score	I-T033
(	O
r	O
=	O
0.728	O
;	O
p	O
=	O
0.026	O
)	O
and	O
between	O
mean	B-T033
AgNOR	I-T033
number	I-T033
and	O
histopathological	B-T033
injury	I-T033
score	I-T033
(	O
r	O
=	O
0.670	O
;	O
p	O
=	O
0.048	O
)	O
.	O
The	O
detection	B-T061
of	O
AgNOR	O
proteins	O
amount	O
may	O
be	O
used	O
as	O
an	O
indicator	O
to	O
obtain	O
information	O
about	O
the	O
cellular	O
behaviour	O
(	O
self	O
-	O
protective	O
mechanism	O
of	O
tubular	O
epithelial	O
cells	O
)	O
against	O
I	O
/	O
R	O
injury	O
and	O
cellular	O
damage	O
levels	O
(	O
Tab	O
.	O
2	O
,	O
Fig	O
.	O
4	O
,	O
Ref	O
.	O
24	O
)	O
.	O
      
From	O
'	O
sense	O
of	O
number	O
'	O
to	O
'	O
sense	O
of	O
magnitude	O
'	O
-	O
The	O
role	O
of	O
continuous	O
magnitudes	O
in	O
numerical	O
cognition	O
In	O
this	O
review	O
,	O
we	O
are	O
pitting	O
two	O
theories	O
against	O
each	O
other	O
:	O
the	O
more	O
accepted	O
theory	O
-the	O
'	O
number	O
sense	O
'	O
theory	O
-suggesting	O
that	O
a	O
sense	O
of	O
number	O
is	O
innate	O
and	O
non	O
-	O
symbolic	O
numerosity	O
is	O
being	O
processed	O
independently	O
of	O
continuous	O
magnitudes	O
(	O
e.g.	O
,	O
size	O
,	O
area	O
,	O
density	O
)	O
;	O
and	O
the	O
newly	O
emerging	O
theory	O
suggesting	O
that	O
(	O
1	O
)	O
both	O
numerosities	O
and	O
continuous	O
magnitudes	O
are	O
processed	O
holistically	O
when	O
comparing	O
numerosities	O
,	O
and	O
(	O
2	O
)	O
a	O
sense	O
of	O
number	O
might	O
not	O
be	O
innate	O
.	O
In	O
the	O
first	O
part	O
of	O
this	O
review	O
,	O
we	O
discuss	O
the	O
'	O
number	O
sense	O
'	O
theory	O
.	O
Against	O
this	O
background	O
,	O
we	O
demonstrate	O
how	O
the	O
natural	O
correlation	O
between	O
numerosities	O
and	O
continuous	O
magnitudes	O
makes	O
it	O
nearly	O
impossible	O
to	O
study	O
non	O
-	O
symbolic	O
numerosity	O
processing	O
in	O
isolation	O
from	O
continuous	O
magnitudes	O
,	O
and	O
therefore	O
the	O
results	O
of	O
behavioral	O
and	O
imaging	B-T060
studies	I-T060
with	O
infants	O
,	O
adults	O
and	O
animals	O
can	O
be	O
explained	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
relying	O
on	O
continuous	O
magnitudes	O
.	O
In	O
the	O
second	O
part	O
,	O
we	O
explain	O
the	O
'	O
sense	O
of	O
magnitude	O
'	O
theory	O
and	O
review	O
studies	O
that	O
directly	O
demonstrate	O
that	O
continuous	O
magnitudes	O
are	O
more	O
automatic	O
and	O
basic	O
than	O
numerosities	O
.	O
Finally	O
,	O
we	O
present	O
outstanding	O
questions	O
.	O
Our	O
conclusion	O
is	O
that	O
there	O
is	O
not	O
enough	O
convincing	O
evidence	O
to	O
support	O
the	O
number	O
sense	O
theory	O
anymore	O
.	O
Therefore	O
,	O
we	O
encourage	O
researchers	O
not	O
to	O
assume	O
that	O
number	O
sense	O
is	O
simply	O
innate	O
,	O
but	O
to	O
put	O
this	O
hypothesis	O
to	O
the	O
test	O
,	O
and	O
to	O
consider	O
if	O
such	O
an	O
assumption	O
is	O
even	O
testable	O
in	O
light	O
of	O
the	O
correlation	O
of	O
numerosity	O
and	O
continuous	O
magnitudes	O
.	O
      
Modified	O
anastomotic	B-T061
technique	I-T061
for	O
thoracolaparoscopic	B-T061
Ivor	I-T061
-	I-T061
Lewis	I-T061
esophagectomy	I-T061
:	O
early	O
outcomes	O
and	O
technical	O
details	O
Thoracoscopic	B-T061
intrathoracic	I-T061
esophagogastrostomy	I-T061
is	O
a	O
technically	O
demanding	O
operation	O
;	O
these	O
technical	O
requirements	O
restrict	O
the	O
extensive	O
application	O
of	O
minimally	O
invasive	O
Ivor	B-T061
-	I-T061
Lewis	I-T061
esophagectomy	I-T061
.	O
In	O
an	O
attempt	O
to	O
reduce	O
the	O
difficulty	O
of	O
this	O
surgical	B-T061
procedure	I-T061
,	O
this	O
study	O
developed	O
a	O
modified	O
anastomotic	B-T061
technique	I-T061
for	O
thoracolaparoscopic	B-T061
Ivor	I-T061
-	I-T061
Lewis	I-T061
esophagectomy	I-T061
.	O
During	O
the	O
entirety	O
of	O
this	O
modified	O
approach	O
,	O
neither	O
technically	O
challenging	O
operations	B-T061
such	O
as	O
intrathoracic	B-T061
suturing	I-T061
or	O
knotting	B-T061
,	O
nor	O
special	O
instruments	O
such	O
as	O
an	O
OrVil	O
system	O
or	O
a	O
reverse	O
-	O
puncture	O
head	O
are	O
required	O
.	O
Between	O
October	O
2015	O
and	O
January	O
2016	O
,	O
15	O
consecutive	O
patients	O
with	O
cancer	B-T191
in	O
the	O
distal	O
third	O
of	O
the	O
esophagus	O
or	O
the	O
gastric	O
cardia	O
underwent	O
this	O
modified	O
surgical	B-T061
procedure	I-T061
.	O
The	O
good	O
short	O
-	O
term	O
outcomes	O
that	O
were	O
achieved	O
suggest	O
that	O
the	O
modified	O
anastomotic	B-T061
technique	I-T061
is	O
safe	O
and	O
feasible	O
for	O
thoracolaparoscopic	B-T061
Ivor	I-T061
-	I-T061
Lewis	I-T061
esophagectomy	I-T061
.	O
      
Water	B-T121
safety	O
in	O
healthcare	O
facilities	O
.	O
The	O
Vieste	O
Charter	O
The	O
Study	O
Group	O
on	O
Hospital	O
Hygiene	O
of	O
the	O
Italian	O
Society	O
of	O
Hygiene	O
,	O
Preventive	O
Medicine	O
and	O
Public	O
Health	O
(	O
GISIO	O
-	O
SItI	O
)	O
and	O
the	O
Local	O
Health	O
Authority	O
of	O
Foggia	O
,	O
Apulia	O
,	O
Italy	O
,	O
after	O
the	O
National	O
Convention	O
"	O
Safe	O
water	B-T121
in	O
healthcare	O
facilities	O
"	O
held	O
in	O
Vieste	O
-	O
Pugnochiuso	O
on	O
27	O
-	O
28	O
May	O
2016	O
,	O
present	O
the	O
"	O
Vieste	O
Charter	O
"	O
,	O
drawn	O
up	O
in	O
collaboration	O
with	O
experts	O
from	O
the	O
National	O
Institute	O
of	O
Health	O
and	O
the	O
Ministry	O
of	O
Health	O
.	O
This	O
paper	O
considers	O
the	O
risk	B-T033
factors	I-T033
that	O
may	O
affect	B-T058
the	O
water	B-T121
safety	O
in	O
healthcare	O
facilities	O
and	O
reports	O
the	O
current	O
regulatory	O
frameworks	O
governing	O
the	O
management	B-T058
of	I-T058
installations	I-T058
and	O
the	O
quality	O
of	O
the	O
water	B-T121
.	O
The	O
Authors	O
promote	O
a	O
careful	O
analysis	O
of	O
the	O
risks	O
that	O
characterize	O
the	O
health	O
facilities	O
,	O
for	O
the	O
control	O
of	O
which	O
specific	O
actions	O
are	O
recommended	O
in	O
various	O
areas	O
,	O
including	O
water	O
safety	O
plans	O
;	O
approval	O
of	O
treatments	O
;	O
healthcare	O
facilities	O
responsibility	O
,	O
installation	O
and	O
maintenance	O
of	O
facilities	O
;	O
multidisciplinary	O
approach	O
;	O
education	O
and	O
research	O
;	O
regional	O
and	O
national	O
coordination	O
;	O
communication	O
.	O
      
Salvianolic	O
Acids	O
for	O
Injection	O
(	O
SAFI	O
)	O
suppresses	O
inflammatory	O
responses	O
in	O
activated	O
microglia	O
to	O
attenuate	O
brain	O
damage	O
in	O
focal	B-T047
cerebral	I-T047
ischemia	I-T047
Inflammatory	O
reactions	O
induced	O
by	O
microglia	O
in	O
the	O
brain	B-T023
play	O
crucial	O
roles	O
in	O
ischemia	B-T047
/	O
reperfusion	O
(	O
I	O
/	O
R	O
)	O
cerebral	O
injuries	O
.	O
Microglia	O
activation	O
has	O
been	O
shown	O
to	O
be	O
closely	O
related	O
to	O
TLR4	O
/	O
NF	O
-	O
κB	O
signal	O
pathways	O
.	O
Salvianolic	O
acids	O
for	O
injection	O
(	O
SAFI	O
)	O
have	O
been	O
used	O
in	O
clinical	O
practice	O
to	O
treat	O
ischemic	B-T047
stroke	I-T047
with	O
reported	B-T058
neuroprotective	O
effects	O
;	O
however	O
,	O
the	O
underlying	O
mechanisms	O
are	O
still	O
uncertain	O
.	O
First	O
,	O
we	O
studied	O
the	O
effect	O
of	O
SAFI	O
on	O
inflammatory	O
responses	O
in	O
LPS	O
-	O
stimulated	O
BV-2	B-T007
microglia	O
.	O
Then	O
,	O
to	O
discover	O
whether	O
the	O
beneficial	O
in	O
vitro	O
effects	O
of	O
SAFI	O
lead	O
to	O
in	O
vivo	O
therapeutic	O
effect	O
s	O
,	O
an	O
MCAO	B-T020
(	O
Middle	B-T020
cerebral	I-T020
artery	I-T020
occlusion	I-T020
)	O
rat	O
model	B-T050
was	O
further	O
employed	B-T033
to	O
elucidate	O
the	O
probable	O
mechanism	O
of	O
SAFI	O
in	O
treating	O
ischemic	B-T047
stroke	I-T047
.	O
Rats	O
in	O
the	O
SAFI	O
group	O
were	O
given	O
SAFI	O
(	O
23	O
or	O
46mg	O
/	O
kg	O
)	O
before	O
I	B-T047
/	O
R	O
injury	O
.	O
The	O
results	O
showed	O
that	O
SAFI	O
treatment	O
significantly	O
decreased	O
neuroinflammation	O
and	O
the	O
infarction	O
volume	O
compared	O
with	O
the	O
vehicle	O
group	O
.	O
Activation	O
of	O
microglia	O
cells	O
was	O
reduced	O
,	O
and	O
TLR4	O
/	O
NF	O
-	O
κB	O
signals	O
,	O
which	O
were	O
markedly	O
inhibited	O
by	O
SAFI	O
treatment	O
in	O
ischemic	O
hemisphere	B-T023
,	O
were	O
accompanied	O
by	O
reduced	O
expression	O
and	O
release	B-T058
of	O
cytokines	O
IL-1β	O
and	O
IL-6	O
.	O
This	O
study	O
provides	O
evidence	O
that	O
SAFI	O
effectively	O
protects	O
the	O
brain	B-T023
after	O
cerebral	B-T047
ischemia	I-T047
,	O
which	O
may	O
be	O
caused	O
by	O
attenuating	O
inflammation	O
in	O
microglia	O
.	O
      
Heat	O
-	O
shock	O
protein	O
60	O
of	O
Porphyromonas	B-T007
gingivalis	I-T007
may	O
induce	O
dysfunction	O
of	O
human	O
umbilical	O
endothelial	O
cells	O
via	O
regulation	O
of	O
endothelial	O
-	O
nitric	O
oxide	O
synthase	O
and	O
vascular	O
endothelial	O
-	O
cadherin	O
Accumulating	O
evidence	O
has	O
established	O
that	O
periodontitis	B-T047
was	O
an	O
independent	O
risk	B-T033
factor	I-T033
for	O
coronary	B-T047
heart	I-T047
disease	I-T047
(	O
CAD	B-T047
)	O
.	O
Porphyromonus	B-T007
gingivalis	I-T007
(	O
P.	B-T007
gingivalis	I-T007
)	O
,	O
a	O
major	O
periodontal	O
pathogen	B-T001
,	O
has	O
already	O
been	O
shown	O
to	O
have	O
a	O
significant	O
role	O
in	O
the	O
inflammatory	O
response	O
of	O
CAD	B-T047
in	O
vivo	O
.	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
identify	O
whether	O
P.	B-T007
gingivalis	I-T007
heat	O
-	O
shock	O
protein	O
60	O
(	O
HSP60	O
)	O
induced	O
the	O
dysfunction	O
of	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
in	O
vitro	O
.	O
HUVECs	O
were	O
stimulated	O
with	O
a	O
range	O
of	O
P.	B-T007
gingivalis	I-T007
HSP60	O
concentrations	O
(	O
1	O
,	O
10	O
and	O
100	O
ng	O
/	O
l	O
)	O
at	O
different	O
time	O
-	O
points	O
.	O
The	O
levels	O
of	O
vascular	O
endothelial	O
(	O
VE)-cadherin	O
,	O
endothelial	O
nitric	O
oxide	O
synthase	O
(	O
eNOS	O
)	O
and	O
cysteinyl	O
aspartate	O
-	O
specific	O
protease-3	O
(	O
caspase-3	O
)	O
were	O
measured	O
using	O
western	B-T059
blot	I-T059
analysis	O
.	O
The	O
apoptotic	O
rate	O
of	O
HUVECs	O
was	O
detected	O
using	O
flow	B-T059
cytometry	I-T059
.	O
P.	B-T007
gingivalis	I-T007
HSP60	O
at	O
a	O
concentration	O
of	O
10	O
ng	O
/	O
l	O
significantly	O
decreased	O
the	O
expression	O
levels	O
of	O
VE	O
-	O
cadherin	O
and	O
eNOS	O
protein	O
at	O
24	O
h	O
stimulation	O
,	O
whereas	O
no	O
difference	O
in	O
these	O
proteins	O
was	O
identified	O
following	O
a	O
low	O
dose	O
of	O
P.	B-T007
gingivalis	I-T007
HSP60	O
(	O
1	O
ng	O
/	O
l	O
)	O
.	O
P.	B-T007
gingivalis	I-T007
HSP60	O
at	O
100	O
ng	O
/	O
l	O
significantly	O
downregulated	O
the	O
expression	O
levels	O
of	O
VE	O
-	O
cadherin	O
and	O
eNOS	O
protein	O
at	O
12	O
h	O
in	O
HUVECs	O
.	O
However	O
,	O
the	O
cleavage	O
of	O
caspase-3	O
showed	O
an	O
opposing	O
change	O
at	O
different	O
concentrations	O
.	O
Consistently	O
,	O
P.	B-T007
gingivalis	I-T007
HSP60	O
induced	O
apoptosis	O
of	O
HUVECs	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O
These	O
results	O
indicated	O
that	O
P.	B-T007
gingivalis	I-T007
HSP60	O
may	O
induce	O
dysfunction	O
and	O
apoptosis	O
in	O
HUVECs	O
via	O
downregulating	O
the	O
expression	O
levels	O
of	O
VE	O
-	O
cadherin	O
and	O
eNOS	O
,	O
and	O
promoting	O
the	O
cleavage	O
of	O
caspase-3	O
.	O
      
Identification	O
and	O
functional	O
analysis	O
of	O
the	O
GTPV	B-T005
bidirectional	O
promoter	O
region	O
The	O
goat	B-T005
pox	I-T005
chick	I-T005
embryo	I-T005
-	I-T005
attenuated	I-T005
virus	I-T005
(	O
GTPV	B-T005
)	O
has	O
been	O
developed	O
as	O
an	O
effective	O
vaccine	B-T121
that	O
can	O
elicit	O
protective	O
immune	O
responses	O
.	O
It	O
possesses	O
a	O
large	O
genome	O
and	O
a	O
robust	O
ability	O
to	O
express	O
exogenous	O
genes	O
.	O
Thus	O
,	O
this	O
virus	B-T005
is	O
an	O
ideal	O
vector	O
for	O
recombinant	B-T121
live	I-T121
vaccines	I-T121
for	O
infectious	B-T047
diseases	I-T047
in	O
ruminant	O
animals	O
.	O
In	O
this	O
study	O
,	O
we	O
identified	O
a	O
novel	O
bidirectional	O
promoter	O
region	O
of	O
GTPV	B-T005
through	O
screening	O
named	O
PbVV(±	O
)	O
.	O
PbVV(±	O
)	O
is	O
located	O
between	O
ETF	O
-	O
l	O
and	O
VITF-3	O
,	O
which	O
are	O
transcribed	O
in	O
opposite	O
directions	O
.	O
A	O
new	O
recombinant	B-T005
goat	I-T005
pox	I-T005
virus	I-T005
(	O
rGTPV	B-T005
)	O
was	O
constructed	O
,	O
in	O
which	O
duplicate	O
PbVV(+	O
)	O
was	O
used	O
as	O
a	O
promoter	O
element	O
to	O
enhance	O
Brucella	O
OMP31	O
expression	O
,	O
and	O
duplicate	O
PbVV	O
(	O
-	O
)	O
was	O
used	O
as	O
a	O
promoter	O
element	O
to	O
regulate	O
enhanced	O
green	O
fluorescent	O
protein	O
(	O
EGFP	O
)	O
at	O
the	O
same	O
time	O
as	O
the	O
selection	O
marker	O
.	O
PbVV(-	O
)	O
promoter	O
activity	O
was	O
compared	O
to	O
that	O
of	O
the	O
P7.5	O
promoter	O
of	O
vaccinia	B-T005
virus	I-T005
,	O
as	O
measured	O
by	O
EGFP	O
expression	O
;	O
the	O
fluorescence	B-T059
intensity	I-T059
of	O
EGFP	O
expressed	O
in	O
cells	O
was	O
confirmed	O
by	O
fluorescence	B-T059
microscopy	I-T059
and	O
flow	B-T059
cytometry	I-T059
.	O
PbVV(+	O
)	O
promoter	O
activity	O
was	O
measured	O
by	O
Brucella	O
OMP31	O
expression	O
.	O
Interaction	O
with	O
the	O
anti	O
-	O
Brucella	O
-	O
OMP31	O
monoclonal	O
antibody	O
was	O
confirmed	O
by	O
western	B-T059
blotting	I-T059
,	O
and	O
OMP31	O
mRNA	O
expression	O
was	O
assessed	O
by	O
qRT	O
-	O
PCR	O
.	O
The	O
results	O
of	O
this	O
study	O
will	O
be	O
useful	O
for	O
the	O
further	O
study	O
of	O
effective	O
multivalent	B-T121
vaccines	I-T121
based	O
on	O
rGTPV	B-T005
.	O
This	O
study	O
also	O
provides	O
a	O
theoretical	O
basis	O
for	O
overcoming	O
the	O
problem	O
of	O
low	O
expression	O
of	O
exogenous	O
genes	O
.	O
      
Clinical	O
and	O
angiographic	B-T060
correlation	O
of	O
high	O
-	O
sensitivity	O
C	O
-	O
reactive	O
protein	O
with	O
acute	B-T047
ST	I-T047
elevation	I-T047
myocardial	I-T047
infarction	I-T047
Vascular	B-T047
inflammation	I-T047
and	O
associated	O
ongoing	O
inflammatory	O
responses	O
are	O
considered	O
as	O
the	O
critical	O
culprits	O
in	O
the	O
pathogenesis	O
of	O
acute	O
atherothrombotic	B-T020
events	O
such	O
as	O
acute	B-T047
coronary	I-T047
syndrome	I-T047
(	O
ACS	B-T047
)	O
and	O
myocardial	B-T047
infarction	I-T047
(	O
MI	B-T047
)	O
.	O
ST	B-T047
segment	I-T047
elevation	I-T047
myocardial	I-T047
infarction	I-T047
(	O
STEMI	B-T047
)	O
is	O
considered	O
as	O
one	O
of	O
the	O
prominent	O
clinical	O
forms	O
of	O
ACS	B-T047
.	O
Moreover	O
,	O
C	O
-	O
reactive	O
protein	O
(	O
CRP	O
)	O
is	O
an	O
important	O
acute	O
phase	O
prsotein	O
,	O
which	O
may	O
be	O
estimated	O
using	O
high	B-T059
-	I-T059
sensitivity	I-T059
methods	I-T059
(	O
hs	B-T059
-	I-T059
CRP	I-T059
)	O
,	O
and	O
its	O
elevated	O
level	O
in	O
body	O
fluids	O
reflects	O
chronic	O
inflammatory	O
status	O
.	O
The	O
circulating	O
hs	B-T059
-	I-T059
CRP	I-T059
level	O
has	O
been	O
proposed	O
as	O
a	O
promising	O
inflammatory	O
marker	O
of	O
coronary	B-T047
artery	I-T047
disease	I-T047
(	O
CAD	B-T047
)	O
.	O
The	O
present	O
study	O
investigated	O
the	O
correlation	O
of	O
hs	B-T059
-	I-T059
CRP	I-T059
level	O
with	O
clinical	O
and	O
angiographic	B-T060
features	O
of	O
STEMI	B-T047
,	O
various	O
other	O
traditional	O
risk	B-T033
factors	I-T033
,	O
complications	O
of	O
myocardial	B-T047
infarction	I-T047
and	O
angiographically	O
significant	O
CAD	B-T047
.	O
Out	O
of	O
190	O
patients	O
with	O
STEMI	B-T047
that	O
were	O
analyzed	O
,	O
the	O
interval	O
between	O
symptom	O
onset	O
and	O
reperfusion	B-T061
therapy	I-T061
(	O
window	O
period	O
)	O
varied	O
from	O
0.5	O
to	O
24	O
h.	O
The	O
hs	B-T059
-	I-T059
CRP	I-T059
value	O
was	O
found	O
to	O
be	O
higher	O
in	O
non	O
-	O
diabetic	O
patients	O
(	O
0.61	O
mg	O
/	O
dl	O
)	O
compared	O
with	O
diabetic	B-T047
patients	O
(	O
0.87	O
mg	O
/	O
dl	O
)	O
.	O
Moreover	O
,	O
a	O
significant	O
correlation	O
between	O
hs	B-T059
-	I-T059
CRP	I-T059
and	O
hs	B-T059
-	I-T059
troponin	I-T059
T	I-T059
was	O
also	O
recorded	O
(	O
P<0.001	O
)	O
.	O
However	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
mean	O
hs	B-T059
-	I-T059
CRP	I-T059
values	O
in	O
patients	O
with	O
or	O
without	O
mortality	O
.	O
It	O
is	O
considered	O
that	O
the	O
present	O
study	O
will	O
increase	O
the	O
understanding	O
of	O
atherosclerosis	B-T047
in	O
general	O
and	O
may	O
also	O
have	O
clinical	B-T058
applications	I-T058
in	O
the	O
targeting	O
of	O
therapy	B-T061
for	O
this	O
harmful	O
disease	B-T047
.	O
      
The	O
epigenetic	O
landscape	O
of	O
age	O
-	O
related	O
diseases	B-T047
:	O
the	O
geroscience	O
perspective	O
In	O
this	O
review	O
,	O
we	O
summarize	O
current	O
knowledge	O
regarding	O
the	O
epigenetics	O
of	O
age	O
-	O
related	O
diseases	B-T047
,	O
focusing	O
on	O
those	O
studies	O
that	O
have	O
described	O
DNA	O
methylation	O
landscape	O
in	O
cardio	B-T047
-	I-T047
vascular	I-T047
diseases	I-T047
,	O
musculoskeletal	O
function	O
and	O
frailty	B-T033
.	O
We	O
stress	O
the	O
importance	O
of	O
adopting	O
the	O
conceptual	O
framework	O
of	O
"	O
geroscience	O
"	O
,	O
which	O
starts	O
from	O
the	O
observation	O
that	O
advanced	O
age	O
is	O
the	O
major	O
risk	B-T033
factor	I-T033
for	O
several	O
of	O
these	O
pathologies	O
and	O
aims	O
at	O
identifying	O
the	O
mechanistic	O
links	O
between	O
aging	O
and	O
age	O
-	O
related	O
diseases	B-T047
.	O
DNA	O
methylation	O
undergoes	O
a	O
profound	O
remodeling	O
during	O
aging	O
,	O
which	O
includes	O
global	O
hypomethylation	O
of	O
the	O
genome	O
,	O
hypermethylation	O
at	O
specific	O
loci	O
and	O
an	O
increase	O
in	O
inter	O
-	O
individual	O
variation	O
and	O
in	O
stochastic	O
changes	O
of	O
DNA	O
methylation	O
values	O
.	O
These	O
epigenetic	O
modifications	B-T033
can	O
be	O
an	O
important	O
contributor	O
to	O
the	O
development	O
of	O
age	O
-	O
related	O
diseases	B-T047
,	O
but	O
our	O
understanding	O
on	O
the	O
complex	O
relationship	O
between	O
the	O
epigenetic	O
signatures	O
of	O
aging	O
and	O
age	O
-	O
related	O
disease	B-T047
is	O
still	O
poor	O
.	O
The	O
most	O
relevant	O
results	B-T033
in	O
this	O
field	O
come	O
from	O
the	O
use	O
of	O
the	O
so	O
called	O
"	O
epigenetics	O
clocks	O
"	O
in	O
cohorts	O
of	O
subjects	O
affected	O
by	O
age	O
-	O
related	O
diseases	B-T047
.	O
We	O
report	O
these	O
studies	O
in	O
final	O
section	O
of	O
this	O
review	O
.	O
      
Investigating	O
Synthetic	O
Oligonucleotide	O
Targeting	O
of	O
Mir31	O
in	O
Duchenne	B-T047
Muscular	I-T047
Dystrophy	I-T047
Exon	O
-	O
skipping	O
via	O
synthetic	O
antisense	O
oligonucleotides	O
represents	O
one	O
of	O
the	O
most	O
promising	O
potential	O
therapies	B-T061
for	O
Duchenne	B-T047
muscular	I-T047
dystrophy	I-T047
(	O
DMD	B-T047
)	O
,	O
yet	O
this	O
approach	O
is	O
highly	O
sequence	O
-	O
specific	O
and	O
thus	O
each	O
oligonucleotide	O
is	O
of	O
benefit	O
to	O
only	O
a	O
subset	O
of	O
patients	O
.	O
The	O
discovery	O
that	O
dystrophin	O
mRNA	O
is	O
subject	O
to	O
translational	O
suppression	O
by	O
the	O
microRNA	O
miR31	O
,	O
and	O
that	O
miR31	O
is	O
elevated	O
in	O
the	O
muscle	O
of	O
DMD	B-T047
patients	O
,	O
raises	O
the	O
possibility	O
that	O
the	O
same	O
oligonucleotide	O
chemistries	O
employed	O
for	O
exon	O
skipping	O
could	O
be	O
directed	O
toward	O
relieving	O
this	O
translational	O
block	O
.	O
This	O
approach	O
would	O
act	O
synergistically	O
with	O
exon	O
skipping	O
where	O
possible	O
,	O
but	O
by	O
targeting	O
the	O
3'UTR	O
it	O
would	O
further	O
be	O
of	O
benefit	O
to	O
the	O
many	O
DMD	B-T047
patients	O
who	O
express	O
low	O
levels	O
of	O
in	O
-	O
frame	O
transcript	O
.	O
We	O
here	O
present	O
investigations	B-T058
into	O
the	O
feasibility	O
of	O
combining	O
exon	O
skipping	O
with	O
several	O
different	O
strategies	O
for	O
miR31	O
-	O
modulation	O
,	O
using	O
both	O
in	B-T059
vitro	I-T059
models	O
and	O
the	O
mdx	O
mouse	O
(	O
the	O
classical	O
animal	O
model	O
of	O
DMD	B-T047
)	O
,	O
and	O
monitoring	B-T058
effects	O
on	O
dystrophin	O
at	O
the	O
transcriptional	O
and	O
translational	O
level	O
.	O
We	O
show	O
that	O
despite	O
promising	O
results	O
from	O
our	O
cell	B-T059
culture	I-T059
model	O
,	O
our	O
in	O
vivo	O
data	O
failed	O
to	O
demonstrate	O
similarly	O
reproducible	O
enhancement	O
of	O
dystrophin	O
translation	O
,	O
suggesting	O
that	O
miR31	O
-	O
modulation	O
may	O
not	O
be	O
practical	O
under	O
current	O
oligonucleotide	O
approaches	O
.	O
Possible	O
explanations	O
for	O
this	O
disappointing	O
outcome	O
are	O
discussed	O
,	O
along	O
with	O
suggestions	O
for	O
future	O
investigations	B-T058
.	O
      
Structural	O
and	O
functional	O
characterization	O
of	O
the	O
TYW3	O
/	O
Taw3	O
class	O
of	O
SAM	O
-	O
dependent	O
methyltransferases	O
S	O
-	O
adenosylmethionine	O
(	O
SAM)-dependent	O
methyltransferases	O
regulate	O
a	O
wide	O
range	O
of	O
biological	O
processes	O
through	O
the	O
modification	O
of	O
proteins	O
,	O
nucleic	O
acids	O
,	O
polysaccharides	B-T121
,	O
as	O
well	O
as	O
various	O
metabolites	O
.	O
TYW3	O
/	O
Taw3	O
is	O
a	O
SAM	O
-	O
dependent	O
methyltransferase	O
responsible	O
for	O
the	O
formation	O
of	O
a	O
tRNA	O
modification	O
known	O
as	O
wybutosine	O
and	O
its	O
derivatives	O
that	O
are	O
required	O
for	O
accurate	O
decoding	O
in	O
protein	O
synthesis	O
.	O
Here	O
,	O
we	O
report	O
the	O
crystal	O
structure	O
of	O
Taw3	O
,	O
a	O
homolog	O
of	O
TYW3	O
from	O
Sulfolobus	O
solfataricus	O
,	O
which	O
revealed	O
a	O
novel	O
α	O
/	O
β	O
fold	O
.	O
The	O
sequence	O
motif	O
(	O
S	O
/	O
T)xSSCxGR	O
and	O
invariant	O
aspartate	O
and	O
histidine	B-T121
,	O
conserved	O
in	O
TYW3	O
/	O
Taw3	O
,	O
cluster	O
to	O
form	O
the	O
catalytic	O
center	O
.	O
These	O
structural	O
and	O
sequence	O
features	O
indicate	O
that	O
TYW3	O
/	O
Taw3	O
proteins	O
constitute	O
a	O
distinct	O
class	O
of	O
SAM	O
-	O
dependent	O
methyltransferases	O
.	O
Using	O
site	O
-	O
directed	O
mutagenesis	O
along	O
with	O
in	B-T059
vivo	I-T059
complementation	I-T059
assays	I-T059
combined	O
with	O
mass	B-T059
spectrometry	I-T059
as	O
well	O
as	O
ligand	O
docking	O
and	O
cofactor	O
binding	O
assays	B-T059
,	O
we	O
have	O
identified	O
the	O
active	O
site	O
of	O
TYW3	O
and	O
residues	O
essential	O
for	O
cofactor	O
binding	O
and	O
methyltransferase	O
activity	O
.	O
      
Prevalence	O
of	O
Psychiatric	B-T048
Disorders	I-T048
among	O
Female	O
Juvenile	O
Offenders	O
Inmates	O
of	O
Juvenile	O
Developmental	O
Centers	O
are	O
the	O
special	O
group	O
of	O
youth	O
population	O
who	O
are	O
in	O
conflict	O
with	O
law	O
.	O
They	O
are	O
vulnerable	O
to	O
psychiatric	B-T048
illness	I-T048
.	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
see	O
the	O
prevalence	O
and	O
type	O
of	O
psychiatric	B-T048
disorders	I-T048
in	O
institutionalized	B-T033
female	O
juvenile	O
offenders	O
and	O
non	O
-	O
offenders	O
of	O
same	O
age	O
,	O
sex	O
and	O
socioeconomic	O
group	O
in	O
the	O
community	O
.	O
The	O
association	O
of	O
mental	B-T048
disorders	I-T048
was	O
examined	B-T033
in	O
43	O
female	O
inmates	O
of	O
Juvenile	O
Development	O
Centers	O
and	O
43	O
randomly	O
selected	O
comparison	O
subjects	O
in	O
community	O
.	O
One	B-T058
stage	I-T058
-	I-T058
structured	I-T058
assessment	I-T058
of	O
psychopathology	O
was	O
carried	O
out	O
by	O
using	O
a	O
structured	O
and	O
valid	O
Bangla	O
version	O
of	O
the	O
Development	B-T058
and	I-T058
Well	I-T058
-	I-T058
Being	I-T058
Assessment	I-T058
(	O
DAWBA	B-T058
)	O
.	O
Development	B-T058
and	I-T058
Well	I-T058
-	I-T058
Being	I-T058
Assessment	I-T058
generated	O
psychiatric	O
diagnosis	B-T033
was	O
assigned	O
based	O
on	O
ICD-10	O
diagnostic	O
criteria	O
for	O
research	O
.	O
The	O
result	B-T033
revealed	O
that	O
,	O
of	O
those	O
who	O
were	O
in	O
conflict	O
with	O
law	O
,	O
93	O
%	O
had	O
mental	B-T048
disorder	I-T048
,	O
whereas	O
14	O
%	O
of	O
non	O
-	O
offenders	O
had	O
psychiatric	B-T048
disorder	I-T048
.	O
Among	O
the	O
offenders	O
with	O
psychiatric	B-T048
disorders	I-T048
,	O
most	O
of	O
them	O
(	O
32.6	O
%	O
)	O
suffered	O
from	O
Major	B-T048
Depressive	I-T048
Disorder	I-T048
(	O
MDD	B-T048
)	O
,	O
followed	O
by	O
combined	O
MDD	B-T048
&	O
Post	B-T048
Traumatic	I-T048
Stress	I-T048
Disorder	I-T048
(	O
PTSD	B-T048
)	O
.	O
On	O
the	O
other	O
hand	O
,	O
among	O
the	O
non	O
-	O
offenders	O
with	O
psychiatric	B-T048
disorder	I-T048
9.3	O
%	O
suffered	O
from	O
MDD	B-T048
.	O
It	O
can	O
be	O
concluded	O
that	O
considerable	O
psychiatric	B-T048
disorders	I-T048
are	O
prevalent	O
among	O
the	O
female	O
juvenile	O
offenders	O
with	O
comparison	O
to	O
non	O
-	O
offenders	O
.	O
Broad	O
-based	O
replication	O
study	O
could	O
confirm	O
these	O
findings	B-T033
.	O
      
Increased	O
cerebral	O
blood	O
volume	O
pulsatility	O
during	O
head	O
-	O
down	O
tilt	O
with	O
elevated	B-T033
carbon	I-T033
dioxide	I-T033
elevated	B-T033
carbon	I-T033
dioxide	I-T033
:	O
The	O
SPACECOT	O
Study	O
Astronauts	O
aboard	O
the	O
International	O
Space	O
Station	O
(	O
ISS	O
)	O
have	O
exhibited	O
hyperopic	B-T047
shifts	I-T047
,	O
posterior	O
eye	B-T023
globe	I-T023
flattening	O
,	O
dilated	B-T033
optic	B-T023
nerve	I-T023
sheaths	I-T023
,	O
and	O
even	O
optic	B-T047
disc	I-T047
swelling	I-T047
from	O
spaceflight	O
.	O
Elevated	B-T047
intracranial	I-T047
pressure	I-T047
(	O
ICP	B-T047
)	O
consequent	O
to	O
cephalad	O
fluid	O
shifts	O
is	O
commonly	O
hypothesized	O
as	O
contributing	O
to	O
these	O
ocular	B-T033
changes	I-T033
.	O
Head	O
-	O
down	O
tilt	O
(	O
HDT	O
)	O
is	O
frequently	O
utilized	O
as	O
an	O
Earth	O
-based	O
analog	O
to	O
study	O
similar	O
fluid	O
shifts	O
.	O
Sealed	O
environments	O
like	O
the	O
ISS	O
also	O
exhibit	O
elevated	O
carbon	O
dioxide	O
(	O
CO2	O
)	O
,	O
a	O
potent	O
arteriolar	B-T121
vasodilator	I-T121
that	O
could	O
further	O
affect	O
cerebral	O
blood	O
volume	O
and	O
flow	B-T033
,	O
intracranial	O
compliance	B-T033
,	O
and	O
ICP	B-T047
.	O
A	O
collaborative	O
pilot	O
study	O
between	O
the	O
National	O
Space	O
Biomedical	O
Research	O
Institute	O
and	O
the	O
German	O
Aerospace	O
Center	O
tested	O
the	O
hypotheses	O
that	O
:	O
(	O
1	O
)	O
HDT	O
and	O
elevated	O
CO2	O
physiologically	O
interact	O
,	O
and	O
(	O
2	O
)	O
cerebrovascular	O
pulsatility	O
is	O
related	O
to	O
HDT	O
and/or	O
elevated	O
CO2	O
In	O
a	O
double	O
-	O
blind	O
crossover	O
study	O
(	O
n=6	O
)	O
,	O
we	O
measured	O
cerebral	O
blood	O
volume	O
(	O
CBV	O
)	O
pulsatility	O
via	O
near	B-T059
-	I-T059
infrared	I-T059
spectroscopy	I-T059
,	O
alongside	O
non	O
-	O
invasive	O
ICP	B-T047
and	O
intraocular	O
pressure	O
(	O
IOP	O
)	O
during	O
28	O
-	O
hr	O
-12	O
°	O
HDT	O
at	O
both	O
nominal	O
(	O
0.04	O
%	O
)	O
and	O
elevated	O
(	O
0.5	O
%	O
)	O
ambient	O
CO2	O
In	O
our	O
cohort	O
,	O
CBV	O
pulsatility	O
increased	O
significantly	O
over	O
time	O
at	O
cardiac	O
frequencies	O
(	O
0.031±0.009	O
μM	O
/	O
hr	O
increase	O
in	O
[	O
HbT	O
]	O
pulsatility	O
amplitude	O
)	O
and	O
Mayer	O
wave	O
frequencies	O
(	O
0.019±0.005	O
μM	O
/	O
hr	O
increase	O
)	O
.	O
The	O
HDT	O
-	O
CO2	O
interaction	O
on	O
pulsatility	O
was	O
not	O
robust	O
,	O
but	O
rather	O
driven	O
by	O
an	O
individual	O
.	O
Significant	O
differences	O
between	O
atmospheres	O
were	O
not	B-T033
detected	I-T033
in	O
ICP	B-T047
or	O
IOP	O
.	O
Further	O
work	O
is	O
needed	O
to	O
reproduce	O
these	O
findings	O
in	O
a	O
larger	O
cohort	O
,	O
to	O
determine	O
whether	O
a	O
"	B-T033
water	I-T033
hammer	I-T033
"	I-T033
effect	I-T033
in	O
cerebral	B-T023
pulsatility	O
is	O
also	O
present	O
during	O
spaceflight	O
,	O
and	O
whether	O
it	O
is	O
associated	O
with	O
ocular	B-T033
changes	I-T033
in	O
astronauts	O
.	O
      
Farnesylthiosalicylic	O
acid	O
-loaded	O
lipid	B-T121
-	I-T121
polyethylene	I-T121
glycol	I-T121
-	I-T121
polymer	I-T121
hybrid	I-T121
nanoparticles	I-T121
for	O
treatment	B-T061
of	O
glioblastoma	B-T191
We	O
aimed	O
to	O
develop	O
lipid	B-T121
-	I-T121
polyethylene	I-T121
glycol	I-T121
(	I-T121
PEG)-polymer	I-T121
hybrid	I-T121
nanoparticles	I-T121
,	O
which	O
have	O
high	O
affinity	O
to	O
tumour	O
tissue	O
with	O
active	O
ingredient	O
,	O
a	O
new	O
generation	O
antineoplastic	B-T121
drug	I-T121
,	O
farnesylthiosalicylic	O
acid	O
(	O
FTA	O
)	O
for	O
treatment	B-T061
of	O
glioblastoma	B-T191
.	O
Farnesylthiosalicylic	O
acid	O
-loaded	O
poly(lactic	B-T121
-	I-T121
co	I-T121
-	I-T121
glycolic	I-T121
acid)-1,2	I-T121
distearoyl	I-T121
-	I-T121
glycerol-3	I-T121
-	I-T121
phospho	I-T121
-	I-T121
ethanolamine	I-T121
-	I-T121
N	I-T121
[	I-T121
methoxy	I-T121
(	I-T121
PEG)-2000	I-T121
]	I-T121
ammonium	I-T121
salt	I-T121
(	O
PLGA	B-T121
-	I-T121
DSPE	I-T121
-	I-T121
PEG	I-T121
)	O
with	O
or	O
without	O
1,2	B-T121
-	I-T121
dioleoyl-3	I-T121
-	I-T121
trimethylammonium	I-T121
-	I-T121
propane	I-T121
(	I-T121
DOTAP	I-T121
)	I-T121
hybrid	I-T121
nanoparticles	I-T121
has	O
been	O
prepared	B-T033
and	O
evaluated	B-T058
for	O
in	O
-	O
vitro	O
characterization	O
.	O
Cytotoxicity	O
of	O
FTA	O
-	O
loaded	O
nanoparticles	O
along	O
with	O
its	O
efficacy	O
on	O
rat	O
glioma-2	O
(	O
RG2	O
)	O
cells	O
was	O
also	O
evaluated	B-T058
both	O
in	O
vitro	O
(	O
in	O
comparison	O
with	O
non	O
-	O
malignant	O
cell	O
line	O
,	O
L929	O
)	O
and	O
in	O
vivo	O
.	O
Scanning	B-T059
electron	I-T059
microscopy	I-T059
studies	I-T059
showed	O
that	O
all	O
formulations	O
prepared	O
had	O
smooth	O
surface	O
and	O
spherical	O
in	O
shape	O
.	O
FTA	O
and	O
FTA	O
-	O
loaded	O
nanoparticles	O
have	O
cytotoxic	O
activity	O
against	O
RG2	O
glioma	O
cell	O
lines	O
in	O
cell	O
culture	O
studies	O
,	O
which	O
further	O
increases	O
with	O
addition	O
of	O
DOTAP	B-T121
.	O
Magnetic	B-T060
resonance	I-T060
imaging	I-T060
and	O
histopathologic	O
evaluation	B-T058
on	O
RG2	O
tumour	O
cells	O
in	O
rat	B-T050
glioma	I-T050
model	I-T050
(	O
49	O
female	O
Wistar	O
rats	O
,	O
250	O
-	O
300	O
g	O
)	O
comparing	O
intravenous	O
and	O
intratumoral	O
injections	O
of	O
the	O
drug	B-T121
have	O
been	O
performed	O
and	O
FTA	O
-	O
loaded	O
nanoparticles	O
reduced	O
tumour	O
size	O
significantly	O
in	O
in	O
-	O
vivo	O
studies	O
,	O
with	O
higher	O
efficiency	O
of	O
intratumoral	O
administration	O
than	O
intravenous	O
route	O
.	O
Farnesylthiosalicylic	O
acid	O
-loaded	O
PLGA	B-T121
-	I-T121
DSPE	I-T121
-	I-T121
PEG	I-T121
-	I-T121
DOTAP	I-T121
hybrid	I-T121
nanoparticles	I-T121
are	O
proven	O
to	O
be	O
effective	O
against	O
glioblastoma	B-T191
in	O
both	O
in	O
-	O
vitro	O
and	O
in	O
-	O
vivo	O
experiments	O
.	O
      
Effect	O
of	O
ultrasound	O
and	O
enzymatic	O
pre	O
-	O
treatment	O
on	O
yield	O
and	O
properties	O
of	O
banana	O
juice	O
Effect	O
of	O
ultrasound	O
and	O
enzymatic	O
pre	O
-	O
treatments	O
with	O
cellulase	B-T121
and	O
pectinase	O
on	O
yield	O
and	O
properties	O
of	O
banana	O
juice	O
were	O
investigated	O
.	O
A	O
two	O
-	O
level	O
full	O
factorial	O
design	O
was	O
employed	O
.	O
The	O
factors	O
selected	O
were	O
ultrasonication	O
time	O
(	O
0	O
and	O
30	O
min	O
)	O
,	O
cellulase	B-T121
concentration	O
(	O
0	O
and	O
0.2	O
%	O
)	O
and	O
pectinase	O
concentration	O
(	O
0	O
and	O
0.2	O
%	O
)	O
.	O
The	O
responses	O
studied	O
were	O
yield	O
,	O
viscosity	O
,	O
clarity	B-T059
,	O
total	O
soluble	O
solids	O
(	O
TSS	O
)	O
and	O
pH.	O
It	O
was	O
observed	O
that	O
pectinase	O
was	O
more	O
effective	O
in	O
increasing	O
the	O
yield	O
of	O
juice	O
compared	O
to	O
cellulase	B-T121
.	O
Ultrasonic	O
pre	O
-	O
treatment	O
alone	O
did	O
not	B-T033
significantly	O
increase	O
the	O
yield	O
of	O
juice	O
.	O
When	O
ultrasound	O
was	O
combined	O
with	O
pre	O
-	O
treatment	O
with	O
both	O
the	O
enzymes	O
maximum	O
yield	O
of	O
89.40	O
%	O
was	O
obtained	O
compared	O
to	O
47.30	O
%	O
in	O
the	O
control	O
.	O
The	O
viscosity	O
of	O
the	O
juice	O
decreased	O
with	O
addition	O
of	O
enzymes	O
and	O
with	O
application	O
of	O
ultrasound	O
.	O
The	O
clarity	O
of	O
the	O
juice	O
was	O
not	O
affected	O
by	O
cellulase	B-T121
treatment	O
,	O
but	O
improved	B-T033
with	O
pectinase	O
treatment	O
.	O
Ultrasonication	O
alone	O
was	O
found	O
to	O
be	O
more	O
effective	O
than	O
pectinase	O
or	O
cellulase	B-T121
treatment	O
in	O
improving	O
the	O
clarity	O
of	O
the	O
juice	O
.	O
The	O
TSS	O
increased	O
with	O
enzymatic	O
treatment	O
,	O
ultrasonication	O
and	O
their	O
combination	O
.	O
pH	O
was	O
not	O
affected	O
by	O
treatment	O
type	O
,	O
but	O
was	O
found	O
to	O
be	O
lower	O
for	O
the	O
treated	O
juices	O
.	O
Significant	O
correlations	O
were	O
observed	O
between	O
the	O
various	O
responses	O
.	O
      
Diazoxide	B-T121
prevents	O
reactive	O
oxygen	O
species	O
and	O
mitochondrial	O
damage	O
,	O
leading	O
to	O
anti	B-T033
-	I-T033
hypertrophic	I-T033
effects	I-T033
Pathological	O
cardiac	O
hypertrophy	O
is	O
characterized	O
by	O
wall	B-T023
thickening	B-T033
or	O
chamber	B-T023
enlargement	O
of	O
the	O
heart	B-T023
in	O
response	O
to	O
pressure	O
or	O
volume	O
overload	O
,	O
respectively	O
.	O
This	O
condition	O
will	O
,	O
initially	O
,	O
improve	B-T033
the	O
organ	B-T023
contractile	O
function	O
,	O
but	O
if	O
sustained	O
will	O
render	O
dysfunctional	O
mitochondria	O
and	O
oxidative	O
stress	O
.	O
Mitochondrial	O
ATP	O
-	O
sensitive	O
K(+	O
)	O
channels	O
(	O
mitoKATP	O
)	O
modulate	O
the	O
redox	O
status	O
of	O
the	O
cell	O
and	O
protect	B-T033
against	O
several	O
cardiac	B-T023
insults	O
.	O
Here	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
mitoKATP	O
opening	O
(	O
using	O
diazoxide	B-T121
)	O
will	O
avoid	O
isoproterenol	B-T121
-	O
induced	O
cardiac	O
hypertrophy	O
in	O
vivo	O
by	O
decreasing	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
production	O
and	O
mitochondrial	O
Ca(2	B-T121
+	I-T121
)	I-T121
-	O
induced	O
swelling	B-T033
.	O
To	O
induce	O
cardiac	O
hypertrophy	O
,	O
Swiss	O
mice	O
were	O
treated	O
intraperitoneally	O
with	O
isoproterenol	B-T121
(	O
30	O
mg	O
/	O
kg/	O
day	O
)	O
for	O
8	O
days	O
.	O
Diazoxide	B-T121
(	O
5	O
mg	O
/	O
kg/	O
day	O
)	O
was	O
used	O
to	O
open	O
mitoKATP	O
and	O
5	B-T121
-	I-T121
hydroxydecanoate	I-T121
(	O
5	O
mg	O
/	O
kg/	O
day	O
)	O
was	O
administrated	O
as	O
a	O
mitoKATP	O
blocker	B-T121
.	O
Isoproterenol	B-T121
-	O
treated	O
mice	O
had	O
elevated	O
heart	B-T023
weight	O
/	O
tibia	B-T023
length	O
ratios	O
and	O
increased	O
myocyte	O
cross	B-T033
-	I-T033
sectional	I-T033
areas	I-T033
.	O
Additionally	O
,	O
hypertrophic	O
hearts	B-T023
produced	O
higher	O
levels	O
of	O
H2O2	B-T121
and	O
had	O
lower	O
glutathione	O
peroxidase	O
activity	O
.	O
In	O
contrast	O
,	O
mitoKATP	O
opening	O
with	O
diazoxide	B-T121
blocked	O
all	O
isoproterenol	B-T121
effects	O
in	O
a	O
manner	O
reversed	O
by	O
5	B-T121
-	I-T121
hydroxydecanoate	I-T121
.	O
Isolated	O
mitochondria	O
from	O
Isoproterenol	B-T121
-	O
induced	O
hypertrophic	O
hearts	B-T023
had	O
increased	O
susceptibility	O
to	O
Ca(2	B-T121
+	I-T121
)	I-T121
-	O
induced	O
swelling	B-T033
secondary	O
to	O
mitochondrial	O
permeability	O
transition	O
pore	O
opening	O
.	O
MitokATP	O
opening	O
was	O
accompanied	O
by	O
lower	O
Ca(2	B-T121
+	I-T121
)	I-T121
-	O
induced	O
mitochondrial	O
swelling	O
,	O
an	O
effect	O
blocked	O
by	O
5	B-T121
-	I-T121
hydroxydecanoate	I-T121
.	O
Our	O
results	O
suggest	O
that	O
mitoKATP	O
opening	O
negatively	B-T033
regulates	O
cardiac	O
hypertrophy	O
by	O
avoiding	O
oxidative	O
impairment	O
and	O
mitochondrial	O
damage	O
.	O
      
Differences	O
in	O
pain	B-T184
experience	O
and	O
cooperation	O
between	O
consecutive	B-T061
surgeries	I-T061
in	O
patients	O
undergoing	O
phacoemulsification	B-T061
The	O
purpose	O
of	O
this	O
study	O
is	O
to	O
compare	O
pain	B-T184
experience	O
and	O
cooperation	O
between	O
consecutive	B-T061
surgeries	I-T061
in	O
patients	O
undergoing	O
phacoemulsification	B-T061
in	O
both	O
eyes	B-T023
,	O
using	O
sub	B-T061
-	I-T061
Tenon	I-T061
's	I-T061
local	I-T061
anesthesia	I-T061
without	O
sedation	B-T061
.	O
In	O
this	O
study	O
,	O
268	O
patients	O
with	O
bilateral	B-T047
senile	I-T047
cataracts	I-T047
were	O
recruited	O
.	O
All	O
operations	B-T061
were	O
performed	O
without	O
sedation	B-T061
,	O
using	O
a	O
clear	O
corneal	B-T023
phacoemulsification	B-T061
technique	I-T061
and	O
sub	B-T061
-	I-T061
Tenon	I-T061
's	I-T061
local	I-T061
anesthesia	I-T061
,	O
by	O
one	O
of	O
four	O
surgeons	O
.	O
The	O
first	O
surgery	B-T061
was	O
performed	O
on	O
the	O
eye	B-T023
with	O
the	O
higher	O
grade	O
cataract	B-T020
.	O
The	O
other	O
eye	B-T023
was	O
operated	O
on	O
within	O
3	O
months	O
by	O
the	O
same	O
surgeon	O
(	O
mean	O
interval	O
1.9	O
±	O
1.1	O
months	O
)	O
.	O
All	O
patients	O
were	O
asked	O
to	O
grade	O
their	O
pain	B-T184
experience	O
during	O
induction	B-T061
and	O
maintenance	O
of	O
anesthesia	B-T061
and	O
also	O
during	O
the	O
phacoemulsification	B-T061
surgery	I-T061
,	O
using	O
a	O
visual	B-T060
analogue	I-T060
scale	I-T060
(	O
VAS	B-T060
)	O
from	O
0	O
(	O
no	B-T033
pain	I-T033
)	O
to	O
10	O
(	O
unbearable	B-T184
pain	I-T184
)	O
administered	O
after	O
the	O
surgery	B-T061
.	O
The	O
cooperation	O
of	O
the	O
patient	O
was	O
graded	O
from	O
0	O
(	O
no	O
event	O
)	O
to	O
3	O
(	O
markedeye	O
and	O
head	O
movement	O
and	O
lid	B-T184
squeezing	I-T184
)	O
by	O
the	O
attending	O
surgeon	O
.	O
The	O
VAS	O
scores	O
and	O
cooperation	O
scores	O
of	O
the	O
patients	O
were	O
the	O
outcome	O
measurements	O
.	O
The	O
mean	B-T033
pain	I-T033
score	I-T033
was	O
2.11	O
±	O
0.79	O
in	O
the	O
first	O
eye	B-T023
and	O
3.33	O
±	O
0.80	O
in	O
the	O
second	O
eye	B-T023
during	O
the	O
administration	B-T061
of	O
sub	B-T061
-	I-T061
Tenon	I-T061
's	I-T061
anesthesia	I-T061
,	O
and	O
1.50	O
±	O
0.60	O
in	O
the	O
first	O
eye	B-T023
and	O
2.10	O
±	O
0.57	O
in	O
the	O
second	O
eye	B-T023
during	O
the	O
phacoemulsification	B-T061
surgery	I-T061
.	O
The	O
patient	O
cooperation	O
score	O
was	O
1.60	O
±	O
0.75	O
in	O
the	O
first	O
surgery	B-T061
and	O
2.08	O
±	O
0.72	O
in	O
the	O
second	O
surgery	B-T061
.	O
The	O
differences	O
between	O
the	O
first	O
and	O
second	O
surgeries	B-T061
were	O
statistically	O
significant	O
for	O
all	O
outcome	O
measures	O
(	O
p	O
<	O
0.01	O
)	O
.	O
Patients	O
who	O
previously	O
underwent	O
phaco	B-T061
surgery	I-T061
in	O
one	O
eye	B-T023
experienced	O
more	O
pain	B-T184
and	O
showed	O
worse	B-T033
cooperation	O
during	O
the	O
phaco	B-T061
surgery	I-T061
in	O
the	O
second	O
eye	B-T023
,	O
especially	O
if	O
there	O
was	O
a	O
short	O
time	O
between	O
the	O
surgeries	B-T061
,	O
viz	O
.	O
,	O
less	O
than	O
3	O
months	O
.	O
Therefore	O
,	O
if	O
the	O
surgeon	O
has	O
difficulty	O
in	O
the	O
first	O
operation	B-T061
gaining	O
the	O
patient	O
's	O
cooperation	O
,	O
the	O
surgeon	O
must	O
be	O
careful	O
:	O
if	O
contralateral	B-T061
eye	I-T061
surgery	I-T061
is	O
required	O
,	O
the	O
addition	O
of	O
sedation	B-T061
/	O
analgesia	B-T061
should	O
be	O
considered	O
or	O
the	O
surgery	B-T061
postponed	O
for	O
a	O
while	O
to	O
abolish	O
the	O
influence	O
of	O
recent	O
memory	O
on	O
the	O
patient	O
's	O
subsequent	O
pain	B-T184
experience	O
.	O
      
Association	O
of	O
Fat	O
Mass	O
and	O
Obesity	B-T047
-	O
associated	O
Gene	O
Variant	O
with	O
Lifestyle	O
Factors	O
and	O
Body	O
Fat	O
in	O
Indian	O
Children	O
Common	O
intronic	O
variants	O
of	O
the	O
fat	O
mass	O
and	O
obesity	B-T047
-	O
associated	O
(	O
FTO	O
)	O
gene	O
have	O
been	O
associated	O
with	O
obesity	B-T047
-related	O
traits	O
in	O
humans	O
.	O
(	O
1	O
)	O
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
study	O
the	O
distribution	O
of	O
FTO	O
gene	O
variants	O
across	O
different	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
categories	O
and	O
(	O
2	O
)	O
to	O
explore	O
the	O
association	O
between	O
FTO	O
gene	O
variants	O
and	O
lifestyle	O
factors	O
in	O
obese	B-T047
and	O
normal	B-T033
weight	I-T033
Indian	O
children	O
.	O
Fifty	O
-	O
six	O
children	O
(	O
26	O
boys	O
,	O
mean	O
age	O
10.3	O
±	O
2.2	O
years	O
)	O
were	O
studied	O
.	O
Height	O
,	O
weight	O
,	O
and	O
waist	O
and	O
hip	O
circumference	O
were	O
measured	O
.	O
Physical	O
activity	O
(	O
questionnaire	O
)	O
and	O
food	O
intake	O
(	O
food	O
frequency	O
questionnaire	O
)	O
were	O
assessed	O
.	O
Body	O
fat	O
percentage	O
(	O
%	O
BF	O
)	O
was	O
measured	O
by	O
dual	B-T060
-	I-T060
energy	I-T060
X	I-T060
-	I-T060
ray	I-T060
absorptiometry	I-T060
.	O
FTO	O
allelic	O
variants	O
at	O
rs9939609	O
site	O
were	O
detected	O
by	O
SYBR	O
Green	O
Amplification	O
Refractory	O
Mutation	O
System	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
using	O
allele	O
-	O
specific	O
primers	O
.	O
Generalized	O
linear	O
model	O
was	O
used	O
to	O
investigate	O
the	O
simultaneous	O
influence	O
of	O
genetic	O
and	O
lifestyle	O
factors	O
on	O
%	O
BF	O
.	O
Mean	O
height	O
,	O
weight	O
,	O
and	O
BMI	O
of	O
normal	O
and	O
obese	B-T047
children	O
were	O
130.6	O
±	O
7.1	O
versus	O
143.2	O
±	O
15.6	O
,	O
24.0	O
±	O
5.2	O
versus	O
53.1	O
±	O
15.8	O
,	O
and	O
13.9	O
±	O
2.1	O
versus	O
25.3	O
±	O
3.2	O
,	O
respectively	O
.	O
The	O
frequency	O
of	O
AA	O
allele	O
was	O
57	O
%	O
among	O
obese	B-T047
children	O
and	O
35	O
%	O
in	O
normal	B-T033
weight	I-T033
children	O
.	O
Children	O
with	O
the	O
AA	O
allele	O
who	O
were	O
obese	B-T047
had	O
least	O
physical	O
activity	O
,	O
whereas	O
children	O
with	O
AT	O
allele	O
and	O
obesity	B-T047
had	O
the	O
highest	O
intake	O
of	O
calories	O
when	O
compared	O
to	O
children	O
who	O
had	O
AT	O
allele	O
and	O
were	O
normal	O
.	O
%	O
BF	O
was	O
positively	O
associated	O
with	O
AA	O
alleles	O
and	O
junk	O
food	O
intake	O
and	O
negatively	O
with	O
healthy	O
food	O
intake	O
and	O
moderate	O
physical	O
activity	O
.	O
Healthy	O
lifestyle	O
with	O
high	O
physical	O
activity	O
and	O
diet	O
low	O
in	O
calories	O
and	O
fat	O
may	O
help	O
in	O
modifying	O
the	O
risk	O
imposed	O
by	O
FTO	O
variants	O
in	O
children	O
.	O
      
The	O
discovery	O
of	O
potent	O
and	O
selective	O
kynurenine	O
3	O
-	O
monooxygenase	O
inhibitors	B-T121
for	O
the	O
treatment	B-T061
of	O
acute	B-T047
pancreatitis	I-T047
A	O
series	O
of	O
potent	O
,	O
competitive	O
and	O
highly	O
selective	O
kynurenine	O
monooxygenase	O
inhibitors	B-T121
have	O
been	O
discovered	O
via	O
a	O
substrate	O
-based	O
approach	O
for	O
the	O
treatment	B-T061
of	O
acute	B-T047
pancreatitis	I-T047
.	O
The	O
lead	O
compound	O
demonstrated	O
good	O
cellular	O
potency	O
and	O
clear	O
pharmacodynamic	O
activity	O
in	O
vivo	O
.	O
      
Skin	O
Conductance	O
Responses	O
and	O
Neural	O
Activations	O
During	O
Fear	O
Conditioning	O
and	O
Extinction	O
Recall	O
Across	O
Anxiety	B-T048
Disorders	I-T048
The	O
fear	O
conditioning	O
and	O
extinction	O
neurocircuitry	O
has	O
been	O
extensively	O
studied	O
in	O
healthy	O
and	O
clinical	O
populations	O
,	O
with	O
a	O
particular	O
focus	O
on	O
posttraumatic	B-T048
stress	I-T048
disorder	I-T048
.	O
Despite	O
significant	O
overlap	O
of	O
symptoms	B-T184
between	O
posttraumatic	B-T048
stress	I-T048
disorder	I-T048
and	O
anxiety	B-T048
disorders	I-T048
,	O
the	O
latter	O
has	O
received	O
less	O
attention	O
.	O
Given	O
that	O
dysregulated	O
fear	O
levels	O
characterize	O
anxiety	B-T048
disorders	I-T048
,	O
examining	B-T058
the	O
neural	O
correlates	O
of	O
fear	O
and	O
extinction	O
learning	O
may	O
shed	O
light	O
on	O
the	O
pathogenesis	O
of	O
underlying	O
anxiety	B-T048
disorders	I-T048
.	O
To	O
investigate	O
the	O
psychophysiological	O
and	O
neural	O
correlates	O
of	O
fear	O
conditioning	O
and	O
extinction	O
recall	O
in	O
anxiety	B-T048
disorders	I-T048
and	O
to	O
document	O
how	O
these	O
features	O
differ	O
as	O
a	O
function	O
of	O
multiple	O
diagnoses	B-T033
or	O
anxiety	B-T033
severity	O
.	O
This	O
investigation	B-T058
was	O
a	O
cross	O
-	O
sectional	O
,	O
case	B-T058
-	I-T058
control	I-T058
,	O
functional	B-T060
magnetic	I-T060
resonance	I-T060
imaging	I-T060
study	O
at	O
an	O
academic	O
medical	O
center	O
.	O
Participants	O
were	O
healthy	O
controls	O
and	O
individuals	O
with	O
at	O
least	O
1	O
of	O
the	O
following	O
anxiety	B-T048
disorders	I-T048
:	O
generalized	B-T048
anxiety	I-T048
disorder	I-T048
,	O
social	B-T048
anxiety	I-T048
disorder	I-T048
,	O
specific	B-T048
phobia	I-T048
,	O
and	O
panic	B-T048
disorder	I-T048
.	O
The	O
study	O
dates	O
were	O
between	O
March	O
2013	O
and	O
May	O
2015	O
.	O
Two	O
-	O
day	O
fear	O
conditioning	O
and	O
extinction	O
paradigm	O
.	O
Skin	O
conductance	O
responses	O
,	O
blood	O
oxygenation	O
level	O
-	O
dependent	O
responses	O
,	O
trait	O
anxiety	B-T033
scores	I-T033
from	O
the	O
State	B-T060
Trait	I-T060
Anxiety	I-T060
Inventory	I-T060
-	O
Trait	O
Form	O
,	O
and	O
functiona	O
l	O
connectivity	O
.	O
This	O
study	O
included	O
21	O
healthy	O
controls	O
(	O
10	O
women	O
)	O
and	O
61	O
individuals	O
with	O
anxiety	B-T048
disorders	I-T048
(	O
36	O
women	O
)	O
.	O
P	O
values	O
reported	B-T058
for	O
the	O
neuroimaging	B-T060
results	O
are	O
all	O
familywise	O
error	O
corrected	O
.	O
Skin	O
conductance	O
responses	O
during	O
extinction	O
recall	O
did	O
not	O
differ	O
between	O
individuals	O
with	O
anxiety	B-T048
disorders	I-T048
and	O
healthy	O
controls	O
(	O
ηp2	O
=	O
0.001	O
,	O
P	O
=	O
.79	O
)	O
,	O
where	O
ηp2	O
is	O
partial	O
eta	O
squared	O
.	O
The	O
anxiety	B-T033
group	O
had	O
lower	O
activation	O
of	O
the	O
ventromedial	B-T023
prefrontal	I-T023
cortex	I-T023
(	O
vmPFC	B-T023
)	O
during	O
extinction	O
recall	O
(	O
ηp2	O
=	O
0.178	O
,	O
P	O
=	O
.02	O
)	O
.	O
A	O
similar	O
hypoactive	B-T033
pattern	O
was	O
found	O
during	O
early	O
conditioning	O
(	O
ηp2	O
=	O
0.106	O
,	O
P	O
=	O
.009	O
)	O
.	O
The	O
vmPFC	B-T023
hypoactivation	O
was	O
associated	O
with	O
anxiety	B-T033
symptom	I-T033
severity	O
(	O
r	O
=	O
-0.420	O
,	O
P	O
=	O
.01	O
for	O
conditioning	O
and	O
r	O
=	O
-0.464	O
,	O
P	O
=	O
.004	O
for	O
extinction	O
recall	O
)	O
and	O
the	O
number	O
of	O
co	O
-	O
occuring	O
anxiety	B-T048
disorders	I-T048
diagnosed	B-T033
(	O
ηp2	O
=	O
0.137	O
,	O
P	O
=	O
.009	O
for	O
conditioning	O
and	O
ηp2	O
=	O
0.227	O
,	O
P	O
=	O
.004	O
for	O
extinction	O
recall	O
)	O
.	O
Psychophysiological	O
interaction	O
analyses	O
revealed	O
that	O
the	O
fear	O
network	O
connectivity	O
differed	O
between	O
healthy	O
controls	O
and	O
the	O
anxiety	B-T033
group	O
during	O
fear	O
learning	O
(	O
ηp2	O
range	O
between	O
0.088	O
and	O
0.176	O
and	O
P	O
range	O
between	O
0.02	O
and	O
0.003	O
)	O
and	O
extinction	O
recall	O
(	O
ηp2	O
range	O
between	O
0.111	O
and	O
0.235	O
and	O
P	O
range	O
between	O
0.02	O
and	O
0.002	O
)	O
.	O
Despite	O
no	O
skin	O
conductance	O
response	O
group	O
differences	O
during	O
extinction	O
recall	O
,	O
brain	B-T023
activation	O
patterns	O
between	O
anxious	B-T048
and	O
healthy	O
individuals	O
differed	O
.	O
These	O
findings	B-T033
encourage	O
future	O
studies	O
to	O
examine	B-T058
the	O
conditions	O
longitudinally	O
and	O
in	O
the	O
context	O
of	O
treatment	O
trials	O
to	O
improve	B-T033
and	O
guide	B-T061
therapeutics	I-T061
via	O
advanced	O
neurobiological	O
understanding	O
of	O
each	O
disorder	B-T047
.	O
      
Effects	O
of	O
an	O
early	O
intervention	B-T061
using	O
human	O
amniotic	B-T018
epithelial	O
cells	O
in	O
a	O
COPD	B-T047
rat	O
model	O
The	O
study	O
aimed	O
to	O
investigate	O
the	O
effect	O
of	O
an	O
early	O
intervention	B-T061
using	O
human	O
amniotic	B-T018
epithelial	O
cell	O
(	O
hAEC	O
)	O
in	O
a	O
rat	O
model	O
of	O
chronic	B-T047
obstructive	I-T047
pulmonary	I-T047
disease	I-T047
(	O
COPD	B-T047
)	O
.	O
Twenty	O
-	O
four	O
specific	B-T001
pathogen	I-T001
-	I-T001
free	I-T001
Wistar	O
rats	O
were	O
randomized	O
to	O
the	O
control	O
,	O
COPD	B-T047
,	O
and	O
COPD	B-T047
+	O
hAEC	O
groups	O
.	O
COPD	B-T047
was	O
established	O
by	O
intratracheal	O
LPS	O
injection	O
combined	O
with	O
smoke	O
fumigation	O
over	O
30	O
days	O
.	O
On	O
the	O
first	O
day	O
of	O
model	O
establishment	O
rats	O
in	O
the	O
AEC	O
group	O
also	O
received	O
intratracheal	O
instillation	O
of	O
500,000	O
hAECs	O
isolated	O
from	O
the	O
placenta	B-T018
of	O
healthy	O
donors	O
.	O
The	O
mean	O
linear	O
intercept	O
(	O
MLI	O
)	O
and	O
mean	O
alveolar	O
number	O
(	O
MAN	O
)	O
were	O
used	O
to	O
assess	O
the	O
degree	O
of	O
lung	B-T047
emphysema	I-T047
.	O
IL-8	O
was	O
measured	O
using	O
a	O
radioimmunoassay	B-T059
,	O
surfactant	O
protein	O
D	O
(	O
SP	O
-	O
D	O
)	O
was	O
measured	O
by	O
ELISA	B-T059
,	O
and	O
matrix	O
metalloproteinase	O
(	O
MMP)2	O
and	O
MMP8	O
expression	O
was	O
assessed	O
by	O
PCR	O
.	O
Smoke	O
fumigation	O
combined	O
to	O
LPS	O
injection	O
successfully	O
established	O
a	O
COPD	B-T047
rat	O
model	O
with	O
significant	O
emphysema	B-T047
and	O
airway	O
inflammation	O
,	O
elevated	O
MLI	O
and	O
MAN	O
,	O
elevated	O
systemic	O
and	O
lung	B-T023
tissue	O
levels	O
of	O
IL-8	O
and	O
SP	O
-	O
D	O
(	O
P<0.05	O
)	O
,	O
and	O
high	O
expression	O
of	O
MMP2	O
and	O
MMP8	O
.	O
Rats	O
in	O
the	O
COPD	B-T047
+	O
hAEC	O
group	O
exhibited	O
alleviated	O
lung	B-T023
damage	O
,	O
MLI	O
and	O
MAN	O
(	O
P<0.05	O
)	O
,	O
reduced	O
systemic	O
and	O
lung	B-T023
tissue	O
levels	O
of	O
IL-8	O
and	O
SP	O
-	O
D	O
(	O
P<0.05	O
)	O
and	O
MMP2	O
and	O
MMP8	O
expression	O
(	O
P<0.05	O
)	O
.	O
Early	O
intervention	B-T061
using	O
hAECs	O
could	O
delay	O
disease	O
progression	O
in	O
rats	O
with	O
COPD	B-T047
.	O
      
Undisclosed	O
HIV	B-T047
infection	I-T047
and	O
art	B-T061
use	O
in	O
the	O
kenya	O
AIDS	O
indicator	O
survey	O
2012	O
:	O
relevance	O
to	O
targets	O
for	O
HIV	B-T060
diagnosis	I-T060
and	O
treatment	B-T061
in	O
kenya	O
To	O
assess	B-T058
the	O
impact	O
of	O
undisclosed	O
HIV	B-T047
infection	I-T047
and	O
antiretroviral	B-T061
(	I-T061
ARV	I-T061
)	I-T061
therapy	I-T061
(	O
ART	B-T061
)	O
on	O
national	O
estimates	O
of	O
diagnosed	B-T033
HIV	I-T033
and	O
ART	B-T061
coverage	O
in	O
Kenya	O
.	O
HIV	B-T033
-	I-T033
positive	I-T033
dried	O
blood	O
spot	O
samples	O
from	O
Kenya	O
's	O
second	O
AIDS	O
Indicator	O
Survey	O
were	O
tested	O
for	O
an	O
ARV	B-T121
biomarker	O
by	O
liquid	B-T059
chromatography	I-T059
-	I-T059
tandem	I-T059
mass	I-T059
spectrometry	I-T059
.	O
Estimates	O
of	O
diagnosed	B-T033
HIV	I-T033
and	O
ART	B-T061
use	O
based	O
on	O
self	O
-	O
report	O
were	O
compared	O
with	O
those	O
corrected	O
for	O
undisclosed	O
HIV	B-T047
infection	I-T047
and	O
ART	B-T061
use	O
based	O
on	O
ARV	B-T121
testing	O
.	O
Multivariate	O
analysis	O
determined	O
factors	O
associated	O
with	O
undisclosed	O
HIV	B-T047
infection	I-T047
and	O
ART	B-T061
use	O
among	O
persons	O
on	O
ART	B-T061
.	O
Among	O
559	O
HIV	B-T033
-	I-T033
positive	I-T033
samples	O
,	O
the	O
ARV	B-T121
biomarker	O
was	O
detected	B-T033
in	O
42.5	O
%	O
(	O
CI	O
37.4	O
-	O
47.7	O
)	O
.	O
ARV	B-T121
drugs	I-T121
were	O
present	O
in	O
90.7	O
%	O
(	O
CI	O
86.1	O
-	O
95.2	O
)	O
reporting	B-T033
HIV	I-T033
-	I-T033
positive	I-T033
status	O
and	O
receiving	O
ART	B-T061
,	O
66.7	O
%	O
(	O
CI	O
59.9	O
-	O
73.4	O
)	O
reporting	B-T033
HIV	I-T033
-	I-T033
positive	I-T033
status	O
irrespective	O
of	O
ART	B-T061
use	O
,	O
21.0	O
%	O
(	O
CI	O
13.4	O
-	O
28.6	O
)	O
reporting	B-T058
HIV	O
-	O
negative	O
status	O
,	O
and	O
19.3	O
%	O
(	O
CI	O
9.0	O
-	O
29.5	O
)	O
reporting	B-T058
no	B-T033
previous	O
HIV	B-T059
test	I-T059
.	O
After	O
correcting	O
for	O
undisclosed	O
HIV	B-T047
infection	I-T047
and	O
ART	B-T061
use	O
,	O
diagnosed	B-T033
HIV	I-T033
increased	O
from	O
46.9	O
%	O
to	O
57.2	O
%	O
and	O
ART	B-T061
coverage	O
increased	O
from	O
31.8	O
%	O
to	O
42.8	O
%	O
.	O
Undisclosed	O
HIV	B-T047
infection	I-T047
on	O
ART	B-T061
was	O
associated	O
with	O
being	O
aged	O
25	O
-	O
39	O
years	O
and	O
not	O
visiting	O
a	O
health	O
provider	O
in	O
the	O
past	O
year	O
,	O
while	O
younger	B-T033
age	I-T033
and	O
higher	O
wealth	O
was	O
associated	O
with	O
undisclosed	O
ART	B-T061
use	O
.	O
Substantial	O
levels	O
of	O
undisclosed	O
HIV	B-T047
infection	I-T047
and	O
ART	B-T061
use	O
while	O
on	O
ART	B-T061
were	O
observed	O
,	O
resulting	O
in	O
diagnosed	B-T033
HIV	I-T033
underestimated	O
by	O
112,000	O
persons	O
and	O
ART	B-T061
coverage	O
by	O
131,000	O
persons	O
.	O
Supplementing	O
self	O
-	O
reported	O
ART	B-T061
status	O
with	O
objective	O
measures	O
of	O
ART	B-T061
use	O
in	O
national	O
population	O
-based	O
sero	B-T058
-	I-T058
surveys	I-T058
can	O
improve	B-T033
monitoring	B-T058
of	O
treatment	B-T061
targets	O
in	O
countries	O
.	O
      
The	O
association	O
between	O
maternal	B-T033
hydronephrosis	B-T047
and	O
acute	O
flank	B-T184
pain	I-T184
during	O
pregnancy	O
:	O
a	O
prospective	O
pilot	O
-	O
study	O
Maternal	B-T033
hydronephrosis	B-T047
may	O
cause	O
flank	B-T184
pain	I-T184
during	O
pregnancy	O
.	O
We	O
aimed	O
to	O
investigate	O
the	O
association	O
between	O
maternal	B-T033
hydronephrosis	B-T047
and	O
flank	B-T184
pain	I-T184
intensity	O
.	O
From	O
2014	O
to	O
2015	O
,	O
all	O
consecutive	O
women	O
with	O
singleton	O
pregnancies	O
,	O
who	O
presented	O
at	O
our	O
tertiary	O
center	O
due	O
to	O
acute	O
flank	B-T184
pain	I-T184
,	O
were	O
prospectively	O
evaluated	B-T058
by	O
renal	B-T023
ultrasonography	B-T060
and	O
pain	B-T184
questionnaires	O
.	O
A	O
visual	B-T060
analogue	I-T060
scale	I-T060
was	O
used	O
to	O
assess	O
pain	O
intensity	O
.	O
The	O
study	O
had	O
90	O
%	O
power	O
to	O
detect	O
a	O
significant	O
correlation	O
between	O
hydronephrosis	B-T047
and	O
flank	B-T184
pain	I-T184
(	O
Spearman	O
's	O
test	O
)	O
.	O
A	O
total	O
of	O
51	O
consecutive	O
women	O
with	O
left	O
-	O
sided	O
(	O
13.7	O
%	O
)	O
,	O
right	O
-	O
sided	O
(	O
64.7	O
%	O
)	O
or	O
bilateral	O
(	O
21.6	O
%	O
)	O
pain	B-T184
were	O
enrolled	O
.	O
The	O
mean	O
gestational	O
age	O
of	O
these	O
women	O
,	O
who	O
presented	O
due	O
to	O
their	O
pain	B-T184
,	O
was	O
27.5	O
±	O
6.8	O
weeks	O
at	O
the	O
time	O
of	O
consultation	B-T058
.	O
The	O
mean	O
VAS	O
score	O
was	O
7.6	O
±	O
2.2	O
.	O
In	O
43/51	O
(	O
84.3	O
%	O
)	O
women	O
,	O
hydronephrosis	B-T047
was	O
found	O
on	O
renal	B-T023
sonograms	O
.	O
No	O
correlation	O
was	O
found	O
between	O
the	O
grade	O
of	O
hydronephrosis	B-T047
and	O
pain	O
intensity	O
(	O
p	O
=	O
0.466	O
;	O
r=	O
-0.28	O
)	O
.	O
Women	O
delivered	O
at	O
a	O
mean	O
gestational	O
age	O
of	O
38.1	O
±	O
2.4	O
weeks	O
and	O
their	O
infants	O
had	O
a	O
mean	O
birthweight	O
of	O
3138	O
±	O
677	O
g.	O
Hydronephrosis	B-T047
is	O
a	O
common	O
finding	B-T033
among	O
pregnant	O
women	O
with	O
acute	O
flank	B-T184
pain	I-T184
.	O
The	O
grade	O
of	O
hydronephrosis	B-T047
does	O
not	O
affect	O
pain	O
intensity	O
.	O
This	O
study	O
suggests	O
normal	B-T033
pregnancy	I-T033
outcomes	B-T033
in	O
these	O
women	O
.	O
      
Electrocardiographic	O
appearance	O
of	O
aortic	B-T047
stenosis	I-T047
before	O
and	O
after	O
aortic	B-T061
valve	I-T061
replacement	I-T061
So	O
far	O
,	O
the	O
specific	O
appearance	O
of	O
QRS	B-T033
complex	I-T033
,	O
ST	B-T033
-	I-T033
segment	I-T033
,	O
and	O
T	B-T033
wave	I-T033
was	O
observed	O
in	O
aortic	B-T047
stenosis	I-T047
(	O
AS	B-T047
)	O
.	O
S	B-T033
-	I-T033
wave	I-T033
dynamic	O
change	O
in	O
leads	O
V1	O
-	O
V3	O
was	O
not	O
reported	O
in	O
AS	B-T047
.	O
In	O
a	O
single	O
-	O
center	O
,	O
prospective	O
study	O
,	O
we	O
included	O
a	O
total	O
number	O
of	O
1.175	O
patients	O
who	O
underwent	O
surgical	B-T061
aortic	B-T061
valve	I-T061
replacement	I-T061
(	O
AVR	B-T061
)	O
.	O
We	O
conducted	O
3	O
-	O
year	O
gathering	O
of	O
patients	O
with	O
symptomatic	O
and	O
asymptomatic	B-T033
severe	O
AS	B-T047
,	O
and	O
separated	O
them	O
by	O
hemodynamic	O
stability	O
into	O
groups	O
A	O
and	O
B	O
,	O
through	O
EFLV	O
(	O
of	O
more	O
or	O
less	O
than	O
50	O
%	O
)	O
,	O
AVA	O
(	O
of	O
more	O
or	O
less	O
than	O
0.9	O
cm(2	O
)	O
)	O
,	O
PG	O
(	O
between	O
55	O
and	O
75	O
mm	O
Hg	O
or	O
over	O
75	O
mm	O
Hg	O
)	O
,	O
and	O
end	B-T033
-	I-T033
diastolic	I-T033
LV	I-T033
dimension	I-T033
(	O
of	O
more	O
or	O
less	O
than	O
56	O
mm	O
)	O
.	O
We	O
evaluated	B-T058
the	O
impact	O
of	O
S	B-T033
-	I-T033
wave	I-T033
magnitude	O
in	O
right	B-T184
precordial	I-T184
leads	O
before	O
and	O
after	O
AVR	B-T061
in	O
all	O
patients	O
.	O
We	O
followed	O
S	B-T033
-	I-T033
wave	I-T033
changes	O
in	O
electrocardiogram	B-T033
altogether	O
with	O
hemodynamic	B-T061
measurements	I-T061
derived	O
from	O
echocardiography	B-T060
.	O
Analysis	O
of	O
echocardiographic	B-T060
parameters	B-T033
,	O
measured	O
in	O
patients	O
before	O
surgery	B-T061
,	O
did	O
not	O
show	O
statistical	O
significance	O
between	O
asymptomatic	B-T033
and	O
symptomatic	O
group	O
.	O
The	O
statistical	O
significance	O
was	O
observed	O
in	O
the	O
change	O
in	O
S	B-T033
-	I-T033
wave	I-T033
magnitude	O
in	O
the	O
right	B-T184
precordial	I-T184
leads	O
in	O
both	O
subsets	O
of	O
patients	O
before	O
AVR	B-T061
.	O
We	O
found	O
statistically	O
significant	O
predictive	O
value	O
of	O
S	B-T033
-	I-T033
wave	I-T033
magnitude	O
in	O
leads	O
V2	O
-	O
V3	O
for	O
dependent	O
variables	O
PG	O
and	O
end	B-T033
-	I-T033
diastolic	I-T033
LV	I-T033
dimension	I-T033
.	O
S	B-T033
-	I-T033
wave	I-T033
changes	O
in	O
right	B-T184
precordial	I-T184
leads	O
can	O
predict	O
increase	O
in	O
PG	O
and	O
critical	O
narrowing	O
of	O
AVA	O
,	O
suggestive	O
of	O
timely	O
referral	B-T058
for	I-T058
AVR	B-T061
.	O
      
Digital	B-T023
Myopericytoma	B-T191
:	O
A	O
Case	O
Report	O
and	O
Systematic	O
Literature	O
Review	O
A	O
myopericytoma	B-T191
(	O
MP	B-T191
)	O
is	O
an	O
exceedingly	O
rare	O
perivascular	B-T191
tumor	I-T191
of	O
unknown	B-T033
etiology	I-T033
.	O
Given	O
their	O
potential	O
for	O
mimicry	O
and	O
malignancy	B-T191
,	O
MP	B-T191
tumors	I-T191
pose	O
a	O
unique	O
challenge	O
for	O
surgeons	O
and	O
may	O
be	O
overlooked	O
on	O
differential	B-T060
diagnosis	I-T060
.	O
We	O
present	O
a	O
case	O
report	O
of	O
an	O
otherwise	O
healthy	O
33	O
-	O
year	O
-	O
old	O
right	O
-	O
hand	O
dominant	O
male	O
who	O
presented	O
to	O
our	O
outpatient	O
clinic	O
with	O
a	O
2	O
-	O
month	O
history	O
of	O
painless	O
swelling	B-T033
and	O
erythema	B-T033
of	I-T033
the	I-T033
pulp	I-T033
of	I-T033
his	I-T033
left	I-T033
index	I-T033
finger	I-T033
.	O
Subsequent	O
plain	B-T060
film	I-T060
X	I-T060
-	I-T060
ray	I-T060
showed	O
near	O
-	O
complete	O
bony	B-T033
destruction	I-T033
of	O
his	O
distal	B-T023
phalanx	I-T023
.	O
Pathological	O
evaluation	B-T058
of	O
an	O
incisional	B-T060
biopsy	I-T060
showed	O
a	O
benign	B-T191
variant	I-T191
of	O
MP	B-T191
.	O
The	O
lesion	B-T033
was	O
treated	O
by	O
excision	B-T061
with	O
tumor	B-T191
shelling	B-T061
,	O
and	O
there	O
was	O
no	O
evidence	O
of	O
recurrence	O
81	O
days	O
postoperatively	O
.	O
A	O
systematic	O
literature	O
review	O
of	O
the	O
management	B-T058
and	O
outcome	O
of	O
all	O
known	O
cases	O
of	O
hand	O
and	O
wrist	O
MP	B-T191
is	O
presented	O
.	O
      
Unintentional	O
Injuries	O
in	O
Children	O
Up	O
to	O
Six	O
Years	O
of	O
Age	O
and	O
Related	O
Parental	O
Knowledge	O
,	O
Attitudes	O
,	O
and	O
Behaviors	O
in	O
Italy	O
To	O
describe	O
risk	B-T033
factors	I-T033
associated	O
with	O
unintentional	O
injuries	O
among	O
children	O
aged	O
<	O
6	O
years	O
and	O
to	O
examine	O
parents	O
'	O
level	O
of	O
knowledge	O
,	O
attitudes	O
,	O
and	O
behaviors	O
about	O
pediatric	O
injuries	O
and	O
related	O
preventive	O
measures	O
.	O
A	O
cross	O
-	O
sectional	O
survey	O
was	O
conducted	O
between	O
May	O
and	O
July	O
2015	O
on	O
a	O
random	O
sample	O
of	O
794	O
parents	O
of	O
3-	O
to	O
6	O
-	O
year	O
-	O
old	O
children	O
through	O
a	O
self	O
-	O
administered	O
anonymous	O
questionnaire	O
.	O
A	O
total	O
of	O
409	O
parents	O
participated	O
.	O
Two	O
-	O
thirds	O
of	O
the	O
children	O
had	O
experienced	O
at	O
least	O
1	O
unintentional	O
injury	O
in	O
the	O
previous	O
12	O
months	O
.	O
More	O
than	O
one	O
-	O
half	O
of	O
these	O
children	O
were	O
boys	O
.	O
The	O
leading	B-T033
cause	I-T033
was	O
falls	O
;	O
the	O
injuries	O
occurred	O
mainly	O
at	O
home	O
,	O
and	O
only	O
9.2	O
%	O
were	O
brought	O
for	O
attention	O
to	O
an	O
emergency	O
department	O
.	O
Parents	O
who	O
did	O
not	O
believe	O
that	O
it	O
is	O
possible	O
to	O
prevent	O
unintentional	O
injuries	O
were	O
more	O
likely	O
to	O
have	O
had	O
a	O
child	O
injured	O
.	O
Approximately	O
70	O
%	O
of	O
respondents	O
were	O
aware	O
of	O
security	O
measures	O
to	O
prevent	O
pediatric	O
injuries	O
,	O
and	O
this	O
knowledge	O
was	O
more	O
prevalent	O
in	O
older	O
parents	O
and	O
in	O
those	O
with	O
at	O
least	O
a	O
college	O
level	O
of	O
education	O
compared	O
with	O
those	O
with	O
a	O
middle	O
school	O
education	O
.	O
The	O
perceived	O
utility	O
of	O
education	O
about	O
preventive	O
measures	O
of	O
pediatric	O
injuries	O
had	O
a	O
mean	O
value	O
of	O
8.9	O
on	O
a	O
Likert	O
scale	O
of	O
1	O
-	O
10	O
(	O
1	O
,	O
not	O
useful	O
,	O
to	O
10	O
,	O
very	O
useful	O
)	O
and	O
was	O
significantly	O
higher	O
in	O
mothers	O
.	O
This	O
study	O
highlights	O
a	O
clear	O
need	O
for	O
public	B-T058
health	I-T058
educational	O
programs	O
for	O
parents	O
regarding	O
prevention	O
of	O
unintentional	O
injuries	O
in	O
children	O
as	O
a	O
valuable	O
tool	O
to	O
increase	O
safety	O
and	O
injury	B-T061
prevention	I-T061
and	O
to	O
reduce	O
risks	O
,	O
because	O
the	O
majority	O
of	O
such	O
injuries	O
occur	O
at	O
home	O
.	O
      
Correlation	O
of	O
the	O
Lipid	O
Profile	B-T059
,	O
BMI	O
and	O
Bone	O
Mineral	O
Density	O
in	O
Postmenopausal	O
Women	O
To	O
the	O
reduction	O
of	O
bone	O
density	O
and	O
osteoporosis	B-T047
in	O
postmenopausal	O
women	O
contribute	O
elevated	O
lipid	O
parameters	B-T033
and	O
Body	O
Mass	O
Index	O
(	O
BMI	O
)	O
.	O
The	O
goal	O
of	O
our	O
study	O
was	O
to	O
determine	O
the	O
correlation	O
between	O
lipid	O
parameters	B-T033
,	O
BMI	O
and	O
osteoporosis	B-T047
in	O
postmenopausal	O
women	O
.	O
The	O
study	O
was	O
carried	O
out	O
by	O
matched	O
type	O
between	O
experimental	O
group	O
and	O
controls	O
.	O
The	O
experimental	O
group	O
consisted	O
of	O
100	O
females	O
at	O
postmenopausal	O
age	O
,	O
in	O
which	O
by	O
the	O
DEXA	B-T060
method	I-T060
was	O
diagnosed	B-T033
osteoporosis	B-T047
at	O
the	O
Department	O
of	O
Endocrinology	O
,	O
Diabetes	O
and	O
Metabolic	O
Diseases	O
,	O
University	O
Medical	O
Center	O
of	O
RS	O
during	O
2015	O
-	O
2016	O
,	O
while	O
the	O
control	O
group	O
consisted	O
of	O
100	O
females	O
in	O
a	O
postmenopausal	O
age	O
but	O
without	O
diagnosed	B-T033
osteoporosis	B-T047
.	O
The	O
groups	O
were	O
matched	O
by	O
age	O
(	O
±	O
2	O
years	O
)	O
.	O
To	O
all	O
participants	O
of	O
the	O
study	O
were	O
carried	O
out	O
biochemical	B-T059
analysis	I-T059
of	I-T059
blood	I-T059
,	O
or	O
the	O
analysis	O
of	O
the	O
lipid	O
profile	B-T059
that	O
included	O
total	O
cholesterol	O
,	O
LDL	O
cholesterol	O
,	O
triglycerides	O
(	O
TG	O
)	O
and	O
HDL	O
cholesterol	O
,	O
and	O
was	O
determined	O
the	O
values	O
of	O
BMI	O
and	O
waist	O
circumference	O
(	O
WC	O
)	O
.	O
Analysis	O
of	O
the	O
data	O
of	O
our	O
research	O
shows	O
that	O
by	O
the	O
univariate	O
logistic	O
regression	O
the	O
values	O
of	O
lipid	O
parameters	B-T033
total	O
cholesterol	O
(	O
p=0.000	O
)	O
,	O
LDL	O
(	O
p=0.005	O
)	O
and	O
TG	O
(	O
p=0.033	O
)	O
were	O
significantly	O
associated	O
with	O
osteoporosis	B-T047
,	O
while	O
in	O
multivariate	O
logistic	O
model	O
only	O
total	O
cholesterol	O
(	O
p=	O
0.018	O
)	O
was	O
found	O
as	O
an	O
independent	O
risk	B-T033
factor	I-T033
for	O
osteoporosis	B-T047
in	O
postmenopausal	O
women	O
.	O
BMI	O
values	O
were	O
not	B-T033
statistically	O
significantly	O
associated	O
with	O
osteoporosis	B-T047
(	O
p=0.727	O
)	O
.	O
On	O
the	O
decrease	O
in	O
bone	O
mineral	O
density	O
and	O
osteoporosis	B-T047
in	O
postmenopausal	O
women	O
influence	O
many	O
risk	B-T033
factors	I-T033
whose	O
identification	O
has	O
the	O
aim	O
to	O
develop	O
more	O
effective	O
prevention	O
of	O
this	O
disease	B-T047
in	O
the	O
elderly	O
.	O
      
Family	O
and	O
healthcare	O
professionals	O
'	O
perceptions	O
of	O
a	O
pilot	O
hospice	B-T058
at	O
home	O
programme	B-T058
for	O
children	O
:	O
a	O
qualitative	O
study	O
Parents	O
commonly	O
report	O
a	O
significant	O
improvement	O
in	O
quality	O
of	O
life	O
following	O
the	O
provision	B-T058
of	O
hospice	B-T058
and	O
supportive	B-T061
care	I-T061
and	O
have	O
identified	O
a	O
need	O
for	O
such	O
a	O
service	B-T058
in	O
the	O
home	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
understand	O
the	O
experiences	O
of	O
families	O
receiving	O
a	O
nurse	O
led	O
pilot	O
hospice	B-T058
at	O
home	O
programme	B-T058
and	O
the	O
experiences	O
of	O
healthcare	O
professionals	O
delivering	O
and	O
engaging	O
with	O
the	O
programme	B-T058
.	O
An	O
exploratory	O
,	O
qualitative	O
study	O
was	O
conducted	O
,	O
including	O
telephone	O
interviews	O
with	O
parents	O
and	O
focus	O
groups	O
and	O
individual	O
interviews	O
with	O
healthcare	O
professionals	O
.	O
All	O
parents	O
of	O
families	O
who	O
received	O
the	O
programme	B-T058
of	O
care	B-T058
between	O
June	O
2014	O
and	O
September	O
2015	O
and	O
healthcare	O
professionals	O
delivering	O
and	O
engaging	O
with	O
the	O
programme	B-T058
were	O
invited	O
to	O
participate	O
.	O
Seven	O
parents	O
participated	O
in	O
telephone	O
interviews	O
.	O
Four	O
focus	O
groups	O
took	O
place	O
,	O
two	O
with	O
external	O
stakeholders	O
(	O
18	O
participants	O
in	O
total	O
)	O
,	O
one	O
with	O
in	O
-	O
patient	O
hospice	O
staff	O
(	O
13	O
participants	O
)	O
and	O
one	O
with	O
the	O
hospice	B-T058
at	O
home	O
team	O
(	O
8	O
participants	O
)	O
.	O
Two	O
additional	O
interviews	O
took	O
place	O
with	O
individual	O
stakeholders	O
who	O
were	O
unable	O
to	O
attend	O
a	O
scheduled	O
focus	O
group	O
.	O
Themes	O
from	O
interviews	O
with	O
parents	O
focused	O
on	O
the	O
value	O
of	O
having	O
consistent	O
and	O
expert	O
care	B-T058
.	O
The	O
findings	O
from	O
healthcare	O
professionals	O
centred	O
on	O
communication	O
within	O
and	O
across	O
services	B-T058
,	O
education	O
and	O
training	O
and	O
lone	O
working	O
.	O
The	O
pilot	O
hospice	B-T058
at	O
home	O
programme	B-T058
was	O
welcomed	O
by	O
all	O
those	O
who	O
took	O
part	O
in	O
the	O
study	O
.	O
The	O
programme	B-T058
may	O
be	O
improved	O
by	O
enhanced	O
clarification	O
of	O
roles	O
,	O
enhanced	O
access	O
to	O
multi	O
-	O
disciplinary	O
services	B-T058
,	O
greater	O
communication	O
across	O
services	B-T058
and	O
improved	O
information	O
provision	O
to	O
families	O
.	O
      
A	O
comparison	O
of	O
functional	O
outcomes	O
in	O
patients	O
undergoing	O
revision	B-T061
arthroscopic	I-T061
repair	I-T061
of	O
massive	O
rotator	B-T047
cuff	I-T047
tears	I-T047
with	O
and	O
without	O
arthroscopic	O
suprascapular	B-T061
nerve	I-T061
release	I-T061
This	O
study	O
was	O
designed	O
to	O
compare	O
functional	O
outcomes	O
in	O
patients	O
undergoing	O
revision	B-T061
repair	I-T061
of	O
massive	O
rotator	B-T047
cuff	I-T047
tears	I-T047
(	O
retracted	O
medial	O
to	O
the	O
glenoid	O
)	O
with	O
Goutallier	O
Grade	O
4	O
atrophy	O
and	O
concomitant	O
release	B-T061
of	I-T061
the	I-T061
suprascapular	I-T061
nerve	I-T061
to	O
a	O
similar	O
group	O
of	O
patients	O
with	O
Grade	O
3	O
atrophy	O
undergoing	O
revision	B-T061
rotator	I-T061
cuff	I-T061
repair	I-T061
(	O
RTCR	B-T061
)	O
without	O
nerve	B-T061
release	I-T061
.	O
We	O
hypothesized	O
that	O
patients	O
undergoing	O
nerve	B-T061
release	I-T061
would	O
have	O
more	O
favorable	O
functional	O
outcomes	O
as	O
measured	O
by	O
the	O
Modified	O
University	O
of	O
California	O
at	O
Los	O
Angeles	O
shoulder	O
rating	O
scale	O
(	O
UCLA	O
)	O
.	O
Twenty	O
-	O
two	O
patients	O
underwent	O
revision	B-T061
repair	I-T061
of	O
massive	O
rotator	B-T047
cuff	I-T047
tears	I-T047
with	O
release	B-T061
of	I-T061
the	I-T061
suprascapular	I-T061
nerve	I-T061
at	O
the	O
suprascapular	O
notch	O
.	O
We	O
compared	O
total	O
preoperative	O
,	O
postoperative	O
,	O
and	O
change	O
in	O
UCLA	O
score	O
in	O
these	O
patients	O
to	O
a	O
similar	O
group	O
of	O
22	O
patients	O
undergoing	O
revision	B-T061
RTCR	I-T061
without	O
suprascapular	B-T061
nerve	I-T061
release	I-T061
.	O
Additionally	O
,	O
UCLA	O
subscores	O
between	O
the	O
two	O
groups	O
were	O
compared	O
preoperatively	O
and	O
at	O
final	O
follow	B-T058
-	I-T058
up	I-T058
.	O
The	O
average	O
preoperative	O
UCLA	O
score	O
in	O
the	O
nerve	O
-	O
release	O
group	O
was	O
7.91	O
,	O
and	O
final	O
follow	B-T058
-	I-T058
up	I-T058
average	O
was	O
27.86	O
;	O
average	O
3.05	O
grades	O
of	O
strength	O
were	O
recovered	O
.	O
In	O
the	O
comparison	O
group	O
,	O
average	O
preoperative	O
UCLA	O
score	O
was	O
11.77	O
,	O
and	O
final	O
follow	B-T058
-	I-T058
up	I-T058
average	O
was	O
29.09	O
;	O
average	O
1.32	O
grades	O
of	O
strength	O
were	O
recovered	O
.	O
The	O
average	O
preoperative	O
UCLA	O
score	O
was	O
significantly	O
worse	O
in	O
the	O
nerve	O
-	O
release	O
group	O
(	O
P=0.007	O
)	O
.	O
The	O
average	O
postoperative	O
UCLA	O
score	O
was	O
not	O
significantly	O
different	O
(	O
P=0.590	O
)	O
between	O
the	O
groups	O
,	O
indicating	O
a	O
better	O
improvement	O
in	O
the	O
nerve	O
-	O
release	O
group	O
with	O
significantly	O
greater	O
improvement	O
in	O
active	O
forward	O
flexion	O
,	O
strength	O
,	O
and	O
pain	B-T061
relief	I-T061
.	O
Patients	O
who	O
underwent	O
concomitant	O
release	B-T061
of	I-T061
the	I-T061
suprascapular	I-T061
nerve	I-T061
during	O
revision	B-T061
RTCR	I-T061
had	O
greater	O
overall	O
improvement	O
as	O
noted	O
in	O
pain	B-T061
relief	I-T061
,	O
active	O
forward	O
flexion	O
,	O
and	O
strength	O
,	O
than	O
a	O
comparable	O
group	O
without	O
nerve	B-T061
release	I-T061
.	O
      
Low	B-T033
birth	I-T033
weight	I-T033
and	O
features	O
of	O
neuroticism	B-T048
and	O
mood	B-T048
disorder	I-T048
in	O
83	O
545	O
participants	O
of	O
the	O
UK	O
Biobank	O
cohort	O
Low	B-T033
birth	I-T033
weight	I-T033
has	O
been	O
inconsistently	O
associated	O
with	O
risk	O
of	O
developing	O
affective	B-T048
disorders	I-T048
,	O
including	O
major	B-T048
depressive	I-T048
disorder	I-T048
(	O
MDD	B-T048
)	O
.	O
To	O
date	O
,	O
studies	O
investigating	O
possible	O
associations	O
between	O
birth	O
weight	O
and	O
bipolar	B-T048
disorder	I-T048
(	O
BD	B-T048
)	O
,	O
or	O
personality	B-T033
traits	I-T033
known	O
to	O
predispose	O
to	O
affective	B-T048
disorders	I-T048
such	O
as	O
neuroticism	B-T048
,	O
have	O
not	O
been	O
conducted	O
in	O
large	O
cohorts	O
.	O
To	O
assess	O
whether	O
very	B-T184
low	I-T184
birth	I-T184
weight	I-T184
(	O
<	O
1500	O
g	O
)	O
and	O
low	B-T033
birth	I-T033
weight	I-T033
(	O
1500	O
-	O
2490	O
g	O
)	O
were	O
associated	O
with	O
higher	B-T033
neuroticism	I-T033
scores	O
assessed	O
in	O
middle	O
age	O
,	O
and	O
lifetime	O
history	O
of	O
either	O
MDD	B-T048
or	O
BD	B-T048
.	O
We	O
controlled	O
for	O
possible	O
confounding	O
factors	O
.	O
Retrospective	O
cohort	O
study	O
using	O
baseline	O
data	O
on	O
the	O
83	O
545	O
UK	O
Biobank	O
participants	O
with	O
detailed	O
mental	O
health	O
and	O
birth	O
weight	O
data	O
.	O
Main	O
outcomes	O
were	O
prevalent	O
MDD	B-T048
and	O
BD	B-T048
,	O
and	O
neuroticism	B-T048
assessed	O
using	O
the	O
Eysenck	O
Personality	O
Inventory	O
Neuroticism	O
scale	O
-	O
Revised	O
(	O
EPIN	O
-	O
R	O
)	O
.	O
Referent	O
to	O
normal	B-T033
birth	I-T033
weight	I-T033
,	O
very	B-T184
low	I-T184
/	O
low	B-T033
birth	I-T033
weight	I-T033
were	O
associated	O
with	O
higher	B-T033
neuroticism	I-T033
scores	O
,	O
increased	O
MDD	B-T048
and	O
BD	B-T048
.	O
The	O
associations	O
between	O
birth	O
weight	O
category	O
and	O
MDD	B-T048
were	O
partially	O
mediated	O
by	O
higher	B-T033
neuroticism	I-T033
.	O
These	O
findings	B-T033
suggest	O
that	O
intrauterine	O
programming	O
may	O
play	O
a	O
role	O
in	O
lifetime	O
vulnerability	B-T033
to	O
affective	B-T048
disorders	I-T048
.	O
None	O
.	O
©	O
The	O
Royal	O
College	O
of	O
Psychiatrists	O
2016	O
.	O
This	O
is	O
an	O
open	O
access	O
article	O
distributed	O
under	O
the	O
terms	O
of	O
the	O
Creative	O
Commons	O
Non	O
-	O
Commercial	O
,	O
No	O
Derivatives	O
(	O
CC	O
BY	O
-	O
NC	O
-	O
ND	O
)	O
licence	O
.	O
      
Dynamic	O
disorder	O
can	O
explain	O
non	O
-	O
exponential	O
kinetics	O
of	O
fast	O
protein	O
mechanical	O
unfolding	O
Protein	O
unfolding	O
often	O
does	O
not	O
obey	O
a	O
simple	O
two	O
-	O
state	O
behavior	O
.	O
Previous	O
single	B-T059
molecule	I-T059
force	I-T059
spectroscopy	I-T059
studies	B-T059
demonstrated	O
stretched	O
exponential	O
kinetics	O
of	O
protein	O
unfolding	O
under	O
a	O
constant	O
pulling	O
force	O
,	O
the	O
molecular	O
origin	O
of	O
which	O
remains	O
subject	O
to	O
debate	O
.	O
We	O
here	O
set	O
out	O
to	O
extensively	O
sample	O
the	O
mechanical	O
unfolding	O
of	O
ubiquitin	O
and	O
NuG2	O
by	O
Molecular	O
Dynamics	O
(	O
MD	O
)	O
simulations	O
.	O
Both	O
proteins	O
show	O
kinetics	O
best	O
fit	O
by	O
stretched	O
exponentials	O
,	O
with	O
stretching	O
exponents	O
similar	O
to	O
those	O
found	O
in	O
experiments	O
,	O
even	O
though	O
static	O
disorder	O
is	O
absent	O
in	O
our	O
short	O
MD	O
simulations	O
.	O
Instead	O
,	O
we	O
can	O
ascribe	O
non	O
-	O
exponential	O
kinetics	O
to	O
dynamic	O
disorder	O
,	O
due	O
to	O
conformational	O
fluctuations	O
on	O
the	O
nanosecond	O
timescale	O
.	O
Our	O
study	O
highlights	O
the	O
general	O
role	O
of	O
dynamic	O
disorder	O
in	O
protein	O
kinetics	O
on	O
a	O
broad	O
range	O
of	O
time	O
scales	O
even	O
including	O
those	O
probed	O
in	O
MD	O
simulations	O
.	O
      
Functional	O
1,3a,6a	O
-	O
triazapentalene	O
scaffold	O
:	O
Design	O
of	O
fluorescent	O
probes	O
for	O
kinesin	O
spindle	O
protein	O
(	O
KSP	O
)	O
1,3a,6a	O
-	O
Triazapentalene	O
is	O
a	O
compact	O
fluorescent	O
chromophore	O
.	O
In	O
this	O
study	O
,	O
triazapentalene	O
was	O
used	O
to	O
modify	O
a	O
series	O
of	O
biphenyl	O
-	O
type	O
inhibitors	B-T121
of	O
kinesin	O
spindle	O
protein	O
(	O
KSP	O
)	O
to	O
develop	O
fluorescent	O
probes	O
for	O
the	O
intracellular	O
visualization	O
of	O
this	O
protein	O
.	O
Microscopic	O
studies	O
demonstrated	O
that	O
these	O
novel	O
triazapentalene	O
-	O
labeled	O
compounds	O
exhibited	O
inhibitory	O
activity	O
towards	O
KSP	O
in	O
cultured	O
cells	O
and	O
provided	O
important	O
information	O
concerning	O
the	O
intracellular	O
distribution	O
.	O
      
Laparoscopic	B-T060
radical	B-T061
lymph	I-T061
node	I-T061
dissection	I-T061
for	O
advanced	B-T191
colon	I-T191
cancer	I-T191
close	O
to	O
the	O
hepatic	O
flexure	O
Complete	B-T061
mesocolic	I-T061
excision	I-T061
is	O
currently	O
recognized	O
as	O
a	O
standard	B-T061
procedure	I-T061
for	O
colon	B-T191
cancer	I-T191
.	O
Gastroepiploic	B-T023
,	O
infrapyloric	B-T023
,	O
and	O
superficial	B-T023
pancreatic	I-T023
head	I-T023
lymph	I-T023
node	I-T023
metastases	B-T191
in	O
the	O
gastrocolic	B-T023
ligament	I-T023
have	O
been	O
reported	O
for	O
colon	B-T191
cancer	I-T191
close	O
to	O
the	O
hepatic	O
flexure	O
.	O
We	O
sought	O
to	O
investigate	O
metastases	B-T191
in	O
the	O
gastrocolic	B-T023
ligament	I-T023
in	O
colon	B-T191
cancer	I-T191
close	O
to	O
the	O
hepatic	O
flexure	O
.	O
This	O
was	O
a	O
single	O
-	O
center	O
retrospective	O
study	O
.	O
All	O
patients	O
with	O
T2	B-T033
or	O
deeper	O
invasive	O
colon	B-T191
cancer	I-T191
in	O
the	O
relevant	O
tumor	O
location	O
who	O
underwent	O
laparoscopic	B-T061
right	I-T061
hemicolectomy	I-T061
or	O
extended	B-T061
right	I-T061
hemicolectomy	I-T061
at	O
our	O
institution	O
between	O
1	O
April	O
2011	O
and	O
31	O
March	O
2015	O
were	O
included	O
.	O
Lymph	B-T061
node	I-T061
dissection	I-T061
in	O
the	O
gastrocolic	B-T023
ligament	I-T023
was	O
performed	O
in	O
35	O
cases	O
.	O
Complications	O
occurred	O
in	O
11	O
patients	O
(	O
31	O
%	O
)	O
and	O
were	O
grades	O
I	O
and	O
II	O
according	O
to	O
the	O
Clavien	O
-	O
Dindo	O
classification	O
.	O
Lymph	B-T191
node	I-T191
metastases	I-T191
in	O
the	O
gastrocolic	B-T023
ligament	I-T023
were	O
found	O
in	O
only	O
three	O
patients	O
(	O
9	O
%	O
)	O
.	O
Each	O
metastasis	B-T191
was	O
larger	O
than	O
9	O
mm	O
.	O
Metastases	B-T191
in	O
the	O
gastrocolic	B-T023
ligament	I-T023
occurred	O
in	O
9	O
%	O
of	O
patients	O
with	O
T2	B-T033
or	O
deeper	O
invasive	O
colon	B-T191
cancer	I-T191
close	O
to	O
the	O
hepatic	O
flexure	O
.	O
Laparoscopy	B-T061
was	O
feasible	O
and	O
useful	O
during	O
gastrocolic	B-T061
ligament	I-T061
resection	I-T061
.	O
This	O
study	O
included	O
a	O
small	O
sample	O
and	O
lacked	O
an	O
extended	O
follow	B-T058
-	I-T058
up	I-T058
.	O
Further	O
studies	O
are	O
needed	O
to	O
determine	O
the	O
clinical	O
relevance	O
of	O
this	O
finding	B-T033
,	O
particularly	O
in	O
terms	O
of	O
recurrence	O
and	O
long	O
-	O
term	O
survival	O
.	O
      
Developmental	O
Profile	B-T059
and	O
Diagnoses	O
in	O
Children	O
Presenting	O
with	O
Motor	B-T033
Stereotypies	I-T033
Motor	B-T033
stereotypies	I-T033
represent	O
a	O
typical	O
example	O
of	O
the	O
difficulty	O
in	O
distinguishing	O
non	O
-	O
clinical	O
behaviors	O
(	O
physiological	O
and	O
transient	O
)	O
from	O
symptoms	B-T184
or	O
among	O
different	O
disorders	B-T047
[	O
"	O
primary	B-T048
stereotypies	I-T048
,	O
"	O
associated	O
with	O
autistic	B-T048
spectrum	I-T048
disorder	I-T048
(	O
ASD	B-T048
)	O
,	O
intellectual	B-T048
disabilities	I-T048
,	O
genetic	B-T047
syndromes	I-T047
,	O
and	O
sensory	B-T033
impairment	I-T033
]	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
obtain	O
an	O
accurate	O
assessment	B-T058
on	O
the	O
relationship	O
between	O
stereotypies	B-T048
and	O
neurodevelopmental	B-T048
disorders	I-T048
.	O
We	O
studied	O
23	O
children	O
(	O
3	O
girls	O
)	O
,	O
aged	O
36	O
-	O
95	O
months	O
,	O
who	O
requested	O
a	O
consultation	B-T058
due	O
to	O
the	O
persistence	B-T033
or	O
increased	O
severity	O
of	O
motor	B-T033
stereotypies	I-T033
.	O
None	O
of	O
the	O
patients	O
had	O
a	O
previous	O
diagnosis	O
of	O
ASD	B-T048
.	O
The	O
assessment	B-T058
included	O
the	O
Motor	O
Severity	O
Stereotypy	O
Scale	O
(	O
MSSS	O
)	O
,	O
the	O
Repetitive	O
Behavior	O
Scale	O
-	O
Revised	O
(	O
RBS	O
-	O
R	O
)	O
,	O
the	O
Raven	B-T033
's	I-T033
Colored	I-T033
Progressive	I-T033
Matrices	I-T033
,	O
the	O
Child	B-T060
Behavior	I-T060
CheckList	I-T060
for	O
ages	O
1½-5	O
or	O
4	O
-	O
18	O
(	O
CBCL	B-T060
)	O
,	O
the	O
Social	O
Responsiveness	O
Scale	O
(	O
SRS	O
)	O
,	O
and	O
the	O
Autism	O
Diagnostic	O
Observation	O
Schedule	O
-	O
second	O
edition	O
(	O
ADOS	O
2	O
)	O
.	O
All	O
patients	O
were	O
showing	O
motor	B-T033
stereotypies	I-T033
for	O
periods	O
of	O
time	O
varying	O
from	O
6	O
to	O
77	O
months	O
.	O
The	O
MSSS	O
showed	O
that	O
each	O
child	O
had	O
a	O
limited	O
number	O
of	O
stereotypies	B-T048
;	O
their	O
frequency	O
and	O
intensity	O
were	O
mild	O
.	O
The	O
interference	O
of	O
stereotypies	B-T048
was	O
variable	O
;	O
the	O
impairment	O
in	O
daily	O
life	O
was	O
mild	O
.	O
The	O
RBS	O
-	O
R	O
scores	O
were	O
positive	O
for	O
the	O
subscale	O
of	O
"	O
stereotypic	B-T048
behaviors	I-T048
"	O
in	O
all	O
children	O
.	O
Moreover	O
,	O
several	O
children	O
presented	O
other	O
repetitive	B-T033
behaviors	I-T033
,	O
mainly	O
"	O
ritualistic	B-T184
behavior	I-T184
"	O
and	O
"	O
sameness	B-T033
behavior	I-T033
.	O
"	O
All	O
patients	O
showed	O
a	O
normal	B-T033
cognitive	I-T033
level	I-T033
.	O
The	O
CBCL	B-T060
evidenced	O
behavioral	B-T048
problems	I-T048
in	O
22	O
%	O
of	O
the	O
children	O
:	O
internalizing	B-T184
problems	I-T184
,	O
attention	O
,	O
and	O
withdrawn	B-T048
were	O
the	O
main	O
complaints	O
.	O
On	O
the	O
SRS	O
,	O
all	O
but	O
one	O
of	O
the	O
tested	O
patients	O
obtained	O
clinical	B-T033
scores	I-T033
in	O
the	O
clinical	O
range	O
for	O
at	O
least	O
one	O
area	O
.	O
On	O
the	O
ADOS	O
2	O
,	O
4	O
patients	O
obtained	O
scores	O
indicating	O
a	O
moderate	O
level	O
of	O
ASD	B-T048
symptoms	B-T184
,	O
4	O
had	O
a	O
mild	O
level	O
,	O
and	O
15	O
showed	O
no	O
or	O
minimal	O
signs	B-T184
of	O
ASD	B-T048
.	O
Motor	B-T033
stereotypies	I-T033
in	O
children	O
with	O
normal	B-T033
cognitive	I-T033
level	I-T033
represent	O
a	O
challenging	O
diagnostic	O
issue	B-T033
for	O
which	O
a	O
finely	O
tailored	O
assessment	B-T058
is	O
mandatory	O
in	O
order	O
to	O
define	O
a	O
precise	O
developmental	O
profile	O
.	O
Thus	O
,	O
careful	O
and	O
cautious	O
use	O
of	O
standardized	O
tests	O
is	O
warranted	O
to	O
avoid	O
misdiagnosis	B-T033
.	O
Furthermore	O
,	O
it	O
is	O
hard	O
to	O
consider	O
motor	B-T033
stereotypies	I-T033
,	O
even	O
the	O
primary	O
ones	O
,	O
exclusively	O
as	O
a	O
movement	B-T047
disorder	I-T047
.	O
      
Who	O
Persuades	O
Who	O
?	O
An	O
Analysis	O
of	O
Persuasion	O
Choices	O
Related	O
to	O
Antibiotic	B-T195
-	O
Free	O
Food	O
Personal	O
communication	O
,	O
in	O
which	O
one	O
person	O
persuades	O
another	O
to	O
engage	O
in	O
a	O
particular	O
behavior	O
,	O
is	O
one	O
means	O
through	O
which	O
behaviors	O
spread	O
.	O
To	O
better	O
understand	O
how	O
personal	O
communication	O
spreads	O
behavior	O
,	O
we	O
investigated	O
adults	O
'	O
(	O
N	O
=	O
228	O
)	O
likelihood	O
of	O
persuading	O
others	O
in	O
a	O
fictitious	O
social	O
network	O
to	O
buy	O
antibiotic	B-T195
-	O
free	O
food	O
,	O
and	O
who	O
they	O
attempted	O
to	O
persuade	O
,	O
based	O
on	O
behavioral	O
determinants	O
,	O
homophily	O
,	O
and	O
superdiffuser	O
traits	O
.	O
For	O
potential	O
consumers	O
,	O
the	O
findings	B-T033
showed	O
that	O
behavioral	O
determinants	O
,	O
behavioral	O
intentions	O
,	O
and	O
mavenism	O
predicted	O
intentions	O
to	O
persuade	O
others	O
.	O
Homophily	O
,	O
mavenism	O
,	O
and	O
connectivity	O
predicted	O
patterns	O
of	O
interpersonal	O
persuasion	O
.	O
For	O
vegetarians	O
(	O
without	O
homophily	O
in	O
action	O
)	O
,	O
behavioral	O
determinants	O
and	O
mavenism	O
predicted	O
persuasion	O
intentions	O
.	O
Persuasiveness	O
was	O
associated	O
with	O
targeting	O
more	O
network	O
members	O
;	O
mavenism	O
was	O
associated	O
with	O
selecting	O
structurally	O
central	O
members	O
.	O
      
Posterior	O
dislocation	O
of	O
the	O
sternoclavicular	O
joint	O
:	O
report	O
of	O
two	O
cases	O
The	O
authors	O
report	O
the	O
cases	O
of	O
two	O
young	O
patients	O
who	O
had	O
suffered	O
a	O
sporting	O
accident	O
with	O
posterior	O
traumatic	O
dislocation	O
of	O
sternoclavicular	O
joint	O
.	O
In	O
one	O
of	O
the	O
patients	O
closed	B-T061
reduction	I-T061
was	O
accomplished	O
by	O
keeping	O
the	O
limb	B-T023
in	O
a	O
sling	O
.	O
The	O
second	O
patient	O
,	O
after	O
reduction	B-T061
was	O
done	O
,	O
presented	O
recurrence	O
of	O
the	O
dislocation	O
,	O
thus	O
requiring	O
surgical	B-T061
treatment	I-T061
.	O
It	O
is	O
important	O
to	O
observe	O
the	O
relevance	O
of	O
computed	B-T060
tomography	I-T060
to	O
help	O
diagnosing	O
,	O
as	O
well	O
as	O
monitoring	O
the	O
reduction	B-T061
procedure	I-T061
.	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
demonstrate	O
two	O
different	O
types	O
of	O
treatment	B-T061
in	O
a	O
rare	O
injury	O
such	O
as	O
the	O
posterior	O
dislocation	O
of	O
sternoclavicular	O
joint	O
.	O
      
Design	O
,	O
synthesis	O
,	O
and	O
evaluation	B-T058
of	O
curcumin	B-T121
derivatives	O
as	O
Nrf2	O
activators	O
and	O
cytoprotectors	O
against	O
oxidative	O
death	O
Activation	O
of	O
nuclear	O
factor	O
erythroid-2	O
-	O
related	O
factor	O
2	O
(	O
Nrf2	O
)	O
has	O
been	O
proven	O
to	O
be	O
an	O
effective	O
means	O
to	O
prevent	O
the	O
development	O
of	O
cancer	B-T191
,	O
and	O
natural	O
curcumin	B-T121
stands	O
out	O
as	O
a	O
potent	O
Nrf2	O
activator	O
and	O
cancer	B-T191
chemopreventive	B-T121
agent	I-T121
.	O
In	O
this	O
study	O
,	O
we	O
synthesized	O
a	O
series	O
of	O
curcumin	B-T121
analogs	O
by	O
introducing	O
the	O
geminal	O
dimethyl	O
substituents	O
on	O
the	O
active	O
methylene	O
group	O
to	O
find	O
more	O
potent	O
Nrf2	O
activators	O
and	O
cytoprotectors	O
against	O
oxidative	O
death	O
.	O
The	O
geminally	O
dimethylated	O
and	O
catechol	B-T121
-type	O
curcumin	B-T121
analog	O
(	O
compound	B-T121
3	I-T121
)	O
was	O
identified	O
as	O
a	O
promising	O
lead	B-T121
molecule	I-T121
in	O
terms	O
of	O
its	O
increased	O
stability	O
and	O
cytoprotective	O
activity	O
against	O
the	O
tert	O
-	O
butyl	O
hydroperoxide	O
(	O
t	O
-	O
BHP)-induced	O
death	O
of	O
HepG2	O
cells	O
.	O
Mechanism	O
studies	O
indicate	O
that	O
its	O
cytoprotective	O
effects	O
are	O
mediated	O
by	O
activating	O
the	O
Nrf2	O
signaling	O
pathway	O
in	O
the	O
Michael	B-T121
acceptor	I-T121
-	O
and	O
catechol	B-T121
-dependent	O
manners	O
.	O
Additionally	O
,	O
we	O
verified	O
by	O
using	O
copper	B-T121
and	O
iron	B-T121
ion	O
chelators	B-T121
that	O
the	O
two	O
metal	O
ion	O
-mediated	O
oxidations	O
of	O
compound	B-T121
3	I-T121
to	O
its	O
corresponding	O
electrophilic	O
o	O
-	O
quinone	O
,	O
contribute	O
significantly	O
to	O
its	O
Nrf2	O
-dependent	O
cytoprotection	O
.	O
This	O
work	O
provides	O
an	O
example	O
of	O
successfully	O
designing	O
natural	O
curcumin	B-T121
-directed	O
Nrf2	O
activators	O
by	O
a	O
stability	O
-increasing	O
and	O
proelectrophilic	O
strategy	O
.	O
      
Hip	B-T023
segmentation	O
from	O
MRI	B-T060
volumes	O
in	O
infants	O
for	O
DDH	B-T019
diagnosis	B-T033
and	O
treatment	O
planning	O
Diagnosis	B-T033
and	O
surgical	B-T058
management	I-T058
of	O
Developmental	B-T019
Dysplasia	I-T019
of	I-T019
the	I-T019
Hip	I-T019
(	O
DDH	B-T019
)	O
relies	O
on	O
physical	B-T058
examination	I-T058
and	O
2D	O
ultrasound	B-T060
scanning	I-T060
.	O
Magnetic	B-T060
Resonance	I-T060
Imaging	I-T060
(	O
MRI	B-T060
)	O
can	O
be	O
used	O
to	O
complement	O
existing	O
techniques	O
and	O
could	O
be	O
advantageous	O
in	O
treatment	O
planning	O
due	O
to	O
its	O
larger	O
field	O
of	O
view	O
.	O
In	O
this	O
paper	O
we	O
propose	O
a	O
semi	O
-	O
automatic	O
method	O
to	O
segment	O
surface	O
models	O
of	O
the	O
acetabulum	B-T023
from	O
MRI	B-T060
images	O
.	O
The	O
method	O
incorporates	O
clinical	O
knowledge	O
in	O
the	O
form	O
of	O
intensity	O
priors	O
which	O
are	O
integrated	O
into	O
a	O
Random	O
Walker	O
(	O
RW	O
)	O
formulation	O
.	O
We	O
use	O
a	O
modified	O
RW	O
framework	O
which	O
compensates	O
for	O
incomplete	O
or	O
blurred	O
boundaries	O
in	O
the	O
image	O
by	O
using	O
information	O
from	O
neighboring	O
slices	O
in	O
the	O
sequence	O
incorporated	O
as	O
node	O
weights	O
.	O
We	O
conducted	O
a	O
pilot	O
study	O
to	O
evaluate	B-T058
the	O
segmentation	O
on	O
a	O
set	O
of	O
10	O
infant	O
hip	B-T023
MRI	B-T060
sequences	O
using	O
a	O
1.5	O
Tesla	O
MR	O
scanner	O
.	O
Contours	O
obtained	O
from	O
the	O
semi	O
-	O
automated	O
segmentation	O
were	O
compared	O
against	O
manually	B-T033
segmented	O
hip	B-T023
contours	O
using	O
Dice	O
Ratio	O
(	O
DR	O
)	O
,	O
Hausdorff	O
Distance	O
(	O
HD	O
)	O
and	O
Root	O
Mean	O
Square	O
(	O
RMS	O
)	O
distance	O
.	O
The	O
proposed	O
method	O
gave	O
values	O
of	O
(	O
DR	O
=	O
0.84	O
±	O
0.5	O
,	O
HD	O
=	O
3.0	O
±	O
0.7	O
,	O
RMS	O
=	O
1.9	O
±	O
0.3	O
)	O
and	O
(	O
DR	O
=	O
0.86	O
±	O
0.2	O
,	O
HD	O
=	O
3.0	O
±	O
0.1	O
,	O
RMS	O
=	O
2.0	O
±	O
0.6	O
)	O
for	O
right	O
and	O
left	O
acetabular	O
contours	O
respectively	O
which	O
was	O
higher	O
than	O
the	O
corresponding	O
values	O
obtained	O
from	O
conventional	O
RW	O
segmentation	O
.	O
The	O
execution	O
time	O
of	O
the	O
segmentation	O
algorithm	O
was	O
less	O
than	O
~4	O
seconds	O
on	O
a	O
3.5	O
GHz	O
CPU	O
.	O
      
The	O
relationship	O
between	O
thiamine	O
and	O
two	O
symbioses	O
:	O
Root	O
nodule	O
symbiosis	O
and	O
arbuscular	O
mycorrhiza	O
Lotus	O
japonicus	O
THIC	O
is	O
expressed	O
in	O
all	O
organs	O
,	O
and	O
the	O
encoded	O
protein	O
catalyzes	O
thiamine	O
biosynthesis	O
.	O
Loss	B-T033
of	I-T033
function	I-T033
produces	O
chlorosis	B-T047
,	O
a	O
typical	O
thiamine	O
-deficiency	O
phenotype	O
,	O
and	O
mortality	O
.	O
To	O
investigate	O
thiamine	O
's	O
role	O
in	O
symbiosis	O
,	O
we	O
focused	O
on	O
THI1	O
,	O
a	O
thiamine	O
-	O
biosynthesis	O
gene	O
expressed	O
in	O
roots	O
,	O
nodules	O
,	O
and	O
seeds	O
.	O
The	O
thi1	O
mutant	O
had	O
green	O
leaves	O
,	O
but	O
formed	O
small	O
nodules	O
and	O
immature	O
seeds	O
.	O
These	O
phenotypes	O
were	O
rescued	O
by	O
THI1	O
complementation	O
and	O
by	O
exogenous	O
thiamine	O
.	O
Thus	O
,	O
THI1	O
is	O
required	O
for	O
nodule	O
enlargement	O
and	O
seed	O
maturation	O
.	O
On	O
the	O
other	O
hand	O
,	O
colonization	B-T033
by	O
arbuscular	O
mycorrhiza	O
(	O
AM	O
)	O
fungus	O
Rhizophagus	O
irregularis	O
was	O
not	O
affected	O
in	O
the	O
thi1	O
mutant	O
or	O
by	O
exogenous	O
thiamine	O
.	O
However	O
,	O
spores	O
of	O
R.	O
irregularis	O
stored	O
more	O
thiamine	O
than	O
the	O
source	O
(	O
host	O
plants	O
)	O
,	O
despite	O
lacking	O
thiamine	O
biosynthesis	O
genes	O
.	O
Therefore	O
,	O
disturbance	O
of	O
the	O
thiamine	O
supply	O
would	O
affect	O
progeny	O
phenotypes	O
such	O
as	O
spore	O
formation	O
and	O
hyphal	O
growth	O
.	O
Further	O
investigation	O
will	O
be	O
required	O
to	O
elucidate	O
thiamine	O
's	O
effect	O
on	O
AM	O
.	O
      
Examining	O
the	O
contribution	O
of	O
motor	O
movement	O
and	O
language	O
dominance	O
to	O
increased	O
left	O
lateralization	O
during	O
sign	O
generation	O
in	O
native	O
signers	O
The	O
neural	O
systems	O
supporting	O
speech	O
and	O
sign	O
processing	O
are	O
very	O
similar	O
,	O
although	O
not	O
identical	O
.	O
In	O
a	O
previous	O
fTCD	O
study	O
of	O
hearing	O
native	O
signers	O
(	O
Gutierrez	O
-	O
Sigut	O
,	O
Daws	O
,	O
et	O
al	O
.	O
,	O
2015	O
)	O
we	O
found	O
stronger	O
left	O
lateralization	O
for	O
sign	O
than	O
speech	O
.	O
Given	O
that	O
this	O
increased	O
lateralization	O
could	O
not	O
be	O
explained	O
by	O
hand	B-T023
movement	O
alone	O
,	O
the	O
contribution	O
of	O
motor	O
movement	O
versus	O
'	O
linguistic	O
'	O
processes	O
to	O
the	O
strength	O
of	O
hemispheric	O
lateralization	O
during	O
sign	O
production	O
remains	O
unclear	O
.	O
Here	O
we	O
directly	O
contrast	O
lateralization	O
strength	O
of	O
covert	O
versus	O
overt	O
signing	O
during	O
phonological	O
and	O
semantic	O
fluency	O
tasks	O
.	O
To	O
address	O
the	O
possibility	O
that	O
hearing	O
native	O
signers	O
'	O
elevated	O
lateralization	O
indices	O
(	O
LIs	O
)	O
were	O
due	O
to	O
performing	O
a	O
task	O
in	O
their	O
less	O
dominant	O
language	O
,	O
here	O
we	O
test	O
deaf	O
native	O
signers	O
,	O
whose	O
dominant	O
language	O
is	O
British	O
Sign	O
Language	O
(	O
BSL	O
)	O
.	O
Signers	O
were	O
more	O
strongly	O
left	O
lateralized	O
for	O
overt	O
than	O
covert	O
sign	O
generation	O
.	O
However	O
,	O
the	O
strength	O
of	O
lateralization	O
was	O
not	O
correlated	O
with	O
the	O
amount	O
of	O
time	O
producing	O
movements	O
of	O
the	O
right	B-T023
hand	I-T023
.	O
Comparisons	O
with	O
previous	O
data	O
from	O
hearing	O
native	O
English	O
speakers	O
suggest	O
stronger	O
laterality	O
indices	O
for	O
sign	O
than	O
speech	O
in	O
both	O
covert	O
and	O
overt	O
tasks	O
.	O
This	O
increased	O
left	O
lateralization	O
may	O
be	O
driven	O
by	O
specific	O
properties	O
of	O
sign	O
production	O
such	O
as	O
the	O
increased	O
use	O
of	O
self	O
-	O
monitoring	O
mechanisms	O
or	O
the	O
nature	O
of	O
phonological	O
encoding	O
of	O
signs	O
.	O
      
Beneficial	O
effects	O
of	O
natural	B-T121
eggshell	I-T121
membrane	I-T121
(	O
NEM	B-T121
)	O
on	O
multiple	O
indices	O
of	O
arthritis	B-T047
in	O
collagen	B-T050
-	I-T050
induced	I-T050
arthritic	I-T050
rats	O
This	O
study	O
was	O
performed	O
to	O
evaluate	B-T058
the	O
potential	O
efficacy	O
of	O
natural	B-T121
eggshell	I-T121
membrane	I-T121
(	O
NEM	B-T121
)	O
in	O
collagen	B-T050
-	I-T050
induced	I-T050
arthritic	I-T050
rats	O
,	O
a	O
well	O
-	O
established	O
rodent	B-T050
model	I-T050
of	I-T050
inflammation	I-T050
and	O
rheumatoid	B-T047
arthritis	I-T047
.	O
Rats	O
with	O
developing	O
type	B-T050
II	I-T050
collagen	I-T050
-	I-T050
induced	I-T050
arthritis	I-T050
(	O
CIA	B-T050
)	O
were	O
treated	O
once	O
daily	O
by	O
oral	O
gavage	O
on	O
study	O
days	O
-14	O
to	O
17	O
with	O
vehicle	O
or	O
NEM	B-T121
(	O
52	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
.	O
Rats	O
were	O
euthanized	O
on	O
study	O
day	O
17	O
.	O
Efficacy	O
was	O
assessed	O
by	O
daily	O
ankle	O
caliper	O
measurements	O
,	O
ankle	O
diameter	O
expressed	O
as	O
area	O
under	O
the	O
curve	O
(	O
AUCd0	O
-	O
17	O
)	O
,	O
and	O
histopathologic	O
evaluation	O
of	O
ankles	O
and	O
knees	B-T023
.	O
Serum	O
biomarkers	O
of	O
cartilage	O
function	O
and	O
inflammation	O
[	O
collagen	B-T059
type	I-T059
II	I-T059
C	I-T059
-	I-T059
telopeptide	I-T059
(	O
CTXII	B-T059
)	O
,	O
cartilage	B-T059
oligomeric	I-T059
matrix	I-T059
protein	I-T059
(	O
COMP	B-T059
)	O
,	O
and	O
alpha-2	B-T059
-	I-T059
macroglobulin	I-T059
(	O
A2	B-T059
M	I-T059
)	O
]	O
were	O
measured	O
by	O
ELISA	B-T059
.	O
Treatment	O
with	O
NEM	B-T121
resulted	O
in	O
significant	O
beneficial	O
effects	O
on	O
the	O
daily	O
ankle	O
diameter	O
measurements	O
and	O
ankle	O
diameter	O
AUC	O
.	O
Ankle	O
and	O
knee	B-T023
histopathology	O
scores	O
were	O
significantly	O
reduced	O
(	O
36	O
%	O
and	O
43	O
%	O
reduction	O
of	O
summed	O
individual	O
histopathology	O
scores	O
for	O
ankle	O
and	O
knee	B-T023
,	O
respectively	O
;	O
p	O
<	O
0.05	O
)	O
toward	O
normal	O
for	O
rats	O
given	O
NEM	B-T121
compared	O
to	O
vehicle	O
controls	O
.	O
The	O
percent	O
reduction	O
of	O
serum	O
CTXII	B-T059
,	O
COMP	B-T059
,	O
and	O
A2	B-T059
M	I-T059
in	O
NEM	B-T121
-	O
treated	O
rats	O
ranged	O
from	O
30	O
%	O
to	O
72	O
%	O
(	O
p	O
<	O
0.05	O
)	O
.	O
NEM	B-T121
significantly	O
improved	O
multiple	O
aspects	O
of	O
inflammatory	B-T047
arthritis	I-T047
including	O
inflammation	O
,	O
pannus	O
,	O
cartilage	O
damage	O
,	O
bone	O
resorption	O
,	O
and	O
periosteal	O
bone	O
formation	O
.	O
This	O
study	O
provides	O
further	O
support	O
for	O
the	O
use	O
of	O
CTXII	O
,	O
COMP	O
,	O
and	O
A2	O
M	O
as	O
relevant	O
biomarkers	O
that	O
were	O
responsive	O
to	O
NEM	B-T121
.	O
      
Anti	B-T121
-	I-T121
helminthic	I-T121
activity	O
of	O
Momordica	O
charantia	O
L.	O
against	O
Fasciola	O
hepatica	O
eggs	O
after	O
twelve	O
days	O
of	O
incubation	B-T059
in	O
vitro	O
Fasciolosis	B-T047
,	O
a	O
parasitic	B-T047
disease	I-T047
caused	O
by	O
the	O
trematode	O
Fasciola	O
hepatica	O
underreported	O
is	O
expanding	O
both	O
in	O
human	O
and	O
animal	O
population	O
,	O
throughout	O
the	O
world	O
.	O
The	O
constant	O
use	O
of	O
synthetic	B-T121
drugs	I-T121
to	O
treat	B-T061
this	O
condition	B-T047
has	O
led	O
to	O
the	O
natural	O
selection	O
of	O
resistant	O
strains	B-T001
of	O
the	O
parasite	O
.	O
Hence	O
,	O
there	O
is	O
a	O
growing	O
focus	O
on	O
the	O
potential	O
anti	B-T121
-	I-T121
helminthic	I-T121
properties	O
of	O
medicinal	O
plants	O
and	O
phytopharmaceuticals	O
.	O
The	O
current	O
study	O
assessed	O
the	O
potential	O
anti	O
-	O
fasciolicide	O
action	O
of	O
Momordica	O
charantia	O
leaf	O
extracts	O
and	O
fractions	O
on	O
the	O
eggs	O
of	O
F.	O
hepatica	O
parasites	O
.	O
The	O
lyophilized	O
crude	O
extract	O
(	O
CE	O
)	O
of	O
M.	O
charantia	O
leaves	O
and	O
its	O
sub	O
-	O
fractions	O
,	O
obtained	O
from	O
liquid	B-T059
-	I-T059
liquid	I-T059
partitioning	I-T059
with	O
organic	O
solvents	O
,	O
were	O
analysed	O
by	O
High	B-T059
Performance	I-T059
Liquid	I-T059
Chromatography	I-T059
(	O
HPLC	B-T059
)	O
,	O
suspended	O
in	O
1	O
%	O
DMSO	B-T121
and	O
used	O
in	O
in	O
vitro	O
tests	B-T059
.	O
Quadruplicates	O
of	O
50	O
F.	O
hepatica	O
eggs	O
were	O
incubated	B-T059
at	O
23	O
°	O
C	O
with	O
M.	O
charantia	O
leaf	O
CE	O
in	O
different	O
concentrations	O
.	O
After	O
12	O
days	O
no	O
larvae	O
were	O
formed	O
in	O
eggs	O
incubated	B-T059
with	O
CE	O
concentrations	O
above	O
12.5mg	O
/	O
mL.	O
Eggs	O
incubated	B-T059
with	O
CE	O
sub	O
-	O
fractions	O
at	O
concentrations	O
of	O
1000	O
,	O
100	O
,	O
10	O
,	O
1	O
,	O
0.1	O
,	O
0.01μg	O
/	O
mL	O
affected	O
embryonic	O
development	O
,	O
with	O
n	O
-	O
butanol	O
presenting	O
the	O
strongest	O
inhibition	O
of	O
miracidia	O
formation	O
.	O
In	O
contrast	O
,	O
on	O
the	O
12th	O
day	O
,	O
90	O
%	O
of	O
the	O
miracidia	O
hatched	O
in	O
the	O
control	O
experiments	O
using	O
0.03	O
%	O
DMSO	B-T121
whereas	O
embryogenesis	O
was	O
completely	O
abolished	O
with	O
any	O
concentration	O
of	O
albendazole	B-T121
sulphoxide	I-T121
ABZ(SO	B-T121
)	I-T121
.	O
Chemical	B-T059
analysis	I-T059
of	O
the	O
CE	O
and	O
sub	O
-	O
fractions	O
revealed	O
a	O
prominent	O
presence	O
of	O
flavonoids	O
.	O
HPLC	B-T059
-	I-T059
MS	I-T059
confirmed	O
Quercetin	B-T121
to	O
be	O
one	O
of	O
the	O
main	O
flavonoids	O
present	O
in	O
the	O
CE	O
and	O
the	O
n	O
-	O
butanol	O
subfraction	O
.	O
This	O
is	O
the	O
first	O
study	O
to	O
analyse	O
the	O
potential	O
anti	O
-	O
fasciolicide	O
action	O
of	O
M.	O
charantia	O
leaf	O
CE	O
and	O
subfractions	O
.	O
      
Graded	O
Structure	O
in	O
Sexual	O
Definitions	O
:	O
Categorizations	O
of	O
Having	O
"	O
Had	B-T033
Sex	I-T033
"	O
and	O
Virginity	O
Loss	O
Among	O
Homosexual	O
and	O
Heterosexual	O
Men	O
and	O
Women	O
Definitions	O
of	O
sexual	O
behavior	O
display	O
a	O
robust	O
hierarchy	O
of	O
agreement	O
regarding	O
whether	O
or	O
not	O
acts	O
should	O
be	O
classed	O
as	O
,	O
for	O
example	O
,	O
sex	O
or	O
virginity	O
loss	O
.	O
The	O
current	O
research	O
offers	O
a	O
theoretical	O
explanation	O
for	O
this	O
hierarchy	O
,	O
proposing	O
that	O
sexual	O
definitions	O
display	O
graded	O
categorical	O
structure	O
,	O
arising	O
from	O
goodness	O
of	O
membership	O
judgments	O
.	O
Moderation	O
of	O
this	O
graded	O
structure	O
is	O
also	O
predicted	O
,	O
with	O
the	O
focus	O
here	O
on	O
how	O
sexual	O
orientation	O
identity	O
affects	O
sexual	O
definitions	O
.	O
A	O
total	O
of	O
300	O
18-	O
to	O
30-	O
year	O
-old	O
participants	O
completed	O
an	O
online	O
survey	O
,	O
rating	O
18	O
behaviors	O
for	O
how	O
far	O
each	O
constitutes	O
having	O
"	O
had	B-T033
sex	I-T033
"	O
and	O
virginity	O
loss	O
.	O
Participants	O
fell	O
into	O
one	O
of	O
four	O
groups	O
:	O
heterosexual	O
male	O
or	O
female	O
,	O
gay	O
male	O
or	O
lesbian	O
.	O
The	O
predicted	O
ratings	O
hierarchy	O
emerged	O
,	O
in	O
which	O
bidirectional	O
genital	O
acts	O
were	O
rated	O
significantly	O
higher	O
than	O
unidirectional	O
or	O
nonpenetrative	B-T033
contact	I-T033
,	O
which	O
was	O
in	O
turn	O
rated	O
significantly	O
higher	O
than	O
acts	O
involving	O
no	B-T033
genital	I-T033
contact	I-T033
.	O
Moderation	O
of	O
graded	O
structure	O
was	O
also	O
in	O
line	O
with	O
predictions	O
.	O
Compared	O
to	O
the	O
other	O
groups	O
,	O
the	O
lesbian	O
group	O
significantly	O
upgraded	O
ratings	O
of	O
genital	O
contact	O
that	O
was	O
either	O
unidirectional	O
or	O
nonpenetrative	B-T033
.	O
There	O
was	O
also	O
evidence	O
of	O
upgrading	O
by	O
the	O
gay	O
male	O
sample	O
of	O
anal	O
intercourse	O
ratings	O
.	O
These	O
effects	O
are	O
theorized	O
to	O
reflect	O
group	O
-level	O
variation	O
in	O
experience	O
,	O
contextual	O
perspective	O
,	O
and	O
identity	O
-management	O
.	O
The	O
implications	O
of	O
the	O
findings	B-T033
in	O
relation	O
to	O
previous	O
research	O
are	O
discussed	O
.	O
It	O
is	O
suggested	O
that	O
a	O
graded	O
structure	O
approach	O
can	O
greatly	O
benefit	O
future	O
research	O
into	O
sexual	O
definitions	O
,	O
by	O
permitting	O
variable	O
definitions	O
to	O
be	O
predicted	O
and	O
explained	O
,	O
rather	O
than	O
merely	O
identified	O
.	O
      
Pharmacological	B-T061
Venous	I-T061
Thromboembolism	I-T061
Prophylaxis	I-T061
in	O
Meningioma	B-T191
Patients	O
:	O
Should	O
It	O
Be	O
Earlier	O
Than	O
Clinical	B-T061
Practice	I-T061
?	O
We	O
read	O
the	O
report	O
by	O
Çeltikçi	O
et	O
al	O
in	O
the	O
Turkish	O
Neurosurgery	O
with	O
great	O
interest	O
.	O
In	O
this	O
single	O
-	O
center	O
retrospective	O
study	O
,	O
they	O
analysed	O
449	O
intracranial	B-T191
meningioma	I-T191
patients	O
underwent	O
open	B-T061
surgery	I-T061
.	O
They	O
stated	O
that	O
venous	B-T047
thromboembolism	I-T047
(	O
VTE	B-T047
)	O
had	O
been	O
seen	O
in	O
21	O
(	O
4.6	O
%	O
)	O
of	O
their	O
patients	O
.	O
This	O
is	O
an	O
important	O
issue	O
because	O
VTE	B-T047
,	O
including	O
deep	B-T047
vein	I-T047
thrombosis	I-T047
(	O
DVT	B-T047
)	O
and	O
pulmonary	B-T047
embolism	I-T047
(	O
PE	B-T047
)	O
,	O
is	O
the	O
most	O
common	O
overall	O
complication	O
in	O
meningioma	B-T061
surgery	I-T061
and	O
is	O
fatal	O
in	O
up	O
to	O
one	O
third	O
of	O
patients	O
(	O
2	O
)	O
.	O
We	O
suppose	O
that	O
prophylaxis	B-T061
of	O
VTE	B-T047
is	O
most	O
effective	O
when	O
mechanical	O
and	O
pharmacological	B-T061
prophylaxis	I-T061
are	O
combined	O
.	O
We	O
consider	O
that	O
there	O
key	O
some	O
practical	O
questions	O
to	O
be	O
answered	O
for	O
a	O
proper	O
clinical	O
extrapolation	O
.	O
      
Kinematic	O
and	O
EMG	B-T060
Responses	O
to	O
Pelvis	B-T023
and	O
Leg	B-T023
Assistance	O
Force	O
during	O
Treadmill	O
Walking	O
in	O
Children	O
with	O
Cerebral	B-T047
Palsy	I-T047
Treadmill	B-T061
training	I-T061
has	O
been	O
used	O
for	O
improving	O
locomotor	O
function	O
in	O
children	O
with	O
cerebral	B-T047
palsy	I-T047
(	O
CP	B-T047
)	O
,	O
but	O
the	O
functional	O
gains	O
are	O
relatively	O
small	O
,	O
suggesting	O
a	O
need	O
to	O
improve	O
current	O
paradigms	O
.	O
The	O
understanding	O
of	O
the	O
kinematic	O
and	O
EMG	B-T060
responses	O
to	O
force	O
s	O
applied	O
to	O
the	O
body	B-T017
of	O
subjects	O
during	O
treadmill	O
walking	O
is	O
crucial	O
for	O
improving	O
current	O
paradigms	O
.	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
kinematic	O
s	O
and	O
EMG	B-T060
responses	O
to	O
the	O
pelvis	B-T023
and/or	O
leg	B-T023
assistance	O
force	O
.	O
Ten	O
children	O
with	O
spastic	B-T019
CP	I-T019
were	O
recruited	O
to	O
participate	B-T058
in	O
this	O
study	O
.	O
A	O
controlled	O
assistance	O
force	O
was	O
applied	O
to	O
the	O
pelvis	B-T023
and/or	O
legs	B-T023
during	O
stance	B-T033
and	O
swing	B-T033
phase	I-T033
of	I-T033
gait	I-T033
through	O
a	O
custom	O
designed	O
robotic	O
system	O
during	O
walking	O
.	O
Muscle	O
activities	O
and	O
spatial	O
-	O
temporal	O
gait	B-T033
parameters	I-T033
were	O
measured	O
at	O
different	O
loading	O
conditions	O
during	O
walking	O
.	O
In	O
addition	O
,	O
the	O
spatial	B-T033
-	I-T033
temporal	I-T033
gait	I-T033
parameters	I-T033
during	O
overground	O
walking	O
before	O
and	O
after	O
treadmill	B-T061
training	I-T061
were	O
also	O
collected	O
.	O
Applying	O
pelvis	B-T023
assistance	O
improved	B-T033
step	B-T033
height	I-T033
and	O
applying	O
leg	B-T023
assistance	O
improved	B-T033
step	B-T033
length	I-T033
during	O
walking	O
,	O
but	O
applying	O
leg	B-T023
assistance	O
also	O
reduced	O
muscle	O
activation	O
of	O
ankle	B-T023
flexor	I-T023
during	O
the	O
swing	B-T033
phase	I-T033
of	I-T033
gait	I-T033
.	O
In	O
addition	O
,	O
step	B-T033
length	I-T033
and	O
self	O
-	O
selected	O
walking	O
speed	O
significantly	O
improved	B-T033
after	O
one	O
session	O
of	O
treadmill	B-T061
training	I-T061
with	O
combined	O
pelvis	B-T023
and	O
leg	B-T023
assistance	O
.	O
      
Identification	O
of	O
markers	O
for	O
quiescent	O
pancreatic	O
stellate	O
cells	O
in	O
the	O
normal	O
human	O
pancreas	B-T023
Pancreatic	O
stellate	O
cells	O
(	O
PSCs	O
)	O
play	O
a	O
central	O
role	O
as	O
source	O
of	O
fibrogenic	O
cells	O
in	O
pancreatic	B-T191
cancer	I-T191
and	O
chronic	B-T047
pancreatitis	I-T047
.	O
In	O
contrast	O
to	O
quiescent	O
hepatic	O
stellate	O
cells	O
(	O
qHSCs	O
)	O
,	O
a	O
specific	O
marker	O
for	O
quiescent	O
PSCs	O
(	O
qPSCs	O
)	O
that	O
can	O
be	O
used	O
in	O
formalin	O
-	O
fixed	O
and	O
paraffin	O
embedded	O
(	O
FFPE	O
)	O
normal	O
human	O
pancreatic	O
tissue	O
has	O
not	O
been	O
identified	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
identify	O
a	O
marker	O
enabling	O
the	O
identification	O
of	O
qPSCs	O
in	O
normal	O
human	O
FFPE	O
pancreatic	O
tissue	O
.	O
Immunohistochemical	B-T059
(	O
IHC	B-T059
)	O
,	O
double	B-T059
-	I-T059
IHC	I-T059
,	O
immunofluorescence	B-T059
(	O
IF	B-T059
)	O
and	O
double	B-T059
-	I-T059
IF	I-T059
analyses	I-T059
were	O
carried	O
out	O
using	O
a	O
tissue	O
microarray	O
consisting	O
of	O
cores	O
with	O
normal	O
human	O
pancreatic	O
tissue	O
.	O
Cores	O
with	O
normal	O
human	O
liver	B-T023
served	O
as	O
control	O
.	O
Antibodies	O
directed	O
against	O
adipophilin	O
,	O
α	O
-	O
SMA	O
,	O
CD146	O
,	O
CRBP-1	O
,	O
cytoglobin	O
,	O
desmin	O
,	O
GFAP	O
,	O
nestin	O
,	O
S100A4	O
and	O
vinculin	O
were	O
examined	O
,	O
with	O
special	O
emphasis	O
on	O
their	O
expression	O
in	O
periacinar	O
cells	O
in	O
the	O
normal	O
human	O
pancreas	B-T023
and	O
perisinusoidal	O
cells	O
in	O
the	O
normal	O
human	O
liver	B-T023
.	O
The	O
immunolabelling	B-T059
capacity	O
was	O
evaluated	O
according	O
to	O
a	O
semiquantitative	O
scoring	O
system	O
.	O
Double	B-T059
-	I-T059
IF	I-T059
of	O
the	O
markers	O
of	O
interest	O
together	O
with	O
markers	O
for	O
other	O
periacinar	O
cells	O
was	O
performed	O
.	O
Moreover	O
,	O
the	O
utility	O
of	O
histochemical	B-T059
stains	I-T059
for	O
the	O
identification	O
of	O
human	O
qPSCs	O
was	O
examined	O
,	O
and	O
their	O
ultrastructure	O
was	O
revisited	O
by	O
electron	B-T059
microscopy	I-T059
.	O
Adipophilin	O
,	O
CRBP-1	O
,	O
cytoglobin	O
and	O
vinculin	O
were	O
expressed	O
in	O
qHSCs	O
in	O
the	O
liver	B-T023
,	O
whereas	O
cytoglobin	O
and	O
adipophilin	O
were	O
expressed	O
in	O
qPSCs	O
in	O
the	O
pancreas	B-T023
.	O
Adipophilin	O
immunohistochemistry	B-T060
was	O
highly	O
dependent	O
on	O
the	O
preanalytical	O
time	O
interval	O
(	O
PATI	O
)	O
from	O
removal	O
of	O
the	O
tissue	O
to	O
formalin	B-T059
fixation	I-T059
.	O
Cytoglobin	O
,	O
S100A4	O
and	O
vinculin	O
were	O
expressed	O
in	O
periacinar	O
fibroblasts	O
(	O
FBs	O
)	O
.	O
The	O
other	O
examined	O
markers	O
were	O
negative	O
in	O
human	O
qPSCs	O
.	O
Our	O
data	O
indicate	O
that	O
cytoglobin	O
and	O
adipophilin	O
are	O
markers	O
of	O
qPSCs	O
in	O
the	O
normal	O
human	O
pancreas	B-T023
.	O
However	O
,	O
the	O
use	O
of	O
adipophilin	O
as	O
a	O
qPSC	O
marker	O
may	O
be	O
limited	O
due	O
to	O
its	O
high	O
dependence	O
on	O
optimal	O
PATI	O
.	O
Cytoglobin	O
,	O
on	O
the	O
other	O
hand	O
,	O
is	O
a	O
sensitive	O
marker	O
for	O
qPSCs	O
but	O
is	O
expressed	O
in	O
FBs	O
as	O
well	O
.	O
      
Characterization	O
and	O
Ectopic	O
Expression	O
of	O
CoWRI1	O
,	O
an	O
AP2	O
/	O
EREBP	O
Domain	O
-	O
Containing	O
Transcription	O
Factor	O
from	O
Coconut	O
(	O
Cocos	O
nucifera	O
L	O
.	O
)	O
Endosperm	O
,	O
Changes	O
the	O
Seeds	O
Oil	O
Content	O
in	O
Transgenic	O
Arabidopsis	O
thaliana	O
and	O
Rice	O
(	O
Oryza	O
sativa	O
L	O
.	O
)	O
Coconut	O
(	O
Cocos	O
nucifera	O
L.	O
)	O
is	O
a	O
key	O
tropical	O
crop	O
and	O
a	O
member	O
of	O
the	O
monocotyledonous	O
family	O
Arecaceae	O
(	O
Palmaceae	O
)	O
.	O
Few	O
genes	O
and	O
related	O
metabolic	O
processes	O
involved	O
in	O
coconut	O
endosperm	O
development	O
have	O
been	O
investigated	O
.	O
In	O
this	O
study	O
,	O
a	O
new	O
member	O
of	O
the	O
WRI1	O
gene	O
family	O
was	O
isolated	O
from	O
coconut	O
endosperm	O
and	O
was	O
named	O
CoWRI1	O
.	O
Its	O
transcriptional	O
activities	O
and	O
interactions	O
with	O
the	O
acetyl	O
-	O
CoA	O
carboxylase	O
(	O
BCCP2	O
)	O
promoter	O
of	O
CoWRI1	O
were	O
confirmed	O
by	O
the	O
yeast	O
two	O
-	O
hybrid	O
and	O
yeast	O
one	O
-	O
hybrid	O
approaches	O
,	O
respectively	O
.	O
Functional	O
characterization	O
was	O
carried	O
out	O
through	O
seed	O
-specific	O
expression	O
in	O
Arabidopsis	O
and	O
endosperm	O
-specific	O
expression	O
in	O
rice	O
.	O
In	O
transgenic	O
Arabidopsis	O
,	O
high	O
over	O
-	O
expressions	O
of	O
CoWRI1	O
in	O
seven	O
independent	O
T2	O
lines	O
were	O
detected	O
by	O
quantitative	O
real	O
-	O
time	O
PCR	O
.	O
The	O
relative	O
mRNA	O
accumulation	O
of	O
genes	O
encoding	O
enzymes	O
involved	O
in	O
either	O
fatty	O
acid	O
biosynthesis	O
or	O
triacylglycerols	O
assembly	O
(	O
BCCP2	O
,	O
KASI	O
,	O
MAT	O
,	O
ENR	O
,	O
FATA	O
,	O
and	O
GPDH	O
)	O
were	O
also	O
assayed	B-T059
in	O
mature	O
seeds	O
.	O
Furthermore	O
,	O
lipid	O
and	O
fatty	O
acids	O
C16:0	O
and	O
C18:0	O
significantly	O
increased	O
.	O
In	O
two	O
homozygous	O
T2	O
transgenic	O
rice	O
lines	O
(	O
G5	O
and	O
G2	O
)	O
,	O
different	O
CoWRI1	O
expression	O
levels	O
were	O
detected	O
,	O
but	O
no	O
CoWRI1	O
transcripts	O
were	O
detected	O
in	O
the	O
wild	O
type	O
.	O
Analyses	O
of	O
the	O
seed	O
oil	O
content	O
,	O
starch	B-T121
content	O
,	O
and	O
total	O
protein	O
content	O
indicated	O
that	O
the	O
two	O
T2	O
transgenic	O
lines	O
showed	O
a	O
significant	O
increase	O
(	O
P	O
<	O
0.05	O
)	O
in	O
seed	O
oil	O
content	O
.	O
The	O
transgenic	O
lines	O
also	O
showed	O
a	O
significant	O
increase	O
in	O
starch	B-T121
content	O
,	O
whereas	O
total	O
protein	O
content	O
decreased	O
significantly	O
.	O
Further	O
analysis	O
of	O
the	O
fatty	O
acid	O
composition	O
revealed	O
that	O
palmitic	O
acid	O
(	O
C16:0	O
)	O
and	O
linolenic	B-T121
acid	I-T121
(	O
C18:3	B-T121
)	O
increased	O
significantly	O
in	O
the	O
seeds	O
of	O
the	O
transgenic	O
rice	O
lines	O
,	O
but	O
oleic	B-T121
acid	I-T121
(	O
C18:1	B-T121
)	O
levels	O
significantly	O
declined	O
.	O
      
Identification	O
of	O
low	O
micromolar	O
dual	O
inhibitors	B-T121
for	O
aldose	O
reductase	O
(	O
ALR2	O
)	O
and	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
(	O
PARP-1	O
)	O
using	O
structure	O
based	O
design	O
approach	O
Clinical	O
studies	O
have	O
revealed	O
that	O
diabetic	B-T047
retinopathy	I-T047
is	O
a	O
multifactorial	O
disorder	B-T047
.	O
Moreover	O
,	O
studies	O
also	O
suggest	O
that	O
ALR2	O
and	O
PARP-1	O
co	O
-	O
occur	O
in	O
retinal	B-T023
cells	O
,	O
making	O
them	O
appropriate	O
targets	O
for	O
the	O
treatment	B-T061
of	O
diabetic	B-T047
retinopathy	I-T047
.	O
To	O
find	O
the	O
dual	O
inhibitors	B-T121
of	O
ALR2	O
and	O
PARP-1	O
,	O
the	O
structure	O
based	O
design	O
was	O
carried	O
out	O
in	O
parallel	O
for	O
both	O
the	O
target	O
proteins	O
.	O
A	O
series	O
of	O
novel	O
thiazolidine-2,4	O
-	O
dione	O
(	O
TZD	O
)	O
derivatives	O
were	O
therefore	O
rationally	O
designed	O
,	O
synthesized	O
and	O
their	O
in	O
vitro	O
inhibitory	O
activities	O
against	O
ALR2	O
and	O
PARP-1	O
were	O
evaluated	O
.	O
The	O
experimental	B-T033
results	I-T033
showed	O
that	O
compounds	B-T121
5b	I-T121
and	O
5f	B-T121
,	O
with	O
2	O
-	O
chloro	O
and	O
4	O
-	O
fluoro	O
substitutions	O
,	O
showed	O
biochemical	O
activities	O
in	O
micromolar	O
and	O
submicromolar	O
range	O
(	O
IC50	O
1.34	O
-	O
5.03μM	O
)	O
against	O
both	O
the	O
targeted	O
enzymes	O
.	O
The	O
structure	O
-	O
activity	O
relationship	O
elucidated	O
for	O
these	O
novel	O
inhibitors	B-T121
against	O
both	O
the	O
enzymes	O
provide	O
new	O
insight	O
into	O
the	O
binding	O
mode	O
of	O
the	O
inhibitors	B-T121
to	O
the	O
active	O
sites	O
of	O
enzymes	O
.	O
The	O
positive	B-T033
results	B-T033
of	O
the	O
biochemical	O
assay	B-T059
suggest	O
that	O
these	O
compounds	B-T121
may	O
be	O
further	O
optimized	O
and	O
utilized	O
for	O
the	O
treatment	B-T061
of	O
diabetic	B-T047
retinopathy	I-T047
.	O
      
Dimerization	O
of	O
EGFR	O
and	O
HER2	O
induces	O
breast	B-T191
cancer	I-T191
cell	O
motility	O
through	O
STAT1	O
-dependent	O
ACTA2	O
induction	O
The	O
dimerization	O
of	O
EGFR	O
and	O
HER2	O
is	O
associated	O
with	O
poor	O
prognosis	B-T058
such	O
as	O
induction	O
of	O
tumor	B-T191
growth	I-T191
and	O
cell	O
invasion	O
compared	O
to	O
when	O
EGFR	O
remains	O
as	O
a	O
homodimer	O
.	O
However	O
,	O
the	O
mechanism	O
for	O
events	O
after	O
dimerization	O
in	O
breast	B-T191
cancer	I-T191
models	O
is	O
not	O
clear	O
.	O
We	O
found	O
that	O
expressions	O
of	O
alpha	O
-	O
smooth	O
muscle	O
actin	O
(	O
ACTA2	O
)	O
and	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
1	O
(	O
STAT1	O
)	O
significantly	O
increased	O
with	O
transient	O
or	O
stable	O
overexpression	O
of	O
HER2	O
in	O
EGFR	O
-	O
positive	B-T033
breast	B-T191
cancer	I-T191
cells	O
.	O
ACTA2	O
and	O
STAT1	O
expression	O
was	O
also	O
increased	O
in	O
HER2	O
-	O
positive	B-T033
breast	B-T191
cancer	I-T191
patients	O
.	O
In	O
contrast	O
,	O
ACTA2	O
expression	O
was	O
decreased	O
by	O
HER2	O
siRNA	O
.	O
Next	O
,	O
we	O
investigated	O
the	O
co	O
-	O
relation	O
between	O
STAT1	O
and	O
ACTA2	O
expression	O
.	O
Basal	O
ACTA2	O
expression	O
was	O
significantly	O
decreased	O
by	O
treatment	B-T061
with	O
the	O
STAT1	B-T121
inhibitor	I-T121
fludarabine	B-T121
or	O
the	O
JAK2	B-T121
inhibitor	I-T121
AG490	B-T121
.	O
In	O
contrast	O
,	O
ACTA2	O
expression	O
was	O
increased	O
by	O
STAT1	O
overexpression	O
.	O
Levels	O
of	O
ACTA2	O
,	O
STAT1	O
,	O
and	O
HER2	O
were	O
increased	O
and	O
relapse	O
free	O
survival	O
was	O
decreased	O
in	O
high	B-T033
-	I-T033
risk	I-T033
breast	B-T191
cancer	I-T191
patients	O
.	O
We	O
also	O
investigated	O
the	O
effect	O
of	O
ACTA2	O
on	O
cell	O
motility	O
,	O
which	O
was	O
suppressed	O
by	O
ACTA2	O
shRNA	O
overexpression	O
in	O
MDA	O
-	O
MB231	O
HER2	O
and	O
4T1	O
mammary	O
carcinoma	O
cells	O
.	O
The	O
number	O
of	O
lung	B-T033
metastatic	I-T033
nodules	I-T033
was	O
significantly	O
decreased	O
in	O
ACTA2	O
knockdown	O
mice	O
.	O
Taken	O
together	O
,	O
these	O
results	O
demonstrated	O
that	O
induction	O
of	O
ACTA2	O
by	O
EGFR	O
and	O
HER2	O
dimerization	O
was	O
regulated	O
through	O
a	O
JAK2	O
/	O
STAT1	O
signaling	O
pathway	O
,	O
and	O
aberrant	O
ACTA2	O
expression	O
accelerated	O
the	O
invasiveness	O
and	O
metastasis	B-T191
of	O
breast	B-T191
cancer	I-T191
cells	O
.	O
      
4	O
-	O
Anilino-2	O
-	O
pyridylquinazolines	O
and	O
-	O
pyrimidines	O
as	O
Highly	O
Potent	O
and	O
Nontoxic	O
Inhibitors	O
of	O
Breast	O
Cancer	O
Resistance	O
Protein	O
(	O
ABCG2	O
)	O
Multidrug	O
resistance	O
(	O
MDR	O
)	O
mediated	O
by	O
ATP	O
-	O
binding	O
cassette	O
(	O
ABC	O
)	O
transport	O
proteins	O
remains	O
a	O
major	O
problem	O
in	O
the	O
chemotherapeutic	B-T061
treatment	I-T061
of	O
cancer	B-T191
and	O
might	O
be	O
overcome	O
by	O
inhibition	O
of	O
the	O
transporter	O
.	O
Because	O
of	O
the	O
lack	O
of	O
understanding	O
,	O
the	O
complex	O
mechanisms	O
involved	O
in	O
the	O
transport	O
process	O
,	O
in	O
particular	O
for	O
breast	O
cancer	O
resistance	O
protein	O
(	O
BCRP	O
/	O
ABCG2	O
)	O
,	O
there	O
is	O
a	O
persistent	O
need	O
for	O
studies	O
of	O
inhibitors	O
of	O
ABCG2	O
.	O
In	O
this	O
study	O
,	O
we	O
investigated	O
a	O
systematic	O
series	O
of	O
4	O
-	O
substituted-2	O
-	O
pyridylquinazolines	O
in	O
terms	O
of	O
their	O
inhibitory	O
potency	O
as	O
well	O
as	O
selectivity	O
toward	O
ABCG2	O
.	O
For	O
comparison	O
,	O
the	O
quinazoline	O
scaffold	O
was	O
reduced	O
to	O
the	O
significantly	O
smaller	O
4	O
-	O
methylpyrimidine	O
basic	O
structure	O
.	O
Furthermore	O
,	O
the	O
cytotoxicity	O
and	O
the	O
ability	O
to	O
reverse	O
MDR	O
was	O
tested	O
with	O
the	O
chemotherapeutic	B-T121
agents	I-T121
SN-38	B-T121
and	O
mitoxantrone	B-T121
(	O
MX	B-T121
)	O
.	O
Interaction	O
of	O
the	O
compounds	O
with	O
ABCG2	O
was	O
investigated	O
by	O
a	O
colorimetric	B-T059
ATPase	O
assay	B-T059
.	O
Enzyme	O
kinetic	O
studies	O
were	O
carried	O
out	O
with	O
Hoechst	B-T121
33342	I-T121
as	O
fluorescent	O
dye	O
and	O
substrate	O
of	O
ABCG2	O
to	O
elucidate	O
the	O
compounds	O
binding	O
modes	O
.	O
      
nursingstandard.com	O
1	O
Nurse	O
Donna	O
Wood	O
has	O
been	O
suspended	O
for	O
2	O
months	O
by	O
the	O
Nursing	O
and	O
Midwifery	O
Council	O
(	O
NMC	O
)	O
for	O
concealing	O
the	O
high	B-T184
temperature	I-T184
of	O
colleague	O
Pauline	O
Cafferkey	O
,	O
who	O
later	O
developed	O
Ebola	B-T047
.	O
Read	O
more	O
:	O
rcni.com/donna-wood	O
.	O
      
Voices	O
:	O
A	O
Conversation	O
with	O
Allen	O
J.	O
Wilcox	O
Allen	O
James	O
Wilcox	O
was	O
born	O
on	O
30	O
September	O
1946	O
in	O
Columbus	O
,	O
OH	O
.	O
He	O
studied	O
medicine	O
at	O
the	O
University	O
of	O
Michigan	O
,	O
graduated	O
in	O
1973	O
,	O
and	O
after	O
a	O
rotating	O
internship	O
,	O
he	O
completed	B-T033
a	I-T033
master	I-T033
's	I-T033
degree	I-T033
in	O
maternal	O
and	O
child	O
health	O
(	O
1976	O
)	O
and	O
a	O
PhD	O
in	O
epidemiology	O
(	O
1979	O
)	O
at	O
the	O
University	O
of	O
North	O
Carolina	O
in	O
Chapel	O
Hill	O
.	O
After	O
graduation	O
,	O
he	O
went	O
to	O
work	O
at	O
the	O
National	O
Institute	O
of	O
Environmental	O
Health	O
Sciences	O
(	O
NIEHS	O
,	O
one	O
of	O
the	O
US	O
National	O
Institutes	O
of	O
Health	O
)	O
in	O
Durham	O
,	O
NC	O
,	O
where	O
he	O
has	O
spent	O
his	O
career	O
.	O
He	O
developed	O
a	O
research	O
program	O
in	O
reproductive	O
and	O
perinatal	O
epidemiology	O
,	O
a	O
relatively	O
unexplored	O
area	O
at	O
the	O
time	O
.	O
His	O
studies	O
include	O
the	O
early	B-T047
pregnancy	I-T047
study	O
,	O
which	O
documented	B-T058
the	O
extent	O
of	O
subclinical	O
pregnancy	O
loss	O
in	O
humans	O
and	O
established	O
the	O
fertile	O
days	O
of	O
a	O
woman	O
's	O
menstrual	O
cycle	O
.	O
He	O
served	O
as	O
the	O
Chief	O
of	O
the	O
Epidemiology	O
Branch	O
from	O
1991	O
to	O
2001	O
,	O
and	O
as	O
Editor	O
-	O
in	O
-	O
Chief	O
of	O
the	O
journal	O
EPIDEMIOLOGY	O
from	O
2001	O
to	O
2014	O
.	O
His	O
textbook	O
,	O
Fertility	O
and	O
Pregnancy	O
-	O
An	O
Epidemiologic	O
Perspective	O
,	O
was	O
published	O
by	O
Oxford	O
University	O
Press	O
in	O
2010	O
.	O
He	O
was	O
elected	O
to	O
the	O
American	O
Epidemiological	O
Society	O
in	O
1989	O
,	O
and	O
served	O
as	O
its	O
president	O
in	O
2003	O
.	O
He	O
also	O
served	O
as	O
president	O
of	O
the	O
Society	O
of	O
Pediatric	O
and	O
Perinatal	O
Epidemiological	O
Research	O
(	O
1996	O
)	O
and	O
the	O
president	O
of	O
the	O
Society	O
of	O
Epidemiological	O
Research	O
(	O
1998	O
)	O
.	O
He	O
holds	O
adjunct	O
teaching	O
appointments	O
at	O
the	O
University	O
of	O
North	O
Carolina	O
,	O
Harvard	O
University	O
,	O
and	O
the	O
University	O
of	O
Bergen	O
(	O
Norway	O
)	O
,	O
which	O
awarded	O
him	O
an	O
honorary	O
doctoral	O
degree	O
in	O
2008	O
.	O
      
The	O
role	O
of	O
miR-451	O
in	O
the	O
switching	O
between	O
proliferation	O
and	O
migration	O
in	O
malignant	B-T191
glioma	I-T191
cells	O
:	O
AMPK	B-T121
signaling	O
,	O
mTOR	O
modulation	O
and	O
Rac1	O
activation	O
required	O
Glioblastoma	B-T191
multiforme	I-T191
(	O
GBM	B-T191
)	O
,	O
WHO	B-T191
grade	I-T191
IV	I-T191
astrocytoma	I-T191
,	O
is	O
the	O
most	O
common	O
primary	B-T191
neoplasm	I-T191
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
and	O
has	O
the	O
highest	O
malignancy	B-T191
and	O
mortality	O
rates	O
.	O
The	O
invasive	O
nature	O
of	O
GBM	B-T191
complicates	O
surgical	B-T061
resection	I-T061
and	O
restricts	O
chemotherapeutic	B-T061
access	I-T061
,	O
contributing	O
to	O
poor	O
patient	O
prognosis	B-T058
.	O
The	O
migration	O
of	O
tumor	O
cells	O
is	O
closely	O
related	O
to	O
the	O
tumor	O
cell	O
proliferation	O
.	O
The	O
acquisition	O
of	O
migratory	O
capability	O
,	O
in	O
addition	O
to	O
intracellular	O
factors	O
,	O
is	O
proposed	O
to	O
be	O
a	O
crucial	O
mechanism	O
during	O
the	O
progression	O
of	O
invasion	B-T033
.	O
Using	O
qRT	O
-	O
PCR	O
analysis	O
,	O
we	O
determined	O
that	O
the	O
expression	O
of	O
miR-451	O
in	O
glioma	B-T191
tissue	O
was	O
lower	O
than	O
in	O
control	B-T023
brain	I-T023
tissue	I-T023
,	O
especially	O
in	O
the	O
central	O
portions	O
of	O
the	O
tumor	B-T191
.	O
In	O
glioma	B-T191
cell	O
lines	O
,	O
we	O
found	O
that	O
decreased	O
miR-451	O
expression	O
suppressed	O
tumor	O
cell	O
proliferation	O
but	O
enhanced	O
migration	O
with	O
a	O
concomitant	O
low	O
level	O
of	O
CAB39	O
/	O
AMPK	B-T121
/	O
mTOR	O
pathway	O
activation	O
and	O
high	O
level	O
of	O
Rac1	O
/	O
cofilin	O
pathway	O
activation	O
,	O
respectively	O
.	O
Notably	O
,	O
the	O
effect	O
of	O
miR-451	O
on	O
cytological	O
behavior	O
and	O
on	O
the	O
activation	O
of	O
mTOR	O
and	O
Rac1	O
was	O
limited	O
when	O
AMPKα1	O
expression	O
was	O
knocked	O
-	O
down	O
with	O
a	O
synthetic	O
shRNA	O
.	O
We	O
suggest	O
that	O
the	O
glioma	B-T191
microenvironment	O
results	O
in	O
heterogeneity	O
of	O
miR-451	O
expression	O
.	O
Our	O
data	O
indicated	O
that	O
miR-451	O
relays	O
environmental	O
signals	O
by	O
upregulating	O
the	O
activity	O
of	O
AMPK	B-T121
signaling	O
,	O
thereby	O
modulating	O
the	O
activation	O
of	O
mTOR	O
and	O
Rac1	O
/	O
cofilin	O
which	O
,	O
in	O
turn	O
,	O
play	O
key	O
roles	O
in	O
glioma	B-T191
cell	O
proliferation	O
and	O
migration	O
,	O
respectively	O
.	O
Our	O
results	O
highlight	O
the	O
need	O
to	O
consider	O
opposing	O
roles	O
of	O
a	O
therapeutic	O
target	O
which	O
,	O
while	O
suppressing	O
tumor	O
cell	O
proliferation	O
,	O
could	O
also	O
promote	O
cell	O
infiltration	O
.	O
      
The	O
role	O
of	O
P2X7	O
receptors	O
in	O
a	O
rodent	O
PCP	B-T121
-	O
induced	O
schizophrenia	B-T048
model	B-T050
P2X7	O
receptors	O
(	O
P2X7Rs	O
)	O
are	O
ligand	O
-	O
gated	O
ion	O
channels	O
sensitive	O
to	O
extracellular	O
ATP	B-T121
.	O
Here	O
we	O
examined	B-T033
for	O
the	O
first	O
time	O
the	O
role	O
of	O
P2X7R	O
in	O
an	O
animal	O
model	O
of	O
schizophrenia	B-T048
.	O
Using	O
the	O
PCP	B-T121
induced	O
schizophrenia	B-T048
model	B-T050
we	O
show	O
that	O
both	O
genetic	O
deletion	O
and	O
pharmacological	O
inhibition	O
of	O
P2X7Rs	O
alleviate	O
schizophrenia	B-T033
-	I-T033
like	I-T033
behavioral	O
alterations	O
.	O
In	O
P2rx7+/+	O
mice	O
,	O
PCP	B-T121
induced	O
hyperlocomotion	B-T033
,	O
stereotype	B-T048
behavior	I-T048
,	O
ataxia	B-T184
and	O
social	B-T033
withdrawal	I-T033
.	O
In	O
P2X7	O
receptor	O
deficient	O
mice	O
(	O
P2rx7-/-	O
)	O
,	O
the	O
social	B-T033
interactions	I-T033
were	O
increased	O
,	O
whereas	O
the	O
PCP	B-T121
induced	O
hyperlocomotion	B-T033
and	O
stereotype	B-T048
behavior	I-T048
were	O
alleviated	O
.	O
The	O
selective	O
P2X7	B-T121
receptor	I-T121
antagonist	I-T121
JNJ-47965567	B-T121
partly	O
replicated	O
the	O
effect	O
of	O
gene	O
deficiency	O
on	O
PCP	B-T121
-	O
induced	O
behavioral	O
changes	O
and	O
counteracted	O
PCP	B-T121
-	O
induced	O
social	B-T033
withdrawal	I-T033
.	O
We	O
also	O
show	O
that	O
PCP	B-T121
treatment	O
upregulates	O
and	O
increases	O
the	O
functional	O
responsiveness	O
of	O
P2X7Rs	O
in	O
the	O
prefrontal	B-T023
cortex	I-T023
of	O
young	O
adult	O
animals	O
.	O
The	O
amplitude	O
of	O
NMDA	O
evoked	O
currents	O
recorded	O
from	O
layer	O
V	O
pyramidal	O
neurons	O
of	O
cortical	B-T023
slices	O
were	O
slightly	O
decreased	O
by	O
both	O
genetic	O
deletion	O
of	O
P2rx7	O
and	O
by	O
JNJ-47965567	B-T121
.	O
PCP	B-T121
induced	O
alterations	O
in	O
mRNA	O
expression	O
encoding	O
schizophrenia	B-T048
-	I-T048
related	I-T048
genes	O
,	O
such	O
as	O
NR2A	O
,	O
NR2B	O
,	O
neuregulin	O
1	O
,	O
NR1	O
and	O
GABA	O
α1	O
subunit	O
were	O
absent	O
in	O
the	O
PFC	O
of	O
young	O
adult	O
P2rx7-/-	O
animals	B-T050
.	O
Our	O
findings	B-T033
point	O
to	O
P2X7R	O
as	O
a	O
potential	O
therapeutic	O
target	O
in	O
schizophrenia	B-T048
.	O
      
Functional	O
adaptation	O
of	O
crustacean	O
exoskeletal	B-T023
elements	O
through	O
structural	O
and	O
compositional	O
diversity	O
:	O
a	O
combined	O
experimental	O
and	O
theoretical	O
study	O
The	O
crustacean	O
cuticle	O
is	O
a	O
composite	O
material	O
that	O
covers	O
the	O
whole	O
animal	O
and	O
forms	O
the	O
continuous	B-T023
exoskeleton	I-T023
.	O
Nano	O
-	O
fibers	O
composed	O
of	O
chitin	O
and	O
protein	O
molecules	O
form	O
most	O
of	O
the	O
organic	O
matrix	B-T121
of	O
the	O
cuticle	O
that	O
,	O
at	O
the	O
macroscale	O
,	O
is	O
organized	O
in	O
up	O
to	O
eight	O
hierarchical	O
levels	O
.	O
At	O
least	O
two	O
of	O
them	O
,	O
the	O
exo-	O
and	O
endocuticle	O
,	O
contain	O
a	O
mineral	O
phase	O
of	O
mainly	O
Mg	O
-	O
calcite	O
,	O
amorphous	O
calcium	B-T121
carbonate	I-T121
and	O
phosphate	B-T121
.	O
The	O
high	O
number	O
of	O
hierarchical	O
levels	O
and	O
the	O
compositional	O
diversity	O
provide	O
a	O
high	O
degree	O
of	O
freedom	O
for	O
varying	O
the	O
physical	O
,	O
in	O
particular	O
mechanical	O
,	O
properties	O
of	O
the	O
material	O
.	O
This	O
makes	O
the	O
cuticle	O
a	O
versatile	O
material	O
ideally	O
suited	O
to	O
form	O
a	O
variety	O
of	O
skeletal	O
elements	O
that	O
are	O
adapted	O
to	O
different	O
functions	O
and	O
the	O
eco	B-T001
-	I-T001
physiological	I-T001
strains	I-T001
of	O
individual	O
species	O
.	O
This	O
review	O
presents	O
our	O
recent	O
analytical	O
,	O
experimental	O
and	O
theoretical	O
studies	O
on	O
the	O
cuticle	O
,	O
summarising	O
at	O
which	O
hierarchical	O
levels	O
structure	O
and	O
composition	O
are	O
modified	O
to	O
achieve	O
the	O
required	O
physical	O
properties	O
.	O
We	O
describe	O
our	O
multi	O
-	O
scale	O
hierarchical	O
modeling	O
approach	O
based	O
on	O
the	O
results	O
from	O
these	O
studies	O
,	O
aiming	O
at	O
systematically	O
predicting	O
the	O
structure	O
-	O
composition	O
-	O
property	O
relations	O
of	O
cuticle	O
composites	O
from	O
the	O
molecular	O
level	O
to	O
the	O
macro	O
-	O
scale	O
.	O
This	O
modeling	O
approach	O
provides	O
a	O
tool	O
to	O
facilitate	O
the	O
development	O
of	O
optimized	O
biomimetic	O
materials	O
within	O
a	O
knowledge	O
-	O
based	O
design	O
approach	O
.	O
      
Mechanisms	O
of	O
Global	O
Cerebral	O
Edema	O
Formation	O
in	O
Aneurysmal	O
Subarachnoid	O
Hemorrhage	O
A	O
growing	O
body	O
of	O
clinical	O
literature	O
emphasizes	O
the	O
impact	O
of	O
cerebral	O
edema	O
in	O
early	O
brain	O
injury	O
following	O
aneurysmal	O
subarachnoid	O
hemorrhage	O
(	O
aSAH	O
)	O
.	O
Aneurysm	B-T047
rupture	I-T047
itself	O
initiates	O
global	O
cerebral	O
edema	O
in	O
up	O
to	O
two	O
thirds	O
of	O
cases	O
.	O
Although	O
cerebral	O
edema	O
is	O
not	O
a	O
universal	O
feature	O
of	O
aSAH	O
,	O
it	O
portends	O
a	O
poor	O
clinical	O
course	O
,	O
with	O
quantitative	O
analysis	O
revealing	O
a	O
direct	O
correlation	O
between	O
cerebral	O
edema	O
and	O
poor	B-T033
outcome	I-T033
,	O
including	O
mortality	O
and	O
cognitive	O
deficits	O
.	O
Mechanistically	O
,	O
global	O
cerebral	O
edema	O
has	O
been	O
linked	O
to	O
global	O
ischemia	O
at	O
the	O
time	O
of	O
aneurysm	B-T047
rupture	I-T047
,	O
dysfunction	O
of	O
autoregulation	O
,	O
blood	O
breakdown	O
products	O
,	O
neuroinflammation	O
,	O
and	O
hyponatremia	B-T047
/	O
endocrine	B-T190
abnormalities	I-T190
.	O
At	O
a	O
molecular	O
level	O
,	O
several	O
culprits	O
have	O
been	O
identified	O
,	O
including	O
aquaporin-4	O
,	O
matrix	O
metalloproteinase-9	O
,	O
SUR1	O
-	O
TRPM4	O
cation	O
channels	O
,	O
vascular	O
endothelial	O
growth	O
factor	O
,	O
bradykinin	O
,	O
and	O
others	O
.	O
Here	O
,	O
we	O
review	O
these	O
cellular	O
and	O
molecular	O
mechanisms	O
of	O
global	O
cerebral	O
edema	O
formation	O
in	O
aSAH	O
.	O
Given	O
the	O
importance	O
of	O
edema	B-T184
to	O
the	O
outcome	O
of	O
patients	O
with	O
aSAH	O
and	O
its	O
status	O
as	O
a	O
highly	O
modifiable	O
pathological	O
process	O
,	O
a	O
better	O
understanding	O
of	O
cerebral	O
edema	O
in	O
aSAH	O
promises	O
to	O
hasten	O
the	O
development	O
of	O
medical	B-T061
therapies	I-T061
to	O
improve	O
outcomes	O
in	O
this	O
frequently	O
devastating	O
disease	B-T047
.	O
      
Association	O
of	O
Exclusive	O
Breastfeeding	O
Duration	O
With	O
Systemic	B-T047
Inflammation	I-T047
Markers	O
in	O
Adolescents	O
:	O
A	O
Cross	O
-	O
Sectional	O
Study	O
Breastfeeding	B-T033
duration	I-T033
has	O
been	O
associated	O
with	O
less	O
low	O
-	O
grade	O
inflammation	O
in	O
healthy	O
adolescents	O
,	O
but	O
there	O
is	O
scarce	O
information	O
regarding	O
obese	B-T047
subjects	O
.	O
This	O
study	O
aimed	O
to	O
evaluate	O
whether	O
exclusive	O
breastfeeding	O
is	O
related	O
to	O
serum	O
concentrations	O
of	O
inflammatory	O
markers	O
in	O
a	O
population	O
of	O
Spanish	O
adolescents	O
.	O
A	O
cross	O
-	O
sectional	O
study	O
was	O
performed	O
on	O
1,001	O
adolescents	O
(	O
13.2	O
±	O
1.2	O
years	O
)	O
randomly	O
recruited	O
from	O
schools	O
in	O
southeast	O
Spain	O
.	O
Data	O
on	O
breastfeeding	B-T033
duration	I-T033
were	O
collected	O
via	O
a	O
parental	O
questionnaire	O
.	O
Interleukin-6	O
(	O
IL-6	O
)	O
and	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
α	O
)	O
were	O
determined	O
by	O
enzyme	B-T059
-	I-T059
linked	I-T059
immunosorbent	I-T059
assay	I-T059
.	O
C	O
-	O
reactive	O
protein	O
(	O
CRP	O
)	O
was	O
determined	O
by	O
solid	B-T059
-	I-T059
phase	I-T059
chemiluminescent	I-T059
immunometric	I-T059
assay	I-T059
.	O
Nonadjusted	O
and	O
adjusted	O
multivariate	O
correlation	O
analyses	O
confirmed	O
a	O
strong	O
association	O
(	O
p	O
<	O
.001	O
,	O
95	O
%	O
confidence	O
interval	O
)	O
between	O
the	O
three	O
markers	O
of	O
inflammation	O
and	O
exclusive	O
breastfeeding	O
duration	O
.	O
No	B-T033
significant	I-T033
differences	O
were	O
observed	O
for	O
IL-6	O
,	O
TNF	O
-	O
α	O
,	O
and	O
CRP	O
serum	O
concentrations	O
among	O
normal	O
weight	O
,	O
overweight	B-T184
,	O
and	O
obese	B-T047
adolescents	O
,	O
except	O
for	O
IL-6	O
between	O
normal	O
weight	O
and	O
obese	B-T047
subjects	O
.	O
Likewise	O
,	O
no	B-T033
significant	I-T033
association	O
was	O
found	B-T033
between	O
these	O
markers	O
of	O
inflammation	O
and	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
z	O
-	O
score	O
.	O
We	O
found	B-T033
a	O
possible	B-T033
association	O
between	O
inflammatory	O
markers	O
and	O
exclusive	O
breastfeeding	O
duration	O
in	O
adolescents	O
,	O
regardless	O
of	O
their	O
BMI	O
.	O
This	O
finding	B-T033
suggests	O
that	O
increased	O
body	O
weight	O
or	O
obesity	B-T047
might	O
not	O
mediate	O
the	O
association	O
between	O
breastfeeding	O
and	O
inflammation	O
.	O
These	O
results	O
contribute	O
to	O
the	O
understanding	O
of	O
the	O
relationship	O
between	O
breastfeeding	O
and	O
inflammatory	O
markers	O
in	O
adolescents	O
.	O
      
The	O
construction	O
of	O
three	O
-	O
dimensional	O
composite	O
fibrous	O
macrostructures	O
with	O
nanotextures	O
for	O
biomedical	O
applications	O
The	O
development	O
of	O
modern	O
biomedical	O
nanotechnology	O
requires	O
three	O
-	O
dimensional	O
macrostructures	O
with	O
nanotextures	O
to	O
meet	O
the	O
requirements	O
for	O
practical	O
applications	O
in	O
intricate	O
biological	O
systems	O
.	O
Additionally	O
,	O
the	O
restoration	O
and	O
regeneration	O
of	O
some	O
specific	O
body	O
tissues	O
and	O
organs	B-T023
rely	O
on	O
the	O
function	O
of	O
conductive	O
polymers	O
,	O
which	O
can	O
provide	O
electrical	O
cues	O
for	O
cells	O
.	O
In	O
this	O
study	O
,	O
we	O
fabricated	O
three	O
-	O
dimensional	O
composite	O
nanofibre	O
macrostructures	O
of	O
polycaprolactone	O
(	O
PCL	O
)	O
with	O
different	O
concentrations	O
of	O
polyaniline	O
(	O
PANi	O
)	O
by	O
employing	O
an	O
improved	O
electrospinning	O
technology	O
with	O
a	O
specially	O
designed	O
collector	O
.	O
The	O
3D	O
structures	O
possessed	O
cap	O
-	O
like	O
macrostructures	O
with	O
centimetre	O
-	O
scale	O
thickness	O
and	O
interconnected	O
pore	O
nanotextures	O
with	O
nanometre	O
-	O
scale	O
nanofibres	O
.	O
To	O
estimate	O
the	O
biocompatibility	O
of	O
the	O
3D	O
PCL	O
/	O
PANi	O
composite	O
nanofibre	O
macrostructures	O
,	O
mouse	O
myoblasts	O
(	O
C2C12	O
cells	O
)	O
were	O
cultured	O
as	O
model	B-T050
cells	O
.	O
The	O
initial	O
responses	O
of	O
C2C12	O
cells	O
to	O
the	O
3D	O
PCL	O
/	O
PANi	O
composite	O
macrostructures	O
were	O
significantly	O
superior	O
to	O
those	O
to	O
pure	O
PCL	O
,	O
that	O
is	O
,	O
the	O
cells	O
exhibited	O
typical	O
myoblast	O
-	O
like	O
morphologies	O
with	O
obvious	O
pseudopodia	O
and	O
the	O
moderate	O
incorporation	O
(	O
less	O
than	O
2.0	O
wt%	O
)	O
of	O
conductive	O
PANi	O
facilitated	O
cell	O
proliferation	O
,	O
which	O
indicated	O
that	O
PANi	O
has	O
appreciable	O
cell	O
affinity	O
.	O
Moreover	O
,	O
the	O
addition	O
of	O
conductive	O
PANi	O
to	O
the	O
3D	O
composite	O
nanofibre	O
macrostructures	O
considerably	O
enhanced	O
myoblast	O
differentiation	O
and	O
myotube	O
maturation	O
.	O
These	O
results	O
suggest	O
that	O
electrospun	O
3D	O
PCL	O
/	O
PANi	O
composite	O
nanofibre	O
macrostructures	O
would	O
have	O
promising	O
applications	O
in	O
tissue	B-T061
engineering	I-T061
.	O
      
Chordoma	B-T191
dedifferentiation	I-T191
after	O
proton	B-T061
beam	I-T061
therapy	I-T061
:	O
a	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
Chordoma	B-T191
is	O
a	O
rare	O
invasive	O
bone	B-T191
tumor	I-T191
that	O
may	O
occur	O
anywhere	O
along	O
the	O
neuraxis	O
.	O
A	O
total	O
of	O
three	O
primary	O
histological	B-T191
varieties	I-T191
have	O
been	O
identified	O
:	O
conventional	B-T191
,	O
chondroid	B-T191
,	O
and	O
dedifferentiated	B-T191
.	O
We	O
report	O
a	O
case	O
of	O
an	O
8	O
-	O
year	O
-	O
old	O
white	O
girl	O
who	O
presented	O
with	O
conventional	B-T191
chordoma	I-T191
,	O
was	O
treated	B-T033
with	O
surgical	B-T061
resection	I-T061
and	O
mixed	O
proton	O
and	O
photon	B-T061
beam	I-T061
therapy	I-T061
,	O
and	O
had	O
a	O
recurrence	O
in	O
the	O
resection	B-T020
cavity	I-T020
2.5	O
years	O
later	O
with	O
dedifferentiated	B-T191
morphology	I-T191
.	O
The	O
recurrent	B-T191
tumor	I-T191
did	O
not	O
express	O
brachyury	O
,	O
a	O
recently	O
identified	O
protein	O
specific	O
to	O
tissue	O
of	O
notochordal	B-T018
origin	O
.	O
The	O
short	O
time	O
period	O
between	O
radiation	B-T061
therapy	I-T061
and	O
dedifferentiation	O
,	O
low	O
dose	O
of	O
photons	O
,	O
and	O
rarity	O
of	O
dedifferentiated	B-T191
skull	I-T191
base	I-T191
chordomas	I-T191
in	O
pediatric	O
patients	O
should	O
alert	O
clinicians	O
to	O
the	O
possibility	B-T033
of	O
chordoma	B-T191
dedifferentiation	I-T191
after	O
proton	B-T061
beam	I-T061
therapy	I-T061
.	O
      
Evaluation	B-T058
of	O
Spontaneous	O
Bone	O
Regeneration	O
after	O
Enucleation	B-T061
of	O
Large	O
Cysts	B-T047
of	O
the	O
Jaws	B-T023
using	O
Radiographic	O
Computed	B-T059
Software	O
Spontaneous	O
regeneration	O
of	O
bone	O
is	O
commonly	O
seen	O
in	O
the	O
small	O
surgical	B-T061
defects	O
caused	O
by	O
enucleation	B-T061
of	O
cysts	B-T047
.	O
However	O
,	O
in	O
case	O
of	O
large	O
surgical	B-T061
defects	O
caused	O
by	O
the	O
enucleation	B-T061
,	O
spontaneous	O
regeneration	O
of	O
bone	O
is	O
a	O
rare	O
phenomenon	O
and	O
it	O
depends	O
on	O
factors	O
,	O
such	O
as	O
age	O
of	O
the	O
patient	O
,	O
intact	O
periosteum	O
,	O
and	O
proper	O
stabilization	B-T061
.	O
The	O
study	O
included	O
16	O
patients	O
,	O
who	O
reported	B-T058
to	O
the	O
department	O
of	O
oral	O
and	O
maxillofacial	O
surgery	O
with	O
the	O
complaint	B-T047
of	O
pain	B-T184
and	O
swelling	B-T033
in	O
the	O
jaws	B-T023
diagnosed	B-T033
as	O
cyst	B-T047
.	O
The	O
sample	O
included	O
equal	O
numbers	O
of	O
male	O
and	O
female	O
subjects	O
aged	O
between	O
15	O
and	O
40	O
years	O
.	O
Panoramic	B-T060
radiographs	I-T060
were	O
taken	O
pre-	O
and	O
postoperatively	O
on	O
day	O
2	O
of	O
the	O
enucleation	B-T061
.	O
The	O
dimensions	O
of	O
the	O
cyst	B-T047
were	O
evaluated	B-T058
on	O
the	O
radiograph	B-T060
according	O
to	O
the	O
proforma	O
.	O
Subsequent	O
radiographs	B-T060
were	O
taken	O
at	O
regular	O
intervals	O
of	O
1.5	O
,	O
3	O
,	O
and	O
6	O
months	O
using	O
standard	O
parameters	O
and	O
were	O
analyzed	O
using	O
MCID	O
™	O
analysis	O
software	O
of	O
imaging	B-T060
research	I-T060
.	O
Mean	O
reduction	B-T061
was	O
seen	O
in	O
up	O
to	O
39	O
and	O
60	O
%	O
in	O
the	O
cystic	O
cavity	B-T190
size	O
and	O
increase	O
in	O
the	O
mean	O
density	O
up	O
to	O
59	O
and	O
90.2	O
%	O
at	O
3	O
and	O
6	O
months	O
intervals	O
respectively	O
.	O
Spontaneous	O
bone	O
regeneration	O
was	O
seen	O
even	O
after	O
primary	O
closure	B-T061
of	O
the	O
large	O
cystic	O
defect	O
without	O
the	O
need	O
for	O
placement	B-T058
of	O
foreign	O
substances	O
or	O
grafts	O
and	O
it	O
also	O
eliminated	O
the	O
complications	O
resulting	O
from	O
placement	B-T058
of	O
foreign	O
substance	O
.	O
Further	O
studies	O
are	O
required	O
in	O
a	O
larger	O
sample	O
with	O
longer	O
follow	B-T058
-	I-T058
up	I-T058
durations	O
to	O
confirm	O
the	O
outcome	O
of	O
the	O
present	O
work	O
for	O
the	O
benefit	O
of	O
patients	O
.	O
The	O
present	O
study	O
depicted	O
that	O
spontaneous	O
bone	O
regeneration	O
can	O
occur	O
with	O
accepted	O
results	B-T033
after	O
simple	O
enucleation	B-T061
of	O
jaw	B-T023
cyst	B-T047
without	O
the	O
aid	O
of	O
any	O
graft	O
material	O
.	O
Hence	O
,	O
simple	O
enucleation	B-T061
may	O
be	O
considered	O
as	O
a	O
first	B-T061
line	I-T061
of	I-T061
treatment	I-T061
modality	O
for	O
cystic	O
lesion	B-T033
of	O
the	O
jaws	B-T023
.	O
This	O
simplifies	O
the	O
surgical	B-T061
procedure	I-T061
,	O
decreases	O
the	O
economic	O
and	O
biologic	O
costs	O
,	O
and	O
reduces	B-T061
the	O
risk	O
of	O
postoperative	O
complications	O
.	O
Follow	B-T058
-	I-T058
up	I-T058
is	O
necessary	O
along	O
with	O
patient	O
's	O
compliance	O
for	O
the	O
success	O
of	O
treatment	O
.	O
      
Impact	O
of	O
cofactor	O
-	O
binding	O
loop	O
mutations	O
on	O
thermotolerance	O
and	O
activity	O
of	O
E.	B-T007
coli	I-T007
transketolase	O
Improvement	O
of	O
thermostability	O
in	O
engineered	O
enzymes	O
can	O
allow	O
biocatalysis	O
on	O
substrates	O
with	O
poor	O
aqueous	O
solubility	O
.	O
Denaturation	O
of	O
the	O
cofactor	O
-	O
binding	O
loops	O
of	O
Escherichia	B-T007
coli	I-T007
transketolase	O
(	O
TK	O
)	O
was	O
previously	O
linked	O
to	O
the	O
loss	O
of	O
enzyme	O
activity	O
under	O
conditions	O
of	O
high	O
pH	O
or	O
urea	B-T121
.	O
Incubation	B-T059
at	O
temperatures	O
just	O
below	O
the	O
thermal	O
melting	O
transition	O
,	O
above	O
which	O
the	O
protein	O
aggregates	O
,	O
was	O
also	O
found	O
to	O
anneal	O
the	O
enzyme	O
to	O
give	O
an	O
increased	O
specific	O
activity	O
.	O
The	O
potential	O
role	O
of	O
cofactor	O
-	O
binding	O
loop	O
instability	B-T033
in	O
this	O
process	O
remained	O
unclear	O
.	O
In	O
this	O
work	O
,	O
the	O
two	O
cofactor	O
-	O
binding	O
loops	O
(	O
residues	O
185	O
-	O
192	O
and	O
382	O
-	O
392	O
)	O
were	O
progressively	O
mutated	O
towards	O
the	O
equivalent	O
sequence	O
from	O
the	O
thermostable	O
Thermus	B-T007
thermophilus	I-T007
TK	O
and	O
variants	O
assessed	O
for	O
their	O
impact	O
on	O
both	O
thermostability	O
and	O
activity	O
.	O
Cofactor	O
-	O
binding	O
loop	O
2	O
variants	O
had	O
detrimental	O
effects	O
on	O
specific	O
activity	O
at	O
elevated	O
temperatures	O
,	O
whereas	O
the	O
H192P	O
mutation	O
in	O
cofactor	O
-	O
binding	O
loop	O
1	O
resulted	O
in	O
a	O
two	O
-	O
fold	O
improved	O
stability	O
to	O
inactivation	O
at	O
elevated	O
temperatures	O
,	O
and	O
increased	O
the	O
critical	O
onset	O
temperature	O
for	O
aggregation	O
.	O
The	O
specific	O
activity	O
of	O
H192P	O
was	O
3	O
-	O
fold	O
and	O
19	O
-	O
fold	O
higher	O
than	O
that	O
for	O
wild	O
-	O
type	O
at	O
60	O
°	O
C	O
and	O
65	O
°	O
C	O
respectively	O
,	O
and	O
also	O
remained	O
2.7	O
-	O
4	O
fold	O
higher	O
after	O
re	O
-	O
cooling	O
from	O
pre	B-T059
-	I-T059
incubations	I-T059
at	O
either	O
55	O
°	O
C	O
or	O
60	O
°	O
C	O
for	O
1h	O
.	O
Interestingly	O
,	O
H192P	O
was	O
also	O
2	O
-	O
times	O
more	O
active	O
than	O
wild	O
-	O
type	O
TK	O
at	O
25	O
°	O
C	O
.	O
Optimal	O
activity	O
was	O
achieved	O
at	O
60	O
°	O
C	O
for	O
H192P	O
compared	O
to	O
55	O
°	O
C	O
for	O
wild	O
type	O
.	O
These	O
results	O
show	O
that	O
cofactor	O
-	O
binding	O
loop	O
1	O
,	O
plays	O
a	O
pivotal	O
role	O
in	O
partial	O
denaturation	O
and	O
aggregation	O
at	O
elevated	O
temperatures	O
.	O
Furthermore	O
,	O
a	O
single	O
rigidifying	O
mutation	O
within	O
this	O
loop	O
can	O
significantly	O
improve	O
the	O
enzyme	O
specific	O
activity	O
,	O
as	O
well	O
as	O
the	O
stability	O
to	O
thermal	O
denaturation	O
and	O
aggregation	O
,	O
to	O
give	O
an	O
increased	O
temperature	O
optimum	O
for	O
activity	O
.	O
      
Draft	O
Genome	O
Sequence	O
of	O
the	O
Soil	O
Isolate	O
Lysinibacillus	B-T007
fusiformis	I-T007
M5	I-T007
,	O
a	O
Potential	O
Hypoxanthine	O
Producer	O
Lysinibacillus	B-T007
fusiformis	I-T007
strain	I-T007
M5	I-T007
is	O
a	O
potential	O
hypoxanthine	O
producer	O
that	O
was	O
isolated	O
from	O
clay	O
soil	O
.	O
Here	O
,	O
we	O
present	O
the	O
draft	O
genome	O
sequence	O
that	O
was	O
annotated	O
in	O
order	O
to	O
facilitate	O
future	O
studies	O
of	O
L.	B-T007
fusiformis	I-T007
M5	I-T007
.	I-T007
      
Reliability	O
of	O
Fear	B-T058
Assessment	I-T058
in	O
Growing	B-T033
Pigs	O
Exposed	O
to	O
a	O
Novel	O
Object	O
Test	O
in	O
Commercial	O
Conditions	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
reliability	O
and	O
feasibility	O
of	O
a	O
novel	O
object	O
test	O
assessing	B-T058
fear	I-T058
in	O
pigs	O
in	O
commercial	O
conditions	O
.	O
A	O
total	O
of	O
18	O
commercial	O
farms	O
were	O
visited	O
,	O
and	O
321	O
pens	O
housing	O
4,220	O
growing	B-T033
pigs	O
were	O
assessed	O
.	O
Three	O
balloons	O
were	O
used	O
as	O
a	O
novel	O
stimulus	O
.	O
Measures	O
were	O
(	O
a	O
)	O
the	O
time	O
it	O
took	O
for	O
the	O
first	O
pig	O
to	O
contact	O
1	O
of	O
the	O
balloons	O
,	O
(	O
b	O
)	O
percentage	O
of	O
nonhuman	O
animals	O
watching	O
the	O
balloons	O
each	O
for	O
10	O
s	O
,	O
and	O
(	O
c	O
)	O
percentage	O
of	O
animals	O
touching	O
the	O
balloons	O
during	O
periods	O
of	O
5	O
s.	O
The	O
time	O
of	O
the	O
first	O
pig	O
to	O
contact	O
1	O
of	O
the	O
balloons	O
ranged	O
from	O
0	O
s	O
to	O
362	O
s.	O
An	O
effect	O
of	O
the	O
farm	O
was	O
found	O
(	O
p	O
<	O
.0001	O
)	O
for	O
contact	O
latency	O
,	O
ranging	O
from	O
6.8	O
s	O
to	O
73.3	O
s	O
,	O
but	O
little	O
difference	O
was	O
found	O
in	O
terms	O
of	O
intrafarm	O
variability	O
.	O
Interobserver	O
repeatability	O
was	O
also	O
high	O
in	O
this	O
measure	O
,	O
ranging	O
from	O
r	O
=	O
.74	O
to	O
r	O
=	O
.96	O
.	O
As	O
a	O
result	O
,	O
it	O
is	O
concluded	O
that	O
contact	O
latency	O
could	O
be	O
a	O
good	O
measure	O
to	O
assess	O
fear	O
of	O
a	O
novel	O
stimulus	O
in	O
commercial	O
farms	O
.	O
      
Differential	O
transcriptome	O
expression	O
in	O
human	O
nucleus	B-T023
accumbens	I-T023
as	O
a	O
function	O
of	O
loneliness	B-T033
Loneliness	B-T033
is	O
associated	O
with	O
impaired	O
mental	O
and	O
physical	O
health	O
.	O
Studies	O
of	O
lonely	O
individuals	O
reported	O
differential	O
expression	O
of	O
inflammatory	O
genes	O
in	O
peripheral	O
leukocytes	O
and	O
diminished	O
activation	O
in	O
brain	B-T023
reward	O
regions	O
such	O
as	O
nucleus	B-T023
accumbens	I-T023
,	O
but	O
could	O
not	O
address	O
gene	O
expression	O
in	O
the	O
human	O
brain	B-T023
.	O
Here	O
,	O
we	O
examined	O
genome	O
-	O
wide	O
RNA	O
expression	O
in	O
post	B-T060
-	I-T060
mortem	I-T060
nucleus	B-T023
accumbens	I-T023
from	O
donors	O
(	O
N=26	O
)	O
with	O
known	O
loneliness	B-T033
measures	O
.	O
Loneliness	B-T033
was	O
associated	O
with	O
1710	O
differentially	O
expressed	O
transcripts	O
and	O
genes	O
from	O
1599	O
genes	O
(	O
DEGs	O
;	O
false	O
discovery	O
rate	O
P<0.05	O
,	O
fold	O
change	O
⩾	O
      
Low	B-T033
literacy	I-T033
and	O
written	O
drug	O
information	O
:	O
information	B-T033
-	I-T033
seeking	I-T033
,	O
leaflet	O
evaluation	O
and	O
preferences	O
,	O
and	O
roles	O
for	O
images	O
Background	O
Low	O
-	O
literate	O
patients	O
are	O
at	O
risk	O
to	O
misinterpret	O
written	O
drug	O
information	O
.	O
For	O
the	O
(	O
co-	O
)	O
design	O
of	O
targeted	O
patient	O
information	O
,	O
it	O
is	O
key	O
to	O
involve	O
this	O
group	O
in	O
determining	O
their	O
communication	O
barriers	O
and	O
information	O
needs	O
.	O
Objective	O
To	O
gain	O
insight	O
into	O
how	O
people	O
with	O
low	B-T033
literacy	I-T033
use	O
and	O
evaluate	O
written	O
drug	O
information	O
,	O
and	O
to	O
identify	O
ways	O
in	O
which	O
they	O
feel	O
the	O
patient	O
leaflet	O
can	O
be	O
improved	O
,	O
and	O
in	O
particular	O
how	O
images	O
could	O
be	O
used	O
.	O
Setting	O
Food	O
banks	O
and	O
an	O
education	O
institution	O
for	O
Dutch	O
language	O
training	O
in	O
the	O
Netherlands	O
.	O
Method	O
Semi	O
-	O
structured	O
focus	O
groups	O
and	O
individual	O
interviews	O
were	O
held	O
with	O
low	O
-	O
literate	O
participants	O
(	O
n	O
=	O
45	O
)	O
.	O
The	O
thematic	O
framework	O
approach	O
was	O
used	O
for	O
analysis	O
to	O
identify	O
themes	O
in	O
the	O
data	O
.	O
Main	O
outcome	O
measure	O
Low	O
-	O
literate	O
people	O
's	O
experience	O
with	O
patient	O
information	O
leaflets	O
,	O
ideas	O
for	O
improvements	O
,	O
and	O
perceptions	O
on	O
possible	O
uses	O
for	O
visuals	O
.	O
Results	O
Patient	O
information	O
leaflets	O
were	O
considered	O
discouraging	O
to	O
use	O
,	O
and	O
information	O
difficult	O
to	O
find	O
and	O
understand	O
.	O
Many	O
rely	O
on	O
alternative	O
information	B-T033
sources	I-T033
.	O
The	O
leaflet	O
should	O
be	O
shorter	O
,	O
and	O
improved	O
in	O
terms	O
of	O
organisation	O
,	O
legibility	B-T033
and	O
readability	O
.	O
Participants	O
thought	O
images	O
could	O
increase	O
the	O
leaflet	O
's	O
appeal	O
,	O
help	O
ask	O
questions	O
,	O
provide	O
an	O
overview	O
,	O
help	O
understand	O
textual	O
information	O
,	O
aid	O
recall	O
,	O
reassure	O
,	O
and	O
even	O
lead	O
to	O
increased	O
confidence	O
,	O
empowerment	O
and	O
feeling	O
of	O
safety	O
.	O
Conclusion	O
Already	O
at	O
the	O
stages	O
of	O
paying	O
attention	O
to	O
the	O
leaflet	O
and	O
maintaining	O
interest	O
in	O
the	O
message	O
,	O
low	O
-	O
literate	O
patients	O
experience	O
barriers	O
in	O
the	O
communication	O
process	O
through	O
written	O
drug	O
information	O
.	O
Short	O
,	O
structured	O
,	O
visual	O
/	O
textual	O
explanations	O
can	O
lower	O
the	O
motivational	O
threshold	O
to	O
use	O
the	O
leaflet	O
,	O
improve	B-T033
understanding	O
,	O
and	O
empower	O
the	O
low	O
-	O
literate	O
target	O
group	O
.	O
      
Sex	O
differences	O
in	O
the	O
effect	O
of	O
chronic	O
mild	O
stress	O
on	O
mouse	O
prefrontal	B-T023
cortical	I-T023
BDNF	O
levels	O
:	O
A	O
role	O
of	O
major	O
ovarian	B-T121
hormones	I-T121
Depression	B-T048
induced	O
by	O
stress	B-T033
is	O
affected	O
by	O
sex	O
,	O
age	O
and	O
hormonal	O
status	O
of	O
the	O
animal	O
and	O
also	O
by	O
duration	O
and	O
type	O
of	O
the	O
stressors	O
.	O
Moreover	O
,	O
higher	O
prevalence	O
of	O
depression	B-T048
and	O
comorbidities	O
in	O
women	O
than	O
men	O
implies	O
the	O
need	O
to	O
include	O
the	O
sex	O
variable	O
in	O
studies	O
on	O
animal	O
models	O
of	O
depression	B-T048
.	O
The	O
present	O
study	O
was	O
therefore	O
initiated	O
to	O
evaluate	O
the	O
effect	O
of	O
sex	O
and	O
ovarian	B-T121
hormones	I-T121
on	O
depression	B-T048
-like	O
phenotypes	O
in	O
mice	O
exposed	O
to	O
a	O
21	O
-	O
day	O
Chronic	O
Variable	O
Mild	O
Stress	O
(	O
CVMS	O
)	O
paradigm	O
.	O
Adult	O
male	O
,	O
intact	B-T033
female	I-T033
and	O
,	O
ovariectomized	B-T033
(	I-T033
OVX	I-T033
)	I-T033
female	I-T033
mice	O
exposed	O
to	O
CVMS	O
displayed	O
despair	O
behavior	O
,	O
a	O
depression	B-T048
-like	O
phenotype	O
,	O
in	O
all	O
the	O
groups	O
.	O
However	O
,	O
intact	B-T033
females	I-T033
alone	O
,	O
but	O
not	O
males	O
and	O
OVX	B-T033
females	I-T033
,	O
showed	O
anhedonia	B-T048
,	O
another	O
depression	B-T048
-like	O
phenotype	O
.	O
At	O
the	O
molecular	O
level	O
,	O
the	O
expression	O
of	O
Brain	O
-	O
Derived	O
Neurotrophic	O
Factor	O
(	O
BDNF	O
)	O
,	O
a	O
neuropeptide	O
associated	O
with	O
depression	B-T048
,	O
and	O
few	O
other	O
stress	B-T033
-specific	O
genes	O
CRH	O
,	O
NR3C1	O
,	O
CART	O
,	O
and	O
NPY	O
were	O
measured	O
in	O
the	O
Prefrontal	B-T023
Cortex	I-T023
(	O
PFC	B-T023
)	O
region	O
of	O
the	O
reward	O
circuitry	O
.	O
There	O
was	O
a	O
significant	O
decrease	O
in	O
the	O
BDNF	O
protein	O
expression	O
along	O
with	O
an	O
increase	O
in	O
the	O
mRNA	O
expression	O
of	O
CRH	O
,	O
NR3C1	O
,	O
CART	O
,	O
and	O
NPY	O
in	O
intact	B-T033
females	I-T033
,	O
but	O
not	O
in	O
the	O
other	O
two	O
groups	O
of	O
mice	O
.	O
OVX	B-T033
females	I-T033
resembled	O
males	O
in	O
behavioral	B-T033
and	O
molecular	B-T033
responses	I-T033
to	O
CVMS	O
.	O
17β	B-T121
-	I-T121
Estradiol	I-T121
(	O
E2	B-T121
)	O
administration	B-T061
,	O
not	O
Progesterone	B-T121
(	O
P4	B-T121
)	O
,	O
to	O
OVX	B-T033
female	I-T033
stress	B-T033
mice	O
,	O
mitigated	O
despair	O
and	O
enhanced	O
hedonic	O
capacity	O
with	O
an	O
increased	O
expression	O
of	O
BDNF	O
in	O
PFC	B-T023
.	O
This	O
study	O
strengthens	O
the	O
evidence	O
for	O
the	O
beneficial	O
effects	O
of	O
E2	B-T121
administration	B-T061
in	O
stress	B-T033
condition	O
.	O
      
Bioengineered	O
3D	O
Models	O
for	O
Studying	O
Human	O
Cell	O
-	O
Tuberculosis	B-T007
Interactions	O
In	O
vivo	O
animal	O
models	O
have	O
intrinsic	O
limitations	O
for	O
studying	O
relationships	O
between	O
tuberculosis	B-T007
and	O
its	O
host	B-T001
and	O
there	O
is	O
a	O
need	O
for	O
alternative	O
,	O
in	O
vitro	O
cellular	O
models	O
.	O
A	O
microsphere	O
-based	O
3D	O
in	O
vitro	O
culture	O
system	O
of	O
Mycobacterium	B-T007
tuberculosis	I-T007
-infected	O
human	O
blood	O
mononuclear	O
cells	O
was	O
reported	O
to	O
address	O
specific	O
aspects	O
of	O
host	B-T001
-	O
pathogen	B-T001
interactions	O
.	O
      
Clinical	O
correlates	O
of	O
faecal	B-T047
incontinence	I-T047
in	O
systemic	B-T047
sclerosis	I-T047
:	O
identifying	O
therapeutic	O
avenues	O
The	O
aim	O
was	O
to	O
establish	O
the	O
prevalence	O
and	O
severity	O
of	O
faecal	B-T047
incontinence	I-T047
(	O
FI	B-T047
)	O
in	O
SSc	B-T047
,	O
its	O
association	O
with	O
other	O
intestinal	B-T023
manifestations	O
and	O
potential	O
predictors	O
of	O
FI	B-T047
,	O
and	O
its	O
impact	O
on	O
quality	O
of	O
life	O
.	O
A	O
multicentre	O
,	O
cross	O
-	O
sectional	O
study	O
of	O
298	O
SSc	B-T047
subjects	O
followed	O
in	O
the	O
Canadian	O
Scleroderma	O
Research	O
Group	O
cohort	O
was	O
performed	O
using	O
validated	O
questionnaires	O
:	O
Jorge	O
-	O
Wexner	O
score	O
(	O
an	O
FI	B-T047
severity	O
scale	O
)	O
,	O
Bristol	O
stool	O
scale	O
(	O
a	O
visual	O
scale	O
of	O
stool	B-T033
consistency	I-T033
)	O
and	O
FI	B-T047
Quality	O
-	O
of	O
-	O
Life	O
scale	O
.	O
Constipation	B-T184
was	O
defined	O
by	O
the	O
Rome	O
III	O
criteria	O
.	O
Associations	O
between	O
the	O
Jorge	O
-	O
Wexner	O
score	O
and	O
other	O
clinical	B-T033
variables	I-T033
were	O
determined	O
using	O
multivariate	O
regression	O
analyses	O
.	O
Eighty	O
-	O
one	O
(	O
27.2	O
%	O
)	O
subjects	O
had	O
FI	B-T047
,	O
which	O
was	O
mild	O
in	O
37	O
(	O
12.4	O
%	O
)	O
and	O
moderate	O
to	O
severe	O
in	O
44	O
(	O
14.8	O
%	O
)	O
.	O
Most	O
patients	O
had	O
well	O
-	O
formed	O
stools	O
,	O
111	O
(	O
38.8	O
%	O
)	O
reported	O
constipation	B-T184
and	O
38	O
(	O
13.4	O
%	O
)	O
had	O
been	O
previously	O
treated	O
for	O
small	B-T047
intestinal	I-T047
bacterial	I-T047
overgrowth	I-T047
(	O
SIBO	B-T047
)	O
.	O
Variables	O
independently	O
associated	O
with	O
FI	B-T047
were	O
:	O
loose	B-T184
vs	O
well	O
-	O
formed	O
stools	O
[	O
odds	O
ratio	O
(	O
OR	O
)	O
=	O
7.01	O
,	O
95	O
%	O
CI	O
:	O
2.09	O
,	O
23.51	O
)	O
]	O
,	O
constipation	B-T184
(	O
OR	O
=	O
3.64	O
,	O
95	O
%	O
CI	O
:	O
1.61	O
,	O
8.27	O
,	O
P	O
=	O
0.002	O
)	O
,	O
history	B-T033
of	O
SIBO	B-T047
(	O
OR	O
=	O
2.97	O
,	O
95	O
%	O
CI	O
:	O
1.06	O
,	O
8.27	O
)	O
and	O
urinary	O
incontinence	O
(	O
OR	O
=	O
2.45	O
,	O
95	O
%	O
CI	O
:	O
1.14	O
,	O
5.27	O
)	O
.	O
Quality	O
of	O
life	O
measured	O
with	O
the	O
FI	B-T047
Quality	O
-	O
of	O
-	O
Life	O
scale	O
was	O
inversely	O
correlated	O
with	O
FI	B-T047
severity	O
(	O
correlation	O
coefficients	O
between	O
-0.602	O
and	O
-0.702	O
,	O
P	O
<	O
0.001	O
)	O
.	O
FI	B-T047
was	O
common	O
and	O
often	O
severe	O
in	O
SSc	B-T047
.	O
Loose	B-T184
stools	I-T184
,	O
SIBO	B-T047
,	O
constipation	B-T184
and	O
urinary	O
incontinence	O
were	O
strongly	O
associated	O
with	O
FI	B-T047
.	O
Other	O
than	O
targeting	O
anorectal	O
dysfunction	O
,	O
concomitant	O
treatment	B-T061
of	O
clinical	O
correlates	O
could	O
lead	O
to	O
improvement	O
in	O
FI	B-T047
and	O
quality	O
of	O
life	O
in	O
SSc	B-T047
.	O
      
Medication	B-T058
,	O
rehabilitation	O
and	O
health	O
care	O
consumption	O
in	O
adults	O
with	O
cerebral	B-T047
palsy	I-T047
:	O
A	O
population	O
based	O
study	O
To	O
evaluate	O
medication	B-T058
,	O
rehabilitation	O
and	O
healthcare	O
consumption	O
in	O
adults	O
with	O
CP	B-T047
as	O
a	O
function	O
of	O
Gross	O
Motor	O
Function	O
Classification	O
System	O
(	O
GMFCS	O
)	O
level	O
.	O
Questionnaire	O
-based	O
cross	O
-	O
sectional	O
study	O
.	O
Brittany	O
,	O
a	O
French	O
county	O
.	O
Adults	O
with	O
cerebral	B-T047
palsy	I-T047
.	O
Questionnaires	O
relating	O
to	O
drugs	B-T121
,	O
orthotic	O
devices	O
,	O
mobility	O
aids	O
,	O
rehabilitation	O
and	O
medical	B-T033
input	I-T033
were	O
sent	O
to	O
435	O
members	O
of	O
a	O
unique	O
regional	O
French	O
network	O
dedicated	O
to	O
adults	O
with	O
cerebral	B-T047
palsy	I-T047
.	O
The	O
questionnaire	O
was	O
completed	O
by	O
the	O
participant	O
or	O
a	O
helper	O
if	O
necessary	O
.	O
Of	O
the	O
282	O
responders	B-T033
,	O
7.8	O
%	O
had	O
a	O
GMFCS	O
level	O
of	O
I	O
,	O
14.2	O
%	O
II	O
,	O
17.7	O
%	O
III	O
,	O
29.1	O
%	O
IV	O
and	O
31.2	O
%	O
V.	O
Participants	O
consumed	O
a	O
large	O
amount	O
of	O
healthcare	O
.	O
Almost	O
three	O
-	O
quarters	O
took	O
orally	B-T121
administered	I-T121
drugs	I-T121
,	O
of	O
which	O
antispastic	B-T121
and	O
antiepileptic	B-T121
drugs	I-T121
were	O
among	O
the	O
most	O
frequent	O
.	O
Nearly	O
all	O
patients	O
had	O
at	O
least	O
one	O
type	O
of	O
rehabilitation	O
,	O
87.2	O
%	O
had	O
physiotherapy	B-T061
,	O
78	O
%	O
used	O
at	O
least	O
one	O
mobility	O
aid	O
and	O
69.5	O
%	O
used	O
at	O
least	O
one	O
orthotic	O
device	O
.	O
The	O
frequency	O
of	O
numerous	O
inputs	O
increased	O
with	O
GMFCS	O
level	O
.	O
Specificities	O
were	O
found	B-T033
for	O
each	O
GMFCS	O
level	O
,	O
e.g.	O
participants	O
with	O
GMFCS	O
level	O
IV	O
and	O
V	O
had	O
a	O
high	O
level	O
of	O
medical	B-T033
input	I-T033
and	O
a	O
greater	O
use	O
of	O
trunk	O
-	O
supporting	O
devices	O
,	O
antireflux	B-T061
and	O
laxative	B-T121
.	O
Profiles	O
could	O
be	O
established	O
based	O
on	O
GMFCS	O
levels	O
.	O
Adults	O
with	O
cerebral	B-T047
palsy	I-T047
use	O
a	O
large	O
amount	O
of	O
drugs	B-T121
,	O
mobility	O
aids	O
,	O
orthotic	O
devices	O
,	O
rehabilitation	O
and	O
medical	B-T033
input	I-T033
.	O
Healthcare	B-T058
is	O
targeted	O
at	O
cerebral	B-T047
palsy	I-T047
cerebral	B-T033
palsy	I-T033
-related	I-T033
issues	I-T033
.	O
GMFCS	O
is	O
a	O
determinant	O
of	O
healthcare	O
consumption	O
and	O
thus	O
a	O
useful	O
tool	O
for	O
clinical	O
practice	O
to	O
target	O
care	O
appropriately	O
.	O
      
Recurrent	O
noncoding	O
regulatory	O
mutations	O
in	O
pancreatic	B-T191
ductal	I-T191
adenocarcinoma	I-T191
The	O
contributions	O
of	O
coding	O
mutations	O
to	O
tumorigenesis	B-T191
are	O
relatively	O
well	O
known	O
;	O
however	O
,	O
little	O
is	O
known	O
about	O
somatic	O
alterations	O
in	O
noncoding	O
DNA	O
.	O
Here	O
we	O
describe	O
GECCO	O
(	O
Genomic	O
Enrichment	O
Computational	O
Clustering	O
Operation	O
)	O
to	O
analyze	O
somatic	O
noncoding	O
alterations	O
in	O
308	O
pancreatic	B-T191
ductal	I-T191
adenocarcinomas	I-T191
(	O
PDAs	B-T191
)	O
and	O
identify	O
commonly	O
mutated	O
regulatory	O
regions	O
.	O
We	O
find	O
recurrent	O
noncoding	O
mutations	O
to	O
be	O
enriched	O
in	O
PDA	B-T191
pathways	O
,	O
including	O
axon	O
guidance	O
and	O
cell	O
adhesion	O
,	O
and	O
newly	O
identified	O
processes	O
,	O
including	O
transcription	O
and	O
homeobox	O
genes	O
.	O
We	O
identified	O
mutations	O
in	O
protein	O
binding	O
sites	O
correlating	O
with	O
differential	O
expression	O
of	O
proximal	O
genes	O
and	O
experimentally	O
validated	O
effects	O
of	O
mutations	O
on	O
expression	O
.	O
We	O
developed	O
an	O
expression	O
modulation	O
score	O
that	O
quantifies	O
the	O
strength	O
of	O
gene	O
regulation	O
imposed	O
by	O
each	O
class	O
of	O
regulatory	O
elements	O
,	O
and	O
found	O
the	O
strongest	O
elements	O
were	O
most	O
frequently	O
mutated	O
,	O
suggesting	O
a	O
selective	O
advantage	O
.	O
Our	O
detailed	O
single	B-T059
-	I-T059
cancer	I-T059
analysis	I-T059
of	O
noncoding	O
alterations	O
identifies	O
regulatory	O
mutations	O
as	O
candidates	O
for	O
diagnostic	O
and	O
prognostic	O
markers	O
,	O
and	O
suggests	O
new	O
mechanisms	O
for	O
tumor	B-T191
evolution	I-T191
.	O
      
Hematological	B-T033
,	O
biochemical	B-T033
,	O
and	O
toxicopathic	B-T033
effects	I-T033
of	O
subchronic	O
acetamiprid	O
toxicity	O
in	O
Wistar	O
rats	O
Acetamiprid	O
is	O
one	O
of	O
the	O
most	O
widely	O
used	O
neonicotinoids	O
.	O
This	O
study	O
investigates	O
toxic	O
effects	O
of	O
repeated	O
oral	O
administration	O
of	O
three	O
doses	O
of	O
acetamiprid	O
(	O
1/20	O
,	O
1/10	O
,	O
and	O
1/5	O
of	O
LD50	O
)	O
during	O
60	O
days	O
.	O
For	O
this	O
,	O
male	O
Wistar	O
rats	O
were	O
divided	O
into	O
four	O
different	O
groups	O
.	O
Hematological	B-T033
,	O
biochemical	B-T033
,	O
and	O
toxicopathic	B-T033
effects	I-T033
of	O
acetamiprid	O
were	O
evaluated	B-T058
.	O
According	O
to	O
the	O
results	O
,	O
a	O
significant	O
decrease	O
in	O
the	O
body	B-T033
weight	I-T033
gain	I-T033
at	O
the	O
highest	O
dose	O
1/5	O
of	O
LD50	O
of	O
acetamiprid	O
was	O
noticed	O
.	O
An	O
increase	O
in	O
the	O
relative	O
liver	B-T023
weight	O
was	O
also	O
observed	O
at	O
this	O
dose	O
level	O
.	O
The	O
hematological	O
constituents	O
were	O
affected	O
.	O
A	O
significant	O
decrease	O
in	O
RBC	O
,	O
HGB	O
,	O
and	O
HCT	B-T033
in	O
rats	O
treated	O
with	O
higher	O
doses	O
of	O
acetamiprid	O
(	O
1/10	O
and	O
1/5	O
of	O
LD50	O
)	O
was	O
noted	O
.	O
However	O
,	O
a	O
significant	O
increase	O
in	O
WBC	O
and	O
PLT	O
were	O
observed	O
at	O
the	O
same	O
doses	O
.	O
Furthermore	O
,	O
acetamiprid	O
induced	B-T047
liver	I-T047
toxicity	I-T047
measured	O
by	O
the	O
increased	O
activities	O
of	O
aspartate	O
aminotransferase	O
(	O
AST	O
)	O
,	O
alanine	O
aminotransferase	O
(	O
ALT	O
)	O
,	O
alkaline	O
phosphates	O
(	O
ALPs	O
)	O
,	O
and	O
lactate	O
dehydrogenase	O
(	O
LDH	O
)	O
which	O
may	O
be	O
due	O
to	O
the	O
loss	O
of	O
hepatic	O
membrane	O
architecture	O
and	O
hepatocellular	O
damage	O
.	O
In	O
addition	O
,	O
exposure	O
to	O
acetamiprid	O
resulted	O
in	O
a	O
significant	O
decrease	O
in	O
the	O
levels	O
of	O
superoxide	B-T121
dismutase	I-T121
and	O
catalase	O
activities	O
(	O
p	O
≤	O
0.01	O
)	O
with	O
concomitant	O
increase	O
in	O
lipid	O
peroxidation	O
in	O
rat	O
liver	B-T023
.	O
These	O
findings	B-T033
highlight	O
the	O
subchronic	O
hepatotoxicity	O
of	O
acetamiprid	O
.	O
      
Analysis	B-T059
of	O
tilianin	O
and	O
acacetin	O
in	O
Agastache	O
rugosa	O
by	O
high	B-T059
-	I-T059
performance	I-T059
liquid	I-T059
chromatography	I-T059
with	O
ionic	O
liquids	O
-	O
ultrasound	O
based	O
extraction	B-T059
Ionic	O
liquid	O
1	O
-	O
butyl-3	O
-	O
methylimidazolium	O
bromide	O
-	O
methanol	O
-based	O
ultrasonic	O
-assisted	O
extraction	B-T059
(	O
ILUAE	B-T059
)	O
was	O
used	O
to	O
extract	B-T059
tilianin	O
and	O
acacetin	O
from	O
the	O
aerial	O
parts	O
of	O
Agastache	O
rugose	O
(	O
A.	O
rugose	O
)	O
,	O
and	O
simultaneously	O
determined	O
by	O
reversed	B-T059
phase	I-T059
high	I-T059
performance	I-T059
liquid	I-T059
chromatographic	I-T059
(	O
RP	B-T059
-	I-T059
HPLC	I-T059
)	O
method	O
with	O
ultraviolet	O
detection	O
(	O
RP	O
-	O
HPLC	O
-	O
UV	O
)	O
.	O
An	O
InertSustain	O
RP	O
-	O
C18	O
column	O
was	O
used	O
with	O
the	O
mobile	O
phase	O
consisting	O
of	O
methanol	O
and	O
0.2	O
%	O
acetic	B-T121
acid	I-T121
as	O
gradient	O
elution	B-T059
at	O
the	O
detection	O
wavelength	O
of	O
332	O
nm	O
.	O
The	O
flow	O
rate	O
was	O
0.8	O
mL	O
/	O
min	O
,	O
and	O
the	O
column	O
temperature	O
was	O
30	O
°	O
C	O
.	O
Under	O
the	O
optimized	O
conditions	O
,	O
tilianin	O
and	O
acacetin	O
displayed	O
good	O
linearity	O
in	O
the	O
ranges	O
of	O
0.0595	O
-	O
4.76	O
and	O
0.0585	O
-	O
4.68	O
μg	O
/	O
mL	O
,	O
respectively	O
,	O
with	O
the	O
average	O
recoveries	O
being	O
96.93	O
and	O
97.88	O
%	O
,	O
respectively	O
.	O
The	O
method	O
of	O
ILUAE	B-T059
was	O
compared	O
with	O
the	O
traditional	O
methods	O
,	O
it	O
exhibited	O
higher	O
efficiency	O
,	O
higher	O
reproducibility	O
and	O
environmental	O
friendly	O
in	O
analyzing	O
the	O
active	O
compounds	O
in	O
traditional	O
Chinese	O
medicines	O
(	O
TCMs	O
)	O
.	O
      
Membrane	O
nanoclusters	O
of	O
FcγRI	O
segregate	O
from	O
inhibitory	O
SIRPα	O
upon	O
activation	O
of	O
human	O
macrophages	O
Signal	O
integration	O
between	O
activating	O
Fc	O
receptors	O
and	O
inhibitory	O
signal	O
regulatory	O
protein	O
α	O
(	O
SIRPα	O
)	O
controls	O
macrophage	O
phagocytosis	O
.	O
Here	O
,	O
using	O
dual	B-T059
-	I-T059
color	I-T059
direct	I-T059
stochastic	I-T059
optical	I-T059
reconstruction	I-T059
microscopy	I-T059
,	O
we	O
report	O
that	O
Fcγ	O
receptor	O
I	O
(	O
FcγRI	O
)	O
,	O
FcγRII	O
,	O
and	O
SIRPα	O
are	O
not	O
homogeneously	O
distributed	O
at	O
macrophage	O
surfaces	O
but	O
are	O
organized	O
in	O
discrete	O
nanoclusters	O
,	O
with	O
a	O
mean	O
radius	O
of	O
71	O
±	O
11	O
nm	O
,	O
60	O
±	O
6	O
nm	O
,	O
and	O
48	O
±	O
3	O
nm	O
,	O
respectively	O
.	O
Nanoclusters	O
of	O
FcγRI	O
,	O
but	O
not	O
FcγRII	O
,	O
are	O
constitutively	O
associated	O
with	O
nanoclusters	O
of	O
SIRPα	O
,	O
within	O
62	O
±	O
5	O
nm	O
,	O
mediated	O
by	O
the	O
actin	O
cytoskeleton	O
.	O
Upon	O
Fc	O
receptor	O
activation	O
,	O
Src	O
-	O
family	O
kinase	O
signaling	O
leads	O
to	O
segregation	O
of	O
FcγRI	O
and	O
SIRPα	O
nanoclusters	O
to	O
be	O
197	O
±	O
3	O
nm	O
apart	O
.	O
Co	O
-	O
ligation	O
of	O
SIRPα	O
with	O
CD47	O
abrogates	O
nanocluster	O
segregation	O
.	O
If	O
the	O
balance	O
of	O
signals	O
favors	O
activation	O
,	O
FcγRI	O
nanoclusters	O
reorganize	O
into	O
periodically	O
spaced	O
concentric	O
rings	O
.	O
Thus	O
,	O
a	O
nanometer	O
-	O
and	O
micron	O
-	O
scale	O
reorganization	O
of	O
activating	O
and	O
inhibitory	O
receptors	O
occurs	O
at	O
the	O
surface	O
of	O
human	O
macrophages	O
concurrent	O
with	O
signal	O
integration	O
.	O
      
Nontoxic	O
Formulations	O
of	O
Scintillation	O
Nanocrystals	O
for	O
Use	O
as	O
X	B-T060
-	I-T060
ray	I-T060
Computed	I-T060
Tomography	I-T060
Contrast	O
Agents	O
X	B-T060
-	I-T060
ray	I-T060
computed	I-T060
tomography	I-T060
(	O
CT	B-T060
)	O
is	O
currently	O
one	O
of	O
the	O
most	O
powerful	O
,	O
noninvasive	O
,	O
clinical	O
in	O
vivo	O
imaging	B-T060
techniques	I-T060
,	O
which	O
has	O
resulted	O
from	O
advances	O
in	O
both	O
X	O
-	O
ray	O
device	O
and	O
contrast	O
enhancement	B-T061
technologies	I-T061
.	O
The	O
present	O
study	O
demonstrates	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
metal	O
tungstates	O
(	O
such	O
as	O
CaWO4	O
)	O
are	O
promising	O
contrast	O
agents	O
for	O
X	B-T060
-	I-T060
ray	I-T060
,	O
radiation	O
,	O
and	O
CT	B-T060
imaging	I-T060
,	O
because	O
of	O
the	O
high	O
X	B-T060
-	I-T060
ray	I-T060
mass	O
attenuation	O
of	O
tungsten	O
(	O
W	O
)	O
.	O
We	O
have	O
developed	O
a	O
method	O
of	O
formulation	O
,	O
in	O
which	O
CaWO4	O
(	O
CWO	O
)	O
nanoparticles	O
(	O
NPs	O
)	O
are	O
encapsulated	O
within	O
a	O
biocompatible	O
poly(ethylene	O
glycol	O
-	O
b	O
-	O
d	O
,	O
l	O
-	O
lactic	O
acid	O
)	O
(	O
PEG	O
-	O
PLA	O
)	O
block	O
copolymer	O
(	O
BCP	O
)	O
capsule	O
.	O
We	O
show	O
that	O
these	O
PEG	O
-	O
PLA	O
-	O
encapsulated	O
CWO	O
NPs	O
(	O
170	O
±	O
10	O
nm	O
hydrodynamic	O
diameter	O
)	O
produce	O
a	O
higher	O
CT	B-T060
contrast	O
(	O
by	O
a	O
factor	O
of	O
about	O
2	O
)	O
than	O
commercial	O
iodine	B-T121
-based	O
radiocontrast	O
agents	O
(	O
e.g.	O
,	O
Iohexol	O
)	O
at	O
identical	O
molar	O
concentrations	O
of	O
W	O
or	O
I	B-T121
atoms	O
.	O
PEG	O
-	O
PLA	O
-	O
coated	O
CWO	O
NPs	O
are	O
chemically	O
stable	O
and	O
completely	O
nontoxic	O
.	O
It	O
was	O
confirmed	O
that	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
this	O
material	O
in	O
mice	O
is	O
significantly	O
higher	O
(	O
250	O
±	O
50	O
mg	O
per	O
kg	O
body	O
weight	O
following	O
a	O
single	O
intravenous	O
(	O
IV	O
)	O
administration	O
)	O
than	O
,	O
for	O
instance	O
,	O
commercially	O
available	O
dextran	B-T121
-	O
coated	O
iron	B-T121
oxide	I-T121
nanoparticles	O
that	O
are	O
currently	O
used	O
clinically	O
as	O
MRI	B-T060
contrast	O
agents	O
(	O
MTD	O
in	O
mice	O
≈	O
168	O
mg	O
/	O
kg	O
per	O
dose	O
IV	O
)	O
.	O
IV-	O
injected	O
PEG	O
-	O
PLA	O
/	O
CWO	O
NPs	O
caused	O
no	B-T033
histopathologic	O
damage	O
in	O
major	O
excretory	B-T023
organs	I-T023
(	O
heart	B-T023
,	O
liver	B-T023
,	O
lungs	B-T023
,	O
spleen	B-T023
,	O
and	O
kidney	B-T023
)	O
.	O
When	O
an	O
IV	O
dose	O
of	O
100	O
mg	O
/	O
kg	O
was	O
given	O
to	O
mice	O
,	O
the	O
blood	O
circulation	O
half	O
-	O
life	O
was	O
measured	O
to	O
be	O
about	O
4	O
h	O
,	O
and	O
more	O
than	O
90	O
%	O
of	O
the	O
NPs	O
were	O
cleared	O
from	O
the	O
mice	O
within	O
24	O
h	O
via	O
the	O
renal	B-T023
and	O
hepatobiliary	O
systems	O
.	O
When	O
intratumorally	O
administered	O
,	O
PEG	O
-	O
PLA	O
-	O
coated	O
CWO	O
NPs	O
showed	O
complete	O
retention	O
in	O
a	O
tumor	B-T050
-	I-T050
bearing	I-T050
mouse	I-T050
model	I-T050
(	O
measurements	O
were	O
made	O
up	O
to	O
1	O
week	O
)	O
.	O
These	O
results	O
suggest	O
that	O
PEG	O
-	O
PLA	O
-	O
coated	O
CWO	O
NPs	O
are	O
promising	O
materials	O
for	O
use	O
in	O
CT	B-T060
contrast	O
.	O
      
Metabolic	B-T033
responses	I-T033
of	O
the	O
growing	O
Daphnia	O
similis	O
to	O
chronic	O
AgNPs	O
exposure	O
as	O
revealed	O
by	O
GC	B-T059
-	I-T059
Q	I-T059
-	I-T059
TOF	I-T059
/	I-T059
MS	I-T059
and	O
LC	B-T059
-	I-T059
Q	I-T059
-	I-T059
TOF	I-T059
/	I-T059
MS	I-T059
Silver	O
nanoparticles	O
(	O
AgNPs	O
)	O
are	O
one	O
of	O
the	O
most	O
widely	O
used	O
nanomaterials	O
.	O
Their	O
fast	B-T033
-	I-T033
growing	I-T033
utilization	O
has	O
increased	O
the	O
occurrence	O
of	O
AgNPs	O
in	O
the	O
environment	O
,	O
posing	O
potential	O
health	O
and	O
ecological	O
risks	O
.	O
In	O
this	O
study	O
,	O
we	O
conducted	O
chronic	B-T060
toxicity	I-T060
tests	I-T060
and	O
investigated	O
the	O
metabolic	O
changes	O
of	O
the	O
growing	O
Daphna	O
similis	O
with	O
exposure	O
to	O
0	O
,	O
0.02	O
,	O
and	O
1	O
ppb	O
AgNPs	O
,	O
using	O
non	B-T059
-	I-T059
targeted	I-T059
mass	I-T059
spectrometry	I-T059
-based	O
metabolomics	O
.	O
To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
study	O
is	O
the	O
first	O
to	O
report	O
the	O
baseline	O
metabolite	O
change	O
of	O
a	O
common	O
aquatic	B-T001
organism	I-T001
Daphnia	O
crustacean	O
through	O
its	O
life	O
-	O
cycle	O
.	O
The	O
results	O
show	O
a	O
dynamic	B-T033
kinetic	I-T033
pattern	I-T033
of	O
the	O
growing	O
Daphnia	O
's	O
metabolome	O
underwent	O
a	O
cycle	O
from	O
day	O
0	O
to	O
day	O
21	O
,	O
with	O
the	O
level	O
of	O
metabolites	O
gradually	O
increasing	O
from	O
day	O
0	O
to	O
day	O
13	O
,	O
before	O
falling	O
back	O
to	O
the	O
baseline	O
level	O
of	O
day	O
0	O
on	O
day	O
21	O
.	O
As	O
for	O
the	O
samples	O
exposed	O
to	O
environmental	O
concentrations	O
of	O
AgNPs	O
,	O
although	O
without	O
morphological	B-T033
or	I-T033
structural	I-T033
changes	I-T033
,	O
numerous	O
metabolite	O
changes	O
occurred	O
abruptly	O
during	O
the	O
first	O
10	O
days	O
,	O
and	O
these	O
changes	O
reached	O
steady	O
state	O
by	O
day	O
13	O
.	O
The	O
significant	O
changes	O
in	O
certain	O
metabolites	O
,	O
such	O
as	O
amino	B-T121
acids	I-T121
(	O
serine	B-T121
,	O
threonine	B-T121
and	O
tyrosine	B-T121
)	O
,	O
sugars	B-T121
(	O
d	O
-	O
allose	O
)	O
and	O
fatty	O
acids	O
(	O
arachidonic	O
acid	O
)	O
revealed	O
new	O
insights	O
into	O
how	O
these	O
metabolites	O
in	O
Daphnia	O
respond	O
to	O
chronic	O
AgNPs	O
stress	O
.	O
These	O
findings	O
highlight	O
the	O
capability	O
of	O
metabolomics	O
to	O
discover	O
early	O
metabolic	B-T033
responses	I-T033
to	O
environmental	O
silver	O
nanoparticles	O
.	O
      
Natural	B-T061
orifice	I-T061
transluminal	I-T061
endoscopic	I-T061
surgery	I-T061
with	O
a	O
snake	O
-	O
mechanism	O
using	O
a	O
movable	O
pulley	O
Natural	B-T061
orifice	I-T061
transluminal	I-T061
endoscopic	I-T061
surgery	I-T061
is	O
an	O
emerging	O
technique	O
.	O
We	O
aimed	O
to	O
develop	O
an	O
advanced	O
surgical	O
robot	O
mechanism	O
for	O
natural	B-T061
orifice	I-T061
surgery	I-T061
.	O
We	O
propose	O
the	O
active	O
-	O
controlled	O
overtube	O
-	O
type	O
platform	O
with	O
multiple	O
channels	O
for	O
an	O
endoscopic	O
camera	O
and	O
surgical	B-T061
tools	O
.	O
To	O
make	O
such	O
a	O
platform	O
,	O
we	O
suggest	O
an	O
advanced	O
snake	O
mechanism	O
comprising	O
movable	O
pulleys	O
to	O
make	O
a	O
snake	O
mechanism	O
with	O
multiple	O
degrees	O
of	O
freedom	O
and	O
high	O
operating	O
force	O
.	O
The	O
stiffness	O
and	O
maneuverability	O
of	O
the	O
active	O
-	O
controlled	O
platform	O
appeared	O
satisfactory	O
.	O
Using	O
prototypes	O
and	O
ex	O
vivo	O
experiments	O
,	O
we	O
confirmed	O
that	O
the	O
mechanism	O
was	O
suitable	O
for	O
a	O
snake	O
-	O
like	O
robotic	O
platform	O
for	O
natural	B-T061
orifice	I-T061
surgery	I-T061
.	O
The	O
suggested	O
snake	O
mechanism	O
using	O
movable	O
pulleys	O
has	O
the	O
advantages	O
of	O
stiffness	O
and	O
maneuverability	O
.	O
This	O
new	O
mechanism	O
can	O
be	O
an	O
alternative	O
platform	O
for	O
natural	B-T061
orifice	I-T061
surgery	I-T061
.	O
      
Brassinosteroid	O
-	O
induced	O
changes	O
of	O
lipid	O
composition	O
in	O
leaves	O
of	O
Pisum	O
sativum	O
L.	O
during	O
senescence	O
The	O
effect	O
of	O
steroid	O
phytohormone	O
24	O
-	O
epibrassinolide	O
(	O
EBR	O
)	O
on	O
the	O
composition	O
of	O
some	O
lipid	O
classes	O
(	O
free	O
fatty	O
acids	O
,	O
triacylglycerols	O
and	O
galactolipids	O
)	O
in	O
detached	O
pea	O
leaves	O
was	O
studied	O
for	O
the	O
first	O
time	O
.	O
EBR	O
(	O
0.1μM	O
)	O
promoted	O
senescence	O
and	O
increased	O
the	O
content	O
of	O
14:0	O
,	O
16:0	O
and	O
18:1	O
free	O
fatty	O
acids	O
as	O
well	O
as	O
18:2	O
and	O
18:3	O
bound	O
to	O
triacylglycerols	O
in	O
the	O
detached	O
leaves	O
in	O
contrast	O
to	O
mock	O
-	O
treated	O
leaves	O
.	O
The	O
content	O
of	O
all	O
identified	O
fatty	O
acids	O
bound	O
to	O
galactolipids	O
decreased	O
in	O
the	O
detached	O
leaves	O
treated	O
with	O
EBR	O
compared	O
to	O
that	O
in	O
mock	O
-	O
treated	O
leaves	O
.	O
These	O
findings	O
suggest	O
that	O
free	O
fatty	O
acids	O
are	O
liberated	O
from	O
polar	O
lipids	O
and	O
then	O
undergo	O
esterification	O
to	O
neutral	O
lipids	O
in	O
the	O
detached	O
leaves	O
upon	O
EBR	O
treatment	O
.	O
We	O
propose	O
that	O
steroid	O
phytohormones	O
may	O
be	O
involved	O
into	O
regulation	O
of	O
leaf	O
senescence	O
via	O
alteration	O
of	O
cell	O
lipid	O
composition	O
.	O
      
Multimodal	B-T060
brain	I-T060
imaging	I-T060
with	O
magnetoencephalography	B-T060
:	O
A	O
method	B-T060
for	O
measuring	O
blood	O
pressure	O
and	O
cardiorespiratory	O
oscillations	O
Studies	O
with	O
magnetoencephalography	B-T060
(	O
MEG	B-T060
)	O
are	O
still	O
quite	O
rarely	O
combined	O
simultaneously	O
with	O
methods	B-T060
that	O
can	O
provide	O
a	O
metabolic	O
dimension	O
to	O
MEG	B-T060
investigation	B-T058
s.	O
In	O
addition	O
,	O
continuous	O
blood	B-T058
pressure	I-T058
measurements	I-T058
which	O
comply	O
with	O
MEG	B-T060
compatibility	O
requirements	O
are	O
lacking	O
.	O
For	O
instance	O
,	O
by	O
combining	O
methods	B-T060
reflecting	O
neurovascular	B-T058
status	I-T058
one	O
could	O
obtain	O
more	O
information	O
on	O
low	O
frequency	O
fluctuations	B-T184
that	O
have	O
recently	O
gained	O
increasing	O
interest	O
as	O
a	O
mediator	O
of	O
functional	O
connectivity	O
within	O
brain	B-T023
networks	I-T023
.	O
This	O
paper	O
presents	O
a	O
multimodal	B-T060
brain	I-T060
imaging	I-T060
setup	O
,	O
capable	O
to	O
non	O
-	O
invasively	O
and	O
continuously	O
measure	O
cerebral	B-T023
hemodynamic	O
,	O
cardiorespiratory	B-T060
and	O
blood	O
pressure	O
oscillations	O
simultaneously	O
with	O
MEG	B-T060
.	O
In	O
the	O
setup	O
,	O
all	O
methods	B-T060
apart	O
from	O
MEG	B-T060
rely	O
on	O
the	O
use	O
of	O
fibre	O
optics	O
.	O
In	O
particular	O
,	O
we	O
present	O
a	O
method	B-T060
for	O
measuring	O
of	O
blood	O
pressure	O
and	O
cardiorespiratory	O
oscillations	O
continuously	O
with	O
MEG	B-T060
.	O
The	O
potential	O
of	O
this	O
type	O
of	O
multimodal	B-T060
setup	O
for	O
brain	O
research	O
is	O
demonstrated	O
by	O
our	O
preliminary	O
studies	O
on	O
human	O
,	O
showing	O
effects	O
of	O
mild	B-T033
hypercapnia	I-T033
,	O
gathered	O
simultaneously	O
with	O
the	O
presented	O
modalities	O
.	O
      
Relationship	O
between	O
polycythemia	B-T047
and	O
in	O
-	O
hospital	O
mortality	O
in	O
chronic	B-T047
obstructive	I-T047
pulmonary	I-T047
disease	I-T047
patients	O
with	O
low	O
-	O
risk	O
pulmonary	B-T047
embolism	I-T047
Pulmonary	B-T047
embolism	I-T047
(	O
PE	B-T047
)	O
is	O
frequent	O
in	O
subjects	O
with	O
chronic	B-T047
obstructive	I-T047
pulmonary	I-T047
disease	I-T047
(	O
COPD	B-T047
)	O
and	O
associated	O
with	O
high	O
mortality	O
.	O
This	O
multi	O
-	O
center	O
retrospective	O
study	O
was	O
performed	O
to	O
investigate	O
if	O
secondary	O
polycythemia	B-T047
is	O
associated	O
with	O
in	O
-	O
hospital	O
mortality	O
in	O
COPD	B-T047
patients	O
with	O
low	O
-	O
risk	O
PE	B-T047
.	O
We	O
identified	O
COPD	B-T047
patients	O
with	O
proven	O
PE	B-T047
between	O
October	O
,	O
2005	O
and	O
October	O
,	O
2015	O
.	O
Patients	O
in	O
risk	O
classes	O
III	O
-	O
V	O
on	O
the	O
basis	O
of	O
the	O
PESI	B-T033
score	I-T033
were	O
excluded	O
.	O
We	O
extracted	O
demographic	O
,	O
clinical	O
and	O
laboratory	O
information	O
at	O
the	O
time	O
of	O
admission	O
from	O
medical	O
records	O
.	O
All	O
subjects	O
were	O
followed	O
until	O
hospital	B-T058
discharge	I-T058
to	O
identify	O
all	O
-	O
cause	O
mortality	O
.	O
We	O
enrolled	O
629	O
consecutive	O
patients	O
with	O
COPD	B-T047
and	O
PE	B-T047
at	O
low	O
risk	O
:	O
132	O
of	O
them	O
(	O
21.0	O
%	O
)	O
with	O
and	O
497	O
(	O
79.0	O
%	O
)	O
without	O
secondary	O
polycythemia	B-T047
.	O
Compared	O
with	O
those	O
without	O
polycythemia	B-T047
,	O
the	O
polycythemia	B-T047
group	O
had	O
significantly	O
lower	O
forced	B-T060
expiratory	I-T060
volume	I-T060
in	I-T060
one	I-T060
second	I-T060
(	I-T060
FEV1	I-T060
)	I-T060
level	I-T060
(	O
0.9±0.3	O
vs.	O
1.4±0.5	O
,	O
P=0.000	O
)	O
,	O
lower	B-T033
PaO2	I-T033
and	O
SpO2	O
as	O
well	O
as	O
higher	O
PaCO2	O
(	O
P=0.03	O
,	O
P=0.03	O
and	O
P=0.000	O
,	O
respectively	O
)	O
.	O
COPD	B-T047
patients	O
with	O
polycythemia	B-T047
had	O
a	O
higher	O
proportion	O
of	O
arrhythmia	B-T033
in	O
electrocardiogram	B-T033
(	O
ECG	B-T033
)	O
(	O
49.5	O
%	O
vs.	O
35.7	O
%	O
,	O
P=0.02	O
)	O
,	O
a	O
longer	O
hospital	O
duration	O
time	O
(	O
15.3±10.1	O
vs.	O
9.7±9.1	O
,	O
P=0.001	O
)	O
,	O
a	O
higher	O
mechanical	B-T061
ventilation	I-T061
rate	I-T061
(	O
noninvasive	O
and	O
invasive	O
,	O
51.7	O
%	O
vs.	O
30.3	O
%	O
,	O
P=0.04	O
and	O
31.0	O
%	O
vs.	O
7.9	O
%	O
,	O
P=0.04	O
,	O
respectively	O
)	O
,	O
and	O
a	O
higher	O
in	O
-	O
hospital	O
mortality	O
(	O
12.1	O
%	O
vs.	O
6.6	O
%	O
,	O
P=0.04	O
)	O
.	O
Multivariate	O
logistic	O
regression	O
analysis	O
revealed	O
that	O
polycythemia	B-T047
was	O
associated	O
with	O
mortality	O
in	O
COPD	B-T047
patients	O
with	O
low	O
-	O
risk	O
PE	B-T047
(	O
adjusted	O
OR	O
1.11	O
;	O
95	O
%	O
CI	O
,	O
1.04	O
-	O
1.66	O
)	O
.	O
Polycythemia	B-T047
is	O
an	O
independent	O
risk	B-T033
factor	I-T033
for	O
all	O
-	O
cause	O
in	O
-	O
hospital	O
mortality	O
in	O
COPD	B-T047
patients	O
with	O
PE	B-T047
at	O
low	O
risk	O
.	O
      
Does	O
infrared	O
visualization	O
improve	O
selection	O
of	O
venipuncture	B-T060
sites	O
for	O
indwelling	O
needle	O
at	O
the	O
forearm	B-T023
in	O
second	O
-	O
year	O
nursing	O
students	O
?	O
To	O
evaluate	O
the	O
effectiveness	O
of	O
a	O
vein	O
visualization	O
display	O
system	O
using	O
near	O
-	O
infrared	O
light	O
(	O
"	O
Vein	O
Display	O
"	O
)	O
for	O
the	O
safe	O
and	O
proper	O
selection	O
of	O
venipuncture	B-T060
sites	O
for	O
indwelling	O
needle	O
placement	O
in	O
the	O
forearm	B-T023
.	O
Ten	O
second	O
year	O
nursing	O
students	O
were	O
recruited	O
to	O
apply	O
an	O
indwelling	O
needle	O
line	O
with	O
and	O
without	O
Vein	B-T023
Display	O
.	O
Another	O
ten	O
participants	O
were	O
recruited	O
from	O
various	O
faculty	O
to	O
serve	O
as	O
patients	O
.	O
The	O
quality	O
of	O
the	O
venipuncture	B-T060
procedure	I-T060
at	O
various	O
selected	O
sites	O
was	O
evaluated	O
according	O
to	O
a	O
scale	O
developed	O
by	O
the	O
authors	O
.	O
Time	O
,	O
scores	O
and	O
patterns	O
of	O
puncture	B-T060
-	O
site	O
selection	O
were	O
compared	O
with	O
respect	O
to	O
three	O
different	O
methods	O
:	O
[	O
1	O
]	O
attempt	O
1	O
(	O
tourniquet	O
only	O
)	O
,	O
[	O
2	O
]	O
attempt	O
2	O
(	O
Vein	O
Display	O
only	O
)	O
and	O
[	O
3	O
]	O
attempt	O
3	O
(	O
both	O
)	O
.	O
To	O
validate	O
the	O
effectiveness	O
of	O
Vein	B-T023
Display	O
,	O
52	O
trials	O
were	O
conducted	O
in	O
total	O
.	O
We	O
found	O
that	O
venipuncture	B-T060
site	O
selection	O
time	O
was	O
significantly	O
improved	O
with	O
the	O
Vein	O
Display	O
,	O
particularly	O
in	O
the	O
case	O
of	O
difficult	O
to	O
administer	O
venipuncture	B-T060
sites	O
.	O
Overall	O
,	O
we	O
found	O
no	O
significant	O
difference	O
with	O
respect	O
to	O
venipuncture	B-T060
quality	O
,	O
as	O
determined	O
by	O
our	O
scale	O
.	O
These	O
results	O
suggest	O
that	O
equipment	O
such	O
as	O
the	O
Vein	O
Display	O
can	O
contribute	O
immensely	O
to	O
the	O
improvement	O
of	O
practical	O
skills	O
,	O
such	O
as	O
venipuncture	B-T060
,	O
especially	O
in	O
the	O
context	O
of	O
elderly	O
patients	O
.	O
      
Diverse	O
Colletotrichum	O
species	O
cause	O
anthracnose	B-T047
of	O
tea	O
plants	O
(	O
Camellia	O
sinensis	O
(	O
L.	O
)	O
O.	O
Kuntze	O
)	O
in	O
China	O
Anthracnose	B-T047
caused	O
by	O
Colletotrichum	O
is	O
one	O
of	O
the	O
most	O
severe	O
diseases	B-T047
that	O
can	O
afflict	O
Camellia	O
sinensis	O
.	O
However	O
,	O
research	O
on	O
the	O
diversity	O
and	O
geographical	O
distribution	O
of	O
Colletotrichum	O
in	O
China	O
remain	O
limited	O
.	O
In	O
this	O
study	O
,	O
106	O
Colletotrichum	O
isolates	O
were	O
collected	O
from	O
diseased	B-T047
leaves	O
of	O
Ca	O
.	O
sinensis	O
cultivated	O
in	O
the	O
15	O
main	O
tea	O
production	O
provinces	O
in	O
China	O
.	O
Multi	O
-	O
locus	O
phylogenetic	O
analysis	O
coupled	O
with	O
morphological	B-T059
identification	I-T059
showed	O
that	O
the	O
collected	O
isolates	O
belonged	O
to	O
11	O
species	O
,	O
including	O
6	O
known	O
species	O
(	O
C.	O
camelliae	O
,	O
C.	O
cliviae	O
,	O
C.	O
fioriniae	O
,	O
C.	O
fructicola	O
,	O
C.	O
karstii	O
,	O
and	O
C.	O
siamense	O
)	O
,	O
3	O
new	O
record	O
species	O
(	O
C.	O
aenigma	O
,	O
C.	O
endophytica	O
,	O
and	O
C.	O
truncatum	O
)	O
,	O
1	O
novel	O
species	O
(	O
C.	O
wuxiense	O
)	O
,	O
and	O
1	O
indistinguishable	O
strain	B-T001
,	O
herein	O
described	O
as	O
Colletotrichum	O
sp	O
.	O
Of	O
these	O
species	O
,	O
C.	O
camelliae	O
and	O
C.	O
fructicola	O
were	O
the	O
dominant	O
species	O
causing	O
anthracnose	B-T047
in	O
Ca	O
.	O
sinensis	O
.	O
In	O
addition	O
,	O
our	O
study	O
provided	O
further	O
evidence	O
that	O
phylogenetic	O
analysis	O
using	O
a	O
combination	O
of	O
ApMat	O
and	O
GS	O
sequences	O
can	O
be	O
used	O
to	O
effectively	O
resolve	O
the	O
taxonomic	O
relationships	O
within	O
the	O
C.	O
gloeosporioides	O
species	O
complex	O
.	O
Finally	O
,	O
pathogenicity	O
tests	B-T059
suggested	O
that	O
C.	O
camelliae	O
,	O
C.	O
aenigma	O
,	O
and	O
C.	O
endophytica	O
are	O
more	O
invasive	O
than	O
other	O
species	O
after	O
the	O
inoculation	B-T061
of	O
the	O
leaves	O
of	O
Ca	O
.	O
sinensis	O
.	O
      
Fatty	O
Acids	O
Have	O
Different	O
Adipogenic	O
Differentiation	O
Potentials	O
in	O
Stromal	O
Vascular	O
Cells	O
Isolated	O
from	O
Abdominal	O
Fat	O
in	O
Laying	O
Hens	O
This	O
study	O
was	O
conducted	O
to	O
examine	O
the	O
effects	O
of	O
fatty	O
acids	O
(	O
FA	O
)	O
with	O
/	O
without	O
chicken	O
serum	O
(	O
CS	O
)	O
on	O
the	O
expression	O
of	O
adipogenic	O
transcripts	O
and	O
adipogenesis	O
in	O
chicken	O
stromal	O
vascular	O
cells	O
(	O
SVC	O
)	O
.	O
In	O
experiment	O
1	O
,	O
SVC	O
were	O
grown	O
in	O
DMEM	B-T121
containing	O
10	O
%	O
FBS	O
(	O
Control	O
)	O
and	O
treated	O
with	O
300	O
µM	O
oleic	B-T121
acid	I-T121
(	O
OLA	B-T121
)	O
+	O
FBS	O
,	O
linoleic	B-T121
acid	I-T121
(	O
LNA	B-T121
)	O
+	O
FBS	O
,	O
palmitic	O
acid	O
(	O
PAM	O
)	O
+	O
FBS	O
,	O
or	O
stearic	B-T121
acid	I-T121
(	O
STA	B-T121
)	O
+	O
FBS	O
for	O
48	O
h.	O
In	O
experiment	O
2	O
,	O
cells	O
were	O
grown	O
in	O
DMEM	B-T121
containing	O
5	O
%	O
CS	O
and	O
treated	O
with	O
300	O
µM	O
OLA	B-T121
(	O
CS	O
+	O
OLA	B-T121
)	O
,	O
PAM	O
(	O
CS	O
+	O
PAM	O
)	O
,	O
STA	B-T121
(	O
CS	O
+	O
STA	B-T121
)	O
or	O
200	O
µM	O
LNA	B-T121
(	O
CS	O
+	O
LNA	B-T121
)	O
for	O
48	O
h.	O
Adipogenesis	O
was	O
determined	O
using	O
Oil	B-T059
Red	I-T059
O	I-T059
staining	I-T059
and	O
glycerol-3	O
-	O
phosphate	O
dehydrogenase	O
(	O
GPDH	O
)	O
activity	O
.	O
The	O
proportion	O
of	O
OLA	B-T121
,	O
PAM	O
,	O
or	O
STA	B-T121
was	O
increased	O
(	O
P	O
<	O
0.05	O
)	O
in	O
SVC	O
grown	O
in	O
either	O
FBS	O
or	O
CS	O
with	O
OLA	B-T121
,	O
PAM	O
or	O
STA	B-T121
.	O
Adipogenesis	O
was	O
induced	O
in	O
FBS	O
+	O
OLA	B-T121
,	O
FBS	O
+	O
LNA	B-T121
,	O
FBS	O
+	O
PAM	O
,	O
FBS	O
+	O
STA	B-T121
,	O
CS	O
+	O
OLA	B-T121
,	O
CS	O
+	O
LNA	B-T121
,	O
CS	O
+	O
PAM	O
,	O
or	O
CS	O
+	O
STA	B-T121
compared	O
to	O
FBS	O
.	O
GPDH	O
activity	O
was	O
significantly	O
higher	O
in	O
FBS	O
+	O
OLA	B-T121
and	O
FBS	O
+	O
LNA	B-T121
than	O
one	O
in	O
FBS	O
.	O
Compared	O
to	O
FBS	O
,	O
the	O
expression	O
of	O
FABP4	O
mRNA	O
increased	O
(	O
P	O
<	O
0.05	O
)	O
in	O
FBS	O
+	O
OLA	B-T121
,	O
FBS	O
+	O
LNA	B-T121
,	O
or	O
FBS	O
+	O
PAM	O
,	O
whereas	O
that	O
of	O
C	O
/	O
EBPα	O
,	O
C	O
/	O
EBPβ	O
,	O
and	O
ATGL	O
increased	O
(	O
P	O
<	O
0.05	O
)	O
in	O
FBS	O
+	O
OLA	B-T121
or	O
FBS	O
+	O
LNA	B-T121
cells	O
.	O
Expression	O
of	O
FABP4	O
and	O
C	O
/	O
EBPβ	O
mRNA	O
was	O
higher	O
in	O
CS	O
,	O
CS	O
+	O
OLA	B-T121
,	O
CS	O
+	O
LNA	B-T121
,	O
CS	O
+	O
PAM	O
,	O
or	O
CS	O
+	O
STA	B-T121
compared	O
with	O
(	O
FBS	O
,	O
whereas	O
the	O
expression	O
of	O
ATGL	O
and	O
C	O
/	O
EBPα	O
was	O
higher	O
in	O
CS	O
,	O
CS	O
+	O
OLA	B-T121
,	O
or	O
CS	O
+	O
LNA	B-T121
than	O
FBS	O
cells	O
.	O
In	O
conclusion	O
,	O
these	O
results	B-T033
showed	O
that	O
FA	O
have	O
different	O
potentials	O
to	O
induce	O
adipogenesis	O
,	O
LNA	B-T121
is	O
the	O
most	O
potent	O
among	O
the	O
tested	O
FA	O
,	O
and	O
these	O
potentials	O
can	O
be	O
improved	O
in	O
the	O
presence	B-T033
of	O
CS	O
.	O
      
A	O
case	O
of	O
bilateral	O
pneumothoraces	B-T047
resulting	O
from	O
tracheostomy	B-T061
for	O
advanced	O
laryngeal	B-T191
cancer	I-T191
Pneumothorax	B-T047
is	O
a	O
possible	O
complication	O
of	O
tracheostomy	B-T061
.	O
We	O
report	B-T058
a	O
rare	O
case	O
of	O
bilateral	O
pneumothoraces	B-T047
resulting	O
from	O
tracheostomy	B-T061
in	O
an	O
advanced	O
laryngeal	B-T191
cancer	I-T191
patient	O
.	O
A	O
59	O
-	O
year	O
-	O
old	O
man	O
was	O
referred	O
to	O
our	O
clinic	O
for	O
evaluation	B-T058
and	O
treatment	B-T061
of	O
laryngeal	B-T191
tumor	I-T191
.	O
Laryngeal	B-T060
endoscopy	I-T060
showed	O
limited	B-T033
movement	I-T033
of	O
bilateral	B-T023
vocal	I-T023
cords	I-T023
,	O
and	O
computed	B-T060
tomography	I-T060
revealed	O
a	O
tumor	B-T191
lesion	B-T033
extending	O
from	O
the	O
vocal	B-T023
cords	I-T023
to	O
the	O
subglottic	B-T023
area	I-T023
.	O
Three	O
days	O
after	O
the	O
first	B-T033
visit	I-T033
,	O
the	O
patient	O
developed	O
respiratory	B-T184
difficulty	I-T184
,	O
and	O
we	O
elected	O
to	O
perform	O
emergency	B-T061
tracheostomy	I-T061
for	O
airway	B-T061
management	I-T061
.	O
Immediately	O
after	O
the	O
start	O
of	O
the	O
procedure	B-T061
,	O
he	O
began	O
hyperventilating	B-T033
,	O
and	O
complained	O
of	O
respiratory	B-T033
discomfort	I-T033
and	O
chest	B-T184
pain	I-T184
.	O
We	O
then	O
recognized	O
a	O
mediastinal	O
air	B-T047
leak	I-T047
,	O
and	O
we	O
suspected	O
pneumothorax	B-T047
resulting	O
from	O
the	O
tracheostomy	B-T061
.	O
Chest	B-T060
X	I-T060
-	I-T060
ray	I-T060
showed	O
bilateral	O
pneumothoraces	B-T047
;	O
therefore	O
,	O
we	O
inserted	B-T058
bilateral	O
chest	O
drainage	O
tubes	O
,	O
which	O
stabilized	B-T033
his	O
respiratory	B-T033
condition	I-T033
.	O
We	O
speculated	O
that	O
the	O
pathogenesis	O
of	O
the	O
bilateral	O
pneumothoraces	B-T047
was	O
weakened	O
alveolar	B-T023
walls	I-T023
secondary	O
to	O
long	O
-	O
term	O
smoking	O
,	O
and	O
a	O
significant	O
rise	O
in	O
airway	O
pressure	O
because	O
of	O
airway	B-T184
constriction	I-T184
by	O
the	O
neck	O
-	O
extended	O
position	O
and	O
hyperventilation	B-T033
,	O
during	O
tracheostomy	B-T061
.	O
      
Personally	O
Meaningful	O
Rituals	O
:	O
A	O
Way	O
to	O
Increase	O
Compassion	O
and	O
Decrease	O
Burnout	B-T033
among	O
Hospice	B-T058
Staff	O
and	O
Volunteers	O
Rituals	O
can	O
increase	O
a	O
sense	O
of	O
connectedness	O
,	O
meaning	O
,	O
and	O
support	O
,	O
especially	O
after	O
the	O
death	O
of	O
those	O
for	O
whom	O
we	O
care	O
.	O
Hospice	B-T058
staff	O
may	O
benefit	O
from	O
the	O
use	O
of	O
personal	O
rituals	O
as	O
they	O
cope	O
with	O
the	O
frequent	O
deaths	O
of	O
their	O
patients	O
,	O
ultimately	O
aiming	O
to	O
provide	O
compassionate	O
care	O
while	O
minimizing	O
burnout	B-T033
.	O
This	O
study	O
investigated	O
the	O
role	O
of	O
personally	O
meaningful	O
rituals	O
in	O
increasing	O
compassion	O
and	O
decreasing	O
burnout	B-T033
among	O
hospice	B-T058
staff	O
and	O
volunteers	O
.	O
An	O
online	O
survey	O
was	O
completed	O
by	O
members	O
of	O
the	O
National	O
Hospice	B-T058
and	O
Palliative	O
Care	O
Organization	O
(	O
NHPCO	O
)	O
which	O
inquired	O
about	O
personal	O
ritual	O
practices	O
,	O
and	O
included	O
the	O
Professional	O
Quality	O
of	O
Life	O
(	O
ProQOL	O
)	O
scale	O
to	O
measure	O
current	O
levels	O
of	O
Compassion	O
Satisfaction	O
,	O
Burnout	B-T033
,	O
and	O
Secondary	B-T048
Traumatic	I-T048
Stress	I-T048
.	O
Three	O
hundred	O
ninety	O
hospice	B-T058
staff	O
and	O
volunteers	O
from	O
across	O
38	O
states	O
completed	O
the	O
online	O
survey	O
.	O
The	O
majority	O
of	O
participants	O
were	O
Caucasian	O
and	O
female	O
,	O
with	O
an	O
average	O
of	O
nine	O
years	O
of	O
experience	O
in	O
hospice	B-T058
and	O
palliative	O
care	O
.	O
The	O
majority	O
of	O
hospice	B-T058
staff	O
and	O
volunteers	O
used	O
personally	O
meaningful	O
rituals	O
after	O
the	O
death	O
of	O
their	O
patients	O
to	O
help	O
them	O
cope	O
(	O
71	O
%	O
)	O
.	O
Those	O
who	O
used	O
rituals	O
demonstrated	O
significantly	O
higher	O
Compassion	O
Satisfaction	O
and	O
significantly	O
lower	O
Burnout	B-T033
as	O
measured	O
by	O
the	O
ProQOL	O
,	O
with	O
professional	B-T033
support	I-T033
,	O
social	O
support	O
,	O
and	O
age	O
playing	O
significant	B-T033
roles	I-T033
as	O
well	O
.	O
Rituals	O
may	O
be	O
an	O
important	O
way	O
to	O
increase	O
compassion	O
and	O
decrease	O
burnout	B-T033
among	O
hospice	B-T058
staff	O
and	O
volunteers	O
.	O
Organizations	O
may	O
benefit	O
from	O
providing	O
training	O
and	O
support	O
for	O
personalized	O
rituals	O
among	O
team	O
members	O
,	O
especially	O
new	O
staff	O
who	O
may	O
be	O
at	O
greater	O
risk	O
for	O
burnout	B-T033
.	O
      
A	O
case	O
based	O
reflection	B-T033
on	O
communicating	O
end	O
of	O
life	O
information	O
in	O
non	B-T033
-	I-T033
English	I-T033
speaking	I-T033
patients	O
Mr	O
X	O
was	O
a	O
56	O
year	O
old	O
Chinese	O
man	O
(	O
non	B-T033
-	I-T033
English	I-T033
speaking	I-T033
)	O
,	O
who	O
presented	O
to	O
the	O
emergency	O
department	O
with	O
a	O
range	O
of	O
non	O
-	O
specific	O
symptoms	B-T184
.	O
On	O
full	O
workup	O
,	O
he	O
was	O
diagnosed	B-T033
with	O
an	O
advanced	B-T191
cancer	I-T191
of	I-T191
the	I-T191
pancreas	I-T191
.	O
It	O
was	O
an	O
aggressive	B-T191
,	O
highly	O
treatment	B-T047
resistant	I-T047
cancer	I-T047
,	O
with	O
an	O
alarmingly	O
poor	B-T033
prognosis	I-T033
.	O
Before	O
the	O
diagnosis	B-T033
had	O
been	O
made	O
,	O
the	O
family	O
had	O
informed	O
our	O
team	B-T058
that	O
we	O
were	O
not	O
to	O
discuss	O
medical	O
issues	B-T033
with	O
Mr	O
X	O
directly	O
,	O
and	O
that	O
upon	O
arriving	O
on	O
a	O
diagnosis	B-T033
we	O
were	O
to	O
come	O
to	O
them	O
first	O
and	O
they	O
would	O
subsequently	O
inform	O
him	O
.	O
They	O
reported	O
that	O
Mr	O
X	O
was	O
in	O
support	O
of	O
this	O
arrangement	O
.	O
Eventually	O
we	O
told	O
the	O
family	O
about	O
Mr	O
X	O
's	O
diagnosis	B-T033
,	O
and	O
they	O
asserted	O
their	O
collective	O
will	O
to	O
keep	O
this	O
information	O
from	O
him	O
,	O
reaffirming	O
that	O
all	O
medical	O
discussion	B-T061
go	O
through	O
them	O
.	O
However	O
,	O
the	O
doctor	O
in	O
charge	O
explained	O
the	O
diagnosis	B-T033
to	O
Mr	O
X	O
using	O
an	O
interpreter	O
while	O
his	O
family	O
were	O
away	O
from	O
his	O
bed	O
.	O
In	O
this	O
discussion	O
,	O
I	O
consider	O
this	O
case	O
from	O
the	O
perspective	O
of	O
respecting	B-T061
patients	I-T061
'	I-T061
and	I-T061
families	I-T061
'	I-T061
preferences	I-T061
around	O
medical	B-T058
treatment	I-T058
and	I-T058
care	I-T058
.	O
      
Numerical	O
simulation	O
of	O
emitted	O
particle	O
characteristics	O
and	O
airway	B-T023
deposition	O
distribution	O
of	O
Symbicort	B-T121
(	I-T121
®	I-T121
)	I-T121
Turbuhaler	I-T121
(	I-T121
®	I-T121
)	I-T121
dry	O
powder	O
fixed	O
combination	B-T121
aerosol	O
drug	O
One	O
of	O
the	O
most	O
widespread	O
dry	O
powder	O
fixed	O
combinations	B-T121
used	O
in	O
asthma	B-T047
and	O
chronic	B-T047
obstructive	I-T047
pulmonary	I-T047
disease	I-T047
(	O
COPD	B-T047
)	O
management	B-T058
is	O
Symbicort	B-T121
(	I-T121
®	I-T121
)	I-T121
Turbuhaler	I-T121
(	I-T121
®	I-T121
)	I-T121
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
simulate	O
the	O
deposition	O
distribution	O
of	O
both	O
components	O
of	O
this	O
drug	B-T121
within	O
the	O
airways	B-T023
based	O
on	O
realistic	O
airflow	B-T060
measurements	I-T060
.	O
Breathing	O
parameters	O
of	O
25	O
healthy	B-T033
adults	I-T033
(	O
11	O
females	O
and	O
14	O
males	O
)	O
were	O
acquired	O
while	O
inhaling	O
through	O
Turbuhaler	O
(	O
®	O
)	O
.	O
Individual	O
specific	O
emitted	O
doses	O
and	O
particle	O
size	O
distributions	O
of	O
Symbicort	B-T121
(	I-T121
®	I-T121
)	I-T121
Turbuhaler	I-T121
(	I-T121
®	I-T121
)	I-T121
were	O
determined	O
.	O
A	O
self	O
-	O
developed	O
particle	O
deposition	O
model	O
was	O
adapted	O
and	O
validated	O
to	O
simulate	O
the	O
deposition	O
of	O
budesonide	B-T121
(	O
inhaled	B-T121
corticosteroid	I-T121
;	O
ICS	B-T121
)	O
and	O
formoterol	B-T121
(	O
long	B-T121
acting	I-T121
β2	I-T121
agonist	I-T121
;	O
LABA	B-T121
)	O
in	O
the	O
upper	O
airways	O
and	O
lungs	B-T023
of	O
the	O
healthy	O
volunteers	O
.	O
Based	O
on	O
current	O
simulations	O
the	O
emitted	O
doses	O
varied	O
between	O
50.4	O
%	O
and	O
92.5	O
%	O
of	O
the	O
metered	O
dose	O
for	O
the	O
ICS	B-T121
,	O
and	O
between	O
38	O
%	O
and	O
96.1	O
%	O
in	O
case	O
of	O
LABA	B-T121
component	O
depending	O
on	O
the	O
individual	O
inhalation	O
flow	O
rate	O
.	O
This	O
variability	O
induced	O
a	O
notable	O
inter-	O
individual	O
spread	O
of	O
the	O
deposited	O
lung	B-T023
doses	O
(	O
mean	O
:	O
33.6	O
%	O
,	O
range	O
:	O
20.4%-48.8	O
%	O
for	O
budesonide	B-T121
and	O
mean	O
:	O
29.8	O
%	O
,	O
range	O
:	O
16.4%-42.9	O
%	O
for	O
formoterol	B-T121
)	O
.	O
Significant	O
inter	O
-	O
gender	O
differences	O
were	O
also	O
observed	O
.	O
Average	O
lung	B-T023
dose	O
of	O
budesonide	B-T121
was	O
29.2	O
%	O
of	O
the	O
metered	O
dose	O
for	O
females	O
and	O
37	O
%	O
for	O
males	O
,	O
while	O
formoterol	B-T121
deposited	O
with	O
26.4	O
%	O
efficiency	O
for	O
females	O
and	O
32.5	O
%	O
for	O
males	O
.	O
Present	O
results	O
also	O
highlighted	O
the	O
importance	O
of	O
breath	B-T033
-	I-T033
holding	I-T033
after	O
inhalation	O
of	O
the	O
drug	B-T121
.	O
About	O
a	O
half	O
of	O
the	O
total	O
lung	B-T023
deposition	O
occurred	O
during	O
breath	B-T033
-	I-T033
hold	I-T033
at	O
9.6s	O
average	O
breath	B-T033
-	I-T033
hold	I-T033
time	O
.	O
Calculated	O
depositions	O
confirmed	O
appropriate	O
lung	B-T023
deposition	O
of	O
Symbicort	B-T121
(	I-T121
®	I-T121
)	I-T121
Turbuhaler	I-T121
(	I-T121
®	I-T121
)	I-T121
for	O
both	O
genders	O
,	O
however	O
more	O
effort	O
for	O
optimal	B-T061
inhalation	I-T061
technique	I-T061
is	O
advised	O
for	O
persons	O
with	O
low	B-T033
vital	I-T033
capacity	I-T033
.	O
This	O
study	O
demonstrated	O
the	O
possibility	O
of	O
personalized	O
prediction	O
of	O
airway	B-T023
deposition	O
of	O
aerosol	O
drugs	O
by	O
numerical	O
simulations	O
.	O
The	O
methodology	O
developed	O
in	O
this	O
study	O
will	O
be	O
applicable	O
also	O
to	O
other	O
marketed	O
drugs	B-T121
in	O
the	O
future	O
.	O
      
Heart	O
rate	O
variability	O
as	O
a	O
biomarker	O
for	O
sedation	B-T033
depth	I-T033
estimation	O
in	O
ICU	O
patients	O
An	O
automated	O
patient	O
-	O
specific	O
system	O
to	O
classify	O
the	O
level	B-T033
of	I-T033
sedation	I-T033
in	O
ICU	O
patients	O
using	O
heart	O
rate	O
variability	O
signal	O
is	O
presented	O
in	O
this	O
paper	O
.	O
ECG	B-T033
from	O
70	O
mechanically	B-T061
ventilated	I-T061
adult	O
patients	O
with	O
administered	O
sedatives	B-T121
in	O
an	O
ICU	O
setting	O
were	O
used	O
to	O
develop	O
a	O
support	O
vector	O
machine	O
based	O
system	O
for	O
sedation	B-T033
depth	I-T033
monitoring	B-T058
using	O
several	O
heart	O
rate	O
variability	O
measures	O
.	O
A	O
leave	O
-	O
one	O
-	O
subject	O
-	O
out	O
cross	O
validation	O
was	O
used	O
for	O
classifier	O
training	O
and	O
performance	O
evaluations	B-T058
.	O
The	O
proposed	O
patient	O
-	O
specific	O
system	O
provided	O
a	O
sensitivity	O
,	O
specificity	O
and	O
an	O
AUC	O
of	O
64	O
%	O
,	O
84.8	O
%	O
and	O
0.72	O
,	O
respectively	O
.	O
It	O
is	O
hoped	O
that	O
with	O
the	O
help	O
of	O
additional	O
physiological	O
signals	O
the	O
proposed	O
patient	O
-	O
specific	O
sedation	B-T033
level	I-T033
prediction	O
system	O
could	O
lead	O
to	O
a	O
fully	O
automated	O
multimodal	O
system	O
to	O
assist	O
clinical	O
staff	O
in	O
ICUs	O
to	O
interpret	O
the	O
sedation	B-T033
level	I-T033
of	O
the	O
patient	O
.	O
      
Epidemiology	O
and	O
outcomes	O
of	O
injuries	O
in	O
Kenya	O
:	O
A	O
multisite	O
surveillance	O
study	O
Injury	O
is	O
a	O
leading	O
cause	O
of	O
disability	B-T033
and	O
death	B-T033
worldwide	O
,	O
accounting	O
for	O
over	O
5	O
million	O
deaths	B-T033
each	O
year	O
.	O
The	O
injury	O
burden	O
is	O
higher	O
in	O
low-	O
and	O
middle	O
-	O
income	O
countries	O
where	O
more	O
than	O
90	O
%	O
of	O
injury	B-T033
-related	I-T033
deaths	I-T033
occur	O
.	O
Despite	O
this	O
burden	O
,	O
the	O
use	O
of	O
prospective	O
trauma	O
registries	O
to	O
describe	O
injury	O
epidemiology	O
and	O
outcomes	O
is	O
limited	O
in	O
low-	O
and	O
middle	O
-	O
income	O
countries	O
.	O
Kenya	O
lacks	O
robust	O
data	O
to	O
describe	O
injury	O
epidemiology	O
and	O
care	O
.	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
epidemiology	O
and	O
outcomes	O
of	O
injuries	O
at	O
4	O
referral	O
hospitals	O
in	O
Kenya	O
using	O
hospital	O
-based	O
trauma	O
registries	O
.	O
From	O
January	O
2014	O
to	O
May	O
2015	O
,	O
all	O
injured	O
patients	O
presenting	O
to	O
the	O
casualty	O
departments	O
of	O
Kenyatta	O
National	O
,	O
Thika	O
Level	O
5	O
,	O
Machakos	O
Level	O
5	O
,	O
and	O
Meru	O
Level	O
5	O
Hospitals	O
were	O
enrolled	O
prospectively	O
.	O
Data	O
collected	O
included	O
demographic	O
characteristics	O
,	O
type	O
of	O
prehospital	B-T058
care	I-T058
received	O
,	O
prehospital	O
time	O
,	O
injury	O
pattern	O
,	O
and	O
outcomes	O
.	O
A	O
total	O
of	O
14,237	O
patients	O
were	O
enrolled	O
in	O
our	O
study	O
.	O
Patients	O
were	O
predominantly	O
male	O
(	O
76.1	O
%	O
)	O
and	O
young	O
(	O
mean	O
age	O
28	O
years	O
)	O
.	O
The	O
most	O
common	O
mechanisms	O
of	O
injury	O
were	O
road	O
traffic	O
injuries	O
(	O
36.8	O
%	O
)	O
,	O
falls	O
(	O
26.4	O
%	O
)	O
,	O
and	O
being	O
struck	O
/	O
hit	O
by	O
a	O
person	O
or	O
object	O
(	O
20.1	O
%	O
)	O
.	O
Burn	O
was	O
the	O
most	O
common	O
mechanism	O
of	O
injury	O
in	O
the	O
age	O
category	O
under	O
5	O
years	O
.	O
Body	O
regions	O
commonly	O
injured	O
were	O
lower	B-T023
extremity	I-T023
(	O
35.1	O
%	O
)	O
,	O
upper	B-T023
extremity	I-T023
(	O
33.4	O
%	O
)	O
,	O
and	O
head	O
(	O
26.0	O
%	O
)	O
.	O
The	O
overall	O
mortality	O
rate	O
was	O
2.4	O
%	O
.	O
Significant	O
predictors	O
of	O
mortality	O
from	O
multivariate	O
analysis	O
were	O
Glasgow	B-T033
Coma	I-T033
Scale	I-T033
≤12	I-T033
,	O
estimated	O
injury	O
severity	O
score	O
≥9	O
,	O
burns	O
,	O
and	O
gunshot	O
injuries	O
.	O
Hospital	O
-based	O
trauma	O
registries	O
can	O
be	O
important	O
sources	O
of	O
data	O
to	O
study	O
the	O
epidemiology	O
of	O
injuries	O
in	O
low-	O
and	O
middle	O
-	O
income	O
countries	O
.	O
Data	O
from	O
such	O
trauma	O
registries	O
can	O
highlight	O
key	O
needs	O
and	O
be	O
used	O
to	O
design	O
public	O
health	O
interventions	B-T061
and	O
quality	B-T058
-	I-T058
of	I-T058
-	I-T058
care	I-T058
improvement	I-T058
programs	I-T058
.	O
      
Patient	O
Satisfaction	O
With	O
Postpartum	O
Teaching	O
Methods	O
Postpartum	O
discharge	O
instructions	O
are	O
a	O
crucial	O
part	O
of	O
a	O
mother	O
's	O
birth	O
experience	O
.	O
Finding	B-T033
the	O
method	O
to	O
provide	O
those	O
discharge	O
instructions	O
in	O
a	O
manner	O
that	O
increases	O
the	O
mother	O
's	O
satisfaction	O
with	O
her	O
hospital	O
experience	O
is	O
important	O
.	O
This	O
quasi	O
-	O
experimental	O
study	O
examined	B-T033
the	O
relationship	O
between	O
new	O
mothers	O
'	O
interaction	B-T033
with	O
nurses	O
providing	O
postpartum	O
instructions	O
by	O
the	O
traditional	O
and	O
class	O
methods	O
and	O
their	O
satisfaction	O
with	O
discharge	O
teaching	O
.	O
The	O
results	O
indicated	O
new	O
mothers	O
were	O
satisfied	O
with	O
both	O
methods	O
of	O
discharge	O
teaching	O
;	O
however	O
,	O
they	O
were	O
more	O
likely	O
to	O
report	O
stronger	O
agreement	O
with	O
overall	O
satisfaction	O
with	O
the	O
traditional	O
method	O
of	O
discharge	O
teaching	O
than	O
with	O
attending	O
the	O
discharge	O
class	O
.	O
      
Inhibited	O
Temperament	O
and	O
Hippocampal	B-T023
Volume	O
in	O
Offspring	O
of	O
Parents	O
with	O
Bipolar	B-T048
Disorder	I-T048
Prior	O
studies	O
have	O
suggested	O
that	O
inhibited	O
temperament	O
may	O
be	O
associated	O
with	O
an	O
increased	O
risk	O
for	O
developing	O
anxiety	B-T048
or	O
mood	B-T048
disorder	I-T048
,	O
including	O
bipolar	B-T048
disorder	I-T048
.	O
However	O
,	O
the	O
neurobiological	O
basis	O
for	O
this	O
increased	O
risk	O
is	O
unknown	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	B-T033
temperament	O
in	O
symptomatic	O
and	O
asymptomatic	B-T033
child	O
offspring	O
of	O
parents	O
with	O
bipolar	B-T048
disorder	I-T048
(	O
OBD	B-T048
)	O
and	O
to	O
investigate	O
whether	O
inhibited	O
temperament	O
is	O
associated	O
with	O
aberrant	O
hippocampal	B-T023
volumes	O
compared	O
with	O
healthy	O
control	O
(	O
HC	O
)	O
youth	O
.	O
The	O
OBD	B-T048
group	O
consisted	O
of	O
45	O
youth	O
,	O
24	O
of	O
whom	O
had	O
current	O
psychiatric	B-T184
symptoms	I-T184
(	B-T048
OBD(+)s	I-T048
)	I-T048
and	O
21	O
without	O
any	O
psychiatric	B-T184
symptoms	I-T184
(	O
OBD(-)s	O
)	O
,	O
and	O
were	O
compared	O
with	O
24	O
HC	O
youth	O
.	O
Temperament	O
characteristics	O
were	O
measured	O
by	O
using	O
the	O
Revised	B-T060
Dimensions	I-T060
of	I-T060
Temperament	I-T060
Survey	I-T060
.	O
Magnetic	B-T060
resonance	I-T060
imaging	I-T060
was	O
used	O
to	O
measure	O
hippocampal	B-T023
volumes	O
.	O
The	O
association	O
between	O
temperament	O
and	O
hippocampal	B-T023
volumes	O
was	O
tested	O
by	O
using	O
multiple	O
regression	O
analysis	O
.	O
Compared	O
with	O
the	O
OBD(-)s	O
group	O
,	O
the	O
OBD(+)s	B-T048
group	O
had	O
significantly	O
more	O
inhibited	O
temperament	O
traits	O
,	O
less	O
flexibility	O
,	O
more	O
negative	B-T033
mood	O
,	O
and	O
less	O
regular	O
rhythm	B-T033
in	O
their	O
daily	O
routines	O
.	O
In	O
contrast	O
,	O
the	O
OBD(-)s	O
group	O
was	O
more	O
likely	O
to	O
approach	O
novel	O
situations	O
compared	O
with	O
OBD(+)s	B-T048
or	O
HC	O
groups	O
.	O
Within	O
the	O
OBD(+)s	B-T048
group	O
,	O
a	O
more	O
inhibited	O
temperament	O
was	O
associated	O
with	O
smaller	O
right	O
hippocampal	B-T023
volumes	O
.	O
In	O
this	O
study	O
,	O
symptomatic	O
OBD	B-T048
were	O
characterized	O
by	O
an	O
inhibited	O
temperament	O
that	O
was	O
inversely	O
correlated	O
with	O
hippocampal	B-T023
volume	O
.	O
Additional	O
longitudinal	O
studies	O
are	O
needed	O
to	O
determine	O
whether	O
inverse	O
correlations	O
between	O
hippocampal	B-T023
volume	O
and	O
inhibited	O
temperament	O
represent	O
early	O
markers	O
of	O
risk	O
for	O
later	O
developing	O
bipolar	B-T048
disorder	I-T048
.	O
      
Far	O
-	O
infrared	O
protects	B-T033
vascular	O
endothelial	O
cells	O
from	O
advanced	O
glycation	O
end	O
products	O
-	O
induced	O
injury	O
via	O
PLZF	O
-mediated	O
autophagy	O
in	O
diabetic	O
mice	O
The	O
accumulation	O
of	O
advanced	O
glycation	O
end	O
products	O
(	O
AGEs	O
)	O
in	O
diabetic	B-T047
patients	O
induces	O
vascular	O
endothelial	O
injury	O
.	O
Promyelocytic	O
leukemia	O
zinc	O
finger	O
protein	O
(	O
PLZF	O
)	O
is	O
a	O
transcription	O
factor	O
that	O
can	O
be	O
activated	O
by	O
low	O
-	O
temperature	O
far	O
-	O
infrared	O
(	O
FIR	O
)	O
irradiation	O
to	O
exert	O
beneficial	O
effects	O
on	O
the	O
vascular	O
endothelium	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
influence	O
of	O
FIR	O
-	O
induced	O
PLZF	O
activation	O
on	O
AGE	O
-	O
induced	O
endothelial	O
injury	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
FIR	O
irradiation	O
inhibited	O
AGE	O
-	O
induced	O
apoptosis	O
in	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
.	O
PLZF	O
activation	O
increased	O
the	O
expression	O
of	O
phosphatidylinositol-3	O
kinases	O
(	O
PI3	O
K	O
)	O
,	O
which	O
are	O
important	O
kinases	O
in	O
the	O
autophagic	O
signaling	O
pathway	O
.	O
FIR	O
-	O
induced	O
PLZF	O
activation	O
led	O
to	O
autophagy	O
in	O
HUVEC	O
,	O
which	O
was	O
mediated	O
through	O
the	O
upregulation	O
of	O
PI3K.	O
Immunofluorescence	B-T059
staining	B-T059
showed	O
that	O
AGEs	O
were	O
engulfed	O
by	O
HUVECs	O
and	O
localized	O
to	O
lysosomes	O
.	O
FIR	O
-	O
induced	O
autophagy	O
promoted	O
AGEs	O
degradation	O
in	O
HUVECs	O
.	O
In	O
nicotinamide	B-T121
/	O
streptozotocin	B-T195
-	O
induced	O
diabetic	O
mice	O
,	O
FIR	O
therapy	B-T061
reduced	O
serum	O
AGEs	O
and	O
AGEs	O
deposition	O
at	O
the	O
vascular	O
endothelium	O
.	O
FIR	O
therapy	B-T061
also	O
reduced	O
diabetes	B-T047
-	O
induced	O
inflammatory	B-T033
markers	I-T033
in	O
the	O
vascular	O
endothelium	O
and	O
improved	B-T033
vascular	O
endothelial	O
function	O
.	O
These	O
protective	O
effects	O
of	O
FIR	O
therapy	B-T061
were	O
not	B-T033
found	I-T033
in	O
PLZF	O
-	O
knockout	O
mice	O
.	O
Our	O
data	O
suggest	O
that	O
FIR	O
-	O
induced	O
PLZF	O
activation	O
in	O
vascular	O
endothelial	O
cells	O
protects	O
the	O
vascular	O
endothelium	O
in	O
diabetic	O
mice	O
from	O
AGE	O
-	O
induced	O
injury	O
.	O
      
Clonal	O
and	O
serotype	O
dynamics	O
of	O
serogroup	B-T007
6	I-T007
isolates	O
causing	O
invasive	B-T047
pneumococcal	I-T047
disease	I-T047
in	O
Portugal	O
:	O
1999	O
-	O
2012	O
Although	O
serogroup	B-T007
6	I-T007
was	O
among	O
the	O
first	O
to	O
be	O
recognized	O
among	O
Streptococcus	B-T007
pneumoniae	I-T007
,	O
several	O
new	O
serotypes	O
were	O
identified	O
since	O
the	O
introduction	O
of	O
pneumococcal	B-T121
conjugate	I-T121
vaccines	I-T121
(	O
PCVs	B-T121
)	O
.	O
A	O
decrease	O
of	O
the	O
6B-2	O
variant	O
among	O
invasive	B-T047
pneumococcal	I-T047
disease	I-T047
(	O
IPD	B-T047
)	O
,	O
but	O
not	O
6B-1	O
,	O
was	O
noted	O
post	O
conjugate	B-T121
vaccine	I-T121
introduction	O
,	O
underpinned	O
by	O
a	O
decrease	O
of	O
CC273	O
isolates	O
.	O
Serotype	B-T007
6C	I-T007
was	O
associated	O
with	O
adult	O
IPD	B-T047
and	O
increased	O
in	O
this	O
age	O
group	O
representing	O
two	O
lineages	O
(	O
CC315	O
and	O
CC395	O
)	O
,	O
while	O
the	O
same	O
lineages	O
expressed	O
other	O
serogroup	B-T007
6	I-T007
serotypes	O
in	O
children	O
.	O
Taken	O
together	O
,	O
these	O
findings	O
suggest	O
a	O
potential	O
cross	O
-	O
protection	O
of	O
PCVs	B-T121
against	O
serotype	B-T007
6C	I-T007
IPD	B-T047
among	O
vaccinated	B-T033
children	O
but	O
not	O
among	O
adults	O
.	O
Serotype	B-T007
6A	I-T007
became	O
the	O
most	O
important	O
serogroup	B-T007
6	I-T007
serotype	O
in	O
children	O
but	O
it	O
decreased	O
in	O
adult	O
IPD	B-T047
.	O
No	O
other	O
serogroup	B-T007
6	I-T007
serotypes	O
were	O
detected	B-T033
,	O
so	O
available	O
phenotypic	O
or	O
simple	O
genotypic	O
assays	B-T059
remain	O
adequate	O
for	O
distinguishing	O
serotypes	O
within	O
serogroup	B-T007
6	I-T007
isolates	O
.	O
      
Long	B-T121
-	I-T121
chain	I-T121
n-3	I-T121
PUFA	I-T121
supplied	O
by	O
the	O
usual	O
diet	O
decrease	O
plasma	O
stearoyl	O
-	O
CoA	O
desaturase	O
index	O
in	O
non	B-T033
-	I-T033
hypertriglyceridemic	I-T033
older	O
adults	O
at	O
high	O
vascular	B-T023
risk	O
The	O
activity	O
of	O
stearoyl	O
-	O
CoA	O
desaturase-1	O
(	O
SCD1	O
)	O
,	O
the	O
central	O
enzyme	O
in	O
the	O
synthesis	O
of	O
monounsaturated	O
fatty	O
acids	O
(	O
MUFA	O
)	O
,	O
has	O
been	O
associated	O
with	O
de	O
novo	O
lipogenesis	O
.	O
In	O
experimental	O
models	O
SCD1	O
is	O
down	O
-	O
regulated	O
by	O
polyunsaturated	O
fatty	O
acids	O
(	O
PUFA	O
)	O
,	O
but	O
clinical	O
studies	O
are	O
scarce	O
.	O
The	O
effect	O
of	O
long	B-T121
-	I-T121
chain	I-T121
n-3	I-T121
PUFA	I-T121
(	O
LCn-3PUFA	B-T121
)	O
supplied	O
by	O
the	O
regular	O
diet	O
,	O
in	O
the	O
absence	O
of	O
fatty	O
fish	O
or	O
fish	O
oil	O
supplementation	O
,	O
remains	O
to	O
be	O
explored	O
.	O
We	O
related	O
1	O
-	O
y	O
changes	O
in	O
plasma	O
SCD1	O
index	O
,	O
as	O
assessed	O
by	O
the	O
C16:1n-7	O
/	O
C16:0	O
ratio	O
,	O
to	O
both	O
adiposity	O
traits	O
and	O
nutrient	B-T033
intake	I-T033
changes	O
in	O
a	O
sub	O
-	O
cohort	O
(	O
n	O
=	O
243	O
)	O
of	O
non	B-T033
-	I-T033
hypertriglyceridemic	I-T033
subjects	O
of	O
the	O
PREDIMED	O
(	O
PREvención	O
con	O
DIeta	O
MEDiterranea	O
)	O
trial	O
.	O
After	O
adjustment	O
for	O
confounders	O
,	O
including	O
changes	O
in	O
fasting	B-T033
triglycerides	O
,	O
plasma	O
SCD1	O
index	O
increased	O
in	O
parallel	O
with	O
body	O
weight	O
(	O
0.221	O
[	O
95	O
%	O
confidence	O
interval	O
,	O
0.021	O
to	O
0.422	O
]	O
,	O
P	O
=	O
0.031	O
)	O
and	O
BMI	O
(	O
0.115	O
[	O
0.027	O
to	O
0.202	O
]	O
,	O
P	O
=	O
0.011	O
)	O
.	O
Additionally	O
,	O
dietary	O
LCn-3PUFA	B-T121
(	O
but	O
not	O
MUFA	O
or	O
plant	O
-	O
derived	O
PUFA	O
)	O
were	O
associated	O
with	O
decreased	O
plasma	O
SCD1	O
index	O
(	O
-0.544	O
[	O
-1.044	O
to	O
-0.043	O
]	O
,	O
P	O
=	O
0.033	O
,	O
for	O
each	O
1	O
g	O
/	O
d-	O
increase	O
in	O
LCn-3PUFA	B-T121
)	O
.	O
No	O
associations	O
were	O
found	O
for	O
other	O
food	O
groups	O
,	O
but	O
there	O
was	O
a	O
trend	O
for	O
fatty	O
fish	O
intake	O
(	O
-0.083	O
[	O
-0.177	O
to	O
0.012	O
]	O
,	O
P	O
=	O
0.085	O
,	O
for	O
each	O
10	O
g	O
/	O
d-	O
increase	O
)	O
.	O
Our	O
data	O
add	O
clinical	O
evidence	O
on	O
the	O
down	O
-	O
regulation	O
of	O
plasma	O
SCD1	O
index	O
by	O
LCn-3PUFA	B-T121
in	O
the	O
context	O
of	O
realistic	O
changes	O
in	O
fish	O
consumption	O
in	O
the	O
customary	O
,	O
non	B-T033
-	I-T033
supplemented	I-T033
diet	O
.	O
http://www.Controlled-trials.com/ISRCTN35739639	O
.	O
      
Chaetomium	O
thermophilum	O
formate	O
dehydrogenase	O
has	O
high	O
activity	O
in	O
the	O
reduction	O
of	O
hydrogen	O
carbonate	O
(	O
HCO3	O
-	O
)	O
to	O
formate	O
While	O
formate	O
dehydrogenases	O
(	O
FDHs	O
)	O
have	O
been	O
used	O
for	O
cofactor	O
recycling	O
in	O
chemoenzymatic	O
synthesis	O
,	O
the	O
ability	O
of	O
FDH	O
to	O
reduce	O
CO2	O
could	O
also	O
be	O
utilized	O
in	O
the	O
conversion	O
of	O
CO2	O
to	O
useful	O
products	O
via	O
formate	O
(	O
HCOO(-	O
)	O
)	O
.	O
In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
reduction	O
of	O
CO2	O
in	O
the	O
form	O
of	O
hydrogen	O
carbonate	O
(	O
HCO3(-	O
)	O
)	O
to	O
formate	O
by	O
FDHs	O
from	O
Candida	O
methylica	O
(	O
CmFDH	O
)	O
and	O
Chaetomium	O
thermophilum	O
(	O
CtFDH	O
)	O
in	O
a	O
NADH	B-T121
-dependent	O
reaction	O
.	O
The	O
catalytic	O
performance	O
with	O
HCO3(-	O
)	O
as	O
a	O
substrate	O
was	O
evaluated	O
by	O
measuring	O
the	O
kinetic	O
rates	O
and	O
conducting	O
productivity	B-T059
assays	I-T059
.	O
CtFDH	O
showed	O
a	O
higher	O
efficiency	O
in	O
converting	O
HCO3(-	O
)	O
to	O
formate	O
than	O
CmFDH	O
,	O
whereas	O
CmFDH	O
was	O
better	O
in	O
the	O
oxidation	O
of	O
formate	O
.	O
The	O
pH	O
optimum	O
of	O
the	O
reduction	O
was	O
at	O
pH	O
7	O
-	O
8	O
.	O
However	O
,	O
the	O
high	O
concentrations	O
of	O
HCO3(-	O
)	O
reduced	O
the	O
reaction	O
rate	O
.	O
CtFDH	O
was	O
modeled	O
in	O
the	O
presence	O
of	O
HCO3(-	O
)	O
showing	O
that	O
it	O
fits	O
to	O
the	O
active	O
site	O
.	O
The	O
active	O
site	O
setting	O
for	O
hydride	O
transfer	O
in	O
CO2	O
reduction	O
was	O
modeled	O
.	O
The	O
hydride	O
donated	O
by	O
NADH	B-T121
would	O
form	O
a	O
favorable	O
contact	O
to	O
the	O
carbon	O
atom	O
of	O
HCO3(-	O
)	O
,	O
resulting	O
in	O
a	O
surplus	O
of	O
electrons	O
within	O
the	O
molecule	O
.	O
This	O
would	O
cause	O
the	O
complex	O
formed	O
by	O
hydrogen	O
carbonate	O
and	O
the	O
hydride	O
to	O
break	O
into	O
formate	O
and	O
hydroxide	O
ions	O
.	O
      
Central	B-T191
Myxoma	I-T191
/	O
Myxofibroma	B-T191
of	O
the	O
Jaws	B-T023
:	O
A	O
Clinico	O
-	O
Epidemiologic	O
Review	O
Myxomas	B-T191
are	O
a	O
group	O
of	O
benign	O
rare	B-T047
tumors	I-T047
of	O
connective	O
-	O
tissue	O
origin	O
that	O
occur	O
in	O
both	O
hard	O
(	O
central	O
)	O
and	O
soft	O
tissues	O
of	O
the	O
body	O
.	O
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
highlight	O
our	O
experience	O
in	O
the	O
management	O
of	O
central	B-T191
myxoma	I-T191
of	I-T191
the	I-T191
jaw	I-T191
,	O
with	O
emphasis	O
on	O
its	O
clinic	O
-	O
epidemiologic	O
features	O
as	O
seen	O
in	O
our	O
environment	O
.	O
All	O
patients	O
who	O
were	O
managed	O
for	O
central	B-T191
myxoma	I-T191
of	I-T191
the	I-T191
jaw	I-T191
at	O
the	O
Oral	O
and	O
Maxillofacial	O
Surgery	O
department	O
of	O
a	O
regional	O
University	O
Teaching	O
Hospital	O
between	O
September	O
1997	O
and	O
October	O
2015	O
were	O
retrospectively	O
studied	O
.	O
Details	O
sourced	O
included	O
age	O
,	O
sex	O
,	O
site	O
of	O
tumor	O
,	O
duration	O
,	O
signs	B-T033
/	I-T033
symptoms	I-T033
,	O
treatment	B-T033
given	I-T033
,	O
and	O
complications	O
.	O
Data	O
were	O
analyzed	O
using	O
Statistical	O
Package	O
for	O
Social	O
Sciences	O
(	O
SPSS	O
)	O
version	O
16	O
(	O
SPSS	O
Inc	O
.	O
,	O
Chicago	O
,	O
IL	O
,	O
USA	O
)	O
and	O
Microsoft	O
Excel	O
2007	O
(	O
Microsoft	O
,	O
Redmond	O
,	O
WA	O
,	O
USA	O
)	O
.	O
Results	O
from	O
descriptive	O
statistics	O
were	O
represented	O
in	O
the	O
form	O
of	O
tables	O
and	O
charts	O
,	O
with	O
a	O
test	O
for	O
significance	O
(	O
ρ	O
)	O
using	O
Pearson	O
Chi	O
-	O
square	O
(	O
χ(2	O
)	O
)	O
set	O
at	O
0.05	O
.	O
A	O
total	O
of	O
16	O
patients	O
were	O
managed	O
within	O
the	O
period	O
reviewed	O
,	O
consisting	O
of	O
10	O
(	O
62.5	O
%	O
)	O
females	O
and	O
six	O
(	O
37.5	O
%	O
)	O
males	O
,	O
giving	O
a	O
male	O
-	O
to	O
-	O
female	O
ratio	O
of	O
1:1.7	O
.	O
The	O
ages	O
of	O
patients	O
ranged	O
from	O
5	O
to	O
70	O
years	O
,	O
with	O
a	O
mean	O
of	O
27.06±15.45	O
years	O
.	O
The	O
mandible	B-T023
accounted	O
for	O
nine	O
(	O
56.3	O
%	O
)	O
cases	O
and	O
the	O
maxilla	B-T023
for	O
six	O
(	O
37.5	O
%	O
)	O
cases	O
,	O
while	O
a	O
combination	O
of	O
the	O
maxilla	B-T023
and	O
the	O
zygoma	B-T023
were	O
involved	O
in	O
one	O
(	O
6.3	O
%	O
)	O
case	O
.	O
Bucco	B-T023
-	I-T023
lingual	I-T023
or	O
bucco	B-T023
-	I-T023
palatal	I-T023
expansion	O
were	O
the	O
most	O
common	O
presentation	O
(	O
six	O
[	O
46.2	O
%	O
]	O
cases	O
each	O
)	O
.	O
Histological	O
assessment	B-T058
of	O
tissue	O
specimens	O
showed	O
that	O
fibromyxoma	B-T191
accounted	O
for	O
seven	O
(	O
43.8	O
%	O
)	O
cases	O
,	O
while	O
the	O
remaining	O
nine	O
(	O
56.3	O
%	O
)	O
cases	O
were	O
diagnosed	B-T033
as	O
myxoma	B-T191
.	O
All	O
patients	O
had	O
jaw	B-T061
resections	I-T061
,	O
and	O
these	O
consisted	O
of	O
mandibulectomies	B-T061
in	O
nine	O
(	O
60.0	O
%	O
)	O
patients	O
and	O
maxillectomies	B-T061
in	O
six	O
(	O
40.0	O
%	O
)	O
patients	O
.	O
The	O
duration	O
of	O
hospital	O
stay	O
ranged	O
from	O
5	O
to	O
29	O
days	O
,	O
with	O
a	O
mean	O
of	O
17.86±7.68	O
days	O
.	O
Complications	O
were	O
noted	O
in	O
three	O
patients	O
,	O
and	O
all	O
were	O
surgical	O
wound	O
infections	O
.	O
Most	O
patients	O
in	O
our	O
environment	O
present	O
late	O
with	O
large	O
tumors	O
and	O
are	O
usually	O
not	O
compliant	O
with	O
follow	B-T058
-	I-T058
up	I-T058
review	O
.	O
Thus	O
,	O
a	O
radical	O
approach	O
is	O
favored	O
in	O
most	O
patients	O
.	O
      
Using	O
a	O
graphical	B-T058
risk	I-T058
tool	I-T058
to	O
examine	O
willingness	B-T033
to	I-T033
take	I-T033
migraine	B-T047
prophylactic	B-T061
medications	B-T121
Many	O
migraine	B-T047
sufferers	O
use	O
daily	O
prophylactic	B-T061
therapy	I-T061
to	O
reduce	O
the	O
frequency	O
of	O
their	O
headache	B-T184
attacks	O
.	O
The	O
Food	O
and	O
Drug	O
Administration	O
has	O
approved	O
several	O
different	O
medications	B-T121
for	O
migraine	B-T047
prophylaxis	B-T061
,	O
but	O
it	O
is	O
not	O
clear	O
whether	O
sufferers	O
perceive	O
these	O
treatments	B-T061
to	O
provide	O
clinically	O
significant	O
benefits	O
given	O
their	O
side	O
effect	O
profiles	B-T059
.	O
Three	O
hundred	O
headache	B-T184
sufferers	O
were	O
recruited	O
from	O
the	O
community	O
and	O
local	O
headache	B-T184
clinics	O
using	O
print	O
and	O
television	O
advertising	O
.	O
Participants	O
reported	O
experiencing	O
problematic	O
headache	B-T184
attacks	O
with	O
a	O
median	O
(	O
IQR	O
)	O
frequency	O
of	O
7.0	O
(	O
4	O
-	O
13	O
)	O
headache	B-T184
days	O
per	O
month	O
.	O
These	O
sufferers	O
participated	O
in	O
a	O
cross	O
-	O
sectional	O
,	O
single	O
-	O
site	O
,	O
study	O
that	O
used	O
a	O
specially	O
designed	O
computer	O
assessment	O
task	O
.	O
Participants	O
were	O
instructed	O
on	O
the	O
probability	O
of	O
experiencing	O
the	O
3	O
most	O
commonly	O
experienced	O
side	O
effects	O
for	O
several	O
blinded	O
medication	B-T121
profiles	B-T059
:	O
divalproex	B-T121
sodium	I-T121
,	O
venlafaxine	B-T121
,	O
gabapentin	B-T121
,	O
propranolol	B-T121
,	O
and	O
topiramate	B-T121
.	O
After	O
learning	O
the	O
likelihood	O
of	O
experiencing	O
side	O
effect	O
profiles	B-T059
of	O
each	O
medication	B-T121
,	O
participants	O
were	O
asked	O
whether	O
they	O
would	O
be	O
willing	B-T033
to	I-T033
take	I-T033
the	O
medication	B-T121
for	O
a	O
given	O
headache	B-T184
reduction	O
level	O
,	O
which	O
ranged	O
from	O
0	O
to	O
7	O
days	O
per	O
month	O
.	O
The	O
side	O
effect	O
profile	B-T059
for	O
divalproex	B-T121
sodium	I-T121
was	O
associated	O
with	O
the	O
smallest	B-T033
willingness	I-T033
to	I-T033
take	I-T033
,	O
with	O
gabapentin	B-T121
,	O
propranolol	B-T121
,	O
and	O
topiramate	B-T121
perceived	O
to	O
be	O
much	O
more	O
agreeable	O
.	O
However	O
,	O
<	O
60	O
%	O
of	O
participants	O
reported	O
willingness	B-T033
to	I-T033
take	I-T033
any	O
of	O
these	O
medications	B-T121
even	O
if	O
they	O
provided	O
a	O
50	O
%	O
reduction	O
in	O
headache	B-T184
frequency	O
.	O
Several	O
general	O
predictors	O
of	O
willingness	B-T033
to	I-T033
take	I-T033
were	O
observed	O
including	O
high	O
headache	B-T184
-related	O
disability	B-T033
,	O
depressive	B-T184
symptoms	I-T184
,	O
and	O
pain	B-T121
medication	I-T121
concerns	O
including	O
fear	O
of	O
tolerance	O
.	O
These	O
findings	B-T033
suggest	O
that	O
if	O
properly	O
informed	O
of	O
the	O
side	O
effect	O
profiles	B-T059
of	O
these	O
medications	B-T121
,	O
many	O
patients	O
might	O
opt	O
for	O
other	O
treatments	B-T061
.	O
      
Condition	O
-	O
dependent	O
co	O
-	O
regulation	O
of	O
genomic	O
clusters	O
of	O
virulence	O
factors	O
in	O
the	O
grapevine	B-T047
trunk	I-T047
pathogen	B-T001
Neofusicoccum	O
parvum	O
The	O
ascomycete	O
Neofusicoccum	O
parvum	O
,	O
one	O
of	O
the	O
causal	B-T033
agents	I-T033
of	O
Botryosphaeria	O
dieback	O
,	O
is	O
a	O
destructive	O
wood	O
-	O
infecting	B-T033
fungus	O
and	O
a	O
serious	O
threat	O
to	O
grape	O
production	O
worldwide	O
.	O
The	O
capability	O
of	O
colonizing	B-T033
woody	O
tissue	O
combined	O
with	O
the	O
secretion	O
of	O
phytotoxic	O
compounds	O
is	O
thought	O
to	O
underlie	O
its	O
pathogenicity	O
and	O
virulence	O
.	O
Here	O
,	O
we	O
describe	O
the	O
repertoire	O
of	O
virulence	O
factors	O
and	O
their	O
transcriptional	O
dynamics	O
as	O
the	O
fungus	O
feeds	O
on	O
different	O
substrates	O
and	O
colonizes	B-T033
the	O
woody	O
stem	O
.	O
We	O
assembled	O
and	O
annotated	O
a	O
highly	O
contiguous	O
genome	O
using	O
single	O
molecule	O
real	O
-	O
time	O
DNA	O
sequencing	O
.	O
Transcriptome	B-T059
profiling	I-T059
by	O
RNA	B-T059
-	I-T059
sequencing	I-T059
determined	O
the	O
genome	O
-wide	O
patterns	O
of	O
expression	O
of	O
virulence	O
factors	O
both	O
in	O
vitro	O
(	O
potato	O
dextrose	O
agar	O
or	O
medium	O
amended	O
with	O
grape	O
wood	O
as	O
substrate	O
)	O
and	O
in	O
planta	O
.	O
Pairwise	O
statistical	O
testing	O
of	O
differential	O
expression	O
followed	O
by	O
co	O
-	O
expression	O
network	O
analysis	O
revealed	O
that	O
physically	O
clustered	O
genes	O
coding	O
for	O
putative	O
virulence	O
functions	O
were	O
induced	O
depending	O
on	O
substrate	O
or	O
stage	O
of	O
plant	O
infection	O
.	O
Co	O
-	O
expressed	O
gene	O
clusters	O
were	O
significantly	O
enriched	O
not	O
only	O
in	O
genes	O
associated	O
with	O
secondary	O
metabolism	O
,	O
but	O
also	O
with	O
cell	O
wall	O
degradation	O
,	O
suggesting	O
that	O
dynamic	O
co	O
-	O
regulation	O
of	O
transcriptional	O
networks	O
contribute	O
to	O
multiple	O
aspects	O
of	O
N.	O
parvum	O
virulence	O
.	O
In	O
most	O
of	O
the	O
co	O
-	O
expressed	O
clusters	O
,	O
all	O
genes	O
shared	O
at	O
least	O
a	O
common	O
motif	O
in	O
their	O
promoter	O
region	O
indicative	O
of	O
co	O
-	O
regulation	O
by	O
the	O
same	O
transcription	O
factor	O
.	O
Co	O
-	O
expression	O
analysis	O
also	O
identified	O
chromatin	O
regulators	O
with	O
correlated	O
expression	O
with	O
inducible	O
clusters	O
of	O
virulence	O
factors	O
,	O
suggesting	O
a	O
complex	O
,	O
multi	O
-	O
layered	O
regulation	O
of	O
the	O
virulence	O
repertoire	O
of	O
N.	O
parvum	O
.	O
This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O
All	O
rights	O
reserved	O
.	O
      
Evaluation	B-T058
of	O
Tobacco	O
Control	O
Policies	O
in	O
San	O
Francisco	O
Homeless	O
Housing	O
Programs	O
The	O
2014	O
Surgeon	O
General	O
's	O
Report	O
noted	O
that	O
high	O
smoking	B-T033
rates	I-T033
in	O
vulnerable	O
populations	O
such	O
as	O
the	O
homeless	O
have	O
been	O
a	O
persistent	O
public	O
health	B-T033
problem	I-T033
;	O
smoking	O
prevalence	O
among	O
individuals	O
experiencing	O
homelessness	B-T033
exceeds	O
70	O
%	O
.	O
Historically	O
,	O
service	B-T058
providers	I-T058
for	O
the	O
homeless	O
have	O
not	O
enacted	O
comprehensive	O
tobacco	O
control	O
policies	O
.	O
We	O
conducted	O
a	O
qualitative	O
study	O
of	O
homeless	O
housing	O
programs	O
in	O
San	O
Francisco	O
.	O
Administrators	O
representing	O
9	O
of	O
the	O
city	O
's	O
11	O
homeless	O
service	O
agencies	O
were	O
interviewed	O
to	O
assess	B-T058
institutional	O
smoking	O
-related	O
policies	O
and	O
cessation	O
programs	O
and	O
perceived	O
barriers	O
and	O
receptivity	O
to	O
instituting	O
tobacco	O
control	O
interventions	B-T061
.	O
Respondents	O
indicated	B-T033
that	O
although	O
most	O
programs	O
had	O
adopted	O
smoke	O
-	O
free	O
grounds	O
and	O
some	O
had	O
eliminated	O
evidence	O
of	O
staff	O
smoking	O
,	O
the	O
smoking	O
status	O
of	O
clients	O
was	O
assessed	O
only	O
when	O
required	O
by	O
funders	O
.	O
None	O
of	O
the	O
programs	O
offered	B-T033
smoking	O
cessation	O
interventions	B-T061
.	O
Most	O
administrators	O
were	O
receptive	O
to	O
adopting	O
policies	O
that	O
would	O
promote	O
a	O
tobacco	O
-	O
free	O
culture	O
;	O
however	O
,	O
they	O
noted	O
that	O
their	O
clients	O
had	O
unique	O
challenges	B-T058
that	O
made	O
traditional	O
smoking	O
cessation	O
programs	O
unfeasible	O
.	O
Homeless	O
housing	O
programs	O
in	O
San	O
Francisco	O
have	O
not	O
yet	O
adopted	O
a	O
tobacco	O
-	O
free	O
culture	O
.	O
Existing	O
policies	O
were	O
created	O
in	O
response	O
to	O
external	O
mandates	O
,	O
and	O
smoking	O
cessation	O
programs	O
may	O
need	O
to	O
be	O
modified	O
in	O
order	O
to	O
effectively	O
reach	O
clients	O
.	O
      
Differential	O
effects	O
of	O
crude	O
oil	O
on	O
denitrification	O
and	O
anammox	O
,	O
and	O
the	O
impact	O
on	O
N2O	B-T121
production	O
Denitrification	O
and	O
anammox	O
are	O
key	O
processes	O
for	O
reducing	O
the	O
external	O
nitrogen	O
loads	O
delivered	O
to	O
coastal	O
ecosystems	O
,	O
and	O
these	O
processes	O
can	O
be	O
affected	O
by	O
pollutants	O
.	O
In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
crude	O
oil	O
on	O
denitrification	O
and	O
anammox	O
.	O
Controlled	O
laboratory	O
experiments	O
were	O
performed	O
using	O
sediment	O
slurries	O
from	O
the	O
Lima	O
Estuary	O
(	O
NW	O
Portugal	O
)	O
.	O
Anammox	O
and	O
denitrification	O
rates	O
were	O
measured	O
using	O
(	O
15)N	O
-	O
labeled	O
NO3(-	O
)	O
,	O
and	O
the	O
production	O
of	O
(	O
29)N2	O
and	O
(	O
30)N2	O
quantified	O
by	O
membrane	B-T059
inlet	I-T059
mass	I-T059
spectrometry	I-T059
.	O
Results	O
revealed	O
that	O
while	O
denitrification	O
rates	O
were	O
stimulated	O
between	O
10	O
and	O
25	O
000	O
times	O
after	O
crude	O
oil	O
amendment	O
,	O
anammox	O
activity	O
was	O
partially	O
(	O
between	O
2	O
and	O
5	O
times	O
)	O
or	O
completely	O
inhibited	O
by	O
the	O
addition	O
of	O
crude	O
oil	O
when	O
comparing	O
to	O
rates	O
in	O
unamended	O
controls	O
.	O
Similar	O
results	O
were	O
observed	O
across	O
four	O
estuarine	O
sediment	O
types	O
,	O
despite	O
their	O
different	O
physical	O
-	O
chemical	O
characteristics	O
.	O
Moreover	O
,	O
N2O	B-T121
production	O
was	O
reduced	O
by	O
2	O
-	O
36	O
times	O
following	O
crude	O
oil	O
addition	O
.	O
Further	O
work	O
is	O
required	O
to	O
fully	O
understand	O
the	O
mechanism(s	O
)	O
of	O
the	O
observed	O
reduction	O
in	O
N2O	B-T121
production	O
.	O
This	O
study	O
represents	O
one	O
of	O
the	O
first	O
contributions	O
to	O
the	O
understanding	O
of	O
the	O
impact	O
of	O
crude	O
oil	O
pollution	O
on	O
denitrification	O
and	O
anammox	O
,	O
with	O
profound	O
implications	O
for	O
the	O
management	O
of	O
aquatic	O
ecosystems	O
regarding	O
eutrophication	O
(	O
N	O
-	O
removal	O
)	O
.	O
      
Role	O
of	O
infrared	B-T059
spectroscopy	I-T059
and	O
imaging	B-T060
in	O
cancer	B-T191
diagnosis	B-T033
FTIR	O
imaging	B-T060
has	O
been	O
used	O
to	O
diagnose	B-T033
and	O
differentiate	O
the	O
molecular	O
differences	O
between	O
normal	O
and	O
diseased	B-T047
tissues	O
.	O
The	O
differences	O
correspond	O
to	O
the	O
distribution	O
and	O
structure	O
of	O
lipids	O
,	O
proteins	O
,	O
nucleic	O
acids	O
as	O
well	O
as	O
other	O
metabolites	O
.	O
These	O
differences	O
depended	O
on	O
the	O
type	B-T033
and	O
the	O
grade	O
of	O
cancer	B-T191
.	O
The	O
sensitivity	O
of	O
chemotherapy	B-T061
drugs	B-T121
on	O
individual	O
specific	O
was	O
also	O
discussed	O
.	O
Here	O
,	O
we	O
emphasize	O
that	O
FTIR	O
spectroscopy	O
and	O
imaging	B-T060
can	O
be	O
considered	O
as	O
a	O
promising	O
technique	O
and	O
will	O
find	O
its	O
place	O
on	O
the	O
detection	B-T061
of	O
this	O
dreadful	B-T047
disease	I-T047
because	O
of	O
high	B-T059
sensitivity	I-T059
,	O
accuracy	O
and	O
inexpensive	O
technique	O
.	O
Now	O
the	O
medical	O
community	O
started	O
using	O
and	O
accepting	O
this	O
technique	O
for	O
early	O
stage	O
cancer	B-T191
detection	B-T061
.	O
But	O
,	O
this	O
technique	O
endures	O
several	O
challenges	B-T058
on	O
its	O
application	O
into	O
the	O
diagnosis	B-T033
of	O
cancer	B-T191
in	O
regards	O
of	O
sample	B-T059
preparations	I-T059
,	O
data	B-T058
interpretation	I-T058
,	O
and	O
data	O
analysis	O
.	O
In	O
general	O
,	O
more	O
research	O
is	O
needed	O
in	O
this	O
field	O
and	O
it	O
is	O
necessary	O
to	O
understand	O
the	O
morphology	O
and	O
biology	O
of	O
the	O
sample	O
before	O
using	O
the	O
spectroscopy	O
and	O
imaging	B-T060
because	O
invaluable	O
information	O
to	O
be	O
figured	O
out	O
.	O
      
A	O
Novel	O
BRCA1	O
-	O
Associated	O
Protein-1	O
Isoform	O
Affects	O
Response	O
of	O
Mesothelioma	B-T191
Cells	I-T191
to	O
Drugs	B-T121
Impairing	O
BRCA1	O
-Mediated	O
DNA	O
Repair	O
BRCA1	O
associated	O
protein1	O
(	O
BAP1	O
)	O
is	O
a	O
tumor	O
suppressor	O
involved	O
in	O
multiple	O
cellular	O
processes	O
such	O
as	O
transcriptional	O
regulation	O
,	O
chromatin	O
modification	O
by	O
deubiquitinating	O
histone	O
2A	O
,	O
and	O
DNA	O
repair	O
.	O
BAP1	O
mutations	O
are	O
frequent	O
in	O
malignant	B-T191
pleural	I-T191
mesothelioma	I-T191
(	O
MPM	B-T191
)	O
.	O
Our	O
aim	O
was	O
to	O
functionally	O
characterize	O
a	O
newly	O
identified	O
isoform	O
of	O
BAP1	O
and	O
investigate	O
the	O
effects	O
of	O
its	O
expression	O
on	O
drug	O
sensitivity	O
in	O
MPM	B-T191
.	O
Expression	O
of	O
BAP1	O
isoforms	O
was	O
detected	B-T033
by	O
quantitative	B-T059
polymerase	I-T059
chain	I-T059
reaction	I-T059
in	O
MPM	B-T191
and	O
normal	O
mesothelium	O
cell	O
lines	O
and	O
tumor	O
and	O
nontumor	O
samples	O
.	O
Histone	O
H2A	O
ubiquitination	O
levels	O
were	O
analyzed	O
by	O
Western	B-T059
blot	I-T059
after	O
acidic	B-T059
extraction	I-T059
of	O
core	O
histones	O
.	O
Subcellular	O
localization	O
of	O
BAP1	O
isoforms	O
was	O
examined	B-T033
by	O
immunofluorescence	B-T059
.	O
MPM	B-T191
cell	O
survival	O
in	O
response	O
to	O
poly(adenosine	O
diphosphate	O
-	O
ribose	O
)	O
polymerase	O
(	O
PARP	O
)	O
and	O
dual	O
phosphoinositide	O
3	O
-	O
kinase	O
(	O
PI3K)-	O
mammalian	O
target	O
of	O
rapamycin	O
(	O
mTOR	O
)	O
inhibitors	B-T121
was	O
analyzed	O
by	O
in	O
vitro	O
assays	O
.	O
We	O
have	O
identified	O
a	O
novel	O
alternative	O
splice	O
isoform	O
of	O
BAP1	O
(	O
BAP1Δ	O
)	O
that	O
misses	O
part	O
of	O
the	O
catalytic	O
domain	O
.	O
Cells	O
transfected	O
with	O
BAP1Δ	O
showed	O
reduced	O
deubiquitinating	O
activity	O
compared	O
with	O
full	O
-	O
length	O
BAP1	O
.	O
The	O
expression	O
of	O
BAP1Δ	O
transcript	O
is	O
more	O
abundant	O
in	O
nontumor	O
than	O
in	O
tumor	O
samples	O
.	O
MPM	B-T191
cell	O
lines	O
expressing	O
more	O
than	O
20	O
%	O
of	O
BAP1Δ	O
are	O
more	O
sensitive	O
to	O
olaparib	B-T121
(	O
a	O
PARP1	O
inhibitor	B-T121
)	O
cytotoxicity	O
,	O
and	O
this	O
sensitivity	O
is	O
enhanced	O
when	O
olaparib	B-T121
treatment	B-T058
is	O
combined	O
with	O
GDC0980	B-T121
(	O
a	O
dual	O
PI3	O
K	O
-	O
mTOR	O
inhibitor	B-T121
)	O
,	O
which	O
induces	O
downregulation	O
of	O
BRCA1	O
.	O
These	O
observations	O
suggest	O
that	O
BAP1Δ	O
does	O
regulate	O
DNA	O
damage	O
response	O
and	O
influences	O
drug	O
sensitivity	O
.	O
It	O
might	O
therefore	O
be	O
relevant	O
to	O
investigate	O
whether	O
patients	O
with	O
high	O
expression	O
of	O
BAP1Δ	O
may	O
be	O
responsive	O
to	O
PARP	O
/	O
PI3	O
K	O
-	O
mTOR	O
inhibitors	B-T121
.	O
      
Minor	B-T019
physical	I-T019
anomalies	I-T019
and	O
dermatoglyphic	O
signs	O
in	O
affective	B-T048
disorders	I-T048
:	O
A	O
systematic	O
review	O
The	O
increased	O
prevalence	O
of	O
minor	B-T019
physical	I-T019
anomalies	I-T019
(	O
MPAs	B-T019
)	O
and	O
the	O
abnormalities	B-T019
of	I-T019
dermatoglyphic	I-T019
patterns	I-T019
may	O
be	O
physical	O
manifestations	O
of	O
neurodevelopmental	O
disruption	O
in	O
affective	B-T048
disorders	I-T048
.	O
This	O
paper	O
aims	O
to	O
review	O
the	O
current	O
state	O
of	O
knowledge	O
on	O
the	O
frequency	O
of	O
MPAs	B-T019
and	O
dermatoglyphic	B-T019
abnormalities	I-T019
in	O
mood	B-T048
disorders	I-T048
.	O
A	O
MEDLINE	O
,	O
PsychInfo	O
and	O
Web	O
of	O
Science	O
search	O
was	O
carried	O
out	O
to	O
collect	O
all	O
publications	O
on	O
the	O
frequency	O
of	O
MPAs	B-T019
and	O
on	O
dermatoglyphic	B-T190
traits	I-T190
in	O
bipolar	B-T048
disorder	I-T048
and	O
unipolar	B-T048
depression	I-T048
.	O
24	O
studies	O
on	O
MPAs	B-T019
,	O
19	O
on	O
dermatoglyphics	B-T059
,	O
and	O
5	O
dealing	O
with	O
both	O
were	O
found	O
with	O
discrepant	B-T033
findings	O
.	O
The	O
relative	O
contribution	O
of	O
neurodevelopmental	O
retardation	O
to	O
the	O
aetiology	O
of	O
affective	B-T048
disorders	I-T048
remains	O
undetermined	O
,	O
the	O
field	O
is	O
open	O
for	O
further	O
research	O
.	O
Increased	O
recognition	O
of	O
neurodevelopmental	O
processes	O
in	O
the	O
origin	O
of	O
affective	B-T048
disorders	I-T048
may	O
allow	O
for	O
earlier	O
and	O
more	O
effective	O
intervention	B-T061
and	O
prevention	B-T061
.	O
      
Effect	O
of	O
primary	B-T058
health	I-T058
care	I-T058
reforms	O
in	O
Turkey	O
on	O
health	B-T058
service	I-T058
utilization	I-T058
and	O
user	B-T033
satisfaction	I-T033
Strengthening	O
primary	B-T058
health	I-T058
care	I-T058
(	O
PHC	B-T058
)	O
is	O
considered	O
a	O
priority	O
for	O
efficient	O
and	O
responsive	O
health	O
systems	O
,	O
but	O
empirical	O
evidence	O
from	O
low-	O
and	O
middle-	O
income	O
countries	O
is	O
limited	O
.	O
The	O
stepwise	B-T061
introduction	I-T061
of	O
family	O
medicine	O
across	O
all	O
81	O
provinces	O
of	O
Turkey	O
(	O
a	O
middle	O
-	O
income	O
country	O
)	O
between	O
2005	O
and	O
2010	O
,	O
aimed	O
at	O
PHC	B-T058
strengthening	O
,	O
presents	O
a	O
natural	O
experiment	O
for	O
assessing	O
the	O
effect	O
of	O
family	O
medicine	O
on	O
health	B-T058
service	I-T058
utilization	I-T058
and	O
user	B-T033
satisfaction	I-T033
.The	O
effect	O
of	O
health	O
system	O
reforms	O
,	O
that	O
introduced	O
family	O
medicine	O
,	O
on	O
utilization	O
was	O
assessed	O
using	O
longitudinal	O
,	O
province	O
-	O
level	O
data	O
for	O
12	O
years	O
and	O
multivariate	O
regression	O
models	O
adjusting	O
for	O
supply	O
-	O
side	O
variables	O
,	O
demographics	O
,	O
socio	O
-	O
economic	O
development	O
and	O
underlying	O
yearly	O
trends	O
.	O
User	B-T033
satisfaction	I-T033
with	O
primary	B-T058
and	O
secondary	B-T058
care	I-T058
services	B-T058
was	O
explored	O
using	O
data	O
from	O
annual	O
Life	O
Satisfaction	O
Surveys	O
.	O
Trends	O
in	O
preferred	O
first	O
point	O
of	O
contact	O
(	O
primary	B-T058
vs	O
secondary	B-T058
,	O
public	O
vs.	O
private	O
)	O
,	O
reason	O
for	O
choice	O
and	O
health	B-T058
services	I-T058
issues	O
,	O
were	O
described	O
and	O
stratified	O
by	O
patient	O
characteristics	O
,	O
provider	O
type	O
,	O
and	O
rural	O
/	O
urban	O
settings	O
.Between	O
2002	O
and	O
2013	O
,	O
the	O
average	O
number	O
of	O
PHC	B-T058
consultations	B-T058
increased	O
from	O
1.75	O
to	O
2.83	O
per	O
person	O
per	O
year	O
.	O
In	O
multivariate	O
models	O
,	O
family	O
medicine	O
introduction	B-T061
was	O
associated	O
with	O
an	O
increase	O
of	O
0.37	O
PHC	B-T058
consultations	B-T058
per	O
person	O
(	O
P	O
<	O
0.001	O
)	O
,	O
and	O
slower	O
annual	O
growth	O
in	O
PHC	B-T058
and	O
secondary	B-T058
care	I-T058
consultations	B-T058
.	O
Following	O
family	O
medicine	O
introduction	B-T061
,	O
the	O
growth	O
of	O
PHC	B-T058
and	O
secondary	B-T058
care	I-T058
consultations	B-T058
per	O
person	O
was	O
0.08	O
and	O
0.30	O
,	O
respectively	O
,	O
a	O
year	O
.	O
PHC	B-T058
increased	O
as	O
preferred	O
provider	O
by	O
9.5	O
%	O
over	O
7	O
years	O
with	O
the	O
reasons	O
of	O
proximity	O
and	O
service	B-T033
satisfaction	I-T033
,	O
which	O
increased	O
by	O
14.9	O
%	O
and	O
11.8	O
%	O
,	O
respectively	O
.	O
Reporting	B-T058
of	O
poor	B-T033
facility	I-T033
hygiene	I-T033
,	O
difficulty	B-T033
getting	I-T033
an	I-T033
appointment	I-T033
,	O
poor	O
physician	O
behaviour	O
and	O
high	O
costs	O
of	O
health	O
care	O
all	O
declined	O
(	O
P	O
<	O
0.001	O
)	O
in	O
PHC	B-T058
settings	O
,	O
but	O
remained	O
higher	O
among	O
urban	O
,	O
low	B-T033
-	I-T033
income	I-T033
and	O
working	O
-	O
age	O
populations	O
.	O
      
Study	B-T059
of	O
the	O
Microfocus	O
X	O
-	O
Ray	O
Tube	O
Based	O
on	O
a	O
Point	O
-	O
Like	O
Target	O
Used	O
for	O
Micro	B-T060
-	I-T060
Computed	I-T060
Tomography	I-T060
For	O
a	O
micro	B-T060
-	I-T060
Computed	I-T060
Tomography	I-T060
(	I-T060
Micro	I-T060
-	I-T060
CT	I-T060
)	I-T060
system	I-T060
,	O
the	O
microfocus	O
X	O
-	O
ray	O
tube	O
is	O
an	O
essential	O
component	O
because	O
the	O
spatial	O
resolution	O
of	O
CT	B-T060
images	O
,	O
in	O
theory	O
,	O
is	O
mainly	O
determined	O
by	O
the	O
size	O
and	O
stability	O
of	O
the	O
X	B-T060
-	I-T060
ray	I-T060
focal	O
spot	O
of	O
the	O
microfocus	O
X	O
-	O
ray	O
tube	O
.	O
However	O
,	O
many	O
factors	O
,	O
including	O
voltage	O
fluctuations	O
,	O
mechanical	O
vibrations	O
,	O
and	O
temperature	O
changes	O
,	O
can	O
cause	O
the	O
size	O
and	O
the	O
stability	O
of	O
the	O
X	B-T060
-	I-T060
ray	I-T060
focal	O
spot	O
to	O
degrade	O
.	O
A	O
new	O
microfocus	O
X	O
-	O
ray	O
tube	O
based	O
on	O
a	O
point	O
-	O
like	O
micro	O
-	O
target	O
in	O
which	O
the	O
X	B-T060
-	I-T060
ray	I-T060
target	O
is	O
irradiated	O
with	O
an	O
unfocused	O
electron	O
beam	O
was	O
investigated	O
.	O
EGS4	O
Monte	O
Carlo	O
simulation	O
code	O
was	O
employed	O
for	O
the	O
calculation	O
of	O
the	O
X	B-T060
-	I-T060
ray	I-T060
intensity	O
produced	O
from	O
the	O
point	O
-	O
like	O
micro	O
-	O
target	O
and	O
the	O
substrate	O
.	O
The	O
effects	O
of	O
several	O
arrangements	O
of	O
the	O
target	O
material	O
,	O
target	O
and	O
beam	O
size	O
were	O
studied	B-T059
.	O
The	O
simulation	O
results	O
demonstrated	O
that	O
if	O
the	O
intensity	O
of	O
X	B-T060
-	I-T060
rays	I-T060
generated	O
at	O
the	O
point	O
-	O
like	O
target	O
is	O
greater	O
than	O
half	O
of	O
the	O
X	B-T060
-	I-T060
ray	I-T060
intensity	O
produced	O
on	O
the	O
substrate	O
,	O
the	O
X	B-T060
-	I-T060
ray	I-T060
focal	O
spot	O
is	O
determined	O
in	O
part	O
by	O
the	O
point	O
-	O
like	O
target	O
rather	O
than	O
by	O
the	O
electron	O
beam	O
in	O
the	O
conventional	O
X	O
-	O
ray	O
tube	O
.	O
In	O
theory	O
,	O
since	O
it	O
is	O
able	O
to	O
reduce	O
those	O
unfavorable	O
effects	O
such	O
as	O
the	O
electron	B-T033
beam	I-T033
trajectory	I-T033
swinging	I-T033
and	O
the	O
beam	O
size	O
changing	O
for	O
the	O
microfocus	O
X	O
-	O
ray	O
tube	O
,	O
it	O
could	O
alleviate	O
CT	B-T060
image	O
artifacts	O
caused	O
by	O
the	O
X	B-T060
-	I-T060
ray	I-T060
focal	O
spot	O
shift	B-T033
and	O
size	O
change	O
.	O
      
Evaluating	O
the	O
relative	O
effectiveness	O
of	O
high	O
-	O
intensity	O
and	O
low	O
-	O
intensity	O
models	O
of	O
behaviour	O
change	O
communication	B-T061
interventions	I-T061
for	O
abortion	B-T033
care	O
-	O
seeking	O
in	O
Bihar	O
and	O
Jharkhand	O
,	O
India	O
:	O
a	O
cross	O
-	O
sectional	O
study	O
This	O
study	O
aimed	O
to	O
compare	O
the	O
effectiveness	O
of	O
a	O
high	O
-	O
intensity	O
model	O
(	O
HIM	O
)	O
and	O
a	O
low	O
-	O
intensity	O
model	O
(	O
LIM	O
)	O
of	O
behaviour	O
change	O
communication	B-T061
interventions	I-T061
in	O
Bihar	O
and	O
Jharkhand	O
states	O
of	O
India	O
designed	O
to	O
improve	O
women	O
's	O
knowledge	B-T033
and	O
usage	O
of	O
safe	B-T033
abortion	I-T033
services	O
,	O
as	O
well	O
as	O
the	O
dose	O
effect	O
of	O
intervention	B-T061
exposure	O
.	O
We	O
conducted	O
two	O
cross	O
-	O
sectional	O
household	O
surveys	O
among	O
married	B-T033
women	O
aged	O
15	O
-	O
49	O
years	O
in	O
intervention	B-T061
and	O
comparison	O
districts	O
.	O
Difference	O
-	O
in	O
-	O
difference	O
models	O
were	O
used	O
to	O
assess	O
the	O
efficacy	O
of	O
the	O
intervention	B-T061
,	O
adjusting	O
for	O
sociodemographic	B-T033
characteristics	I-T033
.	O
Although	O
both	O
intervention	B-T061
types	O
improved	O
abortion	B-T033
knowledge	O
,	O
the	O
HIM	O
intervention	B-T061
was	O
more	O
effective	O
in	O
improving	O
comprehensive	O
knowledge	O
about	O
abortion	B-T033
.	O
In	O
particular	O
,	O
there	O
were	O
improvements	O
in	O
knowledge	O
on	O
legality	B-T061
of	I-T061
abortion	I-T061
(	O
AOR=2.2	O
;	O
95	O
%	O
CI	O
1.6	O
to	O
2.9	O
)	O
and	O
nearby	O
sources	O
of	O
safe	B-T058
abortion	I-T058
care	I-T058
(	O
AOR=1.7	O
;	O
95	O
%	O
CI	O
1.2	O
to	O
1.3	O
)	O
.	O
Higher	O
level	O
of	O
exposure	O
to	O
abortion	O
-	O
related	O
messages	O
was	O
related	O
to	O
more	O
accurate	O
knowledge	O
about	O
abortion	B-T033
within	O
both	O
intervention	B-T061
groups	O
.	O
Evidence	O
was	O
mixed	O
on	O
changes	O
in	O
abortion	B-T033
care	O
-	O
seeking	O
behaviour	O
.	O
More	O
work	O
is	O
needed	O
to	O
ensure	O
that	O
women	O
seek	O
safe	B-T033
abortion	I-T033
services	O
in	O
lieu	O
of	O
informal	O
services	O
that	O
may	O
be	O
more	O
likely	O
to	O
lead	O
to	O
postabortion	O
complications	O
.	O
      
The	O
Value	O
of	O
Biosamples	O
in	O
Smoking	O
Cessation	O
Trials	O
:	O
A	O
Review	O
of	O
Genetic	O
,	O
Metabolomic	O
,	O
and	O
Epigenetic	O
Findings	B-T033
Evidence	O
is	O
emerging	O
that	O
certain	O
genotypes	O
and	O
biomarkers	O
are	O
associated	O
with	O
smoking	O
cessation	O
success	O
and	O
efficacy	O
of	O
smoking	B-T061
cessation	I-T061
treatments	I-T061
.	O
We	O
review	O
key	O
findings	O
that	O
open	O
potential	O
avenues	O
for	O
personalizing	O
smoking	B-T061
cessation	I-T061
treatment	I-T061
according	O
to	O
an	O
individual	O
's	O
genetic	B-T059
or	O
metabolic	O
profile	O
.	O
These	O
results	O
provide	O
important	O
incentive	O
for	O
smoking	O
cessation	O
researchers	O
to	O
collect	O
biosamples	O
and	O
perform	O
genotyping	B-T059
in	O
research	O
studies	O
and	O
clinical	O
trials	O
.	O
      
A	O
Microfluidic	O
Platform	O
to	O
design	O
crosslinked	O
Hyaluronic	O
Acid	O
Nanoparticles	O
(	O
cHANPs	O
)	O
for	O
enhanced	B-T060
MRI	I-T060
Recent	O
advancements	O
in	O
imaging	B-T060
diagnostics	I-T060
have	O
focused	O
on	O
the	O
use	O
of	O
nanostructures	O
that	O
entrap	O
Magnetic	B-T060
Resonance	I-T060
Imaging	I-T060
(	O
MRI	B-T060
)	O
Contrast	O
Agents	O
(	O
CAs	O
)	O
,	O
without	O
the	O
need	O
to	O
chemically	O
modify	O
the	O
clinically	O
approved	O
compounds	O
.	O
Nevertheless	O
,	O
the	O
exploitation	O
of	O
microfluidic	O
platforms	O
for	O
their	O
controlled	O
and	O
continuous	O
production	O
is	O
still	O
missing	O
.	O
Here	O
,	O
a	O
microfluidic	O
platform	O
is	O
used	O
to	O
synthesize	O
crosslinked	O
Hyaluronic	O
Acid	O
NanoParticles	O
(	O
cHANPs	O
)	O
in	O
which	O
a	O
clinically	O
relevant	O
MRI	B-T060
-	O
CAs	O
,	O
gadolinium	O
diethylenetriamine	O
penta	O
-	O
acetic	O
acid	O
(	O
Gd	O
-	O
DTPA	O
)	O
,	O
is	O
entrapped	O
.	O
This	O
microfluidic	O
process	O
facilitates	O
a	O
high	O
degree	O
of	O
control	O
over	O
particle	O
synthesis	O
,	O
enabling	O
the	O
production	O
of	O
monodisperse	O
particles	O
as	O
small	O
as	O
35	O
nm	O
.	O
Furthermore	O
,	O
the	O
interference	O
of	O
Gd	O
-	O
DTPA	O
during	O
polymer	O
precipitation	O
is	O
overcome	O
by	O
finely	O
tuning	O
process	O
parameters	O
and	O
leveraging	O
the	O
use	O
of	O
hydrophilic	O
-	O
lipophilic	O
balance	O
(	O
HLB	O
)	O
of	O
surfactants	O
and	O
pH	O
conditions	O
.	O
For	O
both	O
production	O
strategies	O
proposed	O
to	O
design	O
Gd	O
-loaded	O
cHANPs	O
,	O
a	O
boosting	O
of	O
the	O
relaxation	O
rate	O
T1	O
is	O
observed	O
since	O
a	O
T1	O
of	O
1562	O
is	O
achieved	O
with	O
a	O
10	O
μM	O
of	O
Gd	O
-loaded	O
cHANPs	O
while	O
a	O
similar	O
value	O
is	O
reached	O
with	O
100	O
μM	O
of	O
the	O
relevant	O
clinical	O
Gd	O
-	O
DTPA	O
in	O
solution	O
.	O
The	O
advanced	O
microfluidic	O
platform	O
to	O
synthesize	O
intravascularly	O
-	O
injectable	O
and	O
completely	O
biocompatible	B-T121
hydrogel	I-T121
nanoparticles	O
entrapping	O
clinically	O
approved	O
CAs	O
enables	O
the	O
implementation	O
of	O
straightforward	O
and	O
scalable	O
strategies	O
in	O
diagnostics	O
and	O
therapy	B-T061
applications	O
.	O
      
Evaluation	B-T058
of	O
the	O
Condom	O
Barriers	O
Scale	O
for	O
Young	O
Black	O
Men	O
Who	O
Have	O
Sex	O
With	O
Men	O
:	O
Reliability	O
and	O
Validity	O
of	O
3	O
Subscales	O
Reliable	O
and	O
valid	O
scale	O
measures	O
of	O
barriers	B-T061
to	O
condom	O
use	O
are	O
not	O
available	O
for	O
young	O
black	O
men	O
who	O
have	O
sex	O
with	O
men	O
(	O
YBMSM	O
)	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
Condom	O
Barriers	O
Scales	O
for	O
application	O
with	O
YBMSM	O
.	O
A	O
clinic	O
-	O
based	O
sample	O
of	O
600	O
YBMSM	O
completed	O
a	O
computer	B-T059
-	I-T059
assisted	I-T059
self	O
-	O
interview	O
.	O
The	O
primary	O
measure	O
was	O
a	O
14	O
-	O
item	O
abbreviated	O
version	O
of	O
the	O
Condom	O
Barriers	O
Scale	O
.	O
Reliability	O
and	O
criterion	O
validity	O
were	O
assessed	O
.	O
All	O
3	O
subscales	O
were	O
reliable	O
:	O
partner	O
-related	O
barriers	B-T061
(	O
Cronbach	O
α	O
=	O
0.73	O
)	O
,	O
sensation	O
-related	O
barriers	B-T061
(	O
α=0.70	O
)	O
,	O
and	O
motivation	O
-related	O
barriers	B-T061
(	O
α	O
=	O
0.81	O
)	O
.	O
A	O
complete	B-T033
absence	I-T033
of	I-T033
barriers	I-T033
was	O
common	O
:	O
47.0	O
%	O
(	O
partner	O
-related	O
)	O
,	O
30.7	O
%	O
(	O
sensation	O
-related	O
)	O
,	O
and	O
46.5	O
%	O
(	O
motivation	O
-related	O
)	O
.	O
Dichotomized	O
subscales	O
were	O
significantly	O
associated	O
with	O
reporting	O
any	O
condomless	B-T033
insertive	O
anal	O
sex	O
(	O
all	O
Ps	O
<	O
0.001	O
)	O
and	O
any	O
condomless	B-T033
receptive	O
anal	O
sex	O
(	O
all	O
Ps	O
<	O
0.001	O
)	O
.	O
The	O
subscales	O
were	O
significantly	O
associated	O
with	O
these	O
measures	O
of	O
condomless	B-T033
sex	O
preserved	O
at	O
a	O
continuous	O
level	O
(	O
all	O
Ps	O
<	O
0.001	O
,	O
except	O
for	O
sensation	O
barriers	B-T061
associated	O
with	O
condomless	B-T033
receptive	O
anal	O
sex	O
=	O
0.03	O
)	O
.	O
Further	O
,	O
the	O
subscales	O
were	O
significantly	O
associated	O
with	O
reporting	O
any	O
condom	O
use	O
problems	O
(	O
all	O
Ps	O
<	O
0.001	O
)	O
and	O
a	O
measure	O
of	O
condomless	B-T033
oral	O
sex	O
(	O
all	O
Ps	O
<	O
0.001	O
,	O
except	O
for	O
partner	O
-related	O
barriers	B-T061
=	O
0.31	O
)	O
.	O
Finally	O
,	O
the	O
sensation	O
-related	O
barriers	B-T061
subscale	O
was	O
significantly	O
associated	O
with	O
testing	O
positive	B-T033
for	O
Chlamydia	B-T007
and/or	O
gonorrhea	B-T047
(	O
P=0.049	O
)	O
.	O
The	O
3	O
identified	O
subscales	O
yielded	O
adequate	O
reliability	O
and	O
strong	O
evidence	O
of	O
validity	O
,	O
thereby	O
suggesting	O
the	O
utility	O
of	O
these	O
brief	O
measures	O
for	O
use	O
in	O
observational	O
and	O
experimental	O
research	O
with	O
YBMSM	O
.	O
      
Function	O
and	O
clinical	O
meaningfulness	O
of	O
treatments	B-T061
for	O
mild	O
Alzheimer	B-T047
's	I-T047
disease	I-T047
Effectiveness	O
of	O
Alzheimer	B-T047
's	I-T047
disease	I-T047
(	O
AD	B-T047
)	O
treatments	B-T061
is	O
commonly	O
evaluated	O
with	O
coprimary	O
outcomes	O
;	O
cognition	O
with	O
function	O
to	O
ensure	O
clinical	O
meaningfulness	O
of	O
a	O
cognitive	O
effect	O
.	O
We	O
reviewed	O
the	O
literature	O
for	O
functional	O
outcomes	O
in	O
mild	O
AD	B-T047
or	O
mild	B-T048
cognitive	I-T048
impairment	I-T048
(	O
MCI	B-T048
)	O
patients	O
(	O
distinct	O
from	O
combined	O
mild	O
-	O
moderate	O
/	O
severe	O
AD	B-T047
)	O
treated	B-T061
with	I-T061
approved	O
AD	B-T047
drugs	B-T121
.	O
Cognitive	B-T061
and	O
functional	O
treatment	B-T061
differences	O
in	O
mild	O
AD	B-T047
patients	O
in	O
solanezumab	B-T121
EXPEDITION	O
/	O
EXPEDITION2	O
studies	O
were	O
compared	O
across	O
time	O
.	O
Seven	O
publications	O
provided	O
MCI	B-T048
/	O
mild	O
AD	B-T047
functional	O
outcomes	O
,	O
one	O
of	O
which	O
reported	O
a	O
significant	O
functional	O
treatment	B-T033
effect	I-T033
.	O
Secondary	O
analyses	O
of	O
EXPEDITION	O
studies	O
suggested	O
a	O
smaller	O
functional	O
effect	O
of	O
solanezumab	B-T121
relative	O
to	O
cognition	O
.	O
An	O
increasing	O
effect	O
of	O
solanezumab	B-T121
over	O
18	O
months	O
was	O
shown	O
for	O
cognition	O
and	O
function	O
.	O
Function	O
as	O
the	O
sole	O
measure	O
to	O
demonstrate	O
clinical	O
meaningfulness	O
of	O
cognitive	O
effects	O
in	O
mild	O
AD	B-T047
may	O
have	O
limitations	O
.	O
For	O
disease	B-T047
-	O
modifying	O
treatments	B-T061
,	O
point	O
differences	O
on	O
cognitive	O
and	O
functional	O
scales	O
should	O
be	O
qualified	O
with	O
duration	O
of	O
treatment	O
.	O
      
High	O
Transferability	O
of	O
Homoeolog	O
-	O
Specific	O
Markers	O
between	O
Bread	O
Wheat	O
and	O
Newly	O
Synthesized	O
Hexaploid	O
Wheat	O
Lines	O
Bread	O
wheat	O
(	O
Triticum	O
aestivum	O
,	O
2n	O
=	O
6x	O
=	O
42	O
,	O
AABBDD	O
)	O
has	O
a	O
complex	O
allohexaploid	O
genome	O
,	O
which	O
makes	O
it	O
difficult	O
to	O
differentiate	O
between	O
the	O
homoeologous	O
sequences	O
and	O
assign	O
them	O
to	O
the	O
chromosome	O
A	O
,	O
B	O
,	O
or	O
D	O
subgenomes	O
.	O
The	O
chromosome	O
-based	O
draft	O
genome	O
sequence	O
of	O
the	O
'	O
Chinese	O
Spring	O
'	O
common	O
wheat	O
cultivar	O
enables	O
the	O
large	O
-	O
scale	O
development	O
of	O
polymerase	O
chain	O
reaction	O
(	O
PCR)-based	O
markers	O
specific	O
for	O
homoeologs	O
.	O
Based	O
on	O
high	O
-	O
confidence	O
'	O
Chinese	O
Spring	O
'	O
genes	O
with	O
known	O
functions	O
,	O
we	O
developed	O
183	O
putative	O
homoeolog	O
-	O
specific	O
markers	O
for	O
chromosomes	O
4B	O
and	O
7B.	O
These	O
markers	O
were	O
used	O
in	O
PCR	O
assays	O
for	O
the	O
4B	O
and	O
7B	O
nullisomes	O
and	O
their	O
euploid	O
synthetic	O
hexaploid	O
wheat	O
(	O
SHW	O
)	O
line	O
that	O
was	O
newly	O
generated	O
from	O
a	O
hybridization	O
between	O
Triticum	O
turgidum	O
(	O
AABB	O
)	O
and	O
the	O
wild	O
diploid	O
species	O
Aegilops	O
tauschii	O
(	O
DD	O
)	O
.	O
Up	O
to	O
64	O
%	O
of	O
the	O
markers	O
for	O
chromosomes	O
4B	O
or	O
7B	O
in	O
the	O
SHW	O
background	O
were	O
confirmed	O
to	O
be	O
homoeolog	O
-	O
specific	O
.	O
Thus	O
,	O
these	O
markers	O
were	O
highly	O
transferable	O
between	O
the	O
'	O
Chinese	O
Spring	O
'	O
bread	O
wheat	O
and	O
SHW	O
lines	O
.	O
Homoeolog	O
-	O
specific	O
markers	O
designed	O
using	O
genes	O
with	O
known	O
functions	O
may	O
be	O
useful	O
for	O
genetic	B-T059
investigations	I-T059
involving	O
homoeologous	O
chromosome	O
tracking	O
and	O
homoeolog	O
expression	O
and	O
interaction	O
analyses	O
.	O
      
From	O
training	O
to	O
practice	O
:	O
the	O
impact	O
of	O
ENGAGE	O
,	O
Ireland	O
's	O
national	O
men	O
's	O
health	O
training	O
programme	O
Ireland	O
's	O
National	O
Men	O
's	O
Health	O
Policy	O
recommended	O
developing	O
training	O
programmes	O
tailored	B-T058
to	O
the	O
needs	O
of	O
those	O
working	O
in	O
health	O
and	O
allied	O
health	O
professionals	O
and	O
ENGAGE	O
was	O
developed	O
to	O
meet	O
that	O
recommendation	O
.	O
This	O
study	O
evaluated	B-T058
the	O
impact	O
of	O
ENGAGE	O
on	O
frontline	B-T058
service	I-T058
providers	I-T058
'	I-T058
self	B-T033
-	I-T033
reported	I-T033
knowledge	I-T033
,	O
skills	O
,	O
capacity	O
and	O
practice	O
up	O
to	O
5	O
-	O
months	O
post	O
training	O
.	O
Between	O
2012	O
and	O
2015	O
,	O
ENGAGE	O
Trainers	O
(	O
n	O
=	O
57	O
)	O
delivered	O
62	O
1	O
-	O
day	O
training	O
programmes	O
to	O
810	O
participants	O
.	O
This	O
study	O
was	O
conducted	O
on	O
a	O
subset	O
of	O
those	O
training	O
days	O
(	O
n	O
=	O
26	O
)	O
and	O
participants	O
.	O
Quantitative	O
methodologies	O
were	O
used	O
to	O
collect	O
pre	O
(	O
n	O
=	O
295	O
)	O
,	O
post	O
(	O
n	O
=	O
295	O
)	O
and	O
5	O
-	O
month	O
post	O
(	O
n	O
=	O
128	O
)	O
training	O
questionnaire	O
data	O
.	O
Overall	O
,	O
participants	O
were	O
highly	O
satisfied	O
with	O
the	O
training	O
immediately	O
post	O
training	O
(	O
8.60	O
±	O
1.60	O
out	O
of	O
10	O
)	O
and	O
at	O
5	O
-	O
month	O
follow	B-T033
up	I-T033
(	O
8.06	O
±	O
1.43	O
out	O
of	O
10	O
)	O
.	O
Participants	O
'	O
self	B-T033
-	I-T033
reported	I-T033
level	I-T033
of	I-T033
knowledge	I-T033
,	O
skill	O
and	O
capacity	O
in	O
identifying	O
priorities	O
,	O
engaging	O
men	O
and	O
influencing	O
practice	O
beyond	O
their	O
own	O
organisation	O
increased	O
immediately	O
following	O
training	O
(	O
P	O
<	O
0.001	O
)	O
and	O
,	O
with	O
the	O
exception	O
of	O
improving	O
capacity	O
to	O
engage	O
men	O
and	O
influencing	O
practice	O
beyond	O
their	O
organisation	O
,	O
these	O
improvements	O
were	O
sustained	O
at	O
5	O
-	O
month	O
post	O
training	O
(	O
P	O
<	O
0.001	O
)	O
.	O
The	O
vast	O
majority	O
of	O
service	B-T058
providers	I-T058
(	O
93.4	O
%	O
)	O
reported	B-T058
that	O
ENGAGE	O
had	O
impacted	O
their	O
work	O
practice	O
up	O
to	O
5	O
-	O
month	O
post	O
training	O
.	O
The	O
findings	B-T033
suggest	O
that	O
ENGAGE	O
has	O
succeeded	B-T033
in	O
improving	O
service	B-T058
providers	I-T058
'	I-T058
capacity	O
to	O
engage	O
and	O
work	O
with	O
men	O
;	O
improving	O
gender	O
competency	O
in	O
the	O
delivery	O
of	O
health	O
and	O
health	B-T058
related	I-T058
services	I-T058
may	O
increase	O
the	O
utilisation	B-T058
of	O
such	O
services	B-T058
by	O
men	O
and	O
thereby	O
improve	B-T033
health	O
outcomes	O
for	O
men	O
.	O
      
Arsenic	O
Triglutathione	O
[	O
As(GS)3	O
]	O
Transport	O
by	O
Multidrug	O
Resistance	O
Protein	O
1	O
(	O
MRP1	O
/	O
ABCC1	O
)	O
Is	O
Selectively	O
Modified	O
by	O
Phosphorylation	O
of	O
Tyr920	O
/	O
Ser921	O
and	O
Glycosylation	O
of	O
Asn19	O
/	O
Asn23	O
The	O
ATP	O
-	O
binding	O
cassette	O
(	O
ABC	O
)	O
transporter	O
multidrug	O
resistance	O
protein	O
1	O
(	O
MRP1	O
/	O
ABCC1	O
)	O
is	O
responsible	O
for	O
the	O
cellular	O
export	O
of	O
a	O
chemically	O
diverse	O
array	O
of	O
xenobiotics	O
and	O
endogenous	O
compounds	O
.	O
Arsenic	B-T121
,	O
a	O
human	O
carcinogen	O
,	O
is	O
a	O
high	O
-	O
affinity	O
MRP1	O
substrate	O
as	O
arsenic	O
triglutathione	O
[	O
As(GS)3	O
]	O
.	O
In	O
this	O
study	O
,	O
marked	O
differences	O
in	O
As(GS)3	O
transport	O
kinetics	O
were	O
observed	O
between	O
MRP1	O
-enriched	O
membrane	O
vesicles	O
prepared	O
from	O
human	O
embryonic	B-T018
kidney	B-T023
293	O
(	O
HEK	O
)	O
(	O
Km	O
3.8	O
µM	O
and	O
Vmax	O
307	O
pmol	O
/	O
mg	O
per	O
minute	O
)	O
and	O
HeLa	O
(	O
Km	O
0.32	O
µM	O
and	O
Vmax	O
42	O
pmol	O
/	O
mg	O
per	O
minute	O
)	O
cells	O
.	O
Mutant	O
MRP1	O
lacking	O
N	O
-	O
linked	O
glycosylation	O
[	O
Asn19/23/1006Gln	O
;	O
sugar	O
-	O
free	O
(	O
SF)-MRP1	O
]	O
expressed	O
in	O
either	O
HEK293	O
or	O
HeLa	O
cells	O
had	O
low	O
Km	O
and	O
Vmax	O
values	O
for	O
As(GS)3	O
,	O
similar	O
to	O
HeLa	O
wild	O
-	O
type	O
(	O
WT	O
)	O
MRP1	O
.	O
When	O
prepared	O
in	O
the	O
presence	B-T033
of	O
phosphatase	B-T121
inhibitors	I-T121
,	O
both	O
WT-	O
and	O
SF	O
-	O
MRP1	O
-enriched	O
membrane	O
vesicles	O
had	O
a	O
high	O
Km	O
value	O
for	O
As(GS)3	O
(	O
3	O
-	O
6	O
µM	O
)	O
,	O
regardless	O
of	O
the	O
cell	O
line	O
.	O
Kinetic	B-T033
parameters	I-T033
of	O
As(GS)3	O
for	O
HEK	O
-	O
Asn19/23Gln	O
-	O
MRP1	O
were	O
similar	O
to	O
those	O
of	O
HeLa	O
/	O
HEK	O
-	O
SF	O
-	O
MRP1	O
and	O
HeLa	O
-	O
WT	O
-	O
MRP1	O
,	O
whereas	O
those	O
of	O
single	O
glycosylation	O
mutants	O
were	O
like	O
those	O
of	O
HEK	O
-	O
WT	O
-MRP1	O
.	O
Mutation	O
of	O
19	O
potential	O
MRP1	O
phosphorylation	O
sites	O
revealed	O
that	O
HEK	O
-	O
Tyr920Phe	O
/	O
Ser921Ala	O
-	O
MRP1	O
transported	O
As(GS)3	O
like	O
HeLa	O
-	O
WT	O
-	O
MRP1	O
,	O
whereas	O
individual	O
HEK	O
-	O
Tyr920Phe-	O
and	O
-	O
Ser921Ala	O
-	O
MRP1	O
mutants	O
were	O
similar	O
to	O
HEK	O
-	O
WT	O
-	O
MRP1	O
.	O
Together	O
,	O
these	O
results	B-T033
suggest	O
that	O
Asn19	O
/	O
Asn23	O
glycosylation	O
and	O
Tyr920	O
/	O
Ser921	O
phosphorylation	O
are	O
responsible	O
for	O
altering	O
the	O
kinetics	O
of	O
MRP1	O
-mediated	O
As(GS)3	O
transport	O
.	O
The	O
kinetics	O
of	O
As(GS)3	O
transport	O
by	O
HEK	O
-	O
Asn19/23Gln	O
/	O
Tyr920Glu	O
/	O
Ser921Glu	O
were	O
similar	O
to	O
HEK	O
-	O
WT	O
-	O
MRP1	O
,	O
indicating	O
that	O
the	O
phosphorylation	O
-mimicking	O
substitutions	O
abrogated	O
the	O
influence	O
of	O
Asn19/23Gln	O
glycosylation	O
.	O
Overall	O
,	O
these	O
data	O
suggest	O
that	O
cross	O
-	O
talk	O
between	O
MRP1	O
glycosylation	O
and	O
phosphorylation	O
occurs	O
and	O
that	O
phosphorylation	O
of	O
Tyr920	O
and	O
Ser921	O
can	O
switch	O
MRP1	O
to	O
a	O
lower	O
-	O
affinity	O
,	O
higher	O
-	O
capacity	O
As(GS)3	O
transporter	O
,	O
allowing	O
arsenic	B-T121
detoxification	O
over	O
a	O
broad	O
concentration	O
range	O
.	O
      
MODEM	O
:	O
A	O
comprehensive	O
approach	O
to	O
modelling	O
outcome	O
and	O
costs	O
impacts	O
of	O
interventions	B-T061
for	O
dementia	B-T048
.	O
Protocol	O
paper	O
The	O
MODEM	O
project	O
(	O
A	O
comprehensive	O
approach	O
to	O
MODelling	O
outcome	O
and	O
costs	O
impacts	O
of	O
interventions	B-T061
for	O
DEMentia	B-T048
)	O
explores	O
how	O
changes	O
in	O
arrangements	O
for	O
the	O
future	O
treatment	B-T061
and	O
care	O
of	O
people	O
living	O
with	O
dementia	B-T048
,	O
and	O
support	B-T061
for	O
family	O
and	O
other	O
unpaid	B-T033
carers	O
,	O
could	O
result	O
in	O
better	O
outcomes	O
and	O
more	O
efficient	O
use	O
of	O
resources	O
.	O
MODEM	O
starts	O
with	O
a	O
systematic	O
mapping	O
of	O
the	O
literature	O
on	O
effective	O
and	O
(	O
potentially	O
)	O
cost	O
-	O
effective	O
interventions	B-T061
in	O
dementia	B-T048
care	O
.	O
Those	O
findings	O
,	O
as	O
well	O
as	O
data	O
from	O
a	O
cohort	O
,	O
will	O
then	O
be	O
used	O
to	O
model	O
the	O
quality	O
of	O
life	O
and	O
cost	O
impacts	O
of	O
making	O
these	O
evidence	O
-based	O
interventions	B-T061
more	O
widely	O
available	O
in	O
England	O
over	O
the	O
period	O
from	O
now	O
to	O
2040	O
.	O
Modelling	O
will	O
use	O
a	O
suite	O
of	O
models	O
,	O
combining	O
microsimulation	O
and	O
macrosimulation	O
methods	O
,	O
modelling	O
the	O
costs	O
and	O
outcomes	O
of	O
care	O
,	O
both	O
for	O
an	O
individual	O
over	O
the	O
life	O
-	O
course	O
from	O
the	O
point	O
of	O
dementia	B-T048
diagnosis	I-T048
,	O
and	O
for	O
individuals	O
and	O
England	O
as	O
a	O
whole	O
in	O
a	O
particular	O
year	O
.	O
Project	O
outputs	O
will	O
include	O
an	O
online	O
Dementia	O
Evidence	O
Toolkit	O
,	O
making	O
evidence	O
summaries	O
and	O
a	O
literature	O
database	O
available	O
free	O
to	O
anyone	O
,	O
papers	O
in	O
academic	O
journals	O
and	O
other	O
written	O
outputs	O
,	O
and	O
a	O
MODEM	O
Legacy	O
Model	O
,	O
which	O
will	O
enable	O
local	O
commissioners	O
of	O
services	O
to	O
apply	O
the	O
model	O
to	O
their	O
own	O
populations	O
.	O
Modelling	O
the	O
effects	O
of	O
evidence	O
-based	O
cost	O
-	O
effective	O
interventions	B-T061
and	O
making	O
this	O
information	O
widely	O
available	O
has	O
the	O
potential	O
to	O
improve	B-T033
the	O
health	O
and	O
quality	O
of	O
life	O
both	O
of	O
people	O
with	O
dementia	B-T048
and	O
their	O
carers	O
,	O
while	O
ensuring	O
that	O
resources	O
are	O
used	O
efficiently	O
.	O
      
Clinical	B-T033
and	O
radiological	B-T060
outcome	O
following	O
pneumothorax	B-T047
after	O
endoscopic	B-T061
lung	I-T061
volume	I-T061
reduction	I-T061
with	O
valves	O
Valve	O
implantation	B-T061
has	O
evolved	O
as	O
a	O
therapy	B-T061
for	O
patients	O
with	O
advanced	O
emphysema	B-T047
.	O
Although	O
it	O
is	O
a	O
minimally	B-T061
invasive	I-T061
treatmen	I-T061
t	O
,	O
it	O
is	O
associated	O
with	O
complications	O
,	O
the	O
most	O
common	O
being	O
pneumothorax	B-T047
.	O
Pneumothorax	B-T047
occurs	O
due	O
to	O
the	O
rapid	O
target	O
lobe	B-T023
volume	B-T061
reduction	I-T061
and	O
may	O
be	O
a	O
predictor	O
of	O
clinical	O
benefit	O
despite	O
this	O
complication	O
.	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
conduct	O
an	O
exploratory	O
data	O
analysis	O
of	O
patients	O
who	O
developed	O
a	O
pneumothorax	B-T047
following	O
endoscopic	B-T061
valve	I-T061
therapy	I-T061
for	O
emphysema	B-T047
.	O
This	O
study	O
performed	O
a	O
retrospective	O
evaluation	O
of	O
pneumothorax	B-T047
management	B-T058
and	O
the	O
impact	O
of	O
pneumothorax	B-T047
on	O
clinical	B-T033
outcomes	I-T033
in	O
70	O
patients	O
following	O
valve	B-T061
therapy	I-T061
in	O
381	O
consecutive	O
patients	O
.	O
Pneumothorax	B-T047
rate	O
following	O
valve	B-T061
therapy	I-T061
was	O
18	O
%	O
.	O
Pneumothorax	B-T047
management	B-T058
consisted	O
of	O
chest	B-T061
tube	I-T061
insertion	I-T061
,	O
valve	O
removal	B-T061
,	O
and	O
surgical	B-T033
intervention	I-T033
in	O
87	O
%	O
(	O
61/70	O
)	O
,	O
44	O
%	O
(	O
31/70	O
)	O
,	O
and	O
19	O
%	O
(	O
13/70	O
)	O
of	O
the	O
patients	O
,	O
respectively	O
.	O
Despite	O
pneumothorax	B-T047
,	O
patients	O
experienced	O
modest	O
but	O
significant	O
improvements	O
in	O
lung	O
function	O
parameters	O
(	O
forced	O
expiratory	O
volume	O
in	O
1	O
second	O
:	O
55±148	O
mL	O
,	O
residual	O
volume	O
:	O
-390±964	O
mL	O
,	O
total	B-T033
lung	I-T033
capacity	I-T033
:	O
-348±876	O
;	O
all	O
P<0.05	O
)	O
.	O
Persistent	O
lobar	O
atelectasis	O
3	O
months	O
after	O
recovering	O
from	O
pneumothorax	B-T047
,	O
which	O
was	O
associated	O
with	O
relevant	O
clinical	O
improvement	O
,	O
was	O
observed	O
in	O
only	O
21	O
%	O
(	O
15/70	O
)	O
of	O
the	O
patients	O
.	O
Pneumothorax	B-T047
is	O
a	O
frequent	O
severe	O
complication	O
following	O
valve	B-T061
therapy	I-T061
that	O
requires	O
further	O
intervention	B-T061
.	O
Nevertheless	O
,	O
the	O
pneumothorax	B-T047
does	O
not	O
impair	O
the	O
clinical	O
status	O
in	O
the	O
majority	O
of	O
patients	O
.	O
Patients	O
with	O
lobar	O
atelectasis	O
benefit	O
after	O
recovering	O
from	O
pneumothorax	B-T047
in	O
terms	O
of	O
lung	O
function	O
parameters	O
.	O
      
Fall	B-T033
risk	B-T033
factors	I-T033
analysis	O
based	O
on	O
sample	O
entropy	O
of	O
plantar	O
kinematic	O
signal	O
during	O
stance	B-T033
phase	I-T033
Falls	B-T033
are	O
a	O
multi	O
-	O
causal	O
phenomenon	O
with	O
a	O
complex	O
interaction	O
.	O
The	O
aim	O
of	O
our	O
research	O
is	O
to	O
study	O
the	O
effect	O
of	O
multiple	O
variables	O
for	O
potential	O
risk	B-T033
of	I-T033
falls	I-T033
and	O
construct	O
an	O
elderly	O
fall	O
risk	O
assessment	O
model	O
based	O
on	O
demographics	O
data	O
and	O
gait	B-T033
characteristics	I-T033
.	O
A	O
total	O
of	O
101	O
subjects	O
,	O
whom	O
belong	O
to	O
Malianwa	O
Street	O
,	O
aged	O
above	O
50	O
years	O
old	O
and	O
participated	O
in	O
questionnaire	O
survey	O
.	O
Participants	O
were	O
classified	O
into	O
three	O
groups	O
(	O
high	O
,	O
medium	O
and	O
low	O
risk	O
group	O
)	O
according	O
to	O
the	O
score	O
of	O
elderly	O
fall	O
risk	O
assessment	O
scale	O
.	O
In	O
addition	O
,	O
the	O
data	O
of	O
ground	O
reaction	O
force	O
(	O
GRF	O
)	O
and	O
ground	O
reaction	O
moment	O
(	O
GRM	O
)	O
was	O
record	O
when	O
they	O
performed	O
walking	O
at	O
comfortable	B-T033
state	I-T033
.	O
The	O
demographic	O
variables	O
,	O
sample	O
entropy	O
of	O
GRF	O
and	O
GRM	O
,	O
and	O
impulse	O
difference	O
of	O
bilateral	B-T023
foot	I-T023
were	O
considered	O
as	O
potential	O
explanatory	O
variables	O
of	O
risk	B-T058
assessment	I-T058
model	O
.	O
Firstly	O
,	O
we	O
investigated	O
whether	O
different	O
groups	O
could	O
present	O
difference	O
in	O
every	O
variable	O
.	O
Statistical	O
differences	O
were	O
found	B-T033
for	O
the	O
following	O
variables	O
:	O
age	O
(	O
p=2.28e-05	O
)	O
;	O
impulse	O
difference	O
(	O
p=0.02036	O
)	O
;	O
sample	O
entropy	O
of	O
GRF	O
in	O
vertical	O
direction	O
(	O
p=0.0144	O
)	O
;	O
sample	O
entropy	O
of	O
GRM	O
in	O
anterior	O
-	O
posterior	O
direction	O
(	O
p=0.0387	O
)	O
.	O
Finally	O
,	O
the	O
multiple	O
regression	O
analysis	O
results	O
indicated	B-T033
that	O
age	O
,	O
impulse	O
difference	O
and	O
sample	O
entropy	O
of	O
resultant	O
GRM	O
could	O
identify	O
individuals	O
who	O
had	O
different	O
levels	B-T058
of	I-T058
fall	I-T058
risk	I-T058
.	O
Therefore	O
,	O
those	O
results	O
could	O
potentially	O
be	O
useful	O
in	O
the	O
fall	B-T058
risk	I-T058
assessment	I-T058
and	O
monitor	B-T058
the	O
state	O
of	O
physical	B-T033
function	I-T033
in	O
elderly	O
population	O
.	O
      
Increased	O
risk	O
of	O
PTLD	B-T191
in	O
lung	B-T033
transplant	I-T033
recipients	I-T033
with	O
cystic	B-T047
fibrosis	I-T047
Post	B-T191
-	I-T191
transplant	I-T191
lymphoproliferative	I-T191
disease	I-T191
(	O
PTLD	B-T191
)	O
is	O
an	O
important	O
cause	O
of	O
morbidity	O
and	O
mortality	O
following	O
lung	B-T061
transplantation	I-T061
.	O
Recipients	O
with	O
cystic	B-T047
fibrosis	I-T047
(	O
CF	B-T047
)	O
may	O
have	O
an	O
increased	O
risk	O
of	O
PTLD	B-T191
although	O
the	O
literature	O
is	O
limited	O
to	O
single	O
center	O
cohorts	O
.	O
Our	O
primary	O
aim	O
is	O
to	O
examine	O
PTLD	B-T191
in	O
an	O
adult	O
lung	B-T061
transplant	I-T061
population	O
by	O
utilizing	O
the	O
International	O
Society	O
for	O
Heart	O
and	O
Lung	O
Transplantation	O
Registry	O
.	O
We	O
studied	O
30,598	O
adult	O
recipients	O
of	O
lung	B-T061
transplants	I-T061
performed	O
between	O
1999	O
and	O
2011	O
.	O
The	O
primary	O
outcome	O
was	O
development	O
of	O
and	O
time	O
to	O
PTLD	B-T191
.	O
In	O
addition	O
to	O
indication	O
for	O
transplant	B-T061
,	O
other	O
predictors	O
examined	O
included	O
Epstein	B-T005
-	I-T005
Barr	I-T005
virus	I-T005
(	O
EBV	B-T005
)	O
and	O
cytomegalovirus	B-T005
(	O
CMV	B-T005
)	O
serostatus	O
,	O
gender	O
,	O
and	O
age	O
.	O
Outcomes	O
were	O
assessed	O
with	O
univariable	O
and	O
multivariable	O
Cox	O
proportional	O
hazard	O
models	O
to	O
obtain	O
hazard	O
ratios	O
(	O
HR	O
)	O
.	O
17	O
%	O
of	O
the	O
cohort	O
had	O
a	O
diagnosis	B-T033
of	O
CF	B-T047
.	O
PTLD	B-T191
developed	O
in	O
2	O
%	O
of	O
CF	B-T047
recipients	O
compared	O
to	O
1	O
%	O
for	O
non	B-T033
-	I-T033
CF	I-T033
recipients	I-T033
(	O
p<0.001	O
)	O
.	O
Compared	O
to	O
non	B-T033
-	I-T033
CF	I-T033
recipients	I-T033
,	O
CF	B-T047
recipients	O
had	O
higher	O
prevalence	O
of	O
EBV	B-T005
and	O
CMV	O
seronegativity	O
and	O
higher	O
prevalences	O
of	O
high	O
risk	O
EBV	B-T005
and	O
CMV	B-T005
mismatch	O
(	O
D+/R-	O
)	O
.	O
There	O
is	O
a	O
significant	O
association	O
between	O
CF	B-T047
and	O
the	O
development	O
of	O
PTLD	B-T191
[	O
HR	O
1.66	O
(	O
95	O
%	O
CI	O
1.30	O
-	O
2.12	O
)	O
]	O
.	O
Stratified	O
multivariable	O
analysis	O
controlling	O
for	O
age	O
revealed	O
EBV	B-T005
negative	B-T033
non	B-T033
-	I-T033
CF	I-T033
recipients	I-T033
have	O
an	O
almost	O
2	O
fold	O
increased	O
risk	O
of	O
developing	O
PTLD	B-T191
,	O
whereas	O
EBV	B-T005
negative	O
CF	B-T047
recipients	O
had	O
an	O
almost	O
6.5	O
fold	O
increased	O
risk	O
.	O
CF	B-T047
recipients	O
have	O
a	O
higher	O
risk	O
for	O
PTLD	B-T191
compared	O
to	O
non	B-T033
-	I-T033
CF	I-T033
recipients	I-T033
.	O
Further	O
studies	O
are	O
needed	O
to	O
account	O
for	O
additional	O
risk	B-T033
factors	I-T033
and	O
management	B-T058
in	O
this	O
population	B-T033
post	I-T033
-	I-T033
transplant	I-T033
.	O
      
Importance	O
of	O
Ecological	O
Factors	O
and	O
Colony	O
Handling	B-T033
for	O
Optimizing	O
Health	O
Status	O
of	O
Apiaries	O
in	O
Mediterranean	O
Ecosystems	O
We	O
analyzed	O
six	O
apiaries	O
in	O
several	O
natural	O
environments	O
with	O
a	O
Mediterranean	O
ecosystem	O
in	O
Madrid	O
,	O
central	O
Spain	O
,	O
in	O
order	O
to	O
understand	O
how	O
landscape	O
and	O
management	O
characteristics	O
may	O
influence	O
apiary	O
health	O
and	O
bee	O
production	O
in	O
the	O
long	O
term	O
.	O
We	O
focused	O
on	O
five	O
criteria	O
(	O
habitat	O
quality	O
,	O
landscape	O
heterogeneity	O
,	O
climate	O
,	O
management	O
and	O
health	O
)	O
,	O
as	O
well	O
as	O
30	O
subcriteria	O
,	O
and	O
we	O
used	O
the	O
analytic	O
hierarchy	O
process	O
(	O
AHP	O
)	O
to	O
rank	O
them	O
according	O
to	O
relevance	O
.	O
Habitat	O
quality	O
proved	O
to	O
have	O
the	O
highest	O
relevance	O
,	O
followed	O
by	O
beehive	O
management	O
.	O
Within	O
habitat	O
quality	O
,	O
the	O
following	O
subcriteria	O
proved	O
to	O
be	O
most	O
relevant	O
:	O
orographic	O
diversity	O
,	O
elevation	O
range	O
and	O
important	O
plant	O
species	O
located	O
1.5	O
km	O
from	O
the	O
apiary	O
.	O
The	O
most	O
important	O
subcriteria	O
under	O
beehive	O
management	O
were	O
honey	O
production	O
,	O
movement	O
of	O
the	O
apiary	O
to	O
a	O
location	O
with	O
a	O
higher	O
altitude	O
and	O
wax	O
renewal	O
.	O
Temperature	O
was	O
the	O
most	O
important	O
subcriterion	O
under	O
climate	O
,	O
while	O
pathogen	B-T001
and	O
Varroa	O
loads	B-T033
were	O
the	O
most	O
significant	O
under	O
health	O
.	O
Two	O
of	O
the	O
six	O
apiaries	O
showed	O
the	O
best	O
values	O
in	O
the	O
AHP	O
analysis	O
and	O
showed	O
annual	O
honey	O
production	O
of	O
70	O
and	O
28	O
kg/	O
colony	O
.	O
This	O
high	O
productivity	O
was	O
due	O
primarily	O
to	O
high	O
elevation	O
range	O
and	O
high	O
orographic	O
diversity	O
,	O
which	O
favored	O
high	O
habitat	O
quality	O
.	O
In	O
addition	O
,	O
one	O
of	O
these	O
apiaries	O
showed	O
the	O
best	O
value	O
for	O
beehive	O
management	O
,	O
while	O
the	O
other	O
showed	O
the	O
best	O
value	O
for	O
health	O
,	O
reflected	O
in	O
the	O
low	O
pathogen	B-T001
load	B-T033
and	O
low	O
average	O
number	O
of	O
viruses	B-T005
.	O
These	O
results	O
highlight	O
the	O
importance	O
of	O
environmental	O
factors	O
and	O
good	O
sanitary	O
practices	O
to	O
maximize	O
apiary	O
health	O
and	O
honey	O
productivity	O
.	O
      
Physiology	O
of	O
respiratory	B-T033
disturbances	I-T033
in	O
muscular	B-T047
dystrophies	I-T047
Muscular	B-T047
dystrophy	I-T047
is	O
a	O
group	O
of	O
inherited	O
myopathies	B-T047
characterised	O
by	O
progressive	O
skeletal	O
muscle	O
wasting	O
,	O
including	O
of	O
the	O
respiratory	B-T023
muscles	I-T023
.	O
Respiratory	B-T047
failure	I-T047
,	O
i.e.	O
when	O
the	O
respiratory	O
system	O
fails	O
in	O
its	O
gas	O
exchange	O
functions	O
,	O
is	O
a	O
common	O
feature	O
in	O
muscular	B-T047
dystrophy	I-T047
,	O
being	O
the	O
main	O
cause	O
of	O
death	B-T033
,	O
and	O
it	O
is	O
a	O
consequence	O
of	O
lung	B-T023
failure	B-T047
,	O
pump	B-T047
failure	I-T047
or	O
a	O
combination	O
of	O
the	O
two	O
.	O
The	O
former	O
is	O
due	O
to	O
recurrent	O
aspiration	O
,	O
the	O
latter	O
to	O
progressive	O
weakness	B-T033
of	I-T033
respiratory	I-T033
muscles	I-T033
and	O
an	O
increase	O
in	O
the	O
load	O
against	O
which	O
they	O
must	O
contract	O
.	O
In	O
fact	O
,	O
both	O
the	O
resistive	O
and	O
elastic	O
components	O
of	O
the	O
work	O
of	O
breathing	O
increase	O
due	O
to	O
airway	B-T047
obstruction	I-T047
and	O
chest	B-T023
wall	I-T023
and	O
lung	B-T023
stiffening	B-T184
,	O
respectively	O
.	O
The	O
respiratory	B-T033
disturbances	I-T033
in	O
muscular	B-T047
dystrophy	I-T047
are	O
restrictive	B-T033
pulmonary	I-T033
function	I-T033
,	O
hypoventilation	O
,	O
altered	O
thoracoabdominal	O
pattern	O
,	O
hypercapnia	B-T033
,	O
dyspnoea	B-T184
,	O
impaired	O
regulation	O
of	O
breathing	O
,	O
inefficient	B-T033
cough	I-T033
and	O
sleep	B-T047
disordered	I-T047
breathing	I-T047
.	O
They	O
can	O
be	O
present	O
at	O
different	O
rates	O
according	O
to	O
the	O
type	O
of	O
muscular	B-T047
dystrophy	I-T047
and	O
its	O
progression	O
,	O
leading	O
to	O
different	O
onset	O
of	O
each	O
symptom	B-T184
,	O
prognosis	B-T058
and	O
degree	B-T033
of	I-T033
respiratory	I-T033
involvement	I-T033
.	O
A	O
common	O
feature	O
of	O
muscular	B-T047
dystrophy	I-T047
is	O
respiratory	B-T047
failure	I-T047
,	O
i.e.	O
the	O
inability	O
of	O
the	O
respiratory	O
system	O
to	O
provide	O
proper	O
oxygenation	O
and	O
carbon	O
dioxide	O
elimination	O
.In	O
the	O
lung	B-T023
,	O
respiratory	B-T047
failure	I-T047
is	O
caused	O
by	O
recurrent	O
aspiration	O
,	O
and	O
leads	O
to	O
hypoxaemia	B-T033
and	O
hypercarbia	B-T033
.	O
Ventilatory	O
failure	O
in	O
muscular	B-T047
dystrophy	I-T047
is	O
caused	O
by	O
increased	O
respiratory	B-T033
load	I-T033
and	O
respiratory	B-T033
muscles	I-T033
weakness	I-T033
.	O
Respiratory	B-T033
load	I-T033
increases	O
in	O
muscular	B-T047
dystrophy	I-T047
because	O
scoliosis	B-T190
makes	O
chest	O
wall	O
compliance	O
decrease	O
,	O
atelectasis	O
and	O
fibrosis	O
make	O
lung	O
compliance	O
decrease	O
,	O
and	O
airway	B-T047
obstruction	I-T047
makes	O
airway	O
resistance	O
increase	O
.The	O
consequences	O
of	O
respiratory	B-T047
pump	I-T047
failure	I-T047
are	O
restrictive	B-T033
pulmonary	I-T033
function	I-T033
,	O
hypoventilation	O
,	O
altered	O
thoracoabdominal	O
pattern	O
,	O
hypercapnia	B-T033
,	O
dyspnoea	B-T184
,	O
impaired	O
regulation	O
of	O
breathing	O
,	O
inefficient	B-T033
cough	I-T033
and	O
sleep	B-T047
disordered	I-T047
breathing	I-T047
.	O
To	O
understand	O
the	O
mechanisms	B-T033
leading	O
to	O
respiratory	B-T033
disturbances	I-T033
in	O
patients	O
with	O
muscular	B-T047
dystrophy	I-T047
.To	O
understand	O
the	O
impact	O
of	O
respiratory	B-T033
disturbances	I-T033
in	O
patients	O
with	O
muscular	B-T047
dystrophy	I-T047
.To	O
provide	O
a	O
brief	O
description	O
of	O
the	O
main	O
forms	O
of	O
muscular	B-T047
dystrophy	I-T047
with	O
their	O
respiratory	B-T033
implications	I-T033
.	O
      
A	O
holistic	O
approach	O
to	O
age	O
estimation	O
in	O
refugee	O
children	O
Many	O
refugee	O
children	O
arriving	O
in	O
Australia	O
have	O
an	O
inaccurately	O
documented	B-T058
date	O
of	O
birth	O
(	O
DOB	O
)	O
.	O
A	O
medical	B-T058
assessment	I-T058
of	O
a	O
child	O
's	O
age	O
is	O
often	O
requested	O
when	O
there	O
is	O
a	O
concern	O
that	O
their	O
documented	B-T058
DOB	O
is	O
incorrect	O
.	O
This	O
study	O
's	O
aim	O
was	O
to	O
assess	B-T058
the	O
accuracy	O
a	O
holistic	O
age	O
assessment	O
tool	O
(	O
AAT	O
)	O
in	O
estimating	O
the	O
age	O
of	O
refugee	O
children	O
newly	O
settled	O
in	O
Australia	O
.	O
A	O
holistic	O
AAT	O
that	O
combines	O
medical	O
and	O
non	O
-	O
medical	O
approaches	O
was	O
used	O
to	O
estimate	O
the	O
ages	O
of	O
60	O
refugee	O
children	O
with	O
a	O
known	O
DOB	O
.	O
The	O
tool	O
used	O
four	O
components	O
to	O
assess	B-T058
age	O
:	O
an	O
oral	O
narrative	O
,	O
developmental	O
assessment	B-T058
,	O
anthropometric	O
measures	O
and	O
pubertal	B-T033
assessment	B-T058
.	O
Assessors	O
were	O
blinded	O
to	O
the	O
true	O
age	O
of	O
the	O
child	O
.	O
Correlation	O
coefficients	O
for	O
the	O
actual	O
and	O
estimated	O
age	O
were	O
calculated	O
for	O
the	O
tool	O
overall	O
and	O
individual	O
components	O
.	O
The	O
correlation	O
coefficient	O
between	O
the	O
actual	O
and	O
estimated	O
age	O
from	O
the	O
AAT	O
was	O
very	O
strong	O
at	O
0.9802	O
(	O
boys	O
0.9748	O
,	O
girls	O
0.9876	O
)	O
.	O
The	O
oral	O
narrative	O
component	O
of	O
the	O
tool	O
performed	O
best	O
(	O
R	O
=	O
0.9603	O
)	O
.	O
Overall	O
,	O
86.7	O
%	O
of	O
age	O
estimates	O
were	O
within	O
1	O
year	O
of	O
the	O
true	O
age	O
.	O
The	O
range	O
of	O
differences	O
was	O
-1.43	O
to	O
3.92	O
years	O
with	O
a	O
standard	O
deviation	O
of	O
0.77	O
years	O
(	O
9.24	O
months	O
)	O
.	O
The	O
AAT	O
is	O
a	O
holistic	O
,	O
simple	O
and	O
safe	O
instrument	O
that	O
can	O
be	O
used	O
to	O
estimate	O
age	O
in	O
refugee	O
children	O
with	O
results	O
comparable	O
with	O
radiological	O
methods	O
currently	O
used	O
.	O
      
Bilateral	O
C1	O
laminar	O
hooks	O
combined	O
with	O
C2	O
pedicle	O
screw	O
fixation	B-T061
in	O
the	O
treatment	B-T061
of	O
atlantoaxial	O
subluxation	O
after	O
Grisel	B-T047
syndrome	I-T047
Many	O
etiologies	O
can	O
lead	O
to	O
atlantoaxial	O
subluxaion	O
.	O
In	O
Grisel	B-T047
syndrome	I-T047
(	O
GS	B-T047
)	O
,	O
this	O
subluxation	O
occurs	O
spontaneously	O
after	O
inflammatory	O
processes	O
of	O
the	O
head	O
and	O
neck	O
.	O
Diagnosis	B-T033
is	O
typically	O
based	O
on	O
clinical	B-T033
history	I-T033
and	O
a	O
strong	O
suspicion	O
of	O
this	O
syndrome	B-T047
.	O
Nonsurgical	B-T061
treatment	I-T061
most	O
often	O
resolves	O
the	O
symptoms	B-T184
;	O
however	O
,	O
in	O
some	O
cases	O
surgical	B-T061
treatment	I-T061
is	O
necessary	O
to	O
repair	B-T061
the	O
subluxation	O
.	O
Various	O
surgical	B-T060
techniques	I-T060
and	O
instrumentation	O
systems	O
have	O
been	O
used	O
to	O
treat	B-T061
atlantoaxial	O
subluxation	O
,	O
although	O
there	O
is	O
no	O
consensus	O
regarding	O
the	O
best	O
treatment	B-T061
method	I-T061
for	O
the	O
pediatric	O
population	O
.	O
To	O
describe	O
a	O
case	O
of	O
atlantoaxial	O
subluxation	O
in	O
a	O
child	O
with	O
GS	B-T047
treated	B-T033
surgically	B-T061
with	O
an	O
alternative	O
construct	O
.	O
This	O
is	O
a	O
case	O
report	O
and	O
literature	O
review	O
.	O
Our	O
case	O
study	O
involves	O
a	O
5-	O
year	O
-old	O
girl	O
with	O
a	O
6-	O
month	O
history	B-T033
of	O
unresolved	O
Fielding	O
type	O
II	O
atlantoaxial	O
subluxation	O
caused	O
by	O
GS	B-T047
.	O
Despite	O
conservative	B-T061
treatment	I-T061
,	O
the	O
patient	O
's	O
symptoms	B-T184
continued	O
to	O
progress	O
.	O
After	O
two	O
failed	O
closed	B-T061
reduction	I-T061
attempts	O
,	O
open	B-T061
reduction	I-T061
and	O
C1	B-T061
-	I-T061
C2	I-T061
fusion	I-T061
were	O
performed	O
with	O
atlas	O
laminar	O
hook	O
and	O
axis	O
pedicle	O
polyaxial	O
screws	O
.	O
A	O
literature	O
review	O
of	O
the	O
surgical	B-T061
treatment	I-T061
of	O
GS	B-T047
was	O
also	O
performed	O
.	O
After	O
surgery	O
,	O
the	O
patient	O
exhibited	O
full	O
clinical	O
and	O
functional	B-T184
recovery	I-T184
with	O
complete	O
resolution	O
of	O
symptoms	B-T184
.	O
At	O
the	O
36-	O
month	O
follow	B-T058
-	I-T058
up	I-T058
examination	B-T058
,	O
there	O
was	O
continual	O
evidence	O
of	O
satisfactory	B-T033
reduction	B-T061
and	O
fusion	B-T061
.	O
No	O
complications	O
were	O
observed	O
.	O
Upon	O
completion	O
of	O
the	O
literature	O
review	O
,	O
eight	O
GS	B-T047
cases	O
were	O
found	O
to	O
have	O
been	O
treated	O
surgically	B-T061
with	O
the	O
minimum	O
patient	O
age	O
being	O
9	O
years	O
.	O
Conservative	B-T061
management	I-T061
of	O
GS	B-T047
is	O
the	O
most	O
common	O
and	O
effective	O
treatment	B-T061
;	O
however	O
,	O
a	O
few	O
surgical	O
cases	O
have	O
been	O
reported	B-T058
in	O
the	O
literature	O
with	O
good	O
results	O
.	O
Satisfactory	B-T033
clinical	B-T033
results	I-T033
and	O
fusion	B-T061
at	O
36	O
months	O
post	B-T033
surgery	I-T033
were	O
seen	O
in	O
a	O
pediatric	O
patient	O
with	O
atlantoaxial	O
subluxation	O
and	O
instability	B-T033
using	O
atlas	O
laminar	O
hook	O
and	O
axis	O
pedicle	O
polyaxial	O
screws	O
.	O
      
Mesenchymal	O
stem	O
cells	O
enhance	O
the	O
oncolytic	O
effect	O
of	O
Newcastle	B-T005
disease	I-T005
virus	I-T005
in	O
glioma	B-T191
cells	O
and	O
glioma	B-T191
stem	O
cells	O
via	O
the	O
secretion	O
of	O
TRAIL	O
Newcastle	B-T005
disease	I-T005
virus	I-T005
(	O
NDV	B-T005
)	O
is	O
an	O
avian	B-T005
paramyxovirus	I-T005
,	O
which	O
selectively	O
exerts	O
oncolytic	O
effects	O
in	O
cancer	O
cells	O
.	O
Mesenchymal	O
stem	O
cells	O
(	O
MSCs	O
)	O
have	O
been	O
reported	O
to	O
affect	O
tumor	B-T191
growth	I-T191
and	O
deliver	O
anti	B-T121
-	I-T121
tumor	I-T121
agents	I-T121
to	O
experimental	O
glioblastoma	B-T191
(	O
GBM	B-T191
)	O
.	O
Here	O
,	O
we	O
explored	O
the	O
effects	O
of	O
NDV	B-T005
-	O
infected	B-T033
MSCs	O
derived	O
from	O
different	O
sources	B-T033
,	O
on	O
glioma	B-T191
cells	O
and	O
glioma	B-T191
stem	O
cells	O
(	O
GSCs	O
)	O
and	O
the	O
mechanisms	O
involved	O
in	O
their	O
effects	O
.	O
The	O
glioma	B-T191
cell	O
lines	O
(	O
A172	O
and	O
U87	O
)	O
and	O
primary	O
GSCs	O
that	O
were	O
generated	O
from	O
GBM	B-T191
tumors	B-T191
were	O
used	O
in	O
this	O
study	O
.	O
MSCs	O
derived	O
from	O
bone	O
marrow	O
,	O
adipose	O
tissue	O
or	O
umbilical	B-T018
cord	I-T018
were	O
infected	B-T033
with	O
NDV	B-T005
(	O
MTH-68	B-T061
/	I-T061
H	I-T061
)	O
.	O
The	O
ability	O
of	O
these	O
cells	O
to	O
deliver	O
the	O
virus	B-T005
to	O
glioma	B-T191
cell	O
lines	O
and	O
GSCs	O
and	O
the	O
effects	O
of	O
NDV	B-T005
-	O
infected	B-T033
MSCs	O
on	O
cell	O
death	O
and	O
on	O
the	O
stemness	O
and	O
self	O
-	O
renewal	O
of	O
GSCs	O
were	O
examined	B-T033
.	O
The	O
mechanisms	O
involved	O
in	O
the	O
cytotoxic	O
effects	O
of	O
the	O
NDV	B-T005
-	O
infected	B-T033
MSCs	O
and	O
their	O
influence	O
on	O
the	O
radiation	O
sensitivity	O
of	O
GSCs	O
were	O
examined	B-T033
as	O
well	O
.	O
NDV	B-T005
induced	O
a	O
dose	O
-	O
dependent	O
cell	O
death	O
in	O
glioma	B-T191
cells	O
and	O
a	O
low	O
level	O
of	O
apoptosis	O
and	O
inhibition	O
of	O
self	O
-	O
renewal	O
in	O
GSCs	O
.	O
MSCs	O
derived	O
from	O
bone	O
marrow	O
,	O
adipose	O
and	O
umbilical	B-T018
cord	I-T018
that	O
were	O
infected	B-T033
with	O
NDV	B-T005
delivered	O
the	O
virus	B-T005
to	O
co	B-T059
-	I-T059
cultured	I-T059
glioma	B-T191
cells	O
and	O
GSCs	O
.	O
Conditioned	O
medium	O
of	O
NDV	B-T005
-	O
infected	B-T033
MSCs	O
induced	O
higher	O
level	O
of	O
apoptosis	O
in	O
the	O
tumor	O
cells	O
compared	O
with	O
the	O
apoptosis	O
induced	O
by	O
their	O
direct	B-T047
infection	I-T047
with	O
similar	O
virus	O
titers	O
.	O
These	O
results	B-T033
suggest	O
that	O
factor(s	O
)	O
secreted	O
by	O
the	O
infected	B-T033
MSCs	O
sensitized	O
the	O
glioma	B-T191
cells	O
to	O
the	O
cytotoxic	O
effects	O
of	O
NDV	B-T005
.	O
We	O
identified	O
TRAIL	O
as	O
a	O
mediator	O
of	O
the	O
cytotoxic	O
effects	O
of	O
the	O
infected	B-T033
MSCs	O
and	O
demonstrated	O
that	O
TRAIL	O
synergized	O
with	O
NDV	B-T005
in	O
the	O
induction	O
of	O
cell	O
death	O
in	O
glioma	B-T191
cells	O
and	O
GSCs	O
.	O
Moreover	O
,	O
conditioned	O
medium	O
of	O
infected	B-T033
MSCs	O
enhanced	O
the	O
sensitivity	O
of	O
GSCs	O
to	O
γ	O
-	O
radiation	O
.	O
NDV	B-T005
-	O
infected	B-T033
umbilical	B-T018
cord	I-T018
-	O
derived	O
MSCs	O
may	O
provide	O
a	O
novel	O
effective	O
therapeutic	O
approach	O
for	O
targeting	O
GSCs	O
and	O
GBM	B-T191
and	O
for	O
sensitizing	O
these	O
tumors	B-T191
to	O
γ	O
-	O
radiation	O
.	O
      
Arthrobacter	B-T007
ginkgonis	I-T007
sp	I-T007
.	I-T007
nov	I-T007
.	I-T007
,	O
an	O
actinomycete	B-T007
isolated	O
from	O
rhizosphere	O
of	O
Ginkgo	O
biloba	O
L	O
A	O
Gram	O
-	O
stain	O
-	O
positive	O
,	O
aerobic	O
actinobacterial	B-T007
strain	I-T007
(	O
designated	O
SYP	B-T007
-	I-T007
A7299	I-T007
T	I-T007
)	O
,	O
which	O
displayed	O
a	O
rod	B-T007
-	I-T007
coccus	I-T007
growth	I-T007
lifecycle	I-T007
,	O
was	O
isolated	O
from	O
the	O
rhizosphere	O
of	O
Ginkgo	O
biloba	O
L.	O
Phylogenetic	O
analyses	O
based	O
on	O
16S	O
rRNA	O
gene	O
sequences	O
indicated	O
that	O
strain	B-T007
SYP	I-T007
-	I-T007
A7299	I-T007
T	I-T007
belongs	O
to	O
the	O
genus	O
Arthrobacter	B-T007
and	O
is	O
most	O
closely	O
related	O
to	O
Arthrobacter	B-T007
halodurans	I-T007
JSM	I-T007
078085	I-T007
T	I-T007
(	O
97.4	O
%	O
16S	O
rRNA	O
gene	O
sequence	O
similarity	O
)	O
.	O
The	O
DNA	O
-	O
DNA	O
relatedness	O
value	O
between	O
strain	B-T007
SYP	I-T007
-	I-T007
A7299	I-T007
T	I-T007
and	O
A.	B-T007
halodurans	I-T007
JSM	I-T007
078085	I-T007
T	I-T007
was	O
37	O
%	O
±2.9	O
.	O
The	O
cell	O
-	O
wall	O
peptidoglycan	O
was	O
A4α	O
,	O
and	O
glucose	B-T121
and	O
galactose	O
were	O
whole	B-T121
-	I-T121
cell	I-T121
sugars	I-T121
.	O
The	O
polar	O
lipids	O
consisted	O
of	O
diphosphatidylglycerol	O
,	O
phosphatidylglycerol	O
,	O
phosphatidylinositol	O
,	O
two	O
glycolipids	O
and	O
an	O
unknown	O
polar	O
lipid	O
.	O
The	O
major	O
menaquinone	B-T121
were	O
MK-8(H2	O
)	O
(	O
72	O
%	O
)	O
and	O
MK-9(H2	B-T121
)	I-T121
(	O
28	O
%	O
)	O
,	O
and	O
the	O
predominant	O
cellular	O
fatty	O
acids	O
were	O
anteiso	O
-	O
C15	O
:	O
0	O
,	O
iso	B-T121
-	I-T121
C15	I-T121
:	I-T121
0	I-T121
and	O
anteiso	O
-	O
C17	O
:	O
0	O
.	O
The	O
DNA	O
G+C	O
content	O
was	O
68.9	O
mol%	O
.	O
Based	O
on	O
the	O
morphological	O
,	O
physiological	O
,	O
biochemical	O
and	O
chemotaxonomic	O
characters	O
presented	O
in	O
this	O
study	O
,	O
strain	B-T007
SYP	I-T007
-	I-T007
A7299	I-T007
T	I-T007
represents	O
a	O
novel	O
species	O
of	O
the	O
genus	O
Arthrobacter	B-T007
,	O
for	O
which	O
the	O
name	O
Arthrobacter	B-T007
ginkgonis	I-T007
sp	I-T007
.	I-T007
nov	I-T007
.	I-T007
is	O
proposed	O
.	O
The	O
type	B-T001
strain	I-T001
is	O
SYP	B-T007
-	I-T007
A7299	I-T007
T	I-T007
=	B-T007
(=	O
DSM	I-T007
100491T	I-T007
=	I-T007
KCTC	I-T007
39	I-T007
592	I-T007
T	I-T007
)	O
.	O
      
Chlamydia	B-T007
pneumoniae	I-T007
infection	O
promotes	O
vascular	O
endothelial	O
cell	O
angiogenesis	O
through	O
an	O
IQGAP1	O
-related	O
signaling	O
pathway	O
Chlamydia	B-T007
pneumoniae	I-T007
(	O
C.	B-T007
pneumoniae	I-T007
)	O
infection	O
plays	O
a	O
potential	O
role	O
in	O
angiogenesis	O
.	O
However	O
,	O
it	O
is	O
still	O
an	O
enigma	O
how	O
C.	B-T007
pneumoniae	I-T007
is	O
involved	O
in	O
this	O
process	O
.	O
Therefore	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
C.	B-T007
pneumoniae	I-T007
infection	O
on	O
angiogenesis	O
,	O
and	O
then	O
explored	O
the	O
roles	O
of	O
IQGAP1	O
-related	O
signaling	O
in	O
C.	B-T007
pneumoniae	I-T007
infection	O
-	O
induced	O
angiogenesis	O
.	O
C.	B-T007
pneumoniae	I-T007
infection	O
significantly	O
enhanced	O
angiogenesis	O
as	O
assessed	O
by	O
the	O
tube	B-T059
formation	I-T059
assay	I-T059
possibly	B-T033
by	O
inducing	O
vascular	O
endothelial	O
cell	O
(	O
VEC	O
)	O
migration	O
in	O
the	O
wound	O
healing	O
and	O
Transwell	B-T059
migration	I-T059
assays	I-T059
.	O
Subsequently	O
,	O
immunoprecipitation	B-T059
,	O
Western	B-T059
blot	I-T059
and	O
tube	B-T059
formation	I-T059
assay	I-T059
results	O
showed	O
that	O
the	O
phosphorylation	O
of	O
both	O
IQGAP1	O
and	O
N	O
-	O
WASP	O
was	O
required	O
for	O
the	O
angiogenesis	O
induced	O
by	O
C.	B-T007
pneumoniae	I-T007
infection	O
.	O
Our	O
co	B-T059
-	I-T059
immunoprecipitation	I-T059
study	B-T059
revealed	O
that	O
IQGAP1	O
physically	O
associated	O
with	O
N	O
-	O
WASP	O
after	O
C.	B-T007
pneumoniae	I-T007
infection	O
of	O
VECs	O
.	O
Actin	O
polymerization	O
assay	B-T059
further	O
showed	O
that	O
in	O
C.	B-T007
pneumoniae	I-T007
-	O
infected	B-T033
VECs	O
,	O
both	O
IQGAP1	O
and	O
N	O
-	O
WASP	O
were	O
recruited	O
to	O
filamentous	O
actin	O
,	O
and	O
shared	O
some	O
common	O
compartments	O
localized	O
at	O
the	O
leading	O
edge	O
of	O
lamellipodia	O
,	O
which	O
was	O
impaired	O
after	O
the	O
depletion	O
of	O
IQGAP1	O
by	O
using	O
the	O
small	O
interference	O
RNA	O
.	O
Moreover	O
,	O
the	O
knockdown	O
of	O
IQGAP1	O
also	O
significantly	O
decreased	O
N	O
-	O
WASP	O
phosphorylation	O
at	O
Tyr256	B-T121
induced	O
by	O
C.	B-T007
pneumoniae	I-T007
infection	O
.	O
We	O
conclude	O
that	O
C.	B-T007
pneumoniae	I-T007
infection	O
promotes	O
VEC	O
migration	O
and	O
angiogenesis	O
presumably	O
through	O
the	O
IQGAP1	O
-related	O
signaling	O
pathway	O
.	O
      
Function	O
analysis	O
of	O
Mef2c	O
promoter	O
in	O
muscle	O
differentiation	O
Regeneration	O
of	O
adult	O
skeletal	O
muscle	O
following	O
injury	O
occurs	O
through	O
the	O
activation	O
of	O
satellite	O
cells	O
,	O
that	O
proliferates	O
,	O
differentiates	O
,	O
and	O
fuses	O
with	O
injured	O
myofibers	B-T023
.	O
Myocyte	O
enhancer	O
factor	O
2	O
(	O
MEF2	O
)	O
proteins	O
are	O
reported	O
that	O
they	O
have	O
the	O
potential	O
contributions	O
to	O
adult	O
muscle	B-T033
regeneration	I-T033
.	O
In	O
order	O
to	O
further	O
understand	O
Mef2c	O
gene	O
,	O
the	O
promoter	O
of	O
pig	O
Mef2c	O
gene	O
was	O
analyzed	O
in	O
this	O
paper	O
.	O
Quantitative	O
real	O
-	O
time	O
PCR	O
(	O
qRT	O
-	O
PCR	O
)	O
revealed	O
the	O
expression	O
pattern	O
of	O
Mef2c	O
gene	O
in	O
muscle	O
of	O
eight	O
tissues	O
.	O
The	O
Mef2c	O
promoter	O
had	O
the	O
higher	O
transcriptional	O
activity	O
in	O
differentiated	O
C2C12	O
cells	O
than	O
that	O
in	O
proliferating	O
C2C12	O
cells	O
,	O
which	O
was	O
accompanied	O
by	O
the	O
up	O
-	O
regulation	O
of	O
mRNA	O
expression	O
of	O
Mef2c	O
gene	O
.	O
Function	O
deletion	O
and	O
mutation	O
analyses	O
showed	O
that	O
MyoD	O
and	O
MEF2	O
binding	O
sites	O
within	O
the	O
Mef2c	O
promoter	O
were	O
responsible	O
for	O
the	O
regulation	O
of	O
Mef2c	O
transcription	O
.	O
MEF2C	O
could	O
up	O
-	O
regulate	O
the	O
transcriptional	O
activities	O
of	O
Mef2c	O
promoter	O
constructs	O
which	O
contained	O
a	O
3'-end	O
nucleotide	O
sequence	O
with	O
p300	O
binding	O
site	O
.	O
The	O
Electrophoretic	B-T059
mobility	I-T059
shift	I-T059
assays	I-T059
(	O
EMSA	B-T059
)	O
and	O
chromatin	B-T059
immunoprecipitation	I-T059
(	I-T059
ChIP	I-T059
)	I-T059
assays	I-T059
determined	O
the	O
MyoD	O
binding	O
site	O
in	O
Mef2c	O
promoter	O
.	O
These	O
results	O
advanced	O
our	O
knowledge	O
of	O
the	O
promoter	O
of	O
the	O
pig	O
Mef2c	O
gene	O
.	O
And	O
the	O
study	O
of	O
Mef2c	O
promoter	O
regulator	O
elements	O
helped	O
to	O
elucidating	O
the	O
regulation	O
mechanisms	O
of	O
Mef2c	O
in	O
muscle	O
differentiation	O
or	O
muscle	B-T061
repair	I-T061
and	O
regeneration	B-T033
.	O
This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O
All	O
rights	O
reserved	O
.	O
      
Smartphone	O
-Based	O
Psychotherapeutic	B-T061
Micro	B-T061
-	I-T061
Interventions	I-T061
to	O
Improve	O
Mood	O
in	O
a	O
Real	O
-	O
World	O
Setting	O
Using	O
mobile	O
communication	O
technology	O
as	O
new	O
personalized	O
approach	O
to	O
treat	B-T061
mental	B-T048
disorders	I-T048
or	O
to	O
more	O
generally	O
improve	O
quality	O
of	O
life	O
is	O
highly	O
promising	O
.	O
Knowledge	O
about	O
intervention	B-T061
components	O
that	O
target	O
key	O
psychopathological	O
processes	O
in	O
terms	O
of	O
transdiagnostic	O
psychotherapy	B-T061
approaches	O
is	O
urgently	O
needed	O
.	O
We	O
explored	O
the	O
use	O
of	O
smartphone	O
-based	O
micro	B-T061
-	I-T061
interventions	I-T061
based	O
on	O
psychotherapeutic	O
techniques	O
,	O
guided	O
by	O
short	O
video	O
-	O
clips	O
,	O
to	O
elicit	O
mood	B-T048
changes	I-T048
.	O
As	O
part	O
of	O
a	O
larger	O
neurofeedback	B-T061
study	O
,	O
all	O
subjects	O
-after	O
being	O
randomly	O
assigned	O
to	O
an	O
experimental	O
or	O
control	O
neurofeedback	B-T061
condition	O
-underwent	O
daily	O
smartphone	O
-based	O
micro	B-T061
-	I-T061
interventions	I-T061
for	O
13	O
consecutive	O
days	O
.	O
They	O
were	O
free	O
to	O
choose	O
out	O
of	O
provided	O
techniques	O
,	O
including	O
viscerosensory	O
attention	O
,	O
emotional	B-T033
imagery	O
,	O
facial	B-T033
expression	I-T033
,	O
and	O
contemplative	O
repetition	O
.	O
Changes	O
in	O
mood	O
were	O
assessed	O
in	O
real	O
world	O
using	O
the	O
Multidimensional	O
Mood	O
State	O
Questionnaire	O
(	O
scales	O
:	O
good	O
-	O
bad	O
,	O
GB	O
;	O
awake	B-T033
-	O
tired	B-T184
,	O
AT	O
;	O
and	O
calm	O
-	O
nervous	B-T184
,	O
CN	O
)	O
.	O
Twenty	O
-	O
seven	O
men	O
participated	O
on	O
at	O
least	O
11	O
days	O
and	O
were	O
thus	O
included	O
in	O
the	O
analyses	O
.	O
Altogether	O
,	O
they	O
underwent	O
335	O
,	O
generally	O
well	O
-	O
tolerated	O
,	O
micro	O
-	O
intervention	O
sessions	O
,	O
with	O
viscerosensory	O
attention	O
(	O
178	O
sessions	O
,	O
53.13	O
%	O
)	O
and	O
contemplative	O
repetition	O
(	O
68	O
sessions	O
,	O
20.30	O
%	O
)	O
being	O
the	O
most	O
frequently	O
applied	O
techniques	O
.	O
Mixed	O
models	O
indicated	O
that	O
subjects	O
showed	O
better	O
mood	O
[	O
GB	O
:	O
b	O
=	O
0.464	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
[	O
0.068	O
,	O
0.860	O
]	O
,	O
t	O
(	O
613.3	O
)	O
=	O
2.298	O
,	O
p	O
=	O
0.022	O
]	O
and	O
became	O
more	O
awake	B-T033
[	O
AT	O
:	O
b	O
=	O
0.514	O
,	O
95	O
%	O
CI	O
[	O
0.103	O
,	O
0.925	O
]	O
,	O
t	O
(	O
612.4	O
)	O
=	O
2.456	O
,	O
p	O
=	O
0.014	O
]	O
and	O
calmer	O
[	O
CN	O
:	O
b	O
=	O
0.685	O
,	O
95	O
%	O
CI	O
[	O
0.360	O
,	O
1.010	O
]	O
,	O
t	O
(	O
612.3	O
)	O
=	O
4.137	O
,	O
p	O
<	O
0.001	O
]	O
from	O
pre	O
-	O
to	O
post	O
-	O
micro	O
-	O
intervention	O
.	O
These	O
mood	O
improvements	O
from	O
pre	O
-	O
to	O
post	O
-	O
micro	O
-	O
intervention	O
were	O
associated	O
with	O
changes	B-T048
in	I-T048
mood	I-T048
from	O
the	O
1st	O
day	O
until	O
the	O
last	O
day	O
with	O
regard	O
to	O
GB	O
mood	O
(	O
r	O
=	O
0.614	O
,	O
95	O
%	O
CI	O
[	O
0.297	O
,	O
0.809	O
]	O
,	O
p	O
<	O
0.001	O
)	O
,	O
but	O
not	O
AT	O
mood	O
(	O
r	O
=	O
0.279	O
,	O
95	O
%	O
CI	O
[	O
-0.122	O
,	O
0.602	O
]	O
,	O
p	O
=	O
0.167	O
)	O
and	O
CN	O
mood	O
(	O
r	O
=	O
0.277	O
,	O
95	O
%	O
CI	O
[	O
0.124	O
,	O
0.601	O
]	O
,	O
p	O
=	O
0.170	O
)	O
.	O
Our	O
findings	B-T033
provide	O
evidence	O
for	O
the	O
applicability	O
of	O
smartphone	O
-based	O
micro	B-T061
-	I-T061
interventions	I-T061
eliciting	O
short	O
-	O
term	O
mood	B-T048
changes	I-T048
,	O
based	O
on	O
techniques	O
used	O
in	O
psychotherapeutic	B-T061
approaches	O
,	O
such	O
as	O
mindfulness	O
-based	O
psychotherapy	B-T061
,	O
transcendental	O
meditation	O
,	O
and	O
other	O
contemplative	O
therapies	B-T061
.	O
The	O
results	O
encourage	O
exploring	O
these	O
techniques	O
'	O
capability	O
to	O
improve	O
mood	O
in	O
randomized	O
controlled	O
studies	O
and	O
patients	O
.	O
Smartphone	O
-based	O
micro	B-T061
-	I-T061
interventions	I-T061
are	O
promising	O
to	O
modify	O
mood	O
in	O
real	O
-	O
world	O
settings	O
,	O
complementing	O
other	O
psychotherapeutic	B-T061
interventions	I-T061
,	O
in	O
line	O
with	O
the	O
precision	O
medicine	O
approach	O
.	O
The	O
here	O
presented	O
data	O
were	O
collected	O
within	O
a	O
randomized	O
trial	O
,	O
registered	O
at	O
ClinicalTrials.gov	O
(	O
Identifier	O
:	O
NCT01921088	O
)	O
https://clinicaltrials.gov/ct2/show/NCT01921088	O
.	O
      
Antibacterial	B-T195
Activity	O
of	O
Polyaniline	O
Coated	O
Silver	O
Nanoparticles	O
Synthesized	O
from	O
Piper	O
Betle	O
Leaves	O
Extract	O
Plants	O
or	O
natural	O
resources	O
have	O
been	O
found	O
to	O
be	O
a	O
good	O
alternative	O
method	O
for	O
nanoparticles	O
synthesis	O
.	O
In	O
this	O
study	O
,	O
polyaniline	O
coated	O
silver	O
nanoparticles	O
(	O
AgNPs	O
)	O
synthesized	O
from	O
Piper	O
betle	O
leaves	O
extract	O
were	O
investigated	O
for	O
their	O
antibacterial	B-T195
activity	O
.	O
Silver	O
nanoparticles	O
were	O
prepared	O
from	O
the	O
reduction	O
of	O
silver	B-T121
nitrate	I-T121
and	O
NaBH4	O
was	O
used	O
as	O
reducing	O
agent	O
.	O
Silver	O
nanoparticles	O
and	O
extracts	O
were	O
mixed	O
thoroughly	O
and	O
then	O
coated	O
by	O
polyaniline	O
.	O
Prepared	O
nanoparticles	O
were	O
characterized	O
by	O
Visual	O
inspection	O
,	O
Ultraviolet	B-T059
-	I-T059
visible	I-T059
spectroscopy	I-T059
(	O
UV	B-T059
)	O
,	O
Fourier	O
transform	O
infrared	O
Spectroscopy	O
(	O
FT	O
-	O
IR	O
)	O
,	O
Transmission	B-T059
Electron	I-T059
Microscopy	I-T059
(	I-T059
TEM	I-T059
)	I-T059
techniques	I-T059
.	O
Antibacterial	B-T195
activities	O
of	O
the	O
synthesized	O
silver	O
nanoparticles	O
were	O
tested	O
against	O
Staphylococcus	B-T007
aureus	I-T007
ATCC	I-T007
25923	I-T007
,	O
Salmonella	B-T007
typhi	I-T007
ATCC	I-T007
14028	I-T007
,	O
Escherichia	B-T007
coli	I-T007
ATCC	I-T007
25922	I-T007
and	O
Pseudomonas	B-T007
aeruginosa	I-T007
ATCC	I-T007
27853	I-T007
.	O
UV	B-T059
-	I-T059
Vis	I-T059
spectrum	I-T059
of	O
reaction	O
mixture	O
showed	O
strong	O
absorption	O
peak	O
with	O
centering	O
at	O
400	O
nm	O
.	O
The	O
FT	O
-	O
IR	O
results	O
imply	O
that	O
Ag	O
-	O
NPs	O
were	O
successfully	O
synthesized	O
and	O
capped	O
with	O
bio	O
-	O
compounds	O
present	O
in	O
P.	O
betle	O
.	O
TEM	B-T059
image	O
showed	O
that	O
Ag	O
-	O
NPs	O
formed	O
were	O
well	O
dispersed	O
with	O
a	O
spherical	O
structures	O
and	O
particle	O
size	O
ranging	O
from	O
10	O
to	O
30	O
nm	O
.	O
The	O
result	O
revealed	O
that	O
Ag	O
-	O
Extract	O
NPs	O
showed	O
32.78±0.64	O
mm	O
zone	O
of	O
inhibition	O
against	O
S.	B-T007
aureus	I-T007
,	O
whereas	O
norfloxacin	B-T195
(	O
positive	O
control	O
)	O
showed	O
maximum	O
32.15±0.40	O
mm	O
zone	O
of	O
inhibition	O
for	O
S.	B-T007
aureus	I-T007
.	O
Again	O
,	O
maximum	O
zone	O
of	O
inhibition	O
29.55±0.45	O
mm	O
was	O
found	O
for	O
S.	B-T007
typhi	I-T007
,	O
27.12±0.38	O
mm	O
for	O
E.	B-T007
coli	I-T007
and	O
21.95±0.45	O
mm	O
for	O
P.	B-T007
aeruginosa	I-T007
.	O
The	O
results	O
obtained	O
by	O
this	O
study	O
ca	O
n't	O
be	O
directly	O
extrapolated	O
to	O
human	O
;	O
so	O
further	O
studies	O
should	O
be	O
undertaken	O
to	O
established	O
the	O
strong	O
antimicrobial	B-T121
activity	O
of	O
Ag	O
-	O
Extract	O
NPs	O
for	O
drug	O
development	O
program	O
.	O
      
Anti	O
-	O
CD45RB	O
and	O
donor	O
-	O
specific	O
spleen	O
cells	O
transfusion	O
inhibition	O
allograft	O
skin	O
rejection	O
mediated	O
by	O
memory	O
T	O
cells	O
Donor	O
-	O
reactive	O
memory	O
T	O
(	O
Tm)cells	O
mediate	O
accelerated	O
rejection	O
,	O
which	O
is	O
known	O
as	O
a	O
barrier	O
to	O
the	O
survival	O
of	O
transplanted	B-T023
organs	I-T023
.	O
Selective	O
interference	O
with	O
the	O
anti	O
-	O
CD45RB	O
monoclonal	O
antibody	O
(	O
α	O
-	O
CD45RB	O
)	O
reliably	O
induces	O
donor	O
-	O
specific	O
tolerance	O
.	O
In	O
this	O
study	O
,	O
pre	O
-	O
sensitization	O
to	O
female	O
C57BL/6	O
mice	O
with	O
the	O
skin	O
of	O
female	O
BLAB	O
/	O
c	O
mice	O
generated	O
a	O
large	O
number	O
of	O
Tm	O
cells	O
and	O
resulted	O
in	O
rapid	O
rejection	O
of	O
the	O
secondly	O
transplanted	O
allografts	O
.	O
α	O
-	O
CD45RB	O
did	O
induce	O
the	O
tolerance	O
to	O
skin	O
allograft	O
primarily	O
transplanted	O
but	O
failed	O
to	O
induce	O
tolerance	O
in	O
the	O
pre	O
-	O
sensitized	O
mice	O
.	O
Donor	O
-	O
specific	O
spleen	O
cell	O
transfusion	O
(	O
DST	O
)	O
alone	O
also	O
failed	O
to	O
induce	O
the	O
tolerance	O
in	O
the	O
pre	O
-	O
sensitized	O
recipients	O
.	O
Interestingly	O
,	O
combination	O
of	O
α	O
-	O
CD45RB	O
with	O
DST	O
inhibited	O
the	O
rejection	O
induced	O
by	O
memory	O
T	O
cells	O
in	O
the	O
pre	O
-	O
sensitized	O
mice	O
.	O
CD25	O
+	O
T	O
-	O
cell	O
depletion	B-T061
in	O
α	O
-	O
CD45RB	O
combined	O
with	O
DST	O
therapy	B-T061
recipients	O
could	O
prevent	O
skin	O
allograft	O
tolerance	O
from	O
establishing	O
.	O
In	O
addition	O
,	O
adoptive	B-T061
transfer	I-T061
of	O
donor	O
-primed	O
memory	O
T	O
cells	O
into	O
the	O
tolerant	O
recipients	O
markedly	O
broke	O
the	O
established	O
tolerance	O
.	O
Our	O
findings	B-T033
indicate	O
that	O
α	O
-	O
CD45RB	O
and	O
DST	O
can	O
synergistically	O
inhibit	O
the	O
accelerated	O
rejection	O
mediated	O
by	O
memory	O
T	O
cells	O
and	O
induce	O
long	O
-	O
term	O
skin	O
allograft	O
acceptance	O
in	O
mice	O
.	O
      
Development	O
of	O
a	O
Novel	O
Quantitative	O
Structure	O
-	O
Activity	O
Relationship	O
Model	O
to	O
Accurately	O
Predict	O
Pulmonary	O
Absorption	O
and	O
Replace	O
Routine	O
Use	O
of	O
the	O
Isolated	O
Perfused	O
Respiring	O
Rat	B-T023
Lung	I-T023
Model	O
We	O
developed	O
and	O
tested	O
a	O
novel	O
Quantitative	O
Structure	O
-	O
Activity	O
Relationship	O
(	O
QSAR	O
)	O
model	O
to	O
better	O
understand	O
the	O
physicochemical	O
drivers	O
of	O
pulmonary	O
absorption	O
,	O
and	O
to	O
facilitate	O
compound	O
design	O
through	O
improved	O
prediction	O
of	O
absorption	O
.	O
The	O
model	O
was	O
tested	O
using	O
a	O
large	O
array	O
of	O
both	O
existing	O
and	O
newly	O
designed	O
compounds	B-T121
.	O
Pulmonary	O
absorption	O
data	O
was	O
generated	O
using	O
the	O
isolated	O
perfused	O
respiring	O
rat	B-T023
lung	I-T023
(	O
IPRLu	B-T023
)	O
model	O
for	O
82	O
drug	O
discovery	O
compounds	B-T121
and	O
17	O
marketed	B-T121
drugs	I-T121
.	O
This	O
dataset	O
was	O
used	O
to	O
build	O
a	O
novel	O
QSAR	O
model	O
based	O
on	O
calculated	O
physicochemical	O
properties	O
.	O
A	O
further	O
9	O
compounds	B-T121
were	O
used	O
to	O
test	O
the	O
model	O
's	O
predictive	O
capability	O
.	O
The	O
QSAR	O
model	O
performed	O
well	O
on	O
the	O
9	O
compounds	B-T121
in	O
the	O
"	O
Test	O
set	O
"	O
with	O
a	O
predicted	O
versus	O
observed	O
correlation	O
of	O
R(2	O
)	O
=	O
0.85	O
,	O
and	O
>	O
65	O
%	O
of	O
compounds	B-T121
correctly	O
categorised	O
.	O
Calculated	O
descriptors	O
associated	O
with	O
permeability	O
and	O
hydrophobicity	O
positively	O
correlated	O
with	O
pulmonary	O
absorption	O
,	O
whereas	O
those	O
associated	O
with	O
charge	O
,	O
ionisation	O
and	O
size	O
negatively	O
correlated	O
.	O
The	O
novel	O
QSAR	O
model	O
described	O
here	O
can	O
replace	O
routine	O
generation	O
of	O
IPRLu	B-T023
model	O
data	O
for	O
ranking	O
and	O
classifying	O
compounds	B-T121
prior	O
to	O
synthesis	O
.	O
It	O
will	O
also	O
provide	O
scientists	O
working	O
in	O
the	O
field	O
of	O
inhaled	O
drug	O
discovery	O
with	O
a	O
deeper	O
understanding	O
of	O
the	O
physicochemical	O
drivers	O
of	O
pulmonary	O
absorption	O
based	O
on	O
a	O
relevant	O
respiratory	O
compound	B-T121
dataset	O
.	O
      
Association	O
between	O
neutrophil	O
-to-	O
lymphocyte	O
ratio	O
and	O
differentiated	B-T191
thyroid	I-T191
cancer	I-T191
:	O
a	O
meta	O
-	O
analysis	O
The	O
association	O
between	O
neutrophil	O
-to-	O
lymphocyte	O
ratio	O
(	O
NLR	O
)	O
and	O
differentiated	B-T191
thyroid	I-T191
cancer	I-T191
(	O
DTC	B-T191
)	O
is	O
undecided	O
.	O
To	O
rectify	O
this	O
question	O
,	O
we	O
conducted	O
a	O
systematic	O
meta	O
-	O
analysis	O
based	O
on	O
7	O
prospective	O
cohort	O
studies	O
published	O
between	O
2013	O
and	O
2015	O
,	O
comprising	O
7349	O
patients	O
.	O
Six	O
of	O
these	O
cohorts	O
included	O
pretreatment	O
(	O
baseline	O
)	O
NLR	O
data	O
for	O
patients	O
with	O
thyroid	B-T191
nodules	I-T191
.	O
The	O
meta	O
-	O
analysis	O
of	O
these	O
6	O
cohorts	O
showed	O
that	O
the	O
NLR	O
of	O
patients	O
with	O
DTC	B-T191
(	O
4617	O
cases	O
)	O
was	O
statistically	O
similar	O
to	O
patients	O
with	O
benign	B-T191
nodules	I-T191
only	O
(	O
1666	O
cases	O
)	O
,	O
with	O
a	O
mean	O
difference	O
(	O
MD	O
)	O
of	O
0.19	O
(	O
95	O
%	O
CI	O
:	O
-0.09	O
to	O
0.46	O
;	O
I(2	O
)	O
=	O
93	O
%	O
;	O
P	O
<	O
0.001	O
)	O
.	O
No	O
significant	O
difference	O
in	O
NLR	O
was	O
found	O
between	O
patients	O
with	O
DTC	B-T191
and	O
patients	O
with	O
benign	B-T191
nodules	I-T191
.	O
Two	O
studies	B-T059
addressed	O
an	O
association	O
between	O
NLR	O
and	O
papillary	B-T191
thyroid	I-T191
carcinoma	I-T191
in	O
patients	O
stratified	O
by	O
age	O
<	O
45	O
and	O
≥45	O
years	O
(	O
496	O
and	O
891	O
cases	O
,	O
respectively	O
)	O
;	O
the	O
pooled	O
MD	O
was	O
0.09	O
(	O
95	O
%	O
CI	O
:	O
-0.37	O
to	O
0.55	O
;	O
I(2	O
)	O
=	O
92.2	O
%	O
,	O
P	O
<	O
0.001	O
)	O
.	O
An	O
elevated	O
NLR	O
seems	O
not	O
a	O
reliable	O
indicator	O
of	O
progressing	O
DTC	B-T191
in	O
patients	O
with	O
goiters	O
,	O
and	O
there	O
was	O
no	O
difference	O
in	O
NLR	O
between	O
patients	O
aged	O
<	O
45	O
years	O
and	O
those	O
aged	O
≥45	O
years	O
.	O
Well	O
-	O
designed	O
and	O
large	O
-	O
scale	O
investigations	B-T058
are	O
warranted	O
to	O
understand	O
the	O
value	O
of	O
NLR	O
in	O
the	O
prognosis	B-T033
of	O
DTC	B-T191
.	O
      
A	O
modified	O
ESBL	B-T059
Nordmann	I-T059
/	I-T059
Dortet	I-T059
/	I-T059
Poirel	I-T059
-	I-T059
based	I-T059
protocol	I-T059
to	O
optimize	O
early	O
sepsis	B-T047
management	B-T058
We	O
evaluated	O
a	O
modification	O
of	O
a	O
colorimetric	B-T059
test	I-T059
recently	O
described	O
by	O
Dortet	O
et	O
al	O
.	O
(	O
2015	O
)	O
for	O
the	O
rapid	O
detection	B-T061
of	O
ESBL	O
-producing	O
Enterobacteriaceae	B-T007
directly	O
from	O
positive	B-T033
blood	B-T059
cultures	I-T059
that	O
requires	O
less	O
manipulation	B-T059
,	O
materials	O
and	O
hands	O
-	O
on	O
time	O
.	O
The	O
simplified	O
protocol	B-T059
showed	O
a	O
sensitivity	O
and	O
specificity	O
of	O
100	O
%	O
and	O
95.7	O
%	O
respectively	O
.	O
      
Long	O
-	O
term	O
antibiofilm	O
activity	O
of	O
carboxymethyl	B-T121
chitosan	I-T121
on	O
mixed	B-T007
biofilm	I-T007
on	O
silicone	O
Silicone	O
voice	O
prostheses	O
are	O
most	O
frequently	O
used	O
in	O
voice	B-T061
rehabilitation	I-T061
of	O
laryngectomized	B-T061
patients	O
.	O
However	O
,	O
the	O
functional	B-T033
device	I-T033
lifetimes	O
are	O
limited	O
due	O
to	O
formation	O
of	O
mixed	B-T007
biofilms	I-T007
.	O
Existing	O
in	O
vitro	O
models	O
simulating	O
biofilm	O
formation	O
are	O
restricted	O
to	O
only	O
short	O
-	O
term	O
periods	O
.	O
The	O
goal	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effect	O
of	O
carboxymethyl	B-T121
chitosan	I-T121
on	O
mixed	O
biofilm	O
formation	O
of	O
fungi	O
and	O
bacteria	B-T007
on	O
silicone	O
over	O
a	O
long	O
-	O
term	O
period	O
.	O
Mixed	O
species	O
biofilms	B-T007
of	O
Candida	O
albicans	O
,	O
Candida	O
tropicalis	O
,	O
Lactobacillus	B-T007
gasseri	I-T007
,	O
Streptococcus	B-T007
salivarius	I-T007
,	O
Rothia	B-T007
dentocariosa	I-T007
,	O
and	O
Staphylococcus	B-T007
epidermidis	I-T007
were	O
cultivated	O
on	O
the	O
surfaces	O
of	O
medical	O
-	O
grade	O
silicone	O
with	O
and	O
without	O
addition	O
of	O
carboxymethyl	B-T121
chitosan	I-T121
.	O
Biofilm	O
kinetics	O
was	O
monitored	O
using	O
specially	O
designed	O
image	O
analysis	O
software	O
to	O
calculate	O
the	O
percentual	O
surface	O
covering	O
of	O
each	O
platelet	O
.	O
Biofilm	O
architecture	O
was	O
investigated	O
by	O
scanning	B-T059
electron	I-T059
microscopy	I-T059
.	O
A	O
cover	O
of	O
living	O
mixed	B-T007
biofilm	I-T007
could	O
be	O
generated	O
over	O
22	O
days	O
on	O
silicone	O
and	O
the	O
maximum	O
of	O
22	O
%	O
biofilm	B-T007
surface	O
covering	O
at	O
day	O
22	O
.	O
However	O
,	O
less	O
than	O
4	O
%	O
surface	O
coverage	O
was	O
observed	O
on	O
the	O
carboxymethyl	B-T121
chitosan	I-T121
-	O
treated	O
plates	O
in	O
the	O
testing	O
period	O
.	O
Scanning	B-T059
electron	I-T059
microscopy	I-T059
confirms	B-T033
that	O
,	O
on	O
surfaces	O
treated	O
by	O
carboxymethyl	B-T121
chitosan	I-T121
,	O
the	O
biofilm	B-T007
was	O
less	O
dense	O
.	O
In	O
addition	O
,	O
there	O
were	O
fewer	O
layers	O
of	O
cells	O
and	O
profuse	B-T033
cellular	I-T033
debris	I-T033
,	O
together	O
with	O
degrading	O
and	O
morphologically	B-T190
altered	I-T190
yeast	O
cells	O
.	O
Carboxymethyl	B-T121
chitosan	I-T121
may	O
serve	O
as	O
a	O
possible	B-T033
antibiofilm	O
agent	O
to	O
limit	O
biofilm	O
formation	O
on	O
voice	O
prostheses	O
.	O
NA	O
Laryngoscope	O
,	O
126	O
:	O
E404	O
-	O
E408	O
,	O
2016	O
.	O
      
High	B-T061
-	I-T061
fructose	I-T061
diet	I-T061
is	O
as	O
detrimental	O
as	O
high	B-T061
-	I-T061
fat	I-T061
diet	I-T061
in	O
the	O
induction	B-T061
of	O
insulin	O
resistance	O
and	O
diabetes	B-T047
mediated	O
by	O
hepatic	O
/	O
pancreatic	B-T023
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
stress	O
In	O
the	O
context	O
of	O
high	O
human	O
consumption	O
of	O
fructose	B-T121
diets	O
,	O
there	O
is	O
an	O
imperative	O
need	O
to	O
understand	O
how	O
dietary	O
fructose	B-T033
intake	I-T033
influence	O
cellular	O
and	O
molecular	O
mechanisms	O
and	O
thereby	O
affect	O
β	B-T033
-	I-T033
cell	I-T033
dysfunction	I-T033
and	O
insulin	O
resistance	O
.	O
While	O
evidence	O
exists	O
for	O
a	O
relationship	O
between	O
high	O
-	O
fat	B-T121
-	O
induced	O
insulin	O
resistance	O
and	O
metabolic	B-T047
disorders	I-T047
,	O
there	O
is	O
lack	O
of	O
studies	O
in	O
relation	O
to	O
high	B-T061
-	I-T061
fructose	I-T061
diet	I-T061
.	O
Therefore	O
,	O
we	O
attempted	O
to	O
study	O
the	O
effect	O
of	O
different	O
diets	O
viz	O
.	O
,	O
high	B-T061
-	I-T061
fat	I-T061
diet	I-T061
(	O
HFD	B-T061
)	O
,	O
high	B-T061
-	I-T061
fructose	I-T061
diet	I-T061
(	O
HFS	B-T061
)	O
,	O
and	O
a	O
combination	O
(	O
HFS	B-T061
+	O
HFD	B-T061
)	O
diet	O
on	O
glucose	O
homeostasis	O
and	O
insulin	O
sensitivity	O
in	O
male	O
Wistar	O
rats	O
compared	O
to	O
control	O
animals	O
fed	O
with	O
normal	O
pellet	O
diet	O
.	O
Investigations	O
include	O
oral	B-T060
glucose	I-T060
tolerance	I-T060
test	I-T060
,	O
insulin	B-T059
tolerance	I-T059
test	I-T059
,	O
histopathology	B-T059
by	O
H&E	B-T059
and	O
Masson	B-T059
's	I-T059
trichrome	I-T059
staining	I-T059
,	O
mRNA	O
expression	O
by	O
real	O
-	O
time	O
PCR	O
,	O
protein	B-T059
expression	I-T059
by	O
Western	B-T059
blot	I-T059
,	O
and	O
caspase-3	O
activity	O
by	O
colorimetry	B-T059
.	O
Rats	O
subjected	O
to	O
high	B-T061
-	I-T061
fat	I-T061
/	O
fructose	B-T061
diets	I-T061
became	O
glucose	B-T121
intolerant	O
,	O
insulin	O
-	O
resistant	O
,	O
and	O
dyslipidemic	B-T033
.	O
Compared	O
to	O
control	O
animals	O
,	O
rats	O
subjected	O
to	O
different	O
combination	O
of	O
fat	B-T061
/	O
fructose	B-T061
diets	I-T061
showed	O
increased	O
mRNA	O
and	O
protein	O
expression	O
of	O
a	O
battery	O
of	O
ER	O
stress	O
markers	O
both	O
in	O
pancreas	B-T023
and	O
liver	B-T023
.	O
Transcription	O
factors	O
of	O
β	O
-	O
cell	O
function	O
(	O
INSIG1	O
,	O
SREBP1c	O
and	O
PDX1	O
)	O
as	O
well	O
as	O
hepatic	O
gluconeogenesis	O
(	O
FOXO1	O
and	O
PEPCK	O
)	O
were	O
adversely	O
affected	O
in	O
diet	O
-	O
induced	O
insulin	O
-	O
resistant	O
rats	O
.	O
The	O
convergence	O
of	O
chronic	O
ER	O
stress	O
towards	O
apoptosis	O
in	O
pancreas	B-T023
/	O
liver	B-T023
was	O
also	O
indicated	B-T033
by	O
increased	O
levels	O
of	O
CHOP	O
mRNA	O
&	O
increased	O
activity	O
of	O
both	O
JNK	O
and	O
Caspase-3	O
in	O
rats	O
subjected	O
to	O
high	B-T061
-	I-T061
fat	I-T061
/	O
fructose	B-T061
diets	I-T061
.	O
Our	O
study	O
exposes	O
the	O
experimental	O
support	O
in	O
that	O
high	B-T061
-	I-T061
fructose	I-T061
diet	I-T061
is	O
equally	O
detrimental	O
in	O
causing	O
metabolic	B-T047
disorders	I-T047
.	O
      
Reappraisal	B-T058
Modulates	O
Attentional	O
Bias	O
to	O
Angry	B-T033
Faces	I-T033
Heightened	O
attentional	O
bias	O
to	O
emotional	B-T033
information	O
is	O
one	O
of	O
the	O
main	O
characteristics	O
of	O
disorders	B-T047
related	O
to	O
emotion	O
dysregulation	B-T048
such	O
as	O
anxiety	B-T048
,	O
depression	B-T048
,	O
and	O
substance	B-T048
abuse	I-T048
.	O
Although	O
reappraisal	B-T058
,	O
an	O
emotion	O
regulation	O
strategy	O
,	O
is	O
known	O
to	O
effectively	O
modulate	O
subjective	O
experience	O
of	O
emotions	O
,	O
it	O
remains	O
unknown	O
whether	O
reappraisal	B-T058
can	O
alter	O
attentional	O
biases	O
to	O
emotional	B-T033
information	O
.	O
In	O
the	O
current	O
research	O
,	O
we	O
investigated	O
the	O
influence	O
of	O
instruction	B-T058
-	I-T058
induced	I-T058
state	I-T058
reappraisal	I-T058
(	O
Study	O
1	O
)	O
and	O
trait	B-T058
reappraisal	I-T058
(	O
Study	O
2	O
)	O
on	O
attentional	O
biases	O
to	O
happy	B-T033
and	O
angry	B-T033
faces	I-T033
.	O
In	O
Study	O
1	O
,	O
healthy	O
young	O
women	O
were	O
recruited	O
and	O
randomly	O
assigned	O
to	O
one	O
of	O
the	O
three	O
groups	O
:	O
up	O
-	O
,	O
down	O
-	O
,	O
and	O
no	O
-	O
regulation	O
.	O
Participants	O
were	O
instructed	O
to	O
reappraise	B-T058
their	O
emotions	O
to	O
increase	O
and	O
decrease	O
emotional	B-T033
experience	O
while	O
viewing	O
an	O
emotionally	O
negative	O
film	O
clip	O
.	O
Attentional	O
bias	O
was	O
assessed	O
with	O
a	O
dot	B-T061
-	I-T061
probe	I-T061
task	I-T061
with	O
pictures	O
of	O
angry	O
and	O
happy	O
facial	B-T033
expressions	I-T033
.	O
In	O
Study	O
2	O
,	O
a	O
separate	O
group	O
of	O
healthy	O
young	O
men	O
and	O
women	O
participated	O
.	O
Participants	O
'	O
trait	B-T058
reappraisal	I-T058
and	O
suppression	O
as	O
well	O
as	O
state	B-T048
and	O
trait	B-T033
anxiety	I-T033
were	O
assessed	O
.	O
A	O
dot	B-T061
-	I-T061
probe	I-T061
task	I-T061
was	O
completed	O
by	O
all	O
participants	O
.	O
Statistical	O
tests	O
in	O
Study	O
1	O
revealed	O
that	O
participants	O
who	O
reappraised	B-T058
to	O
decrease	O
negative	O
emotions	O
while	O
viewing	O
an	O
emotionally	O
negative	O
film	O
clip	O
had	O
reduced	O
attentional	O
bias	O
to	O
subsequently	O
presented	O
angry	B-T033
faces	I-T033
compared	O
to	O
participants	O
who	O
reappraised	B-T058
to	O
increase	O
negative	O
emotions	O
.	O
Multiple	O
regression	O
analyses	O
in	O
Study	O
2	O
revealed	O
that	O
trait	B-T058
reappraisal	I-T058
predicted	O
slower	O
orienting	O
toward	O
angry	B-T033
faces	I-T033
,	O
whereas	O
state	B-T048
anxiety	I-T048
predicted	O
slower	O
disengagement	O
from	O
angry	B-T033
faces	I-T033
.	O
Interestingly	O
,	O
trait	O
suppression	O
predicted	O
slower	O
disengagement	O
from	O
happy	B-T033
faces	I-T033
.	O
Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
both	O
instruction	B-T058
-	I-T058
induced	I-T058
state	I-T058
reappraisal	I-T058
and	O
trait	B-T058
reappraisal	I-T058
are	O
linked	O
to	O
reduced	O
attentional	O
bias	O
to	O
negative	B-T033
information	O
and	O
contribute	O
to	O
better	O
understanding	O
of	O
how	O
everyday	O
emotion	O
regulation	O
styles	O
contribute	O
to	O
attentional	O
processing	O
of	O
emotional	B-T033
information	O
.	O
      
Improved	B-T033
risk	O
stratification	O
for	O
patients	O
with	O
high	O
-	O
grade	O
urothelial	B-T191
carcinoma	I-T191
following	O
application	O
of	O
the	O
Paris	O
System	O
for	O
Reporting	B-T058
Urinary	B-T059
Cytology	I-T059
The	O
Paris	O
System	O
for	O
Reporting	B-T058
Urinary	B-T059
Cytology	I-T059
(	O
TPS	B-T059
)	O
requires	O
4	O
cytomorphologic	O
criteria	O
for	O
a	O
definitive	O
diagnosis	B-T033
of	O
high	B-T191
-	I-T191
grade	I-T191
urothelial	I-T191
carcinoma	I-T191
(	O
HGUC	B-T191
)	O
in	O
urinary	B-T059
tract	I-T059
cytology	I-T059
(	O
UTC	B-T059
)	O
specimens	O
:	O
an	O
elevated	O
nuclear	O
-	O
to	O
-	O
cytoplasmic	O
(	O
N	O
/	O
C	O
)	O
ratio	O
(	O
at	O
or	O
above	O
0.7	O
)	O
,	O
markedly	O
atypical	O
nuclear	O
borders	O
,	O
moderate	O
to	O
severe	O
hyperchromasia	B-T033
,	O
and	O
coarse	B-T033
chromatin	I-T033
.	O
However	O
,	O
malignant	O
UTC	B-T059
specimens	O
often	O
contain	O
degenerative	O
changes	O
,	O
and	O
this	O
limits	O
the	O
number	O
of	O
malignant	O
cells	O
meeting	O
all	O
4	O
TPS	B-T059
cytomorphologic	O
criteria	O
.	O
One	O
hundred	O
twelve	O
UTC	B-T059
specimens	O
from	O
patients	O
with	O
a	O
subsequent	O
diagnosis	B-T033
of	O
HGUC	B-T191
were	O
reviewed	O
and	O
reclassified	O
according	O
to	O
TPS	B-T059
criteria	O
.	O
The	O
presence	B-T033
of	O
TPS	B-T059
cytomorphologic	O
criteria	O
for	O
HGUC	B-T191
in	O
each	O
specimen	O
was	O
recorded	O
,	O
as	O
was	O
the	O
proportion	O
of	O
atypical	O
cells	O
meeting	O
all	O
4	O
criteria	O
.	O
The	O
number	O
of	O
specimens	O
definitively	O
diagnosed	B-T033
as	O
HGUC	B-T191
did	O
not	O
significantly	O
change	O
upon	O
reclassification	O
.	O
However	O
,	O
approximately	O
40	O
%	O
of	O
indeterminate	O
specimens	O
(	O
21	O
of	O
51	O
)	O
were	O
reclassified	O
into	O
a	O
higher	O
risk	O
category	O
.	O
The	O
most	O
restrictive	O
cytomorphologic	O
criterion	O
was	O
an	O
N	O
/	O
C	O
ratio	O
of	O
0.7	O
or	O
higher	O
(	O
seen	O
in	O
78	O
%	O
of	O
specimens	O
)	O
,	O
and	O
approximately	O
half	O
of	O
specimens	O
containing	O
all	O
4	O
cytomorphologic	O
criteria	O
did	O
not	O
meet	O
TPS	B-T059
's	O
numerical	O
criterion	O
for	O
HGUC	B-T191
(	O
at	O
least	O
5	O
malignant	O
cells	O
)	O
.	O
In	O
the	O
majority	O
of	O
specimens	O
qualifying	O
for	O
HGUC	B-T191
by	O
TPS	B-T059
standards	O
,	O
only	O
a	O
small	O
fraction	O
of	O
atypical	O
cells	O
(	O
10%-20	O
%	O
)	O
met	O
all	O
the	O
criteria	O
.	O
When	O
applied	O
to	O
malignant	O
UTC	B-T059
specimens	O
,	O
TPS	B-T059
criteria	O
improved	B-T033
specimen	O
risk	O
stratification	O
by	O
upgrading	O
approximately	O
40	O
%	O
of	O
indeterminate	O
specimens	O
into	O
higher	O
risk	O
categories	O
while	O
not	O
significantly	O
changing	O
the	O
frequency	O
of	O
HGUC	B-T191
diagnoses	B-T033
.	O
Cancer	B-T191
Cytopathol	O
2017	O
.	O
©	O
2017	O
American	O
Cancer	O
Society	O
.	O
      
Expectations	O
for	O
the	O
methodology	O
and	O
translation	O
of	O
animal	O
research	O
:	O
a	O
survey	O
of	O
the	O
general	O
public	O
,	O
medical	O
students	O
and	O
animal	O
researchers	O
in	O
North	O
America	O
To	O
determine	O
what	O
are	O
considered	O
acceptable	O
standards	O
for	O
animal	O
research	O
(	O
AR	O
)	O
methodology	O
and	O
translation	O
rate	O
to	O
humans	O
,	O
a	O
validated	O
survey	O
was	O
sent	O
to	O
:	O
a	O
)	O
a	O
sample	O
of	O
the	O
general	O
public	O
,	O
via	O
Sampling	O
Survey	O
International	O
(	O
SSI	O
;	O
Canada	O
)	O
,	O
Amazon	O
Mechanical	O
Turk	O
(	O
AMT	O
;	O
USA	O
)	O
,	O
a	O
Canadian	O
city	O
festival	O
(	O
CF	O
)	O
and	O
a	O
Canadian	O
children	O
's	O
hospital	O
(	O
CH	O
)	O
;	O
b	O
)	O
a	O
sample	O
of	O
medical	O
students	O
(	O
two	O
first	O
-	O
year	O
classes	O
)	O
;	O
and	O
c	O
)	O
a	O
sample	O
of	O
scientists	O
(	O
corresponding	O
authors	O
and	O
academic	O
paediatricians	O
)	O
.	O
There	O
were	O
1379	O
responses	O
from	O
the	O
general	O
public	O
sample	O
(	O
SSI	O
,	O
n	O
=	O
557	O
;	O
AMT	O
,	O
n	O
=	O
590	O
;	O
CF	O
,	O
n	O
=	O
195	O
;	O
CH	O
,	O
n	O
=	O
102	O
)	O
,	O
205/330	O
(	O
62	O
%	O
)	O
medical	O
student	O
responses	O
,	O
and	O
23/323	O
(	O
7	O
%	O
,	O
too	O
few	O
to	O
report	O
)	O
scientist	O
responses	O
.	O
Asked	O
about	O
methodological	O
quality	O
,	O
most	O
of	O
the	O
general	O
public	O
and	O
medical	O
student	O
respondents	O
expect	O
that	O
:	O
AR	O
is	O
of	O
high	O
quality	O
(	O
e.g.	O
anaesthesia	B-T061
and	O
analgesia	B-T061
are	O
monitored	O
,	O
even	O
overnight	O
,	O
and	O
'	O
humane	O
'	O
euthanasia	B-T058
,	O
optimal	O
statistical	O
design	O
,	O
comprehensive	O
literature	O
review	O
,	O
randomisation	O
and	O
blinding	O
,	O
are	O
performed	O
)	O
,	O
and	O
costs	O
and	O
difficulty	O
are	O
not	O
acceptable	O
justifications	O
for	O
lower	O
quality	O
(	O
e.g.	O
costs	O
of	O
expert	O
consultation	B-T058
,	O
or	O
more	O
laboratory	O
staff	O
)	O
.	O
Asked	O
about	O
their	O
expectations	O
of	O
translation	O
to	O
humans	O
(	O
of	O
toxicity	O
,	O
carcinogenicity	B-T191
,	O
teratogenicity	O
and	O
treatment	O
findings	O
)	O
,	O
most	O
expect	O
translation	O
more	O
than	O
60	O
%	O
of	O
the	O
time	O
.	O
If	O
translation	O
occurred	O
less	O
than	O
20	O
%	O
of	O
the	O
time	O
,	O
a	O
minority	O
disagreed	O
that	O
this	O
would	O
"	O
significantly	O
reduce	O
your	O
support	O
for	O
AR	O
"	O
.	O
Medical	O
students	O
were	O
more	O
supportive	O
of	O
AR	O
,	O
even	O
if	O
translation	O
occurred	O
less	O
than	O
20	O
%	O
of	O
the	O
time	O
.	O
Expectations	O
for	O
AR	O
are	O
much	O
higher	O
than	O
empirical	O
data	O
show	O
to	O
have	O
been	O
achieved	O
.	O
      
The	O
clinico-	O
radiological	O
paradox	B-T033
of	O
cognitive	O
function	O
and	O
MRI	B-T060
burden	O
of	O
white	O
matter	O
lesions	B-T033
in	O
people	O
with	O
multiple	B-T047
sclerosis	I-T047
:	O
A	O
systematic	O
review	O
and	O
meta	O
-	O
analysis	O
Moderate	O
correlation	O
exists	O
between	O
the	O
imaging	O
quantification	O
of	O
brain	B-T023
white	O
matter	O
lesions	B-T033
and	O
cognitive	O
performance	O
in	O
people	O
with	O
multiple	B-T047
sclerosis	I-T047
(	O
MS	B-T047
)	O
.	O
This	O
may	O
reflect	O
the	O
greater	O
importance	O
of	O
other	O
features	O
,	O
including	O
subvisible	O
pathology	O
,	O
or	O
methodological	O
limitations	O
of	O
the	O
primary	O
literature	O
.	O
To	O
summarise	O
the	O
cognitive	O
clinico-	O
radiological	O
paradox	B-T033
and	O
explore	O
the	O
potential	O
methodological	O
factors	O
that	O
could	O
influence	O
the	O
assessment	O
of	O
this	O
relationship	O
.	O
Systematic	O
review	O
and	O
meta	O
-	O
analysis	O
of	O
primary	O
research	O
relating	O
cognitive	O
function	O
to	O
white	O
matter	O
lesion	B-T033
burden	O
.	O
Fifty	O
papers	O
met	O
eligibility	O
criteria	O
for	O
review	O
,	O
and	O
meta	O
-	O
analysis	O
of	O
overall	O
results	O
was	O
possible	O
in	O
thirty	O
-	O
two	O
(	O
2050	O
participants	O
)	O
.	O
Aggregate	O
correlation	O
between	O
cognition	O
and	O
T2	B-T033
lesion	B-T033
burden	O
was	O
r	O
=	O
-0.30	O
(	O
95	O
%	O
confidence	O
interval	O
:	O
-0.34	O
,	O
-0.26	O
)	O
.	O
Wide	O
methodological	O
variability	O
was	O
seen	O
,	O
particularly	O
related	O
to	O
key	O
factors	O
in	O
the	O
cognitive	O
data	O
capture	O
and	O
image	B-T059
analysis	I-T059
techniques	I-T059
.	O
Resolving	O
the	O
persistent	O
clinico-	O
radiological	O
paradox	B-T033
will	O
likely	O
require	O
simultaneous	O
evaluation	B-T058
of	O
multiple	O
components	O
of	O
the	O
complex	O
pathology	O
using	O
optimum	O
measurement	O
techniques	O
for	O
both	O
cognitive	O
and	O
MRI	B-T060
feature	O
quantification	O
.	O
We	O
recommend	O
a	O
consensus	O
initiative	O
to	O
support	O
common	O
standards	O
for	O
image	B-T059
analysis	I-T059
in	O
MS	B-T047
,	O
enabling	O
benchmarking	O
while	O
also	O
supporting	O
ongoing	O
innovation	O
.	O
      
Bending	O
rules	O
:	O
the	O
shape	O
of	O
the	O
perceptual	O
generalisation	O
gradient	O
is	O
sensitive	O
to	O
inference	O
rules	O
Generalising	O
what	O
is	O
learned	O
about	O
one	O
stimulus	O
to	O
other	O
but	O
perceptually	O
related	O
stimuli	O
is	O
a	O
basic	O
behavioural	O
phenomenon	O
.	O
We	O
evaluated	B-T058
whether	O
a	O
rule	O
learning	O
mechanism	O
may	O
serve	O
to	O
explain	O
such	O
generalisation	O
.	O
To	O
this	O
end	O
,	O
we	O
assessed	O
whether	O
inference	O
rules	O
communicated	B-T033
through	O
verbal	B-T058
instructions	I-T058
affect	O
generalisation	O
.	O
Expectancy	O
ratings	O
,	O
but	O
not	O
valence	O
ratings	O
,	O
proved	O
sensitive	O
to	O
this	O
manipulation	O
.	O
In	O
addition	O
to	O
revealing	O
a	O
role	O
for	O
inference	O
rules	O
in	O
generalisation	O
,	O
our	O
study	O
has	O
clinical	O
implications	O
as	O
well	O
.	O
More	O
specifically	O
,	O
we	O
argue	O
that	O
targeting	O
inference	O
rules	O
might	O
prove	O
to	O
be	O
an	O
effective	O
strategy	O
to	O
affect	O
the	O
excessive	O
generalisation	O
that	O
is	O
often	O
observed	O
in	O
psychopathology	O
.	O
      
Fuzheng	O
Qingjie	O
Granules	O
Inhibit	O
Growth	O
of	O
Hepatoma	O
Cells	O
via	O
Inducing	O
Mitochondria	O
-Mediated	O
Apoptosis	O
and	O
Enhancing	O
Immune	O
Function	O
Fuzheng	O
Qingjie	O
(	O
FZQJ	O
)	O
granules	O
,	O
a	O
compound	O
Chinese	O
medicine	O
,	O
have	O
been	O
used	O
as	O
an	O
adjuvant	B-T061
therapy	I-T061
for	O
alimentary	O
tract	O
cancers	B-T191
.	O
However	O
,	O
the	O
underlying	O
anticancer	B-T033
mechanisms	O
are	O
still	O
not	O
well	O
understood	O
.	O
In	O
the	O
present	O
study	O
,	O
HepG2	O
cells	O
were	O
treated	O
with	O
FZQJ	O
-	O
containing	O
serum	O
.	O
Cell	O
proliferation	O
was	O
evaluated	B-T058
using	O
MTT	O
assay	O
.	O
Apoptosis	O
was	O
analyzed	O
using	O
a	O
flow	O
cytometer	O
.	O
Cell	O
ultrastructure	O
was	O
observed	O
under	O
a	O
transmission	O
electron	O
microscope	O
.	O
The	O
mitochondrial	O
membrane	O
potential	O
(	O
Δψ	O
)	O
was	O
examined	B-T033
with	O
JC-1	O
dye	O
.	O
In	O
H22	B-T191
tumor	I-T191
-	I-T191
bearing	I-T191
mice	I-T191
,	O
CD4(+	O
)	O
T	O
cells	O
,	O
CD8(+	O
)	O
T	O
cells	O
,	O
CD3(+	O
)	O
T	O
cells	O
,	O
and	O
natural	O
killer	O
cells	O
(	O
NK	O
)	O
in	O
peripheral	O
blood	O
were	O
evaluated	O
cytometrically	O
.	O
Interleukin	O
(	O
IL)-2	O
and	O
tumor	O
necrosis	O
factor	O
(	O
TNF)-α	O
levels	O
were	O
measured	O
using	O
radioimmunoassay	B-T059
.The	O
mRNA	O
levels	O
of	O
Bax	O
and	O
Bcl-2	O
were	O
examined	B-T033
by	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
.	O
The	O
protein	O
levels	O
of	O
Bax	O
,	O
Bcl-2	O
,	O
cytochrome	O
C	O
,	O
caspase	O
3	O
and	O
9	O
,	O
PARP	O
,	O
and	O
CD69	O
were	O
examined	B-T033
by	O
Western	B-T059
blotting	I-T059
.	O
The	O
apoptotic	O
cells	O
in	O
tissues	O
were	O
observed	O
using	O
TUNEL	O
method	O
.	O
Alanine	O
transaminase	O
(	O
ALT	O
)	O
,	O
aspartate	O
transaminase	O
(	O
AST	O
)	O
,	O
blood	O
urea	O
nitrogen	O
(	O
BUN	O
)	O
,	O
and	O
creatinine	O
(	O
CRE	O
)	O
were	O
detected	B-T033
by	O
an	O
automatic	O
biochemical	O
analyzer	O
.	O
The	O
results	O
showed	O
that	O
FZQJ	O
-	O
containing	O
serum	O
remarkably	O
inhibited	O
proliferation	O
of	O
HepG2	O
cells	O
in	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
manners	O
,	O
induced	O
HepG2	O
cell	O
apoptosis	O
and	O
caused	O
a	O
decrease	O
of	O
Δψ	O
.	O
Analysis	O
of	O
tumor	O
tissue	O
showed	O
that	O
FZQJ	O
-	O
induced	O
apoptosis	O
was	O
accompanied	O
by	O
downregulation	O
of	O
Bcl-2	O
and	O
upregulation	O
of	O
Bax	O
,	O
release	O
of	O
cytochrome	O
c	O
,	O
activation	O
of	O
caspase	O
3	O
and	O
9	O
,	O
and	O
cleavage	O
of	O
PARP	O
.	O
In	O
addition	O
,	O
FZQJ	O
increased	O
the	O
percentages	O
of	O
CD4(+	O
)	O
T	O
and	O
NK	O
cells	O
,	O
the	O
ratio	O
of	O
CD4(+	O
)	O
/	O
CD8(+	O
)	O
T	O
cells	O
as	O
well	O
as	O
the	O
levels	O
of	O
serum	O
TNF	O
-	O
α	O
.	O
FZQJ	O
also	O
increased	O
CD69	O
expression	O
in	O
tumor	O
tissue	O
.	O
No	B-T033
hepatorenal	I-T033
toxicity	I-T033
was	O
observed	O
in	O
H22	B-T191
tumor	I-T191
-	I-T191
bearing	I-T191
mice	I-T191
.	O
These	O
results	O
indicated	B-T033
that	O
FZQJ	O
could	O
inhibit	O
the	O
growth	O
of	O
hepatoma	O
cells	O
via	O
regulating	O
immune	O
function	O
and	O
inducing	O
mitochondria	O
mediated	O
apoptosis	O
.	O
      
Aspirin	B-T121
Suppresses	O
Growth	O
in	O
PI3	O
K	O
-	O
Mutant	O
Breast	B-T191
Cancer	I-T191
by	O
Activating	O
AMPK	O
and	O
Inhibiting	O
mTORC1	O
Signaling	O
Despite	O
the	O
high	O
incidence	O
of	O
oncogenic	O
mutations	O
in	O
PIK3CA	O
,	O
the	O
gene	O
encoding	O
the	O
catalytic	O
subunit	O
of	O
PI3	O
K	O
,	O
PI3	O
K	O
inhibitors	B-T121
have	O
yielded	O
little	O
clinical	B-T033
benefit	I-T033
for	O
breast	B-T191
cancer	I-T191
patients	O
.	O
Recent	O
epidemiologic	O
studies	O
have	O
suggested	O
a	O
therapeutic	O
benefit	O
from	O
aspirin	B-T121
intake	O
in	O
cancers	B-T191
harboring	O
oncogenic	O
PIK3CA	O
Here	O
,	O
we	O
show	O
that	O
mutant	O
PIK3CA	O
-	O
expressing	O
breast	O
cancer	O
cells	O
have	O
greater	O
sensitivity	O
to	O
aspirin	B-T121
-mediated	O
growth	O
suppression	O
than	O
their	O
wild	O
-	O
type	O
counterparts	O
.	O
Aspirin	B-T121
decreased	O
viability	O
and	O
anchorage	B-T059
-	I-T059
independent	I-T059
growth	I-T059
of	O
mutant	O
PIK3CA	O
breast	O
cancer	O
cells	O
independently	B-T033
of	O
its	O
effects	O
on	O
COX-2	O
and	O
NF	O
-	O
κB.	O
We	O
ascribed	O
the	O
effects	O
of	O
aspirin	B-T121
to	O
AMP	O
-	O
activated	O
protein	O
kinase	O
(	O
AMPK	O
)	O
activation	O
,	O
mTORC1	O
inhibition	O
,	O
and	O
autophagy	O
induction	O
.	O
In	O
vivo	O
,	O
oncogenic	O
PIK3CA	O
-driven	O
mouse	O
mammary	B-T191
tumors	I-T191
treated	O
daily	O
with	O
aspirin	B-T121
resulted	O
in	O
decreased	O
tumor	B-T191
growth	I-T191
kinetics	O
,	O
whereas	O
combination	O
therapy	B-T061
of	O
aspirin	B-T121
and	O
a	O
PI3	O
K	O
inhibitor	O
further	O
attenuated	O
tumor	B-T191
growth	I-T191
.	O
Our	O
study	O
supports	O
the	O
evaluation	B-T058
of	O
aspirin	B-T121
and	O
PI3	O
K	O
pathway	O
inhibitors	B-T121
as	O
a	O
combination	O
therapy	B-T061
for	O
targeting	O
breast	B-T191
cancer	I-T191
.	O
Cancer	O
Res	O
;	O
77(3	O
)	O
;	O
790	O
-	O
801	O
.	O
©	O
2016	O
AACR	O
.	O
      
Direct	O
Repair	B-T058
of	O
Lumbar	B-T023
Pars	I-T023
Interarticularis	I-T023
Defects	O
by	O
Utilizing	O
Intraoperative	O
O	O
-	O
Arm	O
-	O
Based	O
Navigation	O
and	O
Microendoscopic	B-T060
Techniques	I-T060
A	O
retrospective	O
analysis	O
of	O
the	O
clinical	B-T033
outcomes	I-T033
of	O
eight	O
patients	O
with	O
the	O
lumbar	B-T023
pars	I-T023
interarticulars	I-T023
defects	O
treated	B-T033
by	O
direct	O
repair	B-T058
with	O
the	O
aid	O
of	O
intraoperative	O
O	O
-	O
arm	O
based	O
navigation	O
and	O
microendoscopic	B-T060
techniques	I-T060
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
efficacy	O
and	O
safety	O
of	O
direct	O
screw	O
repair	B-T058
by	O
using	O
minimally	B-T061
invasive	I-T061
surgery	I-T061
for	O
the	O
lumbar	B-T023
pars	I-T023
interarticulars	I-T023
defects	O
in	O
a	O
pilot	O
study	O
.	O
Direct	O
repair	B-T058
of	O
pars	B-T023
interarticulars	I-T023
defects	O
has	O
been	O
used	O
to	O
treat	B-T061
young	O
adult	O
patients	O
.	O
Reports	O
concerning	O
direct	O
repair	B-T058
by	O
minimally	B-T061
invasive	I-T061
techniques	I-T061
for	O
pars	B-T023
interarticulars	I-T023
defects	O
are	O
quite	O
rare	O
.	O
Review	O
of	O
medical	O
records	O
identified	O
eight	O
consecutive	O
patients	O
treated	B-T033
with	O
intraoperative	O
O	O
-	O
arm	O
based	O
navigation	O
and	O
microendoscopic	B-T060
techniques	I-T060
.	O
Debridement	B-T061
and	O
autograft	B-T061
of	O
pars	B-T023
interarticularis	I-T023
defects	O
was	O
performed	O
under	O
microendoscopic	B-T060
procedure	I-T060
.	O
Then	O
,	O
percutaneous	O
bilateral	O
intralaminar	O
screws	O
were	O
inserted	B-T058
by	O
utilizing	O
intraoperative	O
navigation	O
.	O
The	O
clinical	O
and	O
radiological	O
data	O
were	O
collected	O
and	O
analyzed	O
retrospectively	O
.	O
Eight	O
patients	O
had	O
a	O
mean	O
age	O
of	O
28.4	O
years	O
,	O
and	O
five	O
were	O
30	O
years	O
or	O
younger	O
at	O
the	O
time	O
of	O
treatment	B-T061
.	O
Symptoms	B-T184
included	O
axial	O
back	B-T184
pain	I-T184
in	O
100	O
%	O
of	O
patients	O
without	O
concomitant	O
radiculopathy	B-T047
.	O
Autograft	B-T061
was	O
used	O
in	O
all	O
cases	O
.	O
The	O
average	O
follow	B-T058
-	I-T058
up	I-T058
duration	O
was	O
27.4	O
months	O
with	O
a	O
range	O
of	O
20	O
to	O
33	O
months	O
.	O
Symptoms	B-T184
resolved	B-T033
completely	O
or	O
partially	O
in	O
all	O
patients	O
.	O
Low	B-T184
back	I-T184
pain	I-T184
visual	O
analog	O
scores	O
decrease	O
from	O
preoperative	O
6.8	O
to	O
postoperative	O
1.4	O
of	O
eight	O
cases	O
.	O
Of	O
16	O
pars	B-T023
defects	O
,	O
healing	O
was	O
observed	O
in	O
13	O
(	O
81.3	O
%	O
)	O
at	O
last	O
radiological	O
follow	B-T058
-	I-T058
up	I-T058
.	O
One	O
patient	O
with	O
bilateral	B-T019
fusion	I-T019
failure	I-T019
refused	O
revision	B-T061
surgery	I-T061
because	O
of	O
mild	B-T033
complaint	I-T033
.	O
No	B-T033
complications	I-T033
such	O
as	O
dural	O
tear	O
,	O
nerve	O
root	O
injury	O
,	O
and	O
infection	O
occurred	O
.	O
Minimally	B-T061
invasive	I-T061
direct	O
repair	B-T058
of	O
the	O
pars	B-T023
interarticularis	I-T023
defects	O
with	O
intralaminar	O
screws	O
by	O
using	O
microendoscopic	B-T060
system	I-T060
and	O
navigation	O
procedure	O
can	O
provide	O
safe	O
and	O
effective	O
treatment	B-T061
of	O
spondylolysis	B-T047
with	O
satisfactory	O
clinical	O
and	O
radiological	O
outcomes	O
,	O
which	O
need	O
some	O
special	O
tools	O
with	O
steep	O
learning	O
curve	O
.	O
4	O
.	O
      
Improving	O
exchange	O
with	O
consumers	O
within	O
mental	O
health	O
organizations	O
:	O
Recognizing	O
mental	B-T048
ill	I-T048
health	I-T048
experience	O
as	O
a	O
'	O
sneaky	O
,	O
special	O
degree	O
'	O
Stigmatizing	B-T033
views	O
towards	O
consumers	O
may	O
be	O
held	O
even	O
by	O
those	O
working	O
within	O
mental	O
health	O
organizations	O
.	O
Contemporary	O
mental	O
health	O
policies	O
require	O
organizations	O
to	O
work	O
collaboratively	O
with	O
consumers	O
in	O
producing	O
and	O
delivering	B-T058
services	O
.	O
Using	O
social	O
exchange	O
theory	O
,	O
which	O
emphasises	O
mutual	O
exchange	O
to	O
maximise	O
benefits	O
in	O
partnership	O
,	O
the	O
current	O
study	O
explores	O
the	O
perspectives	O
of	O
those	O
working	O
within	O
organizations	O
that	O
have	O
some	O
level	O
of	O
consumer	O
leadership	O
.	O
Interviews	O
were	O
conducted	O
with	O
14	O
participants	O
from	O
a	O
range	O
of	O
mental	O
health	O
organizations	O
.	O
Data	O
were	O
transcribed	O
,	O
and	O
analyzed	O
using	O
thematic	O
analytic	O
and	O
discursive	B-T033
psychological	B-T060
techniques	I-T060
.	O
Findings	B-T033
suggest	O
stigma	B-T033
is	O
still	O
prevalent	O
even	O
in	O
organizations	O
that	O
have	O
consumers	O
in	O
leadership	O
positions	O
,	O
and	O
consumers	O
are	O
often	O
perceived	O
as	O
less	O
able	O
to	O
work	O
in	O
mental	O
health	O
organizations	O
than	O
non	O
-	O
consumers	O
.	O
Several	O
discourses	O
challenged	O
such	O
a	O
view	O
-	O
showing	O
how	O
consumers	O
bring	O
value	O
to	O
mental	O
health	O
organizations	O
through	O
their	O
expertise	O
in	O
the	O
mental	O
health	O
system	O
,	O
and	O
their	O
ability	O
to	O
provide	O
safety	B-T058
and	O
support	O
to	O
other	O
consumers	O
.	O
Through	O
a	O
social	O
exchange	O
theory	O
lens	O
,	O
the	O
authors	O
call	O
for	O
organizations	O
to	O
challenge	O
stigma	B-T033
and	O
promote	O
the	O
value	O
that	O
consumers	O
can	O
bring	O
to	O
maximize	O
mutual	O
benefits	O
.	O
      
Effects	O
of	O
siRNA	O
-mediated	O
suppression	O
of	O
HPV-11	O
L1	O
expression	O
on	O
the	O
proliferation	O
and	O
apoptosis	O
of	O
vaginal	O
epithelial	O
cells	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
human	B-T047
papillomavirus	I-T047
(	I-T047
HPV	I-T047
)	I-T047
infection	I-T047
on	O
the	O
gynecological	B-T047
disease	I-T047
of	O
vaginitis	B-T047
and	O
to	O
demonstrate	O
how	O
the	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
method	O
may	O
be	O
used	O
for	O
HPV	B-T005
prevention	B-T061
in	O
the	O
clinic	O
.	O
Human	O
vaginal	O
epithelial	O
cells	O
were	O
transfected	O
with	O
HPV-11	O
L1	O
expression	O
vector	O
and	O
siRNA	O
-	O
HPV-11	O
L1	O
vectors	O
and	O
a	O
control	O
group	O
was	O
transfected	O
with	O
scrambled	O
siRNA	O
.	O
Cell	O
proliferation	O
in	O
each	O
group	O
was	O
analyzed	O
using	O
the	O
MTT	B-T059
assay	I-T059
and	O
the	O
expression	O
of	O
apoptosis	O
-associated	O
proteins	O
was	O
measured	O
by	O
western	B-T059
blot	I-T059
analysis	I-T059
.	O
Compared	O
with	O
the	O
control	O
group	O
,	O
HPV-11	O
L1	O
mRNA	O
and	O
protein	O
levels	O
were	O
significantly	O
increased	O
following	O
transfection	O
with	O
the	O
HPV-11	O
L1	O
expression	O
vector	O
in	O
cells	O
(	O
P<0.05	O
)	O
,	O
but	O
this	O
result	O
was	O
significantly	O
reversed	O
by	O
silencing	O
of	O
HPV-11	O
L1	O
(	O
P<0.05	O
)	O
.	O
In	O
addition	O
,	O
cell	O
proliferation	O
in	O
the	O
HPV-11	O
group	O
was	O
lower	O
than	O
that	O
in	O
the	O
control	O
group	O
;	O
however	O
,	O
cell	O
proliferation	O
was	O
significantly	O
increased	O
in	O
cells	O
transfected	O
with	O
silenced	O
L1	O
compared	O
with	O
that	O
in	O
the	O
control	O
group	O
(	O
P<0.05	O
)	O
.	O
Furthermore	O
,	O
silencing	O
of	O
HPV-11	O
L1	O
significantly	O
decreased	O
caspase-3	O
and	O
caspase-9	O
expressions	O
in	O
cells	O
,	O
whereas	O
the	O
expression	O
was	O
increased	O
in	O
the	O
HPV-11	O
L1	O
group	O
(	O
P<0.05	O
)	O
.	O
The	O
present	O
study	O
suggested	O
that	O
siRNA	O
-mediated	O
silencing	O
of	O
HPV-11	O
L1	O
may	O
have	O
potential	O
therapeutic	B-T061
applications	I-T061
for	O
treating	O
gynecological	B-T047
diseases	I-T047
associated	O
with	O
HPV-11	B-T005
infection	O
.	O
      
Distinct	O
cortical	O
and	O
sub	O
-	O
cortical	O
neurogenic	O
domains	O
for	O
GABAergic	O
interneuron	O
precursor	O
transcription	O
factors	O
NKX2.1	O
,	O
OLIG2	O
and	O
COUP	O
-	O
TFII	O
in	O
early	O
fetal	O
human	O
telencephalon	B-T018
The	O
extent	O
of	O
similarities	O
and	O
differences	O
between	O
cortical	O
GABAergic	O
interneuron	O
generation	O
in	O
rodent	O
and	O
primate	O
telencephalon	B-T018
remains	O
contentious	O
.	O
We	O
examined	O
expression	O
of	O
three	O
interneuron	O
precursor	O
transcription	O
factors	O
,	O
alongside	O
other	O
markers	O
,	O
using	O
immunohistochemistry	B-T060
on	O
8	O
-	O
12	O
post	O
-	O
conceptional	O
weeks	O
(	O
PCW	O
)	O
human	O
telencephalon	B-T018
sections	O
.	O
NKX2.1	O
,	O
OLIG2	O
,	O
and	O
COUP	O
-	O
TFII	O
expression	O
occupied	O
distinct	O
(	O
although	O
overlapping	O
)	O
neurogenic	O
domains	O
which	O
extended	O
into	O
the	O
cortex	B-T023
and	O
revealed	O
three	O
CGE	B-T018
compartments	I-T018
:	O
lateral	O
,	O
medial	O
,	O
and	O
ventral	O
.	O
NKX2.1	O
expression	O
was	O
very	O
largely	O
confined	O
to	O
the	O
MGE	B-T018
,	O
medial	O
CGE	B-T018
,	O
and	O
ventral	O
septum	B-T023
confirming	O
that	O
,	O
at	O
this	O
developmental	O
stage	O
,	O
interneuron	O
generation	O
from	O
NKX2.1	O
+	O
precursor	O
s	O
closely	O
resembles	O
the	O
process	O
observed	O
in	O
rodents	O
.	O
OLIG2	O
immunoreactivity	O
was	O
observed	O
in	O
GABAergic	O
cells	O
of	O
the	O
proliferative	O
zones	O
of	O
the	O
MGE	B-T018
and	O
septum	B-T023
,	O
but	O
not	O
necessarily	O
co	O
-	O
expressed	O
with	O
NKX2.1	O
,	O
and	O
OLIG2	O
expression	O
was	O
also	O
extensively	O
seen	O
in	O
the	O
LGE	B-T018
,	O
CGE	B-T018
,	O
and	O
cortex	B-T023
.	O
At	O
8	O
PCW	O
,	O
OLIG2	O
+	O
cells	O
were	O
only	O
present	O
in	O
the	O
medial	O
and	O
anterior	O
cortical	B-T023
wall	I-T023
suggesting	O
a	O
migratory	O
pathway	O
for	O
interneuron	O
precursor	O
s	O
via	O
the	O
septum	B-T023
into	O
the	O
medial	O
cortex	B-T023
.	O
By	O
12	O
PCW	O
,	O
OLIG2	O
+	O
cells	O
were	O
present	O
throughout	O
the	O
cortex	B-T023
and	O
many	O
were	O
actively	O
dividing	O
but	O
without	O
co	O
-	O
expressing	O
cortical	B-T023
progenitor	O
markers	O
.	O
Dividing	O
COUP	O
-	O
TFII	O
+	O
progenitor	O
cells	O
were	O
localized	O
to	O
ventral	O
CGE	B-T018
as	O
previously	O
described	O
but	O
were	O
also	O
numerous	O
in	O
adjacent	O
ventral	O
cortex	B-T023
;	O
in	O
both	O
the	O
cases	O
,	O
COUP	O
-	O
TFII	O
was	O
co	O
-	O
expressed	O
with	O
PAX6	O
in	O
proliferative	O
zones	O
and	O
TBR1	O
or	O
calretinin	O
in	O
post-	O
mitotic	O
cortical	O
neurons	O
.	O
Thus	O
COUP	O
-	O
TFII	O
+	O
progenitors	O
gave	O
rise	O
to	O
pyramidal	O
cells	O
,	O
but	O
also	O
interneurons	O
which	O
not	O
only	O
migrated	O
posteriorly	O
into	O
the	O
cortex	B-T023
from	O
ventral	O
CGE	B-T018
but	O
also	O
anteriorly	O
via	O
the	O
LGE	B-T018
.	O
      
Assessment	O
of	O
the	O
Extravascular	O
Implantable	O
Defibrillator	O
:	O
Feasibility	O
of	O
Substernal	B-T061
Ventricular	I-T061
Pacing	I-T061
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
assess	O
feasibility	O
of	O
ventricular	B-T061
pacing	I-T061
and	O
thresholds	O
from	O
within	O
the	O
substernal	O
space	O
to	O
examine	O
a	O
new	O
extravascular	O
ICD	O
configuration	O
with	O
pacing	B-T061
capabilities	O
.	O
In	O
patients	O
undergoing	O
midline	B-T061
sternotomy	I-T061
,	O
a	O
duodecapolar	O
diagnostic	O
pacing	O
catheter	O
was	O
positioned	O
in	O
the	O
substernal	O
space	O
anterior	O
to	O
the	O
pericardium	B-T023
,	O
and	O
a	O
cutaneous	B-T033
patch	I-T033
in	O
left	O
lateral	O
position	O
.	O
Different	O
unipolar	O
and	O
bipolar	O
pacing	B-T061
configurations	O
were	O
assessed	O
.	O
Strength	B-T059
-	I-T059
duration	I-T059
curves	I-T059
were	O
performed	O
to	O
identify	O
the	O
optimal	O
output	B-T060
,	O
starting	O
at	O
25	O
mA	O
with	O
a	O
pulse	O
width	O
of	O
10	O
milliseconds	O
.	O
Eight	O
patients	O
with	O
mean	O
age	O
69	O
±	O
9	O
years	O
were	O
included	O
.	O
In	O
5	O
,	O
ventricular	O
capture	O
was	O
achieved	O
in	O
≥1	O
configuration	O
.	O
The	O
mean	O
bipolar	O
pacing	B-T061
thresholds	O
at	O
PW	O
10	O
,	O
5	O
,	O
3	O
,	O
1	O
milliseconds	O
were	O
12.4	O
±	O
3.7	O
mA	O
(	O
5	O
patients	O
)	O
,	O
13.3	O
±	O
5.8	O
mA	O
(	O
3	O
patients	O
)	O
,	O
18.3	O
±	O
5.7	O
mA	O
(	O
3	O
patients	O
)	O
,	O
and	O
25	O
±	O
0	O
mA	O
(	O
2	O
patients	O
)	O
,	O
respectively	O
.	O
The	O
60	O
-	O
mm	O
electrode	O
spacing	O
was	O
the	O
most	O
successful	O
bipolar	O
configuration	O
.	O
Unipolar	O
pacing	B-T061
was	O
successful	O
in	O
3	O
out	O
of	O
4	O
patients	O
with	O
mean	O
thresholds	O
of	O
10	O
±	O
0	O
mA	O
at	O
10	O
milliseconds	O
(	O
3	O
patients	O
)	O
,	O
15	O
±	O
0	O
mA	O
at	O
5	O
milliseconds	O
(	O
3	O
patients	O
)	O
,	O
16.7	O
±	O
2.9	O
mA	O
at	O
3	O
milliseconds	O
(	O
3	O
patients	O
)	O
,	O
and	O
20	O
±	O
7.1	O
mA	O
at	O
1	O
milliseconds	O
(	O
2	O
patients	O
)	O
.	O
Ventricular	B-T061
pacing	I-T061
pacing	B-T061
from	O
the	O
substernal	O
space	O
in	O
patients	O
with	O
midline	B-T061
sternotomy	I-T061
is	O
feasible	O
.	O
Closed	O
sternum	B-T023
studies	O
are	O
needed	O
to	O
determine	O
pacing	B-T061
thresholds	O
more	O
accurately	O
.	O
      
Metabolomics	O
analysis	O
of	O
anaphylactoid	O
reaction	O
reveals	O
its	O
mechanism	O
in	O
a	O
rat	O
model	O
Anaphylactoid	O
reactions	O
,	O
accounting	O
for	O
more	O
than	O
77	O
%	O
of	O
all	O
immune	B-T047
-	I-T047
mediated	I-T047
immediate	I-T047
hypersensitivity	I-T047
reactions	I-T047
,	O
have	O
become	O
a	O
serious	O
threat	O
to	O
public	B-T058
health	I-T058
,	O
but	O
their	O
effect	O
mechanism	O
is	O
not	B-T033
clear	I-T033
and	O
diagnostic	B-T060
tests	I-T060
are	O
limited	O
.	O
Comprehensive	O
metabolite	O
analysis	O
may	O
reveal	O
the	O
anaphylactoid	O
effect	O
mechanism	O
systematically	O
and	O
provide	O
reference	O
for	O
future	O
diagnostic	O
purposes	O
.	O
Plasma	O
from	O
Brown	O
Norway	O
rats	O
given	O
intravenous	O
injection	O
of	O
saline	O
,	O
compound	B-T121
48/80	I-T121
(	O
2.5	O
mL	O
/	O
kg	O
)	O
or	O
ovalbumin	O
(	O
20	O
mL	O
/	O
kg	O
)	O
in	O
20	O
s	O
for	O
the	O
first	O
time	O
was	O
used	O
to	O
study	O
the	O
effect	O
mechanism	O
of	O
anaphylactoid	O
reactions	O
through	O
metabolomics	O
(	O
UPLC	O
-	O
qTOF	O
-	O
MS	O
/	O
MS	O
)	O
.	O
Metabolomics	O
integrated	O
with	O
proteomics	O
data	O
were	O
used	O
to	O
analyze	O
the	O
anaphylactoid	O
pathways	O
by	O
MetaboAnalyst	O
followed	O
by	O
integrated	O
pathway	O
analysis	O
.	O
Thirty	O
metabolites	O
were	O
identified	O
through	O
the	O
METLIN	O
database	O
by	O
MS	O
/	O
MS	O
and	O
18	O
of	O
them	O
were	O
confirmed	O
by	O
authentic	O
standards	O
.	O
The	O
results	O
showed	O
that	O
adenosine	B-T121
,	O
histamine	O
,	O
N	O
-	O
acetylhistamine	O
,	O
N(α)-γ	O
-	O
glutamylhistamine	O
,	O
malate	O
and	O
xanthine	O
are	O
important	O
indices	O
for	O
anaphylactoid	O
reactions	O
.	O
It	O
could	O
be	O
concluded	O
that	O
the	O
effect	O
mechanism	O
is	O
mainly	O
composed	O
of	O
histidine	O
metabolism	O
,	O
arachidonic	O
acid	O
metabolism	O
,	O
energy	O
metabolism	O
,	O
purine	O
metabolism	O
and	O
other	O
small	O
molecules	O
through	O
30	O
metabolites	O
.	O
Multiple	O
linear	O
regression	O
analysis	O
indicated	B-T033
that	O
not	O
only	O
histamine	O
but	O
also	O
N(α)-γ	O
-	O
glutamylhistamine	O
and	O
arachidonic	O
acid	O
could	O
be	O
used	O
to	O
evaluate	O
anaphylactoid	O
symptoms	B-T184
of	O
animals	O
.	O
Furthermore	O
,	O
the	O
citrate	O
cycle	O
,	O
histidine	O
metabolism	O
and	O
arachidonic	O
acid	O
metabolism	O
could	O
be	O
the	O
main	O
pathways	O
of	O
anaphylactoid	O
reactions	O
as	O
determined	O
by	O
MetaboAnalyst	O
.	O
The	O
results	O
may	O
provide	O
a	O
reference	O
to	O
improve	B-T033
diagnostic	O
accuracy	O
and	O
predict	O
and	O
monitor	O
treatment	O
efficacy	O
in	O
anaphylactoid	O
reactions	O
in	O
the	O
clinical	O
setting	O
.	O
      
Characterising	O
bias	O
in	O
regulatory	O
risk	O
and	O
decision	O
analysis	O
:	O
An	O
analysis	O
of	O
heuristics	O
applied	O
in	O
health	B-T058
technology	I-T058
appraisal	B-T058
,	O
chemicals	O
regulation	O
,	O
and	O
climate	O
change	O
governance	O
In	O
many	O
environmental	O
and	O
public	O
health	O
domains	O
,	O
heuristic	O
methods	O
of	O
risk	O
and	O
decision	O
analysis	O
must	O
be	O
relied	O
upon	O
,	O
either	O
because	O
problem	B-T033
structures	I-T033
are	O
ambiguous	O
,	O
reliable	O
data	O
is	O
lacking	O
,	O
or	O
decisions	O
are	O
urgent	O
.	O
This	O
introduces	O
an	O
additional	O
source	B-T033
of	O
uncertainty	B-T033
beyond	O
model	O
and	O
measurement	O
error	O
-	O
uncertainty	B-T033
stemming	O
from	O
relying	O
on	O
inexact	O
inference	O
rules	O
.	O
Here	O
we	O
identify	O
and	O
analyse	O
heuristics	O
used	O
to	O
prioritise	O
risk	O
objects	O
,	O
to	O
discriminate	O
between	O
signal	O
and	O
noise	O
,	O
to	O
weight	O
evidence	O
,	O
to	O
construct	O
models	O
,	O
to	O
extrapolate	O
beyond	O
datasets	O
,	O
and	O
to	O
make	O
policy	O
.	O
Some	O
of	O
these	O
heuristics	O
are	O
based	O
on	O
causal	O
generalisations	O
,	O
yet	O
can	O
misfire	O
when	O
these	O
relationships	O
are	O
presumed	O
rather	O
than	O
tested	O
(	O
e.g.	O
surrogates	O
in	O
clinical	O
trials	O
)	O
.	O
Others	O
are	O
conventions	O
designed	O
to	O
confer	O
stability	O
to	O
decision	O
analysis	O
,	O
yet	O
which	O
may	O
introduce	O
serious	O
error	O
when	O
applied	O
ritualistically	O
(	O
e.g.	O
significance	O
testing	O
)	O
.	O
Some	O
heuristics	O
can	O
be	O
traced	O
back	O
to	O
formal	O
justifications	O
,	O
but	O
only	O
subject	O
to	O
strong	O
assumptions	O
that	O
are	O
often	O
violated	O
in	O
practical	O
applications	O
.	O
Heuristic	O
decision	O
rules	O
(	O
e.g.	O
feasibility	O
rules	O
)	O
in	O
principle	O
act	O
as	O
surrogates	O
for	O
utility	O
maximisation	O
or	O
distributional	O
concerns	O
,	O
yet	O
in	O
practice	O
may	O
neglect	O
costs	O
and	O
benefits	O
,	O
be	O
based	O
on	O
arbitrary	O
thresholds	O
,	O
and	O
be	O
prone	O
to	O
gaming	O
.	O
We	O
highlight	O
the	O
problem	B-T033
of	O
rule	O
-	O
entrenchment	O
,	O
where	O
analytical	O
choices	O
that	O
are	O
in	O
principle	O
contestable	O
are	O
arbitrarily	O
fixed	O
in	O
practice	O
,	O
masking	O
uncertainty	B-T033
and	O
potentially	O
introducing	O
bias	O
.	O
Strategies	O
for	O
making	O
risk	O
and	O
decision	O
analysis	O
more	O
rigorous	O
include	O
:	O
formalising	O
the	O
assumptions	O
and	O
scope	O
conditions	O
under	O
which	O
heuristics	O
should	O
be	O
applied	O
;	O
testing	O
rather	O
than	O
presuming	O
their	O
underlying	O
empirical	O
or	O
theoretical	O
justifications	O
;	O
using	O
sensitivity	O
analysis	O
,	O
simulations	O
,	O
multiple	O
bias	O
analysis	O
,	O
and	O
deductive	O
systems	O
of	O
inference	O
(	O
e.g.	O
directed	O
acyclic	O
graphs	O
)	O
to	O
characterise	O
rule	O
uncertainty	B-T033
and	O
refine	O
heuristics	O
;	O
adopting	O
"	O
recovery	O
schemes	O
"	O
to	O
correct	O
for	O
known	O
biases	O
;	O
and	O
basing	O
decision	O
rules	O
on	O
clearly	O
articulated	O
values	O
and	O
evidence	O
,	O
rather	O
than	O
convention	O
.	O
      
Acute	O
macular	B-T047
edema	I-T047
and	O
peripapillary	O
soft	O
exudate	O
after	O
pancreas	B-T061
transplantation	I-T061
with	O
accelerated	O
progression	O
of	O
diabetic	B-T047
retinopathy	I-T047
The	O
effect	O
of	O
pancreas	B-T061
transplantation	I-T061
on	O
diabetic	B-T047
retinopathy	I-T047
remains	O
inconclusive	O
.	O
Herein	O
,	O
we	O
report	O
six	O
patients	O
with	O
type	B-T047
1	I-T047
diabetes	I-T047
mellitus	I-T047
(	O
DM	B-T047
)	O
who	O
underwent	O
pancreas	B-T061
transplantation	I-T061
and	O
developed	O
acute	O
macular	B-T047
edema	I-T047
and	O
peripapillary	O
soft	O
exudate	O
with	O
rapid	O
progression	O
to	O
proliferative	B-T047
diabetic	I-T047
retinopathy	I-T047
.	O
In	O
this	O
retrospective	O
observational	O
study	O
,	O
diabetic	B-T047
patients	O
who	O
underwent	O
pancreas	B-T061
transplantation	I-T061
in	O
a	O
single	O
medical	O
center	O
and	O
developed	O
symptomatic	O
acute	O
macular	B-T047
edema	I-T047
and	O
peripapillary	O
soft	O
exudate	O
within	O
3	O
months	O
after	O
the	O
operation	B-T061
were	O
enrolled	O
.	O
The	O
complete	O
ophthalmic	O
course	O
and	O
medical	O
records	O
of	O
the	O
patients	O
were	O
retrospectively	O
reviewed	O
.	O
Diabetic	B-T047
retinopathy	I-T047
and	O
progression	O
following	O
treatment	B-T061
after	O
pancreas	B-T061
transplantation	I-T061
were	O
measured	O
.	O
Six	O
Chinese	O
women	O
with	O
type	B-T047
1	I-T047
DM	I-T047
were	O
enrolled	O
in	O
this	O
study	O
.	O
Mean	O
hemoglobin	O
(	O
Hb	O
)	O
A1c	O
was	O
13.4	O
%	O
prior	O
to	O
transplantation	B-T061
and	O
decreased	O
rapidly	O
to	O
6.5	O
%	O
within	O
2	O
months	O
postsurgery	O
.	O
The	O
patients	O
had	O
no	O
or	O
mild	O
pretransplant	O
diabetic	B-T047
retinopathy	I-T047
and	O
developed	O
acute	O
symptomatic	O
macular	B-T047
edema	I-T047
and	O
peripapillary	O
soft	O
exudate	O
in	O
both	B-T023
eyes	I-T023
after	O
pancreas	B-T061
transplantation	I-T061
.	O
All	O
macular	B-T047
edema	I-T047
resolved	B-T033
either	O
with	O
or	O
without	O
treatment	B-T061
.	O
Five	O
cases	O
progressed	O
to	O
proliferative	B-T047
diabetic	I-T047
retinopathy	I-T047
and	O
received	O
panretinal	B-T061
photocoagulation	I-T061
.	O
Diabetic	B-T047
retinopathy	I-T047
remained	O
stable	O
in	O
all	O
eyes	B-T023
after	O
treatment	B-T061
,	O
and	O
the	O
visual	O
prognosis	B-T033
was	I-T033
good	I-T033
,	O
except	O
in	O
one	O
eye	B-T023
that	O
had	O
macular	O
branch	B-T047
retinal	I-T047
artery	I-T047
occlusion	I-T047
with	O
foveal	B-T023
involvement	O
.	O
Acute	O
macular	B-T047
edema	I-T047
after	O
pancreas	B-T061
transplantation	I-T061
has	O
a	O
favorable	O
treatment	O
outcome	O
despite	O
rapid	O
progression	O
to	O
proliferative	B-T047
diabetic	I-T047
retinopathy	I-T047
.	O
High	O
pretransplant	O
HbA1c	O
and	O
abrupt	O
blood	O
sugar	O
normalization	O
may	O
be	O
related	O
to	O
the	O
disease	O
course	O
.	O
      
Role	O
of	O
breast	B-T060
magnetic	I-T060
resonance	I-T060
imaging	I-T060
in	O
predicting	O
residual	O
lobular	B-T191
carcinoma	I-T191
in	I-T191
situ	I-T191
after	O
initial	O
excision	B-T061
Breast	B-T060
magnetic	I-T060
resonance	I-T060
(	I-T060
MR	I-T060
)	I-T060
imaging	I-T060
is	O
a	O
useful	O
screening	B-T060
modality	O
in	O
detecting	B-T061
suspicious	B-T033
lesions	B-T033
in	O
patients	O
with	O
a	O
history	B-T033
of	O
lobular	B-T191
carcinoma	I-T191
in	I-T191
situ	I-T191
(	O
LCIS	B-T191
)	O
.	O
This	O
study	O
aimed	O
to	O
evaluate	B-T058
the	O
effectiveness	O
of	O
breast	B-T060
MR	I-T060
imaging	I-T060
in	O
detecting	B-T061
remnant	B-T018
LCIS	B-T191
lesions	B-T033
after	O
initial	O
excision	B-T061
.	O
Between	O
2011	O
and	O
2015	O
,	O
29	O
patients	O
with	O
LCIS	B-T191
who	O
underwent	B-T033
initial	O
excision	B-T061
were	O
enrolled	O
.	O
Breast	B-T060
ultrasonography	I-T060
and	O
breast	B-T060
MR	I-T060
imaging	I-T060
was	O
conducted	O
after	O
initial	O
excision	B-T061
.	O
Imaging	O
findings	O
were	O
compared	O
with	O
pathologic	O
results	O
.	O
There	O
were	O
nine	O
(	O
31.0	O
%	O
)	O
cases	O
with	O
positive	B-T033
margins	I-T033
after	O
initial	O
excision	B-T061
;	O
they	O
were	O
LCIS	B-T191
(	O
n=8	O
)	O
and	O
atypical	O
lobular	O
hyperplasia	O
(	O
n=1	O
)	O
.	O
Residual	O
lesions	B-T033
were	O
identified	O
in	O
12	O
cases	O
;	O
they	O
were	O
invasive	B-T191
lobular	I-T191
carcinoma	I-T191
(	O
n=1	O
;	O
3.4	O
%	O
)	O
,	O
LCIS	B-T191
(	O
n=9	O
;	O
31.0	O
%	O
)	O
,	O
atypical	O
lobular	O
hyperplasia	O
(	O
n=1	O
;	O
3.4	O
%	O
)	O
,	O
and	O
papillary	B-T191
carcinoma	I-T191
in	I-T191
situ	I-T191
(	O
n=1	O
;	O
3.4	O
%	O
)	O
.	O
Prior	O
to	O
the	O
second	O
operation	B-T061
,	O
these	O
lesions	B-T033
could	O
be	O
detected	O
in	O
seven	O
cases	O
using	O
ultrasonography	B-T060
(	O
sensitivity	O
,	O
53.3	O
%	O
;	O
specificity	O
,	O
100	O
%	O
)	O
and	O
in	O
10	O
cases	O
using	O
breast	B-T060
MR	I-T060
imaging	I-T060
(	O
sensitivity	O
,	O
83.3	O
%	O
;	O
specificity	O
,	O
100	O
%	O
)	O
.	O
Breast	B-T060
MR	I-T060
imaging	I-T060
showed	O
higher	O
sensitivity	O
than	O
breast	B-T060
ultrasonography	I-T060
in	O
detecting	B-T061
remnant	B-T018
LCIS	B-T191
lesions	B-T033
.	O
If	O
a	O
suspicious	B-T033
lesion	B-T033
was	O
found	O
using	O
breast	B-T060
MR	I-T060
imaging	I-T060
,	O
a	O
second	O
operation	B-T061
should	O
be	O
considered	O
because	O
of	O
the	O
possibility	B-T033
of	O
multifocality	B-T033
,	O
even	O
if	O
LCIS	B-T191
was	O
confirmed	B-T033
at	O
the	O
initial	O
operation	B-T061
.	O
      
Efficacy	O
of	O
Synbiotics	O
for	O
Treatment	B-T061
of	O
Bacillary	B-T047
Dysentery	I-T047
in	O
Children	O
:	O
A	O
Double	O
-	O
Blind	O
,	O
Randomized	O
,	O
Placebo	O
-	O
Controlled	O
Study	O
Bacillary	B-T047
dysentery	I-T047
is	O
a	O
major	O
cause	O
of	O
children	O
's	O
admission	B-T058
to	I-T058
hospitals	I-T058
.	O
To	O
assess	B-T058
the	O
probiotic	B-T007
and	O
prebiotic	O
(	O
synbiotics	O
)	O
effects	O
in	O
children	O
with	O
dysentery	B-T047
in	O
a	O
randomized	O
clinical	O
trial	O
,	O
200	O
children	O
with	O
dysentery	B-T047
were	O
studied	O
in	O
2	O
groups	O
:	O
the	O
synbiotic	O
group	O
received	O
1	O
tablet	O
/day	O
of	O
synbiotic	O
for	O
3	O
-	O
5	O
days	O
and	O
the	O
placebo	O
group	O
received	O
placebo	O
tablets	O
(	O
identical	O
tablet	O
form	O
like	O
probiotics	B-T007
)	O
.	O
The	O
standard	O
treatment	B-T061
was	O
administered	O
for	O
all	O
patients	O
.	O
Duration	O
of	O
hospitalization	B-T058
,	O
dysentery	B-T047
,	O
fever	B-T184
,	O
and	O
the	O
weight	B-T033
loss	I-T033
were	O
assessed	O
in	O
each	O
group	O
.	O
It	O
was	O
concluded	O
that	O
there	O
was	O
no	B-T033
significant	I-T033
difference	I-T033
in	O
both	O
groups	O
in	O
the	O
baseline	O
characteristics	O
.	O
The	O
mean	O
duration	O
of	O
dysentery	B-T047
reduced	O
(	O
P	O
<	O
0.05	O
)	O
.	O
The	O
mean	O
duration	O
of	O
fever	B-T184
has	O
been	O
significantly	O
reduced	O
in	O
the	O
synbiotic	O
group	O
(	O
1.64	O
±	O
0.87	O
days	O
)	O
in	O
comparison	O
to	O
the	O
placebo	O
group	O
(	O
2.13	O
±	O
0.94	O
days	O
)	O
(	O
P	O
<	O
0.001	O
)	O
.	O
Average	O
amount	O
of	O
weight	B-T033
loss	I-T033
was	O
significantly	O
lower	O
in	O
the	O
synbiotic	O
group	O
in	O
comparison	O
to	O
that	O
in	O
the	O
placebo	O
group	O
(	O
129.5	O
±	O
23.388	O
grams	O
and	O
278	O
±	O
28.385	O
grams	O
,	O
resp	O
.	O
;	O
P	O
<	O
0.001	O
)	O
.	O
There	O
was	O
no	B-T033
significant	I-T033
difference	I-T033
in	O
the	O
mean	O
duration	O
of	O
hospitalization	B-T058
in	O
both	O
groups	O
(	O
P	O
>	O
0.05	O
)	O
.	O
The	O
use	O
of	O
synbiotics	O
as	O
an	O
adjuvant	B-T061
therapy	I-T061
to	O
the	O
standard	O
treatment	B-T061
of	O
dysentery	B-T047
significantly	O
reduces	O
the	O
duration	O
of	O
dysentery	B-T047
,	O
fever	B-T184
,	O
and	O
rate	B-T033
of	I-T033
weight	I-T033
losses	I-T033
.	O
The	O
trial	O
is	O
registered	B-T058
with	O
IRCT201109267647N1	O
.	O
      
Anti	B-T033
-	I-T033
inflammatory	I-T033
activity	O
of	O
Elaeagnus	O
angustifolia	O
fruit	B-T121
extract	I-T121
on	O
rat	O
paw	B-T023
edema	B-T184
The	O
Elaeagnus	O
angustifolia	O
fruit	O
has	O
been	O
traditionally	O
used	O
in	O
Iranian	O
herbal	B-T121
medicine	I-T121
to	O
treat	O
diarrhea	B-T184
and	O
rheumatoid	B-T047
arthritis	I-T047
.	O
In	O
the	O
present	O
study	O
,	O
the	O
effects	O
of	O
E.	O
angustifolia	O
fruit	B-T121
extract	I-T121
on	O
the	O
acute	O
and	O
chronic	O
phases	O
of	O
formalin	B-T121
-	O
induced	O
rat	O
paw	B-T023
edema	B-T184
were	O
examined	B-T033
.	O
The	O
acute	O
and	O
chronic	O
anti	B-T033
-	I-T033
inflammatory	I-T033
effects	I-T033
of	O
E.	O
angustifolia	O
fruit	B-T121
extract	I-T121
were	O
investigated	O
through	O
the	O
subcutaneous	O
injection	O
of	O
100	O
μL	O
of	O
formalin	B-T121
(	O
2.5	O
%	O
)	O
into	O
a	O
rat	O
's	O
hind	O
paw	B-T023
.	O
Thirty	O
minutes	O
before	O
the	O
procedure	O
,	O
the	O
experimental	O
groups	O
were	O
treated	O
intraperitoneally	O
with	O
hydroalcoholic	B-T121
fruit	I-T121
extracts	I-T121
of	O
E.	O
angustifolia	O
(	O
concentrations	O
of	O
100	O
,	O
300	O
,	O
700	O
,	O
and	O
1000	O
mg	O
/	O
kg	O
)	O
;	O
sodium	B-T121
salicylate	I-T121
(	O
SS	B-T121
,	O
400	O
mg	O
/	O
kg	O
)	O
and	O
distilled	B-T121
water	I-T121
were	O
used	O
as	O
positive	B-T033
and	O
negative	B-T033
control	O
groups	O
,	O
respectively	O
.	O
Treatment	O
with	O
SS	B-T121
and	O
the	O
fruit	B-T121
extracts	I-T121
were	O
performed	O
daily	O
for	O
8	O
days	O
,	O
and	O
the	O
degree	O
of	O
edema	B-T184
was	O
measured	O
by	O
using	O
mercury	O
plethysmometer	O
and	O
digital	O
caliper	O
.	O
In	O
the	O
acute	O
anti	B-T033
-	I-T033
inflammatory	I-T033
study	O
,	O
the	O
extract	O
showed	O
a	O
significant	O
anti	O
-	O
inflammatory	O
effect	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O
The	O
results	O
of	O
1000	O
mg	O
/	O
kg	O
of	O
the	O
extract	O
was	O
significantly	O
different	O
compared	O
with	O
the	O
negative	B-T033
control	O
group	O
(	O
p<0.05	O
)	O
and	O
was	O
comparable	O
to	O
sodium	B-T121
salicylate	I-T121
(	O
p<0.05	O
)	O
.	O
Results	O
from	O
the	O
chronic	O
study	O
suggested	O
that	O
E.	O
angustifolia	O
extract	O
significantly	O
reduced	O
paw	B-T023
edema	B-T184
and	O
inflammation	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O
The	O
results	O
also	O
showed	O
that	O
the	O
measurement	O
by	O
digital	O
caliper	O
and	O
mercury	O
plethysmometer	O
were	O
both	O
reliable	O
and	O
might	O
be	O
applied	O
interchangeably	O
(	O
p<0.01	O
)	O
.	O
Phytochemical	B-T059
tests	I-T059
indicated	O
that	O
the	O
hydroalcoholic	B-T121
fruit	I-T121
extract	I-T121
of	O
E.	O
angustifolia	O
was	O
positive	B-T033
for	O
cardiac	B-T121
glycosides	I-T121
,	O
flavonoids	O
,	O
terpenoids	O
,	O
and	O
saponins	O
.	O
Based	O
on	O
our	O
findings	B-T033
,	O
the	O
E.	O
angustifolia	O
fruit	B-T121
extract	I-T121
probably	O
has	O
acute	O
and	O
chronic	O
anti	B-T033
-	I-T033
inflammatory	I-T033
activities	O
to	O
support	O
its	O
applications	O
in	O
folk	B-T061
medicine	I-T061
.	O
      
'	O
Yarn	B-T058
with	O
me	O
'	O
:	O
applying	O
clinical	B-T058
yarning	I-T058
to	O
improve	O
clinician	O
-	O
patient	O
communication	O
in	O
Aboriginal	O
health	B-T058
care	I-T058
Although	O
successful	O
communication	O
is	O
at	O
the	O
heart	O
of	O
the	O
clinical	B-T058
consultation	I-T058
,	O
communication	O
between	O
Aboriginal	O
patients	O
and	O
practitioners	O
such	O
as	O
doctors	O
,	O
nurses	O
and	O
allied	O
health	O
professionals	O
,	O
continues	O
to	O
be	O
problematic	B-T033
and	O
is	O
arguably	O
the	O
biggest	O
barrier	O
to	O
the	O
delivery	O
of	O
successful	O
health	B-T058
care	I-T058
to	O
Aboriginal	O
people	O
.	O
This	O
paper	O
presents	O
an	O
overarching	O
framework	O
for	O
practitioners	O
to	O
help	O
them	O
reorientate	O
their	O
communication	O
with	O
Aboriginal	O
patients	O
using	O
'	O
clinical	B-T058
yarning	I-T058
'	O
.	O
Clinical	B-T058
yarning	I-T058
is	O
a	O
patient	O
-centred	O
approach	O
that	O
marries	O
Aboriginal	O
cultural	O
communication	O
preferences	O
with	O
biomedical	O
understandings	O
of	O
health	O
and	O
disease	O
.	O
Clinical	B-T058
yarning	I-T058
consists	O
of	O
three	O
interrelated	O
areas	O
:	O
the	O
social	O
yarn	B-T058
,	O
in	O
which	O
the	O
practitioner	O
aims	O
to	O
find	O
common	O
ground	O
and	O
develop	O
the	O
interpersonal	O
relationship	O
;	O
the	O
diagnostic	O
yarn	B-T058
,	O
in	O
which	O
the	O
practitioner	O
facilitates	O
the	O
patient	O
's	O
health	O
story	O
while	O
interpreting	O
it	O
through	O
a	O
biomedical	O
or	O
scientific	B-T059
lens	I-T059
;	O
and	O
the	O
management	O
yarn	B-T058
,	O
that	O
employs	O
stories	O
and	O
metaphors	O
as	O
tools	O
for	O
patients	O
to	O
help	O
them	O
understand	O
a	O
health	B-T033
issue	I-T033
so	O
a	O
collaborative	O
management	O
approach	O
can	O
be	O
adopted	O
.	O
There	O
is	O
cultural	O
and	O
research	O
evidence	O
that	O
supports	O
this	O
approach	O
.	O
Clinical	B-T058
yarning	I-T058
has	O
the	O
potential	O
to	O
improve	O
outcomes	O
for	O
patients	O
and	O
practitioners	O
.	O
      
Computational	B-T059
analysis	I-T059
of	O
conserved	O
coil	O
functional	O
residues	O
in	O
the	O
mitochondrial	B-T059
genomic	I-T059
sequences	I-T059
of	O
dermatophytes	O
Dermatophyte	O
is	O
a	O
group	O
of	O
closely	O
related	O
fungi	O
that	O
have	O
the	O
capacity	O
to	O
invade	O
keratinized	O
tissue	O
of	O
humans	O
and	O
other	O
animals	O
.	O
The	O
infection	O
known	O
as	O
dermatophytosis	B-T047
,	O
caused	O
by	O
members	O
of	O
the	O
genera	O
Microsporum	O
,	O
Trichophyton	O
,	O
and	O
Epidermophyton	O
includes	O
infection	O
to	O
the	O
groin	O
(	O
tinea	B-T047
cruris	I-T047
)	O
,	O
beard	B-T023
(	O
tinea	B-T047
barbae	I-T047
)	O
,	O
scalp	B-T023
(	O
tinea	B-T047
capitis	I-T047
)	O
,	O
feet	B-T023
(	O
tinea	B-T047
pedis	I-T047
)	O
,	O
glabrous	B-T023
skin	I-T023
(	O
tinea	B-T047
corporis	I-T047
)	O
,	O
nail	B-T023
(	O
tinea	B-T047
unguium	I-T047
)	O
,	O
and	O
hand	B-T023
(	O
tinea	B-T047
manuum	I-T047
)	O
.	O
The	O
identification	O
of	O
evolutionary	O
relationship	O
between	O
these	O
three	O
genera	O
of	O
dermatophyte	O
is	O
epidemiologically	O
important	O
to	O
understand	O
their	O
pathogenicity	O
.	O
Mitochondrial	O
DNA	O
evolves	O
more	O
rapidly	O
than	O
a	O
nuclear	O
DNA	O
due	O
to	O
higher	O
rate	O
of	O
mutation	O
but	O
is	O
very	O
less	O
affected	O
by	O
genetic	O
recombination	O
,	O
making	O
it	O
an	O
important	O
tool	O
for	O
phylogenetic	O
studies	O
.	O
Thus	O
,	O
here	O
we	O
present	O
a	O
novel	O
scheme	O
to	O
identify	O
the	O
conserved	O
coil	O
functional	O
residues	O
of	O
Trichophyton	O
rubrum	O
,	O
Trichophyton	O
mentagrophytes	O
,	O
Epidermophyton	O
floccosum	O
and	O
Microsporum	O
canis	O
.	O
Protein	O
coding	O
sequences	O
of	O
the	O
mitochondrial	O
genome	O
were	O
aligned	O
for	O
their	O
similar	O
sequences	O
and	O
homology	O
modelling	O
was	O
performed	O
for	O
structure	O
and	O
pocket	O
identification	O
.	O
The	O
results	O
obtained	O
from	O
comparative	O
analysis	O
of	O
the	O
protein	O
sequences	O
revealed	O
the	O
presence	O
of	O
functionally	O
active	O
sites	O
in	O
all	O
the	O
species	O
of	O
the	O
genera	O
Trichophyton	O
and	O
Microsporum	O
.	O
However	O
in	O
Epidermophyton	O
floccosum	O
it	O
was	O
observed	O
in	O
three	O
protein	O
sequences	O
of	O
the	O
five	O
studied	O
.	O
The	O
absence	O
of	O
these	O
conserved	O
coil	O
functional	O
residues	O
in	O
E.	O
floccusum	O
may	O
be	O
correlated	O
with	O
lesser	O
infectivity	O
of	O
this	O
organism	B-T001
.	O
The	O
functional	O
residues	O
identified	O
in	O
the	O
present	O
study	O
could	O
be	O
responsible	O
for	O
the	O
disease	B-T047
and	O
thus	O
can	O
act	O
as	O
putative	O
target	O
sites	O
for	O
drug	O
designing	O
.	O
      
Amphetamine	B-T048
Withdrawal	I-T048
Differentially	O
Increases	O
the	O
Expression	O
of	O
Organic	O
Cation	O
Transporter	O
3	O
and	O
Serotonin	O
Transporter	O
in	O
Limbic	O
Brain	B-T023
Regions	I-T023
Amphetamine	B-T048
withdrawal	I-T048
increases	O
anxiety	B-T033
and	O
stress	B-T033
sensitivity	O
related	O
to	O
blunted	O
ventral	O
hippocampus	B-T023
(	O
vHipp	B-T023
)	O
and	O
enhances	O
the	O
central	B-T023
nucleus	I-T023
of	I-T023
the	I-T023
amygdala	I-T023
(	O
CeA	B-T023
)	O
serotonin	O
responses	O
.	O
Extracellular	O
serotonin	O
levels	O
are	O
regulated	O
by	O
the	O
serotonin	O
transporter	O
(	O
SERT	O
)	O
and	O
organic	O
cation	O
transporter	O
3	O
(	O
OCT3	O
)	O
,	O
and	O
vHipp	B-T023
OCT3	O
expression	O
is	O
enhanced	O
during	O
24	O
hours	O
of	O
amphetamine	B-T048
withdrawal	I-T048
,	O
while	O
SERT	O
expression	O
is	O
unaltered	O
.	O
Here	O
,	O
we	O
tested	O
whether	O
OCT3	O
and	O
SERT	O
expression	O
in	O
the	O
CeA	B-T023
is	O
also	O
affected	O
during	O
acute	O
withdrawal	B-T048
to	O
explain	O
opposing	O
regional	O
alterations	O
in	O
limbic	O
serotonergic	O
neurotransmission	O
and	O
if	O
respective	O
changes	O
continued	O
with	O
two	O
weeks	O
of	O
withdrawal	B-T048
.	O
We	O
also	O
determined	O
whether	O
changes	O
in	O
transporter	O
expression	O
were	O
confined	O
to	O
these	O
regions	O
.	O
Male	O
rats	O
received	O
amphetamine	B-T121
or	O
saline	O
for	O
two	O
weeks	O
followed	O
by	O
24	O
hours	O
or	O
two	O
weeks	O
of	O
withdrawal	B-T048
,	O
with	O
transporter	O
expression	O
measured	O
using	O
Western	B-T059
immunoblot	I-T059
.	O
OCT3	O
and	O
SERT	O
expression	O
increased	O
in	O
the	O
CeA	B-T023
at	O
both	O
withdrawal	B-T048
timepoints	O
.	O
In	O
the	O
vHipp	B-T023
,	O
OCT3	O
expression	O
increased	O
only	O
at	O
24	O
hours	O
of	O
withdrawal	B-T048
,	O
with	O
an	O
equivalent	O
pattern	O
seen	O
in	O
the	O
dorsomedial	B-T023
hypothalamus	I-T023
.	O
No	B-T033
changes	I-T033
were	O
evident	O
in	O
any	O
other	O
regions	O
sampled	O
.	O
These	O
regionally	O
specific	O
changes	O
in	O
limbic	O
OCT3	O
and	O
SERT	O
expression	O
may	O
partially	O
contribute	O
to	O
the	O
serotonergic	O
imbalance	B-T184
and	O
negative	B-T033
affect	I-T033
during	O
amphetamine	B-T048
withdrawal	I-T048
.	O
      
Palliative	O
Care	O
with	O
Attachment	O
Hybrid	B-T061
Removable	I-T061
Prosthesis	I-T061
Abutment	B-T023
injury	O
,	O
unsatisfactory	O
aesthetics	O
and	O
lesser	O
retention	B-T061
exist	O
with	O
the	O
cast	O
partial	O
denture	O
.	O
Though	O
these	O
constraints	O
exist	O
in	O
the	O
Removable	O
Partial	O
Denture	O
(	O
RPD	O
)	O
it	O
is	O
still	O
widely	O
used	O
because	O
of	O
the	O
simplicity	O
in	O
design	B-T058
,	O
fabrication	O
,	O
economics	O
and	O
patient	B-T058
comfort	I-T058
.	O
This	O
clinical	O
report	O
describes	O
a	O
hybrid	O
RPD	O
technique	O
which	O
uses	O
extra	O
coronal	O
attachment	O
that	O
reduces	O
the	O
limitations	O
and	O
provides	O
better	O
comfort	O
for	O
the	O
patient	O
.	O
      
Liver	O
Fatty	O
Acid	O
Binding	O
Protein	O
Deficiency	O
Provokes	O
Oxidative	O
Stress	O
,	O
Inflammation	O
,	O
and	O
Apoptosis	O
-Mediated	O
Hepatotoxicity	O
Induced	O
by	O
Pyrazinamide	B-T121
in	O
Zebrafish	O
Larvae	O
Pyrazinamide	B-T121
(	O
PZA	B-T121
)	O
is	O
an	O
essential	O
antitubercular	B-T121
drug	I-T121
,	O
but	O
little	O
is	O
still	O
known	O
about	O
its	O
hepatotoxicity	O
potential	O
.	O
This	O
study	O
examined	O
the	O
effects	O
of	O
PZA	B-T121
exposure	O
on	O
zebrafish	O
(	O
Danio	O
rerio	O
)	O
larvae	O
and	O
the	O
mechanisms	O
underlying	O
its	O
hepatotoxicity	O
.	O
A	O
transgenic	O
line	O
of	O
zebrafish	O
larvae	O
that	O
expressed	O
enhanced	O
green	O
fluorescent	O
protein	O
(	O
EGFP	O
)	O
in	O
the	O
liver	B-T023
was	O
incubated	B-T059
with	O
1	O
,	O
2.5	O
,	O
and	O
5	O
mM	O
PZA	B-T121
from	O
72	O
h	O
postfertilization	O
(	O
hpf	O
)	O
.	O
Different	O
endpoints	O
such	O
as	O
mortality	O
,	O
morphology	B-T033
changes	O
in	O
the	O
size	O
and	O
shape	O
of	O
the	O
liver	B-T023
,	O
histological	O
changes	O
,	O
transaminase	B-T059
analysis	I-T059
and	O
apoptosis	O
,	O
markers	O
of	O
oxidative	O
and	O
genetic	O
damage	O
,	O
as	O
well	O
as	O
the	O
expression	O
of	O
certain	O
genes	O
were	O
selected	O
to	O
evaluate	B-T058
PZA	B-T121
-	O
induced	O
hepatotoxicity	O
.	O
Our	O
results	O
confirm	B-T033
the	O
manner	O
of	O
PZA	B-T121
dose	O
-	O
dependent	O
hepatotoxicity	O
.	O
PZA	B-T121
was	O
found	O
to	O
induce	O
marked	O
injury	O
in	O
zebrafish	O
larvae	O
,	O
such	O
as	O
liver	B-T047
atrophy	I-T047
,	O
elevations	B-T033
of	I-T033
transaminase	I-T033
levels	I-T033
,	O
oxidative	O
stress	O
,	O
and	O
hepatocyte	O
apoptosis	O
.	O
To	O
further	O
understand	O
the	O
mechanism	O
behind	O
PZA	B-T121
-	O
induced	O
hepatotoxicity	O
,	O
changes	O
in	O
gene	O
expression	O
levels	O
in	O
zebrafish	O
larvae	O
exposed	O
to	O
PZA	B-T121
for	O
72	O
h	O
postexposure	O
(	O
hpe	O
)	O
were	O
determined	O
.	O
The	O
results	O
of	O
this	O
study	O
demonstrated	O
that	O
PZA	B-T121
decreased	O
the	O
expression	O
levels	O
of	O
liver	O
fatty	O
acid	O
binding	O
protein	O
(	O
L	O
-	O
FABP	O
)	O
and	O
its	O
target	O
gene	O
,	O
peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
α	O
(	O
PPAR	O
-	O
α	O
)	O
,	O
and	O
provoked	O
more	O
severe	O
oxidative	O
stress	O
and	O
hepatitis	B-T047
via	O
the	O
upregulation	O
of	O
inflammatory	O
cytokines	O
such	O
as	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
α	O
)	O
and	O
transforming	O
growth	O
factor	O
β	O
(	O
TGF	O
-	O
β	O
)	O
.	O
These	O
findings	O
suggest	O
that	O
L	O
-	O
FABP	O
-mediated	O
PPAR	O
-	O
α	O
downregulation	O
appears	O
to	O
be	O
a	O
hepatotoxic	O
response	O
resulting	O
from	O
zebrafish	O
larva	O
liver	O
cell	O
apoptosis	O
,	O
and	O
L	O
-	O
FABP	O
can	O
be	O
used	O
as	O
a	O
biomarker	O
for	O
the	O
early	B-T060
detection	I-T060
of	O
PZA	B-T121
-	O
induced	O
liver	O
damage	O
in	O
zebrafish	O
larvae	O
.	O
      
Viral	B-T121
Vector	I-T121
Biosafety	O
in	O
Laboratory	O
Animal	O
Research	O
Viral	B-T121
vector	I-T121
research	O
presents	O
unique	O
occupational	O
health	O
and	O
safety	O
challenges	B-T058
to	O
institutions	O
due	O
to	O
the	O
rapid	O
development	O
ofboth	O
in	O
vivo	O
and	O
in	O
vitro	O
gene	O
-	O
editing	O
technologies	O
.	O
Risks	O
to	O
human	O
and	O
animal	O
health	O
make	O
it	O
incumbent	O
on	O
institutions	O
to	O
appropriately	O
evaluate	B-T058
viral	B-T121
vector	I-T121
usage	O
in	O
research	O
on	O
the	O
basis	O
of	O
available	O
information	O
and	O
governmental	O
regulations	O
and	O
guidelines	O
.Here	O
we	O
review	O
the	O
factors	O
related	O
to	O
risk	B-T058
assessment	I-T058
regarding	O
viral	B-T121
vector	I-T121
usage	O
in	O
animals	O
and	O
the	O
relevant	O
regulatory	O
documents	O
associated	O
with	O
this	O
research	O
,	O
and	O
we	O
highlight	O
the	O
most	O
commonly	O
used	O
viral	B-T121
vectors	I-T121
in	O
research	O
today	O
.	O
This	O
review	O
is	O
particularly	O
focused	O
on	O
the	O
background	O
,	O
use	O
in	O
research	O
and	O
associated	O
health	O
and	O
environmental	O
risks	O
related	O
to	O
adenoviral	B-T005
,	O
adeno	B-T005
-	I-T005
associated	I-T005
viral	I-T005
,	O
lentiviral	B-T005
,	O
and	O
herpesviral	B-T005
vectors	B-T121
.	O
      
Hand	B-T061
-	I-T061
Assisted	I-T061
Laparoscopic	I-T061
Versus	O
Standard	B-T061
Laparoscopic	I-T061
Colectomy	I-T061
:	O
Are	O
Outcomes	O
and	O
Operative	O
Time	O
Different	O
?	O
HAL	B-T061
colectomy	B-T061
is	O
a	O
technique	O
perceived	O
to	O
provide	O
the	O
benefits	O
of	O
laparoscopic	B-T061
surgery	I-T061
while	O
improving	O
tactile	O
feedback	O
and	O
operative	O
time	O
.	O
Published	O
data	O
are	O
largely	O
limited	O
to	O
small	O
,	O
single	O
-	O
institution	O
studies	O
.	O
The	O
2012	O
-	O
2013	O
National	O
Surgical	O
Quality	O
Improvement	O
Program	O
Participant	O
Data	O
Use	O
File	O
was	O
queried	O
for	O
patients	O
undergoing	O
elective	O
SL	B-T061
or	O
HAL	B-T061
colectomy	B-T061
.	O
Patients	O
underwent	O
1:1	O
propensity	O
matching	O
and	O
had	O
outcomes	O
compared	O
.	O
An	O
additional	O
subgroup	O
analysis	O
was	O
performed	O
for	O
patients	O
undergoing	O
segmental	O
resections	B-T061
only	O
.	O
13,949	O
patients	O
were	O
identified	O
,	O
of	O
whom	O
6084	O
(	O
43.6	O
%	O
)	O
underwent	O
HAL	B-T061
colectomy	B-T061
.	O
Patients	O
undergoing	O
HAL	B-T061
versus	O
SL	B-T061
colectomy	I-T061
had	O
higher	O
rates	O
of	O
postoperative	B-T047
ileus	I-T047
(	O
8.7	O
vs.	O
6.3	O
%	O
,	O
p	O
<	O
0.001	O
)	O
,	O
wound	O
complication	O
(	O
8.8	O
vs.	O
6.8	O
%	O
,	O
p	O
=	O
0.006	O
)	O
,	O
and	O
30-	O
day	O
readmission	B-T058
(	O
7.5	O
vs.	O
6.0	O
%	O
,	O
p	O
=	O
0.002	O
)	O
,	O
without	O
any	O
differences	O
in	O
operative	O
time	O
(	O
156	O
vs.	O
157	O
min	O
,	O
p	O
=	O
0.713	O
)	O
.	O
Amongst	O
segmental	O
colectomies	B-T061
,	O
HAL	B-T061
remained	O
associated	O
with	O
higher	O
rates	O
of	O
wound	O
complications	O
(	O
8.6	O
vs.	O
6.5	O
%	O
,	O
p	O
=	O
0.016	O
)	O
,	O
postoperative	B-T047
ileus	I-T047
(	O
8.9	O
vs.	O
6.3	O
%	O
,	O
p	O
<	O
0.001	O
)	O
,	O
and	O
30-	O
day	O
readmission	B-T058
(	O
7.1	O
vs.	O
5.9	O
%	O
,	O
p	O
=	O
0.041	O
)	O
with	O
no	O
difference	O
in	O
operative	O
time	O
between	O
HAL	B-T061
and	O
SL	O
(	O
145	O
vs.	O
145	O
min	O
,	O
p	O
=	O
0.334	O
)	O
.	O
Use	O
of	O
HAL	B-T061
colectomy	B-T061
is	O
associated	O
with	O
increased	O
risk	B-T058
of	O
wound	O
complications	O
,	O
postoperative	B-T047
ileus	I-T047
,	O
and	O
readmissions	B-T058
.	O
Importantly	O
,	O
this	O
technique	O
is	O
not	O
associated	O
with	O
any	O
decrease	O
in	O
operative	O
time	O
.	O
      
Survey	O
of	O
Trichinella	B-T047
infection	I-T047
from	O
domestic	O
pigs	O
in	O
the	O
historical	B-T033
endemic	O
areas	O
of	O
Henan	O
province	O
,	O
central	O
China	O
The	O
aim	O
of	O
this	O
work	O
was	O
to	O
investigate	O
the	O
current	B-T033
situation	I-T033
of	O
Trichinella	B-T047
infection	I-T047
from	O
domestic	O
pigs	O
in	O
the	O
historical	B-T033
endemic	O
areas	O
of	O
Henan	O
province	O
,	O
central	O
China	O
.	O
A	O
total	O
of	O
823	O
diaphragm	O
samples	O
from	O
the	O
indoor	O
-	O
raised	O
pigs	O
were	O
collected	O
in	O
five	O
cities	O
of	O
Henan	O
during	O
2014	O
-	O
2015	O
and	O
examined	B-T033
by	O
artificial	O
digestion	O
method	O
.	O
The	O
overall	O
prevalence	O
of	O
Trichinella	B-T047
infection	I-T047
in	O
pigs	O
was	O
0.61	O
%	O
(	O
5/823	O
)	O
.	O
Trichinella	O
larvae	O
were	O
detected	B-T033
in	O
0.91	O
%	O
(	O
5/550	O
)	O
of	O
pigs	O
from	O
Nanyang	O
city	O
of	O
Henan	O
.	O
The	O
larval	O
burden	O
in	O
infected	B-T033
animals	I-T033
was	O
0.03	O
larvae	O
per	O
gram	O
(	O
lpg	O
)	O
of	O
muscles	O
with	O
a	O
range	O
from	O
0.02	O
to	O
0.05	O
lpg	O
.	O
The	O
larvae	O
were	O
identified	O
as	O
Trichinella	O
spiralis	O
by	O
multiple	O
PCR	O
.	O
Our	O
study	O
confirms	O
the	O
existence	O
of	O
swine	O
trichinellosis	B-T047
in	O
Henan	O
,	O
but	O
the	O
infection	O
level	O
was	O
under	O
the	O
minimum	O
level	O
for	O
defining	O
infectious	B-T001
sources	I-T001
for	O
humans	O
.	O
However	O
,	O
the	O
prevalence	O
of	O
swine	O
Trichinella	B-T047
infection	I-T047
in	O
Henan	O
need	O
to	O
be	O
further	O
evaluated	B-T058
with	O
a	O
large	O
scale	O
of	O
pork	O
samples	O
for	O
ensuring	O
meat	O
food	O
safety	O
.	O
      
Beyond	O
"	O
Median	O
Waiting	O
Time	O
"	O
:	O
Development	O
and	O
Validation	O
of	O
a	O
Competing	O
Risk	O
Model	O
to	O
Predict	O
Outcomes	O
on	O
the	O
Kidney	B-T023
Transplant	O
Waiting	O
List	O
Median	O
historical	O
time	O
to	O
kidney	B-T061
transplant	I-T061
is	O
misleading	O
because	O
it	O
does	O
not	O
convey	O
the	O
competing	O
risks	O
of	O
death	O
or	O
removal	B-T033
from	I-T033
the	I-T033
waiting	I-T033
list	I-T033
.	O
We	O
developed	O
and	O
validated	O
a	O
competing	O
risk	O
model	O
to	O
calculate	O
likelihood	O
of	O
outcomes	O
for	O
kidney	B-T061
transplant	I-T061
candidates	O
and	O
demonstrate	O
how	O
this	O
information	O
differs	O
from	O
median	O
time	O
to	O
transplant	B-T061
.	O
Data	O
were	O
obtained	O
from	O
the	O
US	O
Scientific	O
Registry	O
of	O
Transplant	O
Recipients	O
.	O
The	O
retrospective	O
cohort	O
included	O
163	O
636	O
adults	O
listed	O
for	O
kidney	B-T061
transplant	I-T061
before	O
December	O
31	O
,	O
2011	O
.	O
Predictors	B-T033
were	O
age	O
,	O
sex	O
,	O
blood	O
type	O
,	O
calculated	B-T059
panel	B-T059
-	I-T059
reactive	I-T059
antibodies	I-T059
,	O
donation	B-T061
service	O
area	O
,	O
dialysis	B-T061
duration	O
,	O
comorbid	B-T033
conditions	I-T033
,	O
and	O
body	O
mass	O
index	O
.	O
Outcomes	O
were	O
deceased	O
or	O
living	O
donor	O
transplant	B-T061
,	O
death	O
or	O
removal	B-T033
from	I-T033
the	I-T033
list	I-T033
due	O
to	O
deteriorating	O
medical	O
condition	O
,	O
or	O
removal	B-T033
due	O
to	O
other	B-T033
reasons	I-T033
.	O
We	O
calculated	O
hazards	O
for	O
the	O
possible	B-T033
outcomes	O
,	O
then	O
the	O
cumulative	O
incidence	O
function	O
for	O
a	O
given	O
candidate	O
using	O
competing	O
risk	O
methodology	O
.	O
Discrimination	O
and	O
calibration	O
were	O
assessed	O
through	O
C	O
statistics	O
and	O
calibration	O
plots	O
for	O
each	O
cause	O
-	O
specific	O
Cox	O
proportional	O
hazard	O
model	O
.	O
C	O
statistics	O
ranged	O
from	O
0.64	O
to	O
0.73	O
.	O
Calibration	O
plots	O
showed	O
good	O
calibration	O
.	O
The	O
competing	O
risk	O
model	O
shows	O
probability	O
of	O
all	O
possible	B-T033
outcomes	O
for	O
up	O
to	O
12	O
years	O
given	O
a	O
candidate	O
's	O
characteristics	O
,	O
contrasted	O
with	O
the	O
median	O
waiting	O
time	O
for	O
that	O
candidate	O
's	O
donation	B-T061
service	O
area	O
.	O
A	O
competing	O
risk	O
model	O
conveys	O
more	O
relevant	O
information	O
than	O
the	O
median	O
waiting	O
time	O
for	O
a	O
given	O
transplant	O
center	O
.	O
This	O
model	O
will	O
be	O
updated	O
to	O
create	O
a	O
calculator	O
reflecting	O
the	O
most	O
recent	O
outcomes	O
and	O
changes	O
in	O
allocation	O
policy	O
.	O
It	O
illustrates	O
the	O
conversations	O
that	O
should	O
be	O
initiated	O
with	O
transplant	B-T061
candidates	O
.	O
      
Nucleic	B-T059
acid	I-T059
detection	I-T059
with	O
CRISPR	O
-	O
Cas13a	O
/	O
C2c2	O
Rapid	O
,	O
inexpensive	O
,	O
and	O
sensitive	O
nucleic	B-T059
acid	I-T059
detection	I-T059
may	O
aid	O
point	O
-	O
of	O
-	O
care	O
pathogen	B-T001
detection	B-T061
,	O
genotyping	B-T059
,	O
and	O
disease	B-T047
monitoring	B-T058
.	O
The	O
RNA	O
-guided	O
,	O
RNA	O
-	O
targeting	O
clustered	O
regularly	O
interspaced	O
short	O
palindromic	O
repeats	O
(	O
CRISPR	O
)	O
effector	O
Cas13a	O
(	O
previously	O
known	O
as	O
C2c2	O
)	O
exhibits	O
a	O
"	O
collateral	O
effect	O
"	O
of	O
promiscuous	O
ribonuclease	O
activity	O
upon	O
target	O
recognition	O
.	O
We	O
combine	O
the	O
collateral	O
effect	O
of	O
Cas13a	O
with	O
isothermal	B-T059
amplification	I-T059
to	O
establish	O
a	O
CRISPR	O
-based	O
diagnostic	O
(	O
CRISPR	O
-	O
Dx	O
)	O
,	O
providing	O
rapid	O
DNA	O
or	O
RNA	O
detection	B-T061
with	O
attomolar	O
sensitivity	O
and	O
single	O
-	O
base	O
mismatch	O
specificity	O
.	O
We	O
use	O
this	O
Cas13a	O
-based	O
molecular	O
detection	B-T061
platform	O
,	O
termed	O
Specific	O
High	O
-	O
Sensitivity	O
Enzymatic	O
Reporter	O
UnLOCKing	O
(	O
SHERLOCK	O
)	O
,	O
to	O
detect	B-T033
specific	O
strains	B-T001
of	O
Zika	B-T005
and	O
Dengue	B-T005
virus	I-T005
,	O
distinguish	O
pathogenic	B-T001
bacteria	B-T007
,	O
genotype	O
human	O
DNA	O
,	O
and	O
identify	O
mutations	O
in	O
cell	O
-	O
free	O
tumor	O
DNA	O
.	O
Furthermore	O
,	O
SHERLOCK	O
reaction	O
reagents	O
can	O
be	O
lyophilized	B-T059
for	O
cold	O
-	O
chain	O
independence	O
and	O
long	O
-	O
term	O
storage	O
and	O
be	O
readily	O
reconstituted	O
on	O
paper	O
for	O
field	O
applications	O
.	O
      
The	O
platelet	O
-	O
activating	O
receptor	O
C	O
-	O
type	O
lectin	O
receptor-2	O
plays	O
an	O
essential	O
role	O
in	O
liver	O
regeneration	O
after	O
partial	B-T061
hepatectomy	I-T061
in	O
mice	O
Essentials	O
Regeneration	O
role	O
of	O
C	O
-	O
type	O
lectin	O
receptor-2	O
(	O
CLEC-2	O
)	O
after	O
70	B-T061
%	I-T061
hepatectomy	I-T061
(	O
HPx	B-T061
)	O
was	O
investigated	O
.	O
Wild	O
-	O
type	O
or	O
CLEC-2	O
deleted	O
from	O
platelets	O
of	O
chimeric	O
mice	O
(	O
flKO	O
)	O
underwent	O
HPx	B-T061
.	O
The	O
liver	O
/	O
body	O
weight	O
ratio	O
was	O
significantly	O
lower	O
in	O
the	O
flKO	O
than	O
in	O
the	O
wild	O
-	O
type	O
.	O
CLEC-2	O
plays	O
an	O
essential	O
role	O
in	O
liver	O
regeneration	O
after	O
HPx	B-T061
.	O
Background	O
and	O
aim	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
role	O
of	O
C	O
-	O
type	O
lectin	O
receptor	O
(	O
CLEC)-2	O
in	O
liver	O
regeneration	O
following	O
partial	B-T061
liver	I-T061
resection	I-T061
in	O
mice	O
.	O
Materials	O
and	O
methods	O
Irradiated	O
chimeric	O
mice	O
transplanted	O
with	O
fetal	O
liver	O
cells	O
from	O
wild	O
-	O
type	O
(	O
WT	O
)	O
mice	O
,	O
CLEC-2	O
-	O
deleted	O
(	O
KO	O
)	O
mice	O
or	O
mice	O
with	O
CLEC-2	O
deleted	O
specifically	O
from	O
platelets	O
(	O
flKO	O
)	O
were	O
generated	O
.	O
Mice	O
underwent	O
70	B-T061
%	I-T061
partial	I-T061
hepatectomy	I-T061
(	O
PH	B-T061
)	O
.	O
Immunohistochemical	B-T059
staining	I-T059
was	O
performed	O
to	O
investigate	O
the	O
expression	O
of	O
the	O
endogenous	O
ligand	O
for	O
CLEC-2	O
,	O
podoplanin	O
.	O
The	O
accumulation	O
of	O
platelets	O
in	O
the	O
liver	B-T023
was	O
also	O
quantified	O
.	O
The	O
hepatic	O
expression	O
of	O
the	O
IL-6	O
/	O
gp130	O
and	O
STAT3	O
,	O
Akt	O
and	O
ERK1/2	O
was	O
also	O
examined	O
.	O
Results	O
The	O
liver	O
/	O
body	O
weight	O
ratio	O
and	O
expression	O
of	O
all	O
cell	O
proliferation	O
markers	B-T059
were	O
significantly	O
lower	O
in	O
the	O
flKO	O
group	O
than	O
in	O
the	O
WT	O
group	O
.	O
The	O
expression	O
of	O
phosphorylated	O
(	O
p	O
)	O
Akt	O
and	O
pERK1	O
/2	O
was	O
similar	O
in	O
the	O
WT	O
and	O
flKO	O
groups	O
.	O
On	O
the	O
other	O
hand	O
,	O
the	O
expression	O
of	O
pSTAT3	O
and	O
IL-6	O
was	O
significantly	O
stronger	O
in	O
the	O
WT	O
group	O
than	O
in	O
the	O
flKO	O
group	O
.	O
The	O
expression	O
of	O
podoplanin	O
was	O
detected	O
in	O
the	O
hepatic	B-T023
sinusoids	I-T023
of	O
both	O
groups	O
.	O
However	O
,	O
the	O
extent	O
to	O
which	O
platelets	O
accumulated	O
in	O
hepatic	B-T023
sinusoids	I-T023
was	O
significantly	O
less	O
in	O
the	O
flKO	O
group	O
than	O
in	O
the	O
WT	O
group	O
.	O
Conclusion	O
CLEC-2	O
was	O
involved	O
in	O
hepatic	O
regeneration	O
after	O
liver	B-T061
resection	I-T061
and	O
CLEC-2	O
-related	O
liver	O
regeneration	O
was	O
attributed	O
to	O
the	O
interaction	O
between	O
platelets	O
and	O
sinusoidal	O
endothelial	O
cells	O
.	O
      
Neural	O
correlates	O
of	O
experimental	O
trauma	O
memory	O
retrieval	O
Traumatic	O
memories	O
such	O
as	O
intrusions	O
and	O
flashbacks	B-T033
play	O
a	O
major	O
role	O
in	O
the	O
development	O
and	O
maintenance	O
of	O
post	B-T048
-	I-T048
traumatic	I-T048
stress	I-T048
disorder	I-T048
(	O
PTSD	B-T048
)	O
.	O
A	O
thorough	O
understanding	O
of	O
the	O
neural	O
mechanisms	O
underlying	O
traumatic	O
memories	O
is	O
indispensable	O
for	O
precise	O
diagnosis	B-T033
,	O
for	O
personalized	O
treatment	B-T061
and	O
prevention	B-T061
.	O
In	O
particular	O
,	O
the	O
identification	O
of	O
early	O
neural	O
predictor	O
variables	O
for	O
intrusion	O
development	O
shortly	O
after	O
trauma	O
exposure	O
requires	O
detailed	O
investigation	B-T058
.	O
Here	O
,	O
we	O
examined	B-T033
the	O
neural	O
correlates	O
of	O
early	O
experimental	O
trauma	O
memory	O
retrieval	O
in	O
a	O
traumatic	O
film	O
paradigm	O
in	O
42	O
young	O
healthy	O
females	O
,	O
using	O
both	O
implicit	B-T033
and	O
explicit	O
retrieval	O
tasks	O
.	O
We	O
show	O
that	O
implicit	B-T033
experimental	O
trauma	O
retrieval	O
specifically	O
involved	O
the	O
retrosplenial	B-T023
cortex	I-T023
and	O
the	O
anterior	B-T023
cingulate	I-T023
cortex	I-T023
(	O
ACC	B-T023
)	O
,	O
while	O
both	O
retrieval	O
tasks	O
resulted	O
in	O
trauma	B-T033
-	I-T033
related	I-T033
activity	O
in	O
the	O
posterior	B-T023
cingulate	I-T023
cortex	I-T023
(	O
PCC	B-T023
)	O
and	O
the	O
precuneus	B-T023
.	O
Importantly	O
,	O
neural	O
activity	O
early	O
after	O
experimental	O
trauma	O
exposure	O
predicted	O
later	O
intrusion	O
development	O
,	O
with	O
independent	O
contributions	O
from	O
activity	O
in	O
the	O
retrosplenial	B-T023
cortex	I-T023
(	O
implicit	B-T033
retrieval	O
)	O
and	O
the	O
PCC	B-T023
(	O
explicit	O
retrieval	O
)	O
.	O
Additional	O
analyses	O
revealed	O
a	O
stronger	O
connectivity	O
between	O
the	O
bilateral	B-T023
amygdala	I-T023
and	O
the	O
supplementary	O
motor	O
area	O
,	O
precentral	B-T023
and	O
paracentral	B-T023
lobule	I-T023
for	O
the	O
control	O
group	O
compared	O
to	O
the	O
experimental	O
trauma	O
group	O
.	O
Our	O
study	O
gives	O
new	O
insights	O
in	O
the	O
neural	O
correlates	O
of	O
experimental	O
trauma	O
memory	O
retrieval	O
and	O
their	O
predictive	O
value	O
for	O
subsequent	O
symptom	B-T184
development	O
.	O
Our	O
results	O
could	O
provide	O
the	O
basis	O
for	O
personalized	O
early	O
treatment	O
and	O
prevention	O
of	O
PTSD	B-T048
.	O
Hum	O
Brain	O
Mapp	O
,	O
2017	O
.	O
©	O
2017	O
Wiley	O
Periodicals	O
,	O
Inc.	O
      
In	O
Vitro	O
Differentiation	O
of	O
Human	O
Pluripotent	O
Stem	O
Cells	O
into	O
Trophoblastic	O
Cells	O
The	O
placenta	B-T018
is	O
the	O
first	O
organ	B-T023
to	O
develop	O
during	O
embryogenesis	O
and	O
is	O
required	O
for	O
the	O
survival	O
of	O
the	O
developing	O
embryo	B-T018
.	O
The	O
placenta	B-T018
is	O
comprised	O
of	O
various	O
trophoblastic	O
cells	O
that	O
differentiate	O
from	O
the	O
extra	O
-	O
embryonic	O
trophectoderm	O
cells	O
of	O
the	O
preimplantation	O
blastocyst	B-T018
.	O
As	O
such	O
,	O
our	O
understanding	O
of	O
the	O
early	O
differentiation	O
events	O
of	O
the	O
human	O
placenta	B-T018
is	O
limited	O
because	O
of	O
ethical	O
and	O
legal	O
restrictions	O
on	O
the	O
isolation	B-T061
and	O
manipulation	B-T061
of	O
human	O
embryogenesis	O
.	O
Human	O
pluripotent	O
stem	O
cells	O
(	O
hPSCs	O
)	O
are	O
a	O
robust	O
model	O
system	O
for	O
investigating	O
human	O
development	O
and	O
can	O
also	O
be	O
differentiated	O
in	O
vitro	O
into	O
trophoblastic	O
cells	O
that	O
express	O
markers	O
of	O
the	O
various	O
trophoblast	O
cell	O
types	O
.	O
Here	O
,	O
we	O
present	O
a	O
detailed	O
protocol	O
for	O
differentiating	O
hPSCs	O
into	O
trophoblastic	O
cells	O
using	O
bone	O
morphogenic	O
protein	O
4	O
and	O
inhibitors	O
of	O
the	O
Activin	O
/	O
Nodal	O
signaling	O
pathways	O
.	O
This	O
protocol	O
generates	O
various	O
trophoblast	O
cell	O
types	O
that	O
can	O
be	O
transfected	O
with	O
siRNAs	O
for	O
investigating	O
loss	O
-	O
of	O
-	O
function	O
phenotypes	O
or	O
can	O
be	O
infected	B-T033
with	O
pathogens	B-T001
.	O
Additionally	O
,	O
hPSCs	O
can	O
be	O
genetically	O
modified	O
and	O
then	O
differentiated	O
into	O
trophoblast	B-T018
progenitors	O
for	O
gain	O
-	O
of	O
-	O
function	O
analyses	O
.	O
This	O
in	O
vitro	O
differentiation	O
method	O
for	O
generating	O
human	O
trophoblasts	B-T018
starting	O
from	O
hPSCs	O
overcomes	O
the	O
ethical	O
and	O
legal	O
restrictions	O
of	O
working	O
with	O
early	O
human	O
embryos	B-T018
,	O
and	O
this	O
system	O
can	O
be	O
used	O
for	O
a	O
variety	O
of	O
applications	O
,	O
including	O
drug	O
discovery	O
and	O
stem	O
cell	O
research	O
.	O
      
Tooth	B-T033
Discoloration	I-T033
Resulting	O
from	O
a	O
Nano	O
Zinc	O
Oxide	O
-	O
Eugenol	O
Sealer	O
A	O
desirable	O
quality	O
of	O
any	O
endodontic	O
sealer	O
is	O
its	O
ability	O
to	O
be	O
tooth	B-T033
color	I-T033
friendly	O
.	O
Therefore	O
the	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
tooth	B-T033
discoloration	I-T033
potential	O
of	O
a	O
nano	O
zinc	O
oxide	O
-	O
eugenol	O
(	O
NZOE	O
)	O
sealer	O
.	O
In	O
order	O
to	O
evaluate	O
tooth	B-T033
discoloration	I-T033
,	O
the	O
pulp	O
chamber	O
of	O
60	O
human	O
maxillary	B-T023
central	I-T023
and	O
lateral	B-T023
incisors	I-T023
were	O
filled	O
with	O
one	O
of	O
the	O
sealers	O
,	O
naming	O
AH-26	O
(	O
resin	O
-	O
based	O
sealer	O
)	O
,	O
Pulpdent	O
sealer	O
(	O
ZOE	O
-based	O
)	O
and	O
a	O
NZOE	O
experimental	O
sealer	O
.	O
Color	O
measurements	O
was	O
assessed	O
at	O
the	O
baseline	O
(	O
before	O
placement	O
of	O
sealers	O
)	O
(	O
T0	O
)	O
,	O
24	O
h	O
(	O
T1	O
)	O
and	O
72	O
h	O
(	O
T2	O
)	O
h	O
,	O
1-	O
week	O
(	O
T3	O
)	O
,	O
and	O
1-	O
month	O
(	O
T4	O
)	O
after	O
the	O
placement	O
of	O
sealers	O
using	O
the	O
Easy	O
Shade	O
spectrophotometer	O
.	O
Data	O
were	O
analyzed	O
in	O
SPSS	O
software	O
using	O
one	O
-	O
way	O
ANOVA	O
,	O
and	O
repeated	O
measured	O
ANOVA	O
.	O
No	O
significant	O
differences	O
were	O
observed	O
when	O
the	O
paired	O
comparison	O
test	O
was	O
performed	O
(	O
P>0.05	O
)	O
.	O
The	O
tested	O
NZOE	O
sealer	O
had	O
similar	O
tooth	B-T033
discoloration	I-T033
potential	O
in	O
comparison	O
with	O
AH-26	O
and	O
ZOE	O
sealer	O
.	O
      
Relationship	O
between	O
LRRK2	O
R1628P	O
polymorphism	O
and	O
Parkinson	B-T047
's	I-T047
disease	I-T047
in	O
Asian	O
populations	O
Although	O
the	O
leucine	O
-	O
rich	O
repeat	O
kinase	O
2	O
(	O
LRRK2	O
)	O
R1628P	O
polymorphism	O
has	O
been	O
associated	O
with	O
the	O
risk	O
of	O
Parkinson	B-T047
's	I-T047
disease	I-T047
(	O
PD	B-T047
)	O
in	O
Taiwan	O
,	O
China	O
,	O
and	O
Singapore	O
,	O
there	O
are	O
conflicting	O
findings	O
regarding	O
this	O
relationship	O
.	O
Thus	O
,	O
the	O
aim	O
of	O
the	O
present	O
meta	O
-	O
analysis	O
was	O
to	O
evaluate	O
the	O
associations	O
between	O
the	O
LRRK2	O
R1628P	O
polymorphism	O
(	O
rs33949390	O
)	O
and	O
PD	B-T047
in	O
Asian	O
populations	O
.	O
A	O
search	O
for	O
eligible	O
studies	O
was	O
performed	O
in	O
PubMed	O
,	O
Embase	O
,	O
SinoMed	O
,	O
and	O
the	O
China	O
Knowledge	O
Resource	O
Integrated	O
Database	O
,	O
and	O
pooled	O
odds	O
ratios	O
and	O
95	O
%	O
confidence	O
intervals	O
were	O
used	O
to	O
evaluate	O
the	O
strength	O
of	O
the	O
association	O
between	O
the	O
R1628P	O
polymorphism	O
and	O
PD	B-T047
.	O
This	O
meta	O
-	O
analysis	O
assessed	O
19	O
studies	O
from	O
14	O
papers	O
that	O
involved	O
a	O
total	O
of	O
9,927	O
PD	B-T047
patients	O
and	O
8,602	O
controls	O
and	O
found	O
that	O
the	O
R1628P	O
polymorphism	O
was	O
significantly	O
associated	O
with	O
the	O
risk	O
of	O
PD	B-T047
in	O
Asian	O
populations	O
.	O
Moreover	O
,	O
stratification	O
analyses	O
indicated	O
that	O
the	O
R1628P	O
polymorphism	O
was	O
significantly	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
PD	B-T047
among	O
Chinese	O
as	O
well	O
as	O
non	O
-	O
Chinese	O
Asian	O
populations	O
and	O
an	O
increased	O
risk	O
of	O
PD	B-T047
in	O
Chinese	O
patients	O
from	O
China	O
,	O
Taiwan	O
,	O
and	O
Singapore	O
.	O
In	O
a	O
stratified	O
analysis	O
conducted	O
according	O
to	O
age	O
,	O
significant	O
associations	O
were	O
found	O
for	O
both	O
late	O
-	O
onset	O
PD	B-T047
and	O
early	O
-	O
onset	O
PD	B-T047
.	O
The	O
present	O
data	O
indicate	O
that	O
the	O
R1628P	O
polymorphism	O
of	O
the	O
LRRK2	O
gene	O
contributes	O
to	O
PD	B-T047
susceptibility	O
in	O
Asian	O
,	O
especially	O
Chinese	O
,	O
populations	O
.	O
      
The	O
Usefulness	O
of	O
Employing	B-T033
an	O
Electronic	O
Traction	O
Table	O
to	O
Determine	O
Flexibility	O
in	O
Adolescent	B-T190
Idiopathic	I-T190
Scoliosis	I-T190
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
develop	O
new	O
equipment	O
for	O
the	O
assessment	B-T058
of	O
the	O
flexibility	O
of	O
the	O
spine	B-T023
with	O
different	O
forces	O
.	O
This	O
new	O
system	O
should	O
provide	O
a	O
different	O
perspective	O
to	O
adolescent	B-T190
idiopathic	I-T190
scoliosis	I-T190
(	O
AIS	B-T190
)	O
for	O
the	O
selection	O
of	O
fusion	O
levels	O
and	O
surgical	B-T061
success	O
.	O
Eighteen	O
patients	O
suffering	O
from	O
AIS	B-T190
who	O
were	O
scheduled	O
to	O
undergo	O
posterior	O
instrumented	B-T061
spinal	I-T061
fusion	I-T061
in	O
our	O
clinic	O
were	O
recruited	O
in	O
this	O
study	O
.	O
The	O
Electronic	O
Traction	O
Table	O
(	O
ETT	O
)	O
that	O
was	O
designed	O
in	O
our	O
clinic	O
was	O
used	O
to	O
evaluate	O
the	O
radiogical	O
and	O
clinical	O
parameters	O
of	O
the	O
spine	B-T023
.	O
The	O
significant	O
prescriptive	O
angle	O
of	O
major	O
Cobb	B-T033
angles	I-T033
between	O
postoperative	O
angles	O
were	O
longitudinal	O
traction	B-T061
and	O
lateral	B-T033
pushing	I-T033
Cobb	I-T033
angles	I-T033
.	O
Longitudinal	O
traction	B-T061
and	O
lateral	B-T033
pushing	I-T033
angles	I-T033
were	O
more	O
correlated	O
with	O
correction	O
ratios	O
.	O
There	O
was	O
a	O
significant	O
difference	O
between	O
longitudinal	O
traction	B-T061
minor	O
Cobb	B-T033
angle	I-T033
,	O
longitudinal	O
traction	B-T061
lateral	B-T033
pushing	I-T033
minor	I-T033
Cobb	I-T033
angle	I-T033
and	O
postoperative	B-T033
minor	I-T033
Cobb	I-T033
angles	I-T033
.	O
The	O
deformity	B-T190
is	O
needed	O
to	O
balance	O
both	O
tractional	B-T061
and	O
rotational	O
forces	O
and	O
useful	O
technique	O
to	O
evaluate	O
curve	O
flexibility	O
before	O
the	O
operation	B-T061
.	O
Electronic	O
traction	O
table	O
is	O
a	O
new	O
device	O
for	O
determining	O
preoperative	O
flexibility	O
with	O
longitudinal	O
traction	B-T061
and	O
lateral	B-T060
pushing	I-T060
radiographs	I-T060
.	O
It	O
can	O
be	O
useful	O
for	O
choosing	O
selective	O
fusion	O
levels	O
at	O
the	O
proximal	O
and	O
distal	O
end	O
of	O
the	O
vertebral	B-T023
column	I-T023
.	O
      
Evaluating	O
clinical	O
,	O
dietary	O
and	O
psychological	O
risk	B-T033
factors	I-T033
for	O
relapse	O
of	O
ulcerative	B-T047
colitis	I-T047
in	O
clinical	O
,	O
endoscopic	O
and	O
histological	O
remission	O
The	O
literature	O
on	O
possible	O
factors	O
that	O
could	O
trigger	O
a	O
relapse	O
in	O
patients	O
with	O
ulcerative	B-T047
colitis	I-T047
(	O
UC	B-T047
)	O
in	O
clinical	O
,	O
endoscopic	O
and	O
histological	O
remission	O
on	O
long	O
term	O
follow	B-T058
up	I-T058
is	O
scarce	O
.	O
To	O
determine	O
the	O
relapse	O
rate	O
in	O
patients	O
with	O
UC	B-T047
in	O
clinical	O
,	O
endoscopic	O
and	O
histological	O
remission	O
and	O
identify	O
factors	O
that	O
may	O
influence	O
the	O
risk	O
of	O
relapse	O
.	O
Patients	O
with	O
UC	B-T047
in	O
clinical	O
,	O
endoscopic	O
and	O
histological	O
remission	O
were	O
enrolled	O
between	O
January	O
-	O
July	O
2010	O
and	O
followed	B-T058
up	I-T058
for	O
1	O
year	O
to	O
determine	O
the	O
effect	O
of	O
clinical	O
,	O
dietary	O
and	O
psychological	O
factors	B-T033
on	O
relapse	O
.	O
Information	O
regarding	O
factors	O
that	O
may	O
affect	O
relapse	O
such	O
as	O
infection	O
,	O
antibiotic	B-T195
or	O
NSAIDs	B-T121
use	O
and	O
any	O
other	O
factor	O
which	O
the	O
patient	O
felt	O
important	O
,	O
and	O
compliance	O
with	O
medications	B-T058
was	O
obtained	O
.	O
97	O
patients	O
(	O
59	O
males	O
,	O
mean	O
age	O
39	O
+	O
11.9	O
years	O
)	O
were	O
followed	B-T058
up	I-T058
for	O
a	O
mean	O
duration	O
of	O
9	O
+	O
2.3	O
months	O
.	O
18(18.6	O
%	O
)	O
relapsed	O
with	O
the	O
median	O
time	O
to	O
relapse	O
being	O
3.5	O
months	O
.	O
On	O
univariate	O
analysis	O
more	O
relapsers	O
had	O
significantly	O
higher	O
NSAIDs	B-T121
use	O
within	O
15	O
days	O
of	O
relapse	O
,	O
respiratory	B-T047
tract	I-T047
infection	I-T047
within	O
4	O
weeks	O
,	O
use	O
of	O
steroids	O
more	O
than	O
once	O
in	O
past	O
,	O
higher	O
consumption	O
of	O
calcium	B-T121
,	O
riboflavin	B-T121
,	O
vitamin	B-T121
A	I-T121
and	O
lower	O
consumption	O
of	O
sugars	B-T121
.	O
On	O
multivariate	O
analysis	O
,	O
NSAIDs	B-T121
use	O
[	O
HR(95%CI):6.41(1.88	O
-	O
21.9)]and	O
intake	O
of	O
Vitamin	B-T121
A	I-T121
[	O
HR(95%CI):1.008(1.000	O
-	O
1.016	O
)	O
]	O
were	O
statistically	O
significant	O
predictors	O
of	O
relapse	O
.	O
With	O
a	O
relapse	O
rate	O
of	O
18.6	O
%	O
over	O
a	O
follow	B-T058
up	I-T058
of	O
9	O
months	O
in	O
patients	O
with	O
UC	B-T047
in	O
clinical	O
,	O
endoscopic	O
and	O
histological	O
remission	O
,	O
independent	O
predictors	O
of	O
relapse	O
were	O
history	O
of	O
NSAIDs	B-T121
use	O
within	O
15	O
days	O
of	O
relapse	O
and	O
higher	O
intake	O
of	O
Vitamin	B-T121
A	I-T121
A.	O
      
Effect	O
of	O
Protein	O
Repetitiveness	O
on	O
Protein	O
-	O
Protein	O
Interaction	O
Prediction	O
Results	O
Using	O
Support	O
Vector	O
Machines	O
There	O
are	O
many	O
computational	O
approaches	O
to	O
predict	O
the	O
protein	O
-	O
protein	O
interactions	O
using	O
support	O
vector	O
machines	O
(	O
SVMs	O
)	O
with	O
high	O
performance	O
.	O
In	O
fact	O
,	O
performance	O
of	O
currently	O
reported	O
methods	O
are	O
significantly	O
over	O
-	O
estimated	O
and	O
affected	O
by	O
the	O
object	O
repetitiveness	O
in	O
the	O
datasets	O
used	O
.	O
To	O
study	O
the	O
effect	O
of	O
object	O
repetitiveness	O
of	O
datasets	O
on	O
predicting	O
results	O
.	O
We	O
present	O
novel	O
methods	O
to	O
construct	O
different	O
positive	B-T033
datasets	O
with	O
or	O
without	O
repeating	O
proteins	O
using	O
graph	O
maximum	O
matching	O
in	O
the	O
protein	O
-	O
protein	O
interaction	O
datasets	O
and	O
corresponding	O
series	O
of	O
negative	B-T033
datasets	O
with	O
different	O
proteins	O
repetitiveness	O
are	O
constructed	O
using	O
graph	O
adjacency	O
matrix	O
.	O
The	O
relationship	O
between	O
the	O
SVM	O
prediction	O
results	O
and	O
the	O
repeated	O
proteins	O
(	O
repeat	O
numbers	O
and	O
repeat	O
rates	O
)	O
and	O
the	O
distributions	O
of	O
repeated	O
proteins	O
in	O
the	O
datasets	O
are	O
analyzed	O
.	O
Protein	O
repetitiveness	O
of	O
positive	B-T033
and	O
negative	B-T033
datasets	O
can	O
affect	O
the	O
prediction	O
result	O
:	O
high	O
protein	O
repetitiveness	O
of	O
positive	B-T033
or	O
negative	B-T033
datasets	O
yield	O
high	O
performance	O
prediction	O
result	O
.	O
This	O
indicate	O
that	O
dealing	O
with	O
object	O
repetitiveness	O
of	O
datasets	O
is	O
a	O
key	O
issue	O
in	O
protein	O
-	O
protein	O
interactions	O
prediction	O
using	O
SVMs	O
since	O
real	O
world	O
data	O
contain	O
certain	O
degrees	O
of	O
repeat	O
proteins	O
.	O
      
Inducible	O
Expression	O
of	O
both	O
ermB	O
and	O
ermT	O
Conferred	O
High	O
Macrolide	B-T033
Resistance	I-T033
in	O
Streptococcus	B-T007
gallolyticus	I-T007
subsp	I-T007
.	I-T007
pasteurianus	I-T007
Isolates	B-T001
in	O
China	O
Streptococcus	B-T007
gallolyticus	I-T007
subsp	I-T007
.	I-T007
pasteurianus	I-T007
is	O
an	O
under	O
-	O
recognized	O
pathogen	B-T001
and	O
zoonotic	B-T007
agent	I-T007
causing	O
opportunistic	B-T047
infections	I-T047
in	O
humans	O
.	O
Despite	O
increasing	O
recognition	O
of	O
this	O
subspecies	B-T007
as	O
a	O
cause	O
for	O
human	O
infectious	B-T047
diseases	I-T047
,	O
limited	O
information	O
is	O
known	O
about	O
its	O
antibiotic	O
resistance	O
mechanism	O
.	O
In	O
this	O
study	O
,	O
we	O
aim	O
to	O
identify	O
the	O
molecular	O
mechanism	O
underlying	O
the	O
high	O
macrolide	B-T033
resistance	I-T033
of	O
six	O
S.	B-T007
gallolyticus	I-T007
subsp	I-T007
.	I-T007
pasteurianus	I-T007
isolates	B-T001
from	O
dead	B-T033
ducklings	O
collected	O
in	O
several	O
natural	O
outbreaks	O
in	O
China	O
during	O
2010	O
-	O
2013	O
.	O
All	O
isolates	B-T001
exhibited	O
multi	O
-	O
drug	O
resistance	O
including	O
high	O
macrolide	B-T033
resistance	I-T033
(	O
MIC	O
≥	O
1024	O
mg	O
/	O
L	O
for	O
erythromycin	B-T195
,	O
and	O
512	O
mg	O
/	O
L	O
for	O
clarithromycin	B-T195
)	O
.	O
Efflux	O
-	O
encoding	O
mefA	O
and	O
mefE	O
genes	O
were	O
not	O
detectable	O
in	O
these	O
isolates	B-T001
.	O
The	O
presence	O
of	O
23S	O
rRNA	O
mutations	O
in	O
specific	O
isolates	B-T001
did	O
not	O
significantly	O
change	O
macrolide	B-T121
MIC	O
s.	O
No	O
nucleotide	O
substitutions	O
were	O
found	O
in	O
genes	O
encoding	O
ribosomal	O
proteins	O
L4	O
or	O
L22	O
.	O
The	O
ermB	O
and	O
ermT	O
genes	O
were	O
found	O
in	O
the	O
genomes	O
of	O
all	O
isolates	B-T001
.	O
These	O
two	O
genes	O
were	O
acquired	O
independently	O
in	O
one	O
highly	O
virulent	B-T001
isolate	I-T001
AL101002	I-T001
,	O
and	O
clustered	O
with	O
Tn916	B-T001
and	O
IS1216	B-T001
,	O
respectively	O
.	O
The	O
expression	O
of	O
both	O
ermB	O
and	O
ermT	O
in	O
all	O
isolates	B-T001
was	O
erythromycin	B-T195
inducible	O
and	O
yielded	O
comparable	O
macrolide	B-T121
MICs	O
in	O
all	O
six	O
isolates	B-T001
.	O
Taken	O
together	O
,	O
inducible	O
expression	O
of	O
both	O
ermB	O
and	O
ermT	O
conferred	O
high	O
macrolide	B-T033
resistance	I-T033
in	O
these	O
S.	B-T007
gallolyticus	I-T007
subsp	I-T007
.	I-T007
pasterianus	I-T007
isolates	B-T001
.	O
Our	O
findings	B-T033
reveal	O
new	O
macrolide	B-T033
resistance	I-T033
features	O
in	O
S.	B-T007
gallolyticus	I-T007
subsp	I-T007
.	I-T007
pasteurianus	I-T007
by	O
both	O
ermB	O
and	O
ermT.	O
      
Human	O
amnion	B-T018
epithelial	O
cells	O
rescue	O
cell	O
death	O
via	O
immunomodulation	B-T061
of	O
microglia	O
in	O
a	O
mouse	B-T050
model	I-T050
of	O
perinatal	O
brain	O
injury	O
Human	O
amnion	B-T018
epithelial	O
cells	O
(	O
hAECs	O
)	O
are	O
clonogenic	O
and	O
have	O
been	O
proposed	O
to	O
reduce	O
inflammatory	O
-	O
induced	O
tissue	O
injury	O
.	O
Perturbation	O
of	O
the	O
immune	O
response	O
is	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
perinatal	O
brain	O
injury	O
;	O
modulating	O
this	O
response	O
could	O
thus	O
be	O
a	O
novel	O
therapy	B-T061
for	O
treating	O
or	O
preventing	O
such	O
injury	O
.	O
The	O
immunomodulatory	B-T061
properties	O
of	O
hAECs	O
have	O
been	O
shown	O
in	O
other	O
animal	O
models	O
,	O
but	O
a	O
detailed	O
investigation	B-T058
of	O
the	O
effects	O
on	O
brain	B-T023
immune	O
cells	O
following	O
injury	O
has	O
not	O
been	O
undertaken	O
.	O
Here	O
,	O
we	O
investigate	B-T058
the	O
effects	O
of	O
hAECs	O
on	O
microglia	O
,	O
the	O
first	O
immune	O
responders	O
to	O
injury	O
within	O
the	O
brain	B-T023
.	O
We	O
generated	O
a	O
mouse	B-T050
model	I-T050
combining	O
neonatal	O
inflammation	O
and	O
perinatal	O
hyperoxia	B-T184
,	O
both	O
of	O
which	O
are	O
risk	B-T033
factors	I-T033
associated	O
with	O
perinatal	O
brain	O
injury	O
.	O
On	O
embryonic	O
day	O
16	O
we	O
administered	B-T061
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
or	O
saline	O
(	O
control	O
)	O
,	O
intra	O
-	O
amniotically	O
to	O
C57Bl/6	O
J	O
mouse	O
pups	O
.	O
On	O
postnatal	O
day	O
(	O
P)0	O
,	O
LPS	O
pups	O
were	O
placed	O
in	O
hyperoxia	B-T184
(	O
65	O
%	O
oxygen	B-T121
)	O
and	O
control	O
pups	O
in	O
normoxia	O
for	O
14	O
days	O
.	O
Pups	O
were	O
given	O
either	O
hAECs	O
or	O
saline	O
intravenously	B-T061
on	O
P4	O
.	O
At	O
P14	O
,	O
relative	O
to	O
controls	O
,	O
LPS	O
and	O
hyperoxia	B-T184
pups	O
had	O
reduced	O
body	O
weight	O
,	O
increased	O
density	O
of	O
apoptotic	O
cells	O
(	O
TUNEL	O
)	O
in	O
the	O
cortex	B-T023
,	O
striatum	B-T023
and	O
white	O
matter	O
,	O
astrocytes	O
(	O
GFAP	O
)	O
in	O
the	O
white	O
matter	O
and	O
activated	O
microglia	O
(	O
CD68	O
)	O
in	O
the	O
cortex	B-T023
and	O
striatum	B-T023
,	O
but	O
no	O
change	O
in	O
total	O
microglia	O
density	O
(	O
Iba1	O
)	O
.	O
hAEC	O
administration	B-T061
rescued	O
the	O
decreased	O
body	O
weight	O
and	O
reduced	O
apoptosis	O
and	O
astrocyte	O
areal	O
coverage	O
in	O
the	O
white	O
matter	O
,	O
but	O
increased	O
the	O
density	O
of	O
total	O
and	O
activated	O
microglia	O
.	O
We	O
then	O
stimulated	O
primary	O
microglia	O
(	O
CD45	O
(	O
low	O
)	O
CD11b	O
(	O
+	O
)	O
)	O
with	O
LPS	O
for	O
24	O
h	O
,	O
followed	O
by	O
co	B-T059
-	I-T059
culture	I-T059
with	O
hAEC	O
conditioned	O
medium	O
for	O
48	O
h.	O
hAEC	O
conditioned	O
medium	O
increased	O
microglial	O
phagocytic	O
activity	O
,	O
decreased	O
microglia	O
apoptosis	O
and	O
decreased	O
M1	O
activation	O
markers	O
(	O
CD86	O
)	O
.	O
Stimulating	O
hAECs	O
for	O
24	O
h	O
with	O
LPS	O
did	O
not	O
alter	O
release	B-T061
of	O
cytokines	O
known	O
to	O
modulate	O
microglia	O
activity	O
.	O
These	O
data	O
demonstrate	O
that	O
hAECs	O
can	O
directly	O
immunomodulate	B-T061
brain	B-T023
microglia	O
,	O
probably	O
via	O
release	B-T061
of	O
trophic	O
factors	O
.	O
This	O
observation	O
offers	O
promise	O
that	O
hAECs	O
may	O
afford	O
therapeutic	B-T061
utility	I-T061
in	O
the	O
management	B-T058
of	O
perinatal	O
brain	O
injury	O
.	O
      
Optimizing	O
Survival	O
of	O
Patients	O
With	O
Marginally	O
Operable	O
Stage	B-T191
IIIA	I-T191
Non	I-T191
-	I-T191
Small	I-T191
-	I-T191
Cell	I-T191
Lung	I-T191
Cancer	I-T191
Receiving	O
Chemoradiotherapy	B-T061
With	O
or	O
Without	O
Surgery	O
For	O
marginally	O
operable	O
stage	B-T191
IIIA	I-T191
non	I-T191
-	I-T191
small	I-T191
-	I-T191
cell	I-T191
lung	I-T191
cancer	I-T191
(	O
NSCLC	B-T191
)	O
,	O
surgery	O
might	O
not	O
be	O
done	O
as	O
planned	O
after	O
neoadjuvant	B-T061
concurrent	B-T061
chemoradiotherapy	I-T061
(	O
CCRT	B-T061
)	O
for	O
reasons	O
(	O
unresectable	O
or	O
medically	O
inoperable	O
conditions	O
,	O
or	O
patient	O
refusal	O
)	O
.	O
This	O
study	O
aims	O
to	O
investigate	O
the	O
outcomes	O
of	O
a	O
phased	B-T061
CCRT	I-T061
protocol	I-T061
established	O
to	O
maximize	O
the	O
operability	O
of	O
marginally	O
operable	O
stage	B-T191
IIIA	I-T191
NSCLC	I-T191
and	O
to	O
care	O
for	O
reassessed	O
inoperable	O
patients	O
,	O
in	O
comparison	O
with	O
continuous	B-T061
-	I-T061
course	I-T061
definitive	I-T061
CCRT	I-T061
.	O
Forty	O
-	O
seven	O
patients	O
with	O
marginally	O
operable	O
stage	B-T191
IIIA	I-T191
NSCLC	I-T191
receiving	O
CCRT	B-T061
were	O
included	O
.	O
Twenty	O
-	O
eight	O
patients	O
were	O
treated	O
with	O
our	O
phased	B-T061
CCRT	I-T061
protocol	I-T061
,	O
including	O
neoadjuvant	B-T061
CCRT	B-T061
followed	O
by	O
surgery	O
(	O
group	O
A	O
,	O
n	O
=	O
16	O
)	O
or	O
,	O
for	O
reassessed	O
inoperable	O
patients	O
,	O
maintenance	B-T033
chemotherapy	I-T033
and	O
split	B-T061
-	I-T061
course	I-T061
CCRT	I-T061
boost	O
(	O
group	O
B	O
,	O
n	O
=	O
12	O
)	O
.	O
The	O
other	O
19	O
were	O
treated	O
with	O
continuous	B-T061
-	I-T061
course	I-T061
definitive	I-T061
CCRT	I-T061
(	O
group	O
C	O
)	O
.	O
Overall	O
survival	O
(	O
OS	O
)	O
and	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
were	O
analyzed	O
.	O
Among	O
all	O
,	O
median	O
OS	O
and	O
PFS	O
were	O
35.6	O
and	O
12.8	O
months	O
,	O
respectively	O
(	O
median	O
follow	B-T058
-	I-T058
up	I-T058
,	O
22.3	O
months	O
)	O
.	O
The	O
median	O
OS	O
of	O
group	O
A	O
(	O
not	O
reached	O
)	O
was	O
better	O
than	O
that	O
of	O
group	O
B	O
(	O
34.4	O
months	O
)	O
and	O
group	O
C	O
(	O
15.2	O
months	O
)	O
(	O
P	O
=	O
.009	O
)	O
.	O
On	O
multivariate	O
analysis	O
,	O
performance	O
status	O
0	O
to	O
1	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
,	O
0.026	O
;	O
P	O
<	O
.001	O
)	O
,	O
adenocarcinoma	B-T191
(	O
HR	O
,	O
0.156	O
;	O
P	O
=	O
.003	O
)	O
,	O
and	O
group	O
A	O
(	O
HR	O
,	O
0.199	O
;	O
P	O
=	O
.033	O
)	O
were	O
independent	O
prognostic	O
factors	O
.	O
The	O
OS	O
of	O
group	O
B	O
(	O
HR	O
,	O
0.450	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
0.118	O
-	O
1.717	O
;	O
P	O
=	O
.243	O
)	O
was	O
not	O
statistically	O
different	O
from	O
that	O
of	O
group	O
C.	O
For	O
marginally	O
operable	O
stage	B-T191
IIIA	I-T191
NSCLC	I-T191
,	O
our	O
phased	B-T061
CCRT	I-T061
strategy	I-T061
may	O
optimize	O
survival	O
by	O
maximizing	O
operability	O
and	O
maintain	O
an	O
acceptable	O
survival	O
for	O
reassessed	O
inoperable	O
patients	O
by	O
split	B-T061
-	I-T061
course	I-T061
CCRT	I-T061
boost	O
following	O
maintenance	B-T033
chemotherapy	I-T033
.	O
      
Normal	O
Levels	O
of	O
Urinary	O
CC16	B-T121
Protein	I-T121
.	O
Comments	O
on	O
Beamer	O
et	O
al	O
.	O
Association	O
of	O
Children	O
's	O
Urinary	O
CC16	B-T121
Levels	B-T059
with	O
Arsenic	B-T059
Concentrations	I-T059
in	O
Multiple	O
Environmental	O
Media	O
.	O
Int	O
.	O
J.	O
Environ	O
.	O
Res	O
.	O
Public	O
Health	O
2016	O
,	O
13	O
,	O
521	O
In	O
1937	O
,	O
Max	O
Clara	O
described	O
a	O
new	O
type	O
of	O
cell	O
in	O
the	O
human	O
lung	B-T023
,	O
which	O
was	O
later	O
determined	O
to	O
be	O
an	O
exocrine	O
secretory	O
cell	O
type	O
containing	O
granules	O
composed	O
of	O
proteins	O
[	O
1	O
]	O
.	O
[	O
...	O
]	O
.	O
      
Work	O
process	O
,	O
performance	B-T033
and	O
professional	O
profile	O
of	O
a	O
Hearing	B-T058
Health	I-T058
Network	I-T058
:	O
reference	O
for	O
satisfaction	O
To	O
analyze	O
the	O
correlation	O
between	O
the	O
satisfaction	O
of	O
professionals	O
from	O
the	O
Hearing	B-T058
Health	I-T058
Care	I-T058
network	I-T058
in	O
two	O
micro	O
-	O
regions	O
of	O
Minas	O
Gerais	O
state	O
and	O
the	O
sociodemographic	O
profile	O
,	O
work	O
process	O
,	O
and	O
work	B-T033
performance	I-T033
in	O
the	O
health	B-T058
service	I-T058
.	O
This	O
is	O
a	O
cross	O
-	O
sectional	O
,	O
observational	O
,	O
analytic	O
study	O
with	O
a	O
non	O
-	O
probabilistic	O
sample	O
including	O
34	O
professionals	O
from	O
the	O
Hearing	B-T058
Health	I-T058
Care	I-T058
services	I-T058
.	O
Data	O
collection	O
occurred	O
through	O
individual	O
interviews	O
in	O
the	O
municipality	O
of	O
professional	O
practice	O
.	O
Associations	O
between	O
the	O
Professional	O
Satisfaction	O
variable	O
and	O
the	O
explanatory	O
variables	O
Sociodemographic	O
Data	O
,	O
Work	O
Routine	O
,	O
and	O
Developed	O
Actions	O
were	O
conducted	O
.	O
Professionals	O
with	O
graduate	O
studies	O
were	O
more	O
satisfied	O
with	O
the	O
human	O
resources	O
policy	O
and	O
the	O
activities	O
developed	O
,	O
whereas	O
health	B-T058
civil	O
servants	O
showed	O
more	O
satisfaction	O
with	O
the	O
wage	O
policy	O
and	O
the	O
work	O
schedule	O
.	O
The	O
correlation	O
analysis	O
between	O
work	O
process	O
and	O
satisfaction	O
revealed	O
a	O
moderate	O
positive	B-T033
correlation	O
between	O
items	O
such	O
as	O
Health	B-T058
Promotion	I-T058
Actions	O
,	O
Satisfaction	O
with	O
Diagnostic	O
Equipment	O
,	O
and	O
Satisfaction	O
with	O
Maintenance	B-T033
Equipment	I-T033
.	O
The	O
present	O
study	O
revealed	O
a	O
higher	O
level	O
of	O
satisfaction	O
among	O
professionals	O
with	O
graduate	O
studies	O
(	O
human	O
resources	O
policy	O
and	O
activities	O
developed	O
)	O
and	O
civil	O
servants	O
(	O
wage	O
policy	O
and	O
work	O
schedule	O
)	O
.	O
The	O
relevance	O
of	O
this	O
study	O
lies	O
on	O
the	O
important	O
role	O
that	O
health	O
professionals	O
play	O
on	O
the	O
Health	B-T058
Care	I-T058
Network	I-T058
.	O
Additionally	O
,	O
the	O
study	O
of	O
satisfaction	O
level	O
can	O
provide	O
a	O
search	O
for	O
improvements	O
,	O
considering	O
that	O
satisfied	O
professionals	O
not	O
only	O
improve	B-T033
service	O
quality	O
,	O
but	O
also	O
show	B-T033
greater	I-T033
creativity	I-T033
,	O
commitment	O
,	O
and	O
performance	B-T033
.	O
      
Interferon	O
gamma	O
and	O
interleukin	O
10	O
polymorphisms	O
in	O
Chinese	O
children	O
with	O
hemophagocytic	B-T047
lymphohistiocytosis	I-T047
The	O
aim	O
of	O
the	O
study	O
is	O
to	O
investigate	O
the	O
association	O
of	O
interferon	O
gamma	O
(	O
IFN	O
-	O
γ	O
)	O
and	O
interleukin-10	O
(	O
IL-10	O
)	O
gene	O
single	O
nucleotide	O
polymorphisms	O
with	O
the	O
susceptibility	O
of	O
hemophagocytic	B-T047
lymphohistiocytosis	I-T047
(	O
HLH	B-T047
)	O
in	O
Chinese	O
children	O
without	B-T033
known	I-T033
family	I-T033
history	I-T033
of	I-T033
HLH	B-T047
.	O
Forty	O
children	O
with	O
HLH	B-T047
and	O
160	O
age	O
-	O
and	O
gender	O
-matched	O
healthy	O
controls	O
from	O
Xuzhou	O
Children	O
's	O
Hospital	O
were	O
enrolled	O
in	O
the	O
study	O
.	O
Serum	O
IFN	B-T121
-	I-T121
γ	I-T121
and	O
IL-10	O
levels	O
were	O
measured	O
by	O
enzyme	B-T059
linked	I-T059
-	I-T059
immunosorbent	I-T059
assay	I-T059
.	O
Polymorphisms	O
of	O
the	O
IFN	O
-	O
γ	O
gene	O
at	O
position	O
+874	O
and	O
+2109	O
,	O
and	O
IL-10	O
at	O
position	O
-1082	O
were	O
analyzed	B-T033
by	O
allele	O
-	O
specific	O
PCR	O
.	O
Median	O
serum	O
concentrations	O
of	O
IFN	B-T121
-γ	I-T121
and	O
IL-10	O
were	O
significantly	O
higher	O
in	O
children	O
with	O
HLH	B-T047
compared	O
to	O
healthy	O
controls	O
.	O
The	O
frequencies	O
of	O
IFN	O
-	O
γ	O
+874	O
T	O
/	O
A	O
and	O
T	O
/	O
T	O
genotypes	O
,	O
as	O
well	O
as	O
T	O
allele	O
,	O
were	O
significantly	O
higher	O
in	O
the	O
HLH	B-T047
group	O
compared	O
with	O
those	O
in	O
the	O
control	O
group	O
.	O
The	O
frequencies	O
of	O
IL-10	O
-1082	O
G	O
/	O
A	O
genotype	O
and	O
G	O
allele	O
were	O
significantly	O
increased	O
in	O
HLH	B-T047
patients	O
compared	O
with	O
healthy	O
controls	O
.	O
No	B-T033
significant	I-T033
difference	B-T033
was	O
found	O
in	O
the	O
distribution	O
of	O
IFN	O
-	O
γ	O
+2109	O
G	O
/	O
A	O
genotypes	O
between	O
children	O
with	O
HLH	B-T047
and	O
controls	O
.	O
This	O
study	O
presents	B-T033
preliminary	O
evidence	O
for	O
the	O
association	O
between	O
IFN	O
+874	O
T	O
/	O
A	O
,	O
T	O
/	O
T	O
,	O
IL-10	O
-1082	O
A	O
/	O
G	O
genotypes	O
,	O
and	O
HLH	B-T047
susceptibility	O
in	O
Chinese	O
children	O
with	O
HLH	B-T047
.	O
      
A	O
Case	O
of	O
Koch	B-T047
's	I-T047
Spine	I-T047
Treated	O
with	O
Modified	O
Transpedicular	B-T061
Vertebral	I-T061
Curettage	I-T061
and	O
Posterior	O
Fixation	B-T061
:	O
A	O
Novel	O
Technique	O
Tuberculosis	B-T047
(	O
TB	B-T047
)	O
is	O
a	O
chronic	O
granulomatous	B-T047
infection	I-T047
caused	O
by	O
acid	B-T007
-	I-T007
fast	I-T007
mycobacterium	I-T007
tuberculosis	I-T007
bacilli	I-T007
.	O
Spinal	O
involvement	O
occurs	O
in	O
less	O
than	O
one	O
percent	O
of	O
TB	B-T047
.	O
Spinal	B-T047
TB	I-T047
(	O
Pott	B-T047
's	I-T047
disease	I-T047
)	O
accounts	O
for	O
50	O
%	O
of	O
skeletal	O
TB	O
.	O
Though	O
it	O
most	O
commonly	O
affects	O
the	O
thoracolumbar	O
junction	O
,	O
it	O
can	O
occur	O
at	O
any	O
level	O
of	O
the	O
spine	B-T023
.	O
Early	O
diagnosis	B-T033
and	O
treatment	B-T061
is	O
mandatory	O
in	O
order	O
to	O
avoid	O
neurological	O
complications	O
and	O
spinal	B-T190
deformity	I-T190
.	O
We	O
report	O
a	O
case	O
of	O
a	O
young	O
female	O
with	O
tuberculosis	B-T047
of	O
D12	O
-	O
L1	O
who	O
was	O
treated	O
with	O
posterior	O
decompression	B-T061
using	O
a	O
modified	O
transpedicular	B-T061
approach	I-T061
and	O
posterior	O
instrumentation	B-T061
with	O
a	O
successful	O
outcome	O
.	O
      
TREK-1	O
(	O
K2P2.1	O
)	O
K(+	O
)	O
channels	O
are	O
suppressed	O
in	O
patients	O
with	O
atrial	B-T047
fibrillation	I-T047
and	O
heart	B-T047
failure	I-T047
and	O
provide	O
therapeutic	O
targets	O
for	O
rhythm	O
control	O
Atrial	B-T047
fibrillation	I-T047
(	O
AF	B-T047
)	O
is	O
the	O
most	O
common	O
cardiac	B-T033
arrhythmia	I-T033
.	O
Concomitant	B-T047
heart	I-T047
failure	I-T047
(	O
HF	B-T047
)	O
poses	O
a	O
particular	O
therapeutic	O
challenge	B-T059
and	O
is	O
associated	O
with	O
prolonged	O
atrial	O
electrical	O
refractoriness	O
compared	O
with	O
non	B-T023
-	I-T023
failing	I-T023
hearts	I-T023
.	O
We	O
hypothesized	O
that	O
downregulation	O
of	O
atrial	O
repolarizing	O
TREK-1	O
(	O
K2P2.1	O
)	O
K(+	O
)	O
channels	O
contributes	O
to	O
electrical	O
remodeling	O
during	O
AF	B-T047
with	O
HF	B-T047
,	O
and	O
that	O
TREK-1	O
gene	O
transfer	O
would	O
provide	O
rhythm	O
control	O
via	O
normalization	O
of	O
atrial	B-T033
effective	I-T033
refractory	I-T033
periods	I-T033
in	O
this	O
AF	B-T047
subset	O
.	O
In	O
patients	O
with	O
chronic	B-T047
AF	I-T047
and	O
HF	B-T047
,	O
atrial	O
TREK-1	O
mRNA	O
levels	O
were	O
reduced	O
by	O
82	O
%	O
(	O
left	B-T023
atrium	I-T023
)	O
and	O
81	O
%	O
(	O
right	B-T023
atrium	I-T023
)	O
compared	O
with	O
sinus	B-T033
rhythm	I-T033
(	O
SR	B-T033
)	O
subjects	O
.	O
Human	O
findings	B-T033
were	O
recapitulated	O
in	O
a	O
porcine	O
model	O
of	O
atrial	B-T047
tachypacing	I-T047
-	I-T047
induced	I-T047
AF	I-T047
and	O
reduced	O
left	O
ventricular	O
function	O
.	O
TREK-1	O
mRNA	O
(	O
-66	O
%	O
)	O
and	O
protein	O
(	O
-61	O
%	O
)	O
was	O
suppressed	O
in	O
AF	B-T047
animals	O
at	O
14	O
-	O
day	O
follow	O
-	O
up	O
compared	O
with	O
SR	B-T033
controls	O
.	O
Downregulation	O
of	O
repolarizing	O
TREK-1	O
channels	O
was	O
associated	O
with	O
prolongation	O
of	O
atrial	B-T033
effective	I-T033
refractory	I-T033
periods	I-T033
versus	O
baseline	O
conditions	O
,	O
consistent	O
with	O
prior	O
observations	O
in	O
humans	O
with	O
HF	B-T047
.	O
In	O
a	O
preclinical	O
therapeutic	O
approach	O
,	O
pigs	O
were	O
randomized	O
to	O
either	O
atrial	B-T061
Ad	I-T061
-	I-T061
TREK-1	I-T061
gene	I-T061
therapy	I-T061
or	O
sham	B-T061
treatment	I-T061
.	O
Gene	O
transfer	O
effectively	O
increased	O
TREK-1	O
protein	O
levels	O
and	O
attenuated	O
atrial	B-T033
effective	I-T033
refractory	I-T033
period	I-T033
prolongation	O
in	O
the	O
porcine	O
AF	O
model	O
.	O
Ad	O
-	O
TREK-1	O
increased	O
the	O
SR	B-T033
prevalence	O
to	O
62	O
%	O
during	O
follow	O
-	O
up	O
in	O
AF	B-T047
animals	O
,	O
compared	O
to	O
35	O
%	O
in	O
the	O
untreated	O
AF	B-T047
group	O
.	O
In	O
conclusion	O
,	O
TREK-1	O
downregulation	O
and	O
rhythm	O
control	O
by	O
Ad	O
-	O
TREK-1	O
transfer	O
suggest	O
mechanistic	B-T061
and	I-T061
potential	I-T061
therapeutic	I-T061
significance	O
of	O
TREK-1	O
channels	O
in	O
a	O
subgroup	O
of	O
AF	B-T047
patients	O
with	O
HF	B-T047
and	O
prolonged	O
atrial	B-T033
effective	I-T033
refractory	I-T033
periods	I-T033
.	O
Functional	O
correction	O
of	O
ionic	O
remodeling	O
through	O
TREK-1	B-T061
gene	I-T061
therapy	I-T061
represents	O
a	O
novel	O
paradigm	O
to	O
optimize	O
and	O
specify	O
AF	B-T047
management	O
.	O
      
BORA	O
-dependent	O
PLK1	O
regulation	O
:	O
A	O
new	O
weapon	O
for	O
cancer	B-T061
therapy	I-T061
?	O
The	O
mitotic	O
kinase	O
polo	O
like	O
kinase	O
1	O
(	O
PLK1	O
)	O
is	O
overexpressed	O
in	O
many	O
cancers	O
and	O
its	O
inhibition	O
slows	O
down	O
proliferation	O
and	O
increases	O
apoptosis	O
in	O
cancer	O
cell	O
lines	O
.	O
Understanding	O
how	O
PLK1	O
is	O
activated	O
is	O
therefore	O
crucial	O
for	O
the	O
development	O
of	O
novel	O
PLK1	B-T121
inhibitors	I-T121
with	O
anticancer	B-T121
properties	I-T121
.	O
We	O
recently	O
identified	O
a	O
conserved	O
regulatory	O
loop	O
leading	O
to	O
PLK1	O
activation	O
that	O
involves	O
cyclin	O
-	O
dependent	O
kinase	O
1	O
(	O
CDK1	O
)	O
.	O
      
Catastrophic	O
expenditure	O
and	O
impoverishment	O
of	O
patients	O
affected	O
by	O
7	O
rare	B-T047
diseases	I-T047
in	O
China	O
China	O
is	O
actively	O
promoting	O
regulation	O
of	O
rare	B-T047
diseases	I-T047
,	O
rare	B-T047
disease	I-T047
and	O
orphan	B-T121
drugs	I-T121
have	O
been	O
formally	O
incorporated	O
into	O
the	O
national	O
planning	O
.	O
However	O
,	O
few	O
studies	O
have	O
been	O
done	O
to	O
evaluate	O
the	O
affordability	O
of	O
rare	B-T047
disease	I-T047
patients	O
in	O
China	O
.	O
This	O
study	O
aims	O
to	O
provide	O
policy	O
recommendations	O
for	O
the	O
establishment	O
of	O
social	O
security	O
mechanism	O
for	O
rare	B-T047
diseases	I-T047
in	O
China	O
,	O
so	O
as	O
to	O
address	O
the	O
problem	O
of	O
poverty	O
caused	O
by	O
these	O
diseases	B-T047
.	O
A	O
total	O
of	O
7	O
rare	B-T047
diseases	I-T047
were	O
selected	O
by	O
Delphi	O
method	O
.	O
Affordability	O
of	O
treatment	B-T061
for	O
the	O
7	O
rare	B-T047
diseases	I-T047
was	O
assessed	O
through	O
annual	O
per	O
capital	O
income	O
,	O
catastrophic	O
expenditure	O
and	O
impoverishment	O
expenditure	O
among	O
urban	O
and	O
rural	O
residents	O
in	O
China	O
.	O
Assessed	O
through	O
annual	O
per	O
capital	O
income	O
,	O
health	O
expenditure	O
for	O
the	O
7	O
rare	B-T047
diseases	I-T047
are	O
all	O
rather	O
high	O
.	O
The	O
highest	O
health	O
expenditure	O
is	O
equivalent	O
to	O
income	O
of	O
69.34	O
years	O
of	O
one	O
urban	O
resident	O
,	O
and	O
the	O
burden	O
is	O
heavier	O
for	O
rural	O
residents	O
.	O
Through	O
catastrophic	O
expenditure	O
assessment	O
,	O
proportions	O
of	O
the	O
population	O
experiencing	O
catastrophic	O
expenditure	O
caused	O
by	O
the	O
7	O
rare	B-T047
diseases	I-T047
are	O
all	O
under	O
0.167	O
‰.	O
However	O
,	O
once	O
one	O
is	O
ill	B-T184
and	O
taking	O
medications	O
,	O
he	O
will	O
suffer	O
from	O
catastrophic	O
health	O
expenditure	O
.	O
Through	O
impoverishment	O
expenditure	O
assessment	O
,	O
the	O
proportions	O
of	O
impoverishment	O
payment	O
are	O
low	O
among	O
both	O
urban	O
and	O
rural	O
residents	O
,	O
but	O
the	O
7	O
rare	B-T047
diseases	I-T047
could	O
lead	O
nearly	O
4.6	O
million	O
people	O
into	O
poverty	O
on	O
a	O
national	O
scale	O
.	O
The	O
affordability	O
of	O
treatment	B-T061
for	O
rare	B-T047
disease	I-T047
as	O
well	O
as	O
orphan	B-T121
drugs	I-T121
is	O
rather	O
poor	O
.	O
Residents	O
of	O
different	O
income	O
levels	O
all	O
have	O
difficulties	O
to	O
afford	O
the	O
treatment	B-T061
for	O
rare	B-T047
diseases	I-T047
,	O
so	O
poverty	O
caused	O
by	O
rare	B-T047
diseases	I-T047
is	O
quite	O
widespread	O
.	O
Therefore	O
,	O
social	O
security	O
mechanism	O
for	O
rare	B-T047
disease	I-T047
patients	O
should	O
be	O
established	O
and	O
specific	O
payment	O
pattern	O
for	O
orphan	B-T121
drugs	I-T121
should	O
be	O
set	O
up	O
.	O
      
Extracellular	O
vesicles	O
from	O
bone	O
marrow	O
derived	O
mesenchymal	O
stem	O
cells	O
protect	B-T033
against	O
murine	O
hepatic	O
ischemia	O
-	O
reperfusion	O
injury	O
Hepatic	O
ischemia	O
-	O
reperfusion	O
injury	O
(	O
IRI	O
)	O
and	O
associated	O
inflammation	O
contributes	O
to	O
liver	O
dysfunction	O
and	O
complications	O
after	O
liver	B-T061
surgery	I-T061
and	O
transplantation	B-T061
.	O
Mesenchymal	O
stem	O
cells	O
(	O
MSC	O
)	O
have	O
been	O
reported	O
to	O
reduce	O
hepatic	O
IRI	O
because	O
of	O
their	O
reparative	B-T058
immunomodulatory	B-T121
effects	O
in	O
injured	O
tissues	O
.	O
Recent	O
studies	O
have	O
highlighted	O
beneficial	O
effects	O
of	O
extracellular	O
vesicles	O
from	O
MSCs	O
(	O
MSC	O
-	O
EV	O
)	O
on	O
tissue	B-T033
injury	I-T033
.	O
The	O
effects	O
of	O
systemically	O
administered	O
mouse	O
bone	O
marrow	O
derived	O
MSC	O
-	O
EV	O
were	O
evaluated	O
in	O
an	O
experimental	O
murine	O
model	O
of	O
hepatic	O
IRI	O
induced	O
by	O
cross	O
clamping	O
the	O
hepatic	B-T023
artery	I-T023
and	O
portal	B-T023
vein	I-T023
for	O
90	O
minutes	O
followed	O
by	O
reperfusion	B-T061
for	O
periods	O
of	O
upto	O
6	O
hours	O
.	O
Compared	O
with	O
controls	O
,	O
intravenous	O
administration	O
of	O
MSC	O
-	O
EV	O
30	O
minutes	O
prior	O
to	O
IRI	O
dramatically	O
reduced	O
the	O
extent	O
of	O
tissue	O
necrosis	O
,	O
decreased	O
caspase-3	O
positive	O
and	O
apoptotic	O
cells	O
,	O
and	O
reduced	O
serum	O
aminotransferase	O
levels	O
.	O
MSC	O
-	O
EV	O
increased	O
hepatic	O
mRNA	O
expression	O
of	O
NACHT	O
,	O
LRR	O
and	O
PYD	O
domains	O
-	O
containing	O
protein	O
12	O
(	O
Nlrp12	O
)	O
,	O
and	O
the	O
chemokine	O
(	O
C	O
-	O
X	O
-	O
C	O
motif	O
)	O
ligand	O
1	O
(	O
CXCL1	O
)	O
,	O
and	O
reduced	O
mRNA	O
expression	O
of	O
several	O
inflammatory	O
cytokines	O
such	O
as	O
IL-6	O
during	O
IRI	O
.	O
MSC	O
-	O
EV	O
increased	O
cell	O
viability	O
and	O
suppressed	O
both	O
oxidative	O
injury	O
and	O
NF	O
-	O
κB	O
activity	O
in	O
AML12	O
murine	O
hepatocytes	O
in	O
vitro	O
.	O
In	O
conclusion	O
,	O
the	O
administration	B-T061
of	O
EV	O
derived	O
from	O
bone	O
marrow	O
derived	O
MSCs	O
may	O
ameliorate	B-T033
hepatic	O
IRI	O
by	O
reducing	O
hepatic	O
injury	O
through	O
modulation	O
of	O
the	O
inflammatory	O
response	O
.	O
This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O
All	O
rights	O
reserved	O
.	O
      
Membrane	O
Protein	O
Solubilization	O
and	O
Composition	O
of	O
Protein	O
Detergent	O
Complexes	O
Membrane	O
proteins	O
are	O
typically	O
expressed	O
in	O
heterologous	O
systems	O
with	O
a	O
view	O
to	O
in	O
vitro	O
characterization	O
.	O
A	O
critical	O
step	O
in	O
the	O
preparation	O
of	O
membrane	O
proteins	O
after	O
expression	O
in	O
any	O
system	O
is	O
the	O
solubilization	O
of	O
the	O
protein	O
in	O
aqueous	B-T121
solution	I-T121
,	O
typically	O
using	O
detergents	O
and	O
lipids	O
,	O
to	O
obtain	O
the	O
protein	O
in	O
a	O
form	O
suitable	O
for	O
purification	O
,	O
structural	B-T061
or	O
functional	O
analysis	O
.	O
This	O
process	O
is	O
particularly	O
difficult	O
as	O
the	O
objective	O
is	O
to	O
prepare	O
the	O
protein	O
in	O
an	O
unnatural	O
environment	O
,	O
a	O
protein	O
detergent	O
complex	O
,	O
separating	O
it	O
from	O
its	O
natural	O
lipid	O
partners	O
while	O
causing	O
the	O
minimum	O
destabilization	O
or	O
modification	B-T033
of	O
the	O
structure	O
.	O
Although	O
the	O
process	O
is	O
difficult	O
,	O
and	O
relatively	O
hard	O
to	O
master	O
,	O
an	O
increasing	O
number	O
of	O
membrane	O
proteins	O
have	O
been	O
successfully	O
isolated	O
after	O
expression	O
in	O
a	O
wide	O
variety	O
of	O
systems	O
.	O
In	O
this	O
chapter	O
we	O
give	O
a	O
general	O
protocol	O
for	O
preparing	O
protein	O
detergent	O
complexes	O
that	O
is	O
aimed	O
at	O
guiding	O
the	O
reader	O
through	O
the	O
different	O
critical	O
steps	O
.	O
In	O
the	O
second	O
part	O
of	O
the	O
chapter	O
we	O
illustrate	O
how	O
to	O
analyze	O
the	O
composition	O
of	O
protein	O
detergent	O
complexes	O
;	O
this	O
analysis	O
is	O
important	O
as	O
it	O
has	O
been	O
found	O
that	O
compositional	O
variation	O
often	O
causes	O
irreproducible	O
results	O
.	O
      
Biological	O
basis	B-T121
of	O
radiation	B-T061
protection	I-T061
needs	O
rejuvenation	B-T061
Human	O
beings	O
encounter	O
radiation	O
in	O
many	O
different	O
situations	O
-	O
from	O
proximity	O
to	O
radioactive	O
waste	O
sites	O
to	O
participation	O
in	O
medical	B-T058
procedures	I-T058
using	O
X	O
-	O
rays	O
etc	O
.	O
Limits	O
for	O
radiation	O
exposures	O
are	O
legally	O
regulated	O
;	O
however	O
,	O
current	O
radiation	B-T061
protection	I-T061
policy	O
does	O
not	O
explicitly	O
acknowledge	O
that	O
biological	O
,	O
cellular	B-T059
and	O
molecular	O
effects	O
of	O
low	O
doses	O
and	O
low	O
dose	O
rates	O
of	O
radiation	O
differ	O
from	O
effects	O
induced	O
by	O
medium	O
and	O
high	O
dose	O
radiation	O
exposures	O
.	O
Recent	O
technical	O
developments	O
in	O
biology	O
and	O
medicine	O
,	O
from	O
single	B-T059
cell	I-T059
techniques	I-T059
to	O
big	B-T059
data	I-T059
computational	I-T059
research	I-T059
,	O
have	O
enabled	O
new	O
approaches	O
for	O
study	O
of	O
biology	O
of	O
low	O
doses	O
of	O
radiation	O
.	O
Results	O
of	O
the	O
work	O
done	O
so	O
far	O
support	O
the	O
idea	O
that	O
low	O
doses	O
of	O
radiation	O
have	O
effects	O
that	O
differ	O
from	O
those	O
associated	O
with	O
high	O
dose	O
exposures	O
;	O
this	O
work	O
,	O
however	O
,	O
is	O
far	O
from	O
sufficient	O
for	O
the	O
development	O
of	O
a	O
new	O
theoretical	O
framework	O
needed	O
for	O
the	O
understanding	O
of	O
low	O
dose	O
radiation	O
exposures	O
.	O
Mechanistic	O
understanding	O
of	O
radiation	O
effects	O
at	O
low	O
doses	O
is	O
necessary	O
in	O
order	O
to	O
develop	O
better	O
radiation	B-T061
protection	I-T061
policy	O
.	O
      
Did	O
municipal	O
solid	O
waste	O
landfill	O
have	O
obvious	O
influence	O
on	O
polychlorinated	O
dibenzo	O
-	O
p	O
-	O
dioxins	O
and	O
polychlorinated	O
dibenzofurans	O
(	O
PCDD	O
/	O
Fs	O
)	O
in	O
ambient	O
air	O
:	O
A	O
case	O
study	O
in	O
East	O
China	O
Municipal	O
solid	O
waste	O
(	O
MSW	O
)	O
landfill	O
was	O
a	O
main	O
way	O
to	O
disposal	O
of	O
MSW	O
and	O
almost	O
95	O
%	O
of	O
MSW	O
was	O
disposed	O
by	O
landfills	O
in	O
the	O
world	O
.	O
In	O
order	O
to	O
understand	O
the	O
influence	O
of	O
MSW	O
landfill	O
on	O
polychlorinated	O
dibenzo	O
-	O
p	O
-	O
dioxins	O
and	O
polychlorinated	O
dibenzofurans	O
(	O
PCDD	O
/	O
Fs	O
)	O
in	O
surrounding	O
atmosphere	O
,	O
42	O
ambient	O
air	O
samples	O
were	O
collected	O
and	O
analyzed	O
from	O
surrounding	O
sites	O
,	O
background	O
site	O
,	O
upwind	O
site	O
and	O
downwind	O
site	O
of	O
a	O
MSW	O
landfill	O
in	O
East	O
China	O
.	O
The	O
results	O
of	O
present	O
study	O
were	O
summarized	O
as	O
follows	O
.	O
(	O
1	O
)	O
The	O
total	O
concentrations	O
of	O
PCDD	O
/	O
Fs	O
(	O
∑	O
PCDD	O
/	O
Fs	O
)	O
in	O
ambient	O
air	O
from	O
surrounding	O
sites	O
,	O
background	O
site	O
,	O
upwind	O
site	O
and	O
downwind	O
site	O
were	O
2.215±1.004	O
,	O
2.058±0.458	O
,	O
2.617±1.092	O
and	O
1.822±0.566pgNm(-3	O
)	O
,	O
respectively	O
.	O
(	O
2	O
)	O
The	O
toxic	O
equivalent	O
concentrations	O
(	O
TEQ	O
)	O
of	O
PCDD	O
/	O
Fs	O
in	O
ambient	O
air	O
from	O
surrounding	O
sites	O
,	O
background	O
site	O
,	O
upwind	O
site	O
and	O
downwind	O
site	O
were	O
0.103±0.017	O
,	O
0.096±0.015	O
,	O
0.120±0.024	O
and	O
0.108±0.014pg	O
I	O
-	O
TEQNm(-3	O
)	O
,	O
respectively	O
.	O
(	O
3	O
)	O
The	O
congener	B-T059
profiles	I-T059
,	O
∑	O
PCDD	O
/	O
Fs	O
and	O
TEQ	O
between	O
background	O
atmosphere	O
and	O
surrounding	O
atmosphere	O
of	O
landfill	O
did	O
not	O
show	O
statistically	O
significant	O
difference	O
.	O
(	O
4	O
)	O
The	O
∑	O
PCDD	O
/	O
Fs	O
and	O
TEQ	O
in	O
ambient	O
air	O
of	O
downwind	O
site	O
were	O
not	O
higher	O
than	O
that	O
of	O
upwind	O
site	O
,	O
suggesting	O
that	O
studied	O
landfill	O
did	O
not	O
have	O
obvious	O
influence	O
on	O
PCDD	O
/	O
Fs	O
in	O
ambient	O
air	O
from	O
downwind	O
site	O
.	O
(	O
5	O
)	O
The	O
95th	O
percentile	O
carcinogenic	O
risk	O
(	O
CR	O
)	O
of	O
PCDD	O
/	O
Fs	O
in	O
ambient	O
air	O
from	O
s	O
urrounding	O
sites	O
,	O
background	O
site	O
,	O
upwind	O
site	O
and	O
downwind	O
site	O
were	O
8.03×10(-9	O
)	O
,	O
7.57×10(-9	O
)	O
,	O
9.69×10(-9	O
)	O
and	O
8.15×10(-9	O
)	O
,	O
respectively	O
,	O
which	O
were	O
much	O
lower	O
than	O
the	O
threshold	O
value	O
of	O
CR	O
(	O
10(-6	O
)	O
)	O
,	O
suggesting	O
that	O
studied	O
landfill	O
did	O
not	O
influence	O
the	O
CR	O
of	O
PCDD	O
/	O
Fs	O
in	O
surrounding	O
atmosphere	O
and	O
negligible	O
cancer	O
risk	O
occurred	O
.	O
(	O
6	O
)	O
The	O
non	B-T033
-	I-T033
carcinogenic	I-T033
risk	I-T033
(	O
non	B-T033
-	I-T033
CR	I-T033
)	O
analysis	O
indicated	O
that	O
landfill	O
did	O
not	O
have	O
influence	O
on	O
the	O
non	B-T033
-	I-T033
CR	I-T033
of	O
PCDD	O
/	O
Fs	O
in	O
surrounding	O
atmosphere	O
and	O
no	O
obvious	O
non	O
-	O
carcinogenic	O
effects	O
developed	O
.	O
      
Multiplex	O
social	O
ecological	O
network	O
analysis	O
reveals	O
how	O
social	O
changes	O
affect	O
community	O
robustness	O
more	O
than	O
resource	O
depletion	O
Network	O
analysis	O
provides	O
a	O
powerful	O
tool	O
to	O
analyze	O
complex	O
influences	O
of	O
social	O
and	O
ecological	O
structures	O
on	O
community	O
and	O
household	O
dynamics	O
.	O
Most	O
network	O
studies	O
of	O
social	O
-	O
ecological	O
systems	O
use	O
simple	O
,	O
undirected	O
,	O
unweighted	O
networks	O
.	O
We	O
analyze	O
multiplex	O
,	O
directed	O
,	O
and	O
weighted	O
networks	O
of	O
subsistence	O
food	O
flows	O
collected	O
in	O
three	O
small	O
indigenous	O
communities	O
in	O
Arctic	O
Alaska	O
potentially	O
facing	O
substantial	O
economic	O
and	O
ecological	O
changes	O
.	O
Our	O
analysis	O
of	O
plausible	O
future	O
scenarios	O
suggests	O
that	O
changes	O
to	O
social	O
relations	O
and	O
key	O
households	O
have	O
greater	O
effects	O
on	O
community	O
robustness	O
than	O
changes	O
to	O
specific	O
wild	O
food	O
resources	O
.	O
      
Uveitis	B-T047
in	O
spondyloarthritis	B-T047
patients	O
and	O
its	O
association	O
with	O
HLA	O
-	O
B27	O
histocompatibility	O
antigen	O
:	O
prospective	O
study	O
T	O
o	O
perform	O
a	O
prospective	O
study	O
of	O
clinical	O
presentation	O
and	O
course	O
of	O
uveitis	B-T047
in	O
spondyloarthritis	B-T047
(	O
SpA	B-T047
)	O
patients	O
as	O
well	O
as	O
its	O
association	O
with	O
the	O
HLA	O
-	O
B27	O
histocompatibility	O
antigen	O
.	O
The	O
study	O
included	O
219	O
patients	O
with	O
uveitis	B-T047
,	O
all	O
tested	O
for	O
HLA	O
-	O
B27	O
antigen	O
and	O
various	O
infections	O
(	O
viral	B-T047
,	O
bacterial	B-T047
,	O
and	O
parasitic	B-T047
)	O
as	O
well	O
as	O
examined	B-T033
for	O
locomotive	O
system	O
involvement	O
.	O
The	O
presence	B-T033
of	O
the	O
HLA	O
-	O
B27	O
antigen	O
was	O
determined	O
in	O
142	O
(	O
64.8	O
%	O
)	O
out	O
of	O
219	O
patients	O
,	O
of	O
them	O
87	O
were	O
diagnosed	B-T033
with	O
an	O
entity	O
of	O
the	O
SpA	B-T047
group	O
.	O
The	O
remaining	O
77	O
(	O
35.2	O
%	O
)	O
patients	O
appeared	O
to	O
be	O
HLA	O
-	O
B27	O
-	O
negative	B-T033
,	O
but	O
13	O
were	O
still	O
diagnosed	B-T033
with	O
an	O
entity	O
of	O
the	O
SpA	B-T047
group	O
.	O
There	O
were	O
10	O
(	O
4.6	O
%	O
)	O
patients	O
with	O
2	O
or	O
more	O
diseases	B-T047
from	O
the	O
SpA	B-T047
group	O
(	O
«	O
clinical	O
decussation	O
»	O
)	O
.	O
When	O
comparing	O
the	O
two	O
groups	O
of	O
HLA	O
-	O
B27	O
-	O
positive	O
and	O
negative	B-T033
patients	O
having	O
both	O
SpA	B-T047
and	O
uveitis	B-T047
,	O
no	O
statistically	O
significant	O
difference	O
was	O
found	O
as	O
to	O
the	O
age	O
of	O
onset	O
,	O
site	O
,	O
frequency	O
of	O
attacks	O
,	O
and	O
uni	O
-	O
or	O
bilateral	O
involvement	O
(	O
p>0.05	O
)	O
.	O
We	O
also	O
performed	O
a	O
comparison	O
of	O
HLA	O
-	O
B27	O
-	O
positive	O
and	O
negative	B-T033
patients	O
with	O
no	O
account	O
to	O
their	O
SpA	B-T047
status	O
and	O
revealed	O
a	O
higher	O
complication	O
rate	O
in	O
those	O
that	O
were	O
«	O
negative	B-T033
»	O
(	O
p<0.0001	O
)	O
,	O
which	O
can	O
be	O
explained	O
by	O
the	O
fact	O
that	O
HLA	O
-	O
B27	O
-	O
negative	B-T033
patients	O
often	O
have	O
autoimmune	B-T047
or	O
infectious	B-T047
uveitis	I-T047
of	O
different	O
origin	O
notable	O
for	O
long	O
attacks	O
and	O
short	O
remissions	B-T033
.	O
Assessing	B-T058
the	O
site	O
and	O
course	O
of	O
uveitis	B-T047
as	O
well	O
as	O
HLA	O
-	O
B27	O
testing	O
of	O
uveitis	B-T047
patients	O
has	O
proved	O
important	O
for	O
etiological	O
diagnosis	B-T033
.	O
Diseases	B-T047
of	O
the	O
SpA	B-T047
group	O
have	O
been	O
shown	O
to	O
be	O
6.7	O
times	O
more	O
common	O
in	O
HLA	O
-	O
B27	O
-	O
positive	O
patients	O
as	O
compared	O
to	O
HLA	O
-	O
B27	O
-	O
negative	B-T033
ones	O
.	O
Clinical	O
presentation	O
of	O
uveitis	B-T047
in	O
the	O
presence	B-T033
of	O
SpA	B-T047
in	O
both	O
HLA	O
-	O
B27	O
-	O
positive	O
and	O
negative	B-T033
patients	O
resembles	O
that	O
of	O
idiopathic	B-T047
uveitis	I-T047
-	O
an	O
independent	O
HLA	O
-	O
B27	O
-	O
associated	O
syndrome	B-T047
(	O
р>0.05	O
)	O
.	O
Cases	O
of	O
«	O
decussation	O
»	O
between	O
entities	O
of	O
the	O
SpA	B-T047
group	O
are	O
usually	O
more	O
severe	O
in	O
terms	O
of	O
clinical	O
presentation	O
and	O
course	O
of	O
uveitis	B-T047
and	O
are	O
associated	O
with	O
a	O
worse	B-T033
prognosis	I-T033
.	O
Complications	O
of	O
uveitis	B-T047
are	O
more	O
likely	O
to	O
be	O
found	O
in	O
non	B-T033
-	I-T033
SpA	I-T033
HLA	O
-	O
B27	O
-	O
negative	B-T033
patients	O
(	O
р<0.0001	O
)	O
.	O
      
Shift	O
Work	O
Is	O
Associated	O
with	O
Metabolic	B-T047
Syndrome	I-T047
in	O
Young	O
Female	O
Korean	O
Workers	O
Shift	O
work	O
is	O
associated	O
with	O
health	O
problems	O
,	O
including	O
metabolic	B-T047
syndrome	I-T047
.	O
This	O
study	O
investigated	O
the	O
association	O
between	O
shift	O
work	O
and	O
metabolic	B-T047
syndrome	I-T047
in	O
young	O
workers	O
.	O
A	O
total	O
of	O
3,317	O
subjects	O
aged	O
20	O
-	O
40	O
years	O
enrolled	O
in	O
the	O
2011	O
-	O
2012	O
Korean	O
National	O
Health	O
and	O
Nutrition	O
Examination	O
Survey	O
were	O
divided	O
into	O
shift	B-T033
and	O
day	B-T033
workers	I-T033
.	O
We	O
conducted	O
a	O
cross	O
-	O
sectional	O
study	O
and	O
calculated	O
odds	O
ratios	O
using	O
multivariate	O
logistic	O
regression	O
analysis	O
in	O
order	O
to	O
examine	B-T033
the	O
association	O
between	O
shift	O
work	O
and	O
metabolic	B-T047
syndrome	I-T047
.	O
The	O
prevalence	O
of	O
metabolic	B-T047
syndrome	I-T047
was	O
14.3	O
%	O
and	O
7.1	O
%	O
among	O
male	O
and	O
female	O
shift	B-T033
workers	I-T033
,	O
respectively	O
.	O
After	O
adjusting	O
for	O
confounding	O
factors	O
,	O
shift	O
work	O
was	O
associated	O
with	O
metabolic	B-T047
syndrome	I-T047
in	O
female	O
workers	O
(	O
odds	O
ratio	O
,	O
2.53	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.12	O
to	O
5.70	O
)	O
.	O
Shift	O
work	O
was	O
associated	O
with	O
metabolic	B-T047
syndrome	I-T047
in	O
young	O
women	O
.	O
Timely	O
efforts	O
are	O
necessary	O
to	O
manage	B-T058
metabolic	B-T047
syndrome	I-T047
in	O
the	O
workplace	O
.	O
      
N	O
-	O
Terminal	O
Hypothesis	O
for	O
Alzheimer	B-T047
's	I-T047
Disease	I-T047
Although	O
the	O
amyloid	O
(	O
abeta	O
peptide	O
,	O
Aβ	O
)	O
hypothesis	O
is	O
25	O
years	O
old	O
,	O
is	O
the	O
dominant	O
model	O
of	O
Alzheimer	B-T047
's	I-T047
disease	I-T047
(	O
AD	B-T047
)	O
pathogenesis	O
,	O
and	O
guides	O
the	O
development	O
of	O
potential	O
treatments	B-T061
,	O
it	O
is	O
still	O
controversial	O
.	O
One	O
possible	O
reason	O
is	O
a	O
lack	O
of	O
a	O
mechanistic	O
path	O
from	O
the	O
cleavage	O
products	O
of	O
the	O
amyloid	O
precursor	O
protein	O
(	O
APP	O
)	O
such	O
as	O
soluble	O
Aβ	O
monomer	O
and	O
soluble	O
molecular	O
fragments	O
to	O
the	O
deleterious	O
effects	O
on	O
synaptic	O
form	O
and	O
function	O
.	O
From	O
a	O
review	O
of	O
the	O
recent	O
literature	O
and	O
our	O
own	O
published	O
work	O
including	O
aggregation	O
kinetics	O
and	O
structural	O
morphology	O
,	O
Aβ	O
clearance	O
,	O
molecular	O
simulations	O
,	O
long	O
-	O
term	O
potentiation	O
measurements	O
with	O
inhibition	O
binding	O
,	O
and	O
the	O
binding	O
of	O
a	O
commercial	O
monoclonal	O
antibody	O
,	O
aducanumab	O
,	O
we	O
hypothesize	O
that	O
the	O
N	O
-	O
terminal	O
domains	O
of	O
neurotoxic	O
Aβ	O
oligomers	O
are	O
implicated	O
in	O
causing	O
the	O
disease	B-T047
.	O
      
An	O
ultrasensitive	O
electrochemiluminescence	B-T059
sensor	O
based	O
on	O
reduced	O
graphene	O
oxide	O
-	O
copper	O
sulfide	O
composite	O
coupled	O
with	O
capillary	B-T059
electrophoresis	I-T059
for	O
determination	B-T059
of	O
amlodipine	B-T121
besylate	I-T121
in	O
mice	O
plasma	O
A	O
new	O
electrochemiluminescence	B-T059
(	O
ECL	B-T059
)	O
sensor	O
based	O
on	O
reduced	O
graphene	O
oxide	O
-	O
copper	O
sulfide	O
(	O
rGO	O
-	O
CuS	O
)	O
composite	O
coupled	O
with	O
capillary	B-T059
electrophoresis	I-T059
(	O
CE	B-T059
)	O
was	O
constructed	O
for	O
the	O
ultrasensitive	O
detection	B-T061
of	O
amlodipine	B-T121
besylate	I-T121
(	O
AML	B-T121
)	O
for	O
the	O
first	O
time	O
.	O
In	O
this	O
work	O
,	O
rGO	O
-	O
CuS	O
composite	O
was	O
synthesized	O
by	O
one	O
-	O
pot	O
hydrothermal	O
method	O
and	O
used	O
for	O
electrode	O
modification	B-T033
.	O
The	O
electrochemical	B-T059
and	O
ECL	B-T059
behaviors	O
of	O
the	O
sensor	O
were	O
investigated	O
.	O
More	O
than	O
5	O
-	O
fold	O
enhance	O
in	O
ECL	B-T059
intensity	O
was	O
observed	O
after	O
modified	O
with	O
rGO	O
-	O
CuS	O
composite	O
.	O
The	O
results	O
can	O
be	O
ascribed	O
to	O
the	O
presence	O
of	O
rGO	O
-	O
CuS	O
composite	O
on	O
the	O
electrode	O
surface	O
that	O
facilitates	O
the	O
electron	O
transfer	O
rate	O
between	O
the	O
electroactive	O
center	O
of	O
Ru(bpy)3(2	O
+	O
)	O
and	O
the	O
electrode	O
.	O
The	O
ECL	B-T059
sensor	O
was	O
coupled	O
with	O
CE	B-T059
to	O
improve	O
the	O
selectivity	O
and	O
the	O
CE	B-T059
-	O
ECL	B-T059
parameters	B-T033
that	O
affect	O
separation	O
and	O
detection	B-T061
were	O
optimized	O
.	O
Under	O
the	O
optimum	O
conditions	O
,	O
the	O
linear	O
ranges	O
for	O
AML	B-T121
was	O
0.008	O
-	O
5.0μg	O
/	O
mL	O
with	O
a	O
detection	O
limit	O
of	O
2.8ng	O
/	O
mL	O
(	O
S	O
/	O
N=3	O
)	O
.	O
The	O
method	B-T059
displayed	O
the	O
advantages	O
of	O
high	O
sensitivity	O
,	O
good	O
selectivity	O
,	O
wide	O
linear	O
range	O
,	O
low	O
detection	O
limit	O
and	O
fine	O
reproducibility	O
,	O
and	O
was	O
used	O
to	O
analyze	O
AML	B-T121
in	O
mice	O
plasma	O
with	O
a	O
satisfactory	O
result	O
,	O
which	O
holds	O
a	O
great	O
potential	O
in	O
the	O
field	O
of	O
pharmaceutical	O
analysis	O
.	O
      
Identification	O
of	O
MiR-21	O
-	O
5p	O
as	O
a	O
Functional	O
Regulator	O
of	O
Mesothelin	O
Expression	O
Using	O
MicroRNA	O
Capture	O
Affinity	O
Coupled	O
with	O
Next	O
Generation	O
Sequencing	O
MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
small	O
non	O
-	O
coding	O
RNAs	O
that	O
regulate	O
mRNA	O
expression	O
mainly	O
by	O
silencing	O
target	O
transcripts	O
via	O
binding	O
to	O
miRNA	O
recognition	O
elements	O
(	O
MREs	O
)	O
in	O
the	O
3'untranslated	O
region	O
(	O
3'UTR	O
)	O
.	O
The	O
identification	O
of	O
bona	O
fide	O
targets	O
is	O
challenging	O
for	O
researchers	B-T033
working	I-T033
on	O
the	O
functional	O
aspect	O
of	O
miRNAs	O
.	O
Recently	O
,	O
we	O
developed	O
a	O
method	O
(	O
miR	O
-	O
CATCH	O
)	O
based	O
on	O
biotinylated	O
DNA	O
antisense	O
oligonucleotides	O
that	O
capture	O
the	O
mRNA	O
of	O
interest	O
and	O
facilitates	O
the	O
characterisation	O
of	O
miRNAs::mRNA	O
interactions	O
in	O
a	O
physiological	O
cellular	O
context	O
.	O
Here	O
,	O
the	O
miR	O
-	O
CATCH	O
technique	O
was	O
applied	O
to	O
the	O
mesothelin	O
(	O
MSLN	O
)	O
gene	O
and	O
coupled	O
with	O
next	O
generation	O
sequencing	O
(	O
NGS	O
)	O
,	O
to	O
identify	O
miRNAs	O
that	O
regulate	O
MSLN	O
mRNA	O
and	O
that	O
may	O
be	O
responsible	O
for	O
its	O
increased	O
protein	O
levels	O
found	O
in	O
malignant	B-T191
pleural	I-T191
mesothelioma	I-T191
(	O
MPM	B-T191
)	O
.	O
Biotinylated	O
MSLN	O
oligos	O
were	O
employed	O
to	O
isolate	O
miRNA::MSLN	O
mRNA	O
complexes	O
from	O
a	O
normal	O
cell	O
line	O
(	O
Met-5A	O
)	O
which	O
expresses	O
low	O
levels	O
of	O
MSLN	O
.	O
MiRNAs	O
targeting	O
the	O
MSLN	O
mRNA	O
were	O
identified	O
by	O
NGS	O
and	O
miR-21	O
-	O
5p	O
and	O
miR-100	O
-	O
5p	O
were	O
selected	O
for	O
further	O
validation	O
analyses	O
.	O
MiR-21	O
-	O
5p	O
was	O
shown	O
to	O
be	O
able	O
to	O
modulate	O
MSLN	O
expression	O
in	O
miRNA	O
mimic	B-T061
experiments	O
in	O
a	O
panel	O
of	O
malignant	O
and	O
non	O
-	O
malignant	O
cell	O
lines	O
.	O
Further	O
miRNA	O
inhibitor	O
experiments	O
and	O
luciferase	O
assays	B-T059
in	O
Mero-14	O
cells	O
validated	O
miR-21	O
-	O
5p	O
as	O
a	O
true	O
regulator	O
of	O
MSLN	O
.	O
Moreover	O
,	O
in	O
vitro	O
experiments	O
showed	O
that	O
treatment	B-T061
with	O
miR-21	O
-	O
5p	O
mimic	B-T061
reduced	O
proliferation	O
of	O
MPM	B-T191
cell	O
lines	O
.	O
Altogether	O
,	O
this	O
work	O
shows	O
that	O
the	O
miR	O
-	O
CATCH	O
technique	O
,	O
coupled	O
with	O
NGS	O
and	O
in	O
vitro	O
validation	O
,	O
represents	O
a	O
reliable	O
method	O
to	O
identify	O
native	O
miRNA::mRNA	O
interactions	O
.	O
MiR-21	O
-	O
5p	O
is	O
suggested	O
as	O
novel	O
regulator	O
of	O
MSLN	O
with	O
a	O
possible	O
functional	O
role	O
in	O
cellular	O
growth	O
.	O
      
Effect	O
of	O
Punica	O
granatum	O
fruit	O
peel	O
on	O
glucose-6	O
-	O
phosphate	O
dehydrogenase	O
and	O
malate	O
dehydrogenase	O
in	O
amphistome	O
Gastrothylax	O
indicus	O
Increasing	O
anthelmintic	B-T121
resistance	O
and	O
the	O
impact	O
of	O
conventional	O
anthelmintics	B-T121
on	O
the	O
environment	O
,	O
it	O
is	O
important	O
to	O
look	O
for	O
alternative	O
strategies	O
against	O
helminth	O
parasite	O
in	O
sheep	O
.	O
Important	O
lipogenic	O
enzymes	O
like	O
glucose-6	O
-	O
phosphate	O
dehydrogenase	O
(	O
G-6	O
-	O
PDH	O
)	O
and	O
malate	O
dehydrogenase	O
(	O
MDH	O
)	O
show	O
subcellular	O
distribution	O
pattern	O
.	O
Activity	O
of	O
G-6	O
-	O
PDH	O
was	O
largely	O
restricted	O
to	O
cytosolic	O
fraction	O
while	O
MDH	O
was	O
found	O
in	O
both	O
cytosolic	O
and	O
mitochondrial	O
fraction	O
in	O
Gastrothylax	O
indicus	O
.	O
Following	O
in	O
vitro	O
treatment	O
with	O
ethanolic	B-T121
and	O
aqueous	O
extracts	O
of	O
Punica	O
granatum	O
fruit	O
peel	O
and	O
commercial	O
anthelmintic	B-T121
,	O
albendazole	B-T121
G-6	O
-	O
PDH	O
activity	O
was	O
decreased	O
by	O
19	O
-	O
32	O
%	O
,	O
whereas	O
MDH	O
was	O
suppressed	O
by	O
24	O
-	O
41	O
%	O
,	O
compared	O
to	O
the	O
respective	O
control	O
.	O
Albendazole	B-T121
was	O
quite	O
effective	O
when	O
compared	O
with	O
negative	O
control	O
and	O
both	O
the	O
extracts	O
.	O
The	O
results	O
indicate	O
that	O
phytochemicals	O
of	O
plant	O
may	O
act	O
as	O
potential	O
vermifuge	B-T121
or	O
vermicide	O
.	O
      
Prevalence	O
of	O
Hypothyroidism	B-T047
in	O
Andalusia	O
,	O
Spain	O
,	O
Determined	O
by	O
Thyroid	O
Hormone	O
Comsumption	O
Hypothyroidism	B-T047
is	O
the	O
most	O
common	O
condition	O
linked	O
to	O
a	O
hormone	B-T047
deficiency	I-T047
,	O
nevertheless	O
data	O
on	O
its	O
prevalence	O
are	O
scarce	O
in	O
Spain	O
.	O
For	O
that	O
reason	O
,	O
we	O
have	O
estimated	O
its	O
prevalence	O
through	O
the	O
registration	B-T058
of	O
patients	O
who	O
had	O
used	O
thyroid	O
hormones	O
in	O
Andalusia	O
(	O
South	O
Spain	O
)	O
.	O
Data	O
of	O
patients	O
who	O
had	O
withdrawn	O
levothyroxine	B-T121
under	O
the	O
public	O
system	O
during	O
2014	O
from	O
the	O
base	O
of	O
the	O
Andalusian	B-T058
Health	I-T058
Service	I-T058
were	O
considered	O
.	O
Prevalence	O
were	O
calculated	O
with	O
confidence	O
intervals	O
of	O
95	O
%	O
for	O
each	O
management	O
area	O
,	O
stratified	O
by	O
sex	O
and	O
age	O
groups	O
,	O
and	O
differences	O
between	O
them	O
were	O
evaluated	B-T058
.	O
321,368	O
people	O
(	O
98	O
%	O
older	O
than	O
18	O
years	O
and	O
83	O
%	O
female	O
)	O
were	O
identified	O
as	O
levothyroxine	B-T121
users	O
and	O
a	O
prevalence	O
of	O
hypothyroidism	B-T047
of	O
3.95	O
%	O
(	O
95	O
%	O
CI	O
:	O
3.94	O
-	O
3.96	O
)	O
was	O
estimated	O
for	O
the	O
general	O
population	O
.	O
The	O
condition	O
was	O
more	O
common	O
in	O
females	O
,	O
in	O
the	O
older	O
18	O
years	O
7.81	O
%	O
(	O
95	O
%	O
CI	O
:	O
7.80	O
to	O
7.82	O
)	O
compared	O
to	O
males	O
1.75	O
%	O
(	O
95	O
%	O
CI	O
:	O
1.73	O
-	O
1.77	O
)	O
with	O
a	O
ratio	O
of	O
4.5	O
-	O
fold	O
.	O
It	O
increases	O
in	O
the	O
population	O
of	O
women	O
older	O
than	O
45	O
years	O
,	O
10.32	O
%	O
(	O
95	O
%	O
CI	O
:	O
10.30	O
-	O
0.32	O
)	O
and	O
in	O
the	O
over	O
60	O
years	O
11.37	O
%	O
(	O
95	O
%	O
CI	O
:	O
11.35	O
-	O
11.40	O
)	O
.	O
The	O
prevalence	O
in	O
adult	O
women	O
in	O
the	O
western	O
provinces	O
is	O
7.38	O
%	O
(	O
95	O
%	O
CI	O
:	O
7.36	O
-	O
7.40	O
)	O
,	O
in	O
the	O
eastern	O
provinces	O
8.59	O
%	O
(	O
95	O
%	O
CI	O
:	O
8.57	O
-	O
8.62	O
)	O
and	O
in	O
coastal	O
areas	O
6.70	O
%	O
(	O
95	O
%	O
CI	O
:	O
6.68	O
-	O
6.72	O
)	O
compared	O
to	O
the	O
mountainous	O
ones	O
,	O
which	O
is	O
8.91	O
%	O
(	O
95	O
%	O
CI	O
:	O
8.88	O
-	O
8.94	O
)	O
.	O
The	O
results	O
denote	O
a	O
high	O
prevalence	O
of	O
hypothyroidism	B-T047
in	O
the	O
adult	O
population	O
of	O
Andalusia	O
compared	O
to	O
the	O
nearby	O
countries	O
,	O
with	O
a	O
clear	O
increased	O
associated	O
with	O
females	O
and	O
age	O
.	O
Furthermore	O
,	O
the	O
prevalence	O
of	O
the	O
illness	B-T184
presents	O
also	O
a	O
geographically	O
-	O
related	O
variability	O
.	O
      
Civil	O
Society	O
-Driven	O
Drug	O
Policy	O
Reform	O
for	O
Health	O
and	O
Human	O
Welfare	O
-	O
India	O
The	O
lack	O
of	O
adequate	O
access	O
to	O
opioids	B-T121
in	O
India	O
as	O
analgesics	B-T121
and	O
for	O
agonist	B-T121
therapies	B-T061
,	O
forces	O
millions	O
to	O
live	O
with	O
severe	O
unalleviated	B-T184
pain	I-T184
,	O
or	O
languish	O
with	O
suffering	B-T048
associated	O
with	O
drug	B-T048
dependence	I-T048
.	O
Although	O
India	O
is	O
a	O
major	O
opium	B-T121
exporter	O
,	O
the	O
excessively	O
prohibitive	O
1985	O
narcotics	O
law	O
formulated	O
to	O
control	O
harmful	B-T048
use	I-T048
of	I-T048
drugs	I-T048
,	O
impeded	O
the	O
availability	O
and	O
access	O
to	O
opioids	B-T121
for	O
medical	O
and	O
scientific	O
purposes	O
.	O
Amendment	O
of	O
this	O
law	O
in	O
2014	O
established	O
a	O
new	O
national	O
regulatory	O
framework	O
for	O
improved	O
access	O
to	O
essential	O
opioid	B-T121
analgesics	I-T121
.	O
This	O
article	O
reflects	O
on	O
key	O
elements	O
and	O
processes	O
that	O
led	O
to	O
this	O
landmark	O
achievement	O
.	O
Unlike	O
quick	O
timelines	O
associated	O
with	O
effecting	O
policy	O
reforms	O
for	O
law	O
enforcement	O
,	O
realizing	O
the	O
2014	O
drug	O
policy	O
change	O
primarily	O
to	O
mitigate	O
human	B-T048
suffering	I-T048
,	I-T048
was	O
a	O
22	O
-	O
year	O
-	O
long	O
process	O
.	O
The	O
most	O
exacting	O
challenges	O
included	O
recognizing	O
the	O
multilayered	B-T033
complexities	I-T033
of	O
the	O
prior	O
policy	O
framework	O
and	O
understanding	O
their	O
adverse	O
impact	O
on	O
field	O
practices	O
to	O
chart	O
an	O
appropriate	O
and	O
viable	O
path	O
for	O
reform	O
.	O
The	O
evolution	O
of	O
an	O
informal	O
civil	O
society	O
movement	O
involving	O
health	O
care	O
professionals	O
,	O
lawyers	O
,	O
media	O
,	O
policy	O
analysts	O
,	O
government	O
officials	O
,	O
and	O
the	O
public	O
was	O
pivotal	O
in	O
addressing	O
these	O
challenges	B-T058
and	O
garnering	O
momentum	O
for	O
reform	O
.	O
The	O
success	O
of	O
the	O
effort	O
for	O
improving	O
access	O
to	O
opioid	B-T121
medications	B-T058
was	O
underpinned	O
by	O
a	O
three	O
-	O
pronged	O
strategy	O
of	O
1	O
)	O
persuading	O
the	O
executive	O
arm	O
of	O
the	O
government	O
to	O
take	O
interim	O
enabling	O
measures	O
;	O
2	O
)	O
leveraging	O
judicial	O
intervention	O
through	O
public	O
interest	O
litigation	O
;	O
and	O
3	O
)	O
crafting	O
a	O
viable	O
policy	O
document	O
for	O
legislative	O
approval	O
and	O
implementation	O
.	O
We	O
hope	O
our	O
findings	O
are	O
useful	O
for	O
realizing	O
drug	O
policy	O
reforms	O
,	O
given	O
the	O
current	O
transformed	O
global	O
policy	O
mandates	O
emphasizing	O
humanitarian	O
,	O
healthcare	B-T058
,	O
and	O
quality	O
-	O
of	O
-	O
life	O
considerations	B-T033
.	O
      
Results	B-T033
for	O
patients	O
with	O
sarcoma	B-T191
not	O
otherwise	O
specified	O
and	O
other	O
diagnoses	B-T033
than	O
Ewing	B-T191
sarcoma	I-T191
treated	B-T033
according	O
to	O
the	O
Euro	O
-	O
EWING	O
99	O
trial	O
Euro	O
-	O
EWING	O
99	O
trial	O
of	O
the	O
European	O
Ewing	B-T191
tumor	I-T191
Working	O
Initiative	B-T033
of	O
National	O
Groups	O
(	O
EE99	O
)	O
was	O
an	O
international	O
phase	O
III	O
study	O
in	O
patients	O
with	O
Ewing	B-T191
sarcoma	I-T191
.	O
The	O
German	O
Society	O
of	O
Pediatric	O
Oncology	O
and	O
Hematology	O
(	O
GPOH	O
)	O
data	O
center	O
registered	B-T058
and	O
followed	O
patients	O
with	O
other	O
diagnoses	B-T033
than	O
Ewing	B-T191
sarcoma	I-T191
who	O
were	O
treated	B-T033
according	O
to	O
the	O
EE99	O
protocol	O
in	O
an	O
additional	O
non	O
-	O
Ewing	O
database	O
.	O
Data	O
of	O
27	O
patients	O
with	O
other	O
diagnoses	B-T033
than	O
Ewing	B-T191
sarcoma	I-T191
treated	B-T033
according	O
to	O
the	O
EE99	O
protocol	O
were	O
analyzed	O
.	O
Patients	O
had	O
miscellaneous	O
histologic	O
diagnoses	B-T033
,	O
the	O
majority	O
were	O
diagnosed	B-T033
with	O
sarcoma	B-T191
not	O
otherwise	O
specified	O
(	O
NOS	O
)	O
arising	O
in	O
bone	O
and	O
soft	O
tissue	O
(	O
63	O
%	O
)	O
.	O
The	O
median	O
age	O
at	O
diagnosis	B-T033
was	O
16.9	O
years	O
(	O
range	O
4.5	O
-	O
41.4	O
)	O
.	O
Localized	B-T047
disease	I-T047
was	O
diagnosed	B-T033
in	O
61.5	O
%	O
of	O
the	O
patients	O
and	O
38.5	O
%	O
had	O
distant	B-T191
metastases	I-T191
at	O
time	O
of	O
primary	O
diagnosis	B-T033
.	O
The	O
median	O
follow	B-T058
-	I-T058
up	I-T058
time	O
was	O
3.7	O
years	O
(	O
range	O
0.5	O
-	O
9.5	O
)	O
.	O
Patients	O
with	O
localized	B-T047
disease	I-T047
showed	O
a	O
3	O
-	O
year	O
event	O
-	O
free	O
survival	O
(	O
EFS	O
)	O
of	O
68	O
%	O
,	O
compared	O
to	O
3	O
-	O
year	O
EFS	O
of	O
20	O
%	O
in	O
patients	O
with	O
metastases	B-T191
(	O
P	O
=	O
0.042	O
)	O
.	O
Three	O
-	O
year	O
EFS	O
for	O
patients	O
with	O
sarcoma	B-T191
NOS	O
was	O
52	O
%	O
,	O
patients	O
with	O
localized	B-T047
and	O
metastatic	B-T191
disease	I-T191
showed	O
3	O
-	O
year	O
EFS	O
of	O
66	O
and	O
20	O
%	O
,	O
respectively	O
.	O
EFS	O
in	O
patients	O
with	O
other	O
diagnoses	B-T033
than	O
Ewing	B-T191
sarcoma	I-T191
treated	B-T033
according	O
to	O
EE99	O
was	O
significantly	O
higher	O
in	O
patients	O
with	O
localized	B-T047
than	O
metastatic	B-T191
disease	I-T191
.	O
Sarcomas	B-T191
of	O
soft	O
tissue	O
and	O
bone	O
that	O
can	O
not	O
be	O
classified	O
to	O
current	O
diagnostic	O
categories	O
constitute	O
a	O
therapeutic	O
challenge	B-T058
.	O
      
Folate	B-T121
-based	O
single	B-T059
cell	I-T059
screening	I-T059
using	O
surface	B-T059
enhanced	I-T059
Raman	I-T059
microimaging	I-T059
Recent	O
progress	O
in	O
nanotechnology	O
and	O
its	O
application	O
to	O
biomedical	O
settings	O
have	O
generated	O
great	O
advantages	O
in	O
dealing	O
with	O
early	B-T060
cancer	I-T060
diagnosis	I-T060
.	O
The	O
identification	O
of	O
the	O
specific	O
properties	O
of	O
cancer	O
cells	O
,	O
such	O
as	O
the	O
expression	O
of	O
particular	O
plasma	O
membrane	O
molecular	O
receptors	O
,	O
has	O
become	O
crucial	O
in	O
revealing	O
the	O
presence	O
and	O
in	O
assessing	B-T058
the	I-T058
stage	I-T058
of	I-T058
development	I-T058
of	I-T058
the	I-T058
disease	I-T058
.	O
Here	O
we	O
report	O
a	O
single	B-T059
cell	I-T059
screening	I-T059
approach	O
based	O
on	O
Surface	B-T059
Enhanced	I-T059
Raman	I-T059
Scattering	I-T059
(	I-T059
SERS	I-T059
)	I-T059
microimaging	I-T059
SERS	B-T059
.	O
We	O
fabricated	O
a	O
SERS	B-T059
-	I-T059
labelled	I-T059
nanovector	O
based	O
on	O
the	O
biofunctionalization	O
of	O
gold	O
nanoparticles	O
with	O
folic	B-T121
acid	I-T121
.	O
After	O
treating	O
the	O
cells	O
with	O
the	O
nanovector	O
,	O
we	O
were	O
able	O
to	O
distinguish	B-T059
three	I-T059
different	I-T059
cell	I-T059
populations	I-T059
from	O
different	O
cell	O
lines	O
(	O
cancer	O
HeLa	O
and	O
PC-3	B-T050
,	O
and	O
normal	O
HaCaT	O
lines	O
)	O
,	O
suitably	O
chosen	O
for	O
their	O
different	O
expressions	O
of	O
folate	O
binding	O
proteins	O
.	O
The	O
nanovector	O
,	O
indeed	O
,	O
binds	O
much	O
more	O
efficiently	O
on	O
cancer	O
cell	O
lines	O
than	O
on	O
normal	O
ones	O
,	O
resulting	O
in	O
a	O
higher	O
SERS	B-T059
signal	O
measured	O
on	O
cancer	O
cells	O
.	O
These	O
results	O
pave	O
the	O
way	O
for	O
applications	O
in	O
single	B-T059
cell	I-T059
diagnostics	I-T059
and	O
,	O
potentially	O
,	O
in	O
theranostics	O
.	O
      
The	O
genetic	O
basis	O
for	O
variation	O
in	O
resistance	O
to	O
infection	O
in	O
the	O
Drosophila	O
melanogaster	O
genetic	O
reference	O
panel	O
Individuals	O
vary	O
extensively	O
in	O
the	O
way	O
they	O
respond	O
to	O
disease	B-T047
but	O
the	O
genetic	O
basis	O
of	O
this	O
variation	O
is	O
not	O
fully	O
understood	O
.	O
We	O
found	O
substantial	O
individual	O
variation	O
in	O
resistance	O
and	O
tolerance	O
to	O
the	O
fungal	O
pathogen	O
Metarhizium	O
anisopliae	O
Ma549	O
using	O
the	O
Drosophila	O
melanogaster	O
Genetic	O
Reference	O
Panel	O
(	O
DGRP	O
)	O
.	O
In	O
addition	O
,	O
we	O
found	O
that	O
host	O
defense	O
to	O
Ma549	O
was	O
correlated	O
with	O
defense	O
to	O
the	O
bacterium	B-T007
Pseudomonas	B-T007
aeruginosa	I-T007
Pa14	I-T007
,	O
and	O
several	O
previously	O
published	O
DGRP	O
phenotypes	O
including	O
oxidative	O
stress	O
sensitivity	O
,	O
starvation	B-T033
stress	O
resistance	O
,	O
hemolymph	O
glucose	B-T059
levels	I-T059
,	O
and	O
sleep	O
indices	O
.	O
We	O
identified	O
polymorphisms	O
associated	O
with	O
differences	O
between	O
lines	O
in	O
both	O
their	O
mean	O
survival	O
times	O
and	O
microenvironmental	O
plasticity	O
,	O
suggesting	O
that	O
lines	O
differ	O
in	O
their	O
ability	O
to	O
adapt	O
to	O
variable	O
pathogen	B-T001
exposures	O
.	O
The	O
majority	O
of	O
polymorphisms	O
increasing	O
resistance	O
to	O
Ma549	O
were	O
sex	O
biased	O
,	O
located	O
in	O
non	O
-	O
coding	O
regions	O
,	O
had	O
moderately	O
large	O
effect	O
and	O
were	O
rare	O
,	O
suggesting	O
that	O
there	O
is	O
a	O
general	O
cost	O
to	O
defense	O
.	O
Nevertheless	O
,	O
host	O
defense	O
was	O
not	O
negatively	O
correlated	O
with	O
overall	O
longevity	O
and	O
fecundity	O
.	O
In	O
contrast	O
to	O
Ma549	O
,	O
minor	O
alleles	O
were	O
concentrated	O
in	O
the	O
most	O
Pa14	B-T007
-	O
susceptible	O
as	O
well	O
as	O
the	O
most	O
Pa14	B-T007
-	O
resistant	O
lines	O
.	O
A	O
pathway	O
based	O
analysis	O
revealed	O
a	O
network	O
of	O
Pa14	B-T007
and	O
Ma549	O
-	O
resistance	O
genes	O
that	O
are	O
functionally	O
connected	O
through	O
processes	O
that	O
encompass	O
phagocytosis	O
and	O
engulfment	O
,	O
cell	O
mobility	O
,	O
intermediary	O
metabolism	O
,	O
protein	O
phosphorylation	O
,	O
axon	O
guidance	O
,	O
response	O
to	O
DNA	O
damage	O
,	O
and	O
drug	O
metabolism	O
.	O
Functional	O
testing	O
with	O
insertional	O
mutagenesis	O
lines	O
indicates	O
that	O
12/13	O
candidate	O
genes	O
tested	O
influence	O
susceptibility	O
to	O
Ma549	O
.	O
Many	O
candidate	O
genes	O
have	O
homologs	O
identified	O
in	O
studies	O
of	O
human	O
disease	B-T047
,	O
suggesting	O
that	O
genes	O
affecting	O
variation	O
in	O
susceptibility	O
are	O
conserved	O
across	O
species	O
.	O
      
Metalloproteinase	O
meprin	O
α	O
regulates	O
migration	O
and	O
invasion	B-T033
of	O
human	O
hepatocarcinoma	B-T191
cells	O
and	O
is	O
a	O
mediator	O
of	O
the	O
oncoprotein	O
Reptin	O
Hepatocellular	B-T191
carcinoma	I-T191
is	O
associated	O
with	O
a	O
high	O
rate	O
of	O
intra	O
-	O
hepatic	O
invasion	B-T033
that	O
carries	O
a	O
poor	B-T033
prognosis	I-T033
.	O
Meprin	O
alpha	O
(	O
Mep1A	O
)	O
is	O
a	O
secreted	O
metalloproteinase	O
with	O
many	O
substrates	O
relevant	O
to	O
cancer	B-T033
invasion	I-T033
.	O
We	O
found	O
that	O
Mep1A	O
was	O
a	O
target	O
of	O
Reptin	O
,	O
a	O
protein	O
that	O
is	O
oncogenic	O
in	O
HCC	B-T191
.	O
We	O
studied	O
Mep1A	O
regulation	O
by	O
Reptin	O
,	O
its	O
role	O
in	O
HCC	B-T191
,	O
and	O
whether	O
it	O
mediates	O
Reptin	O
oncogenic	O
effects	O
.	O
MepA	O
and	O
Reptin	O
expression	O
was	O
measured	O
in	O
human	O
HCC	B-T191
by	O
qRT	O
-	O
PCR	O
and	O
in	O
cultured	O
cells	O
by	O
PCR	O
,	O
western	B-T059
blot	I-T059
and	O
enzymatic	O
activity	O
measurements	O
.	O
Cell	O
growth	O
was	O
assessed	O
by	O
counting	B-T059
and	O
MTS	O
assay	O
.	O
Cell	O
migration	O
was	O
measured	O
in	O
Boyden	O
chambers	O
and	O
wound	O
healing	O
assays	B-T059
,	O
and	O
cell	B-T033
invasion	I-T033
in	O
Boyden	O
chambers	O
.	O
Silencing	O
Reptin	O
decreased	O
Mep1A	O
expression	O
and	O
activity	O
,	O
without	O
affecting	O
meprin	O
β	O
.	O
Mep1A	O
,	O
but	O
not	O
meprin	O
β	O
,	O
was	O
overexpressed	O
in	O
a	O
series	O
of	O
242	O
human	O
HCC	B-T191
(	O
2.04	O
fold	O
,	O
p	O
<	O
0.0001	O
)	O
,	O
and	O
a	O
high	O
expression	O
correlated	O
with	O
a	O
poor	B-T033
prognosis	I-T033
.	O
Mep1A	O
and	O
Reptin	O
expressions	O
were	O
positively	O
correlated	O
(	O
r	O
=	O
0.39	O
,	O
p	O
<	O
0.0001	O
)	O
.	O
Silencing	O
Mep1A	O
had	O
little	O
effect	O
on	O
cell	O
proliferation	O
,	O
but	O
decreased	O
cell	O
migration	O
and	O
invasion	B-T033
of	O
HuH7	O
and	O
Hep3B	O
cells	O
.	O
Conversely	O
,	O
overexpression	O
of	O
Mep1A	O
or	O
addition	O
of	O
recombinant	B-T001
Mep1A	O
increased	O
migration	O
and	O
invasion	B-T033
.	O
Finally	O
,	O
overexpression	O
of	O
Mep1A	O
restored	O
a	O
normal	O
cell	O
migration	O
in	O
cells	O
where	O
Reptin	O
was	O
depleted	O
.	O
Mep1A	O
is	O
overexpressed	O
in	O
most	O
HCC	B-T191
and	O
induces	O
HCC	B-T191
cell	O
migration	O
and	O
invasion	B-T033
.	O
Mep1A	O
expression	O
is	O
regulated	O
by	O
Reptin	O
,	O
and	O
Mep1A	O
mediates	O
Reptin	O
-	O
induced	O
migration	O
.	O
Overall	O
,	O
we	O
suggest	O
that	O
Mep1A	O
may	O
be	O
a	O
useful	O
target	O
in	O
HCC	B-T191
.	O
      
Shear	O
modulus	O
of	O
structured	O
electrorheological	O
fluid	O
mixtures	O
Some	O
immiscible	O
blends	O
under	O
a	O
strong	O
electric	O
field	O
often	O
exhibit	O
periodic	O
structures	O
,	O
bridging	O
the	O
gap	O
between	O
two	O
electrodes	O
.	O
Upon	O
shear	O
,	O
the	O
structures	O
tilt	O
,	O
and	O
exhibit	O
an	O
elastic	O
response	O
which	O
is	O
mostly	O
governed	O
by	O
the	O
electric	O
energy	O
.	O
Assuming	O
a	O
two	O
-	O
dimensional	O
stripe	O
structure	O
,	O
we	O
calculate	O
the	O
Maxwell	O
stress	O
,	O
and	O
derive	O
an	O
expression	O
for	O
the	O
shear	O
modulus	O
,	O
demonstrating	O
how	O
it	O
depends	O
on	O
the	O
external	O
electric	O
field	O
,	O
the	O
composition	O
,	O
and	O
the	O
dielectric	O
properties	O
of	O
the	O
blend	O
.	O
We	O
also	O
suggest	O
the	O
notion	O
of	O
effective	O
interfacial	O
tension	O
,	O
which	O
renormalizes	O
the	O
effect	O
of	O
the	O
electric	O
field	O
.	O
This	O
leads	O
to	O
a	O
simple	O
derivation	O
of	O
the	O
scaling	O
law	O
for	O
the	O
selection	O
of	O
the	O
wavelength	O
of	O
the	O
structure	O
formed	O
under	O
an	O
electric	O
field	O
.	O
      
A	O
Novel	O
Selective	O
Inhibitor	B-T121
of	O
Delta-5	O
Desaturase	O
Lowers	O
Insulin	O
Resistance	O
and	O
Reduces	B-T033
Body	I-T033
Weight	I-T033
in	O
Diet	O
-Induced	O
Obese	B-T047
C57BL/6J	O
Mice	O
Obesity	B-T047
is	O
now	O
recognized	O
as	O
a	O
state	O
of	O
chronic	O
low	O
-	O
grade	O
inflammation	O
and	O
is	O
called	O
as	O
metabolic	O
inflammation	O
.	O
Delta-5	O
desaturase	O
(	O
D5D	O
)	O
is	O
an	O
enzyme	O
that	O
metabolizes	O
dihomo	O
-	O
γ	O
-	O
linolenic	O
acid	O
(	O
DGLA	O
)	O
to	O
arachidonic	O
acid	O
(	O
AA	O
)	O
.	O
Thus	O
,	O
D5D	O
inhibition	O
increases	O
DGLA	O
(	O
precursor	O
to	O
anti	O
-	O
inflammatory	O
eicosanoids	O
)	O
while	O
decreasing	O
AA	O
(	O
precursor	O
to	O
pro	O
-	O
inflammatory	O
eicosanoids	O
)	O
,	O
and	O
could	O
result	O
in	O
synergistic	O
improvement	O
in	O
the	O
low	O
-	O
grade	O
inflammatory	O
state	O
.	O
Here	O
,	O
we	O
demonstrate	O
reduced	O
insulin	O
resistance	O
and	O
the	O
anti	B-T121
-	I-T121
obesity	I-T121
effect	O
of	O
a	O
D5D	O
selective	O
inhibitor	O
(	O
compound-326	B-T121
)	O
,	O
an	O
orally	O
active	O
small	O
-	O
molecule	O
,	O
in	O
a	O
high	O
-	O
fat	O
diet	O
-induced	O
obese	O
(	O
DIO	O
)	O
mouse	O
model	B-T050
.	O
In	O
vivo	O
D5D	O
inhibition	O
was	O
confirmed	O
by	O
determining	O
changes	O
in	O
blood	O
AA	O
/	O
DGLA	O
profiles	B-T059
.	O
In	O
DIO	O
mice	O
,	O
chronic	O
treatment	O
with	O
compound-326	B-T121
lowered	O
insulin	O
resistance	O
and	O
caused	O
body	B-T033
weight	I-T033
loss	I-T033
without	O
significant	O
impact	O
on	O
cumulative	O
calorie	O
intake	O
.	O
Decreased	O
macrophage	B-T033
infiltration	I-T033
into	I-T033
adipose	I-T033
tissue	I-T033
was	O
expected	O
from	O
mRNA	B-T059
analysis	I-T059
.	O
Increased	O
daily	O
energy	O
expenditure	O
was	O
also	O
observed	O
following	O
administration	B-T061
of	O
compound-326	B-T121
,	O
in	O
line	O
with	O
sustained	O
body	B-T033
weight	I-T033
loss	I-T033
.	O
These	O
data	O
indicate	O
that	O
the	O
novel	O
D5D	O
selective	O
inhibitor	B-T121
,	O
compound-326	B-T121
,	O
will	O
be	O
a	O
new	O
class	O
of	O
drug	O
for	O
the	O
treatment	O
of	O
obese	B-T047
and	O
diabetic	B-T047
patients	O
.	O
      
Estrogen	B-T121
deficiency	O
accelerates	O
lumbar	O
facet	O
joints	O
arthritis	B-T047
Dramatic	O
increase	O
in	O
the	O
prevalence	O
of	O
lumbar	O
facet	O
joint	O
(	O
LFJ	O
)	O
arthritis	B-T047
in	O
women	O
around	O
the	O
age	O
of	O
menopause	O
indicates	O
a	O
protective	O
role	O
for	O
estrogen	B-T121
in	O
LFJ	O
arthritis	B-T047
.	O
To	O
date	O
,	O
there	O
is	O
no	O
evidence	O
for	O
this	O
indication	O
and	O
the	O
mechanism	O
of	O
such	O
an	O
effect	O
remains	O
poorly	O
understood	O
.	O
In	O
this	O
study	O
,	O
ovariectomized	O
(	O
OVX	O
)	O
mice	O
were	O
used	O
to	O
mimic	O
the	O
estrogen	B-T121
-	O
deficient	O
status	O
of	O
post	O
-	O
menopausal	O
women	O
.	O
Micro	B-T060
-	I-T060
CT	I-T060
and	O
immunohistochemistry	B-T060
was	O
employed	O
to	O
assess	B-T058
the	O
morphological	O
and	O
molecular	O
changes	O
in	O
ovariectomy	B-T061
-	O
induced	O
LFJ	O
arthritis	B-T047
.	O
The	O
results	O
show	O
that	O
the	O
LFJ	O
subchondral	O
bone	O
mass	O
was	O
significantly	O
decreased	O
in	O
OVX	O
mice	O
,	O
with	O
increased	O
cavities	O
on	O
the	O
interface	O
of	O
the	O
subchondral	B-T023
bone	I-T023
.	O
Severe	O
cartilage	O
degradation	O
was	O
observed	O
in	O
ovariectomy	B-T061
-	O
induced	O
LFJ	O
arthritis	B-T047
.	O
Increased	O
blood	B-T023
vessels	I-T023
and	O
innervations	O
were	O
also	O
found	O
in	O
degenerated	O
LFJ	O
,	O
particularly	O
in	O
the	O
subchondral	B-T023
bone	I-T023
area	O
.	O
17β	B-T121
-	I-T121
Estradiol	I-T121
treatment	B-T061
efficiently	O
suppressed	O
LFJ	O
subchondral	B-T033
bone	I-T033
turnover	I-T033
,	O
markedly	O
inhibited	O
cartilage	O
degradation	O
,	O
and	O
increased	O
blood	B-T023
vessel	I-T023
and	O
nerve	O
ending	O
growth	O
in	O
degenerated	O
LFJ	O
in	O
OVX	O
mice	O
.	O
Our	O
study	O
reveals	O
that	O
estrogen	B-T121
is	O
a	O
key	O
factor	O
in	O
regulating	O
LFJ	O
metabolism	O
.	O
Severe	O
LFJ	O
degeneration	O
occurs	O
when	O
estrogen	B-T121
is	O
absent	O
in	O
vivo	O
.	O
Collapsed	O
subchondral	B-T023
bone	I-T023
may	O
be	O
the	O
initiation	O
of	O
this	O
process	O
,	O
and	O
estrogen	B-T061
replacement	I-T061
therapy	I-T061
can	O
effectively	O
prevent	O
degeneration	O
of	O
LFJ	O
under	O
estrogen	B-T121
-	O
deficient	O
conditions	O
.	O
      
High	B-T060
throughput	I-T060
selection	O
of	O
antibiotic	O
-	O
resistant	O
transgenic	O
Arabidopsis	O
plants	O
Kanamycin	B-T195
resistance	O
is	O
the	O
most	O
frequently	O
used	O
antibiotic	O
-	O
resistance	O
marker	O
for	O
Arabidopsis	O
transformations	O
,	O
however	O
,	O
this	O
method	O
frequently	O
causes	O
escape	O
of	O
untransformed	O
plants	O
,	O
particularly	O
at	O
the	O
high	O
seedling	O
density	O
during	O
the	O
selection	O
.	O
Here	O
we	O
developed	O
a	O
robust	O
high	O
-	O
density	O
selection	O
method	O
using	O
top	O
agar	B-T121
for	O
Arabidopsis	O
thaliana	O
.	O
Top	O
agar	B-T121
effectively	O
suppressed	O
growth	O
of	O
untransformed	O
wild	O
-	O
type	O
plants	O
on	O
selection	O
media	O
at	O
high	O
density	O
.	O
Survival	O
of	O
the	O
transformed	O
plants	O
during	O
the	O
selection	O
were	O
confirmed	B-T033
by	O
production	O
of	O
green	O
true	O
leaves	O
and	O
expression	O
of	O
a	O
firefly	O
luciferase	O
reporter	O
gene	O
.	O
Top	O
agar	B-T121
method	O
allowed	O
selection	O
using	O
a	O
large	O
amount	O
of	O
seeds	O
in	O
Arabidopsis	O
transformation	O
.	O
      
Netarsudil	B-T121
Increases	O
Outflow	B-T060
Facility	I-T060
in	O
Human	O
Eyes	B-T023
Through	O
Multiple	O
Mechanisms	O
Netarsudil	B-T121
is	O
a	O
Rho	B-T121
kinase	I-T121
/	I-T121
norepinephrine	I-T121
transporter	I-T121
inhibitor	I-T121
currently	O
in	O
phase	O
3	O
clinical	O
development	O
for	O
glaucoma	B-T047
treatment	B-T061
.	O
We	O
investigated	O
the	O
effects	O
of	O
its	O
active	O
metabolite	O
,	O
netarsudil	B-T121
-	I-T121
M1	I-T121
,	O
on	O
outflow	B-T060
facility	I-T060
(	O
C	B-T060
)	O
,	O
outflow	O
hydrodynamics	O
,	O
and	O
morphology	O
of	O
the	O
conventional	O
outflow	O
pathway	O
in	O
enucleated	O
human	O
eyes	O
.	O
Paired	O
human	O
eyes	B-T023
(	O
n	O
=	O
5	O
)	O
were	O
perfused	B-T061
with	O
either	O
0.3	O
μM	O
netarsudil	B-T121
-	I-T121
M1	I-T121
or	O
vehicle	O
solution	O
at	O
constant	O
pressure	O
(	O
15	O
mm	O
Hg	O
)	O
.	O
After	O
3	O
hours	O
,	O
fluorescent	O
microspheres	O
were	O
added	O
to	O
perfusion	B-T061
media	O
to	O
trace	O
the	O
outflow	O
patterns	O
before	O
perfusion	B-T061
-	O
fixation	B-T061
.	O
The	O
percentage	O
effective	O
filtration	O
length	O
(	O
PEFL	O
)	O
was	O
calculated	O
from	O
the	O
measured	O
lengths	O
of	O
tracer	O
distribution	O
in	O
the	O
trabecular	B-T023
meshwork	I-T023
(	O
TM	B-T023
)	O
,	O
episcleral	B-T023
veins	I-T023
(	O
ESVs	B-T023
)	O
,	O
and	O
along	O
the	O
inner	O
wall	O
(	O
IW	O
)	O
of	O
Schlemm	O
's	O
canal	O
after	O
global	O
and	O
confocal	B-T059
imaging	I-T059
.	O
Morphologic	B-T190
changes	I-T190
along	O
the	O
trabecular	B-T023
outflow	O
pathway	O
were	O
investigated	O
by	O
confocal	B-T059
,	O
light	B-T059
,	O
and	O
electron	B-T059
microscopy	I-T059
.	O
Perfusion	B-T061
with	O
netarsudil	B-T121
-	I-T121
M1	I-T121
significantly	O
increased	O
C	B-T060
when	O
compared	O
to	O
baseline	O
(	O
51	O
%	O
,	O
P	O
<	O
0.01	O
)	O
and	O
to	O
paired	O
controls	O
(	O
102	O
%	O
,	O
P	O
<	O
0.01	O
)	O
,	O
as	O
well	O
as	O
significantly	O
increased	O
PEFL	O
in	O
both	O
IW	O
(	O
P	O
<	O
0.05	O
)	O
and	O
ESVs	B-T023
(	O
P	O
<	O
0.01	O
)	O
.	O
In	O
treated	O
eyes	B-T023
,	O
PEFL	O
was	O
significantly	O
higher	O
in	O
ESVs	B-T023
than	O
in	O
the	O
IW	O
(	O
P	O
<	O
0.01	O
)	O
and	O
was	O
associated	O
with	O
increased	O
cross	O
-	O
sectional	O
area	O
of	O
ESVs	B-T023
(	O
P	O
<	O
0.01	O
)	O
.	O
Percentage	O
effective	O
filtration	O
length	O
in	O
ESVs	B-T023
positively	O
correlated	O
with	O
the	O
percentage	O
change	O
in	O
C	B-T060
(	O
R2	O
=	O
0.58	O
,	O
P	O
=	O
0.01	O
)	O
.	O
A	O
significant	O
increase	O
in	O
juxtacanalicular	O
connective	O
tissue	O
(	O
JCT	O
)	O
thickness	O
(	O
P	O
<	O
0.05	O
)	O
was	O
found	O
in	O
treated	O
eyes	B-T023
compared	O
to	O
controls	O
.	O
Netarsudil	B-T121
acutely	O
increased	O
C	B-T060
by	O
expansion	O
of	O
the	O
JCT	O
and	O
dilating	O
the	O
ESVs	B-T023
,	O
which	O
led	O
to	O
redistribution	O
of	O
aqueous	O
outflow	O
through	O
a	O
larger	O
area	O
of	O
the	O
IW	O
and	O
ESVs	B-T023
.	O
      
Opposing	O
Roles	O
of	O
Acetylation	O
and	O
Phosphorylation	O
in	O
LIFR	O
-	O
Dependent	O
Self	O
-	O
Renewal	O
Growth	O
Signaling	O
in	O
Mouse	O
Embryonic	O
Stem	O
Cells	O
LIF	O
promotes	O
self	O
-	O
renewal	O
of	O
mouse	O
embryonic	O
stem	O
cells	O
(	O
mESCs	O
)	O
,	O
and	O
in	O
its	O
absence	O
,	O
the	O
cells	O
differentiate	O
.	O
LIF	O
binds	O
to	O
the	O
LIF	O
receptor	O
(	O
LIFR	O
)	O
and	O
activates	O
the	O
JAK	O
-	O
STAT3	O
pathway	O
,	O
but	O
it	O
remains	O
unknown	O
how	O
the	O
receptor	O
complex	O
triggers	O
differentiation	O
or	O
self	O
-	O
renewal	O
.	O
Here	O
,	O
we	O
report	O
that	O
the	O
LIFR	O
cytoplasmic	O
domain	O
contains	O
a	O
self	O
-	O
renewal	O
domain	O
within	O
the	O
juxtamembrane	O
region	O
and	O
a	O
differentiation	O
domain	O
within	O
the	O
C	O
-	O
terminal	O
region	O
.	O
The	O
differentiation	O
domain	O
contains	O
four	O
SPXX	O
repeats	O
that	O
are	O
phosphorylated	O
by	O
MAPK	O
to	O
restrict	O
STAT3	O
activation	O
;	O
the	O
self	O
-	O
renewal	O
domain	O
is	O
characterized	O
by	O
a	O
3	O
K	O
motif	O
that	O
is	O
acetylated	O
by	O
p300	O
.	O
In	O
mESCs	O
,	O
acetyl-	O
LIFR	O
undergoes	O
homodimerization	O
,	O
leading	O
to	O
STAT3	O
hypo-	O
or	O
hyper	O
-	O
activation	O
depending	O
on	O
the	O
presence	B-T033
or	O
absence	O
of	O
gp130	O
.	O
LIFR	O
-	O
activated	O
STAT3	O
restricts	O
differentiation	O
via	O
cytokine	O
induction	O
.	O
Thus	O
,	O
LIFR	O
acetylation	O
and	O
serine	O
phosphorylation	O
differentially	O
promote	O
stem	O
cell	O
self	O
-	O
renewal	O
and	O
differentiation	O
.	O
      
Hard	O
ticks	O
(	O
Acari	O
:	O
Ixodidae	O
)	O
of	O
livestock	O
in	O
Nicaragua	O
,	O
with	O
notes	O
about	O
distribution	O
We	O
document	O
the	O
species	O
of	O
ticks	O
that	O
parasitize	B-T047
livestock	O
in	O
Nicaragua	O
.	O
The	O
study	O
was	O
based	O
on	O
tick	O
collection	O
on	O
cattle	O
and	O
horses	O
from	O
437	O
farms	O
in	O
nine	O
departments	O
.	O
Of	O
4841	O
animals	O
examined	O
(	O
4481	O
cows	O
and	O
360	O
horses	O
)	O
,	O
3299	O
were	O
parasitized	B-T047
,	O
which	O
represent	O
68	O
%	O
of	O
the	O
bovines	O
and	O
67	O
%	O
of	O
the	O
equines	O
in	O
study	O
:	O
59	O
cows	O
and	O
25	O
horses	O
were	O
parasitized	B-T047
by	O
more	O
than	O
one	O
species	O
.	O
In	O
addition	O
,	O
280	O
specimens	O
of	O
the	O
entomological	O
museum	O
in	O
León	O
were	O
examined	O
.	O
The	O
ticks	O
found	O
on	O
cattle	O
were	O
Rhipicephalus	O
microplus	O
(	O
75.2	O
%	O
of	O
the	O
ticks	O
collected	O
)	O
,	O
Amblyomma	O
mixtum	O
(	O
20.8	O
%	O
)	O
,	O
A.	O
parvum	O
(	O
2.6	O
%	O
)	O
,	O
A.	O
tenellum	O
(	O
0.7	O
%	O
)	O
,	O
A.	O
maculatum	O
(	O
0.7	O
%	O
)	O
.	O
While	O
the	O
ticks	O
collected	O
from	O
the	O
horses	O
were	O
:	O
Dermacentor	O
nitens	O
(	O
41.5	O
%	O
)	O
,	O
A.	O
mixtum	O
(	O
31.7	O
%	O
)	O
,	O
R.	O
microplus	O
(	O
13.8	O
%	O
)	O
,	O
A.	O
parvum	O
(	O
6.5	O
%	O
)	O
,	O
A.	O
tenellum	O
(	O
3.3	O
%	O
)	O
,	O
D.	O
dissimilis	O
(	O
2.4	O
%	O
)	O
and	O
A.	O
maculatum	O
(	O
0.8	O
%	O
)	O
.	O
      
Of	O
Kindlins	O
and	O
Cancer	B-T191
Kindlins	O
are	O
4.1	O
-	O
ezrin	O
-	O
ridixin	O
-	O
moesin	O
(	O
FERM	O
)	O
domain	O
containing	O
proteins	O
.	O
There	O
are	O
three	O
kindlins	O
in	O
mammals	O
,	O
which	O
share	O
high	O
sequence	O
identity	O
.	O
Kindlin-1	O
is	O
expressed	O
primarily	O
in	O
epithelial	O
cells	O
,	O
kindlin-2	O
is	O
widely	O
distributed	O
and	O
is	O
particularly	O
abundant	O
in	O
adherent	O
cells	O
,	O
and	O
kindlin-3	O
is	O
expressed	O
primarily	O
in	O
hematopoietic	O
cells	O
.	O
These	O
distributions	O
are	O
not	O
exclusive	O
;	O
some	O
cells	O
express	O
multiple	O
kindlins	O
,	O
and	O
transformed	O
cells	O
often	O
exhibit	O
aberrant	O
expression	O
,	O
both	O
in	O
the	O
isoforms	O
and	O
the	O
levels	O
of	O
kindlins	O
.	O
Great	O
interest	O
in	O
the	O
kindlins	O
has	O
emerged	O
from	O
the	O
recognition	O
that	O
they	O
play	O
major	O
roles	O
in	O
controlling	O
integrin	O
function	O
.	O
In	O
vitro	O
studies	O
,	O
in	O
vivo	O
studies	O
of	O
mice	O
deficient	O
in	O
kindlins	O
,	O
and	O
studies	O
of	O
patients	O
with	O
genetic	O
deficiencies	O
of	O
kindlins	O
have	O
clearly	O
established	O
that	O
they	O
regulate	O
the	O
capacity	O
of	O
integrins	O
to	O
mediate	O
their	O
functions	O
.	O
Kindlins	O
are	O
adaptor	O
proteins	O
;	O
their	O
function	O
emanate	O
from	O
their	O
interaction	O
with	O
binding	O
partners	O
,	O
including	O
the	O
cytoplasmic	O
tails	O
of	O
integrins	O
and	O
components	O
of	O
the	O
actin	O
cytoskeleton	O
.	O
The	O
purpose	O
of	O
this	O
review	O
is	O
to	O
provide	O
a	O
brief	O
overview	O
of	O
kindlin	O
structure	O
and	O
function	O
,	O
a	O
consideration	B-T033
of	O
their	O
binding	O
partners	O
,	O
and	O
then	O
to	O
focus	O
on	O
the	O
relationship	O
of	O
each	O
kindlin	O
family	O
member	O
with	O
cancer	B-T191
.	O
In	O
view	O
of	O
many	O
correlations	O
of	O
kindlin	O
expression	O
levels	O
and	O
neoplasia	B-T191
and	O
the	O
known	O
association	O
of	O
integrins	O
with	O
tumor	B-T191
progression	I-T191
and	O
metastasis	B-T191
,	O
we	O
consider	O
whether	O
regulation	O
of	O
kindlins	O
or	O
their	O
function	O
would	O
be	O
attractive	O
targets	O
for	O
treatment	B-T061
of	I-T061
cancer	I-T061
.	O
      
Gleason	O
grade	O
grouping	O
of	O
prostate	B-T191
cancer	I-T191
is	O
of	O
prognostic	O
value	O
in	O
Asian	O
men	O
The	O
International	O
Society	O
of	O
Urological	O
Pathology	O
made	O
recommendations	O
for	O
the	O
use	O
of	O
Grade	O
Groups	O
(	O
GG	O
)	O
originally	O
described	O
by	O
Epstein	O
and	O
colleagues	O
over	O
Gleason	B-T033
score	I-T033
(	O
GS	B-T033
)	O
alone	O
in	O
2014	O
,	O
which	O
was	O
subsequently	O
adopted	B-T033
by	O
the	O
WHO	O
classification	O
in	O
2016	O
.	O
The	O
majority	O
of	O
studies	O
validating	O
this	O
revision	O
have	O
been	O
in	O
Caucasian	O
populations	O
.	O
We	O
therefore	O
asked	O
whether	O
the	O
new	O
GG	O
system	O
was	O
retrospectively	O
associated	O
with	O
biochemical	O
disease	O
-	O
free	O
survival	O
in	O
a	O
mixed	O
-	O
ethnicity	O
cohort	O
of	O
Asian	O
men	O
.	O
A	O
total	O
of	O
680	O
radical	B-T061
prostatectomies	I-T061
(	O
RPs	B-T061
)	O
from	O
2005	O
to	O
2014	O
were	O
included	O
.	O
GS	B-T033
from	O
initial	O
biopsy	B-T060
and	O
RP	B-T061
were	O
compared	O
and	O
used	O
to	O
allocate	O
cases	O
to	O
GG	O
,	O
defined	O
as	O
:	O
1	O
(	O
GS	B-T033
≤6	O
)	O
;	O
2	O
(	O
GS	B-T033
3	O
+	O
4=7	O
)	O
;	O
3	O
(	O
GS	B-T033
4	O
+	O
3=7	O
)	O
;	O
4	O
(	O
GS	B-T033
4	O
+	O
4=8/5	O
+	O
3=8/3	O
+	O
5=8	O
)	O
and	O
5	O
(	O
GS	B-T033
9	O
-	O
10	O
)	O
.	O
Biochemical	B-T033
recurrence	I-T033
was	O
defined	O
as	O
two	O
consecutive	O
post-	O
RP	B-T061
prostate	O
-	O
specific	O
antigen	O
(	O
PSA	O
)	O
levels	O
of	O
>	O
0.2	O
ng	O
/	O
mL	O
after	O
post-	O
RP	B-T061
PSA	O
reaching	O
the	O
nadir	O
of	O
<	O
0.1	O
ng	O
/	O
mL.	O
Our	O
data	O
showed	O
that	O
Kaplan	O
-	O
Meier	O
analysis	O
revealed	O
significant	O
differences	O
in	O
biochemical	B-T033
recurrence	I-T033
within	O
Gleason	O
GG	O
based	O
on	O
either	O
biopsy	B-T060
or	O
prostatectomy	B-T061
scoring	O
.	O
Multivariate	O
analysis	O
further	O
confirmed	O
that	O
a	O
higher	O
GG	O
was	O
significantly	O
associated	O
with	O
risk	O
of	O
biochemical	B-T033
recurrence	I-T033
.	O
This	O
GG	O
system	O
had	O
a	O
higher	O
prognostic	O
discrimination	O
for	O
both	O
initial	O
biopsy	B-T060
and	O
RP	B-T061
than	O
GS	B-T033
.	O
Our	O
study	O
validates	O
the	O
use	O
of	O
the	O
revised	O
and	O
updated	O
GG	O
system	O
in	O
a	O
mixed	O
-	O
ethnicity	O
population	O
of	O
Asian	O
men	O
.	O
Higher	O
GG	O
was	O
significantly	O
associated	O
with	O
increased	O
risk	O
of	O
biochemical	B-T033
recurrence	I-T033
.	O
We	O
therefore	O
recommend	O
its	O
use	O
to	O
inform	O
clinical	B-T058
management	I-T058
for	O
patients	O
with	O
prostate	B-T191
cancer	I-T191
.	O
      
Complete	O
Genome	B-T059
Sequence	I-T059
Analysis	I-T059
of	O
a	O
Naturally	O
Reassorted	O
Infectious	B-T005
Bursal	I-T005
Disease	I-T005
Virus	I-T005
from	O
India	O
The	O
novel	O
infectious	B-T005
bursal	I-T005
disease	I-T005
virus	I-T005
(	O
IBDV	B-T005
)	O
isolate	O
BGE14	B-T005
/	I-T005
ABT1	I-T005
/	I-T005
MVC	I-T005
/	I-T005
India	I-T005
is	O
a	O
very	O
virulent	O
IBDV	B-T005
that	O
was	O
isolated	O
from	O
broiler	O
flocks	O
in	O
southern	O
parts	O
of	O
India	O
during	O
2014	O
.	O
Here	O
,	O
we	O
report	O
,	O
for	O
the	O
first	O
time	O
in	O
India	O
,	O
the	O
complete	O
genome	O
sequence	O
of	O
BGE14	B-T005
/	I-T005
ABT1	I-T005
/	I-T005
MVC	I-T005
/	I-T005
India	I-T005
,	O
a	O
reassortment	O
strain	B-T001
with	O
segments	O
A	O
and	O
B	O
derived	O
from	O
a	O
very	O
virulent	O
IBDV	B-T005
strain	B-T001
and	O
an	O
attenuated	O
IBDV	B-T005
,	O
respectively	O
.	O
The	O
findings	O
from	O
this	O
study	O
provide	O
additional	O
insight	O
into	O
the	O
genetic	O
exchange	O
between	O
attenuated	O
and	O
very	O
virulent	O
strains	B-T001
of	O
IBDV	B-T005
circulating	O
in	O
the	O
field	O
.	O
      
Zinc	B-T121
and	O
Wound	O
Healing	O
:	O
A	O
Review	O
of	O
Zinc	B-T121
Physiology	O
and	O
Clinical	O
Applications	O
Our	O
understanding	O
of	O
the	O
role	O
of	O
zinc	B-T121
in	O
normal	O
human	O
physiology	O
is	O
constantly	O
expanding	O
,	O
yet	O
there	O
are	O
major	O
gaps	O
in	O
our	O
knowledge	O
with	O
regard	O
to	O
the	O
function	O
of	O
zinc	B-T121
in	O
wound	O
healing	O
.	O
This	O
review	O
aims	O
to	O
provide	O
the	O
clinician	O
with	O
sufficient	O
understanding	O
of	O
zinc	B-T121
biology	O
and	O
an	O
up	O
-	O
to	O
-	O
date	O
perspective	O
on	O
the	O
role	O
of	O
zinc	B-T121
in	O
wound	O
healing	O
.	O
Zinc	B-T121
is	O
an	O
essential	O
ion	O
that	O
is	O
crucial	O
for	O
maintenance	O
of	O
normal	O
physiology	O
,	O
and	O
zinc	B-T047
deficiency	I-T047
has	O
many	O
manifestations	O
ranging	O
from	O
delayed	O
wound	O
healing	O
to	O
immune	B-T047
dysfunction	I-T047
and	O
impairment	O
of	O
multiple	O
sensory	O
systems	O
.	O
While	O
consensus	O
has	O
been	O
reached	O
regarding	O
the	O
detrimental	O
effects	O
of	O
zinc	B-T047
deficiency	I-T047
on	O
wound	O
healing	O
,	O
there	O
is	O
considerable	O
discord	O
in	O
the	O
literature	O
on	O
the	O
optimal	O
methods	O
and	O
true	O
benefits	O
of	O
zinc	B-T121
supplementation	O
.	O
      
Discontinued	B-T033
Splenogonadal	B-T019
Fusion	I-T019
and	O
Bilateral	B-T019
Empty	I-T019
Scrotum	I-T019
in	O
an	O
18-	O
Month	O
-Old	O
Boy	O
Splenogonadal	B-T019
fusion	I-T019
is	O
a	O
rare	O
benign	O
congenital	B-T019
anomaly	I-T019
defined	O
as	O
the	O
presence	O
of	O
splenic	O
tissue	O
adherent	O
to	O
gonads	B-T023
.	O
It	O
was	O
first	O
described	O
in	O
1883	O
by	O
Bostroem	O
,	O
a	O
German	O
pathologist	O
.	O
We	O
present	O
a	O
case	O
of	O
an	O
18-	O
month	O
-old	O
boy	O
who	O
was	O
referred	O
as	O
a	O
case	O
of	O
bilateral	B-T019
empty	I-T019
scrotum	I-T019
since	O
birth	O
.	O
During	O
routine	O
laparoscopic	B-T060
exploration	B-T061
,	O
right	B-T023
vas	I-T023
deferens	I-T023
and	O
testicular	B-T023
vessels	I-T023
were	O
entering	O
the	O
right	B-T023
internal	I-T023
inguinal	I-T023
ring	I-T023
so	O
right	O
inguinal	O
exploration	B-T061
was	O
done	O
,	O
which	O
revealed	O
blind	B-T033
ending	I-T033
vas	B-T023
deferens	I-T023
and	O
testicular	B-T023
vessels	I-T023
and	O
the	O
left	B-T023
testis	I-T023
was	O
found	O
intra	O
-	O
abdominally	O
near	O
the	O
left	O
internal	O
ring	O
with	O
a	O
mass	B-T184
on	O
its	O
upper	B-T023
pole	I-T023
.	O
Wedge	B-T060
biopsy	I-T060
was	O
taken	O
from	O
the	O
upper	B-T023
pole	I-T023
of	I-T023
the	I-T023
testicle	I-T023
(	O
site	O
of	O
the	O
mass	B-T184
)	O
for	O
tissue	O
diagnosis	O
followed	O
by	O
orchidopexy	B-T061
.	O
Histology	B-T059
showed	O
splenic	O
tissue	O
.	O
Although	O
splenogonadal	B-T019
fusion	I-T019
is	O
a	O
rare	O
condition	B-T047
,	O
surgeons	O
should	O
be	O
aware	O
of	O
this	O
rare	B-T047
disease	I-T047
entity	O
to	O
avoid	O
unnecessary	B-T058
aggressive	O
interventions	B-T061
such	O
as	O
orchiectomy	B-T061
.	O
      
Oxytocin	B-T121
Reduces	O
Face	O
Processing	O
Time	O
but	O
Leaves	O
Recognition	O
Accuracy	O
and	O
Eye	B-T023
-	O
Gaze	B-T033
Unaffected	O
Previous	O
studies	O
have	O
found	O
that	O
oxytocin	B-T121
(	O
OXT	B-T121
)	O
can	O
improve	B-T033
the	O
recognition	O
of	O
emotional	B-T033
facial	B-T033
expressions	I-T033
;	O
it	O
has	O
been	O
proposed	O
that	O
this	O
effect	O
is	O
mediated	O
by	O
an	O
increase	O
in	O
attention	O
to	O
the	O
eye	O
-	O
region	O
of	O
faces	O
.	O
Nevertheless	O
,	O
evidence	O
in	O
support	O
of	O
this	O
claim	O
is	O
inconsistent	O
,	O
and	O
few	O
studies	O
have	O
directly	O
tested	O
the	O
effect	O
of	O
oxytocin	B-T121
on	O
emotion	O
recognition	O
via	O
altered	O
eye	B-T023
-	O
gaze	B-T033
Methods	O
:	O
In	O
a	O
double	O
-	O
blind	O
,	O
within	O
-	O
subjects	O
,	O
randomized	O
control	O
experiment	O
,	O
40	O
healthy	O
male	O
participants	O
received	O
24	O
IU	O
intranasal	B-T061
OXT	B-T121
and	O
placebo	O
in	O
two	O
identical	O
experimental	O
sessions	O
separated	O
by	O
a	O
2-	O
week	O
interval	O
.	O
Visual	O
attention	O
to	O
the	O
eye	O
-	O
region	O
was	O
assessed	O
on	O
both	O
occasions	O
while	O
participants	O
completed	O
a	O
static	O
facial	O
emotion	O
recognition	O
task	O
using	O
medium	O
intensity	O
facial	B-T033
expressions	I-T033
.	O
Although	O
OXT	B-T121
had	O
no	O
effect	O
on	O
emotion	O
recognition	O
accuracy	O
,	O
recognition	O
performance	O
was	O
improved	B-T033
because	O
face	O
processing	O
was	O
faster	O
across	O
emotions	O
under	O
the	O
influence	O
of	O
OXT	B-T121
.	O
This	O
effect	O
was	O
marginally	O
significant	O
(	O
p<.06	O
)	O
.	O
Consistent	O
with	O
a	O
previous	O
study	O
using	O
dynamic	O
stimuli	O
,	O
OXT	B-T121
had	O
no	O
effect	O
on	O
eye	B-T023
-	O
gaze	B-T033
patterns	O
when	O
viewing	O
static	O
emotional	B-T033
faces	O
and	O
this	O
was	O
not	O
related	O
to	O
recognition	O
accuracy	O
or	O
face	O
processing	O
time	O
.	O
These	O
findings	B-T033
suggest	O
that	O
OXT	B-T121
-	O
induced	O
enhanced	O
facial	O
emotion	O
recognition	O
is	O
not	O
necessarily	O
mediated	O
by	O
an	O
increase	O
in	O
attention	O
to	O
the	O
eye	O
-	O
region	O
of	O
faces	O
,	O
as	O
previously	O
assumed	O
.	O
We	O
discuss	O
several	O
methodological	O
issues	B-T033
which	O
may	O
explain	O
discrepant	B-T033
findings	I-T033
and	O
suggest	O
the	O
effect	O
of	O
OXT	B-T121
on	O
visual	O
attention	O
may	O
differ	O
depending	O
on	O
task	O
requirements	O
.	O
(	O
JINS	O
,	O
2017	O
,	O
23	O
,	O
23	O
-	O
33	O
)	O
.	O
      
Systematic	O
Identification	O
of	O
Pharmacological	O
Targets	O
from	O
Small	O
-	O
Molecule	O
Phenotypic	B-T059
Screens	I-T059
Phenotypic	O
drug	O
discovery	O
offers	O
some	O
advantages	O
over	O
target	O
-	O
based	O
methods	O
,	O
mainly	O
because	O
it	O
allows	O
drug	B-T121
leads	I-T121
to	O
be	O
tested	O
in	O
systems	O
that	O
more	O
closely	B-T033
model	O
distinct	O
disease	B-T033
states	I-T033
.	O
However	O
,	O
a	O
potential	O
disadvantage	O
is	O
the	O
difficulty	O
of	O
linking	O
the	O
observed	O
phenotype	O
to	O
a	O
specific	O
cellular	O
target	O
.	O
To	O
address	O
this	O
problem	B-T033
,	O
we	O
developed	O
DePick	O
,	O
a	O
computational	O
target	O
de	O
-	O
convolution	O
tool	O
to	O
determine	B-T059
targets	O
specifically	O
linked	O
to	O
small	O
-	O
molecule	O
phenotypic	B-T059
screens	I-T059
.	O
We	O
applied	O
DePick	O
to	O
eight	O
publicly	O
available	O
screens	O
and	O
predicted	O
59	O
drug	B-T121
target	O
-	O
phenotype	O
associations	O
.	O
In	O
addition	O
to	O
literature	O
-	O
based	O
evidence	O
for	O
our	O
predictions	O
,	O
we	O
provide	O
experimental	O
support	O
for	O
seven	O
predicted	O
associations	O
.	O
Interestingly	O
,	O
our	O
analysis	O
led	O
to	O
the	O
discovery	O
of	O
a	O
previously	O
unrecognized	O
connection	O
between	O
the	O
Wnt	O
signaling	O
pathway	O
and	O
an	O
aromatase	O
,	O
CYP19A1	O
.	O
These	O
results	B-T033
demonstrate	O
that	O
the	O
DePick	O
approach	O
can	O
not	O
only	O
accelerate	O
target	O
de	O
-	O
convolution	O
but	O
also	O
aid	O
in	O
discovery	O
of	O
new	O
functionally	O
relevant	O
biological	O
relationships	O
.	O
      
The	O
EpiDerm	O
™	O
3D	B-T059
human	I-T059
reconstructed	I-T059
skin	I-T059
micronucleus	I-T059
(	I-T059
RSMN	I-T059
)	I-T059
assay	I-T059
:	O
Historical	O
control	O
data	O
and	O
proof	B-T033
of	O
principle	O
studies	O
for	O
mechanistic	B-T059
assay	I-T059
adaptations	O
The	O
in	B-T059
vitro	I-T059
human	I-T059
reconstructed	I-T059
skin	I-T059
micronucleus	I-T059
(	I-T059
RSMN	I-T059
)	I-T059
assay	I-T059
in	O
EpiDerm	O
™	O
is	O
a	O
promising	O
novel	O
animal	O
alternative	O
for	O
evaluating	O
genotoxicity	O
of	O
topically	B-T061
applied	I-T061
chemicals	O
.	O
It	O
is	O
particularly	O
useful	O
for	O
assessing	B-T058
cosmetic	O
ingredients	O
that	O
can	O
no	O
longer	O
be	O
tested	O
using	O
in	O
vivo	O
assays	B-T059
.	O
To	O
advance	O
the	O
use	O
of	O
this	O
test	O
especially	O
for	O
regulatory	O
decision	O
-	O
making	O
,	O
we	O
have	O
established	O
the	O
RSMN	B-T059
assay	I-T059
in	O
our	O
laboratory	O
according	O
to	O
Good	O
Laboratory	O
Practice	O
and	O
following	O
the	O
principles	O
of	O
the	O
OECD	O
test	O
guideline	O
487	O
in	O
vitro	O
mammalian	O
cell	O
micronucleus	B-T059
test	I-T059
.	O
Proficiency	O
with	O
the	O
assay	B-T059
was	O
established	O
by	O
correctly	O
identifying	O
direct	O
-	O
acting	O
genotoxins	O
and	O
genotoxins	O
requiring	O
metabolism	O
,	O
as	O
well	O
as	O
non	B-T033
-	I-T033
genotoxic	I-T033
/	O
non	B-T033
-	I-T033
carcinogenic	I-T033
chemicals	O
.	O
We	O
also	O
report	O
the	O
analysis	O
of	O
our	O
historical	O
control	O
data	O
that	O
demonstrate	O
vehicle	O
control	O
and	O
positive	O
control	O
values	O
for	O
%	O
micronuclei	O
in	O
binucleated	O
cells	O
are	O
in	O
the	O
ranges	O
reported	O
previously	O
.	O
Technical	O
issues	O
including	O
evaluating	O
various	O
solvents	O
with	O
both	O
48h	O
and	O
72h	O
treatment	B-T061
regimens	I-T061
were	O
investigated	O
.	O
For	O
the	O
first	O
time	O
,	O
mechanistic	O
studies	O
using	O
CREST	O
analysis	O
revealed	O
that	O
the	O
RSMN	B-T059
assay	I-T059
is	O
suitable	O
for	O
distinguishing	O
aneugens	O
and	O
clastogens	O
.	O
Moreover	O
,	O
the	O
assay	B-T059
is	O
also	O
suitable	O
for	O
measuring	O
cytokines	O
as	O
markers	O
for	O
proliferative	O
and	O
toxic	O
effects	O
of	O
chemicals	O
.	O
      
Trends	O
in	O
dietary	O
intake	O
among	O
adults	O
with	O
type	B-T047
2	I-T047
diabetes	I-T047
:	O
NHANES	O
1988	O
-	O
2012	O
Dietary	O
recommendations	O
for	O
adults	O
with	O
diabetes	B-T047
are	O
to	O
follow	O
a	O
healthy	B-T061
diet	I-T061
in	O
appropriate	O
portion	O
sizes	O
.	O
We	O
determined	O
recent	O
trends	O
in	O
energy	O
and	O
nutrient	O
intakes	O
among	O
a	O
nationally	O
representative	O
sample	O
of	O
US	O
adults	O
with	O
and	O
without	O
type	B-T047
2	I-T047
diabetes	I-T047
.	O
Participants	O
were	O
adults	O
aged	O
≥20	O
years	O
from	O
the	O
cross	O
-	O
sectional	O
National	O
Health	O
and	O
Nutrition	O
Examination	O
Surveys	O
,	O
1988	O
-	O
2012	O
(	O
N	O
=	O
49	O
770	O
)	O
.	O
Diabetes	B-T047
was	O
determined	O
by	O
self	O
-	O
report	O
of	O
a	O
physician	O
's	O
diagnosis	B-T033
(	O
n	O
=	O
4885	O
)	O
.	O
Intake	O
of	O
energy	O
and	O
nutrients	O
were	O
determined	O
from	O
a	O
24-	O
h	O
recall	O
by	O
participants	O
of	O
all	O
food	O
consumed	O
.	O
Linear	O
regression	O
was	O
used	O
to	O
test	O
for	O
trends	O
in	O
mean	O
intake	O
over	O
time	O
for	O
all	O
participants	O
and	O
by	O
demographic	O
characteristics	O
.	O
Among	O
adults	O
with	O
diabetes	B-T047
,	O
overall	O
total	O
energy	O
intake	O
increased	O
between	O
1988	O
-	O
1994	O
and	O
2011	O
-	O
2012	O
(	O
1689	O
kcal	O
versus	O
1895	O
kcal	O
;	O
Ptrend	O
<	O
0.001	O
)	O
with	O
evidence	O
of	O
a	O
plateau	O
between	O
2003	O
-	O
2006	O
and	O
2011	O
-	O
2012	O
.	O
In	O
2007	O
-	O
2012	O
,	O
energy	O
intake	O
was	O
greater	O
for	O
younger	O
than	O
older	O
adults	O
,	O
for	O
men	O
than	O
women	O
,	O
and	O
for	O
non	O
-	O
Hispanic	O
whites	O
versus	O
non	O
-	O
Hispanic	O
blacks	O
.	O
There	O
was	O
no	O
change	O
in	O
the	O
percentage	O
of	O
calories	O
from	O
carbohydrate	O
,	O
total	O
fat	O
or	O
protein	O
.	O
Percentage	O
of	O
calories	O
from	O
saturated	O
fat	O
was	O
similar	O
across	O
study	O
periods	O
but	O
remained	O
above	O
recommendations	O
(	O
11.2	O
%	O
in	O
2011	O
-	O
2012	O
)	O
.	O
Fibre	B-T033
intake	I-T033
significantly	O
decreased	O
and	O
remained	O
below	O
recommendations	O
(	O
Ptrend	O
=	O
0.002	O
)	O
.	O
Sodium	O
,	O
cholesterol	O
and	O
calcium	O
intakes	O
increased	O
.	O
There	O
was	O
no	O
change	O
in	O
energy	O
intake	O
among	O
adults	O
without	O
diabetes	B-T047
and	O
dietary	O
trends	O
were	O
similar	O
to	O
those	O
with	O
diabetes	B-T047
.	O
Future	O
data	O
are	O
needed	O
to	O
confirm	O
a	O
plateau	O
in	O
energy	O
intake	O
among	O
adults	O
with	O
diabetes	B-T047
,	O
although	O
the	O
opportunity	O
exists	O
to	O
increase	O
fibre	O
and	O
reduce	O
saturated	O
fat	O
.	O
      
High	O
HbA1c	O
at	O
onset	O
can	O
not	O
be	O
used	O
as	O
a	O
predictor	O
for	O
future	O
metabolic	O
control	O
for	O
the	O
individual	O
child	O
with	O
type	B-T047
1	I-T047
diabetes	I-T047
mellitus	I-T047
To	O
study	O
how	O
metabolic	O
control	O
at	O
onset	O
of	O
type	B-T047
1	I-T047
diabetes	I-T047
correlates	O
to	O
metabolic	O
control	O
and	O
clinical	O
parameters	B-T033
during	O
childhood	O
until	O
transition	O
from	O
pediatric	B-T061
care	I-T061
to	O
adult	O
diabetes	B-T061
care	I-T061
.	O
Data	O
at	O
onset	O
,	O
three	O
months	O
,	O
one	O
,	O
three	O
,	O
and	O
five	O
years	O
after	O
diagnosis	B-T033
and	O
at	O
transition	O
,	O
on	O
HbA1c	O
and	O
clinical	O
parameters	B-T033
,	O
on	O
8084	O
patients	O
in	O
the	O
Swedish	O
pediatric	O
quality	O
registry	O
,	O
SWEDIABKIDS	O
,	O
were	O
used	O
.	O
Of	O
these	O
patients	O
,	O
26	O
%	O
had	O
been	O
referred	O
to	O
adult	O
diabetes	B-T061
care	I-T061
by	O
2014	O
.	O
Children	O
with	O
HbA1c	O
<	O
72	O
mmol	O
/	O
mol	O
(	O
8.7	O
%	O
)	O
(	O
20	O
%	O
of	O
patients	O
,	O
low	O
group	O
)	O
at	O
diagnosis	B-T033
continued	O
to	O
have	O
good	O
metabolic	O
control	O
during	O
childhood	O
,	O
in	O
contrast	O
to	O
children	O
with	O
HbA1c	O
>	O
114	O
mmol	O
/	O
mol	O
(	O
12.6	O
%	O
)	O
(	O
20	O
%	O
of	O
patients	O
,	O
high	O
group	O
)	O
at	O
diagnosis	B-T033
,	O
who	O
continued	O
to	O
have	O
high	O
HbA1c	O
at	O
follow	B-T058
-	I-T058
up	I-T058
.	O
For	O
the	O
individual	O
,	O
there	O
was	O
no	B-T033
significant	I-T033
correlation	O
between	O
high	O
HbA1c	O
at	O
onset	O
and	O
during	O
follow	B-T058
-	I-T058
up	I-T058
.	O
During	O
follow	B-T058
-	I-T058
up	I-T058
,	O
children	O
in	O
the	O
high	O
group	O
were	O
more	O
often	O
smokers	B-T033
,	O
less	O
physically	B-T033
active	I-T033
,	O
and	O
more	O
often	O
had	O
retinopathy	B-T047
than	O
children	O
in	O
the	O
low	O
group	O
(	O
P	O
<	O
.01	O
,	O
.01	O
,	O
.03	O
respectively	O
)	O
.	O
High	O
HbA1c	O
at	O
onset	O
was	O
associated	O
with	O
high	O
HbA1c	O
during	O
follow	B-T058
-	I-T058
up	I-T058
on	O
a	O
group	O
level	O
,	O
but	O
it	O
can	O
not	O
be	O
used	O
as	O
a	O
predictor	O
of	O
future	O
metabolic	O
control	O
on	O
an	O
individual	O
level	O
.	O
These	O
results	O
emphasize	O
the	O
important	O
work	O
done	O
by	O
the	O
diabetes	B-T047
team	O
in	O
the	O
first	O
years	O
after	O
diagnosis	B-T033
.	O
It	O
is	O
important	O
to	O
continuously	O
set	O
high	O
goals	O
for	O
the	O
achievement	O
of	O
tight	O
metabolic	O
control	O
,	O
in	O
order	O
to	O
decrease	O
the	O
risk	O
of	O
microvascular	B-T047
complications	I-T047
.	O
      
Characterization	O
of	O
electrocorticogram	B-T060
high	O
-	O
gamma	O
signal	O
in	O
response	O
to	O
varying	O
upper	B-T023
extremity	I-T023
movement	O
velocity	O
The	O
mechanism	O
by	O
which	O
the	O
human	O
primary	O
motor	O
cortex	O
(	O
M1	O
)	O
encodes	O
upper	B-T023
extremity	I-T023
movement	O
kinematics	O
is	O
not	O
fully	O
understood	O
.	O
For	O
example	O
,	O
human	O
electrocorticogram	B-T060
(	O
ECoG	B-T060
)	O
signals	O
have	O
been	O
shown	O
to	O
modulate	O
with	O
upper	B-T023
extremity	I-T023
movement	O
s	O
;	O
however	O
,	O
this	O
relationship	O
has	O
not	O
been	O
explicitly	O
characterized	O
.	O
To	O
address	O
this	O
issue	B-T033
,	O
we	O
recorded	O
high	O
-	O
density	O
ECoG	B-T060
signals	O
from	O
patients	O
undergoing	O
epilepsy	B-T047
surgery	B-T061
evaluation	B-T058
as	O
they	O
performed	O
elementary	O
upper	B-T023
extremity	I-T023
movements	O
while	O
systematically	O
varying	O
movement	O
speed	O
and	O
duration	O
.	O
Specifically	O
,	O
subjects	O
performed	O
intermittent	O
pincer	B-T033
grasp	I-T033
/	O
release	O
,	O
elbow	B-T033
flexion	I-T033
/	O
extension	O
,	O
and	O
shoulder	B-T033
flexion	I-T033
/	O
extension	O
at	O
slow	O
,	O
moderate	O
,	O
and	O
fast	O
speeds	O
.	O
In	O
all	O
movements	O
,	O
bursts	O
of	O
power	O
in	O
the	O
high	O
-[Formula	O
:	O
see	O
text	O
]	O
band	O
(	O
80	O
-	O
160	O
Hz	O
)	O
were	O
observed	O
in	O
M1	O
.	O
In	O
addition	O
,	O
the	O
amplitude	O
of	O
these	O
power	O
bursts	O
and	O
the	O
area	O
of	O
M1	O
with	O
elevated	O
high	O
-[Formula	O
:	O
see	O
text	O
]	O
activity	O
were	O
directly	O
proportional	O
to	O
the	O
movement	O
speed	O
.	O
Likewise	O
,	O
the	O
duration	O
of	O
elevated	O
high	O
-[Formula	O
:	O
see	O
text	O
]	O
activity	O
increased	O
with	O
movement	O
duration	O
.	O
Based	O
on	O
linear	O
regression	O
,	O
M1	O
high	O
-[Formula	O
:	O
see	O
text	O
]	O
power	O
amplitude	O
and	O
duration	O
covaried	O
with	O
movement	O
speed	O
and	O
duration	O
,	O
respectively	O
,	O
with	O
an	O
average	O
[	O
Formula	O
:	O
see	O
text	O
]	O
of	O
[	O
Formula	O
:	O
see	O
text	O
]	O
and	O
[	O
Formula	O
:	O
see	O
text	O
]	O
.	O
These	O
findings	B-T033
indicate	O
that	O
the	O
encoding	O
of	O
upper	B-T023
extremity	I-T023
movement	O
speed	O
by	O
M1	O
high	O
-[Formula	O
:	O
see	O
text	O
]	O
activity	O
is	O
primarily	O
linear	O
.	O
Also	O
,	O
the	O
fact	O
that	O
this	O
activity	O
remained	O
elevated	O
throughout	O
a	O
movement	O
suggests	O
that	O
M1	O
does	O
not	O
merely	O
generate	O
transient	O
instructions	O
for	O
a	O
specific	O
movement	O
duration	O
,	O
but	O
instead	O
is	O
responsible	O
for	O
the	O
entirety	O
of	O
the	O
movement	O
.	O
Finally	O
,	O
the	O
spatial	O
distribution	O
of	O
high	O
-[Formula	O
:	O
see	O
text	O
]	O
activity	O
suggests	O
the	O
presence	B-T033
of	O
a	O
recruitment	O
phenomenon	O
in	O
which	O
higher	O
speeds	O
or	O
increased	O
muscle	O
activity	O
involve	O
activation	O
of	O
larger	O
M1	O
area	O
s.	O
      
Urachal	B-T047
carcinoma	I-T047
:	O
Report	O
of	O
two	O
cases	O
and	O
review	O
of	O
the	O
literature	O
Urachal	B-T047
carcinoma	I-T047
is	O
a	O
rare	O
tumor	B-T191
that	O
most	O
commonly	O
occurs	O
in	O
ovaries	B-T023
and	O
less	B-T033
often	I-T033
in	O
the	O
adnexal	B-T023
region	O
and	O
urinary	O
system	O
.	O
We	O
herein	O
present	O
two	O
cases	O
of	O
urachal	B-T047
carcinoma	I-T047
:	O
One	O
case	O
was	O
a	O
32	O
-	O
year	O
-	O
old	O
male	O
patient	O
who	O
presented	O
with	O
painless	B-T184
hematuria	I-T184
with	O
blood	O
clots	O
for	O
1	O
month	O
,	O
whereas	O
the	O
other	O
case	O
was	O
a	O
50	O
-	O
year	O
-	O
old	O
woman	O
who	O
presented	O
with	O
gross	B-T033
hematuria	I-T033
with	O
mild	O
dysuria	B-T184
,	O
urgency	B-T047
and	I-T047
frequent	I-T047
urination	I-T047
for	O
1	O
year	O
.	O
Following	O
surgical	B-T061
resection	I-T061
,	O
the	O
two	O
patients	O
were	O
diagnosed	B-T033
with	O
urachal	B-T047
adenocarcinoma	I-T047
(	O
mixed	O
type	O
)	O
and	O
urachal	B-T047
mucinous	I-T047
adenocarcinoma	I-T047
,	O
respectively	O
,	O
based	O
on	O
the	O
histopathological	O
examination	B-T058
.	O
A	O
review	O
of	O
previously	O
published	O
cases	O
and	O
relevant	O
literature	O
is	O
also	O
presented	O
.	O
The	O
aim	O
of	O
the	O
present	B-T033
study	O
was	O
to	O
help	O
understand	O
this	O
disease	B-T191
better	O
,	O
in	O
order	O
to	O
reduce	O
the	O
rate	O
of	O
clinical	O
and	O
pathological	O
misdiagnosis	B-T033
.	O
      
Theory	O
of	O
Mind	O
in	O
Adolescents	O
with	O
Bipolar	B-T048
Disorder	I-T048
in	O
Euthymic	B-T048
Phase	I-T048
:	O
‎Using	O
the	O
Strange	O
Stories	O
Test	O
Objective	O
:	O
This	O
study	O
evaluated	B-T058
the	O
theory	O
of	O
mind	O
(	O
ToM	O
)	O
in	O
adolescents	O
diagnosed	B-T033
with	O
bipolar	B-T048
disorder	I-T048
BD	B-T048
‎‎(BD	O
)	O
during	O
their	O
euthymic	B-T048
period	I-T048
compared	O
to	O
a	O
typically	O
developing	O
(	O
TD	O
)	O
group	O
.‎	O
Method	O
:	O
The	O
BD	B-T048
group	O
consisted	O
of	O
thirty	O
11	O
-	O
18	O
year	O
old	O
inpatients	O
in	O
euthymic	B-T048
phase	I-T048
.	O
The	O
TD	O
‎group	O
included	O
30	O
age	O
,	O
gender	O
,	O
and	O
IQ	O
matched	O
volunteer	O
students	O
.	O
To	O
assess	O
the	O
diagnosis	B-T033
and	O
‎comorbid	B-T047
disorders	I-T047
,	O
we	O
performed	O
the	O
semi	O
-	O
structured	O
interview	O
of	O
the	O
Kiddie	O
Schedule	O
for	O
Affective	O
Disorders	O
‎and	O
Schizophrenia	O
-	O
Present	O
and	O
Lifetime	O
Version	O
(	O
K	O
-	O
SADS	O
-	O
PL	O
)	O
for	O
the	O
BD	B-T048
adolescents	O
.	O
To	O
‎evaluate	B-T058
the	O
severity	O
of	O
attention	B-T048
deficit	I-T048
hyperactivity	I-T048
disorder	I-T048
(	O
ADHD	B-T048
)	O
and	O
mania	B-T048
,	O
Conner	O
's	O
‎Parent	O
Rating	O
Scale	O
-	O
Revised	O
version	O
(	O
CPRS	O
-	O
R	O
)	O
,	O
and	O
Young	O
Mania	O
Rating	O
Scale	O
(	O
YMRS	O
)	O
were	O
‎used	O
,	O
respectively	O
.	O
Ravens	O
Progressive	O
Matrices	O
was	O
conducted	O
to	O
evaluate	B-T058
intellectual	B-T033
ability	I-T033
in	O
‎the	O
both	O
groups	O
.	O
Happe	O
Strange	O
Stories	O
test	O
was	O
performed	O
to	O
assess	O
ToM	O
in	O
the	O
participants	O
.	O
Data	O
were	O
‎analyzed	O
using	O
the	O
independent	O
t	O
-	O
test	O
,	O
analysis	O
of	O
covariance	O
,	O
and	O
Pearson	O
Correlation	O
analysis	O
.‎	O
Results	O
:	O
The	O
two	O
groups	O
did	O
not	O
show	O
any	O
differences	O
in	O
comprehending	O
the	O
stories	O
;	O
however	O
,	O
the	O
BD	B-T048
‎	O
group	O
's	O
mentalizing	O
scores	O
were	O
significantly	O
weaker	O
than	O
the	O
TD	O
group	O
(	O
p<0.05).‎‎	O
Conclusion	O
:	O
The	O
ToM	O
impairments	O
in	O
adolescents	O
with	O
BD	B-T048
may	O
be	O
explained	O
as	O
a	O
trait	O
marker	O
which	O
may	O
lead	O
‎to	O
continuation	O
of	O
social	B-T033
problems	I-T033
even	O
during	O
remission‏	O
.‏.	O
      
Molecular	O
serum	O
signature	O
of	O
treatment	B-T048
resistant	I-T048
depression	I-T048
A	O
substantial	O
number	O
of	O
patients	O
suffering	O
from	O
major	B-T048
depressive	I-T048
disorder	I-T048
(	O
MDD	B-T048
)	O
do	O
not	O
respond	O
to	O
multiple	O
trials	O
of	O
anti	B-T121
-	I-T121
depressants	I-T121
,	O
develop	O
a	O
chronic	O
course	O
of	O
disease	O
and	O
become	O
treatment	B-T061
resistant	O
.	O
Most	O
of	O
the	O
studies	O
investigating	O
molecular	O
changes	O
in	O
treatment	B-T048
-	I-T048
resistant	I-T048
depression	I-T048
(	O
TRD	B-T048
)	O
have	O
only	O
examined	O
a	O
limited	O
number	O
of	O
molecules	O
and	O
genes	O
.	O
Consequently	O
,	O
biomarkers	O
associated	O
with	O
TRD	B-T048
are	O
still	O
lacking	O
.	O
This	O
study	O
aimed	O
to	O
use	O
recently	O
advanced	O
high	O
-	O
throughput	O
proteomic	O
platforms	O
to	O
identify	O
peripheral	O
biomarkers	O
of	O
TRD	B-T048
defined	O
by	O
two	O
staging	O
models	O
,	O
the	O
Thase	O
and	O
Rush	O
staging	O
model	O
(	O
TRM	O
)	O
and	O
the	O
Maudsley	O
Staging	O
Model	O
(	O
MSM	O
)	O
.	O
Serum	O
collected	O
from	O
an	O
inpatient	O
cohort	O
of	O
65	O
individuals	O
suffering	O
from	O
MDD	B-T048
was	O
analysed	O
using	O
two	O
different	O
mass	B-T059
spectrometric	I-T059
-	I-T059
based	I-T059
platforms	I-T059
,	O
label	B-T059
-	I-T059
free	I-T059
liquid	I-T059
chromatography	I-T059
mass	I-T059
spectrometry	I-T059
(	O
LC	B-T059
-	I-T059
MS(E	I-T059
)	I-T059
)	O
and	O
selective	O
reaction	O
monitoring	O
(	O
SRM	O
)	O
,	O
as	O
well	O
as	O
a	O
multiplex	B-T059
bead	I-T059
based	I-T059
assay	I-T059
.	O
In	O
the	O
LC	B-T059
-	I-T059
MS(E	I-T059
)	I-T059
analysis	I-T059
,	O
proteins	O
involved	O
in	O
the	O
acute	O
phase	O
response	O
and	O
complement	O
activation	O
and	O
coagulation	O
were	O
significantly	O
different	O
between	O
the	O
staging	O
groups	O
in	O
both	O
models	O
.	O
In	O
the	O
multiplex	B-T059
bead	I-T059
-	I-T059
based	I-T059
assay	I-T059
analysis	O
TNF	B-T059
-	I-T059
α	I-T059
levels	I-T059
(	O
log(odds	O
)	O
=	O
-4.95	O
,	O
p	O
=	O
0.045	O
)	O
were	O
significantly	O
different	O
in	O
the	O
TRM	O
comparison	O
.	O
Using	O
SRM	O
,	O
significant	O
changes	O
of	O
three	O
apolipoproteins	O
A	O
-	O
I	O
(	O
β	O
=	O
0.029	O
,	O
p	O
=	O
0.035	O
)	O
,	O
M	O
(	O
β	O
=	O
-0.017	O
,	O
p	O
=	O
0.009	O
)	O
and	O
F	B-T121
(	O
β	O
=	O
-0.031	O
,	O
p	O
=	O
0.024	O
)	O
were	O
associated	O
with	O
the	O
TRM	O
but	O
not	O
the	O
MSM	O
.	O
Overall	O
,	O
our	O
findings	B-T033
suggest	O
that	O
proteins	O
,	O
which	O
are	O
involved	O
in	O
immune	O
and	O
complement	O
activation	O
,	O
may	O
represent	O
potential	O
biomarkers	O
that	O
could	O
be	O
used	O
by	O
clinicians	O
to	O
identify	O
high	B-T033
-	I-T033
risk	I-T033
patients	O
.	O
Nevertheless	O
,	O
given	O
that	O
the	O
molecular	O
changes	O
between	O
the	O
staging	O
groups	O
were	O
subtle	O
,	O
the	O
results	O
need	O
to	O
be	O
interpreted	O
cautiously	O
.	O
      
Sequence	O
-	O
specific	O
DNA	O
binding	O
by	O
long	O
hairpin	O
pyrrole	O
-	O
imidazole	O
polyamides	O
containing	O
an	O
8	O
-	O
amino-3,6	O
-	O
dioxaoctanoic	O
acid	O
unit	O
With	O
the	O
aim	O
of	O
improving	O
aqueous	O
solubility	O
,	O
we	O
designed	O
and	O
synthesized	O
five	O
N	O
-	O
methylpyrrole	O
(	O
Py)-N	O
-	O
methylimidazole	O
(	O
I	O
m	O
)	O
polyamides	O
capable	O
of	O
recognizing	O
9	O
-	O
bp	O
sequences	O
.	O
Their	O
DNA	O
-	O
binding	O
affinities	O
and	O
sequence	O
specificities	O
were	O
evaluated	O
by	O
SPR	O
and	O
Bind	O
-	O
n	O
-	O
Seq	O
analyses	O
.	O
The	O
design	O
of	O
polyamide	O
1	O
was	O
based	O
on	O
a	O
conventional	O
model	O
,	O
with	O
three	O
consecutive	O
Py	O
or	O
I	O
m	O
rings	O
separated	O
by	O
a	O
β	B-T121
-	I-T121
alanine	I-T121
to	O
match	O
the	O
curvature	O
and	O
twist	O
of	O
long	O
DNA	O
helices	O
.	O
Polyamides	O
2	O
and	O
3	O
contained	O
an	O
8	O
-	O
amino-3,6	O
-	O
dioxaoctanoic	O
acid	O
(	O
AO	O
)	O
unit	O
,	O
which	O
has	O
previously	O
only	O
been	O
used	O
as	O
a	O
linker	O
within	O
linear	O
Py	O
-	O
Im	O
polyamides	O
or	O
between	O
Py	O
-	O
I	O
m	O
hairpin	O
motifs	O
for	O
tandem	O
hairpin	O
.	O
It	O
is	O
demonstrated	O
herein	O
that	O
AO	O
also	O
functions	O
as	O
a	O
linker	O
element	O
that	O
can	O
extend	O
to	O
2	O
-	O
bp	O
in	O
hairpin	O
motifs	O
.	O
Notably	O
,	O
although	O
the	O
AO	O
-containing	O
unit	O
can	O
fail	O
to	O
bind	O
the	O
expected	O
sequence	O
,	O
polyamide	O
4	O
,	O
which	O
has	O
two	O
AO	O
units	O
facing	O
each	O
other	O
in	O
a	O
hairpin	O
form	O
,	O
successfully	O
showed	O
the	O
expected	O
motif	O
and	O
a	O
KD	O
value	O
of	O
16nM	O
was	O
recorded	O
.	O
Polyamide	O
5	O
,	O
containing	O
a	O
β	B-T121
-	I-T121
alanine	I-T121
-	I-T121
β	I-T121
-	I-T121
alanine	I-T121
unit	O
instead	O
of	O
the	O
AO	O
of	O
polyamide	O
2	O
,	O
was	O
synthesized	O
for	O
comparison	O
.	O
The	O
aqueous	O
solubilities	O
and	O
nuclear	O
localization	O
of	O
three	O
of	O
the	O
polyamides	O
were	O
also	O
examined	O
.	O
The	O
results	O
suggest	O
the	O
possibility	O
of	O
applying	O
the	O
AO	O
unit	O
in	O
the	O
core	O
of	O
Py	O
-	O
Im	O
polyamide	O
compounds	O
.	O
      
Efficacy	O
and	O
safety	O
of	O
cisplatin	B-T121
,	O
dexamethasone	B-T121
,	O
gemcitabine	B-T121
and	O
pegaspargase	B-T121
(	O
DDGP	B-T121
)	O
regimen	B-T061
in	O
newly	O
diagnosed	O
,	O
advanced	O
-	O
stage	O
extranodal	B-T191
natural	I-T191
killer	I-T191
/	I-T191
T	I-T191
-	I-T191
cell	I-T191
lymphoma	I-T191
:	O
interim	O
analysis	O
of	O
a	O
phase	O
4	O
study	O
NCT01501149	O
To	O
explore	O
a	O
more	O
effective	O
treatment	O
for	O
newly	O
diagnosed	O
,	O
advanced	O
-	O
stage	O
extranodal	B-T191
natural	I-T191
killer	I-T191
/	I-T191
T	I-T191
-	I-T191
cell	I-T191
lymphoma	I-T191
,	I-T191
nasal	I-T191
type	I-T191
(	O
ENKTL	B-T191
)	O
,	O
we	O
conducted	O
a	O
phase	O
4	O
study	O
of	O
the	O
cisplatin	B-T121
,	O
dexamethasone	B-T121
,	O
gemcitabine	B-T121
,	O
pegaspargase	B-T121
(	O
DDGP	B-T121
)	O
regimen	B-T061
.	O
The	O
primary	O
end	O
point	O
was	O
the	O
2	O
-	O
year	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
after	O
the	O
protocol	B-T061
treatment	I-T061
.	O
Secondary	O
endpoints	O
included	O
response	O
rate	O
(	O
RR	O
)	O
,	O
overall	O
survival	O
(	O
OS	O
)	O
and	O
median	O
survival	O
time	O
(	O
MST	O
)	O
.	O
The	O
interim	O
analysis	O
included	O
data	O
only	O
from	O
March	O
2011	O
to	O
September	O
2013	O
,	O
who	O
received	O
six	O
cycles	O
of	O
DDGP	B-T121
chemotherapy	B-T061
.	O
A	O
total	O
of	O
25	O
eligible	O
patients	O
were	O
enrolled	O
.	O
Seventeen	O
patients	O
(	O
17/24	O
,	O
70.83	O
%	O
)	O
achieved	O
complete	B-T033
response	I-T033
(	O
CR	B-T033
)	O
and	O
four	O
(	O
4/24	O
,	O
16.67	O
%	O
)	O
achieved	O
partial	B-T033
response	I-T033
(	O
PR	B-T033
)	O
,	O
three	O
(	O
3/24	O
,	O
12.50	O
%	O
)	O
had	O
progressive	B-T047
disease	I-T047
(	O
PD	B-T047
)	O
.	O
The	O
RR	O
after	O
treatment	O
was	O
87.50	O
%	O
.	O
After	O
a	O
median	O
follow	B-T058
-	I-T058
up	I-T058
duration	O
of	O
24.67	O
months	O
(	O
range	O
4	O
-	O
48	O
months	O
)	O
.	O
The	O
2	O
-	O
year	O
PFS	O
and	O
OS	O
rate	O
were	O
61.80	O
%	O
(	O
95	O
%	O
CI	O
,	O
42.00	O
%	O
to	O
81.60	O
%	O
)	O
and	O
68.50	O
%	O
(	O
95	O
%	O
CI	O
,	O
48.70	O
%	O
to	O
88.30	O
%	O
)	O
,	O
respectively	O
.	O
The	O
MST	O
was	O
36.55	O
months	O
(	O
95	O
%	O
CI	O
,	O
29.41	O
months	O
to	O
43.70	O
months	O
)	O
.	O
Grade	O
3/4	O
leukopenia	B-T047
occurred	O
in	O
fourteen	O
patients	O
(	O
58.33	O
%	O
)	O
and	O
grade	O
3/4	O
thrombocytopenia	B-T047
occurred	O
in	O
eleven	O
patients	O
(	O
45.83	O
%	O
)	O
.	O
Twelve	O
patients	O
(	O
50.00	O
%	O
)	O
experienced	O
Activated	B-T059
Partial	I-T059
Phromboplastin	I-T059
Ptime	I-T059
(	O
APTT	B-T059
)	O
elongation	B-T033
and	O
fourteen	O
patients	O
(	O
58.33	O
%	O
)	O
experienced	O
hypofibrinogenemia	B-T047
.	O
In	O
conclusion	O
,	O
DDGP	B-T121
regimen	B-T061
is	O
an	O
effective	O
and	O
tolerated	B-T033
treatment	O
for	O
newly	O
diagnosed	O
,	O
advanced	O
-	O
stage	O
ENKTL	B-T191
.	O
This	O
trial	O
was	O
registered	B-T058
at	O
www.ClinicalTrials.gov	O
as	O
#	O
NCT01501149	O
.	O
      
Comparative	O
Effectiveness	O
of	O
Treatments	B-T061
for	O
Chronic	B-T047
Low	I-T047
Back	I-T047
Pain	I-T047
:	O
A	O
Multiple	O
Treatment	O
Comparison	O
Analysis	O
A	O
systematic	O
review	O
and	O
network	O
meta	O
-	O
analysis	O
.	O
To	O
determine	O
current	B-T061
treatment	I-T061
options	I-T061
of	O
chronic	B-T047
low	I-T047
back	I-T047
pain	I-T047
(	O
LBP	B-T047
)	O
as	O
defined	O
by	O
randomized	O
controlled	O
trials	O
(	O
RCTs	O
)	O
and	O
to	O
compare	O
effectiveness	O
of	O
those	O
treatments	B-T061
using	O
a	O
mixed	O
-	O
treatment	O
comparison	O
(	O
MTC	O
)	O
.	O
It	O
is	O
important	O
to	O
provide	O
an	O
evidence	O
-	O
based	O
assessment	B-T058
of	O
the	O
treatment	B-T061
options	I-T061
that	O
exist	O
for	O
LBP	B-T047
.	O
A	O
systematic	O
search	O
of	O
RCTs	O
was	O
conducted	O
in	O
MEDLINE	O
and	O
the	O
Cochrane	O
Collaboration	O
Library	O
from	O
1990	O
to	O
2014	O
.	O
From	O
the	O
selected	O
studies	O
,	O
we	O
extracted	O
preoperative	O
and	O
postoperative	O
ODI	B-T033
and	O
VAS	O
back	O
pain	O
scores	O
,	O
additional	B-T058
surgeries	I-T058
,	O
and	O
complications	O
.	O
Standard	O
and	O
network	O
meta	O
-	O
analytic	O
techniques	O
were	O
used	O
.	O
Twelve	O
RCTs	O
were	O
included	O
in	O
the	O
analysis	O
:	O
5	O
total	B-T061
disk	I-T061
replacement	I-T061
(	O
TDR	B-T061
)	O
versus	O
fusion	B-T061
;	O
1	O
TDR	B-T061
versus	O
exercise	B-T061
and	O
cognitive	B-T061
behavioral	I-T061
therapy	I-T061
(	O
CBT	B-T061
)	O
;	O
5	O
fusion	B-T061
versus	O
exercise	B-T061
and	O
CBT	B-T061
;	O
and	O
1	O
fusion	B-T061
versus	O
physical	B-T061
therapy	I-T061
(	O
PT	B-T061
)	O
.	O
On	O
the	O
basis	O
of	O
MTC	O
,	O
with	O
respect	O
to	O
ODI	B-T033
change	I-T033
scores	I-T033
,	O
the	O
pooled	O
mean	O
difference	O
favoring	O
fusion	B-T061
over	O
exercise	B-T061
and	O
CBT	B-T061
was	O
2.0	O
points	O
(	O
95	O
%	O
CI	O
,	O
-1.2	O
to	O
4.8	O
)	O
.	O
The	O
pooled	O
mean	O
difference	O
favoring	O
TDR	B-T061
over	O
exercise	B-T061
and	O
CBT	B-T061
was	O
6.4	O
points	O
(	O
95	O
%	O
CI	O
,	O
3.2	O
-	O
9.3	O
)	O
.	O
The	O
pooled	O
mean	O
difference	O
favoring	O
fusion	B-T061
over	O
PT	B-T061
was	O
8.8	O
points	O
(	O
95	O
%	O
CI	O
,	O
4.1	O
-	O
13.6	O
)	O
.	O
The	O
pooled	O
mean	O
differences	O
favoring	O
TDR	B-T061
over	O
fusion	B-T061
was	O
4.4	O
points	O
(	O
95	O
%	O
CI	O
,	O
2.37	O
-	O
6.63	O
)	O
.	O
For	O
PT	B-T061
versus	O
structured	B-T061
exercise	I-T061
with	O
CBT	B-T061
,	O
the	O
pooled	O
mean	O
difference	O
favoring	O
exercise	B-T061
with	O
CBT	B-T061
over	O
PT	B-T061
was	O
6.8	O
points	O
(	O
95	O
%	O
CI	O
,	O
1.5	O
-	O
12.8	O
)	O
.	O
For	O
TDR	B-T061
versus	O
PT	B-T061
,	O
the	O
pooled	O
mean	O
difference	O
favoring	O
TDR	B-T061
over	O
PT	B-T061
was	O
13.2	O
points	O
(	O
95	O
%	O
CI	O
,	O
8.0	O
-	O
18.4	O
)	O
.	O
Additional	O
surgery	O
rates	O
were	O
similar	O
between	O
treatment	B-T061
options	I-T061
.	O
All	O
4	O
treatments	B-T061
provided	O
some	O
benefit	O
to	O
patients	O
with	O
chronic	B-T047
LBP	I-T047
.	O
According	O
to	O
the	O
MTC	O
analysis	O
,	O
TDR	B-T061
may	O
be	O
the	O
most	O
effective	O
treatment	B-T061
and	O
PT	B-T061
the	O
least	O
effective	O
treatment	B-T061
for	O
chronic	B-T047
LBP	I-T047
.	O
This	O
review	O
is	O
based	O
on	O
a	O
limited	O
number	O
of	O
RCT	O
studies	O
and	O
does	O
not	O
support	O
any	O
1	O
treatment	B-T061
modality	O
for	O
all	O
patients	O
.	O
      
Evolution	O
of	O
Fitness	O
Cost	B-T033
-	I-T033
Neutral	I-T033
Mutant	O
PfCRT	O
Conferring	O
P.	O
falciparum	O
4	B-T121
-	I-T121
Aminoquinoline	I-T121
Drug	O
Resistance	O
Is	O
Accompanied	O
by	O
Altered	O
Parasite	O
Metabolism	O
and	O
Digestive	O
Vacuole	O
Physiology	O
Southeast	O
Asia	O
is	O
an	O
epicenter	O
of	O
multidrug	O
-	O
resistant	O
Plasmodium	O
falciparum	O
strains	O
.	O
Selective	O
pressures	O
on	O
the	O
subcontinent	O
have	O
recurrently	O
produced	O
several	O
allelic	O
variants	O
of	O
parasite	O
drug	O
resistance	O
genes	O
,	O
including	O
the	O
P.	O
falciparum	O
chloroquine	O
resistance	O
transporter	O
(	O
pfcrt	O
)	O
.	O
Despite	O
significant	O
reductions	B-T061
in	O
the	O
deployment	O
of	O
the	O
4	B-T121
-	I-T121
aminoquinoline	I-T121
drug	B-T121
chloroquine	B-T121
(	O
CQ	B-T121
)	O
,	O
which	O
selected	O
for	O
the	O
mutant	O
pfcrt	O
alleles	O
that	O
halted	O
CQ	B-T121
efficacy	O
decades	O
ago	O
,	O
the	O
parasite	O
pfcrt	O
locus	O
is	O
continuously	O
evolving	O
.	O
This	O
is	O
highlighted	O
by	O
the	O
presence	O
of	O
a	O
highly	O
mutated	O
allele	O
,	O
Cam734	O
pfcrt	O
,	O
which	O
has	O
acquired	O
the	O
singular	O
ability	O
to	O
confer	O
parasite	O
CQ	B-T121
resistance	O
without	O
an	O
associated	O
fitness	O
cost	O
.	O
Here	O
,	O
we	O
used	O
pfcrt	O
-specific	O
zinc	O
-	O
finger	O
nucleases	O
to	O
genetically	O
dissect	O
this	O
allele	O
in	O
the	O
pathogenic	B-T033
setting	O
of	O
asexual	O
blood	O
-	O
stage	O
infection	O
.	O
Comparative	O
analysis	O
of	O
drug	O
resistance	O
and	O
growth	O
profiles	O
of	O
recombinant	O
parasites	O
that	O
express	O
Cam734	O
or	O
variants	O
thereof	O
,	O
Dd2	O
(	O
the	O
most	O
common	O
Southeast	O
Asian	O
variant	O
)	O
,	O
or	O
wild	O
-	O
type	O
pfcrt	O
,	O
revealed	O
previously	O
unknown	O
roles	O
for	O
PfCRT	O
mutations	O
in	O
modulating	O
parasite	O
susceptibility	O
to	O
multiple	O
antimalarial	B-T121
agents	I-T121
.	O
These	O
results	O
were	O
generated	O
in	O
the	O
GC03	O
strain	B-T001
,	O
used	O
in	O
multiple	O
earlier	O
pfcrt	O
studies	O
,	O
and	O
might	O
differ	O
in	O
natural	O
isolates	O
harboring	O
this	O
allele	O
.	O
Results	O
presented	O
herein	O
show	O
that	O
Cam734	O
-mediated	O
CQ	B-T121
resistance	O
is	O
dependent	O
on	O
the	O
rare	O
A144F	O
mutation	O
that	O
has	O
not	O
been	O
observed	O
beyond	O
Southeast	O
Asia	O
,	O
and	O
reveal	O
distinct	O
impacts	O
of	O
this	O
and	O
other	O
Cam734	O
-specific	O
mutations	O
on	O
CQ	B-T121
resistance	O
and	O
parasite	O
growth	O
rates	O
.	O
Biochemical	B-T059
assays	I-T059
revealed	O
a	O
broad	O
impact	O
of	O
mutant	O
PfCRT	O
isoforms	O
on	O
parasite	O
metabolism	O
,	O
including	O
nucleoside	O
triphosphate	O
levels	O
,	O
hemoglobin	O
catabolism	O
and	O
disposition	O
of	O
heme	O
,	O
as	O
well	O
as	O
digestive	O
vacuole	O
volume	O
and	O
pH.	O
Results	O
from	O
our	O
study	O
provide	O
new	O
insights	O
into	O
the	O
complex	O
molecular	O
basis	O
and	O
physiological	O
impact	O
of	O
PfCRT	O
-mediated	O
antimalarial	B-T121
drug	O
resistance	O
,	O
and	O
inform	O
ongoing	O
efforts	O
to	O
characterize	O
novel	O
pfcrt	O
alleles	O
that	O
can	O
undermine	O
the	O
efficacy	O
of	O
first	O
-	O
line	O
antimalarial	B-T121
drug	I-T121
regimens	B-T061
.	O
      
CD169	O
identifies	B-T033
an	O
activated	O
CD8(+	O
)	O
T	O
cell	O
subset	O
in	O
regional	B-T023
lymph	I-T023
nodes	I-T023
that	O
predicts	O
favorable	O
prognosis	B-T058
in	O
colorectal	B-T191
cancer	I-T191
patients	O
CD169	O
was	O
first	O
identified	O
on	O
macrophages	O
(	O
Mϕ	O
)	O
and	O
linked	O
to	O
antigen	O
presentation	O
.	O
Here	O
,	O
we	O
showed	O
CD169	O
expression	O
on	O
some	O
CD8(+	O
)	O
T	O
lymphocytes	O
in	O
regional	B-T023
lymph	I-T023
nodes	I-T023
(	O
LNs	B-T023
)	O
and	O
investigated	O
the	O
function	O
and	O
clinical	B-T033
relevance	I-T033
of	O
CD169(+)CD8(+	O
)	O
T	O
cells	O
in	O
tumor	B-T023
-	I-T023
draining	I-T023
LNs	I-T023
of	O
colorectal	B-T191
cancer	I-T191
(	O
CRC	B-T191
)	O
patients	O
.	O
Fresh	O
tumor	O
-	O
draining	O
LN	O
tissues	O
from	O
39	O
randomly	O
enrolled	B-T033
patients	I-T033
were	O
assessed	O
by	O
flow	B-T059
cytometry	I-T059
for	O
activation	O
and	O
differentiation	O
of	O
CD169(+)CD8(+	O
)	O
T	O
cells	O
and	O
T	O
cell	O
-	O
mediated	O
killing	O
of	O
tumor	O
cells	O
.	O
In	O
total	O
,	O
114	O
tumor	B-T023
-	I-T023
draining	I-T023
LN	I-T023
paraffin	O
sections	O
from	O
CRC	B-T191
patients	O
were	O
analyzed	O
by	O
multiple	B-T059
-	I-T059
color	I-T059
immunofluorescence	I-T059
for	O
CD169(+)CD8(+	O
)	O
T	O
cell	O
distribution	O
and	O
clinical	O
values	O
.	O
The	O
prognostic	O
significance	O
of	O
CD169(+)CD8(+	O
)	O
T	O
cells	O
was	O
evaluated	B-T058
by	O
Kaplan	O
-	O
Meier	O
analysis	O
.	O
A	O
fraction	O
of	O
CD8(+	O
)	O
T	O
cells	O
in	O
regional	B-T023
LNs	I-T023
,	O
but	O
not	O
peripheral	O
blood	O
,	O
tonsils	B-T023
,	O
or	O
tumors	B-T191
,	O
expressed	O
surface	O
CD169	O
.	O
In	O
situ	O
detection	B-T061
of	O
draining	B-T023
LNs	I-T023
revealed	O
preferential	O
localization	O
of	O
CD169(+)CD8(+	O
)	O
T	O
cells	O
to	O
subcapsular	O
sinus	O
and	O
interfollicular	O
regions	O
,	O
closely	O
associated	O
with	O
CD169(+	O
)	O
Mϕ.	O
CD169(+)CD8(+	O
)	O
T	O
cell	O
ratios	O
were	O
significantly	O
lower	O
in	O
peri	O
-	O
tumor	O
LNs	B-T023
than	O
distant	O
-	O
tumor	O
LNs	B-T023
.	O
CD169(+)CD8(+	O
)	O
T	O
cells	O
predominantly	O
expressed	O
activation	O
markers	O
(	O
CD69	O
,	O
HLA	O
-	O
DR	O
,	O
PD-1	O
)	O
with	O
slightly	O
lower	O
CD45RA	O
and	O
CD62L	O
levels	O
.	O
They	O
produced	O
high	O
granzyme	O
B	O
,	O
perforin	O
,	O
TNF	O
-	O
α	O
,	O
and	O
IFNγ	B-T121
levels	O
,	O
and	O
promoted	O
tumor	B-T061
-	I-T061
killing	I-T061
efficiency	I-T061
ex	O
vitro	O
.	O
Moreover	O
,	O
CD169(+)CD8(+	O
)	O
T	O
cells	O
infiltrating	O
tumor	B-T023
-	I-T023
draining	I-T023
LNs	I-T023
decreased	O
with	O
disease	O
progression	O
and	O
were	O
strongly	O
associated	O
with	O
CRC	B-T191
patient	O
survival	O
.	O
We	O
identified	O
novel	O
activated	O
/	O
cytolytic	O
CD169(+)CD8(+	O
)	O
T	O
cells	O
selectively	O
present	O
in	O
regional	B-T023
LNs	I-T023
,	O
potentially	O
serving	O
as	O
a	O
powerful	O
prognostic	O
factor	O
and	O
indicator	O
for	O
selecting	O
patients	O
for	O
immunotherapy	B-T061
.	O
      
Regulated	O
Intron	O
Removal	O
Integrates	O
Motivational	O
State	O
and	O
Experience	O
Myriad	O
experiences	O
produce	O
transient	O
memory	O
,	O
yet	O
,	O
contingent	O
on	O
the	O
internal	O
state	O
of	O
the	O
organism	B-T001
and	O
the	O
saliency	O
of	O
the	O
experience	O
,	O
only	O
some	O
memories	O
persist	O
over	O
time	O
.	O
How	O
experience	O
and	O
internal	O
state	O
influence	O
the	O
duration	O
of	O
memory	O
at	O
the	O
molecular	O
level	O
remains	O
unknown	O
.	O
A	O
self	O
-	O
assembled	O
aggregated	O
state	O
of	O
Drosophila	O
Orb2A	O
protein	O
is	O
required	O
specifically	O
for	O
long	O
-	O
lasting	O
memory	O
.	O
We	O
report	O
that	O
in	O
the	O
adult	O
fly	O
brain	B-T023
the	O
mRNA	O
encoding	O
Orb2A	O
protein	O
exists	O
in	O
an	O
unspliced	O
non	O
-	O
protein	O
-	O
coding	O
form	O
.	O
The	O
convergence	O
of	O
experience	O
and	O
internal	O
drive	O
transiently	O
increases	O
the	O
spliced	O
protein	O
-	O
coding	O
Orb2A	O
mRNA	O
.	O
A	O
screen	O
identified	O
pasilla	O
,	O
the	O
fly	O
ortholog	O
of	O
mammalian	O
Nova-1	O
/	O
2	O
,	O
as	O
a	O
mediator	O
of	O
Orb2A	O
mRNA	O
processing	O
.	O
A	O
single	O
-	O
nucleotide	O
substitution	O
in	O
the	O
intronic	O
region	O
that	O
reduces	O
Pasilla	O
binding	O
and	O
intron	O
removal	O
selectively	O
impairs	O
long	O
-	O
term	O
memory	O
.	O
We	O
posit	O
that	O
pasilla	O
-mediated	O
processing	O
of	O
unspliced	O
Orb2A	O
mRNA	O
integrates	O
experience	O
and	O
internal	O
state	O
to	O
control	O
Orb2A	O
protein	O
abundance	O
and	O
long	O
-	O
term	O
memory	O
formation	O
.	O
      
How	O
do	O
wettability	O
,	O
zeta	O
potential	O
and	O
hydroxylation	B-T033
degree	I-T033
affect	O
the	O
biological	B-T033
response	I-T033
of	O
biomaterials	O
?	O
It	O
is	O
well	O
known	O
that	O
composition	O
,	O
electric	O
charge	O
,	O
wettability	O
and	O
roughness	O
of	O
implant	O
surfaces	O
have	O
great	O
influence	O
on	O
their	O
interaction	O
with	O
the	O
biological	O
fluids	O
and	O
tissues	O
,	O
but	O
systematic	O
studies	O
of	O
different	O
materials	O
in	O
the	O
same	O
experimental	O
conditions	O
are	O
still	O
lacking	O
in	O
the	O
scientific	O
literature	O
.	O
The	O
aim	O
of	O
this	O
research	O
is	O
to	O
investigate	O
the	O
correlations	O
between	O
some	O
surface	O
characteristics	O
(	O
wettability	O
,	O
zeta	O
potential	O
and	O
hydroxylation	B-T033
degree	I-T033
)	O
and	O
the	O
biological	B-T033
response	I-T033
(	O
protein	B-T033
adsorption	I-T033
,	O
blood	O
wettability	O
,	O
cell	O
and	O
bacterial	O
adhesion	O
)	O
to	O
some	O
model	O
biomaterials	O
.	O
The	O
resulting	O
knowledge	O
can	O
be	O
applied	O
for	O
the	O
development	O
of	O
future	O
innovative	O
surfaces	O
for	O
implantable	O
biomaterials	O
.	O
Roughness	O
was	O
not	O
considered	O
as	O
a	O
variable	O
because	O
it	O
is	O
a	O
widely	O
explored	O
feature	O
:	O
smooth	O
surfaces	O
prepared	O
by	O
a	O
controlled	O
protocol	O
were	O
compared	O
in	O
order	O
to	O
have	O
no	O
roughness	O
effects	O
.	O
Three	O
oxides	O
(	O
ZrO2	O
,	O
Al2O3	O
,	O
SiO2	O
)	O
,	O
three	O
metals	O
(	O
316LSS	O
steel	O
,	O
Ti	O
,	O
Nb	O
)	O
and	O
two	O
polymers	O
(	O
corona	O
treated	O
polystyrene	O
for	O
cell	B-T059
culture	I-T059
and	O
untreated	O
polystyrene	O
for	O
bacteria	B-T059
culture	I-T059
)	O
,	O
widely	O
used	O
for	O
biomedical	O
applications	O
,	O
were	O
considered	O
.	O
The	O
surfaces	O
were	O
characterized	O
by	O
contact	O
profilometry	O
,	O
SEM	B-T059
-	O
EDS	B-T059
,	O
XPS	B-T059
,	O
FTIR	O
,	O
zeta	O
potential	O
and	O
wettability	O
with	O
different	O
fluids	O
.	O
Protein	B-T033
adsorption	I-T033
,	O
blood	O
wettability	O
,	O
bacterial	O
and	O
cell	O
adhesion	O
were	O
evaluated	O
in	O
order	O
to	O
investigate	O
the	O
correlations	O
between	O
the	O
surface	O
physiochemical	O
properties	O
and	O
biological	B-T033
responses	I-T033
.	O
From	O
a	O
methodological	O
standpoint	O
,	O
XPS	B-T059
and	O
electrokinetic	O
measurements	O
emerged	O
as	O
the	O
more	O
suitable	O
techniques	O
respectively	O
for	O
the	O
evaluation	O
of	O
hydroxylation	B-T033
degree	I-T033
and	O
surface	O
charge	O
/	O
isoelectric	O
point	O
.	O
Moreover	O
,	O
determination	O
of	O
wettability	O
by	O
blood	O
appeared	O
a	O
specific	O
and	O
crucial	O
test	O
,	O
the	O
results	O
of	O
which	O
are	O
not	O
easily	O
predictable	O
by	O
using	O
other	O
type	O
of	O
tests	O
.	O
Hydroxylation	B-T033
degree	I-T033
resulted	O
correlated	O
to	O
the	O
wettability	O
by	O
water	B-T121
,	O
but	O
not	O
directly	O
to	O
surface	O
charge	O
.	O
Wetting	O
tests	O
with	O
different	O
media	O
showed	O
the	O
possibility	O
to	O
highlight	O
some	O
differences	O
among	O
look	O
-	O
alike	O
materials	O
.	O
A	O
dependence	O
of	O
protein	B-T033
absorption	I-T033
on	O
hydroxylation	B-T033
degree	I-T033
,	O
charge	O
and	O
wettability	O
was	O
evidenced	O
and	O
its	O
maximum	O
was	O
registered	O
for	O
surfaces	O
with	O
low	O
wettability	O
in	O
both	O
water	B-T121
based	O
and	O
protein	O
containing	O
media	O
and	O
a	O
moderate	O
surface	O
charge	O
.	O
As	O
far	O
as	O
bacterial	O
adhesion	O
is	O
concerned	O
,	O
no	O
effect	O
of	O
surface	O
charge	O
or	O
protein	B-T033
adsorption	I-T033
was	O
evidenced	O
,	O
while	O
the	O
presence	O
of	O
a	O
high	O
acid	O
component	O
of	O
the	O
surface	O
energy	O
appeared	O
significant	O
.	O
Finally	O
,	O
the	O
combination	O
of	O
hydroxylation	B-T033
degree	I-T033
,	O
wettability	O
,	O
surface	O
charge	O
and	O
energy	O
(	O
polar	O
component	O
)	O
emerged	O
as	O
a	O
key	O
parameter	O
for	O
cell	O
adhesion	O
and	O
viability	O
.	O
      
Toward	O
optimizing	O
dental	O
implant	O
performance	O
:	O
Surface	O
characterization	O
of	O
Ti	O
and	O
TiZr	O
implant	O
materials	O
Targeting	O
understanding	O
enhanced	O
osseointegration	O
kinetics	O
,	O
the	O
goal	O
of	O
this	O
study	O
was	O
to	O
characterize	O
the	O
surface	O
morphology	O
and	O
composition	O
of	O
Ti	O
and	O
TiZr	O
dental	O
implant	O
substrates	O
subjected	O
to	O
one	O
of	O
two	O
surface	O
treatments	O
developed	O
by	O
Straumann	O
.	O
These	O
two	O
treatments	O
are	O
typically	O
known	O
as	O
SLA	O
and	O
SLActive	O
,	O
with	O
the	O
latter	O
resulting	O
in	O
more	O
rapid	O
osseointegration	O
.	O
A	O
range	O
of	O
techniques	O
was	O
applied	O
to	O
characterize	O
four	O
different	O
substrate	O
/	O
surface	O
treatment	O
combinations	O
(	O
TiSLA	O
,	O
TiSLActive	O
,	O
TiZrSLA	O
,	O
and	O
TiZrSLActive	O
)	O
.	O
Contact	O
angle	O
measurements	O
establish	O
establish	O
their	O
hydrophilic	O
/	O
hydrophobic	O
nature	O
.	O
Surface	O
morphology	O
was	O
probed	O
with	O
scanning	B-T059
electron	I-T059
microscopy	I-T059
.	O
X	B-T059
-	I-T059
ray	I-T059
diffraction	I-T059
,	O
Raman	B-T059
μ	I-T059
-	I-T059
spectroscopy	I-T059
,	O
and	O
X	B-T059
-	I-T059
ray	I-T059
photoelectron	I-T059
spectroscopy	I-T059
were	O
used	O
to	O
elucidate	O
the	O
composition	O
of	O
the	O
near-	O
surface	O
region	O
.	O
Consistent	O
with	O
previous	O
work	O
,	O
surface	O
morphology	O
was	O
found	O
to	O
differ	O
only	O
at	O
the	O
nanoscale	O
,	O
with	O
both	O
SLActive	O
substrates	O
displaying	O
nano	O
-	O
protrusions	B-T190
.	O
Spectroscopic	B-T059
data	O
indicate	O
that	O
all	O
substrates	O
exhibit	O
surface	O
films	O
of	O
titanium	B-T121
oxide	I-T121
displaying	O
near	O
TiO2	B-T121
stoichiometry	O
.	O
Raman	B-T059
μ	I-T059
-	I-T059
spectroscopy	I-T059
reveals	O
that	O
amorphous	O
TiO2	B-T121
is	O
most	O
likely	O
the	O
only	O
phase	O
present	B-T033
on	O
TiSLA	O
,	O
whilst	O
rutile	B-T121
-	O
TiO2	B-T121
is	O
also	O
evidenced	O
on	O
TiSLActive	O
,	O
TiZrSLA	O
,	O
and	O
TiZrSLActive	O
.	O
For	O
TiZr	O
alloy	O
substrates	O
,	O
there	O
is	O
no	O
evidence	O
of	O
discrete	O
phases	O
of	O
oxidized	O
Zr	O
.	O
X	B-T059
-	I-T059
ray	I-T059
photoelectron	I-T059
spectra	I-T059
demonstrate	O
that	O
all	O
samples	O
are	O
terminated	O
by	O
adventitious	O
carbon	O
,	O
with	O
it	O
being	O
somewhat	O
thicker	O
(	O
∼1	O
nm	O
)	O
on	O
TiSLA	O
and	O
TiZrSLA	O
.	O
Given	O
previous	O
in	O
vivo	O
studies	O
,	O
acquired	O
data	O
suggest	O
that	O
both	O
nanoscale	O
protrusions	B-T190
,	O
and	O
a	O
thinner	O
layer	O
of	O
adventitious	O
carbon	O
contribute	O
to	O
the	O
more	O
rapid	O
osseointegration	O
of	O
SLActive	O
dental	O
implants	O
.	O
Composition	O
of	O
the	O
surface	O
oxide	O
layer	O
is	O
apparently	O
less	O
important	O
in	O
determining	O
osseointegration	O
kinetics	O
.	O
      
Randomized	O
Trials	O
of	O
the	O
Teen	O
Outreach	O
Program	O
in	O
Louisiana	O
and	O
Rochester	O
,	O
New	O
York	O
To	O
evaluate	B-T058
the	O
Teen	O
Outreach	O
Program	O
,	O
a	O
pregnancy	B-T061
prevention	I-T061
program	O
,	O
in	O
2	O
community	O
-based	O
settings	O
.	O
We	O
evaluated	B-T058
the	O
Teen	O
Outreach	O
Program	O
,	O
a	O
9	O
-	O
month	O
positive	O
youth	O
development	O
program	O
,	O
in	O
3	O
cohorts	O
of	O
youths	O
from	O
2012	O
to	O
2015	O
in	O
2	O
states	O
.	O
In	O
Louisiana	O
,	O
7	O
agencies	O
participated	O
in	O
an	O
individualized	O
randomized	O
controlled	O
trial	O
,	O
with	O
youths	O
randomly	O
assigned	O
to	O
a	O
treatment	B-T061
or	O
control	O
condition	O
.	O
Fourteen	O
agencies	O
in	O
Rochester	O
,	O
New	O
York	O
,	O
participated	O
in	O
a	O
cluster	O
randomized	O
controlled	O
trial	O
.	O
We	O
found	O
no	B-T033
differences	I-T033
between	O
the	O
intervention	B-T061
and	O
control	O
youths	O
on	O
delay	O
of	O
sexual	O
onset	O
in	O
Louisiana	O
(	O
adjusted	O
odds	O
ratio	O
[	O
AOR	O
]	O
=	O
0.80	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
=	O
0.62	O
,	O
1.03	O
)	O
or	O
in	O
Rochester	O
,	O
New	O
York	O
(	O
AOR	O
=	O
0.89	O
;	O
95	O
%	O
CI	O
=	O
0.45	O
,	O
1.77	O
)	O
,	O
or	O
for	O
sex	O
with	O
no	O
effective	O
means	O
of	O
birth	B-T121
control	I-T121
(	O
Louisiana	O
,	O
AOR	O
=	O
1.18	O
;	O
95	O
%	O
CI	O
=	O
0.78	O
,	O
1.78	O
;	O
Rochester	O
,	O
AOR	O
=	O
0.41	O
;	O
95	O
%	O
CI	O
=	O
0.13	O
,	O
1.27	O
)	O
after	O
controlling	O
for	O
relevant	O
covariates	O
.	O
We	O
found	O
no	B-T033
short	O
-	O
term	O
effects	O
for	O
the	O
offer	O
of	O
the	O
intervention	B-T061
.	O
Research	O
might	O
be	O
needed	O
for	O
the	O
long	O
-	O
term	O
and	O
intermediate	O
impacts	O
of	O
youth	O
development	O
programs	O
on	O
these	O
and	O
other	O
adolescent	O
risk	O
behaviors	O
.	O
      
Outlining	O
a	O
Population	O
"	O
at	O
Risk	O
"	O
of	O
Parkinson	B-T047
's	I-T047
Disease	I-T047
:	O
Evidence	O
from	O
a	O
Case	O
-	O
Control	O
Study	O
The	O
multifactorial	O
pathogenesis	O
of	O
Parkinson	B-T047
's	I-T047
Disease	I-T047
(	O
PD	B-T047
)	O
requires	O
a	O
careful	O
identification	O
of	O
populations	O
"	O
at	O
risk	O
"	O
of	O
developing	O
the	O
disease	B-T047
.	O
In	O
this	O
case	O
-	O
control	O
study	O
we	O
analyzed	O
a	O
large	O
Italian	O
population	O
,	O
in	O
an	O
attempt	O
to	O
outline	O
general	O
criteria	O
to	O
define	O
a	O
population	O
"	O
at	O
risk	O
"	O
of	O
PD	B-T047
.	O
We	O
enrolled	O
300	O
PD	B-T047
patients	O
and	O
300	O
controls	O
,	O
gender	O
and	O
age	O
matched	O
,	O
from	O
the	O
same	O
urban	O
geographical	O
area	O
.	O
All	O
subjects	O
were	O
interviewed	O
on	O
demographics	O
,	O
family	B-T033
history	I-T033
of	O
PD	B-T047
,	O
occupational	B-T033
and	I-T033
environmental	I-T033
toxicants	I-T033
exposure	I-T033
,	O
smoking	O
status	O
,	O
and	O
alcohol	O
consumption	O
.	O
A	O
sample	O
of	O
65	O
patients	O
and	O
65	O
controls	O
also	O
underwent	O
serum	O
dosing	O
of	O
iron	B-T059
,	O
copper	B-T059
,	O
mercury	B-T059
,	O
and	O
manganese	B-T059
by	O
means	O
of	O
Inductively	B-T059
Coupled	I-T059
-	I-T059
Plasma	I-T059
-	I-T059
Mass	I-T059
-	I-T059
Spectrometry	I-T059
(	O
ICP	B-T059
-	I-T059
MS	I-T059
)	O
.	O
Positive	B-T033
family	B-T033
history	I-T033
,	O
toxicants	B-T033
exposure	I-T033
,	O
non	B-T033
-	I-T033
current	I-T033
-	I-T033
smoker	I-T033
,	O
and	O
alcohol	B-T033
nonconsumer	I-T033
status	I-T033
occurred	O
as	O
significant	O
risk	B-T033
factors	I-T033
in	O
our	O
population	O
.	O
The	O
number	O
of	O
concurring	B-T033
risk	I-T033
factors	I-T033
overlapping	O
in	O
the	O
same	O
subject	O
impressively	O
increased	O
the	O
overall	O
risk	O
.	O
No	B-T033
significant	I-T033
differences	I-T033
were	O
measured	O
in	O
the	O
metal	O
serum	O
levels	O
.	O
Our	O
findings	B-T033
indicate	O
that	O
combination	O
of	O
three	O
to	O
four	O
concurrent	O
PD	B-T047
-	O
risk	B-T033
factors	I-T033
defines	O
a	O
condition	O
"	O
at	O
risk	O
"	O
of	O
PD	B-T047
.	O
A	O
simple	O
stratification	O
,	O
based	O
on	O
these	O
questionnaires	O
,	O
might	O
be	O
of	O
help	O
in	O
identifying	O
subjects	O
suitable	O
for	O
neuroprotective	O
strategies	O
.	O
      
Initial	O
experience	O
with	O
laparoscopic	B-T061
radical	I-T061
antegrade	I-T061
modular	I-T061
pancreatosplenectomy	I-T061
for	O
left	B-T191
-	I-T191
sided	I-T191
pancreatic	I-T191
cancer	I-T191
in	O
a	O
single	O
institution	O
:	O
technical	O
aspects	O
and	O
oncological	B-T033
outcomes	I-T033
Laparoscopic	B-T061
surgery	I-T061
has	O
been	O
performed	O
less	O
frequently	O
in	O
the	O
era	O
of	O
pancreatic	B-T191
cancer	I-T191
due	O
to	O
technical	O
difficulties	O
and	O
concerns	O
about	O
oncological	B-T191
safety	O
.	O
Radical	B-T061
antegrade	I-T061
modular	I-T061
pancreatosplenectomy	I-T061
(	O
RAMPS	B-T061
)	O
is	O
expected	O
to	O
be	O
helpful	O
to	O
obtain	O
a	O
negative	B-T033
margin	I-T033
during	O
radical	B-T061
lymph	I-T061
node	I-T061
dissection	I-T061
.	O
We	O
hypothesized	O
that	O
it	O
would	O
also	O
be	O
favorable	O
as	O
a	O
laparoscopic	O
application	O
due	O
to	O
unique	O
features	O
.	O
Fifteen	O
laparoscopic	B-T060
RAMPS	B-T061
for	O
well	O
-	O
selected	O
patients	O
with	O
left	B-T191
-	I-T191
sided	I-T191
pancreatic	I-T191
cancer	I-T191
were	O
performed	O
from	O
July	O
2011	O
to	O
April	O
2016	O
.	O
Five	O
trocars	O
were	O
usually	O
used	O
,	O
and	O
the	O
operative	B-T061
procedures	I-T061
and	O
range	B-T061
of	I-T061
dissection	I-T061
were	O
similar	O
to	O
or	O
the	O
same	O
as	O
those	O
of	O
open	O
RAMPS	B-T061
described	O
by	O
Strasberg	O
.	O
All	O
medical	O
records	O
and	O
follow	O
-	O
up	O
data	O
were	O
reviewed	O
and	O
analyzed	O
.	O
All	O
patients	O
had	O
pancreatic	B-T191
ductal	I-T191
adenocarcinoma	I-T191
.	O
Mean	O
operative	O
time	O
was	O
219.3	O
±	O
53.8	O
min	O
,	O
and	O
estimated	B-T033
blood	I-T033
loss	I-T033
was	O
250	O
±	O
70	O
ml	O
.	O
The	O
length	O
of	O
postoperative	O
hospital	O
stay	O
was	O
6.1	O
±	O
1.2	O
days	O
,	O
and	O
postoperative	O
morbidities	O
developed	O
in	O
two	O
patients	O
(	O
13.3	O
%	O
)	O
with	O
urinary	B-T033
retention	I-T033
.	O
The	O
median	O
number	O
of	O
retrieved	O
lymph	B-T023
nodes	I-T023
was	O
18.1	O
±	O
6.2	O
and	O
all	O
had	O
negative	B-T033
margins	I-T033
.	O
Median	O
follow	B-T058
-	I-T058
up	I-T058
time	O
was	O
46.0	O
months	O
,	O
and	O
the	O
3	O
-	O
year	O
disease	O
free	O
survival	O
and	O
overall	O
survival	O
rates	O
were	O
56.3	O
%	O
and	O
74.1	O
%	O
,	O
respectively	O
.	O
Our	O
early	O
experience	O
with	O
laparoscopic	B-T060
RAMPS	B-T061
achieved	O
feasible	O
perioperative	O
results	O
accompanied	O
by	O
acceptable	O
survival	O
outcomes	O
.	O
Laparoscopic	B-T060
RAMPS	B-T061
could	O
be	O
a	O
safe	O
and	O
oncologically	B-T191
feasible	O
procedure	O
in	O
well	O
-	O
selected	O
patients	O
with	O
left	B-T191
-	I-T191
sided	I-T191
pancreatic	I-T191
cancer	I-T191
.	O
      
Ultrasonic	B-T060
computed	I-T060
tomography	I-T060
imaging	I-T060
of	O
iron	O
oxide	O
nanoparticles	O
Iron	O
oxide	O
nanoparticles	O
(	O
IONPs	O
)	O
are	O
becoming	O
increasingly	O
used	O
and	O
intensively	O
investigated	O
in	O
the	O
field	O
of	O
medical	B-T060
imaging	I-T060
.	O
They	O
are	O
currently	O
FDA	O
approved	O
for	O
magnetic	B-T060
resonance	I-T060
imaging	I-T060
(	O
MRI	B-T060
)	O
,	O
and	O
it	O
would	O
be	O
highly	O
desirable	O
to	O
visualize	O
them	O
by	O
ultrasound	O
as	O
well	O
.	O
Previous	O
reports	O
using	O
the	O
conventional	O
ultrasound	B-T060
B	I-T060
-	I-T060
scan	I-T060
(	I-T060
pulse	I-T060
-	I-T060
echo	I-T060
)	I-T060
imaging	I-T060
technique	I-T060
have	O
shown	O
very	O
limited	O
detectability	O
of	O
these	O
particles	O
.	O
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
explore	O
the	O
feasibility	O
of	O
imaging	B-T060
IONPs	O
using	O
the	O
through	O
-	O
transmission	O
ultrasound	O
methodology	O
and	O
demonstrate	O
their	O
detectability	O
using	O
ultrasonic	B-T060
computed	I-T060
tomography	I-T060
(	O
UCT	B-T060
)	O
.	O
Commercially	O
available	O
IONPs	O
were	O
acoustically	O
analysed	O
to	O
quantify	O
their	O
effect	O
on	O
the	O
speed	O
of	O
sound	O
(	O
SOS	O
)	O
and	O
acoustic	O
attenuation	O
as	O
a	O
function	O
of	O
concentration	O
.	O
Next	O
,	O
through	B-T060
-	I-T060
transmission	I-T060
projection	I-T060
and	O
UCT	B-T060
imaging	I-T060
were	O
performed	O
on	O
a	O
breast	B-T023
mimicking	O
phantom	O
and	O
on	O
an	O
ex	B-T050
vivo	I-T050
tissue	I-T050
model	I-T050
,	O
to	O
which	O
IONPs	O
were	O
injected	O
.	O
Finally	O
,	O
an	O
MRI	B-T060
scan	I-T060
was	O
performed	O
to	O
verify	O
that	O
the	O
same	O
particles	O
examined	B-T033
in	O
the	O
ultrasound	O
experiment	O
can	O
be	O
imaged	O
by	O
magnetic	O
resonance	O
,	O
using	O
the	O
same	O
clinically	O
relevant	O
concentrations	O
.	O
The	O
results	B-T033
have	O
shown	O
a	O
consistent	O
concentration	O
dependent	O
speed	O
of	O
sound	O
increase	O
(	O
1.86	O
[	O
Formula	O
:	O
see	O
text	O
]	O
rise	O
per	O
100	O
µg	O
·	O
ml(-1	O
)	O
IONPs	O
)	O
.	O
Imaging	B-T060
based	O
on	O
this	O
property	O
has	O
shown	O
a	O
substantial	O
contrast	O
-	O
to	O
-	O
noise	O
ratio	O
improvement	O
(	O
up	O
to	O
5	O
fold	O
,	O
p	O
<	O
0.01	O
)	O
.	O
The	O
SOS	O
-related	O
effect	O
generated	O
a	O
well	O
discernible	O
image	O
contrast	O
and	O
allowed	O
the	O
detection	B-T033
of	O
the	O
particles	O
existence	O
and	O
location	O
,	O
in	O
both	O
raster	B-T060
-	I-T060
scan	I-T060
projection	I-T060
and	O
UCT	B-T060
imaging	I-T060
.	O
Conversely	O
,	O
no	O
significant	O
change	O
in	O
the	O
acoustic	O
attenuation	O
coefficient	O
was	O
noted	O
.	O
Based	O
on	O
these	O
findings	B-T033
,	O
it	O
is	O
concluded	O
that	O
IONPs	O
can	O
be	O
used	O
as	O
an	O
effective	O
SOS	O
-	O
based	O
contrast	O
agent	O
,	O
potentially	O
useful	O
for	O
ultrasonic	O
breast	B-T023
imaging	B-T060
.	O
Furthermore	O
,	O
the	O
particle	O
offers	O
the	O
capacity	O
of	O
significantly	O
enhancing	O
diagnosis	O
accuracy	O
using	O
multimodal	B-T060
MRI	B-T060
-	O
ultrasound	B-T060
imaging	I-T060
capabilities	O
.	O
      
Neuroprotective	O
Role	O
of	O
MicroRNA-22	O
in	O
a	O
6	B-T121
-	I-T121
Hydroxydopamine	I-T121
-	O
Induced	O
Cell	O
Model	B-T050
of	O
Parkinson	B-T047
's	I-T047
Disease	I-T047
via	O
Regulation	O
of	O
Its	O
Target	O
Gene	O
TRPM7	O
Parkinson	B-T047
's	I-T047
disease	I-T047
(	O
PD	B-T047
)	O
,	O
the	O
second	O
most	O
prevalent	O
neurodegenerative	B-T047
disorder	I-T047
with	O
only	O
symptomatic	O
treatment	B-T061
available	O
,	O
is	O
characterized	O
by	O
a	O
progressive	O
loss	O
of	O
dopaminergic	O
neurons	O
in	O
the	O
midbrain	B-T023
.	O
Ample	O
evidence	O
indicated	O
that	O
microRNAs	O
(	O
miRs	O
)	O
could	O
regulate	O
post	O
-	O
transcriptional	O
gene	O
expression	O
and	O
neuronal	B-T047
disease	I-T047
.	O
In	O
the	O
present	O
study	O
,	O
we	O
have	O
evaluated	O
the	O
effects	O
and	O
mechanism	O
of	O
miR-22	O
in	O
PC12	O
pheochromocytoma	O
cells	O
treated	O
with	O
6	B-T121
-	I-T121
hydroxydopamine	I-T121
(	O
6	B-T121
-	I-T121
OHDA	I-T121
)	O
to	O
mimic	O
PD	B-T047
.	O
RT	O
-	O
PCR	O
results	O
showed	O
that	O
the	O
expression	O
of	O
miR-22	O
is	O
downregulated	O
in	O
6	B-T121
-	I-T121
OHDA	I-T121
-	O
treated	O
PC12	O
cells	O
,	O
and	O
the	O
overexpression	O
of	O
miR-22	O
significantly	O
promoted	O
the	O
survival	O
and	O
proliferation	O
of	O
6	B-T121
-	I-T121
OHDA	I-T121
-	O
induced	O
PC12	O
cells	O
,	O
whereas	O
miR-22	O
inhibitor	O
reversed	O
these	O
effects	O
.	O
In	O
addition	O
,	O
PC12	O
cells	O
were	O
treated	O
with	O
miR-22	O
mimics	O
or	O
inhibitor	O
following	O
6	B-T121
-	I-T121
OHDA	I-T121
administration	B-T061
,	O
which	O
medicated	O
ROS	O
production	O
and	O
upregulation	O
or	O
downregulation	O
of	O
caspase-3	O
activity	O
,	O
respectively	O
.	O
A	O
luciferase	O
reporter	O
assay	B-T059
revealed	O
that	O
transient	O
receptor	O
potential	O
melastatin	O
7	O
(	O
TRPM7	O
)	O
is	O
a	O
direct	O
target	O
gene	O
of	O
miR-22	O
,	O
and	O
miR-22	O
overexpression	O
markedly	O
downregulated	O
the	O
level	O
of	O
TRPM7	O
.	O
Strikingly	O
,	O
further	O
analysis	O
showed	O
that	O
miR-22	O
mediated	O
6	B-T121
-	I-T121
OHDA	I-T121
-	O
induced	O
PC12	O
cell	O
survival	O
and	O
proliferation	O
by	O
targeting	O
TRPM7	O
.	O
Taken	O
together	O
,	O
the	O
present	O
study	O
showed	O
that	O
miR-22	O
overexpression	O
exhibited	O
neuroprotective	O
and	O
reversal	O
effects	O
on	O
the	O
6	B-T121
-	I-T121
OHDA	I-T121
-	O
induced	O
PC12	O
cell	O
growth	O
and	O
apoptosis	O
by	O
targeting	O
TRPM7	O
.	O
      
When	O
Is	O
a	O
Test	O
Score	O
Fair	O
for	O
the	O
Individual	O
Who	O
Is	O
Being	O
Tested	O
?	O
Effects	O
of	O
Different	O
Scoring	O
Procedures	O
across	O
Multiple	O
Attempts	O
When	O
Testing	O
a	O
Motor	O
Skill	O
Task	O
Tests	O
or	O
test	O
batteries	O
used	O
for	O
assessing	O
motor	O
skills	O
,	O
either	O
in	O
research	O
studies	O
or	O
in	O
clinical	O
settings	O
,	O
apply	O
a	O
variety	O
of	O
procedures	O
for	O
scoring	O
performances	O
,	O
including	O
everything	O
from	O
one	O
to	O
ten	O
attempts	O
,	O
of	O
which	O
the	O
best	O
is	O
scored	O
or	O
an	O
average	O
is	O
computed	B-T059
.	O
The	O
rationale	O
behind	O
scoring	O
procedures	O
is	O
rarely	O
stated	O
,	O
and	O
it	O
seems	O
that	O
the	O
number	O
of	O
attempts	O
allowed	O
is	O
decided	O
without	O
much	O
qualification	O
from	O
research	O
.	O
It	O
is	O
uncertain	O
whether	O
procedures	O
fairly	O
capture	O
an	O
individual	O
's	O
skill	O
level	O
.	O
Thus	O
,	O
the	O
validity	O
of	O
the	O
tests	O
may	O
be	O
compromised	O
.	O
The	O
present	O
study	O
tested	O
24	O
young	O
female	O
soccer	O
players	O
on	O
the	O
juggling	O
of	O
a	O
soccer	O
ball	O
.	O
They	O
were	O
given	O
10	O
attempts	O
,	O
and	O
trials	O
were	O
scored	O
according	O
to	O
nine	O
different	O
procedures	O
including	O
the	O
'	O
best	O
of	O
'	O
or	O
'	O
mean	O
of	O
'	O
either	O
one	O
,	O
two	O
,	O
three	O
,	O
five	O
,	O
or	O
ten	O
attempts	O
.	O
Individual	O
raw	O
scores	O
differed	O
widely	O
across	O
trials	O
,	O
but	O
no	O
general	O
effect	O
of	O
trials	O
was	O
found	O
.	O
The	O
mean	O
(	O
SD	O
)	O
percentage	O
difference	O
between	O
the	O
lowest	O
and	O
highest	O
scores	O
was	O
27.7(9.9)%	O
,	O
with	O
17	O
players	O
(	O
71	O
%	O
)	O
demonstrating	O
a	O
significant	O
change	O
from	O
lowest	O
to	O
highest	O
score	O
.	O
Correlations	O
between	O
raw	O
scores	O
were	O
low	O
across	O
trials	O
,	O
while	O
they	O
were	O
generally	O
higher	O
across	O
scoring	O
procedures	O
.	O
The	O
first	O
trial	O
was	O
significantly	O
different	O
from	O
the	O
remaining	O
both	O
as	O
a	O
raw	O
score	O
and	O
as	O
scoring	O
procedure	O
.	O
The	O
mean	O
percentage	O
difference	O
between	O
best	O
-	O
of	O
-	O
two	O
and	O
best	O
-	O
of	O
-	O
ten	O
scores	O
was	O
95	O
%	O
,	O
with	O
50	O
%	O
of	O
the	O
players	O
demonstrating	O
a	O
significant	O
difference	O
between	O
the	O
two	O
scoring	O
procedures	O
.	O
No	B-T033
significant	I-T033
differences	I-T033
were	O
found	O
across	O
mean	O
-	O
of	O
-	O
rule	O
scorings	O
.	O
Best	O
-	O
of	O
-	O
rule	O
and	O
mean	O
-	O
of	O
-	O
rule	O
scorings	O
were	O
significantly	O
different	O
except	O
for	O
the	O
best	O
-	O
of	O
-	O
two	O
vs.	O
mean	O
-	O
of	O
-	O
two	O
.	O
The	O
mean	O
difference	O
between	O
highest	O
and	O
lowest	O
rank	O
across	O
players	O
was	O
6.7	O
(	O
3.6	O
)	O
,	O
with	O
individual	O
rankings	O
within	O
the	O
group	O
varying	O
33	O
%	O
on	O
average	O
across	O
procedures	O
.	O
One	O
player	O
moved	O
from	O
3rd	O
to	O
23rd	O
place	O
because	O
of	O
procedural	O
differences	O
.	O
Therefore	O
,	O
it	O
is	O
concluded	O
that	O
scoring	O
procedures	O
affect	O
results	O
and	O
may	O
have	O
an	O
impact	O
on	O
test	O
outcomes	O
.	O
This	O
may	O
present	O
consequences	O
for	O
decision	O
-	O
making	O
from	O
test	O
results	O
,	O
such	O
as	O
diagnosing	B-T033
and	O
selection	O
of	O
intervention	B-T061
groups	O
.	O
We	O
hope	O
that	O
our	O
results	O
would	O
inspire	O
further	O
research	O
into	O
the	O
scoring	O
procedures	O
of	O
the	O
vast	O
amount	O
of	O
tests	O
and	O
tasks	O
in	O
common	O
use	O
.	O
      
Ethics	O
Hype	O
?	O
There	O
has	O
been	O
growing	O
concern	O
about	O
the	O
phenomenon	O
of	O
science	O
hype	O
,	O
the	O
tendency	O
to	O
exaggerate	O
the	O
value	O
or	O
near	O
-	O
future	O
application	O
of	O
research	B-T033
results	I-T033
.	O
Although	O
this	O
is	O
a	O
problem	B-T033
that	O
touches	O
every	O
area	O
of	O
biomedicine	O
,	O
the	O
topic	O
of	O
genetics	O
seems	O
to	O
be	O
particularly	O
prone	O
to	O
enthusiastic	O
predictions	O
.	O
The	O
world	O
has	O
been	O
told	O
for	O
over	O
two	O
decades	O
-by	O
the	O
media	O
,	O
researchers	O
,	O
politicians	O
,	O
and	O
the	O
biotech	O
industry	O
-that	O
a	O
genome	O
-driven	O
health	B-T058
care	I-T058
revolution	O
is	O
just	O
around	O
the	O
corner	O
.	O
And	O
while	O
the	O
revolution	O
never	O
seems	O
to	O
arrive	O
,	O
the	O
hopeful	O
rhetoric	O
continues	O
.	O
It	O
has	O
been	O
suggested	O
that	O
this	O
unrelenting	O
"	O
genohype	O
"	O
is	O
having	O
a	O
range	O
of	O
adverse	B-T033
social	O
consequences	O
,	O
including	O
misleading	O
the	O
public	O
and	O
hurting	B-T184
the	O
long	O
-	O
term	O
legitimacy	O
of	O
the	O
field	O
.	O
While	O
we	O
need	O
more	O
good	O
data	O
on	O
the	O
nature	O
and	O
magnitude	O
of	O
these	O
possible	O
harms	O
,	O
few	O
would	O
argue	O
with	O
the	O
proposition	O
that	O
sustained	O
science	O
hype	O
is	O
a	O
bad	O
thing	O
.	O
We	O
all	O
benefit	O
from	O
robust	O
science	O
and	O
accurate	O
public	O
representations	O
of	O
biomedical	O
research	O
.	O
But	O
,	O
to	O
date	O
,	O
there	O
has	O
been	O
very	O
little	O
consideration	B-T033
of	O
the	O
degree	O
to	O
which	O
the	O
scholarship	O
on	O
the	O
related	O
ethical	O
,	O
legal	O
,	O
and	O
social	O
issues	O
has	O
been	O
hyped	O
.	O
Are	O
the	O
conclusions	O
from	O
ELSI	O
scholarship	O
also	O
exaggerated	O
?	O
      
On	O
the	O
development	O
of	O
conjunctival	B-T047
hyperemia	I-T047
computer	B-T060
-	I-T060
assisted	I-T060
diagnosis	I-T060
tools	I-T060
:	O
Influence	O
of	O
feature	O
selection	O
and	O
class	O
imbalance	O
in	O
automatic	O
gradings	O
The	O
sudden	O
increase	O
of	O
blood	O
flow	O
in	O
the	O
bulbar	B-T023
conjunctiva	I-T023
,	O
known	O
as	O
hyperemia	B-T047
,	O
is	O
associated	O
to	O
a	O
red	O
hue	O
of	O
variable	O
intensity	O
.	O
Experts	O
measure	O
hyperemia	B-T047
using	O
levels	O
in	O
a	O
grading	O
scale	O
,	O
a	O
procedure	O
that	O
is	O
subjective	O
,	O
non	O
-	O
repeatable	O
and	O
time	O
consuming	O
,	O
thus	O
creating	O
a	O
need	O
for	O
its	O
automatisation	O
.	O
However	O
,	O
the	O
task	O
is	O
far	O
from	O
straightforward	O
due	O
to	O
data	O
issues	O
such	O
as	O
class	O
imbalance	O
or	O
correlated	O
features	O
.	O
In	O
this	O
paper	O
,	O
we	O
study	O
the	O
specific	O
features	O
of	O
hyperemia	B-T047
and	O
propose	O
various	O
approaches	O
to	O
address	O
these	O
problems	O
in	O
the	O
context	O
of	O
an	O
automatic	O
framework	O
for	O
hyperemia	B-T047
grading	B-T033
.	O
Oversampling	O
,	O
undersampling	O
and	O
SMOTE	O
approaches	O
were	O
applied	O
in	O
order	O
to	O
tackle	O
the	O
problem	O
of	O
class	O
imbalance	O
.	O
25	O
features	O
were	O
computed	O
for	O
each	O
image	O
and	O
regression	O
methods	O
were	O
then	O
used	O
to	O
transform	O
them	O
into	O
a	O
value	O
on	O
the	O
grading	O
scale	O
.	O
The	O
values	O
and	O
relationships	O
among	O
features	O
and	O
experts	B-T033
'	I-T033
values	I-T033
were	O
analysed	O
,	O
and	O
five	O
feature	O
selection	O
techniques	O
were	O
subsequently	O
studied	O
.	O
The	O
lowest	O
mean	O
square	O
error	O
(	O
MSE	O
)	O
for	O
the	O
regression	O
systems	O
trained	O
with	O
individual	O
features	O
is	O
below	O
0.1	O
for	O
both	O
scales	O
.	O
Multi	O
-	O
layer	O
perceptron	O
(	O
MLP	O
)	O
obtains	O
the	O
best	O
values	O
,	O
but	O
is	O
less	O
consistent	O
than	O
the	O
random	O
forest	O
(	O
RF	O
)	O
method	O
.	O
When	O
all	O
features	O
are	O
combined	O
,	O
the	O
best	O
results	O
for	O
both	O
scales	O
are	O
achieved	O
with	O
MLP	O
.	O
Correlation	O
based	O
feature	O
selection	O
(	O
CFS	O
)	O
and	O
M5	O
provide	O
the	O
best	O
results	O
,	O
MSE	O
=	O
0.108	O
and	O
MSE	O
=	O
0.061	O
respectively	O
.	O
Finally	O
,	O
the	O
class	O
imbalance	O
problem	O
is	O
minimised	O
with	O
the	O
SMOTE	O
approach	O
for	O
both	O
scales	O
(	O
MSE	O
<	O
0.006	O
)	O
.	O
Machine	O
learning	O
methods	O
are	O
able	O
to	O
perform	O
an	O
objective	O
assessment	O
of	O
hyperemia	B-T047
grading	B-T033
,	O
removing	O
both	O
intra-	O
and	O
inter	O
-	O
expert	O
subjectivity	O
while	O
providing	O
a	O
gain	O
in	O
computation	O
time	O
.	O
SMOTE	O
and	O
oversampling	O
approaches	O
minimise	O
the	O
class	O
imbalance	O
problem	O
,	O
while	O
feature	O
selection	O
reduces	O
the	O
number	O
of	O
features	O
from	O
25	O
to	O
3	O
-	O
5	O
without	O
worsening	O
the	O
MSE	O
.	O
As	O
the	O
differences	O
between	O
the	O
system	O
and	O
a	O
human	O
expert	O
are	O
similar	O
to	O
the	O
differences	O
between	O
experts	O
,	O
we	O
can	O
therefore	O
conclude	O
that	O
the	O
system	O
behaves	O
like	O
an	O
expert	O
.	O
      
Probabilistic	O
acute	O
risk	B-T058
assessment	I-T058
of	O
cumulative	O
exposure	O
to	O
organophosphorus	O
and	O
carbamate	B-T121
pesticides	I-T121
from	O
dietary	O
vegetables	O
and	O
fruits	O
in	O
Shanghai	O
populations	O
Organophosphorus	O
pesticides	O
(	O
OPs	O
)	O
and	O
carbamate	B-T121
pesticides	I-T121
(	O
CPs	B-T121
)	O
are	O
among	O
the	O
most	O
widely	O
used	O
pesticides	O
in	O
China	O
,	O
playing	O
a	O
major	O
role	O
in	O
protecting	B-T033
agricultural	O
commodities	O
.	O
In	O
this	O
study	O
,	O
we	O
determined	O
the	O
cumulative	O
acute	O
exposure	O
to	O
OPs	O
and	O
CPs	B-T121
of	O
Shanghai	O
residents	O
from	O
vegetables	O
and	O
fruits	O
(	O
VFs	O
)	O
.	O
The	O
food	O
consumption	O
data	O
were	O
obtained	O
from	O
the	O
Shanghai	O
Food	O
Consumption	O
Survey	O
(	O
SHFCS	O
)	O
of	O
2012	O
-	O
14	O
including	O
a	O
total	O
of	O
1973	O
participants	O
aged	O
2	O
-	O
90	O
years	O
.	O
The	O
pesticide	O
residue	O
data	O
were	O
obtained	O
from	O
the	O
Shanghai	O
monitoring	B-T058
programme	O
during	O
2008	O
-	O
11	O
with	O
34	O
organophosphates	O
and	O
11	O
carbamates	B-T121
analysed	O
in	O
a	O
total	O
of	O
5335	O
samples	O
of	O
VFs	O
.	O
A	O
probabilistic	O
approach	O
was	O
performed	O
as	O
recommended	O
by	O
the	O
EFSA	O
,	O
using	O
the	O
optimistic	O
model	O
with	O
non	O
-	O
detects	O
set	O
as	O
zero	O
and	O
with	O
processing	O
factors	O
(	O
PFs	O
)	O
being	O
used	O
and	O
the	O
pessimistic	O
model	O
with	O
non	O
-	O
detects	O
replaced	O
by	O
limit	O
of	O
detection	O
(	O
LOD	O
)	O
and	O
without	O
PFs	O
.	O
We	O
used	O
the	O
relative	O
potency	O
factor	O
(	O
RPF	O
)	O
method	O
to	O
normalise	O
the	O
various	O
pesticides	O
to	O
the	O
index	O
compound	O
(	O
IC	O
)	O
of	O
methamidophos	O
and	O
chlorpyrifos	O
separately	O
.	O
Only	O
in	O
the	O
pessimistic	O
model	O
using	O
methamidophos	O
as	O
the	O
IC	O
was	O
there	O
was	O
small	O
risk	O
of	O
exposure	O
exceeding	O
the	O
ARfD	O
(	O
3	O
µg	O
kg(-)(1	O
)	O
bw	O
day	O
(	O
-)(1	O
)	O
)	O
in	O
the	O
populations	O
of	O
preschool	O
children	O
(	O
0.029	O
%	O
)	O
,	O
school	O
-	O
age	O
children	O
(	O
0.022	O
%	O
)	O
and	O
adults	O
(	O
0.002	O
%	O
)	O
.	O
There	O
were	O
no	B-T033
risk	I-T033
of	O
exposure	O
exceeding	O
the	O
ARfD	O
of	O
methamidophos	O
in	O
the	O
optimistic	O
model	O
and	O
of	O
chlorpyrifos	O
(	O
100	O
µg	O
kg(-)(1	O
)	O
bw	O
day	O
(	O
-)(1	O
)	O
)	O
in	O
both	O
optimistic	B-T033
and	O
pessimistic	O
models	O
in	O
all	O
three	O
populations	O
.	O
Considering	O
the	O
Chinese	B-T033
habits	I-T033
of	O
overwhelmingly	O
eating	O
processed	O
food	O
(	O
vegetables	O
being	O
cooked	O
,	O
and	O
fruits	O
being	O
washed	O
or	O
peeled	O
)	O
,	O
we	O
conclude	O
that	O
little	O
acute	O
risk	O
was	O
found	O
for	O
the	O
exposure	O
to	O
VF	O
-	O
sourced	B-T033
OPs	O
and	O
CPs	B-T121
in	O
Shanghai	O
.	O
      
CT	B-T060
angiography	I-T060
for	O
planning	O
transcatheter	B-T061
aortic	I-T061
valve	I-T061
replacement	I-T061
using	O
automated	O
tube	O
voltage	O
selection	O
:	O
Image	O
quality	O
and	O
radiation	O
exposure	O
To	O
assess	B-T058
image	O
quality	O
and	O
accuracy	O
of	O
CT	B-T060
angiography	I-T060
(	O
CTA	B-T060
)	O
for	O
transcatheter	B-T061
aortic	I-T061
valve	I-T061
replacement	I-T061
(	O
TAVR	B-T061
)	O
planning	O
performed	O
with	O
3rd	B-T060
generation	I-T060
dual	I-T060
-	I-T060
source	I-T060
CT	I-T060
(	O
DSCT	B-T060
)	O
.	O
We	O
evaluated	O
125	O
patients	O
who	O
underwent	O
TAVR	B-T061
-	O
planning	O
CTA	B-T060
on	O
3rd	B-T060
generation	I-T060
DSCT	I-T060
.	O
A	O
two	B-T061
-	I-T061
part	I-T061
protocol	I-T061
was	O
performed	O
including	O
retrospectively	O
ECG	B-T060
-	I-T060
gated	I-T060
coronary	I-T060
CTA	I-T060
(	O
CCTA	B-T060
)	O
and	O
prospectively	O
ECG	B-T060
-	I-T060
triggered	I-T060
aortoiliac	I-T060
CTA	I-T060
using	O
60mL	O
of	O
contrast	O
medium	O
.	O
Automated	O
tube	O
voltage	O
selection	O
and	O
advanced	B-T060
iterative	I-T060
reconstruction	I-T060
were	O
applied	O
.	O
Effective	O
dose	O
(	O
ED	O
)	O
,	O
signal	O
-	O
to	O
-	O
noise	O
(	O
SNR	O
)	O
and	O
contrast	O
-	O
to	O
-	O
noise	O
ratios	O
(	O
CNR	O
)	O
were	O
calculated	O
.	O
Five	O
-	O
point	O
scales	O
were	O
used	O
for	O
subjective	O
image	B-T060
quality	I-T060
analysis	I-T060
.	O
In	O
patients	O
who	O
underwent	O
TAVR	B-T061
,	O
sizing	B-T033
parameters	I-T033
were	O
obtained	O
.	O
Image	O
quality	O
was	O
rated	O
good	O
to	O
excellent	O
in	O
97.6	O
%	O
of	O
CCTA	B-T060
and	O
100	O
%	O
of	O
aortoiliac	B-T060
CTAs	I-T060
.	O
CTA	B-T060
studies	O
at	O
>	O
100kV	O
showed	O
decreased	O
objective	O
image	O
quality	O
compared	O
to	O
70	O
-	O
100kV	O
(	O
SNR	O
,	O
all	O
p≤0.0459	O
;	O
CNR	O
,	O
all	O
p≤0.0462	O
)	O
.	O
Mean	O
ED	O
increased	O
continuously	O
from	O
70	O
to	O
>	O
100kV	O
(	O
CCTA	B-T060
:	O
4.5±1.7mSv-13.6±2.9mSv	O
,	O
all	O
p≤0.0233	O
;	O
aortoiliac	B-T060
CTA	I-T060
:	O
2.4±0.9mSv-6.8±2.7mSv	O
,	O
all	O
p≤0.0414	O
)	O
.	O
In	O
39	O
patients	O
TAVR	B-T061
was	O
performed	O
and	O
annulus	B-T023
diameter	O
was	O
within	O
the	O
recommended	O
range	O
in	O
all	O
patients	O
.	O
No	B-T033
severe	O
cardiac	O
or	O
vascular	O
complications	O
were	O
noted	O
.	O
3rd	B-T060
generation	I-T060
DSCT	I-T060
provides	O
diagnostic	O
image	O
quality	O
in	O
TAVR	B-T061
-	O
planning	O
CTA	B-T060
and	O
facilitates	O
reliable	O
assessment	B-T058
of	O
TAVR	B-T061
device	O
and	O
delivery	O
option	O
while	O
reducing	O
radiation	O
dose	O
.	O
      
Evidence	O
-Based	O
Review	O
and	O
Survey	O
of	O
Expert	O
Opinion	O
of	O
Reconstruction	B-T061
of	O
Metastatic	B-T191
Spine	I-T191
Tumors	I-T191
Systematic	O
review	O
and	O
consensus	O
expert	O
opinion	O
.	O
To	O
provide	O
surgeons	O
and	O
other	O
health	O
care	O
professionals	O
with	O
guidelines	O
for	O
surgical	B-T061
reconstruction	I-T061
of	O
metastatic	B-T191
spine	B-T047
disease	I-T047
based	O
on	O
evidence	O
and	O
expert	O
opinion	O
.	O
The	O
surgical	B-T061
treatment	I-T061
of	O
spinal	B-T191
metastases	I-T191
is	O
controversial	O
.	O
Specifically	O
two	O
aspects	O
of	O
surgical	B-T061
reconstruction	I-T061
are	O
addressed	O
in	O
this	O
study	O
:	O
(	O
i	O
)	O
choice	O
of	O
bone	B-T061
graft	I-T061
used	O
during	O
surgery	B-T061
for	O
metastatic	B-T191
spine	I-T191
tumors	I-T191
and	O
(	O
ii	O
)	O
the	O
design	O
of	O
reconstruction	B-T061
or	O
construct	O
to	O
stabilize	B-T033
.	O
A	O
systematic	O
review	O
of	O
the	O
available	O
medical	O
literature	O
from	O
1980	O
to	O
2015	O
was	O
conducted	O
,	O
and	O
combined	O
with	O
consensus	O
expert	O
opinion	O
from	O
a	O
recent	O
survey	O
of	O
spine	B-T023
surgeons	O
who	O
treat	B-T061
metastatic	B-T191
spine	I-T191
tumors	I-T191
.	O
There	O
is	O
very	O
little	O
evidence	O
in	O
the	O
literature	O
to	O
provide	O
guidance	B-T058
on	O
the	O
use	O
of	O
bone	B-T061
graft	I-T061
in	O
metastatic	B-T191
tumor	I-T191
reconstruction	B-T061
.	O
There	O
is	O
little	O
evidence	O
in	O
the	O
literature	O
to	O
support	O
the	O
preferential	O
use	O
of	O
one	O
graft	O
type	O
over	O
the	O
other	O
.	O
Approximately	O
,	O
41	O
%	O
of	O
respondents	O
said	O
they	O
used	O
bone	B-T061
graft	I-T061
or	O
bone	B-T061
graft	I-T061
substitutes	O
to	O
accomplish	O
fusion	B-T061
.	O
There	O
were	O
17	O
studies	O
that	O
described	O
the	O
use	O
of	O
a	O
prefabricated	O
prosthetic	O
,	O
10	O
studies	O
describing	O
the	O
use	O
of	O
polymethyl	O
methacrylate	O
(	O
PMMA	O
)	O
bone	O
cement	O
,	O
and	O
only	O
three	O
studies	O
describing	O
the	O
use	O
of	O
bone	B-T061
graft	I-T061
for	O
anterior	O
column	B-T023
reconstruction	B-T061
.	O
The	O
use	O
of	O
structural	B-T061
allograft	I-T061
was	O
most	O
popular	O
among	O
the	O
experts	O
for	O
anterior	O
reconstruction	B-T061
,	O
followed	O
by	O
cage	O
reconstruction	B-T061
,	O
and	O
PMMA	O
bone	O
cement	O
.	O
Achieving	O
bony	O
union	O
may	O
be	O
of	O
importance	O
for	O
the	O
maintenance	O
of	O
spinal	B-T023
stability	O
in	O
the	O
long	O
term	O
after	O
reconstruction	B-T061
.	O
Whether	O
bony	O
union	O
is	O
required	O
for	O
patients	O
with	O
shorter	O
life	O
expectancies	O
is	O
debatable	O
.	O
The	O
literature	O
supports	O
the	O
use	O
of	O
anterior	O
reconstruction	B-T061
with	O
either	O
a	O
prefabricated	O
prosthetic	O
or	O
PMMA	O
bone	O
cement	O
.	O
It	O
also	O
supports	O
the	O
use	O
of	O
an	O
anterior	O
construct	O
reinforced	O
with	O
bilateral	O
posterior	O
instrumentation	O
when	O
performing	B-T061
a	O
three	B-T061
-	I-T061
column	I-T061
reconstruction	I-T061
.	O
N	O
/	O
A.	O
      
Estrogen	B-T121
and	O
Progesterone	B-T121
hormone	O
receptor	O
expression	O
in	O
oral	B-T191
cavity	I-T191
cancer	I-T191
Recent	O
studies	O
have	O
shown	O
an	O
increase	O
in	O
the	O
incidence	O
of	O
oral	B-T191
squamous	I-T191
cell	I-T191
carcinoma	I-T191
(	O
OSCC	B-T191
)	O
in	O
younger	O
patients	O
.	O
The	O
hypothesis	O
that	O
tumors	B-T191
could	O
be	O
hormonally	O
induced	O
during	O
pregnancy	O
or	O
in	O
young	O
female	O
patients	O
without	O
the	O
well	O
-	O
known	O
risk	B-T033
factors	I-T033
alcohol	B-T048
or	O
tobacco	B-T048
abuse	I-T048
seems	O
to	O
be	O
plausible	O
.	O
Estrogen	O
Receptor	O
alpha	O
(	O
ERα	O
)	O
and	O
Progesterone	O
Receptor	O
(	O
PR	O
)	O
expression	O
were	O
analyzed	O
in	O
normal	O
oral	B-T023
mucosa	I-T023
(	O
n=5	O
)	O
,	O
oral	B-T033
precursor	I-T033
lesions	I-T033
(	O
simple	B-T047
hyperplasia	I-T047
,	O
n=11	O
;	O
squamous	B-T191
intraepithelial	I-T191
neoplasia	I-T191
,	O
SIN	B-T191
I	I-T191
-	I-T191
III	I-T191
,	O
n=35	O
)	O
,	O
and	O
OSCC	B-T191
specimen	O
.	O
OSCCs	B-T191
were	O
stratified	O
in	O
a	O
young	O
female	O
(	O
n=7	O
)	O
study	O
cohort	O
and	O
older	O
patients	O
(	O
n=46	O
)	O
.	O
In	O
the	O
young	O
female	O
study	O
cohort	O
three	O
patients	O
(	O
n=3/7	O
)	O
developed	O
OSCC	B-T191
during	O
or	O
shortly	O
after	O
pregnancy	O
.	O
Breast	B-T191
cancer	I-T191
tissues	O
were	O
used	O
as	O
positive	O
control	O
for	O
ERα	O
and	O
PR	O
expression	O
.	O
ERα	O
expression	O
was	O
found	O
in	O
four	O
oral	B-T033
precursor	I-T033
lesions	I-T033
(	O
squamous	B-T191
intraepithelial	I-T191
neoplasia	I-T191
,	O
SIN	B-T191
I	I-T191
-	I-T191
III	I-T191
,	O
n=4/35	O
,	O
11	O
%	O
)	O
and	O
in	O
five	O
OSCC	B-T191
specimen	O
(	O
n=5/46	O
,	O
11	O
%	O
)	O
.	O
The	O
five	O
ERα	O
positive	B-T033
OSCC	B-T191
samples	O
were	O
older	O
male	O
patients	O
.	O
All	O
patients	O
within	O
the	O
young	O
female	O
study	O
cohort	O
were	O
negatively	B-T033
stained	O
for	O
both	O
ERα	O
and	O
PR	O
.	O
ER	O
expression	O
could	O
be	O
regarded	O
as	O
a	O
seldom	O
risk	B-T033
factor	I-T033
for	O
OSCC	B-T191
.	O
PR	O
expression	O
seems	O
to	O
be	O
not	O
relevant	O
for	O
the	O
development	O
of	O
OSCC	B-T191
.	O
      
Limits	O
of	O
the	O
possible	O
:	O
diagnostic	O
image	O
quality	O
in	O
coronary	B-T060
angiography	I-T060
with	O
third	B-T060
-	I-T060
generation	I-T060
dual	I-T060
-	I-T060
source	I-T060
CT	I-T060
The	O
usage	O
of	O
coronary	B-T060
CT	I-T060
angiography	I-T060
(	O
CTA	B-T060
)	O
is	O
appropriate	O
in	O
patients	O
with	O
acute	B-T184
or	O
chronic	B-T184
chest	I-T184
pain	I-T184
;	O
however	O
the	O
diagnostic	O
accuracy	O
may	O
be	O
challenged	O
with	O
increased	O
Agatston	O
score	O
(	O
AS	O
)	O
,	O
increased	O
heart	O
rate	O
,	O
arrhythmia	B-T033
and	O
severe	B-T047
obesity	I-T047
.	O
Thus	O
,	O
we	O
aim	O
to	O
determine	O
the	O
potential	O
of	O
the	O
recently	O
introduced	O
third	B-T060
-	I-T060
generation	I-T060
dual	I-T060
-	I-T060
source	I-T060
CT	I-T060
(	O
DSCT	B-T060
)	O
for	O
CTA	B-T060
in	O
a	O
'	O
real	O
-	O
life	O
'	O
clinical	O
setting	O
.	O
Two	O
hundred	O
and	O
sixty	O
-	O
eight	O
consecutive	O
patients	O
(	O
age	O
:	O
67	O
±	O
10	O
years	O
;	O
BMI	O
:	O
27	O
±	O
5	O
kg	O
/	O
m²	O
;	O
61	O
%	O
male	O
)	O
undergoing	O
clinically	O
indicated	O
CTA	B-T060
with	O
DSCT	B-T060
were	O
included	O
in	O
the	O
retrospective	O
single	O
-	O
center	O
analysis	O
.	O
A	O
contrast	O
-	O
enhanced	O
volume	O
dataset	O
was	O
acquired	O
in	O
sequential	B-T060
(	O
SSM	B-T060
)	O
(	O
n	O
=	O
151	O
)	O
or	O
helical	B-T060
scan	I-T060
mode	I-T060
(	O
HSM	B-T060
)	O
(	O
n	O
=	O
117	O
)	O
.	O
Coronary	B-T023
segments	I-T023
were	O
classified	O
in	O
diagnostic	O
or	O
non	O
-	O
diagnostic	O
image	O
quality	O
.	O
A	O
subset	O
underwent	O
invasive	B-T060
angiography	I-T060
to	O
determine	O
the	O
diagnostic	O
accuracy	O
of	O
CTA	B-T060
.	O
SSM	B-T060
(	O
96.8	O
±	O
6	O
%	O
)	O
and	O
HSM	B-T060
(	O
97.5	O
±	O
8	O
%	O
)	O
provided	O
no	O
significant	O
differences	O
in	O
the	O
overall	O
diagnostic	O
image	O
quality	O
.	O
However	O
,	O
AS	O
had	O
significant	O
influence	O
on	O
diagnostic	O
image	O
quality	O
exclusively	O
in	O
SSM	B-T060
(	O
B	O
=	O
0.003	O
;	O
p	O
=	O
0.0001	O
)	O
,	O
but	O
not	O
in	O
HSM	B-T060
.	O
Diagnostic	O
image	O
quality	O
significantly	O
decreased	O
in	O
SSM	B-T060
in	O
patients	O
with	O
AS	O
≥2,000	O
(	O
p	O
=	O
0.03	O
)	O
.	O
SSM	B-T060
(	O
sensitivity	O
:	O
93.9	O
%	O
;	O
specificity	O
:	O
96.7	O
%	O
;	O
PPV	O
:	O
88.6	O
%	O
;	O
NPV	O
:	O
98.3	O
%	O
)	O
and	O
HSM	B-T060
(	O
sensitivity	O
:	O
97.4	O
%	O
;	O
specificity	O
:	O
94.3	O
%	O
;	O
PPV	O
:	O
86.0	O
%	O
;	O
NPV	O
:	O
99.0	O
%	O
)	O
provided	O
comparable	O
diagnostic	O
accuracy	O
(	O
p	O
=	O
n.s	O
.	O
)	O
.	O
SSM	B-T060
yielded	O
significantly	O
lower	O
radiation	O
doses	O
as	O
compared	O
to	O
HSM	B-T060
(	O
2.1	O
±	O
2.0	O
vs.	O
5.1	O
±	O
3.3	O
mSv	O
;	O
p	O
=	O
0.0001	O
)	O
in	O
age	O
and	O
BMI	O
-matched	O
cohorts	O
.	O
SSM	B-T060
in	O
third	B-T060
-	I-T060
generation	I-T060
DSCT	I-T060
enables	O
significant	O
dose	O
savings	O
and	O
provides	O
robust	O
diagnostic	O
image	O
quality	O
in	O
patients	O
with	O
AS	O
≤2000	O
independent	O
of	O
heart	O
rate	O
,	O
heart	O
rhythm	O
or	O
obesity	B-T047
.	O
      
Synthesis	O
,	O
SAR	O
and	O
molecular	O
docking	O
study	O
of	O
novel	O
non	B-T121
-	I-T121
β	I-T121
-	I-T121
lactam	I-T121
inhibitors	I-T121
of	O
TEM	O
type	O
β	O
-	O
lactamase	O
The	O
novel	O
classes	O
of	O
acylated	B-T121
phenoxyanilide	I-T121
and	O
thiourea	B-T121
compounds	I-T121
were	O
investigated	O
for	O
their	O
ability	O
to	O
inhibit	O
TEM	O
type	O
β	O
-	O
lactamase	O
enzyme	O
.	O
Two	O
compounds	B-T121
4	I-T121
g	I-T121
and	O
5c	B-T121
reveal	O
the	O
inhibition	O
potency	O
in	O
micromolar	O
range	O
and	O
show	O
their	O
action	O
by	O
non	O
-	O
covalent	O
binding	O
in	O
the	O
vicinity	O
of	O
the	O
TEM-171	O
active	O
site	O
.	O
The	O
structure	O
activity	O
relationship	O
around	O
carbon	O
chain	O
length	O
and	O
different	O
substituents	O
in	O
ortho-	O
and	O
para	O
-	O
positions	O
of	O
acylated	B-T121
phenoxyanilide	I-T121
as	O
well	O
as	O
molecular	O
modelling	O
study	O
has	O
been	O
performed	O
.	O
      
Triterpenoids	O
from	O
the	O
stems	O
of	O
Tripterygium	O
regelii	O
Three	O
new	O
triterpenoids	O
,	O
triregelolides	O
A	O
,	O
B	O
(	O
1	O
,	O
2	O
)	O
,	O
and	O
triregeloic	O
acid	O
(	O
3	O
)	O
,	O
were	O
isolated	O
from	O
the	O
stems	O
of	O
Tripterygium	O
regelii	O
along	O
with	O
twenty	O
known	O
triterpene	O
analogues	O
(	O
4	O
-	O
23	O
)	O
.	O
The	O
structures	O
of	O
three	O
new	O
compounds	O
were	O
identified	O
by	O
analyzing	O
their	O
NMR	B-T060
spectroscopic	I-T060
and	O
HRESIMS	B-T059
data	O
.	O
Compounds	O
4	O
,	O
7	O
,	O
8	O
,	O
10	O
,	O
13	O
,	O
14	O
,	O
17	O
,	O
21	O
-	O
23	O
were	O
isolated	O
from	O
T.	O
regelii	O
for	O
the	O
first	O
time	O
.	O
Compounds	O
3	O
,	O
5	O
,	O
6	O
,	O
8	O
,	O
9	O
,	O
10	O
,	O
14	O
and	O
16	O
showed	O
inhibitory	O
effects	O
on	O
the	O
proliferation	O
of	O
human	O
breast	O
cancer	O
cells	O
MCF-7	O
by	O
24.1	O
%	O
,	O
69.6	O
%	O
,	O
72.8	O
%	O
,	O
21.6	O
%	O
,	O
23.1	O
%	O
,	O
43.3	O
%	O
,	O
25.5	O
%	O
and	O
23.5	O
%	O
(	O
p<0.05	O
)	O
at	O
a	O
concentration	O
of	O
10μM	O
,	O
respectively	O
.	O
      
Lubiprostone	B-T121
Accelerates	O
Intestinal	O
Transit	O
and	O
Alleviates	O
Small	B-T047
Intestinal	I-T047
Bacterial	I-T047
Overgrowth	I-T047
in	O
Patients	O
With	O
Chronic	B-T184
Constipation	I-T184
Lubiprostone	B-T121
is	O
an	O
effective	O
treatment	O
for	O
chronic	B-T184
constipation	I-T184
(	O
CC	B-T184
)	O
.	O
The	O
mechanism	O
of	O
action	O
of	O
lubiprostone	B-T121
is	O
through	O
increasing	O
fluid	O
secretion	O
and	O
lubrication	O
of	O
the	O
intestinal	O
lumen	O
.	O
The	O
effects	O
of	O
lubiprostone	B-T121
on	O
gastrointestinal	O
transit	O
and	O
small	B-T047
intestinal	I-T047
bacterial	I-T047
overgrowth	I-T047
(	O
SIBO	B-T047
)	O
have	O
not	O
been	O
adequately	O
explored	O
.	O
The	O
current	O
study	O
was	O
designed	O
to	O
investigate	O
whether	O
lubiprostone	B-T121
(	O
1	O
)	O
alters	O
gastrointestinal	O
transit	O
and	O
(	O
2	O
)	O
affects	O
SIBO	B-T047
in	O
patients	O
with	O
constipation	B-T184
.	O
A	O
total	O
of	O
29	O
female	O
patients	O
(	O
mean	O
age	O
=	O
39	O
years	O
;	O
range	O
:	O
19	O
-	O
64	O
)	O
with	O
CC	B-T184
received	O
2	O
weeks	O
of	O
lubiprostone	B-T121
(	O
24mcg	O
b.i.d	O
.	O
,	O
P.O.	O
)	O
.	O
Stool	B-T033
consistency	I-T033
based	O
on	O
Bristol	O
stool	O
scale	O
and	O
the	O
frequency	B-T033
of	I-T033
bowel	I-T033
movements	I-T033
(	O
BMs	O
)	O
were	O
recorded	O
.	O
Gastric	O
emptying	O
time	O
,	O
small	O
bowel	O
transit	O
time	O
,	O
colon	B-T023
transit	O
time	O
(	O
CTT	O
)	O
,	O
combined	O
small	O
and	O
large	O
bowel	O
transit	O
time	O
(	O
SLBTT	O
)	O
and	O
whole	O
gut	B-T023
transit	O
time	O
were	O
measured	O
using	O
wireless	B-T060
motility	I-T060
capsule	I-T060
.	O
The	O
SIBO	B-T047
status	O
was	O
assessed	O
by	O
the	O
lactulose	B-T060
breath	I-T060
test	I-T060
.	O
Data	O
were	O
analyzed	O
using	O
Wilcoxon	O
rank	O
,	O
Mann	O
-	O
Whitney	O
U	O
,	O
Spearman׳s	O
rank	O
correlation	O
and	O
Chi	O
-	O
square	O
tests	O
.	O
Lubiprostone	B-T121
significantly	O
softened	O
the	O
stool	O
and	O
increased	O
the	O
frequency	B-T033
of	I-T033
BM	I-T033
from	O
median	O
of	O
2	O
to	O
4	O
times	O
per	O
week	O
.	O
The	O
CTT	O
and	O
SLBTT	O
were	O
significantly	O
shorter	O
in	O
responders	O
to	O
lubiprostone	B-T121
(	O
i.e.	O
,	O
those	O
with	O
≥	O
2	O
times	O
increase	O
in	O
the	O
number	O
of	O
their	O
weekly	O
BM	O
)	O
compared	O
with	O
nonresponders	O
.	O
The	O
higher	O
frequency	B-T033
of	I-T033
BM	I-T033
after	O
treatment	O
was	O
significantly	O
correlated	O
with	O
the	O
acceleration	O
of	O
CTT	O
,	O
SLBTT	O
and	O
whole	O
gut	B-T023
transit	O
time	O
.	O
In	O
all	O
,	O
17	O
out	O
of	O
25	O
(	O
68	O
%	O
)	O
patients	O
,	O
who	O
were	O
tested	O
for	O
SIBO	B-T047
at	O
baseline	O
,	O
were	O
positive	B-T033
.	O
In	O
addition	O
,	O
7	O
out	O
of	O
17	O
(	O
41	O
%	O
)	O
SIBO	B-T047
-	O
positive	B-T033
patients	O
became	O
SIBO	B-T047
-	O
negative	B-T033
after	O
lubiprostone	B-T121
treatment	O
(	O
P	O
<	O
0.05	O
)	O
.	O
In	O
CC	B-T184
,	O
lubiprostone	B-T121
improves	O
the	O
frequency	B-T033
of	I-T033
BMs	I-T033
,	O
softens	O
the	O
stool	O
,	O
accelerates	O
intestinal	O
transit	O
and	O
decreases	O
accompanying	O
SIBO	B-T047
.	O
The	O
improvement	O
of	O
SIBO	B-T047
could	O
be	O
explained	O
by	O
the	O
cleansing	O
effect	O
of	O
increased	O
intestinal	O
fluid	O
and	O
mucus	O
combined	O
with	O
enhanced	O
intestinal	O
motility	O
with	O
lubiprostone	B-T121
.	O
      
Pupil	O
Sizes	O
Scale	O
with	O
Attentional	O
Load	O
and	O
Task	O
Experience	O
in	O
a	O
Multiple	O
Object	O
Tracking	O
Task	O
Previous	O
studies	O
have	O
related	O
changes	O
in	O
attentional	O
load	O
to	O
pupil	O
size	O
modulations	O
.	O
However	O
,	O
studies	O
relating	O
changes	O
in	O
attentional	O
load	O
and	O
task	O
experience	O
on	O
a	O
finer	O
scale	O
to	O
pupil	O
size	O
modulations	O
are	O
scarce	O
.	O
Here	O
,	O
we	O
investigated	O
how	O
these	O
changes	O
affect	O
pupil	O
sizes	O
.	O
To	O
manipulate	O
attentional	O
load	O
,	O
participants	O
covertly	O
tracked	O
between	O
zero	O
and	O
five	O
objects	O
among	O
several	O
randomly	O
moving	O
objects	O
on	O
a	O
computer	O
screen	O
.	O
To	O
investigate	O
effects	O
of	O
task	O
experience	O
,	O
the	O
experiment	O
was	O
conducted	O
on	O
three	O
consecutive	O
days	O
.	O
We	O
found	O
that	O
pupil	O
sizes	O
increased	O
with	O
each	O
increment	O
in	O
attentional	O
load	O
.	O
Across	O
days	O
,	O
we	O
found	O
systematic	O
pupil	O
size	O
reductions	O
.	O
We	O
compared	O
the	O
model	O
fit	O
for	O
predicting	O
pupil	O
size	O
modulations	O
using	O
attentional	O
load	O
,	O
task	O
experience	O
,	O
and	O
task	B-T061
performance	I-T061
as	O
predictors	O
.	O
We	O
found	O
that	O
a	O
model	O
which	O
included	O
attentional	O
load	O
and	O
task	O
experience	O
as	O
predictors	O
had	O
the	O
best	O
model	O
fit	O
while	O
adding	O
performance	B-T061
as	O
a	O
predictor	O
to	O
this	O
model	O
reduced	O
the	O
overall	O
model	O
fit	O
.	O
Overall	O
,	O
results	O
suggest	O
that	O
pupillometry	B-T060
provides	O
a	O
viable	O
metric	O
for	O
precisely	O
assessing	O
attentional	O
load	O
and	O
task	O
experience	O
in	O
visuospatial	O
tasks	O
.	O
      
Jak1	O
-	O
STAT3	O
Signals	O
Are	O
Essential	O
Effectors	O
of	O
the	O
USP6	O
/	O
TRE17	O
Oncogene	O
in	O
Tumorigenesis	B-T191
Bone	B-T191
and	O
soft	B-T191
tissue	I-T191
tumors	I-T191
(	O
BSTT	B-T191
)	O
are	O
relatively	O
poorly	O
understood	O
,	O
hampering	O
the	O
development	O
of	O
effective	O
therapies	B-T061
.	O
Here	O
we	O
report	O
a	O
role	O
for	O
the	O
ubiquitin	O
-	O
specific	O
protease	O
6	O
(	O
USP6)/	O
TRE17	O
oncogene	O
,	O
which	O
is	O
overexpressed	O
upon	O
chromosome	O
translocation	O
in	O
various	O
human	O
tumors	B-T191
,	O
including	O
aneurysmal	B-T047
bone	I-T047
cyst	I-T047
(	O
ABC	B-T047
)	O
,	O
and	O
the	O
related	O
benign	O
lesion	B-T033
nodular	B-T047
fasciitis	I-T047
.	O
Ectopic	O
expression	O
of	O
USP6	O
is	O
known	O
to	O
drive	O
formation	O
of	O
tumors	B-T191
,	O
which	O
recapitulate	O
key	O
features	O
of	O
ABC	B-T047
and	O
nodular	B-T047
fasciitis	I-T047
;	O
however	O
,	O
the	O
identity	O
of	O
USP6	O
's	O
relevant	O
substrates	O
has	O
been	O
obscure	O
.	O
Here	O
we	O
report	O
that	O
the	O
Jak1	O
-	O
STAT3	O
signaling	O
pathway	O
serves	O
as	O
an	O
essential	O
effector	O
of	O
USP6	O
in	O
BSTT	B-T191
formation	O
.	O
We	O
found	O
that	O
USP6	O
directly	O
deubiquitinated	O
Jak1	O
,	O
leading	O
to	O
its	O
stabilization	B-T033
and	O
activation	O
of	O
STAT3	O
.	O
The	O
tumorigenic	B-T191
potential	O
of	O
USP6	O
was	O
attenuated	O
significantly	O
by	O
CRISPR	O
-mediated	O
deletion	O
of	O
Jak1	O
or	O
STAT3	O
,	O
or	O
by	O
administration	O
of	O
a	O
Jak	O
family	O
inhibitor	O
.	O
Analysis	O
of	O
primary	O
clinical	O
samples	O
of	O
nodular	B-T047
fasciitis	I-T047
confirmed	B-T033
the	O
activation	O
of	O
a	O
Jak1	O
-	O
STAT3	O
gene	O
signature	O
in	O
vivo	O
Together	O
,	O
our	O
studies	B-T059
highlight	O
Jak1	O
as	O
the	O
first	O
identified	O
substrate	O
for	O
USP6	O
,	O
and	O
they	O
offer	O
a	O
mechanistic	O
rationale	O
for	O
the	O
clinical	B-T058
investigation	I-T058
of	O
Jak	O
and	O
STAT3	O
inhibitors	O
as	O
therapeutics	O
for	O
the	O
treatment	B-T061
of	O
bone	B-T191
and	O
soft	B-T191
tissue	I-T191
tumors	I-T191
along	O
with	O
other	O
neoplasms	B-T191
driven	O
by	O
USP6	O
overexpression	O
.	O
Cancer	O
Res	O
;	O
76(18	O
)	O
;	O
5337	O
-	O
47	O
.	O
©	O
2016	O
AACR	O
.	O
      
Neutrophil	O
gelatinase	O
-	O
associated	O
lipocalin	O
in	O
a	O
triphasic	O
rat	O
model	O
of	O
adenine	O
-	O
induced	O
kidney	O
injury	O
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
investigate	O
whether	O
NGAL	O
,	O
given	O
its	O
advantages	O
over	O
traditional	O
biomarkers	O
,	O
can	O
be	O
used	O
to	O
describe	O
the	O
dynamic	O
characteristics	O
of	O
the	O
renal	B-T047
tubulointerstitial	I-T047
insult	I-T047
caused	O
by	O
adenine	O
.	O
Subsequently	O
,	O
it	O
will	O
be	O
possible	O
to	O
assess	O
NGAL	O
as	O
a	O
biomarker	O
of	O
any	O
acute	O
kidney	O
injury	O
,	O
on	O
top	O
of	O
chronic	B-T047
interstitial	I-T047
disease	I-T047
,	O
if	O
NGAL	O
levels	O
are	O
stable	O
through	O
the	O
chronic	O
phase	O
of	O
our	O
adenine	O
model	O
.	O
Study	O
group	O
rats	O
were	O
fed	O
an	O
adenine	O
diet	O
,	O
and	O
control	O
group	O
rats	O
were	O
fed	O
a	O
regular	O
diet	O
only	O
.	O
Blood	O
and	O
urine	O
samples	O
for	O
urea	B-T121
,	O
creatinine	O
and	O
NGAL	O
were	O
drawn	O
from	O
each	O
rat	O
at	O
the	O
beginning	O
of	O
the	O
study	O
and	O
after	O
1	O
,	O
3	O
,	O
4	O
,	O
5	O
,	O
6	O
,	O
7	O
and	O
8	O
weeks	O
.	O
Kidney	B-T023
slices	O
from	O
these	O
rats	O
were	O
stained	B-T059
with	O
Hematoxylin	B-T059
-	I-T059
eosin	I-T059
(	O
HE	B-T059
)	O
and	O
β	O
-	O
actin	O
stainings	B-T059
.	O
Serum	O
urea	O
,	O
creatinine	B-T059
and	O
NGAL	O
levels	O
and	O
urinary	O
NGAL	O
/	O
creatinine	O
ratio	O
in	O
the	O
study	O
group	O
were	O
higher	O
than	O
baseline	O
and	O
than	O
in	O
the	O
control	O
group	O
;	O
these	O
differences	O
were	O
statistically	O
significant	O
in	O
some	O
of	O
the	O
intervals	O
.	O
Tubulointerstitial	B-T047
changes	O
and	O
adenine	O
crystals	O
were	O
evident	O
in	O
the	O
study	O
group	O
rats	O
.	O
In	O
the	O
rats	O
fed	O
adenine	O
,	O
serum	O
urea	O
,	O
creatinine	B-T059
and	O
NGAL	O
levels	O
and	O
urinary	O
NGAL	O
/	O
creatinine	O
ratio	O
followed	O
a	O
triphasic	B-T033
pattern	I-T033
of	O
kidney	O
injury	O
:	O
an	O
acute	O
phase	O
while	O
on	O
the	O
adenine	O
diet	O
,	O
a	O
partial	O
recovery	O
phase	O
after	O
switching	O
to	O
the	O
regular	O
diet	O
and	O
a	O
chronic	B-T047
kidney	I-T047
disease	I-T047
phase	O
after	O
stabilization	O
of	O
renal	O
function	O
.	O
NGAL	O
can	O
serve	O
a	O
biomarker	O
for	O
acute	O
kidney	O
injury	O
and	O
possibly	O
for	O
chronic	B-T047
kidney	I-T047
disease	I-T047
in	O
the	O
tubulointerstitial	B-T047
rat	O
model	O
.	O
      
Long	O
Term	O
Outcome	O
in	O
Patients	O
with	O
Esophageal	B-T061
Stenting	I-T061
for	O
Cancer	B-T191
Esophagus	I-T191
-	O
Our	O
Experience	O
at	O
a	O
Rural	O
Hospital	O
of	O
Punjab	O
,	O
India	O
Cancer	B-T191
of	I-T191
the	I-T191
esophagus	I-T191
is	O
among	O
the	O
leading	O
cause	O
of	O
cancer	O
deaths	O
in	O
Punjab	O
,	O
India	O
.	O
Patients	O
generally	O
present	B-T033
with	O
dysphagia	B-T047
as	O
their	O
first	O
symptom	B-T184
and	O
more	O
often	O
they	O
have	O
advanced	O
disease	O
at	O
the	O
time	O
of	O
presentation	O
to	O
a	O
tertiary	O
care	O
centre	O
.	O
Palliative	B-T061
procedures	I-T061
have	O
important	O
roles	O
in	O
this	O
setting	O
.	O
Stenting	B-T061
is	O
the	O
best	O
option	O
to	O
palliate	O
the	O
symptoms	B-T184
of	O
dysphagia	B-T047
,	O
from	O
which	O
patient	O
is	O
suffering	B-T033
the	I-T033
most	I-T033
.	O
To	O
know	O
the	O
success	O
rate	O
,	O
early	B-T184
and	O
long	O
term	O
complications	O
and	O
mortality	O
in	O
esophageal	B-T061
stenting	I-T061
,	O
when	O
it	O
was	O
done	O
in	O
malignant	B-T047
esophageal	I-T047
stricture	I-T047
patients	O
.	O
One	O
hundred	O
patients	O
,	O
who	O
had	O
undergone	O
esophageal	B-T061
stenting	I-T061
from	O
January	O
2012	O
to	O
January	O
2015	O
,	O
were	O
included	O
in	O
the	O
study	O
.	O
We	O
retrospectively	O
analysed	O
the	O
data	O
for	O
patient	O
characteristics	O
,	O
causes	O
of	O
non	O
-	O
operability	O
,	O
early	B-T184
and	O
long	O
term	O
complications	O
,	O
re	B-T061
-	I-T061
interventions	I-T061
,	O
efficacy	O
and	O
mortality	O
.	O
Out	O
of	O
100	O
patients	O
,	O
indications	O
for	O
stenting	B-T061
were	O
locally	O
advanced	O
disease	O
not	O
amenable	O
to	O
surgery	B-T061
(	O
52	O
%	O
)	O
,	O
metastatic	B-T191
disease	I-T191
(	O
35	O
%	O
)	O
,	O
CVA	B-T047
(	O
1	O
%	O
)	O
,	O
cardiac	B-T033
and	O
respiratory	B-T184
problem	I-T184
(	O
8	O
%	O
)	O
,	O
un	O
-	O
willing	O
for	O
surgery	B-T061
in	O
5	O
%	O
of	O
patients	O
.	O
Majority	O
of	O
patients	O
(	O
94	O
%	O
)	O
had	O
squamous	B-T191
cell	I-T191
carcinoma	I-T191
,	O
while	O
only	O
6	O
%	O
had	O
adenocarcinoma	B-T191
.	O
84	O
%	O
of	O
patients	O
presented	O
with	O
dysphagia	B-T047
with	O
or	O
without	O
chest	B-T184
pain	I-T184
and	O
recurrent	B-T033
cough	I-T033
while	O
16	O
%	O
had	O
recurrent	B-T184
vomiting	I-T184
.	O
58	O
%	O
had	O
dysphagia	B-T047
to	O
liquids	O
and	O
solids	O
and	O
17	O
%	O
had	O
complete	B-T047
dysphagia	I-T047
.	O
After	O
stenting	B-T061
93	O
%	O
had	O
significant	O
improvement	O
in	O
dysphagia	B-T047
score	O
from	O
median	O
of	O
3	O
to	O
1	O
.	O
Post	O
procedure	O
stay	O
was	O
3.61±1.0	O
days	O
.	O
One	O
patient	O
had	O
procedure	B-T061
related	O
major	O
complication	O
in	O
the	O
form	O
of	O
post	O
procedural	O
bleed	O
(	O
after	O
16	O
days	O
of	O
stenting	B-T061
)	O
leading	O
to	O
death	B-T033
of	O
that	O
patient	O
.	O
Minor	O
complications	O
were	O
present	B-T033
in	O
52	O
patients	O
treated	O
conservatively	O
not	O
affecting	O
the	O
efficacy	O
of	O
procedure	B-T061
.	O
These	O
include	O
pain	B-T184
after	O
stenting	B-T061
(	O
38	O
%	O
)	O
,	O
stent	O
obstruction	O
(	O
23	O
%	O
)	O
and	O
stent	O
migration	O
(	O
6	O
%	O
)	O
.	O
All	O
the	O
minor	O
complications	O
were	O
treated	O
conservatively	O
except	O
in	O
six	O
patients	O
in	O
whom	O
re	B-T061
-	I-T061
stenting	I-T061
was	O
done	O
.	O
Esophageal	B-T061
stenting	I-T061
is	O
relatively	O
safe	O
procedure	B-T061
with	O
short	O
stay	O
of	O
the	O
patient	O
in	O
the	O
hospital	O
.	O
Although	O
,	O
it	O
helps	O
in	O
alleviating	O
patients	O
'	O
morbidity	O
very	O
effectively	O
and	O
reliably	O
,	O
there	O
are	O
many	O
technical	O
glitches	O
,	O
which	O
needs	O
to	O
be	O
kept	O
into	O
account	O
and	O
patient	O
should	O
be	O
properly	O
counseled	B-T061
before	O
the	O
procedure	B-T061
to	O
prevent	O
and	O
manage	O
post	O
procedure	O
complications	O
and	O
medico	O
legal	O
aspects	O
.	O
      
Hypocretin	O
/	O
Orexin	O
Peptides	O
Excite	O
Rat	O
Neuroendocrine	O
Dopamine	O
Neurons	O
through	O
Orexin	O
2	O
Receptor	O
-Mediated	O
Activation	O
of	O
a	O
Mixed	O
Cation	O
Current	O
Hypocretin	O
/	O
Orexin	O
(	O
H	O
/	O
O	O
)	O
neurons	O
of	O
the	O
lateral	O
hypothalamus	O
are	O
compelling	O
modulator	O
candidates	O
for	O
the	O
chronobiology	O
of	O
neuroendocrine	O
output	O
and	O
,	O
as	O
a	O
consequence	O
,	O
hormone	O
release	O
from	O
the	O
anterior	B-T023
pituitary	I-T023
.	O
Here	O
we	O
investigate	O
the	O
effects	O
of	O
H	O
/	O
O	O
peptides	O
upon	O
tuberoinfundibular	O
dopamine	O
(	O
TIDA	O
)	O
neurons	O
-	O
cells	O
which	O
control	O
,	O
via	O
inhibition	O
,	O
the	O
pituitary	B-T023
secretion	O
of	O
prolactin	O
.	O
In	O
whole	O
cell	O
recordings	O
performed	O
in	O
male	O
rat	O
hypothalamic	O
slices	O
,	O
application	O
of	O
H	O
/	O
O	O
-	O
A	O
,	O
as	O
well	O
as	O
H	O
/	O
O	O
-	O
B	O
,	O
excited	O
oscillating	O
TIDA	O
neurons	O
,	O
inducing	O
a	O
reversible	O
depolarising	O
switch	O
from	O
phasic	O
to	O
tonic	O
discharge	O
.	O
The	O
H	O
/	O
O	O
-	O
induced	O
inward	O
current	O
underpinning	O
this	O
effect	O
was	O
post	O
-	O
synaptic	O
(	O
as	O
it	O
endured	O
in	O
the	O
presence	B-T033
of	O
tetrodotoxin	O
)	O
,	O
appeared	O
to	O
be	O
carried	O
by	O
a	O
Na(+	O
)	O
-	O
dependent	O
transient	O
receptor	O
potential	O
-	O
like	O
channel	O
(	O
as	O
it	O
was	O
blocked	O
by	O
2	O
-	O
APB	O
and	O
was	O
diminished	O
by	O
removal	O
of	O
extracellular	O
Na(+	O
)	O
)	O
,	O
and	O
was	O
a	O
consequence	O
of	O
OX2R	O
receptor	O
activation	O
(	O
as	O
it	O
was	O
blocked	O
by	O
the	O
OX2R	O
receptor	O
antagonist	O
TCS	B-T121
OX2	I-T121
29	I-T121
,	O
but	O
not	O
the	O
OX1R	O
receptor	O
antagonist	O
SB	B-T121
334867	I-T121
)	O
.	O
Application	B-T058
of	O
the	O
hormone	O
,	O
melatonin	B-T121
,	O
failed	O
to	O
alter	O
TIDA	O
membrane	O
potential	O
or	O
oscillatory	B-T061
activity	I-T061
.	O
This	O
first	O
description	O
of	O
the	O
electrophysiological	B-T060
effects	I-T060
of	O
H	O
/	O
Os	O
upon	O
the	O
TIDA	O
network	O
identifies	O
cellular	O
mechanisms	O
that	O
may	O
contribute	O
to	O
the	O
circadian	O
rhythmicity	O
of	O
prolactin	O
secretion	O
.	O
      
Naïve	O
CD8(+	O
)	O
T	O
cell	O
derived	O
tumor	B-T191
-	O
specific	O
cytotoxic	O
effectors	O
as	O
a	O
potential	O
remedy	O
for	O
overcoming	O
TGF	O
-	O
β	O
immunosuppression	B-T047
in	O
the	O
tumor	O
microenvironment	O
Despite	O
of	O
the	O
potential	O
implications	O
for	O
cancer	B-T061
immunotherapy	I-T061
,	O
conventional	O
approaches	O
using	O
in	O
vitro	O
expanded	O
CD8(+	O
)	O
T	O
cells	O
have	O
suboptimal	O
outcomes	O
,	O
mostly	O
due	O
to	O
loss	O
of	O
functionality	O
from	O
cellular	O
exhaustion	O
.	O
We	O
therefore	O
investigated	O
the	O
phenotypic	O
and	O
functional	O
differences	O
among	O
in	O
vitro	O
activated	O
CD8(+	O
)	O
T	O
cells	O
of	O
three	O
different	O
sources	B-T033
,	O
namely	O
naïve	O
(	O
NTeff	O
)	O
,	O
memory	O
(	O
MTeff	O
)	O
and	O
tumor	O
-	O
infiltrating	O
lymphocytes	O
(	O
TILeff	O
)	O
from	O
human	O
and	O
mice	O
,	O
to	O
better	O
understand	O
mechanisms	O
behind	O
potent	O
effector	O
functions	O
and	O
potential	O
for	O
overcoming	O
current	O
limitations	O
.	O
In	O
line	O
with	O
the	O
greater	O
proliferation	O
activity	O
and	O
longer	O
telomere	O
lengths	O
of	O
NTeff	O
populations	O
,	O
cells	O
of	O
naïve	O
origin	O
exhibited	O
significantly	O
less	O
amounts	O
of	O
T	O
cell	O
exhaustion	O
markers	O
than	O
those	O
of	O
MTeff	O
and	O
TILeff	O
,	O
and	O
moreover	O
,	O
acquired	O
distinct	O
expression	O
patterns	O
of	O
memory	O
-	O
promoting	O
transcription	O
factors	O
,	O
T	O
-	O
bet	O
and	O
Eomes	O
,	O
induced	O
in	O
a	O
rapid	O
and	O
sustainable	O
manner	O
.	O
NTeff	O
cells	O
appeared	O
to	O
have	O
lower	O
expression	O
of	O
Foxp1	O
and	O
were	O
refractory	O
to	O
apoptosis	O
upon	O
TGF	O
-	O
β	O
conditioning	O
,	O
implying	O
better	O
survival	O
potential	O
and	O
resistance	O
to	O
tumor	B-T191
-	O
induced	O
immune	B-T047
suppression	I-T047
.	O
Of	O
CD8(+	O
)	O
T	O
cell	O
pools	O
activated	O
to	O
tumor	B-T191
-	O
specific	O
CTLs	O
,	O
naïve	O
cell	O
generated	O
effectors	O
possessed	O
the	O
most	O
potent	O
cytotoxic	B-T033
activity	I-T033
,	O
validating	O
implications	O
for	O
use	O
in	O
rational	O
design	O
of	O
adoptive	B-T061
immunotherapy	I-T061
.	O
      
Psychosocial	O
impact	O
on	O
families	O
with	O
an	O
infant	O
with	O
a	O
hypoplastic	B-T047
left	I-T047
heart	I-T047
syndrome	I-T047
during	O
and	O
after	O
the	O
interstage	O
monitoring	O
period	O
-	O
a	O
prospective	O
mixed	O
-	O
method	O
study	O
To	O
investigate	O
parents	O
'	O
experiences	O
,	O
coping	O
ability	O
and	O
quality	O
of	O
life	O
while	O
monitoring	B-T058
their	O
sick	O
child	O
with	O
hypoplastic	B-T047
left	I-T047
heart	I-T047
syndrome	I-T047
at	O
home	O
.	O
Interstage	B-T058
home	I-T058
monitoring	I-T058
for	O
children	O
with	O
hypoplastic	B-T047
left	I-T047
heart	I-T047
syndrome	I-T047
reduces	O
interstage	O
mortality	O
between	O
Norwood	B-T061
stages	I-T061
I	I-T061
and	I-T061
II	I-T061
.	O
Little	O
is	O
known	O
about	O
the	O
psychosocial	O
impact	O
of	O
interstage	B-T058
home	I-T058
monitoring	I-T058
.	O
Prospective	O
mixed	O
-	O
method	O
study	O
.	O
This	O
study	O
assessed	O
the	O
psychosocial	O
impact	O
on	O
parents	O
during	O
interstage	B-T058
home	I-T058
monitoring	I-T058
.	O
This	O
contains	O
for	O
quantitative	O
assessment	O
the	O
Short	O
Form	O
Health	O
Survey	O
questionnaire	O
and	O
the	O
Impact	O
of	O
Family	B-T033
Scale	I-T033
administered	I-T033
one	O
and	O
five	O
weeks	O
following	O
discharge	B-T058
before	O
and	O
after	O
stage	O
II	O
.	O
For	O
qualitative	O
assessment	O
,	O
semi	O
-	O
structured	O
interviews	O
focussing	O
on	O
the	O
postdischarge	B-T033
coping	B-T061
strategies	I-T061
were	O
conducted	O
twice	O
,	O
five	O
weeks	O
after	B-T033
hospital	I-T033
discharge	I-T033
before	O
and	O
after	O
stage	O
II	O
.	O
Ten	O
infants	O
(	O
eight	O
males	O
)	O
with	O
hypoplastic	B-T047
left	I-T047
heart	I-T047
syndrome	I-T047
(	O
n	O
=	O
7	O
)	O
or	O
other	O
types	O
of	O
univentricular	B-T019
heart	I-T019
malformations	I-T019
(	O
n	O
=	O
3	O
)	O
,	O
and	O
their	O
parents	O
(	O
nine	O
mother	O
/	O
father	O
two-	O
parent	O
households	O
,	O
one	O
single	O
mother	O
)	O
were	O
included	O
.	O
There	O
were	O
no	B-T033
interstage	I-T033
deaths	I-T033
.	O
Mental	O
Health	O
Composite	O
Summary	O
scores	O
were	O
low	O
in	O
both	O
parents	O
(	O
mothers	O
:	O
40·45	O
±	O
9·07	O
;	O
fathers	O
:	O
40·58	O
±	O
9·69	O
)	O
and	O
lowest	O
for	O
the	O
item	O
'	O
vitality	B-T033
'	O
(	O
mothers	O
:	O
37·0	O
±	O
19·46	O
;	O
fathers	O
:	O
43·12	O
±	O
25·9	O
)	O
before	O
and	O
after	O
stage	O
II	O
.	O
Impact	O
of	O
Family	B-T033
Scale	I-T033
values	I-T033
showed	O
higher	O
daily	O
and	O
social	O
burdens	O
for	O
mothers	O
.	O
'	O
Becoming	O
a	O
family	O
'	O
was	O
the	O
most	O
important	O
task	O
as	O
coping	B-T061
strategy	I-T061
to	O
equilibrate	O
the	O
fragile	B-T048
emotional	I-T048
balance	I-T048
.	O
The	O
parents	O
judged	O
interstage	B-T058
home	I-T058
monitoring	I-T058
as	O
a	O
protective	B-T061
intervention	I-T061
.	O
Although	O
psychosocial	O
burden	O
before	O
and	O
after	O
stage	O
II	O
remains	O
high	O
,	O
becoming	O
a	O
family	O
is	O
an	O
essential	O
experience	O
for	O
parents	O
and	O
confirms	O
their	O
parenthood	O
.	O
Healthcare	O
professionals	O
must	O
be	O
aware	O
of	O
parents	O
'	O
needs	O
during	O
this	O
vulnerable	O
interstage	O
period	O
and	O
to	O
provide	O
psychosocial	O
and	O
nursing	B-T061
support	I-T061
.	O
      
Effect	O
of	O
halotolerant	B-T007
rhizobacteria	I-T007
isolated	O
from	O
halophytes	O
on	O
the	O
growth	O
of	O
sugar	O
beet	O
(	O
Beta	O
vulgaris	O
L	O
.	O
)	O
under	O
salt	O
stress	O
Utilization	O
of	O
rhizobacteria	B-T007
that	O
have	O
associated	O
with	O
plant	O
roots	O
in	O
harsh	B-T033
environments	O
could	O
be	O
a	O
feasible	O
strategy	O
to	O
deal	O
with	O
limits	O
to	O
agricultural	O
production	O
caused	O
by	O
soil	O
salinity	O
.	O
Halophytes	O
occur	O
naturally	O
in	O
high	O
-	O
salt	O
environments	O
,	O
and	O
their	O
roots	O
may	O
be	O
associated	O
with	O
promising	O
microbial	B-T001
candidates	I-T001
for	O
promoting	O
growth	O
and	O
salt	O
tolerance	O
in	O
crops	O
.	O
This	O
study	O
aimed	O
to	O
isolate	O
efficient	O
halotolerant	O
plant	O
-	O
growth	O
-	O
promoting	O
rhizobacterial	O
strains	B-T001
from	O
halophytes	O
and	O
evaluate	O
their	O
activity	O
and	O
effects	O
on	O
sugar	O
beet	O
(	O
Beta	O
vulgaris	O
L	O
.	O
)	O
growth	O
under	O
salinity	O
stress	O
.	O
A	O
total	O
of	O
23	O
isolates	O
were	O
initially	O
screened	O
for	O
their	O
ability	O
to	O
secrete	O
1	O
-	O
aminocyclopropane-1	O
-	O
carboxylate	O
deaminase	O
(	O
ACD	O
)	O
as	O
well	O
as	O
other	O
plant	O
-	O
growth	O
-	O
promoting	O
characteristics	O
and	O
subsequently	O
identified	O
by	O
sequencing	O
the	O
16S	O
rRNA	O
gene	O
.	O
Three	O
isolates	O
,	O
identified	O
as	O
Micrococcus	B-T007
yunnanensis	I-T007
,	O
Planococcus	B-T007
rifietoensis	I-T007
and	O
Variovorax	B-T007
paradoxus	I-T007
,	O
enhanced	O
salt	O
stress	O
tolerance	O
remarkably	O
in	O
sugar	O
beet	O
,	O
resulting	O
in	O
greater	O
seed	O
germination	O
and	O
plant	O
biomass	O
,	O
higher	O
photosynthetic	O
capacity	O
and	O
lower	O
stress	B-T033
-	O
induced	O
ethylene	B-T121
production	O
at	O
different	O
NaCl	B-T121
concentrations	O
(	O
50	O
-	O
125	O
mM	O
)	O
.	O
These	O
results	O
demonstrate	O
that	O
salinity	O
-	O
adapted	O
,	O
ACD	O
-producing	O
bacteria	B-T007
isolated	O
from	O
halophytes	O
could	O
promote	O
sugar	O
beet	O
growth	O
under	O
saline	O
stress	O
conditions	O
.	O
      
Graphene	O
/	O
Nafion	O
composite	O
film	O
modified	O
glassy	O
carbon	O
electrode	O
for	O
simultaneous	O
determination	B-T059
of	O
paracetamol	B-T121
,	O
aspirin	B-T121
and	O
caffeine	B-T121
in	O
pharmaceutical	O
formulations	O
A	O
graphene	O
-	O
Nafion	O
composite	O
film	O
was	O
fabricated	O
on	O
the	O
glassy	O
carbon	O
electrode	O
(	O
GR	O
-	O
NF	O
/	O
GCE	O
)	O
,	O
and	O
used	O
for	O
simultaneous	O
determination	B-T059
of	O
paracetamol	B-T121
(	O
PAR	B-T121
)	O
,	O
aspirin	B-T121
(	O
ASA	B-T121
)	O
and	O
caffeine	B-T121
(	O
CAF	B-T121
)	O
.	O
The	O
electrochemical	O
behaviors	O
of	O
PAR	B-T121
,	O
ASA	B-T121
and	O
CAF	B-T121
were	O
investigated	O
by	O
cyclic	O
voltammetry	O
and	O
square	B-T059
-	I-T059
wave	I-T059
adsorptive	I-T059
anodic	I-T059
stripping	I-T059
voltammetry	I-T059
.	O
By	O
using	O
stripping	B-T059
one	O
for	O
simultaneous	O
determination	B-T059
of	O
PAR	B-T121
,	O
ASA	B-T121
and	O
CAF	B-T121
,	O
their	O
electrochemical	O
oxidation	O
peaks	O
appeared	O
at	O
+0.64	O
,	O
1.04	O
and	O
1.44V	O
,	O
and	O
good	O
linear	O
current	O
responses	O
were	O
obtained	O
with	O
the	O
detection	O
limits	O
of	O
18ngmL(-1	O
)	O
(	O
1.2×10(-9)M	O
)	O
,	O
11.7ngmL(-1	O
)	O
(	O
6.5×10(-8)M	O
)	O
and	O
7.3ngmL(-1	O
)	O
(	O
3.8×10(-8)M	O
)	O
,	O
respectively	O
.	O
Finally	O
,	O
the	O
proposed	O
electrochemical	O
sensor	O
was	O
successfully	O
applied	O
for	O
quantifying	O
PAR	B-T121
,	O
ASA	B-T121
and	O
CAF	B-T121
in	O
commercial	O
tablet	O
formulations	O
.	O
      
Carbon	O
Monoxide	O
Improves	B-T033
Efficacy	O
of	O
Mesenchymal	O
Stromal	O
Cells	O
During	O
Sepsis	B-T047
by	O
Production	O
of	O
Specialized	O
Proresolving	B-T033
Lipid	O
Mediators	O
Mesenchymal	O
stromal	O
cells	O
are	O
being	O
investigated	O
as	O
a	O
cell	B-T061
-	I-T061
based	I-T061
therapy	I-T061
for	O
a	O
number	O
of	O
disease	O
processes	O
,	O
with	O
promising	O
results	B-T033
in	O
animal	O
models	O
of	O
systemic	B-T047
inflammation	I-T047
and	O
sepsis	B-T047
.	O
Studies	O
are	O
ongoing	O
to	O
determine	O
ways	O
to	O
further	O
improve	B-T033
the	O
therapeutic	O
potential	O
of	O
mesenchymal	O
stromal	O
cells	O
.	O
A	O
gas	O
molecule	O
that	O
improves	B-T033
outcome	O
in	O
experimental	O
sepsis	B-T047
is	O
carbon	O
monoxide	O
.	O
We	O
hypothesized	O
that	O
preconditioning	O
of	O
mesenchymal	O
stromal	O
cells	O
with	O
carbon	O
monoxide	O
ex	O
vivo	O
would	O
promote	O
further	O
therapeutic	O
benefit	O
when	O
cells	O
are	O
administered	O
in	O
vivo	O
after	O
the	O
onset	O
of	O
polymicrobial	B-T047
sepsis	B-T047
in	O
mice	O
.	O
Animal	O
study	O
and	O
primary	B-T059
cell	I-T059
culture	I-T059
.	O
Laboratory	O
investigation	B-T058
.	O
BALB	O
/	O
c	O
mice	O
.	O
Polymicrobial	B-T047
sepsis	B-T047
was	O
induced	O
by	O
cecal	B-T023
ligation	B-T061
and	O
puncture	B-T058
.	O
Mesenchymal	O
stromal	O
cells	O
,	O
mesenchymal	O
stromal	O
cells	O
-	O
conditioned	O
with	O
carbon	O
monoxide	O
,	O
fibroblasts	O
,	O
or	O
fibroblasts	O
-	O
conditioned	O
with	O
carbon	O
monoxide	O
were	O
delivered	O
by	O
tail	B-T023
vein	I-T023
injections	B-T061
to	O
septic	O
mice	O
.	O
The	O
mice	O
were	O
assessed	O
for	O
survival	O
,	O
bacterial	O
clearance	O
,	O
and	O
the	O
inflammatory	O
response	O
during	O
sepsis	B-T047
in	O
each	O
of	O
the	O
groups	O
.	O
Mesenchymal	O
stromal	O
cells	O
were	O
also	O
assessed	O
for	O
their	O
ability	O
to	O
promote	O
bacterial	O
phagocytosis	O
by	O
neutrophils	O
,	O
the	O
production	O
of	O
specialized	O
proresolving	B-T033
lipid	O
mediators	O
,	O
and	O
their	O
importance	O
for	O
mesenchymal	O
stromal	O
cells	O
function	O
using	O
gene	O
silencing	O
.	O
Ex	O
vivo	O
preconditioning	O
with	O
carbon	O
monoxide	O
allowed	O
mesenchymal	O
stromal	O
cells	O
to	O
be	O
administered	O
later	O
after	O
the	O
onset	O
of	O
sepsis	B-T047
(	O
6	O
hr	O
)	O
,	O
and	O
yet	O
maintain	O
their	O
therapeutic	O
effect	O
with	O
increased	O
survival	O
.	O
Carbon	O
monoxide	O
preconditioned	O
mesenchymal	O
stromal	O
cells	O
were	O
also	O
able	O
to	O
alleviate	O
organ	O
injury	O
,	O
improve	B-T033
bacterial	O
clearance	O
,	O
and	O
promote	O
the	O
resolution	O
of	O
inflammation	O
.	O
Mesenchymal	O
stromal	O
cells	O
exposed	O
to	O
carbon	O
monoxide	O
,	O
with	O
docosahexaenoic	B-T121
acid	I-T121
substrate	O
,	O
produced	O
specialized	O
proresolving	B-T033
lipid	O
mediators	O
,	O
particularly	O
D	O
-	O
series	O
resolvins	O
,	O
which	O
promoted	O
survival	O
.	O
Silencing	O
of	O
lipoxygenase	O
pathways	O
(	O
5	O
-	O
lipoxygenase	O
and	O
12	O
/	O
15	O
-	O
lipoxygenase	O
)	O
,	O
which	O
are	O
important	O
enzymes	O
for	O
specialized	O
proresolving	B-T033
lipid	O
mediator	O
biosynthesis	O
,	O
resulted	O
in	O
a	O
loss	O
of	O
therapeutic	O
benefit	O
bestowed	O
on	O
mesenchymal	O
stromal	O
cells	O
by	O
carbon	O
monoxide	O
.	O
Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
production	O
of	O
specialized	O
proresolving	B-T033
lipid	O
mediators	O
contribute	O
to	O
improved	B-T033
mesenchymal	O
stromal	O
cell	O
efficacy	O
when	O
exposed	O
to	O
carbon	O
monoxide	O
,	O
resulting	O
in	O
an	O
improved	B-T033
therapeutic	O
response	O
during	O
sepsis	B-T047
.	O
      
Biliary	B-T023
Phospholipids	O
Sustain	O
Enterocyte	O
Proliferation	O
and	O
Intestinal	B-T191
Tumor	I-T191
Progression	B-T191
via	O
Nuclear	O
Receptor	O
Lrh1	O
in	O
mice	O
The	O
proliferative-	O
crypt	B-T023
compartment	I-T023
of	O
the	O
intestinal	O
epithelium	O
is	O
enriched	O
in	O
phospholipids	O
and	O
accumulation	B-T033
of	O
phospholipids	O
has	O
been	O
described	O
in	O
colorectal	B-T191
tumors	I-T191
.	O
Here	O
we	O
hypothesize	O
that	O
biliary	B-T023
phospholipid	O
flow	O
could	O
directly	O
contribute	O
to	O
the	O
proliferative	O
power	O
of	O
normal	O
and	O
dysplastic	O
enterocytes	O
.	O
We	O
used	O
Abcb4	O
(	O
-/-	O
)	O
mice	O
which	O
lack	O
biliary	B-T023
phospholipid	O
secretion	O
.	O
We	O
first	O
show	O
that	O
Abcb4	O
(	O
-/-	O
)	O
mice	O
are	O
protected	B-T033
against	O
intestinal	B-T023
tumorigenesis	B-T191
.	O
At	O
the	O
molecular	O
level	O
,	O
the	O
transcriptional	O
activity	O
of	O
the	O
nuclear	O
receptor	O
Liver	O
Receptor	O
Homolog-1	O
(	O
Lrh1	O
)	O
is	O
reduced	O
in	O
Abcb4	O
(	O
-/-	O
)	O
mice	O
and	O
its	O
re	O
-	O
activation	O
re	O
-	O
establishes	O
a	O
tumor	B-T191
burden	O
comparable	O
to	O
control	O
mice	O
.	O
Feeding	O
Abcb4	O
(	O
-/-	O
)	O
mice	O
a	O
diet	O
supplemented	O
with	O
phospholipids	O
completely	O
overcomes	O
the	O
intestinal	B-T191
tumor	I-T191
protective	O
phenotype	O
,	O
thus	O
corroborating	O
the	O
hypothesis	O
that	O
the	O
absence	O
of	O
biliary	B-T023
phospholipids	O
and	O
not	O
lack	O
of	O
Abcb4	O
gene	O
per	O
se	O
is	O
responsible	O
for	O
the	O
protection	B-T033
.	O
In	O
turn	O
,	O
phospholipids	O
can	O
not	O
re	O
-	O
establish	O
intestinal	B-T023
tumorigenesis	B-T191
in	O
Abcb4	O
(	O
-/-	O
)	O
mice	O
crossed	O
with	O
mice	O
with	O
intestinal	B-T023
specific	O
ablation	B-T061
of	O
Lrh1	O
,	O
a	O
nuclear	O
hormone	O
receptor	O
that	O
is	O
activates	O
by	O
phospholipids	O
.	O
Our	O
data	O
identify	O
the	O
key	O
role	O
of	O
biliary	B-T023
phospholipids	O
in	O
sustaining	O
intestinal	O
mucosa	O
proliferation	O
and	O
tumor	B-T191
progression	I-T191
through	O
the	O
activation	O
of	O
nuclear	O
receptor	O
Lrh1	O
.	O
      
Can	O
We	O
Predict	O
Burnout	B-T048
among	O
Student	O
Nurses	O
?	O
An	O
Exploration	O
of	O
the	O
ICWR-1	O
Model	O
of	O
Individual	O
Psychological	O
Resilience	O
The	O
nature	O
of	O
nursing	O
work	O
is	O
demanding	B-T061
and	O
can	O
be	O
stressful	O
.	O
Previous	O
studies	O
have	O
shown	O
a	O
high	O
rate	O
of	O
burnout	B-T048
among	O
employed	B-T033
nurses	O
.	O
Recently	O
,	O
efforts	O
have	O
been	O
made	O
to	O
understand	O
the	O
role	O
of	O
resilience	O
in	O
determining	O
the	O
psychological	O
adjustment	O
of	O
employed	B-T033
nurses	O
.	O
A	O
theoretical	O
model	O
of	O
resilience	O
was	O
proposed	O
recently	O
that	O
includes	O
several	O
constructs	O
identified	O
in	O
the	O
literature	O
related	O
to	O
resilience	O
and	O
to	O
psychological	O
functioning	O
.	O
As	O
nursing	O
students	O
are	O
the	O
future	O
of	O
the	O
nursing	O
workforce	O
it	O
is	O
important	O
to	O
advance	O
our	O
understanding	O
of	O
the	O
determinants	O
of	O
resilience	O
in	O
this	O
population	O
.	O
Student	O
nurses	O
who	O
had	O
completed	O
their	O
final	O
practicum	O
were	O
invited	O
to	O
participate	O
in	O
an	O
online	O
survey	O
measuring	O
the	O
key	O
constructs	O
of	O
the	O
ICWR-1	O
model	O
.	O
422	O
students	O
from	O
across	O
Australia	O
and	O
Canada	O
completed	O
the	O
survey	O
between	O
July	O
2014	O
and	O
July	O
2015	O
.	O
As	O
well	O
as	O
several	O
key	O
demographics	O
,	O
trait	B-T033
negative	I-T033
affect	I-T033
,	O
mindfulness	O
,	O
self	O
-	O
efficacy	O
,	O
coping	O
,	O
resilience	O
,	O
and	O
burnout	B-T048
were	O
measured	O
.	O
We	O
used	O
structural	O
equation	O
modeling	O
and	O
found	O
support	O
for	O
the	O
major	O
pathways	O
of	O
the	O
model	O
;	O
namely	O
that	O
resilience	O
had	O
a	O
significant	O
influence	O
on	O
the	O
relationship	O
between	O
mindfulness	O
,	O
self	O
-	O
efficacy	O
and	O
coping	O
,	O
and	O
psychological	O
adjustment	O
(	O
burnout	B-T048
scores	O
)	O
.	O
Furthermore	O
,	O
as	O
predicted	O
,	O
Neuroticism	B-T048
moderated	O
the	O
relationship	O
between	O
coping	O
and	O
burnout	B-T048
.	O
Results	O
are	O
discussed	O
in	O
terms	O
of	O
potential	O
approaches	O
to	O
supporting	O
nursing	O
students	O
who	O
may	O
be	O
at	O
risk	O
of	O
burnout	B-T048
.	O
      
Treatment	O
of	O
Carcinoma	B-T191
In	I-T191
Situ	I-T191
of	I-T191
the	I-T191
Glans	I-T191
Penis	I-T191
With	O
Topical	B-T200
Imiquimod	I-T200
Followed	O
by	O
Carbon	O
Dioxide	O
Laser	O
Excision	B-T061
Different	O
approaches	O
have	O
been	O
described	O
in	O
published	O
studies	O
for	O
carcinoma	B-T191
in	I-T191
situ	I-T191
(	I-T191
CIS	I-T191
)	I-T191
of	I-T191
the	I-T191
glans	I-T191
penis	I-T191
(	O
erythroplasia	B-T191
of	I-T191
Queyrat	I-T191
)	O
,	O
including	O
topical	B-T061
chemotherapy	I-T061
or	O
immunotherapy	B-T061
and	O
laser	O
or	O
surgical	B-T061
excision	I-T061
.	O
We	O
evaluated	B-T061
the	O
efficacy	O
of	O
topical	B-T200
imiquimod	I-T200
(	O
IQ	B-T200
)	O
followed	O
by	O
carbon	O
dioxide	O
laser	O
ablation	B-T061
of	O
the	O
lesion	B-T033
.	O
From	O
2010	O
to	O
2015	O
,	O
10	O
patients	O
affected	O
by	O
CIS	B-T191
of	O
the	O
glans	B-T023
were	O
treated	B-T061
by	O
IQ	B-T200
,	O
followed	O
by	O
carbon	O
dioxide	O
laser	O
ablation	B-T061
.	O
For	O
every	O
patient	O
,	O
we	O
performed	O
histologic	B-T059
examination	I-T059
before	O
and	O
after	O
IQ	B-T200
.	O
Local	O
toxicity	O
and	O
adverse	O
effects	O
were	O
recorded	O
.	O
After	O
treatment	O
,	O
histologic	B-T059
examination	I-T059
showed	O
no	O
residual	O
tumor	O
in	O
6	O
patients	O
(	O
complete	B-T033
response	I-T033
[	O
CR	B-T033
]	O
)	O
,	O
stable	B-T033
disease	I-T033
in	O
2	O
patients	O
,	O
and	O
progressive	B-T047
disease	I-T047
in	O
2	O
patients	O
.	O
Those	O
with	O
a	O
CR	B-T033
had	O
human	B-T005
papillomavirus	I-T005
-	O
related	O
lesions	B-T033
,	O
and	O
they	O
had	O
no	B-T033
experienced	O
relapses	O
after	O
a	O
mean	O
follow	B-T058
-	I-T058
up	I-T058
of	O
26	O
months	O
.	O
The	O
2	O
patients	O
with	O
progressive	B-T047
disease	I-T047
underwent	O
total	O
penectomy	B-T061
.	O
All	O
patients	O
were	O
alive	B-T033
at	O
the	O
last	O
follow	B-T033
-	I-T033
up	I-T033
examination	I-T033
.	O
All	O
patients	O
experienced	O
a	O
mild	O
local	O
toxicity	O
(	O
burning	B-T184
erythema	I-T184
)	O
but	O
no	B-T033
major	O
adverse	O
effects	O
.	O
Local	O
treatment	O
with	O
IQ	B-T200
for	O
glans	B-T023
CIS	B-T191
is	O
effective	O
mainly	O
for	O
human	B-T005
papillomavirus	I-T005
-	O
related	O
lesions	B-T033
.	O
The	O
present	O
study	O
is	O
the	O
first	O
to	O
record	O
the	O
histologic	B-T059
examination	I-T059
findings	O
before	O
and	O
after	O
IQ	B-T200
treatment	O
.	O
The	O
small	O
number	O
of	O
patients	O
,	O
owing	O
to	O
the	O
rarity	O
of	O
this	O
disease	B-T047
,	O
was	O
the	O
main	O
limitation	O
of	O
the	O
present	O
study	O
.	O
IQ	B-T200
must	O
be	O
used	O
carefully	O
,	O
and	O
a	O
close	O
follow	B-T058
-	I-T058
up	I-T058
protocol	O
is	O
mandatory	B-T061
because	O
of	O
the	O
lack	O
of	O
long	O
-	O
term	O
efficacy	O
data	O
.	O
      
BEST	O
:	O
Next	O
-	O
Generation	O
Biomedical	O
Entity	O
Search	O
Tool	O
for	O
Knowledge	O
Discovery	O
from	O
Biomedical	O
Literature	O
As	O
the	O
volume	O
of	O
publications	O
rapidly	O
increases	O
,	O
searching	O
for	O
relevant	O
information	O
from	O
the	O
literature	O
becomes	O
more	O
challenging	B-T033
.	O
To	O
complement	O
standard	O
search	O
engines	O
such	O
as	O
PubMed	O
,	O
it	O
is	O
desirable	O
to	O
have	O
an	O
advanced	O
search	O
tool	O
that	O
directly	O
returns	O
relevant	O
biomedical	O
entities	O
such	O
as	O
targets	O
,	O
drugs	B-T121
,	O
and	O
mutations	O
rather	O
than	O
a	O
long	O
list	O
of	O
articles	O
.	O
Some	O
existing	B-T033
tools	O
submit	O
a	O
query	O
to	O
PubMed	O
and	O
process	O
retrieved	O
abstracts	O
to	O
extract	O
information	O
at	O
query	O
time	O
,	O
resulting	O
in	O
a	O
slow	O
response	O
time	O
and	O
limited	O
coverage	O
of	O
only	O
a	O
fraction	O
of	O
the	O
PubMed	O
corpus	O
.	O
Other	O
tools	O
preprocess	O
the	O
PubMed	O
corpus	O
to	O
speed	O
up	O
the	O
response	O
time	O
;	O
however	O
,	O
they	O
are	O
not	O
constantly	O
updated	O
,	O
and	O
thus	O
produce	O
outdated	O
results	O
.	O
Further	O
,	O
most	O
existing	O
tools	O
can	O
not	O
process	O
sophisticated	O
queries	O
such	O
as	O
searches	O
for	O
mutations	O
that	O
co	O
-	O
occur	O
with	O
query	O
terms	O
in	O
the	O
literature	O
.	O
To	O
address	O
these	O
problems	B-T033
,	O
we	O
introduce	O
BEST	O
,	O
a	O
biomedical	O
entity	O
search	O
tool	O
.	O
BEST	O
returns	O
,	O
as	O
a	O
result	O
,	O
a	O
list	O
of	O
10	O
different	O
types	O
of	O
biomedical	O
entities	O
including	O
genes	O
,	O
diseases	B-T047
,	O
drugs	B-T121
,	O
targets	O
,	O
transcription	O
factors	O
,	O
miRNAs	O
,	O
and	O
mutations	O
that	O
are	O
relevant	O
to	O
a	O
user	O
's	O
query	O
.	O
To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
BEST	O
is	O
the	O
only	O
system	O
that	O
processes	O
free	O
text	O
queries	O
and	O
returns	O
up	B-T033
-	I-T033
to	I-T033
-	I-T033
date	I-T033
results	O
in	O
real	O
time	O
including	O
mutation	O
information	O
in	O
the	O
results	O
.	O
BEST	O
is	O
freely	O
accessible	O
at	O
http://best.korea.ac.kr	O
.	O
      
Radiation	O
-	O
induced	O
Parotid	O
Gland	O
Atrophy	O
in	O
Patients	O
with	O
Head	B-T191
and	I-T191
Neck	I-T191
Cancer	I-T191
After	O
Carbon	B-T061
-	I-T061
ion	I-T061
Radiotherapy	I-T061
This	O
study	O
aimed	O
to	O
clarify	O
the	O
relationship	O
between	O
dosimetric	B-T059
factors	O
and	O
parotid	O
gland	O
(	O
PG	O
)	O
atrophy	O
after	O
carbon	B-T061
ion	I-T061
radiotherapy	I-T061
(	O
C	B-T061
-	I-T061
ion	I-T061
RT	I-T061
)	O
.	O
Fifty	O
-	O
four	O
patients	O
with	O
head	B-T191
and	I-T191
neck	I-T191
tumours	I-T191
were	O
enrolled	O
and	O
93	O
irradiated	O
PGs	B-T023
were	O
analyzed	O
.	O
Thirty	O
and	O
24	O
patients	O
were	O
treated	B-T061
with	I-T061
total	O
doses	O
[	O
relative	O
biological	O
effectiveness	O
(	O
RBE	O
)	O
]	O
of	O
57.6	O
Gy	O
and	O
64.0	O
Gy	O
,	O
respectively	O
,	O
in	O
16	O
fractions	O
.	O
PG	B-T023
volumes	O
were	O
measured	B-T059
using	O
computed	O
tomographic	O
images	O
obtained	O
before	O
C	B-T061
-	I-T061
ion	I-T061
RT	I-T061
and	O
every	O
3	O
-	O
6	O
months	O
thereafter	O
.	O
The	O
median	O
follow	B-T058
-	I-T058
up	I-T058
period	O
was	O
46.4	O
months	O
(	O
range	O
=	O
24.0	O
-	O
123.0	O
months	O
)	O
.	O
Univariate	O
analysis	O
showed	O
that	O
PG	B-T023
volumes	O
receiving	O
more	O
than	O
5	O
,	O
10	O
,	O
15	O
,	O
and	O
20	O
Gy	O
RBE	O
(	O
V5	O
,	O
V10	O
,	O
V15	O
and	O
V20	O
,	O
respectively	O
)	O
,	O
mean	O
dose	O
,	O
and	O
maximum	O
dose	O
were	O
significantly	O
associated	O
with	O
PG	O
atrophy	O
.	O
Multivariate	O
analysis	O
indicated	O
that	O
only	O
V5	O
was	O
significantly	O
associated	O
with	O
atrophy	O
.	O
Increasing	O
V5	O
was	O
a	O
significant	O
risk	B-T033
factor	I-T033
for	O
PG	O
atrophy	O
after	O
C	B-T061
-	I-T061
ion	I-T061
RT	I-T061
.	O
      
The	O
impact	O
of	O
childhood	B-T048
maltreatment	I-T048
on	O
the	O
differential	O
efficacy	O
of	O
CBASP	B-T061
versus	O
escitalopram	B-T121
in	O
patients	O
with	O
chronic	B-T048
depression	I-T048
:	O
A	O
secondary	O
analysis	O
Childhood	B-T048
maltreatment	I-T048
(	O
CM	B-T048
)	O
has	O
been	O
indicated	B-T033
as	O
a	O
predictor	O
of	O
a	O
differential	O
response	O
to	O
antidepressant	B-T061
treatment	I-T061
with	O
psychotherapy	B-T061
compared	O
to	O
medication	B-T121
.	O
In	O
this	O
secondary	O
analysis	O
,	O
we	O
investigated	O
whether	O
the	O
presence	O
of	O
CM	B-T048
results	O
in	O
a	O
differential	O
indication	O
for	O
the	O
Cognitive	B-T061
Behavioral	I-T061
Analysis	I-T061
System	I-T061
of	I-T061
Psychotherapy	I-T061
(	O
CBASP	B-T061
)	O
or	O
escitalopram	B-T121
plus	O
clinical	B-T058
management	I-T058
(	O
ESC	B-T121
)	O
.	O
Sixty	O
patients	O
with	O
chronic	B-T048
depression	I-T048
were	O
randomized	O
to	O
either	O
22	O
sessions	O
of	O
CBASP	B-T061
or	O
ESC	B-T121
over	O
the	O
course	O
of	O
8	O
weeks	O
of	O
acute	O
and	O
20	O
weeks	O
of	O
extended	O
treatment	B-T061
at	O
2	O
German	O
treatment	O
sites	O
.	O
CM	B-T048
was	O
assessed	O
using	O
the	O
Childhood	O
Trauma	O
Questionnaire	O
and	O
the	O
clinician	O
rated	O
Early	O
Trauma	O
Inventory	O
.	O
Intention	O
-	O
to	O
-	O
treat	O
analyses	O
were	O
used	O
to	O
examine	O
the	O
impact	O
of	O
CM	B-T048
on	O
depression	B-T048
,	O
global	B-T060
functioning	I-T060
,	O
and	O
quality	O
of	O
life	O
.	O
The	O
presence	O
of	O
CM	B-T048
did	O
not	O
result	O
in	O
significant	O
differences	O
in	O
treatment	O
response	O
to	O
CBASP	B-T061
or	O
ESC	B-T121
on	O
any	O
outcome	O
measure	O
after	O
28	O
weeks	O
of	O
treatment	B-T061
independent	O
of	O
the	O
type	O
of	O
CM	B-T048
assessment	B-T058
.	O
After	O
8	O
weeks	O
,	O
a	O
significant	O
CM	B-T048
×	O
treatment	B-T061
interaction	O
was	O
found	B-T033
for	O
scores	O
on	O
the	O
Montgomery	O
-	O
Asberg	O
Depression	O
Rating	O
Scale	O
.	O
Patients	O
with	O
a	O
history	B-T033
of	O
CM	B-T048
receiving	O
CBASP	B-T061
had	O
a	O
significantly	O
lower	O
response	O
rate	O
compared	O
to	O
patients	O
without	O
CM	B-T048
and	O
to	O
those	O
receiving	O
ESC	B-T121
after	O
8	O
weeks	O
.	O
Conclusively	O
,	O
CBASP	B-T061
and	O
ESC	B-T121
are	O
equally	O
effective	O
treatment	B-T061
options	O
for	O
the	O
difficult	O
to	O
treat	O
subgroup	O
of	O
patients	O
with	O
chronic	B-T048
depression	I-T048
and	O
a	O
history	B-T033
of	O
CM	B-T048
.	O
CM	B-T048
may	O
be	O
a	O
predictor	O
of	O
a	O
longer	O
latency	O
of	O
treatment	O
response	O
in	O
the	O
case	O
of	O
psychotherapy	B-T061
.	O
CBASP	B-T061
and	O
escitalopram	B-T121
are	O
equally	O
effective	O
treatment	B-T061
options	O
for	O
chronic	B-T048
depression	I-T048
.	O
Both	O
treatments	B-T061
are	O
also	O
equally	O
effective	O
for	O
the	O
difficult	O
to	O
treat	O
subgroup	O
of	O
patients	O
with	O
chronic	B-T048
depression	I-T048
and	O
a	O
history	B-T033
of	O
childhood	B-T048
maltreatment	I-T048
.	O
Childhood	B-T048
maltreatment	I-T048
may	O
result	O
in	O
a	O
longer	O
latency	O
of	O
treatment	O
response	O
in	O
the	O
case	O
of	O
psychotherapy	B-T061
.	O
      
Calibration	O
of	O
Self	O
-	O
Report	O
Measures	O
of	O
Physical	O
Activity	O
and	O
Sedentary	B-T033
Behavior	I-T033
Calibration	O
equations	O
offer	O
potential	O
to	O
improve	O
the	O
accuracy	O
and	O
utility	O
of	O
self	O
-	O
report	O
measures	O
of	O
physical	O
activity	O
(	O
PA	O
)	O
and	O
sedentary	B-T033
behavior	I-T033
(	O
SB	B-T033
)	O
by	O
re	O
-	O
scaling	O
potentially	O
biased	O
estimates	O
.	O
The	O
present	O
study	O
evaluates	O
calibration	O
models	O
designed	O
to	O
estimate	O
PA	O
and	O
SB	B-T033
in	O
a	O
representative	O
sample	O
of	O
adults	O
from	O
the	O
Physical	O
Activity	O
Measurement	O
Survey	O
(	O
PAMS	O
)	O
.	O
Participants	O
in	O
the	O
PAMS	O
project	O
completed	O
replicate	O
single	O
day	O
trials	O
that	O
involved	O
wearing	O
a	O
Sensewear	O
armband	O
(	O
SWA	O
)	O
monitor	O
for	O
24	O
hours	O
followed	O
by	O
a	O
telephone	O
administered	O
24	O
-	O
hour	O
physical	B-T058
activity	I-T058
recall	I-T058
(	O
PAR	B-T058
)	O
.	O
Comprehensive	O
statistical	O
model	O
selection	O
and	O
validation	O
procedures	O
were	O
used	O
to	O
develop	O
and	O
test	O
separate	O
calibration	O
models	O
designed	O
to	O
predict	O
objectively	O
-	O
measured	O
SB	B-T033
and	O
moderate	O
to	O
vigorous	O
PA	O
(	O
MVPA	O
from	O
self	O
-	O
reported	O
PAR	B-T058
data	O
.	O
Equivalence	O
testing	O
was	O
used	O
to	O
evaluate	O
the	O
equivalence	O
of	O
the	O
model-	O
predicted	O
values	O
with	O
the	O
objective	O
measures	O
in	O
a	O
separate	O
holdout	O
sample	O
.	O
The	O
final	O
prediction	O
model	O
for	O
both	O
SB	B-T033
and	O
MVPA	O
included	O
reported	O
time	O
spent	O
in	O
SB	B-T033
and	O
MVPA	O
,	O
as	O
well	O
as	O
terms	O
capturing	O
sex	O
,	O
age	B-T033
,	O
education	B-T033
,	O
and	O
BMI	O
.	O
Cross	O
-	O
validation	O
analyses	O
on	O
an	O
independent	O
sample	O
exhibited	O
high	O
correlations	O
with	O
observed	O
SB	B-T033
(	O
r	O
=	O
0.72	O
)	O
and	O
MVPA	O
(	O
r	O
=	O
0.75	O
)	O
.	O
Equivalence	O
testing	O
demonstrated	O
that	O
the	O
model-	O
predicted	O
values	O
were	O
statistically	O
equivalent	O
to	O
the	O
corresponding	O
objective	O
values	O
for	O
both	O
SB	B-T033
and	O
MVPA	O
.	O
The	O
results	O
demonstrate	O
that	O
simple	O
regression	O
models	O
can	O
be	O
used	O
to	O
statistically	O
adjust	O
for	O
over	O
or	O
underestimation	O
in	O
self	O
-	O
report	O
measures	O
among	O
different	O
segments	O
of	O
the	O
population	O
.	O
The	O
models	O
produced	O
group	O
estimates	O
from	O
the	O
PAR	B-T058
that	O
were	O
statistically	O
equivalent	O
to	O
the	O
observed	O
time	O
spent	O
in	O
SB	B-T033
and	O
MVPA	O
obtained	O
from	O
the	O
objective	O
SWA	O
monitor	O
;	O
however	O
additional	O
work	O
is	O
needed	O
to	O
correct	O
for	O
estimates	O
of	O
individual	O
behavior	O
.	O
      
Assessment	O
of	O
neuroanatomical	O
and	O
behavioural	O
effects	O
of	O
in	O
ovo	O
methylmercury	O
exposure	O
in	O
zebra	O
finches	O
(	O
Taeniopygia	O
guttata	O
)	O
Methylmercury	O
(	O
MeHg	O
)	O
readily	O
crosses	O
the	O
blood	B-T023
brain	I-T023
barrier	I-T023
and	O
is	O
a	O
known	O
neuro	O
-	O
toxicant	O
.	O
MeHg	O
accumulation	B-T033
in	O
the	O
brain	B-T023
causes	O
histopathological	O
alterations	O
,	O
neurobehavioral	O
changes	O
,	O
and	O
impairments	O
to	O
cognitive	O
motor	O
functions	O
in	O
mammalian	O
models	B-T050
.	O
However	O
,	O
in	O
birds	O
the	O
neurotoxic	O
effects	O
of	O
MeHg	O
on	O
the	O
developing	O
pre	O
-	O
hatching	O
brain	B-T023
and	O
consequent	B-T033
behavioral	O
alterations	O
in	O
adult	O
birds	O
have	O
not	O
received	O
much	O
attention	O
.	O
Moreover	O
,	O
passerine	O
birds	O
are	O
poorly	O
represented	O
in	O
MeHg	O
neurotoxicology	O
studies	O
in	O
comparison	O
to	O
other	O
avian	O
orders	O
.	O
Hence	O
in	O
this	O
study	O
,	O
we	O
used	O
the	O
egg	O
injection	O
method	O
to	O
investigate	O
the	O
long	O
term	O
effects	O
of	O
in	O
ovo	O
MeHg	O
exposure	O
on	O
brain	B-T023
histopathology	O
and	O
courtship	O
behavior	O
in	O
a	O
model	B-T050
songbird	O
species	O
,	O
the	O
zebra	O
finch	O
(	O
Taeniopygia	O
guttata	O
)	O
.	O
Egg	O
treatment	O
groups	O
included	O
:	O
a	O
low	O
MeHg	O
dose	O
of	O
0.2μg	O
Hg	O
g(-1	O
)	O
egg	O
,	O
a	O
high	O
MeHg	O
dose	O
of	O
3.2μg	O
Hg	O
g(-1	O
)	O
egg	O
,	O
and	O
a	O
vehicle	O
control	O
(	O
water	B-T121
)	O
.	O
No	B-T184
adverse	I-T184
effects	I-T184
of	O
in	O
ovo	O
MeHg	O
treatment	O
were	O
detected	B-T033
on	O
courtship	O
song	O
quality	O
or	O
on	O
mating	O
behavior	O
in	O
experimental	O
males	O
at	O
sexually	B-T033
maturity	I-T033
which	O
would	O
suggest	O
that	O
observable	O
neurobehavioral	O
effects	O
of	O
MeHg	O
exposure	O
may	O
depend	O
on	O
the	O
timing	O
of	O
exposure	O
during	O
offspring	O
development	O
.	O
However	O
,	O
neuroanatomical	O
analysis	O
indicated	B-T033
an	O
increase	O
in	O
telencephalon	B-T023
volume	O
with	O
increased	O
MeHg	O
concentrations	O
which	O
may	O
suggest	O
a	O
prolonged	O
inflammatory	O
response	O
in	O
this	O
region	O
of	O
the	O
brain	O
.	O
      
Engineering	O
and	O
In	O
Vivo	O
Applications	O
of	O
Riboswitches	O
Riboswitches	O
are	O
common	O
gene	O
regulatory	O
units	O
mostly	O
found	O
in	O
bacteria	B-T007
that	O
are	O
capable	O
of	O
altering	O
gene	O
expression	O
in	O
response	O
to	O
a	O
small	O
molecule	O
.	O
These	O
structured	O
RNA	O
elements	O
consist	O
of	O
two	O
modular	O
subunits	O
:	O
an	O
aptamer	O
domain	O
that	O
binds	O
with	O
high	O
specificity	O
and	O
affinity	O
to	O
a	O
target	O
ligand	O
and	O
an	O
expression	O
platform	O
that	O
transduces	O
ligand	O
binding	O
to	O
a	O
gene	O
expression	O
output	O
.	O
Significant	O
progress	O
has	O
been	O
made	O
in	O
engineering	O
novel	O
aptamer	O
domains	O
for	O
new	O
small	O
molecule	O
inducers	O
of	O
gene	O
expression	O
.	O
Modified	O
expression	O
platforms	O
have	O
also	O
been	O
optimized	O
to	O
function	O
when	O
fused	O
with	O
both	O
natural	O
and	O
synthetic	O
aptamer	O
domains	O
.	O
As	O
this	O
field	O
expands	O
,	O
the	O
use	O
of	O
these	O
privileged	O
scaffolds	O
has	O
permitted	O
the	O
development	O
of	O
tools	O
such	O
as	O
RNA	O
-based	O
fluorescent	O
biosensors	O
.	O
In	O
this	O
review	O
,	O
we	O
summarize	O
the	O
methods	O
that	O
have	O
been	O
developed	O
to	O
engineer	O
new	O
riboswitches	O
and	O
highlight	O
applications	O
of	O
natural	O
and	O
synthetic	O
riboswitches	O
in	O
enzyme	B-T059
and	O
strain	O
engineering	O
,	O
in	O
controlling	O
gene	O
expression	O
and	O
cellular	O
physiology	O
,	O
and	O
in	O
real	B-T060
-	I-T060
time	I-T060
imaging	I-T060
of	O
cellular	O
metabolites	O
and	O
signals	O
.	O
Expected	O
final	O
online	O
publication	O
date	O
for	O
the	O
Annual	O
Review	O
of	O
Biochemistry	O
Volume	O
86	O
is	O
June	O
20	O
,	O
2017	O
.	O
Please	O
see	O
http://www.annualreviews.org/page/journal/pubdates	O
for	O
revised	O
estimates	O
.	O
      
Cocaine	O
Use	O
Reverses	O
Striatal	O
Plasticity	O
Produced	O
During	O
Cocaine	O
Seeking	O
Relapse	O
is	O
a	O
two	O
-	O
component	O
process	O
consisting	O
of	O
a	O
highly	O
motivated	O
drug	O
-	O
seeking	O
phase	O
that	O
,	O
if	O
successful	O
,	O
is	O
followed	O
by	O
a	O
drug	B-T048
-	I-T048
using	I-T048
phase	O
resulting	O
in	O
temporary	O
satiation	O
.	O
In	O
rodents	O
,	O
cue	O
-	O
induced	O
drug	O
seeking	O
requires	O
transient	O
synaptic	O
potentiation	O
(	O
t	O
-	O
SP	O
)	O
of	O
cortical	O
glutamatergic	O
synapses	O
on	O
nucleus	B-T023
accumbens	I-T023
core	O
medium	O
spiny	O
neurons	O
,	O
but	O
it	O
is	O
unknown	O
how	O
achieving	O
drug	B-T048
use	I-T048
affects	O
this	O
plasticity	O
.	O
We	O
modeled	O
the	O
two	O
phases	O
of	O
relapse	O
after	O
extinction	O
from	O
cocaine	O
self	B-T061
-	I-T061
administration	I-T061
to	O
assess	O
how	O
cocaine	O
use	O
affects	O
t	O
-	O
SP	O
associated	O
with	O
cue	O
-	O
induced	O
drug	O
seeking	O
.	O
Rats	O
were	O
trained	O
to	O
self	B-T061
-	I-T061
administer	I-T061
cocaine	O
(	O
n	O
=	O
96	O
)	O
or	O
were	O
used	O
as	O
yoked	O
-	O
saline	O
control	O
animals	O
(	O
n	O
=	O
21	O
)	O
.	O
After	O
extinction	O
,	O
reinstatement	O
was	O
initiated	O
by	O
10	O
minutes	O
of	O
cue	O
-	O
induced	O
drug	O
seeking	O
,	O
followed	O
by	O
45	O
minutes	O
with	O
contingent	O
cocaine	O
access	O
,	O
after	O
which	O
cocaine	O
was	O
discontinued	B-T033
and	O
unreinforced	B-T033
lever	I-T033
pressing	I-T033
ensued	I-T033
.	O
Three	O
measures	O
of	O
t	O
-	O
SP	O
were	O
assayed	B-T059
during	O
reinstatement	O
:	O
dendritic	O
spine	O
morphology	O
,	O
alpha	B-T121
-	I-T121
amino-3	I-T121
-	I-T121
hydroxy-5	I-T121
-	I-T121
methyl-4	I-T121
-	I-T121
isoxazole	I-T121
propionic	I-T121
acid	I-T121
(	O
AMPA	B-T121
)	O
to	O
N	B-T121
-	I-T121
methyl	I-T121
-	I-T121
D	I-T121
-	I-T121
aspartate	I-T121
(	O
NMDA	B-T121
)	O
ratios	O
,	O
and	O
matrix	O
metalloproteinase	O
activity	O
.	O
We	O
found	B-T033
that	O
cocaine	O
use	O
for	O
10	O
minutes	O
collapsed	O
all	O
three	O
measures	O
of	O
cue	O
-	O
potentiated	O
t	O
-	O
SP	O
back	O
to	O
baseline	O
.	O
Moreover	O
,	O
when	O
cocaine	O
use	O
was	O
discontinued	B-T033
45	O
minutes	O
later	O
,	O
dendritic	O
spine	O
morphology	O
and	O
AMPA	B-T121
to	O
NMDA	B-T121
ratios	O
were	O
restored	O
as	O
animals	O
became	O
motivated	O
to	O
engage	O
unrewarded	O
lever	B-T033
pressing	I-T033
.	O
Nonreinforced	O
drug	O
seeking	O
was	O
positively	B-T033
correlated	O
with	O
changes	O
in	O
spine	O
morphology	O
,	O
and	O
cocaine	O
access	O
reversed	O
this	O
relationship	O
.	O
Using	O
a	O
novel	O
modification	O
of	O
the	O
reinstatement	O
paradigm	O
,	O
we	O
show	O
that	O
achieving	O
cocaine	O
use	O
reversed	O
the	O
synaptic	O
plasticity	O
underpinning	O
the	O
motivation	O
to	O
seek	O
the	O
drug	B-T121
.	O
      
Sella	B-T190
turcica	I-T190
bridging	I-T190
and	O
dental	B-T033
anomalies	I-T033
:	O
is	O
there	O
an	O
association	O
?	O
Sella	B-T190
turcica	I-T190
bridging	I-T190
(	O
STB	B-T190
)	O
,	O
or	O
calcification	O
of	O
the	O
interclinoid	O
ligament	O
of	O
sella	B-T023
turcica	I-T023
,	O
has	O
been	O
reported	O
to	O
be	O
associated	O
with	O
some	O
dental	B-T033
anomalies	I-T033
(	O
palatal	B-T033
canine	I-T033
impaction	B-T190
and	O
transposition	B-T190
)	O
.	O
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
find	O
any	O
association	O
between	O
canine	B-T033
impaction	B-T190
,	O
hyperdontia	B-T033
or	O
hypodontia	B-T019
and	O
sellar	B-T023
dimensions	O
or	O
bridging	B-T190
.	O
Lateral	O
cephalometric	B-T060
radiographs	B-T060
from	O
78	O
patients	O
with	O
impacted	B-T190
canines	B-T033
,	O
68	O
with	O
dental	B-T019
agenesis	I-T019
and	O
17	O
with	O
hyperdontia	B-T033
were	O
collected	O
.	O
Linear	O
dimensions	O
of	O
sella	B-T023
turcica	I-T023
were	O
calculated	O
and	O
compared	O
to	O
those	O
of	O
a	O
control	O
group	O
(	O
47	O
individuals	O
)	O
.	O
A	O
standardize	O
scoring	O
scale	O
was	O
used	O
to	O
quantify	O
the	O
extent	O
of	O
STB	B-T190
from	O
each	O
radiographs	B-T060
.	O
The	O
frequency	O
of	O
partial	O
and	O
complete	O
calcifications	O
of	O
sella	B-T023
in	O
patients	O
with	O
dental	B-T033
anomalies	I-T033
is	O
increased	O
when	O
compared	O
to	O
controls	O
.	O
STB	B-T190
can	O
influence	O
the	O
interclinoid	O
distance	O
but	O
does	O
not	O
affect	O
other	O
linear	O
dimensions	O
of	O
sella	B-T023
.	O
No	O
statistically	O
significant	O
difference	O
has	O
been	O
found	O
in	O
sellar	B-T023
dimensions	O
and	O
STB	B-T190
expression	O
when	O
evaluating	O
radiographs	B-T060
at	O
different	O
ages	O
.	O
STB	B-T190
is	O
frequently	O
found	O
in	O
patients	O
with	O
dental	B-T033
abnormalities	I-T033
.	O
      
The	O
transcription	O
factors	O
MS188	O
and	O
AMS	O
form	O
a	O
complex	O
to	O
activate	O
the	O
expression	O
of	O
CYP703A2	O
for	O
sporopollenin	O
biosynthesis	O
in	O
Arabidopsis	O
thaliana	O
The	O
sexine	O
layer	O
of	O
pollen	O
grain	O
is	O
mainly	O
composed	O
of	O
sporopollenins	O
.	O
The	O
sporophytic	O
secretory	O
tapetum	O
is	O
required	O
for	O
the	O
biosynthesis	O
of	O
sporopollenin	O
.	O
Although	O
several	O
enzymes	O
involved	O
in	O
sporopollenin	O
biosynthesis	O
have	O
been	O
reported	O
,	O
the	O
regulatory	O
mechanism	O
of	O
these	O
enzymes	O
in	O
tapetal	O
layer	O
remains	O
elusive	O
.	O
ABORTED	O
MICROSPORES	O
(	O
AMS	O
)	O
and	O
MALE	O
STERILE	O
188	O
/	O
MYB103	O
/	O
MYB80	O
(	O
MS188	O
/	O
MYB103	O
/	O
MYB80	O
)	O
are	O
two	O
tapetal	O
cell	O
-specific	O
transcription	O
factors	O
required	O
for	O
pollen	O
wall	O
formation	O
.	O
AMS	O
functions	O
upstream	O
of	O
MS188	O
.	O
Here	O
we	O
report	O
that	O
AMS	O
and	O
MS188	O
target	O
the	O
CYP703A2	O
gene	O
,	O
which	O
is	O
involved	O
in	O
sporopollenin	O
biosynthesis	O
.	O
We	O
found	O
that	O
AMS	O
and	O
MS188	O
were	O
localized	O
in	O
tapetum	O
while	O
CYP703A2	O
was	O
localized	O
in	O
both	O
tapetum	O
and	O
locule	O
.	O
Chromatin	B-T059
immunoprecipitation	I-T059
(	O
ChIP	B-T059
)	O
showed	O
that	O
MS188	O
directly	O
bound	O
to	O
the	O
promoter	O
of	O
CYP703A2	O
and	O
luciferase	O
-	O
inducible	O
assay	B-T059
showed	O
that	O
MS188	O
activated	O
the	O
expression	O
of	O
CYP703A2	O
.	O
Yeast	O
two	O
-	O
hybrid	O
and	O
electrophoretic	B-T059
mobility	I-T059
shift	I-T059
assays	I-T059
(	O
EMSAs	B-T059
)	O
further	O
demonstrated	O
that	O
MS188	O
complexed	O
with	O
AMS	O
.	O
The	O
expression	O
of	O
CYP703A2	O
could	O
be	O
partially	O
restored	O
by	O
the	O
elevated	O
levels	O
of	O
MS188	O
in	O
the	O
ams	O
mutant	O
.	O
Therefore	O
,	O
our	O
data	O
reveal	O
that	O
MS188	O
coordinates	O
with	O
AMS	O
to	O
activate	O
CYP703A2	O
in	O
sporopollenin	O
biosynthesis	O
of	O
plant	O
tapetum	O
.	O
      
Immune	B-T033
dysregulation	I-T033
in	O
offspring	O
of	O
a	O
bipolar	B-T048
parent	O
.	O
Altered	O
serum	O
levels	O
of	O
immune	O
growth	O
factors	O
at	O
adolescent	O
age	O
Immune	B-T033
dysregulation	I-T033
plays	O
a	O
role	O
in	O
the	O
vulnerability	B-T033
for	O
mood	B-T048
disorders	I-T048
.	O
Immune	O
growth	O
factors	O
,	O
such	O
as	O
Stem	O
Cell	O
Factor	O
(	O
SCF	O
)	O
,	O
Insulin	O
-	O
like	O
Growth	O
Factor	O
-	O
Binding	O
Protein-2	O
(	O
IGF	O
-	O
BP2	O
)	O
,	O
Epidermal	B-T121
Growth	I-T121
Factor	I-T121
(	O
EGF	B-T121
)	O
,	O
IL-7	B-T121
and	O
sCD25	O
have	O
repeatedly	O
been	O
reported	O
altered	O
in	O
patients	O
with	O
mood	B-T048
disorders	I-T048
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
levels	O
of	O
these	O
factors	O
in	O
serum	O
of	O
adolescent	O
bipolar	B-T048
offspring	O
,	O
who	O
have	O
a	O
heightened	O
risk	O
for	O
mood	B-T048
disorder	I-T048
development	O
and	O
to	O
also	O
analyze	O
the	O
data	O
combined	O
with	O
previously	O
published	O
data	O
.	O
Growth	O
factors	O
were	O
assessed	O
by	O
CBA	B-T059
/	O
ELISA	B-T059
in	O
adolescent	O
bipolar	B-T048
offspring	O
(	O
n=96	O
,	O
mean	O
age	O
=	O
16	O
years	O
)	O
and	O
in	O
age	O
-	O
and	O
gender	O
-	O
matched	O
healthy	O
controls	O
(	O
n=50	O
)	O
.	O
EGF	B-T121
belonged	O
to	O
a	O
mutually	O
correlating	O
cluster	O
of	O
mainly	O
neurotrophic	O
compounds	O
including	O
S100B	O
and	O
BDNF	B-T121
,	O
which	O
were	O
in	O
general	O
decreased	O
in	O
serum	O
.	O
IL-7	B-T121
,	O
SCF	O
,	O
IGF	O
-	O
BP2	O
and	O
sCD25	O
,	O
belonged	O
to	O
a	O
different	O
mutually	O
correlating	O
cluster	O
of	O
immune	O
growth	O
factors	O
,	O
which	O
were	O
in	O
general	O
increased	O
:	O
IGF	O
-	O
BP2	O
significantly	O
in	O
serum	O
of	O
offspring	O
without	O
a	O
mood	B-T048
disorder	I-T048
,	O
IL-7	B-T121
and	O
SCF	O
in	O
serum	O
of	O
offspring	O
who	O
had	O
expirienced	O
a	O
mood	B-T048
episode	I-T048
.	O
This	O
pattern	O
of	O
de	O
-	O
and	O
increases	O
was	O
not	O
different	O
between	O
bipolar	B-T048
offspring	O
that	O
developed	O
or	O
did	O
not	O
develop	O
a	O
mood	B-T048
disorder	I-T048
over	O
time	O
,	O
apart	O
from	O
the	O
IGF	O
-	O
BP2	O
level	O
,	O
which	O
was	O
near	O
significantly	O
higher	O
in	O
offspring	O
later	O
developing	O
a	O
mood	B-T048
disorder	I-T048
.	O
Correlations	O
with	O
the	O
previously	O
published	O
immune	B-T190
-	I-T190
cellular	I-T190
abnormalities	I-T190
were	O
not	O
found	O
.	O
In	O
conclusion	O
non	O
-	O
affected	O
adolescents	O
at	O
familial	O
mood	B-T048
disorder	I-T048
development	O
risk	O
were	O
characterized	O
by	O
a	O
distinct	O
pattern	O
of	O
a	O
series	O
of	O
compounds	O
operating	O
in	O
a	O
network	O
of	O
hematopoiesis	O
,	O
neurogenesis	O
and	O
inflammation	O
.	O
      
The	O
Role	O
of	O
Metal	O
-	O
on	O
-	O
Metal	O
Bearings	O
in	O
Total	B-T061
Hip	I-T061
Arthroplasty	I-T061
and	O
Hip	B-T061
Resurfacing	I-T061
:	O
Review	O
Article	O
The	O
current	O
role	O
of	O
metal	O
-	O
on	O
-	O
metal	O
(	O
MoM	O
)	O
bearings	O
in	O
hip	B-T061
arthroplasty	I-T061
remains	O
controversial	O
.	O
The	O
low	O
wear	O
offered	O
by	O
MoM	O
bearings	O
compared	O
to	O
metal	O
-	O
on	O
-	O
polyethylene	O
and	O
the	O
possibility	O
of	O
a	O
lower	O
risk	O
of	O
dislocation	O
with	O
larger	O
head	O
sizes	O
,	O
encouraged	O
a	O
trend	O
towards	O
the	O
re	B-T061
-	I-T061
introduction	I-T061
of	O
the	O
MoM	O
bearing	O
couple	O
.	O
However	O
,	O
recent	O
evidence	O
has	O
shown	O
that	O
not	O
all	O
designs	O
of	O
the	O
MoM	O
bearing	O
have	O
been	O
successful	O
.	O
The	O
purpose	O
of	O
this	O
paper	O
is	O
to	O
provide	O
an	O
update	O
on	O
the	O
use	O
of	O
MoM	O
bearings	O
and	O
address	O
the	O
following	O
issues	O
:	O
(	O
1	O
)	O
the	O
reintroduction	B-T061
of	O
metal	O
-	O
on	O
-	O
metal	O
bearings	O
in	O
total	B-T061
hip	I-T061
arthroplasty	I-T061
,	O
(	O
2	O
)	O
the	O
failure	O
of	O
metal	O
-	O
on	O
-	O
metal	O
bearings	O
in	O
stemmed	B-T061
total	I-T061
hip	I-T061
arthroplasty	I-T061
,	O
(	O
3	O
)	O
the	O
role	O
of	O
metal	B-T061
-	I-T061
on	I-T061
-	I-T061
metal	I-T061
hip	I-T061
resurfacing	I-T061
in	O
modern	O
orthopaedics	O
and	O
(	O
4	O
)	O
metal	B-T061
-	I-T061
on	I-T061
-	I-T061
metal	I-T061
hip	I-T061
resurfacing	I-T061
versus	O
total	B-T061
hip	I-T061
arthroplasty	I-T061
.	O
A	O
literature	O
search	O
strategy	O
was	O
conducted	O
using	O
various	O
search	O
terms	O
in	O
MEDLINE	O
and	O
Embase	O
.	O
The	O
highest	O
quality	O
articles	O
that	O
met	O
the	O
inclusion	O
criteria	O
and	O
best	O
answered	O
the	O
topics	O
of	O
focus	O
of	O
this	O
review	O
were	O
selected	O
.	O
Key	O
search	O
terms	O
included	O
'	O
metal	O
-	O
on	O
-	O
metal	O
'	O
,	O
'	O
total	B-T061
hip	I-T061
arthroplasty	I-T061
'	O
and	O
'	O
hip	B-T061
resurfacing	I-T061
'	O
.	O
The	O
initial	O
search	O
retrieved	O
1240	O
articles	O
.	O
Twenty	O
-	O
two	O
articles	O
were	O
selected	O
and	O
used	O
in	O
the	O
review	O
.	O
Metal	O
-	O
on	O
-	O
metal	O
hip	O
resurfacing	O
is	O
still	O
a	O
suitable	O
treatment	B-T061
option	O
in	O
specific	O
patient	O
populations	O
with	O
the	O
appropriate	O
implant	B-T061
design	I-T061
and	O
surgical	O
skill	O
,	O
while	O
stemmed	O
metal	O
-	O
on	O
-	O
metal	O
total	O
hip	O
arthroplasty	O
should	O
be	O
avoided	O
in	O
all	O
patient	O
populations	O
.	O
Continued	O
follow	B-T058
-	I-T058
up	I-T058
of	O
patients	O
undergoing	O
metal	B-T061
-	I-T061
on	I-T061
-	I-T061
metal	I-T061
hip	I-T061
resurfacing	I-T061
is	O
critical	O
in	O
order	O
to	O
further	O
understand	O
the	O
long	O
-	O
term	O
outcomes	O
of	O
these	O
patients	O
and	O
why	O
certain	O
complications	O
tend	O
to	O
occur	O
with	O
this	O
procedure	O
.	O
      
Association	O
among	O
prematurity	B-T047
(	O
<	O
30	O
weeks	O
'	O
gestational	O
age	O
)	O
,	O
blood	O
pressure	O
,	O
urinary	O
albumin	O
,	O
calcium	B-T121
,	O
and	O
phosphate	B-T121
in	O
early	O
childhood	O
There	O
is	O
a	O
paucity	O
of	O
data	O
on	O
blood	O
pressures	O
(	O
BP	O
)	O
,	O
urinary	O
albumin	O
,	O
and	O
mineral	O
excretion	O
in	O
early	O
childhood	O
in	O
contemporary	O
cohorts	O
of	O
extremely	O
low	O
gestational	O
age	O
(	O
GA	O
)	O
neonates	O
.	O
Our	O
aim	O
was	O
to	O
compare	O
BPs	O
and	O
the	O
urinary	O
excretion	O
of	O
albumin	O
,	O
calcium	B-T121
,	O
and	O
phosphate	B-T121
in	O
preterm	O
and	O
term	O
-	O
born	O
cohorts	O
in	O
early	O
childhood	O
.	O
This	O
was	O
a	O
prospective	O
observational	O
study	O
conducted	O
at	O
a	O
single	O
center	O
,	O
involving	O
children	O
<	O
5	O
years	O
age	O
,	O
born	B-T033
preterm	I-T033
(	O
GA	B-T033
<	I-T033
30	I-T033
weeks	I-T033
)	O
or	O
at	O
term	O
(	O
≥37	B-T033
weeks	I-T033
'	I-T033
GA	I-T033
)	O
.	O
Urinary	O
albumin	O
(	O
mg	O
/	O
L	O
)	O
,	O
calcium	O
and	O
phosphate	O
levels	O
indexed	O
to	O
creatinine	O
(	O
mg	O
/	O
dL	O
)	O
,	O
and	O
BP	O
were	O
measured	O
.	O
The	O
median	O
(	O
IQR	O
)	O
follow	B-T058
-	I-T058
up	I-T058
age	O
of	O
our	O
cohort	O
(	O
n	O
=	O
106	O
)	O
was	O
30	O
(	O
16	O
-	O
48	O
)	O
months	O
.	O
Preterm	O
-	O
born	O
children	O
(	O
n	O
=	O
55	O
)	O
had	O
a	O
significantly	O
lower	O
mean	O
GA	O
and	O
birth	O
weight	O
and	O
higher	O
mean	O
systolic	O
,	O
diastolic	O
,	O
and	O
mean	B-T033
BPs	I-T033
,	O
compared	O
with	O
term	O
(	O
n	O
=	O
51	O
)	O
controls	O
.	O
A	O
significantly	O
higher	O
proportion	O
of	O
preterm	O
-	O
born	O
children	O
weighed	O
<	B-T033
10th	I-T033
centile	I-T033
and	O
had	O
systolic	O
BP	O
>	B-T033
95th	I-T033
centile	I-T033
at	O
follow	B-T058
-	I-T058
up	I-T058
.	O
Albumin	O
and	O
calcium	B-T121
excretion	O
did	O
not	B-T033
differ	I-T033
between	O
the	O
groups	O
;	O
median	O
urine	O
-	O
phosphate	O
creatinine	O
ratios	O
were	O
higher	O
in	O
the	O
preterm	O
group	O
.	O
On	O
logistic	O
regression	O
,	O
lower	O
GA	O
and	O
younger	O
age	O
at	O
follow	B-T058
-	I-T058
up	I-T058
were	O
significantly	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
systolic	O
and	O
diastolic	O
BP	O
above	O
the	O
95th	B-T033
centile	I-T033
;	O
male	O
gender	O
was	O
associated	O
with	O
decreased	O
risk	O
of	O
diastolic	B-T047
hypertension	I-T047
.	O
Even	O
in	O
early	O
childhood	O
,	O
children	O
born	O
preterm	O
had	O
significantly	O
elevated	O
BP	O
,	O
compared	O
with	O
their	O
term	O
-	O
born	O
counterparts	O
.	O
Closer	O
monitoring	B-T058
of	O
BPs	O
in	O
this	O
population	O
may	O
be	O
warranted	O
.	O
      
Prognostic	O
significance	O
of	O
non	O
-	O
HPV16	O
genotypes	O
in	O
oropharyngeal	B-T191
squamous	I-T191
cell	I-T191
carcinoma	I-T191
Recent	O
studies	O
have	O
found	O
that	O
cases	O
with	O
oropharyngeal	B-T191
squamous	I-T191
cell	I-T191
carcinoma	I-T191
(	O
OPSCC	B-T191
)	O
positive	O
for	O
HPV16	O
genotype	O
have	O
better	O
overall	O
survival	O
compared	O
with	O
cases	O
positive	O
for	O
other	O
HPV	O
genotypes	O
.	O
We	O
sought	O
to	O
further	O
replicate	O
these	O
studies	O
and	O
determine	O
if	O
this	O
relationship	O
is	O
modified	O
by	O
expression	O
of	O
p16	O
tumor	O
suppressor	O
protein	O
.	O
We	O
identified	O
238	O
OPSCC	B-T191
cases	O
from	O
the	O
Carolina	O
Head	O
and	O
Neck	O
Cancer	O
Study	O
(	O
CHANCE	O
)	O
study	O
,	O
a	O
population	O
based	O
case	O
-	O
control	O
study	O
.	O
Tumors	B-T191
that	O
tested	O
positive	O
solely	O
for	O
HPV16	O
genotype	O
and	O
no	O
other	O
genotypes	O
with	O
PCR	O
were	O
classified	O
as	O
HPV16	O
-	O
positive	O
.	O
Tumors	B-T191
positive	O
for	O
any	O
other	O
high	B-T033
-	I-T033
risk	I-T033
HPV	O
genotype	O
were	O
classified	O
as	O
non	O
-	O
HPV16	O
-	O
positive	O
.	O
Expression	O
of	O
p16	O
in	O
the	O
tumor	B-T191
was	O
determined	O
with	O
immunohistochemistry	B-T060
.	O
Follow	O
-	O
up	O
time	O
was	O
calculated	O
from	O
the	O
date	O
of	O
diagnosis	O
to	O
date	O
of	O
death	O
or	O
December	O
31	O
,	O
2013	O
.	O
Overall	O
survival	O
was	O
compared	O
with	O
the	O
Kaplan	O
-	O
Meier	O
curves	O
and	O
log	O
-	O
rank	O
test	O
.	O
Hazard	O
ratios	O
(	O
HR	O
)	O
adjusted	O
for	O
smoking	O
,	O
alcohol	O
use	O
,	O
sex	O
,	O
race	O
,	O
and	O
age	O
was	O
calculated	O
with	O
the	O
Cox	O
proportional	O
hazard	O
regression	O
.	O
Cases	O
with	O
HPV16	O
-	O
positive	O
OPSCC	B-T191
had	O
better	O
overall	O
survival	O
than	O
cases	O
with	O
non	O
-	O
HPV16	O
-	O
positive	O
OPSCC	B-T191
(	O
log	O
-	O
rank	O
p	O
-	O
value	O
:	O
0.010	O
)	O
.	O
When	O
restricted	O
to	O
OPSCC	B-T191
cases	O
positive	B-T033
for	O
p16	O
expression	O
,	O
the	O
same	O
trend	O
continued	O
(	O
log	O
-	O
rank	O
p	O
-	O
value	O
:	O
0.002	O
)	O
.	O
In	O
the	O
adjusted	O
model	O
,	O
cases	O
with	O
non	O
-	O
HPV16	O
-	O
positive	O
OPSCC	B-T191
had	O
greater	B-T033
risk	I-T033
of	I-T033
death	B-T033
compared	O
to	O
cases	O
with	O
HPV16	O
-	O
positive	O
tumors	B-T191
(	O
HR	O
:	O
1.92	O
;	O
95	O
%	O
CI	O
:	O
1.03	O
,	O
3.60	O
)	O
.	O
This	O
finding	B-T033
indicates	B-T033
that	O
HPV	B-T005
genotyping	B-T059
carries	O
valuable	O
prognostic	O
significance	O
in	O
addition	O
to	O
p16	O
status	O
and	O
future	O
survival	O
studies	O
of	O
OPSCC	B-T191
should	O
take	O
into	O
account	O
differing	O
HPV	O
genotypes	O
.	O
      
Ultrasonography	B-T060
and	O
magnetic	B-T060
resonance	I-T060
imaging	I-T060
evaluation	B-T058
of	O
pediatric	O
spinal	B-T019
anomalies	I-T019
Spinal	B-T019
dysraphisms	I-T019
are	O
congenital	B-T019
abnormalities	I-T019
of	O
the	O
spine	B-T023
due	O
to	O
imperfect	O
fusion	O
of	O
midline	O
mesenchymal	O
,	O
bony	O
and	O
neural	O
structures	O
.	O
Imaging	B-T060
plays	O
a	O
vital	O
role	O
in	O
their	O
evaluation	B-T058
as	O
significant	O
portion	O
of	O
patients	O
may	O
present	O
with	O
concurrent	O
anomalies	B-T019
that	O
need	O
to	O
be	O
corrected	O
simultaneously	O
to	O
avoid	O
repeat	B-T061
surgeries	I-T061
.	O
The	O
aims	O
of	O
the	O
study	O
were	O
to	O
evaluate	B-T058
Spinal	B-T019
dysraphisms	I-T019
using	O
USG	B-T060
and	O
MRI	B-T060
and	O
to	O
correlate	O
imaging	B-T060
findings	O
with	O
operative	O
findings	O
in	O
patients	O
undergoing	O
surgery	B-T061
.	O
Hospital	O
based	O
observational	O
study	O
conducted	O
over	O
a	O
period	O
of	O
year	O
.	O
38	O
cases	O
of	O
both	O
sexes	O
and	O
below	O
12	O
years	O
of	O
age	O
with	O
spinal	B-T019
dysraphism	I-T019
were	O
studied	O
.	O
USG	B-T060
was	O
performed	O
in	O
29	O
cases	O
where	O
acoustic	O
window	O
was	O
available	O
for	O
proper	O
evaluation	B-T058
.	O
MRI	B-T060
was	O
performed	O
in	O
all	O
cases	O
.	O
USG	B-T060
findings	O
were	O
compared	O
with	O
MRI	B-T060
findings	O
and	O
operative	O
follow	B-T058
up	I-T058
was	O
taken	O
in	O
23	O
cases	O
who	O
underwent	O
operative	B-T058
management	I-T058
.	O
Results	O
were	O
analysed	O
using	O
percentage	O
and	O
arithmetic	O
mean	O
.	O
39.47	O
%	O
cases	O
were	O
male	O
and	O
60.53	O
%	O
cases	O
were	O
female	O
.	O
Neonatal	O
period	O
was	O
the	O
most	O
common	O
presenting	O
age	O
group	O
.	O
Closed	O
spinal	B-T019
dysraphism	I-T019
(	O
63.16	O
%	O
)	O
was	O
more	O
common	O
than	O
open	O
(	O
36.84	O
%	O
)	O
.	O
79.31	O
%	O
cases	O
showed	O
full	O
agreement	O
between	O
spinal	O
USG	B-T060
and	O
MRI	B-T060
examinations	B-T058
and	O
6	O
out	O
of	O
20.69	O
%	O
showed	O
partial	O
agreement	O
.	O
On	O
operative	O
correlation	O
,	O
USG	B-T060
findings	O
were	O
confirmatory	B-T033
in	O
91.30	O
%	O
cases	O
and	O
MRI	B-T060
findings	O
were	O
confirmatory	B-T033
in	O
100	O
%	O
cases	O
.	O
USG	B-T060
can	O
be	O
used	O
as	O
the	O
initial	O
modality	O
for	O
evaluation	B-T058
of	O
spinal	B-T019
dysraphism	I-T019
as	O
well	O
as	O
for	O
screening	B-T058
of	O
suspected	O
cases	O
.	O
MRI	B-T060
is	O
indicated	O
to	O
confirm	O
abnormal	B-T033
USG	B-T060
findings	O
,	O
which	O
shows	O
all	O
concurrent	O
abnormalities	B-T019
and	O
also	O
provides	O
additional	O
anatomical	O
details	O
relevant	O
to	O
surgical	O
planning	O
.	O
      
MRI	B-T060
-based	O
prostate	B-T191
cancer	I-T191
detection	B-T033
with	O
high	O
-	O
level	O
representation	O
and	O
hierarchical	O
classification	O
Extracting	O
the	O
high	O
-	O
level	O
feature	O
representation	O
by	O
using	O
deep	O
neural	O
networks	O
for	O
detection	B-T033
of	O
prostate	B-T191
cancer	I-T191
,	O
and	O
then	O
based	O
on	O
high	O
-	O
level	O
feature	O
representation	O
constructing	O
hierarchical	O
classification	O
to	O
refine	O
the	O
detection	B-T033
results	O
.	O
High	O
-	O
level	O
feature	O
representation	O
is	O
first	O
learned	O
by	O
a	O
deep	O
learning	O
network	O
,	O
where	O
multiparametric	B-T060
MR	I-T060
images	O
are	O
used	O
as	O
the	O
input	O
data	O
.	O
Then	O
,	O
based	O
on	O
the	O
learned	O
high	O
-	O
level	O
features	O
,	O
a	O
hierarchical	O
classification	O
method	O
is	O
developed	O
,	O
where	O
multiple	O
random	O
forest	O
classifiers	O
are	O
iteratively	O
constructed	O
to	O
refine	O
the	O
detection	B-T033
results	O
of	O
prostate	B-T191
cancer	I-T191
.	O
The	O
experiments	O
were	O
carried	O
on	O
21	O
real	O
patient	O
subjects	O
,	O
and	O
the	O
proposed	O
method	O
achieves	O
an	O
averaged	O
section	B-T058
-	I-T058
based	I-T058
evaluation	I-T058
(	O
SBE	B-T058
)	O
of	O
89.90	O
%	O
,	O
an	O
averaged	O
sensitivity	O
of	O
91.51	O
%	O
,	O
and	O
an	O
averaged	O
specificity	O
of	O
88.47	O
%	O
.	O
The	O
high	O
-	O
level	O
features	O
learned	O
from	O
our	O
proposed	O
method	O
can	O
achieve	O
better	O
performance	O
than	O
the	O
conventional	O
handcrafted	O
features	O
(	O
e.g.	O
,	O
LBP	O
and	O
Haar	O
-	O
like	O
features	O
)	O
in	O
detecting	B-T033
prostate	B-T191
cancer	I-T191
regions	O
,	O
also	O
the	O
context	O
features	O
obtained	O
from	O
the	O
proposed	O
hierarchical	O
classification	O
approach	O
are	O
effective	O
in	O
refining	O
cancer	B-T191
detection	B-T033
result	O
.	O
      
Association	O
of	O
physical	O
activity	O
on	O
body	O
composition	O
,	O
cardiometabolic	B-T033
risk	I-T033
factors	I-T033
,	O
and	O
prevalence	O
of	O
cardiovascular	B-T047
disease	I-T047
in	O
the	O
Korean	O
population	O
(	O
from	O
the	O
fifth	O
Korea	O
national	O
health	O
and	O
nutrition	O
examination	O
survey	O
,	O
2008	O
-	O
2011	O
)	O
Data	O
regarding	O
associations	O
among	O
physical	O
activity	O
(	O
PA	O
)	O
level	O
,	O
body	O
composition	O
,	O
and	O
prevalence	O
of	O
cardiovascular	B-T047
diseases	I-T047
in	O
Asian	O
populations	O
are	O
rare	O
.	O
The	O
International	O
Physical	O
Activity	O
Questionnaire	O
(	O
IPAQ	O
)	O
was	O
utilized	O
to	O
estimate	O
PA	O
levels	O
and	O
analyze	O
the	O
association	O
of	O
PA	O
level	O
with	O
various	O
body	O
composition	O
parameters	O
and	O
the	O
prevalence	O
of	O
cardiovascular	B-T047
diseases	I-T047
by	O
using	O
data	O
from	O
the	O
Korean	O
National	O
Health	O
and	O
Nutrition	O
Examination	O
Survey	O
from	O
2008	O
to	O
2011	O
.	O
Moderate	O
and	O
high	O
PA	O
levels	O
were	O
associated	O
with	O
lower	O
prevalence	O
of	O
hypertension	B-T047
and	O
diabetes	B-T047
mellitus	I-T047
,	O
and	O
lower	O
concentrations	O
of	O
serum	B-T033
ferritin	I-T033
,	O
parathyroid	B-T033
hormone	I-T033
,	O
and	O
alkaline	B-T033
phosphatase	I-T033
.	O
Sarcopenia	B-T047
(	O
low	O
vs.	O
moderate	O
vs.	O
high	O
PA	O
group	O
:	O
14.3	O
%	O
vs.	O
10.5	O
%	O
vs.	O
7.3	O
%	O
,	O
p	O
=	O
0.001	O
)	O
,	O
underweight	B-T033
(	O
5.7	O
%	O
vs.	O
4.9	O
%	O
vs.	O
3.5	O
%	O
,	O
p	O
=	O
0.001	O
)	O
,	O
and	O
central	B-T033
obesity	I-T033
(	O
7.8	O
%	O
vs.	O
6.9	O
%	O
vs.	O
6.3	O
%	O
,	O
p	O
=	O
0.002	O
)	O
were	O
more	O
often	O
observed	O
in	O
the	O
low	O
PA	O
group	O
.	O
The	O
prevalence	O
rates	O
of	O
cardiovascular	B-T047
diseases	I-T047
were	O
lower	O
in	O
the	O
moderate	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
,	O
0.822	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
0.737	O
-	O
0.916	O
;	O
p	O
=	O
0.001	O
)	O
and	O
high	O
activity	O
groups	O
(	O
OR	O
,	O
0.663	O
;	O
95	O
%	O
CI	O
,	O
0.589	O
-	O
0.748	O
;	O
p	O
=	O
0.001	O
)	O
than	O
in	O
the	O
low	O
activity	O
group	O
,	O
even	O
after	O
adjusting	O
for	O
age	O
,	O
sex	O
,	O
smoking	O
,	O
underlying	B-T047
disease	I-T047
,	O
and	O
general	B-T047
or	O
abdominal	B-T033
obesity	I-T033
and	O
muscle	B-T033
mass	I-T033
.	O
Regular	O
physical	O
activity	O
was	O
associated	O
with	O
a	O
low	O
prevalence	O
of	O
cardiovascular	B-T047
diseases	I-T047
(	O
stroke	O
,	O
myocardial	B-T047
infarction	I-T047
,	O
stable	B-T047
angina	I-T047
,	O
and	O
chronic	B-T047
renal	I-T047
disease	I-T047
)	O
,	O
which	O
was	O
independent	O
of	O
body	O
composition	O
and	O
conventional	O
risk	B-T033
factors	I-T033
in	O
the	O
Korean	O
population	O
,	O
with	O
a	O
positive	B-T033
dose	O
-	O
response	O
relationship	O
.	O
      
Divided	O
and	O
Sliding	O
Superficial	B-T023
Temporal	I-T023
Artery	I-T023
Flap	B-T023
for	O
Primary	O
Donor	O
-	O
site	O
Closure	B-T061
Superficial	B-T023
temporal	I-T023
artery	I-T023
(	O
STA	B-T023
)	O
flaps	B-T023
are	O
often	O
used	O
for	O
reconstruction	B-T061
of	O
hair	O
-	O
bearing	O
areas	O
.	O
However	O
,	O
primary	B-T061
closure	I-T061
of	O
the	O
donor	O
site	O
is	O
not	O
easy	O
when	O
the	O
size	O
of	O
the	O
necessary	O
skin	O
island	O
is	O
relatively	O
large	O
.	O
In	O
such	O
cases	O
,	O
skin	B-T023
grafts	I-T023
are	O
needed	O
at	O
the	O
donor	O
site	O
,	O
resulting	O
in	O
baldness	B-T047
.	O
We	O
have	O
solved	O
this	O
issue	O
by	O
applying	O
the	O
divided	O
and	O
sliding	O
flap	B-T023
technique	O
,	O
which	O
was	O
first	O
reported	O
for	O
primary	B-T061
donor	I-T061
-	I-T061
site	I-T061
closure	I-T061
of	O
a	O
latissimus	B-T023
dorsi	I-T023
musculocutaneous	I-T023
flap	B-T023
.	O
We	O
applied	O
this	O
technique	O
to	O
the	O
hair	B-T023
-	I-T023
bearing	I-T023
STA	I-T023
flap	B-T023
,	O
where	O
primary	B-T061
donor	I-T061
-	I-T061
site	I-T061
closure	I-T061
is	O
extremely	O
beneficial	O
for	O
preventing	O
baldness	B-T047
consequent	O
to	O
skin	B-T061
grafting	I-T061
.	O
The	O
STA	B-T023
flap	B-T023
was	O
divided	O
into	O
3	O
,	O
and	O
creation	O
of	O
large	O
flap	B-T023
was	O
possible	O
.	O
Therefore	O
,	O
we	O
concluded	O
that	O
the	O
divided	O
and	O
sliding	O
STA	B-T023
flap	B-T023
could	O
at	O
least	O
partially	O
solve	O
the	O
donor	O
-	O
site	O
problem	B-T033
.	O
Although	O
further	O
investigation	B-T058
is	O
necessary	O
to	O
validate	O
the	O
maximum	O
possible	B-T033
flap	B-T023
size	O
,	O
this	O
technique	O
may	O
be	O
applicable	O
to	O
at	O
least	O
small	O
defects	O
that	O
are	O
common	O
after	O
skin	B-T191
cancer	I-T191
ablation	B-T061
or	O
trauma	O
.	O
      
Aryl	O
hydrocarbon	O
receptor	O
(	O
AhR	O
)	O
rs2066853	O
gene	O
polymorphism	O
association	O
with	O
infertile	O
oligoasthenoteratozoospermic	B-T047
men	O
and	O
seminal	O
oxidative	O
stress	O
This	O
study	O
aimed	O
to	O
assess	O
the	O
association	O
between	O
aryl	O
hydrocarbon	O
receptor	O
(	O
AhR	O
)	O
rs2066853	O
gene	O
polymorphism	O
with	O
infertile	O
oligoasthenoteratozoospermic	B-T047
(	O
OAT	B-T047
)	O
men	O
and	O
seminal	O
oxidative	O
stress	O
(	O
OS	O
)	O
.	O
A	O
total	O
of	O
170	O
Egyptian	O
men	O
were	O
allocated	O
according	O
to	O
their	O
semen	B-T059
analysis	I-T059
into	O
fertile	O
normozoospermic	B-T033
controls	I-T033
(	O
n	O
=	O
50	O
)	O
and	O
infertile	O
OAT	B-T047
men	O
(	O
n	O
=	O
120	O
)	O
.	O
They	O
were	O
subjected	O
to	O
history	B-T058
taking	I-T058
,	O
clinical	O
examination	O
,	O
semen	B-T059
analysis	I-T059
,	O
estimation	O
of	O
seminal	O
glutathione	O
peroxidase	O
(	O
GPx	O
)	O
,	O
and	O
malondialdehyde	O
(	O
MDA	O
)	O
.	O
AhR	O
rs2066853	O
gene	O
polymorphism	O
was	O
identified	O
in	O
the	O
blood	O
by	O
PCR	O
-	O
RFLP	O
.	O
Comparing	O
infertile	O
OAT	B-T047
men	O
with	O
fertile	O
controls	O
,	O
AhR	O
rs2066853	O
genotypes	O
showed	O
decreased	O
prevalence	O
for	O
wild	O
homozygous	O
genotype	O
GG	O
(	O
35.8	O
vs	O
56	O
%	O
)	O
and	O
for	O
heterozygous	O
genotype	O
GA	O
(	O
17.5	O
vs	O
30	O
%	O
)	O
and	O
an	O
increased	O
prevalence	O
for	O
homozygous	O
genotype	O
AA	O
(	O
46.7	O
vs	O
14	O
%	O
)	O
.	O
Distribution	O
of	O
alleles	O
of	O
AhR	O
rs2066853	O
among	O
OAT	B-T047
men	O
compared	O
with	O
fertile	O
men	O
showed	O
decreased	O
prevalence	O
of	O
G	O
allele	O
(	O
44.6	O
vs	O
71	O
%	O
)	O
and	O
an	O
increased	O
prevalence	O
of	O
A	O
allele	O
(	O
55.4	O
vs	O
29	O
%	O
)	O
.	O
Seminal	O
MDA	O
demonstrated	O
significant	O
increase	O
whereas	O
seminal	O
GPx	O
demonstrated	O
significant	O
decrease	O
in	O
cases	O
with	O
AA	O
and	O
GA	O
/	O
AA	O
genotypes	O
compared	O
to	O
cases	O
with	O
GG	O
genotype	O
.	O
It	O
is	O
concluded	O
that	O
there	O
is	O
a	O
significant	O
association	O
between	O
AhR	O
rs2066853	O
genotype	O
polymorphism	O
with	O
decreased	O
sperm	O
parameters	O
as	O
well	O
as	O
increased	O
seminal	O
oxidative	O
stress	O
in	O
infertile	O
OAT	B-T047
men	O
.	O
      
Engaging	B-T033
adolescent	O
girls	O
in	O
transactional	O
sex	O
through	O
compensated	O
dating	O
Transactional	O
sex	O
through	O
so	O
-	O
called	O
compensated	O
dating	O
in	O
adolescent	O
girls	O
is	O
a	O
problem	B-T033
in	O
need	O
of	O
public	O
concern	O
.	O
Compensated	O
dating	O
typically	O
involves	O
the	O
use	O
of	O
information	O
communication	O
technology	O
to	O
advertise	O
,	O
search	O
,	O
bargain	O
,	O
and	O
eventually	O
arrange	O
for	O
transactional	O
sex	O
.	O
The	O
technology	O
enables	O
the	O
sexual	O
partners	O
to	O
maintain	O
privacy	O
and	O
secrecy	O
in	O
transactional	O
sex	O
.	O
Such	O
secrecy	O
necessitates	O
the	O
girls	O
'	O
disclosure	O
about	O
their	O
life	O
experiences	O
in	O
order	O
to	O
address	O
the	O
concern	O
.	O
The	O
disclosure	O
is	O
the	O
focus	O
of	O
the	O
present	O
qualitative	O
study	O
of	O
27	O
girls	O
practicing	O
the	O
dating	O
in	O
Hong	O
Kong	O
,	O
China	O
.	O
Based	O
on	O
the	O
disclosure	O
,	O
the	O
study	O
presents	O
a	O
grounded	O
theory	O
that	O
epitomizes	O
engagement	B-T033
in	O
compensated	O
dating	O
by	O
referential	O
choice	O
.	O
Such	O
a	O
referential	O
choice	O
theory	O
unravels	O
that	O
choice	O
with	O
reference	O
to	O
the	O
family	O
push	O
and	O
social	O
norms	O
sustains	O
the	O
engagement	B-T033
.	O
Meanwhile	O
,	O
the	O
choice	O
rests	O
on	O
expectancy	O
and	O
reinforcement	O
from	O
experiential	O
learning	O
about	O
compensated	O
dating	O
.	O
The	O
theory	O
thus	O
implies	O
ways	O
to	O
undercut	O
the	O
engagement	B-T033
through	O
diverting	O
the	O
referential	O
choice	O
of	O
the	O
dating	O
.	O
      
Lack	O
of	O
antimicrobial	O
efficacy	O
of	O
mecetronium	B-T121
etilsulfate	I-T121
in	O
propanol	O
-based	O
hand	B-T121
rubs	I-T121
for	O
surgical	B-T061
hand	B-T058
disinfection	I-T058
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
mecetronium	B-T121
etilsulfate	I-T121
(	O
MES	B-T121
)	O
contributes	O
to	O
overall	O
efficacy	O
in	O
surgical	B-T061
hand	B-T058
disinfection	I-T058
.	O
Three	O
blinded	O
hand	B-T121
rubs	I-T121
(	O
45	O
%	O
iso	B-T121
-	I-T121
propanol	I-T121
,	O
30	O
%	O
n	B-T121
-	I-T121
propanol	I-T121
)	O
were	O
applied	O
for	O
1.5	O
min	O
and	O
compared	O
with	O
the	O
EN	B-T121
12791	I-T121
reference	O
procedure	O
(	O
crossover	O
design	O
)	O
.	O
One	O
commercial	O
hand	B-T121
rub	I-T121
contained	O
0.2	O
%	O
MES	B-T121
,	O
and	O
the	O
two	O
other	O
hand	B-T121
rubs	I-T121
were	O
identical	O
apart	O
from	O
0.2	O
%	O
MES	B-T121
.	O
None	O
of	O
the	O
formulations	O
had	O
a	O
log10	O
reduction	O
after	O
3	O
h	O
that	O
was	O
significantly	O
better	O
compared	O
with	O
the	O
reference	O
procedure	O
[	O
mean	O
1.72	O
(	O
standard	O
deviation	O
1.15	O
)	O
]	O
.	O
The	O
antimicrobial	O
contribution	O
of	O
MES	B-T121
in	O
hand	B-T121
rubs	I-T121
is	O
questionable	O
.	O
      
The	O
adder	O
(	O
Vipera	O
berus	O
)	O
in	O
Southern	O
Altay	O
Mountains	O
:	O
population	O
characteristics	O
,	O
distribution	O
,	O
morphology	O
and	O
phylogenetic	O
position	O
As	O
the	O
most	O
widely	O
distributed	O
snake	O
in	O
Eurasia	O
,	O
the	O
adder	O
(	O
Vipera	O
berus	O
)	O
has	O
been	O
extensively	O
investigated	O
in	O
Europe	O
but	O
poorly	O
understood	O
in	O
Asia	O
.	O
The	O
Southern	O
Altay	O
Mountains	O
represent	O
the	O
adder	O
's	O
southern	O
distribution	O
limit	O
in	O
Central	O
Asia	O
,	O
whereas	O
its	O
population	O
status	O
has	O
never	O
been	O
assessed	O
.	O
We	O
conducted	O
,	O
for	O
the	O
first	O
time	O
,	O
field	O
surveys	O
for	O
the	O
adder	O
at	O
two	O
areas	O
of	O
Southern	O
Altay	O
Mountains	O
using	O
a	O
combination	O
of	O
line	O
transects	O
and	O
random	O
searches	O
.	O
We	O
also	O
described	O
the	O
morphological	O
characteristics	O
of	O
the	O
collected	B-T059
specimens	I-T059
and	O
conducted	O
analyses	O
of	O
external	O
morphology	O
and	O
molecular	O
phylogeny	O
.	O
The	O
results	B-T033
showed	O
that	O
the	O
adder	O
distributed	O
in	O
both	O
survey	O
sites	O
and	O
we	O
recorded	O
a	O
total	O
of	O
34	O
sightings	O
.	O
In	O
Kanas	O
river	O
valley	O
,	O
the	O
estimated	O
encounter	O
rate	O
over	O
a	O
total	O
of	O
137	O
km	O
transects	O
was	O
0.15	O
±	O
0.05	O
sightings	O
/km	O
.	O
The	O
occurrence	O
of	O
melanism	B-T047
was	O
only	O
17	O
%	O
.	O
The	O
small	B-T033
size	I-T033
was	O
typical	O
for	O
the	O
adders	O
in	O
Southern	O
Altay	O
Mountains	O
in	O
contrast	O
to	O
other	O
geographic	O
populations	O
of	O
the	O
nominate	O
subspecies	O
.	O
A	O
phylogenetic	O
tree	O
obtained	O
by	O
Bayesian	O
Inference	O
based	O
on	O
DNA	O
sequences	O
of	O
the	O
mitochondrial	O
cytochrome	O
b	O
(	O
1,023	O
bp	O
)	O
grouped	O
them	O
within	O
the	O
Northern	O
clade	O
of	O
the	O
species	O
but	O
failed	O
to	O
separate	O
them	O
from	O
the	O
subspecies	O
V.	O
b.	O
sachalinensis	O
.	O
Our	O
discovery	O
extends	O
the	O
distribution	O
range	O
of	O
V.	O
berus	O
and	O
provides	O
a	O
basis	O
for	O
further	O
researches	O
.	O
We	O
discuss	O
the	O
hypothesis	O
that	O
the	O
adder	O
expands	O
its	O
distribution	O
border	O
to	O
the	O
southwest	O
along	O
the	O
mountains	O
'	O
elevation	O
gradient	O
,	O
but	O
the	O
population	O
abundance	O
declines	O
gradually	O
due	O
to	O
a	O
drying	O
climate	O
.	O
      
Effect	O
of	O
ultrasonic	O
processing	O
on	O
the	O
changes	O
in	O
activity	O
,	O
aggregation	O
and	O
the	O
secondary	O
and	O
tertiary	O
structure	O
of	O
polyphenol	O
oxidase	O
in	O
oriental	O
sweet	O
melon	O
(	O
Cucumis	O
melo	O
var	O
.	O
makuwa	O
Makino	O
)	O
Polyphenol	O
oxidase	O
(	O
PPO	O
)	O
mainly	O
contributes	O
to	O
the	O
browning	O
reaction	O
of	O
fruits	O
and	O
vegetables	O
and	O
causes	O
serious	O
damage	O
to	O
the	O
quality	O
of	O
sweet	O
melon	O
products	O
.	O
However	O
,	O
traditional	O
methods	O
to	O
inactivate	O
browning	O
may	O
induce	O
more	O
unexpected	O
risks	O
than	O
ultrasonic	O
processing	O
.	O
Meanwhile	O
,	O
there	O
are	O
no	O
reports	O
on	O
the	O
effect	O
of	O
ultrasound	O
on	O
PPO	O
directly	O
purified	O
from	O
sweet	O
melon	O
.	O
The	O
PPO	O
in	O
the	O
original	O
juice	O
was	O
less	O
inactivated	O
than	O
the	O
purified	O
form	O
when	O
treated	B-T061
with	I-T061
ultrasound	O
.	O
As	O
for	O
purified	O
PPO	O
,	O
superior	O
to	O
thermal	B-T061
treatment	I-T061
,	O
less	O
heat	O
was	O
needed	O
to	O
inactivate	O
the	O
PPO	O
with	O
ultrasonic	O
treatment	B-T061
.	O
At	O
intensity	B-T033
lower	I-T033
than	O
200	O
W	O
,	O
ultrasound	O
did	O
not	O
significantly	O
affect	O
the	O
structure	O
and	O
activity	O
of	O
PPO	O
(	O
P	O
>	O
0.05	O
)	O
,	O
and	O
latent	O
PPO	O
was	O
activated	O
.	O
At	O
intensity	B-T033
higher	I-T033
than	O
200	O
W	O
,	O
ultrasound	O
inactivated	O
PPO	O
,	O
induced	O
aggregation	O
and	O
dissociation	O
of	O
PPO	O
particles	O
and	O
significantly	O
decreased	O
the	O
α	O
-	O
helix	O
structure	O
content	O
.	O
Low	O
-	O
frequency	O
high	O
-	O
intensity	O
ultrasound	O
caused	O
an	O
inactivation	O
effect	O
and	O
conformational	O
changes	O
of	O
purified	O
PPO	O
from	O
oriental	O
sweet	O
melons	O
.	O
Changes	O
in	O
the	O
PPO	O
structure	O
induced	O
by	O
ultrasound	O
eventually	O
inactivated	O
the	O
enzyme	O
.	O
Ultrasound	O
may	O
be	O
a	O
potential	O
method	O
to	O
inactivate	O
PPO	O
in	O
oriental	O
sweet	O
melons	O
.	O
©	O
2016	O
Society	O
of	O
Chemical	O
Industry	O
.	O
      
Decoding	O
the	O
Interactions	O
Regulating	O
the	O
Active	B-T033
State	I-T033
Mechanics	O
of	O
Eukaryotic	O
Protein	O
Kinases	O
Eukaryotic	O
protein	O
kinases	O
regulate	O
most	O
cellular	O
functions	O
by	O
phosphorylating	O
targeted	O
protein	O
substrates	O
through	O
a	O
highly	O
conserved	O
catalytic	O
core	O
.	O
In	O
the	O
active	B-T033
state	I-T033
,	O
the	O
catalytic	O
core	O
oscillates	B-T061
between	O
open	O
,	O
intermediate	O
,	O
and	O
closed	O
conformations	O
.	O
Currently	O
,	O
the	O
intramolecular	O
interactions	O
that	O
regulate	O
the	O
active	B-T033
state	I-T033
mechanics	O
are	O
not	O
well	O
understood	O
.	O
Here	O
,	O
using	O
cAMP	O
-	O
dependent	O
protein	O
kinase	O
as	O
a	O
representative	O
model	O
coupled	O
with	O
biochemical	O
,	O
biophysical	O
,	O
and	O
computational	O
techniques	O
,	O
we	O
define	O
a	O
set	O
of	O
highly	O
conserved	O
electrostatic	O
and	O
hydrophobic	O
interactions	O
working	O
harmoniously	O
to	O
regulate	O
these	O
mechanics	O
.	O
These	O
include	O
the	O
previously	O
identified	O
salt	O
bridge	O
between	O
a	O
lysine	B-T121
from	O
the	O
β3	O
-	O
strand	O
and	O
a	O
glutamate	O
from	O
the	O
αC	O
-	O
helix	O
as	O
well	O
as	O
an	O
electrostatic	O
interaction	O
between	O
the	O
phosphorylated	O
activation	O
loop	O
and	O
αC	O
-	O
helix	O
and	O
an	O
ensemble	O
of	O
hydrophobic	O
residues	O
of	O
the	O
Regulatory	O
spine	O
and	O
Shell	O
.	O
Moreover	O
,	O
for	O
over	O
three	O
decades	O
it	O
was	O
thought	O
that	O
the	O
highly	O
conserved	O
β3	B-T121
-lysine	I-T121
was	O
essential	O
for	O
phosphoryl	O
transfer	O
,	O
but	O
our	O
findings	O
show	O
that	O
the	O
β3	B-T121
-lysine	I-T121
is	O
not	O
required	O
for	O
phosphoryl	O
transfer	O
but	O
is	O
essential	O
for	O
the	O
active	B-T033
state	I-T033
mechanics	O
.	O
      
Changes	O
in	O
risk	B-T033
factors	I-T033
for	O
young	O
male	O
suicide	B-T033
in	O
Newcastle	O
upon	O
Tyne	O
,	O
1961	O
-	O
2009	O
Aims	O
and	O
method	O
To	O
ascertain	O
differences	O
in	O
patterns	B-T033
of	I-T033
suicide	I-T033
in	O
young	O
men	O
over	O
three	O
decades	O
(	O
1960s	O
,	O
1990s	O
and	O
2000s	O
)	O
and	O
discuss	O
implications	O
for	O
suicide	B-T033
prevention	O
.	O
Data	O
on	O
suicides	B-T033
and	O
open	O
verdicts	O
in	O
men	O
aged	O
15	O
-	O
34	O
were	O
obtained	O
from	O
coroner	O
's	O
records	O
in	O
Newcastle	O
upon	O
Tyne	O
and	O
analysed	O
using	O
SPSS	O
software	O
.	O
Results	O
An	O
increase	O
in	O
suicide	B-T033
rates	I-T033
from	O
the	O
first	O
to	O
the	O
second	O
decade	O
was	O
followed	O
by	O
a	O
fall	O
in	O
the	O
third	O
decade	O
.	O
This	O
was	O
associated	O
with	O
an	O
increasing	O
proportion	O
of	O
single	O
men	O
,	O
those	O
living	B-T033
alone	I-T033
,	O
unemployment	B-T033
,	O
consumption	O
of	O
alcohol	O
,	O
use	O
of	O
hanging	O
,	O
previous	O
suicide	B-T033
attempt	I-T033
and	O
history	O
of	O
treatment	O
for	O
mental	B-T048
illness	I-T048
.	O
Clinical	O
implications	O
This	O
study	O
highlights	O
the	O
need	O
for	O
more	O
interventions	B-T061
and	O
focus	O
to	O
be	O
given	O
to	O
young	O
males	O
in	O
the	O
suicide	B-T033
prevention	O
area	O
and	O
is	O
of	O
high	O
importance	O
in	O
the	O
field	O
of	O
public	O
health	O
.	O
Areas	O
that	O
could	O
be	O
tackled	O
include	O
reducing	O
access	O
to	O
means	O
of	O
suicide	B-T033
,	O
reducing	O
alcohol	O
use	O
,	O
support	O
for	O
relationship	O
difficulties	O
,	O
engagement	B-T058
with	O
mental	B-T058
health	I-T058
services	I-T058
and	O
management	B-T058
of	O
chronic	B-T047
illness	I-T047
.	O
      
C4b	O
binding	O
protein	O
negatively	O
regulates	O
TLR1	O
/	O
2	O
response	O
TLR2	O
associates	O
with	O
TLR1	O
and	O
recognizes	O
microbial	B-T001
lipoproteins	O
.	O
Pam3CSK4	O
,	O
a	O
triacylated	O
lipoprotein	O
,	O
is	O
anchored	O
to	O
the	O
extracellular	O
domain	O
of	O
TLR1	O
and	O
TLR2	O
and	O
induces	O
pro	O
-	O
inflammatory	O
signals	O
.	O
Here	O
we	O
show	O
that	O
C4b	O
binding	O
protein	O
(	O
C4BP	O
)	O
,	O
which	O
is	O
a	O
complement	O
pathway	O
inhibitor	O
,	O
is	O
a	O
TLR2	O
-associated	O
molecule	O
.	O
Immunoprecipitation	B-T059
assay	I-T059
using	O
anti	O
-	O
TLR2	O
mAb	O
shows	O
that	O
C4BP	O
binds	O
to	O
TLR2	O
.	O
In	O
C4BP	O
-	O
deficient	O
mice	O
,	O
Pam3CSK4	O
-	O
induced	O
IL-6	O
levels	O
were	O
increased	O
compared	O
with	O
wild	O
type	O
mice	O
.	O
In	O
C4BP	O
-	O
expressing	O
cells	O
,	O
Pam3CSK4	O
-	O
induced	O
IL-8	O
production	O
was	O
reduced	O
depending	O
on	O
the	O
C4BP	O
expression	O
levels	O
.	O
These	O
results	O
reveal	O
the	O
important	O
role	O
of	O
C4BP	O
in	O
negative	O
regulation	O
of	O
TLR1	O
/	O
2	O
-	O
dependent	O
pro	O
-	O
inflammatory	O
cytokine	O
production	O
.	O
Furthermore	O
,	O
using	O
a	O
fluorescent	O
conjugated	O
Pam3CSK4	O
,	O
we	O
show	O
that	O
C4BP	O
blocks	O
the	O
binding	O
of	O
Pam3CSK4	O
to	O
TLR1	O
/	O
2	O
.	O
Finally	O
,	O
we	O
show	O
that	O
exogenous	O
C4BP	O
also	O
inhibits	O
Pam3CSK4	O
-	O
induced	O
signaling	O
leading	O
to	O
IL-8	O
production	O
.	O
Our	O
results	O
indicate	O
C4BP	O
binding	O
to	O
TLR2	O
and	O
consequent	B-T033
neutralization	O
of	O
its	O
activity	O
otherwise	O
inducing	O
pro	O
-	O
inflammatory	O
cytokine	O
production	O
.	O
C4BP	O
is	O
a	O
negative	O
regulator	O
of	O
TLR1	O
/	O
2	O
activity	O
.	O
      
Recent	O
advances	O
in	O
chitosan	B-T121
-based	O
nanoparticulate	O
pulmonary	B-T023
drug	O
delivery	O
The	O
advent	O
of	O
biodegradable	O
polymer	O
-	O
encapsulated	O
drug	B-T121
nanoparticles	O
has	O
made	O
the	O
pulmonary	B-T023
route	O
of	O
administration	O
an	O
exciting	O
area	O
of	O
drug	O
delivery	O
research	O
.	O
Chitosan	B-T121
,	O
a	O
natural	O
biodegradable	O
and	O
biocompatible	O
polysaccharide	B-T121
has	O
received	O
enormous	O
attention	O
as	O
a	O
carrier	O
for	O
drug	O
delivery	O
.	O
Recently	O
,	O
nanoparticles	O
of	O
chitosan	B-T121
(	O
CS	B-T121
)	O
and	O
its	O
synthetic	B-T121
derivatives	I-T121
have	O
been	O
investigated	O
for	O
the	O
encapsulation	O
and	O
delivery	O
of	O
many	O
drugs	B-T121
with	O
improved	B-T033
targeting	O
and	O
controlled	O
release	O
.	O
Herein	O
,	O
recent	O
advances	O
in	O
the	O
preparation	O
and	O
use	O
of	O
micro-	O
/	O
nanoparticles	O
of	O
chitosan	B-T121
and	O
its	O
derivatives	B-T121
for	O
pulmonary	B-T023
delivery	O
of	O
various	O
therapeutic	O
agents	O
(	O
drugs	B-T121
,	O
genes	O
,	O
vaccines	B-T121
)	O
are	O
reviewed	O
.	O
Although	O
chitosan	B-T121
has	O
wide	O
applications	O
in	O
terms	O
of	O
formulations	O
and	O
routes	O
of	O
drug	O
delivery	O
,	O
this	O
review	O
is	O
focused	O
on	O
pulmonary	B-T023
delivery	B-T058
of	I-T058
drug	I-T058
-	I-T058
encapsulated	I-T058
nanoparticles	I-T058
of	O
chitosan	B-T121
and	O
its	O
derivatives	B-T121
.	O
In	O
addition	O
,	O
the	O
controversial	O
toxicological	O
effects	O
of	O
chitosan	B-T121
nanoparticles	O
for	O
lung	B-T023
delivery	O
will	O
also	O
be	O
discussed	O
.	O
      
Sulfur	B-T121
and	O
Zinc	B-T121
Availability	O
from	O
Co	O
-	O
granulated	O
Zn	B-T121
-Enriched	O
Elemental	B-T121
Sulfur	I-T121
Fertilizers	O
Acidification	O
by	O
oxidation	O
of	O
elemental	B-T121
sulfur	I-T121
(	O
ES	B-T121
)	O
can	O
solubilize	O
ZnO	B-T121
,	O
providing	O
slow	O
release	O
of	O
both	O
sulfur	B-T121
(	O
S	B-T121
)	O
and	O
zinc	B-T121
(	O
Zn	B-T121
)	O
in	O
soil	O
.	O
For	O
this	O
study	O
,	O
a	O
new	O
granular	O
fertilizer	O
with	O
ES	B-T121
and	O
ZnO	B-T121
was	O
produced	O
and	O
evaluated	O
.	O
The	O
effect	O
of	O
incorporating	O
microorganisms	B-T001
or	O
a	O
carbon	O
source	B-T033
in	O
the	O
granule	O
was	O
also	O
evaluated	O
.	O
Four	O
granulated	O
ES	O
-	O
Zn	O
fertilizers	O
with	O
and	O
without	O
S	B-T001
-	I-T001
oxidizing	I-T001
microorganisms	I-T001
,	O
a	O
commercial	O
ES	O
pastille	O
,	O
ZnSO4	B-T121
,	O
and	O
ZnO	B-T121
were	O
applied	O
to	O
the	O
center	O
of	O
Petri	O
dishes	O
containing	O
two	O
contrasting	O
pH	O
soils	O
.	O
Soil	O
pH	O
,	O
CaCl2	B-T121
-extractable	O
S	B-T121
and	O
Zn	B-T121
,	O
and	O
remaining	O
ES	B-T121
were	O
evaluated	O
at	O
30	O
and	O
60	O
days	O
in	O
two	O
soil	O
sections	O
(	O
0	O
-	O
5	O
and	O
5	O
-	O
9	O
mm	O
from	O
the	O
fertilizer	O
application	O
site	O
)	O
.	O
A	O
visualization	B-T059
test	I-T059
was	O
performed	O
to	O
evaluate	O
Zn	B-T121
diffusion	O
over	O
time	O
.	O
A	O
significant	O
pH	B-T033
decrease	I-T033
was	O
observed	O
in	O
the	O
acidic	O
soil	O
for	O
all	O
ES	O
-	O
Zn	O
fertilizer	O
treatments	O
and	O
in	O
the	O
alkaline	O
soil	O
for	O
the	O
Acidithiobacillus	B-T007
thiooxidans	I-T007
-	O
inoculated	O
treatment	O
only	O
.	O
In	O
agreement	O
with	O
Zn	B-T121
visualization	B-T059
tests	I-T059
,	O
extractable-	O
Zn	B-T121
concentrations	O
were	O
higher	O
from	O
the	O
point	O
of	O
application	O
in	O
the	O
acidic	O
(	O
62.9	O
mg	O
dm(-3	O
)	O
)	O
compared	O
to	O
the	O
alkaline	O
soil	O
(	O
5.5	O
mg	O
dm(-3	O
)	O
)	O
.	O
Elemental	O
S	O
oxidation	O
was	O
greater	O
in	O
the	O
acidic	O
soil	O
(	O
20.9	O
%	O
)	O
than	O
slightly	O
alkaline	O
soil	O
(	O
12	O
%	O
)	O
.	O
The	O
ES	O
-	O
Zn	O
granular	O
fertilizers	O
increased	O
S	B-T121
and	O
Zn	B-T121
concentrations	O
in	O
soil	O
and	O
can	O
provide	O
a	O
strategically	O
slow	O
release	O
of	O
nutrients	O
to	O
the	O
soil	O
.	O
      
Genomic	O
characterization	O
of	O
a	O
wild	O
-	O
bird	O
-	O
origin	B-T033
pigeon	O
paramyxovirus	B-T005
type	I-T005
1	I-T005
(	O
PPMV-1	B-T005
)	O
first	O
isolated	O
in	O
the	O
northwest	O
region	O
of	O
China	O
Pigeon	O
paramyxovirus	B-T005
type-1	I-T005
(	O
PPMV-1	B-T005
)	O
is	O
an	O
enzootic	O
in	O
pigeon	O
flocks	O
and	O
causes	O
severe	O
economic	O
losses	O
in	O
the	O
poultry	O
industry	O
in	O
many	O
countries	O
.	O
A	O
PPMV-1	B-T005
isolate	O
,	O
abbreviated	O
as	O
PPMV-1	B-T005
/	I-T005
QL-01	I-T005
/	I-T005
CH/15	I-T005
,	O
was	O
isolated	O
from	O
a	O
great	O
spotted	O
woodpecker	O
in	O
the	O
northwest	O
region	O
of	O
China	O
in	O
2015	O
.	O
The	O
complete	O
genome	O
was	O
sequenced	B-T059
,	O
and	O
the	O
results	O
showed	O
that	O
the	O
virus	B-T005
genome	O
was	O
15,192	O
nt	O
in	O
length	O
,	O
in	O
the	O
gene	O
arrangement	O
3'-NP	O
-	O
P	O
-	O
M	O
-	O
F	O
-	O
HN	O
-	O
L-5	O
'	O
.	O
Several	O
amino	B-T121
acid	I-T121
mutations	O
were	O
identified	O
in	O
the	O
functional	O
domains	O
of	O
the	O
F	O
and	O
HN	O
proteins	O
.	O
The	O
pathogenicity	O
index	O
of	O
the	O
isolate	O
was	O
evaluated	B-T058
,	O
and	O
the	O
mean	O
death	O
time	O
(	O
MDT	O
)	O
was	O
72	O
h	O
and	O
the	O
intracerebral	O
pathogenicity	O
index	O
(	O
ICPI	O
)	O
was	O
0.925	O
,	O
indicating	O
that	O
this	O
isolate	O
was	O
mesogenic	O
.	O
Sequencing	B-T059
results	O
showed	O
that	O
it	O
had	O
a	O
virulent	O
Newcastle	B-T005
disease	I-T005
virus	I-T005
cleavage	O
motif	O
(	O
112)R	O
-	O
R	O
-	O
Q	O
-	O
K	O
-	O
R	O
-	O
F(117	O
)	O
at	O
the	O
fusion	O
protein	O
cleavage	O
site	O
.	O
Morbidity	O
and	O
mortality	O
were	O
70	O
%	O
and	O
50	O
%	O
,	O
after	O
inoculation	B-T061
of	O
pigeons	O
,	O
whereas	O
this	O
virus	B-T005
was	O
nonpathogenic	B-T033
in	O
chickens	O
.	O
Different	O
immune	O
responses	O
of	O
pigeons	O
and	O
chickens	O
were	O
induced	O
in	O
vivo	O
,	O
which	O
led	O
to	O
different	O
HI	B-T059
serum	I-T059
antibody	I-T059
titers	I-T059
.	O
The	O
results	O
of	O
phylogenetic	O
and	O
evolutionary	O
distance	O
analysis	O
showed	O
that	O
this	O
PPMV-1	B-T005
strain	B-T001
belonged	O
to	O
sub	O
-	O
genotype	O
VIa	O
in	O
class	O
II	O
.	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
identification	B-T059
and	O
analysis	O
of	O
PPMV-1	B-T005
co	B-T033
-	I-T033
circulation	I-T033
among	O
wild	O
birds	O
and	O
domestic	O
pigeon	O
flocks	O
in	O
China	O
.	O
The	O
data	O
from	O
this	O
study	O
highlight	O
the	O
important	O
role	O
of	O
wild	O
birds	O
in	O
the	O
dissemination	O
of	O
PPMV-1	B-T005
and	O
provide	O
useful	O
references	O
for	O
improving	O
our	O
understanding	O
of	O
the	O
distribution	O
and	O
evolution	O
of	O
PPMV-1	B-T005
in	O
China	O
.	O
      
Self	O
-	O
reported	O
occupational	O
injuries	O
among	O
industrial	O
beef	O
slaughterhouse	O
workers	O
in	O
the	O
Midwestern	O
United	O
States	O
Although	O
workers	O
in	O
meatpacking	O
facilities	O
in	O
the	O
United	O
States	O
experience	O
high	O
rates	O
of	O
occupational	O
injury	O
,	O
their	O
injury	O
experiences	O
have	O
received	O
limited	O
research	O
attention	O
.	O
Prior	O
research	O
indicates	O
underreporting	B-T058
in	O
injury	B-T033
rates	I-T033
in	O
this	O
industry	O
as	O
well	O
significant	O
variation	O
in	O
injury	B-T033
rates	I-T033
among	O
facilities	O
.	O
To	O
add	O
detail	O
to	O
the	O
rates	O
and	O
circumstances	O
surrounding	O
occupational	O
injury	O
among	O
meatpacking	O
workers	O
,	O
we	O
conducted	O
a	O
cross	O
-	O
sectional	O
study	O
of	O
workers	O
employed	O
at	O
an	O
industrial	O
beefpacking	O
plant	O
in	O
Nebraska	O
,	O
United	O
States	O
(	O
n	O
=	O
137	O
)	O
and	O
interviewed	O
workers	O
about	O
recent	O
injury	O
experiences	O
.	O
We	O
assessed	O
frequency	O
,	O
cause	O
and	O
nature	O
of	O
self	O
-	O
reported	O
injury	O
.	O
We	O
estimated	O
annual	O
incidence	O
rates	O
of	O
self	O
-	O
reported	O
injuries	O
using	O
the	O
OSHA	O
formula	O
and	O
compared	O
these	O
rates	O
to	O
industry	O
-	O
wide	O
data	O
.	O
We	O
also	O
evaluated	O
psychological	B-T048
distress	I-T048
in	O
this	O
workforce	O
as	O
measured	O
by	O
the	O
Kessler-6	O
scale	O
to	O
assess	O
whether	O
distress	B-T033
was	O
associated	O
with	O
recent	O
occupational	O
injury	O
.	O
In	O
this	O
study	O
,	O
15.1	O
%	O
of	O
workers	O
experienced	O
occupational	O
injuries	O
that	O
required	O
time	O
off	O
work	O
,	O
job	O
transfer	O
,	O
or	O
restriction	O
during	O
the	O
past	O
three	O
months	O
.	O
The	O
estimated	O
annual	O
incidence	O
rate	O
was	O
15.2	O
injuries	O
per	O
100	O
full	O
-	O
time	O
workers	O
for	O
these	O
injuries	O
at	O
this	O
plant	O
.	O
Rushing	O
was	O
identified	O
as	O
the	O
cause	O
of	O
nearly	O
50	O
%	O
of	O
injuries	O
,	O
and	O
repetitive	O
work	O
as	O
the	O
cause	O
of	O
an	O
additional	O
20	O
%	O
of	O
injuries	O
.	O
Use	O
of	O
metal	O
mesh	O
sleeves	O
(	O
POR	O
:	O
0.10	O
(	O
p	O
=	O
0.008	O
)	O
)	O
and	O
metal	O
mesh	O
gloves	O
(	O
POR	O
:	O
0.41	O
(	O
p	O
=	O
0.05	O
)	O
were	O
associated	O
with	O
reduced	O
risk	O
of	O
injury	O
.	O
Use	O
of	O
a	O
carbon	O
steel	O
for	O
knife	O
sharpening	O
(	O
POR	O
:	O
5.2	O
(	O
p	O
=	O
0.02	O
)	O
)	O
was	O
associated	O
with	O
elevated	O
risk	O
of	O
moderate	O
and	O
severe	O
injury	O
.	O
There	O
were	O
no	O
associations	O
between	O
self	O
-	O
reported	O
occupational	O
injury	O
and	O
overall	O
measures	O
of	O
psychological	B-T048
distress	I-T048
.	O
Self	O
-	O
reported	O
incidence	O
rate	O
of	O
severe	O
injury	O
in	O
this	O
plant	O
was	O
more	O
than	O
twice	O
official	O
industry	O
estimates	O
.	O
Worker	O
self	O
-	O
reports	O
may	O
illustrate	O
key	O
areas	O
for	O
injury	B-T061
prevention	I-T061
.	O
      
IL-27	O
Is	O
Essential	O
for	O
Suppression	B-T061
of	O
Experimental	O
Allergic	B-T047
Asthma	I-T047
by	O
the	O
TLR7	O
/	O
8	O
Agonist	B-T121
R848	B-T121
(	O
Resiquimod	B-T121
)	O
Different	O
models	B-T050
of	I-T050
experimental	I-T050
allergic	B-T047
asthma	I-T047
have	O
shown	O
that	O
the	O
TLR7	O
/	O
8	O
agonist	B-T121
resiquimod	B-T121
(	O
R848	B-T121
)	O
is	O
a	O
potential	O
inhibitor	O
of	O
type	O
2	O
helper	O
cell	O
-driven	O
inflammatory	O
responses	O
.	O
However	O
,	O
the	O
mechanisms	O
mediating	O
its	O
therapeutic	O
effects	O
are	O
not	O
fully	O
understood	O
.	O
Using	O
a	O
model	B-T050
of	I-T050
experimental	I-T050
allergic	B-T047
asthma	I-T047
,	O
we	O
show	O
that	O
induction	B-T061
of	O
IL-27	O
by	O
R848	B-T121
is	O
critical	O
for	O
the	O
observed	O
ameliorative	O
effects	O
.	O
R848	B-T121
significantly	O
inhibited	O
all	O
hallmarks	O
of	O
experimental	O
allergic	B-T047
asthma	I-T047
,	O
including	O
airway	B-T047
hyperreactivity	I-T047
,	O
eosinophilic	O
airway	B-T023
inflammation	O
,	O
mucus	B-T047
hypersecretion	I-T047
,	O
and	O
Ag	O
-	O
specific	B-T121
Ig	I-T121
production	O
.	O
Whereas	O
R848	B-T121
significantly	O
reduced	O
IL-5	O
,	O
IL-13	O
,	O
and	O
IL-17	O
,	O
it	O
induced	O
IFN	B-T121
-	I-T121
γ	I-T121
and	O
IL-27	O
.	O
Neutralization	O
of	O
IL-27	O
completely	O
reversed	O
the	O
therapeutic	O
effect	O
of	O
R848	B-T121
in	O
the	O
experimental	O
asthma	B-T047
model	B-T050
,	O
demonstrating	O
dependence	O
of	O
R848	B-T121
-mediated	O
suppression	B-T061
on	O
IL-27	O
.	O
In	O
vitro	O
,	O
R848	B-T121
induced	B-T061
production	O
of	O
IL-27	O
by	O
murine	O
alveolar	O
macrophages	O
and	O
dendritic	O
cells	O
and	O
enhanced	O
expression	O
of	O
programmed	O
death	O
-	O
ligand	O
1	O
,	O
whose	O
expression	O
on	O
monocytes	O
and	O
dendritic	O
cells	O
has	O
been	O
shown	O
to	O
regulate	O
peripheral	O
tolerance	O
in	O
both	O
murine	O
and	O
human	O
studies	O
.	O
Moreover	O
,	O
in	O
vitro	O
IL-27	O
enhanced	O
secretion	O
of	O
IFN	B-T121
-	I-T121
γ	I-T121
whereas	O
it	O
inhibited	O
IL-5	O
and	O
IL-13	O
,	O
demonstrating	O
its	O
direct	O
effect	O
on	O
attenuating	O
Th2	O
responses	O
.	O
Taken	O
together	O
,	O
our	O
study	O
proves	O
that	O
R848	B-T121
-mediated	O
suppression	B-T061
of	O
experimental	O
asthma	B-T047
is	O
dependent	O
on	O
IL-27	O
.	O
These	O
data	O
provide	O
evidence	O
of	O
a	O
central	O
role	O
of	O
IL-27	O
for	O
the	O
control	O
of	O
Th2	O
-mediated	O
allergic	B-T047
diseases	I-T047
.	O
      
Prediction	O
of	O
Estrogenic	B-T121
Bioactivity	O
of	O
Environmental	O
Chemical	O
Metabolites	O
The	O
US	O
Environmental	O
Protection	O
Agency	O
's	O
(	O
EPA	O
)	O
Endocrine	B-T058
Disruptor	I-T058
Screening	I-T058
Program	I-T058
(	O
EDSP	B-T058
)	O
is	O
using	O
in	O
vitro	O
data	O
generated	O
from	O
ToxCast	O
/	O
Tox21	O
high	B-T059
-	I-T059
throughput	I-T059
screening	I-T059
assays	I-T059
to	O
assess	O
the	O
endocrine	O
activity	O
of	O
environmental	O
chemicals	O
.	O
Considering	O
that	O
in	B-T059
vitro	I-T059
assays	I-T059
may	O
have	O
limited	O
metabolic	O
capacity	O
,	O
inactive	O
chemicals	O
that	O
are	O
biotransformed	O
into	O
metabolites	O
with	O
endocrine	O
bioactivity	O
may	O
be	O
missed	O
for	O
further	O
screening	O
and	O
testing	O
.	O
Therefore	O
,	O
there	O
is	O
a	O
value	O
in	O
developing	O
novel	O
approaches	O
to	O
account	O
for	O
metabolism	O
and	O
endocrine	O
activity	O
of	O
both	O
parent	O
chemicals	O
and	O
their	O
associated	O
metabolites	O
.	O
We	O
used	O
commercially	O
available	O
software	O
to	O
predict	O
metabolites	O
of	O
50	O
parent	O
compounds	O
,	O
out	O
of	O
which	O
38	O
chemicals	O
are	O
known	O
to	O
have	O
estrogenic	B-T121
metabolites	O
,	O
and	O
12	O
compounds	O
and	O
their	O
metabolites	O
are	O
negative	O
for	O
estrogenic	B-T121
activity	O
.	O
Three	O
ER	O
QSAR	O
models	O
were	O
used	O
to	O
determine	O
potential	O
estrogen	B-T121
bioactivity	O
of	O
the	O
parent	O
compounds	O
and	O
predicted	O
metabolites	O
,	O
the	O
outputs	O
of	O
the	O
models	O
were	O
averaged	O
,	O
and	O
the	O
chemicals	O
were	O
then	O
ranked	O
based	O
on	O
the	O
total	O
estrogenicity	O
of	O
the	O
parent	O
chemical	O
and	O
metabolites	O
.	O
The	O
metabolite	O
prediction	O
software	O
correctly	O
identified	O
known	O
estrogenic	B-T121
metabolites	O
for	O
26	O
out	O
of	O
27	O
parent	O
chemicals	O
with	O
associated	O
metabolite	O
data	O
,	O
and	O
39	O
out	O
of	O
46	O
estrogenic	B-T121
metabolites	O
were	O
predicted	O
as	O
potential	O
biotransformation	O
products	B-T121
derived	O
from	O
the	O
parent	O
chemical	O
.	O
The	O
QSAR	O
models	O
estimated	O
stronger	O
estrogenic	B-T121
activity	O
for	O
the	O
majority	O
of	O
the	O
known	O
estrogenic	B-T121
metabolites	O
compared	O
to	O
their	O
parent	O
chemicals	O
.	O
Finally	O
,	O
the	O
three	O
models	O
identified	O
a	O
similar	O
set	O
of	O
parent	O
compounds	O
as	O
top	O
ranked	O
chemicals	O
based	O
on	O
the	O
estrogenicity	O
of	O
putative	O
metabolites	O
.	O
This	O
proposed	O
in	O
silico	O
approach	O
is	O
an	O
inexpensive	O
and	O
rapid	O
strategy	O
for	O
the	O
detection	B-T033
of	O
chemicals	O
with	O
estrogenic	B-T121
metabolites	O
and	O
may	O
reduce	O
potential	O
false	O
negative	O
results	O
from	O
in	B-T059
vitro	I-T059
assays	I-T059
.	O
      
Heavy	B-T061
Resistance	I-T061
Training	I-T061
in	O
Hypoxia	O
Enhances	O
1RM	O
Squat	B-T033
Performance	O
Purpose	O
:	O
To	O
determine	O
if	O
heavy	B-T061
resistance	I-T061
training	I-T061
in	O
hypoxia	O
(	O
IHRT	B-T061
)	O
is	O
more	O
effective	O
at	O
improving	O
strength	O
,	O
power	B-T033
,	O
and	O
increasing	O
lean	O
mass	O
than	O
the	O
same	O
training	O
in	O
normoxia	O
.	O
Methods	O
:	O
A	O
pair	O
-	O
matched	O
,	O
placebo	O
-	O
controlled	O
study	O
design	O
included	O
20	O
resistance	B-T061
-	I-T061
trained	I-T061
participants	O
assigned	O
to	O
IHRT	B-T061
(	O
FIO2	B-T061
0.143	O
)	O
or	O
placebo	O
(	O
FIO2	B-T061
0.20	O
)	O
,	O
(	O
n	O
=	O
10	O
per	O
group	O
)	O
.	O
Participants	O
were	O
matched	O
for	O
strength	O
and	O
training	B-T061
.	O
Both	O
groups	O
performed	O
20	O
sessions	O
over	O
7	O
weeks	O
either	O
with	O
IHRT	B-T061
or	O
placebo	O
.	O
All	O
participants	O
were	O
tested	O
for	O
1RM	O
,	O
20	O
-	O
m	O
sprint	B-T061
,	O
body	O
composition	O
,	O
and	O
countermovement	O
jump	O
pre	O
-	O
,	O
mid	O
-	O
,	O
and	O
post	O
-	O
training	B-T061
and	O
compared	O
via	O
magnitude	O
-	O
based	O
inferences	O
.	O
Presentation	O
of	O
Results	O
:	O
Groups	O
were	O
not	B-T033
clearly	I-T033
different	O
for	O
any	O
test	O
at	O
baseline	O
.	O
Training	B-T061
improved	B-T033
both	O
absolute	O
(	O
IHRT	B-T061
:	O
13.1	O
±	O
3.9	O
%	O
,	O
effect	O
size	O
(	O
ES	O
)	O
0.60	O
,	O
placebo	O
9.8	O
±	O
4.7	O
%	O
,	O
ES	O
0.31	O
)	O
and	O
relative	O
1RM	O
(	O
IHRT	B-T061
:	O
13.4	O
±	O
5.1	O
%	O
,	O
ES	O
0.76	O
,	O
placebo	O
9.7	O
±	O
5.3	O
%	O
,	O
ES	O
0.48	O
)	O
at	O
mid	O
.	O
Similarly	O
,	O
at	O
post	O
both	O
groups	O
increased	O
absolute	O
(	O
IHRT	B-T061
:	O
20.7	O
±	O
7.6	O
%	O
,	O
ES	O
0.74	O
,	O
placebo	O
14.1	O
±	O
6.0	O
%	O
,	O
ES	O
0.58	O
)	O
and	O
relative	O
1RM	O
(	O
IHRT	B-T061
:	O
21.6	O
±	O
8.5	O
%	O
,	O
ES	O
1.08	O
,	O
placebo	O
13.2	O
±	O
6.4	O
%	O
,	O
ES	O
0.78	O
)	O
.	O
Importantly	O
,	O
the	O
change	O
in	O
IHRT	B-T061
was	O
greater	O
than	O
placebo	O
at	O
mid	O
for	O
both	O
absolute	O
[	O
4.4	O
%	O
greater	O
change	O
,	O
90	O
%	O
Confidence	O
Interval	O
(	O
CI	O
)	O
1.0:8.0	O
%	O
,	O
ES	O
0.21	O
,	O
and	O
relative	O
strength	O
(	O
5.6	O
%	O
greater	O
change	O
,	O
90	O
%	O
CI	O
1.0:9.4	O
%	O
,	O
ES	O
0.31	O
(	O
relative	O
)	O
]	O
.	O
There	O
was	O
also	O
a	O
greater	O
change	O
for	O
IHRT	B-T061
at	O
post	O
for	O
both	O
absolute	O
(	O
7.0	O
%	O
greater	O
change	O
,	O
90	O
%	O
CI	O
1.3:13	O
%	O
,	O
ES	O
0.33	O
)	O
,	O
and	O
relative	O
1RM	O
(	O
9.2	O
%	O
greater	O
change	O
,	O
90	O
%	O
CI	O
1.6:14.9	O
%	O
,	O
ES	O
0.49	O
)	O
.	O
Only	O
IHRT	B-T061
increased	O
countermovement	O
jump	O
peak	O
power	B-T033
at	O
Post	O
(	O
4.9	O
%	O
,	O
ES	O
0.35	O
)	O
,	O
however	O
the	O
difference	O
between	O
IHRT	B-T061
and	O
placebo	O
was	O
unclear	B-T033
(	O
2.7	O
,	O
90	O
%	O
CI	O
-2.0:7.6	O
%	O
,	O
ES	O
0.20	O
)	O
with	O
no	B-T033
clear	I-T033
differences	O
in	O
speed	O
or	O
body	O
composition	O
throughout	O
.	O
Conclusion	O
:	O
Heavy	B-T061
resistance	I-T061
training	I-T061
in	O
hypoxia	O
is	O
more	O
effective	O
than	O
placebo	O
for	O
improving	O
absolute	O
and	O
relative	O
strength	O
.	O
      
The	O
Evidence	O
Behind	O
Integrating	O
Palliative	O
Care	O
Into	O
Oncology	B-T191
Practice	O
Palliative	O
care	O
services	O
provided	O
alongside	O
traditional	O
oncology	B-T058
care	I-T058
have	O
been	O
shown	O
to	O
be	O
beneficial	O
to	O
patients	O
and	O
families	O
.	O
This	O
article	O
provides	O
a	O
brief	O
history	O
of	O
palliative	O
care	O
,	O
a	O
pathway	O
to	O
implementing	O
these	O
services	O
into	O
currently	O
established	O
oncology	B-T058
programs	I-T058
,	O
and	O
a	O
brief	O
discussion	O
of	O
common	O
barriers	O
.	O
      
Insecticidal	O
effects	O
of	O
deltamethrin	B-T121
in	O
laboratory	O
and	O
field	O
populations	O
of	O
Culicoides	O
species	O
:	O
how	O
effective	O
are	O
host	B-T001
-	O
contact	O
reduction	O
methods	O
in	O
India	O
?	O
Bluetongue	B-T005
virus	I-T005
(	O
BTV	B-T005
)	O
is	O
transmitted	O
by	O
Culicoides	O
biting	O
midges	O
and	O
causes	O
bluetongue	B-T047
(	O
BT	B-T047
)	O
,	O
a	O
clinical	B-T047
disease	I-T047
observed	O
primarily	O
in	O
sheep	O
.	O
BT	B-T047
has	O
a	O
detrimental	O
effect	O
on	O
subsistence	O
farmers	O
in	O
India	O
,	O
where	O
hyperendemic	B-T047
outbreaks	I-T047
impact	O
on	O
smallholdings	O
in	O
the	O
southern	O
states	O
of	O
the	O
country	O
.	O
In	O
this	O
study	O
,	O
we	O
establish	O
a	O
reliable	O
method	O
for	O
testing	O
the	O
toxic	O
effects	O
of	O
deltamethrin	B-T121
on	O
Culicoides	O
and	O
then	O
compare	O
deltamethrin	B-T121
with	O
traditional	O
control	O
methods	O
used	O
by	O
farmers	O
in	O
India	O
.	O
Effects	O
of	O
deltamethrin	B-T121
were	O
initially	O
tested	O
using	O
a	O
colonised	O
strain	O
of	O
Culicoides	O
nubeculosus	O
Meigen	O
and	O
a	O
modified	O
World	O
Health	O
Organisation	O
exposure	B-T059
assay	I-T059
.	O
This	O
method	O
was	O
then	O
applied	O
to	O
field	O
populations	O
of	O
Culicoides	O
spp	O
.	O
in	O
India	O
.	O
The	O
field	O
population	O
of	O
C.	O
oxystoma	O
in	O
India	O
had	O
a	O
greater	O
LC50	O
(	O
0.012	O
±	O
0.009	O
%	O
)	O
for	O
deltamethrin	B-T121
than	O
laboratory	B-T059
-	I-T059
reared	I-T059
C.nubeculosus	O
(	O
0.0013	O
±	O
0.0002	O
%	O
)	O
.	O
Exposure	O
of	O
C.	O
nubeculosus	O
to	O
deltamethrin	B-T121
at	O
higher	O
ambient	O
temperatures	O
resulted	O
in	O
greater	O
rates	O
of	O
knockdown	O
but	O
a	O
lower	O
mortality	O
rate	O
at	O
24	O
h	O
post	O
-	O
exposure	O
.	O
Behavioural	B-T059
assays	I-T059
with	O
C.	O
nubeculosus	O
in	O
WHO	O
tubes	O
provided	O
evidence	O
for	O
contact	O
irritancy	O
and	O
spatial	O
repellence	O
caused	O
by	O
deltamethrin	B-T121
.	O
The	O
field	O
experiments	O
in	O
India	O
,	O
however	O
,	O
provided	O
no	O
evidence	O
for	O
repellent	O
or	O
toxic	O
effects	O
of	O
deltamethrin	B-T121
.	O
Traditional	O
methods	O
such	O
as	O
the	O
application	O
of	O
neem	B-T121
oil	I-T121
and	O
burning	O
of	O
neem	O
leaves	O
also	O
provided	O
no	B-T033
protection	B-T033
.	O
Our	O
study	O
demonstrates	O
that	O
field	O
-collected	O
Culicoides	O
in	O
India	O
are	O
less	O
susceptible	O
to	O
deltamethrin	B-T121
exposure	O
than	O
laboratory	B-T059
-	I-T059
bred	I-T059
C.	O
nubeculosus	O
and	O
traditional	O
methods	O
of	O
insect	O
control	O
do	O
not	O
provide	O
protection	B-T033
to	O
sheep	O
.	O
These	O
low	O
levels	O
of	O
susceptibility	O
to	O
deltamethrin	B-T121
have	O
not	O
been	O
recorded	O
before	O
in	O
field	O
populations	O
of	O
Culicoides	O
and	O
suggest	O
resistance	O
to	O
synthetic	B-T121
pyrethrioids	I-T121
.	O
Alternative	O
insect	O
control	O
methods	O
,	O
in	O
addition	O
to	O
vaccination	B-T061
,	O
may	O
be	O
needed	O
to	O
protect	O
Indian	O
livestock	O
from	O
BTV	B-T005
transmission	O
.	O
      
An	O
approach	O
to	O
functionally	O
relevant	O
clustering	O
of	O
the	O
protein	O
universe	O
:	O
Active	O
site	O
profile	O
-	O
based	O
clustering	O
of	O
protein	O
structures	O
and	O
sequences	O
Protein	O
function	O
identification	O
remains	O
a	O
significant	O
problem	O
.	O
Solving	O
this	O
problem	O
at	O
the	O
molecular	O
functional	O
level	O
would	O
allow	O
mechanistic	O
determinant	O
identification-	O
amino	B-T121
acids	I-T121
that	O
distinguish	O
details	O
between	O
functional	O
families	O
within	O
a	O
superfamily	O
.	O
Active	O
site	O
profiling	O
was	O
developed	O
to	O
identify	O
mechanistic	O
determinants	O
.	O
DASP	O
and	O
DASP2	O
were	O
developed	O
as	O
tools	O
to	O
search	O
sequence	O
databases	O
using	O
active	O
site	O
profiling	O
.	O
Here	O
,	O
TuLIP	O
(	O
Two	O
-	O
Level	O
Iterative	O
clustering	O
Process	O
)	O
is	O
introduced	O
as	O
an	O
iterative	O
,	O
divisive	O
clustering	O
process	O
that	O
utilizes	O
active	O
site	O
profiling	O
to	O
separate	O
structurally	O
characterized	O
superfamily	O
members	O
into	O
functionally	O
relevant	O
clusters	O
.	O
Underlying	O
TuLIP	O
is	O
the	O
observation	O
that	O
functionally	O
relevant	O
families	O
(	O
curated	O
by	O
Structure	O
-	O
Function	O
Linkage	O
Database	O
,	O
SFLD	O
)	O
self	O
-	O
identify	O
in	O
DASP2	O
searches	O
;	O
clusters	O
containing	O
multiple	O
functional	O
families	O
do	O
not	O
.	O
Each	O
TuLIP	O
iteration	O
produces	O
candidate	O
clusters	O
,	O
each	O
evaluated	O
to	O
determine	O
if	O
it	O
self	O
-	O
identifies	O
using	O
DASP2	O
.	O
If	O
so	O
,	O
it	O
is	O
deemed	O
a	O
functionally	O
relevant	O
group	O
.	O
Divisive	O
clustering	O
continues	O
until	O
each	O
structure	O
is	O
either	O
a	O
functionally	O
relevant	O
group	O
member	O
or	O
a	O
singlet	O
.	O
TuLIP	O
is	O
validated	O
on	O
enolase	O
and	O
glutathione	O
transferase	O
structures	O
,	O
superfamilies	O
well	O
-	O
curated	O
by	O
SFLD	O
.	O
Correlation	O
is	O
strong	O
;	O
small	O
numbers	O
of	O
structures	O
prevent	O
statistically	O
significant	O
analysis	O
.	O
TuLIP	O
-identified	O
enolase	O
clusters	O
are	O
used	O
in	O
DASP2	O
GenBank	O
searches	O
to	O
identify	O
sequences	O
sharing	O
functional	O
site	O
features	O
.	O
Analysis	O
shows	O
a	O
true	O
positive	O
rate	O
of	O
96	O
%	O
,	O
false	O
negative	O
rate	O
of	O
4	O
%	O
,	O
and	O
maximum	O
false	O
positive	O
rate	O
of	O
4	O
%	O
.	O
F	O
-	O
measure	O
and	O
performance	O
analysis	O
on	O
the	O
enolase	O
search	O
results	O
and	O
comparison	O
to	O
GEMMA	O
and	O
SCI	O
-	O
PHY	O
demonstrate	O
that	O
TuLIP	O
avoids	O
the	O
over	O
-	O
division	O
problem	O
of	O
these	O
methods	O
.	O
Mechanistic	O
determinants	O
for	O
enolase	O
families	O
are	O
evaluated	O
and	O
shown	O
to	O
correlate	O
well	O
with	O
literature	O
results	O
.	O
      
Patient	O
Preferences	O
in	O
Treatment	B-T061
Choices	O
for	O
Early	O
-	O
Stage	O
Lung	B-T191
Cancer	I-T191
Decision	O
-	O
making	O
for	O
lung	B-T191
cancer	I-T191
treatment	B-T061
can	O
be	O
complex	O
because	O
it	O
involves	O
both	O
provider	O
recommendations	O
based	O
on	O
the	O
patient	O
's	O
clinical	O
condition	O
and	O
patient	O
preferences	O
.	O
This	O
study	O
describes	O
the	O
relative	O
importance	O
of	O
several	O
considerations	B-T033
in	O
lung	B-T191
cancer	I-T191
treatment	B-T061
from	O
the	O
patient	O
's	O
perspective	O
.	O
A	O
conjoint	O
preference	O
experiment	O
began	O
by	O
asking	O
respondents	O
to	O
imagine	O
that	O
they	O
had	O
just	O
been	O
diagnosed	B-T033
with	O
lung	B-T191
cancer	I-T191
.	O
Respondents	O
then	O
chose	O
among	O
procedures	B-T061
that	O
differed	O
regarding	O
treatment	B-T061
modalities	O
,	O
the	O
potential	O
for	O
treatment	B-T061
-related	O
complications	O
,	O
the	O
likelihood	O
of	O
recurrence	O
,	O
provider	O
case	O
volume	O
,	O
and	O
distance	O
needed	O
to	O
travel	O
for	O
treatment	B-T061
.	O
Conjoint	O
analysis	O
derived	O
relative	O
weights	O
for	O
these	O
attributes	O
.	O
A	O
total	O
of	O
225	O
responses	O
were	O
analyzed	O
.	O
Respondents	O
were	O
most	O
willing	O
to	O
accept	O
minimally	O
invasive	B-T061
operations	I-T061
for	O
treatment	B-T061
of	O
their	O
hypothetical	O
lung	B-T191
cancer	I-T191
,	O
followed	O
by	O
stereotactic	B-T061
body	I-T061
radiation	I-T061
therapy	I-T061
(	O
SBRT	B-T061
)	O
;	O
they	O
were	O
least	O
willing	O
to	O
accept	O
thoracotomy	B-T061
.	O
Treatment	B-T061
type	O
and	O
risk	O
of	O
recurrence	O
were	O
the	O
most	O
important	O
attributes	O
from	O
the	O
conjoint	O
experiment	O
(	O
each	O
with	O
a	O
relative	O
weight	O
of	O
0.23	O
)	O
,	O
followed	O
by	O
provider	O
volume	O
(	O
relative	O
weight	O
of	O
0.21	O
)	O
,	O
risk	O
of	O
major	O
complications	O
(	O
relative	O
weight	O
of	O
0.18	O
)	O
,	O
and	O
distance	O
needed	O
to	O
travel	O
for	O
treatment	B-T061
(	O
relative	O
weight	O
of	O
0.15	O
)	O
.	O
Procedural	B-T061
and	O
treatment	B-T061
preferences	O
did	O
not	O
vary	O
with	O
demographics	O
,	O
self	O
-	O
reported	O
health	O
status	O
,	O
or	O
familiarity	O
with	O
the	O
procedures	B-T061
.	O
Survey	O
respondents	O
preferred	O
minimally	O
invasive	B-T061
operations	I-T061
over	O
SBRT	B-T061
or	O
thoracotomy	B-T061
for	O
treatment	B-T061
of	O
early	O
-	O
stage	O
non	B-T191
-	I-T191
small	I-T191
cell	I-T191
lung	I-T191
cancer	I-T191
.	O
Treatment	B-T061
modality	O
and	O
risk	O
of	O
cancer	B-T191
recurrence	I-T191
were	O
the	O
most	O
important	O
factors	O
associated	O
with	O
treatment	B-T061
preferences	O
.	O
Provider	O
experience	O
outweighed	O
the	O
potential	O
need	O
to	O
travel	O
for	O
lung	B-T191
cancer	I-T191
treatment	B-T061
.	O
      
Assessment	B-T058
of	O
Residual	B-T191
Disease	I-T191
With	O
Molecular	B-T060
Breast	I-T060
Imaging	I-T060
in	O
Patients	O
Undergoing	O
Neoadjuvant	B-T061
Therapy	I-T061
:	O
Association	O
With	O
Molecular	O
Subtypes	O
Assessment	B-T058
of	O
residual	B-T191
disease	I-T191
after	O
neoadjuvant	B-T061
therapy	I-T061
for	O
breast	B-T191
cancer	I-T191
is	O
an	O
ongoing	O
challenge	O
of	O
breast	B-T023
imaging	B-T060
.	O
This	O
study	O
evaluates	B-T058
the	O
accuracy	O
of	O
a	O
novel	O
dedicated	O
system	O
for	O
molecular	B-T060
breast	I-T060
imaging	I-T060
(	O
MBI	B-T060
)	O
composed	O
of	O
the	O
new	O
generation	O
of	O
cadmium	O
zinc	O
telluride	O
detectors	O
in	O
assessing	O
residual	B-T191
disease	I-T191
after	O
neoadjuvant	B-T061
therapy	I-T061
in	O
patients	O
with	O
breast	B-T191
cancer	I-T191
.	O
Clinical	O
data	O
,	O
imaging	B-T060
,	O
surgical	O
,	O
and	O
pathological	O
findings	B-T033
of	O
51	O
women	O
with	O
breast	B-T191
cancer	I-T191
undergoing	O
neoadjuvant	B-T061
therapy	I-T061
were	O
recorded	O
.	O
MBI	B-T060
findings	B-T033
were	O
correlated	O
with	O
surgical	O
pathology	O
results	O
.	O
Accuracy	O
of	O
MBI	B-T060
in	O
predicting	O
complete	B-T033
pathological	I-T033
response	I-T033
and	O
size	O
of	O
residual	B-T191
disease	I-T191
was	O
assessed	O
according	O
to	O
molecular	O
subtypes	O
.	O
The	O
size	O
of	O
the	O
largest	O
focus	O
of	O
uptake	O
on	O
MBI	B-T060
correlated	O
with	O
the	O
largest	O
dimension	O
measured	O
on	O
pathology	O
(	O
r	O
=	O
0.55	O
;	O
P	O
<	O
.001	O
)	O
.	O
This	O
correlation	O
was	O
stronger	O
for	O
triple	B-T191
negative	I-T191
and	O
HER2	O
/	O
neu	O
positive	O
subtypes	O
(	O
r	O
=	O
0.92	O
and	O
0.62	O
,	O
respectively	O
)	O
.	O
Sixteen	O
patients	O
(	O
31	O
%	O
)	O
had	O
complete	B-T033
pathological	I-T033
response	I-T033
.	O
The	O
sensitivity	O
and	O
specificity	O
of	O
MBI	B-T060
for	O
detecting	O
residual	B-T191
disease	I-T191
were	O
83	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
66	O
-	O
93	O
)	O
and	O
69	O
%	O
(	O
95	O
%	O
CI	O
,	O
42	O
-	O
88	O
)	O
,	O
respectively	O
.	O
For	O
triple	B-T191
negative	I-T191
or	O
HER2	O
/	O
neu	O
positive	O
disease	O
the	O
sensitivity	O
and	O
specificity	O
were	O
88	O
%	O
(	O
95	O
%	O
CI	O
,	O
62	O
-	O
98	O
)	O
and	O
75	O
%	O
(	O
95	O
%	O
CI	O
,	O
43	O
-	O
93	O
)	O
,	O
respectively	O
.	O
The	O
accuracy	O
of	O
MBI	B-T060
in	O
assessing	O
residual	B-T191
disease	I-T191
after	O
neoadjuvant	B-T061
treatment	I-T061
might	O
be	O
related	O
to	O
the	O
molecular	O
subtype	O
.	O
Accuracy	O
is	O
highest	O
in	O
the	O
triple	B-T191
negative	I-T191
and	O
HER2	O
/	O
neu	O
positive	O
subtypes	O
.	O
      
Mitotic	O
phosphotyrosine	O
network	O
analysis	O
reveals	O
that	O
tyrosine	O
phosphorylation	O
regulates	O
Polo	O
-	O
like	O
kinase	O
1	O
(	O
PLK1	O
)	O
Tyrosine	O
phosphorylation	O
is	O
closely	O
associated	O
with	O
cell	O
proliferation	O
.	O
During	O
the	O
cell	O
cycle	O
,	O
serine	O
and	O
threonine	O
phosphorylation	O
plays	O
the	O
leading	O
role	O
,	O
and	O
such	O
phosphorylation	O
events	O
are	O
most	O
dynamic	O
during	O
the	O
mitotic	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O
However	O
,	O
mitotic	O
phosphotyrosine	O
is	O
not	O
well	O
characterized	O
.	O
Although	O
a	O
few	O
functionally	O
-	O
relevant	O
mitotic	O
phosphotyrosine	O
sites	O
have	O
been	O
characterized	O
,	O
evidence	O
suggests	O
that	O
this	O
modification	O
may	O
be	O
more	O
prevalent	O
than	O
previously	O
appreciated	O
.	O
Here	O
,	O
we	O
examined	B-T033
tyrosine	O
phosphorylation	O
in	O
mitotic	O
human	O
cells	O
including	O
those	O
on	O
spindle	O
-	O
associated	O
proteins	O
.	O
?	O
Database	O
mining	O
confirmed	O
~2000	O
mitotic	O
phosphotyrosine	O
sites	O
,	O
and	O
network	O
analysis	O
revealed	O
a	O
number	O
of	O
subnetworks	O
that	O
were	O
enriched	O
in	O
tyrosine	O
-	O
phosphorylated	O
proteins	O
,	O
including	O
components	O
of	O
the	O
kinetochore	O
or	O
spindle	O
and	O
SRC	O
family	O
kinases	O
.	O
We	O
identified	O
Polo	O
-	O
like	O
kinase	O
1	O
(	O
PLK1	O
)	O
,	O
a	O
major	O
signaling	O
hub	O
in	O
the	O
spindle	O
subnetwork	O
,	O
as	O
phosphorylated	O
at	O
the	O
conserved	O
Tyr(217	B-T121
)	I-T121
in	O
the	O
kinase	O
domain	O
.	O
Substitution	O
of	O
Tyr(217	B-T121
)	I-T121
with	O
a	O
phosphomimetic	O
residue	O
eliminated	O
PLK1	O
activity	O
in	O
vitro	O
and	O
in	O
cells	O
.	O
Further	O
analysis	O
showed	O
that	O
Tyr(217	B-T121
)	I-T121
phosphorylation	O
reduced	O
the	O
phosphorylation	O
of	O
Thr(210	O
)	O
in	O
the	O
activation	O
loop	O
,	O
a	O
phosphorylation	O
event	O
necessary	O
for	O
PLK1	O
activity	O
.	O
Our	O
data	O
indicate	O
that	O
mitotic	O
tyrosine	O
phosphorylation	O
regulated	O
a	O
key	O
serine	O
/	O
threonine	O
kinase	O
hub	O
in	O
mitotic	O
cells	O
and	O
suggested	O
that	O
spatially	O
separating	O
tyrosine	O
phosphorylation	O
events	O
can	O
reveal	O
previously	O
unrecognized	O
regulatory	O
events	O
and	O
complexes	O
associated	O
with	O
specific	O
structures	O
of	O
the	O
cell	O
cycle	O
.	O
      
Effect	O
of	O
single	O
-	O
dose	O
carbapenem	B-T195
exposure	B-T033
on	O
transcriptional	O
expression	O
of	O
blaNDM-1	O
and	O
mexA	O
in	O
Pseudomonas	B-T007
aeruginosa	I-T007
The	O
therapeutic	O
option	O
of	O
a	O
carbapenem	B-T195
antibiotic	I-T195
is	O
compromised	O
in	O
Pseudomonas	B-T007
aeruginosa	I-T007
owing	O
both	O
to	O
acquired	O
and	O
intrinsic	O
resistance	O
mechanisms	O
.	O
In	O
recent	O
years	O
,	O
New	O
Delhi	O
metallo	O
-	O
β	O
-	O
lactamase	O
has	O
been	O
the	O
focus	O
as	O
a	O
predominant	O
carbapenem	O
resistance	O
determinant	O
.	O
However	O
,	O
it	O
is	O
unclear	O
which	O
of	O
the	O
mechanisms	O
might	O
be	O
adopted	O
by	O
a	O
P.	B-T007
aeruginosa	I-T007
strain	B-T001
possessing	O
both	O
blaNDM-1	O
and	O
an	O
overexpressed	O
MexAB	O
-	O
OprM	O
system	O
during	O
carbapenem	B-T195
therapy	B-T061
.	O
This	O
study	O
investigated	O
the	O
interplay	O
of	O
both	O
mechanisms	O
in	O
clinical	O
isolates	O
of	O
P.	B-T007
aeruginosa	I-T007
when	O
exposed	O
to	O
meropenem	B-T195
.	O
Five	O
strains	B-T001
were	O
used	O
:	O
(	O
i	O
)	O
strain	O
overexpressing	O
MexAB	O
-	O
OprM	O
but	O
with	O
no	O
blaNDM-1	O
;	O
(	O
ii	O
)	O
strain	O
harbouring	O
blaNDM-1	O
but	O
expressing	O
MexAB	O
-	O
OprM	O
at	O
basal	O
level	O
;	O
(	O
iii	O
)	O
strain	B-T001
possessing	O
blaNDM-1	O
and	O
overexpressing	O
MexAB	O
-	O
OprM	O
;	O
(	O
iv	O
)	O
P.	B-T007
aeruginosa	I-T007
PAO1	I-T007
;	O
and	O
(	O
v	O
)	O
P.	B-T007
aeruginosa	I-T007
K2733	I-T007
-	I-T007
PAO1	I-T007
(	O
ΔMexAB	O
-	O
OprM	O
ΔMexCD	O
-	O
OprJ	O
ΔMexEF	O
-	O
OprN	O
ΔMexXY	O
-	O
OprM	O
)	O
into	O
which	O
blaNDM-1	O
was	O
cloned	B-T059
.	O
Strains	B-T001
were	O
incubated	O
in	O
Luria	O
-	O
Bertani	O
broth	O
with	O
and	O
without	O
1μg	O
/	O
mL	O
meropenem	B-T195
.	O
Total	B-T059
RNA	I-T059
was	O
isolated	O
at	O
45	O
-	O
min	O
intervals	O
and	O
was	O
immediately	O
reverse	O
transcribed	O
to	O
cDNA	O
.	O
This	O
was	O
repeated	O
for	O
6h	O
.	O
Quantitative	O
real	O
-	O
time	O
PCR	O
was	O
performed	O
for	O
both	O
resistance	O
mechanisms	O
.	O
Meropenem	B-T195
exposure	B-T033
did	O
not	O
significantly	O
elevate	O
transcription	O
of	O
either	O
the	O
blaNDM-1	O
or	O
mexA	O
gene	O
.	O
However	O
,	O
an	O
interesting	O
finding	O
was	O
that	O
upon	O
single	O
-	O
dose	O
exposure	B-T033
to	I-T033
carbapenem	I-T033
,	O
the	O
efflux	O
pump	O
system	O
played	O
a	O
major	O
role	O
in	O
bacterial	O
survival	O
compared	O
with	O
NDM-1	O
.	O
This	O
study	O
gives	O
an	O
insight	O
into	O
the	O
bacterial	O
response	O
to	O
carbapenem	O
antibiotic	O
when	O
two	O
different	O
resistance	O
mechanisms	O
coexist	O
.	O
This	O
type	O
of	O
study	O
would	O
be	O
helpful	O
in	O
designing	O
future	O
antimicrobials	B-T121
.	O
      
Beneficial	O
Effects	O
of	O
Phyllanthus	O
amarus	O
Against	O
High	O
Fructose	O
Diet	O
Induced	O
Insulin	O
Resistance	O
and	O
Hepatic	O
Oxidative	O
Stress	O
in	O
Male	O
Wistar	O
Rats	O
Insulin	O
resistance	O
(	O
IR	O
)	O
is	O
a	O
characteristic	O
feature	O
of	O
obesity	B-T047
,	O
type	B-T047
2	I-T047
diabetes	I-T047
mellitus	I-T047
,	O
and	O
cardiovascular	B-T047
diseases	I-T047
.	O
Emerging	O
evidence	O
suggests	O
that	O
the	O
high	B-T121
-	I-T121
fructose	I-T121
consumption	O
is	O
a	O
potential	O
and	O
important	O
factor	O
responsible	O
for	O
the	O
rising	O
incidence	O
of	O
IR	O
.	O
The	O
present	O
study	O
investigates	O
the	O
beneficial	O
effects	O
of	O
aqueous	O
extract	O
of	O
Phyllanthus	O
amaru	O
s	O
(	O
PAAE	O
)	O
on	O
IR	O
and	O
oxidative	O
stress	O
in	O
high	B-T121
-	I-T121
fructose	I-T121
(	O
HF	B-T121
)	O
fed	O
male	O
Wistar	O
rats	O
.	O
HF	O
diet	O
(	O
66	O
%	O
of	O
fructose	O
)	O
and	O
PAAE	O
(	O
200	O
mg	O
/	O
kg	O
body	O
weight	O
/	O
day	O
)	O
were	O
given	O
concurrently	O
to	O
the	O
rats	O
for	O
a	O
period	O
of	O
60	O
days	O
.	O
Fructose	O
-	O
fed	O
rats	O
showed	O
weight	B-T033
gain	I-T033
,	O
hyperglycemia	B-T047
,	O
hyperinsulinemia	B-T047
,	O
impaired	B-T047
glucose	I-T047
tolerance	I-T047
,	O
impaired	O
insulin	O
sensitivity	O
,	O
dyslipidemia	B-T047
,	O
hyperleptinemia	B-T047
,	O
and	O
hypoadiponectinemia	B-T047
(	O
P	O
<	O
0.05	O
)	O
after	O
60	O
days	O
.	O
Co	B-T061
-	I-T061
administration	I-T061
of	O
PAAE	O
along	O
with	O
HF	O
diet	O
significantly	O
ameliorated	O
all	O
these	O
alterations	O
.	O
Regarding	O
hepatic	O
antioxidant	O
status	O
,	O
higher	O
lipid	O
peroxidation	O
and	O
protein	O
oxidation	O
,	O
lower	O
reduced	O
glutathione	O
levels	O
and	O
lower	O
activities	O
of	O
enzymatic	B-T121
antioxidants	I-T121
,	O
and	O
the	O
histopathological	O
changes	O
like	O
mild	O
to	O
severe	O
distortion	O
of	O
the	O
normal	O
architecture	O
as	O
well	O
as	O
the	O
prominence	O
and	O
widening	O
of	O
the	O
liver	B-T023
sinusoids	I-T023
observed	O
in	O
the	O
HF	O
diet	O
-fed	O
rats	O
were	O
significantly	O
prevented	O
by	O
PAAE	O
treatment	B-T061
.	O
These	O
findings	O
indicate	O
that	O
PAAE	O
is	O
beneficial	O
in	O
improving	O
insulin	O
sensitivity	O
and	O
attenuating	O
metabolic	B-T047
syndrome	I-T047
and	O
hepatic	O
oxidative	O
stress	O
in	O
fructose	O
-	O
fed	O
rats	O
.	O
      
Predictive	O
Factors	O
for	O
Long	O
-	O
term	O
Outcome	O
of	O
Subthalamic	B-T023
Nucleus	I-T023
Deep	B-T061
Brain	I-T061
Stimulation	I-T061
for	O
Parkinson	B-T047
's	I-T047
Disease	I-T047
Despite	O
the	O
recognition	O
of	O
the	O
usefulness	O
of	O
subthalamic	B-T023
nucleus	I-T023
deep	B-T061
brain	I-T061
stimulation	I-T061
(	O
STN	B-T023
-	O
DBS	B-T061
)	O
for	O
the	O
treatment	O
of	O
Parkinson	B-T047
's	I-T047
disease	I-T047
(	O
PD	B-T047
)	O
,	O
preoperative	O
predictive	O
factors	O
for	O
the	O
long	O
-	O
term	O
outcome	O
of	O
STN	B-T023
-	O
DBS	B-T061
are	O
not	O
sufficiently	O
established	O
.	O
We	O
performed	O
this	O
study	O
to	O
determine	O
such	O
predictive	O
factors	O
.	O
The	O
subjects	O
were	O
66	O
patients	O
who	O
were	O
classified	O
into	O
two	O
groups	O
on	O
the	O
basis	O
of	O
their	O
activities	O
of	O
daily	O
living	O
(	O
ADL	O
)	O
evaluated	O
five	O
years	O
after	O
the	O
STN	B-T023
-	O
DBS	B-T061
surgery	B-T061
:	O
33	O
patients	O
were	O
assigned	O
to	O
the	O
independent	O
ADL	O
group	O
(	O
group	O
I	O
)	O
and	O
the	O
remaining	O
33	O
patients	O
to	O
the	O
dependent	O
ADL	O
group	O
(	O
group	O
D	O
)	O
.	O
Group	O
I	O
patients	O
showed	O
a	O
Schwab	O
and	O
England	O
(	O
S&E	O
)	O
scale	O
score	O
of	O
more	O
than	O
70	O
during	O
the	O
off	O
-	O
period	O
,	O
indicating	O
that	O
these	O
patients	O
can	O
maintain	O
their	O
independent	O
ADL	O
all	O
the	O
time	O
.	O
Group	O
D	O
patients	O
showed	O
a	O
score	O
of	O
70	O
or	O
lower	O
during	O
the	O
off	O
-	O
period	O
,	O
indicating	O
that	O
these	O
patients	O
can	O
not	O
maintain	O
their	O
independent	O
ADL	O
for	O
an	O
entire	O
day	O
.	O
We	O
studied	O
the	O
differences	O
in	O
the	O
preoperative	B-T033
state	I-T033
between	O
these	O
two	O
groups	O
.	O
Statistically	O
significant	O
differences	O
were	O
noted	O
in	O
PD	B-T047
onset	O
age	O
,	O
age	O
at	O
surgery	B-T061
,	O
preoperative	O
unified	O
Parkinson	O
's	O
disease	O
rating	O
scale	O
(	O
UPDRS	O
)	O
part	O
I	O
score	O
,	O
part	O
II	O
score	O
,	O
total	O
subscore	O
for	O
axial	B-T033
symptoms	I-T033
in	O
part	O
III	O
,	O
mini	B-T033
-	I-T033
mental	I-T033
state	I-T033
examination	I-T033
(	I-T033
MMSE	I-T033
)	I-T033
score	I-T033
and	O
S&E	O
score	O
.	O
Multiple	O
logistic	O
regression	O
analysis	O
showed	O
that	O
the	O
significant	O
independent	O
variables	O
related	O
to	O
long	O
-	O
term	O
independent	O
ADL	O
were	O
the	O
age	O
at	O
surgery	B-T061
,	O
MMSE	B-T033
score	I-T033
and	O
preoperative	O
S&E	O
scale	O
score	O
during	O
the	O
off	O
-	O
period	O
.	O
The	O
PD	B-T047
onset	O
age	O
,	O
age	O
at	O
surgery	B-T061
,	O
preoperative	O
high	O
-	O
level	O
ADL	O
,	O
cognitive	O
function	O
,	O
and	O
axial	B-T033
symptoms	I-T033
are	O
important	O
predictive	O
factors	O
for	O
the	O
long	O
-	O
term	O
outcome	O
of	O
STN	B-T023
-	O
DBS	B-T061
.	O
      
Efficient	O
gene	O
targeting	O
in	O
non	O
-	O
homologous	O
end	O
-	O
joining	O
-deficient	O
Lipomyces	O
starkeyi	O
strains	B-T001
Microbial	B-T001
lipids	O
are	O
sustainable	O
feedstock	O
for	O
the	O
production	O
of	O
oleochemicals	O
and	O
biodiesel	O
.	O
Oleaginous	O
yeasts	O
have	O
recently	O
been	O
proposed	O
as	O
alternative	O
lipid	O
producers	O
to	O
plants	O
and	O
animals	O
to	O
promote	O
sustainability	O
in	O
the	O
chemical	O
and	O
fuel	O
industries	O
.	O
The	O
oleaginous	O
yeast	O
Lipomyces	O
starkeyi	O
has	O
great	O
industrial	O
potential	O
as	O
an	O
excellent	O
lipid	O
producer	O
.	O
However	O
,	O
improvement	O
of	O
its	O
lipid	O
productivity	O
is	O
essential	O
for	O
the	O
cost	O
-	O
effective	O
production	O
of	O
oleochemicals	O
and	O
fuels	O
.	O
Genetic	O
and	O
metabolic	O
engineering	O
of	O
L.	O
starkeyi	O
via	O
gene	O
manipulation	O
techniques	O
may	O
result	O
in	O
improvements	O
in	O
lipid	O
production	O
and	O
our	O
understanding	O
of	O
the	O
mechanisms	O
behind	O
lipid	O
biosynthesis	O
pathways	O
.	O
We	O
previously	O
described	O
an	O
integrative	O
transformation	O
system	O
using	O
a	O
drug	B-T121
-resistant	O
marker	O
for	O
L.	O
starkeyi	O
.	O
However	O
,	O
gene	O
-	O
targeting	O
frequencies	O
were	O
very	O
low	O
because	O
non	O
-	O
homologous	O
recombination	O
is	O
probably	O
predominant	O
in	O
L.	O
starkeyi	O
.	O
Genetic	O
engineering	O
tools	O
for	O
L.	O
starkeyi	O
have	O
not	O
been	O
sufficiently	O
developed	O
.	O
In	O
this	O
study	O
,	O
we	O
describe	O
a	O
new	O
genetic	O
tool	O
and	O
its	O
application	O
in	O
L.	O
starkeyi	O
.	O
To	O
develop	O
a	O
highly	O
efficient	O
gene	O
-	O
targeting	O
system	O
for	O
L.	O
starkeyi	O
,	O
we	O
constructed	O
a	O
series	O
of	O
mutants	O
by	O
disrupting	O
genes	O
for	O
LsKu70p	O
,	O
LsKu80p	O
,	O
and/or	O
LsLig4p	O
,	O
which	O
share	O
homology	O
with	O
other	O
yeasts	O
Ku70p	O
,	O
Ku80p	O
,	O
and	O
Lig4p	O
,	O
respectively	O
,	O
being	O
involved	O
in	O
non	O
-	O
homologous	O
end	O
-	O
joining	O
pathway	O
.	O
Deletion	O
of	O
the	O
LsLIG4	O
gene	O
dramatically	O
improved	O
the	O
homologous	O
recombination	O
efficiency	O
(	O
80.0	O
%	O
)	O
at	O
the	O
LsURA3	O
locus	O
compared	O
with	O
that	O
in	O
the	O
wild	O
-	O
type	O
strain	B-T001
(	O
1.4	O
%	O
)	O
,	O
when	O
2000	O
-	O
bp	O
homologous	O
flanking	O
regions	O
were	O
used	O
.	O
The	O
homologous	O
recombination	O
efficiencies	O
of	O
the	O
double	O
mutant	O
∆l	O
sku70∆lslig4	O
and	O
the	O
triple	O
mutant	O
∆lsku70∆lsku80∆lslig4	O
were	O
also	O
markedly	O
enhanced	O
.	O
Therefore	O
,	O
the	O
L.	O
starkeyi	O
∆lslig4	O
background	O
strains	B-T001
have	O
promise	O
as	O
efficient	O
recipient	B-T001
strains	I-T001
for	O
genetic	O
and	O
metabolic	O
engineering	O
approaches	O
in	O
this	O
yeast	O
.	O
      
Predictors	O
of	O
30-	O
day	O
mortality	O
in	O
patients	O
with	O
spontaneous	O
primary	O
intracerebral	B-T033
hemorrhage	I-T033
Intracerebral	B-T033
hemorrhage	I-T033
(	O
ICH	B-T033
)	O
is	O
a	O
life	B-T033
threatening	I-T033
entity	O
,	O
and	O
an	O
early	B-T058
outcome	I-T058
assessment	I-T058
is	O
mandatory	O
for	O
optimizing	O
therapeutic	B-T061
efforts	I-T061
.	O
We	O
retrospectively	O
analyzed	O
data	O
from	O
342	O
patients	O
with	O
spontaneous	O
primary	O
ICH	B-T033
to	O
evaluate	O
possible	O
predictors	O
of	O
30-	O
day	O
mortality	O
considering	O
clinical	O
,	O
radiological	O
,	O
and	O
therapeutical	O
parameters	O
.	O
We	O
also	O
applied	O
three	O
widely	O
accepted	O
outcome	O
grading	O
scoring	O
systems	O
[	O
(	O
ICH	O
score	O
,	O
FUNC	O
score	O
and	O
intracerebral	O
hemorrhage	O
grading	O
scale	O
(	O
ICH	O
-	O
GS	O
)	O
]	O
on	O
our	O
population	O
to	O
evaluate	O
the	O
correlation	O
of	O
these	O
scores	O
with	O
the	O
30-	O
day	O
mortality	O
in	O
our	O
study	O
.	O
We	O
also	O
applied	O
three	O
widely	O
accepted	O
outcome	O
grading	O
scoring	O
systems	O
[	O
(	O
ICH	O
score	O
,	O
FUNC	O
score	O
and	O
intracerebral	O
hemorrhage	O
grading	O
scale	O
(	O
ICH	O
-	O
GS	O
)	O
]	O
on	O
our	O
population	O
to	O
evaluate	O
the	O
correlation	O
of	O
these	O
scores	O
with	O
the	O
30-	O
day	O
mortality	O
in	O
our	O
study	O
.	O
From	O
342	O
patients	O
(	O
mean	O
age	O
:	O
67	O
years	O
,	O
mean	O
Glasgow	O
Coma	O
Scale	O
[	O
GCS	O
]	O
on	O
admission	B-T058
:	O
9	O
,	O
mean	O
ICH	B-T033
volume	O
:	O
62.19	O
ml	O
,	O
most	O
common	O
hematoma	O
location	O
:	O
basal	B-T023
ganglia	I-T023
[	O
43.9	O
%	O
]	O
)	O
,	O
102	O
received	O
surgical	B-T061
and	O
240	O
conservative	B-T061
treatment	I-T061
.	O
The	O
30-	O
day	O
mortality	O
was	O
25.15	O
%	O
.	O
In	O
a	O
multivariate	O
analysis	O
,	O
GCS	O
(	O
Odds	O
ratio	O
[	O
OR	O
]	O
=	O
0.726	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
=	O
0.661	O
-	O
0.796	O
,	O
P	O
<	O
0.001	O
)	O
,	O
bleeding	O
volume	O
(	O
OR	O
=	O
1.012	O
per	O
ml	O
,	O
95	O
%	O
CI	O
=	O
1.007	O
-	O
1.017	O
,	O
P	O
<	O
0.001	O
)	O
,	O
and	O
infratentorial	O
hematoma	O
location	O
(	O
OR	O
=	O
5.381	O
,	O
95	O
%	O
CI	O
=	O
2.166	O
-	O
13.356	O
,	O
P	O
=	O
0.009	O
)	O
were	O
significant	O
predictors	O
for	O
the	O
30-	O
day	O
mortality	O
.	O
After	O
receiver	O
operating	O
characteristics	O
analysis	O
,	O
we	O
defined	O
a	O
"	O
high	O
-	O
risk	O
group	O
"	O
for	O
an	O
unfavorable	O
short	O
-	O
term	O
outcome	O
with	O
GCS	O
<	O
11	O
and	O
ICH	B-T033
volume	O
>	O
32	O
ml	O
supratentorially	O
or	O
21	O
ml	O
infratentorially	O
.	O
Using	O
Pearson	O
correlation	O
,	O
we	O
found	O
a	O
correlation	O
of	O
0.986	O
between	O
ICH	O
score	O
and	O
30-	O
day	O
mortality	O
(	O
P	O
<	O
0.001	O
)	O
,	O
0.853	O
between	O
FUNC	O
score	O
and	O
30-	O
day	O
mortality	O
(	O
P	O
=	O
0.001	O
)	O
,	O
and	O
0.924	O
between	O
ICH	O
-	O
GS	O
and	O
30-	O
day	O
mortality	O
(	O
P	O
=	O
0.001	O
)	O
.	O
GCS	O
score	O
on	O
admission	B-T058
together	O
with	O
the	O
baseline	O
volume	O
and	O
localization	O
of	O
the	O
hemorrhage	O
are	O
strong	O
predictors	O
for	O
30-	O
day	O
mortality	O
in	O
patients	O
with	O
spontaneous	O
primary	O
intracerebral	B-T033
hemorrhage	I-T033
,	O
and	O
by	O
relying	O
on	O
them	O
it	O
is	O
possible	O
to	O
identify	O
high	B-T033
-	I-T033
risk	I-T033
patients	O
with	O
poor	O
short	O
-	O
term	O
outcome	O
.	O
The	O
ICH	O
score	O
and	O
the	O
ICH	O
-	O
GS	O
accurately	O
predict	O
the	O
30-	O
day	O
mortality	O
.	O
      
A	O
Rasch	O
Rating	O
Scale	O
Analysis	O
of	O
the	O
Presence	B-T033
of	O
Nursing	O
Scale	O
-	O
RN	O
The	O
phenomenon	O
of	O
nursing	O
presence	B-T033
encompasses	O
the	O
emotional	B-T033
connection	O
between	O
nurse	O
and	O
patient	O
,	O
and	O
technical	O
skills	O
performed	O
by	O
the	O
nurse	O
.	O
The	O
Presence	B-T033
of	O
Nursing	O
Scale	O
-	O
RN	O
version	O
(	O
PONS	O
-	O
RN	O
)	O
was	O
developed	O
to	O
measure	O
nurses	O
'	O
perceptions	O
of	O
their	O
ability	O
to	O
be	O
present	B-T033
to	O
their	O
patients	O
.	O
This	O
study	O
summarizes	O
the	O
process	O
of	O
re	O
-	O
evaluation	O
of	O
the	O
psychometric	B-T060
properties	I-T060
of	O
the	O
PONS	O
-	O
RN	O
instrument	O
.	O
A	O
sample	O
of	O
76	O
registered	O
nurses	O
providing	O
direct	O
patient	B-T058
care	I-T058
responded	O
to	O
the	O
31-	O
item	O
questionnaire	O
.	O
The	O
Rasch	O
rating	O
scale	O
model	O
was	O
used	O
for	O
assessing	B-T058
construct	O
validity	O
of	O
PONS	O
-	O
RN	O
data	O
.	O
A	O
principal	O
component	O
analysis	O
(	O
PCA	O
)	O
of	O
residuals	O
supported	O
appropriateness	O
of	O
the	O
subscales	O
defined	O
by	O
a	O
2	O
-	O
dimensional	O
structure	O
.	O
The	O
results	B-T033
of	O
item	O
and	O
person	O
fit	O
analysis	O
,	O
rating	O
scale	O
functioning	O
analysis	O
and	O
reliability	O
analysis	O
have	O
demonstrated	O
that	O
the	O
thirty	O
-	O
one	O
item	O
Presence	B-T033
of	O
Nursing	O
Scale	O
-	O
RN	O
instrument	O
yielded	O
measures	O
with	O
high	O
validity	O
and	O
reliability	O
as	O
two	O
sub	O
-	O
scales	O
.	O
Jou	O
rn	O
      
Osseointegration	O
behavior	O
of	O
novel	O
Ti	O
-	O
Nb	O
-	O
Zr	O
-	O
Ta	O
-	O
Si	O
alloy	O
for	O
dental	O
implants	O
:	O
an	O
in	O
vivo	O
study	O
This	O
study	O
aimed	O
to	O
evaluate	B-T058
the	O
effects	O
of	O
Ti	O
-	O
Nb	O
-	O
Zr	O
-	O
Ta	O
-	O
Si	O
alloy	O
implants	O
on	O
mineral	O
apposition	O
rate	O
and	O
new	O
BIC	O
contact	O
in	O
rabbits	O
.	O
Twelve	O
Ti	O
-	O
Nb	O
-	O
Zr	O
-	O
Ta	O
-	O
Si	O
alloy	O
implants	O
were	O
fabricated	O
and	O
placed	B-T058
into	O
the	O
right	O
femur	B-T023
sites	O
in	O
six	O
rabbits	O
,	O
and	O
commercially	O
pure	O
titanium	O
implants	O
were	O
used	O
as	O
controls	O
in	O
the	O
left	O
femur	B-T023
.	O
Tetracycline	B-T195
and	O
alizarin	O
red	O
were	O
administered	O
3	O
weeks	O
and	O
1	O
week	O
before	O
euthanization	B-T058
,	O
respectively	O
.	O
At	O
4	O
weeks	O
and	O
8	O
weeks	O
after	O
implantation	B-T061
,	O
animals	O
were	O
euthanized	B-T058
,	O
respectively	O
.	O
Surface	O
characterization	O
and	O
implant	O
-	O
bone	O
contact	O
surface	O
analysis	O
were	O
performed	O
by	O
using	O
a	O
scanning	O
electron	O
microscope	O
and	O
an	O
energy	O
dispersive	O
X	O
-	O
ray	O
detector	O
.	O
Mineral	O
apposition	O
rate	O
was	O
evaluated	B-T058
using	O
a	O
confocal	B-T059
laser	I-T059
scanning	I-T059
microscope	I-T059
.	O
Toluidine	B-T059
blue	I-T059
staining	I-T059
was	O
performed	O
on	O
undecalcified	B-T033
sections	O
for	O
histology	O
and	O
histomorphology	O
evaluation	O
.	O
Scanning	O
electron	O
microscope	O
and	O
histomorphology	O
observation	O
revealed	O
a	O
direct	O
contact	O
between	O
implants	O
and	O
bone	B-T023
of	O
all	O
groups	O
.	O
After	O
a	O
healing	O
period	O
of	O
4	O
weeks	O
,	O
Ti	O
-	O
Nb	O
-	O
Zr	O
-	O
Ta	O
-	O
Si	O
alloy	O
implants	O
showed	O
significantly	O
higher	O
mineral	O
apposition	O
rate	O
compared	O
to	O
commercially	O
pure	O
titanium	O
implants	O
(	O
P	O
<	O
0.05	O
)	O
,	O
whereas	O
there	O
was	O
no	B-T033
significant	I-T033
difference	O
between	O
Ti	O
-	O
Nb	O
-	O
Zr	O
-	O
Ta	O
-	O
Si	O
alloy	O
implants	O
and	O
commercially	O
pure	O
titanium	O
implants	O
(	O
P	O
>	O
0.05	O
)	O
at	O
8	O
weeks	O
.	O
No	B-T033
significant	I-T033
difference	O
of	O
bone	O
-	O
to	O
-	O
implant	O
contact	O
was	O
observed	O
between	O
Ti	O
-	O
Nb	O
-	O
Zr	O
-	O
Ta	O
-	O
Si	O
alloy	O
implants	O
and	O
commercially	O
pure	O
titanium	O
implants	O
implants	O
after	O
a	O
healing	O
period	O
of	O
4	O
weeks	O
and	O
8	O
weeks	O
.	O
This	O
study	O
showed	O
that	O
Ti	O
-	O
Nb	O
-	O
Zr	O
-	O
Ta	O
-	O
Si	O
alloy	O
implants	O
could	O
establish	O
a	O
close	O
direct	O
contact	O
comparedto	O
commercially	O
pure	O
titanium	O
implants	O
implants	O
,	O
improved	B-T033
mineral	O
matrix	O
apposition	O
rate	O
,	O
and	O
may	O
someday	O
be	O
an	O
alternative	O
as	O
a	O
material	O
for	O
dental	O
implants	O
.	O
      
Microbiological	O
and	O
Clinical	O
Characteristics	O
of	O
Hypermucoviscous	B-T007
Klebsiella	I-T007
pneumoniae	I-T007
Isolates	O
Associated	O
with	O
Invasive	B-T047
Infections	I-T047
in	O
China	O
A	O
distinctive	B-T047
syndrome	I-T047
caused	O
by	O
hypermucoviscous	B-T007
Klebsiella	I-T007
pneumoniae	I-T007
(	O
HMKP	B-T007
)	O
including	O
pyogenic	B-T047
liver	I-T047
abscess	I-T047
(	O
PLA	B-T047
)	O
is	O
now	O
becoming	O
a	O
globally	B-T047
emerging	I-T047
disease	I-T047
.	O
In	O
the	O
present	O
study	O
,	O
22.8	O
%	O
(	O
84/369	O
)	O
of	O
K.	B-T007
pneumoniae	I-T007
clinical	O
isolates	O
associated	O
with	O
various	O
types	O
of	O
invasive	B-T047
infections	I-T047
were	O
identified	O
as	O
HMKP	B-T007
,	O
with	O
45.2	O
%	O
associated	O
with	O
PLA	B-T047
.	O
Multivariate	O
regression	O
analysis	O
showed	O
that	O
male	O
patients	O
with	O
41	O
-	O
50	O
years	O
,	O
PLA	B-T047
,	O
diabetes	B-T047
mellitus	I-T047
,	O
and	O
hypertension	B-T047
were	O
independent	O
risk	B-T033
factors	I-T033
for	O
HMKP	B-T047
infections	I-T047
.	O
K2	O
(	O
42.9	O
%	O
,	O
36/84	O
)	O
was	O
the	O
most	O
common	O
capsular	O
serotype	O
among	O
HMKP	B-T007
isolates	O
,	O
followed	O
by	O
K1	O
(	O
23.8	O
%	O
,	O
20/84	O
)	O
.	O
Seventy	O
-	O
five	O
percentage	O
of	O
K1	O
HMKP	B-T007
isolates	O
were	O
associated	O
with	O
PLA	B-T047
,	O
while	O
K2	O
HMKP	B-T007
isolates	O
accounted	O
for	O
more	O
types	O
of	O
invasive	B-T047
infections	I-T047
.	O
The	O
positive	B-T033
rates	O
of	O
iutA	O
,	O
mrkD	O
,	O
aerobactin	O
,	O
iroN	O
,	O
and	O
rmpA	O
among	O
HMKP	B-T007
isolates	O
were	O
significantly	O
higher	O
than	O
those	O
among	O
non	B-T007
-	I-T007
HMKP	I-T007
isolates	O
(	O
p	O
<	O
0.05	O
)	O
.	O
There	O
was	O
a	O
correlation	O
between	O
magA	O
,	O
ybtS	O
,	O
alls	O
,	O
and	O
wcaG	O
and	O
K1	O
isolates	O
.	O
Interestingly	O
,	O
mrkD	O
was	O
exclusively	B-T033
detected	I-T033
among	O
HMKP	B-T007
(	O
32.1	O
%	O
,	O
27/84	O
)	O
and	O
K2	O
isolates	O
(	O
65.9	O
%	O
,	O
27/41	O
)	O
.	O
All	O
K1	O
and	O
K2	O
HMKP	B-T007
and	O
non	B-T007
-	I-T007
HMKP	I-T007
isolates	O
were	O
positive	B-T033
for	O
rmpA.	O
Aerobactin	O
was	O
found	B-T033
among	O
95.0	O
and	O
97.5	O
%	O
of	O
K1	O
and	O
K2	O
isolates	O
.	O
ST23	O
was	O
found	B-T033
to	O
be	O
the	O
most	O
prevalent	O
ST	O
among	O
69	O
HMKP	B-T007
isolates	O
with	O
K1	O
,	O
K2	O
,	O
K5	O
,	O
K20	O
,	O
and	O
K57	O
(	O
27.5	O
%	O
,	O
19/69	O
)	O
and	O
was	O
only	O
found	B-T033
among	O
K1	O
isolates	O
.	O
ST65	O
was	O
the	O
second	O
most	O
prevalent	O
ST	O
(	O
26.1	O
%	O
,	O
18/69	O
)	O
and	O
was	O
also	O
only	O
found	B-T033
among	O
K2	O
isolates	O
.	O
ST23	O
-	O
K1	O
HMKP	B-T007
isolates	O
(	O
84.2	O
%	O
,	O
16/19	O
)	O
were	O
associated	O
with	O
PLA	B-T047
,	O
while	O
ST65	O
-	O
K2	O
isolates	O
were	O
correlated	O
with	O
more	O
types	O
of	O
infections	O
relative	O
to	O
ST23	O
-	O
K1	O
isolates	O
.	O
PFGE	B-T059
results	O
showed	O
that	O
the	O
homology	O
of	O
84	O
HMKP	B-T007
isolates	O
was	O
diverse	O
.	O
Only	O
five	O
PFGE	B-T059
clusters	O
with	O
more	O
than	O
75	O
%	O
similarity	O
accounted	O
for	O
more	O
than	O
three	O
isolates	O
.	O
These	O
five	O
PFGE	B-T059
clusters	O
only	O
accounted	O
for	O
35	O
(	O
41.7	O
%	O
,	O
35/84	O
)	O
isolates	O
.	O
In	O
conclusion	O
,	O
our	O
study	O
first	O
found	B-T033
that	O
hypertension	B-T047
and	O
male	O
patients	O
with	O
41	O
-	O
50	O
years	O
old	O
were	O
independent	O
risk	B-T033
factors	I-T033
.	O
The	O
composition	O
of	O
ST	O
types	O
and	O
PFGE	B-T059
clusters	O
among	O
K.	B-T007
pneumoniae	I-T007
K2	O
isolates	O
was	O
more	O
diverse	O
than	O
K1	O
isolates	O
.	O
K1	O
and	O
K2	O
HMKP	B-T007
isolates	O
had	O
respective	O
specific	O
profiles	O
of	O
virulence	O
-	O
associated	O
genes	O
.	O
      
A	O
novel	O
assay	B-T059
to	O
measure	O
tertiary	O
and	O
quaternary	O
amines	O
in	O
wastewater	O
:	O
An	O
indicator	O
for	O
NDMA	O
wastewater	O
precursors	O
This	O
study	B-T059
examined	B-T033
the	O
potential	O
of	O
using	O
a	O
novel	O
bulk	B-T059
amine	I-T059
assay	I-T059
as	O
an	O
approximation	O
for	O
the	O
tertiary	O
and	O
quaternary	O
amine	O
load	O
in	O
wastewaters	O
and	O
surface	O
water	O
samples	O
,	O
and	O
this	O
approximation	O
was	O
compared	O
to	O
N	O
-	O
nitrosodimethylamine	O
(	O
NDMA	O
)	O
formation	O
potential	O
using	O
chloramines	O
.	O
An	O
existing	O
colorimetric	B-T059
method	I-T059
was	O
examined	B-T033
and	O
optimized	O
for	O
the	O
detection	B-T033
of	O
amines	O
in	O
environmental	O
water	O
samples	O
.	O
The	O
method	B-T059
consists	O
of	O
liquid	B-T059
-	I-T059
liquid	I-T059
extraction	I-T059
followed	O
by	O
a	O
catalyzed	O
reaction	O
to	O
form	O
a	O
yet-	O
undefined	O
product	O
that	O
is	O
known	O
to	O
be	O
both	O
a	O
strong	O
chromophore	O
and	O
fluorophore	B-T121
.	O
Previous	O
work	O
verified	O
that	O
this	O
reaction	O
was	O
effectively	O
catalyzed	O
by	O
a	O
number	O
of	O
compounds	O
containing	O
tertiary	O
and	O
quaternary	O
amine	O
moieties	O
.	O
Many	O
tertiary	O
and	O
quaternary	O
compounds	O
are	O
also	O
efficient	O
producers	O
of	O
NDMA	O
under	O
chloramination	O
conditions	O
,	O
and	O
a	O
linear	O
correlation	O
was	O
consequently	B-T033
derived	O
from	O
the	O
bulk	O
amine	O
signals	O
vs.	O
NDMA	O
formation	O
potential	O
in	O
various	O
wastewater	O
samples	O
(	O
R(2	O
)	O
=	O
0.74	O
;	O
n	O
=	O
24	O
;	O
p	O
-	O
value	O
<	O
0.05	O
)	O
.	O
The	O
results	O
provide	O
evidence	O
that	O
approximately	O
2	O
%	O
of	O
the	O
tertiary	O
and	O
quaternary	O
amines	O
measured	O
can	O
form	O
NDMA	O
and	O
an	O
estimated	O
0.01	O
-	O
1.3	O
%	O
of	O
nitrogen	O
in	O
dissolved	O
organic	O
nitrogen	O
originates	O
from	O
these	O
bulk	O
amines	O
.	O
The	O
normalization	O
of	O
NDMA	O
concentration	O
by	O
the	O
amine	O
measurement	O
revealed	O
that	O
ozone	O
effectively	O
destroyed	O
those	O
tertiary	O
and	O
quaternary	O
amine	O
structures	O
more	O
likely	O
to	O
form	O
NDMA	O
in	O
treated	O
wastewater	O
samples	O
.	O
This	O
bulk	B-T059
amine	I-T059
assay	I-T059
illustrates	O
that	O
proxy	O
measurements	O
of	O
tertiary	O
and	O
quaternary	O
amines	O
can	O
be	O
linked	O
to	O
the	O
NDMA	O
formation	O
potential	O
of	O
a	O
given	O
sample	O
,	O
and	O
this	O
approach	O
may	O
prove	O
useful	O
as	O
a	O
characterizing	O
tool	O
for	O
NDMA	O
precursors	O
in	O
wastewater	O
.	O
      
Development	O
and	O
validation	O
of	O
an	O
easy	O
-	O
to	O
-	O
use	O
risk	B-T058
assessment	I-T058
tool	I-T058
for	O
cumulative	O
low	B-T023
back	I-T023
loading	O
:	O
The	O
Lifting	O
Fatigue	O
Failure	O
Tool	O
(	O
LiFFT	O
)	O
Recent	O
evidence	O
suggests	O
that	O
musculoskeletal	B-T047
disorders	I-T047
(	O
MSDs	B-T047
)	O
may	O
be	O
the	O
result	O
of	O
a	O
fatigue	B-T184
failure	O
process	O
in	O
affected	O
tissues	O
.	O
This	O
paper	O
describes	O
a	O
new	O
low	O
back	O
exposure	O
assessment	O
tool	O
(	O
the	O
Lifting	O
Fatigue	O
Failure	O
Tool	O
[	O
LiFFT	O
]	O
)	O
,	O
which	O
estimates	O
a	O
"	O
daily	O
dose	O
"	O
of	O
cumulative	O
loading	O
on	O
the	O
low	B-T023
back	I-T023
using	O
fatigue	B-T184
failure	O
principles	O
.	O
Only	O
three	O
variables	O
are	O
necessary	O
to	O
derive	O
the	O
cumulative	O
load	O
associated	O
with	O
a	O
lifting	O
task	O
:	O
the	O
weight	O
of	O
the	O
load	O
,	O
the	O
maximum	O
horizontal	O
distance	O
from	O
the	O
spine	B-T023
to	O
the	O
load	O
,	O
and	O
the	O
number	O
of	O
repetitions	O
for	O
tasks	B-T061
performed	I-T061
during	O
the	O
workday	O
.	O
The	O
new	O
tool	O
was	O
validated	O
using	O
two	O
existing	O
epidemiological	O
databases	O
:	O
the	O
Lumbar	B-T033
Motion	I-T033
Lumbar	B-T033
Motion	I-T033
Monitor	I-T033
(	O
LMM	B-T033
)	O
database	O
,	O
and	O
a	O
database	O
from	O
a	O
U.S.	O
automotive	O
manufacturer	O
.	O
The	O
LiFFT	O
cumulative	B-T058
damage	I-T058
metric	I-T058
explained	O
92	O
%	O
of	O
the	O
deviance	O
in	O
low	B-T184
back	I-T184
disorders	I-T184
(	O
LBDs	B-T184
)	O
in	O
the	O
LMM	O
database	O
and	O
72	O
-	O
95	O
%	O
of	O
the	O
deviance	O
in	O
low	O
back	O
outcomes	O
in	O
the	O
automotive	O
database	O
(	O
depending	O
on	O
the	O
outcome	O
measure	O
)	O
.	O
Thus	O
,	O
LiFFT	O
is	O
practitioner	O
friendly	O
and	O
its	O
cumulative	O
damage	B-T058
metric	I-T058
highly	O
related	O
to	O
low	O
back	O
outcomes	O
.	O
      
Sustained	O
delivery	O
of	O
vincristine	B-T121
inside	O
an	O
orthotopic	O
mouse	B-T191
sarcoma	I-T191
model	O
decreases	O
tumor	B-T191
growth	I-T191
Sarcoma	B-T191
accounts	O
for	O
20	O
%	O
of	O
solid	B-T191
tumors	I-T191
in	O
children	O
.	O
Surgery	B-T061
has	O
significant	O
morbidity	O
.	O
We	O
hypothesized	O
that	O
delivering	O
chemotherapy	B-T061
directly	O
into	O
tumors	B-T191
through	O
sustained	O
release	O
silk	B-T121
systems	O
could	O
slow	O
tumor	B-T191
growth	I-T191
.	O
Human	O
Ewing	B-T191
sarcoma	I-T191
cells	O
A673	O
were	O
cultured	B-T059
with	O
vincristine	B-T121
and	O
doxorubicin	B-T195
to	O
determine	O
half	O
maximal	O
inhibitory	O
concentration	O
(	O
IC50	O
)	O
.	O
Cells	O
were	O
injected	O
into	O
mouse	O
hind	B-T023
leg	I-T023
to	O
create	O
orthotopic	O
tumors	B-T191
.	O
Tumor	O
volumes	O
were	O
measured	O
using	O
ultrasound	B-T060
.	O
When	O
volume	O
reached	O
>	O
250mm(3	O
,	O
)	O
interventions	B-T061
included	O
:	O
implantation	B-T061
of	O
drug	O
-	O
free	O
silk	B-T121
foam	O
(	O
Control	O
-F	O
)	O
,	O
doxorubicin	B-T195
400μg	O
foam	O
(	B-T195
Dox400	I-T195
-F	O
)	O
,	O
vincristine	B-T121
50μg	O
foam	O
(	O
Vin50	B-T121
-F	O
)	O
,	O
drug	O
-	O
free	O
silk	B-T121
gel	O
(	O
Control	O
-G	O
)	O
,	O
vincristine	B-T121
50μg	O
gel	O
(	O
Vin50	B-T121
-G	O
)	O
,	O
or	O
single	O
dose	O
intravenous	O
vincristine	B-T121
50μg	O
(	O
Vin50	B-T121
-IV	O
)	O
.	O
End	O
-	O
point	O
was	O
volume>1000mm(3	O
)	O
.	O
Kaplan	O
Meier	O
and	O
ANOVA	O
were	O
used	O
.	O
IC50	O
for	O
vincristine	B-T121
and	O
doxorubicin	B-T195
was	O
0.5ng	O
/	O
mL	O
and	O
200ng	O
/	O
mL	O
,	O
respectively	O
.	O
There	O
was	O
no	O
difference	O
between	O
Dox400	B-T195
-F	O
[	O
6±	O
1days	O
to	O
end	O
point	O
(	O
DTEP	O
)	O
]	O
and	O
Control	O
-F	O
(	O
5±1.3	O
DTEP	O
)	O
.	O
Vin50	B-T121
-F	O
(	O
12.4±3.5	O
DTEP	O
)	O
had	O
slower	B-T033
growth	I-T033
compared	O
to	O
Control	O
-F	O
(	O
p<0.001	O
)	O
,	O
and	O
there	O
was	O
no	O
difference	O
between	O
Vin50	B-T121
-F	O
and	O
Vin50	B-T121
-IV	O
(	O
14±0	O
DTEP	O
)	O
.	O
Growth	B-T033
was	I-T033
slowest	I-T033
with	O
Vin50	B-T121
-G	O
,	O
28±10.3	O
DTEP	O
compared	O
to	O
all	O
other	O
treatment	O
groups	O
(	O
p<0.05	O
)	O
.	O
Sustained	O
delivery	O
of	O
vincristine	B-T121
inside	O
the	O
sarcoma	B-T191
tumor	B-T191
with	O
silk	B-T121
gel	O
decreased	O
tumor	B-T191
growth	I-T191
.	O
Applying	O
this	O
intratumoral	B-T061
treatment	I-T061
strategy	O
may	O
potentially	O
decrease	O
the	O
extent	O
of	O
surgical	B-T061
excision	I-T061
.	O
      
Phylogeography	O
of	O
the	O
Spanish	O
Moon	O
Moth	O
Graellsia	O
isabellae	O
(	O
Lepidoptera	O
,	O
Saturniidae	O
)	O
Geographic	O
and	O
demographic	O
factors	O
as	O
well	O
as	O
specialisation	O
to	O
a	O
new	O
host	O
-	O
plant	O
may	O
lead	O
to	O
host	O
-	O
associated	O
differentiation	O
in	O
plant	O
-feeding	O
insects	O
.	O
We	O
explored	O
the	O
phylogeography	O
of	O
a	O
protected	O
moth	O
,	O
Graellsia	O
isabellae	O
,	O
and	O
its	O
two	O
recognised	O
host	O
-	O
plant	O
species	O
(	O
Pinus	O
sylvestris	O
and	O
P.	O
nigra	O
)	O
in	O
order	O
to	O
seek	O
for	O
any	O
concordance	O
useful	O
to	O
disentangle	O
the	O
evolutionary	O
history	O
of	O
this	O
iconic	O
lepidopteran	O
.	O
DNA	O
variation	O
in	O
one	O
mitochondrial	O
marker	O
and	O
nine	O
nuclear	O
microsatellite	O
loci	O
revealed	O
a	O
strong	O
phylogeographic	B-T033
pattern	I-T033
across	O
28	O
populations	O
of	O
G.	O
isabellae	O
studied	O
in	O
Spain	O
and	O
France	O
comprising	O
six	O
groups	O
mostly	O
distributed	O
along	O
different	O
mountain	O
ranges	O
.	O
Reanalysis	O
of	O
a	O
previously	O
published	O
chloroplast	O
microsatellite	O
dataset	O
revealed	O
a	O
three	O
and	O
two-	O
group	O
structure	O
for	O
Spanish	O
P.	O
sylvestris	O
and	O
P.	O
nigra	O
,	O
respectively	O
.	O
Overall	O
,	O
the	O
population	O
groupings	O
of	O
this	O
protected	O
moth	O
did	O
not	O
match	O
the	O
ones	O
of	O
P.	O
sylvestris	O
and	O
P.	O
nigra	O
.	O
There	O
was	O
no	O
evidence	O
of	O
host	O
-	O
associated	O
differentiation	O
between	O
populations	O
using	O
P.	O
sylvestris	O
and	O
the	O
ones	O
inhabiting	O
P.	O
nigra	O
.	O
The	O
two	O
major	O
mitochondrial	O
clades	O
of	O
G.	O
isabellae	O
likely	O
diverged	O
before	O
the	O
Last	O
Glacial	O
Maximum	O
and	O
geographically	O
separated	O
the	O
species	O
into	O
a	O
"	O
southern	O
"	O
(	O
Central	O
and	O
Southern	O
Iberian	O
clusters	O
)	O
and	O
a	O
"	O
northern	O
"	O
lineage	O
(	O
Eastern	O
Iberian	O
,	O
Pyrenean	O
and	O
French	O
Alpine	O
clusters	O
)	O
.	O
The	O
Eastern	O
Iberian	O
System	O
,	O
where	O
this	O
insect	O
uses	O
both	O
host	O
-	O
plants	O
,	O
harboured	O
the	O
highest	O
level	O
of	O
genetic	O
diversity	O
.	O
Such	O
a	O
group	O
independently	O
colonised	B-T033
the	O
West	O
and	O
East	O
parts	O
of	O
the	O
Pyrenees	O
.	O
Our	O
results	O
point	O
to	O
a	O
native	O
origin	O
for	O
the	O
French	O
populations	O
occurring	O
in	O
the	O
Alps	O
,	O
genetically	O
related	O
to	O
the	O
Eastern	O
Iberian	O
and	O
Pyrenean	O
sites	O
.	O
The	O
Central	O
Iberian	O
group	O
derived	O
from	O
Southern	O
Iberian	O
ancestors	O
.	O
Secondary	O
contacts	O
were	O
inferred	O
between	O
the	O
Southern	O
/	O
Central	O
Iberian	O
populations	O
and	O
Eastern	O
Iberian	O
cluster	O
as	O
well	O
as	O
between	O
the	O
two	O
Pyrenean	O
ones	O
.	O
The	O
mito	O
-	O
nuclear	O
discordance	O
observed	O
with	O
regard	O
to	O
the	O
Eastern	O
Iberian	O
cluster	O
is	O
congruent	O
with	O
a	O
secondary	O
contact	O
after	O
the	O
evolution	O
of	O
mito	O
-	O
nuclear	O
incompatibilities	O
in	O
geographically	O
isolated	O
areas	O
.	O
      
Gastrointestinal	B-T047
disorders	I-T047
in	O
Curry	B-T047
-	I-T047
Jones	I-T047
syndrome	I-T047
:	O
Clinical	O
and	O
molecular	O
insights	O
from	O
an	O
affected	O
newborn	O
Curry	B-T047
-	I-T047
Jones	I-T047
syndrome	I-T047
(	O
CJS	B-T047
)	O
is	O
a	O
pattern	O
of	O
malformation	B-T190
that	O
includes	O
craniosynostosis	B-T047
,	O
pre	B-T033
-	I-T033
axial	I-T033
polysyndactyly	I-T033
,	O
agenesis	B-T019
of	I-T019
the	I-T019
corpus	I-T019
callosum	I-T019
,	O
cutaneous	B-T033
and	O
gastrointestinal	B-T019
abnormalities	I-T019
.	O
A	O
recurrent	O
,	O
mosaic	O
mutation	O
of	O
SMO	O
(	O
c.1234	O
C	O
>	O
T	O
;	O
p.	O
Leu412Phe	O
)	O
causes	O
CJS	B-T047
.	O
This	O
report	O
describes	O
the	O
gastrointestinal	O
and	O
surgical	B-T033
findings	I-T033
in	O
a	O
baby	O
with	O
CJS	B-T047
who	O
presented	O
with	O
abdominal	B-T047
obstruction	I-T047
and	O
reviews	O
the	O
spectrum	B-T033
of	I-T033
gastrointestinal	I-T033
malformations	I-T033
in	O
this	O
rare	B-T047
disorder	I-T047
.	O
A	O
41-	O
week	O
,	O
4,165	O
g	O
,	O
female	O
presented	O
with	O
craniosynostosis	B-T047
,	O
pre	B-T033
-	I-T033
axial	I-T033
polysyndactyly	I-T033
,	O
and	O
cutaneous	B-T033
findings	I-T033
consistent	O
with	O
a	O
clinical	B-T060
diagnosis	I-T060
of	O
CJS	B-T047
.	O
The	O
infant	O
developed	O
abdominal	B-T033
distension	I-T033
beginning	O
on	O
the	O
second	O
day	O
of	O
life	O
.	O
Surgical	B-T060
exploration	I-T060
revealed	O
an	O
intestinal	B-T019
malrotation	I-T019
for	O
which	O
she	O
underwent	O
a	O
Ladd	B-T061
procedure	I-T061
.	O
Multiple	B-T033
small	I-T033
nodules	I-T033
were	O
found	B-T033
on	O
the	O
surface	O
of	O
the	O
small	O
and	O
large	O
bowel	O
in	O
addition	O
to	O
an	O
apparent	O
intestinal	B-T019
duplication	I-T019
that	O
seemed	O
to	O
originate	O
posterior	O
to	O
the	O
pancreas	B-T023
.	O
Histopathology	O
of	O
serosal	O
nodules	B-T020
revealed	O
bundles	O
of	O
smooth	O
muscle	O
with	O
associated	O
ganglion	O
cells	O
.	O
Molecular	O
analysis	O
demonstrated	O
the	O
SMO	O
c.1234	O
C	O
>	O
T	O
mutation	O
in	O
varying	O
amounts	O
in	O
affected	O
skin	O
(	O
up	O
to	O
35	O
%	O
)	O
and	O
intestinal	B-T191
hamartoma	I-T191
(	O
26	O
%	O
)	O
.	O
Gastrointestinal	O
features	B-T033
including	O
structural	B-T033
malformations	I-T033
malformations	B-T190
,	O
motility	O
disorders	O
,	O
and	O
upper	O
GI	O
bleeding	O
are	O
major	O
causes	O
of	O
morbidity	O
in	O
CJS	B-T047
.	O
Smooth	B-T191
muscle	I-T191
hamartomas	I-T191
are	O
a	O
recognized	B-T033
feature	I-T033
of	O
children	O
with	O
CJS	B-T047
typically	O
presenting	O
with	O
abdominal	B-T047
obstruction	I-T047
requiring	B-T033
surgical	I-T033
intervention	I-T033
.	O
A	O
somatic	O
mutation	O
in	O
SMO	O
likely	O
accounts	O
for	O
the	O
structural	B-T033
malformations	I-T033
malformations	B-T190
and	O
predisposition	O
to	O
form	O
bowel	B-T191
hamartomas	I-T191
and	O
myofibromas	B-T191
.	O
The	O
mutation	O
burden	O
in	O
the	O
involved	O
tissues	O
likely	O
accounts	O
for	O
the	O
variable	B-T033
manifestations	I-T033
.	O
      
Bioelectrochemical	B-T059
anaerobic	O
sewage	O
treatment	O
technology	O
for	O
Arctic	O
communities	O
This	O
study	O
describes	O
a	O
novel	O
wastewater	O
treatment	O
technology	O
suitable	O
for	O
small	O
remote	O
northern	O
communities	O
.	O
The	O
technology	O
is	O
based	O
on	O
an	O
enhanced	O
biodegradation	O
of	O
organic	O
carbon	O
through	O
a	O
combination	O
of	O
anaerobic	O
methanogenic	O
and	O
microbial	B-T001
electrochemical	B-T059
(	O
bioelectrochemical	B-T059
)	O
degradation	O
processes	O
leading	O
to	O
biomethane	O
production	O
.	O
The	O
microbial	B-T001
electrochemical	B-T059
degradation	O
is	O
achieved	O
in	O
a	O
membraneless	B-T033
flow	I-T033
-through	O
bioanode	O
-	O
biocathode	O
setup	O
operating	O
at	O
an	O
applied	O
voltage	O
below	O
the	O
water	B-T121
electrolysis	B-T061
threshold	O
.	O
Laboratory	O
wastewater	O
treatment	O
tests	O
conducted	O
through	O
a	O
broad	O
range	O
of	O
mesophilic	O
and	O
psychrophilic	O
temperatures	O
(	O
5	O
-	O
23	O
°	O
C	O
)	O
using	O
synthetic	O
wastewater	O
showed	O
a	O
biochemical	B-T059
oxygen	I-T059
demand	I-T059
(	O
BOD5	B-T059
)	O
removal	O
efficiency	O
of	O
90	O
-	O
97	O
%	O
and	O
an	O
effluent	O
BOD5	B-T059
concentration	O
as	O
low	O
as	O
7	O
mg	O
L(-1	O
)	O
.	O
An	O
electricity	O
consumption	O
of	O
0.6	O
kWh	O
kg(-1	O
)	O
of	O
chemical	O
oxygen	O
demand	O
(	O
COD	O
)	O
removed	O
was	O
observed	O
.	O
Low	O
energy	O
consumption	O
coupled	O
with	O
enhanced	O
methane	O
production	O
led	O
to	O
a	O
net	O
positive	B-T033
energy	O
balance	O
in	O
the	O
bioelectrochemical	B-T059
treatment	O
system	O
.	O
      
Simulating	O
the	O
potential	O
role	O
of	O
media	O
coverage	O
and	O
infected	B-T033
bats	O
in	O
the	O
2014	O
Ebola	B-T047
outbreak	O
Multiple	O
epidemiological	O
models	O
have	O
been	O
developed	O
to	O
model	O
the	O
transmission	O
dynamics	O
of	O
Ebola	B-T047
virus	I-T047
(	I-T047
EBOV	I-T047
)	I-T047
disease	I-T047
in	O
West	O
Africa	O
in	O
2014	O
because	O
the	O
severity	O
of	O
the	O
epidemic	O
is	O
commonly	O
overestimated	O
.	O
A	O
compartmental	O
model	O
that	O
incorporates	O
the	O
media	O
impact	O
and	O
the	O
effect	O
of	O
infected	B-T033
bats	O
was	O
constructed	O
and	O
calibrated	O
using	O
data	O
reported	O
until	O
the	O
end	O
of	O
2014	O
.	O
The	O
final	O
cumulative	O
number	O
of	O
deaths	O
and	O
confirmed	B-T033
cases	O
were	O
estimated	O
to	O
be	O
1.0921×10(4	O
)	O
(	O
95	O
%	O
CI	O
9.7706×10(3)-1.2072×10(4	O
)	O
)	O
and	O
1.5193×10(4	O
)	O
(	O
95	O
%	O
CI	O
1.3593×10(4)-1.6795×10(4	O
)	O
)	O
,	O
respectively	O
.	O
The	O
epidemic	O
was	O
estimated	O
to	O
end	O
on	O
June	O
2015	O
,	O
which	O
was	O
similar	O
to	O
the	O
data	O
reported	B-T058
by	O
the	O
World	O
Health	O
Organization	O
.	O
A	O
sensitivity	O
analysis	O
indicated	B-T033
that	O
an	O
increase	O
of	O
either	O
the	O
media	O
impact	O
or	O
the	O
number	O
of	O
infectious	O
bats	O
that	O
are	O
captured	O
daily	O
can	O
increase	O
the	O
cumulative	O
number	O
of	O
confirmed	B-T033
cases	O
/	O
deaths	O
.	O
Of	O
the	O
considered	O
epidemiological	O
parameters	O
,	O
only	O
the	O
media	O
coverage	O
can	O
significantly	O
reduce	O
both	O
the	O
peak	B-T033
time	I-T033
and	O
the	O
value	O
of	O
the	O
cumulative	O
confirmed	B-T033
cases	O
/	O
deaths	O
.	O
Thus	O
,	O
we	O
propose	O
'	O
the	O
cumulative	O
confirmed	B-T033
cases	O
and	O
deaths	O
'	O
as	O
another	O
media	O
mechanism	O
.	O
In	O
conclusion	O
,	O
the	O
media	O
impact	O
contributed	O
to	O
the	O
control	O
of	O
the	O
2014	O
Ebola	B-T047
outbreak	O
,	O
and	O
infectious	O
bats	O
may	O
be	O
a	O
potential	O
source	B-T033
of	O
the	O
epidemic	O
.	O
      
The	O
effects	O
of	O
probiotic	B-T007
and	O
synbiotic	O
supplementation	B-T061
on	O
metabolic	B-T047
syndrome	I-T047
indices	O
in	O
adults	O
at	O
risk	O
of	O
type	B-T047
2	I-T047
diabetes	I-T047
:	O
study	O
protocol	O
for	O
a	O
randomized	O
controlled	O
trial	O
The	O
incidence	O
of	O
type	B-T047
2	I-T047
diabetes	I-T047
,	O
cardiovascular	B-T047
diseases	I-T047
,	O
and	O
obesity	B-T047
has	O
been	O
rising	O
dramatically	O
;	O
however	O
,	O
their	O
pathogenesis	O
is	O
particularly	O
intriguing	O
.	O
Recently	O
,	O
dysbiosis	O
of	O
the	O
intestinal	B-T001
microbiota	I-T001
has	O
emerged	O
as	O
a	O
new	O
candidate	O
that	O
may	O
be	O
linked	O
to	O
metabolic	B-T047
diseases	I-T047
.	O
We	O
hypothesize	O
that	O
selective	O
modulation	O
of	O
the	O
intestinal	B-T001
microbiota	I-T001
by	O
probiotic	B-T007
or	O
synbiotic	O
supplementation	B-T061
may	O
improve	O
metabolic	B-T047
dysfunction	I-T047
and	O
prevent	O
diabetes	B-T047
in	O
prediabetics	B-T047
.	O
In	O
this	O
study	O
,	O
a	O
synthesis	O
and	O
study	O
of	O
synbiotics	O
will	O
be	O
carried	O
out	O
for	O
the	O
first	O
time	O
in	O
Iran	O
.	O
In	O
a	O
randomized	O
triple	O
-	O
blind	O
controlled	O
clinical	O
trial	O
,	O
120	O
adults	O
with	O
impaired	B-T047
glucose	I-T047
tolerance	I-T047
based	O
on	O
the	O
inclusion	O
criteria	O
will	O
be	O
selected	O
by	O
a	O
simple	O
random	O
sampling	O
method	O
and	O
will	O
be	O
randomly	O
allocated	O
to	O
6	O
months	O
of	O
6	O
g	O
/	O
d	O
probiotic	B-T007
,	O
synbiotic	O
or	O
placebo	O
.	O
The	O
fecal	O
abundance	O
of	O
bacteria	B-T007
,	O
blood	O
pressure	O
,	O
height	O
,	O
weight	O
,	O
and	O
waist	O
and	O
hip	O
circumferences	O
will	O
be	O
measured	O
at	O
baseline	O
and	O
following	O
treatment	B-T061
.	O
Also	O
,	O
plasma	B-T059
lipid	I-T059
profiles	I-T059
,	O
HbA1C	O
,	O
fasting	B-T059
plasma	I-T059
glucose	I-T059
,	O
and	O
insulin	B-T121
levels	O
,	O
will	O
be	O
measured	O
and	O
insulin	B-T059
resistance	I-T059
(	O
HOMA	B-T059
-	I-T059
IR	I-T059
)	O
and	O
beta	B-T059
-	I-T059
cell	I-T059
function	I-T059
(	O
HOMA	B-T059
-	I-T059
B	I-T059
)	O
will	O
be	O
calculated	O
at	O
baseline	O
and	O
will	O
be	O
repeated	O
at	O
months	O
3	O
,	O
6	O
,	O
12	O
,	O
and	O
18	O
.	O
The	O
data	O
will	O
be	O
compared	O
within	O
and	O
between	O
groups	O
using	O
statistical	O
methods	O
.	O
The	O
results	O
of	O
this	O
trial	O
could	O
contribute	O
to	O
the	O
evidence	O
-	O
based	O
clinical	O
guidelines	O
that	O
address	O
gut	B-T001
microbiota	I-T001
manipulation	B-T061
to	O
maximize	O
health	O
benefits	O
in	O
prevention	B-T061
and	O
management	B-T058
of	O
metabolic	B-T047
syndrome	I-T047
in	O
prediabetes	B-T047
.	O
Iranian	O
Registry	O
of	O
Clinical	O
Trials	O
:	O
IRCT201511032321N2	O
.	O
Registered	O
on	O
27	O
February	O
2016	O
.	O
      
Effect	O
of	O
nutritionally	B-T033
induced	I-T033
hyperlipidaemia	B-T047
on	O
in	O
vitro	O
bovine	O
embryo	B-T018
quality	O
depends	O
on	O
the	O
type	O
of	O
major	O
fatty	O
acid	O
in	O
the	O
diet	O
The	O
present	O
study	O
examined	B-T033
whether	O
the	O
effects	O
of	O
dietary	O
-induced	O
hyperlipidaemia	B-T047
on	O
preimplantation	O
embryo	O
development	O
depend	O
on	O
the	O
predominant	O
fatty	O
acid	O
(	O
FA	O
)	O
type	O
in	O
the	O
diet	O
.	O
In	O
a	O
combined	O
in	O
vivo	O
-	O
in	O
vitro	O
bovine	O
model	O
,	O
two	O
groups	O
of	O
cows	O
(	O
n=3	O
in	O
each	O
group	O
)	O
were	O
fed	O
with	O
three	O
diets	O
consecutively	O
(	O
4	O
weeks	O
feeding	O
for	O
each	O
):	O
(	O
1	O
)	O
a	O
maintenance	O
control	O
diet	O
(	O
CONT	O
)	O
;	O
(	O
2	O
)	O
a	O
high	O
-	O
starch	O
diet	O
rich	O
in	O
saturated	O
fat	O
(	O
SAT	O
)	O
;	O
and	O
(	O
3	O
)	O
a	O
high	O
-	O
starch	O
diet	O
rich	O
in	O
omega-3	B-T121
unsaturated	O
fat	O
(	O
UNSAT	O
)	O
.	O
Two	O
feeding	O
sequences	O
were	O
used	O
to	O
test	O
for	O
carry	O
-	O
over	O
effects	O
:	O
Group	O
A	O
was	O
fed	O
CONT	O
,	O
SAT1	O
and	O
then	O
UNSAT2	O
,	O
whereas	O
Group	O
B	O
was	O
fed	O
CONT	O
,	O
UNSAT1	O
and	O
then	O
SAT2	O
.	O
Serum	O
was	O
collected	O
after	O
each	O
dietary	O
period	O
,	O
analysed	O
and	O
tested	O
in	O
bovine	O
in	O
vitro	O
embryo	B-T059
culture	I-T059
.	O
Introducing	O
SAT	O
and	O
UNSAT	O
diets	O
induced	O
hyperlipidaemia	B-T047
(	O
specifically	O
hypercholesterolaemia	B-T047
and	O
elevated	O
free	O
FAs	O
)	O
and	O
reduced	O
insulin	O
sensitivity	O
.	O
Carry	O
-	O
over	O
effects	O
in	O
serum	O
metabolites	O
and	O
FA	B-T059
profile	I-T059
were	O
dependent	O
on	O
the	O
diet	O
and	O
feeding	O
sequence	O
.	O
SAT1	O
and	O
SAT2	O
serum	O
decreased	O
blastocyst	B-T018
rates	O
and	O
altered	O
blastocyst	B-T018
mRNA	O
expression	O
related	O
to	O
apoptosis	O
and	O
oxidative	O
stress	O
.	O
UNSAT1	O
and	O
UNSAT2	O
serum	O
resulted	O
in	O
normal	O
embryo	B-T018
development	O
and	O
quality	O
.	O
Other	O
in	O
vitro	O
effects	O
depended	O
on	O
the	O
sequence	O
of	O
feeding	O
.	O
In	O
conclusion	O
,	O
substitution	O
of	O
saturated	O
fat	O
with	O
omega-3	B-T121
fat	I-T121
in	O
a	O
high	B-T061
-	I-T061
caloric	I-T061
diet	I-T061
induced	O
hyperlipidaemia	B-T047
with	O
an	O
FA	B-T059
profile	I-T059
yielding	O
similar	O
rates	O
and	O
quality	O
of	O
blastocysts	B-T018
compared	O
with	O
normolipidaemic	O
controls	O
.	O
      
Prednisolone	B-T121
is	O
associated	O
with	O
a	O
worse	B-T033
lipid	I-T033
profile	I-T033
than	O
hydrocortisone	B-T121
in	O
patients	O
with	O
adrenal	B-T047
insufficiency	I-T047
Prednisolone	B-T121
is	O
used	O
as	O
glucocorticoid	O
replacement	B-T061
therapy	I-T061
for	O
adrenal	B-T047
insufficiency	I-T047
(	O
AI	B-T047
)	O
.	O
Recent	O
data	O
indicate	O
that	O
its	O
use	O
in	O
AI	B-T047
is	O
associated	O
with	O
low	O
bone	O
mineral	O
density	O
.	O
Data	O
on	O
risk	B-T033
factors	I-T033
for	O
cardiovascular	B-T047
disease	I-T047
in	O
patients	O
with	O
AI	B-T047
treated	O
with	O
prednisolone	B-T121
are	O
scarce	O
,	O
despite	O
this	O
condition	O
being	O
the	O
predominant	O
cause	B-T033
of	O
excess	O
mortality	O
.	O
We	O
aimed	O
to	O
address	O
this	O
question	O
using	O
real	O
-	O
world	O
data	O
from	O
the	O
European	O
Adrenal	O
Insufficiency	O
Registry	O
(	O
EU	O
-	O
AIR	O
)	O
.	O
EU	O
-	O
AIR	O
,	O
comprising	O
of	O
19	O
centres	O
across	O
Germany	O
,	O
the	O
Netherlands	O
,	O
Sweden	O
and	O
the	O
UK	O
,	O
commenced	O
enrolling	O
patients	O
with	O
AI	B-T047
in	O
August	O
2012	O
.	O
Patients	O
receiving	O
prednisolone	B-T121
(	O
3	O
-	O
6	O
mg	O
/	O
day	O
,	O
n	O
=	O
50	O
)	O
or	O
hydrocortisone	B-T121
(	O
15	O
-	O
30	O
mg	O
/	O
day	O
,	O
n	O
=	O
909	O
)	O
were	O
identified	O
and	O
grouped	O
at	O
a	O
ratio	O
of	O
1:3	O
(	O
prednisolone	B-T121
:	O
hydrocortisone	B-T121
)	O
by	O
matching	O
for	O
gender	O
,	O
age	O
,	O
duration	O
and	O
type	O
of	O
disease	O
.	O
Data	O
from	O
baseline	O
and	O
follow	B-T058
-	I-T058
up	I-T058
visits	B-T058
were	O
analysed	O
.	O
Data	O
from	O
patients	O
with	O
congenital	B-T047
adrenal	I-T047
hyperplasia	I-T047
were	O
excluded	O
.	O
Significantly	O
higher	O
mean	O
±	O
s.d	O
.	O
total	O
(	O
6.3	O
±	O
1.6	O
vs	O
5.4	O
±	O
1.1	O
mmol	O
/	O
L	O
;	O
P	O
=	O
0.003	O
)	O
and	O
low	O
-	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
cholesterol	O
levels	O
(	O
3.9	O
±	O
1.4	O
vs	O
3.2	O
±	O
1.0	O
mmol	O
/	O
L	O
;	O
P	O
=	O
0.013	O
)	O
were	O
identified	O
in	O
47	O
patients	O
on	O
prednisolone	B-T121
vs	O
141	O
receiving	O
hydrocortisone	B-T121
at	O
baseline	O
and	O
at	O
follow	B-T058
-	I-T058
up	I-T058
(	O
P	O
=	O
0.005	O
and	O
P	O
=	O
0.006	O
,	O
respectively	O
)	O
.	O
HbA1c	O
,	O
high	O
-	O
density	O
lipoprotein	O
and	O
triglyceride	O
levels	O
,	O
body	O
mass	O
index	O
,	O
systolic	B-T047
and	O
diastolic	B-T047
blood	I-T047
pressure	I-T047
and	O
waist	O
circumference	O
were	O
not	O
significantly	O
different	O
.	O
This	O
is	O
the	O
first	O
matched	O
analysis	O
of	O
its	O
kind	O
.	O
Significantly	O
higher	O
LDL	O
levels	O
in	O
patients	O
receiving	O
prednisolone	B-T121
relative	O
to	O
hydrocortisone	B-T121
could	O
predict	O
a	O
higher	O
relative	O
risk	O
of	O
cardiovascular	B-T047
disease	I-T047
in	O
the	O
former	O
group	O
.	O
      
Construction	O
of	O
Fused	O
Polyheterocycles	O
through	O
Sequential	O
[	O
4	O
+	O
2	O
]	O
and	O
[	O
3	O
+	O
2	O
]	O
Cycloadditions	O
A	O
method	O
for	O
Pd	O
-	O
catalyzed	O
aerobic	O
oxidative	O
reaction	O
of	O
quinazolinones	O
and	O
alkynes	O
has	O
been	O
developed	O
for	O
sequential	O
[	O
4	O
+	O
2	O
]	O
and	O
[	O
3	O
+	O
2	O
]	O
cycloadditions	O
to	O
assemble	O
a	O
novel	O
fused	O
-	O
polycyclic	O
system	O
containing	O
tetrahydropyridine	O
and	O
dihydrofuran	O
rings	O
.	O
The	O
reaction	O
process	O
involves	O
C	O
-	O
H	O
and	O
N	O
-	O
H	O
bond	O
functionalization	O
for	O
the	O
formation	O
of	O
tetrahydropyridine	O
and	O
an	O
oxygen	B-T121
radical	I-T121
cyclization	O
for	O
the	O
dihydrofuran	O
ring	O
.	O
This	O
atom	O
-	O
and	O
step-	O
economical	O
synthesis	O
is	O
highly	O
efficient	O
and	O
has	O
good	O
substrate	O
tolerance	O
,	O
which	O
provides	O
a	O
new	O
approach	O
for	O
the	O
construction	O
of	O
polycyclic	O
molecules	O
with	O
potential	O
pharmaceutical	O
interest	O
.	O
      
Risk	B-T033
Factors	I-T033
Associated	O
With	O
Repeated	O
HIV	B-T059
Testing	I-T059
Among	O
Internet	O
-Using	O
Men	O
Who	O
Have	O
Sex	O
With	O
Men	O
Men	O
who	O
have	O
sex	O
with	O
men	O
(	O
MSM	O
)	O
represent	O
a	O
disproportionately	O
impacted	O
risk	O
group	O
for	O
HIV	B-T005
incidence	O
among	O
at	O
-	O
risk	O
U.S.	O
Few	O
studies	O
have	O
identified	O
risk	B-T033
factors	I-T033
associated	O
with	O
HIV	B-T059
testing	I-T059
frequency	O
both	O
within	O
and	O
outside	O
of	O
traditional	O
health	B-T058
care	I-T058
settings	I-T058
.	O
MSM	O
enrolled	O
in	O
a	O
prospective	O
cohort	O
were	O
mailed	O
at	O
-	O
home	O
specimen	O
collection	O
kits	O
and	O
followed	O
for	O
a	O
year	O
.	O
Incidence	O
density	O
rate	O
ratios	O
(	O
IDRR	O
)	O
of	O
testing	O
were	O
calculated	O
,	O
and	O
generalized	O
estimating	O
equations	O
were	O
used	O
to	O
analyze	O
the	O
association	O
between	O
HIV	B-T059
testing	I-T059
and	O
behavioral	O
factors	O
.	O
The	O
incidence	O
rate	O
of	O
testing	O
was	O
higher	O
among	O
Black	O
MSM	O
than	O
White	O
MSM	O
(	O
IDRR	O
:	O
1.3	O
,	O
95	O
%	O
confidence	O
interval	O
CI	O
[	O
1.1	O
,	O
1.5	O
]	O
)	O
and	O
higher	O
among	O
MSM	O
who	O
reported	O
3	O
+	O
condomless	B-T033
anal	B-T023
intercourse	O
partners	O
(	O
CAI	O
)	O
than	O
MSM	O
who	O
reported	O
no	B-T033
CAI	O
(	O
IDRR	O
:	O
1.6	O
,	O
95	O
%	O
CI	O
[	O
1.3	O
,	O
2.0	O
]	O
)	O
.	O
Increasing	O
availability	O
of	O
HIV	B-T059
testing	I-T059
outside	O
traditional	O
health	B-T058
care	I-T058
settings	I-T058
,	O
including	O
at	O
-	O
home	O
testing	O
kits	O
,	O
in	O
conjunction	O
with	O
targeted	O
behavioral	O
interventions	O
and	O
biomedical	O
treatment	B-T061
preventions	I-T061
is	O
needed	O
.	O
      
Establishing	O
in-	O
hospital	O
geriatrics	O
services	O
in	O
Africa	O
:	O
Insights	O
from	O
the	O
University	O
of	O
Benin	O
Teaching	O
Hospital	O
geriatrics	O
project	O
Unawareness	O
of	O
the	O
peculiar	O
healthcare	B-T058
needs	O
of	O
the	O
elderly	O
and	O
resource	O
constraints	O
may	O
be	O
some	O
reasons	O
why	O
until	O
recently	O
,	O
Nigerian	O
hospitals	O
have	O
not	O
been	O
equipped	O
with	O
the	O
human	O
and	O
infrastructural	O
resources	O
required	O
to	O
meet	O
older	O
adults	O
'	O
special	O
healthcare	B-T058
needs	O
.	O
There	O
is	O
paucity	O
of	O
specialized	O
health	O
services	O
for	O
the	O
elderly	O
in	O
Africa	O
.	O
Nigeria	O
,	O
with	O
a	O
population	O
of	O
over	O
170	O
million	O
,	O
did	O
not	O
have	O
any	O
healthcare	O
facility	O
with	O
dedicated	O
services	B-T058
for	O
the	O
elderly	O
until	O
2012	O
.	O
The	O
University	O
of	O
Benin	O
Teaching	O
Hospital	O
(	O
UBTH	O
)	O
in	O
Nigeria	O
was	O
established	O
in	O
1973	O
and	O
created	O
its	O
geriatrics	O
unit	O
in	O
October	O
2013	O
.	O
A	O
prepared	O
environment	O
and	O
trained	B-T058
interdisciplinary	I-T058
teams	I-T058
are	O
pivotal	O
in	O
providing	O
effective	O
healthcare	O
services	O
for	O
the	O
elderly	O
.	O
The	O
ongoing	O
UBTH	O
geriatrics	O
project	O
aims	O
to	O
provide	O
specialized	O
interdisciplinary	B-T058
health	B-T058
services	I-T058
to	O
older	O
adults	O
and	O
to	O
provide	O
training	O
and	O
continuing	O
professional	O
development	O
in	O
geriatrics	O
for	O
healthcare	O
staff	O
.	O
In	O
developing	O
our	O
inpatient	O
services	B-T058
,	O
we	O
adopted	O
the	O
acute	B-T058
care	I-T058
for	I-T058
elders	I-T058
(	O
ACE	B-T058
)	O
model	O
and	O
worked	O
in	O
tandem	O
with	O
the	O
"	O
ABCs	O
"	O
of	O
implementing	O
ACE	O
units	O
.	O
In	O
the	O
face	O
of	O
limited	O
resources	O
,	O
it	O
was	O
possible	O
to	O
establish	O
a	O
functional	O
geriatrics	O
unit	O
with	O
a	O
trained	O
interdisciplinary	B-T058
team	I-T058
.	O
Family	O
participation	O
is	O
central	O
in	O
our	O
practice	O
.	O
Since	O
October	O
2013	O
,	O
residents	O
and	O
house	O
officers	O
in	O
internal	B-T121
medicine	I-T121
have	O
been	O
undertaking	O
4-	O
and	O
12-	O
weekly	O
rotations	O
,	O
respectively	O
.	O
There	O
is	O
also	O
a	O
robust	O
academic	B-T033
program	I-T033
,	O
which	O
includes	O
once-	O
weekly	O
geriatric	O
pharmacotherapy	B-T061
seminars	B-T058
,	O
once-	O
weekly	O
interdisciplinary	O
seminars	B-T058
,	O
and	O
2-	O
weekly	O
journal	O
club	O
meetings	O
alternating	O
with	O
seminars	B-T058
on	O
geriatric	O
assessment	O
tools	O
.	O
It	O
is	O
possible	O
to	O
establish	O
geriatric	O
services	O
and	O
achieve	O
best	O
practices	O
in	O
resource	O
-	O
limited	O
settings	O
by	O
investing	O
on	O
improving	O
available	O
human	O
resources	O
and	O
infrastructure	O
.	O
We	O
also	O
make	O
recommendations	O
for	O
setting	O
up	O
similar	O
services	O
in	O
other	O
parts	O
of	O
Africa	O
.	O
      
Heterogeneity	O
of	O
colorectal	B-T191
cancer	I-T191
risk	O
by	O
tumour	B-T191
characteristics	O
:	O
Large	O
prospective	O
study	O
of	O
UK	O
women	O
Associations	O
between	O
behavioural	O
and	O
other	O
personal	O
factors	O
and	O
colorectal	B-T191
cancer	I-T191
risk	O
have	O
been	O
reported	O
to	O
vary	O
by	O
tumour	B-T191
characteristics	O
,	O
but	O
evidence	O
is	O
inconsistent	O
.	O
In	O
a	O
large	O
UK	O
-based	O
prospective	O
study	O
we	O
examined	O
associations	O
of	O
14	O
postulated	O
risk	B-T033
factors	I-T033
with	O
colorectal	B-T191
cancer	I-T191
risk	O
overall	O
,	O
and	O
across	O
three	O
anatomical	O
sites	O
and	O
four	O
morphological	O
subtypes	O
.	O
Among	O
1.3	O
million	O
women	O
,	O
18,518	O
incident	O
colorectal	B-T191
cancers	I-T191
were	O
identified	O
during	O
13.8	O
(	O
SD	O
3.4	O
)	O
years	O
follow	B-T058
-	I-T058
up	I-T058
via	O
record	O
linkage	O
to	O
national	O
cancer	O
registry	O
data	O
.	O
Cox	O
regression	O
yielded	O
adjusted	O
relative	O
risks	O
.	O
Statistical	O
significance	O
was	O
assessed	O
using	O
correction	O
for	O
multiple	O
testing	O
.	O
Overall	O
,	O
colorectal	B-T191
cancer	I-T191
risk	O
was	O
significantly	O
associated	O
with	O
height	O
,	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
,	O
smoking	O
,	O
alcohol	O
intake	O
,	O
physical	O
activity	O
,	O
parity	B-T033
and	O
menopausal	B-T061
hormone	I-T061
therapy	I-T061
use	O
.	O
For	O
smoking	O
there	O
was	O
substantial	O
heterogeneity	O
across	O
morphological	O
types	O
;	O
relative	O
risks	O
around	O
two	O
or	O
greater	O
were	O
seen	O
in	O
current	O
smokers	B-T033
both	O
for	O
signet	O
ring	O
cell	O
and	O
for	O
neuroendocrine	B-T191
tumours	I-T191
.	O
Obese	B-T047
women	O
were	O
also	O
at	B-T033
higher	I-T033
risk	I-T033
for	O
signet	O
ring	O
cell	O
tumours	B-T191
.	O
For	O
adenocarcinomas	B-T191
,	O
the	O
large	O
majority	O
of	O
colorectal	B-T191
cancers	I-T191
in	O
the	O
cohort	O
,	O
all	O
risk	B-T033
factor	I-T033
associations	O
were	O
weak	O
.	O
There	O
was	O
little	O
or	O
no	O
heterogeneity	O
in	O
risk	O
between	O
tumours	B-T191
of	O
the	O
right	B-T023
colon	I-T023
,	O
left	B-T023
colon	I-T023
and	O
rectum	B-T023
for	O
any	O
of	O
the	O
14	O
factors	B-T033
examined	O
.	O
These	O
epidemiological	O
findings	B-T033
complement	O
an	O
emerging	O
picture	O
from	O
molecular	O
studies	O
of	O
possible	O
different	O
developmental	O
pathways	O
for	O
different	O
tumour	B-T191
types	O
.	O
      
Ecotoxicity	O
testing	O
and	O
environmental	B-T058
risk	I-T058
assessment	I-T058
of	O
iron	B-T121
nanomaterials	O
for	O
sub	O
-	O
surface	O
remediation	O
-	O
Recommendations	O
from	O
the	O
FP7	O
project	O
NanoRem	O
Nanoremediation	O
with	O
iron	B-T121
(	O
Fe	B-T121
)	O
nanomaterials	O
opens	O
new	O
doors	O
for	O
treating	O
contaminated	O
soil	O
and	O
groundwater	B-T121
,	O
but	O
is	O
also	O
accompanied	O
by	O
new	O
potential	O
risks	O
as	O
large	O
quantities	O
of	O
engineered	O
nanomaterials	O
are	O
introduced	O
into	O
the	O
environment	O
.	O
In	O
this	O
study	O
,	O
we	O
have	O
assessed	O
the	O
ecotoxicity	O
of	O
four	O
engineered	O
Fe	B-T121
nanomaterials	O
,	O
specifically	O
,	O
Nano	O
-	O
Goethite	O
,	O
Trap	B-T121
-	I-T121
Ox	I-T121
Fe	I-T121
-	I-T121
zeolites	I-T121
,	O
Carbo	B-T121
-	I-T121
Iron	I-T121
(	O
®	O
)	O
and	O
FerMEG12	B-T121
,	O
developed	O
within	O
the	O
European	O
FP7	O
project	O
NanoRem	O
for	O
sub	O
-	O
surface	O
remediation	O
towards	O
a	O
test	B-T059
battery	I-T059
consisting	O
of	O
eight	O
ecotoxicity	O
tests	B-T059
on	O
bacteria	B-T007
(	O
V.	B-T007
fisheri	I-T007
,	O
E.	B-T007
coli	I-T007
)	O
,	O
algae	O
(	O
P.	O
subcapitata	O
,	O
Chlamydomonas	O
sp	O
.	O
)	O
,	O
crustaceans	O
(	O
D.	O
magna	O
)	O
,	O
worms	O
(	O
E.	O
fetida	O
,	O
L.	O
variegatus	O
)	O
and	O
plants	O
(	O
R.	O
sativus	O
,	O
L.	O
multiflorum	O
)	O
.	O
The	O
tested	O
materials	O
are	O
commercially	O
available	O
and	O
include	O
Fe	B-T121
oxide	I-T121
and	O
nanoscale	B-T121
zero	I-T121
valent	I-T121
iron	I-T121
(	O
nZVI	B-T121
)	O
,	O
but	O
also	O
hybrid	O
products	O
with	O
Fe	B-T121
loaded	O
into	O
a	O
matrix	O
.	O
All	O
but	O
one	O
material	O
,	O
a	O
ball	B-T121
milled	I-T121
nZVI	I-T121
(	O
FerMEG12	B-T121
)	O
,	O
showed	O
no	B-T033
toxicity	I-T033
in	O
the	O
test	B-T059
battery	I-T059
when	O
tested	O
in	O
concentrations	O
up	O
to	O
100	O
mg	O
/	O
L	O
,	O
which	O
is	O
the	O
cutoff	O
for	O
hazard	O
labeling	O
in	O
chemicals	O
regulation	O
in	O
Europe	O
.	O
However	O
it	O
should	O
be	O
noted	O
that	O
Fe	B-T121
nanomaterials	O
proved	O
challenging	O
to	O
test	O
adequately	O
due	O
to	O
their	O
turbidity	O
,	O
aggregation	O
and	O
sedimentation	O
behavior	O
in	O
aqueous	O
media	O
.	O
This	O
paper	O
provides	O
a	O
number	O
of	O
recommendations	O
concerning	O
future	O
testing	O
of	O
Fe	B-T121
nanomaterials	O
and	O
discusses	O
environmental	B-T058
risk	I-T058
assessment	I-T058
considerations	O
related	O
to	O
these	O
.	O
      
Microbiology	B-T059
of	O
the	O
Upper	O
and	O
Lower	O
Airways	O
in	O
Pediatric	O
Cystic	B-T047
Fibrosis	I-T047
Patients	O
Objective	O
To	O
evaluate	O
the	O
microbiology	O
of	O
the	O
upper	O
and	O
lower	O
airways	O
in	O
pediatric	O
cystic	B-T047
fibrosis	I-T047
(	O
CF	B-T047
)	O
patients	O
who	O
underwent	O
sinus	B-T061
surgery	I-T061
.	O
Study	O
Design	O
Retrospective	O
case	O
series	O
with	O
chart	O
review	O
.	O
Setting	O
Tertiary	O
care	O
children	O
's	O
hospital	O
.	O
Subjects	O
and	O
Methods	O
A	O
total	O
of	O
201	O
paired	O
sinus	B-T059
and	O
pulmonary	B-T059
cultures	I-T059
from	O
105	O
CF	B-T047
patients	O
were	O
identified	O
between	O
1996	O
and	O
2014	O
.	O
Demographics	O
and	O
culture	B-T059
results	O
were	O
analyzed	O
.	O
Results	O
The	O
mean	O
age	O
of	O
patients	O
was	O
11.2	O
±	O
5.4	O
years	O
(	O
range	O
,	O
1	O
-	O
27	O
years	O
)	O
,	O
and	O
approximately	O
one	O
-	O
half	O
were	O
female	O
.	O
Methicillin	B-T195
-	O
sensitive	O
Staphylococcus	B-T007
aureus	I-T007
was	O
the	O
most	O
common	O
pathogen	B-T001
overall	O
.	O
A	O
significantly	O
higher	O
prevalence	O
of	O
Pseudomonas	B-T007
aeruginosa	I-T007
(	O
32	O
%	O
for	O
pulmonary	B-T059
and	O
37	O
%	O
for	O
sinus	B-T059
cultures	I-T059
)	O
was	O
observed	O
in	O
older	O
patients	O
versus	O
younger	O
patients	O
(	O
P	O
<	O
.001	O
)	O
.	O
There	O
was	O
low	O
to	O
moderate	O
agreement	O
between	O
sinus	B-T059
and	O
pulmonary	B-T059
cultures	I-T059
(	O
Kappa	O
statistic	O
range	O
,	O
0.03	O
-	O
0.56	O
)	O
.	O
The	O
prevalence	O
of	O
methicillin	B-T007
-	I-T007
resistant	I-T007
S	I-T007
aureus	I-T007
(	O
MRSA	B-T007
)	O
increased	O
significantly	O
for	O
lower	B-T059
respiratory	I-T059
tract	I-T059
culture	I-T059
(	O
from	O
5	O
%	O
to	O
16	O
%	O
)	O
and	O
sinus	B-T059
culture	I-T059
(	O
from	O
5	O
%	O
to	O
27	O
%	O
)	O
between	O
1996	O
-	O
2004	O
and	O
2010	O
-	O
2014	O
(	O
P	O
=	O
.016	O
and	O
P	O
<	O
.001	O
,	O
respectively	O
)	O
.	O
The	O
prevalence	O
of	O
positive	B-T033
sinus	B-T059
cultures	I-T059
increased	O
from	O
40	O
%	O
to	O
85	O
%	O
between	O
1996	O
-	O
2004	O
and	O
2010	O
-	O
2014	O
(	O
P	O
=	O
.018	O
)	O
.	O
Patients	O
with	O
pulmonary	O
MRSA	B-T007
were	O
more	O
likely	O
to	O
be	O
coinfected	B-T047
with	O
pulmonary	O
P	B-T007
aeruginosa	I-T007
(	O
risk	O
ratio	O
,	O
2.4	O
;	O
95	O
%	O
CI	O
,	O
1.2	O
-	O
4.8	O
;	O
P	O
=	O
.015	O
)	O
or	O
Aspergillus	O
fumigatus	O
(	O
risk	O
ratio	O
,	O
2.2	O
;	O
95	O
%	O
CI	O
,	O
1.2	O
-	O
4.8	O
;	O
P	O
=	O
.035	O
)	O
.	O
Conclusions	O
There	O
is	O
low	O
to	O
moderate	O
correlation	O
between	O
pulmonary	O
and	O
sinus	O
pathogens	B-T001
in	O
CF	B-T047
patients	O
.	O
This	O
is	O
important	O
to	O
consider	O
when	O
treating	B-T061
infections	O
.	O
The	O
prevalence	O
of	O
MRSA	B-T007
in	O
sinus	B-T059
cultures	I-T059
has	O
increased	O
over	O
time	O
and	O
warrants	O
further	O
investigation	B-T058
.	O
      
Interprofessional	O
primary	B-T058
care	I-T058
team	B-T058
meetings	I-T058
:	O
a	O
qualitative	O
approach	O
comparing	O
observations	O
with	O
personal	O
opinions	O
The	O
number	O
of	O
people	O
with	O
multiple	B-T047
chronic	I-T047
conditions	I-T047
requiring	O
primary	B-T058
care	I-T058
services	I-T058
increases	O
.	O
Professionals	O
from	O
different	O
disciplines	O
collaborate	O
and	O
coordinate	O
care	O
to	O
deal	O
with	O
the	O
complex	O
health	B-T058
care	I-T058
needs	I-T058
.	O
There	O
is	O
lack	O
of	O
information	O
on	O
current	O
practices	O
regarding	O
interprofessional	O
team	B-T058
(	I-T058
IPT	I-T058
)	I-T058
meetings	I-T058
.	O
This	O
study	O
aimed	O
to	O
improve	O
our	O
understanding	O
of	O
the	O
process	O
of	O
interprofessional	O
collaboration	O
in	O
primary	B-T058
care	I-T058
team	B-T058
meetings	I-T058
in	O
the	O
Netherlands	O
by	O
observing	O
the	O
current	O
practice	O
and	O
exploring	O
personal	O
opinions	O
.	O
Qualitative	O
study	O
involving	O
observations	O
of	O
team	B-T058
meeting	I-T058
s	O
and	O
interviews	B-T058
with	O
participants	O
.	O
Eight	O
different	O
IPT	B-T058
meetings	I-T058
(	O
n	O
=	O
8)	O
in	O
different	O
primary	B-T058
care	I-T058
practices	I-T058
were	O
observed	O
by	O
means	O
of	O
video	O
recordings	O
.	O
Experiences	O
were	O
explored	O
by	O
conducting	O
individual	O
semi	O
-	O
structured	O
interviews	O
(	O
n	O
=	O
60	O
)	O
with	O
participants	O
(	O
i.e.	O
health	O
care	O
professionals	O
from	O
different	O
disciplines	O
)	O
of	O
the	O
observed	O
team	B-T058
meetings	I-T058
.	O
The	O
data	O
were	O
analysed	O
by	O
means	O
of	O
content	O
analysis	O
.	O
Most	O
participants	O
expressed	O
favourable	O
opinions	O
about	O
their	O
team	B-T058
meetings	I-T058
.	O
However	O
,	O
observations	O
showed	O
that	O
team	B-T058
meetings	I-T058
were	O
more	O
or	O
less	O
hectic	O
,	O
and	O
lacked	O
a	O
clear	O
structure	O
and	O
team	O
coordinator	O
or	O
leader	O
.	O
There	O
appears	O
to	O
be	O
a	O
discrepancy	B-T033
between	O
findings	B-T033
from	O
observations	O
and	O
interviews	O
.	O
From	O
the	O
interviews	O
,	O
four	O
main	O
themes	O
were	O
extracted	O
:	O
(	O
1	O
)	O
Team	O
structure	O
and	O
composition	O
,	O
(	O
2	O
)	O
Patient	B-T058
-	I-T058
centredness	I-T058
,	O
(	O
3	O
)	O
Interaction	O
and	O
(	O
4	O
)	O
Attitude	O
and	O
motivation	O
.	O
IPT	B-T058
meetings	I-T058
could	O
benefit	O
from	O
improvements	O
in	O
structure	O
,	O
patient	B-T058
-	I-T058
centredness	I-T058
and	O
leadership	O
by	O
the	O
chairpersons	O
.	O
Given	O
the	O
discrepancy	B-T033
between	O
observations	O
and	O
interviews	O
,	O
it	O
would	O
appear	O
useful	O
to	O
improve	O
team	O
members	O
'	O
awareness	O
of	O
aspects	O
that	O
could	O
be	O
improved	O
before	O
training	O
them	O
in	O
dealing	O
with	O
specific	O
challenges	B-T058
.	O
      
Experiences	O
of	O
support	O
in	O
working	O
toward	O
personal	O
recovery	O
goals	O
:	O
a	O
collaborative	O
,	O
qualitative	O
study	O
Recovery	O
can	O
be	O
understood	O
as	O
a	O
subjective	O
process	O
guided	O
by	O
personal	O
expectations	O
,	O
goals	O
and	O
hopes	O
.	O
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
explore	O
how	O
persons	O
using	O
a	O
Community	O
Mental	O
Health	O
Centre	O
(	O
CMHC	O
)	O
experienced	O
that	O
their	O
expectations	O
for	O
treatment	B-T061
,	O
and	O
goals	O
and	O
hopes	O
for	O
recovery	O
were	O
supported	O
by	O
the	O
health	O
professionals	O
during	O
treatment	B-T061
.	O
Employing	O
a	O
hermeneutic	O
-phenomenological	O
approach	O
,	O
eight	O
service	O
users	O
were	O
interviewed	O
about	O
their	O
expectations	O
for	O
treatment	B-T061
and	O
their	O
goals	O
and	O
hopes	O
for	O
recovery	O
at	O
the	O
start	O
of	O
their	O
contact	O
with	O
health	O
professionals	O
at	O
a	O
CMHC	O
.	O
Two	O
years	O
later	O
,	O
they	O
were	O
re	O
-	O
interviewed	O
about	O
their	O
experiences	O
of	O
treatment	B-T061
and	O
support	O
from	O
the	O
health	O
professionals	O
in	O
their	O
work	O
towards	O
these	O
goals	O
and	O
hopes	O
.	O
A	O
collaborative	O
approach	O
was	O
adopted	O
.	O
A	O
co	O
-	O
researcher	O
with	O
lived	O
experience	O
took	O
part	O
in	O
all	O
stages	O
of	O
the	O
study	O
.	O
Data	O
were	O
analysed	O
by	O
means	O
of	O
a	O
data	O
-driven	O
stepwise	O
approach	O
in	O
line	O
with	O
thematic	O
analysis	O
.	O
Five	O
themes	O
reflecting	O
how	O
participants	O
experienced	O
support	O
from	O
health	O
professionals	O
at	O
the	O
CMHC	O
in	O
their	O
work	O
towards	O
their	O
recovery	O
goals	O
were	O
elicited	O
,	O
as	O
follows	O
:	O
developing	O
an	O
understanding	O
of	O
oneself	O
and	O
one	O
's	O
mental	B-T033
health	I-T033
problems	I-T033
;	O
learning	O
how	O
to	O
change	O
feelings	O
and	O
behaviours	O
;	O
being	B-T033
'	I-T033
pushed	I-T033
'	I-T033
into	I-T033
social	I-T033
arenas	I-T033
;	O
finding	B-T033
helpful	I-T033
medication	I-T033
;	O
and	O
counselling	B-T058
in	O
family	B-T033
,	O
practical	B-T033
and	O
financial	B-T033
issues	I-T033
.	O
The	O
participants	O
'	O
expectations	O
about	O
counselling	B-T058
with	O
regard	O
to	O
longer	O
-	O
term	O
family	B-T033
,	O
practical	B-T033
,	O
and	O
financial	B-T033
challenges	I-T033
were	O
insufficiently	O
met	O
by	O
the	O
CMHC	O
.	O
In	O
the	O
experience	O
of	O
the	O
service	O
users	O
,	O
recovery	O
occurred	O
within	O
the	O
context	O
of	O
their	O
everyday	O
life	O
with	O
or	O
without	O
the	O
support	O
of	O
their	O
professional	O
helpers	O
.	O
To	O
facilitate	O
recovery	O
,	O
health	O
professionals	O
should	O
acknowledge	O
the	O
service	O
user	O
's	O
personal	O
goals	O
and	O
hopes	O
and	O
take	O
a	O
more	O
comprehensive	O
and	O
longer	O
-	O
term	O
approach	O
to	O
his	O
or	O
her	O
needs	O
and	O
desires	O
.	O
Acknowledging	O
and	O
facilitating	O
recovery	O
goals	O
by	O
offering	O
counselling	B-T058
with	O
regard	O
to	O
family	B-T033
,	O
practical	B-T033
and	O
financial	B-T033
issues	I-T033
seems	O
particularly	O
important	O
.	O
      
Back	O
to	O
the	O
Roots	O
:	O
Deep	O
View	O
into	O
the	O
Evolutionary	O
History	O
of	O
ADP	O
-	O
Ribosylation	O
Opened	O
by	O
the	O
DNA	O
-	O
Targeting	O
Toxin	O
-	O
Antitoxin	B-T121
Module	O
DarTG	O
In	O
this	O
issue	O
of	O
Molecular	O
Cell	O
,	O
Jankevicius	O
et	O
al	O
.	O
(	O
2016	O
)	O
characterize	O
the	O
DarTG	O
toxin	O
-	O
antitoxin	B-T121
module	O
in	O
which	O
the	O
DarT	O
toxin	O
ADP	O
-	O
ribosylates	O
single	O
-	O
stranded	O
DNA	O
and	O
the	O
DarG	O
antitoxin	B-T121
counteracts	O
DarT	O
by	O
direct	O
binding	O
and	O
by	O
enzymatic	O
remova	O
l	O
of	O
the	O
ADP	O
-	O
ribosylation	O
.	O
      
The	O
FLASHE	O
Study	O
:	O
Survey	O
Development	O
,	O
Dyadic	O
Perspectives	O
,	O
and	O
Participant	O
Characteristics	O
The	O
National	O
Cancer	O
Institute	O
developed	O
the	O
Family	O
Life	O
,	O
Activity	O
,	O
Sun	O
,	O
Health	O
,	O
and	O
Eating	O
(	O
FLASHE	O
)	O
Study	O
to	O
examine	O
multiple	O
cancer	B-T061
preventive	I-T061
behaviors	O
within	O
parent	O
-	O
adolescent	O
dyads	O
.	O
The	O
purpose	O
of	O
creating	O
FLASHE	O
was	O
to	O
enable	O
the	O
examination	O
of	O
physical	O
activity	O
,	O
diet	O
,	O
and	O
other	O
cancer	B-T061
preventive	I-T061
behaviors	I-T061
and	O
potential	O
correlates	O
among	O
parent	O
-	O
adolescent	O
dyads	O
.	O
FLASHE	O
surveys	O
were	O
developed	O
from	O
a	O
process	O
involving	O
literature	O
reviews	O
,	O
scientific	O
input	O
from	O
experts	O
in	O
the	O
field	O
,	O
cognitive	B-T060
testing	I-T060
,	O
and	O
usability	O
testing	O
.	O
This	O
cross	O
-	O
sectional	O
,	O
web	O
-	O
based	O
study	O
of	O
parents	O
and	O
their	O
adolescent	O
children	O
(	O
aged	O
12	O
-	O
17	O
years	O
)	O
was	O
administered	O
between	O
April	O
and	O
October	O
2014	O
.	O
The	O
nationwide	O
sample	O
consisted	O
of	O
1,573	O
parent	O
-	O
adolescent	O
dyads	O
(	O
1,699	O
parents	O
and	O
1,581	O
adolescents	O
)	O
who	O
returned	O
all	O
FLASHE	O
surveys	O
.	O
FLASHE	O
assessed	O
parent	O
and	O
adolescent	O
reports	O
of	O
several	O
intrapersonal	O
and	O
interpersonal	O
domains	O
(	O
including	O
psychosocial	O
variables	O
,	O
parenting	O
,	O
and	O
the	O
community	O
and	O
home	O
environments	O
)	O
.	O
On	O
a	O
subset	O
of	O
example	O
FLASHE	O
items	O
across	O
these	O
domains	O
,	O
responses	O
of	O
parents	O
and	O
adolescents	O
within	O
the	O
same	O
dyads	O
were	O
positively	O
and	O
significantly	O
correlated	O
(	O
r	O
=	O
0.32	O
-	O
0.63	O
)	O
.	O
Analyses	O
were	O
run	O
in	O
2015	O
-	O
2016	O
.	O
FLASHE	O
data	O
present	O
multiple	O
opportunities	O
for	O
studying	O
research	O
questions	O
among	O
individuals	O
or	O
dyads	O
,	O
including	O
the	O
ability	O
to	O
examine	O
similarity	O
between	O
parents	O
and	O
adolescents	O
on	O
many	O
constructs	O
relevant	O
to	O
cancer	B-T061
preventive	I-T061
behaviors	I-T061
.	O
FLASHE	O
data	O
are	O
publicly	O
available	O
for	O
researchers	O
and	O
practitioners	O
to	O
help	O
advance	O
research	O
on	O
cancer	B-T061
preventive	I-T061
health	O
behaviors	O
.	O
      
The	O
AGES	O
-	O
Reykjavik	O
study	O
atlases	O
:	O
Non	O
-	O
linear	O
multi	O
-	O
spectral	O
template	O
and	O
atlases	O
for	O
studies	O
of	O
the	O
ageing	O
brain	B-T023
Quantitative	O
analyses	O
of	O
brain	B-T023
structures	O
from	O
Magnetic	B-T060
Resonance	I-T060
(	O
MR	B-T060
)	O
image	B-T060
data	O
are	O
often	O
performed	O
using	O
automatic	O
segmentation	O
algorithms	O
.	O
Many	O
of	O
these	O
algorithms	O
rely	O
on	O
templates	O
and	O
atlases	O
in	O
a	O
common	O
coordinate	O
space	O
.	O
Most	O
freely	O
available	O
brain	B-T023
atlases	O
are	O
generated	O
from	O
relatively	O
young	O
individuals	O
and	O
not	O
always	O
derived	O
from	O
well	O
-	O
defined	O
cohort	O
studies	O
.	O
In	O
this	O
paper	O
,	O
we	O
introduce	O
a	O
publicly	O
available	O
multi	O
-	O
spectral	O
template	O
with	O
corresponding	O
tissue	O
probability	O
atlases	O
and	O
regional	O
atlases	O
,	O
optimised	O
to	O
use	O
in	O
studies	O
of	O
ageing	O
cohorts	O
(	O
mean	O
age	O
75	O
±	O
5	O
years	O
)	O
.	O
Furthermore	O
,	O
we	O
provide	O
validation	O
data	O
from	O
a	O
regional	O
segmentation	O
pipeline	O
to	O
assure	O
the	O
integrity	O
of	O
the	O
dataset	O
.	O
      
Dominant	B-T033
and	O
Non-	O
Dominant	B-T033
Frequency	O
Structure	O
of	O
Evoked	O
Ventricular	B-T047
Fibrillation	I-T047
in	O
Dogs	O
with	O
Myocardial	B-T047
Ischemia	I-T047
The	O
first	O
10	O
min	O
of	O
electrically	B-T061
provoked	I-T061
ventricular	B-T047
fibrillation	I-T047
in	O
dogs	O
with	O
ischemic	B-T047
heart	I-T047
disease	I-T047
were	O
characterized	O
by	O
organized	O
myocardial	O
activity	O
evidenced	O
by	O
the	O
dominant	B-T033
ECG	I-T033
frequency	I-T033
structure	O
.	O
During	O
the	O
first	O
2	O
min	O
of	O
ventricular	B-T047
fibrillation	I-T047
,	O
low	O
-	O
frequency	O
oscillations	O
(	O
4	O
-	O
7	O
Hz	O
)	O
dominated	O
,	O
while	O
on	O
min	O
3	O
to	O
10	O
after	O
the	O
onset	O
of	O
fibrillation	B-T047
,	O
the	O
dominant	B-T033
frequencies	I-T033
were	O
low	O
and	O
medium	O
(	O
4	O
-	O
12	O
Hz	O
)	O
.	O
After	O
10	O
-	O
min	O
fibrillation	B-T047
,	O
the	O
oscillations	B-T061
became	O
non-	O
dominant	B-T033
.	O
Thus	O
,	O
ischemic	B-T033
myocardium	I-T033
maintains	O
the	O
organized	O
structure	O
of	O
ventricular	B-T047
fibrillation	I-T047
for	O
the	O
first	O
10	O
min	O
,	O
which	O
is	O
important	O
for	O
the	O
development	O
of	O
automatic	B-T060
diagnostics	I-T060
of	O
abnormal	B-T033
cardiac	I-T033
activity	I-T033
in	O
humans	O
.	O
      
Evaluation	O
of	O
Three	O
Protein	B-T059
-	I-T059
Extraction	I-T059
Methods	I-T059
for	O
Proteome	O
Analysis	B-T059
of	O
Maize	O
Leaf	O
Midrib	O
,	O
a	O
Compound	O
Tissue	O
Rich	O
in	O
Sclerenchyma	O
Cells	O
Leaf	O
morphology	O
is	O
closely	O
related	O
to	O
the	O
growth	O
and	O
development	O
of	O
maize	O
(	O
Zea	O
mays	O
L.	O
)	O
plants	O
and	O
final	O
kernel	O
production	O
.	O
As	O
an	O
important	O
part	O
of	O
the	O
maize	O
leaf	O
,	O
the	O
midrib	O
holds	O
leaf	O
blades	O
in	O
the	O
aerial	O
position	O
for	O
maximum	O
sunlight	O
capture	O
.	O
Leaf	O
midrib	O
s	O
of	O
adult	O
plants	O
contain	O
substantial	O
sclerenchyma	O
cells	O
with	O
heavily	O
thickened	O
and	O
lignified	O
secondary	O
walls	O
and	O
have	O
a	O
high	O
amount	O
of	O
phenolics	B-T121
,	O
making	O
protein	B-T059
extraction	I-T059
and	O
proteome	O
analysis	B-T059
difficult	O
in	O
leaf	O
midrib	O
tissue	O
.	O
In	O
the	O
present	O
study	O
,	O
three	O
protein	B-T059
-	I-T059
extraction	I-T059
methods	I-T059
that	O
are	O
commonly	O
used	O
in	O
plant	O
proteomics	O
,	O
i.e.	O
,	O
phenol	B-T121
extraction	B-T059
,	O
TCA	B-T121
/	O
acetone	B-T121
extraction	B-T059
,	O
and	O
TCA	B-T121
/	O
acetone	B-T121
/	O
phenol	B-T121
extraction	B-T059
,	O
were	O
qualitatively	O
and	O
quantitatively	O
evaluated	O
based	O
on	O
2DE	O
maps	O
and	O
MS	B-T059
/	I-T059
MS	I-T059
analysis	I-T059
using	O
the	O
midribs	O
of	O
the	O
10th	O
newly	O
expanded	O
leaves	O
of	O
maize	O
plants	O
.	O
Microscopy	B-T059
revealed	O
the	O
existence	O
of	O
substantial	O
amounts	O
of	O
sclerenchyma	O
underneath	O
maize	O
midrib	O
epidermises	O
(	O
particularly	O
abaxial	O
epidermises	O
)	O
.	O
The	O
spot	O
-	O
number	O
order	O
obtained	O
via	O
2DE	B-T059
mapping	I-T059
was	O
as	O
follows	O
:	O
phenol	B-T121
extraction	B-T059
(	O
655	O
)	O
>	O
TCA	B-T121
/	O
acetone	B-T121
extraction	B-T059
(	O
589	O
)	O
>	O
TCA	B-T121
/	O
acetone	B-T121
/	O
phenol	B-T121
extraction	B-T059
(	O
545	O
)	O
.	O
MS	B-T059
/	I-T059
MS	I-T059
analysis	I-T059
identified	O
a	O
total	O
of	O
17	O
spots	O
that	O
exhibited	O
2	O
-	O
fold	O
changes	O
in	O
abundance	O
among	O
the	O
three	O
methods	O
(	O
using	O
phenol	B-T121
extraction	B-T059
as	O
a	O
control	O
)	O
.	O
Sixteen	O
of	O
the	O
proteins	O
identified	O
were	O
hydrophilic	O
,	O
with	O
GRAVY	O
values	O
ranging	O
from	O
-0.026	O
to	O
-0.487	O
.	O
For	O
all	O
three	O
methods	O
,	O
we	O
were	O
able	O
to	O
obtain	O
high	O
-	O
quality	O
protein	O
samples	O
and	O
good	O
2DE	B-T059
maps	I-T059
for	O
the	O
maize	O
leaf	O
midrib	O
.	O
However	O
,	O
phenol	B-T121
extraction	B-T059
produced	O
a	O
better	O
2DE	B-T059
map	I-T059
with	O
greater	O
resolution	O
between	O
spots	O
,	O
and	O
TCA	B-T121
/	O
acetone	B-T121
extraction	B-T059
produced	O
higher	O
protein	O
yields	O
.	O
Thus	O
,	O
this	O
paper	O
includes	O
a	O
discussion	O
regarding	O
the	O
possible	O
reasons	O
for	O
differential	O
protein	B-T059
extraction	I-T059
among	O
the	O
three	O
methods	O
.	O
This	O
study	O
provides	O
useful	O
information	O
that	O
can	O
be	O
used	O
to	O
select	O
suitable	O
protein	B-T059
extraction	I-T059
methods	O
for	O
the	O
proteome	O
analysis	B-T059
of	O
recalcitrant	O
plant	O
tissues	O
that	O
are	O
rich	O
in	O
sclerenchyma	O
cells	O
.	O
      
Genome	O
Sequences	O
of	O
Mycobacteriophages	B-T005
Jane	I-T005
and	I-T005
Sneeze	I-T005
,	O
New	O
Members	O
of	O
Cluster	O
G	O
Jane	O
and	O
Sneeze	O
are	O
newly	O
isolated	O
phages	B-T005
of	O
Mycobacterium	B-T007
smegmatis	I-T007
mc(2)155	I-T007
from	O
Hillsborough	O
,	O
NJ	O
,	O
and	O
Palo	O
Verde	O
,	O
Costa	O
Rica	O
,	O
respectively	O
.	O
Both	O
are	O
cluster	O
G	O
,	O
subcluster	O
G1	O
mycobacteriophages	B-T005
.	O
Notable	O
nucleotide	O
differences	O
exist	O
between	O
genomes	O
in	O
the	O
right	O
half	O
,	O
including	O
the	O
presence	O
of	O
mycobacteriophage	B-T005
mobile	O
element	O
1	O
(	O
MPME1	O
)	O
in	O
Jane	O
.	O
      
Thermo	O
-	O
reversible	O
capture	O
and	O
release	O
of	O
DNA	O
by	O
zwitterionic	O
surfactants	O
The	O
thermo	O
-	O
reversible	O
capture	O
and	O
release	O
of	O
DNA	O
were	O
studied	O
by	O
the	O
protonation	O
and	O
deprotonation	O
of	O
alkyldimethylamine	O
oxide	O
(	O
CnDMAO	O
,	O
n	O
=	O
10	O
,	O
12	O
and	O
14	O
)	O
in	O
Tris	O
-	O
HCl	O
buffer	O
solution	O
.	O
DNA	O
/	O
C14DMAO	O
in	O
Tris	O
-	O
HCl	O
buffer	O
solution	O
with	O
pH	O
=	O
7.2	O
is	O
transparent	O
at	O
25	O
°	O
C	O
,	O
indicating	O
that	O
DNA	O
molecules	O
exist	O
mainly	O
in	O
individuals	O
and	O
the	O
binding	O
of	O
C14DMAO	O
is	O
weak	O
.	O
With	O
the	O
increase	O
of	O
temperature	O
,	O
the	O
pH	O
of	O
the	O
buffer	O
solution	O
continuously	O
decreases	O
,	O
which	O
leads	O
to	O
protonation	O
of	O
C14DMAO	O
(	O
C14DMAO	O
+	O
H(+	O
)	O
→	O
C14DMAOH(+	O
)	O
)	O
and	O
an	O
obvious	O
increase	B-T033
of	I-T033
the	I-T033
turbidity	I-T033
of	O
the	O
samples	O
.	O
This	O
indicates	O
a	O
stronger	O
binding	O
of	O
the	O
protonated	O
C14DMAOH(+	O
)	O
to	O
DNA	O
.	O
Further	O
investigations	O
demonstrated	O
the	O
formation	O
of	O
DNA	O
/	O
C14DMAOH(+	O
)	O
complexes	O
,	O
in	O
which	O
the	O
stretched	O
DNA	O
molecules	O
are	O
effectively	O
compacted	B-T033
as	O
evidenced	O
from	O
UV	B-T059
-	I-T059
vis	I-T059
absorptions	I-T059
,	O
circular	B-T059
dichroism	I-T059
(	O
CD	B-T059
)	O
measurements	O
,	O
atomic	B-T059
force	I-T059
microscopy	I-T059
(	O
AFM	B-T059
)	O
observations	O
,	O
dynamic	B-T059
light	I-T059
scattering	I-T059
(	O
DLS	B-T059
)	O
measurements	O
and	O
agarose	B-T059
gel	I-T059
electrophoresis	I-T059
(	O
AGE	B-T059
)	O
.	O
Interestingly	O
,	O
when	O
the	O
temperature	O
is	O
turned	O
back	O
to	O
25	O
°	O
C	O
,	O
the	O
compacted	B-T033
DNA	O
molecules	O
can	O
fully	O
recover	O
to	O
the	O
stretched	O
conformation	O
.	O
This	O
cycle	O
can	O
be	O
repeated	O
several	O
times	O
without	O
obvious	O
loss	O
of	O
efficiency	O
.	O
The	O
effect	O
of	O
the	O
chain	O
length	O
of	O
CnDMAO	O
has	O
also	O
been	O
investigated	O
.	O
When	O
C14DMAO	O
was	O
replaced	O
by	O
C12DMAO	O
,	O
similar	O
phenomena	O
can	O
be	O
observed	O
with	O
a	O
slightly	O
higher	O
critical	O
surfactant	O
concentration	O
for	O
DNA	O
compaction	B-T033
and	O
a	O
slightly	O
lower	O
pH	O
of	O
Tris	O
-	O
HCl	O
buffer	O
solution	O
with	O
pH	O
=	O
6.8	O
.	O
For	O
the	O
DNA	O
/	O
C10DMAO	O
system	O
,	O
however	O
,	O
no	O
DNA	O
compaction	B-T033
was	O
observed	O
even	O
in	O
Tris	O
-	O
HCl	O
buffer	O
solution	O
with	O
a	O
much	O
lower	O
pH	O
and	O
a	O
much	O
higher	O
C10DMAO	O
concentration	O
.	O
The	O
negative	O
charges	O
of	O
DNA	O
molecules	O
can	O
easily	O
be	O
neutralized	O
by	O
positive	O
charges	O
of	O
cationic	O
CnDMAOH(+	O
)	O
(	O
n	O
=	O
12	O
and	O
14	O
)	O
micelles	O
.	O
DNA	O
was	O
compacted	B-T033
and	O
then	O
insoluble	O
DNA	O
/	O
CnDMAOH(+	O
)	O
complexes	O
were	O
formed	O
.	O
Because	O
of	O
the	O
much	O
higher	O
critical	O
micelle	O
concentration	O
(	O
cmc	O
)	O
of	O
the	O
shorter	O
chain	O
length	O
C10DMAOH(+	O
)	O
,	O
cationic	O
C10DMAOH(+	O
)	O
micelles	O
can	O
not	O
form	O
under	O
the	O
studied	O
condition	O
to	O
compact	B-T033
DNA	O
.	O
The	O
strategy	O
may	O
provide	O
an	O
efficient	O
and	O
alternative	B-T061
approach	I-T061
for	O
stimuli	B-T061
-	I-T061
responsive	I-T061
gene	I-T061
therapy	I-T061
and	O
drug	O
release	O
.	O
      
Extremely	O
Giant	B-T191
Liver	I-T191
Hemangioma	I-T191
(	O
50	O
cm	O
)	O
with	O
Kasabach	B-T047
-	I-T047
Merritt	I-T047
Syndrome	I-T047
A	O
33-	O
year	O
-	O
old	O
male	O
has	O
been	O
found	B-T033
with	O
a	O
giant	B-T191
liver	I-T191
hemangioma	I-T191
of	O
initial	O
size	O
29	O
cm	O
for	O
5	O
years	O
.	O
He	O
received	O
arterial	B-T061
embolization	I-T061
twice	O
in	O
order	O
to	O
shrink	O
the	O
tumor	B-T191
;	O
however	O
,	O
no	O
effect	O
was	O
obtained	O
.	O
The	O
tumor	B-T191
had	O
rapidly	O
grown	O
to	O
50	O
cm	O
and	O
caused	O
abnormalities	B-T033
in	O
the	O
hematological	O
and	O
coagulative	O
systems	O
.	O
Preoperative	O
computed	B-T060
tomography	I-T060
revealed	O
that	O
the	O
right	O
hepatic	B-T023
vein	I-T023
,	O
right	O
hepatic	B-T023
artery	I-T023
,	O
and	O
right	O
portal	B-T023
vein	I-T023
were	O
not	B-T033
involved	I-T033
by	O
the	O
hemangioma	B-T191
.	O
Resection	B-T061
of	O
the	O
giant	B-T191
liver	I-T191
hemangioma	I-T191
was	O
successfully	O
performed	O
after	O
intraoperative	O
intentional	O
bloodletting	B-T061
with	O
concurrent	O
blood	B-T061
salvage	I-T061
.	O
All	O
hematological	O
and	O
coagulative	O
abnormalities	B-T033
had	O
returned	O
to	O
normal	O
after	O
the	O
procedure	B-T061
.	O
      
Recovery	O
of	O
orthographic	O
processing	O
after	O
stroke	B-T047
:	O
A	O
longitudinal	O
fMRI	B-T060
study	O
An	O
intact	O
orthographic	O
processing	O
system	O
is	O
critical	O
for	O
normal	B-T048
reading	I-T048
and	I-T048
spelling	I-T048
.	O
Here	O
we	O
investigate	O
the	O
neural	O
changes	O
associated	O
with	O
impairment	O
and	O
subsequent	O
recovery	O
of	O
the	O
orthographic	O
lexical	O
processing	O
system	O
in	O
an	O
individual	O
with	O
an	O
ischemic	O
left	B-T047
posterior	I-T047
cerebral	I-T047
artery	I-T047
(	I-T047
PCA	I-T047
)	I-T047
stroke	I-T047
.	O
This	O
work	O
describes	O
a	O
longitudinal	O
case	O
study	O
of	O
a	O
patient	O
,	O
whose	O
initials	O
are	O
MMY	O
,	O
with	O
impairments	O
in	O
orthographic	O
lexical	O
processing	O
for	O
reading	B-T048
and	I-T048
spelling	I-T048
at	O
stroke	B-T047
onset	O
,	O
and	O
who	O
recovered	O
these	O
skills	O
within	O
1	O
year	O
post	O
stroke	B-T047
.	O
We	O
tested	O
the	O
hypothesis	O
that	O
this	O
acute	O
impairment	O
to	O
reading	B-T048
and	I-T048
spelling	I-T048
would	O
be	O
associated	O
with	O
a	O
selective	O
loss	O
of	O
neural	O
activation	O
in	O
the	O
left	B-T023
fusiform	I-T023
gyrus	I-T023
(	O
FG	B-T023
)	O
,	O
and	O
that	O
subsequent	O
recovery	O
would	O
be	O
associated	O
with	O
a	O
gain	O
of	O
neural	O
activation	O
in	O
this	O
region	O
.	O
MMY	O
's	O
case	O
provided	O
a	O
unique	O
opportunity	O
to	O
assess	O
the	O
selectivity	O
of	O
neural	O
changes	O
because	O
she	O
demonstrated	O
a	O
behavioral	O
recovery	O
of	O
naming	O
as	O
well	O
;	O
i.e.	O
,	O
if	O
there	O
is	O
neural	O
recovery	O
for	O
reading	B-T048
and	I-T048
spelling	I-T048
,	O
but	O
not	O
naming	O
,	O
then	O
these	O
neural	O
changes	O
are	O
selective	O
to	O
the	O
recovery	O
of	O
orthographic	O
processing	O
.	O
To	O
test	O
our	O
hypothesis	O
,	O
we	O
examined	O
longitudinal	O
behavioral	O
and	O
functional	B-T060
magnetic	I-T060
resonance	I-T060
imaging	I-T060
(	O
fMRI	B-T060
)	O
data	O
of	O
reading	O
,	O
spelling	O
,	O
and	O
visual	O
object	O
naming	O
acquired	O
acutely	O
,	O
3	O
weeks	O
,	O
5	O
months	O
,	O
and	O
one	O
year	O
post	O
stroke	B-T047
.	O
In	O
confirmation	O
of	O
our	O
hypothesis	O
,	O
the	O
loss	O
and	O
subsequent	O
gain	O
of	O
orthographic	O
lexical	O
processing	O
was	O
associated	O
with	O
up	O
-	O
regulation	O
of	O
neural	O
activation	O
in	O
areas	O
previously	O
associated	O
with	O
orthographic	O
lexical	O
processing	O
:	O
i.e.	O
,	O
the	O
left	O
mid	O
-	O
FG	O
and	O
inferior	B-T023
frontal	I-T023
junction	I-T023
(	O
IFJ	B-T023
)	O
.	O
Furthermore	O
,	O
these	O
neural	O
changes	O
were	O
found	O
to	O
be	O
selective	O
to	O
orthographic	O
processing	O
,	O
as	O
they	O
were	O
observed	O
for	O
reading	O
and	O
spelling	O
,	O
but	O
not	O
for	O
visual	O
object	O
naming	O
within	O
the	O
left	O
mid	O
-	O
FG	O
.	O
This	O
work	O
shows	O
that	O
left	B-T047
PCA	I-T047
stroke	I-T047
can	O
temporarily	O
and	O
selectively	O
disrupt	O
the	O
orthographic	O
lexical	O
processing	O
system	O
,	O
not	O
only	O
in	O
the	O
posterior	O
region	O
adjacent	O
to	O
the	O
stroke	B-T047
,	O
but	O
also	O
in	O
relatively	O
distant	O
frontal	O
orthographic	O
processing	O
regions	O
.	O
      
On	O
the	O
Control	O
of	O
Social	O
Approach	B-T033
-	I-T033
Avoidance	I-T033
Behavior	I-T033
:	O
Neural	O
and	O
Endocrine	O
Mechanisms	O
The	O
ability	O
to	O
control	O
our	O
automatic	O
action	O
tendencies	O
is	O
crucial	O
for	O
adequate	O
social	B-T033
interactions	I-T033
.	O
Emotional	B-T033
events	O
trigger	O
automatic	O
approach	B-T033
and	I-T033
avoidance	I-T033
tendencies	O
.	O
Although	O
these	O
actions	O
may	O
be	O
generally	O
adaptive	O
,	O
the	O
capacity	O
to	O
override	O
these	O
emotional	B-T033
reactions	I-T033
may	O
be	O
key	O
to	O
flexible	O
behavior	O
during	O
social	B-T033
interaction	I-T033
.	O
The	O
present	O
chapter	O
provides	O
a	O
review	O
of	O
the	O
neuroendocrine	O
mechanisms	O
underlying	O
this	O
ability	O
and	O
their	O
relation	O
to	O
social	O
psychopathologies	O
.	O
Aberrant	O
social	O
behavior	O
,	O
such	O
as	O
observed	O
in	O
social	B-T048
anxiety	I-T048
or	O
psychopathy	B-T048
,	O
is	O
marked	O
by	O
abnormalities	B-T033
in	O
approach	B-T033
-	I-T033
avoidance	I-T033
tendencies	O
and	O
the	O
ability	O
to	O
control	O
them	O
.	O
Key	O
neural	O
regions	O
involved	O
in	O
the	O
regulation	O
of	O
approach	B-T033
-	I-T033
avoidance	I-T033
behavior	I-T033
are	O
the	O
amygdala	B-T023
,	O
widely	O
implicated	O
in	O
automatic	O
emotional	B-T033
processing	O
,	O
and	O
the	O
anterior	O
prefrontal	B-T023
cortex	I-T023
,	O
which	O
exerts	O
control	O
over	O
the	O
amygdala	B-T023
.	O
Hormones	O
,	O
especially	O
testosterone	B-T121
and	O
cortisol	B-T121
,	O
have	O
been	O
shown	O
to	O
affect	O
approach	B-T033
-	I-T033
avoidance	I-T033
behavior	I-T033
and	O
the	O
associated	O
neural	O
mechanisms	O
.	O
The	O
present	O
chapter	O
also	O
discusses	O
ways	O
to	O
directly	O
influence	O
social	O
approach	B-T033
and	I-T033
avoidance	I-T033
behavior	I-T033
and	O
will	O
end	O
with	O
a	O
research	O
agenda	O
to	O
further	O
advance	O
this	O
important	O
research	O
field	O
.	O
Control	O
over	O
approach	B-T033
-	I-T033
avoidance	I-T033
tendencies	O
may	O
serve	O
as	O
an	O
exemplar	O
of	O
emotional	B-T033
action	O
regulation	O
and	O
might	O
have	O
a	O
great	O
value	O
in	O
understanding	O
the	O
underlying	O
mechanisms	O
of	O
the	O
development	O
of	O
affective	B-T048
disorders	I-T048
.	O
      
Stressful	O
life	O
events	O
and	O
leucocyte	B-T047
telomere	I-T047
length	I-T047
:	O
Do	O
lifestyle	O
factors	O
,	O
somatic	O
and	O
mental	O
health	O
,	O
or	O
low	O
grade	O
inflammation	O
mediate	O
this	O
relationship	O
?	O
Results	O
from	O
a	O
cohort	O
of	O
Danish	O
men	O
born	O
in	O
1953	O
Exposure	O
to	O
psychosocial	O
stress	B-T033
is	O
associated	O
with	O
increased	O
risk	O
of	O
a	O
number	O
of	O
somatic	O
and	O
mental	B-T048
disorders	I-T048
with	O
relation	O
to	O
immune	O
system	O
functioning	O
.	O
We	O
aimed	O
to	O
explore	O
whether	O
stressful	O
events	O
in	O
early	O
and	O
recent	O
life	O
was	O
associated	O
with	O
leucocyte	B-T047
telomere	I-T047
length	I-T047
(	O
TL	B-T047
)	O
,	O
which	O
is	O
assumed	O
to	O
reflect	O
the	O
accumulated	B-T033
burden	O
of	O
inflammation	O
and	O
oxidative	O
stress	O
occurring	O
during	O
the	O
life	O
course	O
.	O
We	O
specifically	O
aimed	O
to	O
address	O
whether	O
childhood	O
constitutes	O
a	O
sensitive	O
period	O
and	O
how	O
much	O
of	O
the	O
relation	O
between	O
stressful	O
life	O
events	O
and	O
TL	B-T047
is	O
mediated	O
through	O
somatic	O
and	O
mental	O
health	O
,	O
lifestyle	O
,	O
and	O
markers	O
of	O
low	O
-	O
grade	O
inflammation	O
.	O
A	O
cohort	O
of	O
Danish	O
men	O
born	O
in	O
1953	O
has	O
been	O
followed	O
since	O
birth	O
in	O
the	O
Metropolit	O
Cohort	O
.	O
These	O
men	O
underwent	O
a	O
health	B-T058
examination	I-T058
including	O
blood	B-T060
sampling	I-T060
in	O
2010	O
and	O
a	O
subset	O
of	O
324	O
also	O
had	O
a	O
quantitative	B-T059
PCR	I-T059
-	I-T059
based	I-T059
measurement	I-T059
of	O
TL	B-T047
.	O
The	O
relation	O
between	O
stressful	O
life	O
events	O
and	O
TL	B-T047
was	O
analysed	O
using	O
structural	O
equation	O
modelling	O
,	O
which	O
also	O
provided	O
an	O
estimate	O
of	O
the	O
proportion	O
of	O
the	O
total	O
effect	O
mediated	O
by	O
somatic	O
and	O
mental	O
health	O
(	O
cardiovascular	B-T047
disease	I-T047
,	O
body	B-T033
mass	I-T033
and	O
depressive	B-T033
mood	I-T033
)	O
,	O
lifestyle	O
factors	O
,	O
and	O
low	O
grade	O
inflammation	O
(	O
C	O
-	O
reactive	O
protein	O
(	O
CRP	O
)	O
,	O
interleukin	O
(	O
IL)-6	O
and	O
IL-10	O
)	O
.	O
Total	O
number	O
of	O
stressful	O
events	O
experienced	O
during	O
the	O
life	O
course	O
was	O
not	O
associated	O
with	O
TL	B-T047
.	O
In	O
terms	O
of	O
sensitive	O
periods	O
,	O
we	O
found	O
that	O
number	O
of	O
stressful	O
events	O
in	O
childhood	O
was	O
associated	O
with	O
shorter	B-T047
TL	I-T047
(	O
βper	O
number	O
stressful	O
events	O
in	O
childhood	O
=	O
-0.02(SE=-0.02	O
)	O
;	O
P=0.05	O
)	O
.	O
This	O
relation	O
was	O
particularly	O
strong	O
for	O
being	O
placed	O
away	O
from	O
home	O
(	O
β=-0.16	O
;	O
P<0.000	O
)	O
.	O
Thirty	O
percent	O
of	O
the	O
total	O
effect	O
of	O
stressful	O
events	O
in	O
childhood	O
on	O
TL	B-T047
was	O
mediated	O
by	O
the	O
included	O
variables	O
,	O
with	O
the	O
largest	O
proportion	O
being	O
mediated	O
through	O
depressive	B-T033
mood	I-T033
(	O
16	O
%	O
)	O
and	O
CRP	O
(	O
9	O
%	O
)	O
.	O
This	O
study	O
suggests	O
that	O
stressful	O
events	O
in	O
childhood	O
are	O
associated	O
with	O
shorter	B-T047
TL	I-T047
in	O
middle	O
-	O
aged	O
men	O
and	O
that	O
part	O
of	O
this	O
relation	O
is	O
explained	O
by	O
depressive	B-T048
mood	I-T048
and	O
low	O
grade	O
inflammation	O
.	O
      
Shared	O
Decision	O
Making	O
and	O
the	O
promise	O
of	O
a	O
respectful	O
and	O
equitable	O
healthcare	O
system	O
in	O
Peru	O
Peru	O
has	O
achieved	O
sustained	O
development	O
in	O
the	O
last	O
two	O
decades	O
.	O
However	O
,	O
despite	O
this	O
achievement	O
,	O
it	O
has	O
not	O
been	O
matched	O
with	O
improvements	O
in	O
the	O
quality	O
of	O
education	O
and	O
health	B-T058
;	O
investment	O
in	O
both	O
sectors	O
is	O
among	O
the	O
lowest	O
in	O
the	O
region	O
.	O
This	O
situation	O
perpetuates	O
huge	O
gaps	B-T033
in	O
infrastructure	B-T058
and	O
also	O
conditions	O
a	O
poor	B-T033
literacy	I-T033
level	I-T033
of	O
the	O
population	O
specifically	O
in	O
health	O
.	O
Currently	O
,	O
there	O
is	O
a	O
fragmented	O
model	O
of	O
patient	B-T058
care	I-T058
,	O
in	O
which	O
the	O
systems	O
are	O
exclusive	O
of	O
each	O
other	O
.	O
They	O
do	O
not	O
cooperate	O
or	O
communicate	O
with	O
each	O
other	O
;	O
and	O
if	O
there	O
is	O
no	O
vertical	O
communication	O
within	O
the	O
system	O
,	O
preventing	O
referral	B-T058
of	I-T058
patients	I-T058
directly	O
from	O
the	O
basic	B-T033
level	I-T033
to	O
the	O
complex	B-T033
level	I-T033
of	O
care	B-T058
when	O
needed	O
.	O
In	O
addition	O
,	O
there	O
has	O
been	O
no	O
progress	O
in	O
the	O
development	O
of	O
an	O
empathetic	O
,	O
respectful	O
or	O
person	B-T058
-	I-T058
centered	I-T058
clinical	I-T058
practice	I-T058
;	O
instead	O
,	O
economic	O
,	O
social	O
and	O
educational	O
differences	O
perpetuate	O
a	O
paternalistic	O
clinical	B-T058
practice	I-T058
.	O
The	O
task	O
of	O
orienting	O
medical	O
training	O
towards	O
the	O
development	O
of	O
humanism	O
is	O
pending	O
.	O
The	O
patient	O
is	O
the	O
center	O
of	O
the	O
medical	O
act	O
and	O
the	O
main	O
objective	O
of	O
doctors	O
'	O
actions	O
.	O
A	O
humanistic	O
care	O
approach	O
will	O
not	O
only	O
empower	O
the	O
person	O
in	O
the	O
clinical	O
encounter	O
-	O
to	O
participate	O
and	O
make	O
decisions	O
related	O
to	O
his	O
/	O
her	O
health	B-T058
care	I-T058
-	O
but	O
it	O
will	O
allow	O
us	O
to	O
move	O
towards	O
an	O
empathetic	O
,	O
caring	O
,	O
respectful	O
and	O
kind	O
model	O
of	O
clinical	B-T058
practice	I-T058
.	O
      
Effects	O
of	O
complex	O
life	O
cycles	O
on	O
genetic	O
diversity	O
:	O
cyclical	O
parthenogenesis	O
Neutral	O
patterns	O
of	O
population	O
genetic	O
diversity	O
in	O
species	O
with	O
complex	O
life	O
cycles	O
are	O
difficult	O
to	O
anticipate	O
.	O
Cyclical	O
parthenogenesis	O
(	O
CP	O
)	O
,	O
in	O
which	O
organisms	B-T001
undergo	O
several	O
rounds	O
of	O
clonal	O
reproduction	O
followed	O
by	O
a	O
sexual	O
event	O
,	O
is	O
one	O
such	O
life	O
cycle	O
.	O
Many	O
species	O
,	O
including	O
crop	O
pests	O
(	O
aphids	O
)	O
,	O
human	O
parasites	O
(	O
trematodes	O
)	O
or	O
models	O
used	O
in	O
evolutionary	O
science	O
(	O
Daphnia	O
)	O
,	O
are	O
cyclical	B-T001
parthenogens	I-T001
.	O
It	O
is	O
therefore	O
crucial	O
to	O
understand	O
the	O
impact	O
of	O
such	O
a	O
life	O
cycle	O
on	O
neutral	O
genetic	O
diversity	O
.	O
In	O
this	O
paper	O
,	O
we	O
describe	O
distributions	O
of	O
genetic	O
diversity	O
under	O
conditions	O
of	O
CP	O
with	O
various	O
clonal	O
phase	O
lengths	O
.	O
Using	O
a	O
Markov	O
chain	O
model	O
of	O
CP	O
for	O
a	O
single	O
locus	O
and	O
individual	O
-	O
based	O
simulations	O
for	O
two	O
loci	O
,	O
our	O
analysis	O
first	O
demonstrates	O
that	O
strong	O
departures	O
from	O
full	O
sexuality	O
are	O
observed	O
after	O
only	O
a	O
few	O
generations	O
of	O
clonality	O
.	O
The	O
convergence	O
towards	O
predictions	O
made	O
under	O
conditions	O
of	O
full	O
clonality	O
during	O
the	O
clonal	O
phase	O
depends	O
on	O
the	O
balance	O
between	O
mutations	O
and	O
genetic	O
drift	O
.	O
Second	O
,	O
the	O
sexual	O
event	O
of	O
CP	O
usually	O
resets	O
the	O
genetic	O
diversity	O
at	O
a	O
single	O
locus	O
towards	O
predictions	O
made	O
under	O
full	O
sexuality	O
.	O
However	O
,	O
this	O
single	O
recombination	O
event	O
is	O
insufficient	O
to	O
reshuffle	O
gametic	O
phases	O
towards	O
full	O
-	O
sexuality	O
predictions	O
.	O
Finally	O
,	O
for	O
similar	O
levels	O
of	O
clonality	O
,	O
CP	O
and	O
acyclic	O
partial	O
clonality	O
(	O
wherein	O
a	O
fixed	O
proportion	O
of	O
individuals	O
are	O
clonally	O
produced	O
within	O
each	O
generation	O
)	O
differentially	O
affect	O
the	O
distribution	O
of	O
genetic	O
diversity	O
.	O
Overall	O
,	O
this	O
work	O
provides	O
solid	O
predictions	O
of	O
neutral	O
genetic	O
diversity	O
that	O
may	O
serve	O
as	O
a	O
null	O
model	O
in	O
detecting	O
the	O
action	O
of	O
common	O
evolutionary	O
or	O
demographic	O
processes	O
in	O
cyclical	B-T001
parthenogens	I-T001
(	O
for	O
example	O
,	O
selection	O
or	O
bottlenecks	O
)	O
.	O
      
Overnight	O
switching	B-T058
from	O
oxcarbazepine	B-T121
to	O
eslicarbazepine	B-T121
acetate	I-T121
:	O
an	O
observational	O
study	O
There	O
are	O
clinical	O
situations	O
where	O
it	O
might	O
be	O
appropriate	O
to	O
switch	B-T058
patients	O
from	O
immediate	O
-	O
release	O
oxcarbazepine	B-T121
(	O
OXC	B-T121
)	O
to	O
eslicarbazepine	B-T121
acetate	I-T121
(	O
ESL	B-T121
)	O
.	O
We	O
investigated	O
the	O
effects	O
of	O
transitioning	O
patients	O
overnight	O
from	O
OXC	B-T121
to	O
ESL	B-T121
.	O
A	O
retrospective	O
,	O
single	O
-	O
center	O
study	O
was	O
conducted	O
in	O
which	O
patients	O
with	O
drug	O
-	O
resistant	O
focal	B-T047
epilepsy	I-T047
on	O
a	O
stable	O
dose	O
of	O
immediate	O
-	O
release	O
OXC	B-T121
for	O
at	O
least	O
4	O
weeks	O
were	O
switched	B-T058
overnight	O
to	O
ESL	B-T121
.	O
Patients	O
were	O
switched	B-T058
because	O
they	O
experienced	O
persistent	O
seizures	B-T184
with	O
OXC	B-T121
but	O
were	O
unable	B-T033
to	O
tolerate	O
increased	O
OXC	B-T121
dosing	O
due	O
to	O
adverse	O
events	O
.	O
Tolerability	O
was	O
assessed	O
using	O
the	O
Adverse	O
Events	O
Profile	O
(	O
AEP	O
)	O
,	O
quality	O
of	O
life	O
was	O
assessed	O
using	O
the	O
Quality	O
of	O
Life	O
in	O
Epilepsy	O
Inventory	O
10	O
(	O
QOLIE-10	O
)	O
,	O
and	O
alertness	O
was	O
assessed	O
as	O
reaction	O
time	O
using	O
a	O
subtest	O
of	O
the	O
Test	O
Battery	O
for	O
Attention	O
Performance	O
version	O
2.3	O
.	O
Assessments	B-T058
were	O
performed	O
immediately	O
prior	O
to	O
and	O
5	O
days	O
after	O
switching	B-T058
from	O
OXC	B-T121
to	O
ESL	B-T121
(	O
days	O
0	O
and	O
5	O
,	O
respectively	O
)	O
.	O
The	O
analysis	O
included	O
21	O
patients	O
(	O
12	O
women	O
,	O
9	O
men	O
;	O
mean	B-T033
age	I-T033
36	I-T033
years	I-T033
)	O
.	O
After	O
switching	B-T058
from	O
OXC	B-T121
to	O
ESL	B-T121
,	O
there	O
were	O
significant	O
improvements	O
in	O
mean	O
scores	O
for	O
AEP	O
(	O
P<.001	O
)	O
,	O
QOLIE-10	O
(	O
P=.001	O
)	O
,	O
and	O
alertness	O
(	O
P<.05	O
)	O
.	O
Adverse	O
Events	O
Profile	O
total	O
scores	O
improved	B-T033
for	O
21/21	O
(	O
100.0	O
%	O
)	O
patients	O
,	O
QOLIE-10	O
total	O
scores	O
improved	B-T033
for	O
17/21	O
(	O
81.0	O
%	O
)	O
patients	O
,	O
and	O
alertness	O
scores	O
improved	B-T033
for	O
16/21	O
(	O
76.2	O
%	O
)	O
patients	O
.	O
In	O
this	O
short	O
-	O
term	O
,	O
single	O
-	O
center	O
study	O
,	O
an	O
overnight	O
switch	B-T058
from	O
twice	O
-	O
daily	O
OXC	B-T121
to	O
once	O
-	O
daily	O
ESL	B-T121
in	O
patients	O
with	O
drug	O
-	O
resistant	O
focal	B-T047
epilepsies	I-T047
resulted	B-T033
in	O
improvements	O
in	O
side	O
effects	O
,	O
quality	O
of	O
life	O
,	O
and	O
alertness	O
.	O
      
The	O
application	O
of	O
heterogeneous	O
cluster	O
grouping	O
to	O
reflective	O
writing	O
for	O
medical	O
humanities	O
literature	O
study	O
to	O
enhance	O
students	O
'	O
empathy	O
,	O
critical	O
thinking	O
,	O
and	O
reflective	O
writing	O
To	O
facilitate	O
interdisciplinary	B-T058
collaboration	I-T058
and	O
to	O
make	O
connections	O
between	O
patients	O
'	O
diseases	B-T047
and	O
their	O
social	O
/	O
cultural	O
contexts	O
,	O
the	O
study	O
examined	B-T033
whether	O
the	O
use	O
of	O
heterogeneous	O
cluster	O
grouping	O
in	O
reflective	O
writing	O
for	O
medical	O
humanities	O
literature	O
acquisition	O
could	O
have	O
positive	O
effects	O
on	O
medical	O
university	O
students	O
in	O
terms	O
of	O
empathy	O
,	O
critical	O
thinking	O
,	O
and	O
reflective	O
writing	O
.	O
A	O
15	O
-	O
week	O
quasi	O
-	O
experimental	O
design	O
was	O
conducted	O
to	O
investigate	O
the	O
learning	O
outcomes	O
.	O
After	O
conducting	O
cluster	O
algorithms	O
,	O
heterogeneous	O
learning	O
clusters	O
(	O
experimental	O
group	O
;	O
n	O
=	O
43	O
)	O
and	O
non	O
-	O
heterogeneous	O
learning	O
clusters	O
(	O
control	O
group	O
;	O
n	O
=	O
43	O
)	O
were	O
derived	O
for	O
a	O
medical	O
humanities	O
literature	O
study	O
.	O
Before	O
and	O
after	O
the	O
intervention	B-T061
,	O
an	O
Empathy	O
Scale	O
in	O
Patient	B-T058
Care	I-T058
(	O
ES	O
-	O
PC	B-T058
)	O
,	O
a	O
critical	B-T058
thinking	I-T058
disposition	I-T058
assessment	I-T058
(	O
CTDA	B-T058
-	I-T058
R	I-T058
)	O
,	O
and	O
a	O
reflective	B-T058
writing	I-T058
test	I-T058
were	O
administered	O
to	O
both	O
groups	O
.	O
The	O
findings	O
showed	O
that	O
on	O
the	O
empathy	O
scale	O
,	O
significant	O
differences	O
in	O
the	O
"	O
behavioral	O
empathy	O
,	O
"	O
"	O
affective	O
empathy	O
,	O
"	O
and	O
overall	O
sections	O
existed	O
between	O
the	O
post	B-T033
-	I-T033
test	I-T033
mean	I-T033
scores	I-T033
of	O
the	O
experimental	O
group	O
and	O
those	O
of	O
the	O
control	O
group	O
,	O
but	O
such	O
differences	O
did	O
not	O
exist	O
in	O
"	O
intelligent	O
empathy	O
.	O
"	O
Regarding	O
critical	O
thinking	O
,	O
there	O
were	O
significant	O
differences	O
in	O
"	O
systematicity	O
and	O
analyticity	O
,	O
"	O
"	O
skepticism	O
and	O
well	B-T058
-	I-T058
informed	I-T058
,	O
"	O
"	O
maturity	O
and	O
skepticism	O
,	O
"	O
and	O
overall	O
sections	O
.	O
As	O
for	O
reflective	O
writing	O
,	O
significant	O
differences	O
existed	O
in	O
"	O
ideas	O
,	O
"	O
"	O
voice	O
and	O
point	O
of	O
view	O
,	O
"	O
"	O
critical	O
thinking	O
and	O
representation	O
,	O
"	O
"	O
depth	O
of	O
reflection	O
on	O
personal	O
growth	O
,	O
"	O
and	O
overall	O
sections	O
,	O
but	O
not	O
in	O
"	O
focus	O
and	O
context	O
structure	O
"	O
and	O
"	O
language	O
and	O
conventions	O
.	O
"	O
This	O
study	O
outlined	O
an	O
alternative	O
for	O
using	O
heterogeneous	O
cluster	O
grouping	O
in	O
reflective	O
writing	O
about	O
medical	O
humanities	O
literature	O
to	O
facilitate	O
interdisciplinary	O
cooperation	O
to	O
provide	O
more	O
humanizing	O
medical	B-T033
care	I-T033
.	O
      
Rates	O
and	O
predictors	O
of	O
injury	O
in	O
a	O
population	O
-	O
based	O
cohort	O
of	O
people	O
living	O
with	O
HIV	B-T047
Injuries	O
are	O
responsible	O
for	O
10	O
%	O
of	O
the	O
global	O
burden	O
of	O
disease	B-T047
;	O
however	O
,	O
the	O
epidemiology	O
of	O
injury	O
among	O
people	B-T047
living	I-T047
with	I-T047
HIV	I-T047
(	O
PLHIV	B-T047
)	O
has	O
not	B-T033
been	I-T033
well	I-T033
elucidated	O
.	O
This	O
study	O
seeks	O
to	O
characterize	O
rates	O
and	O
predictors	O
of	O
injury	O
among	O
PLHIV	B-T047
compared	O
to	O
the	O
general	O
population	O
in	O
British	O
Columbia	O
(	O
BC	O
)	O
,	O
Canada	O
.	O
A	O
population	O
-	O
based	O
dataset	O
was	O
created	O
via	O
linkage	O
between	O
the	O
BC	O
Centre	O
for	O
Excellence	O
in	O
HIV	O
/	O
AIDS	O
and	O
PopulationDataBC	O
.	O
PLHIV	B-T047
aged	O
20	O
years	O
and	O
older	O
were	O
compared	O
to	O
a	O
random	O
10	O
%	O
sample	O
of	O
the	O
adult	O
general	O
population	O
.	O
The	O
International	O
Classification	O
of	O
Diseases	B-T047
9	O
and	O
10	O
codes	O
were	O
used	O
to	O
classify	O
unintentional	O
and	O
intentional	O
injuries	O
based	O
on	O
the	O
external	B-T033
cause	I-T033
of	O
the	O
injury	O
from	O
1996	O
to	O
2013	O
.	O
Generalized	O
estimating	O
equation	O
(	O
GEE	O
)	O
Poisson	O
regression	O
models	O
were	O
fit	O
to	O
estimate	O
the	O
effect	O
of	O
HIV	B-T047
status	O
on	O
rates	O
of	O
unintentional	O
and	O
intentional	O
injury	O
,	O
and	O
to	O
identify	O
correlates	O
of	O
injury	O
among	O
PLHIV	B-T047
.	O
The	O
crude	O
incidence	O
rate	O
of	O
unintentional	O
injury	O
was	O
18.56/1000	O
person	O
-	O
years	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
17.77	O
-	O
19.39	O
]	O
among	O
PLHIV	B-T047
and	O
8.51/1000	O
person	O
-	O
years	O
(	O
95	O
%	O
CI	O
8.42	O
-	O
8.59	O
)	O
in	O
the	O
general	O
population	O
.	O
Among	O
PLHIV	B-T047
,	O
13.45	O
%	O
of	O
deaths	B-T033
were	O
due	O
to	O
injury	O
,	O
compared	O
to	O
5.52	O
%	O
of	O
deaths	B-T033
in	O
the	O
general	O
population	O
.	O
In	O
adjusted	O
models	O
,	O
PLHIV	B-T047
were	O
more	O
likely	O
to	O
report	B-T058
unintentional	O
(	O
incidence	O
rate	O
ratio	O
1.42	O
,	O
95	O
%	O
CI	O
1.32	O
-	O
1.52	O
)	O
and	O
intentional	O
injury	O
(	O
incidence	O
rate	O
ratio	O
1.93	O
,	O
95	O
%	O
CI	O
1.70	O
-	O
2.18	O
)	O
compared	O
to	O
the	O
general	O
population	O
.	O
We	O
identified	O
elevated	O
rates	O
of	O
intentional	O
and	O
unintentional	O
injury	O
among	O
PLHIV	B-T047
.	O
Injuries	O
are	O
largely	O
preventable	O
;	O
as	O
such	O
,	O
targeted	O
efforts	O
are	O
needed	O
to	O
decrease	O
the	O
burden	O
of	O
injury	O
-	O
related	O
disability	B-T033
and	O
death	B-T033
among	O
PLHIV	B-T047
.	O
      
The	O
Novel	O
miR-9600	O
Suppresses	O
Tumor	B-T191
Progression	I-T191
and	O
Promotes	O
Paclitaxel	B-T121
Sensitivity	O
in	O
Non	B-T191
-	I-T191
small	I-T191
-	I-T191
cell	I-T191
Lung	I-T191
Cancer	I-T191
Through	O
Altering	O
STAT3	O
Expression	O
MicroRNAs	O
have	O
been	O
identified	O
to	O
be	O
involved	O
in	O
center	O
stage	O
of	O
cancer	O
biology	O
.	O
They	O
accommodate	O
cell	O
proliferation	O
and	O
migration	O
by	O
negatively	B-T033
regulate	O
gene	O
expression	O
either	O
by	O
hampering	O
the	O
translation	O
of	O
targeted	O
mRNAs	O
or	O
by	O
promoting	O
their	O
degradation	O
.	O
We	O
characterized	O
and	O
identified	O
the	O
novel	O
miR-9600	O
and	O
its	O
target	O
in	O
human	O
non	B-T191
-	I-T191
small	I-T191
-	I-T191
cell	I-T191
lung	I-T191
cancer	I-T191
(	O
NSCLC	B-T191
)	O
.	O
Our	O
results	O
demonstrated	O
that	O
the	O
miR-9600	O
were	O
downregulated	O
in	O
NSCLC	B-T191
tissues	O
and	O
cells	O
.	O
It	O
is	O
confirmed	O
that	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
3	O
(	O
STAT3	O
)	O
,	O
a	O
putative	O
target	O
gene	O
,	O
is	O
directly	O
inhibited	O
by	O
miR-9600	O
.	O
The	O
miR-9600	O
markedly	O
suppressed	O
the	O
protein	O
expression	O
of	O
STAT3	O
,	O
but	O
with	O
no	B-T033
significant	I-T033
influence	O
in	O
corresponding	O
mRNA	O
levels	O
,	O
and	O
the	O
direct	O
combination	O
of	O
miR-9600	O
and	O
STAT3	O
was	O
confirmed	O
by	O
a	O
luciferase	O
reporter	O
assay	O
.	O
miR-9600	O
inhibited	O
cell	O
growth	O
,	O
hampered	O
expression	O
of	O
cell	O
cycle	O
-related	O
proteins	O
and	O
inhibited	O
cell	O
migration	O
and	O
invasion	O
in	O
human	O
NSCLC	B-T191
cell	O
lines	O
.	O
Further	O
,	O
miR-9600	O
significantly	O
suppressed	O
tumor	B-T191
growth	I-T191
in	O
nude	O
mice	O
.	O
Similarly	O
,	O
miR-9600	O
impeded	O
tumorigenesis	B-T191
and	O
metastasis	O
through	O
directly	O
targeting	O
STAT3	O
.	O
Furthermore	O
,	O
we	O
identified	O
that	O
miR-9600	O
augmented	O
paclitaxel	B-T121
and	O
cisplatin	B-T121
sensitivity	O
by	O
downregulating	O
STAT3	O
and	O
promoting	O
chemotherapy	B-T061
-	O
induced	O
apoptosis	O
.	O
These	O
data	O
demonstrate	O
that	O
miR-9600	O
might	O
be	O
a	O
useful	O
and	O
novel	O
therapeutic	O
target	O
for	O
NSCLC	B-T191
.	O
      
A	O
plea	O
for	O
thoracoscopic	B-T058
resection	B-T061
of	O
solitary	B-T191
pulmonary	I-T191
nodule	I-T191
in	O
cancer	B-T191
patients	O
Solitary	B-T191
pulmonary	I-T191
nodules	I-T191
(	O
SPN	B-T191
)	O
are	O
frequently	O
detected	B-T033
in	O
cancer	B-T191
patients	O
.	O
These	O
lesions	B-T033
are	O
often	O
considered	O
as	O
pulmonary	B-T191
metastases	I-T191
and	O
increasingly	O
treated	O
by	O
non	B-T061
-	I-T061
surgical	I-T061
techniques	I-T061
without	O
histological	O
confirmation	B-T033
.	O
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
determine	O
the	O
histological	O
nature	O
of	O
SPN	B-T191
resected	O
by	O
thoracoscopy	B-T058
and	O
to	O
identify	O
risk	B-T033
factors	I-T033
of	O
malignancy	B-T191
.	O
Single	O
-	O
institution	O
retrospective	O
analysis	O
of	O
all	O
consecutive	O
patients	O
with	O
previously	O
known	O
malignancies	B-T191
who	O
underwent	O
thoracoscopic	B-T058
resection	B-T061
of	O
SPN	B-T191
with	O
unknown	O
diagnosis	B-T033
between	O
2001	O
and	O
2014	O
.	O
One	O
hundred	O
and	O
forty	O
cancer	B-T191
patients	O
underwent	O
thoracoscopic	B-T058
resection	B-T061
of	O
a	O
SPN	B-T191
.	O
The	O
resected	O
SPN	B-T191
was	O
benign	O
in	O
34	O
patients	O
(	O
24.3	O
%	O
)	O
and	O
malignant	O
in	O
106	O
patients	O
.	O
The	O
latter	O
were	O
metastasis	B-T191
in	O
70	O
patients	O
(	O
50	O
%	O
)	O
and	O
a	O
primary	O
lung	B-T191
cancer	I-T191
in	O
36	O
patients	O
(	O
25.7	O
%	O
)	O
.	O
Upon	O
univariate	O
analysis	O
,	O
malignancy	B-T191
was	O
significantly	O
associated	O
with	O
age	O
>	O
60	O
years	O
,	O
disease	B-T047
-free	O
interval	O
≥24	O
months	O
,	O
SPN	B-T191
size	O
>	O
8	O
mm	O
,	O
upper	B-T023
lobe	I-T023
localization	O
and	O
SUVmax	O
>	O
2.5	O
on	O
PET	B-T060
-	I-T060
CT	I-T060
.	O
Upon	O
multivariate	O
analysis	O
,	O
upper	B-T023
lobe	I-T023
localization	O
and	O
SUVmax	O
>	O
2.5	O
were	O
associated	O
with	O
malignancy	B-T191
.	O
Smoking	O
was	O
significantly	O
associated	O
with	O
SPN	B-T191
containing	O
primary	O
lung	B-T191
cancer	I-T191
.	O
In	O
this	O
series	O
,	O
only	O
50	O
%	O
of	O
SPN	B-T191
in	O
patients	O
with	O
known	O
malignant	B-T047
disease	I-T047
were	O
pulmonary	B-T191
metastases	I-T191
and	O
25	O
%	O
had	O
a	O
newly	O
diagnosed	O
NSCLC	B-T191
.	O
Smoking	O
was	O
associated	O
with	O
primary	O
lung	B-T191
cancer	I-T191
but	O
no	B-T033
other	O
predictor	O
was	O
found	O
to	O
allow	O
the	O
distinction	O
between	O
pulmonary	B-T191
metastasis	I-T191
and	O
lung	B-T191
cancer	I-T191
.	O
These	O
results	O
endorse	O
the	O
need	O
of	O
histological	O
confirmation	B-T033
of	O
SPN	B-T191
in	O
patients	O
with	O
previous	O
malignancies	B-T191
to	O
avoid	O
diagnostic	O
uncertainty	B-T033
and	O
suboptimal	O
treatments	B-T061
.	O
      
EZH2	O
and	O
ZFX	O
oncogenes	O
in	O
malignant	O
behaviour	O
of	O
parathyroid	B-T191
neoplasms	I-T191
Several	O
studies	O
reported	O
somatic	O
mutations	O
of	O
many	O
genes	O
(	O
MEN1	O
,	O
CTNNB1	O
,	O
CDKIs	O
and	O
others	O
)	O
in	O
parathyroid	B-T191
adenoma	I-T191
,	O
although	O
with	O
different	O
prevalence	O
.	O
Recently	O
,	O
activating	O
mutations	O
of	O
the	O
EZH2	O
and	O
ZFX	O
oncogenes	O
were	O
identified	O
in	O
benign	O
parathyroid	B-T191
adenoma	I-T191
by	O
whole	O
exome	O
sequencing	O
.	O
The	O
same	O
mutations	O
had	O
been	O
found	O
in	O
blood	O
and	O
ovary	B-T023
malignant	B-T191
tumours	I-T191
.	O
On	O
one	O
hand	O
,	O
this	O
result	O
raised	O
the	O
hypothesis	O
that	O
these	O
oncogenes	O
may	O
play	O
a	O
role	O
in	O
the	O
onset	O
of	O
parathyroid	B-T191
tumour	I-T191
,	O
but	O
it	O
would	O
also	O
suggest	O
they	O
may	O
be	O
involved	O
in	O
malignant	O
,	O
rather	O
benign	O
,	O
parathyroid	B-T191
neoplasm	I-T191
.	O
Our	O
aim	O
was	O
to	O
verify	O
the	O
occurrence	O
of	O
selected	O
mutations	O
of	O
the	O
EZH2	O
and	O
ZFX	O
genes	O
in	O
an	O
Italian	O
cohort	O
of	O
23	O
sporadic	O
parathyroid	B-T191
carcinomas	I-T191
,	O
12	O
atypical	O
and	O
45	O
typical	O
adenomas	B-T191
.	O
DNA	O
was	O
extracted	B-T061
from	O
paraffin	O
-	O
embedded	O
tissues	O
,	O
PCR	O
amplified	O
and	O
directly	O
sequenced	O
.	O
No	B-T033
mutations	O
were	O
detected	B-T033
in	O
the	O
coding	O
sequence	O
and	O
boundaries	O
of	O
both	O
genes	O
in	O
any	O
of	O
the	O
samples	O
.	O
Two	O
polymorphisms	O
of	O
the	O
EZH2	O
gene	O
were	O
identified	O
with	O
different	O
prevalence	O
:	O
the	O
rs2072407	O
variant	O
was	O
present	B-T033
in	O
the	O
30	O
%	O
of	O
the	O
samples	O
,	O
in	O
keeping	O
with	O
the	O
overall	O
frequency	O
in	O
larger	O
populations	O
,	O
while	O
the	O
rs78589034	O
variant	O
,	O
located	O
close	O
to	O
the	O
5	O
'	O
end	O
of	O
the	O
exon	O
16	O
,	O
was	O
detected	B-T033
in	O
only	O
one	O
proband	O
with	O
familial	O
isolated	O
hyperparathyroidism	B-T047
;	O
we	O
investigated	O
the	O
possible	O
outcome	O
on	O
the	O
splicing	O
process	O
.	O
EZH2	O
and	O
ZFX	O
genes	O
do	O
not	O
seem	O
to	O
have	O
an	O
impact	O
on	O
the	O
onset	O
of	O
most	O
parathyroid	B-T191
tumours	I-T191
,	O
both	O
benign	O
and	O
malignant	O
,	O
though	O
further	O
studies	O
on	O
larger	O
cohorts	O
of	O
different	O
ethnicity	O
are	O
needed	O
.	O
      
Memory	O
consolidation	O
effects	O
on	O
memory	O
stabilization	O
and	O
item	O
integration	O
in	O
older	O
adults	O
This	O
study	O
examined	O
the	O
differential	O
effects	O
of	O
aging	O
on	O
consolidation	O
processes	O
that	O
strengthen	O
newly	O
acquired	O
memory	O
traces	O
in	O
veridical	O
form	O
(	O
memory	O
stabilization	O
)	O
versus	O
consolidation	O
processes	O
that	O
are	O
responsible	O
for	O
integrating	O
these	O
memory	O
traces	O
into	O
an	O
existing	O
body	O
of	O
knowledge	O
(	O
item	O
integration	O
)	O
.	O
Older	O
adults	O
learned	O
13	O
nonwords	O
and	O
were	O
tested	O
on	O
their	O
memory	O
for	O
the	O
nonwords	O
,	O
and	O
on	O
whether	O
these	O
nonwords	O
impacted	O
upon	O
processing	O
of	O
similar	O
-	O
sounding	O
English	O
words	O
immediately	O
and	O
24	O
hours	O
later	O
.	O
Participants	O
accurately	O
recognized	O
the	O
nonwords	O
immediately	O
,	O
but	O
showed	O
significant	O
decreases	O
in	O
delayed	O
recognition	O
and	O
recall	O
.	O
In	O
comparison	O
,	O
the	O
nonwords	O
impacted	O
upon	O
processing	O
of	O
similar	O
-	O
sounding	O
words	O
only	O
in	O
the	O
delayed	O
test	O
.	O
Together	O
,	O
these	O
findings	O
suggest	O
that	O
memory	O
consolidation	O
processes	O
may	O
be	O
more	O
evident	O
in	O
item	O
integration	O
than	O
memory	O
stabilization	O
processes	O
for	O
new	O
declarative	O
memories	O
in	O
older	O
adults	O
.	O
      
Comparative	O
and	O
evolutionary	O
analysis	O
of	O
an	O
adapter	O
molecule	O
MyD88	O
in	O
invertebrate	O
metazoans	O
The	O
myeloid	O
differentiation	O
factor	O
88	O
(	O
MyD88	O
)	O
is	O
an	O
essential	O
adapter	O
in	O
Toll	O
-	O
like	O
receptor	O
(	O
TLR	O
)	O
signalling	O
pathways	O
,	O
with	O
TLR	O
the	O
first	O
pattern	O
-	O
recognition	O
receptor	O
(	O
PRR	O
)	O
that	O
was	O
discovered	O
in	O
Drosophila	O
.	O
In	O
the	O
present	O
study	O
,	O
a	O
MyD88	O
gene	O
was	O
identified	O
and	O
characterized	O
from	O
a	O
commercially	O
important	O
shellfish	O
,	O
Scapharca	O
subcrenata	O
,	O
including	O
a	O
DEATH	O
domain	O
and	O
TIR	O
domain	O
conserved	O
within	O
other	O
molluscs	O
.	O
Furthermore	O
,	O
comparative	O
genomic	O
evidence	O
revealed	O
that	O
MyD88	O
was	O
of	O
different	O
lengths	O
and	O
contained	O
quantitative	O
exon	O
and	O
intron	O
regions	O
,	O
which	O
might	O
be	O
involved	O
in	O
specific	O
mechanisms	O
.	O
To	O
further	O
explore	O
the	O
phylogenetic	O
relationships	O
of	O
invertebrate	O
metazoan	O
MyD88	O
,	O
we	O
applied	O
MrBayes	O
and	O
PhyML	O
software	O
to	O
construct	O
phylogenetic	O
trees	O
using	O
Bayesian	O
and	O
maximum	O
likelihood	O
approaches	O
,	O
respectively	O
,	O
which	O
suggested	O
that	O
the	O
MyD88	O
of	O
Arthropoda	O
was	O
closely	O
related	O
to	O
lower	O
invertebrates	O
,	O
in	O
contrast	O
to	O
morphological	O
taxonomy	O
.	O
Finally	O
,	O
we	O
investigated	O
the	O
evolutionary	O
patterns	O
and	O
location	O
of	O
positive	O
selection	O
sites	O
(	O
PSSs	O
)	O
in	O
the	O
MyD88	O
gene	O
from	O
Arthropoda	O
,	O
Mollusca	O
and	O
Insecta	O
using	O
PAML	O
software	O
with	O
the	O
maximum	O
likelihood	O
method	O
.	O
The	O
data	O
showed	O
that	O
positive	O
selection	O
sites	O
were	O
detected	B-T033
in	O
these	O
groups	O
,	O
and	O
partial	O
sites	O
were	O
located	O
in	O
the	O
TIR	O
domain	O
but	O
were	O
not	B-T033
found	I-T033
in	O
the	O
DEATH	O
domain	O
.	O
To	O
summarize	O
,	O
in	O
this	O
study	O
,	O
we	O
report	O
on	O
the	O
diversification	O
of	O
MyD88	O
in	O
invertebrate	O
metazoans	O
,	O
the	O
specific	O
evolutionary	O
position	O
of	O
Arthropoda	O
MyD88	O
,	O
and	O
the	O
positive	B-T033
selection	O
pressures	O
on	O
MyD88	O
of	O
Arthropoda	O
,	O
Mollusca	O
and	O
Insecta	O
.	O
These	O
results	O
are	O
a	O
valuable	O
contribution	O
to	O
understand	O
and	O
clarify	O
the	O
evolutionary	O
pattern	O
of	O
TLR	O
/	O
MyD88	O
signalling	O
pathways	O
in	O
invertebrate	O
and	O
vertebrate	O
taxa	O
.	O
      
Variables	O
associated	O
with	O
unplanned	O
general	O
adult	O
ICU	B-T058
admission	I-T058
in	O
hospitalised	O
patients	O
:	O
protocol	O
for	O
a	O
systematic	O
review	O
Failure	O
to	O
promptly	O
identify	O
deterioration	O
in	O
hospitalised	O
patients	O
is	O
associated	O
with	O
delayed	O
admission	B-T058
to	I-T058
intensive	I-T058
care	I-T058
units	I-T058
(	O
ICUs	O
)	O
and	O
poor	O
outcomes	O
.	O
Existing	O
vital	O
sign	O
-based	O
Early	O
Warning	O
Score	O
(	O
EWS	O
)	O
algorithms	O
do	O
not	O
have	O
a	O
sufficiently	O
high	O
positive	O
predictive	O
value	O
to	O
be	O
used	O
for	O
automated	O
activation	O
of	O
an	O
ICU	O
outreach	O
team	O
.	O
Incorporating	O
additional	O
patient	O
data	O
might	O
improve	B-T033
the	O
predictive	O
power	O
of	O
EWS	O
algorithms	O
;	O
however	O
,	O
it	O
is	O
currently	O
not	O
known	O
which	O
patient	O
data	O
(	O
or	O
variables	O
)	O
are	O
most	O
predictive	O
of	O
ICU	B-T058
admission	I-T058
.	O
We	O
describe	O
the	O
protocol	O
for	O
a	O
systematic	O
review	O
of	O
variables	O
associated	O
with	O
ICU	B-T058
admission	I-T058
.	O
MEDLINE	O
,	O
EMBASE	O
,	O
CINAHL	O
and	O
the	O
Cochrane	O
Library	O
,	O
including	O
Cochrane	O
Database	O
of	O
Systematic	O
Reviews	O
and	O
the	O
Cochrane	O
Central	O
Register	O
of	O
Controlled	O
Trials	O
(	O
CENTRAL	O
)	O
will	O
be	O
searched	O
for	O
studies	O
that	O
assess	B-T058
the	O
association	O
of	O
routinely	O
recorded	O
variables	O
associated	O
with	O
subsequent	O
unplanned	O
ICU	B-T058
admission	I-T058
.	O
Only	O
studies	O
involving	O
adult	O
patients	O
admitted	B-T058
to	I-T058
general	O
ICUs	O
will	O
be	O
included	O
.	O
We	O
will	O
extract	O
data	O
relating	O
to	O
the	O
statistical	O
association	O
between	O
ICU	B-T058
admission	I-T058
and	O
predictor	O
variables	O
,	O
the	O
quality	O
of	O
the	O
studies	O
and	O
the	O
generalisability	O
of	O
the	O
findings	B-T033
.	O
The	O
results	O
of	O
this	O
review	O
will	O
aid	O
the	O
development	O
of	O
future	O
models	O
which	O
predict	O
the	O
risk	O
of	O
unplanned	O
ICU	B-T058
admission	I-T058
.	O
PROSPERO	O
:	O
CRD42015029617	O
.	O
      
The	O
Burden	O
of	O
Mental	B-T048
Disorders	I-T048
in	O
the	O
Eastern	O
Mediterranean	O
Region	O
,	O
1990	O
-	O
2013	O
The	O
Eastern	O
Mediterranean	O
Region	O
(	O
EMR	O
)	O
is	O
witnessing	O
an	O
increase	O
in	O
chronic	B-T047
disorders	I-T047
,	O
including	O
mental	B-T048
illness	I-T048
.	O
With	O
ongoing	O
unrest	O
,	O
this	O
is	O
expected	O
to	O
rise	O
.	O
This	O
is	O
the	O
first	O
study	O
to	O
quantify	O
the	O
burden	O
of	O
mental	B-T048
disorders	I-T048
in	O
the	O
EMR	O
.	O
We	O
used	O
data	O
from	O
the	O
Global	O
Burden	O
of	O
Disease	O
study	O
(	O
GBD	O
)	O
2013	O
.	O
DALYs	O
(	O
disability	O
-	O
adjusted	O
life	O
years	O
)	O
allow	O
assessment	B-T058
of	O
both	O
premature	B-T033
mortality	I-T033
(	O
years	O
of	O
life	O
lost	O
-	O
YLLs	O
)	O
and	O
nonfatal	O
outcomes	O
(	O
years	O
lived	O
with	O
disability	O
-	O
YLDs	O
)	O
.	O
DALYs	O
are	O
computed	O
by	O
adding	O
YLLs	O
and	O
YLDs	O
for	O
each	O
age	O
-	O
sex	O
-	O
country	O
group	O
.	O
In	O
2013	O
,	O
mental	B-T048
disorders	I-T048
contributed	O
to	O
5.6	O
%	O
of	O
the	O
total	O
disease	O
burden	O
in	O
the	O
EMR	O
(	O
1894	O
DALYS	O
/100,000	O
population	O
):	O
2519	O
DALYS	O
/100,000	O
(	O
2590/100,000	O
males	O
,	O
2426/100,000	O
females	O
)	O
in	O
high	B-T033
-	I-T033
income	I-T033
countries	O
,	O
1884	O
DALYS	O
/100,000	O
(	O
1618/100,000	O
males	O
,	O
2157/100,000	O
females	O
)	O
in	O
middle	O
-	O
income	O
countries	O
,	O
1607	O
DALYS	O
/100,000	O
(	O
1500/100,000	O
males	O
,	O
1717/100,000	O
females	O
)	O
in	O
low	B-T033
-	I-T033
income	I-T033
countries	O
.	O
Females	O
had	O
a	O
greater	O
proportion	O
of	O
burden	O
due	O
to	O
mental	B-T048
disorders	I-T048
than	O
did	O
males	O
of	O
equivalent	O
ages	O
,	O
except	O
for	O
those	O
under	O
15	O
years	O
of	O
age	O
.	O
The	O
highest	O
proportion	O
of	O
DALYs	O
occurred	O
in	O
the	O
25	O
-	O
49	O
age	O
group	O
,	O
with	O
a	O
peak	O
in	O
the	O
35	O
-	O
39	O
years	O
age	O
group	O
(	O
5344	O
DALYs	O
/100,000	O
)	O
.	O
The	O
burden	O
of	O
mental	B-T048
disorders	I-T048
in	O
EMR	O
increased	O
from	O
1726	O
DALYs	O
/100,000	O
in	O
1990	O
to	O
1912	O
DALYs	O
/100,000	O
in	O
2013	O
(	O
10.8	O
%	O
increase	O
)	O
.	O
Within	O
the	O
mental	O
disorders	O
group	O
in	O
EMR	O
,	O
depressive	B-T048
disorders	I-T048
accounted	O
for	O
most	O
DALYs	O
,	O
followed	O
by	O
anxiety	B-T048
disorders	I-T048
.	O
Among	O
EMR	O
countries	O
,	O
Palestine	O
had	O
the	O
largest	O
burden	O
of	O
mental	B-T048
disorders	I-T048
.	O
Nearly	O
all	O
EMR	O
countries	O
had	O
a	O
higher	O
mental	O
disorder	O
burden	O
compared	O
to	O
the	O
global	O
level	O
.	O
Our	O
findings	O
call	O
for	O
EMR	O
ministries	O
of	O
health	O
to	O
increase	O
provision	B-T033
of	O
mental	B-T058
health	I-T058
services	I-T058
and	O
to	O
address	O
the	O
stigma	B-T033
of	I-T033
mental	I-T033
illness	I-T033
.	O
Moreover	O
,	O
our	O
results	O
showing	O
the	O
accelerating	O
burden	O
of	O
mental	O
health	O
are	O
alarming	O
as	O
the	O
region	O
is	O
seeing	O
an	O
increased	O
level	O
of	O
instability	B-T033
.	O
Indeed	O
,	O
mental	B-T033
health	I-T033
problems	I-T033
,	O
if	O
not	O
properly	O
addressed	O
,	O
will	O
lead	O
to	O
an	O
increased	O
burden	O
of	O
diseases	O
in	O
the	O
region	O
.	O
      
Predicting	O
violence	B-T048
and	O
recidivism	O
in	O
a	O
large	O
sample	O
of	O
males	O
on	O
probation	O
or	O
parole	O
This	O
study	O
evaluated	O
the	O
utility	O
of	O
items	O
and	O
scales	O
from	O
the	O
Iowa	O
Violence	B-T048
and	O
Victimization	O
Instrument	O
in	O
a	O
sample	O
of	O
1961	O
males	O
from	O
the	O
state	O
of	O
Iowa	O
who	O
were	O
on	O
probation	O
or	O
released	B-T033
from	I-T033
prison	I-T033
to	O
parole	O
supervision	O
.	O
This	O
is	O
the	O
first	O
study	O
to	O
examine	O
the	O
potential	O
of	O
the	O
Iowa	O
Violence	B-T048
and	O
Victimization	O
Instrument	O
to	O
predict	O
criminal	O
offenses	O
.	O
The	O
males	O
were	O
followed	O
for	O
30	O
months	O
immediately	O
following	O
their	O
admission	O
to	O
probation	O
or	O
parole	O
.	O
AUC	O
analyses	O
indicated	O
fair	O
to	O
good	O
predictive	O
power	O
for	O
the	O
Iowa	O
Violence	B-T048
and	O
Victimization	O
Instrument	O
for	O
charges	O
of	O
violence	B-T048
and	O
victimization	O
,	O
but	O
chance	O
predictive	O
power	O
for	O
drug	O
offenses	O
.	O
Notably	O
,	O
both	O
scales	O
of	O
the	O
instrument	O
performed	O
equally	O
well	O
at	O
the	O
30-	O
month	O
follow	B-T058
-	I-T058
up	I-T058
.	O
Items	O
on	O
the	O
Iowa	O
Violence	B-T048
and	O
Victimization	O
Instrument	O
not	O
only	O
predicted	O
violence	B-T048
,	O
but	O
are	O
straightforward	O
to	O
score	O
.	O
Violence	B-T048
management	O
strategies	O
are	O
discussed	O
as	O
they	O
relate	O
to	O
the	O
current	O
findings	O
,	O
including	O
the	O
potential	O
to	O
expand	O
the	O
measure	O
to	O
other	O
jurisdictions	O
and	O
populations	O
.	O
      
Performance	O
and	O
safety	O
of	O
collagenated	O
xenogeneic	O
bone	O
block	O
for	O
lateral	B-T061
alveolar	I-T061
ridge	I-T061
augmentation	I-T061
and	O
staged	B-T061
implant	I-T061
placement	I-T061
.	O
A	O
monocenter	O
,	O
prospective	O
single	O
-	O
arm	O
clinical	O
study	O
To	O
assess	B-T058
the	O
clinical	O
safety	O
and	O
performance	O
of	O
collagenated	O
xenogeneic	O
bone	O
block	O
(	O
CXBB	O
)	O
for	O
lateral	B-T061
alveolar	I-T061
ridge	I-T061
augmentation	I-T061
and	O
two	O
-	O
stage	O
implant	B-T061
placement	I-T061
.	O
In	O
ten	O
patients	O
exhibiting	O
a	O
single	O
-	O
tooth	B-T023
gap	O
,	O
the	O
surgical	B-T061
procedure	I-T061
included	O
the	O
preparation	O
of	O
mucoperiosteal	B-T017
flaps	I-T017
,	O
a	O
rigid	B-T061
fixation	I-T061
of	O
CXBB	O
(	O
Geistlich	O
Bio	O
-	O
Graft	O
(	O
®	O
)	O
)	O
using	O
an	O
osteosynthesis	O
screw	O
,	O
and	O
contour	O
augmentation	B-T061
.	O
After	O
24	O
weeks	O
of	O
submerged	O
healing	O
,	O
the	O
primary	O
endpoint	O
was	O
defined	O
as	O
the	O
final	O
ridge	O
width	O
sufficient	O
to	O
place	O
an	O
adequately	O
dimensioned	O
titanium	B-T061
implant	I-T061
at	O
the	O
respective	O
sites	O
.	O
Secondary	O
outcomes	O
included	O
,	O
for	O
example	O
,	O
the	O
gain	O
in	O
ridge	O
width	O
(	O
mm	O
)	O
.	O
Clinical	O
parameters	O
(	O
e.g.	O
,	O
bleeding	B-T033
on	I-T033
probing	I-T033
-	O
BOP	B-T033
,	O
probing	O
depth	O
-	O
PD	O
,	O
mucosal	B-T190
recession	I-T190
-	O
MR	B-T190
)	O
were	O
assessed	O
immediately	O
after	O
the	O
cementation	B-T061
of	I-T061
the	I-T061
crown	I-T061
and	O
at	O
the	O
final	B-T061
visit	I-T061
.	O
At	O
24	O
weeks	O
,	O
implant	B-T061
placement	I-T061
could	O
be	O
achieved	O
in	O
8	O
of	O
10	O
patients	O
exhibiting	O
a	O
mean	O
gain	O
in	O
ridge	O
width	O
(	O
mean	O
±	O
SD	O
)	O
of	O
3.88	O
±	O
1.75	O
mm	O
.	O
Histological	O
analysis	O
has	O
pointed	O
to	O
a	O
homogeneous	O
osseous	B-T023
organization	O
of	O
CXBB	O
.	O
The	O
changes	O
of	O
mean	O
BOP	B-T033
,	O
PD	O
,	O
and	O
MR	B-T190
values	O
at	O
the	O
final	B-T061
visit	I-T061
amounted	O
to	O
16.62	O
±	O
32.02	O
%	O
,	O
0.04	O
±	O
0.21	O
mm	O
,	O
and	O
-0.04	O
±	O
0.12	O
mm	O
,	O
respectively	O
.	O
CXBB	O
may	O
be	O
successfully	O
used	O
to	O
support	O
lateral	B-T061
alveolar	I-T061
ridge	I-T061
augmentation	I-T061
and	O
two	O
-	O
stage	O
implant	B-T061
placement	I-T061
.	O
      
Gut	B-T001
microbiota	I-T001
-mediated	O
protection	B-T033
against	O
diarrheal	B-T184
infections	O
The	O
mammalian	O
gut	B-T001
microbiota	I-T001
is	O
a	O
highly	O
abundant	O
and	O
diverse	O
microbial	B-T001
community	O
that	O
resides	O
in	O
the	O
gastrointestinal	O
tract	O
.	O
One	O
major	O
benefit	O
that	O
the	O
gut	B-T001
microbiota	I-T001
provides	O
to	O
its	O
host	B-T001
is	O
colonization	B-T033
resistance	O
-the	O
ability	O
to	O
prevent	O
colonization	B-T033
by	O
foreign	B-T001
microbes	I-T001
,	O
including	O
diarrheal	B-T184
pathogens	B-T001
such	O
as	O
Clostridium	B-T007
difficile	I-T007
,	O
Salmonella	B-T007
enterica	I-T007
serovar	I-T007
Typhimurium	I-T007
and	O
diarrheagenic	B-T007
Escherichia	I-T007
coli	I-T007
.	O
We	O
conducted	O
a	O
literature	O
review	O
of	O
the	O
effects	O
of	O
the	O
gut	B-T001
microbiota	I-T001
on	O
infection	O
by	O
diarrheal	B-T184
pathogens	B-T001
.	O
We	O
used	O
PubMed	O
to	O
search	O
for	O
relevant	O
articles	O
published	O
before	O
July	O
2016	O
,	O
as	O
well	O
as	O
incorporated	O
data	O
from	O
our	O
laboratory	O
.	O
The	O
gut	B-T001
microbiota	I-T001
provides	O
protection	B-T033
from	O
diarrheal	B-T184
infections	O
both	O
by	O
direct	O
inhibition	O
of	O
pathogens	B-T001
and	O
by	O
indirect	O
effects	O
on	O
host	B-T001
functions	O
.	O
Direct	O
effects	O
of	O
the	O
microbiota	B-T001
on	O
diarrheal	B-T184
pathogens	B-T001
include	O
competing	O
for	O
nutrients	O
and	O
producing	O
metabolites	O
that	O
inhibit	O
pathogen	B-T001
growth	O
or	O
virulence	O
.	O
Indirect	O
effects	O
of	O
the	O
gut	B-T001
microbiota	I-T001
include	O
promoting	O
maintenance	O
of	O
the	O
gut	O
mucosal	O
barrier	O
and	O
stimulating	O
innate	O
and	O
adaptive	O
immunity	O
.	O
Human	O
epidemiological	O
studies	O
and	O
experimental	O
infections	O
of	O
laboratory	O
animals	O
both	O
demonstrate	O
that	O
antibiotic	B-T061
treatment	I-T061
can	O
alter	O
the	O
gut	B-T001
microbial	I-T001
community	O
and	O
thereby	O
reduce	O
colonization	B-T033
resistance	O
against	O
diarrheal	B-T184
pathogens	B-T001
.	O
Further	O
research	O
might	O
lead	O
to	O
the	O
development	O
of	O
next	B-T007
-	I-T007
generation	I-T007
probiotics	I-T007
that	O
could	O
be	O
used	O
to	O
bolster	O
colonization	B-T033
resistance	O
and	O
thus	O
prevent	O
travellers	B-T047
'	I-T047
diarrheal	I-T047
.	O
      
A	O
new	O
angle	O
and	O
its	O
relationship	O
with	O
early	O
fixation	O
failure	O
of	O
femoral	O
neck	O
fractures	O
treated	O
with	O
three	O
cannulated	O
compression	O
screws	O
The	O
Pauwels	O
angle	O
has	O
been	O
used	O
widely	O
,	O
however	O
an	O
accurate	O
evaluation	O
of	O
this	O
angle	O
is	O
difficult	O
because	O
of	O
deformity	B-T190
of	O
the	O
affected	O
lower	B-T023
extremity	I-T023
.	O
Therefore	O
we	O
designed	O
a	O
new	O
measurement	O
of	O
the	O
orientation	O
of	O
femoral	O
neck	O
fracture	O
and	O
applied	O
this	O
in	O
a	O
retrospective	O
study	O
to	O
assess	O
:	O
(	O
1	O
)	O
its	O
reproducibility	O
,	O
(	O
2	O
)	O
its	O
advantages	O
compared	O
with	O
the	O
Pauwels	O
angle	O
,	O
(	O
3	O
)	O
its	O
relationship	O
with	O
the	O
short	B-T058
-	I-T058
term	I-T058
prognosis	I-T058
treated	O
with	O
three	O
cannulated	O
compression	O
screws	O
.	O
This	O
new	O
measurement	O
is	O
reproducible	O
and	O
has	O
some	O
reference	O
meaning	O
for	O
the	O
treatment	B-T061
of	O
femoral	O
neck	O
fractures	O
.	O
Two	O
hundred	O
and	O
twenty	O
-	O
eight	O
patients	O
with	O
femoral	O
neck	O
fractures	O
treated	O
with	O
three	O
cannulated	O
compression	O
screws	O
were	O
retrospectively	O
analyzed	O
.	O
The	O
VN	O
angle	O
,	O
which	O
was	O
the	O
angle	O
between	O
the	O
fracture	O
line	O
and	O
the	O
vertical	O
of	O
the	O
neck	O
axis	O
,	O
and	O
the	O
Pauwels	O
angle	O
were	O
measured	O
respectively	O
.	O
The	O
method	O
of	O
ICC	O
was	O
performed	O
to	O
assess	O
the	O
reproducibility	O
of	O
the	O
two	O
angles	O
,	O
and	O
the	O
absolute	O
value	O
of	O
difference	O
in	O
pre	O
-	O
operative	O
and	O
post	O
-	O
operative	O
radiographs	B-T060
was	O
used	O
to	O
evaluate	O
the	O
uniformity	O
of	O
the	O
two	O
angles	O
.	O
These	O
fractures	O
were	O
divided	O
into	O
four	O
groups	O
according	O
to	O
VN	O
angle	O
(	O
VN<0	O
°	O
(	O
n=92	O
)	O
,	O
0	O
°	O
≤VN<10	O
°	O
(	O
n=82	O
)	O
,	O
10	O
°	O
≤VN<15	O
°	O
(	O
n=26	O
)	O
,	O
VN≥15	O
°	O
(	O
n=28	O
)	O
)	O
,	O
and	O
the	O
short	O
-	O
term	O
(	O
within	O
6	O
months	O
)	O
fixation	B-T061
results	O
of	O
radiographs	B-T060
in	O
these	O
fractures	O
were	O
evaluated	O
.	O
The	O
ICC	O
of	O
the	O
VN	O
angle	O
and	O
the	O
Pauwels	O
angle	O
in	O
pre	O
-	O
operative	O
radiographs	B-T060
were	O
0.937	O
(	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
):	O
0.922	O
-	O
0.950	O
)	O
and	O
0.942	O
respectively	O
(	O
95	O
%	O
CI	O
:	O
0.914	O
-	O
0.970	O
)	O
,	O
indicating	O
both	O
angles	O
had	O
a	O
good	O
inter	O
-	O
rater	O
reproducibility	O
.	O
However	O
,	O
there	O
was	O
a	O
great	O
difference	O
between	O
the	O
Pauwels	O
angle	O
in	O
pre	O
-	O
operative	O
and	O
post	O
-	O
operative	O
radiographs	B-T060
(	O
P=0.037	O
)	O
,	O
the	O
absolute	O
difference	O
was	O
10.66±6.47	O
(	O
range	O
:	O
1.72	O
-	O
38.48	O
)	O
,	O
while	O
no	O
statistical	O
difference	O
for	O
the	O
VN	O
angle	O
(	O
P=0.084	O
)	O
and	O
the	O
absolute	O
difference	O
was	O
2.20±1.63	O
(	O
range	O
:	O
0.05	O
-	O
7.56	O
)	O
.	O
The	O
overall	O
fixation	O
failure	O
rate	O
which	O
was	O
defined	O
as	O
screw	O
loosening	O
,	O
varus	O
collapse	O
,	O
obvious	O
fracture	O
displacement	O
or	O
femoral	B-T023
neck	I-T023
shortening	O
was	O
11.84	O
%	O
,	O
and	O
the	O
mean	O
failure	O
rates	O
according	O
to	O
VN	O
angles	O
were	O
respectively	O
0	O
%	O
,	O
3.24	O
%	O
(	O
95	O
%	O
CI	O
:	O
1.64	O
-	O
4.84	O
)	O
,	O
22.69	O
%	O
(	O
95	O
%	O
CI	O
:	O
16.43	O
-	O
28.96	O
)	O
,	O
65.45	O
%	O
(	O
95	O
%	O
CI	O
:	O
59.36	O
-	O
71.53	O
)	O
.	O
The	O
mean	O
failure	O
rates	O
of	O
fractures	O
according	O
to	O
post	O
-	O
operative	O
Pauwels	O
angle	O
(	O
<	O
30	O
°	O
,	O
30	O
-	O
50	O
°	O
,	O
>	O
50	O
°	O
)	O
were	O
respectively	O
0	O
%	O
,	O
1.46	O
%	O
(	O
95	O
%	O
CI	O
:	O
1.42	O
-	O
1.50	O
)	O
and	O
36.24	O
%	O
(	O
95	O
%	O
CI	O
:	O
34.93	O
-	O
37.54	O
)	O
.	O
The	O
VN	O
angle	O
has	O
a	O
good	O
inter	O
-	O
rater	O
reproducibility	O
,	O
a	O
higher	O
reliability	O
than	O
the	O
Pauwels	O
angle	O
and	O
is	O
closely	O
related	O
to	O
the	O
short	B-T058
-	I-T058
term	I-T058
prognosis	I-T058
of	O
femoral	O
neck	O
fractures	O
treated	O
with	O
cannulated	O
compression	O
screws	O
.	O
Level	O
IV	O
,	O
retrospective	O
diagnostic	O
study	O
.	O
      
Identification	O
of	O
the	O
anti	B-T121
-	I-T121
mycobacterial	I-T121
functional	O
properties	O
of	O
piperidinol	B-T121
derivatives	I-T121
Tuberculosis	B-T047
(	O
TB	B-T047
)	O
remains	O
a	O
major	O
global	O
health	O
threat	O
and	O
is	O
now	O
the	O
leading	O
cause	B-T033
of	I-T033
death	I-T033
from	O
a	O
single	O
infectious	B-T001
agent	I-T001
worldwide	O
.	O
The	O
current	O
TB	B-T047
drug	B-T121
regimen	B-T061
is	O
inadequate	O
,	O
and	O
new	O
anti	B-T121
-	I-T121
tubercular	I-T121
agents	I-T121
are	O
urgently	O
required	O
to	O
be	O
able	O
to	O
successfully	O
combat	O
the	O
increasing	O
prevalence	O
of	O
drug	B-T047
-	I-T047
resistant	I-T047
TB	I-T047
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
a	O
piperidinol	B-T121
compound	I-T121
derivative	I-T121
that	O
is	O
highly	O
active	O
against	O
the	O
Mycobacterium	B-T007
tuberculosis	I-T007
bacillus	B-T007
.	O
The	O
antibacterial	B-T195
properties	O
of	O
the	O
piperidinol	B-T121
compound	I-T121
and	O
its	O
corresponding	O
bis	O
-	O
Mannich	O
base	O
analogue	O
were	O
evaluated	B-T058
against	O
M.	B-T007
smegmatis	I-T007
and	O
Gram	B-T007
-	I-T007
negative	I-T007
organisms	I-T007
.	O
Cytotoxicity	O
studies	O
were	O
undertaken	O
in	O
order	O
to	O
determine	O
the	O
selectivity	O
index	O
for	O
these	O
compounds	B-T121
.	O
Spontaneous	O
resistant	O
mutants	O
of	O
M.	B-T007
smegmatis	I-T007
were	O
generated	O
against	O
the	O
piperidinol	B-T121
and	O
corresponding	O
bis	B-T121
-	I-T121
Mannich	I-T121
base	I-T121
lead	I-T121
derivatives	I-T121
and	O
whole	O
genome	O
sequencing	O
employed	O
to	O
determine	O
the	O
genetic	O
modifications	O
that	O
lead	O
to	O
selection	O
pressure	O
in	O
the	O
presence	O
of	O
these	O
compounds	B-T121
.	O
The	O
piperidinol	B-T121
and	O
the	O
bis	B-T121
-	I-T121
Mannich	I-T121
base	I-T121
analogue	I-T121
were	O
found	O
to	O
be	O
selective	O
for	O
mycobacteria	B-T007
and	O
rapidly	O
kill	O
this	O
organism	B-T001
with	O
a	O
cytotoxicity	O
selectivity	O
index	O
for	O
mycobacteria	B-T007
of	O
>	O
30	O
-	O
fold	O
.	O
Whole	O
genome	O
sequencing	O
of	O
M.	B-T007
smegmatis	I-T007
strains	B-T001
resistant	O
to	O
the	O
lead	B-T121
compounds	I-T121
led	O
to	O
the	O
identification	O
of	O
a	O
number	O
of	O
single	O
nucleotide	O
polymorphisms	O
indicating	O
multiple	O
targets	O
.	O
Our	O
results	B-T033
indicate	O
that	O
the	O
piperidinol	B-T121
moiety	I-T121
represents	O
an	O
attractive	O
compound	B-T121
class	I-T121
in	O
the	O
pursuit	O
of	O
novel	O
anti	B-T121
-	I-T121
tubercular	I-T121
agents	I-T121
.	O
      
A	O
role	O
for	O
the	O
locus	B-T023
coeruleus	I-T023
in	O
the	O
analgesic	B-T033
efficacy	I-T033
of	O
N	O
-	O
acetylaspartylglutamate	O
peptidase	O
(	O
GCPII	O
)	O
inhibitors	B-T121
ZJ43	B-T121
and	O
2	O
-	O
PMPA	O
N	B-T121
-	I-T121
acetylaspartylglutamate	I-T121
(	O
NAAG	B-T121
)	O
is	O
the	O
third	O
most	O
prevalent	O
and	O
widely	O
distributed	O
neurotransmitter	O
in	O
the	O
mammalian	O
nervous	O
system	O
.	O
NAAG	B-T121
activates	O
a	O
group	O
II	O
metabotropic	O
glutamate	O
receptor	O
(	O
mGluR3	O
)	O
and	O
is	O
inactivated	O
by	O
an	O
extracellular	O
enzyme	O
,	O
glutamate	O
carboxypeptidase	O
II	O
(	O
GCPII	O
)	O
in	O
vivo	O
.	O
Inhibitors	B-T121
of	I-T121
this	I-T121
enzyme	I-T121
are	O
analgesic	B-T121
in	O
animal	O
models	O
of	O
inflammatory	B-T184
,	O
neuropathic	B-T033
and	O
bone	B-T191
cancer	I-T191
pain	B-T184
.	O
NAAG	B-T121
and	O
GCPII	O
are	O
present	O
in	O
the	O
locus	B-T023
coeruleus	I-T023
,	O
a	O
center	O
for	O
the	O
descending	O
noradrenergic	O
inhibitory	O
pain	O
system	O
.	O
In	O
the	O
formalin	B-T121
footpad	B-T023
model	B-T050
,	O
systemic	O
treatment	O
with	O
GCPII	B-T121
inhibitors	I-T121
reduces	O
both	O
phases	O
of	O
the	O
inflammatory	B-T184
pain	I-T184
response	O
and	O
increases	O
release	O
of	O
spinal	O
noradrenaline	B-T121
.	O
This	O
analgesic	B-T033
efficacy	I-T033
is	O
blocked	O
by	O
systemic	O
injection	B-T061
of	O
a	O
group	O
II	O
mGluR	O
antagonist	B-T121
,	O
by	O
intrathecal	B-T061
(	I-T061
spinal	I-T061
)	I-T061
injection	I-T061
of	O
an	O
alpha	B-T121
2	I-T121
adrenergic	I-T121
receptor	I-T121
antagonist	I-T121
and	O
by	O
microinjection	B-T061
of	O
an	O
α	B-T121
-	I-T121
amino-3	I-T121
-	I-T121
hydroxy-5	I-T121
-	I-T121
methylisoxazole-4	I-T121
-	I-T121
propionic	I-T121
acid	I-T121
(	I-T121
AMPA	I-T121
)	I-T121
receptor	I-T121
antagonist	I-T121
directly	O
into	O
the	O
contralateral	O
locus	B-T023
coeruleus	I-T023
.	O
Footpad	B-T023
inflammation	O
increases	O
release	O
of	O
glutamate	O
in	O
the	O
contralateral	O
locus	B-T023
coeruleu	I-T023
s	O
and	O
systemic	O
treatment	O
with	O
a	O
GCPII	B-T121
inhibitor	I-T121
blocks	O
this	O
increase	O
.	O
Direct	O
injection	B-T061
of	O
GCPII	B-T121
inhibitors	I-T121
into	O
the	O
contralateral	O
or	O
ipsilatera	O
l	O
locus	B-T023
coeruleus	I-T023
reduces	O
both	O
phases	O
of	O
the	O
inflammatory	B-T184
pain	I-T184
response	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
and	O
the	O
contralateral	O
effect	O
also	O
is	O
blocked	O
by	O
intrathecal	B-T061
injection	I-T061
of	O
an	O
alpha	B-T121
2	I-T121
adrenergic	I-T121
receptor	I-T121
antagonist	I-T121
.	O
These	O
data	O
support	O
the	O
hypothesis	O
that	O
the	O
analgesic	B-T033
efficacy	I-T033
of	O
systemically	O
administered	O
GCPII	B-T121
inhibitors	I-T121
is	O
mediated	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
the	O
contralatera	O
l	O
locus	B-T023
coeruleus	I-T023
via	O
group	O
II	O
mGluR	O
,	O
AMPA	O
and	O
alpha	O
2	O
adrenergic	O
receptors	O
.	O
      
Safety	O
of	O
transradial	B-T060
diagnostic	I-T060
cardiac	I-T060
catheterization	I-T060
in	O
patients	O
under	O
oral	O
anticoagulant	B-T061
therapy	I-T061
Cardiac	B-T058
catheterization	I-T058
in	O
anticoagulated	O
patients	O
is	O
usually	O
performed	O
after	O
the	O
anticoagulation	B-T061
has	O
been	O
withdrawn	B-T061
,	O
at	O
least	O
in	O
the	O
previous	O
48h	O
,	O
and	O
sometimes	O
bridging	B-T061
therapy	I-T061
with	I-T061
heparin	I-T061
is	O
used	O
.	O
A	O
prospective	O
observational	O
study	O
including	O
489	O
patients	O
undergoing	O
transradial	B-T058
catheterization	I-T058
was	O
conducted	O
.	O
A	O
total	O
of	O
140	O
patients	O
were	O
under	O
acenocoumarol	B-T121
(	O
group	O
A	O
)	O
and	O
they	O
were	O
compared	O
with	O
the	O
remainder	O
(	O
group	O
B	O
)	O
for	O
complications	O
after	O
the	O
procedure	B-T058
(	O
bleeding	O
and	O
vascular	O
access	O
complications	O
)	O
.	O
Patients	O
in	O
group	O
A	O
were	O
older	O
(	O
74±12	O
years	O
vs.	O
68±17	O
years	O
,	O
p<0.01	O
)	O
and	O
the	O
main	O
indication	O
for	O
anticoagulation	B-T061
was	O
atrial	B-T047
fibrillation	I-T047
(	O
58.6	O
%	O
)	O
.	O
No	B-T033
complications	O
occurred	O
during	O
the	O
procedures	B-T058
.	O
There	O
were	O
no	B-T033
acute	O
bleedings	O
just	O
after	O
the	O
bandage	O
removal	O
.	O
During	O
the	O
first	O
24h	O
,	O
only	O
3	O
(	O
2.1	O
%	O
)	O
radial	O
occlusions	O
in	O
group	O
A	O
and	O
2	O
(	O
0.6	O
%	O
)	O
in	O
group	O
B	O
(	O
p=0.14	O
)	O
were	O
recorded	O
.	O
Hematomas	O
between	O
5	O
and	O
10	O
cm	O
appeared	O
in	O
5	O
%	O
of	O
the	O
group	O
A	O
vs.	O
4.6	O
%	O
in	O
group	O
B.	O
During	O
the	O
1	O
-	O
month	O
follow	B-T058
-	I-T058
up	I-T058
period	O
,	O
one	O
more	O
radial	O
occlusion	O
in	O
each	O
group	O
was	O
recorded	O
and	O
there	O
were	O
4	O
(	O
1.1	O
%	O
)	O
additional	O
mild	O
hematomas	O
in	O
group	O
B	O
and	O
none	O
in	O
group	O
A	O
(	O
p=0.48	O
)	O
.	O
Performing	O
a	O
transradial	B-T060
diagnostic	I-T060
cardiac	I-T060
catheterization	I-T060
without	O
removal	O
of	O
the	O
oral	O
chronic	O
anticoagulation	O
appears	O
safe	B-T033
in	O
patients	O
under	O
acenocumarol	B-T121
therapy	B-T061
.	O
      
Nutritional	O
aspects	O
of	O
night	O
eating	O
and	O
its	O
association	O
with	O
weight	O
status	O
among	O
Korean	O
adolescents	O
A	O
growing	O
body	O
of	O
research	O
has	O
indicated	O
that	O
night	O
eating	O
could	O
be	O
associated	O
with	O
poor	B-T033
diet	I-T033
quality	O
and	O
negative	B-T033
health	O
outcomes	O
.	O
This	O
study	O
examined	O
the	O
nutritional	O
aspects	O
of	O
night	O
eating	O
,	O
its	O
related	O
factors	O
,	O
and	O
the	O
association	O
between	O
night	O
eating	O
and	O
body	O
weight	O
among	O
Korean	O
adolescents	O
.	O
This	O
study	O
analysed	O
the	O
data	O
from	O
a	O
one	O
day	O
24	O
-	O
hour	O
dietary	O
recall	O
as	O
well	O
as	O
a	O
demographic	O
survey	O
of	O
1,738	O
Korean	O
adolescents	O
aged	O
12	O
to	O
18-	O
years	O
-old	O
obtained	O
from	O
the	O
2010	O
-	O
2012	O
Korea	O
National	O
Health	O
and	O
Nutrition	O
Examination	O
Survey	O
.	O
'	O
Night	O
eating	O
'	O
was	O
defined	O
as	O
consuming	O
25	O
%	O
or	O
more	O
of	O
one	O
's	O
daily	O
energy	O
intake	O
between	O
21:00	O
and	O
06:00	O
.	O
Subjects	O
complying	O
with	O
the	O
preceding	O
condition	O
were	O
classified	O
as	O
'	O
night	O
eaters	O
'	O
,	O
whereas	O
the	O
rest	O
were	O
considered	O
'	O
non	O
-	O
night	O
eaters	O
'	O
.	O
Logistic	O
regression	O
analysis	O
examined	O
factors	O
related	O
to	O
night	O
eating	O
.	O
Multiple	O
linear	O
regression	O
analyses	O
were	O
used	O
to	O
examine	O
the	O
relationship	O
between	O
night	O
eating	O
and	O
BMI	O
z	O
-	O
scores	O
,	O
whereas	O
multinomial	O
logistic	O
regression	O
analysis	O
was	O
used	O
to	O
examine	O
the	O
relationship	O
between	O
night	O
eating	O
and	O
weight	O
status	O
.	O
About	O
21	O
%	O
of	O
Korean	O
adolescents	O
appeared	O
to	O
be	O
night	O
eaters	O
.	O
Night	O
eaters	O
showed	O
increased	O
breakfast	O
skipping	B-T033
(	O
P	O
=	O
0.001	O
)	O
,	O
higher	O
energy	O
intake	O
from	O
snacks	O
(	O
P	O
<	O
0.001	O
)	O
,	O
greater	O
proportion	O
of	O
energy	O
intake	O
from	O
fat	O
(	O
P	O
=	O
0.029	O
)	O
,	O
and	O
lower	O
Dietary	O
Diversity	O
Scores	O
(	O
P	O
=	O
0.008	O
)	O
than	O
non	O
-	O
night	O
eaters	O
.	O
Male	O
adolescents	O
presented	O
1.9	O
times	O
higher	O
odds	O
of	O
being	O
night	O
eaters	O
than	O
females	O
.	O
Adolescents	O
whose	O
both	O
parents	O
were	O
night	O
eaters	O
were	O
4.4	O
times	O
as	O
likely	O
to	O
be	O
night	O
eaters	O
as	O
those	O
whose	O
neither	O
parents	O
were	O
.	O
Female	O
adolescents	O
showed	O
a	O
significant	O
relationship	O
between	O
night	O
eating	O
and	O
BMI	O
z	O
-	O
scores	O
(	O
β	O
=	O
0.28	O
,	O
P	O
=	O
0.004	O
)	O
.	O
However	O
,	O
night	O
eating	O
did	O
not	O
increase	O
odds	O
of	O
being	O
overweight	B-T184
or	O
obese	B-T047
in	O
adolescents	O
.	O
Night	O
eating	O
in	O
Korean	O
adolescents	O
was	O
related	O
to	O
undesirable	B-T033
dietary	I-T033
behaviours	I-T033
and	O
low	B-T033
diet	I-T033
quality	I-T033
in	O
general	O
as	O
well	O
as	O
higher	O
BMI	O
z	O
-	O
scores	O
in	O
females	O
.	O
Male	O
gender	O
and	O
parental	O
night	O
eating	O
appeared	O
to	O
be	O
the	O
factors	O
that	O
significantly	O
increased	O
odds	O
of	O
night	O
eating	O
.	O
These	O
results	O
suggest	O
that	O
night	O
eating	O
should	O
be	O
considered	O
when	O
designing	O
nutrition	O
education	O
or	O
intervention	B-T061
programs	I-T061
targeting	O
adolescents	O
.	O
      
Selective	O
reaching	O
in	O
macaques	O
:	O
evidence	O
for	O
action	O
-centred	O
attention	O
When	O
a	O
monkey	O
selects	O
a	O
piece	O
of	O
food	O
lying	O
on	O
the	O
ground	O
from	O
among	O
other	O
viable	O
objects	O
in	O
the	O
near	O
vicinity	O
,	O
only	O
the	O
desired	O
item	O
governs	O
the	O
particular	O
pattern	O
and	O
direction	O
of	O
the	O
animal	O
's	O
reaching	O
action	O
.	O
It	O
would	O
seem	O
then	O
that	O
selection	O
is	O
an	O
important	O
component	O
controlling	O
the	O
animal	O
's	O
action	O
.	O
But	O
,	O
we	O
may	O
ask	O
,	O
is	O
the	O
selection	O
process	O
in	O
such	O
cases	O
impervious	O
to	O
the	O
presence	O
of	O
other	O
objects	O
that	O
could	O
constitute	O
potential	O
obstacles	O
to	O
or	O
constraints	O
on	O
movement	O
execution	O
?	O
And	O
if	O
it	O
is	O
,	O
in	O
fact	O
,	O
pervious	O
to	O
other	O
objects	O
,	O
do	O
they	O
have	O
a	O
direct	O
influence	O
on	O
the	O
organization	O
of	O
the	O
response	O
?	O
The	O
kinematics	O
of	O
macaques	O
'	O
reaching	O
movements	O
were	O
examined	B-T033
by	O
the	O
current	O
study	O
that	O
analysed	O
some	O
exemplars	O
as	O
they	O
selectively	O
reached	O
to	O
grasp	O
a	O
food	O
item	O
in	O
the	O
absence	O
as	O
well	O
as	O
in	O
the	O
presence	O
of	O
potential	O
obstacles	O
(	O
i.e.	O
,	O
stones	O
)	O
that	O
could	O
affect	O
the	O
arm	O
trajectory	O
.	O
Changes	O
in	O
movement	O
parameterization	O
were	O
noted	O
in	O
temporal	O
measures	O
,	O
such	O
as	O
movement	O
time	O
,	O
as	O
well	O
as	O
in	O
spatial	O
ones	O
,	O
such	O
as	O
paths	O
of	O
trajectory	O
.	O
Generally	O
speaking	O
,	O
the	O
presence	O
of	O
stones	O
in	O
the	O
vicinity	O
of	O
the	O
acting	O
hand	B-T023
stalled	O
the	O
reaching	O
movement	O
and	O
affected	O
the	O
arm	O
trajectory	O
as	O
the	O
hand	B-T023
veered	B-T033
away	I-T033
from	O
the	O
stone	O
even	O
when	O
it	O
was	O
not	O
a	O
physical	O
obstacle	O
.	O
We	O
concluded	O
that	O
nearby	O
objects	O
evoke	O
a	O
motor	O
response	O
in	O
macaques	O
,	O
and	O
the	O
attentional	O
mechanisms	O
that	O
allow	O
for	O
a	O
successful	O
action	O
selection	O
are	O
revealed	O
in	O
the	O
reaching	O
path	O
.	O
The	O
data	O
outlined	O
here	O
concur	O
with	O
human	O
studies	O
indicating	O
that	O
potential	O
obstacles	O
are	O
internally	O
represented	O
,	O
a	O
finding	B-T033
implying	O
basic	O
cognitive	O
operations	O
allowing	O
for	O
action	O
selection	O
in	O
macaques	O
.	O
      
Delta	B-T033
-	I-T033
frequency	I-T033
stimulation	O
of	O
cerebellar	B-T023
projections	O
can	O
compensate	O
for	O
schizophrenia	B-T048
-related	O
medial	B-T048
frontal	I-T048
dysfunction	I-T048
Schizophrenia	B-T048
involves	O
abnormalities	B-T033
in	O
the	O
medial	B-T023
frontal	I-T023
cortex	I-T023
that	O
lead	O
to	O
cognitive	B-T048
deficits	I-T048
.	O
Here	O
we	O
investigate	O
a	O
novel	O
strategy	O
to	O
normalize	O
medial	O
frontal	O
brain	O
activity	O
by	O
stimulating	O
cerebellar	B-T023
projections	O
.	O
We	O
used	O
an	O
interval	O
timing	O
task	O
to	O
study	O
elementary	O
cognitive	O
processing	O
that	O
requires	O
both	O
frontal	B-T023
and	O
cerebellar	B-T023
networks	I-T023
that	O
are	O
disrupted	O
in	O
patients	O
with	O
schizophrenia	B-T048
.	O
We	O
report	O
three	O
novel	O
findings	B-T033
.	O
First	O
,	O
patients	O
with	O
schizophrenia	B-T048
had	O
dysfunctional	O
delta	O
rhythms	O
between	O
1	O
-	O
4	O
Hz	O
in	O
the	O
medial	B-T023
frontal	I-T023
cortex	I-T023
.	O
We	O
explored	O
cerebellar	B-T023
-	O
frontal	B-T023
interactions	O
in	O
animal	O
models	O
and	O
found	O
that	O
both	O
frontal	B-T023
and	O
cerebellar	O
neurons	O
were	O
modulated	O
during	O
interval	O
timing	O
and	O
had	O
delta	B-T033
-	I-T033
frequency	I-T033
interactions	O
.	O
Finally	O
,	O
delta	B-T033
-	I-T033
frequency	I-T033
optogenetic	O
stimulation	O
of	O
thalamic	B-T023
synaptic	O
terminals	O
of	O
lateral	O
cerebellar	B-T023
projection	O
neurons	O
rescued	O
timing	O
performance	O
as	O
well	O
as	O
medial	O
frontal	O
activity	O
in	O
a	O
rodent	B-T050
model	I-T050
of	O
schizophrenia	B-T048
-	I-T048
related	I-T048
frontal	B-T048
dysfunction	I-T048
.	O
These	O
data	O
provide	O
insight	O
into	O
how	O
the	O
cerebellum	B-T023
influences	O
medial	O
frontal	O
networks	O
and	O
the	O
role	O
of	O
the	O
cerebellum	B-T023
in	O
cognitive	O
processing	O
.	O
      
eNOS	O
S	O
-	O
nitrosylates	O
β	O
-	O
actin	O
on	O
Cys374	O
and	O
regulates	O
PKC	O
-	O
θ	O
at	O
the	O
immune	O
synapse	O
by	O
impairing	O
actin	O
binding	O
to	O
profilin-1	O
The	O
actin	O
cytoskeleton	O
coordinates	O
the	O
organization	O
of	O
signaling	O
microclusters	O
at	O
the	O
immune	O
synapse	O
(	O
IS	O
)	O
;	O
however	O
,	O
the	O
mechanisms	O
involved	O
remain	O
poorly	O
understood	O
.	O
We	O
show	O
here	O
that	O
nitric	B-T121
oxide	I-T121
(	O
NO	B-T121
)	O
generated	O
by	O
endothelial	O
nitric	O
oxide	O
synthase	O
(	O
eNOS	O
)	O
controls	O
the	O
coalescence	O
of	O
protein	O
kinase	O
C	O
-	O
θ	O
(	O
PKC	O
-	O
θ	O
)	O
at	O
the	O
central	O
supramolecular	O
activation	O
cluster	O
(	O
c	O
-	O
SMAC	O
)	O
of	O
the	O
IS	O
.	O
eNOS	O
translocated	O
with	O
the	O
Golgi	O
to	O
the	O
IS	O
and	O
partially	O
colocalized	O
with	O
F	O
-	O
actin	O
around	O
the	O
c	O
-	O
SMAC	O
.	O
This	O
resulted	O
in	O
reduced	O
actin	O
polymerization	O
and	O
centripetal	O
retrograde	O
flow	O
of	O
β	O
-	O
actin	O
and	O
PKC	O
-	O
θ	O
from	O
the	O
lamellipodium	O
-	O
like	O
distal	O
(	O
d)-SMAC	O
,	O
promoting	O
PKC	O
-	O
θ	O
activation	O
.	O
Furthermore	O
,	O
eNOS	O
-derived	O
NO	B-T121
S	O
-	O
nitrosylated	O
β	O
-	O
actin	O
on	O
Cys374	O
and	O
impaired	O
actin	O
binding	O
to	O
profilin-1	O
(	O
PFN1	O
)	O
,	O
as	O
confirmed	O
with	O
the	O
transnitrosylating	O
agent	O
S	B-T121
-	I-T121
nitroso	I-T121
-	I-T121
L	I-T121
-	I-T121
cysteine	I-T121
(	O
Cys	B-T121
-	I-T121
NO	I-T121
)	O
.	O
The	O
importance	O
of	O
NO	B-T121
and	O
the	O
formation	O
of	O
PFN1	O
-	O
actin	O
complexes	O
on	O
the	O
regulation	O
of	O
PKC	O
-	O
θ	O
was	O
corroborated	O
by	O
overexpression	O
of	O
PFN1	O
-	O
and	O
actin	O
-	O
binding	O
defective	O
mutants	O
of	O
β	O
-	O
actin	O
(	O
C374S	O
)	O
and	O
PFN1	O
(	O
H119E	O
)	O
,	O
respectively	O
,	O
which	O
reduced	O
the	O
coalescence	O
of	O
PKC	O
-	O
θ	O
at	O
the	O
c	O
-	O
SMAC	O
.	O
These	O
findings	O
unveil	O
a	O
novel	O
NO	B-T121
-dependent	O
mechanism	O
by	O
which	O
the	O
actin	O
cytoskeleton	O
controls	O
the	O
organization	O
and	O
activation	O
of	O
signaling	O
microclusters	O
at	O
the	O
IS	O
.	O
      
Stromal	B-T033
alterations	I-T033
in	O
ovarian	B-T191
cancers	I-T191
via	O
wavelength	O
dependent	O
Second	B-T059
Harmonic	I-T059
Generation	I-T059
microscopy	I-T059
and	O
optical	O
scattering	O
Ovarian	B-T191
cancer	I-T191
remains	O
the	O
most	O
deadly	O
gynecological	O
cancer	B-T191
with	O
a	O
poor	O
aggregate	O
survival	O
rate	O
;	O
however	O
,	O
the	O
specific	O
rates	O
are	O
highly	O
dependent	O
on	O
the	O
stage	O
of	O
the	O
disease	B-T047
upon	O
diagnosis	B-T033
.	O
Current	O
screening	B-T058
and	O
imaging	O
tools	O
are	O
insufficient	O
to	O
detect	O
early	B-T033
lesions	I-T033
and	O
are	O
not	O
capable	O
of	O
differentiating	O
the	O
subtypes	O
of	O
ovarian	B-T191
cancer	I-T191
that	O
may	O
benefit	O
from	O
specific	O
treatments	B-T061
.	O
As	O
an	O
alternative	O
to	O
current	O
screening	B-T058
and	O
imaging	O
tools	O
,	O
we	O
utilized	O
wavelength	O
dependent	O
collagen	O
-specific	O
Second	B-T059
Harmonic	I-T059
Generation	I-T059
(	I-T059
SHG	I-T059
)	I-T059
imaging	I-T059
microscopy	I-T059
and	O
optical	B-T059
scattering	I-T059
measurements	I-T059
to	O
probe	O
the	O
structural	O
differences	O
in	O
the	O
extracellular	O
matrix	O
(	O
ECM	O
)	O
of	O
normal	O
stroma	B-T023
,	O
benign	B-T191
tumors	I-T191
,	O
endometrioid	B-T191
tumors	I-T191
,	O
and	O
low	B-T191
and	O
high	B-T191
-	I-T191
grade	I-T191
serous	I-T191
tumors	I-T191
.	O
The	O
SHG	B-T059
signatures	O
of	O
the	O
emission	O
directionality	O
and	O
conversion	O
efficiency	O
as	O
well	O
as	O
the	O
optical	O
scattering	O
are	O
related	O
to	O
the	O
organization	O
of	O
collagen	O
on	O
the	O
sub	O
-	O
micron	O
size	O
scale	O
and	O
encode	O
structural	O
information	O
.	O
The	O
wavelength	O
dependence	O
of	O
these	O
readouts	O
adds	O
additional	O
characterization	O
of	O
the	O
size	O
and	O
distribution	O
of	O
collagen	O
fibrils	O
/	O
fibers	O
relative	O
to	O
the	O
interrogating	O
wavelengths	O
.	O
We	O
found	O
a	O
strong	O
wavelength	O
dependence	O
of	O
these	O
metrics	O
that	O
are	O
related	O
to	O
significant	O
structural	O
differences	O
in	O
the	O
collagen	O
organization	O
and	O
are	O
consistent	O
with	O
the	O
dualistic	O
classification	O
of	O
type	B-T191
I	I-T191
and	I-T191
II	I-T191
serous	I-T191
tumors	I-T191
.	O
Moreover	O
,	O
type	B-T191
I	I-T191
endometrioid	I-T191
tumors	I-T191
have	O
strongly	O
differing	O
ECM	O
architecture	O
than	O
the	O
serous	B-T191
malignancies	I-T191
.	O
The	O
SHG	B-T059
metrics	O
and	O
optical	B-T059
scattering	I-T059
measurements	I-T059
were	O
used	O
to	O
form	O
a	O
linear	O
discriminant	O
model	O
to	O
classify	O
the	O
tissues	O
,	O
and	O
we	O
obtained	O
high	O
accuracy	O
(	O
>	O
90	O
%	O
)	O
between	O
high	B-T191
-	I-T191
grade	I-T191
serous	I-T191
tumors	I-T191
from	O
the	O
other	O
tissue	O
types	O
.	O
High	B-T191
-	I-T191
grade	I-T191
serous	I-T191
tumors	I-T191
account	O
for	O
~70	O
%	O
of	O
ovarian	B-T191
cancers	I-T191
,	O
and	O
this	O
delineation	O
has	O
potential	O
clinical	O
applications	O
in	O
terms	O
of	O
supplementing	O
histological	O
analysis	O
,	O
understanding	O
the	O
etiology	O
,	O
as	O
well	O
as	O
development	O
of	O
an	O
in	O
vivo	O
screening	B-T058
tool	I-T058
.	O
SHG	B-T059
and	O
optical	B-T059
scattering	I-T059
measurements	I-T059
provide	O
sub	O
-	O
resolution	O
information	O
and	O
when	O
combined	O
provide	O
superior	B-T060
diagnostic	I-T060
power	I-T060
over	O
clinical	B-T060
imaging	I-T060
modalities	O
.	O
Additionally	O
the	O
measurements	O
are	O
able	O
to	O
delineate	O
the	O
different	O
subtypes	O
of	O
ovarian	B-T191
cancer	I-T191
and	O
may	O
potentially	O
assist	O
in	O
treatment	B-T061
protocols	I-T061
.	O
Understanding	O
the	O
altered	O
collagen	O
assembly	O
can	O
supplement	O
histological	O
analysis	O
and	O
provide	O
new	O
insight	O
into	O
the	O
etiology	O
.	O
These	O
methods	O
could	O
become	O
an	O
in	O
vivo	O
screening	B-T058
tool	I-T058
for	O
earlier	O
detection	O
which	O
is	O
important	O
since	O
ovarian	B-T191
malignancies	I-T191
can	O
metastasize	B-T191
while	O
undetectable	O
by	O
current	O
clinical	B-T060
imaging	I-T060
resolution	O
.	O
      
Benefit	O
and	O
risk	B-T058
in	O
short	O
term	O
after	O
total	B-T061
hip	I-T061
arthroplasty	I-T061
by	O
direct	O
anterior	O
approach	O
combined	O
with	O
dual	O
mobility	O
cup	O
No	O
previous	O
reports	O
have	O
described	O
the	O
benefits	O
and	O
risks	B-T058
associated	O
with	O
the	O
dual	O
mobility	O
cup	O
(	O
DMC	O
)	O
in	O
primary	O
THA	B-T061
via	O
direct	O
anterior	O
approach	O
(	O
DAA	O
)	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
safety	O
and	O
rate	O
of	O
early	O
postoperative	O
complication	O
of	O
the	O
DAA	O
with	O
the	O
DMC	O
for	O
THA	B-T061
with	O
those	O
of	O
the	O
DAA	O
with	O
a	O
single	O
standard	O
cup	O
,	O
and	O
to	O
investigate	O
the	O
influence	O
of	O
the	O
learning	O
curve	O
of	O
the	O
use	O
of	O
DMC	O
on	O
intra	O
-	O
and	O
perioperative	O
outcomes	O
.	O
We	O
retrospectively	O
investigated	O
60	O
hips	B-T023
treated	B-T061
in	O
the	O
single-	O
DAA	O
group	O
and	O
60	O
hips	B-T023
treated	B-T061
in	O
the	O
dual-	O
DAA	O
group	O
.	O
A	O
primary	O
/	O
secondary	O
outcome	O
variable	O
was	O
the	O
presence	O
of	O
any	O
intra	O
-	O
or	O
perioperative	O
complication	O
within	O
the	O
first	O
6	O
months	O
/the	O
operative	O
time	O
and	O
hip	O
function	O
at	O
6	O
months	O
postoperatively	O
.	O
We	O
also	O
analyzed	O
influence	O
of	O
the	O
learning	O
curve	O
of	O
the	O
use	O
of	O
DMC	O
on	O
intra	O
-	O
and	O
perioperative	O
outcomes	O
.	O
No	B-T033
intraoperative	O
complications	O
were	O
observed	O
in	O
either	O
group	O
.	O
One	O
anterior	O
dislocation	O
and	O
one	O
periprosthetic	O
hip	O
fracture	O
were	O
occurred	O
in	O
the	O
single-	O
DAA	O
group	O
.	O
The	O
surgical	O
times	O
in	O
the	O
single-	O
DAA	O
and	O
dual-	O
DAA	O
groups	O
were	O
112.0	O
±	O
20.9	O
and	O
121.0	O
±	O
26.9	O
min	O
(	O
p	O
<	O
0.001	O
)	O
.	O
There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
6-	O
month	O
postoperative	O
hip	O
function	O
scores	O
between	O
the	O
two	O
groups	O
.	O
There	O
was	O
no	O
influence	O
of	O
the	O
learning	O
curve	O
of	O
the	O
use	O
of	O
DMC	O
on	O
intra	O
-	O
and	O
perioperative	O
outcomes	O
.	O
We	O
have	O
demonstrated	O
the	O
short	O
-	O
term	O
safety	O
and	O
lack	O
of	O
inferiority	O
of	O
using	O
the	O
DMC	O
in	O
the	O
DAA	O
compared	O
with	O
the	O
standard	O
single	O
mobility	O
cup	O
.	O
      
Co	O
-	O
occurrence	O
and	O
clustering	O
of	O
health	O
conditions	O
at	O
age	O
11	O
:	O
cross	O
-	O
sectional	O
findings	O
from	O
the	O
Millennium	O
Cohort	O
Study	O
To	O
identify	O
patterns	O
of	O
co	O
-	O
occurrence	O
and	O
clustering	O
of	O
6	O
common	O
adverse	O
health	O
conditions	O
in	O
11-	O
year	O
-old	O
children	O
and	O
explore	O
differences	O
by	O
sociodemographic	O
factors	O
.	O
Nationally	O
representative	O
prospective	O
cohort	O
study	O
.	O
Children	O
born	O
in	O
the	O
UK	O
between	O
2000	O
and	O
2002	O
.	O
11	O
399	O
11-	O
year	O
-old	O
singleton	O
children	O
for	O
whom	O
data	O
on	O
all	O
6	O
health	O
conditions	O
and	O
sociodemographic	O
information	O
were	O
available	O
(	O
complete	O
cases	O
)	O
.	O
Prevalence	O
,	O
co	O
-	O
occurrence	O
and	O
clustering	O
of	O
6	O
common	O
health	O
conditions	O
:	O
wheeze	B-T184
;	O
eczema	B-T047
;	O
long	B-T184
-	I-T184
standing	I-T184
illness	I-T184
(	O
excluding	O
wheeze	B-T184
and	O
eczema	B-T047
)	O
;	O
injury	O
;	O
socioemotional	B-T048
difficulties	I-T048
(	O
measured	O
using	O
Strengths	O
and	O
Difficulties	O
Questionnaire	O
)	O
and	O
unfavourable	O
weight	O
(	O
thin	B-T033
/	O
overweight	B-T184
/	O
obese	B-T047
vs	O
normal	O
)	O
.	O
42.4	O
%	O
of	O
children	O
had	O
2	O
or	O
more	O
adverse	O
health	O
conditions	O
(	O
co	O
-	O
occurrence	O
)	O
.	O
Co	O
-	O
occurrence	O
was	O
more	O
common	O
in	O
boys	O
and	O
children	O
from	O
lower	O
income	O
households	O
.	O
Latent	O
class	O
analysis	O
identified	O
6	O
classes	O
:	O
'	O
normative	O
'	O
(	O
57.4	O
%	O
):	O
'	O
atopic	O
burdened	O
'	O
(	O
14.0	O
%	O
)	O
;	O
'	O
socioemotional	B-T048
burdened	I-T048
'	O
(	O
11.0	O
%	O
)	O
;	O
'	O
unfavourable	O
weight	O
/	O
injury	O
'	O
(	O
7.7	O
%	O
)	O
;	O
'	O
eczema	B-T047
/	O
injury	O
'	O
(	O
6.0	O
%	O
)	O
and	O
'	O
eczema	B-T047
/	O
unfavourable	O
weight	O
'	O
(	O
3.9	O
%	O
)	O
.	O
As	O
with	O
co	O
-	O
occurrence	O
,	O
class	O
membership	O
differed	O
by	O
sociodemographic	O
factors	O
:	O
boys	O
,	O
children	O
of	O
mothers	O
with	O
lower	O
educational	B-T033
attainment	I-T033
and	O
children	O
from	O
lower	O
income	O
households	O
were	O
more	O
likely	O
to	O
be	O
in	O
the	O
'	O
socioemotional	B-T048
burdened	I-T048
'	O
class	O
.	O
Children	O
of	O
mothers	O
with	O
higher	O
educational	B-T033
attainment	I-T033
were	O
more	O
likely	O
to	O
be	O
in	O
the	O
'	O
normative	O
'	O
and	O
'	O
eczema	B-T047
/	O
unfavourable	O
weight	O
'	O
classes	O
.	O
Co	O
-	O
occurrence	O
of	O
adverse	O
health	O
conditions	O
at	O
age	O
11	O
is	O
common	O
and	O
is	O
associated	O
with	O
adverse	O
socioeconomic	O
circumstances	O
.	O
Holistic	O
,	O
child	O
focused	O
care	O
,	O
particularly	O
in	O
boys	O
and	O
those	O
in	O
lower	O
income	O
groups	O
,	O
may	O
help	O
to	O
prevent	O
and	O
reduce	O
co	O
-	O
occurrence	O
in	O
later	O
childhood	O
and	O
adolescence	O
.	O
      
Proximal	B-T059
Soil	I-T059
Sensing	I-T059
-	O
A	O
Contribution	O
for	O
Species	O
Habitat	O
Distribution	O
Modelling	O
of	O
Earthworms	O
in	O
Agricultural	O
Soils	O
?	O
Earthworms	O
are	O
important	O
for	O
maintaining	O
soil	O
ecosystem	O
functioning	O
and	O
serve	O
as	O
indicators	O
of	O
soil	O
fertility	O
.	O
However	O
,	O
detection	O
of	O
earthworms	O
is	O
time	O
-	O
consuming	O
,	O
which	O
hinders	O
the	O
assessment	O
of	O
earthworm	O
abundances	O
with	O
high	O
sampling	O
density	O
over	O
entire	O
fields	O
.	O
Recent	O
developments	O
of	O
mobile	O
terrestrial	O
sensor	O
platforms	O
for	O
proximal	B-T059
soil	I-T059
sensing	I-T059
(	O
PSS	B-T059
)	O
provided	O
new	O
tools	O
for	O
collecting	O
dense	O
spatial	O
information	O
of	O
soils	O
using	O
various	O
sensing	O
principles	O
.	O
Yet	O
,	O
the	O
potential	O
of	O
PSS	B-T059
for	O
assessing	O
earthworm	O
habitats	O
is	O
largely	O
unexplored	O
.	O
This	O
study	O
investigates	O
whether	O
PSS	B-T059
data	O
contribute	O
to	O
the	O
spatial	O
prediction	O
of	O
earthworm	O
abundances	O
in	O
species	O
distribution	O
models	O
of	O
agricultural	O
soils	O
.	O
Proximal	B-T059
soil	I-T059
sensing	I-T059
data	O
,	O
e.g.	O
,	O
soil	O
electrical	O
conductivity	O
(	O
EC	O
)	O
,	O
pH	O
,	O
and	O
near	B-T059
infrared	I-T059
absorbance	I-T059
(	O
NIR	B-T059
)	O
,	O
were	O
collected	O
in	O
real	O
-	O
time	O
in	O
a	O
field	O
with	O
two	O
management	O
strategies	O
(	O
reduced	O
tillage	O
/	O
conventional	O
tillage	O
)	O
and	O
sandy	O
to	O
loam	O
soils	O
.	O
PSS	B-T059
was	O
related	O
to	O
observations	O
from	O
a	O
long	O
-	O
term	O
(	O
11	O
years	O
)	O
earthworm	O
observation	B-T033
study	I-T033
conducted	O
at	O
42	O
plots	O
.	O
Earthworms	O
were	O
sampled	O
from	O
0.5	O
x	O
0.5	O
x	O
0.2	O
m³	O
soil	O
blocks	O
and	O
identified	O
to	O
species	O
level	O
.	O
Sensor	O
data	O
were	O
highly	O
correlated	O
with	O
earthworm	O
abundances	O
observed	O
in	O
reduced	O
tillage	O
but	O
less	O
correlated	O
with	O
earthworm	O
abundances	O
observed	O
in	O
conventional	O
tillage	O
.	O
This	O
may	O
indicate	O
that	O
management	O
influences	O
the	O
sensor	O
-	O
earthworm	O
relationship	O
.	O
Generalized	O
additive	O
models	O
and	O
state	O
-	O
space	O
models	O
showed	O
that	O
modelling	O
based	O
on	O
data	O
fusion	O
from	O
EC	O
,	O
pH	O
,	O
and	O
NIR	B-T059
sensors	O
produced	O
better	O
results	B-T033
than	O
modelling	O
without	O
sensor	O
data	O
or	O
data	O
from	O
just	O
a	O
single	O
sensor	O
.	O
Regarding	O
the	O
individual	O
earthworm	O
species	O
,	O
particular	O
sensor	O
combinations	O
were	O
more	O
appropriate	O
than	O
others	O
due	O
to	O
the	O
different	O
habitat	O
requirements	O
of	O
the	O
earthworms	O
.	O
Earthworm	O
species	O
with	O
soil	O
-specific	O
habitat	O
preferences	O
were	O
spatially	O
predicted	O
with	O
higher	O
accuracy	O
by	O
PSS	B-T059
than	O
more	O
ubiquitous	O
species	O
.	O
Our	O
findings	B-T033
suggest	O
that	O
PSS	B-T059
contributes	O
to	O
the	O
spatial	O
modelling	O
of	O
earthworm	O
abundances	O
at	O
field	O
scale	O
and	O
that	O
it	O
will	O
support	O
species	O
distribution	O
modelling	O
in	O
the	O
attempt	O
to	O
understand	O
the	O
soil	O
-	O
earthworm	O
relationships	O
in	O
agroecosystems	O
.	O
      
Management	B-T061
of	O
precipitated	B-T048
opiate	I-T048
withdrawal	I-T048
syndrome	I-T048
induced	O
by	O
nalmefene	B-T121
mistakenly	O
prescribed	B-T058
in	O
opiate	B-T121
-	O
dependent	O
patients	O
:	O
a	O
review	O
for	O
clinicians	O
Nalmefene	B-T121
,	O
a	O
long	B-T121
-	I-T121
acting	I-T121
µ-opioid	I-T121
antagonist	I-T121
approved	O
to	O
treat	O
alcohol	B-T048
use	I-T048
disorder	I-T048
,	O
is	O
occasionally	O
mistakenly	O
prescribed	B-T058
to	O
opiate	B-T121
-	O
dependent	O
or	O
opioid	B-T121
-	O
treated	O
patients	O
.	O
We	O
review	O
recent	O
literature	O
on	O
drug	O
-	O
drug	O
interactions	O
between	O
nalmefene	B-T121
and	O
opioids	B-T121
that	O
lead	O
to	O
precipitated	B-T048
opioid	I-T048
withdrawal	I-T048
,	O
and	O
focus	O
on	O
its	O
management	B-T061
and	O
planning	O
for	O
care	B-T058
at	O
discharge	B-T058
.	O
Areas	O
covered	O
:	O
This	O
article	O
provides	O
a	O
brief	O
and	O
comprehensive	B-T058
review	I-T058
of	O
management	O
of	O
precipitated	B-T048
opioid	I-T048
withdrawal	I-T048
syndrome	I-T048
when	O
nalmefene	B-T121
is	O
associated	O
with	O
an	O
opioid	B-T121
,	O
whether	O
misused	B-T033
or	O
legally	O
prescribed	B-T058
.	O
Expert	O
opinion	O
:	O
When	O
treating	O
an	O
opiate	B-T121
-	O
dependent	O
patient	O
with	O
co	O
-	O
occurring	O
alcohol	B-T048
use	I-T048
disorder	I-T048
,	O
both	O
conditions	O
need	O
to	O
be	O
a	O
focus	O
of	O
clinical	O
attention	O
.	O
New	O
drugs	B-T121
for	O
alcohol	B-T048
use	I-T048
disorder	I-T048
have	O
been	O
approved	O
,	O
but	O
must	O
be	O
given	O
cautiously	O
and	O
with	O
a	O
full	O
understanding	O
of	O
their	O
potential	O
drug	O
-	O
drug	O
interactions	O
with	O
opioid	B-T121
medications	O
.	O
Opiate	B-T121
-	O
dependent	O
patients	O
should	O
be	O
intensively	O
monitored	O
for	O
risk	B-T033
factors	I-T033
of	O
alcohol	B-T048
use	I-T048
disorder	I-T048
and	O
should	O
be	O
continuously	O
motivated	O
for	O
treatment	B-T061
maintenance	I-T061
.	O
When	O
nalmefene	B-T121
is	O
administered	B-T058
to	O
opiate	B-T121
-	O
dependent	O
patients	O
,	O
acute	O
opioid	B-T048
withdrawal	I-T048
syndrome	I-T048
may	O
occur	O
.	O
Management	B-T061
of	O
precipitated	O
acute	O
opioid	B-T048
withdrawal	I-T048
may	O
include	O
short	O
or	O
long	O
-	O
acting	O
µ-opioid	O
agonists	O
during	O
hospitalization	B-T058
,	O
in	O
addition	O
to	O
supportive	B-T061
treatment	I-T061
.	O
The	O
best	O
management	B-T058
of	O
polydrug	B-T033
abusers	I-T033
is	O
based	O
on	O
a	O
multidisciplinary	B-T060
approach	I-T060
,	O
which	O
should	O
be	O
pursued	O
and	O
improved	B-T033
through	O
continuing	O
medical	O
education	O
.	O
      
Methodological	O
considerations	O
for	O
designing	O
a	O
community	O
water	O
fluoridation	O
cessation	O
study	O
High	O
-	O
quality	O
,	O
up	O
-	O
to	O
-	O
date	O
research	O
on	O
community	O
water	O
fluoridation	O
(	O
CWF	O
)	O
,	O
and	O
especially	O
on	O
the	O
implications	O
of	O
CWF	O
cessation	O
for	O
dental	B-T058
health	I-T058
,	O
is	O
limited	O
.	O
Although	O
CWF	O
cessation	O
studies	O
have	O
been	O
conducted	O
,	O
they	O
are	O
few	O
in	O
number	O
;	O
one	O
of	O
the	O
major	O
reasons	O
is	O
the	O
methodological	O
complexity	O
of	O
conducting	O
such	O
a	O
study	O
.	O
This	O
article	O
draws	O
on	O
a	O
systematic	O
review	O
of	O
existing	O
cessation	O
studies	O
(	O
n=15	O
)	O
to	O
explore	O
methodological	O
considerations	O
of	O
conducting	O
CWF	O
cessation	O
studies	O
in	O
future	O
.	O
We	O
review	O
nine	O
important	O
methodological	O
aspects	O
(	O
study	O
design	O
,	O
comparison	O
community	O
,	O
target	O
population	O
,	O
time	O
frame	O
,	O
sampling	O
strategy	O
,	O
clinical	O
indicators	O
,	O
assessment	O
criteria	O
,	O
covariates	O
and	O
biomarkers	O
)	O
and	O
provide	O
recommendations	O
for	O
planning	B-T058
future	O
CWF	O
cessation	O
studies	O
that	O
examine	O
effects	O
on	O
dental	B-T047
caries	I-T047
.	O
There	O
is	O
no	O
one	O
ideal	O
study	O
design	O
to	O
answer	O
a	O
research	O
question	O
.	O
However	O
,	O
recommendations	O
proposed	O
regarding	O
methodological	O
aspects	O
to	O
conduct	O
an	O
epidemiological	O
study	O
to	O
observe	O
the	O
effects	O
of	O
CWF	O
cessation	O
on	O
dental	B-T047
caries	I-T047
,	O
coupled	O
with	O
our	O
identification	O
of	O
important	O
methodological	O
gaps	O
,	O
will	O
be	O
useful	O
for	O
researchers	O
who	O
are	O
looking	O
to	O
optimize	O
resources	O
to	O
conduct	O
such	O
a	O
study	O
with	O
standards	O
of	O
rigour	O
.	O
      
Clinical	O
Pearls	O
in	O
Tremor	B-T184
and	O
Other	O
Hyperkinetic	B-T048
Movement	I-T048
Disorders	B-T048
Hyperkinetic	B-T048
movements	I-T048
,	O
such	O
as	O
tremor	B-T184
,	O
myoclonus	B-T184
,	O
chorea	B-T047
,	O
and	O
dystonia	B-T184
,	O
occur	O
in	O
many	O
neurologic	B-T047
and	O
medical	B-T047
conditions	I-T047
.	O
Accurate	O
clinical	B-T058
evaluation	I-T058
is	O
the	O
important	O
first	O
step	O
for	O
the	O
proper	O
diagnosis	O
and	O
treatment	B-T061
of	O
patients	O
with	O
abnormal	B-T047
movements	I-T047
.	O
      
Cloud	O
-	O
based	O
MOTIFSIM	O
:	O
Detecting	B-T033
Similarity	O
in	O
Large	O
DNA	O
Motif	O
Data	O
Sets	O
We	O
developed	O
the	O
cloud	O
-	O
based	O
MOTIFSIM	O
on	O
Amazon	O
Web	O
Services	O
(	O
AWS	O
)	O
cloud	O
.	O
The	O
tool	O
is	O
an	O
extended	O
version	O
from	O
our	O
web	O
-	O
based	O
tool	O
version	O
2.0	O
,	O
which	O
was	O
developed	O
based	O
on	O
a	O
novel	O
algorithm	O
for	O
detecting	B-T033
similarity	O
in	O
multiple	O
DNA	O
motif	O
data	O
sets	O
.	O
This	O
cloud	O
-based	O
version	O
further	O
allows	O
researchers	O
to	O
exploit	O
the	O
computing	O
resources	O
available	O
from	O
AWS	O
to	O
detect	B-T033
similarity	O
in	O
multiple	O
large	O
-	O
scale	O
DNA	O
motif	O
data	O
sets	O
resulting	O
from	O
the	O
next	O
-	O
generation	O
sequencing	O
technology	O
.	O
The	O
tool	O
is	O
highly	O
scalable	O
with	O
expandable	O
AWS	O
.	O
      
Potential	O
Sunitinib	B-T121
-	O
Induced	O
Coronary	B-T023
Artery	I-T023
and	O
Aortic	B-T047
Dissections	I-T047
Small	B-T061
-	I-T061
molecule	I-T061
multitargeted	I-T061
tyrosine	I-T061
kinase	I-T061
inhibitor	I-T061
(	I-T061
TKI	I-T061
)	I-T061
therapy	I-T061
is	O
used	O
in	O
different	O
types	O
of	O
cancer	B-T191
.	O
These	O
drugs	B-T121
have	O
been	O
associated	O
with	O
cardiovascular	O
toxicity	O
,	O
including	O
aortic	B-T047
dissection	I-T047
.	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
time	O
that	O
a	O
coronary	B-T047
dissection	I-T047
potentially	O
associated	O
with	O
a	O
TKI	B-T061
treatment	I-T061
has	O
been	O
described	O
.	O
      
Psychometric	B-T060
analysis	I-T060
of	O
the	O
Patient	O
Health	O
Questionnaire	O
in	O
Danish	O
patients	O
with	O
an	O
implantable	O
cardioverter	O
defibrillator	O
(	O
The	O
DEFIB	O
-	O
WOMEN	O
study	O
)	O
To	O
assess	O
the	O
psychometric	B-T060
properties	I-T060
of	O
the	O
Patient	O
Health	O
Questionnaire	O
(	O
PHQ-9	O
)	O
,	O
a	O
measure	O
of	O
depressive	B-T184
symptoms	I-T184
,	O
in	O
a	O
large	O
Danish	O
national	O
cohort	O
of	O
patients	O
with	O
heart	B-T047
disease	I-T047
,	O
implanted	B-T061
with	O
an	O
implantable	O
cardioverter	O
defibrillator	O
(	O
ICD	O
)	O
,	O
using	O
item	O
response	O
theory	O
.	O
A	O
prospective	O
cohort	O
of	O
patients	O
implanted	B-T061
with	O
an	O
ICD	O
(	O
n=1531	O
;	O
80.4	O
%	O
men	O
)	O
completed	O
the	O
PHQ-9	O
at	O
the	O
time	O
of	O
implant	B-T061
.	O
Data	O
were	O
analyzed	O
using	O
two	O
item	O
response	O
theory	O
models	O
,	O
the	O
partial	O
credit	O
model	O
and	O
the	O
generalized	O
partial	O
credit	O
model	O
.	O
The	O
analysis	O
showed	O
disordered	O
response	O
thresholds	O
in	O
eight	O
of	O
nine	O
items	O
for	O
the	O
partial	O
credit	O
model	O
and	O
five	O
of	O
nine	O
items	O
for	O
the	O
generalized	O
partial	O
credit	O
model	O
,	O
indicating	O
that	O
respondents	O
have	O
difficulty	O
discriminating	O
between	O
response	O
options	O
.	O
When	O
collapsing	O
response	O
options	O
2	O
and	O
3	O
,	O
the	O
rescored	O
PHQ-9	O
had	O
a	O
better	O
fit	O
to	O
both	O
models	O
.	O
The	O
unidimensionality	O
and	O
the	O
precision	O
of	O
the	O
rescored	O
PHQ-9	O
were	O
confirmed	O
.	O
Items	O
did	O
not	O
have	O
any	O
differential	O
functioning	O
(	O
DIF	O
)	O
across	O
educational	B-T033
level	I-T033
,	O
age	O
,	O
indication	O
for	O
ICD	O
implantation	B-T061
,	O
and	O
severity	O
of	O
heart	B-T047
failure	I-T047
that	O
influence	O
depression	B-T048
outcomes	O
in	O
patients	O
with	O
an	O
ICD	O
.	O
One	O
item	O
exhibited	O
DIF	O
by	O
gender	O
.	O
Three	O
items	O
did	O
not	O
fit	O
the	O
partial	O
credit	O
model	O
,	O
but	O
the	O
generalized	O
partial	O
credit	O
model	O
could	O
be	O
fitted	O
to	O
the	O
full	O
item	O
set	O
.	O
The	O
unidimensionality	O
and	O
reliability	O
of	O
the	O
Danish	O
version	O
of	O
the	O
PHQ-9	O
were	O
confirmed	B-T033
.	O
However	O
,	O
the	O
associated	O
consequences	O
of	O
the	O
number	O
of	O
response	O
options	O
(	O
3	O
-	O
point	O
versus	O
4	O
-	O
point	O
Likert	O
scale	O
)	O
need	O
to	O
be	O
further	O
examined	B-T033
for	O
the	O
PHQ-9	O
both	O
as	O
a	O
screening	B-T058
tool	O
and	O
outcome	O
measure	O
.	O
      
Heterotopic	O
ossification	O
after	O
the	O
use	O
of	O
recombinant	B-T121
human	I-T121
bone	I-T121
morphogenetic	I-T121
protein-7	I-T121
To	O
present	O
the	O
incidence	O
of	O
heterotopic	O
ossification	O
after	O
the	O
use	O
of	O
recombinant	B-T121
human	I-T121
bone	I-T121
morphogenetic	I-T121
protein-7	I-T121
(	O
rhBMP-7	B-T121
)	O
for	O
the	O
treatment	B-T061
of	O
nonunions	B-T033
.	O
Bone	O
morphogenetic	O
proteins	O
(	O
BMPs	O
)	O
promote	O
bone	O
formation	O
by	O
auto	O
-	O
induction	O
.	O
Recombinant	B-T121
human	I-T121
BMP-7	I-T121
in	O
combination	O
with	O
bone	O
grafts	O
was	O
used	O
in	O
84	O
patients	O
for	O
the	O
treatment	B-T061
of	O
long	B-T033
bone	I-T033
nonunions	I-T033
.	O
All	O
patients	O
were	O
evaluated	B-T058
radiographicaly	B-T060
for	O
the	O
development	O
of	O
heterotopic	O
ossification	O
during	O
the	O
standard	O
assessment	B-T058
for	O
the	O
nonunion	B-T033
healing	O
.	O
In	O
all	O
patients	O
(	O
80.9	O
%	O
)	O
with	O
radiographic	O
signs	B-T184
of	O
heterotopic	O
ossification	O
,	O
a	O
CT	B-T060
scan	I-T060
was	O
performed	O
.	O
Nonunion	B-T033
site	O
palpation	B-T060
and	O
ROM	B-T059
evaluation	I-T059
of	O
the	O
adjacent	O
joints	O
were	O
also	O
carried	O
out	O
.	O
Factors	O
related	O
to	O
the	O
patient	O
(	O
age	O
,	O
gender	O
)	O
,	O
the	O
nonunion	B-T033
(	O
location	O
,	O
size	O
,	O
chronicity	O
,	O
number	O
of	O
previous	O
procedures	O
,	O
infection	O
,	O
surrounding	O
tissues	O
condition	O
)	O
and	O
the	O
surgical	B-T061
procedure	I-T061
(	O
graft	O
and	O
fixation	B-T061
type	O
,	O
amount	O
of	O
rhBMP-7	B-T121
)	O
were	O
correlated	O
with	O
the	O
development	O
of	O
heterotopic	O
ossification	O
and	O
statistical	O
analysis	O
with	O
Pearsons	O
χ	O
(	O
2	O
)	O
test	O
was	O
performed	O
.	O
Eighty	O
point	O
nine	O
percent	O
of	O
the	O
nonunions	B-T033
treated	O
with	O
rhBMP-7	B-T121
,	O
healed	O
with	O
no	O
need	O
for	O
further	O
procedures	O
.	O
Heterotopic	O
bone	O
formation	O
occurred	O
in	O
15	O
of	O
84	O
patients	O
(	O
17.8	O
%	O
)	O
and	O
it	O
was	O
apparent	O
in	O
the	O
routine	O
radiological	B-T058
evaluation	I-T058
of	O
the	O
nonunion	B-T033
site	O
,	O
in	O
a	O
mean	O
time	O
of	O
5.5	O
mo	O
after	O
the	O
rhBMP-7	B-T121
application	O
(	O
range	O
3	O
-	O
12	O
)	O
.	O
The	O
heterotopic	O
ossification	O
was	O
located	O
at	O
the	O
femur	B-T023
in	O
8	O
cases	O
,	O
at	O
the	O
tibia	B-T023
in	O
6	O
,	O
and	O
at	O
the	O
humerus	B-T023
in	O
οne	O
patient	O
.	O
In	O
4	O
patients	O
a	O
palpable	B-T033
mass	I-T033
was	O
present	O
and	O
only	O
in	O
one	O
patient	O
,	O
with	O
a	O
para	B-T033
-	I-T033
articular	I-T033
knee	I-T033
nonunion	I-T033
treated	O
with	O
rhBMP-7	B-T121
,	O
the	O
size	O
of	O
heterotopic	O
ossification	O
affected	O
the	O
knee	B-T033
range	I-T033
of	I-T033
motion	I-T033
.	O
All	O
the	O
patients	O
with	O
heterotopic	O
ossification	O
were	O
male	O
.	O
Statistical	O
analysis	O
proved	O
that	O
patient	O
's	O
gender	O
was	O
the	O
only	O
important	O
factor	O
for	O
the	O
development	O
of	O
heterotopic	O
ossification	O
(	O
P	O
=	O
0.007	O
)	O
.	O
Heterotopic	O
ossification	O
after	O
the	O
use	O
of	O
rhBMP-7	B-T121
in	O
nonunions	B-T033
was	O
common	O
but	O
it	O
did	O
not	O
compromise	O
the	O
final	O
clinical	O
outcome	O
in	O
most	O
cases	O
,	O
and	O
affected	O
only	O
male	O
patients	O
.	O
      
Biomagnetic	B-T059
monitoring	I-T059
of	O
atmospheric	O
pollution	O
:	O
a	O
review	O
of	O
magnetic	O
signatures	O
from	O
biological	O
sensors	O
Biomagnetic	B-T059
monitoring	I-T059
of	O
atmospheric	O
pollution	O
is	O
a	O
growing	O
application	O
in	O
the	O
field	O
of	O
environmental	O
magnetism	O
.	O
Particulate	O
matter	O
(	O
PM	O
)	O
in	O
atmospheric	O
pollution	O
contains	O
readily-	O
measurable	O
concentrations	O
of	O
magnetic	O
minerals	O
.	O
Biological	O
surfaces	O
,	O
exposed	O
to	O
atmospheric	O
pollution	O
,	O
accumulate	O
magnetic	O
particles	O
over	O
time	O
,	O
providing	O
a	O
record	O
of	O
location	O
-	O
specific	O
,	O
time	B-T033
-	I-T033
integrated	I-T033
air	O
quality	O
information	O
.	O
This	O
review	O
summarizes	O
current	O
knowledge	O
of	O
biological	O
material	O
(	O
'	O
sensors	O
'	O
)	O
used	O
for	O
biomagnetic	B-T059
monitoring	I-T059
purposes	O
.	O
Our	O
work	O
addresses	O
:	O
the	O
range	O
of	O
magnetic	O
properties	O
reported	O
for	O
lichens	O
,	O
mosses	O
,	O
leaves	O
,	O
bark	O
,	O
trunk	O
wood	O
,	O
insects	O
,	O
crustaceans	O
,	O
mammal	O
and	O
human	O
tissues	O
;	O
their	O
associations	O
with	O
atmospheric	O
pollutant	O
species	O
(	O
PM	O
,	O
NOx	O
,	O
trace	O
elements	O
,	O
PAHs	O
)	O
;	O
the	O
pros	B-T033
and	I-T033
cons	I-T033
of	O
biomagnetic	B-T059
monitoring	I-T059
of	O
atmospheric	O
pollution	O
;	O
current	O
challenges	O
for	O
large	O
-	O
scale	O
implementation	O
of	O
biomagnetic	B-T059
monitoring	I-T059
;	O
and	O
future	O
perspectives	O
.	O
A	O
summary	O
table	O
is	O
presented	O
,	O
with	O
the	O
aim	O
of	O
aiding	O
researchers	O
and	O
policy	O
makers	O
in	O
selecting	O
the	O
most	O
suitable	O
biological	O
sensor	O
for	O
their	O
intended	O
biomagnetic	B-T059
monitoring	I-T059
purpose	O
.	O
      
Benchmark	O
study	O
on	O
fine	O
-	O
mode	O
aerosol	O
in	O
a	O
big	O
urban	O
area	O
and	O
relevant	O
doses	O
deposited	O
in	O
the	O
human	O
respiratory	B-T023
tract	I-T023
It	O
is	O
well	O
-	O
known	O
that	O
the	O
health	O
effects	O
of	O
PM	O
increase	O
as	O
particle	O
size	O
decreases	O
:	O
particularly	O
,	O
great	O
concern	O
has	O
risen	O
on	O
the	O
role	O
of	O
UltraFine	O
Particles	O
(	O
UFPs	O
)	O
.	O
Starting	O
from	O
the	O
knowledge	O
that	O
the	O
main	O
fraction	O
of	O
atmospheric	O
aerosol	O
in	O
Rome	O
is	O
characterized	O
by	O
significant	O
levels	O
of	O
PM2.5	O
(	O
almost	O
75	O
%	O
of	O
PM10	O
fraction	O
is	O
PM2.5	O
)	O
,	O
the	O
paper	O
is	O
focused	O
on	O
submicron	O
particles	O
in	O
such	O
great	O
urban	O
area	O
.	O
The	O
daytime	O
/	O
nighttime	O
,	O
work-	O
/	O
weekdays	O
and	O
cold	O
/	O
hot	O
seasonal	O
trends	O
of	O
submicron	O
particles	O
will	O
be	O
investigated	O
and	O
discussed	O
along	O
with	O
NOx	O
and	O
total	O
PAH	O
drifts	O
demonstrating	O
the	O
primary	O
origin	O
of	O
UFPs	O
from	O
combustion	O
processes	O
.	O
Furthermore	O
,	O
moving	O
from	O
these	O
data	O
,	O
the	O
total	O
dose	O
of	O
submicron	O
particles	O
deposited	O
in	O
the	O
respiratory	O
system	O
(	O
i.e.	O
,	O
head	O
,	O
tracheobronchial	B-T023
and	O
alveolar	B-T023
regions	I-T023
in	O
different	O
lung	B-T023
lobes	I-T023
)	O
has	O
been	O
estimated	O
.	O
Dosimeter	O
estimates	O
were	O
performed	O
with	O
the	O
Multiple	O
-	O
Path	O
Particle	O
Dosimetry	O
model	O
(	O
MPPD	O
v.2.1	O
)	O
.	O
The	O
paper	O
discusses	O
the	O
aerosol	O
doses	O
deposited	O
in	O
the	O
respiratory	O
system	O
of	O
individuals	O
exposed	O
in	O
proximity	O
of	O
traffic	B-T033
.	O
During	O
traffic	B-T033
peak	O
hours	O
,	O
about	O
6.6	O
×	O
10(10	O
)	O
particles	O
are	O
deposited	O
into	O
the	O
respiratory	O
system	O
.	O
Such	O
dose	O
is	O
almost	O
entirely	O
made	O
of	O
UFPs	O
.	O
According	O
to	O
the	O
greater	O
dose	O
estimated	O
,	O
right	B-T023
lung	I-T023
lobes	I-T023
are	O
expected	O
to	O
be	O
more	O
susceptible	O
to	O
respiratory	O
pathologies	O
than	O
left	B-T023
lobes	I-T023
.	O
      
TRIB3	O
downregulation	O
enhances	O
doxorubicin	B-T195
-	O
induced	O
cytotoxicity	O
in	O
gastric	B-T191
cancer	I-T191
cells	O
TRIB3	O
,	O
which	O
is	O
a	O
pseudokinase	O
known	O
to	O
regulate	O
multiple	O
pro	O
-	O
survival	O
pathways	O
,	O
appears	O
to	O
be	O
a	O
potential	O
therapeutic	B-T061
target	O
for	O
the	O
treatment	B-T061
of	O
human	O
tumors	B-T191
.	O
However	O
,	O
its	O
precise	O
role	O
in	O
cancer	B-T191
is	O
controversial	O
,	O
as	O
TRIB3	O
protein	O
levels	O
have	O
been	O
associated	O
with	O
both	O
good	B-T033
and	O
poor	B-T033
prognosis	I-T033
in	O
cancer	O
patients	O
.	O
Here	O
,	O
we	O
investigated	O
the	O
significance	O
of	O
TRIB3	O
expression	O
in	O
the	O
survival	O
of	O
gastric	B-T191
cancer	I-T191
cells	O
exposed	O
to	O
anticancer	B-T121
drugs	I-T121
.	O
We	O
found	O
that	O
the	O
tested	O
anticancer	B-T121
drug	I-T121
,	O
doxorubicin	B-T195
,	O
induced	O
cytotoxicity	O
by	O
decreasing	O
TRIB3	O
transcription	O
,	O
which	O
was	O
followed	O
by	O
apoptotic	O
cell	O
death	O
.	O
Moreover	O
,	O
TRIB3	O
siRNA	O
knockdown	O
appeared	O
to	O
enhance	O
doxorubicin	B-T195
-	O
induced	O
apoptosis	O
in	O
gastric	B-T191
cancer	I-T191
cells	O
,	O
concurrently	O
with	O
altering	O
the	O
expression	O
of	O
downstream	O
apoptotic	O
factors	O
.	O
Conversely	O
,	O
overexpression	O
of	O
TRIB3	O
significantly	O
protected	O
cells	O
against	O
doxorubicin	B-T195
-	O
induced	O
apoptosis	O
.	O
Our	O
results	O
indicate	O
that	O
downregulation	O
of	O
TRIB3	O
appears	O
to	O
promote	O
cell	O
death	O
and	O
enhance	O
doxorubicin	B-T195
-	O
induced	O
apoptosis	O
,	O
supporting	O
the	O
anti	O
-	O
apoptotic	O
role	O
of	O
TRIB3	O
.	O
The	O
inductions	O
of	O
three	O
classes	O
of	O
MAPKs	O
failed	O
to	O
affect	O
doxorubicin	B-T195
-mediated	O
TRIB3	O
downregulation	O
,	O
while	O
TRIB3	O
overexpression	O
did	O
not	O
affect	O
doxorubicin	B-T195
-	O
induced	O
MAPK	O
activation	O
.	O
In	O
sum	O
,	O
our	O
findings	B-T033
indicate	O
that	O
TRIB3	O
plays	O
an	O
anti	O
-	O
apoptotic	O
role	O
in	O
doxorubicin	B-T195
-treated	O
gastric	B-T191
cancer	I-T191
cell	O
lines	O
,	O
perhaps	O
indicating	O
that	O
the	O
status	O
of	O
TRIB3	O
expression	O
in	O
response	O
to	O
anticancer	B-T121
drugs	I-T121
,	O
such	O
as	O
doxorubicin	B-T195
,	O
irinotecan	B-T121
or	O
oxaliplatin	B-T121
,	O
may	O
reflect	O
the	O
efficiency	O
for	O
cancer	B-T061
therapy	I-T061
.	O
      
Allelic	O
diversity	O
in	O
an	O
NLR	O
gene	O
BPH9	O
enables	O
rice	O
to	O
combat	O
planthopper	O
variation	O
Brown	O
planthopper	O
(	O
BPH	O
)	O
,	O
Nilaparvata	O
lugens	O
Stål	O
,	O
is	O
one	O
of	O
the	O
most	O
devastating	O
insect	O
pests	O
of	O
rice	O
(	O
Oryza	O
sativa	O
L.	O
)	O
.	O
Currently	O
,	O
30	O
BPH	O
-	O
resistance	O
genes	O
have	O
been	O
genetically	O
defined	O
,	O
most	O
of	O
which	O
are	O
clustered	O
on	O
specific	O
chromosome	O
regions	O
.	O
Here	O
,	O
we	O
describe	O
molecular	B-T059
cloning	I-T059
and	O
characterization	O
of	O
a	O
BPH	O
-	O
resistance	O
gene	O
,	O
BPH9	O
,	O
mapped	O
on	O
the	O
long	O
arm	O
of	O
rice	O
chromosome	O
12	O
(	O
12L	O
)	O
.	O
BPH9	O
encodes	O
a	O
rare	O
type	O
of	O
nucleotide	O
-	O
binding	O
and	O
leucine	O
-	O
rich	O
repeat	O
(	O
NLR)-containing	O
protein	O
that	O
localizes	O
to	O
the	O
endomembrane	O
system	O
and	O
causes	O
a	O
cell	O
death	O
phenotype	O
.	O
BPH9	O
activates	O
salicylic	B-T121
acid	I-T121
-	O
and	O
jasmonic	O
acid	O
-	O
signaling	O
pathways	O
in	O
rice	O
plants	O
and	O
confers	O
both	O
antixenosis	O
and	O
antibiosis	O
to	O
BPH	O
.	O
We	O
further	O
demonstrated	O
that	O
the	O
eight	O
BPH	O
-	O
resistance	O
genes	O
that	O
are	O
clustered	O
on	O
chromosome	O
12L	O
,	O
including	O
the	O
widely	O
used	O
BPH1	O
,	O
are	O
allelic	O
with	O
each	O
other	O
.	O
To	O
honor	O
the	O
priority	O
in	O
the	O
literature	O
,	O
we	O
thus	O
designated	O
this	O
locus	O
as	O
BPH1/9	O
These	O
eight	O
genes	O
can	O
be	O
classified	O
into	O
four	O
allelotypes	O
,	O
BPH1/9	O
-	O
1	O
,	O
-2	O
,	O
-7	O
,	O
and	O
-9	O
These	O
allelotypes	O
confer	O
varying	O
levels	O
of	O
resistance	O
to	O
different	O
biotypes	O
of	O
BPH	O
.	O
The	O
coding	O
region	O
of	O
BPH1/9	O
shows	O
a	O
high	O
level	O
of	O
diversity	O
in	O
rice	O
germplasm	O
.	O
Homologous	O
fragments	O
of	O
the	O
nucleotide	O
-	O
binding	O
(	O
NB	O
)	O
and	O
leucine	O
-	O
rich	O
repeat	O
(	O
LRR	O
)	O
domains	O
exist	O
,	O
which	O
might	O
have	O
served	O
as	O
a	O
repository	O
for	O
generating	O
allele	O
diversity	O
.	O
Our	O
findings	O
reveal	O
a	O
rice	O
plant	O
strategy	O
for	O
modifying	O
the	O
genetic	O
information	O
to	O
gain	O
the	O
upper	O
hand	O
in	O
the	O
struggle	O
against	O
insect	O
herbivores	O
.	O
Further	O
exploration	O
of	O
natural	O
allelic	O
variation	O
and	O
artificial	O
shuffling	O
within	O
this	O
gene	O
may	O
allow	O
breeding	O
to	O
be	O
tailored	O
to	O
control	O
emerging	O
biotypes	O
of	O
BPH	O
.	O
      
Starvation	B-T033
-	O
and	O
antibiotics	B-T195
-induced	O
formation	O
of	O
persister	B-T007
cells	I-T007
in	O
Pseudomonas	B-T007
aeruginosa	I-T007
Planktonic	B-T007
stationary	B-T059
and	I-T059
exponential	I-T059
cultures	I-T059
of	O
Pseudomonas	B-T007
aeruginosa	I-T007
are	O
highly	O
resistant	O
to	O
killing	B-T033
by	O
bactericidal	B-T195
antimicrobials	I-T195
because	O
of	O
the	O
presence	O
of	O
persisters	B-T007
,	O
cells	B-T007
that	O
are	O
multidrug	B-T033
tolerant	I-T033
and	O
play	O
a	O
key	O
role	O
in	O
the	O
recalcitrance	O
of	O
biofilm	B-T007
infections	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
formation	O
of	O
persister	B-T007
cells	I-T007
in	O
P.	B-T007
aeruginosa	I-T007
stationary	B-T059
vs.	O
exponential	B-T059
cultures	I-T059
using	O
different	O
class	O
antimicrobials	B-T195
.	O
The	O
susceptibilities	O
of	O
P.	B-T007
aeruginosa	I-T007
PAO1	I-T007
wild	I-T007
-	I-T007
type	I-T007
and	O
mutant	B-T001
strains	I-T001
to	O
antimicrobials	B-T195
were	O
determined	O
by	O
standard	B-T059
microtiter	I-T059
broth	I-T059
dilution	I-T059
method	I-T059
.	O
In	O
order	O
to	O
determine	O
persister	B-T007
formation	O
,	O
dose	O
-	O
and	O
time	O
-dependent	O
killing	B-T059
experiments	I-T059
were	O
performed	O
with	O
antibiotics	B-T195
.	O
Ceftazidime	B-T195
(	O
Cephalosporin	B-T195
)	O
showed	O
little	O
efficacy	O
against	O
either	O
culture	B-T059
.	O
Stationary	B-T007
-	I-T007
phase	I-T007
cells	I-T007
were	O
more	O
tolerant	B-T033
to	O
imipenem	B-T195
(	O
Carbapenem	B-T195
)	O
than	O
exponential	B-T007
cells	I-T007
,	O
leaving	O
a	O
small	O
fraction	O
of	O
persisters	B-T007
at	O
high	O
imipenem	B-T195
concentration	O
in	O
both	O
populations	O
.	O
Polymyxin	B-T195
B	I-T195
(	O
Polymyxin	B-T195
)	O
appeared	O
to	O
be	O
ineffective	O
at	O
low	O
concentrations	O
against	O
both	O
cell	O
populations	O
.	O
Very	O
high	O
polymyxin	B-T195
B	I-T195
concentration	O
completely	O
eradicated	O
exponential	B-T007
cells	I-T007
and	O
regrowth	O
was	O
seen	O
in	O
a	O
stationary	O
population	O
.	O
Stationary	B-T007
cells	I-T007
were	O
more	O
tolerant	B-T033
to	O
tobramycin	B-T195
(	O
Aminoglycoside	B-T121
)	O
than	O
exponential	B-T007
cells	I-T007
but	O
a	O
higher	O
concentration	O
of	O
tobramycin	B-T195
completely	O
eliminated	O
survivors	O
.	O
Ciprofloxacin	B-T121
(	O
Fluoroquinolone	B-T121
)	O
at	O
a	O
low	O
concentration	O
resulted	O
in	O
killing	B-T033
of	O
both	O
cultures	B-T059
of	O
P.	B-T007
aeruginosa	I-T007
,	O
producing	O
persisters	B-T007
that	O
were	O
invulnerable	O
to	O
killing	B-T033
.	O
Stationary	B-T007
cells	I-T007
appear	O
to	O
be	O
somewhat	O
more	O
tolerant	B-T033
than	O
exponential	B-T007
cells	I-T007
in	O
all	O
of	O
these	O
assays	B-T059
.	O
We	O
also	O
showed	O
that	O
nutrient	O
deprivation	O
(	O
serine	B-T121
starvation	B-T033
)	O
regulated	O
by	O
stringent	O
and	O
general	O
stress	O
response	O
,	O
contribute	O
to	O
the	O
increased	B-T033
tolerance	I-T033
of	O
P.	B-T007
aeruginosa	I-T007
exponential	B-T007
and	I-T007
stationary	I-T007
planktonic	I-T007
cells	I-T007
via	O
production	O
of	O
persisters	B-T007
.	O
      
Homogeneous	O
synthesis	O
of	O
Ag	O
nanoparticles	O
-doped	O
water	O
-	O
soluble	O
cellulose	O
acetate	O
for	O
versatile	O
applications	O
We	O
report	O
a	O
facile	O
and	O
efficient	O
approach	O
for	O
synthesis	O
of	O
well	O
-	O
dispersed	O
and	O
stable	O
silver	O
nanoparticles	O
(	O
Ag	O
NPs	O
)	O
using	O
water	O
-	O
soluble	O
cellulose	O
acetate	O
(	O
CA	O
)	O
as	O
both	O
reductant	O
and	O
stabilizer	O
.	O
Partially	O
substituted	O
CA	O
with	O
highly	O
active	O
hydroxyl	O
groups	O
and	O
excellent	O
water	O
-	O
solubility	O
is	O
able	B-T033
to	O
reduce	O
silver	O
ions	O
in	O
homogeneous	O
aqueous	O
medium	O
effectively	O
.	O
The	O
synthesized	O
Ag	O
NPs	O
were	O
characterized	O
by	O
UV	B-T059
-	I-T059
vis	I-T059
spectroscopy	I-T059
,	O
X	B-T059
-	I-T059
ray	I-T059
diffraction	I-T059
,	O
X	B-T059
-	I-T059
ray	I-T059
photoelectron	I-T059
spectroscopy	I-T059
,	O
transmission	B-T059
electron	I-T059
microscopy	I-T059
and	O
energy	B-T059
dispersive	I-T059
X	I-T059
-	I-T059
ray	I-T059
spectroscope	I-T059
analysis	B-T059
.	O
The	O
as-	O
prepared	B-T033
Ag	O
NPs	O
were	O
well	O
-	O
dispersed	O
,	O
showing	O
a	O
surface	O
plasmon	O
resonance	O
peak	O
at	O
426	O
nm	O
.	O
The	O
resulted	O
Ag	O
NPs	O
@	O
CA	O
nanohybrids	O
exhibit	O
high	O
catalytic	O
activity	O
for	O
the	O
reduction	O
of	O
4	O
-	O
nitrophenol	O
to	O
4	O
-	O
aminophenol	O
in	O
the	O
presence	O
of	O
NaBH4	O
.	O
Meanwhile	O
,	O
the	O
nanohybrids	O
are	O
also	O
effective	O
in	O
inhibiting	O
the	O
growth	O
of	O
bacterial	B-T007
.	O
This	O
environmentally	O
friendly	O
method	O
promotes	O
the	O
use	O
of	O
renewable	O
natural	O
resources	O
to	O
prepare	O
a	O
variety	O
of	O
inorganic	O
-	O
organic	O
materials	O
for	O
catalysis	O
,	O
antibacterial	B-T195
,	O
sensors	O
and	O
other	O
applications	O
.	O
      
Obstacle	O
course	O
runs	O
:	O
review	O
of	O
acquired	O
injuries	O
and	O
illnesses	B-T184
at	O
a	O
series	O
of	O
Canadian	B-T033
events	O
(	O
RACE	O
)	O
The	O
growing	O
popularity	O
of	O
obstacle	O
course	O
runs	O
(	O
OCRs	O
)	O
has	O
led	O
to	O
significant	O
concerns	O
regarding	O
their	O
safety	O
.	O
The	O
influx	O
of	O
injuries	O
and	O
illnesses	B-T184
in	O
rural	O
areas	O
where	O
OCRs	O
are	O
often	O
held	O
can	O
impose	O
a	O
large	O
burden	O
on	O
emergency	B-T058
medical	I-T058
services	I-T058
(	O
EMS	B-T058
)	O
and	O
local	O
EDs	O
.	O
Literature	O
concerning	O
the	O
safety	O
of	O
these	O
events	O
is	O
minimal	O
and	O
mostly	O
consists	O
of	O
media	O
reports	O
.	O
We	O
sought	O
to	O
characterise	O
the	O
injury	O
and	O
illness	B-T184
profile	O
of	O
OCRs	O
and	O
the	O
level	O
of	O
medical	B-T061
care	I-T061
required	O
.	O
This	O
study	O
analysed	O
OCR	O
events	O
occurring	O
in	O
eight	O
locations	O
across	O
Canada	O
from	O
May	O
to	O
August	O
2015	O
(	O
total	O
45	O
285	O
participants	O
)	O
.	O
Data	O
were	O
extracted	O
from	O
event	O
medical	O
charts	O
of	O
patients	O
presenting	O
to	O
the	O
onsite	O
medical	B-T058
team	I-T058
,	O
including	O
injury	O
or	O
illness	B-T184
type	O
,	O
onsite	O
treatment	B-T061
and	O
disposition	O
.	O
There	O
were	O
557	O
race	O
participants	O
treated	O
at	O
eight	O
OCR	O
events	O
(	O
1.2	O
%	O
of	O
all	O
participants	O
)	O
.	O
There	O
were	O
609	O
medical	O
complaints	O
in	O
total	O
.	O
Three	O
quarters	O
of	O
injuries	O
were	O
musculoskeletal	O
in	O
nature	O
.	O
Eighty	O
-	O
nine	O
per	O
cent	O
returned	O
to	O
the	O
event	O
with	O
no	O
need	O
for	O
further	O
medical	B-T061
care	I-T061
.	O
The	O
majority	O
of	O
treatments	B-T061
were	O
completed	O
with	O
first	B-T061
aid	I-T061
and	O
basic	O
medical	O
equipment	O
.	O
Eleven	O
patients	O
(	O
2	O
%	O
of	O
patients	O
)	O
required	O
transfer	O
to	O
hospital	O
by	O
EMS	B-T058
for	O
presentations	O
including	O
fracture	O
,	O
dislocation	O
,	O
head	O
injury	O
,	O
chest	B-T184
pain	I-T184
,	O
fall	O
from	O
height	O
,	O
and	O
abdominal	B-T184
pain	I-T184
.	O
We	O
found	O
that	O
1.2	O
%	O
of	O
race	O
participants	O
presented	O
to	O
onsite	O
medical	B-T058
services	I-T058
.	O
The	O
majority	O
of	O
complaints	O
were	O
minor	O
and	O
musculoskeletal	O
in	O
nature	O
.	O
Only	O
2	O
%	O
of	O
those	O
treated	O
were	O
transferred	O
to	O
hospital	O
through	O
EMS	B-T058
.	O
This	O
is	O
consistent	O
with	O
other	O
types	O
of	O
mass	B-T033
gathering	I-T033
events	O
.	O
      
Genotyping	B-T059
of	O
Staphylococcus	B-T007
aureus	I-T007
in	O
bovine	B-T047
mastitis	I-T047
and	O
correlation	O
to	O
phenotypic	O
characteristics	O
Reducing	O
the	O
prevalence	O
of	O
mastitis	B-T047
caused	O
by	O
Staphylococcus	B-T007
aureus	I-T007
(	O
S.	B-T007
aureus	I-T007
)	O
is	O
essential	O
to	O
improve	O
animal	O
health	O
and	O
reduce	O
economic	O
losses	O
for	O
farmers	O
.	O
The	O
clinical	O
outcome	O
of	O
acute	B-T047
mastitis	I-T047
and	O
risk	O
of	O
progression	O
to	O
persistent	O
mastitis	B-T047
can	O
,	O
at	O
least	O
to	O
some	O
extent	O
,	O
be	O
related	O
to	O
genetic	O
variants	O
of	O
the	O
strain	B-T001
causing	O
the	O
infection	O
.	O
In	O
the	O
present	O
study	O
we	O
have	O
used	O
microarrays	O
to	O
investigate	O
the	O
presence	O
of	O
virulence	O
genes	O
in	O
S.	B-T007
aureus	I-T007
isolates	O
from	O
dairy	O
cows	O
with	O
acute	B-T047
clinical	I-T047
mastitis	I-T047
(	O
n=70	O
)	O
and	O
correlated	O
the	O
findings	B-T033
to	O
other	O
genotypic	O
and	O
phenotypic	O
characteristics	O
.	O
Among	O
the	O
most	O
commonly	O
found	O
virulence	O
factors	O
were	O
genes	O
encoding	O
several	O
hemolysin	O
types	O
,	O
leukocidins	O
D	O
and	O
lukM	O
/	O
lukF	O
-	O
P83	O
,	O
clumping	O
factors	O
A	O
and	O
B	O
,	O
fibrinogen	O
binding	O
protein	O
and	O
fibronectin	O
-	O
binding	O
protein	O
A.	O
Some	O
virulence	O
factors	O
e.g.	O
fibronectin	O
-	O
binding	O
protein	O
B	O
and	O
Staphylococcus	B-T007
aureus	I-T007
surface	O
protein	O
G	O
were	O
less	O
common	O
.	O
Genes	O
coding	O
for	O
several	O
staphylococcal	O
enterotoxins	O
and	O
toxic	O
shock	O
syndrome	O
toxin-1	O
(	O
TSST-1	O
)	O
were	O
commonly	O
found	O
,	O
especially	O
in	O
one	O
major	O
pulsotype	B-T001
.	O
No	B-T033
beta	O
-	O
lactamase	O
genes	O
were	O
found	O
in	O
any	O
common	O
pulsotype	B-T001
,	O
while	O
present	O
in	O
some	O
rare	O
pulsotypes	B-T001
,	O
indicated	O
to	O
be	O
of	O
human	O
origin	O
.	O
Production	O
of	O
TSST-1	O
,	O
enterotoxins	O
,	O
hemolysins	O
and	O
beta	O
-	O
lactamase	O
could	O
all	O
be	O
positively	O
correlated	O
to	O
presence	O
of	O
the	O
corresponding	O
genes	O
.	O
This	O
study	O
reveals	O
a	O
number	O
of	O
genotypic	O
differences	O
and	O
similarities	O
among	O
common	O
and	O
rare	O
pulsotypes	B-T001
of	O
S.	B-T007
aureus	I-T007
from	O
cases	O
of	O
mastitis	B-T047
in	O
Sweden	O
.	O
The	O
results	O
could	O
help	O
the	O
design	O
of	O
diagnostic	O
tools	O
to	O
guide	O
on	O
-	O
farm	O
interventions	O
according	O
to	O
the	O
expected	O
impact	O
on	O
udder	B-T023
health	O
from	O
a	O
specific	O
S.	B-T007
aureus	I-T007
genotype	O
.	O
      
Associations	O
of	O
gender	O
and	O
a	O
proxy	O
of	O
female	O
menopausal	O
status	O
with	O
histological	O
features	O
of	O
drug	B-T047
-	I-T047
induced	I-T047
liver	I-T047
injury	I-T047
Gender	O
and	O
menopause	O
may	O
contribute	O
to	O
type	O
and	O
severity	O
of	O
drug	B-T047
-	I-T047
induced	I-T047
liver	I-T047
injury	I-T047
(	O
DILI	B-T047
)	O
by	O
influencing	O
host	B-T001
responses	B-T033
to	O
injury	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
associations	O
of	O
gender	O
and	O
female	O
age	O
50	O
[	O
a	O
proxy	O
of	O
menopause	O
]	O
with	O
histological	O
features	O
of	O
liver	O
injury	O
in	O
212	O
adults	O
enrolled	O
in	O
the	O
Drug	B-T047
-	I-T047
Induced	I-T047
Liver	I-T047
Injury	I-T047
Network	O
(	O
DILIN	O
)	O
registry	O
.	O
All	O
participants	O
had	O
a	O
causality	O
score	O
of	O
at	O
least	O
'	O
probable	B-T033
'	O
,	O
a	O
liver	B-T060
biopsy	I-T060
within	O
30	O
days	O
of	O
DILI	B-T047
onset	O
,	O
and	O
no	O
prior	O
chronic	B-T047
liver	I-T047
disease	I-T047
.	O
Biochemical	O
and	O
histological	O
injury	O
types	O
were	O
classified	O
as	O
hepatocellular	O
or	O
cholestatic	B-T047
/	I-T047
mixed	I-T047
injury	I-T047
.	O
The	O
cohort	O
was	O
divided	O
into	O
three	O
gender	O
/	O
age	O
categories	O
:	O
men	O
(	O
41.0	O
%	O
)	O
,	O
women	O
<	O
50	O
years	O
(	O
27.4	O
%	O
)	O
and	O
women	O
≥50	O
years	O
of	O
age	O
(	O
31.6	O
%	O
)	O
.	O
Interaction	O
of	O
gender	O
and	O
age	O
category	O
(	O
≥50	O
or	O
not	O
)	O
was	O
assessed	O
.	O
Hepatocellular	O
injury	O
was	O
more	O
prevalent	O
in	O
women	O
<	O
50	O
years	O
vs.	O
others	O
(	O
P=.002	O
)	O
.	O
After	O
adjusting	O
for	O
biochemical	O
injury	O
types	O
,	O
black	O
race	O
and	O
possible	B-T033
ageing	O
effects	O
,	O
more	O
severe	O
interface	O
hepatitis	B-T047
was	O
noted	O
in	O
biopsies	B-T060
of	O
women	O
<	O
50	O
years	O
compared	O
to	O
those	O
of	O
men	O
and	O
women	O
≥50	O
years	O
(	O
P=.009	O
and	O
P=.055	O
respectively	O
)	O
.	O
Compared	O
to	O
those	O
of	O
men	O
,	O
biopsies	B-T060
of	O
women	O
showed	O
greater	O
plasma	B-T047
cell	I-T047
infiltration	I-T047
,	O
hepatocyte	O
apoptosis	O
,	O
hepatocyte	O
rosettes	B-T033
and	O
lobular	O
disarray	O
but	O
less	O
iron	B-T121
-	O
positive	B-T033
hepatocytes	O
and	O
histological	O
cholestasis	B-T047
(	O
P<.05	O
)	O
.	O
These	O
associations	O
persisted	O
after	O
excluding	O
cases	O
of	O
amoxicillin	B-T121
/	I-T121
clavulanic	I-T121
acid	I-T121
,	O
anabolic	B-T121
steroids	I-T121
or	O
nitrofurantoin	B-T121
DILI	B-T047
which	O
showed	O
gender	O
-specific	O
distributions	O
.	O
Gender	O
and	O
a	O
proxy	O
of	O
menopause	O
were	O
associated	O
with	O
various	O
features	O
of	O
inflammation	O
and	O
injury	O
in	O
DILI	B-T047
.	O
      
Oral	B-T058
health	I-T058
in	O
transition	O
:	O
The	O
Hadza	O
foragers	O
of	O
Tanzania	O
Conventional	O
wisdom	O
holds	O
that	O
a	O
decline	O
in	O
oral	B-T058
health	I-T058
accompanies	O
the	O
transition	O
from	O
hunting	O
and	O
gathering	O
to	O
agriculture	O
,	O
given	O
increased	O
consumption	O
of	O
carbohydrates	O
.	O
This	O
widely	O
touted	O
example	O
of	O
the	O
mismatch	O
between	O
our	O
biology	O
and	O
modern	O
lifestyle	O
has	O
been	O
intuited	O
largely	O
from	O
the	O
bioarchaeological	O
record	O
of	O
the	O
Neolithic	B-T121
Revolution	I-T121
in	O
the	O
New	O
World	O
.	O
Recent	O
studies	O
of	O
other	O
populations	O
have	O
,	O
however	O
,	O
challenged	O
the	O
universality	O
of	O
this	O
assertion	O
.	O
Here	O
,	O
we	O
present	O
the	O
first	O
comprehensive	O
study	O
of	O
oral	B-T058
health	I-T058
among	O
a	O
living	O
population	O
in	O
transition	O
from	O
the	O
bush	O
to	O
village	O
life	O
,	O
the	O
Hadza	O
hunter	O
-	O
gatherers	O
of	O
Tanzania	O
,	O
to	O
test	O
the	O
hypothesis	O
that	O
the	O
shift	O
from	O
foraging	O
to	O
farming	O
,	O
or	O
agricultural	O
intensification	O
,	O
inevitably	O
leads	O
to	O
increased	O
periodontal	B-T047
disease	I-T047
,	O
caries	B-T047
,	O
and	O
orthodontic	O
disorders	B-T047
.	O
Our	O
results	O
showed	O
that	O
women	O
living	O
in	O
villages	O
consuming	O
a	O
mostly	O
agricultural	O
diet	O
exhibited	O
more	O
caries	B-T047
and	O
periodontal	B-T047
disease	I-T047
than	O
those	O
living	O
in	O
the	O
bush	O
consuming	O
a	O
mostly	O
wild	O
-	O
food	O
diet	O
.	O
Furthermore	O
,	O
men	O
living	O
in	O
the	O
bush	O
consuming	O
mostly	O
a	O
wild	O
-	O
food	O
diet	O
had	O
more	O
than	O
those	O
living	O
in	O
the	O
village	O
consuming	O
a	O
mostly	O
agricultural	O
diet	O
.	O
These	O
findings	B-T033
are	O
explained	O
by	O
the	O
high	O
incidence	O
of	O
maize	O
consumption	O
in	O
village	O
settings	O
,	O
along	O
with	O
previously	O
recognized	O
variation	O
in	O
rate	O
of	O
caries	B-T047
between	O
men	O
and	O
women	O
.	O
The	O
unexpected	O
discovery	O
of	O
high	O
caries	B-T047
incidences	O
for	O
men	O
in	O
the	O
bush	O
is	O
likely	O
explained	O
by	O
heavy	O
reliance	O
on	O
honey	O
,	O
and	O
perhaps	O
differential	O
access	O
to	O
tobacco	O
and	O
marijuana	B-T121
.	I-T121
These	O
data	O
support	O
the	O
notions	O
that	O
mechanisms	O
of	O
cariogenesis	B-T047
are	O
multifactorial	B-T033
and	O
that	O
the	O
relationships	O
between	O
oral	B-T058
health	I-T058
and	O
the	O
shift	O
from	O
a	O
predominantly	O
wild	O
-	O
food	O
diet	O
to	O
one	O
dominated	O
by	O
cultigens	O
are	O
nuanced	O
.	O
      
Coxiella	B-T007
burnetii	I-T007
isolates	O
originating	O
from	O
infected	O
cattle	O
induce	O
a	O
more	O
pronounced	O
proinflammatory	O
cytokine	O
response	O
compared	O
to	O
isolates	O
from	O
infected	O
goats	O
and	O
sheep	O
Coxiella	B-T007
burnetii	I-T007
is	O
the	O
causative	B-T033
agent	I-T033
of	O
Q	B-T047
fever	I-T047
.	O
Although	O
the	O
prevalence	O
of	O
C.	B-T007
burnetii	I-T007
in	O
cattle	O
is	O
much	O
higher	O
than	O
in	O
goats	O
and	O
sheep	O
,	O
infected	O
cattle	O
are	O
rarely	O
associated	O
with	O
human	O
outbreaks	O
.	O
We	O
investigated	O
whether	O
the	O
immune	O
response	O
of	O
humans	O
differs	O
after	O
contact	O
with	O
C.	B-T007
burnetii	I-T007
isolates	O
from	O
different	O
host	B-T001
origins	I-T001
or	O
with	O
different	O
multilocus	B-T059
variable	I-T059
number	I-T059
of	I-T059
tandem	I-T059
repeat	I-T059
analysis	I-T059
(	O
MLVA	B-T059
)	O
genotypes	O
.	O
Cytokine	O
responses	O
were	O
measured	O
in	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
stimulated	O
with	O
16	O
C.	B-T007
burnetii	I-T007
isolates	O
with	O
known	O
MLVA	B-T059
genotype	O
from	O
goats	O
,	O
sheep	O
,	O
cattle	O
,	O
acute	B-T047
and	O
chronic	B-T047
Q	I-T047
fever	I-T047
patients	O
.	O
Coxiella	B-T007
burnetii	I-T007
isolates	O
originating	O
from	O
cattle	O
induce	O
significantly	O
more	O
IL-1β	O
,	O
TNF	O
-	O
α	O
and	O
IL-22	O
than	O
the	O
isolates	O
from	O
goats	O
,	O
sheep	O
or	O
chronic	B-T047
Q	I-T047
fever	I-T047
patients	O
.	O
Comparing	O
the	O
cytokine	O
induction	O
of	O
the	O
isolates	O
based	O
on	O
their	O
MVLA	B-T059
genotype	O
did	O
not	O
reveal	O
differences	O
in	O
response	O
between	O
the	O
MLVA	B-T059
genotypes	O
.	O
The	O
proinflammatory	O
cytokine	O
response	O
induced	O
in	O
human	O
PBMCs	O
by	O
C.	B-T007
burnetii	I-T007
isolates	O
from	O
cattle	O
may	O
explain	O
the	O
low	O
incidence	O
of	O
human	O
Q	B-T047
fever	I-T047
outbreaks	O
caused	O
by	O
cattle	O
.	O
The	O
cytokine	O
profile	O
of	O
PBMCs	O
stimulated	O
with	O
C.	B-T007
burnetii	I-T007
isolates	O
from	O
chronic	B-T047
Q	I-T047
fever	I-T047
patients	O
resembles	O
isolates	O
from	O
goats	O
.	O
Furthermore	O
,	O
cytokine	O
responses	O
seem	O
to	O
be	O
depending	O
on	O
host	B-T001
origin	I-T001
than	O
on	O
MLVA	B-T059
genotype	O
.	O
      
The	O
link	O
between	O
self	O
-	O
perceptions	O
of	O
aging	O
,	O
cancer	B-T191
view	O
and	O
physical	O
and	O
mental	O
health	O
of	O
older	O
people	O
with	O
cancer	B-T191
:	O
A	O
cross	O
-	O
sectional	O
study	O
Older	O
people	O
may	O
suffer	O
from	O
stigmas	B-T048
linked	O
to	O
cancer	B-T191
and	O
aging	O
.	O
Although	O
some	O
studies	O
suggested	O
that	O
a	O
negative	B-T033
view	O
of	O
cancer	B-T191
may	O
increase	O
the	O
level	B-T033
of	I-T033
depression	I-T033
,	O
such	O
an	O
association	O
has	O
never	O
been	O
studied	O
in	O
the	O
elderly	O
population	O
.	O
Similarly	O
,	O
even	O
though	O
it	O
is	O
established	O
that	O
a	O
negative	B-T033
self	O
-	O
perception	O
of	O
aging	O
has	O
deleterious	O
consequences	O
on	O
mental	O
and	O
physical	B-T033
health	I-T033
in	O
normal	O
aging	O
,	O
the	O
influence	O
in	O
pathological	O
contexts	O
,	O
such	O
as	O
oncology	B-T191
,	O
has	O
not	O
been	O
studied	O
.	O
The	O
main	O
aim	O
of	O
this	O
study	O
is	O
thus	O
to	O
analyze	O
the	O
effect	O
of	O
these	O
two	O
stigmas	B-T048
on	O
the	O
health	O
of	O
elderly	O
oncology	B-T191
patients	O
.	O
101	O
patients	O
suffering	O
from	O
a	O
cancer	B-T191
(	O
breast	B-T191
,	O
gynecological	B-T047
,	O
lung	B-T191
or	O
hematological	B-T047
)	O
were	O
seen	O
as	O
soon	O
as	O
possible	O
after	O
their	O
diagnosis	B-T033
.	O
Their	O
self	O
-	O
perception	O
of	O
age	O
,	O
cancer	B-T191
view	O
and	O
health	O
(	O
physical	B-T033
and	O
mental	O
)	O
was	O
assessed	O
.	O
Multiple	O
regressions	O
showed	O
that	O
patients	O
with	O
a	O
more	O
negative	B-T033
self	O
-	O
perception	O
of	O
aging	O
and/or	O
more	O
negative	B-T033
cancer	B-T191
view	O
reported	O
poorer	O
global	O
health	O
.	O
We	O
also	O
observed	O
that	O
negative	B-T033
self	O
-	O
perception	O
of	O
aging	O
was	O
associated	O
with	O
worse	O
physical	B-T033
and	O
mental	O
health	O
,	O
whereas	O
negative	B-T033
cancer	B-T191
views	O
were	O
only	O
linked	O
to	O
worse	O
mental	O
health	O
.	O
No	O
interaction	O
was	O
observed	O
between	O
these	O
two	O
stigmas	B-T048
,	O
suggesting	O
that	O
their	O
action	O
is	O
independent	O
.	O
Older	O
patients	O
with	O
cancer	B-T191
face	O
double	O
stigmatization	O
,	O
due	O
to	O
negative	B-T033
self	O
-	O
perception	O
of	O
aging	O
and	O
cancer	B-T191
,	O
and	O
these	O
stigmas	B-T048
have	O
impacts	O
on	O
global	O
and	O
mental	O
health	O
.	O
Self	O
-	O
perception	O
of	O
aging	O
is	O
also	O
linked	O
to	O
physical	B-T033
health	I-T033
.	O
Longitudinal	O
studies	O
will	O
be	O
necessary	O
to	O
analyze	O
the	O
direction	O
of	O
the	O
association	O
between	O
this	O
double	O
stigmatization	O
and	O
health	O
.	O
      
Pathogenesis	O
of	O
COPD	B-T047
and	O
Asthma	B-T047
Asthma	B-T047
and	O
COPD	B-T047
remain	O
two	O
diseases	B-T047
of	I-T047
the	I-T047
respiratory	I-T047
tract	I-T047
with	O
unmet	O
medical	O
needs	O
.	O
This	O
review	O
considers	O
the	O
current	O
state	O
of	O
play	O
with	O
respect	O
to	O
what	O
is	O
known	O
about	O
the	O
underlying	O
pathogenesis	O
of	O
these	O
two	O
chronic	B-T047
inflammatory	I-T047
diseases	I-T047
of	O
the	O
lung	B-T023
.	O
The	O
review	O
highlights	O
why	O
they	O
are	O
different	O
conditions	O
requiring	O
different	O
approaches	O
to	O
treatment	B-T061
and	O
provides	O
a	O
backdrop	O
for	O
the	O
subsequent	O
chapters	O
in	O
this	O
volume	O
discussing	O
recent	O
advances	O
in	O
the	O
pharmacology	O
and	O
treatment	B-T061
of	O
asthma	B-T047
and	O
COPD	B-T047
.	O
      
Primary	O
pituitary	B-T023
diffuse	B-T191
large	I-T191
B	I-T191
-	I-T191
cell	I-T191
lymphoma	I-T191
with	O
somatotroph	B-T190
hyperplasia	I-T190
and	O
acromegaly	B-T047
:	O
case	O
report	O
Diffuse	B-T191
large	I-T191
B	I-T191
-	I-T191
cell	I-T191
lymphoma	I-T191
(	O
DLBCL	B-T191
)	O
is	O
the	O
most	O
common	O
type	O
of	O
non	B-T191
-	I-T191
Hodgkin	I-T191
lymphoma	I-T191
and	O
comprises	O
approximately	O
30	O
%	O
of	O
all	O
lymphomas	B-T191
.	O
Patients	O
typically	O
present	B-T033
with	O
a	O
nonpainful	O
mass	B-T033
in	O
the	O
neck	O
,	O
groin	O
,	O
or	O
abdomen	O
associated	O
with	O
constitutional	B-T184
symptoms	I-T184
.	O
In	O
this	O
report	O
,	O
however	O
,	O
the	O
authors	O
describe	O
a	O
rare	O
case	O
of	O
a	O
61-	O
year	O
-old	O
woman	O
with	O
hyperprolactinemia	B-T047
,	O
hypothyroidism	B-T047
,	O
and	O
acromegaly	B-T047
(	O
elevation	O
of	O
insulin	O
-	O
like	O
growth	O
factor-1	O
[	O
IGF-1	O
]	O
)	O
with	O
elevated	O
growth	O
hormone	O
-	O
releasing	O
hormone	O
(	O
GHRH	O
)	O
in	O
whom	O
an	O
MRI	B-T060
demonstrated	O
diffuse	B-T184
enlargement	I-T184
of	I-T184
the	I-T184
pituitary	I-T184
gland	I-T184
.	O
Despite	O
medical	B-T061
treatment	I-T061
,	O
the	O
patient	O
had	O
persistent	O
elevation	O
of	O
IGF-1	O
.	O
She	O
underwent	O
a	O
transsphenoidal	B-T060
biopsy	I-T060
,	O
which	O
yielded	O
a	O
diagnosis	B-T033
of	O
DLBCL	B-T191
with	O
an	O
activated	O
B	O
-	O
cell	O
immunophenotype	B-T059
with	O
somatotroph	B-T190
hyperplasia	I-T190
.	O
After	O
stereo	B-T061
-	I-T061
tactic	I-T061
radiation	I-T061
therapy	I-T061
in	O
combination	O
with	O
chemotherapy	B-T061
,	O
she	O
is	O
currently	O
in	O
remission	B-T191
from	O
her	O
lymphoma	B-T191
and	O
has	O
normalized	O
IGF-1	O
levels	O
without	O
medical	B-T061
therapy	I-T061
,	O
8	O
months	O
after	O
her	O
histopathological	O
diagnosis	B-T033
.	O
This	O
is	O
the	O
only	O
reported	O
case	O
of	O
its	O
kind	O
and	O
displays	O
the	O
importance	O
of	O
a	O
broad	O
differential	B-T060
diagnosis	I-T060
,	O
multidisciplinary	B-T060
evaluation	I-T060
,	O
and	O
critical	O
intraoperative	O
decision	O
-	O
making	O
when	O
treating	O
atypical	O
sellar	B-T023
lesions	B-T033
.	O
      
Primary	B-T191
neuroendocrine	I-T191
carcinoma	I-T191
of	O
the	O
breast	B-T023
A	O
single	O
Center	O
experience	O
and	O
review	O
of	O
the	O
literature	O
Neuroendocrine	B-T191
carcinoma	I-T191
of	O
the	O
breast	B-T023
is	O
an	O
extremely	O
rare	O
tumor	B-T191
.	O
A	O
standard	O
treatment	B-T061
has	O
yet	O
to	O
be	O
established	O
because	O
only	O
a	O
few	O
cases	O
have	O
been	O
reported	O
in	O
literature	O
.	O
The	O
authors	O
report	O
five	O
cases	O
observed	O
from	O
January	O
2007	O
to	O
December	O
2014	O
and	O
a	O
review	O
of	O
literature	O
.	O
Four	O
patients	O
underwent	O
quadrantectomy	B-T061
and	O
in	O
two	O
cases	O
axillary	B-T061
nodal	I-T061
dissection	I-T061
and	O
only	O
one	O
to	O
mastectomy	B-T061
with	O
axillary	B-T061
nodal	I-T061
dissection	I-T061
.	O
Tumor	O
size	O
was	O
from	O
T1	B-T033
to	O
T2	B-T033
with	O
N0	B-T033
to	O
N1	B-T033
,	O
according	O
TNM	O
classification	O
.	O
Pathological	O
specimens	O
were	O
stained	O
with	O
hematoxylin	O
and	O
eosin	O
and	O
an	O
immunohistochemical	B-T059
panel	O
of	O
antibodies	O
(	O
Neuron	O
-	O
specific	O
enolase	O
,	O
Chromogranin	O
,	O
Synaptophysin	O
,	O
Estrogen	O
and	O
Progesterone	O
receptors	O
,	O
c	O
-	O
erb	O
and	O
Ki-67	O
)	O
.	O
All	O
cases	O
showed	O
markers	O
positivity	O
to	O
Neuron	O
-	O
specific	O
enolase	O
,	O
Chromogranin	O
,	O
Synaptophysin	O
and	O
Estrogen	O
and	O
Progesterone	O
receptors	O
were	O
found	O
.	O
Ki-67	O
was	O
higher	O
than	O
40	O
%	O
in	O
four	O
patients	O
.	O
Adjuvant	B-T061
chemotherapy	I-T061
was	O
administrated	B-T061
in	O
patients	O
with	O
Ki-67	O
>	O
10	O
%	O
;	O
every	O
patients	O
were	O
treated	O
with	O
radiotherapy	B-T061
and	O
with	O
hormonal	B-T061
therapy	I-T061
too	O
.	O
Although	O
Neuroendocrine	B-T191
breast	I-T191
tumor	I-T191
is	O
considered	O
a	O
distinct	O
entity	O
,	O
the	O
best	O
treatment	B-T061
seems	O
to	O
be	O
correlate	O
to	O
the	O
size	O
of	O
tumor	O
and	O
to	O
the	O
lymph	B-T023
node	I-T023
status	O
and	O
to	O
Ki-67	O
index	O
like	O
the	O
common	O
breast	B-T191
cancer	I-T191
.	O
Diagnosis	B-T033
,	O
Neuroendocrine	B-T191
breast	I-T191
carcinoma	I-T191
.	O
      
Plasma	O
DNA	O
and	O
RNA	O
differentially	O
impact	O
coagulation	O
during	O
abdominal	B-T047
sepsis	I-T047
-an	O
explorative	O
study	O
Cell	O
-	O
free	O
DNA	O
(	O
cfDNA	O
)	O
and	O
extracellular	O
RNA	O
(	O
exRNA	O
)	O
are	O
both	O
suspected	O
to	O
activate	O
coagulation	B-T047
cascades	I-T047
in	O
sepsis	B-T047
.	O
Therefore	O
,	O
our	O
study	O
investigated	O
the	O
influence	O
of	O
plasmatic	O
nucleic	O
acids	O
on	O
coagulation	O
in	O
septic	O
patients	O
in	O
comparison	O
to	O
patients	O
after	O
major	O
abdominal	B-T061
surgery	I-T061
.	O
A	O
total	O
of	O
15	O
patients	O
with	O
sepsis	B-T047
,	O
10	O
postoperative	O
patients	O
,	O
and	O
10	O
healthy	O
volunteers	O
were	O
included	O
in	O
this	O
longitudinal	O
study	O
.	O
Blood	O
was	O
collected	O
at	O
sepsis	B-T047
onset	O
and	O
after	O
surgery	B-T061
respectively	O
,	O
as	O
well	O
as	O
after	O
24	O
,	O
72	O
and	O
168	O
h.	O
Levels	O
of	O
cfDNA	O
and	O
exRNA	O
were	O
measured	O
by	O
quantitative	O
probe	O
-	O
based	O
polymerase	O
chain	O
reaction	O
.	O
In	O
addition	O
,	O
thromboelastography	B-T059
for	O
coagulation	O
as	O
well	O
as	O
thromboaggregometry	B-T059
for	O
platelet	O
function	O
was	O
conducted	O
.	O
Both	O
cfDNA	O
and	O
exRNA	O
were	O
elevated	O
in	O
patients	O
with	O
sepsis	B-T047
compared	O
with	O
postoperative	O
patients	O
and	O
healthy	O
volunteers	O
.	O
While	O
higher	O
exRNA	O
levels	O
correlated	O
with	O
a	O
faster	O
clotting	O
time	O
and	O
more	O
stable	O
clots	O
,	O
cfDNA	O
correlated	O
with	O
a	O
shorter	O
clotting	O
time	O
but	O
also	O
less	O
fibrinolysis	O
.	O
In	O
addition	O
,	O
higher	O
cfDNA	O
seems	O
to	O
be	O
associated	O
with	O
kidney	O
dysfunction	O
as	O
well	O
as	O
with	O
general	O
markers	O
of	O
cell	O
damage	O
(	O
lactate	O
dehydrogenase	O
and	O
lactate	B-T121
)	O
.	O
Both	O
nucleic	O
acid	O
species	O
might	O
be	O
associated	O
with	O
different	O
effects	O
on	O
coagulation	O
during	O
sepsis	B-T047
,	O
with	O
an	O
overall	O
procoagulatory	O
influence	O
.	O
For	O
this	O
reason	O
,	O
individualized	O
therapeutic	B-T061
approaches	I-T061
in	O
patients	O
suffering	B-T184
from	O
coagulation	O
-	O
associated	B-T033
organ	B-T047
dysfunction	I-T047
might	O
be	O
feasible	O
.	O
      
Ocular	O
toxicity	O
of	O
AUY922	B-T121
in	O
pigmented	O
and	O
albino	O
rats	O
AUY922	B-T121
,	O
a	O
heat	O
shock	O
protein	O
90	O
inhibitor	O
is	O
associated	O
with	O
ocular	B-T023
adverse	O
events	O
(	O
AEs	O
)	O
.	O
To	O
provide	O
a	O
better	O
understanding	O
of	O
ocular	B-T023
AEs	O
in	O
patients	O
,	O
4	O
investigative	O
studies	O
were	O
performed	O
in	O
a	O
step	O
-	O
wise	O
approach	O
to	O
assess	O
retinal	B-T023
structure	I-T023
and	O
function	O
in	O
pigmented	O
(	O
Brown	O
Norway	O
)	O
and	O
albino	O
(	O
Wistar	O
)	O
rats	O
.	O
In	O
rats	O
administered	O
30mg	O
/	O
kg	O
of	O
AUY922	B-T121
,	O
the	O
AUC	O
0	O
-	O
24	O
h	O
and	O
Cmax	O
are	O
comparable	O
to	O
that	O
in	O
patients	O
at	O
70mg	O
/	O
m(2	O
)	O
.	O
AUY922	B-T121
at	O
≥30mg	O
/	O
kg	O
was	O
poorly	O
tolerated	O
by	O
rats	O
with	O
morbidity	O
or	O
mortality	O
generally	O
after	O
the	O
third	O
weekly	O
treatment	B-T061
.	O
Electroretinography	B-T060
(	O
ERG	B-T060
)	O
changes	O
were	O
observed	O
at	O
doses	O
≥30mg	O
/	O
kg	O
.	O
The	O
ERG	B-T060
changes	O
were	O
dose	O
dependent	O
,	O
consistent	O
with	O
an	O
effect	O
on	O
the	O
photoreceptors	O
,	O
and	O
fully	O
reversible	O
.	O
The	O
ERG	B-T060
effects	O
could	O
not	O
be	O
minimized	O
by	O
decreasing	O
the	O
Cmax	O
while	O
maintaining	O
AUC	O
.	O
Histopathological	O
changes	O
were	O
seen	O
mainly	O
when	O
rats	O
were	O
administered	O
AUY922	B-T121
at	O
100mg	O
/	O
kg	O
.	O
The	O
2-	O
hour	O
infusion	B-T061
of	O
AUY922	B-T121
at	O
100mg	O
/	O
kg	O
caused	O
disorganization	B-T033
of	O
the	O
outer	O
segment	O
photoreceptor	O
morphology	O
in	O
male	O
Brown	O
Norway	O
rats	O
;	O
the	O
severity	O
of	O
the	O
disorganization	B-T033
increased	O
with	O
the	O
number	O
of	O
administrations	B-T061
,	O
but	O
was	O
reversible	O
during	O
a	O
4-	O
week	O
posttreatment	O
period	O
.	O
There	O
was	O
no	O
major	O
difference	O
in	O
ocular	B-T023
response	O
between	O
Brown	O
Norway	O
and	O
Wistar	O
rats	O
.	O
No	O
changes	O
in	O
serum	O
iron	O
levels	O
,	O
and	O
no	O
changes	O
in	O
rhodopsin	O
,	O
PDE6α	O
,	O
β	O
-	O
transducin	O
concentrations	O
,	O
or	O
retinal	O
pigment	O
epithelium	O
-	O
specific	O
protein	O
RPE65	O
expression	O
were	O
observed	O
after	O
single	O
and	O
multiple	O
infusions	B-T061
of	O
AUY922	B-T121
at	O
100mg	O
/	O
kg	O
compared	O
to	O
vehicle	O
-	O
treated	O
controls	O
.	O
AUY922	B-T121
retinal	B-T190
toxicity	I-T190
in	O
rats	O
recapitulates	O
and	O
further	O
characterizes	O
that	O
reported	O
in	O
patients	O
and	O
is	O
shown	O
to	O
be	O
reversible	O
,	O
while	O
a	O
precise	O
molecular	O
mechanism	O
for	O
the	O
effect	O
was	O
not	O
determined	O
.	O
      
Young	O
people	O
,	O
mental	O
health	O
practitioners	O
and	O
researchers	O
co	O
-	O
produce	O
a	O
Transition	O
Preparation	O
Programme	O
to	O
improve	O
outcomes	O
and	O
experience	O
for	O
young	O
people	O
leaving	O
Child	B-T058
and	I-T058
Adolescent	I-T058
Mental	I-T058
Health	I-T058
Services	I-T058
(	O
CAMHS	B-T058
)	O
In	O
the	O
UK	O
young	O
people	O
attending	O
child	B-T058
and	I-T058
adolescent	I-T058
mental	I-T058
health	I-T058
services	I-T058
(	O
CAMHS	B-T058
)	O
are	O
required	O
to	O
move	O
on	O
,	O
either	O
through	O
discharge	O
or	O
referral	B-T058
to	I-T058
an	O
adult	B-T058
service	I-T058
,	O
at	O
age	O
17/18	O
,	O
a	O
period	O
of	O
increased	O
risk	O
for	O
onset	O
of	O
mental	B-T033
health	I-T033
problems	I-T033
and	O
other	O
complex	O
psychosocial	O
and	O
physical	O
changes	O
.	O
CAMHS	B-T058
transitions	O
are	O
often	O
poorly	O
managed	O
with	O
negative	B-T033
outcomes	O
for	O
young	O
people	O
.	O
Better	O
preparation	O
may	O
improve	O
outcomes	O
and	O
experience	O
.	O
This	O
study	O
aimed	O
to	O
co	O
-	O
produce	O
,	O
with	O
young	O
people	O
who	O
had	O
transitioned	O
or	O
were	O
facing	O
transition	O
from	O
CAMHS	B-T058
,	O
a	O
CAMHS	B-T058
Transition	O
Preparation	O
Programme	O
(	O
TPP	O
)	O
,	O
deliverable	O
in	O
routine	O
NHS	B-T058
settings	O
.	O
Eighteen	O
young	O
people	O
,	O
aged	O
17	O
-	O
22	O
,	O
from	O
three	O
UK	O
National	B-T058
Health	I-T058
Service	I-T058
(	O
NHS	B-T058
)	O
mental	O
health	O
foundation	O
trusts	O
participated	O
in	O
creative	O
,	O
participatory	O
research	O
workshops	O
.	O
Seven	O
parents	O
completed	O
short	O
questionnaires	O
.	O
Thirty	O
clinical	O
staff	O
from	O
two	O
trusts	O
took	O
part	O
in	O
workshops	O
to	O
ensure	O
deliverability	O
of	O
young	O
people	O
's	O
ideas	O
.	O
Young	O
people	O
were	O
offered	O
co	O
-	O
research	O
opportunities	O
.	O
Most	O
young	O
people	O
felt	O
anxious	B-T033
,	O
fearful	O
and	O
uncertain	O
on	O
leaving	O
CAMHS	B-T058
and	O
perceived	O
mental	B-T058
health	I-T058
services	I-T058
as	O
uncaring	O
.	O
Participants	O
outlined	O
transition	O
procedures	O
and	O
drafted	O
a	O
range	O
of	O
preparation	O
activities	O
,	O
centred	O
around	O
dedicated	O
Transition	O
Peer	B-T061
Support	I-T061
and	O
a	O
transition	O
booklet	O
,	O
which	O
should	O
be	O
offered	O
to	O
all	O
CAMHS	B-T058
leavers	O
,	O
irrespective	O
of	O
discharge	O
or	O
transfer	O
to	O
an	O
adult	B-T058
service	I-T058
.	O
Preparation	O
should	O
aim	O
to	O
build	O
confidence	O
to	O
help	O
young	O
people	O
take	O
responsibility	O
for	O
themselves	O
and	O
flourish	O
in	O
the	O
adult	O
world	O
:	O
coping	O
or	O
getting	O
through	O
it	O
was	O
not	O
enough	O
.	O
Some	O
clinicians	O
also	O
felt	O
anxious	B-T033
at	O
transition	O
and	O
recognised	O
the	O
potential	O
impact	O
on	O
young	O
people	O
of	O
poor	O
communication	O
and	O
lack	O
of	O
understanding	O
between	O
services	B-T058
.	O
Parents	O
would	O
appreciate	O
help	O
to	O
support	O
their	O
offspring	O
during	O
the	O
transition	O
period	O
.	O
Clinicians	O
cited	O
lack	O
of	O
funding	O
and	O
inflexible	O
NHS	B-T058
procedures	O
and	O
policies	O
as	O
potential	O
barriers	O
to	O
the	O
implementation	O
of	O
young	O
people	O
's	O
ideas	O
.	O
Nine	O
young	O
people	O
took	O
up	O
co	O
-	O
research	O
opportunities	O
.	O
Mental	B-T058
health	I-T058
services	I-T058
underestimate	O
the	O
anxiety	B-T033
of	O
CAMHS	B-T058
leavers	O
.	O
Young	O
people	O
have	O
clear	O
ideas	O
about	O
the	O
preparation	O
they	O
require	O
to	O
leave	O
CAMHS	B-T058
with	O
the	O
confidence	O
to	O
take	O
responsibility	O
for	O
their	O
own	O
health	B-T058
care	I-T058
.	O
Close	O
collaboration	O
of	O
NHS	B-T058
staff	O
and	O
researchers	O
facilitates	O
the	O
implementation	O
of	O
research	O
findings	O
.	O
      
A	O
Course	O
-Based	O
Approach	O
to	O
the	O
Doctor	O
of	O
Nursing	O
Practice	O
Project	O
:	O
Supporting	O
Student	O
Growth	O
From	O
Concept	O
to	O
Completion	O
We	O
describe	O
a	O
course	O
-based	O
approach	O
to	O
the	O
doctor	O
of	O
nursing	O
practice	O
project	O
in	O
which	O
students	O
work	O
in	O
groups	O
of	O
8	O
to	O
12	O
with	O
a	O
faculty	O
member	O
to	O
complete	O
individual	O
final	O
projects	O
that	O
require	O
a	O
minimum	O
of	O
360	O
practicum	O
hours	O
in	O
3-	O
semester	O
-long	O
courses	O
.	O
Project	O
teams	O
include	O
agency	O
or	O
community	O
-based	O
mentors	O
.	O
Project	B-T033
findings	I-T033
are	O
disseminated	O
through	O
written	O
and	O
oral	O
reports	O
.	O
This	O
approach	O
preserves	O
faculty	O
resources	O
and	O
provides	O
students	O
with	O
mentoring	O
,	O
opportunities	O
for	O
reflection	O
,	O
and	O
time	O
for	O
project	O
development	O
.	O
      
The	O
Prevalence	O
of	O
Sleep	B-T047
Apnea	I-T047
in	O
Type	B-T190
B	I-T190
Aortic	I-T190
Dissection	I-T190
:	O
Implications	O
for	O
False	O
Lumen	O
Thrombosis	O
Obstructive	B-T047
sleep	I-T047
apnea	I-T047
(	O
OSA	B-T047
)	O
has	O
been	O
implicated	O
in	O
aortic	B-T047
dissection	I-T047
.	O
Thrombosis	O
of	O
the	O
false	O
lumen	O
is	O
associated	O
with	O
a	O
prognosis	B-T058
of	O
type	B-T190
B	I-T190
aortic	I-T190
dissection	I-T190
(	O
AoD	B-T190
)	O
,	O
and	O
partial	B-T020
thrombosis	I-T020
has	O
been	O
reported	O
to	O
be	O
an	O
independent	O
predictor	O
of	O
mortality	O
.	O
This	O
study	O
sought	O
to	O
explore	O
whether	O
the	O
severity	O
of	O
OSA	B-T047
is	O
associated	O
with	O
false	O
lumen	O
thrombosis	O
.	O
In	O
this	O
observational	O
study	O
,	O
151	O
type	B-T190
B	I-T190
AoD	I-T190
patients	O
were	O
recruited	O
consecutively	O
from	O
2013	O
to	O
2015	O
.	O
The	O
status	O
of	O
the	O
false	O
lumen	O
was	O
classified	O
as	O
patent	O
,	O
partially	O
thrombosed	O
,	O
or	O
completely	O
thrombosed	O
based	O
on	O
a	O
computer	B-T060
tomography	I-T060
angiography	I-T060
image	O
.	O
Patients	O
were	O
divided	O
into	O
non	O
-	O
OSA	O
group	O
(	O
apnea	O
-	O
hypopnea	O
index	O
[	O
AHI	O
]	O
<	O
5	O
)	O
,	O
and	O
mild	O
(	O
5	O
≤	O
AHI	O
≤	O
15	O
)	O
,	O
moderate	O
(	O
15	O
<	O
AHI	O
≤	O
30	O
)	O
,	O
and	O
severe	O
OSA	O
groups	O
(	O
AHI	O
>	O
30	O
)	O
using	O
the	O
AHI	O
.	O
The	O
prevalence	O
of	O
OSA	B-T047
in	O
type	B-T190
B	I-T190
dissection	I-T190
was	O
66.2	O
%	O
.	O
Among	O
151	O
cases	O
,	O
51	O
patients	O
(	O
33.8	O
%	O
)	O
were	O
in	O
the	O
non	O
-	O
OSA	O
group	O
,	O
56	O
(	O
37.1	O
%	O
)	O
were	O
in	O
the	O
mild	O
group	O
,	O
21	O
(	O
13.9	O
%	O
)	O
were	O
in	O
the	O
moderate	O
group	O
,	O
and	O
23	O
(	O
15.2	O
%	O
)	O
were	O
in	O
the	O
severe	O
group	O
.	O
Additionally	O
,	O
a	O
partially	O
thrombosed	O
false	O
lumen	O
was	O
observed	O
in	O
88	O
patients	O
(	O
58.3	O
%	O
)	O
.	O
Multivariable	O
analysis	O
revealed	O
that	O
OSA	B-T047
severity	O
was	O
positively	B-T033
associated	O
with	O
partial	O
thrombosis	O
(	O
odds	O
ratio	O
,	O
1.784	O
,	O
95	O
%	O
confidence	O
interval	O
:	O
1.182	O
-	O
2.691	O
,	O
P	O
=	O
.006	O
)	O
after	O
adjusting	O
for	O
other	O
confounding	O
factors	O
.	O
OSA	B-T047
was	O
present	O
in	O
two	O
-	O
thirds	O
of	O
patients	O
with	O
type	B-T190
B	I-T190
AoD	I-T190
AoD.	O
The	O
severity	O
of	O
OSA	B-T047
was	O
significantly	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
partial	O
false	O
lumen	O
thrombosis	O
.	O
OSA	B-T047
may	O
therefore	O
be	O
implicated	O
in	O
both	O
the	O
etiology	O
and	O
prognosis	B-T058
AoD	B-T190
of	O
AoD.	O
      
Effectiveness	O
of	O
workers	O
'	O
general	B-T060
health	I-T060
examination	I-T060
in	O
Korea	O
by	O
health	B-T058
examination	I-T058
period	I-T058
and	O
compliance	B-T033
:	O
retrospective	O
cohort	O
study	O
using	O
nationwide	O
data	O
Our	O
study	O
evaluated	B-T058
the	O
effectiveness	O
of	O
the	O
Workers	O
'	O
General	B-T060
Health	I-T060
Examination	I-T060
by	O
health	B-T058
examination	I-T058
period	I-T058
and	O
compliance	B-T033
.	O
A	O
retrospective	O
cohort	O
of	O
the	O
health	B-T058
examination	I-T058
participants	O
in	O
2006	O
(	O
baseline	O
year	O
:	O
N	O
�	O
€‰=	O
�	O
€‰6,527,045	O
)	O
was	O
used	O
.	O
We	O
identified	O
newly	O
occurring	O
cardio	B-T047
-	O
cerebrovascular	B-T047
disease	I-T047
over	O
7	O
years	O
(	O
from	O
2007	O
to	O
2013	O
)	O
.	O
After	O
stratification	O
by	O
age	O
,	O
sex	O
,	O
and	O
national	B-T058
health	I-T058
insurance	I-T058
type	I-T058
,	O
we	O
identified	O
7	O
years	O
'	O
cumulative	O
incidence	O
of	O
cardio	B-T047
-	O
cerebrovascular	B-T047
disease	I-T047
by	O
health	B-T058
examination	I-T058
compliance	B-T033
and	O
estimated	O
its	O
relative	O
risk	O
by	O
health	B-T058
examination	I-T058
period	I-T058
and	O
compliance	B-T033
.	O
The	O
compliant	O
group	O
presented	O
a	O
lower	O
cumulative	O
incidence	O
of	O
cardio	B-T047
-	O
cerebrovascular	B-T047
disease	I-T047
than	O
the	O
non	O
-	O
compliant	O
group	O
;	O
this	O
result	O
was	O
consistent	O
across	O
sex	O
,	O
working	O
age	O
(	O
40s	O
and	O
50s	O
)	O
,	O
and	O
workplace	O
policyholder	O
.	O
Relative	O
risk	O
of	O
cardio	B-T047
-	O
cerebrovascular	B-T047
disease	I-T047
by	O
health	B-T058
examination	I-T058
period	I-T058
(	O
1	O
and	O
2	O
years	O
)	O
showed	O
statistically	O
significant	O
results	O
in	O
ischemic	B-T047
heart	I-T047
disease	I-T047
for	O
male	O
participants	O
.	O
Of	O
men	O
in	O
their	O
40s	O
,	O
office	B-T033
workers	I-T033
(	O
over	O
a	O
2	O
-	O
year	O
period	O
)	O
presented	O
statistically	O
higher	B-T033
relative	I-T033
risk	I-T033
of	I-T033
ischemic	B-T047
heart	I-T047
disease	I-T047
than	O
non	O
-	O
office	O
workers	O
(	O
over	O
a	O
1	O
-	O
year	O
period	O
:	O
1.03	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.02	O
-	O
1.03	O
)	O
.	O
However	O
,	O
there	O
were	O
no	O
consistent	O
results	O
in	O
ischemic	O
cerebrovascular	B-T047
disease	I-T047
and	O
hemorrhagic	O
cerebrovascular	B-T047
disease	I-T047
for	O
men	O
or	O
cardio	B-T047
-	O
cerebrovascular	B-T047
disease	I-T047
for	O
women	O
.	O
A	O
1	O
-	O
year	O
period	O
of	O
Workers	O
'	O
General	B-T060
Health	I-T060
Examinations	I-T060
in	O
non	O
-	O
office	O
workers	O
had	O
a	O
more	O
significant	O
prevention	B-T061
effect	O
on	O
ischemic	B-T047
heart	I-T047
disease	I-T047
than	O
a	O
2	O
-	O
year	O
period	O
in	O
office	B-T033
workers	I-T033
among	O
working	O
age	O
(	O
40s-50s	O
)	O
men	O
.	O
It	O
is	O
,	O
however	O
,	O
necessary	O
to	O
consider	O
that	O
prevention	B-T061
of	O
cardio	B-T047
-	O
cerebrovascular	B-T047
disease	I-T047
can	O
be	O
partially	O
explained	O
by	O
their	O
occupational	O
characteristics	O
rather	O
than	O
by	O
health	B-T058
examination	I-T058
period	I-T058
.	O
      
Does	O
sex	O
really	O
matter	O
?	O
Explaining	O
intraspecies	O
variation	O
in	O
ocean	O
acidification	O
responses	O
Ocean	O
acidification	O
(	O
OA	O
)	O
poses	O
a	O
major	O
threat	O
to	O
marine	O
ecosystems	O
globally	O
,	O
having	O
significant	O
ecological	O
and	O
economic	O
importance	O
.	O
The	O
number	O
and	O
complexity	O
of	O
experiments	O
examining	B-T033
the	O
effects	O
of	O
OA	O
has	O
substantially	O
increased	O
over	O
the	O
past	O
decade	O
,	O
in	O
an	O
attempt	O
to	O
address	O
multi	O
-	O
stressor	O
interactions	O
and	O
long	O
-	O
term	O
responses	O
in	O
an	O
increasing	O
range	O
of	O
aquatic	B-T001
organisms	I-T001
.	O
However	O
,	O
differences	O
in	O
the	O
response	O
of	O
males	O
and	O
females	O
to	O
elevated	B-T033
pCO2	I-T033
have	O
been	O
investigated	O
in	O
fewer	O
than	O
4	O
%	O
of	O
studies	O
to	O
date	O
,	O
often	O
being	O
precluded	O
by	O
the	O
difficulty	O
of	O
determining	O
sex	O
non	O
-	O
destructively	O
,	O
particularly	O
in	O
early	O
life	O
stages	O
.	O
Here	O
we	O
highlight	O
that	O
sex	O
can	O
significantly	O
impact	O
organism	B-T001
responses	O
to	O
OA	O
,	O
differentially	O
affecting	O
physiology	O
,	O
reproduction	O
,	O
biochemistry	O
and	O
ultimately	O
survival	O
.	O
What	O
is	O
more	O
,	O
these	O
impacts	O
do	O
not	O
always	O
conform	O
to	O
ecological	O
theory	O
based	O
on	O
differential	O
resource	O
allocation	O
towards	O
reproduction	O
,	O
which	O
would	O
predict	O
females	O
to	O
be	O
more	O
sensitive	O
to	O
OA	O
owing	O
to	O
the	O
higher	O
production	O
cost	O
of	O
eggs	O
compared	O
with	O
sperm	O
.	O
Therefore	O
,	O
non-	O
sex	O
-	O
specific	O
studies	O
may	O
overlook	O
subtle	O
but	O
ecologically	O
significant	O
differences	O
in	O
the	O
responses	O
of	O
males	O
and	O
females	O
to	O
OA	O
,	O
with	O
consequences	O
for	O
forecasting	O
the	O
fate	O
of	O
natural	O
populations	O
in	O
a	O
near	O
-	O
future	O
ocean	O
.	O
      
Discovering	O
key	O
residues	O
of	O
dengue	B-T005
virus	I-T005
NS2b	O
-	O
NS3	O
-	O
protease	O
:	O
New	O
binding	O
sites	O
for	O
antiviral	O
inhibitors	O
design	O
The	O
NS2B	O
-	O
NS3	O
protease	O
is	O
essential	O
for	O
the	O
Dengue	B-T005
Virus	I-T005
(	O
DENV	B-T005
)	O
replication	O
process	O
.	O
This	O
complex	O
constitutes	O
a	O
target	O
for	O
efficient	O
antiviral	B-T121
discovery	O
because	O
a	O
drug	B-T121
could	O
inhibit	O
the	O
viral	O
polyprotein	O
processing	O
.	O
Furthermore	O
,	O
since	O
the	O
protease	O
is	O
highly	O
conserved	O
between	O
the	O
four	O
Dengue	B-T005
virus	I-T005
serotypes	O
,	O
it	O
is	O
probable	O
that	O
a	O
drug	B-T121
would	O
be	O
equally	O
effective	O
against	O
all	O
of	O
them	O
.	O
In	O
this	O
article	O
,	O
a	O
strategy	O
is	O
reported	O
that	O
allowed	O
us	O
to	O
identify	O
influential	O
residues	O
on	O
the	O
function	O
of	O
the	O
Dengue	B-T005
NS2b	O
-	O
NS3	O
Protease	O
.	O
Moreover	O
,	O
this	O
is	O
a	O
strategy	O
that	O
could	O
be	O
applied	O
to	O
virtually	O
any	O
protein	O
for	O
the	O
search	O
of	O
alternative	O
influential	O
residues	O
,	O
and	O
for	O
non	O
-	O
competitive	O
inhibitor	O
development	O
.	O
First	O
,	O
we	O
incorporated	O
several	O
features	O
derived	O
from	O
computational	O
alanine	O
scanning	O
mutagenesis	O
,	O
sequence	O
,	O
structure	O
conservation	O
,	O
and	O
other	O
structure	O
-based	O
characteristics	O
.	O
Second	O
,	O
these	O
features	O
were	O
used	O
as	O
variables	O
to	O
obtain	O
a	O
multilayer	O
perceptron	O
model	O
to	O
identify	O
defined	O
groups	O
(	O
clusters	O
)	O
of	O
key	O
residues	O
as	O
possible	O
candidate	O
pockets	O
for	O
binding	O
sites	O
of	O
new	O
leads	O
on	O
the	O
DENV	B-T005
protease	O
.	O
The	O
identified	O
residues	O
included	O
:	O
i	O
)	O
amino	B-T121
acids	I-T121
close	O
to	O
the	O
beta	O
sheet	O
-loop-	O
beta	O
sheet	O
known	O
to	O
be	O
important	O
in	O
its	O
closed	O
conformation	O
for	O
NS2b	O
ii	O
)	O
residues	O
close	O
to	O
the	O
active	O
site	O
,	O
iii	O
)	O
several	O
residues	O
evenly	O
spread	O
on	O
the	O
NS2b	O
-	O
NS3	O
contact	O
surface	O
,	O
and	O
iv	O
)	O
some	O
inner	O
residues	O
most	O
likely	O
related	O
to	O
the	O
overall	O
stability	O
of	O
the	O
protease	O
.	O
In	O
addition	O
,	O
we	O
found	O
concordance	O
on	O
our	O
list	O
of	O
residues	O
with	O
previously	O
identified	O
amino	B-T121
acids	I-T121
part	O
of	O
a	O
highly	O
conserved	O
peptide	O
studied	O
for	O
vaccine	O
development	O
.	O
      
Effective	O
mercury(II	O
)	O
bioremoval	O
from	O
aqueous	B-T121
solution	I-T121
,	O
and	O
its	O
electrochemical	O
determination	O
This	O
work	O
proposed	O
mercury	O
elimination	O
using	O
agricultural	O
waste	O
(	O
Allium	O
Cepa	O
L	O
.	O
)	O
.	O
The	O
biomass	O
removed	O
99.4	O
%	O
of	O
mercury	O
,	O
following	O
a	O
pseudo	O
-	O
second	O
order	O
kinetics	O
(	O
r(2	O
)	O
=	O
0.9999	O
)	O
.	O
The	O
Langmuir	O
model	O
was	O
adequately	O
fitted	O
to	O
the	O
adsorption	O
isotherm	O
,	O
thereby	O
obtaining	O
the	O
maximum	O
mercury	O
adsorption	B-T059
capacity	O
of	O
111.1	O
±	O
0.3	O
mg	O
g(-1	O
)	O
.	O
The	O
biomass	O
showed	O
high	O
density	O
of	O
strong	O
mercury	O
chelating	B-T121
groups	I-T121
,	O
thus	O
making	O
it	O
economically	O
attractive	O
.	O
Also	O
,	O
the	O
implementation	O
of	O
a	O
mercury	O
-	O
selective	B-T059
electrode	I-T059
for	O
continuous	O
determination	B-T059
in	O
real	O
time	O
is	O
proposed	O
;	O
this	O
electrode	O
replaces	O
techniques	O
like	O
atomic	B-T059
absorption	I-T059
spectroscopy	I-T059
,	O
thus	O
it	O
can	O
be	O
applied	O
to	O
real	O
time	O
studies	O
.	O
This	O
work	O
therefore	O
presents	O
a	O
new	O
perspective	O
for	O
removing	O
mercury(II	O
)	O
from	O
contaminated	O
water	O
for	O
environmental	O
remediation	O
.	O
      
Epigenome	O
-	O
wide	O
analysis	O
links	O
SMAD3	O
methylation	O
at	O
birth	O
to	O
asthma	B-T047
in	I-T047
children	I-T047
of	O
asthmatic	B-T047
mothers	O
The	O
timing	O
and	O
mechanisms	O
of	O
asthma	B-T047
inception	O
remain	O
imprecisely	O
defined	O
.	O
Although	O
epigenetic	O
mechanisms	O
likely	O
contribute	O
to	O
asthma	B-T047
pathogenesis	O
,	O
little	O
is	O
known	O
about	O
their	O
role	O
in	O
asthma	B-T047
inception	O
.	O
We	O
sought	O
to	O
assess	B-T058
whether	O
the	O
trajectory	O
to	O
asthma	B-T047
begins	O
already	O
at	O
birth	O
and	O
whether	O
epigenetic	O
mechanisms	O
,	O
specifically	O
DNA	O
methylation	O
,	O
contribute	O
to	O
asthma	B-T047
inception	O
.	O
We	O
used	O
the	O
Methylated	B-T059
CpG	I-T059
Island	I-T059
Recovery	I-T059
Assay	I-T059
chip	I-T059
to	O
survey	O
DNA	O
methylation	O
in	O
cord	O
blood	O
mononuclear	O
cells	O
from	O
36	O
children	O
(	O
18	O
nonasthmatic	O
and	O
18	O
asthmatic	B-T047
subjects	O
by	O
age	O
9	O
years	O
)	O
from	O
the	O
Infant	O
Immune	O
Study	O
(	O
IIS	O
)	O
,	O
an	O
unselected	O
birth	O
cohort	O
closely	O
monitored	O
for	O
asthma	B-T047
for	O
a	O
decade	O
.	O
SMAD3	O
methylation	O
in	O
IIS	O
(	O
n	O
=	O
60	O
)	O
and	O
in	O
2	O
replication	O
cohorts	O
(	O
the	O
Manchester	O
Asthma	B-T047
and	O
Allergy	B-T059
Study	I-T059
[	O
n	O
=	O
30	O
]	O
and	O
the	O
Childhood	B-T047
Origins	I-T047
of	I-T047
Asthma	I-T047
Study	O
[	O
n	O
=	O
28	O
]	O
)	O
was	O
analyzed	O
by	O
using	O
bisulfite	O
sequencing	O
or	O
Illumina	B-T059
450	I-T059
K	I-T059
arrays	I-T059
.	O
Cord	O
blood	O
mononuclear	O
cell	O
-derived	O
IL-1β	O
levels	O
were	O
measured	O
by	O
means	O
of	O
ELISA	B-T059
.	O
Neonatal	O
immune	O
cells	O
harbored	O
589	O
differentially	O
methylated	O
regions	O
that	O
distinguished	O
IIS	O
children	O
who	O
did	O
and	O
did	O
not	O
have	O
asthma	B-T047
by	O
age	O
9	O
years	O
.	O
In	O
all	O
3	O
cohorts	O
methylation	O
in	O
SMAD3	O
,	O
the	O
most	O
connected	O
node	O
within	O
the	O
network	O
of	O
asthma	B-T047
-	O
associated	O
,	O
differentially	O
methylated	O
regions	O
,	O
was	O
selectively	O
increased	O
in	O
asthmatic	B-T047
children	O
of	O
asthmatic	B-T047
mothers	O
and	O
was	O
associated	O
with	O
childhood	B-T047
asthma	I-T047
risk	O
.	O
Moreover	O
,	O
SMAD3	O
methylation	O
in	O
IIS	O
neonates	O
with	O
maternal	O
asthma	B-T047
was	O
strongly	O
and	O
positively	O
associated	O
with	O
neonatal	O
production	O
of	O
IL-1β	O
,	O
an	O
innate	B-T121
inflammatory	I-T121
mediator	I-T121
.	O
The	O
trajectory	O
to	O
childhood	B-T047
asthma	I-T047
begins	O
at	O
birth	O
and	O
involves	O
epigenetic	O
modifications	O
in	O
immunoregulatory	O
and	O
proinflammatory	O
pathways	O
.	O
Maternal	O
asthma	B-T047
influences	O
epigenetic	O
mechanisms	O
that	O
contribute	O
to	O
the	O
inception	O
of	O
this	O
trajectory	O
.	O
      
Individual	O
classification	O
of	O
strong	O
risk	O
attitudes	O
:	O
An	O
application	O
across	O
lottery	O
types	O
and	O
age	O
groups	O
Empirical	O
evaluations	O
of	O
risk	O
attitudes	O
often	O
rely	O
on	O
a	O
weak	O
definition	O
of	O
risk	O
that	O
concerns	O
preferences	O
towards	O
risky	O
and	O
riskless	O
options	O
(	O
e.g.	O
,	O
a	O
lottery	O
vs.	O
a	O
sure	O
outcome	O
)	O
.	O
A	O
large	O
body	O
of	O
work	O
has	O
shown	O
that	O
individuals	O
tend	O
to	O
be	O
weak	O
risk	O
averse	O
in	O
choice	O
contexts	O
involving	O
risky	O
and	O
riskless	O
gains	O
but	O
weak	O
risk	O
seeking	O
in	O
contexts	O
involving	O
losses	O
,	O
a	O
phenomenon	O
known	O
as	O
the	O
reflection	O
effect	O
.	O
Recent	O
attempts	O
to	O
evaluate	O
age	O
differences	O
in	O
risk	O
attitudes	O
have	O
relied	O
on	O
this	O
weak	O
definition	O
,	O
testing	O
whether	O
the	O
reflection	O
effect	O
increases	O
or	O
diminishes	O
as	O
we	O
grow	O
older	O
.	O
The	O
present	O
work	O
argues	O
that	O
weak	O
risk	O
attitudes	O
have	O
limited	O
generalizability	O
and	O
proposes	O
the	O
use	O
of	O
a	O
strong	O
definition	O
of	O
risk	O
that	O
is	O
concerned	O
with	O
preferences	O
towards	O
options	O
with	O
the	O
same	O
expected	O
value	O
but	O
different	O
degrees	O
of	O
risk	O
(	O
i.e.	O
,	O
outcome	O
variance	O
)	O
.	O
A	O
reanalysis	O
of	O
previously	O
-	O
published	O
data	O
and	O
the	O
results	O
from	O
a	O
new	O
study	O
show	O
that	O
only	O
a	O
minority	O
of	O
individuals	O
manifests	O
the	O
reflection	O
effect	O
under	O
a	O
strong	O
definition	O
of	O
risk	O
,	O
and	O
that	O
,	O
when	O
facing	O
certain	O
lottery	O
-	O
pair	O
types	O
,	O
older	O
adults	O
appear	O
to	O
be	O
more	O
risk	O
seeking	O
than	O
younger	O
adults	O
.	O
      
High	O
Performance	O
Reduction	O
of	O
H2O2	B-T121
with	O
an	O
Electron	O
Transport	O
Decaheme	O
Cytochrome	O
on	O
a	O
Porous	O
ITO	O
Electrode	O
The	O
decaheme	O
cytochrome	O
MtrC	O
from	O
Shewanella	B-T007
oneidensis	I-T007
MR-1	I-T007
immobilized	O
on	O
an	O
ITO	O
electrode	O
displays	O
unprecedented	O
H2O2	B-T121
reduction	O
activity	O
.	O
Although	O
MtrC	O
showed	O
lower	O
peroxidase	O
activity	O
in	O
solution	O
compared	O
to	O
horseradish	O
peroxidase	O
,	O
the	O
ten	O
heme	O
cofactors	O
enable	O
excellent	O
electronic	O
communication	O
and	O
a	O
superior	O
activity	O
on	O
the	O
electrode	O
surface	O
.	O
A	O
hierarchical	O
ITO	O
electrode	O
enabled	O
optimal	O
immobilization	O
of	O
MtrC	O
and	O
a	O
high	O
current	O
density	O
of	O
1	O
mA	O
cm(-2	O
)	O
at	O
0.4	O
V	O
vs	O
SHE	O
could	O
be	O
obtained	O
at	O
pH	O
6.5	O
(	O
Eonset	O
=	O
0.72	O
V	O
)	O
.	O
UV	O
-	O
visible	O
and	O
Resonance	B-T059
Raman	I-T059
spectroelectrochemical	I-T059
studies	I-T059
suggest	O
the	O
formation	O
of	O
a	O
high	O
valent	O
iron	O
-	O
oxo	O
species	O
as	O
the	O
catalytic	O
intermediate	O
.	O
Our	O
findings	O
demonstrate	O
the	O
potential	O
of	O
multiheme	O
cytochromes	O
to	O
catalyze	O
technologically	O
relevant	O
reactions	O
and	O
establish	O
MtrC	O
as	O
a	O
new	O
benchmark	O
in	O
biotechnological	O
H2O2	B-T121
reduction	O
with	O
scope	O
for	O
applications	O
in	O
fuel	O
cells	O
and	O
biosensors	O
.	O
      
